<SEC-DOCUMENT>0001628280-23-014856.txt : 20230502
<SEC-HEADER>0001628280-23-014856.hdr.sgml : 20230502
<ACCEPTANCE-DATETIME>20230502160755
ACCESSION NUMBER:		0001628280-23-014856
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		82
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230502
DATE AS OF CHANGE:		20230502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38042
		FILM NUMBER:		23878957

	BUSINESS ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105
		BUSINESS PHONE:		626-696-4702

	MAIL ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARROWHEAD RESEARCH CORP
		DATE OF NAME CHANGE:	20040112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>arwr-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:838ae12b-ce84-423c-b3bd-d5043611fe16,g:09a7ef9b-3d5a-4a38-9975-37e1f59f1b78,d:c86d56462a0d40c99d8026254ea2d4d6--><html xmlns:utr="http://www.xbrl.org/2009/utr" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:arwr="http://www.arrowheadresearch.com/20230331" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>arwr-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80L2ZyYWc6YWY1NjFlOTE0MGViNDA0MWI3OWU3YzQzMmI1OTFkZGUvdGFibGU6OGY5MDMxN2JiYTczNDFmYjg2Y2I2OGFmYTQ0NDUwN2IvdGFibGVyYW5nZTo4ZjkwMzE3YmJhNzM0MWZiODZjYjY4YWZhNDQ0NTA3Yl8yLTEtMS0xLTQ2NjQy_09fbb423-84cf-46fb-9034-9160d4922f25">0000879407</ix:nonNumeric><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80L2ZyYWc6YWY1NjFlOTE0MGViNDA0MWI3OWU3YzQzMmI1OTFkZGUvdGFibGU6OGY5MDMxN2JiYTczNDFmYjg2Y2I2OGFmYTQ0NDUwN2IvdGFibGVyYW5nZTo4ZjkwMzE3YmJhNzM0MWZiODZjYjY4YWZhNDQ0NTA3Yl8zLTEtMS0xLTQ2NjQy_af8b0345-0f6e-4133-a095-7f814a4ddaa4">09-30</ix:nonNumeric><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80L2ZyYWc6YWY1NjFlOTE0MGViNDA0MWI3OWU3YzQzMmI1OTFkZGUvdGFibGU6OGY5MDMxN2JiYTczNDFmYjg2Y2I2OGFmYTQ0NDUwN2IvdGFibGVyYW5nZTo4ZjkwMzE3YmJhNzM0MWZiODZjYjY4YWZhNDQ0NTA3Yl80LTEtMS0xLTQ2NjQy_339a3e59-d71d-4780-9038-2d7f94693707">2023</ix:nonNumeric><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80L2ZyYWc6YWY1NjFlOTE0MGViNDA0MWI3OWU3YzQzMmI1OTFkZGUvdGFibGU6OGY5MDMxN2JiYTczNDFmYjg2Y2I2OGFmYTQ0NDUwN2IvdGFibGVyYW5nZTo4ZjkwMzE3YmJhNzM0MWZiODZjYjY4YWZhNDQ0NTA3Yl81LTEtMS0xLTQ2NjQy_5c63a36e-5c39-401a-b9ab-c8870fb8629b">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80L2ZyYWc6YWY1NjFlOTE0MGViNDA0MWI3OWU3YzQzMmI1OTFkZGUvdGFibGU6OGY5MDMxN2JiYTczNDFmYjg2Y2I2OGFmYTQ0NDUwN2IvdGFibGVyYW5nZTo4ZjkwMzE3YmJhNzM0MWZiODZjYjY4YWZhNDQ0NTA3Yl82LTEtMS0xLTQ2NjQy_7ecfb885-17b7-44cd-ba33-4e1df9e556f6">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="arwr-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32b8a1c0e5854d3ba284b51410976f38_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i8658828dac144310891d79034519aac1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i0f0b57d9696a4178850cfeeb887a0527_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ef217d1ae014653950af714ba114e79_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50a4e54f5bfb4716b45f934eaa14113d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3d20c6e34ff445d941da59d04a42801_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0d8fd51248444d7b2cc18251bffd261_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fab671f9d1f4bcc811ab238a0e9d2aa_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae8bf4236a96463d85eb67cec5f9436c_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if22a765bc5e6493cb9f1b2ed13cb4e3a_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea981497ed1441a1adcdec1001a8e970_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d6492fefa7340f3887bfa04169628a6_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie91d240ca96944a3b6fa19d2e3be66f2_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id07ee53b35c546489aa1141fb795a81e_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f0f0f39856c41238ff79dc13354c8e0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if30cb9af4bf44698ad1355d4cb3e5076_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c12fc21190440f4b646777c6721e378_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07b211def5654e32b5476f84e9f9dd7a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40ebfdae8cd740beb807ce422f45197d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie756775941ef43fd80b1a267081ca9a1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib195d18380a947c684949421e1dcd365_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fa04963a7944b6d8829bc8de0678c19_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01a9fa326aef4dc0830ea895f2568994_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i808343e416724a7ab9e17a71f299ad91_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98f503ba5e1a4de99077aecc556aa3ce_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie34dd58815de44edb4894780fe72ea8f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a699bc0f28f4ae7aeca3fe229161d36_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b4b2f94dd8f410e88a3c296a630fd9a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeb60a45426b407eb7975d28f670c511_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3613bbfc4a8440c99ce1bf55975a119_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84b78e6fbe2a41cdbc5069a20bac2479_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac8802180c9145218b8bd2c6aa534a09_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id534cbaab59b43ad982991d831ecc480_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i154ad50f88ea4503a5defebce13af0ba_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3144d66a7c174bff86ddf2ab9afe90cd_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadfd6b159c9446f4ad12848ede62bfea_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f3fdde941ae47dfb11186c305ab632c_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26989504186e41ed84cd5f5d555e3de0_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc7933727b4b46368d3b521b47747ef5_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b43fbce18ea4f85835fbd0288c1735d_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d11611625c842c192a76949637ab1ad_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18800dd8b03b46b48aaf88b9fb7044b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1161b10586074a64b54fd01340222fd9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82df41dcbf8c408098779e2309253d00_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3c56824a9954cc8afb80ad2017d4a48_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice8878b3a2d14233b9b372038ed81850_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7611db3737a4c7a959ce6e212f2636a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00be0b1806084dec8196472cc1ddf3df_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5de09ecb41b49789bdf45c6d67a4d62_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab63cc1254d34693ab73656849db98e4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d29a460a2c54ed2abee1109c64c2f63_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0151ff9c71de4a0499c8804305f5adc0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b0b1cc7a9a8460aa79e6b253f97b6ea_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6ff5ed1bf3742a98dc9cde7d7ace25c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68254b76d5ec47889b72791c3fea708a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib25506c96c484cef99aa0e6030c5ad3c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b1b88ad17754cd781fd0282509470f4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43a3ecb8edc343d68a3d398bc46eaa91_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieab41d2e8cba4cf79954078e0cabd689_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5defaeb7ae444faaeff3aef533d099f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98ffa0a0b1d34836b2777d4632a82434_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id543e56d77b6424381c9e219cda252c8_D20221109-20221109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:RoyaltyPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-09</xbrli:startDate><xbrli:endDate>2022-11-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f80c327fd0f46fcb58660b1d4a93b3f_D20221001-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:RoyaltyPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77ee61f67e7d4807a1b41dc07bbe6011_D20221001-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:HorizonTherapeuticsIrelandDACAndAmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15c28c33dc6b4b10bbc915f499ad8066_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1384505727044d59609bba3ee71e812_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccbf1d7ac531418d9578213f88b95f24_D20221001-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i269e350e160c4ea6ad74071baf18573a_D20211001-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60b798e3a061472cbe491224489dd4fd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i825f9542073f4d75985f228f8558ca2e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cd6b96847294914b272df50802b449e_D20221001-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i243b609737ea4d7eb695ad185cb74491_D20211001-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i082bc8d425934d3a809c260cf43f2098_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4920d739b45b45edbeea74ee7c5f1a5e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i233b4f8cd26e4e908334e04db7e1672d_D20221001-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36bee665f89b4b8bb8cf30907efbb23d_D20211001-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41d99afba4a04457ae92c14f6d2288e4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2d18d01d1ba459c819e19a2f426f844_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64ad46fbf63445bbab41c28a191959cc_D20221001-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cddef21baaf4bf9bfe75fd694a89239_D20211001-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a36c9033466491aa13ecfd0d8b71fd8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66bbdb26e9194e4fbb451ef54849270f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee762a06741d4eb7a18728ac4c642e6b_D20221001-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeb9254172ee4a51a8dd7073ba5f92c6_D20211001-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i691de1d520624cd1b1ffd39dc3bdc01d_I20211122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3271e7a0f6144468b240efa725ae2d39_I20211122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i237d8e5c7b234033bc777c8a0a3b0d52_D20211122-20211122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-22</xbrli:startDate><xbrli:endDate>2021-11-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d90a2de7f4e49f596cb460bdc10f3ca_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i882e29fc588d4797a46ee5a39680339a_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59d79924ebeb447c886bc284402909d2_I20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82576571409c4b7f9b8bb80fb3c9a00e_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="bundle"><xbrli:measure>arwr:bundle</xbrli:measure></xbrli:unit><xbrli:unit id="obligation"><xbrli:measure>arwr:obligation</xbrli:measure></xbrli:unit><xbrli:context id="i8b82750996f043c38f0f0871c175613b_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i711eaa11f2714195b20f945bbd192ec3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idadf7ab9198248d8be15ad2d0459d433_D20201007-20201007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-07</xbrli:startDate><xbrli:endDate>2020-10-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ia6534598f573472fa49c88f3543fef50_D20201007-20201007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-07</xbrli:startDate><xbrli:endDate>2020-10-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3776d7ed0187438ba605de53d95d0524_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5df73d39e5de43059a0154473c1fc57f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2220001e31ea4ab6af2ee0d3e5c38388_D20201007-20201007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-07</xbrli:startDate><xbrli:endDate>2020-10-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee5b7af13da443ca9a9e86096b5e0768_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i587c88b790cf4957a1f2e9ff83d976c3_D20221001-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a2e6ffc46c94788ab81d4390fdee866_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">arwr:DeferredRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecaadb3d3d994f3383d71ba13d40433e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66aef91f08484848847318e56657242a_D20181003-20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JohnsonAndJohnsonInnovationJJDCIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-03</xbrli:startDate><xbrli:endDate>2018-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0ed9d7c6a704f9c9edc96118a125065_D20181003-20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:CommonStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JohnsonAndJohnsonInnovationJJDCIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-03</xbrli:startDate><xbrli:endDate>2018-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82a308c1dd274f2e8e0a6f7e4ad9c114_I20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i076faa12769447e9be5b69d21b9bf0ed_I20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c30ebd6d9024acdba5d304d894ee2a4_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia34c6824ddbd426ea939bb344ff03287_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cf61607a2de42a1b21f3f65fa7d4921_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69f05a11406a48f2a92c762736aedab3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a26ad8e16504e72b2689ba702142228_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6ca215027754381a471291a60f53443_D20181003-20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-03</xbrli:startDate><xbrli:endDate>2018-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i497a7ae1faa04b0b9671b12bf3055d80_I20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd242108c98b440c9d40f8441267573b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57ec6b70a6104026b8b41cb652df4ebb_I20160928"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>arwr:agreement</xbrli:measure></xbrli:unit><xbrli:context id="i5f5f8caf41684c1ab6c099861fb8c323_D20160928-20160928"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-28</xbrli:startDate><xbrli:endDate>2016-09-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9405e8a861cd439b9331928b2bbd63e1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75cdb28a2e3a4ffd972787e5034b8cb6_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd5f89a84f804aad9a58e70315cd9ffe_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18dfb4f2db2a4e89865ff817bb733953_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d8b33b9a77247749e39326804eed524_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1923b3729416425e9e9c1f77d0a63e84_D20220425-20220425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:VisirnaLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-25</xbrli:startDate><xbrli:endDate>2022-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bca132899c842c2905496adc8f95181_D20221001-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:VisirnaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6de19fc5f51b4e9888754036904b53f2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:VisirnaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2763c2350df84087ae24e66c081a59da_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i770057db11544c24ad5a17c97ffb3a9f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4963dadcf66e4834a7a45b5f75765cb7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3f0180b2cd14a14919b19c765f13d23_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b40500b5f154e638fec3502314b61ad_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43111cfc508d42d1a23d0e3818674d52_D20221001-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaefcccfc8a3c49a885837a695c3852d6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d9b66e3437446e6a4e87dc026f2f51d_D20221001-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae265843759f4671ae3ffdba000744f2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e874cdd6f5c448fb4d8544628558c18_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i633b04e751e24ba3905af5e05905fd6e_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0176372a9404016aaf7cbb1312079fa_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99c440889d934b9a991b649900bea075_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6d2dec926374fd7a06a9cc5ff555ad3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e6eba04dc734b4d8c9dac99153326ea_I20230426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a2307967ccd4758a76576f944c97966_I20230427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i946d734bd0924e3c88051efb2fda8a0b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68db699bce364d8482aa0ec6406b9e97_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93974846852e4d2e86d9713058a0d972_I20221202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb7a13077dbb473bbf383cb6cf031d5f_D20221202-20221202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-02</xbrli:startDate><xbrli:endDate>2022-12-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibec649ac666a4282b702eb4164c1aa47_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabd7d953444246219ae89c140ed43582_D20211220-20211220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:VeronaTechnologyParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-20</xbrli:startDate><xbrli:endDate>2021-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="acre"><xbrli:measure>utr:acre</xbrli:measure></xbrli:unit><xbrli:context id="i6f6537bef0da416db817189fd3163b28_I20211220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:DrugManufacturingFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="icaf4446772ec44ed9ba6f8dddc59fe68_I20211220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:LaboratoryAndOfficeFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f101a6f09c746a696cf6e40e90e0784_I20211220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i608519b3c5264256971820f095be404f_I20211220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i174690ddc75d4855ac133c1051fa0058_I20211220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87a265da333847a7a7a27032890bbae3_D20211220-20211220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-20</xbrli:startDate><xbrli:endDate>2021-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21fbfd552ab74a5b8d34cf53f412fb99_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id49087344a124915998dbc4016b35524_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if91aa501385d4acda003508cc04433bd_D20221001-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c55337dc9d5489f93889b362e414346_D20211001-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd3e5aec48f6451c954c613028ae62ea_I20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5ae44bfc90d442180f61be9e9844f29_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc3f86aeb9e54ad2a0c1aea7e97e6026_I20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="option"><xbrli:measure>arwr:option</xbrli:measure></xbrli:unit><xbrli:context id="i68677c28e8fe477fa44323fceff8350f_I20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbd2b67bde2642ceb93902cc376061d6_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:ColoradoOwnerLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15669b32d03d4c7994f8ce62df1576ee_I20221223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SorrentoValleyOwnerDELLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia816458e6d964f63bac38dc0e0214686_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i159523f6f89347ed97ef204e3f438e67_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5215e7abf324f20be6a6162e55086ae_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica3faf3d13c049288fea256fa28a33f5_D20221001-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a9802653ed047b494adfc65fd05c202_D20211001-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2202af7f697f4a768cccd43c0a966d51_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a904235b2704d1281b976507352cfcc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0104fc96cb744d06baa957d09374a4b9_D20221001-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie31baa0092254ca4a31017b25a53ca08_D20211001-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0eb27783d00443259f37672e22a51d89_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f8f5aa4479d4452a8f944d74f31a91a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i474bf33fa2dd4412b27d2d7dadd0143f_I20210318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85d0e738f7ad46a78439146ca6b1ce57_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia821a22f759c491095cdffcc22a16326_D20221001-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82aee549d7ee4c17a0af2cb7b4160c1d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i415e58bd2ac14492bc9b71cfcaa0eb68_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3814d26ffec743bdbd368c8d17e1c599_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i513ac43a6b4641d5aa151e55bdb1adb8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife4b80c909b0481bb55da5cc80d82206_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6930053b987b4dcb9ec1e29905995970_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6cd39bcc4aa4f2bb3274f9594d5294a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie621a6d7b2894935b2a8275238e99a30_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id48977f119694d19b519cfbd1b536975_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9390b1d02afc409d88c4726d14169331_D20221001-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a8a84b6b8274985b99c61c1887f17e4_D20211001-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd78c85c0ede4725b46aebc7e69ca686_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9777e3d0f0044f9a5ae125314a8b62e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied3ebc51b45741a1b31064cbf68604f1_D20221001-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2c010a50c4c41249cf51a81f611ddb4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i805db888d835420986d4e8a91b283687_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17e779fd14684b3e966d950f0421cb5d_D20211001-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia24340fff8444dbb848ee908a5350d12_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2860ca5f992241c38da43e79e2b1c5f5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8730e93a554e482bbc30293e7122903d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e07cc9368c3473882925939ec3292a4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5e50e79a52647fd8ae13612e15c69cf_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a17cbdd764b419ab72a0c4122118bba_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5266edfdef7545fb95e73d3313d505d6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8049c9628c0e483abd37d06554b9e7d1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib089174a5cf348c1802beeaa2b977442_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib16740a1de40482aba6561a9747b4a94_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75aef6171137470d8e8e9cb8a2a83af6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2164b78caabc43fda358fdbd89914f21_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e3601b78983427db6b155d1b0307701_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1b3c3e0baf84de3bd52125e28ec4b76_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f174aafdabf4608bf7c653ec8825fdd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if15ee248bfc441c796bf3f458c740ed7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia24fba933c2d4cd0b16bded19b1bb09c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fbaa59436d843fe988d685090ab4af0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if043a0f1a28f41ad9782a0f46b2240b1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a07989748524f1f9e510ca832e4367d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ca3440b89af4805ae8534cd78394ea4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbc036b73a0349f8aeef68b475d74e60_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f8f0fdb41494916a8ccd82071a0dfa2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04d5b678d5744ea1bb9862b56fd512dd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1024c68fa8084ef7ba0a4aa7d7e3620a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37966ce3d820452881dc0a4feb57c9d8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e92174f5fd64f259dd75f387bad521c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1df1d8731bf74f8f93e44854a34edda1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22bc3c1a36b14889bca7b7d519b1e3a1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fbe7cc097934385a0f7656c8c178477_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14946c523e3c4c16a7a727f5f8768473_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic88cc70b817c4141873c6deeb572df1c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6a9654ad2f04e9eb78471c7b782bdc0_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i783e40d9f7b349e687c2fafc7b31322b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2cf83fb724d4e508f15e0cdb9fed5a5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b8bc25ae7384b7b86bdeee4af8033ca_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fe25e9421f84420b7997e575e069958_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf039f9333f3461faaee52cf3325669f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bbf95567b5f4f188e2a8249da064586_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2193adeae864400ea2611b5ffcc9bdf0_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64d56047f58a464c9b4c5f44f3ce0413_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i213da95ed9fc43649772cb98aa5ba619_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d13c9a5b243437ea4291fc58b35695b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie16b8c3eba024536a3a52b37dbdf8bd8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ba6acf54b0d4e5e9290dc7371ab7074_D20221109-20221109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-09</xbrli:startDate><xbrli:endDate>2022-11-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3454e80f761434b82e05233642d0a59_D20221109-20221109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-09</xbrli:startDate><xbrli:endDate>2022-11-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1daa5e406944e308bb4bedb06fb3198_I20221109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72781a23d66b49918170b8f70f504ec4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c76d9b4843b4551a837b21eebd9dfdb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55d4c31deffd475f8b184224f06e6834_D20221001-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_1"></div><div style="min-height:22.5pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF8yMjU0_527670ea-74f3-49db-b4c9-59fc07e3b6d7">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.796%"><tr><td style="width:1.0%"></td><td style="width:3.009%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGFibGU6ODVlYTU3YWUwZTA3NGMzNTgwMWJmZjcwNDBiM2NlYTEvdGFibGVyYW5nZTo4NWVhNTdhZTBlMDc0YzM1ODAxYmZmNzA0MGIzY2VhMV8wLTAtMS0xLTQ2NjQy_cbd918ba-79f7-4585-a882-d4de0794231d">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF8zMjk4NTM0ODg1NjE5_371af999-af95-43c0-a999-e5304c40167f">March 31, 2023</ix:nonNumeric></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGFibGU6Y2FiMDlhYTJkNWQ1NDU2ZGE3ZjEzMTA0YmFmNDBjNmIvdGFibGVyYW5nZTpjYWIwOWFhMmQ1ZDU0NTZkYTdmMTMxMDRiYWY0MGM2Yl8wLTAtMS0xLTQ2NjQy_1e630b41-2822-4392-a302-77e43c8b30cf">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF8yMjYw_c51b8b14-ee90-46e3-b873-499b25db20f5">001-38042</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF8yMjU1_f5f4468b-1b13-44aa-9455-f71aba600330">ARROWHEAD PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"></td><td style="width:48.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGFibGU6MjQ0MTVlOGExM2RmNGZjNzk3ZTkxNWZlNzQyOWE5YjYvdGFibGVyYW5nZToyNDQxNWU4YTEzZGY0ZmM3OTdlOTE1ZmU3NDI5YTliNl8wLTAtMS0xLTQ2NjQy_1492cf38-eb1d-4898-b688-30996c6a2e40">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGFibGU6MjQ0MTVlOGExM2RmNGZjNzk3ZTkxNWZlNzQyOWE5YjYvdGFibGVyYW5nZToyNDQxNWU4YTEzZGY0ZmM3OTdlOTE1ZmU3NDI5YTliNl8wLTItMS0xLTQ2NjQy_91c0316b-fb7c-4df5-8465-c8a39a1cc639">46-0408024</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF80ODA_869656dc-d81c-4ea9-925d-cfbdff10a841">177 E. Colorado Blvd</ix:nonNumeric>, <ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF80ODQ_694aa62e-72f5-487e-97ef-04e5ef0fc9c7">Suite 700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF80ODc_1ce9f0c8-e932-4d92-ab5e-b03233ea1c23">Pasadena</ix:nonNumeric>, <ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF80OTE_05a3000f-a323-4ab6-bc18-aa3fcfc4a8b8">California</ix:nonNumeric> <ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF80OTQ_fa264b43-b2c9-41f2-8ec7-18b4633f182d">91105</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF80OTg_ae52be97-4647-453f-99a7-d6a1f4707cf4">626</ix:nonNumeric>) <ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF81MDI_94553d35-c1d0-49c7-9e29-4281664f219a">304-3400</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address and telephone number of principal executive offices) </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Former name, former address, and former fiscal year, if changed since last report: N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Exchange Act:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"></td><td style="width:37.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 2.78pt;text-align:center;text-indent:-0.8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 2.38pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGFibGU6YTg0OTE3MWFmNjkxNDMzMThhMTYwZTY0ZmRhYjA5ZjgvdGFibGVyYW5nZTphODQ5MTcxYWY2OTE0MzMxOGExNjBlNjRmZGFiMDlmOF8xLTAtMS0xLTQ2NjQy_d37cd16c-999c-4266-9c85-d1baa3b74287">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:1.38pt;padding-right:1.38pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGFibGU6YTg0OTE3MWFmNjkxNDMzMThhMTYwZTY0ZmRhYjA5ZjgvdGFibGVyYW5nZTphODQ5MTcxYWY2OTE0MzMxOGExNjBlNjRmZGFiMDlmOF8xLTItMS0xLTQ2NjQyL3RleHRyZWdpb246MzIxZGYwNzAwNTRiNGI3NWEwN2ZlMmQzZGIxYzA2YjFfNA_cabd31d0-456b-47e9-8fe0-6cd554605559">ARWR</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 2.38pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGFibGU6YTg0OTE3MWFmNjkxNDMzMThhMTYwZTY0ZmRhYjA5ZjgvdGFibGVyYW5nZTphODQ5MTcxYWY2OTE0MzMxOGExNjBlNjRmZGFiMDlmOF8xLTQtMS0xLTQ2NjQy_18f70943-3e00-4d6e-b6de-66a1d486f052">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF8yMjU2_287ef12f-63ed-42c8-b2eb-1458774e0ef2">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF8yMjU3_76f1340b-46ea-437b-9f9c-28d730541ac9">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"></td><td style="width:44.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGFibGU6MGMxZTYwNTQ2MGVjNDZmZGIzOGNiNDRhOTRlYjJjZjUvdGFibGVyYW5nZTowYzFlNjA1NDYwZWM0NmZkYjM4Y2I0NGE5NGViMmNmNV8wLTAtMS0xLTQ2NjQyL3RleHRyZWdpb246ZDdmZGIyMDc2MWY1NDZiMjkzNzg1NmVjNDQzMDcyMjlfNA_3b4f3a65-45dc-42c7-ae2f-4a5bc583dc1b">Large Accelerated Filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:114%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-Accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Smaller Reporting Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGFibGU6MGMxZTYwNTQ2MGVjNDZmZGIzOGNiNDRhOTRlYjJjZjUvdGFibGVyYW5nZTowYzFlNjA1NDYwZWM0NmZkYjM4Y2I0NGE5NGViMmNmNV8yLTMtMS0xLTQ2NjQy_88e9f6c5-93a4-4f3d-a53e-7373cd5c6279">o</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Emerging Growth Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGFibGU6MGMxZTYwNTQ2MGVjNDZmZGIzOGNiNDRhOTRlYjJjZjUvdGFibGVyYW5nZTowYzFlNjA1NDYwZWM0NmZkYjM4Y2I0NGE5NGViMmNmNV80LTEtMS0xLTQ2NjQy_30afddd0-d7c0-4235-a6e0-2ef44929f864">o</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF8yMjUz_471ddcd0-e154-4718-b6f6-5bf7cd5cf93a">x</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of the registrant&#8217;s common stock outstanding as of April&#160;24, 2023 was <ix:nonFraction unitRef="shares" contextRef="i32b8a1c0e5854d3ba284b51410976f38_I20230424" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF8yMjQ4_5903f111-5bfb-4786-8e08-f3a3dae60d36">106,900,421</ix:nonFraction>. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.636%"><tr><td style="width:1.0%"></td><td style="width:91.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Page(s)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#ic86d56462a0d40c99d8026254ea2d4d6_10">PART I &#8212; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ic86d56462a0d40c99d8026254ea2d4d6_13">ITEM 1. FINANCIAL STATEMENTS </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ic86d56462a0d40c99d8026254ea2d4d6_13">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt;text-indent:-13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ic86d56462a0d40c99d8026254ea2d4d6_16">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ic86d56462a0d40c99d8026254ea2d4d6_16">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt;text-indent:-13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ic86d56462a0d40c99d8026254ea2d4d6_19">Consolidated Statements of Operations and Comprehensive </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ic86d56462a0d40c99d8026254ea2d4d6_19">Income (</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ic86d56462a0d40c99d8026254ea2d4d6_19">Loss</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ic86d56462a0d40c99d8026254ea2d4d6_19">)</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ic86d56462a0d40c99d8026254ea2d4d6_19"> </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ic86d56462a0d40c99d8026254ea2d4d6_19">2</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt;text-indent:-13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline">Consolidated Statements of Stockholders&#8217; Equity</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ic86d56462a0d40c99d8026254ea2d4d6_2748779069835">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt;text-indent:-13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ic86d56462a0d40c99d8026254ea2d4d6_25">Consolidated Statements of Cash Flows</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ic86d56462a0d40c99d8026254ea2d4d6_25">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt;text-indent:-13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ic86d56462a0d40c99d8026254ea2d4d6_28">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ic86d56462a0d40c99d8026254ea2d4d6_28">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic86d56462a0d40c99d8026254ea2d4d6_64">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ic86d56462a0d40c99d8026254ea2d4d6_64">23</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic86d56462a0d40c99d8026254ea2d4d6_82">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ic86d56462a0d40c99d8026254ea2d4d6_82">33</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic86d56462a0d40c99d8026254ea2d4d6_85">ITEM 4. CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ic86d56462a0d40c99d8026254ea2d4d6_85">33</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#ic86d56462a0d40c99d8026254ea2d4d6_88">PART II &#8212; OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ic86d56462a0d40c99d8026254ea2d4d6_88">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic86d56462a0d40c99d8026254ea2d4d6_91">ITEM 1. LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ic86d56462a0d40c99d8026254ea2d4d6_91">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic86d56462a0d40c99d8026254ea2d4d6_94">ITEM 1A. RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ic86d56462a0d40c99d8026254ea2d4d6_94">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic86d56462a0d40c99d8026254ea2d4d6_97">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ic86d56462a0d40c99d8026254ea2d4d6_97">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic86d56462a0d40c99d8026254ea2d4d6_100">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ic86d56462a0d40c99d8026254ea2d4d6_100">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic86d56462a0d40c99d8026254ea2d4d6_103">ITEM 4. MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ic86d56462a0d40c99d8026254ea2d4d6_103">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic86d56462a0d40c99d8026254ea2d4d6_106">ITEM 5. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ic86d56462a0d40c99d8026254ea2d4d6_106">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic86d56462a0d40c99d8026254ea2d4d6_109">ITEM 6. EXHIBITS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ic86d56462a0d40c99d8026254ea2d4d6_109">35</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic86d56462a0d40c99d8026254ea2d4d6_112">SIGNATURE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ic86d56462a0d40c99d8026254ea2d4d6_112">36</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_10"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION </span></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_13"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS </span></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_16"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.083%"><tr><td style="width:1.0%"></td><td style="width:68.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.923%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfNC0xLTEtMS00NjY0Mg_48dd0e40-06e8-4ef3-8564-e88dc0b6f827">134,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfNC0zLTEtMS00NjY0Mg_ab37ed06-7070-4513-9bb5-c1d5858da46b">108,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfNS0xLTEtMS00NjY0Mg_d073cacc-54c4-4a5a-95c3-474840bf30db">69,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfNS0zLTEtMS00NjY0Mg_54874135-6f7f-4653-9434-4e2c66c16cd3">1,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Short term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfNi0xLTEtMS00NjY0Mg_21e68537-d7ed-43f8-aa52-4d4a5f79348b">346,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfNi0zLTEtMS00NjY0Mg_b5ce376a-c166-43ec-a026-729377eb4355">268,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfNy0xLTEtMS00NjY0Mg_bba2a328-0e0c-40c9-8f05-fbeb71b3a6b1">9,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfNy0zLTEtMS00NjY0Mg_56337aea-619d-413c-86bc-3d0b1edc4018">7,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfOC0xLTEtMS00NjY0Mg_30554da7-68a3-4336-9b99-7a10f3e575e4">14,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfOC0zLTEtMS00NjY0Mg_9e1b0a6f-538a-4038-a2ef-e871678cd535">20,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfOS0xLTEtMS00NjY0Mg_0918c131-3508-4602-93ae-14da6edd43ac">574,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfOS0zLTEtMS00NjY0Mg_541f3512-154c-4e58-b29b-829677bae0b0">405,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMTAtMS0xLTEtNDY2NDI_66ab3394-4800-46d9-b122-74558e6718ac">185,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMTAtMy0xLTEtNDY2NDI_880cae80-4516-4119-b7c8-77e125408c8d">110,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMTEtMS0xLTEtNDY2NDI_693ae0b4-aef2-4b40-bae0-b5912f30e214">11,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMTEtMy0xLTEtNDY2NDI_e0429a22-1ae5-4b87-ae54-a512451bea47">11,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Long-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMTItMS0xLTEtNDY2NDI_64a5fb5b-36df-47f0-bd11-1b70a8d81aaa">78,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMTItMy0xLTEtNDY2NDI_b74b7d03-2942-498b-9329-97c96124a98a">105,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMTMtMS0xLTEtNDY2NDI_cda583ff-49bd-4357-a1ce-6e04586c7c95">41,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMTMtMy0xLTEtNDY2NDI_2acf0cf4-36a8-401a-8f50-65754b1677fc">58,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMTQtMS0xLTEtNDY2NDI_2dfc06e6-4ade-40c1-8242-a32f22c930ce">210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMTQtMy0xLTEtNDY2NDI_b0a0dd34-1751-47a8-b477-186c8395735d">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMTUtMS0xLTEtNDY2NDI_510cb478-aa43-4404-804c-1f51d3c3cb60">891,308</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMTUtMy0xLTEtNDY2NDI_d47a32d0-25dd-417f-914f-65ec56d4981b">691,939</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMTktMS0xLTEtNDY2NDI_ca7534ca-3ab2-4aa1-8366-c78dfee903d3">9,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMTktMy0xLTEtNDY2NDI_64e537a5-4f75-4054-b3de-7fde55f433e5">2,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjAtMS0xLTEtNDY2NDI_b60dcfb4-1d26-4f28-8d22-cd81a5c64a75">39,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjAtMy0xLTEtNDY2NDI_bf6968be-d481-48b0-9702-3e6d3028b7a7">46,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjEtMS0xLTEtNDY2NDI_92c8758d-bc08-49a0-a5a2-584db4d0afc8">5,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjEtMy0xLTEtNDY2NDI_3f946a5d-9e82-4597-836e-154f1eb9f5a4">12,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjItMS0xLTEtNDY2NDI_8f0d48a8-c208-4601-9051-ae9c40de2e18">2,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjItMy0xLTEtNDY2NDI_b51715cd-62e8-4631-8ec5-e43c36803cae">2,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjMtMS0xLTEtNDY2NDI_d670f986-4694-445c-9c29-cbd6c60b8d37">29,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjMtMy0xLTEtNDY2NDI_704be648-df52-4c6a-a94e-1d1c3f925468">74,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjQtMS0xLTEtNDY2NDI_a27bd374-4b7b-4cd2-8d8c-858c8012358e">87,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjQtMy0xLTEtNDY2NDI_50758edf-362d-4d57-9ac5-89b32004bda4">138,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Long-term liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjYtMS0xLTEtNDY2NDI_50798f35-772b-4bc3-a20f-08f72212b20d">80,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjYtMy0xLTEtNDY2NDI_923582ed-e4b5-4250-9615-ff3660a6c0b8">78,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjctMS0xLTEtNDY2NDI_cf021839-4df5-4bf1-a613-d73b9d2ea1e9">1,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjctMy0xLTEtNDY2NDI_2809e855-a1fc-4c1f-b34d-db7bd0dd139b">55,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="arwr:RoyaltiesLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjgtMS0xLTEtNDY2NDI_421c249c-b704-4702-b0b4-c58323d84123">257,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="arwr:RoyaltiesLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjgtMy0xLTEtNDY2NDI_69fa4a71-f8cd-49d6-963b-afe708f83e94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjktMS0xLTEtNDY2NDI_0a423d3a-60af-4090-b562-4c3055d2ba87">339,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjktMy0xLTEtNDY2NDI_701d2929-695b-4e44-a2dd-2b34cb6ac0ca">134,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Commitments and contingencies (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzAtMS0xLTEtNDY2NDI_6199af1b-64db-49d2-ad17-3c869c887125"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzAtMy0xLTEtNDY2NDI_7dfddae8-46e3-4c7a-be71-4b92886eb0af"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Noncontrolling interest and stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzItMC0xLTEtNDY2NDIvdGV4dHJlZ2lvbjpkYzBmY2JiODBlYmU0MWJhYjM2MzM3ZGRmY2JlMDNhZV8xOA_0d697c91-02e7-40cf-b909-ee902a657e1d"><ix:nonFraction unitRef="usdPerShare" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzItMC0xLTEtNDY2NDIvdGV4dHJlZ2lvbjpkYzBmY2JiODBlYmU0MWJhYjM2MzM3ZGRmY2JlMDNhZV8xOA_21f6e68d-cc62-4cfb-ac91-3702e0a72a50">0.001</ix:nonFraction></ix:nonFraction> par value:</span></div><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Authorized <ix:nonFraction unitRef="shares" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzItMC0xLTEtNDY2NDIvdGV4dHJlZ2lvbjpkYzBmY2JiODBlYmU0MWJhYjM2MzM3ZGRmY2JlMDNhZV81NDk3NTU4MTQwODE_68878432-9267-4d27-92ff-52e38f88eaca">290,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzItMC0xLTEtNDY2NDIvdGV4dHJlZ2lvbjpkYzBmY2JiODBlYmU0MWJhYjM2MzM3ZGRmY2JlMDNhZV81NDk3NTU4MTM5ODU_37ea2947-f45c-43a0-ad66-de455a3e23e3">145,000</ix:nonFraction> shares; issued and outstanding <ix:nonFraction unitRef="shares" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzItMC0xLTEtNDY2NDIvdGV4dHJlZ2lvbjpkYzBmY2JiODBlYmU0MWJhYjM2MzM3ZGRmY2JlMDNhZV83Nw_620f3319-af46-4c81-ad88-e71499d6965c"><ix:nonFraction unitRef="shares" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzItMC0xLTEtNDY2NDIvdGV4dHJlZ2lvbjpkYzBmY2JiODBlYmU0MWJhYjM2MzM3ZGRmY2JlMDNhZV83Nw_eccbf077-9547-422f-bade-26f51551839f">106,869</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzItMC0xLTEtNDY2NDIvdGV4dHJlZ2lvbjpkYzBmY2JiODBlYmU0MWJhYjM2MzM3ZGRmY2JlMDNhZV84NA_5221e5fb-5384-4204-9e88-6e9426f68a58"><ix:nonFraction unitRef="shares" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzItMC0xLTEtNDY2NDIvdGV4dHJlZ2lvbjpkYzBmY2JiODBlYmU0MWJhYjM2MzM3ZGRmY2JlMDNhZV84NA_56203224-4966-4b5a-a24e-e7919cdcb5e9">105,960</ix:nonFraction></ix:nonFraction> shares</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzItMS0xLTEtNDY2NDI_71c0b202-b66f-41c6-a935-00e246814f00">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzItMy0xLTEtNDY2NDI_214f83d4-48fd-44aa-9cb6-d210524d0692">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzMtMS0xLTEtNDY2NDI_4db92913-7625-4818-91c9-6ec5084f2c99">1,260,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzMtMy0xLTEtNDY2NDI_7e4aede2-6ca9-42f8-8fa8-4c103e45bfef">1,219,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzQtMS0xLTEtNDY2NDI_6815d31a-4818-48b9-9d93-3a778fedc2f2">332</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzQtMy0xLTEtNDY2NDI_995e1fee-4eff-47eb-93d6-bbe4f4ff6914">136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzUtMS0xLTEtNDY2NDI_cd664a42-4499-4aa1-99fb-710d03ac6679">813,405</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzUtMy0xLTEtNDY2NDI_f3d9e68d-7802-45e9-9d7b-51f22bbad10a">820,755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total Arrowhead Pharmaceuticals, Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzYtMS0xLTEtNDY2NDI_2213b9e7-2892-4987-be9c-6c263f83f77d">446,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzYtMy0xLTEtNDY2NDI_267553da-970f-46de-8fd6-43266a5dbc7c">398,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzctMS0xLTEtNDY2NDI_0e9b81a9-2b02-4b10-a772-3735184f403d">18,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzctMy0xLTEtNDY2NDI_2f4629b9-312c-4480-87d8-ac9ff97261c7">19,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total noncontrolling interest and stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzgtMS0xLTEtNDY2NDI_0fa8a271-3a6a-4b2b-b17c-68a37f9eb2ca">465,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzgtMy0xLTEtNDY2NDI_9a6b4f8f-0f3b-4a09-a214-96ac8dee5dd5">418,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total Liabilities, Noncontrolling Interest and Stockholders&#8217; Equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzktMS0xLTEtNDY2NDI_56d5b9cd-9c27-440e-8629-3c40db9fe2f0">891,308</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzktMy0xLTEtNDY2NDI_9811d40b-d36d-4dfe-b2fb-cafc936575fe">691,939</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements. </span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Income (Loss)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited) </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Revenue</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMi0xLTEtMS00NjY0Mg_a9ac8f37-dc6b-4f4a-8bec-65d278821aec">146,267</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMi0zLTEtMS00NjY0Mg_1b1cc81a-e90c-4025-8d3d-589fad468b7d">151,805</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMi01LTEtMS00Nzk1MA_88b851c5-c3f5-4594-8065-e989d2a6aa5e">208,813</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMi03LTEtMS00Nzg3NA_20978eef-b079-4d4f-ae40-0e88e003dad0">179,244</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Operating expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Research and development</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNC0xLTEtMS00NjY0Mg_1cfffc65-a00c-4e55-bb53-296451b43706">74,881</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNC0zLTEtMS00NjY0Mg_41fba41f-10bf-4b1c-9163-9774d3331a61">75,985</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNC01LTEtMS00Nzk1MA_74a5ea54-629f-4bf5-992f-fcad19a2e2ec">158,576</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNC03LTEtMS00Nzg4Mg_de026be0-cf6f-4595-b773-dd808947acb9">141,750</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNS0xLTEtMS00NjY0Mg_581e594a-5160-40ee-862a-73645c4c3a1a">23,221</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNS0zLTEtMS00NjY0Mg_c62880ef-9003-4e4a-a759-4a414fe7b19f">34,267</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNS01LTEtMS00Nzk1MA_60c08bfc-d4bb-445e-8daf-c5d3add4050e">44,206</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNS03LTEtMS00Nzg4Mg_ca3119e4-e5fc-466d-9916-a019f3dac4aa">59,262</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total operating expenses</span></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNi0xLTEtMS00NjY0Mg_e1727091-7135-4786-b2ae-e6a9ac4fb8d8">98,102</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNi0zLTEtMS00NjY0Mg_71b68290-84f8-43f7-b969-123733e41d01">110,252</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNi01LTEtMS00Nzk1MA_90a19d3b-198d-491b-adf9-46a5c5b5cb1c">202,782</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNi03LTEtMS00Nzg4Mg_ac0a0d0e-e7d5-42a7-b879-da4e8f2ac737">201,012</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating income (loss)</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNy0xLTEtMS00NjY0Mg_7f929f9c-7910-48ec-9e3a-d8341d93fcf2">48,165</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNy0zLTEtMS00NjY0Mg_4b68f936-4d9a-402d-b23f-05187c0e87e6">41,553</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNy01LTEtMS00Nzk2Nw_e100ff59-ac0d-43c5-aa7e-83fd34c0857b">6,031</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNy03LTEtMS01MDIwMQ_4ffd8411-e758-461e-b1af-7d4db6f6105b">21,768</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Other income (expense):</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTAtMS0xLTEtNDY2NDI_1f298cff-8df0-4aa9-8864-ae0e25595abd">4,560</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTAtMy0xLTEtNDY2NDI_a0a09d10-0b88-4130-9d31-6f11a235fbe8">1,054</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTAtNS0xLTEtNDc5NTA_34adf2c4-d153-4337-aa82-442dcba56d80">7,242</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTAtNy0xLTEtNDc4OTA_4bb0b89d-370b-417c-ad01-1fb221c11ed7">2,210</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTEtMS0xLTEtNTU0NDY_164558e2-b695-4c65-8fd3-ef613dfc6ec2">5,057</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTEtMy0xLTEtNTU0Njg_dbc1007e-01f6-46b9-844e-09b468d7dc79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTEtNS0xLTEtNTU0MjU_bcfb836a-ca9a-4e01-9914-9b6830e4ff0b">7,906</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTEtNy0xLTEtNTU0NTk_9b7a88b8-9887-42cf-8718-8eb78faf0216">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTEtMS0xLTEtNDY2NDI_86415db8-7ccb-4d12-bff5-9d4c2c05f140">8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTEtMy0xLTEtNDY2NDI_b457a947-6a19-4ab7-a749-f4467670bc48">1,759</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTEtNS0xLTEtNDc5NTA_c95d839f-221a-43ff-b0f9-0c69e2367c64">515</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTEtNy0xLTEtNDc4OTA_17138869-98f6-4ff1-acd1-bb553f2c0138">1,052</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total other (loss) income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTItMS0xLTEtNDY2NDI_38d179d9-0fd1-4655-b7fb-0ceb6d7e101d">489</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTItMy0xLTEtNDY2NDI_0b20b606-9d40-4110-8de2-5fac86064fde">2,813</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTItNS0xLTEtNDc5NTA_aa6cb6b9-9a10-4b74-937c-45ab8b49bd5e">149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTItNy0xLTEtNDc4OTA_305a824e-ec09-4bda-8dae-ed5afba9307f">3,262</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Income (loss) before income tax expense and noncontrolling interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTQtMS0xLTEtNDY2NDI_fd342931-bd33-48f7-9786-1b9a7cfea3f1">47,676</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTQtMy0xLTEtNDY2NDI_30a6bd66-d127-41fa-a837-5801d4194b1e">44,366</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTQtNS0xLTEtNDc5NTA_c9f91157-1a55-429d-a091-a2dd4dfc9be0">5,882</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTQtNy0xLTEtNDc5MDE_f9200491-4c5c-4387-8e36-bacb7b832728">18,506</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTUtMS0xLTEtNDY2NDI_058f9c9f-3af9-42d2-b388-9ad108c79ee1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTUtMy0xLTEtNDY2NDI_26f1f4e5-b2d4-4fed-a698-dd0c4bd8c916">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTUtNS0xLTEtNDc5NTA_540ed32c-25ce-4b89-8e76-7ef6fc997eab">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTUtNy0xLTEtNDc5MDE_3407fcd9-0389-430a-a4b3-99e35bec17a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net income (loss) including noncontrolling interest</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTYtMS0xLTEtNDY2NDI_21a628e5-fa85-495b-8d31-85227ffc8ed7">47,676</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTYtMy0xLTEtNDY2NDI_1cca6dd3-5395-42bf-b585-9866de8b5476">44,366</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTYtNS0xLTEtNDc5NTA_f963e2c9-6127-4d21-9b7b-3010cd3f1621">5,865</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTYtNy0xLTEtNDc5MDE_0d7cbbe4-177f-4bb1-8f03-857557c1525a">18,506</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss attributable to noncontrolling interest, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTctMS0xLTEtNDY2NDI_cf7ea14a-46e2-49eb-9c72-c36c68c96bed">999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTctMy0xLTEtNDY2NDI_5607e2c6-592a-4579-963f-fd3fd8075e43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTctNS0xLTEtNDc5NTk_6bb92f85-c01f-46da-a2c9-4357619ed565">1,485</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTctNy0xLTEtNDc5MDk_d2e29d31-78f6-47f8-930c-cf23c29feb78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net income (loss) attributable to Arrowhead Pharmaceuticals, Inc.</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTgtMS0xLTEtNDY2NDI_c89a5c05-418e-4378-a6e5-abe5e17b078e">48,675</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTgtMy0xLTEtNDY2NDI_b9a34c73-bc39-46ed-aadd-5a77770950e8">44,366</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTgtNS0xLTEtNDc5NTA_d8fa2d1d-bfc2-4d43-8efa-2139635b977a">7,350</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTgtNy0xLTEtNDc5MDk_ccf0f792-f284-44ca-aa98-dae2218a8c25">18,506</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income (loss) per share attributable to Arrowhead Pharmaceuticals, Inc.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Basic</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjEtMS0xLTEtNDY2NDI_390be610-b125-4f84-8fa1-352a648eb9d9">0.46</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjEtMy0xLTEtNDY2NDI_c94657e0-3e29-4765-8bd1-8196414c2000">0.42</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjEtNS0xLTEtNDc5NTA_92b2b925-9f44-422e-978e-c4788c4eeff2">0.07</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjEtNy0xLTEtNDc5MTc_0ed0174a-bbfd-415b-bdd2-dfcb9f261641">0.18</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjItMS0xLTEtNDY2NDI_fe654c12-b00b-4b4f-b3b9-d8eedaa52213">0.45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjItMy0xLTEtNDY2NDI_dab3270d-f2a3-4184-9036-d3f3f89a3148">0.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjItNS0xLTEtNDc5NTA_3e688076-7139-4e85-af8e-04a684a26b18">0.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjItNy0xLTEtNDc5MTc_7a5a69fa-2b76-4445-b2f2-531ad103289c">0.18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Weighted-average shares used in calculating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt 0 13pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt 0 13pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjQtMS0xLTEtNDY2NDI_43b2b571-4f98-4b2e-9b7c-00ab552530e4">106,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjQtMy0xLTEtNDY2NDI_e0bea119-f5a0-4d4a-ab14-e2aabdccf4d1">105,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjQtNS0xLTEtNDc5NTA_b5d1eeb6-d1e1-4c26-9e5c-9cec6028d380">106,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjQtNy0xLTEtNDc5MTc_65cc41a3-26ed-4d2a-81d8-17e06f9820d0">105,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjUtMS0xLTEtNDY2NDI_6f168b64-c634-4cb2-b4c5-f99231bd993e">108,143</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjUtMy0xLTEtNDY2NDI_90f17e91-616e-4d8a-be64-0f031a60b81e">107,929</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjUtNS0xLTEtNDc5NTA_e941440e-0067-4dc9-9b7b-cee73b5b6747">107,893</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjUtNy0xLTEtNDc5MTc_f1c2852d-377a-4e9a-8dbb-9691e5ca8999">105,034</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt 0 13pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other comprehensive income (loss), net of tax:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjgtMS0xLTEtNDY2NDI_f3847e8b-35fb-441e-9f94-7151da646701">74</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjgtMy0xLTEtNDY2NDI_4b92ee2d-3ab5-4104-86ac-3d6adb6d3905">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjgtNS0xLTEtNDc5NTA_68a3ee7d-4616-4df4-ab6e-13353b495091">196</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjgtNy0xLTEtNDc5Mjk_87141f03-d745-4ee4-ac5a-6684461a1b82">38</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Comprehensive income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjktMS0xLTEtNDY2NDI_f409f75e-0104-4c8e-9087-842b9780cf33">47,602</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjktMy0xLTEtNDY2NDI_02d47a6f-903e-4488-a60e-92b9b623b9af">44,367</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjktNS0xLTEtNDc5NTA_50106183-6236-4df8-8d5f-89d00144fe50">5,669</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjktNy0xLTEtNDc5Mjk_96680a7a-31e0-400c-9e96-f0631ecfaa2c">18,544</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_2748779069835"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.305%"><tr><td style="width:1.0%"></td><td style="width:35.123%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.270%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.711%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.157%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Common</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Amount ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Additional</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Paid-In</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Accumulated </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Other </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Comprehensive </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Loss</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Accumulated</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Non-<br/>controlling Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Totals </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Balance at September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i3ef217d1ae014653950af714ba114e79_I20220930" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xLTEtMS0xLTQ4MzM4_6acb5e9e-60ea-4728-86dd-3308c8ceb0be">105,960</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i3ef217d1ae014653950af714ba114e79_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xLTMtMS0xLTQ4MzM4_7de1d55c-affb-46b3-a218-3123b4975f7d">198</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i50a4e54f5bfb4716b45f934eaa14113d_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xLTUtMS0xLTQ4MzM4_3a9fc751-4b95-49af-a2a7-cf194e434412">1,219,213</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib3d20c6e34ff445d941da59d04a42801_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xLTctMS0xLTQ4MzM4_92289d4f-f262-4776-96fb-b9c1e0ed3235">136</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia0d8fd51248444d7b2cc18251bffd261_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xLTktMS0xLTQ4MzM4_640f2e66-b6d7-4550-b2cc-dea259315179">820,755</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8fab671f9d1f4bcc811ab238a0e9d2aa_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xLTExLTEtMS00ODMzOA_14763fc7-9c8f-41c0-8d05-a403a67fcbfd">19,819</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xLTEzLTEtMS00ODMzOA_e0ec15f1-fe8c-4d9a-98a9-56fa7c66d404">418,339</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iae8bf4236a96463d85eb67cec5f9436c_D20221001-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8yLTUtMS0xLTQ4MzM4_3b375606-331b-4329-9372-e9ac40567b84">19,390</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if22a765bc5e6493cb9f1b2ed13cb4e3a_D20221001-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8yLTEzLTEtMS00ODMzOA_e6bba5b6-dc5d-441e-ad6a-f50941960d46">19,390</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="iea981497ed1441a1adcdec1001a8e970_D20221001-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8zLTEtMS0xLTQ4MzM4_c9f01236-7c17-4f2f-8673-f3510b2c55ae">82</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iae8bf4236a96463d85eb67cec5f9436c_D20221001-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8zLTUtMS0xLTQ4MzM4_f790dff7-100e-4ebf-9c2f-66fe0c985972">576</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if22a765bc5e6493cb9f1b2ed13cb4e3a_D20221001-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8zLTEzLTEtMS00ODMzOA_82123c31-80b6-4745-98db-1cac8e414bbe">576</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="iea981497ed1441a1adcdec1001a8e970_D20221001-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV80LTEtMS0xLTQ4MzM4_8e9c0728-0f24-4f0e-a4e9-cf4ad175a87b">98</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iea981497ed1441a1adcdec1001a8e970_D20221001-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV80LTMtMS0xLTQ4MzM4_d41a828b-9446-4145-93a3-22ddb0bf3778">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="iae8bf4236a96463d85eb67cec5f9436c_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV80LTUtMS0xLTQ4MzM4_14530284-2691-45f9-b879-19c5f3aa01bc">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if22a765bc5e6493cb9f1b2ed13cb4e3a_D20221001-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV80LTEzLTEtMS00ODMzOA_74d7ac8c-9747-42c3-8493-965679f9fba4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0d6492fefa7340f3887bfa04169628a6_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV81LTctMS0xLTQ4MzM4_68f76e48-ff03-423a-baef-bf3fa1f974a3">122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="if22a765bc5e6493cb9f1b2ed13cb4e3a_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV81LTEzLTEtMS00ODMzOA_5a684adb-f74b-42ed-afed-ae648114d737">122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Interest in joint venture</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ie91d240ca96944a3b6fa19d2e3be66f2_D20221001-20221231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV82LTExLTEtMS00ODQwNw_83b8cf00-e378-4537-bd3b-b79006801fef">486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="if22a765bc5e6493cb9f1b2ed13cb4e3a_D20221001-20221231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV82LTEzLTEtMS00ODQxNw_d1b70449-9a94-4cf5-877f-6d272c7d0fbb">486</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Net loss for the three months ended December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id07ee53b35c546489aa1141fb795a81e_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV82LTktMS0xLTQ4MzM4_a5ab09fd-7843-43aa-bc29-7fca10612a20">41,325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="if22a765bc5e6493cb9f1b2ed13cb4e3a_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV82LTEzLTEtMS00ODMzOA_5aab13a8-74cd-4f6b-9c42-5ccdc6119872">41,325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Balance at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i9f0f0f39856c41238ff79dc13354c8e0_I20221231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV83LTEtMS0xLTQ4MzM4_25b6df04-d141-423b-af1e-df85bbaeea3f">106,140</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9f0f0f39856c41238ff79dc13354c8e0_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV83LTMtMS0xLTQ4MzM4_17a23ea2-0c6a-431d-bc04-bb4927d253a4">199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if30cb9af4bf44698ad1355d4cb3e5076_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV83LTUtMS0xLTQ4MzM4_3869c83c-0e62-4173-82a7-3ae2e084b951">1,239,178</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i8c12fc21190440f4b646777c6721e378_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV83LTctMS0xLTQ4MzM4_a48099c4-987b-4d84-863c-b179cd0375cc">258</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i07b211def5654e32b5476f84e9f9dd7a_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV83LTktMS0xLTQ4MzM4_4e0869d4-8982-4cf9-8aee-097044f21706">862,080</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i40ebfdae8cd740beb807ce422f45197d_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV83LTExLTEtMS00ODMzOA_ac1fabec-1dbb-423c-a1dd-74bf22ac12d3">19,333</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ie756775941ef43fd80b1a267081ca9a1_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV83LTEzLTEtMS00ODMzOA_268e80aa-58dc-4af5-b64d-0ae0ed3b9cfe">396,372</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib195d18380a947c684949421e1dcd365_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV85LTUtMS0xLTQ4Mzk0_d6bc99cf-e665-4a6c-940d-d60df8a1b288">20,612</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV85LTEzLTEtMS00ODM5NA_1e57434f-d109-481f-a703-85449134b5f1">20,612</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i4fa04963a7944b6d8829bc8de0678c19_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xMC0xLTEtMS00ODM5NA_f78dae9f-dd5c-4575-91e0-0082feaf9080">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib195d18380a947c684949421e1dcd365_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xMC01LTEtMS00ODM5NA_5e625ea3-e3d4-4993-bea9-4f1e4892f704">520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xMC0xMy0xLTEtNDgzOTQ_da53ef73-cb0a-4fb5-808b-894213cf71f2">520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i4fa04963a7944b6d8829bc8de0678c19_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xMS0xLTEtMS00ODM5NA_8e762351-846a-444e-8835-f5bd7855ced6">665</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i01a9fa326aef4dc0830ea895f2568994_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xMi03LTEtMS00ODM5NA_38a47f5f-2bb5-41d9-a7ef-0a161f898551">74</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xMi0xMy0xLTEtNDgzOTQ_3441c682-5991-4c97-9e35-54879e1755c4">74</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Interest in joint venture</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i808343e416724a7ab9e17a71f299ad91_D20230101-20230331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xMy0xMS0xLTEtNDgzOTQ_f946224b-6252-4f8b-bb9e-b3d6868cff4e">999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xMy0xMy0xLTEtNDgzOTQ_a84d54ce-b970-49c8-9abd-c5377070365f">999</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Net income for the three months ended March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i98f503ba5e1a4de99077aecc556aa3ce_D20230101-20230331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xNC05LTEtMS00ODM5NA_47bcf542-4341-41b0-a1fc-c1c2633594fb">48,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xNC0xMy0xLTEtNDgzOTQ_cf5e2968-b022-410e-8c2c-900dd3e9dc88">48,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Balance at March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ie34dd58815de44edb4894780fe72ea8f_I20230331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xNS0xLTEtMS00ODM5NA_b05fed92-01d1-4578-b0b7-f54e500f6fe5">106,869</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ie34dd58815de44edb4894780fe72ea8f_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xNS0zLTEtMS00ODM5NA_5b039c4d-0dc9-45fa-b37b-89189b25d974">199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8a699bc0f28f4ae7aeca3fe229161d36_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xNS01LTEtMS00ODM5NA_15132e4b-a67d-4aaa-bbc2-5532c036b5b4">1,260,310</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i8b4b2f94dd8f410e88a3c296a630fd9a_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xNS03LTEtMS00ODM5NA_ca0ef1a9-cdb8-4ec1-9112-4581b0a28c6e">332</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ifeb60a45426b407eb7975d28f670c511_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xNS05LTEtMS00ODM5NA_149fc9f9-aef6-4010-840d-afedd45040d2">813,405</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic3613bbfc4a8440c99ce1bf55975a119_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xNS0xMS0xLTEtNDgzOTQ_c4268cc8-7e5d-47b7-ab62-2e7b1166852b">18,334</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xNS0xMy0xLTEtNDgzOTQ_c68842c0-c76a-4444-98d4-efe2e382b31b">465,106</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.444%"><tr><td style="width:1.0%"></td><td style="width:34.933%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.978%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.149%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Common</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Amount ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Additional</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Paid-In</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Accumulated </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Other </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Comprehensive </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Loss</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Accumulated</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Non-<br/>controlling Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Totals </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Balance at September&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i84b78e6fbe2a41cdbc5069a20bac2479_I20210930" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xLTEtMS0xLTQ4MzM4_23d3e5c2-1543-4f11-a5d6-f7ef4cec6b86">104,327</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i84b78e6fbe2a41cdbc5069a20bac2479_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xLTMtMS0xLTQ4MzM4_45388b9c-43eb-45d2-b3b0-065d1731ae8e">197</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iac8802180c9145218b8bd2c6aa534a09_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xLTUtMS0xLTQ4MzM4_e5c30be8-216c-4c1c-9a47-e1efa0174405">1,053,386</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id534cbaab59b43ad982991d831ecc480_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xLTctMS0xLTQ4MzM4_38159181-5302-4585-b32d-b62c5e5ce08f">69</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i154ad50f88ea4503a5defebce13af0ba_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xLTktMS0xLTQ4MzM4_a60ed6a1-a18e-4225-adc6-87df3084efbc">644,692</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i3144d66a7c174bff86ddf2ab9afe90cd_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xLTExLTEtMS00ODMzOA_2ef3ca59-f59a-454f-b236-4be7da17f218">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iadfd6b159c9446f4ad12848ede62bfea_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xLTEzLTEtMS00ODMzOA_f2e8969a-9649-482c-8fed-b08f07e489e2">408,822</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6f3fdde941ae47dfb11186c305ab632c_D20211001-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8yLTUtMS0xLTQ4MzM4_de12aa51-9907-4962-baae-a97efe3e858f">24,504</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i26989504186e41ed84cd5f5d555e3de0_D20211001-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8yLTEzLTEtMS00ODMzOA_33d5e8ed-e79f-477c-9d6f-b2bfd6e3fc10">24,504</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="idc7933727b4b46368d3b521b47747ef5_D20211001-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8zLTEtMS0xLTQ4MzM4_84a8ff61-b63c-45b6-a0ae-301cd904e5c0">208</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6f3fdde941ae47dfb11186c305ab632c_D20211001-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8zLTUtMS0xLTQ4MzM4_eff0339a-53f5-4d7c-9136-5d75af2597f7">2,145</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i26989504186e41ed84cd5f5d555e3de0_D20211001-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8zLTEzLTEtMS00ODMzOA_6d67e06b-a0f4-4df9-af83-7894343e950e">2,145</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="idc7933727b4b46368d3b521b47747ef5_D20211001-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF80LTEtMS0xLTQ4MzM4_d38a0269-4d50-4b3b-a84c-3448ea3f561f">263</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i5b43fbce18ea4f85835fbd0288c1735d_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF81LTctMS0xLTQ4MzM4_38b495b3-40a9-4093-9f10-364915eeb9c6">39</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i26989504186e41ed84cd5f5d555e3de0_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF81LTEzLTEtMS00ODMzOA_53be6843-f3bc-4172-885d-25724e9d2480">39</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Net loss for the three months ended December&#160;31, 2021</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0d11611625c842c192a76949637ab1ad_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF83LTktMS0xLTQ4MzM4_a6c09778-9b0d-4ea3-ad13-6e6362ad36fa">62,872</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i26989504186e41ed84cd5f5d555e3de0_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF83LTEzLTEtMS00ODMzOA_6549d9eb-77a5-4885-bdd4-6c5f4e766f7c">62,872</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Balance at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i18800dd8b03b46b48aaf88b9fb7044b1_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF84LTEtMS0xLTQ4MzM4_b8922727-49c7-4ce1-9c02-1e69fdd8209f">104,798</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i18800dd8b03b46b48aaf88b9fb7044b1_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF84LTMtMS0xLTQ4MzM4_60efdc9d-a3a3-4064-9d43-16c2e29fba39">197</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1161b10586074a64b54fd01340222fd9_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF84LTUtMS0xLTQ4MzM4_02c1a4d9-22db-4379-92d9-f47f29f6f306">1,080,035</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i82df41dcbf8c408098779e2309253d00_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF84LTctMS0xLTQ4MzM4_f2a4c080-8781-4983-8057-4f7263dbcd1c">108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia3c56824a9954cc8afb80ad2017d4a48_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF84LTktMS0xLTQ4MzM4_07b452c0-fe4a-4507-a9d7-caedb558a9df">707,564</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ice8878b3a2d14233b9b372038ed81850_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF84LTExLTEtMS00ODMzOA_2fc36793-2ecf-4347-a903-2c08d8b695a7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib7611db3737a4c7a959ce6e212f2636a_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF84LTEzLTEtMS00ODMzOA_dd43b2f1-0189-48c0-af54-8c7c50b1001d">372,560</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i00be0b1806084dec8196472cc1ddf3df_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF85LTUtMS0xLTQ4NDk4_23593cd4-a4db-494d-a91f-002d2ef837d3">33,802</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF85LTEzLTEtMS00ODQ5OA_f2efbeeb-a656-4ef2-9adc-263d47b63c4f">33,802</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ia5de09ecb41b49789bdf45c6d67a4d62_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xMC0xLTEtMS00ODQ5OA_cd733635-8d78-4052-9551-934b1020c3fe">237</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i00be0b1806084dec8196472cc1ddf3df_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xMC01LTEtMS00ODQ5OA_53f5d129-e49b-4c9c-8db8-10912723bd19">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xMC0xMy0xLTEtNDg0OTg_88ff1145-10cb-413b-921a-dbd27def2de5">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ia5de09ecb41b49789bdf45c6d67a4d62_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xMS0xLTEtMS00ODQ5OA_1205424c-45ff-49f3-a79d-9b3713f7948f">667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5de09ecb41b49789bdf45c6d67a4d62_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xMS0zLTEtMS00ODQ5OA_8b6e30ea-9f87-403d-a0a6-1d6d83c66647">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i00be0b1806084dec8196472cc1ddf3df_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xMS01LTEtMS00ODQ5OA_112186ad-a1c7-4ce9-b23e-61150564c696">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xMS0xMy0xLTEtNDg0OTg_9ff084f4-cb4e-4187-b7d0-13f7317d1d32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iab63cc1254d34693ab73656849db98e4_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xMi03LTEtMS00ODQ5OA_65a8c747-54da-4224-a4fb-e5000e42ab2b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xMi0xMy0xLTEtNDg0OTg_44a95ff4-9f99-451c-92ce-bfec2b4c502b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Net income for the three months ended March&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i3d29a460a2c54ed2abee1109c64c2f63_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xNC05LTEtMS00ODQ5OA_d2cfa232-eea4-45a6-8b9e-879269ce91a8">44,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xNC0xMy0xLTEtNDg0OTg_408031aa-9c5d-43cd-81d5-bb3b7c0b37d5">44,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Balance at March&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i0151ff9c71de4a0499c8804305f5adc0_I20220331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xNS0xLTEtMS00ODQ5OA_c5fbf1e5-1558-4c31-88aa-8a550915f8b4">105,702</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0151ff9c71de4a0499c8804305f5adc0_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xNS0zLTEtMS00ODQ5OA_dd3130c7-9042-487b-bd20-4f54b6970f03">198</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9b0b1cc7a9a8460aa79e6b253f97b6ea_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xNS01LTEtMS00ODQ5OA_e39f94c2-bc9b-4f57-bb95-ba30d58da6a1">1,115,373</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic6ff5ed1bf3742a98dc9cde7d7ace25c_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xNS03LTEtMS00ODQ5OA_78ac4192-32ce-41dc-ab33-2279798e057b">107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i68254b76d5ec47889b72791c3fea708a_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xNS05LTEtMS00ODQ5OA_1b5bb2cf-06e8-420a-a977-09c92ff8410d">663,198</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib25506c96c484cef99aa0e6030c5ad3c_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xNS0xMS0xLTEtNDg0OTg_024108b2-1275-4be1-b093-de86a94c5d4d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2b1b88ad17754cd781fd0282509470f4_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xNS0xMy0xLTEtNDg0OTg_b080f251-fba2-4ffd-8116-e348cfe18702">452,266</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMy0xLTEtMS00NjY0Mg_9066091b-205b-4984-9f2f-bb68a3ba9232">5,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMy0zLTEtMS00NjY0Mg_d75bfb83-5f27-4267-9877-7ab627d39041">18,506</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Adjustments to reconcile net income (loss) to net cash flow from operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfNS0xLTEtMS00NjY0Mg_d3931ddc-b812-48f1-9b0a-942f1ca61f22">40,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfNS0zLTEtMS00NjY0Mg_35ad094c-7b31-4bd5-a876-49e6ecad3e55">58,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfNi0xLTEtMS00NjY0Mg_1b4429d4-92f6-4cbc-ac37-872cdd2a05a9">5,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfNi0zLTEtMS00NjY0Mg_496e02b4-be55-4b2a-8bd7-36b79fe830d2">5,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(Accretion) amortization of note premiums/discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfNy0xLTEtMS00NjY0Mg_d38f3ac1-deb0-4e55-a36a-30fc0c1207fd">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfNy0zLTEtMS00NjY0Mg_f0a67c51-6e30-48b9-9e7c-01d922c47dc0">329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Non-cash interest expense on liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfOC0xLTEtMS00NjY0Mg_8bfb6280-2de8-408b-b67c-7ddc701325cf">7,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfOC0zLTEtMS00NjY0Mg_1a7e3423-5fe2-4e2c-9d51-4f6cf0073c10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTAtMS0xLTEtNDY2NDI_858e685d-b2ff-468d-8cdb-6a2e2cf93f16">68,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTAtMy0xLTEtNDY2NDI_aa10348d-1d08-4a0f-9a39-199934702884">8,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTEtMS0xLTEtNDY2NDI_3d627fdb-02d9-4230-ac6d-b1201a4f4ae6">20,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTEtMy0xLTEtNDY2NDI_188739e1-d0ad-4cd2-add9-81f07d905511">3,313</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTItMS0xLTEtNDY2NDI_fcfa6ef3-8186-4ff7-a76b-ff4770a2701c">6,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTItMy0xLTEtNDY2NDI_477a14d4-367c-4ea5-8f58-4346736a4b70">1,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTMtMS0xLTEtNDY2NDI_62a40a61-f337-41f4-bd23-4f0e5c0af805">27,279</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTMtMy0xLTEtNDY2NDI_4bfb8945-be01-4de6-995e-12b64d5192ec">3,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTQtMS0xLTEtNDY2NDI_1efa19c0-da98-437b-8a67-a67605528620">99,135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTQtMy0xLTEtNDY2NDI_9b51faa0-519f-4f37-b8ab-3bccbae5d384">54,926</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTUtMS0xLTEtNDY2NDI_5cb03aa3-2f7f-4222-92b5-75a4fd357452">1,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTUtMy0xLTEtNDY2NDI_2702e40c-71e7-419b-a912-7eda377e97cc">580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net cash (used in) provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTYtMS0xLTEtNDY2NDI_8088e1f3-785e-46c3-9afe-71bf9da63aec">107,187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTYtMy0xLTEtNDY2NDI_8dd92aca-03d9-4926-8063-21005b632c06">1,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTktMS0xLTEtNDY2NDI_a5cdd201-01fb-4cc1-bb4a-084eaba569ec">66,225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTktMy0xLTEtNDY2NDI_bf868e38-9573-4df3-a28a-d5c1ecf83ed2">10,530</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMjAtMS0xLTEtNDY2NDI_92aed93c-14ab-41b2-9d40-b0015249c056">192,528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMjAtMy0xLTEtNDY2NDI_952faa29-8008-40d6-aa82-c794562fe071">148,391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from maturities of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMjEtMS0xLTEtNDY2NDI_feb979af-4a9b-4580-89eb-f927c0dad596">141,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMjEtMy0xLTEtNDY2NDI_802a7469-616a-4df1-b012-2a05601be849">55,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMjItMS0xLTEtNDY2NDI_276f8c1f-d926-4e7a-9ba1-b88a256dbec1">116,759</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMjItMy0xLTEtNDY2NDI_b921d1a2-a11a-439d-866f-6350b91065de">103,140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from the exercises of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMjUtMS0xLTEtNDY2NDI_f55c30d4-0060-4546-9641-19de32939a91">1,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMjUtMy0xLTEtNDY2NDI_dade8206-17a6-4cd5-bb79-ab3a4411fcd3">3,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from the sale of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:ProceedsFromContributedCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMjYtMS0xLTEtNDY2NDI_15a6cedd-4c64-4e53-babc-af57b2541fa3">250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt 0 8.5pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:ProceedsFromContributedCapital" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMjYtMy0xLTEtNDY2NDI_4ec58a45-88c8-4dba-b4ea-2c18819c50c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMjctMS0xLTEtNDY2NDI_2bfc7bd3-bcd1-4523-bfa5-62c04501399d">251,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMjctMy0xLTEtNDY2NDI_f9e7c8aa-69d7-4d11-a431-ca859b24a3df">3,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMjktMS0xLTEtNDY2NDI_28c0530e-e438-407e-a4e4-feac24ebe3d8">27,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMjktMy0xLTEtNDY2NDI_615903fe-1b1f-4956-9b71-baed07dccb3e">97,988</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Effect of exchange rate on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMzEtMS0xLTEtNDY2NDI_97fdd19a-7438-4129-872a-534fdb232964">196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMzEtMy0xLTEtNDY2NDI_8c27354a-8adf-4389-b811-a507a67a90dd">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH:</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">BEGINNING OF PERIOD</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMzMtMS0xLTEtNDY2NDI_2658a225-2e7b-44ad-9e30-3d4847cfc220">108,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iadfd6b159c9446f4ad12848ede62bfea_I20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMzMtMy0xLTEtNDY2NDI_aa78d23d-c08e-42c6-8f25-aafcadf83ab6">184,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">END OF PERIOD</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMzQtMS0xLTEtNDY2NDI_6e8865c3-b4c4-427f-8b35-721dd15f5a2c">134,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2b1b88ad17754cd781fd0282509470f4_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMzQtMy0xLTEtNDY2NDI_04f2bf41-bf1c-4475-9bb4-16428df86636">86,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Supplementary disclosures:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMzctMS0xLTEtNDY2NDI_f6fabe42-551c-445f-83fa-e5048cc9848b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMzctMy0xLTEtNDY2NDI_6d5fef60-d576-4a91-a0fb-f936061c2669">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income taxes (paid) refunded</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMzgtMS0xLTEtNDY2NDI_26e3ff19-aa5d-48b4-92d5-1874dda11684">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMzgtMy0xLTEtNDY2NDI_fae8541f-04c2-4b21-a30e-a4630031197b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_31"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. <ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfNjY0Mg_75f75db6-d7e5-405a-a73d-5dc3e86ecfc8" continuedAt="i11035be6c6b54a969f7f01fda718f631" escape="true">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i11035be6c6b54a969f7f01fda718f631" continuedAt="i15768ef7b9c0425990b3b10be8c66f9a"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Recent Developments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead Pharmaceuticals, Inc. and its subsidiaries (referred to herein collectively as the &#8220;Company&#8221;) are primarily engaged in developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company&#8217;s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#8220;RNAi&#8221;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. The Company&#8217;s RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. </span></div><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="arwr:ScheduleOfCurrentProductsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfNjY0NA_115db421-049b-4d33-a7d6-ba445937362e" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s current pipeline:</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"></td><td style="width:16.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.316%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Therapeutic Area</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Stage</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Product Rights</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cardiometabolic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-APOC3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2b and Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-ANG3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2b</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Olpasiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amgen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pulmonary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-ENAC2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-Clinical</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-RAGE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-MUC5AC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-MMP7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liver</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK-4532990 (formerly ARO-HSD)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fazirsiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Takeda and Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">JNJ-3989</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Janssen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">HZN-457 (formerly ARO-XDH)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Horizon</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-C3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-PNPLA3 (formerly JNJ-75220795)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Muscle</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-DUX4</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-Clinical</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CNS</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-SOD1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-Clinical</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates lab facilities in San Diego, California and Madison, Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company&#8217;s principal executive offices are located in Pasadena, California.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first half of fiscal 2023, the Company continued to develop and advance its pipeline and partnered candidates. Several key recent developments include: </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">announced interim results from ARO-RAGE administration in Part 1 of the ongoing Phase 1/2 study in normal healthy volunteers which included:</span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">reductions in soluble RAGE (sRAGE) as measured in serum after two doses on Day 1 and Day 29;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">duration of pharmacologic effect persisted for at least 6 weeks after the second administration of the 92 mg does with further follow up ongoing;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">reduction in sRAGE as measured in bronchoalveolar lavage fluid (BALF) at Day 31 after a single dose;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">reduction in in serum sRAGE were observed after a single dose;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">the pooled placebo groups experienced a mean sRAGE increase of 8% in BALF and a mean decrease of 1% serum</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">safety and tolerability;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expanded TRiM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform to include an optimized intrathecal administration for central nervous system (CNS) delivery with distribution throughout the brain and in all relevant brain cell types. The first development candidate to utilize this new delivery platform, ARO-SOD1, is anticipated to have a clinical trial </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i15768ef7b9c0425990b3b10be8c66f9a" continuedAt="i56be4d083c7c4cc4b9fc64f8e10b6050"><div style="margin-top:6pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">application (CTA) filing in the third quarter of 2023 to begin clinical studies. In preclinical studies, ARO-SOD1 achieved 95% spinal cord tissue mRNA knockdown after a single intrathecal dose in human SOD1 transgenic rats and maintained greater than 80% spinal cord tissue mRNA knockdown three months after a single intrathecal dose in non-human primates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">dosed the first patient in Takeda&#8217;s Phase 3 REDWOOD clinical study of Fazirsiran for the treatment of alpha-1 antitrypsin deficiency associated liver diseases, triggering a $<ix:nonFraction unitRef="usd" contextRef="i43a3ecb8edc343d68a3d398bc46eaa91_I20230331" decimals="-5" name="arwr:MilestonePaymentReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfMzI5ODUzNDkwNTg0Ng_960b4608-1095-4796-8a05-e7185838b7dd">40.0</ix:nonFraction>&#160;million milestone payment to the Company which is expected to be paid in the third quarter of fiscal 2023;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">dosed the first patient in GSK&#8217;s Phase 2b trial of GSK4532990, formerly called ARO-HSD, an investigational RNAi therapeutic for the treatment of patients with non-alcoholic steatohepatitis (NASH), triggering a $<ix:nonFraction unitRef="usd" contextRef="ieab41d2e8cba4cf79954078e0cabd689_I20230331" decimals="-5" name="arwr:MilestonePaymentReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfMzI5ODUzNDkwNTg2MQ_fca2bdba-c460-4b2c-a5a6-79c94156e60b">30.0</ix:nonFraction>&#160;million milestone payment to the Company which is expected to be paid in the third quarter of fiscal 2023;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARO-APOC3 for reducing triglycerides in adult patients with familial chylomicronemia syndrome (FCS). ARO-APOC3 was previously granted Orphan Drug designation by the FDA and the European Union;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">announced interim results from Part 1 of AROC3-1001, an ongoing Phase 1/2 clinical study of ARO-C3,  which included;</span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">a dose-dependent reduction in serum C3, with 88% mean reduction at highest dose tested;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">a dose-dependent reduction in AH50, a marker of alternative complement pathway hemolytic activity, with 91% mean reduction at highest dose tested;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">duration of pharmacologic effect supportive of quarterly or less frequent subcutaneous dose administration;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">safety and tolerability;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">received notice from Janssen of its decision to voluntarily terminate the Research Collaboration and Option Agreement (the &#8220;Janssen Collaboration Agreement&#8221;) between the Company and Janssen. The Company regained full rights to ARO-PNPLA3, formerly called JNJ-75220795, upon termination of the Janssen Collaboration Agreement, which took effect on April 7, 2023. ARO-PNPLA3 is in Phase 1 clinical trials that are now being developed by the Company;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">initiated dosing in ARO-MMP7-1001 (NCT05537025), a Phase 1/2a single ascending dose and multiple ascending dose clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-MMP7, an investigational RNAi therapeutic designed to reduce expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF), in up to 56 healthy volunteers and in up to 21 patients with IPF;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">enrolled the first subject in a Phase 1 randomized, placebo-controlled trial to assess the safety tolerability, pharmacokinetics and pharmacodynamics of a development-stage medicine, HZN-457 (formerly ARO-XDH), which is out-licensed to Horizon, triggering a $<ix:nonFraction unitRef="usd" contextRef="ib5defaeb7ae444faaeff3aef533d099f_D20230101-20230331" decimals="-5" name="arwr:UpfrontMilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfMzI5ODUzNDg5NTY4MA_5a2ef277-0cea-40f7-8a56-47a903bae2e4">15.0</ix:nonFraction>&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2023;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">enrolled the first subject in Amgen&#8217;s Phase 3 trial of Olpasiran, triggering a $<ix:nonFraction unitRef="usd" contextRef="i98ffa0a0b1d34836b2777d4632a82434_D20230101-20230331" decimals="-5" name="arwr:UpfrontMilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfMzI5ODUzNDg5NTY5NQ_3e38f089-c47c-4d62-844f-7d8da903471f">25.0</ix:nonFraction>&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2023;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">entered into a Royalty Purchase Agreement (the &#8220;Royalty Pharma Agreement&#8221;) with Royalty Pharma Investments 2019 ICAV (&#8220;Royalty Pharma&#8221;) on November 9, 2022, pursuant to which Royalty Pharma paid $<ix:nonFraction unitRef="usd" contextRef="id543e56d77b6424381c9e219cda252c8_D20221109-20221109" decimals="-5" name="arwr:UpfrontMilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfMzI5ODUzNDg5NTcxMA_42ee71e6-a65f-47d1-8b1e-bec5a8f0d273">250.0</ix:nonFraction>&#160;million upfront (See Note 11 &#8212; Liability Related to the Sale of Future Royalties of Notes to Consolidated Financial Statements of Part I, &#8220;Item 1. Financial Statements.&#8221;);</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">announced Topline Results from SEQUOIA Phase 2 Study of Fazirsiran (formerly ARO-AAT) in patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease in which;</span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">fibrosis regression was observed in 50% of patients receiving Fazirsiran;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">median reductions of 94% of Z-AAT accumulation in the liver and mean reductions of 68% in histologic globule burden were observed;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">treatment emergent adverse events were generally well balanced between Fazirsiran and placebo groups;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">results were consistent with AROAAT-2002 open-label study previously published in The New England Journal of Medicine.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i56be4d083c7c4cc4b9fc64f8e10b6050"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Consolidated Financial Statements include the accounts of Arrowhead Pharmaceuticals, Inc. and its subsidiaries (wholly-owned subsidiaries and a variable interest entity for which the Company is the primary beneficiary). Subsidiaries refer to Arrowhead Madison, Inc., Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;), and Arrowhead Australia Pty Ltd. For subsidiaries in which the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interests retained in such entity by the respective noncontrolling party.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The financial data of the Company included herein are unaudited. In the opinion of management, all material adjustments of a normal recurring nature have been made to present fairly the Company&#8217;s financial position at March&#160;31, 2023 and the results of operations and cash flows for the periods presented. All intercompany transactions and balances have been eliminated. Certain prior period amounts have been reclassified to conform with the current period presentation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain financial information that is normally included in annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, has been omitted from the accompanying interim consolidated financial statements and related notes. Readers are urged to review the Company&#8217;s Annual Report on Form 10-K for the year ended September&#160;30, 2022 for more complete descriptions and discussions. Operating results and cash flows for the six months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the fiscal year ending September&#160;30, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s primary sources of financing have been through the sale of its securities, revenue from its licensing and collaboration agreements and the sale of certain future royalties. Research and development activities have required significant capital investment since the Company&#8217;s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company&#8217;s pipeline of drug candidates and its headcount have both expanded significantly. Additionally, significant capital investment will be required as the Company&#8217;s pipeline matures into later stage clinical trials and as the Company plans to increase its internal manufacturing capabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, the Company had $<ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfNTQ0MQ_e30b5eb8-0e31-495c-b0bd-83dccac0dc89">135.0</ix:nonFraction> million in cash and cash equivalents (including $<ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfNTQ4NA_9626c1c8-e4dc-4c23-a78b-5318396b5de5">7.3</ix:nonFraction> million in restricted cash), $<ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-5" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfNTUwOA_085ea4f5-4c58-4c59-88ed-1df0e31ca2a0">346.0</ix:nonFraction> million in short-term investments and $<ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-5" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfNTU0MQ_c72e9663-7d48-427c-ad24-a7e262fe1ec5">78.8</ix:nonFraction>&#160;million in long-term investments to fund operations. During the six months ended March&#160;31, 2023, the Company&#8217;s cash and cash equivalents and investments balance increased by $<ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-5" name="arwr:IncreaseDecreaseInCashAndInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfNTY5Nw_289cf1eb-13ea-4afd-8d20-d437b133796e">77.6</ix:nonFraction> million which was primarily due to the $<ix:nonFraction unitRef="usd" contextRef="i9f80c327fd0f46fcb58660b1d4a93b3f_D20221001-20230331" decimals="-5" name="arwr:UpfrontMilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfNTQ5NzU1ODQwOTY1_da7e4f4a-043a-4acb-a10b-d8e12b501709">250.0</ix:nonFraction>&#160;million upfront payment received from Royalty Pharma (Note 11) and $<ix:nonFraction unitRef="usd" contextRef="i77ee61f67e7d4807a1b41dc07bbe6011_D20221001-20230331" decimals="-5" name="arwr:UpfrontMilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfNTQ5NzU1ODMzNzc0_5070b3ad-0e21-4bc6-9a1c-0123201cd92b">40.0</ix:nonFraction> million in milestone payments from Horizon and Amgen, partially offset by cash used to fund its operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-8" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfMjc0ODc3OTA5MjAyMg_a1f0274a-2632-4e2d-aac5-32b7dd652899">3.6</ix:nonFraction> billion in developmental, regulatory and sales milestones, and may receive various royalties on net sales from its licensing and collaboration agreements, subject to the terms and conditions of those agreements. The revenue recognition for these collaboration agreements is discussed further in Note 2.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Significant Accounting Policies </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to the significant accounting policies disclosed in the Company&#8217;s most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2022.</span></div><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfNjY0Mw_6fdad132-25d7-4127-853b-b8655ab2992d" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no recent accounting pronouncements that have significantly impacted this Quarterly Report on Form 10-Q, beyond those disclosed in the Company&#8217;s most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2022.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMTgyMjc_0badf8f2-737b-4cb5-bbaa-42af9ead7590" continuedAt="i447957b9b5c643ba8a3f93df21dc16ba" escape="true">COLLABORATION AND LICENSE AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="i447957b9b5c643ba8a3f93df21dc16ba" continuedAt="if9b6f773f5274c1caba4e524ff564836"><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk2NzQxMg_c6f94478-7418-430c-982d-e3566dab8e5a" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of revenue recognized:</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.818%"><tr><td style="width:1.0%"></td><td style="width:33.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.555%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i15c28c33dc6b4b10bbc915f499ad8066_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfMy0yLTEtMS01MzYwMA_d40a8f07-e479-48de-b4a4-ab36a7bbde45">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia1384505727044d59609bba3ee71e812_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfMy00LTEtMS01MzYyMw_fee2bb3d-97cc-4519-a7e4-2601f9f89834">120,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iccbf1d7ac531418d9578213f88b95f24_D20221001-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfMy02LTEtMS01MzYzMw_6c596975-5df1-4676-89d3-07b5bc70af56">29,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i269e350e160c4ea6ad74071baf18573a_D20211001-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfMy04LTEtMS01MzY0Mg_61df706c-3315-4237-8e8f-2f2578496180">120,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Horizon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i60b798e3a061472cbe491224489dd4fd_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNC0yLTEtMS01MzYwMA_9fcdff37-45e8-4dc8-843e-7173f749199e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i825f9542073f4d75985f228f8558ca2e_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNC00LTEtMS01MzYyMw_09be4e36-a304-48b3-befd-5cfc8966851e">7,918</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6cd6b96847294914b272df50802b449e_D20221001-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNC02LTEtMS01MzYzMw_e747a5d7-6735-4200-bd74-0eb7e306e577">21,667</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i243b609737ea4d7eb695ad185cb74491_D20211001-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNC04LTEtMS01MzY0Mg_3dfa2ce3-bc67-4d1f-8153-a0ccd15d864f">14,585</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Takeda</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i082bc8d425934d3a809c260cf43f2098_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNS0yLTEtMS01MzYwMA_64aac0cc-ee4a-47a4-834c-34e8ce6c9ba2">116,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4920d739b45b45edbeea74ee7c5f1a5e_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNS00LTEtMS01MzYyMw_f0f49a0c-6478-4409-8f9a-77294a1e27cc">20,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i233b4f8cd26e4e908334e04db7e1672d_D20221001-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNS02LTEtMS01MzYzMw_946aa4cd-8606-4d1f-a3d8-0d42ab8b5b0b">132,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i36bee665f89b4b8bb8cf30907efbb23d_D20211001-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNS04LTEtMS01MzY0Mg_90897013-f67a-42ec-9498-d681c6660592">41,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Janssen</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i41d99afba4a04457ae92c14f6d2288e4_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNi0yLTEtMS01MzYwMA_3d8366d2-804f-4aa0-83d1-aaec033543c9">111</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic2d18d01d1ba459c819e19a2f426f844_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNi00LTEtMS01MzYyMw_5c7a4b01-6e74-4f39-b7b3-ea3a5c5969e4">3,066</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i64ad46fbf63445bbab41c28a191959cc_D20221001-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNi02LTEtMS01MzYzMw_0529aa6a-069c-461e-9053-06d1a69fec73">355</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8cddef21baaf4bf9bfe75fd694a89239_D20211001-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNi04LTEtMS01MzY0Mg_631d2033-2a68-496f-bf64-d3a8765a5045">3,066</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amgen</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4a36c9033466491aa13ecfd0d8b71fd8_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNy0yLTEtMS01MzYwMA_52ce82ea-77ee-4d10-bb9f-e769ec457eee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i66bbdb26e9194e4fbb451ef54849270f_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNy00LTEtMS01MzYyMw_f72673db-3b1d-43e6-ac41-30a147ebc202">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iee762a06741d4eb7a18728ac4c642e6b_D20221001-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNy02LTEtMS01MzYzMw_7599cc38-1d97-44cb-9432-2543838cf356">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iaeb9254172ee4a51a8dd7073ba5f92c6_D20211001-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNy04LTEtMS01MzY0Mg_7fa28eec-b3a9-4207-bbd7-4c13cf770579">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfOC0yLTEtMS01MzYwMA_5ee0a318-ee98-4e75-b3d7-f6c959e96727">146,267</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfOC00LTEtMS01MzYyMw_c9dc324d-45be-4b3a-8884-a8274edf28de">151,805</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfOC02LTEtMS01MzYzMw_23e5ea76-0b60-48b0-b975-c74dce1a0269">208,813</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfOC04LTEtMS01MzY0Mg_5f3d553d-46a5-4488-a41b-73a022af09c4">179,244</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk2NzQxMw_df43b9c8-62c8-4a42-a526-8706d50ce387" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance of receivables and contract liabilities related to the Company&#8217;s collaboration and license agreements:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.696%"><tr><td style="width:1.0%"></td><td style="width:57.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Receivables included in accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOmEzZjg0NzllNzQ1MjQ4ZTQ4MzQ2MTBhZWVlY2NhNzM5L3RhYmxlcmFuZ2U6YTNmODQ3OWU3NDUyNDhlNDgzNDYxMGFlZWVjY2E3MzlfMi0yLTEtMS01Mzc0Nw_37f0768e-2b28-41d1-bcf8-58e587885d75">70,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOmEzZjg0NzllNzQ1MjQ4ZTQ4MzQ2MTBhZWVlY2NhNzM5L3RhYmxlcmFuZ2U6YTNmODQ3OWU3NDUyNDhlNDgzNDYxMGFlZWVjY2E3MzlfMi00LTEtMS02MDQwNQ_ec3b5236-5217-4fbf-86d9-f61c86a05503">6,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contract liabilities included in deferred revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOmEzZjg0NzllNzQ1MjQ4ZTQ4MzQ2MTBhZWVlY2NhNzM5L3RhYmxlcmFuZ2U6YTNmODQ3OWU3NDUyNDhlNDgzNDYxMGFlZWVjY2E3MzlfMy0yLTEtMS01Mzc0Nw_6ee33f7c-1bda-4921-8b31-58c9018a03cb">30,914</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOmEzZjg0NzllNzQ1MjQ4ZTQ4MzQ2MTBhZWVlY2NhNzM5L3RhYmxlcmFuZ2U6YTNmODQ3OWU3NDUyNDhlNDgzNDYxMGFlZWVjY2E3MzlfMy00LTEtMS02MDQwMg_35960ab8-731e-4a98-97eb-dc63d8ab055e">130,049</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Glaxosmithkline Intellectual Property (No. 3) Limited (&#8220;GSK&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 22, 2021, GSK and the Company entered into an Exclusive License Agreement (the &#8220;GSK License Agreement&#8221;). Under the GSK License Agreement, GSK has received an exclusive license for GSK-4532990 (formerly ARO-HSD). The exclusive license is worldwide with the exception of greater China, for which the Company retained rights to develop and commercialize GSK-4532990. The Company completed its Phase 1/2 study of GSK-4532990, and GSK is wholly responsible for all clinical development and commercialization of GSK-4532990 in its territory. Under the terms of the agreement, the Company has received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i691de1d520624cd1b1ffd39dc3bdc01d_I20211122" decimals="-5" name="arwr:MilestonePaymentEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzUzMQ_1b37ff2d-319b-45f4-88f5-8025a7a2c102">120.0</ix:nonFraction>&#160;million and recognized an additional $<ix:nonFraction unitRef="usd" contextRef="i691de1d520624cd1b1ffd39dc3bdc01d_I20211122" decimals="-5" name="arwr:MilestonePaymentReceivableAtStartOfPhaseTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzU0Nw_cc8abd13-6d66-4bf2-8de8-0430fbde80b5">30.0</ix:nonFraction>&#160;million at the start of a Phase 2 trial. The Company is also eligible for an additional payment of $<ix:nonFraction unitRef="usd" contextRef="i691de1d520624cd1b1ffd39dc3bdc01d_I20211122" decimals="-5" name="arwr:MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzU2Mg_506db687-80c4-43f3-af21-10ba7cf8de96">100.0</ix:nonFraction>&#160;million upon achieving a successful Phase 2 trial readout and the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to the Company of up to $<ix:nonFraction unitRef="usd" contextRef="i3271e7a0f6144468b240efa725ae2d39_I20211122" decimals="-5" name="arwr:CommercialMilestonePaymentsAtFirstCommercialSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzU3OA_4076c555-df74-477c-91f1-5418eda36931">190.0</ix:nonFraction>&#160;million at first commercial sale, and up to $<ix:nonFraction unitRef="usd" contextRef="i3271e7a0f6144468b240efa725ae2d39_I20211122" decimals="-5" name="arwr:SalesRelatedMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzU5NA_ec349108-315c-486c-bf17-3e26808e19da">590.0</ix:nonFraction>&#160;million in sales-related milestone payments. The Company is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the GSK License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibility to complete the Phase 1/2 study (the &#8220;GSK R&amp;D Services&#8221;). Due to the specialized and unique nature of the GSK R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. Beyond the GSK R&amp;D Services, which are the responsibility of the Company, GSK will be responsible for managing future clinical development and commercialization in its territory. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price totaled $<ix:nonFraction unitRef="usd" contextRef="i237d8e5c7b234033bc777c8a0a3b0d52_D20211122-20211122" decimals="INF" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzYxMA_d21931d5-4366-4c63-9e61-f94c5b7437f3">120.0</ix:nonFraction>&#160;million, including the upfront payment, which was collected in January 2022. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company has allocated the total $<ix:nonFraction unitRef="usd" contextRef="i237d8e5c7b234033bc777c8a0a3b0d52_D20211122-20211122" decimals="INF" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzY0MA_d21931d5-4366-4c63-9e61-f94c5b7437f3">120.0</ix:nonFraction>&#160;million initial transaction price to its one distinct performance obligation for the GSK-4532990 license and the associated GSK R&amp;D Services. As the Company has completed its performance obligation related to this agreement, the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i237d8e5c7b234033bc777c8a0a3b0d52_D20211122-20211122" decimals="INF" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzY1Nw_d21931d5-4366-4c63-9e61-f94c5b7437f3">120.0</ix:nonFraction>&#160;million was fully recognized during the six months ended March 31, 2022. Further, GSK dosed the first patient in a Phase 2 trial in March 2023, triggering a $<ix:nonFraction unitRef="usd" contextRef="ieab41d2e8cba4cf79954078e0cabd689_I20230331" decimals="-5" name="arwr:MilestonePaymentReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzY2MA_b3be8a7b-b6ee-4d41-a876-03b7e836d553">30.0</ix:nonFraction>&#160;million milestone payment to the Company which is expected to be paid in the third quarter of fiscal 2023. There were <ix:nonFraction unitRef="usd" contextRef="ieab41d2e8cba4cf79954078e0cabd689_I20230331" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfNDk0NzgwMjQxMDY5OQ_1e0c2d53-220a-490a-a215-7e2895704dc7"><ix:nonFraction unitRef="usd" contextRef="ieab41d2e8cba4cf79954078e0cabd689_I20230331" decimals="INF" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfNDk0NzgwMjQxMDY5OQ_35b5ac89-f84d-43e9-ae74-31ec9532adce">no</ix:nonFraction></ix:nonFraction> contract assets and liabilities recorded as of March&#160;31, 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Horizon Therapeutics Ireland DAC (&#8220;Horizon&#8221;) </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021, Horizon and the Company entered into a collaboration and license agreement (the &#8220;Horizon License Agreement&#8221;). Under the terms of the Horizon License Agreement, Horizon received a worldwide exclusive license for HZN-457, a clinical-stage medicine being developed by Horizon as a potential treatment for people with uncontrolled gout. The Company conducted all activities through the preclinical stages of development of, and Horizon is now wholly </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if9b6f773f5274c1caba4e524ff564836" continuedAt="iecd1d09e0d634b58955ff0cab45fae52"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">responsible for clinical development and commercialization of, HZN-457. The Company received $<ix:nonFraction unitRef="usd" contextRef="i3d90a2de7f4e49f596cb460bdc10f3ca_I20210731" decimals="-5" name="arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzY3NQ_f75f8f1c-b4d3-40c2-9381-96346d7f3c71">40.0</ix:nonFraction>&#160;million as an upfront payment in July 2021 and an additional $<ix:nonFraction unitRef="usd" contextRef="i882e29fc588d4797a46ee5a39680339a_I20230131" decimals="-5" name="arwr:MilestonePaymentEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzY5MA_bf2e911f-a671-40ba-98ab-4d986e364a3d">15.0</ix:nonFraction>&#160;million upon Horizon&#8217;s initiation of a Phase 1 clinical trial in January 2023, and is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i59d79924ebeb447c886bc284402909d2_I20210618" decimals="-5" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzcwNQ_57d86c61-1d3b-4aa7-9f9e-82a2e28b4e37">645.0</ix:nonFraction>&#160;million in additional potential development, regulatory and sales milestones. The Company is also eligible to receive royalties in the low- to mid-teens range on net product sales. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Horizon License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibilities to conduct all activities through the preclinical stages of development of HZN-457 (the &#8220;Horizon R&amp;D Services&#8221;). Due to the specialized and unique nature of these Horizon R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented <ix:nonFraction unitRef="bundle" contextRef="i82576571409c4b7f9b8bb80fb3c9a00e_D20210618-20210618" decimals="INF" name="arwr:NumberOfDistinctBundle" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzcyMA_eabe34fe-629c-4147-a901-26cdca7c3301">one</ix:nonFraction> distinct bundle and, thus, <ix:nonFraction unitRef="obligation" contextRef="i82576571409c4b7f9b8bb80fb3c9a00e_D20210618-20210618" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzcyMQ_7b57bb33-2a0f-402e-b932-0ef90f58c94d">one</ix:nonFraction> performance obligation. Beyond the Horizon R&amp;D Services, which are the responsibility of the Company, Horizon is responsible for managing future clinical development and commercialization of HZN-457. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price totaled $<ix:nonFraction unitRef="usd" contextRef="i8b82750996f043c38f0f0871c175613b_D20210618-20210618" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzczNw_a7ecebe4-ad54-4f66-9f67-dca7faaaf0af">40.0</ix:nonFraction>&#160;million, including the upfront payment. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company allocated the total $<ix:nonFraction unitRef="usd" contextRef="i8b82750996f043c38f0f0871c175613b_D20210618-20210618" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1Mzc2NQ_a7ecebe4-ad54-4f66-9f67-dca7faaaf0af">40.0</ix:nonFraction>&#160;million initial transaction price to its <ix:nonFraction unitRef="obligation" contextRef="i8b82750996f043c38f0f0871c175613b_D20210618-20210618" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1Mzc2Nw_b3921d03-af37-4afa-9433-a9ef949642a1">one</ix:nonFraction> distinct performance obligation for the HZN-457 license and the associated Horizon R&amp;D Services. Revenue was recognized on a straight-line basis over the timeframe for completing the Horizon R&amp;D Services. The Company determined that the straight-line basis was appropriate as its efforts were expended evenly over the course of completing its performance obligation. Further, Horizon enrolled the first subject in December 2022 in a Phase 1 randomized, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HZN-457, triggering a $<ix:nonFraction unitRef="usd" contextRef="ib5defaeb7ae444faaeff3aef533d099f_D20230101-20230331" decimals="-5" name="arwr:UpfrontMilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1Mzc3OA_daad74ad-617a-4587-834a-e425fa28c88d">15.0</ix:nonFraction>&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2023. There were <ix:nonFraction unitRef="usd" contextRef="i711eaa11f2714195b20f945bbd192ec3_I20230331" decimals="INF" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfNTQ5NzU1ODM0NjI0_b863dd36-9d2a-4f76-bef0-65b1dd06c7af"><ix:nonFraction unitRef="usd" contextRef="i711eaa11f2714195b20f945bbd192ec3_I20230331" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfNTQ5NzU1ODM0NjI0_f0a41a0b-aa83-4e91-94da-7f3aa5151eaf">no</ix:nonFraction></ix:nonFraction> contract assets and liabilities recorded as of March&#160;31, 2023.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 7, 2020, Takeda and the Company entered into an Exclusive License and Co-Funding Agreement (the &#8220;Takeda License Agreement&#8221;). Under the Takeda License Agreement, Takeda and the Company will co-develop its Fazirsiran program, the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, Fazirsiran, if approved, will be co-commercialized under a 50/50 profit sharing structure. Outside the United States, Takeda will lead the global commercialization strategy and will receive an exclusive license to commercialize Fazirsiran, while the Company will be eligible to receive tiered royalties of <ix:nonFraction unitRef="number" contextRef="idadf7ab9198248d8be15ad2d0459d433_D20201007-20201007" decimals="2" name="arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1Mzc5Mw_245a6bcc-e221-4146-b635-3e360e68fcdb">20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ia6534598f573472fa49c88f3543fef50_D20201007-20201007" decimals="2" name="arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1Mzc5OA_6ed996d2-5e84-4c42-ab9c-efa29d5634f9">25</ix:nonFraction>% on net sales. The Company received $<ix:nonFraction unitRef="usd" contextRef="i3776d7ed0187438ba605de53d95d0524_I20210131" decimals="-5" name="arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzgwMw_070555fc-5dee-43d9-8b0f-9017b5174fcf">300.0</ix:nonFraction>&#160;million as an upfront payment in January 2021, recognized an additional $<ix:nonFraction unitRef="usd" contextRef="i43a3ecb8edc343d68a3d398bc46eaa91_I20230331" decimals="-5" name="arwr:MilestonePaymentEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzgzNQ_7f25f1cc-281e-42a1-952a-b54ed397a2c6">40.0</ix:nonFraction>&#160;million upon Takeda&#8217;s initiation of a Phase 3 clinical study in March 2023, and is eligible to receive potential development, regulatory and commercial milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i5df73d39e5de43059a0154473c1fc57f_I20230331" decimals="-5" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzgxOQ_44360422-fee6-46be-bfb8-c173e43ff308">527.5</ix:nonFraction>&#160;million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Takeda License Agreement, the Company identified <ix:nonFraction unitRef="obligation" contextRef="i2220001e31ea4ab6af2ee0d3e5c38388_D20201007-20201007" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk2NzQxNA_65e58ef6-48f0-4504-8471-a8c4a1dc1f25">one</ix:nonFraction> distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of Fazirsiran drug product is completed and delivered to Takeda (the &#8220;Takeda R&amp;D Services&#8221;). Due to the specialized and unique nature of these Takeda R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent <ix:nonFraction unitRef="bundle" contextRef="i2220001e31ea4ab6af2ee0d3e5c38388_D20201007-20201007" decimals="INF" name="arwr:NumberOfDistinctBundle" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk2NzQyMg_8f1b863a-48bb-483b-bf8c-819ece79fbee">one</ix:nonFraction> distinct bundle and, thus, <ix:nonFraction unitRef="obligation" contextRef="i2220001e31ea4ab6af2ee0d3e5c38388_D20201007-20201007" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk2NzQyMw_24eda9ef-fe4b-4bd6-8dab-4c40db2f555d">one</ix:nonFraction> performance obligation. Beyond the Takeda R&amp;D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States. Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the 50/50 profit sharing structure within the United States. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts are recorded as research and development expenses or general and administrative expenses, as appropriate.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has allocated the total $<ix:nonFraction unitRef="usd" contextRef="i2220001e31ea4ab6af2ee0d3e5c38388_D20201007-20201007" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1Mzg1MA_323a9fe4-56d9-4e3f-8ac5-567082a5d871">300.0</ix:nonFraction>&#160;million initial transaction price to its one distinct performance obligation for the Fazirsiran license and the associated Takeda R&amp;D Services. Revenue is recognized using a proportional performance method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). The Company previously expected these clinical trials to extend to September 2025 in order to demonstrate long term safety and efficacy in the open label extension part of the studies; however, Takeda now intends to initiate a new open label extension (OLE) study available to patients participating in these Phase 2 studies that will initiate as early as July 2023. Based on this new information, patients enrolled in the SEQUOIA and AROAAT2002 studies are expected to complete their Phase 2 study visits between June 2023 and June 2024, shortening the Company&#8217;s performance obligation. As a result, effective the second quarter of fiscal 2023, the Company changed its estimates of the revenue recognition to better reflect these newly estimated proportional performance periods. The effect of these changes in estimates resulted in accelerated revenue by $<ix:nonFraction unitRef="usd" contextRef="iee5b7af13da443ca9a9e86096b5e0768_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfNDk0NzgwMjQxMjE1MQ_0ce95761-1b96-422f-9681-7c4a2fd8d373"><ix:nonFraction unitRef="usd" contextRef="i587c88b790cf4957a1f2e9ff83d976c3_D20221001-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfNDk0NzgwMjQxMjE1MQ_303125b1-c891-4b5f-8b7b-3a95092e193f">61.4</ix:nonFraction></ix:nonFraction>&#160;million, or $<ix:nonFraction unitRef="usdPerShare" contextRef="iee5b7af13da443ca9a9e86096b5e0768_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfNDk0NzgwMjQxMjE2Ng_10376751-a99e-4182-a060-fcb63a811d71"><ix:nonFraction unitRef="usdPerShare" contextRef="i587c88b790cf4957a1f2e9ff83d976c3_D20221001-20230331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfNDk0NzgwMjQxMjE2Ng_3e9170b6-e3c1-4b43-9671-595c85f394d4">0.57</ix:nonFraction></ix:nonFraction> per share (diluted) for </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iecd1d09e0d634b58955ff0cab45fae52" continuedAt="i1c35713c4e094837b0786b51b5e3786c"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each of the three and six months ended March&#160;31, 2023. There were $<ix:nonFraction unitRef="usd" contextRef="i5a2e6ffc46c94788ab81d4390fdee866_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfNTQ5NzU1ODUxNjY0_ce4e5666-31dc-4808-81f6-68eacab06842">30.9</ix:nonFraction> million of contract liabilities recorded as deferred revenue, of which $<ix:nonFraction unitRef="usd" contextRef="i5a2e6ffc46c94788ab81d4390fdee866_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMjc0ODc3OTE0MTU5OA_49a0d6a3-f222-4cb1-a8fd-82b2e570c8a0">29.8</ix:nonFraction> million  was classified as current as of March&#160;31, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, Takeda dosed the first patient in the Phase 3 REDWOOD clinical study of Fazirsiran, triggering a $<ix:nonFraction unitRef="usd" contextRef="i43a3ecb8edc343d68a3d398bc46eaa91_I20230331" decimals="-5" name="arwr:MilestonePaymentReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1Mzg4MA_42b095e5-5de3-4f78-b8b8-0d77155f202d">40.0</ix:nonFraction>&#160;million milestone payment to the Company which is expected to be paid in the third quarter of fiscal 2023. The Company also recorded $<ix:nonFraction unitRef="usd" contextRef="iecaadb3d3d994f3383d71ba13d40433e_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1Mzg2Ng_4537c17f-15f8-4437-94d8-3d0e2a7702ba">9.4</ix:nonFraction>&#160;million as accrued expenses as of March&#160;31, 2023 that was primarily driven by co-development and co-commercialization activities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 3, 2018, Janssen, part of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, and the Company entered into a License Agreement (the &#8220;Janssen License Agreement&#8221;) and the Janssen Collaboration Agreement. The Company also entered into a stock purchase agreement with JJDC, Inc. (&#8220;JJDC&#8221;), Johnson &amp; Johnson&#8217;s venture capital arm (the &#8220;JJDC Stock Purchase Agreement&#8221;). Under the Janssen License Agreement, Janssen received a worldwide, exclusive license to the Company&#8217;s JNJ-3989 (ARO-HBV) program, the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. Beyond the Company&#8217;s Phase 1/2 study of JNJ-3989 (ARO-HBV), which the Company was responsible for completing, Janssen is wholly responsible for clinical development and commercialization of JNJ-3989 (ARO-HBV). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Janssen License Agreement, the Company has received $<ix:nonFraction unitRef="usd" contextRef="i66aef91f08484848847318e56657242a_D20181003-20181003" decimals="-5" name="arwr:CashReceivedAsDueUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1Mzg5NQ_b523835b-6ed1-439b-b61a-e4dc529c1ca3">175.0</ix:nonFraction>&#160;million as an upfront payment, $<ix:nonFraction unitRef="usd" contextRef="id0ed9d7c6a704f9c9edc96118a125065_D20181003-20181003" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzkxMQ_8f98d0f3-f7cc-46e0-982c-c452a553bb91">75.0</ix:nonFraction>&#160;million in the form of an equity investment by JJDC in the Company&#8217;s common stock under the JJDC Stock Purchase Agreement, and milestone and option payments totaling $<ix:nonFraction unitRef="usd" contextRef="i82a308c1dd274f2e8e0a6f7e4ad9c114_I20181003" decimals="-5" name="arwr:MilestonePaymentEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzkyNg_627c6dd6-96bf-4190-ade3-906caabafec0">73.0</ix:nonFraction>&#160;million, and the Company may receive up to $<ix:nonFraction unitRef="usd" contextRef="i076faa12769447e9be5b69d21b9bf0ed_I20181003" decimals="INF" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1Mzk0MQ_208c9d33-9530-4823-8e57-03fe142c446e">0.8</ix:nonFraction> billion in development and sales milestone payments for the Janssen License Agreement. The Company is further eligible to receive tiered royalties on product sales up to mid-teens under the Janssen License Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 7, 2023, Janssen voluntarily terminated the Janssen Collaboration Agreement. Upon termination, the Company regained full rights to ARO-PNPLA3, formerly called JNJ-75220795, the only candidate for which Janssen had exercised its option.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, Janssen exercised its option right for JNJ-75220795 (ARO-JNJ1), which resulted in a $<ix:nonFraction unitRef="usd" contextRef="i2c30ebd6d9024acdba5d304d894ee2a4_I20210531" decimals="-5" name="arwr:MilestonePaymentEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1NDEwNA_9d3fdaeb-0e07-48f8-8f75-334efcad6f95">10.0</ix:nonFraction>&#160;million milestone payment to the Company. This $<ix:nonFraction unitRef="usd" contextRef="ia34c6824ddbd426ea939bb344ff03287_I20210930" decimals="-5" name="arwr:MilestonePaymentEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1NDExOQ_178ec5cf-0d55-43e7-9f85-a506dd4c8b17">10.0</ix:nonFraction>&#160;million milestone payment was recognized entirely as of September 30, 2021. The Company conducted its discovery, optimization and preclinical research and development of JNJ-75220795 (ARO-JNJ1), ARO-JNJ2, and ARO-JNJ3 under the Janssen Collaboration Agreement. All costs and labor hours spent by the Company have been entirely funded by Janssen. There was <ix:nonFraction unitRef="usd" contextRef="i0cf61607a2de42a1b21f3f65fa7d4921_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1NDEzMw_1e0d5c21-56e5-4134-b1d1-3af4350954e1"><ix:nonFraction unitRef="usd" contextRef="i69f05a11406a48f2a92c762736aedab3_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1NDEzMw_a009d228-0725-45e1-b211-4abc7811344e">no</ix:nonFraction></ix:nonFraction> revenue recorded associated with the Company&#8217;s agreement with Janssen for the six months ended March 31, 2023 and 2022. There were <ix:nonFraction unitRef="usd" contextRef="i6a26ad8e16504e72b2689ba702142228_I20230331" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1NDEzNA_31863aef-3bc8-46b9-a9a8-ed809068ceeb"><ix:nonFraction unitRef="usd" contextRef="i6a26ad8e16504e72b2689ba702142228_I20230331" decimals="INF" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1NDEzNA_e88a1895-ce2b-429c-b8fe-53d51fe8476e">no</ix:nonFraction></ix:nonFraction> contract assets and liabilities recorded as of March 31, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Janssen License Agreement, the Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibility to complete the Phase 1/2 study of JNJ-3989 (ARO-HBV) and the Company&#8217;s responsibility to ensure certain manufacturing of JNJ-3989 (ARO-HBV) drug product is completed and delivered to Janssen (the &#8220;Janssen R&amp;D Services&#8221;). Due to the specialized and unique nature of these Janssen R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the transaction price totaled approximately $<ix:nonFraction unitRef="usd" contextRef="ib6ca215027754381a471291a60f53443_D20181003-20181003" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1Mzk3OA_409dac45-11fb-4cfe-adaa-9fe820e4c1ea">252.7</ix:nonFraction>&#160;million, which includes the upfront payment, the premium paid by JJDC for its equity investment in the Company, two $<ix:nonFraction unitRef="usd" contextRef="i497a7ae1faa04b0b9671b12bf3055d80_I20181003" decimals="-5" name="arwr:MilestonePaymentEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1Mzk5NA_575e847d-e0af-4889-9077-eab108f38ac3">25.0</ix:nonFraction>&#160;million milestone payments related to JNJ-3989 (ARO-HBV), and estimated payments for reimbursable Janssen R&amp;D Services to be performed. The Company has allocated the total $<ix:nonFraction unitRef="usd" contextRef="ib6ca215027754381a471291a60f53443_D20181003-20181003" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1NDAwOQ_1bc3381f-1955-4b82-96be-a3637e89ce8c">252.7</ix:nonFraction>&#160;million initial transaction price to its one distinct performance obligation for the JNJ-3989 (ARO-HBV) license and the associated Janssen R&amp;D Services. The Company recognized this transaction price in its entirety as of September 30, 2021, as its performance obligations were substantially completed. Future milestones and royalties achieved will be recognized in their entirety when earned. There were <ix:nonFraction unitRef="usd" contextRef="ibd242108c98b440c9d40f8441267573b_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1NDAyNA_48d66b0e-84c7-4a88-a12a-a1e23011fa02"><ix:nonFraction unitRef="usd" contextRef="ibd242108c98b440c9d40f8441267573b_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1NDAyNA_4b2c4e45-5020-416e-aa55-bbdba42390cb">no</ix:nonFraction></ix:nonFraction> contract assets and liabilities recorded as of March 31, 2023. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Amgen Inc. (&#8220;Amgen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2016, Amgen and the Company entered into <ix:nonFraction unitRef="agreement" contextRef="i57ec6b70a6104026b8b41cb652df4ebb_I20160928" decimals="INF" name="arwr:NumberOfAgreements" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMTQzODg_25f17bc8-245e-4260-9cc0-04146c1d8eae">two</ix:nonFraction> collaboration and license agreements and a common stock purchase agreement. Under the Second Collaboration and License Agreement (the &#8220;Olpasiran Agreement&#8221;), Amgen received a worldwide, exclusive license to the Company&#8217;s novel RNAi Olpasiran program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the first collaboration and license agreement (the &#8220;First Collaboration and License Agreement&#8221; or the &#8220;ARO-AMG1 Agreement&#8221;), Amgen received an option to a worldwide, exclusive license to ARO-AMG1, an RNAi therapy for an undisclosed genetically validated cardiovascular target. Under both agreements, Amgen is wholly responsible for clinical development and commercialization. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1c35713c4e094837b0786b51b5e3786c" continuedAt="i10ace0e2b0b24ade8c8fccde73d8ee73"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Olpasiran Agreement and the ARO-AMG1 Agreement, the Company has received $<ix:nonFraction unitRef="usd" contextRef="i5f5f8caf41684c1ab6c099861fb8c323_D20160928-20160928" decimals="-5" name="arwr:CashReceivedAsDueUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk2NzMxMw_2c7b54a0-390b-4bf2-8a91-60d11c1f349f">35.0</ix:nonFraction>&#160;million in upfront payments and $<ix:nonFraction unitRef="usd" contextRef="i5f5f8caf41684c1ab6c099861fb8c323_D20160928-20160928" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk2NzMyOA_decd54f7-cb02-44ac-9762-88728e0fcfef">21.5</ix:nonFraction>&#160;million in the form of an equity investment by Amgen in the Company&#8217;s common stock. Further, the Company received additional an $<ix:nonFraction unitRef="usd" contextRef="i9405e8a861cd439b9331928b2bbd63e1_I20230331" decimals="-5" name="arwr:MilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk2NzM0Mw_f0fc60aa-269c-40b9-830b-890ceb0b0c41">55.0</ix:nonFraction>&#160;million in milestone payments; $<ix:nonFraction unitRef="usd" contextRef="i75cdb28a2e3a4ffd972787e5034b8cb6_I20180930" decimals="-5" name="arwr:MilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk2NzM1OA_1959b620-4852-4121-a252-6f14ae1f2db1">10.0</ix:nonFraction>&#160;million upon Amgen&#8217;s initiation of Phase 1 study in September 2018,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ibd5f89a84f804aad9a58e70315cd9ffe_I20200731" decimals="-5" name="arwr:MilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk2NzM3Mw_d989e5d0-60fe-4e0f-b27b-8e97eeb80acc">20.0</ix:nonFraction>&#160;million upon its initiation of a Phase 2 clinical study in July 2020, and $<ix:nonFraction unitRef="usd" contextRef="i18dfb4f2db2a4e89865ff817bb733953_I20221231" decimals="-5" name="arwr:MilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk2NzM4OQ_0f1874d8-b14e-43d8-889c-3a7394c24fc3">25.0</ix:nonFraction> million upon its first subject enrollment in a Phase 3 trial in December 2022. The Company has substantially completed its performance obligations under the Olpasiran Agreement and the ARO-AMG1 Agreement. There were <ix:nonFraction unitRef="usd" contextRef="i9405e8a861cd439b9331928b2bbd63e1_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk2NzQwNA_46d06d2f-e0d2-40da-9455-cd6e47ff55c7"><ix:nonFraction unitRef="usd" contextRef="i9405e8a861cd439b9331928b2bbd63e1_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk2NzQwNA_8c2b686f-b18f-48f7-86d0-d4d144b16ae8">no</ix:nonFraction></ix:nonFraction> contract assets and liabilities recorded as of March&#160;31, 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, Royalty Pharma and the Company entered into the Royalty Pharma Agreement. In consideration for the payments under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="i1d8b33b9a77247749e39326804eed524_I20230331" decimals="-5" name="arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1NDE1MQ_15c47ca9-e7a1-47c9-a5e7-2d150c95df74">535.0</ix:nonFraction>&#160;million in remaining development, regulatory and sales milestone payments payable from Amgen and Royalty Pharma. See Note 11.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Joint Venture and License Agreement with Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2022, Visirna and the Company entered into a License Agreement (the &#8220;Visirna License Agreement&#8221;), pursuant to which Visirna received an exclusive license to develop, manufacture and commercialize four of the Company&#8217;s RNAi-based investigational cardiometabolic medicines in Greater China (including the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan). Pursuant to a Share Purchase Agreement (the &#8220;Visirna SPA&#8221;) entered into simultaneously with the Visirna License Agreement, the Company acquired a majority stake in Visirna as partial consideration for the Visirna License Agreement. Under the Visirna SPA, entities affiliated with Vivo Capital also acquired a minority stake in Visirna in exchange for $<ix:nonFraction unitRef="usd" contextRef="i1923b3729416425e9e9c1f77d0a63e84_D20220425-20220425" decimals="-5" name="us-gaap:ProceedsFromContributedCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMTc2NzU_c32bac54-961f-4ffd-8e48-7e9f338975ee">60.0</ix:nonFraction>&#160;million in upfront capital to support the operations of Visirna. As further consideration under the Visirna License Agreement, the Company is also eligible to receive potential royalties on commercial sales.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i10ace0e2b0b24ade8c8fccde73d8ee73">During the six months ended March&#160;31, 2023, the Company performed manufacturing and development work pursuant to a Clinical Supply Agreement between the parties contemplated by the Visirna License Agreement. The Company received $<ix:nonFraction unitRef="usd" contextRef="i6bca132899c842c2905496adc8f95181_D20221001-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1NDE2Nw_0733466d-5d62-41e7-8c5f-b56023c943ad">0.9</ix:nonFraction>&#160;million as consideration for this manufacturing and development work, and there were <ix:nonFraction unitRef="usd" contextRef="i6de19fc5f51b4e9888754036904b53f2_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1NDE4MA_c0b6ba94-02e5-46b3-8e8f-8be42dabe5a7"><ix:nonFraction unitRef="usd" contextRef="i6de19fc5f51b4e9888754036904b53f2_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1NDE4MA_e9c6e24d-3e00-4ea1-8c4e-00bf50ad10a2">no</ix:nonFraction></ix:nonFraction> contract assets and liabilities recorded as of March&#160;31, 2023.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RleHRyZWdpb246N2E5NDNlYWZmYjJhNDhjOTkyZDg4YjFlMjQ1OWE0NjRfNTM4_dd23f202-b2ee-4df8-bb4e-9d84328bedae" continuedAt="i8303b24d026b442bb8d20cfbf97d434b" escape="true">PROPERTY AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="i8303b24d026b442bb8d20cfbf97d434b"><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RleHRyZWdpb246N2E5NDNlYWZmYjJhNDhjOTkyZDg4YjFlMjQ1OWE0NjRfNTM5_a8aa93cd-80db-469d-bb59-4c991ef27906" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s major classes of property and equipment:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Computers, software, office equipment and furniture</span></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfMi0xLTEtMS00NjY0Mg_a1306196-ff6d-41a4-81db-eb75e254350c">2,198</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfMi0zLTEtMS00NjY0Mg_438aafb5-2b20-44dc-965b-b77d519848b7">2,182</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:Land" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfMy0xLTEtMS00NjY0Mg_a4930c6b-7aef-43e1-ac9d-9aa918cc488b">2,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:Land" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfMy0zLTEtMS00NjY0Mg_584b2883-4c8a-4a3a-9bd4-c98341bfd622">2,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Research equipment</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="arwr:ResearchEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfNC0xLTEtMS00NjY0Mg_72591d8e-15b9-49b6-afc2-546d1d06bc38">46,873</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="arwr:ResearchEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfNC0zLTEtMS00NjY0Mg_5e84da18-6e9b-42d0-a661-1ba1fe14a559">38,283</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:LeaseholdImprovementsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfNS0xLTEtMS00NjY0Mg_57b2425b-bc67-4acf-880d-dd40202e2514">42,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:LeaseholdImprovementsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfNS0zLTEtMS00NjY0Mg_250834b0-e4ee-4541-8252-9859894b3999">42,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfNi0xLTEtMS00NjY0Mg_e0c21d09-9d3d-42e2-8676-287db8a9e5c8">127,216</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfNi0zLTEtMS00NjY0Mg_0217f7a6-26c1-4821-9f83-c5cd3a88547f">56,373</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfNy0xLTEtMS00NjY0Mg_196dafe5-db84-48b7-a12d-448e9c4433ee">221,300</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfNy0zLTEtMS00NjY0Mg_09d0f609-d33f-47db-8b4c-80ae8b6143b6">141,851</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfOC0xLTEtMS00NjY0Mg_b8a3bc0e-5402-47f0-8e0e-13699e190938">36,072</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfOC0zLTEtMS00NjY0Mg_4cd41ec0-445c-496d-8900-20159280d0d4">31,554</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfOS0xLTEtMS00NjY0Mg_e0b10a66-ca48-435c-a688-42caddc895bd">185,228</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfOS0zLTEtMS00NjY0Mg_9ca47d73-2c9e-487e-ac41-cc82afa166f3">110,297</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for property and equipment for each of the three months ended March&#160;31, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RleHRyZWdpb246N2E5NDNlYWZmYjJhNDhjOTkyZDg4YjFlMjQ1OWE0NjRfMjMx_6fc7ec88-31d9-4f6a-98a5-5bea2aa7b33e"><ix:nonFraction unitRef="usd" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RleHRyZWdpb246N2E5NDNlYWZmYjJhNDhjOTkyZDg4YjFlMjQ1OWE0NjRfMjMx_6ffd94ed-4daa-43ea-ae97-790260701f64">2.2</ix:nonFraction></ix:nonFraction> million. Depreciation and amortization expense for property and equipment for the six months ended March&#160;31, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RleHRyZWdpb246N2E5NDNlYWZmYjJhNDhjOTkyZDg4YjFlMjQ1OWE0NjRfNTQ5NzU1ODE0NjMy_2ce4aecb-09d8-425f-afb3-e0b43c2aa7e4">4.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RleHRyZWdpb246N2E5NDNlYWZmYjJhNDhjOTkyZDg4YjFlMjQ1OWE0NjRfNTQ5NzU1ODE0NjE2_8cda687a-c29c-4c39-a42a-bb9b30b40a28">4.3</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in the construction in progress during the six months ended March&#160;31, 2023 was mainly due to the continuing developments of manufacturing, laboratory and office facilities in Verona, Wisconsin as well as a new laboratory and office facility in San Diego, California. See Note 7.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_40"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. <ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RleHRyZWdpb246MWRkZTQ0ZGYwM2Y5NDA2MmJjMDk5MTM5Yzk5MzA3YmNfODE_c33eb79a-77f1-4cb9-ac68-b1683b4c7be3" continuedAt="i18f856426ec4427db45e992c85bbd1dc" escape="true">INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="i18f856426ec4427db45e992c85bbd1dc"><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RleHRyZWdpb246MWRkZTQ0ZGYwM2Y5NDA2MmJjMDk5MTM5Yzk5MzA3YmNfODI_568f401c-8ceb-4b33-be08-da87c437ef86" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.265%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.265%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.265%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Short-term investments (due within one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2763c2350df84087ae24e66c081a59da_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfNS0xLTEtMS00NjY0Mg_6bf88455-b8da-4ec8-84ca-2ee04afd42c2">346,046</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2763c2350df84087ae24e66c081a59da_I20230331" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfNS0zLTEtMS00NjY0Mg_7acded8f-11e5-46b4-bd5e-6f6cba55c3bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2763c2350df84087ae24e66c081a59da_I20230331" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfNS01LTEtMS00NjY0Mg_e6dcb382-b28a-4079-8d2d-8a982095a198">3,755</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2763c2350df84087ae24e66c081a59da_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfNS03LTEtMS00NjY0Mg_0a4be636-57ef-44c1-b064-7e62e6af7329">342,291</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity certificate of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i770057db11544c24ad5a17c97ffb3a9f_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfNi0xLTEtMS00NjY0Mg_bef67d42-6c94-413c-a9cb-99dac965a583">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i770057db11544c24ad5a17c97ffb3a9f_I20230331" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfNi0zLTEtMS00NjY0Mg_de049feb-cd0b-43bd-9e99-94b35d9e826b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i770057db11544c24ad5a17c97ffb3a9f_I20230331" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfNi01LTEtMS00NjY0Mg_ada71fa6-1523-4264-b45b-832ca17be177">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i770057db11544c24ad5a17c97ffb3a9f_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfNi03LTEtMS00NjY0Mg_09c99b05-f9cd-4018-bf53-e0ce6aa07a34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total short-term investments</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfNy0xLTEtMS00NjY0Mg_bbbb5ce7-ba2a-431f-b7ca-2f2936975273">346,046</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfNy0zLTEtMS00NjY0Mg_d280d863-9c7c-417b-9d59-1c9df820e2f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfNy01LTEtMS00NjY0Mg_918eb891-05f4-4542-b7fe-49b91da94782">3,755</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfNy03LTEtMS00NjY0Mg_48f100a8-2139-44b8-bb8b-4ede925cb565">342,291</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Long-term investments (due within one through three years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2763c2350df84087ae24e66c081a59da_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfMTAtMS0xLTEtNDY2NDI_59ee8223-4118-4326-a027-1f419974031a">78,834</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2763c2350df84087ae24e66c081a59da_I20230331" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfMTAtMy0xLTEtNDY2NDI_d336351c-6eba-49ce-8d8a-0f396bd9ec22">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2763c2350df84087ae24e66c081a59da_I20230331" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfMTAtNS0xLTEtNDY2NDI_1cae1181-9f21-473b-8286-6c8f2f519666">1,709</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2763c2350df84087ae24e66c081a59da_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfMTAtNy0xLTEtNDY2NDI_bbd61950-a6a9-4f07-a327-5602705ab718">77,125</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total long-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfMTEtMS0xLTEtNDY2NDI_ee4bbf33-61b0-4cd7-939f-cf638fb6eccb">78,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfMTEtMy0xLTEtNDY2NDI_f3fd44d0-6336-4572-bd07-9d641e577487">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfMTEtNS0xLTEtNDY2NDI_e1061ee6-3753-4719-8773-997875bf5795">1,709</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfMTEtNy0xLTEtNDY2NDI_ea47fb6e-9811-4666-9328-5a50c426a435">77,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.596%"><tr><td style="width:1.0%"></td><td style="width:45.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.185%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Short-term investments (due within one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4963dadcf66e4834a7a45b5f75765cb7_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfNS0xLTEtMS00NjY0Mg_c9e29cff-4fad-4d08-99d4-8c947ad9c692">218,391</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4963dadcf66e4834a7a45b5f75765cb7_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfNS0zLTEtMS00NjY0Mg_38c4326c-89c7-4ce2-a8d8-c1a3fcc819fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i4963dadcf66e4834a7a45b5f75765cb7_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfNS01LTEtMS00NjY0Mg_ed2aefcd-e369-47d9-b47d-57e032a40b46">3,661</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4963dadcf66e4834a7a45b5f75765cb7_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfNS03LTEtMS00NjY0Mg_06c7ea18-e9a4-4d03-af19-61eea2311a41">214,730</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity certificate of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie3f0180b2cd14a14919b19c765f13d23_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfNi0xLTEtMS00NjY0Mg_e721c65c-2fdf-426d-a907-5a024697d2a7">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie3f0180b2cd14a14919b19c765f13d23_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfNi0zLTEtMS00NjY0Mg_cf0e7e02-ad0d-4864-ab68-e72dcd5a3cce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie3f0180b2cd14a14919b19c765f13d23_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfNi01LTEtMS00NjY0Mg_5a794ddd-26c8-419b-8ee2-6fbf7627101d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie3f0180b2cd14a14919b19c765f13d23_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfNi03LTEtMS00NjY0Mg_b94b9746-8f23-49dd-b662-28c87a060779">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total short-term investments</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfNy0xLTEtMS00NjY0Mg_ca159b22-a136-4e5a-9480-e27ec269f46e">268,391</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfNy0zLTEtMS00NjY0Mg_5cb3c7f2-3fe8-422e-848c-1c68eca6c4e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfNy01LTEtMS00NjY0Mg_cbf25486-84cd-4c64-b5cd-ca62437bfab7">3,661</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfNy03LTEtMS00NjY0Mg_251ae7e6-0d85-41c8-82fb-4bbcf32d8884">264,730</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Long-term investments (due within one through three years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4963dadcf66e4834a7a45b5f75765cb7_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfMTAtMS0xLTEtNDY2NDI_e936db46-c540-4b20-99ce-b13b9823f9fb">105,872</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4963dadcf66e4834a7a45b5f75765cb7_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfMTAtMy0xLTEtNDY2NDI_79d0e3e4-03a5-441c-bb18-027552fef4e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i4963dadcf66e4834a7a45b5f75765cb7_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfMTAtNS0xLTEtNDY2NDI_0ef9c284-15c0-4883-a9d7-7a9e430ef104">5,569</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4963dadcf66e4834a7a45b5f75765cb7_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfMTAtNy0xLTEtNDY2NDI_513d50c7-43ca-4b7a-880f-532c7f28f0aa">100,303</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total long-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfMTEtMS0xLTEtNDY2NDI_2e075cb7-1158-4035-aa10-abc203e36597">105,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfMTEtMy0xLTEtNDY2NDI_ee61a79e-a727-4451-a619-59d8a4a09232">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfMTEtNS0xLTEtNDY2NDI_08dccc90-671c-401d-975d-af7bdee2ecb4">5,569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfMTEtNy0xLTEtNDY2NDI_5c10c98e-2e21-4940-95ad-575e3478946a">100,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_43"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RleHRyZWdpb246YTQxM2FkNzlhMTNmNGQ5MTlhNTBmMDQ4MjQzMGYyNzhfODY2_d8505421-3346-44f9-949d-fdf18e90f666" continuedAt="ia6ac0f69512d4f94bd6027f03d0b7551" escape="true">INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="ia6ac0f69512d4f94bd6027f03d0b7551"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. <ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RleHRyZWdpb246YTQxM2FkNzlhMTNmNGQ5MTlhNTBmMDQ4MjQzMGYyNzhfODY3_766fa0bb-49b1-4977-81c4-935bffa27384" continuedAt="i0622c7d94fd74e5fa5206b34f5a8c066" escape="true">The following table presents the components of intangible assets: </ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><ix:continuation id="i0622c7d94fd74e5fa5206b34f5a8c066"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Impairment</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Useful Lives</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(amounts in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5b40500b5f154e638fec3502314b61ad_I20230331" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfMy0xLTEtMS01MjY2OA_91650265-54d2-493d-bb95-f850f8228312">21,728</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5b40500b5f154e638fec3502314b61ad_I20230331" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfMy0zLTEtMS01MjY2OA_6ca6039a-9aec-48c4-bb8f-bd21f3cee6eb">12,545</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5b40500b5f154e638fec3502314b61ad_I20230331" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfMy01LTEtMS01MjY2OA_cdfeda7e-15af-4021-8d2e-c133a1bc9a89">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5b40500b5f154e638fec3502314b61ad_I20230331" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfMy03LTEtMS01MjY2OA_6fa3f9e3-a1d4-48cf-bfda-e14d5e43b2fe">9,183</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i43111cfc508d42d1a23d0e3818674d52_D20221001-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfMy05LTEtMS01MjY2OA_75084d2d-8fb9-4a0c-8343-0736d3e51840">14</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iaefcccfc8a3c49a885837a695c3852d6_I20230331" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNC0xLTEtMS01MjY2OA_46f37db0-8228-48cf-afe7-275741d4b89a">3,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iaefcccfc8a3c49a885837a695c3852d6_I20230331" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNC0zLTEtMS01MjY2OA_a482742d-d672-4c1c-9a16-e132919e31f3">1,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iaefcccfc8a3c49a885837a695c3852d6_I20230331" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNC01LTEtMS01MjY2OA_80df4e69-76b9-4a9e-9151-08c870b91464">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iaefcccfc8a3c49a885837a695c3852d6_I20230331" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNC03LTEtMS01MjY2OA_d980d9c1-aff6-4035-8115-fcea2fc13211">1,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5d9b66e3437446e6a4e87dc026f2f51d_D20221001-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNC05LTEtMS01MjY2OA_a5511b72-8042-421f-899c-c7bbe70f7f4c">21</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae265843759f4671ae3ffdba000744f2_I20230331" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNS0xLTEtMS01MjY2OA_ab05dfd6-e385-4b50-af92-49eb821c42cf">24,857</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae265843759f4671ae3ffdba000744f2_I20230331" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNS0zLTEtMS01MjY2OA_520b2dbd-3f17-4060-bbf8-b5776db90538">13,745</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae265843759f4671ae3ffdba000744f2_I20230331" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNS01LTEtMS01MjY2OA_da79601d-cbcf-4b44-9e8f-9d1a2e4cb676">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae265843759f4671ae3ffdba000744f2_I20230331" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNS03LTEtMS01MjY2OA_7a38a631-c8ac-49f2-b1b6-ffc630f2b3c8">11,112</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1e874cdd6f5c448fb4d8544628558c18_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfMy0xLTEtMS00NjY0Mg_cb7380d4-018b-4eec-81a1-9bdc4162a92a">21,728</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1e874cdd6f5c448fb4d8544628558c18_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfMy0zLTEtMS00NjY0Mg_e1bfe6a7-999c-44af-a449-94debac647f2">11,770</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1e874cdd6f5c448fb4d8544628558c18_I20220930" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfMy01LTEtMS00NjY0Mg_f0e6a1eb-0417-4d9e-b436-0f4fcfe19fd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1e874cdd6f5c448fb4d8544628558c18_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfMy03LTEtMS00NjY0Mg_8522afdf-63af-44a4-978c-5cfe08b31994">9,958</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i633b04e751e24ba3905af5e05905fd6e_D20211001-20220930" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfMy05LTEtMS00NjY0Mg_c0583a76-ef5f-45b3-bdcd-977a6b03276c">14</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia0176372a9404016aaf7cbb1312079fa_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNC0xLTEtMS00NjY0Mg_10087a1a-5e1b-4e88-bc1c-692c175ea9eb">3,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia0176372a9404016aaf7cbb1312079fa_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNC0zLTEtMS00NjY0Mg_6ecb9f29-b133-407c-b376-1182293d7d96">1,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia0176372a9404016aaf7cbb1312079fa_I20220930" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNC01LTEtMS00NjY0Mg_f6ea478c-0001-4a6b-9d1d-543667287a74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia0176372a9404016aaf7cbb1312079fa_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNC03LTEtMS00NjY0Mg_ac4c5287-14a7-4ea0-906d-fb329a945e2b">2,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i99c440889d934b9a991b649900bea075_D20211001-20220930" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNC05LTEtMS00NjY0Mg_958fc78f-03ef-4c35-ada2-f4b04da71c4b">21</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia6d2dec926374fd7a06a9cc5ff555ad3_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNS0xLTEtMS00NjY0Mg_07d17bdf-178d-4cf4-a54b-01ee8494017a">24,857</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia6d2dec926374fd7a06a9cc5ff555ad3_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNS0zLTEtMS00NjY0Mg_d69e8cfd-07e0-489b-b6f2-eba338dd4366">12,895</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia6d2dec926374fd7a06a9cc5ff555ad3_I20220930" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNS01LTEtMS00NjY0Mg_82990ea0-2722-4031-88f1-c5d2cbb27db0">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia6d2dec926374fd7a06a9cc5ff555ad3_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNS03LTEtMS00NjY0Mg_326b44f1-b53b-4869-aca2-acf58910c0ee">11,962</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed annually for impairment and more frequently if potential impairment indicators exist. No impairment indicators were identified during the six months ended March&#160;31, 2023 and 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with definite useful lives are amortized on a straight-line basis over their useful lives. Intangible assets amortization expense was $<ix:nonFraction unitRef="usd" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RleHRyZWdpb246YTQxM2FkNzlhMTNmNGQ5MTlhNTBmMDQ4MjQzMGYyNzhfNTQ5NzU1ODE0ODYz_40875f54-1d68-44f0-811e-fc6bdfccd17c"><ix:nonFraction unitRef="usd" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RleHRyZWdpb246YTQxM2FkNzlhMTNmNGQ5MTlhNTBmMDQ4MjQzMGYyNzhfNTQ5NzU1ODE0ODYz_e91bf4b4-01a2-4906-ac7f-71d366adc71a">0.4</ix:nonFraction></ix:nonFraction> million for each of the three months ended March&#160;31, 2023 and 2022, and $<ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RleHRyZWdpb246YTQxM2FkNzlhMTNmNGQ5MTlhNTBmMDQ4MjQzMGYyNzhfNTQ5NzU1ODE1MTMw_da8bb87c-d08d-4497-8ee2-e13ab39e95b2"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RleHRyZWdpb246YTQxM2FkNzlhMTNmNGQ5MTlhNTBmMDQ4MjQzMGYyNzhfNTQ5NzU1ODE1MTMw_dd1ab035-a1a6-4087-bfe3-b5baf5c711eb">0.9</ix:nonFraction></ix:nonFraction> million and for each of the six months ended March&#160;31, 2023 and 2022. None of the intangible assets with definite useful lives are anticipated to have a residual value.</span></div><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RleHRyZWdpb246YTQxM2FkNzlhMTNmNGQ5MTlhNTBmMDQ4MjQzMGYyNzhfODY4_6f00f351-d4d2-4802-87f7-a76db8817630" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated future amortization expense related to intangible assets as of March&#160;31, 2023:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"><tr><td style="width:1.0%"></td><td style="width:71.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortization Expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ending September 30, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2023 (remainder)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOjkxMTI4Y2NkZjFmNzQxM2U4YmM0OWM1ODRmNzYwM2JmL3RhYmxlcmFuZ2U6OTExMjhjY2RmMWY3NDEzZThiYzQ5YzU4NGY3NjAzYmZfMi0yLTEtMS00NjY0Mg_d79ef93a-38ca-4699-9452-382516a3b4dc">850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOjkxMTI4Y2NkZjFmNzQxM2U4YmM0OWM1ODRmNzYwM2JmL3RhYmxlcmFuZ2U6OTExMjhjY2RmMWY3NDEzZThiYzQ5YzU4NGY3NjAzYmZfMy0yLTEtMS00NjY0Mg_7f3f325f-11a3-4317-8f9c-ee920ed623d5">1,700</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOjkxMTI4Y2NkZjFmNzQxM2U4YmM0OWM1ODRmNzYwM2JmL3RhYmxlcmFuZ2U6OTExMjhjY2RmMWY3NDEzZThiYzQ5YzU4NGY3NjAzYmZfNC0yLTEtMS00NjY0Mg_4017e555-67b9-4cb8-b243-829b644a574a">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOjkxMTI4Y2NkZjFmNzQxM2U4YmM0OWM1ODRmNzYwM2JmL3RhYmxlcmFuZ2U6OTExMjhjY2RmMWY3NDEzZThiYzQ5YzU4NGY3NjAzYmZfNS0yLTEtMS00NjY0Mg_4818532e-b714-4353-a5cd-a4f932710f89">1,700</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOjkxMTI4Y2NkZjFmNzQxM2U4YmM0OWM1ODRmNzYwM2JmL3RhYmxlcmFuZ2U6OTExMjhjY2RmMWY3NDEzZThiYzQ5YzU4NGY3NjAzYmZfNi0yLTEtMS00NjY0Mg_1782be16-a056-4f46-a296-b081794c3287">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="arwr:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOjkxMTI4Y2NkZjFmNzQxM2U4YmM0OWM1ODRmNzYwM2JmL3RhYmxlcmFuZ2U6OTExMjhjY2RmMWY3NDEzZThiYzQ5YzU4NGY3NjAzYmZfNy0yLTEtMS00NjY0Mg_4ded4757-60fa-4760-9190-6d4d57d5fe0a">3,462</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOjkxMTI4Y2NkZjFmNzQxM2U4YmM0OWM1ODRmNzYwM2JmL3RhYmxlcmFuZ2U6OTExMjhjY2RmMWY3NDEzZThiYzQ5YzU4NGY3NjAzYmZfOC0yLTEtMS00NjY0Mg_2c837120-e3b1-4ece-b2a0-9d851ef7c393">11,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_46"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. <ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RleHRyZWdpb246MzU3YjIwNjYxMWJlNDBmNTg1YjMxYmIyODUyZWY3NjZfMTUyMw_3e4fa470-ec0d-42ea-a9af-484500dd5dd2" continuedAt="i9614df0bca0e422a9c6a3339d338dda0" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="i9614df0bca0e422a9c6a3339d338dda0"><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RleHRyZWdpb246MzU3YjIwNjYxMWJlNDBmNTg1YjMxYmIyODUyZWY3NjZfMTUyNA_ec26ffc8-539a-457c-a02d-119c332dc648" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s shares of common stock and preferred stock:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"><tr><td style="width:1.0%"></td><td style="width:27.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.826%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Par Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Authorized</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfNC0xLTEtMS00NjY0Mg_a763e7d5-9c28-4da5-a90b-39c9406eeb0e">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfNC0yLTEtMS00NjY0Mg_68878432-9267-4d27-92ff-52e38f88eaca">290,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfNC0zLTEtMS00NjY0Mg_93cbed37-c7d5-4bf7-b9d1-b17aae226da4">106,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfNC00LTEtMS00NjY0Mg_7815066b-78bf-40d4-9046-5a669c0f3334">106,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfNS0xLTEtMS00NjY0Mg_123ceabf-d1c9-4700-ade0-f5acf2bc67bc">0.001</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfNS0yLTEtMS00NjY0Mg_84cdf664-8042-4c87-957c-ba52c76c3805">5,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfNS0zLTEtMS00NjY0Mg_e4d301ab-3b61-4d73-ac4e-57dcef3f6f73">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfNS00LTEtMS00NjY0Mg_1e5774bd-2a52-4524-abf4-5fc3fc7b68fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfOC0xLTEtMS00NjY0Mg_1a305e1e-07db-427b-b467-775c2173e2eb">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfOC0yLTEtMS00NjY0Mg_b3d513f4-39ad-4182-aa3c-1892c12dac6d">145,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfOC0zLTEtMS00NjY0Mg_ab1d569e-f02b-4d15-ac30-8f824e744579">105,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfOC00LTEtMS00NjY0Mg_df868778-c401-4c01-9a6a-191a164a85a4">105,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfOS0xLTEtMS00NjY0Mg_bfeb5512-80ce-4491-91e9-17f0d5420a9f">0.001</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfOS0yLTEtMS00NjY0Mg_2619fe6e-bb40-43c1-a8fd-14f12b16b7bf">5,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfOS0zLTEtMS00NjY0Mg_75084334-78c3-4d4b-bf55-6d63d432d6d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfOS00LTEtMS00NjY0Mg_b42f5ebc-1f39-4490-9547-4194309f55c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;16, 2023, the Company&#8217;s stockholders approved an increase in authorized common shares, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RleHRyZWdpb246MzU3YjIwNjYxMWJlNDBmNTg1YjMxYmIyODUyZWY3NjZfNTQ5NzU1ODE2MDk0_a763e7d5-9c28-4da5-a90b-39c9406eeb0e">0.001</ix:nonFraction> per share, from <ix:nonFraction unitRef="shares" contextRef="i5e6eba04dc734b4d8c9dac99153326ea_I20230426" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RleHRyZWdpb246MzU3YjIwNjYxMWJlNDBmNTg1YjMxYmIyODUyZWY3NjZfMzg0ODI5MDcwMDA5NA_52dacc92-9a69-4040-8123-484f1159a8ff">145,000,000</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="i5a2307967ccd4758a76576f944c97966_I20230427" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RleHRyZWdpb246MzU3YjIwNjYxMWJlNDBmNTg1YjMxYmIyODUyZWY3NjZfMjc0ODc3OTA3MjEwMg_e35da04a-de1e-4bd2-bf3f-b7be7cb8c875">290,000,000</ix:nonFraction>. The amendment to the Amended and Restated Certificate of Incorporation was filed on April 27, 2023. The Company does not have any current intention to issue shares in connection with acquisitions or pursuant to any equity financing outside of its existing equity compensation plans.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and September&#160;30, 2022, respectively, <ix:nonFraction unitRef="shares" contextRef="i946d734bd0924e3c88051efb2fda8a0b_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RleHRyZWdpb246MzU3YjIwNjYxMWJlNDBmNTg1YjMxYmIyODUyZWY3NjZfMjc0ODc3OTA3MTc3MA_0004f534-5d04-4072-95e4-fa8cedca8615">13,075,198</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i68db699bce364d8482aa0ec6406b9e97_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RleHRyZWdpb246MzU3YjIwNjYxMWJlNDBmNTg1YjMxYmIyODUyZWY3NjZfMjc0ODc3OTA3MTc3NQ_469e4e91-82bf-46d7-9f47-9d5f33fda0b5">14,000,392</ix:nonFraction> shares of common stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under the Company&#8217;s 2004 Equity Incentive Plan, 2013 Incentive Plan, and 2021 Incentive Plan, as well as for inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 2, 2022, the Company entered into an open market sale agreement (the &#8220;Open Market Sale Agreement&#8221;), pursuant to which the Company may, from time to time, sell up to $<ix:nonFraction unitRef="usd" contextRef="i93974846852e4d2e86d9713058a0d972_I20221202" decimals="INF" name="arwr:CommonStockCapitalSharesValueReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RleHRyZWdpb246MzU3YjIwNjYxMWJlNDBmNTg1YjMxYmIyODUyZWY3NjZfNTQ5NzU1ODE2MTMy_2f584913-f037-4345-90bb-3023d97944b2">250,000,000</ix:nonFraction> in shares of the Company&#8217;s common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering (&#8220;ATM Offering&#8221;). The Company is not required to sell shares under the Open Market Sale Agreement. The Company will pay Jefferies LLC a commission of up to <ix:nonFraction unitRef="number" contextRef="idb7a13077dbb473bbf383cb6cf031d5f_D20221202-20221202" decimals="3" name="arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RleHRyZWdpb246MzU3YjIwNjYxMWJlNDBmNTg1YjMxYmIyODUyZWY3NjZfNTQ5NzU1ODE2MTM2_1c8b1d08-927b-4b6d-aace-6aa9e7a22dad">3.0</ix:nonFraction>% of the aggregate gross proceeds received from all sales of the common stock under the Open Market Sale Agreement. Unless otherwise terminated, the ATM Offering shall terminate upon the earlier of (i) the sale of all shares of common stock subject to the Sales Agreement and (ii) the termination of the Sales Agreement as permitted therein. The Company and Jefferies may each terminate the Open Market Sale Agreement at any time upon prior notice. As of March&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="ibec649ac666a4282b702eb4164c1aa47_I20230331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RleHRyZWdpb246MzU3YjIwNjYxMWJlNDBmNTg1YjMxYmIyODUyZWY3NjZfNTQ5NzU1ODE2MTg2_28d00d1d-ede2-4a2b-9d8e-0aac9af4857c">no</ix:nonFraction> shares have been issued under the Open Market Sale Agreement.</span></div></ix:continuation><div id="ic86d56462a0d40c99d8026254ea2d4d6_49"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. <ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80OS9mcmFnOjA5YzM1M2Y1OTYyOTQzY2JiZWRjYjAyMWZmZTBkZWYwL3RleHRyZWdpb246MDljMzUzZjU5NjI5NDNjYmJlZGNiMDIxZmZlMGRlZjBfMjI4Mw_13d4a746-6529-4180-a3f6-626d33703c56" continuedAt="i5567c0ab70f741c2a41d9f02f15de7bc" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i5567c0ab70f741c2a41d9f02f15de7bc" continuedAt="ic2f4b26878934013a2462e595b6844c4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were <ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80OS9mcmFnOjA5YzM1M2Y1OTYyOTQzY2JiZWRjYjAyMWZmZTBkZWYwL3RleHRyZWdpb246MDljMzUzZjU5NjI5NDNjYmJlZGNiMDIxZmZlMGRlZjBfMzky_2b4fe717-2518-43e5-b21b-a53a07ed7fd2">no</ix:nonFraction> contingent liabilities recorded as of March&#160;31, 2023. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;20, 2021, the Company completed a purchase of <ix:nonFraction unitRef="acre" contextRef="iabd7d953444246219ae89c140ed43582_D20211220-20211220" decimals="INF" name="arwr:NumberOfAcresOfLandPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80OS9mcmFnOjA5YzM1M2Y1OTYyOTQzY2JiZWRjYjAyMWZmZTBkZWYwL3RleHRyZWdpb246MDljMzUzZjU5NjI5NDNjYmJlZGNiMDIxZmZlMGRlZjBfNDkz_ca0a8561-cf3b-42e8-82cb-0fbe708954f3">13</ix:nonFraction> acres of land in the Verona Technology Park in Verona, Wisconsin, which is being developed into an approximately <ix:nonFraction unitRef="sqft" contextRef="i6f6537bef0da416db817189fd3163b28_I20211220" decimals="-3" name="us-gaap:AreaOfLand" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80OS9mcmFnOjA5YzM1M2Y1OTYyOTQzY2JiZWRjYjAyMWZmZTBkZWYwL3RleHRyZWdpb246MDljMzUzZjU5NjI5NDNjYmJlZGNiMDIxZmZlMGRlZjBfNjA5_d8e1c1b7-88f6-4953-b296-9df5e8dd4758">160,000</ix:nonFraction> square foot drug manufacturing facility and an approximately <ix:nonFraction unitRef="sqft" contextRef="icaf4446772ec44ed9ba6f8dddc59fe68_I20211220" decimals="-3" name="us-gaap:AreaOfLand" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80OS9mcmFnOjA5YzM1M2Y1OTYyOTQzY2JiZWRjYjAyMWZmZTBkZWYwL3RleHRyZWdpb246MDljMzUzZjU5NjI5NDNjYmJlZGNiMDIxZmZlMGRlZjBfNjcz_22318aab-ca8e-4b60-a84c-b834f6037197">140,000</ix:nonFraction> square foot laboratory and office facility which will support the Company&#8217;s process development and analytical activities. The Company intends to invest between $<ix:nonFraction unitRef="usd" contextRef="i0f101a6f09c746a696cf6e40e90e0784_I20211220" decimals="-5" name="arwr:AmountIntendsToInvestForBuildoutOfFacilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80OS9mcmFnOjA5YzM1M2Y1OTYyOTQzY2JiZWRjYjAyMWZmZTBkZWYwL3RleHRyZWdpb246MDljMzUzZjU5NjI5NDNjYmJlZGNiMDIxZmZlMGRlZjBfODM3_17bd2d99-0312-45f7-b46b-167ce3934c3a">200.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i608519b3c5264256971820f095be404f_I20211220" decimals="-5" name="arwr:AmountIntendsToInvestForBuildoutOfFacilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80OS9mcmFnOjA5YzM1M2Y1OTYyOTQzY2JiZWRjYjAyMWZmZTBkZWYwL3RleHRyZWdpb246MDljMzUzZjU5NjI5NDNjYmJlZGNiMDIxZmZlMGRlZjBfODQ0_0e779cc4-ae5c-4d11-bc24-7b6c10b11920">260.0</ix:nonFraction> million into the build-out of the facilities. As part of this acquisition, the Company entered into a development agreement with the City of Verona to construct certain infrastructure improvements within the tax incremental district and will be reimbursed up to $<ix:nonFraction unitRef="usd" contextRef="i174690ddc75d4855ac133c1051fa0058_I20211220" decimals="-5" name="arwr:TaxIncrementFinancingAward" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80OS9mcmFnOjA5YzM1M2Y1OTYyOTQzY2JiZWRjYjAyMWZmZTBkZWYwL3RleHRyZWdpb246MDljMzUzZjU5NjI5NDNjYmJlZGNiMDIxZmZlMGRlZjBfMTEwMQ_eb2f0c54-9044-45a0-93b2-ae920d64a697">16.0</ix:nonFraction>&#160;million by the City of Verona by future tax increment revenue generated from the developed property. The total amount of funding that the City of Verona will pay under the Tax Incremental Financing program is not guaranteed and will depend on future tax revenues generated from the developed property. The Company will also receive up to $<ix:nonFraction unitRef="usd" contextRef="i87a265da333847a7a7a27032890bbae3_D20211220-20211220" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCredits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80OS9mcmFnOjA5YzM1M2Y1OTYyOTQzY2JiZWRjYjAyMWZmZTBkZWYwL3RleHRyZWdpb246MDljMzUzZjU5NjI5NDNjYmJlZGNiMDIxZmZlMGRlZjBfMTQzNA_141afa3f-71b3-4102-8a08-31d8ea062932">2.5</ix:nonFraction> million of refundable Wisconsin state income tax credits from the Wisconsin Economic Development Corporation (WEDC) as incentives to invest in the local community and create new jobs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Technology License Commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has licensed from third parties the rights to use certain technologies for its research and development activities, as well as in any products it may develop using these licensed technologies. These agreements and other similar </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic2f4b26878934013a2462e595b6844c4">agreements often require milestone and royalty payments. Milestone payments, for example, may be required as the research and development process progresses through various stages of development, such as when clinical candidates enter or progress through clinical trials, upon NDA and/or certain sales level milestones. During the three and six months ended March&#160;31, 2023 and 2022, the Company did <ix:nonFraction unitRef="usd" contextRef="i21fbfd552ab74a5b8d34cf53f412fb99_D20230101-20230331" decimals="INF" name="arwr:MilestonePayments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80OS9mcmFnOjA5YzM1M2Y1OTYyOTQzY2JiZWRjYjAyMWZmZTBkZWYwL3RleHRyZWdpb246MDljMzUzZjU5NjI5NDNjYmJlZGNiMDIxZmZlMGRlZjBfMjI1OA_401e8f48-0cde-456d-a956-a7bec159a4b9"><ix:nonFraction unitRef="usd" contextRef="id49087344a124915998dbc4016b35524_D20220101-20220331" decimals="INF" name="arwr:MilestonePayments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80OS9mcmFnOjA5YzM1M2Y1OTYyOTQzY2JiZWRjYjAyMWZmZTBkZWYwL3RleHRyZWdpb246MDljMzUzZjU5NjI5NDNjYmJlZGNiMDIxZmZlMGRlZjBfMjI1OA_50aa96ee-d578-42a2-a292-919864e14cb1"><ix:nonFraction unitRef="usd" contextRef="if91aa501385d4acda003508cc04433bd_D20221001-20230331" decimals="INF" name="arwr:MilestonePayments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80OS9mcmFnOjA5YzM1M2Y1OTYyOTQzY2JiZWRjYjAyMWZmZTBkZWYwL3RleHRyZWdpb246MDljMzUzZjU5NjI5NDNjYmJlZGNiMDIxZmZlMGRlZjBfMjI1OA_7c3b52b7-c433-43a3-96c6-10a8f9f2b498"><ix:nonFraction unitRef="usd" contextRef="i7c55337dc9d5489f93889b362e414346_D20211001-20220331" decimals="INF" name="arwr:MilestonePayments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80OS9mcmFnOjA5YzM1M2Y1OTYyOTQzY2JiZWRjYjAyMWZmZTBkZWYwL3RleHRyZWdpb246MDljMzUzZjU5NjI5NDNjYmJlZGNiMDIxZmZlMGRlZjBfMjI1OA_ce89f8d4-2e08-41cd-babe-69bf73e9dcf2">not</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> reach any milestones.</ix:continuation> </span></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_52"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. <ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfMzAxMw_9327b49b-7495-4d94-b178-c7913c6adaf2" continuedAt="ib9aecd8b1adc417fbdbb6135d884c903" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="ib9aecd8b1adc417fbdbb6135d884c903" continuedAt="i8459f695dbd2461d8c66289e8b9ad049"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;19, 2021, the Company entered into a <ix:nonNumeric contextRef="idd3e5aec48f6451c954c613028ae62ea_I20211119" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfNTg_26e45a35-9ee9-4634-844e-8130d3457033">15</ix:nonNumeric>-year lease for approximately <ix:nonFraction unitRef="sqft" contextRef="idd3e5aec48f6451c954c613028ae62ea_I20211119" decimals="0" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfOTA_cf7fdef8-1d3b-496a-a597-8e591b632288">144,000</ix:nonFraction> square feet of office and research and development laboratory space in San Diego, California. This facility replaces the Company&#8217;s current office and research facility located in San Diego, California. The increased capacity of this new facility compared to the Company&#8217;s current research facility in San Diego will accommodate increased personnel for its expanding pipeline of current and future drug candidates. The lease payments which began on April 19, 2023, the rent commencement date, will be approximately $<ix:nonFraction unitRef="usd" contextRef="idd3e5aec48f6451c954c613028ae62ea_I20211119" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfNzU1_5e5fb5c8-a75c-4b9a-b73d-94a7c69d30a7">119.0</ix:nonFraction> million over the initial <ix:nonNumeric contextRef="idd3e5aec48f6451c954c613028ae62ea_I20211119" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfNzc1_26e45a35-9ee9-4634-844e-8130d3457033">15</ix:nonNumeric>-year term. The Company also estimates payments for operating expenses to be approximately $<ix:nonFraction unitRef="usd" contextRef="idd3e5aec48f6451c954c613028ae62ea_I20211119" decimals="-5" name="arwr:EstimatedPaymentsForOperatingExpensesYearOne" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfODY4_9e77c97d-88f2-4dc2-8d98-884222bdd2f6">3.0</ix:nonFraction> million for the first year of the lease, and these payments will continue throughout the initial <ix:nonNumeric contextRef="idd3e5aec48f6451c954c613028ae62ea_I20211119" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfOTYw_26e45a35-9ee9-4634-844e-8130d3457033">15</ix:nonNumeric>-year term. The Company expects to pay approximately $<ix:nonFraction unitRef="usd" contextRef="ic5ae44bfc90d442180f61be9e9844f29_D20211119-20211119" decimals="-5" name="arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfMzI5ODUzNDg4NjgzMA_32b3a1a5-d405-48f7-83f3-06a04dd76564">32.0</ix:nonFraction>&#160;million for leasehold improvements, net of tenant improvement allowances. Pursuant to the lease, within twelve months of the expiration of the initial <ix:nonNumeric contextRef="idd3e5aec48f6451c954c613028ae62ea_I20211119" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfMTE2MQ_26e45a35-9ee9-4634-844e-8130d3457033">15</ix:nonNumeric>-year term, the Company has the option to extend the lease for up to <ix:nonFraction unitRef="option" contextRef="idc3f86aeb9e54ad2a0c1aea7e97e6026_I20211119" decimals="INF" name="arwr:NumberOfOptionsToRenew" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfMTIzMg_be158c19-5f39-4be7-befa-20fcaf7dd187">one</ix:nonFraction> additional <ix:nonNumeric contextRef="idd3e5aec48f6451c954c613028ae62ea_I20211119" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfMzAwOQ_2c503502-1772-4d1c-ace8-3d3116ecd7e4">ten-year</ix:nonNumeric> term, with certain annual increases in base rent. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Significant Leases</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pasadena, California</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases <ix:nonFraction unitRef="sqft" contextRef="i68677c28e8fe477fa44323fceff8350f_I20211119" decimals="0" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfMzI5ODUzNDg4Njg0NQ_a9f914f5-9cdc-431e-a3ad-f8f8b73e129c">49,000</ix:nonFraction> square feet of office space located at 177 Colorado Blvd. for its corporate headquarters from 177 Colorado Owner, LLC, which lease expires on April&#160;30, 2027. The lease contains an option to renew for <ix:nonFraction unitRef="option" contextRef="ifbd2b67bde2642ceb93902cc376061d6_I20190930" decimals="INF" name="arwr:NumberOfOptionsToRenew" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfMTU1Nw_707adc11-0986-4fdf-af4a-7196e3346e28">one</ix:nonFraction> term of <ix:nonNumeric contextRef="ifbd2b67bde2642ceb93902cc376061d6_I20190930" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfMTU2OA_285ddf5d-d8fb-4d6b-9252-ec53d5726c66">five years</ix:nonNumeric>. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">San Diego, California</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company subleased space from Halozyme, Inc. for additional research and development facility in San Diego, California. The term of this sublease commenced on April&#160;1, 2020 and ended on January&#160;14, 2023. On December 23, 2022, the Company entered into a new <ix:nonNumeric contextRef="i15669b32d03d4c7994f8ce62df1576ee_I20221223" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfMzAxMA_2067725b-615b-4a34-ae5e-033f28b77720">six-month</ix:nonNumeric> lease agreement with 11404 &amp; 11408 Sorrento Valley Owner (DE) LLC, effective January 15, 2023. The lease will end on July 15, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Madison, Wisconsin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases space for office and laboratory facilities, which expires on September 30, 2031. The lease contains options to renew for <ix:nonFraction unitRef="option" contextRef="ia816458e6d964f63bac38dc0e0214686_I20230331" decimals="INF" name="arwr:NumberOfOptionsToRenew" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfMjI3OA_316228af-532d-43b2-a8be-b0f77e3d1e33">two</ix:nonFraction> terms of <ix:nonNumeric contextRef="ia816458e6d964f63bac38dc0e0214686_I20230331" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfMjI5MA_0477252e-6949-4a76-9873-d218d5463143">five years</ix:nonNumeric>. After accounting for additional rental square feet added pursuant to amendments to the lease agreement in 2019 and 2020, the Company currently leases a total of <ix:nonFraction unitRef="sqft" contextRef="ia816458e6d964f63bac38dc0e0214686_I20230331" decimals="-3" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfMjQ1NQ_8fe05848-393d-4fd4-b8df-db4ac194ca68">111,000</ix:nonFraction> square feet.</span></div><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfMzAxMQ_5f9327ff-1f95-491c-8c69-373b2b6ad32c" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease assets and liabilities along with their classification on the Company&#8217;s consolidated balance sheets were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"><tr><td style="width:1.0%"></td><td style="width:28.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.807%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.382%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOjc5YTgzMzZkZjZkNjQ4N2M4MjA4ZWEyZGZmM2NjYzAzL3RhYmxlcmFuZ2U6NzlhODMzNmRmNmQ2NDg3YzgyMDhlYTJkZmYzY2NjMDNfMy0zLTEtMS00NjY0Mg_7a036cae-7eba-4c29-b59d-68069236ec1d">41,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOjc5YTgzMzZkZjZkNjQ4N2M4MjA4ZWEyZGZmM2NjYzAzL3RhYmxlcmFuZ2U6NzlhODMzNmRmNmQ2NDg3YzgyMDhlYTJkZmYzY2NjMDNfMy01LTEtMS00NjY0Mg_535d6a1a-a577-46d4-a0d6-4f8262400764">58,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOjc5YTgzMzZkZjZkNjQ4N2M4MjA4ZWEyZGZmM2NjYzAzL3RhYmxlcmFuZ2U6NzlhODMzNmRmNmQ2NDg3YzgyMDhlYTJkZmYzY2NjMDNfNS0zLTEtMS00NjY0Mg_a1f1b8c7-2e75-4ede-b673-313ef4068342">2,711</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOjc5YTgzMzZkZjZkNjQ4N2M4MjA4ZWEyZGZmM2NjYzAzL3RhYmxlcmFuZ2U6NzlhODMzNmRmNmQ2NDg3YzgyMDhlYTJkZmYzY2NjMDNfNS01LTEtMS00NjY0Mg_cebaceaf-d4e2-4650-8ce6-74e322e6b40b">2,776</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOjc5YTgzMzZkZjZkNjQ4N2M4MjA4ZWEyZGZmM2NjYzAzL3RhYmxlcmFuZ2U6NzlhODMzNmRmNmQ2NDg3YzgyMDhlYTJkZmYzY2NjMDNfNi0zLTEtMS00NjY0Mg_6f951844-0134-42e3-9c40-f406a8105452">80,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOjc5YTgzMzZkZjZkNjQ4N2M4MjA4ZWEyZGZmM2NjYzAzL3RhYmxlcmFuZ2U6NzlhODMzNmRmNmQ2NDg3YzgyMDhlYTJkZmYzY2NjMDNfNi01LTEtMS00NjY0Mg_6509b918-b00c-4e64-81b7-fdce3e37dcee">78,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lease Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i159523f6f89347ed97ef204e3f438e67_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfNC0zLTEtMS00NjY0Mg_543b98e5-36e4-40de-a7f7-038cba7488c5">2,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia5215e7abf324f20be6a6162e55086ae_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfNC01LTEtMS00NjY0Mg_703a141c-a733-464f-8aaf-133760238d29">905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ica3faf3d13c049288fea256fa28a33f5_D20221001-20230331" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfNC03LTEtMS01MzI5Mg_eefe7f88-0e32-44da-81f2-77cd8f6b45c5">4,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3a9802653ed047b494adfc65fd05c202_D20211001-20220331" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfNC05LTEtMS01MzMwMA_7d0b22d7-a91a-4e85-94a0-1097435ac574">1,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2202af7f697f4a768cccd43c0a966d51_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfNS0zLTEtMS00NjY0Mg_4c9457e2-cc76-4b72-8a08-eb304de41cd9">500</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7a904235b2704d1281b976507352cfcc_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfNS01LTEtMS00NjY0Mg_473dabdd-e4f9-4e35-8218-8bff399a69ce">420</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0104fc96cb744d06baa957d09374a4b9_D20221001-20230331" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfNS03LTEtMS01MzI5Mg_3c679d63-4745-4d43-af66-333d52e92533">1,033</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie31baa0092254ca4a31017b25a53ca08_D20211001-20220331" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfNS05LTEtMS01MzMwMA_dbcd16a9-2e43-4654-819e-8551abdf459f">840</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i159523f6f89347ed97ef204e3f438e67_D20230101-20230331" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfNy0zLTEtMS00NjY0Mg_80eddad3-80c8-435c-87df-b6b45fc8a0fd">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia5215e7abf324f20be6a6162e55086ae_D20220101-20220331" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfNy01LTEtMS00NjY0Mg_737b9b70-fdd7-4351-b031-9b5d8a52e4e5">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ica3faf3d13c049288fea256fa28a33f5_D20221001-20230331" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfNy03LTEtMS01MzI5Mg_c9d90d57-86e4-41cf-a882-a7b11594d873">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3a9802653ed047b494adfc65fd05c202_D20211001-20220331" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfNy05LTEtMS01MzMwMA_b839a690-2992-492d-8416-4b5c251f032c">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2202af7f697f4a768cccd43c0a966d51_D20230101-20230331" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfOC0zLTEtMS00NjY0Mg_dbf4f371-d0b9-41dd-a924-54bf09699862">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7a904235b2704d1281b976507352cfcc_D20220101-20220331" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfOC01LTEtMS00NjY0Mg_a26e83fd-e6db-4eaa-9fb4-5b8f166f491b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0104fc96cb744d06baa957d09374a4b9_D20221001-20230331" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfOC03LTEtMS01MzI5Mg_8825e082-8ff4-4c91-b785-e00329f9a701">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie31baa0092254ca4a31017b25a53ca08_D20211001-20220331" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfOC05LTEtMS01MzMwMA_65069419-c06c-4ef3-9333-4547f2526d76">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfMTAtMy0xLTEtNDY2NDI_5a4f7b62-513e-4489-bea5-1348d1553b57">3,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfMTAtNS0xLTEtNDY2NDI_85c9279a-9450-4d25-96d7-11d097afb5ec">1,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfMTAtNy0xLTEtNTMzMTY_896d5631-7baf-4e7e-8602-4d1ca0ce24fe">5,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfMTAtOS0xLTEtNTMzNTY_eecb3c5f-bfb9-47f1-ac20-2818f7c71065">2,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost primarily related to operating expenses associated with the Company&#8217;s operating leases. There was $<ix:nonFraction unitRef="usd" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-5" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfNTQ5NzU1ODE3MDMw_43f993c7-a601-4b42-92e6-61caf8a96f75">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-5" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfNTQ5NzU1ODE3MDM4_e84537b8-5f28-4a22-b0af-8807c730d498">0.3</ix:nonFraction>&#160;million short-term lease cost during the three months ended March&#160;31, 2023, and 2022, respectively. There was $<ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-5" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfNTQ5NzU1ODE3MDQ1_17ffc282-d77e-4a2f-b33c-d6e960dc296c">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-5" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfNTQ5NzU1ODE3MDUy_902410d5-cf5f-427d-9799-4c7b2c5200c1">0.5</ix:nonFraction>&#160;million short-term lease cost during the six months ended March&#160;31, 2023, and 2022, respectively.   </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8459f695dbd2461d8c66289e8b9ad049"><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfMzAxMg_4b891fd9-3962-4396-ae13-74c826e2bdb8" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents payments of operating lease liabilities on an undiscounted basis as of March&#160;31, 2023:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.545%"><tr><td style="width:1.0%"></td><td style="width:79.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.803%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amounts</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2023 (remainder of fiscal year)</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmRjZmUzOGM4OWM1ZjQyMTY5OTg0MDVjMTA5NTM3ZjVkL3RhYmxlcmFuZ2U6ZGNmZTM4Yzg5YzVmNDIxNjk5ODQwNWMxMDk1MzdmNWRfMi0xLTEtMS00NjY0Mg_5e5c8648-73b3-4839-9c9f-fcd7710f4d7c">3,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmRjZmUzOGM4OWM1ZjQyMTY5OTg0MDVjMTA5NTM3ZjVkL3RhYmxlcmFuZ2U6ZGNmZTM4Yzg5YzVmNDIxNjk5ODQwNWMxMDk1MzdmNWRfMy0xLTEtMS00NjY0Mg_0a7b5950-9075-4d51-8f58-c1caf33ac293">8,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmRjZmUzOGM4OWM1ZjQyMTY5OTg0MDVjMTA5NTM3ZjVkL3RhYmxlcmFuZ2U6ZGNmZTM4Yzg5YzVmNDIxNjk5ODQwNWMxMDk1MzdmNWRfNC0xLTEtMS00NjY0Mg_7625f58b-8ef3-4a66-920f-0bb6fd9e91ca">11,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmRjZmUzOGM4OWM1ZjQyMTY5OTg0MDVjMTA5NTM3ZjVkL3RhYmxlcmFuZ2U6ZGNmZTM4Yzg5YzVmNDIxNjk5ODQwNWMxMDk1MzdmNWRfNS0xLTEtMS00NjY0Mg_5de8ca92-c498-47ea-9a17-15f33692f942">12,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmRjZmUzOGM4OWM1ZjQyMTY5OTg0MDVjMTA5NTM3ZjVkL3RhYmxlcmFuZ2U6ZGNmZTM4Yzg5YzVmNDIxNjk5ODQwNWMxMDk1MzdmNWRfNi0xLTEtMS00NjY0Mg_c75eda20-e66a-45d3-8385-2a0193cbbb7a">11,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="arwr:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmRjZmUzOGM4OWM1ZjQyMTY5OTg0MDVjMTA5NTM3ZjVkL3RhYmxlcmFuZ2U6ZGNmZTM4Yzg5YzVmNDIxNjk5ODQwNWMxMDk1MzdmNWRfNy0xLTEtMS00NjY0Mg_436b9cf9-6937-490d-aeb0-3bc2d3c6ad95">102,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmRjZmUzOGM4OWM1ZjQyMTY5OTg0MDVjMTA5NTM3ZjVkL3RhYmxlcmFuZ2U6ZGNmZTM4Yzg5YzVmNDIxNjk5ODQwNWMxMDk1MzdmNWRfOC0xLTEtMS00NjY0Mg_9a97bd54-67e2-473e-bc80-23ed992a3471">149,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmRjZmUzOGM4OWM1ZjQyMTY5OTg0MDVjMTA5NTM3ZjVkL3RhYmxlcmFuZ2U6ZGNmZTM4Yzg5YzVmNDIxNjk5ODQwNWMxMDk1MzdmNWRfOS0xLTEtMS00NjY0Mg_91ed4656-b61b-4209-9461-9f2a36235c6b">66,431</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total operating lease liabilities (includes current portion)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmRjZmUzOGM4OWM1ZjQyMTY5OTg0MDVjMTA5NTM3ZjVkL3RhYmxlcmFuZ2U6ZGNmZTM4Yzg5YzVmNDIxNjk5ODQwNWMxMDk1MzdmNWRfMTAtMS0xLTEtNDY2NDI_081b82cb-aae3-4330-802b-ef87b1e8631e">82,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.969%"><tr><td style="width:1.0%"></td><td style="width:60.349%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.519%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating cash flows from operating leases (in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOjZkMDFjMzVmYzMxYjQ2ZTViZTFiNjhhOGEzNTIzZWJiL3RhYmxlcmFuZ2U6NmQwMWMzNWZjMzFiNDZlNWJlMWI2OGE4YTM1MjNlYmJfMy0yLTEtMS00NjY0Mg_395e9ecc-c26d-4e13-aa23-97f99abd5fe1">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOjZkMDFjMzVmYzMxYjQ2ZTViZTFiNjhhOGEzNTIzZWJiL3RhYmxlcmFuZ2U6NmQwMWMzNWZjMzFiNDZlNWJlMWI2OGE4YTM1MjNlYmJfMy00LTEtMS00NjY0Mg_01eeae30-d2fa-4b15-9797-49211ad24a64">2,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8658828dac144310891d79034519aac1_I20230331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOjZkMDFjMzVmYzMxYjQ2ZTViZTFiNjhhOGEzNTIzZWJiL3RhYmxlcmFuZ2U6NmQwMWMzNWZjMzFiNDZlNWJlMWI2OGE4YTM1MjNlYmJfNS0yLTEtMS00NjY0Mg_f92ca510-0b52-4ac1-8859-74464a27b595">6.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2b1b88ad17754cd781fd0282509470f4_I20220331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOjZkMDFjMzVmYzMxYjQ2ZTViZTFiNjhhOGEzNTIzZWJiL3RhYmxlcmFuZ2U6NmQwMWMzNWZjMzFiNDZlNWJlMWI2OGE4YTM1MjNlYmJfNS00LTEtMS00NjY0Mg_5cc043fc-1a59-44f0-ac86-4d51e52a3a2b">7.6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOjZkMDFjMzVmYzMxYjQ2ZTViZTFiNjhhOGEzNTIzZWJiL3RhYmxlcmFuZ2U6NmQwMWMzNWZjMzFiNDZlNWJlMWI2OGE4YTM1MjNlYmJfNi0yLTEtMS00NjY0Mg_7ba26c9c-9072-498b-88ed-d85d40465ffc">8.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i2b1b88ad17754cd781fd0282509470f4_I20220331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOjZkMDFjMzVmYzMxYjQ2ZTViZTFiNjhhOGEzNTIzZWJiL3RhYmxlcmFuZ2U6NmQwMWMzNWZjMzFiNDZlNWJlMWI2OGE4YTM1MjNlYmJfNi00LTEtMS00NjY0Mg_f00445ed-9d55-4059-9b8f-481f2b6c450c">8.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_55"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. <ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfNDg0NQ_624efc4b-b585-4d4a-8d97-68e0842011b9" continuedAt="ic6547a0c24bd43bbbebab7b59920b88e" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="ic6547a0c24bd43bbbebab7b59920b88e" continuedAt="i2ecb085299ca4b27b16df81b2cbddb8f"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three plans that provide for equity-based compensation. Under the 2004 Equity Incentive Plan (the &#8220;2004 Plan&#8221;) and 2013 Incentive Plan (the &#8220;2013 Plan&#8221;), <ix:nonFraction unitRef="shares" contextRef="i0eb27783d00443259f37672e22a51d89_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMjA4_31a28fd5-3b17-4944-956a-c119de600ff5">173,983</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i6f8f5aa4479d4452a8f944d74f31a91a_I20230331" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMjc0ODc3OTA3NDI5Ng_499c2b9e-4eb4-4252-b3f7-1d70d24f168b"><ix:nonFraction unitRef="shares" contextRef="i6f8f5aa4479d4452a8f944d74f31a91a_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMjc0ODc3OTA3NDI5Ng_9f0f12f7-fc94-4b59-b541-0607970f970b">3,518,957</ix:nonFraction></ix:nonFraction> shares, respectively, of the Company&#8217;s common stock are reserved for the grant of stock options, stock appreciation rights, restricted stock awards and performance unit/share awards to employees, consultants and others as of March&#160;31, 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 18, 2021, the Company&#8217;s Board of Directors approved the Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan (the &#8220;2021 Plan&#8221;), which authorizes <ix:nonFraction unitRef="shares" contextRef="i474bf33fa2dd4412b27d2d7dadd0143f_I20210318" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfNjAx_ab34b581-d780-463f-ae69-3e96a755d022">8,000,000</ix:nonFraction> shares (subject to certain adjustments) to be awarded for grants of stock options, stock appreciation rights, restricted and unrestricted stock and stock units, performance awards, cash awards and other awards convertible into or otherwise based on shares of the Company&#8217;s common stock. The maximum number of shares authorized under the 2021 Plan will be (i) reduced by any shares subject to awards made under the 2013 Plan after January 1, 2021, and (ii) increased by any shares subject to outstanding awards under the 2013 Plan as of January 1, 2021 that, after January 1, 2021, are canceled, expired, forfeited or otherwise not issued under such awards (other than as a result of being tendered or withheld to pay the exercise price or withholding taxes in connection with any such awards) or settled in cash. As of March&#160;31, 2023, the total number of shares reserved for issuance under the 2021 Incentive Plan was <ix:nonFraction unitRef="shares" contextRef="i85d0e738f7ad46a78439146ca6b1ce57_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMTUxMA_c2b80836-5913-4aa4-b847-ea9307977e79">6,126,788</ix:nonFraction> shares, which includes <ix:nonFraction unitRef="shares" contextRef="ia821a22f759c491095cdffcc22a16326_D20221001-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMTUzNg_cd996014-9ed1-459b-a157-8307a679ebc3">139,053</ix:nonFraction> shares that were forfeited under the 2013 Plan. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there were <ix:nonFraction unitRef="shares" contextRef="i82aee549d7ee4c17a0af2cb7b4160c1d_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMTYxMg_de5665e2-128e-4fb6-a62d-88b67208aa2d">743,726</ix:nonFraction> shares reserved for options and <ix:nonFraction unitRef="shares" contextRef="i415e58bd2ac14492bc9b71cfcaa0eb68_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMTY0Nw_f867709e-32fb-4aac-b0a7-4ac6711847c8">738,875</ix:nonFraction> shares reserved for restricted stock units issued as inducement grants to new employees granted outside of the Company&#8217;s equity-based compensation plans under Rule 5635(c)(4) of the Nasdaq Listing Rules.   </span></div><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfNDg0Mg_8465ea04-7fb0-4288-9166-0dfec185a652" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of awards outstanding:</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.711%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2004 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2013 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Inducement Awards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Granted and outstanding awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0eb27783d00443259f37672e22a51d89_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfMy0xLTEtMS00NjY0Mg_2b068925-6b09-45dc-8702-8e5045d8a713">173,983</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6f8f5aa4479d4452a8f944d74f31a91a_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfMy0zLTEtMS00NjY0Mg_ec4ee187-0bd5-43fe-a32c-2a405490df00">1,629,457</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i85d0e738f7ad46a78439146ca6b1ce57_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfMy01LTEtMS00NjY0Mg_7b1f9c62-9031-45f8-bd2e-ec4993790b5a">35,151</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3814d26ffec743bdbd368c8d17e1c599_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfMy03LTEtMS00NjY0Mg_3901a358-e391-4a1a-aba4-41c83c28dd3b">743,726</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfMy05LTEtMS00NjY0Mg_1f121558-d145-4e22-8533-df72dc700de9">2,582,317</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i513ac43a6b4641d5aa151e55bdb1adb8_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfNC0xLTEtMS00NjY0Mg_2a6b15df-6c0a-4790-9f99-afc1f6c50fec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ife4b80c909b0481bb55da5cc80d82206_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfNC0zLTEtMS00NjY0Mg_81b7161b-a715-4c0a-b5e4-ef2e48dbf714">1,889,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6930053b987b4dcb9ec1e29905995970_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfNC01LTEtMS00NjY0Mg_65cc24db-59fb-4dad-a2d5-28717b7172b0">1,701,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i415e58bd2ac14492bc9b71cfcaa0eb68_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfNC03LTEtMS00NjY0Mg_9b7c9724-dbda-4f03-a561-c111ab5e993d">738,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib6cd39bcc4aa4f2bb3274f9594d5294a_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfNC05LTEtMS00NjY0Mg_ad4f0a0f-c5e0-496c-b289-f32b9bba3ae2">4,330,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0eb27783d00443259f37672e22a51d89_I20230331" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfNS0xLTEtMS00NjY0Mg_a03f9258-0216-4356-ab0b-34fe6f878835">173,983</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6f8f5aa4479d4452a8f944d74f31a91a_I20230331" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfNS0zLTEtMS00NjY0Mg_499c2b9e-4eb4-4252-b3f7-1d70d24f168b"><ix:nonFraction unitRef="shares" contextRef="i6f8f5aa4479d4452a8f944d74f31a91a_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfNS0zLTEtMS00NjY0Mg_9f0f12f7-fc94-4b59-b541-0607970f970b">3,518,957</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i85d0e738f7ad46a78439146ca6b1ce57_I20230331" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfNS01LTEtMS00NjY0Mg_5ed782b2-db91-4176-bd26-92878cd7ec35">1,737,119</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3814d26ffec743bdbd368c8d17e1c599_I20230331" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfNS03LTEtMS00NjY0Mg_a59f2f60-1d1f-43aa-b72d-0a60a0a30c3e">1,482,601</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfNS05LTEtMS00NjY0Mg_95893998-9e39-4c04-8cf6-2ba25100cbc8">6,912,660</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Awards</span></div><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfNDg0Mw_a2b9f15c-b5da-4f6c-8fe5-801659264b94" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the stock option activity for the six months ended March&#160;31, 2023:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfMS0xLTEtMS00NjY0Mg_c746cdf6-6543-4f34-a2fc-c3e24f5940bc">2,721,384</ix:nonFraction></span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfMS0zLTEtMS00NjY0Mg_89d4a25e-5765-430e-8f17-60b2f17ee0d6">20.73</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfMi0xLTEtMS00NjY0Mg_0147ce4c-2172-43b5-bfd2-ef870fdfe3f9">32,151</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfMi0zLTEtMS00NjY0Mg_64da63e5-04fb-4914-a763-565656a491c7">33.03</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cancelled or expired</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfMy0xLTEtMS00NjY0Mg_e2236dd1-b738-4fb8-9ef2-84ec64b34a71">25,581</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfMy0zLTEtMS00NjY0Mg_f020b441-5d8b-4cfe-8c0c-1cd03a547b79">58.07</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfNC0xLTEtMS00NjY0Mg_ed323ba3-a284-4008-9424-a48fc77cd7c4">145,637</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfNC0zLTEtMS00NjY0Mg_a9926038-4ba8-4f7e-94bf-09ea700097af">7.50</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfNS0xLTEtMS00NjY0Mg_4187b4b1-89b1-4e4a-8162-aac30ddf2580">2,582,317</ix:nonFraction></span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfNS0zLTEtMS00NjY0Mg_7e5eb66c-1a89-444e-8ac2-bc06f9dd1054">21.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfNS01LTEtMS00NjY0Mg_e285a4ab-63e5-40a1-a5f9-cda23f21d74f">4.5</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfNS03LTEtMS00NjY0Mg_ae0d43f6-1f0d-4b9e-8e2f-cc0a7b7bcbb0">30,107,439</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercisable at March&#160;31, 2023</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfNi0xLTEtMS00NjY0Mg_d4a13504-1368-4214-84a4-afcee7507d8e">2,348,193</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfNi0zLTEtMS00NjY0Mg_62dc77da-3444-471d-a34d-70e15818dfcb">18.75</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfNi01LTEtMS00NjY0Mg_16757f4d-1af3-4283-b192-93d5cc940b0d">4.2</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8658828dac144310891d79034519aac1_I20230331" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfNi03LTEtMS00NjY0Mg_9023b2d6-f3f5-45a8-a278-832a30a0c557">30,100,306</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values represents the amount by which the market price of the underlying stock exceeds the exercise price of the option. The total intrinsic value of the options exercised during the three months ended March&#160;31, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="ie621a6d7b2894935b2a8275238e99a30_D20230101-20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMjQyNQ_93b094f9-6b16-4f5f-9486-0b8da6c27e95">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id48977f119694d19b519cfbd1b536975_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMjQzMg_12480c50-816a-46ad-824f-c4c16c8aabcd">10.8</ix:nonFraction> million, respectively. The total intrinsic value of the options exercised during the six months ended March&#160;31, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="i9390b1d02afc409d88c4726d14169331_D20221001-20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfNTQ5NzU1ODE5NjEz_3fbad3b1-c646-413d-8a90-def2d5e34fc0">3.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3a8a84b6b8274985b99c61c1887f17e4_D20211001-20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfNTQ5NzU1ODE5NjQ1_bc190aa8-bac9-435a-a70d-3f9f85197448">23.3</ix:nonFraction> million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to stock options outstanding for the three months ended March&#160;31, 2023 and 2022, was $<ix:nonFraction unitRef="usd" contextRef="ie621a6d7b2894935b2a8275238e99a30_D20230101-20230331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMjU2Mg_19e5df5e-be75-4a22-ac0f-7da9ba2f8e0c">2.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id48977f119694d19b519cfbd1b536975_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMjU2OQ_8af653ed-e833-44e4-8a00-4dbffba646bb">2.7</ix:nonFraction> million, respectively. Stock-based compensation expense related to stock options for the six months ended March&#160;31, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="i9390b1d02afc409d88c4726d14169331_D20221001-20230331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfOTM0NTg0ODg0MTM0NQ_abb5a5f4-1c39-4ddf-9bda-3c0245ad8599">4.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3a8a84b6b8274985b99c61c1887f17e4_D20211001-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfNTQ5NzU1ODE5NjMy_f6dc5959-29ef-4e9a-958c-bc39d5b7ad73">5.7</ix:nonFraction> million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the pre-tax compensation expense for all outstanding unvested stock options in the amount of $<ix:nonFraction unitRef="usd" contextRef="icd78c85c0ede4725b46aebc7e69ca686_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMjY5MQ_a6363d02-1a13-4686-8ba2-e58119289ffd">7.6</ix:nonFraction> million will be recognized in the Company&#8217;s results of operations over a weighted average period of <ix:nonNumeric contextRef="ie621a6d7b2894935b2a8275238e99a30_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMzI5ODUzNDg4OTA5NQ_f73a3266-7d22-45be-9027-b20670e3a88f">1.0</ix:nonNumeric> year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2ecb085299ca4b27b16df81b2cbddb8f"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#8217;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. </span></div><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMzI5ODUzNDg5MjI2Mg_46495058-2938-4d44-9e03-f331d0db9e3a" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the assumptions used in the calculation of grant-date fair values of these stock options based on the Back-Scholes option pricing model:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Expected dividend yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:114%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjA5NWY3YjA1NGE2ZDRmZDM5YTI3NDM2ZDdkYzY4YzdkL3RhYmxlcmFuZ2U6MDk1ZjdiMDU0YTZkNGZkMzlhMjc0MzZkN2RjNjhjN2RfMi0xLTEtMS01OTY5Mg_51363651-f444-4269-846e-800dfeb0df5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:114%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjA5NWY3YjA1NGE2ZDRmZDM5YTI3NDM2ZDdkYzY4YzdkL3RhYmxlcmFuZ2U6MDk1ZjdiMDU0YTZkNGZkMzlhMjc0MzZkN2RjNjhjN2RfMy0xLTEtMS01OTY5Mg_399739a7-144d-4eac-95ca-e7635a24e5b8">3.69</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:114%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjA5NWY3YjA1NGE2ZDRmZDM5YTI3NDM2ZDdkYzY4YzdkL3RhYmxlcmFuZ2U6MDk1ZjdiMDU0YTZkNGZkMzlhMjc0MzZkN2RjNjhjN2RfNC0xLTEtMS01OTY5Mg_6f89d120-44c6-4062-bfac-3a4ad2b1b694">86.4</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Expected term (in years)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:114%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjA5NWY3YjA1NGE2ZDRmZDM5YTI3NDM2ZDdkYzY4YzdkL3RhYmxlcmFuZ2U6MDk1ZjdiMDU0YTZkNGZkMzlhMjc0MzZkN2RjNjhjN2RfNS0xLTEtMS01OTY5Mg_e10af671-7f45-46c4-8cad-938e48793730">6.25</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Weighted average grant date fair value per share of options granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:114%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjA5NWY3YjA1NGE2ZDRmZDM5YTI3NDM2ZDdkYzY4YzdkL3RhYmxlcmFuZ2U6MDk1ZjdiMDU0YTZkNGZkMzlhMjc0MzZkN2RjNjhjN2RfNi0xLTEtMS01OTY5Mg_b0377c51-8b6b-44cd-833e-badfe4632142">24.80</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">N/A</span></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) The dividend yield is <ix:nonFraction unitRef="number" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMzI5ODUzNDg5MjI2Mw_68ef4ffd-260d-494d-ac41-3bee99cbb459">zero</ix:nonFraction> as the Company currently does not pay a dividend. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(2) The risk-free interest rate is based on that of the U.S. Treasury yields with equivalent terms in effect at the time of the grant. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(3) Volatility is estimated based on volatility average of the Company&#8217;s common stock price. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(4) The expected term represents the period of time that stock options granted are expected to be outstanding, by using historical exercise patterns and post-vesting termination behavior. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(5) No options were granted during the six months ended March 31, 2022.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units (&#8220;RSUs&#8221;), including market-based, time-based and performance-based awards, have been granted under the Company&#8217;s 2013 and 2021 Plans and as inducements grants granted outside of the Company&#8217;s equity-based compensation plans. At vesting, each outstanding RSU will be exchanged for one share of the Company&#8217;s common stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.</span></div><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfNDg0MQ_52ab47d6-59f0-410c-9a52-27815bb94471" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of the Company&#8217;s RSUs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Grant<br/>Date<br/>Fair Value<br/>Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="id9777e3d0f0044f9a5ae125314a8b62e_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjU4YzM0Y2E2MGQyZTQyYjJhNzc4OTVmYzQxMTRiZWE1L3RhYmxlcmFuZ2U6NThjMzRjYTYwZDJlNDJiMmE3Nzg5NWZjNDExNGJlYTVfMS0xLTEtMS00NjY0Mg_626da335-cf21-454b-b80e-407381dcfe5b">4,069,431</ix:nonFraction></span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="id9777e3d0f0044f9a5ae125314a8b62e_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjU4YzM0Y2E2MGQyZTQyYjJhNzc4OTVmYzQxMTRiZWE1L3RhYmxlcmFuZ2U6NThjMzRjYTYwZDJlNDJiMmE3Nzg5NWZjNDExNGJlYTVfMS0zLTEtMS00NjY0Mg_4dea1ccb-d0b0-4ce3-a95a-ecb222522e3a">62.96</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ied3ebc51b45741a1b31064cbf68604f1_D20221001-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjU4YzM0Y2E2MGQyZTQyYjJhNzc4OTVmYzQxMTRiZWE1L3RhYmxlcmFuZ2U6NThjMzRjYTYwZDJlNDJiMmE3Nzg5NWZjNDExNGJlYTVfMi0xLTEtMS00NjY0Mg_28ba23eb-99b8-4cf3-bb57-b3d1e58af1c7">1,098,544</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="ied3ebc51b45741a1b31064cbf68604f1_D20221001-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjU4YzM0Y2E2MGQyZTQyYjJhNzc4OTVmYzQxMTRiZWE1L3RhYmxlcmFuZ2U6NThjMzRjYTYwZDJlNDJiMmE3Nzg5NWZjNDExNGJlYTVfMi0zLTEtMS00NjY0Mg_15a3c528-2c93-40d0-86ab-3d4b5a04e92e">34.67</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="ied3ebc51b45741a1b31064cbf68604f1_D20221001-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjU4YzM0Y2E2MGQyZTQyYjJhNzc4OTVmYzQxMTRiZWE1L3RhYmxlcmFuZ2U6NThjMzRjYTYwZDJlNDJiMmE3Nzg5NWZjNDExNGJlYTVfMy0xLTEtMS00NjY0Mg_f10c8120-67a3-4157-a14b-516be876f8ac">763,132</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="ied3ebc51b45741a1b31064cbf68604f1_D20221001-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjU4YzM0Y2E2MGQyZTQyYjJhNzc4OTVmYzQxMTRiZWE1L3RhYmxlcmFuZ2U6NThjMzRjYTYwZDJlNDJiMmE3Nzg5NWZjNDExNGJlYTVfMy0zLTEtMS00NjY0Mg_806275c4-e084-4a73-9bff-26d818dfad93">54.20</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="ied3ebc51b45741a1b31064cbf68604f1_D20221001-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjU4YzM0Y2E2MGQyZTQyYjJhNzc4OTVmYzQxMTRiZWE1L3RhYmxlcmFuZ2U6NThjMzRjYTYwZDJlNDJiMmE3Nzg5NWZjNDExNGJlYTVfNC0xLTEtMS00NjY0Mg_a75b6b9b-bdb3-4b55-bab8-bc97c08a298a">74,500</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="ied3ebc51b45741a1b31064cbf68604f1_D20221001-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjU4YzM0Y2E2MGQyZTQyYjJhNzc4OTVmYzQxMTRiZWE1L3RhYmxlcmFuZ2U6NThjMzRjYTYwZDJlNDJiMmE3Nzg5NWZjNDExNGJlYTVfNC0zLTEtMS00NjY0Mg_14edda48-3b6f-4e20-afd1-c93ff29e2a11">57.28</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ib6cd39bcc4aa4f2bb3274f9594d5294a_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjU4YzM0Y2E2MGQyZTQyYjJhNzc4OTVmYzQxMTRiZWE1L3RhYmxlcmFuZ2U6NThjMzRjYTYwZDJlNDJiMmE3Nzg5NWZjNDExNGJlYTVfNS0xLTEtMS00NjY0Mg_12b3ee7c-f2dc-4800-8e3d-97275bdc9ece">4,330,343</ix:nonFraction></span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib6cd39bcc4aa4f2bb3274f9594d5294a_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjU4YzM0Y2E2MGQyZTQyYjJhNzc4OTVmYzQxMTRiZWE1L3RhYmxlcmFuZ2U6NThjMzRjYTYwZDJlNDJiMmE3Nzg5NWZjNDExNGJlYTVfNS0zLTEtMS00NjY0Mg_256fb540-72cd-41e7-b6df-7dca48efbbef">57.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs was determined based on the closing price of the Company&#8217;s common stock on the grant date, with consideration given to the probability of achieving service and/or performance conditions for awards.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023 and 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="ib2c010a50c4c41249cf51a81f611ddb4_D20230101-20230331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfOTM0NTg0ODg0MTUyOA_36c9f74e-fd94-41d5-b67a-caaced790fea">18.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i805db888d835420986d4e8a91b283687_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfOTM0NTg0ODg0MTYwMg_80f3b67d-4f11-41cd-b373-885e4c2c6685">28.2</ix:nonFraction> million of expense related to RSUs, respectively. For the six months ended March&#160;31, 2023 and 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="ied3ebc51b45741a1b31064cbf68604f1_D20221001-20230331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfOTM0NTg0ODg0MTQwMw_5c52b424-02ed-4fa7-9151-9536a80b6e94">35.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i17e779fd14684b3e966d950f0421cb5d_D20211001-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfOTM0NTg0ODg0MTQyNw_ce02b5d9-fcad-4256-8bcc-4151d3d0e84e">49.7</ix:nonFraction> million of expense related RSUs, respectively. As of March&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="ib6cd39bcc4aa4f2bb3274f9594d5294a_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfOTM0NTg0ODg0MTY1Mg_7938242f-a2cb-4e39-a29a-890c813c523c">153.6</ix:nonFraction> million of total unrecognized compensation cost related to RSUs that is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="ied3ebc51b45741a1b31064cbf68604f1_D20221001-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfOTM0NTg0ODg0MTY3MQ_8a8e1150-ca2f-4e33-9b51-bad8c5f1aa4c">2.5</ix:nonNumeric> years.</span></div></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. <ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RleHRyZWdpb246OGJiOWUwNTJiZTJkNDE1MGI3YWQ5ZWU2NWI4NDhhMGNfMzAzMw_32dc6ef2-6182-4979-8248-26ccddf3081d" continuedAt="i2caa236bb63146fab6cdd2cf2a9be78e" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i2caa236bb63146fab6cdd2cf2a9be78e" continuedAt="iec235bdedec5484bad00fe25170c6bb8"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company employs a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value of a financial instrument is the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date using the exit price. Accordingly, when market observable data are not readily available, the Company&#8217;s own assumptions are used to reflect those that market participants would be presumed to use in pricing the asset or liability at the measurement date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on the consolidated balance sheets are categorized based on the level of judgment associated with inputs used to measure their fair values and the level of market price observability, as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#160;&#160;&#160;&#160;Unadjusted quoted prices are available in active markets for identical assets or liabilities as of the  reporting date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#160;&#160;&#160;&#160;Pricing inputs are other than quoted prices in active markets, which are based on the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     Quoted prices for similar assets or liabilities in active markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     Quoted prices for identical or similar assets or liabilities in non-active markets; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     Either directly or indirectly observable inputs as of the reporting date.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#160;&#160;&#160;&#160;Pricing inputs are unobservable and significant to the overall fair value measurement, and the determination of fair value requires significant management judgment or estimation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. Thus, a Level 3 fair value measurement may include inputs that are observable (Level 1 or Level 2) and unobservable (Level 3). The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and consideration of factors specific to the asset or liability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses prices and inputs that are current as of the measurement date, including during periods of market disruption. In periods of market disruption, the ability to observe prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level 1 to Level 2, or from Level 2 to Level 3. The Company recognizes transfers between levels at either the actual date of the event or a change in circumstances that caused the transfer. At March&#160;31, 2023 and September&#160;30, 2022, the Company did not have any financial assets or financial liabilities based on Level 3 measurements.</span></div><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RleHRyZWdpb246OGJiOWUwNTJiZTJkNDE1MGI3YWQ5ZWU2NWI4NDhhMGNfMzAzNA_4277abce-40f5-4078-9b28-5e52817d995a" continuedAt="i71e89ad4920144a891d52fa3e3ba79fb" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques utilized by the Company:  </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:33.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia24340fff8444dbb848ee908a5350d12_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNC0xLTEtMS00NjY0Mg_724dc5eb-6c5a-4c9a-b36d-ee494173e599">23,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2860ca5f992241c38da43e79e2b1c5f5_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNC0zLTEtMS00NjY0Mg_5276bb09-5f92-4e47-ba03-c95aad6035b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8730e93a554e482bbc30293e7122903d_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNC01LTEtMS00NjY0Mg_dc43237d-d17c-451b-a82a-f96e7c0ff272">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9e07cc9368c3473882925939ec3292a4_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNC03LTEtMS00NjY0Mg_6f888bb7-cc59-4f05-9078-525fa0646c62">23,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Municipal securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if5e50e79a52647fd8ae13612e15c69cf_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNS0xLTEtMS01MzQzMw_9ac07017-1fba-4818-bead-ff4be70a8619">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a17cbdd764b419ab72a0c4122118bba_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNS0zLTEtMS01MzQzMw_0c351a5d-0908-4982-86f5-ab4a612a459e">7,034</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5266edfdef7545fb95e73d3313d505d6_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNS01LTEtMS01MzQzMw_a5a330a4-e7de-4c12-90a8-4dc8730cee19">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8049c9628c0e483abd37d06554b9e7d1_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNS03LTEtMS01MzQzMw_ccc27183-8359-41a8-aad5-a163d6769bce">7,034</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib089174a5cf348c1802beeaa2b977442_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNS0xLTEtMS00NjY0Mg_5561dc4d-0720-43ac-b9d2-23da17f4be42">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib16740a1de40482aba6561a9747b4a94_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNS0zLTEtMS00NjY0Mg_45b0e64c-4d1e-4853-b1c7-4c2a1aeaadd3">95,786</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i75aef6171137470d8e8e9cb8a2a83af6_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNS01LTEtMS00NjY0Mg_0db0083c-e63b-45a0-a291-abc7e35212b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2164b78caabc43fda358fdbd89914f21_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNS03LTEtMS00NjY0Mg_1139c951-d309-463c-b329-cc07e5616684">95,786</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5e3601b78983427db6b155d1b0307701_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNi0xLTEtMS00NjY0Mg_bfc9c6f7-7fe1-4fb2-8164-1da99843291f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib1b3c3e0baf84de3bd52125e28ec4b76_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNi0zLTEtMS00NjY0Mg_5dccd698-3069-4e92-af3d-9518be8da98f">306,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9f174aafdabf4608bf7c653ec8825fdd_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNi01LTEtMS00NjY0Mg_6b720efd-3e86-43dd-85e0-4ead1d863e0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if15ee248bfc441c796bf3f458c740ed7_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNi03LTEtMS00NjY0Mg_cd04e9c3-5780-4a0d-972b-af57a1ef2e20">306,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certificate of deposits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia24fba933c2d4cd0b16bded19b1bb09c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNy0xLTEtMS00NjY0Mg_a9670593-5f03-4714-ba63-cf1b8b4760c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5fbaa59436d843fe988d685090ab4af0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNy0zLTEtMS00NjY0Mg_dbe58e0a-c99e-4e8e-8a83-17f5aadcd185">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if043a0f1a28f41ad9782a0f46b2240b1_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNy01LTEtMS00NjY0Mg_8d4d7a56-2d87-47a9-876b-77b530d92b09">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3a07989748524f1f9e510ca832e4367d_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNy03LTEtMS00NjY0Mg_311118ee-f607-4804-91ab-0d8985b55b62">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4ca3440b89af4805ae8534cd78394ea4_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfOC0xLTEtMS00NjY0Mg_ca2afffd-85b2-40c4-8fb4-b9d490e95bfa">53,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idbc036b73a0349f8aeef68b475d74e60_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfOC0zLTEtMS00NjY0Mg_c945b078-adc4-4905-8348-cdf7ffa33b86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f8f0fdb41494916a8ccd82071a0dfa2_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfOC01LTEtMS00NjY0Mg_fc981fdc-5d49-44a5-bfc0-f7c149cc4d5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i04d5b678d5744ea1bb9862b56fd512dd_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfOC03LTEtMS00NjY0Mg_38664d95-991b-414f-ad07-6355167290ad">53,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><ix:continuation id="iec235bdedec5484bad00fe25170c6bb8"><ix:continuation id="i71e89ad4920144a891d52fa3e3ba79fb"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:33.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1024c68fa8084ef7ba0a4aa7d7e3620a_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNC0xLTEtMS00NjY0Mg_1cf29f2f-0de5-497a-a96d-a0f3f974769e">1,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i37966ce3d820452881dc0a4feb57c9d8_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNC0zLTEtMS00NjY0Mg_2b181344-edd6-48b8-b7a6-f8b9a9d9bcc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8e92174f5fd64f259dd75f387bad521c_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNC01LTEtMS00NjY0Mg_dd25f7cd-2580-407b-9707-5824b19de236">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1df1d8731bf74f8f93e44854a34edda1_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNC03LTEtMS00NjY0Mg_7e46a4d2-71b2-4b64-b013-4dcc1789f92e">1,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i22bc3c1a36b14889bca7b7d519b1e3a1_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNS0xLTEtMS00NjY0Mg_89d351b5-c5d9-4a28-b778-ec770acfcc30">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3fbe7cc097934385a0f7656c8c178477_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNS0zLTEtMS00NjY0Mg_04e7592d-b0fe-4d05-8339-4a11fa6cccbd">41,727</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i14946c523e3c4c16a7a727f5f8768473_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNS01LTEtMS00NjY0Mg_1a0af1a4-89f0-4326-b737-26c627bbbb28">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic88cc70b817c4141873c6deeb572df1c_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNS03LTEtMS00NjY0Mg_1da03057-6eb4-4951-9100-68fb78a47c1b">41,727</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id6a9654ad2f04e9eb78471c7b782bdc0_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNi0xLTEtMS00NjY0Mg_04b1625b-6cb9-4cb2-b3e8-5d84cdfc2b13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i783e40d9f7b349e687c2fafc7b31322b_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNi0zLTEtMS00NjY0Mg_ee6967bc-d48e-4a34-8e81-fcae7c6cab21">271,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if2cf83fb724d4e508f15e0cdb9fed5a5_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNi01LTEtMS00NjY0Mg_e2eeaa68-e964-45cc-b7c1-1f6e84c13c67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b8bc25ae7384b7b86bdeee4af8033ca_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNi03LTEtMS00NjY0Mg_0ed0587b-e1e6-4f93-b5a6-047e5dca80a5">271,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certificate of deposits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5fe25e9421f84420b7997e575e069958_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNy0xLTEtMS00NjY0Mg_7eaa5aae-026b-441b-803f-7f5d9606f370">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf039f9333f3461faaee52cf3325669f_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNy0zLTEtMS00NjY0Mg_881f64f7-0a93-4b88-a51e-7f77ca7b82d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2bbf95567b5f4f188e2a8249da064586_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNy01LTEtMS00NjY0Mg_5ca32dcf-0dc4-4b4d-891e-64d300c796ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2193adeae864400ea2611b5ffcc9bdf0_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNy03LTEtMS00NjY0Mg_adc7617b-8b95-4b6c-88e6-054e4a8e03fc">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i64d56047f58a464c9b4c5f44f3ce0413_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfOC0xLTEtMS00NjY0Mg_5e5ad9a0-d5bd-4534-8afe-774ce1212693">39,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i213da95ed9fc43649772cb98aa5ba619_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfOC0zLTEtMS00NjY0Mg_bfb4719e-583e-4f63-93e2-8f7e13daf866">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3d13c9a5b243437ea4291fc58b35695b_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfOC01LTEtMS00NjY0Mg_3cd79976-145a-4672-81a0-41b747b1b8e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie16b8c3eba024536a3a52b37dbdf8bd8_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfOC03LTEtMS00NjY0Mg_cd7dc528-0d7d-468d-820d-9695866c0b0c">39,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_61"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. <ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl82MS9mcmFnOmQzZDQ2Njc4Y2ZlNDQzZjJhN2M3OTVmNDk5NGQ4ZWNmL3RleHRyZWdpb246ZDNkNDY2NzhjZmU0NDNmMmE3Yzc5NWY0OTk0ZDhlY2ZfMjcwNA_a8715b44-eb5b-49d5-97b4-6a37344aaaff" continuedAt="i9459f5d2a912434ab51f9ddfc58313e1" escape="true">LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES</ix:nonNumeric></span></div><ix:continuation id="i9459f5d2a912434ab51f9ddfc58313e1"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2022, the Company and Royalty Pharma entered into the Royalty Pharma Agreement, pursuant to which Royalty Pharma agreed to pay up to $<ix:nonFraction unitRef="usd" contextRef="i3ba6acf54b0d4e5e9290dc7371ab7074_D20221109-20221109" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl82MS9mcmFnOmQzZDQ2Njc4Y2ZlNDQzZjJhN2M3OTVmNDk5NGQ4ZWNmL3RleHRyZWdpb246ZDNkNDY2NzhjZmU0NDNmMmE3Yzc5NWY0OTk0ZDhlY2ZfNTQ5NzU1ODE2ODI3_63bad34a-3227-4301-b599-037882760f0a">410.0</ix:nonFraction>&#160;million in cash to the Company in consideration for the Company&#8217;s future royalty interest in Olpasiran, a small interfering RNA (siRNA) originally developed by the Company and licensed to Amgen in 2016 under the Olpasiran Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Royalty Pharma Agreement, Royalty Pharma paid $<ix:nonFraction unitRef="usd" contextRef="ie3454e80f761434b82e05233642d0a59_D20221109-20221109" decimals="-5" name="arwr:CashReceivedAsDueUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl82MS9mcmFnOmQzZDQ2Njc4Y2ZlNDQzZjJhN2M3OTVmNDk5NGQ4ZWNmL3RleHRyZWdpb246ZDNkNDY2NzhjZmU0NDNmMmE3Yzc5NWY0OTk0ZDhlY2ZfMjc0ODc3OTA3MjQyMw_5bdce068-5b4e-4004-bc89-c3ef4445c3e2">250.0</ix:nonFraction> million upfront and agreed to pay up to an additional $<ix:nonFraction unitRef="usd" contextRef="ie1daa5e406944e308bb4bedb06fb3198_I20221109" decimals="-5" name="arwr:MilestonePaymentReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl82MS9mcmFnOmQzZDQ2Njc4Y2ZlNDQzZjJhN2M3OTVmNDk5NGQ4ZWNmL3RleHRyZWdpb246ZDNkNDY2NzhjZmU0NDNmMmE3Yzc5NWY0OTk0ZDhlY2ZfNTQ5NzU1ODE2ODMz_d51da58a-7fb5-4380-84d2-b5c8d97b9895">160.0</ix:nonFraction>&#160;million in aggregate one-time milestone payments due if and when the following milestone events occur: (i) $<ix:nonFraction unitRef="usd" contextRef="ie1daa5e406944e308bb4bedb06fb3198_I20221109" decimals="-5" name="arwr:MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl82MS9mcmFnOmQzZDQ2Njc4Y2ZlNDQzZjJhN2M3OTVmNDk5NGQ4ZWNmL3RleHRyZWdpb246ZDNkNDY2NzhjZmU0NDNmMmE3Yzc5NWY0OTk0ZDhlY2ZfNTQ5NzU1ODE2ODQw_636b8278-8941-4bd6-b44a-17ce18fb1980">50.0</ix:nonFraction>&#160;million on completion of enrollment in the planned OCEAN Phase 3 clinical trial for Olpasiran, (ii) $<ix:nonFraction unitRef="usd" contextRef="ie1daa5e406944e308bb4bedb06fb3198_I20221109" decimals="-5" name="arwr:MilestonePaymentReceivableUponFDAApproval" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl82MS9mcmFnOmQzZDQ2Njc4Y2ZlNDQzZjJhN2M3OTVmNDk5NGQ4ZWNmL3RleHRyZWdpb246ZDNkNDY2NzhjZmU0NDNmMmE3Yzc5NWY0OTk0ZDhlY2ZfNTQ5NzU1ODE2ODQ3_fb6c0e5c-c59d-4d74-8a88-192735c18955">50.0</ix:nonFraction>&#160;million upon receipt of FDA approval of Olpasiran for an approved indication (reduction in the risk of myocardial infarction, urgent coronary revascularization, or coronary heart disease death in adults with established cardiovascular disease and elevated Lp(a)), and (iii) $<ix:nonFraction unitRef="usd" contextRef="ie1daa5e406944e308bb4bedb06fb3198_I20221109" decimals="-5" name="arwr:MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl82MS9mcmFnOmQzZDQ2Njc4Y2ZlNDQzZjJhN2M3OTVmNDk5NGQ4ZWNmL3RleHRyZWdpb246ZDNkNDY2NzhjZmU0NDNmMmE3Yzc5NWY0OTk0ZDhlY2ZfNTQ5NzU1ODE2ODU0_39ef0bfc-01f2-4eaf-a24d-b6177b02303b">60.0</ix:nonFraction>&#160;million upon Royalty Pharma&#8217;s receipt of at least $<ix:nonFraction unitRef="usd" contextRef="ie1daa5e406944e308bb4bedb06fb3198_I20221109" decimals="-5" name="arwr:RoyaltyPaymentThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl82MS9mcmFnOmQzZDQ2Njc4Y2ZlNDQzZjJhN2M3OTVmNDk5NGQ4ZWNmL3RleHRyZWdpb246ZDNkNDY2NzhjZmU0NDNmMmE3Yzc5NWY0OTk0ZDhlY2ZfNTQ5NzU1ODE2ODYx_e0085bf7-3798-47f5-9802-ec978c338da4">70.0</ix:nonFraction>&#160;million of royalty payments under the Royalty Pharma Agreement in any single calendar year. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the payment of the foregoing amounts under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the terms of the Royalty Pharma Agreement and concluded in accordance with the relevant accounting guidance that the Company accounted for the transaction as debt and the funding of $<ix:nonFraction unitRef="usd" contextRef="i72781a23d66b49918170b8f70f504ec4_I20230331" decimals="-5" name="arwr:LiabilitySaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl82MS9mcmFnOmQzZDQ2Njc4Y2ZlNDQzZjJhN2M3OTVmNDk5NGQ4ZWNmL3RleHRyZWdpb246ZDNkNDY2NzhjZmU0NDNmMmE3Yzc5NWY0OTk0ZDhlY2ZfNTQ5NzU1ODE2ODY3_6cd4646b-edf9-409b-a9d5-ec67681e0361">250.0</ix:nonFraction>&#160;million from Royalty Pharma was recorded as a liability related to the sale of future royalties on its consolidated balance sheets. The Company is not obligated to repay this upfront funding received under the  Royalty Pharma Agreement. This liability is amortized over the expected repayment term using an effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. The interest rate may vary during the term of the agreement depending on a number of factors, including the amount and timing of forecasted net revenues which affects the repayment timing and ultimate amount of repayment. The Company will evaluate the effective interest rate quarterly based on its current revenue forecasts utilizing the prospective method. For the three and six months ended March&#160;31, 2023, the Company recognized non-cash interest expense of $<ix:nonFraction unitRef="usd" contextRef="i2c76d9b4843b4551a837b21eebd9dfdb_D20230101-20230331" decimals="-5" name="arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl82MS9mcmFnOmQzZDQ2Njc4Y2ZlNDQzZjJhN2M3OTVmNDk5NGQ4ZWNmL3RleHRyZWdpb246ZDNkNDY2NzhjZmU0NDNmMmE3Yzc5NWY0OTk0ZDhlY2ZfNTQ5NzU1ODE2NzA2_b54dd923-63be-4636-b9b4-df9a56f50362">5.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i55d4c31deffd475f8b184224f06e6834_D20221001-20230331" decimals="-5" name="arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl82MS9mcmFnOmQzZDQ2Njc4Y2ZlNDQzZjJhN2M3OTVmNDk5NGQ4ZWNmL3RleHRyZWdpb246ZDNkNDY2NzhjZmU0NDNmMmE3Yzc5NWY0OTk0ZDhlY2ZfNTQ5NzU1ODE2NzI0_d76b0191-2209-4220-8f25-f876a258949f">7.9</ix:nonFraction>&#160;million, respectively, on the consolidated statements of operations and comprehensive income (loss).</span></div></ix:continuation><div id="ic86d56462a0d40c99d8026254ea2d4d6_421"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12. <ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90ZXh0cmVnaW9uOmFhMDUyZTRlNDEzMDRkODY4YzUyMDliMTVmYTA4MDI4XzMyOTg1MzQ4ODc5NDY_a63a7d27-49e7-4c5e-a65c-6e71bba8da81" continuedAt="i938bb534763d41dcb44bd0045a30047e" escape="true">EARNINGS PER SHARE</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i938bb534763d41dcb44bd0045a30047e" continuedAt="ifee1200b7251438a985ddb7436120d77"><ix:nonNumeric contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90ZXh0cmVnaW9uOmFhMDUyZTRlNDEzMDRkODY4YzUyMDliMTVmYTA4MDI4XzQ5NDc4MDIzMjk2MTk_93b48d78-6c5a-4648-9e27-e9de900fecbb" continuedAt="i987a2b45c2ba4d72b9a400f3759a0a07" escape="true">The following table presents the computation of basic and diluted earnings per share for the six months ended </ix:nonNumeric></ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ifee1200b7251438a985ddb7436120d77"><ix:continuation id="i987a2b45c2ba4d72b9a400f3759a0a07"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023 and 2022. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzQtMi0xLTEtNjE2ODQ_c89a5c05-418e-4378-a6e5-abe5e17b078e">48,675</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzQtNC0xLTEtNjE2ODQ_b9a34c73-bc39-46ed-aadd-5a77770950e8">44,366</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzQtMS0xLTEtNjAwMTM_6653344e-7290-4f1b-a216-a2448ea31f0b">7,350</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzQtMy0xLTEtNjAwMjQ_fa99b872-13e5-4bb4-b9ee-bc24019a365a">18,506</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average basic shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzctMi0xLTEtNjE2ODQ_43b2b571-4f98-4b2e-9b7c-00ab552530e4">106,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzctNC0xLTEtNjE2ODQ_e0bea119-f5a0-4d4a-ab14-e2aabdccf4d1">105,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzctMS0xLTEtNjAwMTM_219673e7-6e68-420a-a455-3d04c2ce69d8">106,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzctMy0xLTEtNjAwMzA_e54cbc2c-d03f-4152-8bf3-855265075ef5">105,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of dilutive securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzgtMi0xLTEtNjE2ODQ_20b21b2e-2579-4b87-9519-d8456bd743d3">1,386</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzgtNC0xLTEtNjE2ODQ_bd35fc42-7010-4255-984b-fc33f8f1724e">2,384</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzgtMS0xLTEtNjAwMTM_56576fe9-9ad4-4278-9e16-a1e230b36176">1,499</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzgtMy0xLTEtNjAwMzA_a8837bed-b629-4b7e-adcb-f43260f9dc72">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average diluted shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzktMi0xLTEtNjE2ODQ_6f168b64-c634-4cb2-b4c5-f99231bd993e">108,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzktNC0xLTEtNjE2ODQ_90f17e91-616e-4d8a-be64-0f031a60b81e">107,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzktMS0xLTEtNjAwMTM_509e6301-5bc6-43d6-ab2c-8b355d7a53ef">107,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzktMy0xLTEtNjAwMzA_095af4df-1a2e-4ee2-a47b-38eeea36d7df">105,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzExLTItMS0xLTYxNjg0_d5e36991-9958-4131-88e8-9875c7757531">0.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzExLTQtMS0xLTYxNjg0_0c1808ae-e617-4f9d-a6d1-9ef64a98cdf9">0.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzExLTEtMS0xLTYwMDEz_1d07f3ac-a21c-4689-8121-db19601964da">0.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzExLTMtMS0xLTYwMDQw_e16b6a67-1aba-40eb-b842-5f324f6772c9">0.18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzEyLTItMS0xLTYxNjg0_5d55b7a7-0bfd-4d3e-918c-b3bc3f76970e">0.45</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzEyLTQtMS0xLTYxNjg0_8fc86bcd-968f-48c4-9dbd-5f5563306efa">0.41</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzEyLTEtMS0xLTYwMDEz_475d4bd4-ff91-466f-83c9-8a1f4ccadd60">0.07</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzEyLTMtMS0xLTYwMDQw_332aafea-9780-4b41-b3aa-8703c90ec6ad">0.18</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities representing approximately <ix:nonFraction unitRef="shares" contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90ZXh0cmVnaW9uOmFhMDUyZTRlNDEzMDRkODY4YzUyMDliMTVmYTA4MDI4XzU0OTc1NTgxODU3Mw_b882762a-1cec-419a-b57e-1efdf2659c59">4,350,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90ZXh0cmVnaW9uOmFhMDUyZTRlNDEzMDRkODY4YzUyMDliMTVmYTA4MDI4XzU0OTc1NTgxODEyMQ_c92c2d30-5fd5-47b3-b55e-bff4cf9f078e">4,069,000</ix:nonFraction> shares of common stock were excluded from the computation of diluted earnings per share for the three and six months ended March&#160;31, 2023, respectively, because their effect would have been anti-dilutive. There were <ix:nonFraction unitRef="shares" contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90ZXh0cmVnaW9uOmFhMDUyZTRlNDEzMDRkODY4YzUyMDliMTVmYTA4MDI4XzMyOTg1MzQ4ODc5NDc_dc02d67b-6ae7-478a-9d0d-321b40545a9f">no</ix:nonFraction> potentially dilutive securities with anti-dilutive effect for the six months ended March&#160;31, 2022.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_64"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and we intend that such forward-looking statements be subject to the safe harbors created thereby. For this purpose, any statements contained in this Quarterly Report on Form 10-Q except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;target,&#8221; &#8220;forecast&#8221; or &#8220;continue&#8221; or the negative of these words or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to projections of the Company&#8217;s future financial performance, trends in its business, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of the Company&#8217;s preclinical studies and clinical trials, and its research and development programs; its expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions the Company has entered into or may enter into in the future; its beliefs and expectations regarding the amount and timing of future milestone, royalty or other payments that could be due to or from third parties under existing agreements; and its estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The forward-looking statements included herein are based on current expectations of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> management based on available information and involve a number of risks and uncertainties, all of which are difficult or impossible to predict accurately, and many of which are beyond the Company&#8217;s control. As such, the Company&#8217;s actual results and timing of certain events may differ materially from the results discussed, projected, anticipated or indicated in any forward-looking statements. Forward-looking statements are not guarantees of future performance and the Company&#8217;s actual results of operations, financial condition and cash flows may differ materially. Factors that may cause or contribute to such differences include, but are not limited to, those discussed in more detail in &#8220;Item 1. Business&#8221; and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors&#8221; of Part I and &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of Part II of the Company&#8217;s most recent Annual Report on Form 10-K. Readers should carefully review these risks, as well as the additional risks described in other documents the Company files from time to time with the Securities and Exchange Commission (the &#8220;SEC&#8221;). In light of the significant risks and uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by the Company or any other person that such results will be achieved, and readers are cautioned not to place undue reliance on such forward-looking information. Statements made herein are as of the date of the filing of this Quarterly Report on Form 10-Q with the SEC and should not be relied upon as of any subsequent date. Except as may be required by law, the Company disclaims any intent to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.</span></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_67"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company&#8217;s therapies trigger the RNAi  mechanism to induce rapid, deep and durable knockdown of target genes. RNAi is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has focused its resources on therapeutics that exclusively utilize its high levels of pharmacologic activity in multiple animal models spanning several therapeutic areas. The Company believes that TRiM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> enabled therapeutics offer several potential advantages over prior generation and competing technologies, including: simplified manufacturing and reduced costs; multiple routes of administration including subcutaneous injection and inhaled administration; the ability to target multiple tissue types including liver, lung, muscle and others; and the potential for improved safety and reduced risk of intracellular buildup, because there are fewer metabolites from smaller, simpler molecules. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s pipeline includes:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Hypertriglyceridemia - ARO-APOC3</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Dyslipidemia - ARO-ANG3</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Cardiovascular disease - Olpasiran (formerly AMG 890 or ARO-LPA, out-licensed to Amgen)</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Cystic fibrosis - ARO-ENAC2</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Muco-obstructive or inflammatory pulmonary conditions - ARO-RAGE and ARO-MUC5AC</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Idiopathic pulmonary fibrosis - ARO-MMP7</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Liver disease - GSK-4532990 (formerly ARO-HSD, out-licensed to GSK)</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Liver disease associated with alpha-1 antitrypsin deficiency (AATD) - Fazirsiran (formerly ARO-AAT, a collaboration with Takeda)</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Chronic hepatitis B virus - JNJ-3989 (formerly ARO-HBV, out-licensed to Janssen) </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Uncontrolled gout - HZN-457 (formerly ARO-XDH, out-licensed to Horizon)</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Complement mediated diseases - ARO-C3</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Non-alcoholic steatohepatitis (NASH) - ARO-PNPLA3 (formerly JNJ-75220795or ARO-JNJ1)</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Facioscapulohumeral muscular dystrophy - ARO-DUX4</span></div><div style="padding-left:36pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">Amyotrophic lateral sclerosis &#8220;ALS&#8221; (CNS) - ARO-SOD1 </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates lab facilities in San Diego, California and Madison, Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company&#8217;s principal executive offices are located in Pasadena, California.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to develop other clinical candidates for future clinical trials. Clinical candidates are tested internally and through GLP toxicology studies at outside laboratories. Drug materials for such studies and clinical trials are either manufactured internally or contracted to third-party manufacturers. The Company engages third-party contract research organizations (CROs) to manage clinical trials and works cooperatively with such organizations on all aspects of clinical trial management, including plan design, patient recruiting, and follow up. These outside costs, relating to the preparation for and administration of clinical trials, are referred to as &#8220;candidate costs.&#8221; As clinical candidates progress through clinical development, candidate costs will increase. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The First Half of Fiscal 2023 Business Highlights</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key recent developments during the first half of fiscal 2023 included the following: </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">secured stockholder approval to increase authorized common shares to 290,000,000 from 145,000,000 to provide the Company with additional flexibility to issue common stock for a variety of general corporate purposes;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">announced interim results from ARO-RAGE administration in Part 1 of the ongoing Phase 1/2 study in normal healthy volunteers which included:</span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">reductions in soluble RAGE (sRAGE) as measured in serum after two doses on Day 1 and Day 29;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">duration of pharmacologic effect persisted for at least 6 weeks after the second administration of the 92 mg does with further follow up ongoing;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">reduction in sRAGE as measured in bronchoalveolar lavage fluid (BALF) at Day 31 after a single dose;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">reduction in in serum sRAGE were observed after a single dose;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">the pooled placebo groups experienced a mean sRAGE increase of 8% in BALF and a mean decrease of 1% serum</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">safety and tolerability;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expanded TRiM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform to include an optimized intrathecal administration for central nervous system (CNS) delivery with distribution throughout the brain and in all relevant brain cell types. The first development candidate to utilize this new delivery platform, ARO-SOD1, is anticipated to have a clinical trial application (CTA) filing in the third quarter of 2023 to begin clinical studies. In preclinical studies, ARO-SOD1 achieved 95% spinal cord tissue mRNA knockdown after a single intrathecal dose in human SOD1 transgenic rats and maintained greater than 80% spinal cord tissue mRNA knockdown three months after a single intrathecal dose in non-human primates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="background-color:#def3c0;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">dosed the first patient in Takeda&#8217;s Phase 3 REDWOOD clinical study of Fazirsiran for the treatment of alpha-1 antitrypsin deficiency associated liver diseases, triggering a $40.0&#160;million milestone payment to the Company which is expected be paid in the third quarter of fiscal 2023;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">dosed the first patient in GSK&#8217;s Phase 2 trial of GSK4532990, formerly called ARO-HSD, an investigational RNAi therapeutic for the treatment of patients with non-alcoholic steatohepatitis (NASH), triggering a $30.0&#160;million milestone payment to the Company which is expected to be paid in the third quarter of fiscal 2023;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARO-APOC3 for reducing triglycerides in adult patients with familial chylomicronemia syndrome (FCS). ARO-APOC3 was previously granted Orphan Drug designation by the FDA and the European Union;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">announced interim results from Part 1 of AROC3-1001, an ongoing Phase 1/2 clinical study of ARO-C3, which included;</span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">a dose-dependent reduction in serum C3, with 88% mean reduction at highest dose tested;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">a dose-dependent reduction in AH50, a marker of alternative complement pathway hemolytic activity, with 91% mean reduction at highest dose tested;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">duration of pharmacologic effect supportive of quarterly or less frequent subcutaneous dose administration;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">safety and tolerability;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">received notice from Janssen of its decision to voluntarily terminate the Janssen Collaboration Agreement between the Company and Janssen. The Company regained full rights to ARO-PNPLA3, formerly called JNJ-75220795,  upon termination of the Janssen Collaboration Agreement which took effect on April 7, 2023. ARO-PNPLA3 is in Phase 1 clinical trials that are now being developed by the Company;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.65pt">initiated dosing in AROMMP7-1001 (NCT05537025), a Phase 1/2a single ascending dose and multiple ascending dose clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-MMP7, an investigational RNAi therapeutic designed to reduce expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF), in up to 56 healthy volunteers and in up to 21 patients with IPF;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">enrolled the first subject in a Phase 1 randomized, placebo-controlled trial to assess the safety tolerability, pharmacokinetics and pharmacodynamics of a development-stage medicine, HZN-457 (previously known as ARO-XDH), which is out-licensed to Horizon, triggering a $15.0 million milestone payment to the Company which was paid in the second quarter of fiscal 2023;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">enrolled the first subject in Amgen&#8217;s Phase 3 trial of Olpasiran, which triggered a $25.0 million milestone payment to the Company, which was paid in the second quarter of fiscal 2023;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">entered into the Royalty Pharma Agreement on November 9, 2022, pursuant to which Royalty Pharma paid $250.0 million upfront (See Note 11 &#8212; Liability Related to the Sale of Future Royalties of Notes to Consolidated Financial Statements of Part I, &#8220;Item 1. Financial Statements.&#8221;);</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">announced top line results from the SEQUOIA Phase 2 Study of Fazirsiran in patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease in which;</span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">fibrosis regression was observed in 50% of patients receiving Fazirsiran;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">median reductions of 94% of Z-AAT accumulation in the liver and mean reductions of 68% in histologic globule burden were observed;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">treatment emergent adverse events were generally well balanced between Fazirsiran and placebo groups;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">results were consistent with AROAAT-2002 open-label study previously published in The New England Journal of Medicine.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income was $48.7 million for the three months ended March&#160;31, 2023 as compared to $44.4 million for the three months ended March&#160;31, 2022. Net income was $7.4 million for the six months ended March&#160;31, 2023 as compared to net losses of $18.5 million for the six months ended March&#160;31, 2022. Net income per share &#8211; diluted was $0.45 for the three months ended March&#160;31, 2023 as compared to $0.41 for the three months ended March&#160;31, 2022. Net income per share &#8211; diluted was $0.07 for the six months ended March&#160;31, 2023 as compared to net losses per share &#8211; diluted of $0.18 for the six months ended March&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in net income for the three months ended March&#160;31, 2023 was due to an increase in revenue from the Company&#8217;s license and collaboration agreements, primarily from the license agreements with Takeda and GSK, in conjunction with decreased general and administrative expenses. The increase in net income for the six months ended March&#160;31, 2023 was due to an increase in revenue from the Company&#8217;s license and collaboration agreements, primarily from the license agreements with Horizon, Amgen, Takeda and GSK, partially offset by increased research and development expenses, which have continued to increase as the Company&#8217;s pipeline of candidates has expanded and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progressed through clinical trial phases. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $135.0 million of cash, cash equivalents and restricted cash, $346.0 million in short-term investments, $78.8 million of long-term investments and $891.3 million of total assets as of March&#160;31, 2023, as compared to $108.0 million of cash, cash equivalents and restricted cash, $268.4 million in short-term investments, $105.9 million of long-term investments and $691.9 million of total assets as of September&#160;30, 2022. Based upon the Company&#8217;s current cash and investment resources and operating plan, the Company expects to have sufficient liquidity to fund operations for at least the next twelve months. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Accounting Estimates </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the Company&#8217;s critical accounting estimates disclosed in the most recent Annual Report on Form 10-K for the fiscal year ended September&#160;30, 2022, except Takeda revenue recognition described in Note 2 &#8212; Collaboration and License Agreements of Notes to Consolidated Financial Statements of Part I, &#8220;Item 1. Financial Statements.&#8221;</span></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_70"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following data summarizes the Company&#8217;s results of operations for the following periods indicated: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.121%"><tr><td style="width:1.0%"></td><td style="width:49.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.756%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.756%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.756%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.758%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(in thousands, except per share amounts)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">Revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">146,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">151,805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">208,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">179,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">Operating income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(21,768)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">Net income (loss) attributable to Arrowhead Pharmaceuticals, Inc.</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18,506)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">Net income (loss) per share-diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_73"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue for the three months ended March&#160;31, 2023 decreased to $146.3 million, or 3.6% from the same period of 2022. Total revenue for the six and months ended March&#160;31, 2023 increased to $208.8 million, or 16.5% from the same period of 2022. The changes were primarily driven by the revenue recognition associated with GSK, Horizon, Takeda and Amgen license agreements, as discussed below. The Company has evaluated each agreement in accordance with FASB Topic 808&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Topic 606-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue for Contracts from Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GSK</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the GSK License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibility to complete the Phase 1/2 study (the &#8220;GSK R&amp;D Services&#8221;). Due to the specialized and unique nature of the GSK R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. Beyond the GSK R&amp;D Services, which are the responsibility of the Company, GSK will be responsible for managing future clinical development and commercialization in its territory.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price totaled $120.0&#160;million, including the upfront payment, which was collected in January 2022 (see Note 2 &#8212; Collaboration and License Agreements to Consolidated Financial Statements of Part I, &#8220;Item 1. Financial Statements&#8221; for more information on revenue recognized under the GSK License Agreement). The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company has allocated the total $120.0&#160;million initial transaction price to its one distinct performance obligation for the GSK-4532990 license and the associated GSK R&amp;D Services. As the Company has completed its performance obligation related to this agreement, the upfront payment of $120.0&#160;million was fully recognized during the six months ended March 31, 2022. Further, GSK dosed the first patient in a Phase 2b trial in March 2023, triggering a $30.0&#160;million milestone payment to the Company which is expected to be paid in the third quarter of fiscal 2023. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Horizon </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021, Horizon and the Company entered into the Horizon License Agreement. At the inception of the Horizon License Agreement, the Company identified one distinct performance obligation. The Company determined that </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibilities to conduct all activities through the preclinical stages of development of HZN-457 (the &#8220;Horizon R&amp;D Services&#8221;). Due to the specialized and unique nature of these Horizon R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. Beyond the Horizon R&amp;D Services, which are the responsibility of the Company, Horizon is responsible for managing future clinical development and commercialization of HZN-457. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price totaled $40.0&#160;million, including the upfront payment (see Note 2 &#8212; Collaboration and License Agreements to Consolidated Financial Statements of Part I, &#8220;Item 1. Financial Statements&#8221; for more information on revenue recognized under the Horizon License Agreement). The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company allocated the total $40.0 million initial transaction price to its one distinct performance obligation for the HZN-457 license and the associated Horizon R&amp;D Services. Revenue was recognized on a straight-line basis over the timeframe for completing the Horizon R&amp;D Services. The Company determined that the straight-line basis was appropriate as its efforts were expended evenly over the course of completing its performance obligation. Further, Horizon enrolled the first subject in December 2022 in a Phase 1 randomized, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HZN-457, triggering a $15.0&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2023. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 7, 2020, Takeda and the Company entered into the Takeda License Agreement. At the inception of the Takeda License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of Fazirsiran drug product is completed and delivered to Takeda (the &#8220;Takeda R&amp;D Services&#8221;). Due to the specialized and unique nature of these Takeda R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. Beyond the Takeda R&amp;D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States. Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the 50/50 profit sharing structure within the United States. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts are recorded as research and development expenses or general and administrative expenses, as appropriate.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has allocated the total $300.0 million initial transaction price to its one distinct performance obligation for the Fazirsiran license and the associated Takeda R&amp;D Services. Revenue is recognized using a proportional performance method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). See Note 2 &#8212; Collaboration and License Agreements to Consolidated Financial Statements of Part I, &#8220;Item 1. Financial Statements&#8221; for more information on revenue recognized under the Takeda License Agreement. The Company previously expected these clinical trials to extend to September 2025 in order to demonstrate long term safety and efficacy in the open label extension part of the studies; however, Takeda now intends to initiate a new open label extension (OLE) study available to patients participating in these Phase 2 studies that will initiate as early as July 2023. Based on this new information, patients enrolled in the SEQUOIA and AROAAT2002 studies are expected to complete their Phase 2 study visits between June 2023 and June 2024, shortening the Company&#8217;s performance obligation. As a result, effective the second quarter of fiscal 2023, the Company changed its estimates of the revenue recognition to better reflect these newly estimated proportional performance periods. The effect of these changes in estimates resulted in accelerated revenue by $61.4 million, or $0.55 per share (diluted) for each of the three and six months ended March&#160;31, 2023. There were $30.9 million of contract liabilities recorded as deferred revenue, of which $29.8 million was classified as current as of March&#160;31, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, Takeda dosed the first patient in the Phase 3 REDWOOD clinical study of Fazirsiran, triggering a $40.0&#160;million milestone payment to the Company which is expected to be paid in the third quarter of fiscal 2023.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amgen Inc. (&#8220;Amgen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2016, Amgen and the Company entered into two collaboration and license agreements and a common stock purchase agreement. Under the Olpasiran Agreement, Amgen received a worldwide, exclusive license to the Company&#8217;s novel RNAi Olpasiran program. Olpasiran is designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Amgen is wholly responsible for clinical development and commercialization. The Company has substantially completed its performance obligations under the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Olpasiran Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, in November 2022, Royalty Pharma and the Company entered into the Royalty Pharma Agreement. In consideration for the payments under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In December 2022, Amgen enrolled the first subject in its Phase 3 trial of Olpasiran, which triggered a $25.0 million milestone payment to the Company, which was paid in the second quarter of fiscal 2023. The Company is further eligible to receive up to an additional $535.0&#160;million in aggregate development, regulatory, and sales milestone payments from Amgen and Royalty Pharma. See Note 2 &#8212; Collaboration and License Agreements to Consolidated Financial Statements of Part I, &#8220;Item 1. Financial Statements&#8221; for more information on revenue recognized under the collaboration and license agreements with Amgen. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_76"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating Expenses </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The analysis below details the operating expenses and discusses the expenditures of the Company within the major expense categories. For purposes of comparison, the amounts for the three and six months ended March&#160;31, 2023 and 2022 are shown in the tables below. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses are related to the Company&#8217;s research and development discovery efforts and related candidate costs, which are comprised primarily of outsourced costs related to the manufacturing of clinical supplies, toxicity/efficacy studies and clinical trial expenses. Internal costs primarily relate to discovery operations at the Company&#8217;s research facilities in San Diego, California and Madison, Wisconsin, including facility costs and laboratory-related expenses. The Company does not separately track R&amp;D expenses by individual research and development projects, or by individual drug candidates. The Company operates in a cross-functional manner across projects and does not separately allocate facilities-related costs, candidate costs, discovery costs, compensation expenses, depreciation and amortization expenses, and other expenses related to research and development activities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details of research and development expenses for the periods indicated:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.278%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(in thousands)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended <br/>March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">% of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Expense</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Category </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended <br/>March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">% of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Expense</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Category </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Increase (Decrease) </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">% </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Candidate costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37,713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11,127)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(30)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">R&amp;D discovery costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Salaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Facilities related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total research and development expense, excluding non-cash expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">63,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65,162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,291)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,745&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,642&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">103&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74,881&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75,985&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,104)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.278%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(in thousands)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended <br/>March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">% of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Expense</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Category </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended <br/>March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">% of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Expense</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Category </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Increase (Decrease) </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">% </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Candidate costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">68,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70,058&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,188)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">R&amp;D discovery costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Salaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Facilities related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total research and development expense, excluding non-cash expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">136,878&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">121,539&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,147&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,860&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,287&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">158,576&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">141,750&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,826&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Candidate costs decreased $11.1 million, or 30%, for the three months ended March&#160;31, 2023 and $1.2 million, or 2%, for the six months ended March&#160;31, 2023 compared to the same period of 2022. This decrease was primarily due to the reduction in outsourced manufacturing and toxicity study costs as the Company&#8217;s pipeline of candidates progressed through clinical trials in 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D discovery costs increased $3.2 million, or 22%, for the three months ended March&#160;31, 2023 and $4.9 million, or 19%, for the six months ended March&#160;31, 2023 compared to the same period of 2022. This increase was due to the growth of the Company&#8217;s discovery efforts and continued advancement into novel therapeutic areas and tissue types. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salaries and stock compensation expense consist of salary, bonuses, payroll taxes, related benefits and stock compensation for the Company&#8217;s R&amp;D personnel. The increases in salaries and stock comp expenses were primarily due to an increase in R&amp;D headcount that has occurred as the Company has expanded its pipeline of candidates, in addition to annual salary increases. Stock compensation expense was based upon the valuation of stock options and restricted stock units </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">granted to employees, directors and certain consultants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities-related expense included lease costs for the Company&#8217;s research and development facilities in San Diego, California and Madison, Wisconsin. Facilities-related costs increased $1.7 million, or 94%, for the three months ended March&#160;31, 2023 and $3.0 million, or 78%, for the six months ended March&#160;31, 2023 compared to the same period of 2022. This increase was mainly due to the additional lease expense as the Company expands discovery efforts to identify new drug candidates. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense, a non-cash expense, relates to depreciation on lab equipment and leasehold improvements at the facilities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates these R&amp;D expenses to continue to increase as its pipeline of candidates grows and progresses to later phase clinical trials, in addition to inflationary pressure on goods and services and the labor market. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General &amp; Administrative Expenses </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details of the Company&#8217;s general and administrative expenses for the periods indicated: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.959%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.279%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended <br/>March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">% of<br/>Expense<br/>Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended <br/>March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">% of<br/>Expense<br/>Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Increase (Decrease)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Salaries</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Professional, outside services, and others </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Facilities related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total general &amp; administrative expense, excluding non-cash expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,948&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,703&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,245&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(13,292)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(53)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total general &amp; administrative expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,221&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34,267&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11,046)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(32)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.959%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.279%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended <br/>March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">% of<br/>Expense<br/>Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended <br/>March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">% of<br/>Expense<br/>Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Increase (Decrease)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Salaries</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,022&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Professional, outside services, and others </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Facilities related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total general &amp; administrative expense, excluding non-cash expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,543&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,008&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,535&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,855&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42,447&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(19,592)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(46)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total general &amp; administrative expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,206&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">59,262&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(15,056)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(25)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salaries expense increased $1.2 million, or 33%, for the three months ended March&#160;31, 2023 and $2.0 million, or 28%, for the six months ended March&#160;31, 2023 compared to the same period of  2022. The increase was driven by the combination of annual salary increases and increased headcount required to support the Company&#8217;s growth. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional, outside services, and others expense includes legal, consulting, patent expenses, business insurance expenses, other outside services, travel, communication and technology expenses. This expense increased $0.7 million, or 16%, for the three months ended March&#160;31, 2023 and $1.9 million, or 25%, for the six months ended March&#160;31, 2023 compared to the same period of 2022. The increase was mainly due to consulting expenses related to software implementation and administrative expenses in support of additional headcount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities related expense primarily includes rental costs and other facilities-related costs for the Company&#8217;s corporate headquarters in Pasadena, California. Depreciation and amortization expense, a noncash expense, was primarily related to amortization of leasehold improvements for the Company&#8217;s corporate headquarters. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock compensation expense, a non-cash expense, decreased by $13.3 million, or 53%, for the three months ended March&#160;31, 2023 and $19.6 million, or 46%, for the six months ended March&#160;31, 2023 compared to the same period of 2022. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease was mainly due to the reversal of recognized compensation costs related to a performance award where the minimum performance goal was not met. The fair value of market condition-based awards was expensed ratably over the service period and was not adjusted for actual achievement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the stock compensation costs described above, the Company anticipates these general and administrative expenses to continue to increase as its pipeline of candidates grows and progresses to later phase clinical trials, in addition to inflationary pressure on goods and services and the labor market. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income is primarily related to interest income/expense and realized/unrealized gain/loss on investments. Other income decreased $3.3 million and $3.4 million for the three and six months ended March&#160;31, 2023, respectively, compared to the same periods of 2022. The decrease was primarily due to the interest expense on the liability related to the sale of future royalties, offset by higher yields on investments due to increased interest rates as well as credits the Company received during the first half of fiscal 2023. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically financed its operations through the sale of its common stock, and revenue from its licensing and collaboration agreements as well as more recently the sale of certain future royalties. Research and development activities have required significant capital investment since the Company&#8217;s inception and are expected to continue to require significant cash expenditure as the Company&#8217;s pipeline continues to expand and matures into later stage clinical trials. Additionally, the Company expanded its facilities in Verona, Wisconsin, and commenced the lease agreement for additional facilities in San Diego, California. Each of these expansions is designed to increase the Company&#8217;s internal manufacturing and discovery capabilities, and each will require significant capital investment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash, cash equivalents and restricted cash increased to $135.0 million at March&#160;31, 2023 compared to $108.0 million at September&#160;30, 2022. Cash invested in short-term fixed income securities was $346.0 million at March&#160;31, 2023 compared to $268.4 million at September&#160;30, 2022. Cash invested in long-term fixed income securities was $78.8 million at March&#160;31, 2023, compared to $105.9 million at September&#160;30, 2022. On December 2, 2022, the Company entered into the Open Market Sale Agreement, pursuant to which the Company may, from time to time, sell up to $250.0 million in shares of the Company&#8217;s common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering. As of  March&#160;31, 2023, no shares have been issued under the Open Market Sale Agreement. The Company believes its current financial resources are sufficient to fund its operations through at least the next twelve months. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of cash flows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash Flow from:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(107,187)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(116,759)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(103,140)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">251,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">3,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">27,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(97,988)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">134,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">86,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended March&#160;31, 2023, cash flows used by operating activities was $107.2 million, which was primarily due to the ongoing expenses related to the Company&#8217;s research and development programs and general and administrative expenses, partially offset by the receipt of $40.0 million from Amgen and Horizon (see Note 2 &#8212; Collaboration and License Agreements to Consolidated Financial Statements of Part I, &#8220;Item 1. Financial Statements&#8221;). Cash used in investing activities was $116.8 million, which was primarily related to capital expenditures, $66.2 million of  construction in progress, and $192.5 million of investments, offset by net sales and maturities of investments of $142.0 million. Cash provided by financing activities of $251.1 million was primarily related to the $250.0&#160;million payment from Royalty Pharma as well as cash received from stock option exercises.</span><span style="color:#0094ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 11 &#8212; Liability Related to the Sale of Future Royalties of Notes to Consolidated Financial Statements of Part I, &#8220;Item 1. Financial Statements.&#8221;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended March&#160;31, 2022, cash flows provided by operating activities was $1.4 million, which was primarily due to the receipt of the $120.0 million upfront payment from GSK, partially offset by the ongoing expenses related to the Company&#8217;s research and development programs and general and administrative expenses. Cash used in investing activities was $103.1 million, which was primarily related to the purchase of property and equipment of $10.5 million and net purchases of investments of $92.6 million. Cash provided by financing activities of $3.7 million was related to cash received from stock option exercises.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2021, the Company completed a purchase of 13 acres of land in the Verona Technology Park in Verona, Wisconsin, which is being developed into an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility which will support the Company&#8217;s process development and analytical activities. The Company has spent approximately $80.0 million and intends to spend an additional between $180.0&#160;million and $210.0&#160;million to complete the build out of the facilities. As part of this land purchase, the Company entered into a development agreement with the City of Verona to construct certain infrastructure improvements within the tax incremental district and expects to be reimbursed up to $16.0&#160;million by the City of Verona by future tax increment revenue generated from the developed property. The total amount of funding that City of Verona is expected to pay under the Tax Incremental Financing program is not guaranteed and will depend on future tax revenues generated from the developed property. The Company also expects receive up to $2.5&#160;million of refundable Wisconsin </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">state income tax credits from the Wisconsin Economic Development Corporation (WEDC) as incentives to invest in the local community and create new jobs.</span></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no material change in the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> exposure to market risk from that described in Item 7A of its Annual Report on Form 10-K for the year ended September 30, 2022.</span></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:12pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains disclosure controls and procedures designed to ensure that information required to be disclosed in its reports filed under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to its management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by Rule 13a-15(b) of the Exchange Act, the Company carried out an evaluation, under the supervision and with the participation of its management, including its Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company&#8217;s disclosure controls and procedures as of the end of the quarter covered by this Quarterly Report on Form 10-Q. Based on the foregoing, the Company&#8217;s Chief Executive Officer and Chief Financial Officer concluded that the Company&#8217;s disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in the Company&#8217;s internal control over financial reporting during the Company&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. The Company regularly evaluates its controls and procedures and makes improvements in the design and effectiveness of established controls and procedures and the remediation of any deficiencies which may be identified during this process.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in routine legal proceedings, as well as demands, claims and threatened litigation, which arise in the normal course of its business. Litigation can be expensive and disruptive to normal business operations. Moreover, the results of legal proceedings, particularly complex legal proceedings, cannot be predicted with any certainty. There have been no material developments in the legal proceedings that the Company disclosed in Part I, Item 3 of its Annual Report on Form 10-K for the year ended September 30, 2022.</span></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s business, results of operations and financial conditions are subject to various risks. These risks are described elsewhere in this Quarterly Report on Form 10-Q and in the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s other filings with the SEC, including the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Annual Report on Form 10-K for the year ended September 30, 2022. There have been no material changes from the risk factors identified in the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Annual Report on Form 10-K for the year ended September 30, 2022.</span></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_97"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_100"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable. </span></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_106"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">None. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.173%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Document Description</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000119312516532364/d175317dex33.htm">Amended and Restated Certificate of Incorporation (incorporated by reference from Exhibit 3.3 of the Company&#8217;s Form 8-K filed on April 6, 2016)</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="arrowheadpharmaceuticals.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Arrowhead Pharmaceuticals, Inc. </a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828023001757/arrowheadpharmaceuticals.htm">Second Amended and Restated Bylaws of Arrowhead Pharmaceuticals, Inc., as amended January 24, 2023</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="arwr-20230331xexx311.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="arwr-20230331xexx312.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="arwr-20230331xexx321.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="arwr-20230331xexx322.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Instance Document </span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cover page from this Quarterly Report on Form 10-Q, formatted in Inline XBRL (included as Exhibit 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31pt">Filed herewith.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26pt">Furnished herewith.</span></div><div style="text-indent:-18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="ic86d56462a0d40c99d8026254ea2d4d6_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURE</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: May&#160;2, 2023</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARROWHEAD PHARMACEUTICALS, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Kenneth A. Myszkowski</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kenneth A. Myszkowski<br/>Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer and Duly Authorized Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>2
<FILENAME>arrowheadpharmaceuticals.htm
<DESCRIPTION>EX-3.2
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>arrowheadpharmaceuticals</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- arrowheadpharmaceuticals001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="arrowheadpharmaceuticals001.jpg" title="slide1" width="965" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">Delaware The First State Page 1                    3354811   8100 Authentication: 203227797 SR# 20231665245 Date: 04-27-23 You may verify this certificate online at corp.delaware.gov/authver.shtml I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF  DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT  COPY OF THE CERTIFICATE OF AMENDMENT OF &#8220;ARROWHEAD  PHARMACEUTICALS, INC.&#8221;, FILED IN THIS OFFICE ON THE TWENTY- SEVENTH DAY OF APRIL, A.D. 2023, AT 10:05 O`CLOCK A.M.     </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- arrowheadpharmaceuticals002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="arrowheadpharmaceuticals002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- arrowheadpharmaceuticals003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="arrowheadpharmaceuticals003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>arwr-20230331xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>arwr-20230331xexx311</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- arwr-20230331xexx311001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="arwr-20230331xexx311001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>arwr-20230331xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>arwr-20230331xexx312</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- arwr-20230331xexx312001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="arwr-20230331xexx312001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>arwr-20230331xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>arwr-20230331xexx321</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- arwr-20230331xexx321001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="arwr-20230331xexx321001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>arwr-20230331xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>arwr-20230331xexx322</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- arwr-20230331xexx322001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="arwr-20230331xexx322001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>arwr-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:838ae12b-ce84-423c-b3bd-d5043611fe16,g:09a7ef9b-3d5a-4a38-9975-37e1f59f1b78-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:arwr="http://www.arrowheadresearch.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arrowheadresearch.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.arrowheadresearch.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss">
        <link:definition>0000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000005 - Statement - Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPolicies" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies">
        <link:definition>0000007 - Disclosure - Organization and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreements" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements">
        <link:definition>0000008 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipment">
        <link:definition>0000009 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.arrowheadresearch.com/role/Investments">
        <link:definition>0000010 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssets" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssets">
        <link:definition>0000011 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.arrowheadresearch.com/role/StockholdersEquity">
        <link:definition>0000012 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingencies">
        <link:definition>0000013 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.arrowheadresearch.com/role/Leases">
        <link:definition>0000014 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensation">
        <link:definition>0000015 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurements">
        <link:definition>0000016 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheSaleofFutureRoyalties" roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties">
        <link:definition>0000017 - Disclosure - Liability Related to the Sale of Future Royalties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.arrowheadresearch.com/role/EarningsPerShare">
        <link:definition>0000018 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesPolicies" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies">
        <link:definition>0000019 - Disclosure - Organization and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesTables" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables">
        <link:definition>0000020 - Disclosure - Organization and Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsTables" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables">
        <link:definition>0000021 - Disclosure - Collaboration and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentTables">
        <link:definition>0000022 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.arrowheadresearch.com/role/InvestmentsTables">
        <link:definition>0000023 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsTables" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsTables">
        <link:definition>0000024 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityTables">
        <link:definition>0000025 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.arrowheadresearch.com/role/LeasesTables">
        <link:definition>0000026 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationTables">
        <link:definition>0000027 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsTables">
        <link:definition>0000028 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.arrowheadresearch.com/role/EarningsPerShareTables">
        <link:definition>0000029 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>0000030 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsRevenueDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails">
        <link:definition>0000031 - Disclosure - Collaboration and License Agreements - Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails">
        <link:definition>0000032 - Disclosure - Collaboration and License Agreements - Receivables and Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails">
        <link:definition>0000033 - Disclosure - Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails">
        <link:definition>0000034 - Disclosure - Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails">
        <link:definition>0000035 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails">
        <link:definition>0000036 - Disclosure - Collaboration and License Agreements - Janssen Pharmaceuticals, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsAmgenIncDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails">
        <link:definition>0000037 - Disclosure - Collaboration and License Agreements - Amgen, Inc (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails">
        <link:definition>0000038 - Disclosure - Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentSummaryofPropertyandEquipmentDetail" roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail">
        <link:definition>0000039 - Disclosure - Property and Equipment - Summary of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentAdditionalInformationDetail" roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetail">
        <link:definition>0000040 - Disclosure - Property and Equipment - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" roleURI="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails">
        <link:definition>0000041 - Disclosure - Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsScheduleofIntangibleAssetsDetails" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails">
        <link:definition>0000042 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsExpectedFutureAmortizationDetails" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails">
        <link:definition>0000043 - Disclosure - Intangible Assets - Expected Future Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityDetails">
        <link:definition>0000044 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetail" roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail">
        <link:definition>0000045 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails">
        <link:definition>0000046 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseAssetsandLiabilitiesDetails" roleURI="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails">
        <link:definition>0000047 - Disclosure - Leases - Components of Lease Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails">
        <link:definition>0000048 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1">
        <link:definition>0000048 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails" roleURI="http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails">
        <link:definition>0000049 - Disclosure - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>0000050 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails">
        <link:definition>0000051 - Disclosure - Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails">
        <link:definition>0000052 - Disclosure - Stock-Based Compensation - Summarize Information about Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails">
        <link:definition>0000053 - Disclosure - Stock-Based Compensation - Assumptions Used to Value Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofRSUsActivityDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails">
        <link:definition>0000054 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>0000055 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheSaleofFutureRoyaltiesDetails" roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails">
        <link:definition>0000056 - Disclosure - Liability Related to the Sale of Future Royalties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.arrowheadresearch.com/role/EarningsPerShareDetails">
        <link:definition>0000057 - Disclosure - Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="arwr_NumberOfAcresOfLandPurchased" abstract="false" name="NumberOfAcresOfLandPurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponFDAApproval" abstract="false" name="MilestonePaymentReceivableUponFDAApproval" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_TaxIncrementFinancingAward" abstract="false" name="TaxIncrementFinancingAward" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_NumberOfDistinctBundle" abstract="false" name="NumberOfDistinctBundle" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_CommercialMilestonePaymentsAtFirstCommercialSale" abstract="false" name="CommercialMilestonePaymentsAtFirstCommercialSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_InitialTransactionPrice" abstract="false" name="InitialTransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_LicenseAgreementMember" abstract="true" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_SorrentoValleyOwnerDELLCMember" abstract="true" name="SorrentoValleyOwnerDELLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" abstract="false" name="NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_NumberOfAgreements" abstract="false" name="NumberOfAgreements" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" abstract="false" name="LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arwr_TwoThousandsThirteenIncentivePlanMember" abstract="true" name="TwoThousandsThirteenIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross" abstract="false" name="ComputersSoftwareOfficeEquipmentAndFurnitureGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" abstract="false" name="DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_RoyaltyPaymentThreshold" abstract="false" name="RoyaltyPaymentThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_AROXDHAgreementMember" abstract="true" name="AROXDHAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_VisirnaTherapeuticsIncMember" abstract="true" name="VisirnaTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_UpfrontMilestonePaymentReceived" abstract="false" name="UpfrontMilestonePaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" abstract="false" name="HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arwr_LiabilitySaleOfFutureRoyalties" abstract="false" name="LiabilitySaleOfFutureRoyalties" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_LicenseAndCoFundingAgreementMember" abstract="true" name="LicenseAndCoFundingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" abstract="false" name="DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_AmountIntendsToInvestForBuildoutOfFacilities" abstract="false" name="AmountIntendsToInvestForBuildoutOfFacilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_JanssenPharmaceuticalsIncorporationMember" abstract="true" name="JanssenPharmaceuticalsIncorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" abstract="false" name="PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arwr_CashReceivedAsDueUnderCollaborationAgreement" abstract="false" name="CashReceivedAsDueUnderCollaborationAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ResearchFacilityInMadisonMember" abstract="true" name="ResearchFacilityInMadisonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_NumberOfOptionsToRenew" abstract="false" name="NumberOfOptionsToRenew" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_ResearchEquipmentGross" abstract="false" name="ResearchEquipmentGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" abstract="false" name="DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_SalesRelatedMilestonePayments" abstract="false" name="SalesRelatedMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CommercialNotesMember" abstract="true" name="CommercialNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_EstimatedPaymentsForOperatingExpensesYearOne" abstract="false" name="EstimatedPaymentsForOperatingExpensesYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_HorizonTherapeuticsIrelandDACMember" abstract="true" name="HorizonTherapeuticsIrelandDACMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_NovartisMember" abstract="true" name="NovartisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_VeronaTechnologyParkMember" abstract="true" name="VeronaTechnologyParkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_TwoThousandsFourEquityIncentivePlanMember" abstract="true" name="TwoThousandsFourEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_OlpasiranAndAROAMG1AgreementMember" abstract="true" name="OlpasiranAndAROAMG1AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ScheduleOfCurrentProductsTableTextBlock" abstract="false" name="ScheduleOfCurrentProductsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" abstract="false" name="CommonStockCapitalSharesValueReservedForFutureIssuance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_JNJ3989AROHBVAgreementMember" abstract="true" name="JNJ3989AROHBVAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" abstract="true" name="ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arwr_CommonStockPurchaseAgreementMember" abstract="true" name="CommonStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_CollaborationAndLicenseAgreementMember" abstract="true" name="CollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_GlaxosmithklineIntellectualPropertyLimitedMember" abstract="true" name="GlaxosmithklineIntellectualPropertyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_MilestonePayments" abstract="false" name="MilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" abstract="true" name="TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" abstract="false" name="MilestonePaymentReceivableAtStartOfPhaseTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_RoyaltiesLiabilityNoncurrent" abstract="false" name="RoyaltiesLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_TwoThousandTwentyOneIncentivePlanMember" abstract="true" name="TwoThousandTwentyOneIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" abstract="true" name="OrganizationAndSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" abstract="false" name="PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" abstract="true" name="TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_DeferredRevenueMember" abstract="true" name="DeferredRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_JNJ75220795AROJNJ1Member" abstract="true" name="JNJ75220795AROJNJ1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ResearchFacilityInSanDiegoMember" abstract="true" name="ResearchFacilityInSanDiegoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_LaboratoryAndOfficeFacilityMember" abstract="true" name="LaboratoryAndOfficeFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_MilestonePaymentEarned" abstract="false" name="MilestonePaymentEarned" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_TechnologyLicenseCommitmentsMember" abstract="true" name="TechnologyLicenseCommitmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_CorporateHeadquartersInPasadenaMember" abstract="true" name="CorporateHeadquartersInPasadenaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_VisirnaLicenseAgreementMember" abstract="true" name="VisirnaLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_FiniteLivedIntangibleAssetsImpairment" abstract="false" name="FiniteLivedIntangibleAssetsImpairment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_InducementAwardsMember" abstract="true" name="InducementAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_DrugManufacturingFacilityMember" abstract="true" name="DrugManufacturingFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_HorizonTherapeuticsIrelandDACAndAmgenIncorporatedMember" abstract="true" name="HorizonTherapeuticsIrelandDACAndAmgenIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" abstract="false" name="DevelopmentRegulatoryAndSalesMilestonesPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_NumberOfDistinctPerformanceObligations" abstract="false" name="NumberOfDistinctPerformanceObligations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" abstract="false" name="MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_OlpasiranAgreementMember" abstract="true" name="OlpasiranAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_FacilitiesMember" abstract="true" name="FacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" abstract="true" name="LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" abstract="true" name="ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_RoyaltyPharmaAgreementMember" abstract="true" name="RoyaltyPharmaAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_AmgenIncorporatedMember" abstract="true" name="AmgenIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" abstract="false" name="CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" abstract="false" name="MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivable" abstract="false" name="MilestonePaymentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ColoradoOwnerLLCMember" abstract="true" name="ColoradoOwnerLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_AtTheMarketAgreementMember" abstract="true" name="AtTheMarketAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_RoyaltyPharmaMember" abstract="true" name="RoyaltyPharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" abstract="false" name="MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" abstract="false" name="DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" abstract="true" name="JohnsonAndJohnsonInnovationJJDCIncorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" abstract="false" name="PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentReceived" abstract="false" name="MilestonePaymentReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_IncreaseDecreaseInCashAndInvestments" abstract="false" name="IncreaseDecreaseInCashAndInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_OrganizationAndSignificantAccountingPoliciesTable" abstract="true" name="OrganizationAndSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" abstract="false" name="AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>arwr-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:838ae12b-ce84-423c-b3bd-d5043611fe16,g:09a7ef9b-3d5a-4a38-9975-37e1f59f1b78-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="arwr-20230331.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_93e6451c-20fa-455a-b056-cbe7ae62b26f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c039a8fd-05a7-49f9-a347-6554d0c5e1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_93e6451c-20fa-455a-b056-cbe7ae62b26f" xlink:to="loc_us-gaap_StockholdersEquity_c039a8fd-05a7-49f9-a347-6554d0c5e1bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_23f1276e-dc9d-4291-80f2-688da3ab2a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_93e6451c-20fa-455a-b056-cbe7ae62b26f" xlink:to="loc_us-gaap_MinorityInterest_23f1276e-dc9d-4291-80f2-688da3ab2a40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0f8dd8aa-43ef-4a36-94bd-483799e908a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_92a04557-8bdd-4323-a8aa-c46d97a180d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0f8dd8aa-43ef-4a36-94bd-483799e908a5" xlink:to="loc_us-gaap_AssetsCurrent_92a04557-8bdd-4323-a8aa-c46d97a180d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_facf5328-834e-47a7-b840-97154d316fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0f8dd8aa-43ef-4a36-94bd-483799e908a5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_facf5328-834e-47a7-b840-97154d316fe6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_765bf698-d975-4ab1-851b-7567a2850c67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0f8dd8aa-43ef-4a36-94bd-483799e908a5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_765bf698-d975-4ab1-851b-7567a2850c67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_63f95463-7f50-4188-91a9-c241b3383d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0f8dd8aa-43ef-4a36-94bd-483799e908a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_63f95463-7f50-4188-91a9-c241b3383d8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_70a768d4-b348-42ee-a151-969c028b9315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0f8dd8aa-43ef-4a36-94bd-483799e908a5" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_70a768d4-b348-42ee-a151-969c028b9315" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_674c8efa-a7cc-45be-9ac5-7bd15aa22fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0f8dd8aa-43ef-4a36-94bd-483799e908a5" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_674c8efa-a7cc-45be-9ac5-7bd15aa22fdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_353957f7-a57f-416f-beda-d81cf15b0123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_5fae5462-366d-4bba-abc3-ce28540e5294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_353957f7-a57f-416f-beda-d81cf15b0123" xlink:to="loc_us-gaap_AccountsPayableCurrent_5fae5462-366d-4bba-abc3-ce28540e5294" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4220d325-9106-42d0-9622-4fd7521f24b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_353957f7-a57f-416f-beda-d81cf15b0123" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4220d325-9106-42d0-9622-4fd7521f24b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5341bc57-f52c-4d23-a967-7501c7f84494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_353957f7-a57f-416f-beda-d81cf15b0123" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5341bc57-f52c-4d23-a967-7501c7f84494" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4f6d072b-c207-4a16-9af8-6bf2b6e0c7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_353957f7-a57f-416f-beda-d81cf15b0123" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4f6d072b-c207-4a16-9af8-6bf2b6e0c7e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_dd01cbd2-bda1-4222-a2d1-acd07647efc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_353957f7-a57f-416f-beda-d81cf15b0123" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_dd01cbd2-bda1-4222-a2d1-acd07647efc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_8c37138f-9dde-4cf5-8957-a8d9646af035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_0fc8d68c-65ec-4841-9308-86f61e18b6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_8c37138f-9dde-4cf5-8957-a8d9646af035" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_0fc8d68c-65ec-4841-9308-86f61e18b6e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltiesLiabilityNoncurrent_70ef8d0c-3b5d-43c7-9d10-1697a1f9150c" xlink:href="arwr-20230331.xsd#arwr_RoyaltiesLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_8c37138f-9dde-4cf5-8957-a8d9646af035" xlink:to="loc_arwr_RoyaltiesLiabilityNoncurrent_70ef8d0c-3b5d-43c7-9d10-1697a1f9150c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_57203817-9309-4507-805a-9f349beab9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_8c37138f-9dde-4cf5-8957-a8d9646af035" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_57203817-9309-4507-805a-9f349beab9a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5cedd43d-7c74-4e40-ac87-e3e9edb24cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_096f1dfa-7cf4-459e-9956-5738ede80ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5cedd43d-7c74-4e40-ac87-e3e9edb24cf9" xlink:to="loc_us-gaap_LiabilitiesCurrent_096f1dfa-7cf4-459e-9956-5738ede80ca4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_89663937-df8a-4bb2-bb6a-278ad6d2b1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5cedd43d-7c74-4e40-ac87-e3e9edb24cf9" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_89663937-df8a-4bb2-bb6a-278ad6d2b1fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c2175a93-ad29-4b2f-95a9-459682c0c566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5cedd43d-7c74-4e40-ac87-e3e9edb24cf9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c2175a93-ad29-4b2f-95a9-459682c0c566" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0ad85490-342a-4c39-8f99-6dfdf29c0a53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5cedd43d-7c74-4e40-ac87-e3e9edb24cf9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0ad85490-342a-4c39-8f99-6dfdf29c0a53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_51f847fe-c356-48e9-bb00-64fb10a69775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ccc37bee-c1c7-4873-98a2-640bfa9213b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_51f847fe-c356-48e9-bb00-64fb10a69775" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ccc37bee-c1c7-4873-98a2-640bfa9213b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_663f0180-0719-4763-baec-f99df42e9778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_51f847fe-c356-48e9-bb00-64fb10a69775" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_663f0180-0719-4763-baec-f99df42e9778" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7e8956a1-e1fd-49e7-8d66-2dc041b0881f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_51f847fe-c356-48e9-bb00-64fb10a69775" xlink:to="loc_us-gaap_CommonStockValue_7e8956a1-e1fd-49e7-8d66-2dc041b0881f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_15f7b23a-ec77-4940-9f50-461addc5e2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_51f847fe-c356-48e9-bb00-64fb10a69775" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_15f7b23a-ec77-4940-9f50-461addc5e2f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_388e9f60-0125-40e0-bab5-e77a2a2fe31b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1883e65e-64bf-4461-af7a-5603b82442ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_388e9f60-0125-40e0-bab5-e77a2a2fe31b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1883e65e-64bf-4461-af7a-5603b82442ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e2788802-0d19-4423-a681-397c953ee0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_388e9f60-0125-40e0-bab5-e77a2a2fe31b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e2788802-0d19-4423-a681-397c953ee0fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_7daf2065-cde0-4651-b6eb-f07149c85ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_388e9f60-0125-40e0-bab5-e77a2a2fe31b" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_7daf2065-cde0-4651-b6eb-f07149c85ac2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_9d9cf5d4-c7ea-422f-8765-575b9a5eda42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_388e9f60-0125-40e0-bab5-e77a2a2fe31b" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_9d9cf5d4-c7ea-422f-8765-575b9a5eda42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_990913be-bfa2-4420-892c-4cee25c22716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_388e9f60-0125-40e0-bab5-e77a2a2fe31b" xlink:to="loc_us-gaap_OtherAssetsCurrent_990913be-bfa2-4420-892c-4cee25c22716" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" xlink:type="simple" xlink:href="arwr-20230331.xsd#ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_80822f2e-2cb1-494c-a7fd-77f10ce1e97b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2b533b6c-aba1-4a98-ba46-d98380a08a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_80822f2e-2cb1-494c-a7fd-77f10ce1e97b" xlink:to="loc_us-gaap_ProfitLoss_2b533b6c-aba1-4a98-ba46-d98380a08a89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a75f0d64-345f-431b-a854-633b03b5e47b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_80822f2e-2cb1-494c-a7fd-77f10ce1e97b" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a75f0d64-345f-431b-a854-633b03b5e47b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f88b398b-f60e-4272-b807-bc71d4286514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_17c912fb-d3a7-4bc4-807b-3c5e192561ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f88b398b-f60e-4272-b807-bc71d4286514" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_17c912fb-d3a7-4bc4-807b-3c5e192561ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_dd2599f7-97bd-4418-93da-992de71e33ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f88b398b-f60e-4272-b807-bc71d4286514" xlink:to="loc_us-gaap_OperatingExpenses_dd2599f7-97bd-4418-93da-992de71e33ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_81cbb819-82a5-42aa-9381-6175b00df2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1883e055-7365-4e25-af88-92d8a82548eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_81cbb819-82a5-42aa-9381-6175b00df2b6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1883e055-7365-4e25-af88-92d8a82548eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_c3fd47c0-14aa-485c-ad95-d54516f468a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_81cbb819-82a5-42aa-9381-6175b00df2b6" xlink:to="loc_us-gaap_InterestExpense_c3fd47c0-14aa-485c-ad95-d54516f468a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_6d30959a-d5bc-4b66-9b5c-56ec5ef0624d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_81cbb819-82a5-42aa-9381-6175b00df2b6" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_6d30959a-d5bc-4b66-9b5c-56ec5ef0624d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_92c3ab88-7e87-48be-bf3e-d1a1acc10cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_3932ed05-e791-4733-87b4-c669daf5c957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_92c3ab88-7e87-48be-bf3e-d1a1acc10cae" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_3932ed05-e791-4733-87b4-c669daf5c957" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_14bdb7bb-0b70-4dbc-8f46-89d979c2c1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_92c3ab88-7e87-48be-bf3e-d1a1acc10cae" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_14bdb7bb-0b70-4dbc-8f46-89d979c2c1ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_85baf91e-caec-429f-a7ac-1786525b1808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_13e323e6-a1ba-40e3-9197-f42d7f1e6da3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_85baf91e-caec-429f-a7ac-1786525b1808" xlink:to="loc_us-gaap_ProfitLoss_13e323e6-a1ba-40e3-9197-f42d7f1e6da3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_863ba0cc-2cb8-44ac-8494-324d4c19f358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_85baf91e-caec-429f-a7ac-1786525b1808" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_863ba0cc-2cb8-44ac-8494-324d4c19f358" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7ca9a74f-0eeb-47ff-ac66-652220c23665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b99b122c-b875-43eb-be2d-05f2adae869e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_7ca9a74f-0eeb-47ff-ac66-652220c23665" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b99b122c-b875-43eb-be2d-05f2adae869e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9658e8ee-0121-4800-a4de-33fec85f47ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_7ca9a74f-0eeb-47ff-ac66-652220c23665" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9658e8ee-0121-4800-a4de-33fec85f47ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d3cb4ecb-284b-43d6-8ee2-1504f85db6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_aaea3439-9a98-4351-bbca-99b581e6b40d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d3cb4ecb-284b-43d6-8ee2-1504f85db6eb" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_aaea3439-9a98-4351-bbca-99b581e6b40d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_470b3685-d945-4ca1-a674-7d972361067b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d3cb4ecb-284b-43d6-8ee2-1504f85db6eb" xlink:to="loc_us-gaap_OperatingIncomeLoss_470b3685-d945-4ca1-a674-7d972361067b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="arwr-20230331.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d46b615f-cf7c-4578-99f2-b669a9ec6308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_860c7bde-9377-4fd6-8546-fc78fbad355d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d46b615f-cf7c-4578-99f2-b669a9ec6308" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_860c7bde-9377-4fd6-8546-fc78fbad355d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributedCapital_560f843d-bb76-4e78-8b16-ccd4ddbef975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d46b615f-cf7c-4578-99f2-b669a9ec6308" xlink:to="loc_us-gaap_ProceedsFromContributedCapital_560f843d-bb76-4e78-8b16-ccd4ddbef975" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d82e9ce0-2b23-44f7-a889-8d35cfa0450d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a6ec3e1e-f1a1-44de-a664-a8d7fd1519e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d82e9ce0-2b23-44f7-a889-8d35cfa0450d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a6ec3e1e-f1a1-44de-a664-a8d7fd1519e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_b096dffc-3d4d-4964-97e7-b31c0b242521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d82e9ce0-2b23-44f7-a889-8d35cfa0450d" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_b096dffc-3d4d-4964-97e7-b31c0b242521" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_64edbf0f-a77a-4baf-bd3a-ae8fccdb9714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d82e9ce0-2b23-44f7-a889-8d35cfa0450d" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_64edbf0f-a77a-4baf-bd3a-ae8fccdb9714" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7dfb0bdd-ce74-41fc-bbbb-53debf498db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e9375839-812d-4cef-bcf2-3db21c989186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7dfb0bdd-ce74-41fc-bbbb-53debf498db3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e9375839-812d-4cef-bcf2-3db21c989186" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9c887f3e-8be3-41bb-a0a5-44d4c5cc9d04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7dfb0bdd-ce74-41fc-bbbb-53debf498db3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9c887f3e-8be3-41bb-a0a5-44d4c5cc9d04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_48b299e6-a8c5-481d-9f80-28bed9911ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7dfb0bdd-ce74-41fc-bbbb-53debf498db3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_48b299e6-a8c5-481d-9f80-28bed9911ef7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c069183b-6b72-4815-9acb-f810b3415981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0a960104-a40c-416d-b478-e6bcc7a8bdc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c069183b-6b72-4815-9acb-f810b3415981" xlink:to="loc_us-gaap_ShareBasedCompensation_0a960104-a40c-416d-b478-e6bcc7a8bdc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8800c6c6-60a9-4ffa-8ea3-ec95b83158a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c069183b-6b72-4815-9acb-f810b3415981" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8800c6c6-60a9-4ffa-8ea3-ec95b83158a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_323794c0-d8ff-4948-b962-b2f1efc45854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c069183b-6b72-4815-9acb-f810b3415981" xlink:to="loc_us-gaap_DepreciationAndAmortization_323794c0-d8ff-4948-b962-b2f1efc45854" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f530baf7-6b84-42e3-a9dc-4d1b5143e6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c069183b-6b72-4815-9acb-f810b3415981" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f530baf7-6b84-42e3-a9dc-4d1b5143e6f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_3bbaf094-8545-4d4e-8aa0-2c37c328d271" xlink:href="arwr-20230331.xsd#arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c069183b-6b72-4815-9acb-f810b3415981" xlink:to="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_3bbaf094-8545-4d4e-8aa0-2c37c328d271" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_4a698be9-8461-4a27-b96f-502f6ed7fd0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c069183b-6b72-4815-9acb-f810b3415981" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_4a698be9-8461-4a27-b96f-502f6ed7fd0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_505c7906-10e1-4f90-a080-7bfcad5eed93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c069183b-6b72-4815-9acb-f810b3415981" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_505c7906-10e1-4f90-a080-7bfcad5eed93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2e3fc7bc-1636-49b3-baab-d7b03425d1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c069183b-6b72-4815-9acb-f810b3415981" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2e3fc7bc-1636-49b3-baab-d7b03425d1e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_615f3834-3263-4751-adea-73a242306c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c069183b-6b72-4815-9acb-f810b3415981" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_615f3834-3263-4751-adea-73a242306c34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fe88d270-db66-44fd-82b4-a5cdc4cad54d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c069183b-6b72-4815-9acb-f810b3415981" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fe88d270-db66-44fd-82b4-a5cdc4cad54d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d8d38cfa-b2d8-4c52-9949-0838fb78f790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c069183b-6b72-4815-9acb-f810b3415981" xlink:to="loc_us-gaap_ProfitLoss_d8d38cfa-b2d8-4c52-9949-0838fb78f790" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail" xlink:type="simple" xlink:href="arwr-20230331.xsd#PropertyandEquipmentSummaryofPropertyandEquipmentDetail"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c73caed7-abb4-4fc9-b07e-84a174846248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_088c6bff-5622-496d-8851-29c211f4ec1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c73caed7-abb4-4fc9-b07e-84a174846248" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_088c6bff-5622-496d-8851-29c211f4ec1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e5d0cd3b-1359-4a6e-8959-149901be0bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c73caed7-abb4-4fc9-b07e-84a174846248" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e5d0cd3b-1359-4a6e-8959-149901be0bbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9049a971-3051-48d0-819c-a5721b32091c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross_d967e9c8-5ee4-4768-9627-f63f0fe5c7fc" xlink:href="arwr-20230331.xsd#arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_9049a971-3051-48d0-819c-a5721b32091c" xlink:to="loc_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross_d967e9c8-5ee4-4768-9627-f63f0fe5c7fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_caf9ff23-4fec-4d06-baec-9235689e17b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_9049a971-3051-48d0-819c-a5721b32091c" xlink:to="loc_us-gaap_Land_caf9ff23-4fec-4d06-baec-9235689e17b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentGross_de404658-8542-4c23-8526-42e68e1412cd" xlink:href="arwr-20230331.xsd#arwr_ResearchEquipmentGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_9049a971-3051-48d0-819c-a5721b32091c" xlink:to="loc_arwr_ResearchEquipmentGross_de404658-8542-4c23-8526-42e68e1412cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_9ab94715-2ba3-41c5-8f7f-03f23b6a3536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_9049a971-3051-48d0-819c-a5721b32091c" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_9ab94715-2ba3-41c5-8f7f-03f23b6a3536" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_eb9379ad-95db-4070-b4f8-0e8f42118a41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_9049a971-3051-48d0-819c-a5721b32091c" xlink:to="loc_us-gaap_ConstructionInProgressGross_eb9379ad-95db-4070-b4f8-0e8f42118a41" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_c7c27652-0b0a-40ab-9250-6691b0f79441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_305e3696-06cb-42dc-951f-279aea58b543" xlink:href="arwr-20230331.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent_c7c27652-0b0a-40ab-9250-6691b0f79441" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_305e3696-06cb-42dc-951f-279aea58b543" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_d86840ee-e51a-4cf9-8f9f-e4b0dcc205b2" xlink:href="arwr-20230331.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent_c7c27652-0b0a-40ab-9250-6691b0f79441" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_d86840ee-e51a-4cf9-8f9f-e4b0dcc205b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_72a0529a-e764-495b-8a5c-cdaa3f37169f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent_c7c27652-0b0a-40ab-9250-6691b0f79441" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_72a0529a-e764-495b-8a5c-cdaa3f37169f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_2eef3f2b-ec56-4665-8a0f-06f710e2a5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_eacad3bb-e0aa-41d5-bd17-ca2a1b2d8761" xlink:href="arwr-20230331.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_2eef3f2b-ec56-4665-8a0f-06f710e2a5fe" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_eacad3bb-e0aa-41d5-bd17-ca2a1b2d8761" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_e268c8c6-e035-4ce0-acd9-2a78e5b9e51a" xlink:href="arwr-20230331.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_2eef3f2b-ec56-4665-8a0f-06f710e2a5fe" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_e268c8c6-e035-4ce0-acd9-2a78e5b9e51a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_59b1d38d-2c50-45a9-bd36-4719bba79e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_2eef3f2b-ec56-4665-8a0f-06f710e2a5fe" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_59b1d38d-2c50-45a9-bd36-4719bba79e69" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_500ffc43-8742-44cb-9894-4162220c0e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_86177a40-bee4-43a7-baa6-d344e946594b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_500ffc43-8742-44cb-9894-4162220c0e2e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_86177a40-bee4-43a7-baa6-d344e946594b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6fb2f500-8d22-4e34-bb2a-9ccebc51cd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_500ffc43-8742-44cb-9894-4162220c0e2e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6fb2f500-8d22-4e34-bb2a-9ccebc51cd3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsImpairment_f265e635-2bb0-422b-8e0b-5e5afcc75e0e" xlink:href="arwr-20230331.xsd#arwr_FiniteLivedIntangibleAssetsImpairment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_500ffc43-8742-44cb-9894-4162220c0e2e" xlink:to="loc_arwr_FiniteLivedIntangibleAssetsImpairment_f265e635-2bb0-422b-8e0b-5e5afcc75e0e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#IntangibleAssetsExpectedFutureAmortizationDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8e91bbdb-0349-4c2e-a59e-181fc039bd88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_e37f0bd1-2ad7-4874-8af6-a3452f957292" xlink:href="arwr-20230331.xsd#arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8e91bbdb-0349-4c2e-a59e-181fc039bd88" xlink:to="loc_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_e37f0bd1-2ad7-4874-8af6-a3452f957292" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3d39c728-fb40-47bc-9ba0-339e11ba25cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8e91bbdb-0349-4c2e-a59e-181fc039bd88" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3d39c728-fb40-47bc-9ba0-339e11ba25cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_bbf896a2-a0af-464e-8702-dfc93fa75581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8e91bbdb-0349-4c2e-a59e-181fc039bd88" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_bbf896a2-a0af-464e-8702-dfc93fa75581" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_4a97a086-0338-40d0-a360-4cfb0b61c77f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8e91bbdb-0349-4c2e-a59e-181fc039bd88" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_4a97a086-0338-40d0-a360-4cfb0b61c77f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5b664b29-4199-4723-a10f-a6bcb5678495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8e91bbdb-0349-4c2e-a59e-181fc039bd88" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5b664b29-4199-4723-a10f-a6bcb5678495" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8a7bb986-1566-4166-b298-cb3fc6c8f347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8e91bbdb-0349-4c2e-a59e-181fc039bd88" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8a7bb986-1566-4166-b298-cb3fc6c8f347" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#LeasesComponentsofLeaseAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_eb933260-9e6d-477f-9c01-ff79df340b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_452040b4-c94a-4353-9ebf-cbe7d9dca7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_eb933260-9e6d-477f-9c01-ff79df340b4d" xlink:to="loc_us-gaap_VariableLeaseCost_452040b4-c94a-4353-9ebf-cbe7d9dca7c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_72a9ecd8-2053-4a1d-8a6b-c3c09671d7db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_eb933260-9e6d-477f-9c01-ff79df340b4d" xlink:to="loc_us-gaap_OperatingLeaseCost_72a9ecd8-2053-4a1d-8a6b-c3c09671d7db" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c0df12ab-b3bb-4130-9657-0cb22f657459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e63f7c6b-5b73-4f53-9730-0601323ffa4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c0df12ab-b3bb-4130-9657-0cb22f657459" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e63f7c6b-5b73-4f53-9730-0601323ffa4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d089e02a-8142-4993-ba5e-4a174ef5396b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c0df12ab-b3bb-4130-9657-0cb22f657459" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d089e02a-8142-4993-ba5e-4a174ef5396b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_418556af-ad14-40c8-bb0c-8464eee16f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c0df12ab-b3bb-4130-9657-0cb22f657459" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_418556af-ad14-40c8-bb0c-8464eee16f2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_82771614-dc27-4345-9fee-fd1ae77363fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c0df12ab-b3bb-4130-9657-0cb22f657459" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_82771614-dc27-4345-9fee-fd1ae77363fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_878c9031-ebca-4e23-bb3a-e5cdb1759a03" xlink:href="arwr-20230331.xsd#arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c0df12ab-b3bb-4130-9657-0cb22f657459" xlink:to="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_878c9031-ebca-4e23-bb3a-e5cdb1759a03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d2d43487-e0e5-4e82-9b3f-c9cc2d0349c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c0df12ab-b3bb-4130-9657-0cb22f657459" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d2d43487-e0e5-4e82-9b3f-c9cc2d0349c0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" xlink:type="simple" xlink:href="arwr-20230331.xsd#LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d6c687d4-f8be-4a8a-b359-bbd025c9b2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_103cdbda-0796-4d61-b4b9-3845517018c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d6c687d4-f8be-4a8a-b359-bbd025c9b2ca" xlink:to="loc_us-gaap_OperatingLeaseLiability_103cdbda-0796-4d61-b4b9-3845517018c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_90ece20a-e167-4f8a-949e-6d3f6c3b5be8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d6c687d4-f8be-4a8a-b359-bbd025c9b2ca" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_90ece20a-e167-4f8a-949e-6d3f6c3b5be8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_86891fe7-27d9-482e-9e1e-fd16b7f884af" xlink:href="arwr-20230331.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d84fce62-a2ac-43ca-ba09-eabe8256a110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_86891fe7-27d9-482e-9e1e-fd16b7f884af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d84fce62-a2ac-43ca-ba09-eabe8256a110" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c9501448-49c5-4a48-95f7-e24cdd30ea59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_86891fe7-27d9-482e-9e1e-fd16b7f884af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c9501448-49c5-4a48-95f7-e24cdd30ea59" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#EarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ba4ecde8-f9b4-47ab-b8ad-c35f03e18a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_4cbb8f2b-f4ae-484f-8767-823043ea089c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ba4ecde8-f9b4-47ab-b8ad-c35f03e18a30" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_4cbb8f2b-f4ae-484f-8767-823043ea089c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5d184505-02f5-4c99-aa87-bce541959868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ba4ecde8-f9b4-47ab-b8ad-c35f03e18a30" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5d184505-02f5-4c99-aa87-bce541959868" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>arwr-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:838ae12b-ce84-423c-b3bd-d5043611fe16,g:09a7ef9b-3d5a-4a38-9975-37e1f59f1b78-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="arwr-20230331.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i33ba0d3f0470464390d226897e2504ae_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9cd12166-0ec9-4685-a9a5-39eb9a1ba8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1c228f6f-1f40-4a27-a2de-a1d0c95bc985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9cd12166-0ec9-4685-a9a5-39eb9a1ba8bd" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1c228f6f-1f40-4a27-a2de-a1d0c95bc985" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_63312f11-820e-4662-b5ea-cfcfb75604d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1c228f6f-1f40-4a27-a2de-a1d0c95bc985" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_63312f11-820e-4662-b5ea-cfcfb75604d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e3a7edbc-0c55-440d-9229-6737c7d843a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1c228f6f-1f40-4a27-a2de-a1d0c95bc985" xlink:to="loc_us-gaap_SharesOutstanding_e3a7edbc-0c55-440d-9229-6737c7d843a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_39520180-1c20-43e0-81b7-bae3417d7f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1c228f6f-1f40-4a27-a2de-a1d0c95bc985" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_39520180-1c20-43e0-81b7-bae3417d7f1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d3666d5e-8e40-4cff-b40e-84fb77f8d687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1c228f6f-1f40-4a27-a2de-a1d0c95bc985" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d3666d5e-8e40-4cff-b40e-84fb77f8d687" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ac6fc31f-eece-4bb4-a17a-cd3d27c5d6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1c228f6f-1f40-4a27-a2de-a1d0c95bc985" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ac6fc31f-eece-4bb4-a17a-cd3d27c5d6a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_59a95683-973c-4dc6-a3d8-1717fd054dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1c228f6f-1f40-4a27-a2de-a1d0c95bc985" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_59a95683-973c-4dc6-a3d8-1717fd054dc0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_9b4dad9b-c09d-453e-a445-9ac5598ca439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1c228f6f-1f40-4a27-a2de-a1d0c95bc985" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_9b4dad9b-c09d-453e-a445-9ac5598ca439" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6ece975d-317c-403d-9b6f-ddf75780aa88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1c228f6f-1f40-4a27-a2de-a1d0c95bc985" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6ece975d-317c-403d-9b6f-ddf75780aa88" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_b64f9689-f814-4fc0-b6ea-ecec759f33e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1c228f6f-1f40-4a27-a2de-a1d0c95bc985" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_b64f9689-f814-4fc0-b6ea-ecec759f33e5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fd4560b4-49d5-4646-891c-5bff50becb51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1c228f6f-1f40-4a27-a2de-a1d0c95bc985" xlink:to="loc_us-gaap_NetIncomeLoss_fd4560b4-49d5-4646-891c-5bff50becb51" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dabb34f5-d472-41c3-b099-6aac61538b40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_0aad99b5-1e2d-4da4-b10c-407b72b59894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4c4f8e31-560a-4dc0-9a05-004f0b50971f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9cd12166-0ec9-4685-a9a5-39eb9a1ba8bd" xlink:to="loc_us-gaap_StatementTable_4c4f8e31-560a-4dc0-9a05-004f0b50971f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9d15701a-6c50-4f0f-99c8-a19241865078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4c4f8e31-560a-4dc0-9a05-004f0b50971f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9d15701a-6c50-4f0f-99c8-a19241865078" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9d15701a-6c50-4f0f-99c8-a19241865078_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9d15701a-6c50-4f0f-99c8-a19241865078" xlink:to="loc_us-gaap_EquityComponentDomain_9d15701a-6c50-4f0f-99c8-a19241865078_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_da0f5626-78f9-4145-8203-7599af579c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9d15701a-6c50-4f0f-99c8-a19241865078" xlink:to="loc_us-gaap_EquityComponentDomain_da0f5626-78f9-4145-8203-7599af579c0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9bb7eec1-0c14-41bc-bf04-e16a29fb0993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_da0f5626-78f9-4145-8203-7599af579c0a" xlink:to="loc_us-gaap_CommonStockMember_9bb7eec1-0c14-41bc-bf04-e16a29fb0993" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_627b6816-1817-4e51-b040-c42b989cd882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_da0f5626-78f9-4145-8203-7599af579c0a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_627b6816-1817-4e51-b040-c42b989cd882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_94dfa576-112d-4d99-8ee6-fc91b3d64da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_da0f5626-78f9-4145-8203-7599af579c0a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_94dfa576-112d-4d99-8ee6-fc91b3d64da1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8087f33b-c4bb-4d5e-b45b-91ffb405fe98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_da0f5626-78f9-4145-8203-7599af579c0a" xlink:to="loc_us-gaap_RetainedEarningsMember_8087f33b-c4bb-4d5e-b45b-91ffb405fe98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_ea7844f3-e52a-41d3-b0e2-63101e261ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_da0f5626-78f9-4145-8203-7599af579c0a" xlink:to="loc_us-gaap_NoncontrollingInterestMember_ea7844f3-e52a-41d3-b0e2-63101e261ea1" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20230331.xsd#OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" id="i96780424e3264b5aa38502bc88e5fedd_OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_cc35bf60-4d51-4baf-b6e5-9424d9965041" xlink:href="arwr-20230331.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable_76b5001a-99f1-4ee2-a0dd-245b5833c516" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_cc35bf60-4d51-4baf-b6e5-9424d9965041" xlink:to="loc_arwr_MilestonePaymentReceivable_76b5001a-99f1-4ee2-a0dd-245b5833c516" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontMilestonePaymentReceived_7abec897-6177-457c-8dff-72e005706563" xlink:href="arwr-20230331.xsd#arwr_UpfrontMilestonePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_cc35bf60-4d51-4baf-b6e5-9424d9965041" xlink:to="loc_arwr_UpfrontMilestonePaymentReceived_7abec897-6177-457c-8dff-72e005706563" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_93161085-5cbf-47c6-a8df-142e4eea1eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_cc35bf60-4d51-4baf-b6e5-9424d9965041" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_93161085-5cbf-47c6-a8df-142e4eea1eeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ee0f97e5-5417-42ef-8669-febc48848f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_cc35bf60-4d51-4baf-b6e5-9424d9965041" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ee0f97e5-5417-42ef-8669-febc48848f2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_059ace03-b20e-4e67-bd4d-2fa7437ccc85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_cc35bf60-4d51-4baf-b6e5-9424d9965041" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_059ace03-b20e-4e67-bd4d-2fa7437ccc85" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_7196184b-fb5c-4d7b-9c9f-116e0e0f8e13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_cc35bf60-4d51-4baf-b6e5-9424d9965041" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_7196184b-fb5c-4d7b-9c9f-116e0e0f8e13" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_IncreaseDecreaseInCashAndInvestments_17782ce7-1863-42f1-81e5-773941356b91" xlink:href="arwr-20230331.xsd#arwr_IncreaseDecreaseInCashAndInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_cc35bf60-4d51-4baf-b6e5-9424d9965041" xlink:to="loc_arwr_IncreaseDecreaseInCashAndInvestments_17782ce7-1863-42f1-81e5-773941356b91" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_484f585a-d4d9-459f-b6a5-370be0d99bb1" xlink:href="arwr-20230331.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_cc35bf60-4d51-4baf-b6e5-9424d9965041" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_484f585a-d4d9-459f-b6a5-370be0d99bb1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_34cce2f8-3087-4702-9f06-5ac2121a9f6f" xlink:href="arwr-20230331.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_cc35bf60-4d51-4baf-b6e5-9424d9965041" xlink:to="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_34cce2f8-3087-4702-9f06-5ac2121a9f6f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_093b2e4e-0a37-4777-8d63-8950e70c9786" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_34cce2f8-3087-4702-9f06-5ac2121a9f6f" xlink:to="loc_dei_LegalEntityAxis_093b2e4e-0a37-4777-8d63-8950e70c9786" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_093b2e4e-0a37-4777-8d63-8950e70c9786_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_093b2e4e-0a37-4777-8d63-8950e70c9786" xlink:to="loc_dei_EntityDomain_093b2e4e-0a37-4777-8d63-8950e70c9786_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e5115929-e00d-4d89-8b1c-5ce8a483420b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_093b2e4e-0a37-4777-8d63-8950e70c9786" xlink:to="loc_dei_EntityDomain_e5115929-e00d-4d89-8b1c-5ce8a483420b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_eb97869e-f1c2-4be1-aafa-efd72cb1c54c" xlink:href="arwr-20230331.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e5115929-e00d-4d89-8b1c-5ce8a483420b" xlink:to="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_eb97869e-f1c2-4be1-aafa-efd72cb1c54c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_aa4ceda6-ec5f-4296-8665-bc88ff12c84e" xlink:href="arwr-20230331.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e5115929-e00d-4d89-8b1c-5ce8a483420b" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_aa4ceda6-ec5f-4296-8665-bc88ff12c84e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember_731f8b35-b3b5-4840-bb10-627baf4754ea" xlink:href="arwr-20230331.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e5115929-e00d-4d89-8b1c-5ce8a483420b" xlink:to="loc_arwr_HorizonTherapeuticsIrelandDACMember_731f8b35-b3b5-4840-bb10-627baf4754ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_c2f908f2-e982-453f-9b57-a1b926317031" xlink:href="arwr-20230331.xsd#arwr_AmgenIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e5115929-e00d-4d89-8b1c-5ce8a483420b" xlink:to="loc_arwr_AmgenIncorporatedMember_c2f908f2-e982-453f-9b57-a1b926317031" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaMember_8dd39447-04ff-461e-be20-34ea279a34d0" xlink:href="arwr-20230331.xsd#arwr_RoyaltyPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e5115929-e00d-4d89-8b1c-5ce8a483420b" xlink:to="loc_arwr_RoyaltyPharmaMember_8dd39447-04ff-461e-be20-34ea279a34d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d784a8af-ade3-4b5c-b2ef-af14c60099e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_34cce2f8-3087-4702-9f06-5ac2121a9f6f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d784a8af-ade3-4b5c-b2ef-af14c60099e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d784a8af-ade3-4b5c-b2ef-af14c60099e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d784a8af-ade3-4b5c-b2ef-af14c60099e6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d784a8af-ade3-4b5c-b2ef-af14c60099e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9f011189-eb3b-49ba-be7e-93a0216d5884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d784a8af-ade3-4b5c-b2ef-af14c60099e6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9f011189-eb3b-49ba-be7e-93a0216d5884" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAndCoFundingAgreementMember_35be3269-621f-429e-ace2-c61375da17f2" xlink:href="arwr-20230331.xsd#arwr_LicenseAndCoFundingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9f011189-eb3b-49ba-be7e-93a0216d5884" xlink:to="loc_arwr_LicenseAndCoFundingAgreementMember_35be3269-621f-429e-ace2-c61375da17f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember_07527625-b2b0-4e36-b1d9-c8a0b1a00df6" xlink:href="arwr-20230331.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9f011189-eb3b-49ba-be7e-93a0216d5884" xlink:to="loc_arwr_CollaborationAndLicenseAgreementMember_07527625-b2b0-4e36-b1d9-c8a0b1a00df6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_12e9287c-a407-414f-a92a-403142d036bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_34cce2f8-3087-4702-9f06-5ac2121a9f6f" xlink:to="loc_srt_CounterpartyNameAxis_12e9287c-a407-414f-a92a-403142d036bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_12e9287c-a407-414f-a92a-403142d036bf_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_12e9287c-a407-414f-a92a-403142d036bf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_12e9287c-a407-414f-a92a-403142d036bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eed77e24-c783-49f2-8a1a-73a1afc3cc50" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_12e9287c-a407-414f-a92a-403142d036bf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eed77e24-c783-49f2-8a1a-73a1afc3cc50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACAndAmgenIncorporatedMember_82082681-27b9-48b3-8881-030df40d1d54" xlink:href="arwr-20230331.xsd#arwr_HorizonTherapeuticsIrelandDACAndAmgenIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eed77e24-c783-49f2-8a1a-73a1afc3cc50" xlink:to="loc_arwr_HorizonTherapeuticsIrelandDACAndAmgenIncorporatedMember_82082681-27b9-48b3-8881-030df40d1d54" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#CollaborationandLicenseAgreementsRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails" xlink:type="extended" id="i48369bd1e1654711bc22986c709d42b8_CollaborationandLicenseAgreementsRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5f01b559-0161-40cf-acbe-a2810bf706fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_31870e48-210d-4fc2-8933-da6d98599da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5f01b559-0161-40cf-acbe-a2810bf706fd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_31870e48-210d-4fc2-8933-da6d98599da7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ba2db5bc-11d3-4844-a87e-370fcd7f5d30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5f01b559-0161-40cf-acbe-a2810bf706fd" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ba2db5bc-11d3-4844-a87e-370fcd7f5d30" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_4bb0f3b7-eaee-4899-9930-a9355e83c60d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ba2db5bc-11d3-4844-a87e-370fcd7f5d30" xlink:to="loc_srt_MajorCustomersAxis_4bb0f3b7-eaee-4899-9930-a9355e83c60d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4bb0f3b7-eaee-4899-9930-a9355e83c60d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_4bb0f3b7-eaee-4899-9930-a9355e83c60d" xlink:to="loc_srt_NameOfMajorCustomerDomain_4bb0f3b7-eaee-4899-9930-a9355e83c60d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_54d6f77a-de9a-4597-b3c6-ab4efe9770de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_4bb0f3b7-eaee-4899-9930-a9355e83c60d" xlink:to="loc_srt_NameOfMajorCustomerDomain_54d6f77a-de9a-4597-b3c6-ab4efe9770de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_9d992e09-a359-4f9b-bc78-28306c090bc0" xlink:href="arwr-20230331.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_54d6f77a-de9a-4597-b3c6-ab4efe9770de" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_9d992e09-a359-4f9b-bc78-28306c090bc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember_a786b49a-10d8-4f63-b14b-8508b6a345f9" xlink:href="arwr-20230331.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_54d6f77a-de9a-4597-b3c6-ab4efe9770de" xlink:to="loc_arwr_HorizonTherapeuticsIrelandDACMember_a786b49a-10d8-4f63-b14b-8508b6a345f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_1471c791-82a7-49a3-8412-49649c647f80" xlink:href="arwr-20230331.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_54d6f77a-de9a-4597-b3c6-ab4efe9770de" xlink:to="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_1471c791-82a7-49a3-8412-49649c647f80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember_7ff7528b-e35a-408f-a358-c708c3dd0403" xlink:href="arwr-20230331.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_54d6f77a-de9a-4597-b3c6-ab4efe9770de" xlink:to="loc_arwr_JanssenPharmaceuticalsIncorporationMember_7ff7528b-e35a-408f-a358-c708c3dd0403" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_31c8e67e-0a78-4b93-b627-f1fb64ab8304" xlink:href="arwr-20230331.xsd#arwr_AmgenIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_54d6f77a-de9a-4597-b3c6-ab4efe9770de" xlink:to="loc_arwr_AmgenIncorporatedMember_31c8e67e-0a78-4b93-b627-f1fb64ab8304" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails" xlink:type="extended" id="ib74bd0304cab42d2922fbcc820ebbcff_CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3de9cc84-dc6d-4bfd-9881-a159efe005f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_64bd2d58-a703-41a7-888f-0498a1ae987e" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3de9cc84-dc6d-4bfd-9881-a159efe005f2" xlink:to="loc_arwr_MilestonePaymentEarned_64bd2d58-a703-41a7-888f-0498a1ae987e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_8efeb35a-a73d-4f0f-ad4f-4b8ec79b0b3d" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentReceivableAtStartOfPhaseTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3de9cc84-dc6d-4bfd-9881-a159efe005f2" xlink:to="loc_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_8efeb35a-a73d-4f0f-ad4f-4b8ec79b0b3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_4763c562-fbbc-4696-8670-124b622364a2" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3de9cc84-dc6d-4bfd-9881-a159efe005f2" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_4763c562-fbbc-4696-8670-124b622364a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_3b2aa193-70bf-483a-9ceb-b5757d7b9543" xlink:href="arwr-20230331.xsd#arwr_CommercialMilestonePaymentsAtFirstCommercialSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3de9cc84-dc6d-4bfd-9881-a159efe005f2" xlink:to="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_3b2aa193-70bf-483a-9ceb-b5757d7b9543" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments_15a9fc00-c49a-49dd-b3e5-bd3e02442c44" xlink:href="arwr-20230331.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3de9cc84-dc6d-4bfd-9881-a159efe005f2" xlink:to="loc_arwr_SalesRelatedMilestonePayments_15a9fc00-c49a-49dd-b3e5-bd3e02442c44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_0b965cb5-635b-45e4-ac1f-19bcacef3690" xlink:href="arwr-20230331.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3de9cc84-dc6d-4bfd-9881-a159efe005f2" xlink:to="loc_arwr_InitialTransactionPrice_0b965cb5-635b-45e4-ac1f-19bcacef3690" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable_21650332-1936-472c-9562-837e2209bcb7" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3de9cc84-dc6d-4bfd-9881-a159efe005f2" xlink:to="loc_arwr_MilestonePaymentReceivable_21650332-1936-472c-9562-837e2209bcb7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_7e148b97-43ff-4311-a4c1-8538c78b7a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3de9cc84-dc6d-4bfd-9881-a159efe005f2" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_7e148b97-43ff-4311-a4c1-8538c78b7a7b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cd8d130a-441f-4f0d-9bb7-44fe4d41b137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3de9cc84-dc6d-4bfd-9881-a159efe005f2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cd8d130a-441f-4f0d-9bb7-44fe4d41b137" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fc80252f-098b-4fb5-891a-91eb625c4758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3de9cc84-dc6d-4bfd-9881-a159efe005f2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fc80252f-098b-4fb5-891a-91eb625c4758" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c112f6e0-8a22-48be-ae50-2d8dbaf9a39d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fc80252f-098b-4fb5-891a-91eb625c4758" xlink:to="loc_dei_LegalEntityAxis_c112f6e0-8a22-48be-ae50-2d8dbaf9a39d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c112f6e0-8a22-48be-ae50-2d8dbaf9a39d_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_c112f6e0-8a22-48be-ae50-2d8dbaf9a39d" xlink:to="loc_dei_EntityDomain_c112f6e0-8a22-48be-ae50-2d8dbaf9a39d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9a774c8e-8cde-4f29-ac53-7d752db3d053" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_c112f6e0-8a22-48be-ae50-2d8dbaf9a39d" xlink:to="loc_dei_EntityDomain_9a774c8e-8cde-4f29-ac53-7d752db3d053" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_03f6d08e-38ff-4a1a-9f37-17caa6fd8562" xlink:href="arwr-20230331.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9a774c8e-8cde-4f29-ac53-7d752db3d053" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_03f6d08e-38ff-4a1a-9f37-17caa6fd8562" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4da9d7eb-d804-4904-a91d-f285a14642d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fc80252f-098b-4fb5-891a-91eb625c4758" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4da9d7eb-d804-4904-a91d-f285a14642d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4da9d7eb-d804-4904-a91d-f285a14642d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4da9d7eb-d804-4904-a91d-f285a14642d6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4da9d7eb-d804-4904-a91d-f285a14642d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b64fad99-9823-469e-9173-9a354ab89690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4da9d7eb-d804-4904-a91d-f285a14642d6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b64fad99-9823-469e-9173-9a354ab89690" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember_a7151d6b-19c4-415e-848e-312f8a8c5050" xlink:href="arwr-20230331.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b64fad99-9823-469e-9173-9a354ab89690" xlink:to="loc_arwr_CollaborationAndLicenseAgreementMember_a7151d6b-19c4-415e-848e-312f8a8c5050" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_64f24a0b-a6ad-43ed-ad89-e1a0f9c6ddc8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fc80252f-098b-4fb5-891a-91eb625c4758" xlink:to="loc_srt_RangeAxis_64f24a0b-a6ad-43ed-ad89-e1a0f9c6ddc8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_64f24a0b-a6ad-43ed-ad89-e1a0f9c6ddc8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_64f24a0b-a6ad-43ed-ad89-e1a0f9c6ddc8" xlink:to="loc_srt_RangeMember_64f24a0b-a6ad-43ed-ad89-e1a0f9c6ddc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d43e830a-9b97-40e0-90ef-e5596d3121bb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_64f24a0b-a6ad-43ed-ad89-e1a0f9c6ddc8" xlink:to="loc_srt_RangeMember_d43e830a-9b97-40e0-90ef-e5596d3121bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f4e85206-1e47-4be4-b7a7-6cbcef819cbe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d43e830a-9b97-40e0-90ef-e5596d3121bb" xlink:to="loc_srt_MaximumMember_f4e85206-1e47-4be4-b7a7-6cbcef819cbe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails" xlink:type="extended" id="i4fba47c1c93f4fcb8f377dea4d4be0bd_CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54267d7-65c0-4def-aa3c-213c4f1ce84b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_e98c2acc-fa33-4cc8-acbe-0267853a1bc3" xlink:href="arwr-20230331.xsd#arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54267d7-65c0-4def-aa3c-213c4f1ce84b" xlink:to="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_e98c2acc-fa33-4cc8-acbe-0267853a1bc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_a1c3cda5-3318-48c1-b75c-c9fac36b07ae" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54267d7-65c0-4def-aa3c-213c4f1ce84b" xlink:to="loc_arwr_MilestonePaymentEarned_a1c3cda5-3318-48c1-b75c-c9fac36b07ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_c03dd5cc-ed29-489f-85bb-7c81d85a0b58" xlink:href="arwr-20230331.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54267d7-65c0-4def-aa3c-213c4f1ce84b" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_c03dd5cc-ed29-489f-85bb-7c81d85a0b58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_80fdb939-8708-4cfc-aa0b-0c1c74663f74" xlink:href="arwr-20230331.xsd#arwr_NumberOfDistinctBundle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54267d7-65c0-4def-aa3c-213c4f1ce84b" xlink:to="loc_arwr_NumberOfDistinctBundle_80fdb939-8708-4cfc-aa0b-0c1c74663f74" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_68d1d117-422d-441d-a0fa-f1274e4d4664" xlink:href="arwr-20230331.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54267d7-65c0-4def-aa3c-213c4f1ce84b" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_68d1d117-422d-441d-a0fa-f1274e4d4664" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_89044abd-638e-46d6-b8f2-f0b2e8d59ae7" xlink:href="arwr-20230331.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54267d7-65c0-4def-aa3c-213c4f1ce84b" xlink:to="loc_arwr_InitialTransactionPrice_89044abd-638e-46d6-b8f2-f0b2e8d59ae7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontMilestonePaymentReceived_adf4871e-c896-411b-aefc-1437343fe739" xlink:href="arwr-20230331.xsd#arwr_UpfrontMilestonePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54267d7-65c0-4def-aa3c-213c4f1ce84b" xlink:to="loc_arwr_UpfrontMilestonePaymentReceived_adf4871e-c896-411b-aefc-1437343fe739" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_e3a41fcb-572c-40fc-98e8-dfbcf159ebec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54267d7-65c0-4def-aa3c-213c4f1ce84b" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_e3a41fcb-572c-40fc-98e8-dfbcf159ebec" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_49b86a6e-d655-40dc-b2df-a2691d68f879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54267d7-65c0-4def-aa3c-213c4f1ce84b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_49b86a6e-d655-40dc-b2df-a2691d68f879" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc5014ee-de42-4b44-af9c-d033c4338e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54267d7-65c0-4def-aa3c-213c4f1ce84b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc5014ee-de42-4b44-af9c-d033c4338e45" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_bedf5f95-2f1d-4add-a919-e886f60d3deb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc5014ee-de42-4b44-af9c-d033c4338e45" xlink:to="loc_dei_LegalEntityAxis_bedf5f95-2f1d-4add-a919-e886f60d3deb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bedf5f95-2f1d-4add-a919-e886f60d3deb_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_bedf5f95-2f1d-4add-a919-e886f60d3deb" xlink:to="loc_dei_EntityDomain_bedf5f95-2f1d-4add-a919-e886f60d3deb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2d15fa1b-2a24-40b7-aba7-d1c7d80b4b7a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_bedf5f95-2f1d-4add-a919-e886f60d3deb" xlink:to="loc_dei_EntityDomain_2d15fa1b-2a24-40b7-aba7-d1c7d80b4b7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember_5f9cfcf1-839d-42ba-ac53-ca2c09d5bc4e" xlink:href="arwr-20230331.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2d15fa1b-2a24-40b7-aba7-d1c7d80b4b7a" xlink:to="loc_arwr_HorizonTherapeuticsIrelandDACMember_5f9cfcf1-839d-42ba-ac53-ca2c09d5bc4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d3c43916-48ae-4480-b995-db41f78da932" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc5014ee-de42-4b44-af9c-d033c4338e45" xlink:to="loc_srt_RangeAxis_d3c43916-48ae-4480-b995-db41f78da932" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d3c43916-48ae-4480-b995-db41f78da932_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d3c43916-48ae-4480-b995-db41f78da932" xlink:to="loc_srt_RangeMember_d3c43916-48ae-4480-b995-db41f78da932_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8246b7ec-4cff-47af-ab33-6cbae9356bfb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d3c43916-48ae-4480-b995-db41f78da932" xlink:to="loc_srt_RangeMember_8246b7ec-4cff-47af-ab33-6cbae9356bfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5b27cb67-3a0e-4cd2-9719-0f045edd15fc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8246b7ec-4cff-47af-ab33-6cbae9356bfb" xlink:to="loc_srt_MaximumMember_5b27cb67-3a0e-4cd2-9719-0f045edd15fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_348db157-83cf-466b-b7b3-630ee59612f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc5014ee-de42-4b44-af9c-d033c4338e45" xlink:to="loc_us-gaap_TypeOfArrangementAxis_348db157-83cf-466b-b7b3-630ee59612f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_348db157-83cf-466b-b7b3-630ee59612f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_348db157-83cf-466b-b7b3-630ee59612f8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_348db157-83cf-466b-b7b3-630ee59612f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a72b424b-76af-41e4-824b-a545e5119c94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_348db157-83cf-466b-b7b3-630ee59612f8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a72b424b-76af-41e4-824b-a545e5119c94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROXDHAgreementMember_cab3a597-e6bc-4a90-9ff4-e7e79da481dc" xlink:href="arwr-20230331.xsd#arwr_AROXDHAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a72b424b-76af-41e4-824b-a545e5119c94" xlink:to="loc_arwr_AROXDHAgreementMember_cab3a597-e6bc-4a90-9ff4-e7e79da481dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAgreementMember_06992aed-0c4a-4cf0-a40e-36cbacd4736f" xlink:href="arwr-20230331.xsd#arwr_LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a72b424b-76af-41e4-824b-a545e5119c94" xlink:to="loc_arwr_LicenseAgreementMember_06992aed-0c4a-4cf0-a40e-36cbacd4736f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" xlink:type="extended" id="id3641a077b7e4ae6817258b933581ebe_CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d832ae-d794-46d1-acdb-155e2cc81c12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_575bee5d-4eeb-4750-ad8d-ad6d0ac6e3cb" xlink:href="arwr-20230331.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d832ae-d794-46d1-acdb-155e2cc81c12" xlink:to="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_575bee5d-4eeb-4750-ad8d-ad6d0ac6e3cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_af7b7390-9d65-480e-8033-8d6139f5039f" xlink:href="arwr-20230331.xsd#arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d832ae-d794-46d1-acdb-155e2cc81c12" xlink:to="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_af7b7390-9d65-480e-8033-8d6139f5039f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_45ef0f8c-8b09-498b-a75c-2cd0bb80858e" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d832ae-d794-46d1-acdb-155e2cc81c12" xlink:to="loc_arwr_MilestonePaymentEarned_45ef0f8c-8b09-498b-a75c-2cd0bb80858e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_d4e99471-944d-46da-978d-17341261d557" xlink:href="arwr-20230331.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d832ae-d794-46d1-acdb-155e2cc81c12" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_d4e99471-944d-46da-978d-17341261d557" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_dfa0045e-163e-4588-835c-10acae270536" xlink:href="arwr-20230331.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d832ae-d794-46d1-acdb-155e2cc81c12" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_dfa0045e-163e-4588-835c-10acae270536" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_8225199b-1d7a-43b1-ad68-08d21df45801" xlink:href="arwr-20230331.xsd#arwr_NumberOfDistinctBundle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d832ae-d794-46d1-acdb-155e2cc81c12" xlink:to="loc_arwr_NumberOfDistinctBundle_8225199b-1d7a-43b1-ad68-08d21df45801" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_222844bc-2258-448d-91fd-2c758321424d" xlink:href="arwr-20230331.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d832ae-d794-46d1-acdb-155e2cc81c12" xlink:to="loc_arwr_InitialTransactionPrice_222844bc-2258-448d-91fd-2c758321424d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_05ec0ecf-b735-4a19-91ed-40e2af07e592" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d832ae-d794-46d1-acdb-155e2cc81c12" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_05ec0ecf-b735-4a19-91ed-40e2af07e592" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1ddc454b-e8fb-4992-8f5c-77f517f34d38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d832ae-d794-46d1-acdb-155e2cc81c12" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1ddc454b-e8fb-4992-8f5c-77f517f34d38" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b44fbe98-3073-4fb8-9de8-594930dbac09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d832ae-d794-46d1-acdb-155e2cc81c12" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b44fbe98-3073-4fb8-9de8-594930dbac09" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_fb4e945b-797e-4e97-b60f-3dbc465bf349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d832ae-d794-46d1-acdb-155e2cc81c12" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_fb4e945b-797e-4e97-b60f-3dbc465bf349" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable_846482a8-c040-42a8-b174-1dfedf70308b" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d832ae-d794-46d1-acdb-155e2cc81c12" xlink:to="loc_arwr_MilestonePaymentReceivable_846482a8-c040-42a8-b174-1dfedf70308b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_994d33bf-7c9e-449e-ae50-5b3ac670259a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d832ae-d794-46d1-acdb-155e2cc81c12" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_994d33bf-7c9e-449e-ae50-5b3ac670259a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_22f2152f-a4d1-40ba-baba-59570e71ea8a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_994d33bf-7c9e-449e-ae50-5b3ac670259a" xlink:to="loc_dei_LegalEntityAxis_22f2152f-a4d1-40ba-baba-59570e71ea8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_22f2152f-a4d1-40ba-baba-59570e71ea8a_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_22f2152f-a4d1-40ba-baba-59570e71ea8a" xlink:to="loc_dei_EntityDomain_22f2152f-a4d1-40ba-baba-59570e71ea8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_35a503de-e43b-486c-9843-25706c3a77f7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_22f2152f-a4d1-40ba-baba-59570e71ea8a" xlink:to="loc_dei_EntityDomain_35a503de-e43b-486c-9843-25706c3a77f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_55dcbbc8-e8ad-4bcb-8c4b-46698dce89d5" xlink:href="arwr-20230331.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_35a503de-e43b-486c-9843-25706c3a77f7" xlink:to="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_55dcbbc8-e8ad-4bcb-8c4b-46698dce89d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_896b8e26-5ed8-4d63-9360-abf2cad75798" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_994d33bf-7c9e-449e-ae50-5b3ac670259a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_896b8e26-5ed8-4d63-9360-abf2cad75798" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_896b8e26-5ed8-4d63-9360-abf2cad75798_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_896b8e26-5ed8-4d63-9360-abf2cad75798" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_896b8e26-5ed8-4d63-9360-abf2cad75798_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_834364a9-4e29-462a-bf5f-f3e0f4b7b55b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_896b8e26-5ed8-4d63-9360-abf2cad75798" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_834364a9-4e29-462a-bf5f-f3e0f4b7b55b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAndCoFundingAgreementMember_1822aa9c-a425-40db-8644-0cf99dff5d4e" xlink:href="arwr-20230331.xsd#arwr_LicenseAndCoFundingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_834364a9-4e29-462a-bf5f-f3e0f4b7b55b" xlink:to="loc_arwr_LicenseAndCoFundingAgreementMember_1822aa9c-a425-40db-8644-0cf99dff5d4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3754df41-9631-47ba-85aa-42f5969fa8c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_994d33bf-7c9e-449e-ae50-5b3ac670259a" xlink:to="loc_srt_RangeAxis_3754df41-9631-47ba-85aa-42f5969fa8c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3754df41-9631-47ba-85aa-42f5969fa8c6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3754df41-9631-47ba-85aa-42f5969fa8c6" xlink:to="loc_srt_RangeMember_3754df41-9631-47ba-85aa-42f5969fa8c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d6f5922c-442b-4a4d-8f23-0aeee773450c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3754df41-9631-47ba-85aa-42f5969fa8c6" xlink:to="loc_srt_RangeMember_d6f5922c-442b-4a4d-8f23-0aeee773450c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1065b2aa-b11f-4899-ba71-173ded9e7113" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d6f5922c-442b-4a4d-8f23-0aeee773450c" xlink:to="loc_srt_MinimumMember_1065b2aa-b11f-4899-ba71-173ded9e7113" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_09d82a66-a81c-4527-a578-b278c91e38eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d6f5922c-442b-4a4d-8f23-0aeee773450c" xlink:to="loc_srt_MaximumMember_09d82a66-a81c-4527-a578-b278c91e38eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7a68f36c-23b0-4c95-8cc3-e94943d3f533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_994d33bf-7c9e-449e-ae50-5b3ac670259a" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7a68f36c-23b0-4c95-8cc3-e94943d3f533" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7a68f36c-23b0-4c95-8cc3-e94943d3f533_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7a68f36c-23b0-4c95-8cc3-e94943d3f533" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7a68f36c-23b0-4c95-8cc3-e94943d3f533_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cc0b09de-104b-432f-a27d-a3fedad0167a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7a68f36c-23b0-4c95-8cc3-e94943d3f533" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cc0b09de-104b-432f-a27d-a3fedad0167a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredRevenueMember_37eb2ec4-a7f2-4b53-97f4-1c55e93c8a09" xlink:href="arwr-20230331.xsd#arwr_DeferredRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cc0b09de-104b-432f-a27d-a3fedad0167a" xlink:to="loc_arwr_DeferredRevenueMember_37eb2ec4-a7f2-4b53-97f4-1c55e93c8a09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_026a697e-b327-4e40-8c7d-cfb1d2d9b156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cc0b09de-104b-432f-a27d-a3fedad0167a" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_026a697e-b327-4e40-8c7d-cfb1d2d9b156" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails" xlink:type="extended" id="i1b2efa6a0e214b71a45bb91ece1dce0a_CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39c0edf9-edc0-4f1c-b744-27edf3e0b352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_77d3851f-c4b1-4a11-80fd-dc8494fbf474" xlink:href="arwr-20230331.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39c0edf9-edc0-4f1c-b744-27edf3e0b352" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_77d3851f-c4b1-4a11-80fd-dc8494fbf474" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bca9e417-7435-4369-913f-99f696e088b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39c0edf9-edc0-4f1c-b744-27edf3e0b352" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bca9e417-7435-4369-913f-99f696e088b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_7347b66d-ebcd-4b73-ae0f-197d00bed05e" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39c0edf9-edc0-4f1c-b744-27edf3e0b352" xlink:to="loc_arwr_MilestonePaymentEarned_7347b66d-ebcd-4b73-ae0f-197d00bed05e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_da9322ae-87d6-4c5e-947c-2425108b2881" xlink:href="arwr-20230331.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39c0edf9-edc0-4f1c-b744-27edf3e0b352" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_da9322ae-87d6-4c5e-947c-2425108b2881" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ab9df8b2-7922-42e0-aabf-2fda6de294e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39c0edf9-edc0-4f1c-b744-27edf3e0b352" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ab9df8b2-7922-42e0-aabf-2fda6de294e0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_4f186cbf-4bd6-42ec-8381-83940c61be0e" xlink:href="arwr-20230331.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39c0edf9-edc0-4f1c-b744-27edf3e0b352" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_4f186cbf-4bd6-42ec-8381-83940c61be0e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_5f71a64a-9b7e-4ca7-b85b-c848c00db303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39c0edf9-edc0-4f1c-b744-27edf3e0b352" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_5f71a64a-9b7e-4ca7-b85b-c848c00db303" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_80b30edd-9a0f-4b4e-a1b8-595e6625278e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39c0edf9-edc0-4f1c-b744-27edf3e0b352" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_80b30edd-9a0f-4b4e-a1b8-595e6625278e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_fb2c516c-424e-4334-aa36-4fec10b8c2a8" xlink:href="arwr-20230331.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39c0edf9-edc0-4f1c-b744-27edf3e0b352" xlink:to="loc_arwr_InitialTransactionPrice_fb2c516c-424e-4334-aa36-4fec10b8c2a8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4cf35c5-18a3-463b-82ef-a6413f54df0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39c0edf9-edc0-4f1c-b744-27edf3e0b352" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4cf35c5-18a3-463b-82ef-a6413f54df0b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_37693928-1272-464b-89d2-ce350a9a4985" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4cf35c5-18a3-463b-82ef-a6413f54df0b" xlink:to="loc_dei_LegalEntityAxis_37693928-1272-464b-89d2-ce350a9a4985" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_37693928-1272-464b-89d2-ce350a9a4985_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_37693928-1272-464b-89d2-ce350a9a4985" xlink:to="loc_dei_EntityDomain_37693928-1272-464b-89d2-ce350a9a4985_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a9a2ba16-9064-456c-81d5-8944313e498d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_37693928-1272-464b-89d2-ce350a9a4985" xlink:to="loc_dei_EntityDomain_a9a2ba16-9064-456c-81d5-8944313e498d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_1a3cf8f6-b6d0-4eab-b2b2-69ed32a8a5cb" xlink:href="arwr-20230331.xsd#arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a9a2ba16-9064-456c-81d5-8944313e498d" xlink:to="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_1a3cf8f6-b6d0-4eab-b2b2-69ed32a8a5cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember_a4311f7c-7179-4216-ba28-0aaa3163303f" xlink:href="arwr-20230331.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a9a2ba16-9064-456c-81d5-8944313e498d" xlink:to="loc_arwr_JanssenPharmaceuticalsIncorporationMember_a4311f7c-7179-4216-ba28-0aaa3163303f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_fcbfe791-5412-4418-ac9f-946ff442b1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4cf35c5-18a3-463b-82ef-a6413f54df0b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_fcbfe791-5412-4418-ac9f-946ff442b1e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fcbfe791-5412-4418-ac9f-946ff442b1e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fcbfe791-5412-4418-ac9f-946ff442b1e1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fcbfe791-5412-4418-ac9f-946ff442b1e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dbf1e470-95d7-42ff-9ad1-2a91ffe1bb18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fcbfe791-5412-4418-ac9f-946ff442b1e1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dbf1e470-95d7-42ff-9ad1-2a91ffe1bb18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockPurchaseAgreementMember_8698a7a1-5058-41be-a174-8b6c384b6893" xlink:href="arwr-20230331.xsd#arwr_CommonStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dbf1e470-95d7-42ff-9ad1-2a91ffe1bb18" xlink:to="loc_arwr_CommonStockPurchaseAgreementMember_8698a7a1-5058-41be-a174-8b6c384b6893" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c8925961-9271-46b4-ba4d-9f254e509b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4cf35c5-18a3-463b-82ef-a6413f54df0b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c8925961-9271-46b4-ba4d-9f254e509b8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c8925961-9271-46b4-ba4d-9f254e509b8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c8925961-9271-46b4-ba4d-9f254e509b8d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c8925961-9271-46b4-ba4d-9f254e509b8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b53f7084-a821-4e49-9c19-fde331a4be92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c8925961-9271-46b4-ba4d-9f254e509b8d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b53f7084-a821-4e49-9c19-fde331a4be92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember_84c7baa9-4744-4ad5-add2-9b1e196f4e3b" xlink:href="arwr-20230331.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b53f7084-a821-4e49-9c19-fde331a4be92" xlink:to="loc_arwr_CollaborationAndLicenseAgreementMember_84c7baa9-4744-4ad5-add2-9b1e196f4e3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAgreementMember_680a5db5-dec8-48cc-9968-2ede21c000a2" xlink:href="arwr-20230331.xsd#arwr_LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b53f7084-a821-4e49-9c19-fde331a4be92" xlink:to="loc_arwr_LicenseAgreementMember_680a5db5-dec8-48cc-9968-2ede21c000a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JNJ75220795AROJNJ1Member_f21df10c-dc47-4bb0-95c0-b08db76f116d" xlink:href="arwr-20230331.xsd#arwr_JNJ75220795AROJNJ1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b53f7084-a821-4e49-9c19-fde331a4be92" xlink:to="loc_arwr_JNJ75220795AROJNJ1Member_f21df10c-dc47-4bb0-95c0-b08db76f116d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JNJ3989AROHBVAgreementMember_2fd9e155-7c0a-49c8-8002-977c02f59292" xlink:href="arwr-20230331.xsd#arwr_JNJ3989AROHBVAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b53f7084-a821-4e49-9c19-fde331a4be92" xlink:to="loc_arwr_JNJ3989AROHBVAgreementMember_2fd9e155-7c0a-49c8-8002-977c02f59292" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bed3ee1f-f836-49bc-8dcc-f529afe1746e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4cf35c5-18a3-463b-82ef-a6413f54df0b" xlink:to="loc_srt_RangeAxis_bed3ee1f-f836-49bc-8dcc-f529afe1746e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bed3ee1f-f836-49bc-8dcc-f529afe1746e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bed3ee1f-f836-49bc-8dcc-f529afe1746e" xlink:to="loc_srt_RangeMember_bed3ee1f-f836-49bc-8dcc-f529afe1746e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_41a01a85-66ae-4a3e-ac4c-0f597b9c9aac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bed3ee1f-f836-49bc-8dcc-f529afe1746e" xlink:to="loc_srt_RangeMember_41a01a85-66ae-4a3e-ac4c-0f597b9c9aac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b9da71f8-59d9-4652-a8c5-ec168ca5a716" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_41a01a85-66ae-4a3e-ac4c-0f597b9c9aac" xlink:to="loc_srt_MaximumMember_b9da71f8-59d9-4652-a8c5-ec168ca5a716" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#CollaborationandLicenseAgreementsAmgenIncDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails" xlink:type="extended" id="ibef6fb68d24848ce887ea4b78c502668_CollaborationandLicenseAgreementsAmgenIncDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5907ef1-9695-4088-9601-bddefd65070a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAgreements_4a23f5dc-8b8d-42fb-a30b-ac6b165ee625" xlink:href="arwr-20230331.xsd#arwr_NumberOfAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5907ef1-9695-4088-9601-bddefd65070a" xlink:to="loc_arwr_NumberOfAgreements_4a23f5dc-8b8d-42fb-a30b-ac6b165ee625" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_bf6446b9-3a6a-4f65-9f64-2762b3296137" xlink:href="arwr-20230331.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5907ef1-9695-4088-9601-bddefd65070a" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_bf6446b9-3a6a-4f65-9f64-2762b3296137" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_47e30e30-f360-451f-bb6b-66f9005d6965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5907ef1-9695-4088-9601-bddefd65070a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_47e30e30-f360-451f-bb6b-66f9005d6965" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceived_425ffa01-d8b5-43f6-95eb-9cce5bc602e5" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5907ef1-9695-4088-9601-bddefd65070a" xlink:to="loc_arwr_MilestonePaymentReceived_425ffa01-d8b5-43f6-95eb-9cce5bc602e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_09bcbecc-08f4-4ea7-8aa1-afb1865e1150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5907ef1-9695-4088-9601-bddefd65070a" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_09bcbecc-08f4-4ea7-8aa1-afb1865e1150" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_126a293b-c74d-41a0-8d0b-98395ea4199f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5907ef1-9695-4088-9601-bddefd65070a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_126a293b-c74d-41a0-8d0b-98395ea4199f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_d42bab40-9edf-457b-aa85-10997e8a873e" xlink:href="arwr-20230331.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5907ef1-9695-4088-9601-bddefd65070a" xlink:to="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_d42bab40-9edf-457b-aa85-10997e8a873e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8f4c3a0-00f0-484a-99fc-9dea06c1a5b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5907ef1-9695-4088-9601-bddefd65070a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8f4c3a0-00f0-484a-99fc-9dea06c1a5b3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_323b1a7f-e56b-4061-8636-0c69f9ca7805" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8f4c3a0-00f0-484a-99fc-9dea06c1a5b3" xlink:to="loc_dei_LegalEntityAxis_323b1a7f-e56b-4061-8636-0c69f9ca7805" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_323b1a7f-e56b-4061-8636-0c69f9ca7805_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_323b1a7f-e56b-4061-8636-0c69f9ca7805" xlink:to="loc_dei_EntityDomain_323b1a7f-e56b-4061-8636-0c69f9ca7805_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_239caab0-639f-4d41-9bad-fbc1852e5aed" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_323b1a7f-e56b-4061-8636-0c69f9ca7805" xlink:to="loc_dei_EntityDomain_239caab0-639f-4d41-9bad-fbc1852e5aed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_a2cd2c34-392b-43b3-8719-b1bf7cf35aad" xlink:href="arwr-20230331.xsd#arwr_AmgenIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_239caab0-639f-4d41-9bad-fbc1852e5aed" xlink:to="loc_arwr_AmgenIncorporatedMember_a2cd2c34-392b-43b3-8719-b1bf7cf35aad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_81751317-3cc1-4b45-81b8-a2042f6f9799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8f4c3a0-00f0-484a-99fc-9dea06c1a5b3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_81751317-3cc1-4b45-81b8-a2042f6f9799" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_81751317-3cc1-4b45-81b8-a2042f6f9799_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_81751317-3cc1-4b45-81b8-a2042f6f9799" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_81751317-3cc1-4b45-81b8-a2042f6f9799_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5aa1da77-ad4a-4e8d-a868-07191c81c4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_81751317-3cc1-4b45-81b8-a2042f6f9799" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5aa1da77-ad4a-4e8d-a868-07191c81c4a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember_dd00da60-0e52-4270-a98c-160c636ec87b" xlink:href="arwr-20230331.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5aa1da77-ad4a-4e8d-a868-07191c81c4a6" xlink:to="loc_arwr_CollaborationAndLicenseAgreementMember_dd00da60-0e52-4270-a98c-160c636ec87b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAndAROAMG1AgreementMember_0de395ba-2a2b-4cad-a72f-b8a8475aceea" xlink:href="arwr-20230331.xsd#arwr_OlpasiranAndAROAMG1AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5aa1da77-ad4a-4e8d-a868-07191c81c4a6" xlink:to="loc_arwr_OlpasiranAndAROAMG1AgreementMember_0de395ba-2a2b-4cad-a72f-b8a8475aceea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAgreementMember_683b9b73-3d81-4b35-b0b8-64591f251e54" xlink:href="arwr-20230331.xsd#arwr_OlpasiranAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5aa1da77-ad4a-4e8d-a868-07191c81c4a6" xlink:to="loc_arwr_OlpasiranAgreementMember_683b9b73-3d81-4b35-b0b8-64591f251e54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_39cd0d2b-b0cc-4bbc-8dd3-5f8040cce428" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8f4c3a0-00f0-484a-99fc-9dea06c1a5b3" xlink:to="loc_srt_RangeAxis_39cd0d2b-b0cc-4bbc-8dd3-5f8040cce428" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_39cd0d2b-b0cc-4bbc-8dd3-5f8040cce428_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_39cd0d2b-b0cc-4bbc-8dd3-5f8040cce428" xlink:to="loc_srt_RangeMember_39cd0d2b-b0cc-4bbc-8dd3-5f8040cce428_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_918a2d8b-633e-4e85-be6a-e89274e88a09" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_39cd0d2b-b0cc-4bbc-8dd3-5f8040cce428" xlink:to="loc_srt_RangeMember_918a2d8b-633e-4e85-be6a-e89274e88a09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9a545397-45dd-4ffa-adb9-1987beb5f121" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_918a2d8b-633e-4e85-be6a-e89274e88a09" xlink:to="loc_srt_MaximumMember_9a545397-45dd-4ffa-adb9-1987beb5f121" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails" xlink:type="extended" id="i714220c02f37406e82090de2facdcb9a_CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09a58e36-bff3-43aa-a03f-57be99794da4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributedCapital_cee3453c-68b7-4fc1-957b-4e5bbdccee6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09a58e36-bff3-43aa-a03f-57be99794da4" xlink:to="loc_us-gaap_ProceedsFromContributedCapital_cee3453c-68b7-4fc1-957b-4e5bbdccee6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1fd8da40-b567-4459-92fc-6ec8696ea3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09a58e36-bff3-43aa-a03f-57be99794da4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1fd8da40-b567-4459-92fc-6ec8696ea3e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_0b47d524-b13f-43d4-a917-5064b7c467a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09a58e36-bff3-43aa-a03f-57be99794da4" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_0b47d524-b13f-43d4-a917-5064b7c467a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b71b9622-3a32-4ef4-8e12-851ce2e53f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09a58e36-bff3-43aa-a03f-57be99794da4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b71b9622-3a32-4ef4-8e12-851ce2e53f8f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8c7f456b-53ea-438b-9b44-3f8b6118e27c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09a58e36-bff3-43aa-a03f-57be99794da4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8c7f456b-53ea-438b-9b44-3f8b6118e27c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a989467a-dbcf-40e8-8e7c-cffb46dc256d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8c7f456b-53ea-438b-9b44-3f8b6118e27c" xlink:to="loc_dei_LegalEntityAxis_a989467a-dbcf-40e8-8e7c-cffb46dc256d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a989467a-dbcf-40e8-8e7c-cffb46dc256d_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_a989467a-dbcf-40e8-8e7c-cffb46dc256d" xlink:to="loc_dei_EntityDomain_a989467a-dbcf-40e8-8e7c-cffb46dc256d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a93962e2-cb29-41c4-98f3-aae4485ebf27" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_a989467a-dbcf-40e8-8e7c-cffb46dc256d" xlink:to="loc_dei_EntityDomain_a93962e2-cb29-41c4-98f3-aae4485ebf27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaTherapeuticsIncMember_2c5a98b2-b298-4f95-8946-1b805aa9f247" xlink:href="arwr-20230331.xsd#arwr_VisirnaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a93962e2-cb29-41c4-98f3-aae4485ebf27" xlink:to="loc_arwr_VisirnaTherapeuticsIncMember_2c5a98b2-b298-4f95-8946-1b805aa9f247" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_33144336-5d3e-4454-bf70-1d520a3ae878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8c7f456b-53ea-438b-9b44-3f8b6118e27c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_33144336-5d3e-4454-bf70-1d520a3ae878" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_33144336-5d3e-4454-bf70-1d520a3ae878_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_33144336-5d3e-4454-bf70-1d520a3ae878" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_33144336-5d3e-4454-bf70-1d520a3ae878_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a47802c9-c70c-4293-b6f7-f9180d8d36ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_33144336-5d3e-4454-bf70-1d520a3ae878" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a47802c9-c70c-4293-b6f7-f9180d8d36ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaLicenseAgreementMember_48c7a10c-46e5-4f6f-8331-a04bb9b43108" xlink:href="arwr-20230331.xsd#arwr_VisirnaLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a47802c9-c70c-4293-b6f7-f9180d8d36ce" xlink:to="loc_arwr_VisirnaLicenseAgreementMember_48c7a10c-46e5-4f6f-8331-a04bb9b43108" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_a8465d68-254e-4867-a9bc-3d78512a0df9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8c7f456b-53ea-438b-9b44-3f8b6118e27c" xlink:to="loc_srt_ConsolidatedEntitiesAxis_a8465d68-254e-4867-a9bc-3d78512a0df9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_a8465d68-254e-4867-a9bc-3d78512a0df9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_a8465d68-254e-4867-a9bc-3d78512a0df9" xlink:to="loc_srt_ConsolidatedEntitiesDomain_a8465d68-254e-4867-a9bc-3d78512a0df9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_6023dddf-f646-4ce6-b878-c05b8985d4aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_a8465d68-254e-4867-a9bc-3d78512a0df9" xlink:to="loc_srt_ConsolidatedEntitiesDomain_6023dddf-f646-4ce6-b878-c05b8985d4aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_4b6d0043-31ce-41b9-89ea-c35a93a51153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_6023dddf-f646-4ce6-b878-c05b8985d4aa" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_4b6d0043-31ce-41b9-89ea-c35a93a51153" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="extended" id="i89dc3a5105174bcb8ccf48ba6489293a_InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_d5b61299-5582-4e5b-9361-461353f7d2bd" xlink:href="arwr-20230331.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_9ae1ddae-3b00-4c43-83ff-ee1bac78d77a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_d5b61299-5582-4e5b-9361-461353f7d2bd" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_9ae1ddae-3b00-4c43-83ff-ee1bac78d77a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_de361f3e-7941-495b-a655-769c43eda552" xlink:href="arwr-20230331.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_d5b61299-5582-4e5b-9361-461353f7d2bd" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_de361f3e-7941-495b-a655-769c43eda552" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_790252ec-a739-40b3-b36a-87a423259e15" xlink:href="arwr-20230331.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_d5b61299-5582-4e5b-9361-461353f7d2bd" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_790252ec-a739-40b3-b36a-87a423259e15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_9a48a9de-143c-42ca-964e-a5b42a235b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_d5b61299-5582-4e5b-9361-461353f7d2bd" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_9a48a9de-143c-42ca-964e-a5b42a235b3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_33383518-211f-4078-b048-0771b9e943a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_d5b61299-5582-4e5b-9361-461353f7d2bd" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_33383518-211f-4078-b048-0771b9e943a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_cb8d8b13-477c-4718-b8b0-ac607f16172f" xlink:href="arwr-20230331.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_d5b61299-5582-4e5b-9361-461353f7d2bd" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_cb8d8b13-477c-4718-b8b0-ac607f16172f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_15c6e0d6-c386-41b0-8ff4-50aa2b3c761d" xlink:href="arwr-20230331.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_d5b61299-5582-4e5b-9361-461353f7d2bd" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_15c6e0d6-c386-41b0-8ff4-50aa2b3c761d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_18d98caa-a629-4c9f-957a-ab50c2c6889f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_d5b61299-5582-4e5b-9361-461353f7d2bd" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_18d98caa-a629-4c9f-957a-ab50c2c6889f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_e1f3e396-d7d6-44f8-80fe-b0fc4345974b" xlink:href="arwr-20230331.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_d5b61299-5582-4e5b-9361-461353f7d2bd" xlink:to="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_e1f3e396-d7d6-44f8-80fe-b0fc4345974b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_11637df3-9940-4a45-ac76-ff0038e76929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_e1f3e396-d7d6-44f8-80fe-b0fc4345974b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_11637df3-9940-4a45-ac76-ff0038e76929" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_11637df3-9940-4a45-ac76-ff0038e76929_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_11637df3-9940-4a45-ac76-ff0038e76929" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_11637df3-9940-4a45-ac76-ff0038e76929_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_11978b5b-86c1-4c1b-a659-34c5d4c5573f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_11637df3-9940-4a45-ac76-ff0038e76929" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_11978b5b-86c1-4c1b-a659-34c5d4c5573f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_c91ee773-2ea5-49ef-a8b9-c0d84e0bef62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_11978b5b-86c1-4c1b-a659-34c5d4c5573f" xlink:to="loc_us-gaap_DebtSecuritiesMember_c91ee773-2ea5-49ef-a8b9-c0d84e0bef62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_46258328-58b5-4ddf-973a-2ddae5fa0899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_11978b5b-86c1-4c1b-a659-34c5d4c5573f" xlink:to="loc_us-gaap_CertificatesOfDepositMember_46258328-58b5-4ddf-973a-2ddae5fa0899" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i9521f274dac7459d8f49590aee9ce461_IntangibleAssetsScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8a4d3e3-28d0-4476-9a5d-c0c4eda0220c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2c7fef13-9109-49e0-a218-28c0bf377f50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8a4d3e3-28d0-4476-9a5d-c0c4eda0220c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2c7fef13-9109-49e0-a218-28c0bf377f50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bb9d6944-106b-427e-9d15-db4a4989f9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8a4d3e3-28d0-4476-9a5d-c0c4eda0220c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bb9d6944-106b-427e-9d15-db4a4989f9c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsImpairment_5a089c20-532c-4081-b11e-4a0bfc25f0b4" xlink:href="arwr-20230331.xsd#arwr_FiniteLivedIntangibleAssetsImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8a4d3e3-28d0-4476-9a5d-c0c4eda0220c" xlink:to="loc_arwr_FiniteLivedIntangibleAssetsImpairment_5a089c20-532c-4081-b11e-4a0bfc25f0b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bda60689-5d4a-4eb1-918a-d28b56ff8d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8a4d3e3-28d0-4476-9a5d-c0c4eda0220c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bda60689-5d4a-4eb1-918a-d28b56ff8d6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8061383e-8b33-41de-adec-cc6419171cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8a4d3e3-28d0-4476-9a5d-c0c4eda0220c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8061383e-8b33-41de-adec-cc6419171cc7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e9c80601-9008-44c2-b6c5-98821d383f99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8a4d3e3-28d0-4476-9a5d-c0c4eda0220c" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e9c80601-9008-44c2-b6c5-98821d383f99" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_3759b6c7-af4b-4001-95db-926a00ce460b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e9c80601-9008-44c2-b6c5-98821d383f99" xlink:to="loc_us-gaap_AssetAcquisitionAxis_3759b6c7-af4b-4001-95db-926a00ce460b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_3759b6c7-af4b-4001-95db-926a00ce460b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_3759b6c7-af4b-4001-95db-926a00ce460b" xlink:to="loc_us-gaap_AssetAcquisitionDomain_3759b6c7-af4b-4001-95db-926a00ce460b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_d7342b84-9f61-4a00-96b6-95af2b600c49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_3759b6c7-af4b-4001-95db-926a00ce460b" xlink:to="loc_us-gaap_AssetAcquisitionDomain_d7342b84-9f61-4a00-96b6-95af2b600c49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisMember_4b6ce4ae-ecfb-460e-aa20-ba3845da3f15" xlink:href="arwr-20230331.xsd#arwr_NovartisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_d7342b84-9f61-4a00-96b6-95af2b600c49" xlink:to="loc_arwr_NovartisMember_4b6ce4ae-ecfb-460e-aa20-ba3845da3f15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_711bf9c9-e7be-4096-8094-0a7900254afe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e9c80601-9008-44c2-b6c5-98821d383f99" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_711bf9c9-e7be-4096-8094-0a7900254afe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_711bf9c9-e7be-4096-8094-0a7900254afe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_711bf9c9-e7be-4096-8094-0a7900254afe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_711bf9c9-e7be-4096-8094-0a7900254afe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4523b65c-695c-4b9d-b798-ab5f56cb720b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_711bf9c9-e7be-4096-8094-0a7900254afe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4523b65c-695c-4b9d-b798-ab5f56cb720b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_920592e1-2ae7-44e5-9dbb-fcc0792125be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4523b65c-695c-4b9d-b798-ab5f56cb720b" xlink:to="loc_us-gaap_PatentsMember_920592e1-2ae7-44e5-9dbb-fcc0792125be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_f270a197-ebf7-4cab-a9d9-e1f931f273a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4523b65c-695c-4b9d-b798-ab5f56cb720b" xlink:to="loc_us-gaap_LicensingAgreementsMember_f270a197-ebf7-4cab-a9d9-e1f931f273a9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquityDetails" xlink:type="extended" id="ib0a4d027b77f4a4d8534b5fbd2d8c7ef_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_73d9f5b9-a78c-4e29-90bf-3882a1d3a61e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9437bbfe-0ebe-44b5-b032-7013fb2432c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_73d9f5b9-a78c-4e29-90bf-3882a1d3a61e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9437bbfe-0ebe-44b5-b032-7013fb2432c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_705b713c-33f5-40d4-9ad1-de3dea77742c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_73d9f5b9-a78c-4e29-90bf-3882a1d3a61e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_705b713c-33f5-40d4-9ad1-de3dea77742c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_0cbe9db7-74b4-4062-8109-a742b5825120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_73d9f5b9-a78c-4e29-90bf-3882a1d3a61e" xlink:to="loc_us-gaap_CommonStockSharesIssued_0cbe9db7-74b4-4062-8109-a742b5825120" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3910a217-c4cb-43cd-aa3d-7610a4889706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_73d9f5b9-a78c-4e29-90bf-3882a1d3a61e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3910a217-c4cb-43cd-aa3d-7610a4889706" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f1113f9f-828d-4368-803b-ad1fa769a6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_73d9f5b9-a78c-4e29-90bf-3882a1d3a61e" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f1113f9f-828d-4368-803b-ad1fa769a6f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_34113ac6-c8a9-469a-8ca0-066dea645359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_73d9f5b9-a78c-4e29-90bf-3882a1d3a61e" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_34113ac6-c8a9-469a-8ca0-066dea645359" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_99af0d8b-cd64-4713-a7f6-5ffb360a7d54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_73d9f5b9-a78c-4e29-90bf-3882a1d3a61e" xlink:to="loc_us-gaap_PreferredStockSharesIssued_99af0d8b-cd64-4713-a7f6-5ffb360a7d54" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_887b8371-6db7-410d-950c-c79a67561f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_73d9f5b9-a78c-4e29-90bf-3882a1d3a61e" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_887b8371-6db7-410d-950c-c79a67561f6e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_72fb06da-ae13-4388-a534-3de3fd1b450e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_73d9f5b9-a78c-4e29-90bf-3882a1d3a61e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_72fb06da-ae13-4388-a534-3de3fd1b450e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_2af8db68-a007-4476-9def-f76926ba94ca" xlink:href="arwr-20230331.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_73d9f5b9-a78c-4e29-90bf-3882a1d3a61e" xlink:to="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_2af8db68-a007-4476-9def-f76926ba94ca" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_fd49844f-0d0a-4120-81c7-1cf65b148acf" xlink:href="arwr-20230331.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_73d9f5b9-a78c-4e29-90bf-3882a1d3a61e" xlink:to="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_fd49844f-0d0a-4120-81c7-1cf65b148acf" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_353f1a67-a3a0-4e40-bcab-79c9a197a35b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_73d9f5b9-a78c-4e29-90bf-3882a1d3a61e" xlink:to="loc_us-gaap_SharesIssued_353f1a67-a3a0-4e40-bcab-79c9a197a35b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_690984f0-b602-49ec-94c2-5ee35dc99bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_73d9f5b9-a78c-4e29-90bf-3882a1d3a61e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_690984f0-b602-49ec-94c2-5ee35dc99bcc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d1598229-06a9-4b56-81cf-07db499992af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_690984f0-b602-49ec-94c2-5ee35dc99bcc" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d1598229-06a9-4b56-81cf-07db499992af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d1598229-06a9-4b56-81cf-07db499992af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d1598229-06a9-4b56-81cf-07db499992af" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d1598229-06a9-4b56-81cf-07db499992af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_04735908-8b31-4b80-9172-29a695ab2204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d1598229-06a9-4b56-81cf-07db499992af" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_04735908-8b31-4b80-9172-29a695ab2204" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_37f8650b-a6a9-41eb-bd19-2b25dd8bdfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_04735908-8b31-4b80-9172-29a695ab2204" xlink:to="loc_us-gaap_SubsequentEventMember_37f8650b-a6a9-41eb-bd19-2b25dd8bdfa0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0242b8cf-64a2-413c-821e-a559736550e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_690984f0-b602-49ec-94c2-5ee35dc99bcc" xlink:to="loc_us-gaap_PlanNameAxis_0242b8cf-64a2-413c-821e-a559736550e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0242b8cf-64a2-413c-821e-a559736550e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_0242b8cf-64a2-413c-821e-a559736550e5" xlink:to="loc_us-gaap_PlanNameDomain_0242b8cf-64a2-413c-821e-a559736550e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e3d31ae8-c9b8-4250-a87b-99d3a39dfd27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_0242b8cf-64a2-413c-821e-a559736550e5" xlink:to="loc_us-gaap_PlanNameDomain_e3d31ae8-c9b8-4250-a87b-99d3a39dfd27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_5de05e7e-0e6d-44a6-979d-55ca14c85777" xlink:href="arwr-20230331.xsd#arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e3d31ae8-c9b8-4250-a87b-99d3a39dfd27" xlink:to="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_5de05e7e-0e6d-44a6-979d-55ca14c85777" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b63bf135-489a-4b56-b1d3-49c71a070314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_690984f0-b602-49ec-94c2-5ee35dc99bcc" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b63bf135-489a-4b56-b1d3-49c71a070314" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b63bf135-489a-4b56-b1d3-49c71a070314_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b63bf135-489a-4b56-b1d3-49c71a070314" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b63bf135-489a-4b56-b1d3-49c71a070314_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_762c9a98-5bf2-4535-b175-6f4e51f34663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b63bf135-489a-4b56-b1d3-49c71a070314" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_762c9a98-5bf2-4535-b175-6f4e51f34663" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AtTheMarketAgreementMember_4d09330b-b04a-4490-a60d-343a5eaf5281" xlink:href="arwr-20230331.xsd#arwr_AtTheMarketAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_762c9a98-5bf2-4535-b175-6f4e51f34663" xlink:to="loc_arwr_AtTheMarketAgreementMember_4d09330b-b04a-4490-a60d-343a5eaf5281" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0a3be423-b854-48ed-8a65-d1eb362dd6b0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_690984f0-b602-49ec-94c2-5ee35dc99bcc" xlink:to="loc_srt_RangeAxis_0a3be423-b854-48ed-8a65-d1eb362dd6b0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0a3be423-b854-48ed-8a65-d1eb362dd6b0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0a3be423-b854-48ed-8a65-d1eb362dd6b0" xlink:to="loc_srt_RangeMember_0a3be423-b854-48ed-8a65-d1eb362dd6b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3ee23d51-1897-41f0-97d8-d23757e24350" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0a3be423-b854-48ed-8a65-d1eb362dd6b0" xlink:to="loc_srt_RangeMember_3ee23d51-1897-41f0-97d8-d23757e24350" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_157ca472-a054-4a76-a53d-ff3fd6cf58c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3ee23d51-1897-41f0-97d8-d23757e24350" xlink:to="loc_srt_MaximumMember_157ca472-a054-4a76-a53d-ff3fd6cf58c6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20230331.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended" id="ib5bba6363a2b485bbf137305adefd7c8_CommitmentsandContingenciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_89b7037f-f6fd-44ec-af6b-8870a91d913f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_e074fd38-aea4-4504-89ac-44fb5b7da8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_89b7037f-f6fd-44ec-af6b-8870a91d913f" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_e074fd38-aea4-4504-89ac-44fb5b7da8f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAcresOfLandPurchased_c06a4c13-1a96-4096-8a01-b3f1a6d6e73e" xlink:href="arwr-20230331.xsd#arwr_NumberOfAcresOfLandPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_89b7037f-f6fd-44ec-af6b-8870a91d913f" xlink:to="loc_arwr_NumberOfAcresOfLandPurchased_c06a4c13-1a96-4096-8a01-b3f1a6d6e73e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_12cf6cff-7702-46a8-9175-c4ae5427ba66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_89b7037f-f6fd-44ec-af6b-8870a91d913f" xlink:to="loc_us-gaap_AreaOfLand_12cf6cff-7702-46a8-9175-c4ae5427ba66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities_aa306bea-e24e-48ac-98fb-26525e348f34" xlink:href="arwr-20230331.xsd#arwr_AmountIntendsToInvestForBuildoutOfFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_89b7037f-f6fd-44ec-af6b-8870a91d913f" xlink:to="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities_aa306bea-e24e-48ac-98fb-26525e348f34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TaxIncrementFinancingAward_fc080bae-f192-47b3-8ac1-68f4ad5277d7" xlink:href="arwr-20230331.xsd#arwr_TaxIncrementFinancingAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_89b7037f-f6fd-44ec-af6b-8870a91d913f" xlink:to="loc_arwr_TaxIncrementFinancingAward_fc080bae-f192-47b3-8ac1-68f4ad5277d7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_29302104-f4ba-4f8d-b44c-4da9b1eb8a47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_89b7037f-f6fd-44ec-af6b-8870a91d913f" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_29302104-f4ba-4f8d-b44c-4da9b1eb8a47" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePayments_bdfa1375-f60e-438c-93a4-1d7d6eef9987" xlink:href="arwr-20230331.xsd#arwr_MilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_89b7037f-f6fd-44ec-af6b-8870a91d913f" xlink:to="loc_arwr_MilestonePayments_bdfa1375-f60e-438c-93a4-1d7d6eef9987" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_99434624-1fca-4840-8a2c-c79799318949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_89b7037f-f6fd-44ec-af6b-8870a91d913f" xlink:to="loc_us-gaap_OtherCommitmentsTable_99434624-1fca-4840-8a2c-c79799318949" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4ada3866-b37f-4fb0-b469-27e887e5e240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_99434624-1fca-4840-8a2c-c79799318949" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4ada3866-b37f-4fb0-b469-27e887e5e240" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ada3866-b37f-4fb0-b469-27e887e5e240_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4ada3866-b37f-4fb0-b469-27e887e5e240" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ada3866-b37f-4fb0-b469-27e887e5e240_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aa24faf8-e3a0-4e53-8a5c-aa3891ba7fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4ada3866-b37f-4fb0-b469-27e887e5e240" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aa24faf8-e3a0-4e53-8a5c-aa3891ba7fb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VeronaTechnologyParkMember_283b39e6-0afb-49c9-8392-48fb4064df0e" xlink:href="arwr-20230331.xsd#arwr_VeronaTechnologyParkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aa24faf8-e3a0-4e53-8a5c-aa3891ba7fb9" xlink:to="loc_arwr_VeronaTechnologyParkMember_283b39e6-0afb-49c9-8392-48fb4064df0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DrugManufacturingFacilityMember_02c75a18-5b95-4b0c-b8d4-d176c29b6e00" xlink:href="arwr-20230331.xsd#arwr_DrugManufacturingFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aa24faf8-e3a0-4e53-8a5c-aa3891ba7fb9" xlink:to="loc_arwr_DrugManufacturingFacilityMember_02c75a18-5b95-4b0c-b8d4-d176c29b6e00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LaboratoryAndOfficeFacilityMember_209d7bf6-2108-45bd-85e0-02d030ac05e8" xlink:href="arwr-20230331.xsd#arwr_LaboratoryAndOfficeFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aa24faf8-e3a0-4e53-8a5c-aa3891ba7fb9" xlink:to="loc_arwr_LaboratoryAndOfficeFacilityMember_209d7bf6-2108-45bd-85e0-02d030ac05e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FacilitiesMember_764bd8b4-a396-4f17-a45c-97974b98845e" xlink:href="arwr-20230331.xsd#arwr_FacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aa24faf8-e3a0-4e53-8a5c-aa3891ba7fb9" xlink:to="loc_arwr_FacilitiesMember_764bd8b4-a396-4f17-a45c-97974b98845e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f938fc56-f519-4f1d-bdd3-7b55e0bc214d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_99434624-1fca-4840-8a2c-c79799318949" xlink:to="loc_srt_StatementGeographicalAxis_f938fc56-f519-4f1d-bdd3-7b55e0bc214d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f938fc56-f519-4f1d-bdd3-7b55e0bc214d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_f938fc56-f519-4f1d-bdd3-7b55e0bc214d" xlink:to="loc_srt_SegmentGeographicalDomain_f938fc56-f519-4f1d-bdd3-7b55e0bc214d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2c2b3b09-7b90-41d1-b70f-c887779bb0c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_f938fc56-f519-4f1d-bdd3-7b55e0bc214d" xlink:to="loc_srt_SegmentGeographicalDomain_2c2b3b09-7b90-41d1-b70f-c887779bb0c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_fd5a8012-d543-46dd-9003-d5f665497ad7" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2c2b3b09-7b90-41d1-b70f-c887779bb0c5" xlink:to="loc_stpr_WI_fd5a8012-d543-46dd-9003-d5f665497ad7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_29b80bb8-2708-41c0-84b6-be75899c8174" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_99434624-1fca-4840-8a2c-c79799318949" xlink:to="loc_srt_RangeAxis_29b80bb8-2708-41c0-84b6-be75899c8174" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_29b80bb8-2708-41c0-84b6-be75899c8174_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_29b80bb8-2708-41c0-84b6-be75899c8174" xlink:to="loc_srt_RangeMember_29b80bb8-2708-41c0-84b6-be75899c8174_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_965d99f4-324c-4f24-996b-435ac8ac83bd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_29b80bb8-2708-41c0-84b6-be75899c8174" xlink:to="loc_srt_RangeMember_965d99f4-324c-4f24-996b-435ac8ac83bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f7d0f563-af46-4e95-aada-93d67a0feaac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_965d99f4-324c-4f24-996b-435ac8ac83bd" xlink:to="loc_srt_MinimumMember_f7d0f563-af46-4e95-aada-93d67a0feaac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a7427cb0-fd68-437d-9997-47f7752ae8fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_965d99f4-324c-4f24-996b-435ac8ac83bd" xlink:to="loc_srt_MaximumMember_a7427cb0-fd68-437d-9997-47f7752ae8fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_2031de9a-f3b3-48e4-9468-b29378f76d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_99434624-1fca-4840-8a2c-c79799318949" xlink:to="loc_us-gaap_OtherCommitmentsAxis_2031de9a-f3b3-48e4-9468-b29378f76d92" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_2031de9a-f3b3-48e4-9468-b29378f76d92_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_2031de9a-f3b3-48e4-9468-b29378f76d92" xlink:to="loc_us-gaap_OtherCommitmentsDomain_2031de9a-f3b3-48e4-9468-b29378f76d92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_89858e84-3b0c-45f8-8ce9-95c1ab0bfa51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_2031de9a-f3b3-48e4-9468-b29378f76d92" xlink:to="loc_us-gaap_OtherCommitmentsDomain_89858e84-3b0c-45f8-8ce9-95c1ab0bfa51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TechnologyLicenseCommitmentsMember_832a2799-439e-4a02-b1b5-bef39b6c4cdd" xlink:href="arwr-20230331.xsd#arwr_TechnologyLicenseCommitmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_89858e84-3b0c-45f8-8ce9-95c1ab0bfa51" xlink:to="loc_arwr_TechnologyLicenseCommitmentsMember_832a2799-439e-4a02-b1b5-bef39b6c4cdd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i963d15cb75104b98b73ad4bd2cd0b5e0_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_1da1686d-feb9-4a96-aecc-f33b21279363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ef5a4b64-9329-4dd2-94a7-9d67581c076e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1da1686d-feb9-4a96-aecc-f33b21279363" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ef5a4b64-9329-4dd2-94a7-9d67581c076e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_9c5ce116-0b0e-43b3-ba6e-27d3d6572dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1da1686d-feb9-4a96-aecc-f33b21279363" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_9c5ce116-0b0e-43b3-ba6e-27d3d6572dfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_df2b1187-d965-4caa-9603-ed8cb20bb99c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1da1686d-feb9-4a96-aecc-f33b21279363" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_df2b1187-d965-4caa-9603-ed8cb20bb99c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EstimatedPaymentsForOperatingExpensesYearOne_a5e98774-6fbd-41d9-aea2-cf7dc0416a97" xlink:href="arwr-20230331.xsd#arwr_EstimatedPaymentsForOperatingExpensesYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1da1686d-feb9-4a96-aecc-f33b21279363" xlink:to="loc_arwr_EstimatedPaymentsForOperatingExpensesYearOne_a5e98774-6fbd-41d9-aea2-cf7dc0416a97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_aa7bfafa-2221-4ceb-9fb7-dc9744fac37d" xlink:href="arwr-20230331.xsd#arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1da1686d-feb9-4a96-aecc-f33b21279363" xlink:to="loc_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_aa7bfafa-2221-4ceb-9fb7-dc9744fac37d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfOptionsToRenew_89315e68-df80-48d9-adc8-236d16b7e24a" xlink:href="arwr-20230331.xsd#arwr_NumberOfOptionsToRenew"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1da1686d-feb9-4a96-aecc-f33b21279363" xlink:to="loc_arwr_NumberOfOptionsToRenew_89315e68-df80-48d9-adc8-236d16b7e24a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_80d107a7-c5c1-4ebf-a3ca-725605ff04cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1da1686d-feb9-4a96-aecc-f33b21279363" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_80d107a7-c5c1-4ebf-a3ca-725605ff04cf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_3ea3318e-e52f-427f-b126-d2838974d619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1da1686d-feb9-4a96-aecc-f33b21279363" xlink:to="loc_us-gaap_ShortTermLeaseCost_3ea3318e-e52f-427f-b126-d2838974d619" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_3a956c6c-fb80-45b6-9659-6851cdc44274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1da1686d-feb9-4a96-aecc-f33b21279363" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_3a956c6c-fb80-45b6-9659-6851cdc44274" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_244196e8-d63c-45e0-959d-74f3dc484feb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3a956c6c-fb80-45b6-9659-6851cdc44274" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_244196e8-d63c-45e0-959d-74f3dc484feb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_244196e8-d63c-45e0-959d-74f3dc484feb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_244196e8-d63c-45e0-959d-74f3dc484feb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_244196e8-d63c-45e0-959d-74f3dc484feb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_11376fdb-ebe8-4386-bbb9-2732258c9b50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_244196e8-d63c-45e0-959d-74f3dc484feb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_11376fdb-ebe8-4386-bbb9-2732258c9b50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInSanDiegoMember_13b1456f-8281-4f90-824e-1109665011bc" xlink:href="arwr-20230331.xsd#arwr_ResearchFacilityInSanDiegoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_11376fdb-ebe8-4386-bbb9-2732258c9b50" xlink:to="loc_arwr_ResearchFacilityInSanDiegoMember_13b1456f-8281-4f90-824e-1109665011bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CorporateHeadquartersInPasadenaMember_718d287e-68ad-423b-9f01-e3513068f45d" xlink:href="arwr-20230331.xsd#arwr_CorporateHeadquartersInPasadenaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_11376fdb-ebe8-4386-bbb9-2732258c9b50" xlink:to="loc_arwr_CorporateHeadquartersInPasadenaMember_718d287e-68ad-423b-9f01-e3513068f45d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInMadisonMember_8a23909d-e058-4276-a624-001c11901ccd" xlink:href="arwr-20230331.xsd#arwr_ResearchFacilityInMadisonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_11376fdb-ebe8-4386-bbb9-2732258c9b50" xlink:to="loc_arwr_ResearchFacilityInMadisonMember_8a23909d-e058-4276-a624-001c11901ccd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_08b5643f-fa91-4b3c-a23c-8f62dd661c0d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3a956c6c-fb80-45b6-9659-6851cdc44274" xlink:to="loc_srt_StatementGeographicalAxis_08b5643f-fa91-4b3c-a23c-8f62dd661c0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_08b5643f-fa91-4b3c-a23c-8f62dd661c0d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_08b5643f-fa91-4b3c-a23c-8f62dd661c0d" xlink:to="loc_srt_SegmentGeographicalDomain_08b5643f-fa91-4b3c-a23c-8f62dd661c0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e4bc02c7-1863-4f63-9a47-9f93703bc5bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_08b5643f-fa91-4b3c-a23c-8f62dd661c0d" xlink:to="loc_srt_SegmentGeographicalDomain_e4bc02c7-1863-4f63-9a47-9f93703bc5bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_a1414d36-c9a8-4407-a472-6d57bc2b32b9" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e4bc02c7-1863-4f63-9a47-9f93703bc5bf" xlink:to="loc_stpr_CA_a1414d36-c9a8-4407-a472-6d57bc2b32b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_81c16974-e9a2-468c-b47d-b362090142db" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e4bc02c7-1863-4f63-9a47-9f93703bc5bf" xlink:to="loc_stpr_WI_81c16974-e9a2-468c-b47d-b362090142db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a16954b3-7866-4a64-b033-ac0a7a983d66" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3a956c6c-fb80-45b6-9659-6851cdc44274" xlink:to="loc_srt_RangeAxis_a16954b3-7866-4a64-b033-ac0a7a983d66" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a16954b3-7866-4a64-b033-ac0a7a983d66_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a16954b3-7866-4a64-b033-ac0a7a983d66" xlink:to="loc_srt_RangeMember_a16954b3-7866-4a64-b033-ac0a7a983d66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fcb1d849-b75d-4b70-9031-694523a8024f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a16954b3-7866-4a64-b033-ac0a7a983d66" xlink:to="loc_srt_RangeMember_fcb1d849-b75d-4b70-9031-694523a8024f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b33e711c-7c7b-4969-9f94-aa7583040883" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fcb1d849-b75d-4b70-9031-694523a8024f" xlink:to="loc_srt_MaximumMember_b33e711c-7c7b-4969-9f94-aa7583040883" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1c8aed6a-2c7f-48a5-93fe-ee15f0e5f124" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3a956c6c-fb80-45b6-9659-6851cdc44274" xlink:to="loc_srt_CounterpartyNameAxis_1c8aed6a-2c7f-48a5-93fe-ee15f0e5f124" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1c8aed6a-2c7f-48a5-93fe-ee15f0e5f124_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1c8aed6a-2c7f-48a5-93fe-ee15f0e5f124" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1c8aed6a-2c7f-48a5-93fe-ee15f0e5f124_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f9ba3788-d2b0-414c-b74e-42d3f2370f9d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1c8aed6a-2c7f-48a5-93fe-ee15f0e5f124" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f9ba3788-d2b0-414c-b74e-42d3f2370f9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ColoradoOwnerLLCMember_ddcc47d5-bb3f-4d87-8924-de47e631ba73" xlink:href="arwr-20230331.xsd#arwr_ColoradoOwnerLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f9ba3788-d2b0-414c-b74e-42d3f2370f9d" xlink:to="loc_arwr_ColoradoOwnerLLCMember_ddcc47d5-bb3f-4d87-8924-de47e631ba73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SorrentoValleyOwnerDELLCMember_417bb895-1c9b-4555-a85e-5b6baa6dc7b6" xlink:href="arwr-20230331.xsd#arwr_SorrentoValleyOwnerDELLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f9ba3788-d2b0-414c-b74e-42d3f2370f9d" xlink:to="loc_arwr_SorrentoValleyOwnerDELLCMember_417bb895-1c9b-4555-a85e-5b6baa6dc7b6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#LeasesComponentsofLeaseAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="extended" id="if739a17a0d66410dbd801da9445477db_LeasesComponentsofLeaseAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_c1a9bff3-c054-4dc8-bab1-88340dd07e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_284d5c82-074f-499e-9397-a152778cd295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_c1a9bff3-c054-4dc8-bab1-88340dd07e0e" xlink:to="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_284d5c82-074f-499e-9397-a152778cd295" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4de706b6-37ac-411f-8186-13dfec45218f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_284d5c82-074f-499e-9397-a152778cd295" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4de706b6-37ac-411f-8186-13dfec45218f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_dd69a605-759a-48e3-81e8-d5211fd47f53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_284d5c82-074f-499e-9397-a152778cd295" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_dd69a605-759a-48e3-81e8-d5211fd47f53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f580a3ce-d80f-48ed-91d5-7c329048ace1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_284d5c82-074f-499e-9397-a152778cd295" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f580a3ce-d80f-48ed-91d5-7c329048ace1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_55f7781e-815b-46ae-9ac4-cb3eb0e84200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_c1a9bff3-c054-4dc8-bab1-88340dd07e0e" xlink:to="loc_us-gaap_LeaseCostAbstract_55f7781e-815b-46ae-9ac4-cb3eb0e84200" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_af3f9d73-8af1-44a4-a09c-196b2815d74d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseCostAbstract_55f7781e-815b-46ae-9ac4-cb3eb0e84200" xlink:to="loc_us-gaap_OperatingLeaseCost_af3f9d73-8af1-44a4-a09c-196b2815d74d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_468be18f-12bf-446f-9459-279ee922fc64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseCostAbstract_55f7781e-815b-46ae-9ac4-cb3eb0e84200" xlink:to="loc_us-gaap_VariableLeaseCost_468be18f-12bf-446f-9459-279ee922fc64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_580cb3c8-621c-45b0-a1bc-e21a350b7cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseCostAbstract_55f7781e-815b-46ae-9ac4-cb3eb0e84200" xlink:to="loc_us-gaap_LeaseCost_580cb3c8-621c-45b0-a1bc-e21a350b7cbf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_a76bb339-9fa4-4ac3-9b21-24462cf6b181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_c1a9bff3-c054-4dc8-bab1-88340dd07e0e" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_a76bb339-9fa4-4ac3-9b21-24462cf6b181" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d6abb543-c00a-4c23-896b-27ae67710ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_a76bb339-9fa4-4ac3-9b21-24462cf6b181" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d6abb543-c00a-4c23-896b-27ae67710ae6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d6abb543-c00a-4c23-896b-27ae67710ae6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d6abb543-c00a-4c23-896b-27ae67710ae6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d6abb543-c00a-4c23-896b-27ae67710ae6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6b070898-d62b-4ff7-aa63-bc58fe052c43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d6abb543-c00a-4c23-896b-27ae67710ae6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6b070898-d62b-4ff7-aa63-bc58fe052c43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d0255213-ef46-4548-81bc-752ba1a7811e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6b070898-d62b-4ff7-aa63-bc58fe052c43" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d0255213-ef46-4548-81bc-752ba1a7811e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_0dd624c6-7fac-4084-807b-528548767e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6b070898-d62b-4ff7-aa63-bc58fe052c43" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_0dd624c6-7fac-4084-807b-528548767e3d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="icd67d5d04e734717bf0fa024f4408014_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1419e6a-a3e3-4d58-b222-6cf6c4aadb31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7b8b76a5-a5e6-4b86-8ac8-9521791927ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1419e6a-a3e3-4d58-b222-6cf6c4aadb31" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7b8b76a5-a5e6-4b86-8ac8-9521791927ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2735e73d-22c0-4704-985f-ba8b31c5d537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1419e6a-a3e3-4d58-b222-6cf6c4aadb31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2735e73d-22c0-4704-985f-ba8b31c5d537" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_437d7af2-4a44-4ab3-9d95-cae76688230f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1419e6a-a3e3-4d58-b222-6cf6c4aadb31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_437d7af2-4a44-4ab3-9d95-cae76688230f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_05f46952-aa04-488a-adaa-3dbcc7cfeb3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1419e6a-a3e3-4d58-b222-6cf6c4aadb31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_05f46952-aa04-488a-adaa-3dbcc7cfeb3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0ee0f74b-420b-40b4-b5ef-1978ff887ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1419e6a-a3e3-4d58-b222-6cf6c4aadb31" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0ee0f74b-420b-40b4-b5ef-1978ff887ecc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0f6f19ea-bfc3-48ee-83ef-0d76aa7e9800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1419e6a-a3e3-4d58-b222-6cf6c4aadb31" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0f6f19ea-bfc3-48ee-83ef-0d76aa7e9800" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3aa4d51c-faea-43b0-ab76-2817c28023c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1419e6a-a3e3-4d58-b222-6cf6c4aadb31" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3aa4d51c-faea-43b0-ab76-2817c28023c5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1b037966-522e-4ad0-ab83-15458d2082c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1419e6a-a3e3-4d58-b222-6cf6c4aadb31" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1b037966-522e-4ad0-ab83-15458d2082c9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d83449a-9cbe-478d-8405-86273b4528f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1419e6a-a3e3-4d58-b222-6cf6c4aadb31" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d83449a-9cbe-478d-8405-86273b4528f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_df9d34a6-556c-4ed7-b3fb-0d0d7a82b104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d83449a-9cbe-478d-8405-86273b4528f2" xlink:to="loc_us-gaap_PlanNameAxis_df9d34a6-556c-4ed7-b3fb-0d0d7a82b104" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_df9d34a6-556c-4ed7-b3fb-0d0d7a82b104_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_df9d34a6-556c-4ed7-b3fb-0d0d7a82b104" xlink:to="loc_us-gaap_PlanNameDomain_df9d34a6-556c-4ed7-b3fb-0d0d7a82b104_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_131d5dae-9bbd-4a57-a585-d5818417bdee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_df9d34a6-556c-4ed7-b3fb-0d0d7a82b104" xlink:to="loc_us-gaap_PlanNameDomain_131d5dae-9bbd-4a57-a585-d5818417bdee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_39cd5866-1f0e-403d-b1b3-10c5464a8047" xlink:href="arwr-20230331.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_131d5dae-9bbd-4a57-a585-d5818417bdee" xlink:to="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_39cd5866-1f0e-403d-b1b3-10c5464a8047" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_2aff7c66-5f52-45db-abcf-8054ddc94de8" xlink:href="arwr-20230331.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_131d5dae-9bbd-4a57-a585-d5818417bdee" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_2aff7c66-5f52-45db-abcf-8054ddc94de8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_371ce57a-5bd9-4fe4-9b89-1406c894871e" xlink:href="arwr-20230331.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_131d5dae-9bbd-4a57-a585-d5818417bdee" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_371ce57a-5bd9-4fe4-9b89-1406c894871e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementAwardsMember_ec092998-6723-40dc-8e61-9bdb28636738" xlink:href="arwr-20230331.xsd#arwr_InducementAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_131d5dae-9bbd-4a57-a585-d5818417bdee" xlink:to="loc_arwr_InducementAwardsMember_ec092998-6723-40dc-8e61-9bdb28636738" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_01716a3d-9879-42f7-b3cb-9596fa7380a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d83449a-9cbe-478d-8405-86273b4528f2" xlink:to="loc_us-gaap_AwardTypeAxis_01716a3d-9879-42f7-b3cb-9596fa7380a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01716a3d-9879-42f7-b3cb-9596fa7380a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_01716a3d-9879-42f7-b3cb-9596fa7380a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01716a3d-9879-42f7-b3cb-9596fa7380a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5403ee58-cf70-4e78-b54b-377b202f47e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_01716a3d-9879-42f7-b3cb-9596fa7380a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5403ee58-cf70-4e78-b54b-377b202f47e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0209609c-25bc-4cd7-afc9-4c03abe580ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5403ee58-cf70-4e78-b54b-377b202f47e4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0209609c-25bc-4cd7-afc9-4c03abe580ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e4421ed0-f380-47c8-ac0a-5bf8c7b5b501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5403ee58-cf70-4e78-b54b-377b202f47e4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e4421ed0-f380-47c8-ac0a-5bf8c7b5b501" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="extended" id="i5ec84fb150a9431dbb8dff5e06992eeb_StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba4eebc0-7f64-41f0-96d1-050f9d6383ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5e0b33b8-8cbf-454f-a63e-7fa6b937e2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba4eebc0-7f64-41f0-96d1-050f9d6383ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5e0b33b8-8cbf-454f-a63e-7fa6b937e2bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_709de95d-7c27-4c85-8b74-fc3182b29391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba4eebc0-7f64-41f0-96d1-050f9d6383ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_709de95d-7c27-4c85-8b74-fc3182b29391" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_91e70d90-15b1-4081-9042-e0d3a18567fe" xlink:href="arwr-20230331.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba4eebc0-7f64-41f0-96d1-050f9d6383ce" xlink:to="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_91e70d90-15b1-4081-9042-e0d3a18567fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cee5cb3b-223b-49e0-95c8-c9cb7bb5e1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba4eebc0-7f64-41f0-96d1-050f9d6383ce" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cee5cb3b-223b-49e0-95c8-c9cb7bb5e1bd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_724d456d-c6ff-4fcb-bab7-0659f6fa4d63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cee5cb3b-223b-49e0-95c8-c9cb7bb5e1bd" xlink:to="loc_us-gaap_AwardTypeAxis_724d456d-c6ff-4fcb-bab7-0659f6fa4d63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_724d456d-c6ff-4fcb-bab7-0659f6fa4d63_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_724d456d-c6ff-4fcb-bab7-0659f6fa4d63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_724d456d-c6ff-4fcb-bab7-0659f6fa4d63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31fa804a-625b-4d68-898d-2c0614e684a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_724d456d-c6ff-4fcb-bab7-0659f6fa4d63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31fa804a-625b-4d68-898d-2c0614e684a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_edc4b2cf-8113-4156-b94a-6ffa5ee9d18f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31fa804a-625b-4d68-898d-2c0614e684a0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_edc4b2cf-8113-4156-b94a-6ffa5ee9d18f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1e799c9b-454e-4fb7-ae72-989f82f48d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cee5cb3b-223b-49e0-95c8-c9cb7bb5e1bd" xlink:to="loc_us-gaap_PlanNameAxis_1e799c9b-454e-4fb7-ae72-989f82f48d64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1e799c9b-454e-4fb7-ae72-989f82f48d64_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1e799c9b-454e-4fb7-ae72-989f82f48d64" xlink:to="loc_us-gaap_PlanNameDomain_1e799c9b-454e-4fb7-ae72-989f82f48d64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5101f235-2471-405d-b6c8-9c92814b7297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1e799c9b-454e-4fb7-ae72-989f82f48d64" xlink:to="loc_us-gaap_PlanNameDomain_5101f235-2471-405d-b6c8-9c92814b7297" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_49b55c55-a934-4bcb-96b7-f6fee0d8c830" xlink:href="arwr-20230331.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5101f235-2471-405d-b6c8-9c92814b7297" xlink:to="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_49b55c55-a934-4bcb-96b7-f6fee0d8c830" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_b534b39b-e85d-466a-937c-7aa4910ce3a5" xlink:href="arwr-20230331.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5101f235-2471-405d-b6c8-9c92814b7297" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_b534b39b-e85d-466a-937c-7aa4910ce3a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_d9891e27-f8b1-47fa-87d1-e04d71e80ece" xlink:href="arwr-20230331.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5101f235-2471-405d-b6c8-9c92814b7297" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_d9891e27-f8b1-47fa-87d1-e04d71e80ece" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementAwardsMember_d1e4a9ee-b40b-433d-a616-843c72815e92" xlink:href="arwr-20230331.xsd#arwr_InducementAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5101f235-2471-405d-b6c8-9c92814b7297" xlink:to="loc_arwr_InducementAwardsMember_d1e4a9ee-b40b-433d-a616-843c72815e92" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#StockBasedCompensationSummaryofRSUsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails" xlink:type="extended" id="ia83551eafad84340867aac731eb7626c_StockBasedCompensationSummaryofRSUsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_488bbafc-910e-498e-932a-542a6ca46c56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b3db0f8c-92a2-4b18-ba96-3991a488c534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_488bbafc-910e-498e-932a-542a6ca46c56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b3db0f8c-92a2-4b18-ba96-3991a488c534" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1cbf6769-038e-416c-9cd7-dad978f6b511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b3db0f8c-92a2-4b18-ba96-3991a488c534" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1cbf6769-038e-416c-9cd7-dad978f6b511" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_52087326-a1d4-4782-b083-a066df20dc27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b3db0f8c-92a2-4b18-ba96-3991a488c534" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_52087326-a1d4-4782-b083-a066df20dc27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2e78c8e2-3438-449a-a298-74e5f6c53f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b3db0f8c-92a2-4b18-ba96-3991a488c534" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2e78c8e2-3438-449a-a298-74e5f6c53f31" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1197b29d-312d-4f2c-a03e-ab05bba630c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b3db0f8c-92a2-4b18-ba96-3991a488c534" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1197b29d-312d-4f2c-a03e-ab05bba630c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6233a2a1-81b0-44ab-8672-1778d34049b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7ec7d5d9-2662-4913-b4f1-e4150e64a759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_488bbafc-910e-498e-932a-542a6ca46c56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7ec7d5d9-2662-4913-b4f1-e4150e64a759" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7c815f97-1586-4b8b-b606-ef18ab3adaed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7ec7d5d9-2662-4913-b4f1-e4150e64a759" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7c815f97-1586-4b8b-b606-ef18ab3adaed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_39f33ca9-007b-44db-b0d2-056e21a9368a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7ec7d5d9-2662-4913-b4f1-e4150e64a759" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_39f33ca9-007b-44db-b0d2-056e21a9368a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d4a50ae9-8d0a-4a9b-a783-b97e75002925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7ec7d5d9-2662-4913-b4f1-e4150e64a759" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d4a50ae9-8d0a-4a9b-a783-b97e75002925" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0bb39e3c-6699-4e09-be3f-99a65feda730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7ec7d5d9-2662-4913-b4f1-e4150e64a759" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0bb39e3c-6699-4e09-be3f-99a65feda730" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e6685d24-3344-47a5-a543-52001fb5afee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da1490d6-cc94-4183-8fed-cf859a9d947f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_488bbafc-910e-498e-932a-542a6ca46c56" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da1490d6-cc94-4183-8fed-cf859a9d947f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8a98fb46-7f41-4dd3-a2bd-67e353765f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da1490d6-cc94-4183-8fed-cf859a9d947f" xlink:to="loc_us-gaap_AwardTypeAxis_8a98fb46-7f41-4dd3-a2bd-67e353765f5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a98fb46-7f41-4dd3-a2bd-67e353765f5c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8a98fb46-7f41-4dd3-a2bd-67e353765f5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a98fb46-7f41-4dd3-a2bd-67e353765f5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f8a641b7-d982-4df1-bee0-d2ffc92ae558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8a98fb46-7f41-4dd3-a2bd-67e353765f5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f8a641b7-d982-4df1-bee0-d2ffc92ae558" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2fc1b3c5-51a4-43cd-b0ba-e6ef443428aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f8a641b7-d982-4df1-bee0-d2ffc92ae558" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2fc1b3c5-51a4-43cd-b0ba-e6ef443428aa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="i7acafa43675d46f1a09aba84dad0a4d0_FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5fb293f1-dcd7-44c6-bf1b-de89f9f55f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_e2fa51f3-2988-44fd-a11d-65eb847dedde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5fb293f1-dcd7-44c6-bf1b-de89f9f55f0c" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_e2fa51f3-2988-44fd-a11d-65eb847dedde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1a904a3e-7810-4496-9dd1-179f2caaa894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5fb293f1-dcd7-44c6-bf1b-de89f9f55f0c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1a904a3e-7810-4496-9dd1-179f2caaa894" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_84de6fea-7b6c-45a4-9e29-e6e4d5799808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5fb293f1-dcd7-44c6-bf1b-de89f9f55f0c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_84de6fea-7b6c-45a4-9e29-e6e4d5799808" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c182cff6-d826-45cb-9dcc-335749d75bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5fb293f1-dcd7-44c6-bf1b-de89f9f55f0c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c182cff6-d826-45cb-9dcc-335749d75bba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8fa48f32-2e1b-4d61-9c05-5bf525d4ce04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c182cff6-d826-45cb-9dcc-335749d75bba" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8fa48f32-2e1b-4d61-9c05-5bf525d4ce04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8fa48f32-2e1b-4d61-9c05-5bf525d4ce04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8fa48f32-2e1b-4d61-9c05-5bf525d4ce04" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8fa48f32-2e1b-4d61-9c05-5bf525d4ce04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_128ff8db-f779-48b3-8d01-e140cd995796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8fa48f32-2e1b-4d61-9c05-5bf525d4ce04" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_128ff8db-f779-48b3-8d01-e140cd995796" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a2c3bc42-7640-4c51-895e-6334869d3197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_128ff8db-f779-48b3-8d01-e140cd995796" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a2c3bc42-7640-4c51-895e-6334869d3197" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_182de0e8-4420-495b-908c-085f58baf77e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c182cff6-d826-45cb-9dcc-335749d75bba" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_182de0e8-4420-495b-908c-085f58baf77e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_182de0e8-4420-495b-908c-085f58baf77e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_182de0e8-4420-495b-908c-085f58baf77e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_182de0e8-4420-495b-908c-085f58baf77e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c49b66b2-ca13-48d5-841f-48f540037024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_182de0e8-4420-495b-908c-085f58baf77e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c49b66b2-ca13-48d5-841f-48f540037024" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8d7f18f9-ae93-4c77-9f8f-2b31b0f0c097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c49b66b2-ca13-48d5-841f-48f540037024" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8d7f18f9-ae93-4c77-9f8f-2b31b0f0c097" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_46dc3457-fc62-4dce-a916-1c7e2be6235b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c49b66b2-ca13-48d5-841f-48f540037024" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_46dc3457-fc62-4dce-a916-1c7e2be6235b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0890d862-e65a-4345-a4ba-029b23ef2f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c49b66b2-ca13-48d5-841f-48f540037024" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0890d862-e65a-4345-a4ba-029b23ef2f2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ea13b4f0-c951-46ae-a9f7-a8f193b3dd13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c182cff6-d826-45cb-9dcc-335749d75bba" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ea13b4f0-c951-46ae-a9f7-a8f193b3dd13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ea13b4f0-c951-46ae-a9f7-a8f193b3dd13_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ea13b4f0-c951-46ae-a9f7-a8f193b3dd13" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ea13b4f0-c951-46ae-a9f7-a8f193b3dd13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e7a6e392-1711-4355-8d21-104377fe48d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ea13b4f0-c951-46ae-a9f7-a8f193b3dd13" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e7a6e392-1711-4355-8d21-104377fe48d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_ce2aeb1f-d689-4e73-86e3-4d552e4f048a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e7a6e392-1711-4355-8d21-104377fe48d5" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_ce2aeb1f-d689-4e73-86e3-4d552e4f048a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_e0b7f91c-d849-4585-8dac-3c8070359a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e7a6e392-1711-4355-8d21-104377fe48d5" xlink:to="loc_us-gaap_MunicipalBondsMember_e0b7f91c-d849-4585-8dac-3c8070359a2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotesMember_6ee253f4-caea-4ee3-ad9a-b3bfe2c10072" xlink:href="arwr-20230331.xsd#arwr_CommercialNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e7a6e392-1711-4355-8d21-104377fe48d5" xlink:to="loc_arwr_CommercialNotesMember_6ee253f4-caea-4ee3-ad9a-b3bfe2c10072" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d5a370cb-2119-40ed-bb84-e4f0dd39a3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e7a6e392-1711-4355-8d21-104377fe48d5" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d5a370cb-2119-40ed-bb84-e4f0dd39a3e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_d7c26fd5-7e70-44cb-84d9-af1560587638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e7a6e392-1711-4355-8d21-104377fe48d5" xlink:to="loc_us-gaap_CertificatesOfDepositMember_d7c26fd5-7e70-44cb-84d9-af1560587638" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_771d90df-19fd-4f1f-848d-645d3220c75a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c182cff6-d826-45cb-9dcc-335749d75bba" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_771d90df-19fd-4f1f-848d-645d3220c75a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_771d90df-19fd-4f1f-848d-645d3220c75a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_771d90df-19fd-4f1f-848d-645d3220c75a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_771d90df-19fd-4f1f-848d-645d3220c75a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b96e3731-5668-4694-a01a-02dd45c4386d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_771d90df-19fd-4f1f-848d-645d3220c75a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b96e3731-5668-4694-a01a-02dd45c4386d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_07dc6247-ef7b-4c48-bf70-a92123cd9501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b96e3731-5668-4694-a01a-02dd45c4386d" xlink:to="loc_us-gaap_MoneyMarketFundsMember_07dc6247-ef7b-4c48-bf70-a92123cd9501" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails" xlink:type="extended" id="ia3d3ee5ef88043bb9357b1b2f8275bbd_LiabilityRelatedtotheSaleofFutureRoyaltiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41083d56-4b99-413e-95f4-b4c7ce22b262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_5365f937-0786-41dc-b51d-be82c2fb0fdf" xlink:href="arwr-20230331.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41083d56-4b99-413e-95f4-b4c7ce22b262" xlink:to="loc_arwr_InitialTransactionPrice_5365f937-0786-41dc-b51d-be82c2fb0fdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_8609744c-3dc9-4913-b03d-a977a55fdbba" xlink:href="arwr-20230331.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41083d56-4b99-413e-95f4-b4c7ce22b262" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_8609744c-3dc9-4913-b03d-a977a55fdbba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable_fe3e8fef-b98e-4708-bcb6-62b213b35212" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41083d56-4b99-413e-95f4-b4c7ce22b262" xlink:to="loc_arwr_MilestonePaymentReceivable_fe3e8fef-b98e-4708-bcb6-62b213b35212" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_cc995809-7166-4528-b3b2-95ac59e4c263" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41083d56-4b99-413e-95f4-b4c7ce22b262" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_cc995809-7166-4528-b3b2-95ac59e4c263" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponFDAApproval_bef4a019-bd72-469b-8642-154dadd31550" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentReceivableUponFDAApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41083d56-4b99-413e-95f4-b4c7ce22b262" xlink:to="loc_arwr_MilestonePaymentReceivableUponFDAApproval_bef4a019-bd72-469b-8642-154dadd31550" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_05f94da4-f7d2-4930-b10d-08554154a1bd" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41083d56-4b99-413e-95f4-b4c7ce22b262" xlink:to="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_05f94da4-f7d2-4930-b10d-08554154a1bd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPaymentThreshold_5b0e2cf5-19d9-42c6-8f8e-cf9f8f7339d6" xlink:href="arwr-20230331.xsd#arwr_RoyaltyPaymentThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41083d56-4b99-413e-95f4-b4c7ce22b262" xlink:to="loc_arwr_RoyaltyPaymentThreshold_5b0e2cf5-19d9-42c6-8f8e-cf9f8f7339d6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilitySaleOfFutureRoyalties_629b9527-7ea9-4f80-b140-84be9d45cdf8" xlink:href="arwr-20230331.xsd#arwr_LiabilitySaleOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41083d56-4b99-413e-95f4-b4c7ce22b262" xlink:to="loc_arwr_LiabilitySaleOfFutureRoyalties_629b9527-7ea9-4f80-b140-84be9d45cdf8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_0da93f98-397b-460a-a47d-8cad8a7781c0" xlink:href="arwr-20230331.xsd#arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41083d56-4b99-413e-95f4-b4c7ce22b262" xlink:to="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_0da93f98-397b-460a-a47d-8cad8a7781c0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8544012-638e-4030-aab6-7d359d4adbac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41083d56-4b99-413e-95f4-b4c7ce22b262" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8544012-638e-4030-aab6-7d359d4adbac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_93c92b41-b325-4b6c-904d-76ac9d2764d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8544012-638e-4030-aab6-7d359d4adbac" xlink:to="loc_us-gaap_TypeOfArrangementAxis_93c92b41-b325-4b6c-904d-76ac9d2764d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93c92b41-b325-4b6c-904d-76ac9d2764d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_93c92b41-b325-4b6c-904d-76ac9d2764d8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93c92b41-b325-4b6c-904d-76ac9d2764d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5284deda-6f72-4cc4-92b0-a2138fa40927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_93c92b41-b325-4b6c-904d-76ac9d2764d8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5284deda-6f72-4cc4-92b0-a2138fa40927" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaAgreementMember_79b60433-6ab8-43f3-95b2-9deebf619223" xlink:href="arwr-20230331.xsd#arwr_RoyaltyPharmaAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5284deda-6f72-4cc4-92b0-a2138fa40927" xlink:to="loc_arwr_RoyaltyPharmaAgreementMember_79b60433-6ab8-43f3-95b2-9deebf619223" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_45f9d37b-b24c-4754-b52e-6a4eb7be2489" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8544012-638e-4030-aab6-7d359d4adbac" xlink:to="loc_srt_RangeAxis_45f9d37b-b24c-4754-b52e-6a4eb7be2489" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_45f9d37b-b24c-4754-b52e-6a4eb7be2489_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_45f9d37b-b24c-4754-b52e-6a4eb7be2489" xlink:to="loc_srt_RangeMember_45f9d37b-b24c-4754-b52e-6a4eb7be2489_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ff01ff7d-099c-4a0f-929d-407c36d3c642" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_45f9d37b-b24c-4754-b52e-6a4eb7be2489" xlink:to="loc_srt_RangeMember_ff01ff7d-099c-4a0f-929d-407c36d3c642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ac46d90e-9382-414c-9cdf-b675d46c1aa1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ff01ff7d-099c-4a0f-929d-407c36d3c642" xlink:to="loc_srt_MaximumMember_ac46d90e-9382-414c-9cdf-b675d46c1aa1" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>arwr-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:838ae12b-ce84-423c-b3bd-d5043611fe16,g:09a7ef9b-3d5a-4a38-9975-37e1f59f1b78-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_arwr_RoyaltiesLiabilityNoncurrent_18e26241-55cd-446c-8fca-b6e81f9820f9_terseLabel_en-US" xlink:label="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to the sale of future royalties</link:label>
    <link:label id="lab_arwr_RoyaltiesLiabilityNoncurrent_label_en-US" xlink:label="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties, Liability, Noncurrent</link:label>
    <link:label id="lab_arwr_RoyaltiesLiabilityNoncurrent_documentation_en-US" xlink:label="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltiesLiabilityNoncurrent" xlink:href="arwr-20230331.xsd#arwr_RoyaltiesLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RoyaltiesLiabilityNoncurrent" xlink:to="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_942bb20a-eef1-44a4-8d7c-74ef123f3e31_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_094392cc-bb34-4ebe-bcbd-77bd24beff5c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5fbb0700-5788-441f-be66-e5b129e4d652_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_6a5957c3-908d-4b20-9f70-356a33d2e0da_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) including noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_19d2118a-9a42-4ebd-9d1b-84389365d80e_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_ef3285c5-8d0d-4f05-b88a-c3c47255d3b1_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_f7f5782f-4973-4c37-bde0-da17fe14c9ef_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_854a0fd5-a8ab-4985-b9b7-3196e07d65d3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TechnologyLicenseCommitmentsMember_21516947-dc8d-4285-8333-3ca3482e856e_terseLabel_en-US" xlink:label="lab_arwr_TechnologyLicenseCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology License Commitments</link:label>
    <link:label id="lab_arwr_TechnologyLicenseCommitmentsMember_label_en-US" xlink:label="lab_arwr_TechnologyLicenseCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology License Commitments [Member]</link:label>
    <link:label id="lab_arwr_TechnologyLicenseCommitmentsMember_documentation_en-US" xlink:label="lab_arwr_TechnologyLicenseCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology license commitments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TechnologyLicenseCommitmentsMember" xlink:href="arwr-20230331.xsd#arwr_TechnologyLicenseCommitmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TechnologyLicenseCommitmentsMember" xlink:to="lab_arwr_TechnologyLicenseCommitmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_e44487fd-cc0b-424c-8a33-06c53cc240ae_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_581ef650-ad0a-41d5-8bd6-ad81198164fa_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable at start of phase two</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable At Start Of Phase Two</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable at start of phase two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentReceivableAtStartOfPhaseTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" xlink:to="lab_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_c4877362-f62a-4345-90bb-d84c20e15d46_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TaxIncrementFinancingAward_41d83861-ceda-4e2a-977f-58e3821a4382_terseLabel_en-US" xlink:label="lab_arwr_TaxIncrementFinancingAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax increment financing award</link:label>
    <link:label id="lab_arwr_TaxIncrementFinancingAward_label_en-US" xlink:label="lab_arwr_TaxIncrementFinancingAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Increment Financing Award</link:label>
    <link:label id="lab_arwr_TaxIncrementFinancingAward_documentation_en-US" xlink:label="lab_arwr_TaxIncrementFinancingAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Increment Financing Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TaxIncrementFinancingAward" xlink:href="arwr-20230331.xsd#arwr_TaxIncrementFinancingAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TaxIncrementFinancingAward" xlink:to="lab_arwr_TaxIncrementFinancingAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5ee6b261-c13e-4017-82ab-56c14a4c4d32_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_82c3009f-a0f6-45f4-981b-cf660a140456_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7ddd4b44-c1ff-4a67-be09-9c125207ef07_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_27ce04d8-b0d6-44dc-9c39-517b768a8a8a_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e4089568-d438-42fd-9ee7-26fc5b8678b5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1199acbf-580b-468a-8a51-a30f88776799_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_25bc28ae-60ad-411a-b540-0a407aac377c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_4f905060-efb8-40be-8846-167205687643_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to Arrowhead Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f4e310e1-8a0a-43ad-bbc5-74fcb2b4769c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_f780ff55-8136-4a69-b0f8-98cb2802b9f5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Lease Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_be739803-b820-43f4-84a1-a7067df1e12d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive securities excluded from computation of diluted earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_4fd251a8-aef2-4357-bf29-c97b717d763b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_87b9533c-07b7-4d28-aa7e-a085ac2d2270_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement_755579c8-acde-43ee-9666-bdc9592a3c9b_terseLabel_en-US" xlink:label="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement_label_en-US" xlink:label="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Received As Due Under Collaboration Agreement</link:label>
    <link:label id="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement_documentation_en-US" xlink:label="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received as due under collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:href="arwr-20230331.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:to="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_7e79df23-fee5-4a2c-9a87-615c36435e3a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_e1789ef0-0e47-430e-afe5-6deb42e8ee1e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_08089ffb-d668-459c-bfbe-651642405d52_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share attributable to Arrowhead Pharmaceuticals, Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_275a6aa8-1589-4a78-a904-88dbc4768edb_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest and Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_a2452c97-245c-4acd-b971-f637db4e06ad_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_c3910ece-d30d-4c84-8055-ca07e0fd8fbc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Lease Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_016e06b0-7d73-45d4-8d8b-8a8b47775b36_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_22416630-6846-4ce6-877a-be6b8fc92579_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of deposits</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_8cc765fa-dccd-4959-bb6a-2b05fbe51758_terseLabel_en-US" xlink:label="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock shares value reserved for future issuance</link:label>
    <link:label id="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_label_en-US" xlink:label="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Capital Shares Value Reserved For Future Issuance</link:label>
    <link:label id="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_documentation_en-US" xlink:label="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, capital shares value reserved for future issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:href="arwr-20230331.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:to="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_911a9b45-50d8-4fe0-8ea4-d8e9577e2cd3_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c3b2cbd2-7409-491e-949f-3a4f988da2cd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized pre-tax compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_6b2ae45f-3f2e-439c-8eb9-ee05af6f995a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e8a2cd36-53d1-4b17-9888-595cc597418f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 (remainder of fiscal year)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_6f5e9500-29cf-429e-93f5-12f87b0cb9f8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_a37e412b-93d7-4f29-8734-60e1c94272b1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_440cd0d2-62a7-4f30-ac28-0be0bb3e90e4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_8debe533-d2c9-404e-9f6a-5046cbf4893e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_SorrentoValleyOwnerDELLCMember_b4454400-802e-4d02-a77a-a266d62286eb_terseLabel_en-US" xlink:label="lab_arwr_SorrentoValleyOwnerDELLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sorrento Valley Owner (DE) LLC</link:label>
    <link:label id="lab_arwr_SorrentoValleyOwnerDELLCMember_label_en-US" xlink:label="lab_arwr_SorrentoValleyOwnerDELLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sorrento Valley Owner (DE) LLC [Member]</link:label>
    <link:label id="lab_arwr_SorrentoValleyOwnerDELLCMember_documentation_en-US" xlink:label="lab_arwr_SorrentoValleyOwnerDELLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sorrento Valley Owner (DE) LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SorrentoValleyOwnerDELLCMember" xlink:href="arwr-20230331.xsd#arwr_SorrentoValleyOwnerDELLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_SorrentoValleyOwnerDELLCMember" xlink:to="lab_arwr_SorrentoValleyOwnerDELLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4f69fd02-aeb6-410a-9bba-5c69b60cf7ac_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_3c579823-597d-469f-9249-2a3f413a808b_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandsThirteenIncentivePlanMember_46277ddc-82e0-48c0-bc01-8e2e7981c4d4_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2013 Incentive Plan</link:label>
    <link:label id="lab_arwr_TwoThousandsThirteenIncentivePlanMember_label_en-US" xlink:label="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousands Thirteen Incentive Plan [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandsThirteenIncentivePlanMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousands thirteen incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:href="arwr-20230331.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:to="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfLand_9d5a4560-47ff-492c-a5c2-78eae5ffba97_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planned area of the site (in sq ft)</link:label>
    <link:label id="lab_us-gaap_AreaOfLand_label_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfLand" xlink:to="lab_us-gaap_AreaOfLand" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f52fd7c-0bbf-40cb-99c7-35bace790fab_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_SalesRelatedMilestonePayments_f1fba703-06c1-4a32-bb59-10fe81ea3264_terseLabel_en-US" xlink:label="lab_arwr_SalesRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-related milestone payments</link:label>
    <link:label id="lab_arwr_SalesRelatedMilestonePayments_label_en-US" xlink:label="lab_arwr_SalesRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Related Milestone Payments</link:label>
    <link:label id="lab_arwr_SalesRelatedMilestonePayments_documentation_en-US" xlink:label="lab_arwr_SalesRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-related milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments" xlink:href="arwr-20230331.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_SalesRelatedMilestonePayments" xlink:to="lab_arwr_SalesRelatedMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_0d9e31b5-ec9a-4d29-bd57-6671b1c3f80e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0775551c-8ab2-4510-b9ef-8ea83bd149e6_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_1d6be715-f484-45e2-9bf2-8fcde662ba72_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6eb72150-8fce-4271-89ba-f604be1d19f3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_354960c0-2a32-4130-9167-e385d3bb0ee0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_60111708-f991-4e41-b8b3-17a786543d26_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_361c47fc-ff73-466a-a5c1-4bd49f3f0bef_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of deposits</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfDistinctPerformanceObligations_6dd1cc43-e304-4eef-962e-3c49e0421e07_terseLabel_en-US" xlink:label="lab_arwr_NumberOfDistinctPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distinct performance obligations</link:label>
    <link:label id="lab_arwr_NumberOfDistinctPerformanceObligations_label_en-US" xlink:label="lab_arwr_NumberOfDistinctPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Distinct Performance Obligations</link:label>
    <link:label id="lab_arwr_NumberOfDistinctPerformanceObligations_documentation_en-US" xlink:label="lab_arwr_NumberOfDistinctPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distinct performance obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations" xlink:href="arwr-20230331.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfDistinctPerformanceObligations" xlink:to="lab_arwr_NumberOfDistinctPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_b8f5d1e0-1aba-4c40-a541-cf02d13b6751_terseLabel_en-US" xlink:label="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of commission to sales agent</link:label>
    <link:label id="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_label_en-US" xlink:label="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Commission On Aggregate Gross Proceeds From Sale Of Common Stock</link:label>
    <link:label id="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_documentation_en-US" xlink:label="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of commission on aggregate gross proceeds from sale of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:href="arwr-20230331.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:to="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_90a573c1-f0ea-4564-8805-d60d6a45bcfc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c17cf93a-7a46-493f-8e52-c248e1d6babd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_30c58a3a-314c-4688-8a1f-f1c700b20065_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_814bf716-2bf3-4ef7-8c19-4ebf7698804f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_feab6772-78c5-415b-8bd4-d94895c6e1c8_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Accretion) amortization of note premiums/discounts</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommercialNotesMember_d9418811-8df4-434a-96b2-1fbbb5756089_terseLabel_en-US" xlink:label="lab_arwr_CommercialNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial notes</link:label>
    <link:label id="lab_arwr_CommercialNotesMember_label_en-US" xlink:label="lab_arwr_CommercialNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Notes [Member]</link:label>
    <link:label id="lab_arwr_CommercialNotesMember_documentation_en-US" xlink:label="lab_arwr_CommercialNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotesMember" xlink:href="arwr-20230331.xsd#arwr_CommercialNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommercialNotesMember" xlink:to="lab_arwr_CommercialNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_4be83c22-0988-4358-806b-df285cc27bb2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_0994e3f0-7e8c-4c02-9db6-40a8eaecbfbc_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2550e259-c03d-48c2-8340-ef85dd36a9d4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_90d02639-a334-4b82-911f-5cbd1b484b39_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_120557db-35c0-4a95-aded-75ff31115f27_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6f91aeae-9509-494b-8ad2-c648b414b195_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e204d341-a312-45b8-9f7d-0d59faeaa007_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_c3e21a19-1b1c-4935-9d15-c4eb2f0fef8c_terseLabel_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space leases (in sq ft)</link:label>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_label_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land Subject to Ground Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandSubjectToGroundLeases" xlink:to="lab_us-gaap_LandSubjectToGroundLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f7e5e7e7-6ad6-4f97-80f5-e4e9f9f3efea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_05b9b981-f4a9-499e-a136-bb24f277205b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchFacilityInSanDiegoMember_355527d0-8413-4731-b788-56293b93a007_terseLabel_en-US" xlink:label="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Facility in San Diego</link:label>
    <link:label id="lab_arwr_ResearchFacilityInSanDiegoMember_label_en-US" xlink:label="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Facility In San Diego [Member]</link:label>
    <link:label id="lab_arwr_ResearchFacilityInSanDiegoMember_documentation_en-US" xlink:label="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Facility in San Diego.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInSanDiegoMember" xlink:href="arwr-20230331.xsd#arwr_ResearchFacilityInSanDiegoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchFacilityInSanDiegoMember" xlink:to="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_b5cd88f3-ec04-41a6-8817-45e43789d136_terseLabel_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development regulatory and sales milestones payments</link:label>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_5262300a-2383-46b4-81d6-ad38e0d7a6aa_verboseLabel_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development, regulatory and sales milestones payments</link:label>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_label_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Regulatory And Sales Milestones Payments</link:label>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_documentation_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development regulatory and sales milestones payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:href="arwr-20230331.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:to="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ac2ef965-fecd-4bed-b2aa-9e67199f303b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cc1d7d88-ee31-4b77-98a1-c694ca3d65a3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_07b76f94-4084-470e-bbaf-fe4df953f994_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_4f1c7f2d-b0ba-41a1-aadb-784ef38fe199_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_f4f0e808-fd60-4ea7-9718-38e17fe4d0e7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c7abe394-c286-41c8-96e5-25abb4e58b1b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_2808aa5c-00e5-44f2-ac22-f22d19f50dc9_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_5250303e-bf60-41b6-a7df-7158220ebd9c_terseLabel_en-US" xlink:label="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Short-term and Long-term Investments and Marketable Securities</link:label>
    <link:label id="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_label_en-US" xlink:label="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held To Maturity Securities And Marketable Securities Table [Table Text Block]</link:label>
    <link:label id="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_documentation_en-US" xlink:label="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held to maturity securities and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:href="arwr-20230331.xsd#arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:to="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_d5654b37-ec81-4536-ab33-4be7622b6c83_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_ce0ecd5e-ac1d-446c-9e27-a3a34f43233d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Receivables and Contract Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_bbe069ac-01d5-47d2-bb1e-dc192033ce5d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_d14cd58c-cef1-45d3-81cd-c5a88a122203_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_be8f0523-cc71-494a-8f66-d557d2461503_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_7bf2ca7d-c7eb-4895-8268-082f0f3295e5_verboseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_812ff7f8-7328-4c09-b312-55872122cedc_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_681522d8-e2df-4bda-86ad-9c553722733d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d3bdf8a-dcf9-4d25-a828-179ee234c176_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_836f9b12-53fe-400a-850a-ba65bcbbc6e5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_b4dcbeb7-9032-42df-9590-1aa260d16623_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_92a0c5c1-fc4e-4321-ae82-10c9d492dc29_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_b9e6fbe8-d0cf-4c77-9545-34b7f5677672_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_35d44d67-413f-46d7-851a-436110b57464_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income tax expense and noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_40ea5c6b-a510-4f90-bd7f-9a5a7ac367b1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_3b0a8656-14fa-4f1b-b490-72805d30379a_terseLabel_en-US" xlink:label="lab_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received as due under collaboration agreement</link:label>
    <link:label id="lab_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_label_en-US" xlink:label="lab_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Receivable As Upfront Payment Due Under Collaboration Agreement</link:label>
    <link:label id="lab_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_documentation_en-US" xlink:label="lab_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash receivable as upfront payment due under collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:href="arwr-20230331.xsd#arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:to="lab_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_13aa74d6-6cf3-4b87-b3ab-8ef302c6365c_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_81b73d26-89e4-4bdf-9e7c-ac05c3217efd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions Used to Value Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_f2273d98-67e1-4d84-a6dd-8e924b99b8ac_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal securities</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ScheduleOfCurrentProductsTableTextBlock_902a2621-4067-46a8-8d7e-5ce164f25b4a_terseLabel_en-US" xlink:label="lab_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Company's Current Pipeline</link:label>
    <link:label id="lab_arwr_ScheduleOfCurrentProductsTableTextBlock_label_en-US" xlink:label="lab_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Current Products [Table Text Block]</link:label>
    <link:label id="lab_arwr_ScheduleOfCurrentProductsTableTextBlock_documentation_en-US" xlink:label="lab_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Current Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:href="arwr-20230331.xsd#arwr_ScheduleOfCurrentProductsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:to="lab_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_9e026140-864d-4c9c-82f5-3de776eb35bf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in joint venture</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_JanssenPharmaceuticalsIncorporationMember_d552f3bd-18e5-4b0e-9b87-d11371ca1858_terseLabel_en-US" xlink:label="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen</link:label>
    <link:label id="lab_arwr_JanssenPharmaceuticalsIncorporationMember_label_en-US" xlink:label="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceuticals Incorporation [Member]</link:label>
    <link:label id="lab_arwr_JanssenPharmaceuticalsIncorporationMember_documentation_en-US" xlink:label="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceuticals, Incorporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:href="arwr-20230331.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:to="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_fadebf7f-2a46-4b99-95f2-d89ad7b0b830_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0d0f5922-79a8-452c-b724-0f6f8f1f3366_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_062f1415-aedb-4b1b-8754-d7a0d6c22b85_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_132dab74-da4d-41c0-bb55-620df65fa4b4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period to recognize pre-tax compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_InducementAwardsMember_c499927d-d828-425d-8f0d-516033c2d487_terseLabel_en-US" xlink:label="lab_arwr_InducementAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Awards</link:label>
    <link:label id="lab_arwr_InducementAwardsMember_label_en-US" xlink:label="lab_arwr_InducementAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Awards [Member]</link:label>
    <link:label id="lab_arwr_InducementAwardsMember_documentation_en-US" xlink:label="lab_arwr_InducementAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementAwardsMember" xlink:href="arwr-20230331.xsd#arwr_InducementAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_InducementAwardsMember" xlink:to="lab_arwr_InducementAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1fda6143-cd84-44e1-be01-4cb35c7ae82f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_0f4627dd-53d5-4ca4-9601-f000f311ab63_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_85cd18ce-957e-4e57-8570-1dede6f3a1ab_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock - restricted stock units vesting</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_InitialTransactionPrice_3159b09d-6484-4650-b13c-c25da973e6cd_terseLabel_en-US" xlink:label="lab_arwr_InitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial transaction price</link:label>
    <link:label id="lab_arwr_InitialTransactionPrice_label_en-US" xlink:label="lab_arwr_InitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Transaction Price</link:label>
    <link:label id="lab_arwr_InitialTransactionPrice_documentation_en-US" xlink:label="lab_arwr_InitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice" xlink:href="arwr-20230331.xsd#arwr_InitialTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_InitialTransactionPrice" xlink:to="lab_arwr_InitialTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_082f5724-61e3-4e34-8168-d616f24844d7_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_23337dcf-033d-44ee-8586-411863fa5217_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_eff10dab-abac-4b3b-9ef8-ca4f5f4c617d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_42aa1232-0a7b-47da-9b29-8f951c87523b_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_9456a28e-319d-4c7f-83fa-4aa33249c4a8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_32d1062f-3582-4701-a669-53bd00159980_terseLabel_en-US" xlink:label="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial milestone payments at first commercial sale</link:label>
    <link:label id="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_label_en-US" xlink:label="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Milestone Payments At First Commercial Sale</link:label>
    <link:label id="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_documentation_en-US" xlink:label="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial milestone payments at first commercial sale.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:href="arwr-20230331.xsd#arwr_CommercialMilestonePaymentsAtFirstCommercialSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:to="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_25bd7fda-33b9-4f27-ad5e-56a93e3a6f18_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_ac4a6537-d9b3-4229-9002-6102dd055ef3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4aaa0631-4172-4a55-af52-9387b62523b4_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total noncontrolling interest and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e34dcdfb-ddb9-4b6b-bed9-a636390897cf_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_63d04627-7911-4ff6-997a-70429789e50d_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_c725ac2b-3c8b-4414-863e-cacb0a34f647_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_04062e16-84cb-43db-954e-ff9c89968fc5_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_f7fe04ea-eaff-41e0-8619-e655dafccbbd_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_98ce1251-d150-4fbb-9013-71e36f32acd7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2a412ff1-be90-477a-b9e1-7191b3da1e66_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1cdc0056-4df0-4d1b-88e8-59995821f0fe_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OlpasiranAndAROAMG1AgreementMember_74cb0789-dfd7-45b1-9d6a-acbf1efbc215_terseLabel_en-US" xlink:label="lab_arwr_OlpasiranAndAROAMG1AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olpasiran and ARO-AMG1 Agreement</link:label>
    <link:label id="lab_arwr_OlpasiranAndAROAMG1AgreementMember_label_en-US" xlink:label="lab_arwr_OlpasiranAndAROAMG1AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olpasiran And A R O A M G1 Agreement [Member]</link:label>
    <link:label id="lab_arwr_OlpasiranAndAROAMG1AgreementMember_documentation_en-US" xlink:label="lab_arwr_OlpasiranAndAROAMG1AgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olpasiran and ARO-AMG1 agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAndAROAMG1AgreementMember" xlink:href="arwr-20230331.xsd#arwr_OlpasiranAndAROAMG1AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OlpasiranAndAROAMG1AgreementMember" xlink:to="lab_arwr_OlpasiranAndAROAMG1AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ca265935-7df9-4ce7-9fa1-6840657ad280_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_61abba54-d54b-469c-b649-65e42bc63781_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_5c74d588-921b-4013-9a5f-835e88f20b06_terseLabel_en-US" xlink:label="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional remaining development regulatory and sales milestones payments</link:label>
    <link:label id="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_label_en-US" xlink:label="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Remaining Development Regulatory And Sales Milestones Payments</link:label>
    <link:label id="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_documentation_en-US" xlink:label="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional remaining development regulatory and sales milestones payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:href="arwr-20230331.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:to="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandTwentyOneIncentivePlanMember_34c35b28-d426-4769-be49-16b4179ce588_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Incentive Plan</link:label>
    <link:label id="lab_arwr_TwoThousandTwentyOneIncentivePlanMember_label_en-US" xlink:label="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty One Incentive Plan [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandTwentyOneIncentivePlanMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand twenty one incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:href="arwr-20230331.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:to="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_8ef81d8f-3507-45ad-a3c0-81bc8f1b31d2_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_fa0742c1-02c5-43d3-908b-73f6ae8869ae_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_1d51b917-db10-45a7-a184-ebed8f8cc4c5_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_bf433371-5080-4ee6-b883-34f3f7dfd73e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_ac87d354-82a5-461f-9ea2-43b6bf380c89_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_4f3d863e-4052-43ed-af20-f53b85e8a06c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross" xlink:to="lab_us-gaap_LeaseholdImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5dbd9757-46cd-4987-8b6f-9e7a8f453a79_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_a3b33093-9420-4471-a460-bbecd4d0f5aa_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_66ab380d-c579-4145-a447-5268c9e13899_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market instruments</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LicenseAgreementMember_56be3241-e9cf-461a-83e4-7f91e1f9c823_terseLabel_en-US" xlink:label="lab_arwr_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement</link:label>
    <link:label id="lab_arwr_LicenseAgreementMember_label_en-US" xlink:label="lab_arwr_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Member]</link:label>
    <link:label id="lab_arwr_LicenseAgreementMember_documentation_en-US" xlink:label="lab_arwr_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAgreementMember" xlink:href="arwr-20230331.xsd#arwr_LicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LicenseAgreementMember" xlink:to="lab_arwr_LicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromContributedCapital_79d8ab95-014e-4017-a70a-7143defeae14_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromContributedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of future royalties</link:label>
    <link:label id="lab_us-gaap_ProceedsFromContributedCapital_label_en-US" xlink:label="lab_us-gaap_ProceedsFromContributedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Contributed Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributedCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromContributedCapital" xlink:to="lab_us-gaap_ProceedsFromContributedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_e106f119-2f31-44f2-872c-7f5a531e27d1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_VisirnaTherapeuticsIncMember_7dfe40ad-a988-440a-8811-331a7e6bb635_terseLabel_en-US" xlink:label="lab_arwr_VisirnaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visirna Therapeutics, Inc.</link:label>
    <link:label id="lab_arwr_VisirnaTherapeuticsIncMember_label_en-US" xlink:label="lab_arwr_VisirnaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visirna Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_arwr_VisirnaTherapeuticsIncMember_documentation_en-US" xlink:label="lab_arwr_VisirnaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visirna Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaTherapeuticsIncMember" xlink:href="arwr-20230331.xsd#arwr_VisirnaTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_VisirnaTherapeuticsIncMember" xlink:to="lab_arwr_VisirnaTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_e7488f79-e66b-4518-a667-abe27fa4744e_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentEarned_e50b4617-7b6a-4208-95b7-7dd2a16bd96d_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_arwr_MilestonePaymentEarned_label_en-US" xlink:label="lab_arwr_MilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Earned</link:label>
    <link:label id="lab_arwr_MilestonePaymentEarned_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment earned.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentEarned" xlink:to="lab_arwr_MilestonePaymentEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_ffc3f8f5-4ef4-4baf-a14f-9ff8164eb6b1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments, Held to maturity, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent" xlink:to="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_6e620ae0-8b18-46ec-865c-1efca5d6f5f8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_8d22856f-35c8-4c9c-b7b7-44ca2b9e1498_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_2ef8ab4e-83ab-43de-b17e-68453f4d71c7_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_6eec1c3a-88c7-4448-8c62-9f81bf1d25b1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_80ad48a7-b4d9-4246-86c4-fb6aeb21c335_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_f8d09579-5b9a-4e06-9818-d1f56bc5de3b_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_9a348b72-8ebe-45af-a616-14047a51b159_terseLabel_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Table]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_label_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Table]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_documentation_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of held to maturity securities and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:href="arwr-20230331.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:to="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_3b82b022-6cf0-4809-95fd-fa2bd71f3354_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term investments</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_f0d6e03f-6a56-481c-8980-2a18d80cc944_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Held to maturity, Adjusted Bases</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_e5030a1a-4686-445e-b21b-0289293f9936_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OlpasiranAgreementMember_3b206a9d-629a-46ee-a698-1197a9e5684f_terseLabel_en-US" xlink:label="lab_arwr_OlpasiranAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olpasiran Agreement</link:label>
    <link:label id="lab_arwr_OlpasiranAgreementMember_label_en-US" xlink:label="lab_arwr_OlpasiranAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olpasiran Agreement [Member]</link:label>
    <link:label id="lab_arwr_OlpasiranAgreementMember_documentation_en-US" xlink:label="lab_arwr_OlpasiranAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olpasiran agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAgreementMember" xlink:href="arwr-20230331.xsd#arwr_OlpasiranAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OlpasiranAgreementMember" xlink:to="lab_arwr_OlpasiranAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_d5ca7a37-3da9-4356-9895-9a763d3e3acc_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Arrowhead Pharmaceuticals, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_342aabde-3ba9-48b5-887b-9ce17b08e845_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BEGINNING OF PERIOD</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_d48f0d4e-cc86-4984-83d6-a01a18089c9e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">END OF PERIOD</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_d8d44ebc-58b7-4cdb-ab1e-9282e902ab84_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_90048460-2b95-48da-82cc-9753dbeb05fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_ba5d227e-3333-41dc-b589-3185cac18fa5_verboseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1cbb6402-3760-48b0-a0d1-d931904aceaa_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_3e6dff57-9d51-49c4-943d-686626a776be_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable upon achievement of phase two and first patient dosed in phase three</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable Upon Achievement Of Phase Two And First Patient Dosed In Phase Three</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable upon achievement of phase two and first patient dosed in phase three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:to="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_17564b64-3912-4433-9c21-737ba1774f82_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7ae29df5-5294-48a4-bc72-6dfd8a5369da_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_102966f2-59cb-4a7a-8b08-8313b910fd9f_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market instruments</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DrugManufacturingFacilityMember_4b3fbed8-2523-4ffe-ab6a-51e3f56be4f4_terseLabel_en-US" xlink:label="lab_arwr_DrugManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Manufacturing Facility</link:label>
    <link:label id="lab_arwr_DrugManufacturingFacilityMember_label_en-US" xlink:label="lab_arwr_DrugManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Manufacturing Facility [Member]</link:label>
    <link:label id="lab_arwr_DrugManufacturingFacilityMember_documentation_en-US" xlink:label="lab_arwr_DrugManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug manufacturing facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DrugManufacturingFacilityMember" xlink:href="arwr-20230331.xsd#arwr_DrugManufacturingFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DrugManufacturingFacilityMember" xlink:to="lab_arwr_DrugManufacturingFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f451f000-9674-4b53-8d7f-691123b08587_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_eb92e04b-d862-4848-bc81-cd39a803ed30_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized pre-tax compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_41ea8ec7-205b-4e81-a8cd-2781a707c627_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2004 Equity Incentive Plan, 2013 Equity Incentive Plan, 2021 Equity Incentive Plan and Inducement Grants</link:label>
    <link:label id="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_label_en-US" xlink:label="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Four Equity Incentive Plan Two Thousand Thirteen Equity Incentive Plan Two Thousand Twenty One Equity Incentive Plan And Inducement Grants [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand four equity incentive plan two thousand thirteen equity incentive plan Two thousand twenty one equity incentive plan and inducement grants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:href="arwr-20230331.xsd#arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:to="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_4708d68c-27c7-4f6c-8ad8-d312593869aa_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementsAbstract_570a310f-a128-4874-8d36-a6618b0fc82b_terseLabel_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreements [Abstract]</link:label>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreements [Abstract]</link:label>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:href="arwr-20230331.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_f3a01338-28e2-434e-9e4d-02235a7c0fbe_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_7f5e0cc3-acdf-4376-bc80-415ec85ca8fe_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Assets and Liabilities and Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_09a86dda-dee8-4833-a205-50b270fe7b33_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, share reserve for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_385e61f8-a5f5-43be-8257-b753ce4ee3a6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_75e357ed-3bf5-40e3-af76-1e25aa60ceb3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_3fbe9321-b531-4cee-9b10-33024d112658_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_146681af-6e1a-4e01-b067-baa22018396b_terseLabel_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_label_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_documentation_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of held to maturity securities and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:href="arwr-20230331.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_a5221e9e-36c5-40da-bab0-d4f703f3938b_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_c798423b-0c3d-4140-9410-edce66907655_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LiabilitySaleOfFutureRoyalties_7b3e022d-3287-49bb-9eae-e758ea23a317_terseLabel_en-US" xlink:label="lab_arwr_LiabilitySaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to the sale of future royalties</link:label>
    <link:label id="lab_arwr_LiabilitySaleOfFutureRoyalties_label_en-US" xlink:label="lab_arwr_LiabilitySaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Sale of Future Royalties</link:label>
    <link:label id="lab_arwr_LiabilitySaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_arwr_LiabilitySaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Sale of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilitySaleOfFutureRoyalties" xlink:href="arwr-20230331.xsd#arwr_LiabilitySaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LiabilitySaleOfFutureRoyalties" xlink:to="lab_arwr_LiabilitySaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_892c8948-6853-4b58-bd2a-d24d54986644_terseLabel_en-US" xlink:label="lab_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for leasehold improvements, net of tenant improvement allowances</link:label>
    <link:label id="lab_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_label_en-US" xlink:label="lab_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Leasehold Improvements Net Of Tenant Improvement Allowances</link:label>
    <link:label id="lab_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_documentation_en-US" xlink:label="lab_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of leasehold improvements net of tenant improvement allowances.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:href="arwr-20230331.xsd#arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:to="lab_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4846764b-9c9f-4eca-b79f-7714197f8b23_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable_0d79f734-ef08-42c0-9e74-19be1acc6b6c_terseLabel_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:href="arwr-20230331.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_d17d3197-931e-440a-aac9-2e4a924c6b3e_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_b4ea8a48-d23d-4c0e-9e43-bd03a0f46e22_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_RoyaltyPharmaMember_7130d517-0fc9-4d5a-8d82-4b875c183b1f_terseLabel_en-US" xlink:label="lab_arwr_RoyaltyPharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma</link:label>
    <link:label id="lab_arwr_RoyaltyPharmaMember_label_en-US" xlink:label="lab_arwr_RoyaltyPharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma [Member]</link:label>
    <link:label id="lab_arwr_RoyaltyPharmaMember_documentation_en-US" xlink:label="lab_arwr_RoyaltyPharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaMember" xlink:href="arwr-20230331.xsd#arwr_RoyaltyPharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RoyaltyPharmaMember" xlink:to="lab_arwr_RoyaltyPharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_f5e515eb-fb5c-4fdb-b874-800cd4be617a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_9d72c869-227d-4633-ac14-c86926f8a597_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d4224cb7-d929-46e3-aad8-4912fd6897ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_26819ceb-62d5-4fd6-bcf3-b8c84823c4c5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_5217b2a8-caf5-4a28-ad6a-edd0da23a5f8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_afb384b5-9605-4e30-8538-9cd05ad3fc2b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0c259193-92d9-4586-97ff-d06be30ae761_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_62d5e05d-85e1-4980-a919-d9dafb96f79f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfOptionsToRenew_6cbcac2d-037d-4fdc-a4dc-2b383c42247b_terseLabel_en-US" xlink:label="lab_arwr_NumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to renew</link:label>
    <link:label id="lab_arwr_NumberOfOptionsToRenew_label_en-US" xlink:label="lab_arwr_NumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Options To Renew</link:label>
    <link:label id="lab_arwr_NumberOfOptionsToRenew_documentation_en-US" xlink:label="lab_arwr_NumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to renew.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfOptionsToRenew" xlink:href="arwr-20230331.xsd#arwr_NumberOfOptionsToRenew"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfOptionsToRenew" xlink:to="lab_arwr_NumberOfOptionsToRenew" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_76bdc296-5d53-4470-9624-6ec33e094e00_terseLabel_en-US" xlink:label="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda</link:label>
    <link:label id="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_label_en-US" xlink:label="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceuticals United States Of America Incorporated [Member]</link:label>
    <link:label id="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_documentation_en-US" xlink:label="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceuticals United States of America Incorporated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:href="arwr-20230331.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:to="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_47322d18-994d-4bd6-9cc9-8243f1ca6c34_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_94ed9a9a-90ce-4308-94db-c7b571516e27_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6fa60c2d-90c0-46e8-89eb-e6878bfd91ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment award (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1a4ed3c3-bc6e-4257-be74-7939044559dc_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9d30535a-9346-4fd3-b8ff-47f28a014561_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_bbb7c6fe-f8a2-480b-8d4b-023c2268852e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Held to maturity, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent" xlink:to="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_13c00d58-be71-4f36-9409-3d9886e9c49d_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other (loss) income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1f736f14-e9c1-4b3f-92a0-423616b34374_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_1acae6cb-3886-42e3-a653-3ebbeddd3289_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_310b3760-4287-4638-89bb-0c0b71e5be7b_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_8a2835b2-f704-4e93-943c-389b43af9422_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b6d9af8f-fbaa-47b0-a2d7-fb475f5c0347_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_HorizonTherapeuticsIrelandDACMember_c9c2960a-18c8-40eb-93eb-5cca855af8a8_terseLabel_en-US" xlink:label="lab_arwr_HorizonTherapeuticsIrelandDACMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon</link:label>
    <link:label id="lab_arwr_HorizonTherapeuticsIrelandDACMember_label_en-US" xlink:label="lab_arwr_HorizonTherapeuticsIrelandDACMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon Therapeutics Ireland DAC [Member]</link:label>
    <link:label id="lab_arwr_HorizonTherapeuticsIrelandDACMember_documentation_en-US" xlink:label="lab_arwr_HorizonTherapeuticsIrelandDACMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon Therapeutics Ireland DAC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember" xlink:href="arwr-20230331.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_HorizonTherapeuticsIrelandDACMember" xlink:to="lab_arwr_HorizonTherapeuticsIrelandDACMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_a5bbbe27-bd9b-40b2-a0f9-9ddd53d8efb0_terseLabel_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to the Sale of Future Royalties</link:label>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_label_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Text Block]</link:label>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_documentation_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:href="arwr-20230331.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:to="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_23421a0f-b0a4-4086-90ab-1d9fbf3a46d2_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_6b42a3e1-4919-402f-8937-e39e4c783a2c_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d34fedac-20ef-4f3a-af18-64887bc91045_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summarized Information about Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_d600acf7-75c1-45f5-83db-34c75f0ec769_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_b0990382-4f60-4a11-9a3b-edd5def0081f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Awards Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_UpfrontMilestonePaymentReceived_e42b31b0-c248-472f-8497-1c9abaa38795_terseLabel_en-US" xlink:label="lab_arwr_UpfrontMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront milestone payment received</link:label>
    <link:label id="lab_arwr_UpfrontMilestonePaymentReceived_label_en-US" xlink:label="lab_arwr_UpfrontMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Milestone Payment Received</link:label>
    <link:label id="lab_arwr_UpfrontMilestonePaymentReceived_documentation_en-US" xlink:label="lab_arwr_UpfrontMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront milestone payment received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontMilestonePaymentReceived" xlink:href="arwr-20230331.xsd#arwr_UpfrontMilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_UpfrontMilestonePaymentReceived" xlink:to="lab_arwr_UpfrontMilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7fe7d91c-440a-4448-9d31-f70ada3c996b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePayments_e7325ade-34ae-4bf3-a468-54f745028967_verboseLabel_en-US" xlink:label="lab_arwr_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_arwr_MilestonePayments_label_en-US" xlink:label="lab_arwr_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments</link:label>
    <link:label id="lab_arwr_MilestonePayments_documentation_en-US" xlink:label="lab_arwr_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePayments" xlink:href="arwr-20230331.xsd#arwr_MilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePayments" xlink:to="lab_arwr_MilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ed37644f-0a88-4287-b50d-5a8051460c3f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_586fbf8e-ef1c-488f-86de-b9e2566b51f4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in calculating</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_706edc17-e470-4fb9-95c2-6941e481da43_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_85bae849-e015-4cb6-9088-8fc8b0377d3a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b5571b72-cc14-4dd3-917f-4c09b5829381_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e6117072-ad5b-457d-91de-97acff9ea26a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash flow from operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_b4a11838-53cd-4a2a-b415-2dcb0985588e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_2ffa796b-eafe-4b15-9cf6-eecc183a6aa2_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3401e942-2266-4dfc-acc9-0766a5fbe4aa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_1fad9ad0-6ef1-4f0c-83dd-fb91e92007eb_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_43c7fea6-9c92-4135-8e60-78e6c4536dc2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_1373aa28-ab09-436c-bf60-a2259d28f122_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7d9ff86f-5b30-4dfa-8301-84873bce81f5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_d6d060f9-4939-46d4-a86f-2381870f9fb0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_fcbfc1c5-a29d-4926-b912-a14c02dfa86a_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_3280b961-c9c9-4128-8322-e7911eeebe87_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ea2b2e9d-987d-43a6-8456-d455906556ec_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_cc40b39d-5725-44a7-8dfa-20b437283989_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4f940e66-43d0-4b23-88d5-80a239ac9d65_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8330d7fd-bd26-4a68-95e2-099d55b8419e_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average diluted shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_22034781-63a1-4b12-b969-2999bfc3c1f0_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross_6df3e932-3ac1-497c-8f14-d30c4cb18102_terseLabel_en-US" xlink:label="lab_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers, software, office equipment and furniture</link:label>
    <link:label id="lab_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross_label_en-US" xlink:label="lab_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers Software Office Equipment And Furniture Gross</link:label>
    <link:label id="lab_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross_documentation_en-US" xlink:label="lab_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers, software, office equipment and furniture gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross" xlink:href="arwr-20230331.xsd#arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross" xlink:to="lab_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_label_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Abstract]</link:label>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_documentation_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:href="arwr-20230331.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:to="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_310f8883-3cbd-4ee8-a2df-c79106027499_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_924da9fe-50d3-4164-86ba-8cc0f6e6f26d_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NovartisMember_aadd0c18-294f-46b7-ac6a-fdda208270fe_terseLabel_en-US" xlink:label="lab_arwr_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis</link:label>
    <link:label id="lab_arwr_NovartisMember_label_en-US" xlink:label="lab_arwr_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis [Member]</link:label>
    <link:label id="lab_arwr_NovartisMember_documentation_en-US" xlink:label="lab_arwr_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisMember" xlink:href="arwr-20230331.xsd#arwr_NovartisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NovartisMember" xlink:to="lab_arwr_NovartisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_00c82897-0add-481a-bac5-5fd828b9c832_negatedTerseLabel_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Held to maturity, Gross Unrealized Losses</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_label_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Current</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_documentation_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" xlink:href="arwr-20230331.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" xlink:to="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_2aa86f8d-d5d9-4db2-aacd-f4e17ff8eaa0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value: Authorized 290,000 and 145,000 shares; issued and outstanding 106,869 and 105,960 shares</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_IncreaseDecreaseInCashAndInvestments_af8797b6-8844-489b-ab73-01722ae528bd_terseLabel_en-US" xlink:label="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in cash and investments</link:label>
    <link:label id="lab_arwr_IncreaseDecreaseInCashAndInvestments_label_en-US" xlink:label="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash And Investments</link:label>
    <link:label id="lab_arwr_IncreaseDecreaseInCashAndInvestments_documentation_en-US" xlink:label="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in cash and investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_IncreaseDecreaseInCashAndInvestments" xlink:href="arwr-20230331.xsd#arwr_IncreaseDecreaseInCashAndInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_IncreaseDecreaseInCashAndInvestments" xlink:to="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LicenseAndCoFundingAgreementMember_882fedbd-14cc-4356-af85-c1603a193512_terseLabel_en-US" xlink:label="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Co-Funding Agreement</link:label>
    <link:label id="lab_arwr_LicenseAndCoFundingAgreementMember_label_en-US" xlink:label="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Co Funding Agreement [Member]</link:label>
    <link:label id="lab_arwr_LicenseAndCoFundingAgreementMember_documentation_en-US" xlink:label="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and co-funding agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAndCoFundingAgreementMember" xlink:href="arwr-20230331.xsd#arwr_LicenseAndCoFundingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LicenseAndCoFundingAgreementMember" xlink:to="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cfb6670b-1d09-4b3f-83b9-8a02e63b049b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_27c9594a-fa47-4784-bc1e-02cb312e31de_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock - restricted stock units vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_035d8046-02a2-4c4e-abfd-81f14d3cb3ed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_e81c74e6-d153-4281-9f9e-a63a3e1fca48_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_b332566e-413f-45b0-94cd-8a2f2381f471_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_2e02cf78-e3f7-4c9b-bef8-91a6ae47bf35_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b3cb585c-045f-46fc-8225-f6dd69d90f1a_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_10f3369a-5304-4d24-8fa5-26515fc9a554_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6dc37e77-60f3-4417-90b8-536cd2017e47_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_dbc26bc2-4ec6-4b5b-aec3-9ff15a2f1c4e_terseLabel_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:href="arwr-20230331.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AtTheMarketAgreementMember_cd8d7002-d32c-4241-808c-edd5aace3a04_terseLabel_en-US" xlink:label="lab_arwr_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Agreement</link:label>
    <link:label id="lab_arwr_AtTheMarketAgreementMember_label_en-US" xlink:label="lab_arwr_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Agreement [Member]</link:label>
    <link:label id="lab_arwr_AtTheMarketAgreementMember_documentation_en-US" xlink:label="lab_arwr_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AtTheMarketAgreementMember" xlink:href="arwr-20230331.xsd#arwr_AtTheMarketAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AtTheMarketAgreementMember" xlink:to="lab_arwr_AtTheMarketAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CorporateHeadquartersInPasadenaMember_810208a5-9ec8-4596-8e58-d36ecdb1c0c0_terseLabel_en-US" xlink:label="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Headquarters In Pasadena</link:label>
    <link:label id="lab_arwr_CorporateHeadquartersInPasadenaMember_label_en-US" xlink:label="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Headquarters In Pasadena [Member]</link:label>
    <link:label id="lab_arwr_CorporateHeadquartersInPasadenaMember_documentation_en-US" xlink:label="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Headquarters in Pasadena</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CorporateHeadquartersInPasadenaMember" xlink:href="arwr-20230331.xsd#arwr_CorporateHeadquartersInPasadenaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CorporateHeadquartersInPasadenaMember" xlink:to="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4b12f591-e840-47ff-a7b3-cf245df568cb_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to noncontrolling interest, net of tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ef67884d-60d2-4863-901a-cad93913ff2c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_253215a8-de20-4489-9320-adec0852f87e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_c11bb32d-4f8a-4f72-a5ec-1f21b6c87b0a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercises of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_3e1ef39e-aea9-47fd-a939-ea22f7a5b033_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_6e71d813-baa4-4109-81de-fb02b4e965fe_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_c9980236-d6ad-4d79-a2de-1979a68eecc1_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfDistinctBundle_ed1332d2-eeca-4d22-80c6-426d8f70ebb2_terseLabel_en-US" xlink:label="lab_arwr_NumberOfDistinctBundle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distinct bundle</link:label>
    <link:label id="lab_arwr_NumberOfDistinctBundle_label_en-US" xlink:label="lab_arwr_NumberOfDistinctBundle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Distinct Bundle</link:label>
    <link:label id="lab_arwr_NumberOfDistinctBundle_documentation_en-US" xlink:label="lab_arwr_NumberOfDistinctBundle" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distinct bundle.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle" xlink:href="arwr-20230331.xsd#arwr_NumberOfDistinctBundle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfDistinctBundle" xlink:to="lab_arwr_NumberOfDistinctBundle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_31e80434-fa7d-4684-a59d-df97582b0120_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_RoyaltyPaymentThreshold_7bc0f27b-fbad-46e2-b74b-78f3c4d5aceb_terseLabel_en-US" xlink:label="lab_arwr_RoyaltyPaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment threshold</link:label>
    <link:label id="lab_arwr_RoyaltyPaymentThreshold_label_en-US" xlink:label="lab_arwr_RoyaltyPaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Payment Threshold</link:label>
    <link:label id="lab_arwr_RoyaltyPaymentThreshold_documentation_en-US" xlink:label="lab_arwr_RoyaltyPaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Payment Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPaymentThreshold" xlink:href="arwr-20230331.xsd#arwr_RoyaltyPaymentThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RoyaltyPaymentThreshold" xlink:to="lab_arwr_RoyaltyPaymentThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cd7f1df9-9533-4aec-bfcb-de3ae784c4fe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_8eae9512-6915-4d0a-a560-24be800d9ab2_verboseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FacilitiesMember_76abfe2c-82e8-45b0-8c84-c5f4d9cf47a5_terseLabel_en-US" xlink:label="lab_arwr_FacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities</link:label>
    <link:label id="lab_arwr_FacilitiesMember_label_en-US" xlink:label="lab_arwr_FacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities [Member]</link:label>
    <link:label id="lab_arwr_FacilitiesMember_documentation_en-US" xlink:label="lab_arwr_FacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FacilitiesMember" xlink:href="arwr-20230331.xsd#arwr_FacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FacilitiesMember" xlink:to="lab_arwr_FacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b3598274-8335-4a77-ae49-c3513baa6f23_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful Lives</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_c1225082-fb2f-42a3-9744-7478702d6f7e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_7b47d98c-41ec-4098-b95d-35f478eabdff_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AROXDHAgreementMember_4a54c086-277d-4a65-ad2d-b5093d6c5963_terseLabel_en-US" xlink:label="lab_arwr_AROXDHAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARO-XDH</link:label>
    <link:label id="lab_arwr_AROXDHAgreementMember_label_en-US" xlink:label="lab_arwr_AROXDHAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A R O X D H Agreement [Member]</link:label>
    <link:label id="lab_arwr_AROXDHAgreementMember_documentation_en-US" xlink:label="lab_arwr_AROXDHAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARO-XDH Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROXDHAgreementMember" xlink:href="arwr-20230331.xsd#arwr_AROXDHAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AROXDHAgreementMember" xlink:to="lab_arwr_AROXDHAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_2c4805e3-e183-4a93-a74c-4e752c0654e0_terseLabel_en-US" xlink:label="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense on liability related to the sale of future royalties</link:label>
    <link:label id="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_label_en-US" xlink:label="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Expense, Liability Related to Sale of Future Royalties</link:label>
    <link:label id="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Expense, Liability Related to Sale of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:href="arwr-20230331.xsd#arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:to="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_b1bc0722-d91f-4dcc-9cdf-1b9cee3a4b37_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f35237a3-db3e-422a-886a-f6d5e65f2e05_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_c4ffd8bb-a7c9-426f-9b67-811f54c2e528_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_93bb0340-c288-4c35-a9f2-0a51e7a52531_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options Outstanding, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_c86d7ea6-6494-47fb-a5ac-d4c4645cd66f_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense for property and equipment</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_93328d27-f9d5-4770-8c8e-275be6896ad3_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_RoyaltyPharmaAgreementMember_2ad8e5e4-38e9-42ab-b89d-b2da20a89ee7_terseLabel_en-US" xlink:label="lab_arwr_RoyaltyPharmaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma Agreement</link:label>
    <link:label id="lab_arwr_RoyaltyPharmaAgreementMember_label_en-US" xlink:label="lab_arwr_RoyaltyPharmaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma Agreement [Member]</link:label>
    <link:label id="lab_arwr_RoyaltyPharmaAgreementMember_documentation_en-US" xlink:label="lab_arwr_RoyaltyPharmaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaAgreementMember" xlink:href="arwr-20230331.xsd#arwr_RoyaltyPharmaAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RoyaltyPharmaAgreementMember" xlink:to="lab_arwr_RoyaltyPharmaAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommonStockPurchaseAgreementMember_fb127fcc-f185-48bd-9190-c562ce7b45a3_terseLabel_en-US" xlink:label="lab_arwr_CommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Purchase Agreement</link:label>
    <link:label id="lab_arwr_CommonStockPurchaseAgreementMember_label_en-US" xlink:label="lab_arwr_CommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_arwr_CommonStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_arwr_CommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockPurchaseAgreementMember" xlink:href="arwr-20230331.xsd#arwr_CommonStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommonStockPurchaseAgreementMember" xlink:to="lab_arwr_CommonStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_b41e563a-11b1-427d-bd1f-8390c333934a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_b0e38375-6eff-4e89-8733-d6ec87c73eb0_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_27345f5e-9470-425f-bdf9-e09fad5cceda_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ffcd3834-0241-4c00-b752-1ae3044673eb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d7e6caaf-12d0-4f75-ad5e-4995766efe4c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_3a3cb6f2-cf67-4274-a698-52fb87a257b2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_645d19c3-4453-4a2e-8a71-b4e8eca6f87f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Stock By Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_e4981d39-b514-4257-9044-347e82533399_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b60d6e63-7b07-4544-996d-4b1c384e3c10_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_38fb6c3f-4ed7-475a-9071-0d17508cbbf3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0ff091c2-01bb-4e53-a07b-922e30bcbe39_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_39214be9-22c2-4e20-9122-9b30a9b5d1a2_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_VeronaTechnologyParkMember_7f00f334-c053-4b89-afc1-af1108458b9b_terseLabel_en-US" xlink:label="lab_arwr_VeronaTechnologyParkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verona Technology Park</link:label>
    <link:label id="lab_arwr_VeronaTechnologyParkMember_label_en-US" xlink:label="lab_arwr_VeronaTechnologyParkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verona Technology Park [Member]</link:label>
    <link:label id="lab_arwr_VeronaTechnologyParkMember_documentation_en-US" xlink:label="lab_arwr_VeronaTechnologyParkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verona technology park.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VeronaTechnologyParkMember" xlink:href="arwr-20230331.xsd#arwr_VeronaTechnologyParkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_VeronaTechnologyParkMember" xlink:to="lab_arwr_VeronaTechnologyParkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_a26107c3-0e0c-43b5-833d-4024ae8097c8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_e6d6713d-2a21-40f6-8888-7036b05bd341_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_a2fc483e-4ea5-4b1d-b117-97adcded2226_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_6b91774a-b137-48af-adfe-0136922b89be_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AmgenIncorporatedMember_bc17511e-4655-4f69-924c-5fab3c56c094_terseLabel_en-US" xlink:label="lab_arwr_AmgenIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen</link:label>
    <link:label id="lab_arwr_AmgenIncorporatedMember_label_en-US" xlink:label="lab_arwr_AmgenIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen Incorporated [Member]</link:label>
    <link:label id="lab_arwr_AmgenIncorporatedMember_documentation_en-US" xlink:label="lab_arwr_AmgenIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen Incorporated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember" xlink:href="arwr-20230331.xsd#arwr_AmgenIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AmgenIncorporatedMember" xlink:to="lab_arwr_AmgenIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4c488de8-1717-42aa-9a38-4a13265d8a5b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b1410dcb-9790-4759-93fd-61648e14527f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_feac2f50-62b5-43ac-8c86-4712a0325a64_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_1e7e5e41-2441-480f-bda1-eb8e1e432769_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_3cd19e77-71a3-468c-896e-c20f4a5f1d3c_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_e3791389-ad09-4fb4-a0cd-1e1eeff8798e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_7d4a2e6d-5a16-4b59-b6ae-dc5a21beb0c4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_83152fa2-0c03-4710-9dc5-29612adccb2d_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1fb66779-9b4f-4891-933e-7a864913bb27_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2b344fc3-567d-41a7-a043-83c8c6b9039d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_4f61a741-874e-45e6-8a4f-f38b1a5b519d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_b39c0f01-e26f-43ad-b433-938b29e31b1f_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_d7d574f8-373a-4fc0-86d2-fdaa4bfdde6c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes (paid) refunded</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_7dc07364-55b4-4bd4-8b03-ddbee706177d_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_cdee4328-616a-4f8d-bdf9-38b0cdb38c8f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_10658d17-6c2d-4fc9-bf53-4a0b46693e3a_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_ac21b652-84f5-4418-ae14-28f6f73c3018_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_59120d67-a030-4e2e-a980-30cdae5fe7a1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a827ad32-229c-4a93-bf3d-323bda28e0e1_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DeferredRevenueMember_0b29f747-4ca9-4b82-8bca-858a82231afb_terseLabel_en-US" xlink:label="lab_arwr_DeferredRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue</link:label>
    <link:label id="lab_arwr_DeferredRevenueMember_label_en-US" xlink:label="lab_arwr_DeferredRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue [Member]</link:label>
    <link:label id="lab_arwr_DeferredRevenueMember_documentation_en-US" xlink:label="lab_arwr_DeferredRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredRevenueMember" xlink:href="arwr-20230331.xsd#arwr_DeferredRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DeferredRevenueMember" xlink:to="lab_arwr_DeferredRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_a3a0b6df-da09-4b39-bbca-fc2531c194a4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_210f3734-2817-4da8-9b4e-a1d3b3fce073_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ad2b4696-1040-4c4b-918f-d61d0eb7d03b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1c0cd62b-6e15-4165-a4a7-15e72fc25792_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_aa89d171-7b75-4eda-b80a-cecec4433bc7_terseLabel_en-US" xlink:label="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028 and thereafter</link:label>
    <link:label id="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_label_en-US" xlink:label="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Payments Due Year Five And After Year Five</link:label>
    <link:label id="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_documentation_en-US" xlink:label="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee operating lease liability payments due year five and after year five.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:href="arwr-20230331.xsd#arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:to="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponFDAApproval_e11d527c-a249-4d5f-b142-3a76e5a04261_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable upon FDA approval</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponFDAApproval_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable Upon FDA Approval</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponFDAApproval_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable Upon FDA Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentReceivableUponFDAApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:to="lab_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4725da47-30e3-4646-9b05-b3f79218b49d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_0d08089c-a46f-4368-9bb5-937b2852276c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_VisirnaLicenseAgreementMember_04f91db3-4574-4035-88bb-27fc2493bd2d_terseLabel_en-US" xlink:label="lab_arwr_VisirnaLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visirna License Agreement</link:label>
    <link:label id="lab_arwr_VisirnaLicenseAgreementMember_label_en-US" xlink:label="lab_arwr_VisirnaLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visirna License Agreement [Member]</link:label>
    <link:label id="lab_arwr_VisirnaLicenseAgreementMember_documentation_en-US" xlink:label="lab_arwr_VisirnaLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visirna License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaLicenseAgreementMember" xlink:href="arwr-20230331.xsd#arwr_VisirnaLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_VisirnaLicenseAgreementMember" xlink:to="lab_arwr_VisirnaLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_cb282726-16f2-45ad-95f8-c702a47b286c_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable Upon Achievement of Enrollment in Phase 3 Clinical Trial</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable Upon Achievement of Enrollment in Phase 3 Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:to="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_20c566e5-c51a-4a28-8c03-1d2b95f8a28d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_21d847e9-7c69-429c-bd07-7bcef4920721_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_6c0c354e-74de-4701-bbf7-9505db89f4f4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_c96f3507-bdef-4cfc-a5c6-07c71571dfe2_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetsImpairment_e978d317-2ee4-4616-a709-680d3324f606_terseLabel_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetsImpairment_label_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Impairment</link:label>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetsImpairment_documentation_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:href="arwr-20230331.xsd#arwr_FiniteLivedIntangibleAssetsImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:to="lab_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_874ae007-1829-4d24-9bff-a907cd19a4a1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_a7ae0431-ed0d-4bd3-a99e-de4e39897588_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities (includes current portion)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Land_02f9e662-2596-4c2f-ae6a-e7db355d29e6_terseLabel_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_Land_label_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceived_19fcd16e-96ea-4352-96aa-601b32e7f0a3_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceived_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Received</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceived_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceived" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceived" xlink:to="lab_arwr_MilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandsFourEquityIncentivePlanMember_f4b3ad00-5b94-4bf6-986b-da6b4faa7d06_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2004 Equity Incentive Plan</link:label>
    <link:label id="lab_arwr_TwoThousandsFourEquityIncentivePlanMember_label_en-US" xlink:label="lab_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousands Four Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandsFourEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousands four equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:href="arwr-20230331.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:to="lab_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_176ba39c-5b1a-4234-b83c-35c4016c9cc7_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1257c855-17f1-4efd-87ad-a739bdbe1dd9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchEquipmentGross_2c4481f0-0807-42a6-9650-4b7184af0d01_terseLabel_en-US" xlink:label="lab_arwr_ResearchEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research equipment</link:label>
    <link:label id="lab_arwr_ResearchEquipmentGross_label_en-US" xlink:label="lab_arwr_ResearchEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Equipment Gross</link:label>
    <link:label id="lab_arwr_ResearchEquipmentGross_documentation_en-US" xlink:label="lab_arwr_ResearchEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research equipment gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentGross" xlink:href="arwr-20230331.xsd#arwr_ResearchEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchEquipmentGross" xlink:to="lab_arwr_ResearchEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7840eb0f-8fe6-4817-93b9-a296685b76e5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6de338e9-8175-45a4-a83e-0d4ab297722b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_08adcdae-89ae-4ed0-8447-98e745246a92_terseLabel_en-US" xlink:label="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of eligible to receive tiered royalties on net sales</link:label>
    <link:label id="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_label_en-US" xlink:label="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Eligible To Receive Tiered Royalties On Net Sales</link:label>
    <link:label id="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_documentation_en-US" xlink:label="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of eligible to receive tiered royalties on net sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:href="arwr-20230331.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:to="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fc7bc436-8bd9-4504-8c48-456cef807c02_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfAcresOfLandPurchased_75b54b2e-6c8c-4c46-9645-861f92b6e426_terseLabel_en-US" xlink:label="lab_arwr_NumberOfAcresOfLandPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land purchased, number of acres</link:label>
    <link:label id="lab_arwr_NumberOfAcresOfLandPurchased_label_en-US" xlink:label="lab_arwr_NumberOfAcresOfLandPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Acres Of Land Purchased</link:label>
    <link:label id="lab_arwr_NumberOfAcresOfLandPurchased_documentation_en-US" xlink:label="lab_arwr_NumberOfAcresOfLandPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of acres of land purchased.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAcresOfLandPurchased" xlink:href="arwr-20230331.xsd#arwr_NumberOfAcresOfLandPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfAcresOfLandPurchased" xlink:to="lab_arwr_NumberOfAcresOfLandPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_a65521d8-6e83-4b02-b566-acf9e01cf9f3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_228e8175-28c3-46e9-a7af-12437684a2ea_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c45e4b5a-30db-4b40-9395-65b69cfc0fa8_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_bf98ddd7-c49c-4693-95e8-2a3a83f1242b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3f5514ca-a183-4cd8-8b38-5a423a0a35dc_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_42fc265c-28c8-47f7-a39c-b3991ef44230_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average basic shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0656384c-e3c8-468f-92d3-d1638b139255_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest and stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_c1415fde-5eb1-4635-9a93-0ef94b0ff34d_totalLabel_en-US" xlink:label="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (in shares)</link:label>
    <link:label id="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_label_en-US" xlink:label="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding</link:label>
    <link:label id="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_documentation_en-US" xlink:label="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:href="arwr-20230331.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:to="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_12ad465b-ecea-4e79-846d-1f78290cd86d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_3f66e4ab-cf56-473a-bf7a-e36611b1fdb2_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_232bdc50-0783-48aa-ad5a-93be0d7abc5f_negatedTerseLabel_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments, Held to maturity, Gross Unrealized Losses</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_label_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Noncurrent</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_documentation_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" xlink:href="arwr-20230331.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" xlink:to="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_7ddeda4e-930c-4508-a9a3-00680ae416dd_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_2628dfd7-e5e7-4e06-b269-42a024a9a3a4_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_15a878c1-ebca-4687-8d40-cf60a284fdf0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f65f2e9d-573c-4fb4-9078-494e3b1f600b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_4a73b86a-2c4e-496e-9795-69b28514a7b3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables included in accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_81ac013f-19ff-4e2a-90e0-8442d80d155d_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e5bbed81-666a-4e70-9cc2-a18f7ceba350_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_34c73138-a77c-4979-868d-b91f0d016a3e_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_d47510f3-5211-4ddb-a7d8-d3e0baffd357_terseLabel_en-US" xlink:label="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK</link:label>
    <link:label id="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_label_en-US" xlink:label="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glaxosmithkline Intellectual Property Limited [Member]</link:label>
    <link:label id="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_documentation_en-US" xlink:label="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glaxosmithkline Intellectual Property Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:href="arwr-20230331.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:to="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9b44e274-c247-4be9-973a-91832216e164_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ColoradoOwnerLLCMember_e0c829ed-4a8c-4529-a940-963b944f54f1_terseLabel_en-US" xlink:label="lab_arwr_ColoradoOwnerLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Colorado Owner, LLC</link:label>
    <link:label id="lab_arwr_ColoradoOwnerLLCMember_label_en-US" xlink:label="lab_arwr_ColoradoOwnerLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Colorado Owner L L C [Member]</link:label>
    <link:label id="lab_arwr_ColoradoOwnerLLCMember_documentation_en-US" xlink:label="lab_arwr_ColoradoOwnerLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Colorado Owner, LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ColoradoOwnerLLCMember" xlink:href="arwr-20230331.xsd#arwr_ColoradoOwnerLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ColoradoOwnerLLCMember" xlink:to="lab_arwr_ColoradoOwnerLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_42380503-f4eb-4da4-bf7b-4552bc948d03_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserve for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_660d5047-e8f8-4879-8f95-fb673150d530_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_17b26048-50b4-40bb-802f-13dc18daa9e8_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_a79449bf-d1f5-4360-8f94-a74af1128c3e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfAgreements_e03afb20-5e28-4df3-b7a2-d0ee9f4b4d2d_terseLabel_en-US" xlink:label="lab_arwr_NumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of agreements</link:label>
    <link:label id="lab_arwr_NumberOfAgreements_label_en-US" xlink:label="lab_arwr_NumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Agreements</link:label>
    <link:label id="lab_arwr_NumberOfAgreements_documentation_en-US" xlink:label="lab_arwr_NumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAgreements" xlink:href="arwr-20230331.xsd#arwr_NumberOfAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfAgreements" xlink:to="lab_arwr_NumberOfAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_cb4855f0-77c8-4d19-b9cb-ab45103d4ee0_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_68985689-6c92-4ef2-8d7b-52a9348a567b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_db8fcc78-e5b2-4983-8389-0f8af65841a5_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held to maturity securities</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_36b9c165-ab79-4bf7-97af-f7cfe764b0d8_terseLabel_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Held to maturity, Gross Unrealized Gains</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_label_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Current</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_documentation_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" xlink:href="arwr-20230331.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" xlink:to="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_JNJ3989AROHBVAgreementMember_dbbaeb15-df84-43de-9ad7-afa740e92958_terseLabel_en-US" xlink:label="lab_arwr_JNJ3989AROHBVAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JNJ-3989 (ARO-HBV) Agreement</link:label>
    <link:label id="lab_arwr_JNJ3989AROHBVAgreementMember_label_en-US" xlink:label="lab_arwr_JNJ3989AROHBVAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">J N J3989 A R O H B V Agreement [Member]</link:label>
    <link:label id="lab_arwr_JNJ3989AROHBVAgreementMember_documentation_en-US" xlink:label="lab_arwr_JNJ3989AROHBVAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JNJ-3989 (ARO-HBV) Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JNJ3989AROHBVAgreementMember" xlink:href="arwr-20230331.xsd#arwr_JNJ3989AROHBVAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_JNJ3989AROHBVAgreementMember" xlink:to="lab_arwr_JNJ3989AROHBVAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_31790997-ed90-48e1-8acc-b7d7285406cb_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_d119537e-7c04-4bb2-a7f3-0ccc602ba010_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments, Held to maturity, Adjusted Basis</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_280a2477-8ae4-4861-84af-20523306de36_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government bonds</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_d006ea30-397a-42da-aab5-1db46306e48a_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8744d68b-73e4-4b32-a7df-f98d0f5c84a0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_a53c1a20-0137-4835-946b-8bde512e06b5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities, Noncontrolling Interest and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_237f8bb7-abea-412e-97aa-727c3964f4a4_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_00dda353-25e3-4799-baf8-2180d8baf517_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_a5c90469-51a8-466c-b1aa-02d527506091_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_21c1e61a-fa47-4555-85d7-5deafe048a8a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_30f680f1-5c03-4562-96ef-610e1b6d18ac_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities_65ad04f9-2758-4c01-bde4-1d364b89c756_terseLabel_en-US" xlink:label="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount intends to invest for buildout of the facilities</link:label>
    <link:label id="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities_label_en-US" xlink:label="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Intends To Invest For Buildout Of Facilities</link:label>
    <link:label id="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities_documentation_en-US" xlink:label="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount intends to invest for buildout of facilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:href="arwr-20230331.xsd#arwr_AmountIntendsToInvestForBuildoutOfFacilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:to="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_HorizonTherapeuticsIrelandDACAndAmgenIncorporatedMember_97c24181-7cc6-4389-a419-6c5b8c9d4e9b_terseLabel_en-US" xlink:label="lab_arwr_HorizonTherapeuticsIrelandDACAndAmgenIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon and Amgen</link:label>
    <link:label id="lab_arwr_HorizonTherapeuticsIrelandDACAndAmgenIncorporatedMember_label_en-US" xlink:label="lab_arwr_HorizonTherapeuticsIrelandDACAndAmgenIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon Therapeutics Ireland DAC and Amgen Incorporated [Member]</link:label>
    <link:label id="lab_arwr_HorizonTherapeuticsIrelandDACAndAmgenIncorporatedMember_documentation_en-US" xlink:label="lab_arwr_HorizonTherapeuticsIrelandDACAndAmgenIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon Therapeutics Ireland DAC and Amgen Incorporated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACAndAmgenIncorporatedMember" xlink:href="arwr-20230331.xsd#arwr_HorizonTherapeuticsIrelandDACAndAmgenIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_HorizonTherapeuticsIrelandDACAndAmgenIncorporatedMember" xlink:to="lab_arwr_HorizonTherapeuticsIrelandDACAndAmgenIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8dcd34b9-8a80-4225-8ec1-544506cc1278_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_fec40422-9ec2-4d31-9a44-d4cdc2f412ea_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_1d23671b-d252-4075-ab8f-cda25b42603d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_99db696d-f124-4f7b-8ff9-0a317cc92283_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_24832589-9e52-40a5-8ef5-11b0eda5f03c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Shares of Common Stock and Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_45bbe7e5-c992-4dc9-9241-615569c6b227_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_eb8abcbc-55d1-46cb-945f-c32b75d8e80d_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable upon receipt of royalty payments</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable, Upon Receipt Of Royalty Payments</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable, Upon Receipt Of Royalty Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:to="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_77da18ef-cfc7-4491-a4ee-e94173b2b869_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fc9e6753-ce8b-4014-b770-63470a268b0e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_2edf374c-e9f0-41fd-a8ca-e1b0ea9ec484_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_36e9b932-f57e-4234-ba2a-8058ef5a3357_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Share Activity Related to RSUs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementMember_367c8cad-1a72-490b-910f-ec55630e60db_terseLabel_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License agreements</link:label>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember" xlink:href="arwr-20230331.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CollaborationAndLicenseAgreementMember" xlink:to="lab_arwr_CollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_497082ae-c88d-43ff-8001-e266661d6854_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_f8246699-9326-4dc3-8c32-48e51394b447_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_64154288-73bd-4d33-a29c-5cc004f65775_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_d3a15acd-b0e9-412f-a81e-fdbc56fe62b6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2af96fc5-eecd-4003-a113-3b1d24a23ea6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_JNJ75220795AROJNJ1Member_a6ee83cf-aa40-4ac0-b713-42b3c6e9ac97_terseLabel_en-US" xlink:label="lab_arwr_JNJ75220795AROJNJ1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JNJ-75220795 (ARO-JNJ1)</link:label>
    <link:label id="lab_arwr_JNJ75220795AROJNJ1Member_label_en-US" xlink:label="lab_arwr_JNJ75220795AROJNJ1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">J N J75220795 A R O J N J1 [Member]</link:label>
    <link:label id="lab_arwr_JNJ75220795AROJNJ1Member_documentation_en-US" xlink:label="lab_arwr_JNJ75220795AROJNJ1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JNJ 75220795 ARO JNJ1.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JNJ75220795AROJNJ1Member" xlink:href="arwr-20230331.xsd#arwr_JNJ75220795AROJNJ1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_JNJ75220795AROJNJ1Member" xlink:to="lab_arwr_JNJ75220795AROJNJ1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_1d00f658-6cda-4eb6-a036-5e90a124eaa7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities included in deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_dd8b7669-62bb-44fc-8b28-4818b1526cb5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_ed269db6-8920-4a06-a28a-4375ecd3cce5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ea30bf0d-f126-4a71-893d-c04dcd53ab62_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_5cc6b1f4-2a85-4fd3-8ef3-033061731c57_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_51861cfc-7137-4a65-b9a1-ed1700fdc057_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_b3e8d04c-6470-48f8-9e3e-4b7427b8acff_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_666220ba-32ec-40df-98a9-a35672367dcb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivable_a110ee92-7813-4ee4-8b43-ee45b86b8917_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivable_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivable_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivable" xlink:to="lab_arwr_MilestonePaymentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WI_45f062af-9199-43e8-9625-31f218c6143b_terseLabel_en-US" xlink:label="lab_stpr_WI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wisconsin</link:label>
    <link:label id="lab_stpr_WI_label_en-US" xlink:label="lab_stpr_WI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WISCONSIN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WI" xlink:to="lab_stpr_WI" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_dfce5a37-5498-49ee-a072-de5bae865903_terseLabel_en-US" xlink:label="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JJDC</link:label>
    <link:label id="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_label_en-US" xlink:label="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Johnson And Johnson Innovation J J D C Incorporation [Member]</link:label>
    <link:label id="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_documentation_en-US" xlink:label="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Johnson and Johnson Innovation-JJDC, Incorporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:href="arwr-20230331.xsd#arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:to="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_487eb9f6-0524-470f-b5c7-c0a106afdd87_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_cbf0fc53-4bdf-4d15-9035-bd851fc7b9e6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 (remainder)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_19d72477-4dd6-4db2-85f1-70ea9803ce64_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_dc8bbce6-ad02-477c-8f41-318a04f6d12f_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_df094ffe-ef9e-410a-b595-c4c5876e5466_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_a9b66bb4-a246-4a09-bfca-2443d5ecd8ce_terseLabel_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Four</link:label>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="arwr-20230331.xsd#arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_de13a050-9583-41f8-a9de-4578e86c3640_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_811c527a-6b38-4f23-a200-ca440f02079c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e878184b-935e-491e-9906-ba9026808305_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c51192f3-ade1-4017-97de-55441212914b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_EstimatedPaymentsForOperatingExpensesYearOne_dd716513-dacb-4987-8be1-562f464e6842_terseLabel_en-US" xlink:label="lab_arwr_EstimatedPaymentsForOperatingExpensesYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated payments for operating expenses</link:label>
    <link:label id="lab_arwr_EstimatedPaymentsForOperatingExpensesYearOne_label_en-US" xlink:label="lab_arwr_EstimatedPaymentsForOperatingExpensesYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Payments For Operating Expenses Year One</link:label>
    <link:label id="lab_arwr_EstimatedPaymentsForOperatingExpensesYearOne_documentation_en-US" xlink:label="lab_arwr_EstimatedPaymentsForOperatingExpensesYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated payments for operating expenses year one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EstimatedPaymentsForOperatingExpensesYearOne" xlink:href="arwr-20230331.xsd#arwr_EstimatedPaymentsForOperatingExpensesYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_EstimatedPaymentsForOperatingExpensesYearOne" xlink:to="lab_arwr_EstimatedPaymentsForOperatingExpensesYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_58e0878f-4799-484e-ba89-2cf139edd1bd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_296952a0-a8d0-478e-a926-9c32d950580e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant Date Fair Value Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0c1adb15-aa63-4d17-acac-627ecb9ae18d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_906bc6ef-bba6-4793-9946-3905a823c7d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_a93f8176-9c4e-466e-8d13-747ac462df93_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_e2ca26af-2330-47e6-aa5a-ccaa40247b32_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f7aedbe6-0932-40c0-9a8b-991c2ac6e7a5_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_b69af605-ba53-4a1b-9dc0-a24588f6e3cd_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_a09cfd5e-0d21-4401-ac59-b2b8b0c60bd0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_38b72747-42c1-4d48-9745-7ce525a86b72_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_cf779689-3283-483c-9826-e8c2ef98893f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_015d9325-2a55-46f2-99be-918254427c1d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LaboratoryAndOfficeFacilityMember_eaff7978-fa6c-48ff-a762-2b951a1f91e8_terseLabel_en-US" xlink:label="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and Office Facility</link:label>
    <link:label id="lab_arwr_LaboratoryAndOfficeFacilityMember_label_en-US" xlink:label="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory And Office Facility [Member]</link:label>
    <link:label id="lab_arwr_LaboratoryAndOfficeFacilityMember_documentation_en-US" xlink:label="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and office facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LaboratoryAndOfficeFacilityMember" xlink:href="arwr-20230331.xsd#arwr_LaboratoryAndOfficeFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LaboratoryAndOfficeFacilityMember" xlink:to="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2aa804ba-b032-4ee5-af91-bca446d7f8f5_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_8088d863-1993-4cb3-94d6-38da2cdcef26_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED CASH:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_0ba5f02f-7859-4640-8d4d-325b439795be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a25c221f-6abd-4ee7-9e4d-ef23ad6b7850_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value per share of options granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchFacilityInMadisonMember_e010cb8b-3d4a-4f2b-b94d-27d4e0bd4f23_terseLabel_en-US" xlink:label="lab_arwr_ResearchFacilityInMadisonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Facility in Madison</link:label>
    <link:label id="lab_arwr_ResearchFacilityInMadisonMember_label_en-US" xlink:label="lab_arwr_ResearchFacilityInMadisonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Facility In Madison [Member]</link:label>
    <link:label id="lab_arwr_ResearchFacilityInMadisonMember_documentation_en-US" xlink:label="lab_arwr_ResearchFacilityInMadisonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research facility in Madison.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInMadisonMember" xlink:href="arwr-20230331.xsd#arwr_ResearchFacilityInMadisonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchFacilityInMadisonMember" xlink:to="lab_arwr_ResearchFacilityInMadisonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_f1231646-b47f-46d6-bf05-dc510e3dc98f_terseLabel_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments, Held to maturity, Gross Unrealized Gains</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_label_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Noncurrent</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_documentation_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" xlink:href="arwr-20230331.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" xlink:to="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6815ec39-6950-4c63-a5c5-0051981bd6c3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_c37783ef-a9af-4027-b23d-e623982d3c92_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_ffb64d4e-a1d3-46aa-85c3-8197583c58c9_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e280e141-340a-4332-9fd8-45f8eb40cebf_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_d2e2b679-cb28-4ccb-b6b9-c4e2b9de9942_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_e772ef23-6480-4867-9d3c-29eed585fc7e_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>arwr-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:838ae12b-ce84-423c-b3bd-d5043611fe16,g:09a7ef9b-3d5a-4a38-9975-37e1f59f1b78-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/Cover" xlink:type="simple" xlink:href="arwr-20230331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5af6c4b0-1215-46a5-9de5-b1f203c8e9fc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_DocumentType_5af6c4b0-1215-46a5-9de5-b1f203c8e9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_b179e884-fc39-4e68-a174-17a515b02be5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_DocumentQuarterlyReport_b179e884-fc39-4e68-a174-17a515b02be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4f8cf97c-0fe6-4c05-a16b-fd226a5c16b2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_DocumentPeriodEndDate_4f8cf97c-0fe6-4c05-a16b-fd226a5c16b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_51bf52c3-d37d-4011-bb24-087d40451c86" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_DocumentTransitionReport_51bf52c3-d37d-4011-bb24-087d40451c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_edd4d330-6cf7-4553-b91e-39315e30e0a1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_EntityFileNumber_edd4d330-6cf7-4553-b91e-39315e30e0a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_34ab5739-5d26-44ec-b97b-654e6b21bd88" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_EntityRegistrantName_34ab5739-5d26-44ec-b97b-654e6b21bd88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3c0f1272-6da0-453d-b5ec-95000f62b009" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3c0f1272-6da0-453d-b5ec-95000f62b009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_62a91854-3d56-43b0-a7ec-b030e079f2a4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_EntityTaxIdentificationNumber_62a91854-3d56-43b0-a7ec-b030e079f2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_16284727-2257-40af-9d23-dc7d8f4d3edd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_EntityAddressAddressLine1_16284727-2257-40af-9d23-dc7d8f4d3edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_05c675e6-24c5-495f-a32e-d048f1470b59" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_EntityAddressAddressLine2_05c675e6-24c5-495f-a32e-d048f1470b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_72ef8d15-18ed-4b2a-aaaf-b8a971ec79c7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_EntityAddressCityOrTown_72ef8d15-18ed-4b2a-aaaf-b8a971ec79c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ecb7ae09-08a0-4794-a68d-336b8d4e5195" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_EntityAddressStateOrProvince_ecb7ae09-08a0-4794-a68d-336b8d4e5195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b38610fb-1312-4c6c-b104-65407fd51f23" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_EntityAddressPostalZipCode_b38610fb-1312-4c6c-b104-65407fd51f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_9983a195-a387-4a63-9c1f-08629823937c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_CityAreaCode_9983a195-a387-4a63-9c1f-08629823937c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_53d0ba77-b408-449f-8a84-c4e4c76a7ad0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_LocalPhoneNumber_53d0ba77-b408-449f-8a84-c4e4c76a7ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5afaa1c3-5d86-48f9-aed5-22b866f2529c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_Security12bTitle_5afaa1c3-5d86-48f9-aed5-22b866f2529c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1c5d96c2-ae9f-4be9-82be-00978824b456" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_TradingSymbol_1c5d96c2-ae9f-4be9-82be-00978824b456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a3985bf6-a05f-47e5-a9df-032d0d8c2bfe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_SecurityExchangeName_a3985bf6-a05f-47e5-a9df-032d0d8c2bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_8fedb1a0-e36a-4228-883c-2e3ec737b181" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_EntityCurrentReportingStatus_8fedb1a0-e36a-4228-883c-2e3ec737b181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_5f7fd29f-033e-4e65-9eef-9f556938bab6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_EntityInteractiveDataCurrent_5f7fd29f-033e-4e65-9eef-9f556938bab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_b3fa8c2d-cb4a-485b-a0ee-c9514e8f8fac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_EntityFilerCategory_b3fa8c2d-cb4a-485b-a0ee-c9514e8f8fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_24f38f1b-b487-4a64-9ba2-95e0258acb19" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_EntityEmergingGrowthCompany_24f38f1b-b487-4a64-9ba2-95e0258acb19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_612f44b2-68bf-4b45-b7ec-18325a56bec7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_EntitySmallBusiness_612f44b2-68bf-4b45-b7ec-18325a56bec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_fee7f1a5-07aa-4d7c-a592-481767394bdc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_EntityShellCompany_fee7f1a5-07aa-4d7c-a592-481767394bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_4643ba33-7b93-4d8b-83fe-d882dee215ba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_4643ba33-7b93-4d8b-83fe-d882dee215ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e1e539c9-df53-450e-af68-574f533323a6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_EntityCentralIndexKey_e1e539c9-df53-450e-af68-574f533323a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_58001dfd-cb5d-40d6-842e-8d5cae9ea2ee" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_CurrentFiscalYearEndDate_58001dfd-cb5d-40d6-842e-8d5cae9ea2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_bfd7e185-673c-495c-81ac-c5bb3404eca8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_DocumentFiscalYearFocus_bfd7e185-673c-495c-81ac-c5bb3404eca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0af4808f-a0e8-4a0a-b35b-088b601c751a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_DocumentFiscalPeriodFocus_0af4808f-a0e8-4a0a-b35b-088b601c751a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e9c85b4d-3229-459a-8115-ea8ceb4417b9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8350d81c-0546-4fda-aec9-fdf8381737d7" xlink:to="loc_dei_AmendmentFlag_e9c85b4d-3229-459a-8115-ea8ceb4417b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="arwr-20230331.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ed50e14e-b231-4a69-b96f-39d5a40ad5db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_aa58b086-8ec3-4fda-a446-66d08504b046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ed50e14e-b231-4a69-b96f-39d5a40ad5db" xlink:to="loc_us-gaap_AssetsAbstract_aa58b086-8ec3-4fda-a446-66d08504b046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1d422705-04ef-4874-a890-a520f3657ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_aa58b086-8ec3-4fda-a446-66d08504b046" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1d422705-04ef-4874-a890-a520f3657ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5a604f7a-0c60-43c8-8c73-e1b8aa660d07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d422705-04ef-4874-a890-a520f3657ecf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5a604f7a-0c60-43c8-8c73-e1b8aa660d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_16003900-92a2-4ced-86cc-d8cada42a4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d422705-04ef-4874-a890-a520f3657ecf" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_16003900-92a2-4ced-86cc-d8cada42a4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_734b406f-e0e1-4bb0-bf94-7e27f2e9753b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d422705-04ef-4874-a890-a520f3657ecf" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_734b406f-e0e1-4bb0-bf94-7e27f2e9753b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_a95a1ee6-800c-4013-963e-4bd18f1ee0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d422705-04ef-4874-a890-a520f3657ecf" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_a95a1ee6-800c-4013-963e-4bd18f1ee0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_19b07e42-6de1-4ae5-9b4c-2be31ccb4e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d422705-04ef-4874-a890-a520f3657ecf" xlink:to="loc_us-gaap_OtherAssetsCurrent_19b07e42-6de1-4ae5-9b4c-2be31ccb4e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d847a14c-7945-40d3-8e4d-4252c7063fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d422705-04ef-4874-a890-a520f3657ecf" xlink:to="loc_us-gaap_AssetsCurrent_d847a14c-7945-40d3-8e4d-4252c7063fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_54dd70fe-9dfa-419f-a81d-bf19d4b904c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_aa58b086-8ec3-4fda-a446-66d08504b046" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_54dd70fe-9dfa-419f-a81d-bf19d4b904c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c1b117cc-a587-4793-b9f8-5c501a4c1dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_aa58b086-8ec3-4fda-a446-66d08504b046" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c1b117cc-a587-4793-b9f8-5c501a4c1dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_5ff1a774-7c86-48b3-a2ac-77c68e45ef25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_aa58b086-8ec3-4fda-a446-66d08504b046" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_5ff1a774-7c86-48b3-a2ac-77c68e45ef25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_611a42a8-1756-4b40-bcd8-988ebe408de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_aa58b086-8ec3-4fda-a446-66d08504b046" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_611a42a8-1756-4b40-bcd8-988ebe408de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_761f5922-bfb4-43f2-a56d-4bbda91793e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_aa58b086-8ec3-4fda-a446-66d08504b046" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_761f5922-bfb4-43f2-a56d-4bbda91793e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a934db1b-3c4d-4651-ab1b-a1ae35d3cae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_aa58b086-8ec3-4fda-a446-66d08504b046" xlink:to="loc_us-gaap_Assets_a934db1b-3c4d-4651-ab1b-a1ae35d3cae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_751ce1e6-b681-49ef-8c8c-846fd2d1a261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ed50e14e-b231-4a69-b96f-39d5a40ad5db" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_751ce1e6-b681-49ef-8c8c-846fd2d1a261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_ba148711-649b-4c55-b4fe-72ce7a41bb3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_751ce1e6-b681-49ef-8c8c-846fd2d1a261" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_ba148711-649b-4c55-b4fe-72ce7a41bb3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_691a87bf-cf8d-4714-8803-802b93b57537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ba148711-649b-4c55-b4fe-72ce7a41bb3f" xlink:to="loc_us-gaap_AccountsPayableCurrent_691a87bf-cf8d-4714-8803-802b93b57537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_87af9d83-7a60-42a3-a75a-8b17b42c5c03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ba148711-649b-4c55-b4fe-72ce7a41bb3f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_87af9d83-7a60-42a3-a75a-8b17b42c5c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1388a979-3b82-4964-b194-310e272a6b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ba148711-649b-4c55-b4fe-72ce7a41bb3f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1388a979-3b82-4964-b194-310e272a6b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5f8fa2a2-decb-4b49-ada5-d76c730e9e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ba148711-649b-4c55-b4fe-72ce7a41bb3f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5f8fa2a2-decb-4b49-ada5-d76c730e9e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cfefbabf-3791-4eb8-ba18-5bae854acf34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ba148711-649b-4c55-b4fe-72ce7a41bb3f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cfefbabf-3791-4eb8-ba18-5bae854acf34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4612df28-dfca-45a4-831b-8345ec337949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ba148711-649b-4c55-b4fe-72ce7a41bb3f" xlink:to="loc_us-gaap_LiabilitiesCurrent_4612df28-dfca-45a4-831b-8345ec337949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a5c3c4c-6dea-4dad-8c2f-a1f078970d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_751ce1e6-b681-49ef-8c8c-846fd2d1a261" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a5c3c4c-6dea-4dad-8c2f-a1f078970d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a0a831f3-0d16-4e39-a1ac-9bdd34adb695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a5c3c4c-6dea-4dad-8c2f-a1f078970d1a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a0a831f3-0d16-4e39-a1ac-9bdd34adb695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_92e2b5a0-8ed5-4249-835f-98accd34c5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a5c3c4c-6dea-4dad-8c2f-a1f078970d1a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_92e2b5a0-8ed5-4249-835f-98accd34c5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltiesLiabilityNoncurrent_2c29a18d-e2cf-4ddf-b8b2-0909067f2cbc" xlink:href="arwr-20230331.xsd#arwr_RoyaltiesLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a5c3c4c-6dea-4dad-8c2f-a1f078970d1a" xlink:to="loc_arwr_RoyaltiesLiabilityNoncurrent_2c29a18d-e2cf-4ddf-b8b2-0909067f2cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_9d285fd7-79a7-442c-b841-ef11e4860e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a5c3c4c-6dea-4dad-8c2f-a1f078970d1a" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_9d285fd7-79a7-442c-b841-ef11e4860e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e249bc40-46f9-4f5b-8c0c-1efb7a10e7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_751ce1e6-b681-49ef-8c8c-846fd2d1a261" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e249bc40-46f9-4f5b-8c0c-1efb7a10e7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e77e737a-78dc-44e0-ac8a-10bd817a36e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_751ce1e6-b681-49ef-8c8c-846fd2d1a261" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e77e737a-78dc-44e0-ac8a-10bd817a36e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2a396d01-0e0f-420e-9f53-fae301d678d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e77e737a-78dc-44e0-ac8a-10bd817a36e3" xlink:to="loc_us-gaap_CommonStockValue_2a396d01-0e0f-420e-9f53-fae301d678d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f5426a4a-ace5-4a38-b419-697924fd9835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e77e737a-78dc-44e0-ac8a-10bd817a36e3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f5426a4a-ace5-4a38-b419-697924fd9835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d8205019-b097-471f-8de3-185ca658f497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e77e737a-78dc-44e0-ac8a-10bd817a36e3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d8205019-b097-471f-8de3-185ca658f497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065d56f3-5c31-422e-8fbd-f6e18555c87a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e77e737a-78dc-44e0-ac8a-10bd817a36e3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065d56f3-5c31-422e-8fbd-f6e18555c87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_507056c9-16f6-44b5-8b5a-999b8243f8e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e77e737a-78dc-44e0-ac8a-10bd817a36e3" xlink:to="loc_us-gaap_StockholdersEquity_507056c9-16f6-44b5-8b5a-999b8243f8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_e73c32cb-a812-47e6-8569-e9f175a8e326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e77e737a-78dc-44e0-ac8a-10bd817a36e3" xlink:to="loc_us-gaap_MinorityInterest_e73c32cb-a812-47e6-8569-e9f175a8e326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_516f9a80-6097-42c8-b4c5-f494a3f23d38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e77e737a-78dc-44e0-ac8a-10bd817a36e3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_516f9a80-6097-42c8-b4c5-f494a3f23d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f050bcae-53ad-4429-a6f1-f6f549d4d48f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_751ce1e6-b681-49ef-8c8c-846fd2d1a261" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_f050bcae-53ad-4429-a6f1-f6f549d4d48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="arwr-20230331.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2a195e96-f00d-448f-8a4f-56c93441a0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0b1aac10-fc42-43f2-b0e2-45dd13ded714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2a195e96-f00d-448f-8a4f-56c93441a0bf" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0b1aac10-fc42-43f2-b0e2-45dd13ded714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7dee6f05-2ffb-49d2-87f7-327eba612d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2a195e96-f00d-448f-8a4f-56c93441a0bf" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7dee6f05-2ffb-49d2-87f7-327eba612d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ad65244a-db9e-419c-8d62-6676cd9ca3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2a195e96-f00d-448f-8a4f-56c93441a0bf" xlink:to="loc_us-gaap_CommonStockSharesIssued_ad65244a-db9e-419c-8d62-6676cd9ca3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_dd81e4c8-424c-4612-8d8f-0ba775f4f9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2a195e96-f00d-448f-8a4f-56c93441a0bf" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_dd81e4c8-424c-4612-8d8f-0ba775f4f9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" xlink:type="simple" xlink:href="arwr-20230331.xsd#ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_75d47ef8-6b1f-4e8f-8c8b-de74aeef3ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ced582c5-60d4-48b4-b04d-dff2960656b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_75d47ef8-6b1f-4e8f-8c8b-de74aeef3ea4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ced582c5-60d4-48b4-b04d-dff2960656b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_aa981ce8-d4c4-41d0-baa9-3ca56d4935ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_75d47ef8-6b1f-4e8f-8c8b-de74aeef3ea4" xlink:to="loc_us-gaap_OperatingExpensesAbstract_aa981ce8-d4c4-41d0-baa9-3ca56d4935ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4e02a20d-ad48-4b0f-ad85-215a22b43e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_aa981ce8-d4c4-41d0-baa9-3ca56d4935ec" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4e02a20d-ad48-4b0f-ad85-215a22b43e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3122e4ea-bacf-47ad-92ad-3b27256a10ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_aa981ce8-d4c4-41d0-baa9-3ca56d4935ec" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3122e4ea-bacf-47ad-92ad-3b27256a10ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9176b9f8-c84b-47b2-9404-5430a418431c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_aa981ce8-d4c4-41d0-baa9-3ca56d4935ec" xlink:to="loc_us-gaap_OperatingExpenses_9176b9f8-c84b-47b2-9404-5430a418431c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e034a9dc-9321-4975-8587-ba35d0134ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_75d47ef8-6b1f-4e8f-8c8b-de74aeef3ea4" xlink:to="loc_us-gaap_OperatingIncomeLoss_e034a9dc-9321-4975-8587-ba35d0134ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_81a7948c-48ce-44ac-a3bf-9c65b1340968" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_75d47ef8-6b1f-4e8f-8c8b-de74aeef3ea4" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_81a7948c-48ce-44ac-a3bf-9c65b1340968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_1b1c7564-9969-4683-bb67-b91b31bd15c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_81a7948c-48ce-44ac-a3bf-9c65b1340968" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_1b1c7564-9969-4683-bb67-b91b31bd15c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_5ae41249-aa85-414e-a936-dcb027393ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_81a7948c-48ce-44ac-a3bf-9c65b1340968" xlink:to="loc_us-gaap_InterestExpense_5ae41249-aa85-414e-a936-dcb027393ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e3985299-a45e-411a-b95b-a611f8f0f27c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_81a7948c-48ce-44ac-a3bf-9c65b1340968" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e3985299-a45e-411a-b95b-a611f8f0f27c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b7e95fb5-642e-45a7-b6ac-d3a9e94b7a10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_81a7948c-48ce-44ac-a3bf-9c65b1340968" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_b7e95fb5-642e-45a7-b6ac-d3a9e94b7a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0a6d6326-ac4c-43d4-b7a5-a0500a851d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_75d47ef8-6b1f-4e8f-8c8b-de74aeef3ea4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0a6d6326-ac4c-43d4-b7a5-a0500a851d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e6e51989-802e-4a46-905a-6237ae4af859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_75d47ef8-6b1f-4e8f-8c8b-de74aeef3ea4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e6e51989-802e-4a46-905a-6237ae4af859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_14f11fcd-71c6-4f54-b284-eef0925749c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_75d47ef8-6b1f-4e8f-8c8b-de74aeef3ea4" xlink:to="loc_us-gaap_ProfitLoss_14f11fcd-71c6-4f54-b284-eef0925749c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8645ce18-535b-4344-9889-b568cb58d3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_75d47ef8-6b1f-4e8f-8c8b-de74aeef3ea4" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8645ce18-535b-4344-9889-b568cb58d3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ab5c898b-a745-49b6-82ac-1edcb70397a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_75d47ef8-6b1f-4e8f-8c8b-de74aeef3ea4" xlink:to="loc_us-gaap_NetIncomeLoss_ab5c898b-a745-49b6-82ac-1edcb70397a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_904f578f-c3f9-4599-b5ef-5a20794a3edc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_75d47ef8-6b1f-4e8f-8c8b-de74aeef3ea4" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_904f578f-c3f9-4599-b5ef-5a20794a3edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_19ceff28-d602-46ef-825c-72c9798e393e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_904f578f-c3f9-4599-b5ef-5a20794a3edc" xlink:to="loc_us-gaap_EarningsPerShareBasic_19ceff28-d602-46ef-825c-72c9798e393e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7d98f1ca-6d84-4cb9-a2da-0b6526f2f66a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_904f578f-c3f9-4599-b5ef-5a20794a3edc" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7d98f1ca-6d84-4cb9-a2da-0b6526f2f66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_852b1a35-85f1-460d-8598-455e268a21a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_75d47ef8-6b1f-4e8f-8c8b-de74aeef3ea4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_852b1a35-85f1-460d-8598-455e268a21a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f66b3ae9-bc0e-44f7-97b6-72d980ca012b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_852b1a35-85f1-460d-8598-455e268a21a1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f66b3ae9-bc0e-44f7-97b6-72d980ca012b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1a85ca19-5d48-425c-90e2-ff469d965d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_852b1a35-85f1-460d-8598-455e268a21a1" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1a85ca19-5d48-425c-90e2-ff469d965d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_84128f37-5f47-458e-b62e-941e5f95b070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_75d47ef8-6b1f-4e8f-8c8b-de74aeef3ea4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_84128f37-5f47-458e-b62e-941e5f95b070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_08fdd9b4-9de8-43f8-afab-48c1b6f8bbde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_84128f37-5f47-458e-b62e-941e5f95b070" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_08fdd9b4-9de8-43f8-afab-48c1b6f8bbde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7407ca59-98f4-4d96-bda9-ede60a7cd28d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_75d47ef8-6b1f-4e8f-8c8b-de74aeef3ea4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7407ca59-98f4-4d96-bda9-ede60a7cd28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="arwr-20230331.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_27892526-2d78-4118-a04a-f020d9e9bec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4c4f8e31-560a-4dc0-9a05-004f0b50971f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_27892526-2d78-4118-a04a-f020d9e9bec7" xlink:to="loc_us-gaap_StatementTable_4c4f8e31-560a-4dc0-9a05-004f0b50971f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9d15701a-6c50-4f0f-99c8-a19241865078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4c4f8e31-560a-4dc0-9a05-004f0b50971f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9d15701a-6c50-4f0f-99c8-a19241865078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_da0f5626-78f9-4145-8203-7599af579c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9d15701a-6c50-4f0f-99c8-a19241865078" xlink:to="loc_us-gaap_EquityComponentDomain_da0f5626-78f9-4145-8203-7599af579c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9bb7eec1-0c14-41bc-bf04-e16a29fb0993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_da0f5626-78f9-4145-8203-7599af579c0a" xlink:to="loc_us-gaap_CommonStockMember_9bb7eec1-0c14-41bc-bf04-e16a29fb0993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_627b6816-1817-4e51-b040-c42b989cd882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_da0f5626-78f9-4145-8203-7599af579c0a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_627b6816-1817-4e51-b040-c42b989cd882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_94dfa576-112d-4d99-8ee6-fc91b3d64da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_da0f5626-78f9-4145-8203-7599af579c0a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_94dfa576-112d-4d99-8ee6-fc91b3d64da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8087f33b-c4bb-4d5e-b45b-91ffb405fe98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_da0f5626-78f9-4145-8203-7599af579c0a" xlink:to="loc_us-gaap_RetainedEarningsMember_8087f33b-c4bb-4d5e-b45b-91ffb405fe98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_ea7844f3-e52a-41d3-b0e2-63101e261ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_da0f5626-78f9-4145-8203-7599af579c0a" xlink:to="loc_us-gaap_NoncontrollingInterestMember_ea7844f3-e52a-41d3-b0e2-63101e261ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9cd12166-0ec9-4685-a9a5-39eb9a1ba8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4c4f8e31-560a-4dc0-9a05-004f0b50971f" xlink:to="loc_us-gaap_StatementLineItems_9cd12166-0ec9-4685-a9a5-39eb9a1ba8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1c228f6f-1f40-4a27-a2de-a1d0c95bc985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9cd12166-0ec9-4685-a9a5-39eb9a1ba8bd" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1c228f6f-1f40-4a27-a2de-a1d0c95bc985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_63312f11-820e-4662-b5ea-cfcfb75604d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1c228f6f-1f40-4a27-a2de-a1d0c95bc985" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_63312f11-820e-4662-b5ea-cfcfb75604d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e3a7edbc-0c55-440d-9229-6737c7d843a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1c228f6f-1f40-4a27-a2de-a1d0c95bc985" xlink:to="loc_us-gaap_SharesOutstanding_e3a7edbc-0c55-440d-9229-6737c7d843a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_39520180-1c20-43e0-81b7-bae3417d7f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1c228f6f-1f40-4a27-a2de-a1d0c95bc985" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_39520180-1c20-43e0-81b7-bae3417d7f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d3666d5e-8e40-4cff-b40e-84fb77f8d687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1c228f6f-1f40-4a27-a2de-a1d0c95bc985" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d3666d5e-8e40-4cff-b40e-84fb77f8d687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ac6fc31f-eece-4bb4-a17a-cd3d27c5d6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1c228f6f-1f40-4a27-a2de-a1d0c95bc985" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ac6fc31f-eece-4bb4-a17a-cd3d27c5d6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_59a95683-973c-4dc6-a3d8-1717fd054dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1c228f6f-1f40-4a27-a2de-a1d0c95bc985" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_59a95683-973c-4dc6-a3d8-1717fd054dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_9b4dad9b-c09d-453e-a445-9ac5598ca439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1c228f6f-1f40-4a27-a2de-a1d0c95bc985" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_9b4dad9b-c09d-453e-a445-9ac5598ca439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6ece975d-317c-403d-9b6f-ddf75780aa88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1c228f6f-1f40-4a27-a2de-a1d0c95bc985" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6ece975d-317c-403d-9b6f-ddf75780aa88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_b64f9689-f814-4fc0-b6ea-ecec759f33e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1c228f6f-1f40-4a27-a2de-a1d0c95bc985" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_b64f9689-f814-4fc0-b6ea-ecec759f33e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fd4560b4-49d5-4646-891c-5bff50becb51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1c228f6f-1f40-4a27-a2de-a1d0c95bc985" xlink:to="loc_us-gaap_NetIncomeLoss_fd4560b4-49d5-4646-891c-5bff50becb51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dabb34f5-d472-41c3-b099-6aac61538b40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1c228f6f-1f40-4a27-a2de-a1d0c95bc985" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dabb34f5-d472-41c3-b099-6aac61538b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_0aad99b5-1e2d-4da4-b10c-407b72b59894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1c228f6f-1f40-4a27-a2de-a1d0c95bc985" xlink:to="loc_us-gaap_SharesOutstanding_0aad99b5-1e2d-4da4-b10c-407b72b59894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="arwr-20230331.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_dd90ee82-d034-41bd-bd1a-dba4403063bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_49e6febf-2b80-4af5-b46b-19f964135d26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dd90ee82-d034-41bd-bd1a-dba4403063bf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_49e6febf-2b80-4af5-b46b-19f964135d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b0e2a266-6bbb-4364-82b0-2d02ad77577b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_49e6febf-2b80-4af5-b46b-19f964135d26" xlink:to="loc_us-gaap_ProfitLoss_b0e2a266-6bbb-4364-82b0-2d02ad77577b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0fd3bebe-9427-401a-a574-66af8b68adf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_49e6febf-2b80-4af5-b46b-19f964135d26" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0fd3bebe-9427-401a-a574-66af8b68adf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9ebb0e73-38fd-42ec-a4e9-7e5a155b9be5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_49e6febf-2b80-4af5-b46b-19f964135d26" xlink:to="loc_us-gaap_ShareBasedCompensation_9ebb0e73-38fd-42ec-a4e9-7e5a155b9be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_cd63b178-f2a8-41ea-b1e7-0cb1684863c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_49e6febf-2b80-4af5-b46b-19f964135d26" xlink:to="loc_us-gaap_DepreciationAndAmortization_cd63b178-f2a8-41ea-b1e7-0cb1684863c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_2af57a31-5903-4496-9343-31a7b2d860f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_49e6febf-2b80-4af5-b46b-19f964135d26" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_2af57a31-5903-4496-9343-31a7b2d860f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_bb275592-c3eb-4d1b-bdbc-18d4e12166fa" xlink:href="arwr-20230331.xsd#arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_49e6febf-2b80-4af5-b46b-19f964135d26" xlink:to="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_bb275592-c3eb-4d1b-bdbc-18d4e12166fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a1983b9e-2ef0-4ef7-8e5d-67194f4acb14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_49e6febf-2b80-4af5-b46b-19f964135d26" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a1983b9e-2ef0-4ef7-8e5d-67194f4acb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f7552998-60d4-40a6-ba53-a416291a6f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a1983b9e-2ef0-4ef7-8e5d-67194f4acb14" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f7552998-60d4-40a6-ba53-a416291a6f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1f6ad650-7c61-4f50-9d13-0b52b78466b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a1983b9e-2ef0-4ef7-8e5d-67194f4acb14" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1f6ad650-7c61-4f50-9d13-0b52b78466b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5bc6db2d-90e0-4758-9fed-afaeacac3316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a1983b9e-2ef0-4ef7-8e5d-67194f4acb14" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5bc6db2d-90e0-4758-9fed-afaeacac3316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a6fb9707-0402-4713-bb39-0b990731c41c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a1983b9e-2ef0-4ef7-8e5d-67194f4acb14" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a6fb9707-0402-4713-bb39-0b990731c41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_24f5f316-e1e7-48c0-b8df-66f4e27b7e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a1983b9e-2ef0-4ef7-8e5d-67194f4acb14" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_24f5f316-e1e7-48c0-b8df-66f4e27b7e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_009b5bdb-0485-45a5-becd-0248df99e76e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a1983b9e-2ef0-4ef7-8e5d-67194f4acb14" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_009b5bdb-0485-45a5-becd-0248df99e76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_76a8e819-4cca-45b9-b87f-9fb698f5f29f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_49e6febf-2b80-4af5-b46b-19f964135d26" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_76a8e819-4cca-45b9-b87f-9fb698f5f29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c46365a8-0b46-43ee-8b94-cfccc4cdeb2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dd90ee82-d034-41bd-bd1a-dba4403063bf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c46365a8-0b46-43ee-8b94-cfccc4cdeb2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0e3cb2b2-ce7d-4feb-b22d-74f17237db74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c46365a8-0b46-43ee-8b94-cfccc4cdeb2c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0e3cb2b2-ce7d-4feb-b22d-74f17237db74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_2c6b27df-d86c-423d-9c6a-ab11badd9b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c46365a8-0b46-43ee-8b94-cfccc4cdeb2c" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_2c6b27df-d86c-423d-9c6a-ab11badd9b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_3b3fd164-1cbb-4938-b2ef-8f90bb9af148" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c46365a8-0b46-43ee-8b94-cfccc4cdeb2c" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_3b3fd164-1cbb-4938-b2ef-8f90bb9af148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f9cba8b6-0793-4eeb-9d87-1268cf697d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c46365a8-0b46-43ee-8b94-cfccc4cdeb2c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f9cba8b6-0793-4eeb-9d87-1268cf697d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d9e4eb50-513f-45e7-af4f-08489fdc097e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dd90ee82-d034-41bd-bd1a-dba4403063bf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d9e4eb50-513f-45e7-af4f-08489fdc097e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6e8640ac-be7c-4d18-9468-3ec8745e4176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d9e4eb50-513f-45e7-af4f-08489fdc097e" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_6e8640ac-be7c-4d18-9468-3ec8745e4176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributedCapital_16775a04-44f8-4b13-9f6b-591368ae9a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d9e4eb50-513f-45e7-af4f-08489fdc097e" xlink:to="loc_us-gaap_ProceedsFromContributedCapital_16775a04-44f8-4b13-9f6b-591368ae9a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fe56921a-3609-4016-95de-c2f6be7ad2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d9e4eb50-513f-45e7-af4f-08489fdc097e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fe56921a-3609-4016-95de-c2f6be7ad2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_232bdeaf-58c5-46e7-8ecd-fae14f7b2a86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dd90ee82-d034-41bd-bd1a-dba4403063bf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_232bdeaf-58c5-46e7-8ecd-fae14f7b2a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e0c83486-58e4-4c05-ab6f-56d012ea4c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dd90ee82-d034-41bd-bd1a-dba4403063bf" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e0c83486-58e4-4c05-ab6f-56d012ea4c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_450e8c7e-b26e-46b8-a9ce-804dff7f0005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dd90ee82-d034-41bd-bd1a-dba4403063bf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_450e8c7e-b26e-46b8-a9ce-804dff7f0005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_085948ef-dbcd-4eb3-9333-2067a6d3e081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_450e8c7e-b26e-46b8-a9ce-804dff7f0005" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_085948ef-dbcd-4eb3-9333-2067a6d3e081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_a8c10dff-a698-4ff1-b01d-691890d46e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_450e8c7e-b26e-46b8-a9ce-804dff7f0005" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_a8c10dff-a698-4ff1-b01d-691890d46e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6ebfb656-e4b0-4350-b6e6-03e14f9d1481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dd90ee82-d034-41bd-bd1a-dba4403063bf" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_6ebfb656-e4b0-4350-b6e6-03e14f9d1481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_82c7840b-37fd-43b8-b9e1-75b4eae32538" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6ebfb656-e4b0-4350-b6e6-03e14f9d1481" xlink:to="loc_us-gaap_InterestPaidNet_82c7840b-37fd-43b8-b9e1-75b4eae32538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_1c6f763c-69b5-4811-96cf-5725c9b3134b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6ebfb656-e4b0-4350-b6e6-03e14f9d1481" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_1c6f763c-69b5-4811-96cf-5725c9b3134b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="arwr-20230331.xsd#OrganizationandSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cc92227b-f0cf-4b20-b17a-0862e004ca6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_889ab44f-0011-497d-9f7a-03a45f398684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cc92227b-f0cf-4b20-b17a-0862e004ca6f" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_889ab44f-0011-497d-9f7a-03a45f398684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="arwr-20230331.xsd#CollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_98d5a112-5155-4180-bb7d-721ff983a5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_395e49ae-cf5a-495f-b634-f73fe59ca47f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_98d5a112-5155-4180-bb7d-721ff983a5e2" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_395e49ae-cf5a-495f-b634-f73fe59ca47f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="arwr-20230331.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_43c5c8c2-e666-4294-b61d-689d7d44a9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_dbb6d68a-e8ea-42c5-affb-3815b1bf0987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_43c5c8c2-e666-4294-b61d-689d7d44a9ca" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_dbb6d68a-e8ea-42c5-affb-3815b1bf0987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/Investments" xlink:type="simple" xlink:href="arwr-20230331.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3639fdab-b664-4b5c-87cc-669781dee96f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_20e531da-9848-41b7-bed0-2bf1d2fa79e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3639fdab-b664-4b5c-87cc-669781dee96f" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_20e531da-9848-41b7-bed0-2bf1d2fa79e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssets" xlink:type="simple" xlink:href="arwr-20230331.xsd#IntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e7ce8e28-d301-40b2-a649-bbf0335ad9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_95d36414-2fb1-482b-ba5e-94d39688a09d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e7ce8e28-d301-40b2-a649-bbf0335ad9a6" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_95d36414-2fb1-482b-ba5e-94d39688a09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquity" xlink:type="simple" xlink:href="arwr-20230331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_160e3330-8813-4821-af05-41490ed960f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_45fb97dc-9055-4ce6-957b-1f8388ba564f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_160e3330-8813-4821-af05-41490ed960f6" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_45fb97dc-9055-4ce6-957b-1f8388ba564f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="arwr-20230331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1e96b537-81ab-403a-8041-092f8db73502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_54ee2446-03df-45cd-9c97-36f16cb7768c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1e96b537-81ab-403a-8041-092f8db73502" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_54ee2446-03df-45cd-9c97-36f16cb7768c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/Leases" xlink:type="simple" xlink:href="arwr-20230331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3f9c506a-8403-4841-94a6-8afa057913c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_d10eb863-0e89-4bc2-ae95-d16c763fdba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3f9c506a-8403-4841-94a6-8afa057913c1" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_d10eb863-0e89-4bc2-ae95-d16c763fdba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="arwr-20230331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7d090fb2-f482-48f3-9fc6-b925c22efce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_174563c0-d972-4ff2-a35d-cd3fe7ad96d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7d090fb2-f482-48f3-9fc6-b925c22efce8" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_174563c0-d972-4ff2-a35d-cd3fe7ad96d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="arwr-20230331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_011622fe-4c25-4ffd-a574-6fb8b61034fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_27feaa01-f9e3-4850-a3c1-45e38d1a592f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_011622fe-4c25-4ffd-a574-6fb8b61034fc" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_27feaa01-f9e3-4850-a3c1-45e38d1a592f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties" xlink:type="simple" xlink:href="arwr-20230331.xsd#LiabilityRelatedtotheSaleofFutureRoyalties"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_0c211eb3-4daf-4fcc-bedb-c681e55af33f" xlink:href="arwr-20230331.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_471a1034-f130-4708-aa3d-a2759473fa36" xlink:href="arwr-20230331.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_0c211eb3-4daf-4fcc-bedb-c681e55af33f" xlink:to="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_471a1034-f130-4708-aa3d-a2759473fa36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/EarningsPerShare" xlink:type="simple" xlink:href="arwr-20230331.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_27ee7af0-21a0-456c-a5c8-32a48a346fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_e6768935-981a-4393-8449-b2a514fc18c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_27ee7af0-21a0-456c-a5c8-32a48a346fa8" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_e6768935-981a-4393-8449-b2a514fc18c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="arwr-20230331.xsd#OrganizationandSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3dfe3c7b-fbfd-4882-a81e-dfc06da1e265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_97125857-bcf5-4da1-9f1f-a31d80ab67d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3dfe3c7b-fbfd-4882-a81e-dfc06da1e265" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_97125857-bcf5-4da1-9f1f-a31d80ab67d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="arwr-20230331.xsd#OrganizationandSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d1aa5eb3-6911-4a6d-aefc-7e31156d2c44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfCurrentProductsTableTextBlock_1657db91-ff51-4c1d-b60b-b7ccfd5ef545" xlink:href="arwr-20230331.xsd#arwr_ScheduleOfCurrentProductsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d1aa5eb3-6911-4a6d-aefc-7e31156d2c44" xlink:to="loc_arwr_ScheduleOfCurrentProductsTableTextBlock_1657db91-ff51-4c1d-b60b-b7ccfd5ef545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables" xlink:type="simple" xlink:href="arwr-20230331.xsd#CollaborationandLicenseAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a5db6bf6-91b4-4dbe-80f9-e638a018bb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_bdcf57b4-74bb-44cd-89fd-53261544d3c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a5db6bf6-91b4-4dbe-80f9-e638a018bb2f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_bdcf57b4-74bb-44cd-89fd-53261544d3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_194f66ce-a6d3-46d7-8fd6-aad2f9ff4cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a5db6bf6-91b4-4dbe-80f9-e638a018bb2f" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_194f66ce-a6d3-46d7-8fd6-aad2f9ff4cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="arwr-20230331.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_115729ea-f65e-42ec-ae63-4791ec02f23f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_29e73cfb-2a88-4da2-82a9-af6e149ff931" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_115729ea-f65e-42ec-ae63-4791ec02f23f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_29e73cfb-2a88-4da2-82a9-af6e149ff931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsTables" xlink:type="simple" xlink:href="arwr-20230331.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_41871cdd-d1d8-46b8-8970-8c1f69cc98cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_4d14878b-864c-4c41-b23c-b05f8d7fea93" xlink:href="arwr-20230331.xsd#arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_41871cdd-d1d8-46b8-8970-8c1f69cc98cc" xlink:to="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_4d14878b-864c-4c41-b23c-b05f8d7fea93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="arwr-20230331.xsd#IntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8667286b-5cf1-496f-9c48-33d8b2474973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_d1f96ee1-6cf4-4af4-b34f-3cb39ae78613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8667286b-5cf1-496f-9c48-33d8b2474973" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_d1f96ee1-6cf4-4af4-b34f-3cb39ae78613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_ef11939a-859f-42be-a8e6-7b3d14c439b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8667286b-5cf1-496f-9c48-33d8b2474973" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_ef11939a-859f-42be-a8e6-7b3d14c439b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="arwr-20230331.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4e667291-76d9-43a6-a374-159a5381fef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_ca82290f-1fdc-447e-9c53-d84df815dafd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4e667291-76d9-43a6-a374-159a5381fef3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_ca82290f-1fdc-447e-9c53-d84df815dafd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesTables" xlink:type="simple" xlink:href="arwr-20230331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1081b53d-ebb1-4429-84c8-38f49baf8624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_4f43b46a-23f7-4b84-bd43-27bcfe4b9700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1081b53d-ebb1-4429-84c8-38f49baf8624" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_4f43b46a-23f7-4b84-bd43-27bcfe4b9700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7d1515c0-7c7e-48e3-9388-7e7ae31829de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1081b53d-ebb1-4429-84c8-38f49baf8624" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7d1515c0-7c7e-48e3-9388-7e7ae31829de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="arwr-20230331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_04ca87c9-b9d8-4569-a931-e1a513de13cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_c548dd07-cb91-4332-8f52-af1c8f06b1df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_04ca87c9-b9d8-4569-a931-e1a513de13cc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_c548dd07-cb91-4332-8f52-af1c8f06b1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e57c181f-0ce0-4008-9475-8136d6ca809e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_04ca87c9-b9d8-4569-a931-e1a513de13cc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e57c181f-0ce0-4008-9475-8136d6ca809e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3e10ea13-a86e-4061-b9a2-e345309ccabe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_04ca87c9-b9d8-4569-a931-e1a513de13cc" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3e10ea13-a86e-4061-b9a2-e345309ccabe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_9dec8616-983f-42ba-bbff-f55e4fe49e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_04ca87c9-b9d8-4569-a931-e1a513de13cc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_9dec8616-983f-42ba-bbff-f55e4fe49e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="arwr-20230331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b20c531b-c159-4a66-b5b3-71bfab3cd381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ed9dc201-a99c-4033-bc87-c5abf441a1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b20c531b-c159-4a66-b5b3-71bfab3cd381" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ed9dc201-a99c-4033-bc87-c5abf441a1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="arwr-20230331.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9a053a07-38f8-41ee-b4c6-ee6523a9427c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8765de55-f857-4c29-9205-3fcb5a4d215c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9a053a07-38f8-41ee-b4c6-ee6523a9427c" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8765de55-f857-4c29-9205-3fcb5a4d215c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20230331.xsd#OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7a04733a-6bdb-4eaa-8231-2194ac69ac50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_34cce2f8-3087-4702-9f06-5ac2121a9f6f" xlink:href="arwr-20230331.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a04733a-6bdb-4eaa-8231-2194ac69ac50" xlink:to="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_34cce2f8-3087-4702-9f06-5ac2121a9f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_093b2e4e-0a37-4777-8d63-8950e70c9786" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_34cce2f8-3087-4702-9f06-5ac2121a9f6f" xlink:to="loc_dei_LegalEntityAxis_093b2e4e-0a37-4777-8d63-8950e70c9786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e5115929-e00d-4d89-8b1c-5ce8a483420b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_093b2e4e-0a37-4777-8d63-8950e70c9786" xlink:to="loc_dei_EntityDomain_e5115929-e00d-4d89-8b1c-5ce8a483420b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_eb97869e-f1c2-4be1-aafa-efd72cb1c54c" xlink:href="arwr-20230331.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e5115929-e00d-4d89-8b1c-5ce8a483420b" xlink:to="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_eb97869e-f1c2-4be1-aafa-efd72cb1c54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_aa4ceda6-ec5f-4296-8665-bc88ff12c84e" xlink:href="arwr-20230331.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e5115929-e00d-4d89-8b1c-5ce8a483420b" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_aa4ceda6-ec5f-4296-8665-bc88ff12c84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember_731f8b35-b3b5-4840-bb10-627baf4754ea" xlink:href="arwr-20230331.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e5115929-e00d-4d89-8b1c-5ce8a483420b" xlink:to="loc_arwr_HorizonTherapeuticsIrelandDACMember_731f8b35-b3b5-4840-bb10-627baf4754ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_c2f908f2-e982-453f-9b57-a1b926317031" xlink:href="arwr-20230331.xsd#arwr_AmgenIncorporatedMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e5115929-e00d-4d89-8b1c-5ce8a483420b" xlink:to="loc_arwr_AmgenIncorporatedMember_c2f908f2-e982-453f-9b57-a1b926317031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaMember_8dd39447-04ff-461e-be20-34ea279a34d0" xlink:href="arwr-20230331.xsd#arwr_RoyaltyPharmaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e5115929-e00d-4d89-8b1c-5ce8a483420b" xlink:to="loc_arwr_RoyaltyPharmaMember_8dd39447-04ff-461e-be20-34ea279a34d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d784a8af-ade3-4b5c-b2ef-af14c60099e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_34cce2f8-3087-4702-9f06-5ac2121a9f6f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d784a8af-ade3-4b5c-b2ef-af14c60099e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9f011189-eb3b-49ba-be7e-93a0216d5884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d784a8af-ade3-4b5c-b2ef-af14c60099e6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9f011189-eb3b-49ba-be7e-93a0216d5884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAndCoFundingAgreementMember_35be3269-621f-429e-ace2-c61375da17f2" xlink:href="arwr-20230331.xsd#arwr_LicenseAndCoFundingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9f011189-eb3b-49ba-be7e-93a0216d5884" xlink:to="loc_arwr_LicenseAndCoFundingAgreementMember_35be3269-621f-429e-ace2-c61375da17f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember_07527625-b2b0-4e36-b1d9-c8a0b1a00df6" xlink:href="arwr-20230331.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9f011189-eb3b-49ba-be7e-93a0216d5884" xlink:to="loc_arwr_CollaborationAndLicenseAgreementMember_07527625-b2b0-4e36-b1d9-c8a0b1a00df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_12e9287c-a407-414f-a92a-403142d036bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_34cce2f8-3087-4702-9f06-5ac2121a9f6f" xlink:to="loc_srt_CounterpartyNameAxis_12e9287c-a407-414f-a92a-403142d036bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eed77e24-c783-49f2-8a1a-73a1afc3cc50" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_12e9287c-a407-414f-a92a-403142d036bf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eed77e24-c783-49f2-8a1a-73a1afc3cc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACAndAmgenIncorporatedMember_82082681-27b9-48b3-8881-030df40d1d54" xlink:href="arwr-20230331.xsd#arwr_HorizonTherapeuticsIrelandDACAndAmgenIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eed77e24-c783-49f2-8a1a-73a1afc3cc50" xlink:to="loc_arwr_HorizonTherapeuticsIrelandDACAndAmgenIncorporatedMember_82082681-27b9-48b3-8881-030df40d1d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_cc35bf60-4d51-4baf-b6e5-9424d9965041" xlink:href="arwr-20230331.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_34cce2f8-3087-4702-9f06-5ac2121a9f6f" xlink:to="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_cc35bf60-4d51-4baf-b6e5-9424d9965041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable_76b5001a-99f1-4ee2-a0dd-245b5833c516" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_cc35bf60-4d51-4baf-b6e5-9424d9965041" xlink:to="loc_arwr_MilestonePaymentReceivable_76b5001a-99f1-4ee2-a0dd-245b5833c516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontMilestonePaymentReceived_7abec897-6177-457c-8dff-72e005706563" xlink:href="arwr-20230331.xsd#arwr_UpfrontMilestonePaymentReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_cc35bf60-4d51-4baf-b6e5-9424d9965041" xlink:to="loc_arwr_UpfrontMilestonePaymentReceived_7abec897-6177-457c-8dff-72e005706563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_93161085-5cbf-47c6-a8df-142e4eea1eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_cc35bf60-4d51-4baf-b6e5-9424d9965041" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_93161085-5cbf-47c6-a8df-142e4eea1eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ee0f97e5-5417-42ef-8669-febc48848f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_cc35bf60-4d51-4baf-b6e5-9424d9965041" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ee0f97e5-5417-42ef-8669-febc48848f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_059ace03-b20e-4e67-bd4d-2fa7437ccc85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_cc35bf60-4d51-4baf-b6e5-9424d9965041" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_059ace03-b20e-4e67-bd4d-2fa7437ccc85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_7196184b-fb5c-4d7b-9c9f-116e0e0f8e13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_cc35bf60-4d51-4baf-b6e5-9424d9965041" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_7196184b-fb5c-4d7b-9c9f-116e0e0f8e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_IncreaseDecreaseInCashAndInvestments_17782ce7-1863-42f1-81e5-773941356b91" xlink:href="arwr-20230331.xsd#arwr_IncreaseDecreaseInCashAndInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_cc35bf60-4d51-4baf-b6e5-9424d9965041" xlink:to="loc_arwr_IncreaseDecreaseInCashAndInvestments_17782ce7-1863-42f1-81e5-773941356b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_484f585a-d4d9-459f-b6a5-370be0d99bb1" xlink:href="arwr-20230331.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_cc35bf60-4d51-4baf-b6e5-9424d9965041" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_484f585a-d4d9-459f-b6a5-370be0d99bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#CollaborationandLicenseAgreementsRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6eb56c7d-3227-45ae-9b1f-7ebc3f522f75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ba2db5bc-11d3-4844-a87e-370fcd7f5d30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6eb56c7d-3227-45ae-9b1f-7ebc3f522f75" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ba2db5bc-11d3-4844-a87e-370fcd7f5d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_4bb0f3b7-eaee-4899-9930-a9355e83c60d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ba2db5bc-11d3-4844-a87e-370fcd7f5d30" xlink:to="loc_srt_MajorCustomersAxis_4bb0f3b7-eaee-4899-9930-a9355e83c60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_54d6f77a-de9a-4597-b3c6-ab4efe9770de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_4bb0f3b7-eaee-4899-9930-a9355e83c60d" xlink:to="loc_srt_NameOfMajorCustomerDomain_54d6f77a-de9a-4597-b3c6-ab4efe9770de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_9d992e09-a359-4f9b-bc78-28306c090bc0" xlink:href="arwr-20230331.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_54d6f77a-de9a-4597-b3c6-ab4efe9770de" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_9d992e09-a359-4f9b-bc78-28306c090bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember_a786b49a-10d8-4f63-b14b-8508b6a345f9" xlink:href="arwr-20230331.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_54d6f77a-de9a-4597-b3c6-ab4efe9770de" xlink:to="loc_arwr_HorizonTherapeuticsIrelandDACMember_a786b49a-10d8-4f63-b14b-8508b6a345f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_1471c791-82a7-49a3-8412-49649c647f80" xlink:href="arwr-20230331.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_54d6f77a-de9a-4597-b3c6-ab4efe9770de" xlink:to="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_1471c791-82a7-49a3-8412-49649c647f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember_7ff7528b-e35a-408f-a358-c708c3dd0403" xlink:href="arwr-20230331.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_54d6f77a-de9a-4597-b3c6-ab4efe9770de" xlink:to="loc_arwr_JanssenPharmaceuticalsIncorporationMember_7ff7528b-e35a-408f-a358-c708c3dd0403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_31c8e67e-0a78-4b93-b627-f1fb64ab8304" xlink:href="arwr-20230331.xsd#arwr_AmgenIncorporatedMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_54d6f77a-de9a-4597-b3c6-ab4efe9770de" xlink:to="loc_arwr_AmgenIncorporatedMember_31c8e67e-0a78-4b93-b627-f1fb64ab8304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5f01b559-0161-40cf-acbe-a2810bf706fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ba2db5bc-11d3-4844-a87e-370fcd7f5d30" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_5f01b559-0161-40cf-acbe-a2810bf706fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_31870e48-210d-4fc2-8933-da6d98599da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5f01b559-0161-40cf-acbe-a2810bf706fd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_31870e48-210d-4fc2-8933-da6d98599da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad56e872-9950-464e-b64f-2dd3d5d85d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_f50f6782-676d-4d98-8029-225f0ab560f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad56e872-9950-464e-b64f-2dd3d5d85d5d" xlink:to="loc_us-gaap_AccountsReceivableNet_f50f6782-676d-4d98-8029-225f0ab560f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_b843bbac-a642-428b-8f10-c7e752bed05b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad56e872-9950-464e-b64f-2dd3d5d85d5d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_b843bbac-a642-428b-8f10-c7e752bed05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_abcd39ba-935e-4a82-b3ab-b7e06aadf55b" xlink:href="arwr-20230331.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fc80252f-098b-4fb5-891a-91eb625c4758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_abcd39ba-935e-4a82-b3ab-b7e06aadf55b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fc80252f-098b-4fb5-891a-91eb625c4758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c112f6e0-8a22-48be-ae50-2d8dbaf9a39d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fc80252f-098b-4fb5-891a-91eb625c4758" xlink:to="loc_dei_LegalEntityAxis_c112f6e0-8a22-48be-ae50-2d8dbaf9a39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9a774c8e-8cde-4f29-ac53-7d752db3d053" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_c112f6e0-8a22-48be-ae50-2d8dbaf9a39d" xlink:to="loc_dei_EntityDomain_9a774c8e-8cde-4f29-ac53-7d752db3d053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_03f6d08e-38ff-4a1a-9f37-17caa6fd8562" xlink:href="arwr-20230331.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9a774c8e-8cde-4f29-ac53-7d752db3d053" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_03f6d08e-38ff-4a1a-9f37-17caa6fd8562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4da9d7eb-d804-4904-a91d-f285a14642d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fc80252f-098b-4fb5-891a-91eb625c4758" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4da9d7eb-d804-4904-a91d-f285a14642d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b64fad99-9823-469e-9173-9a354ab89690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4da9d7eb-d804-4904-a91d-f285a14642d6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b64fad99-9823-469e-9173-9a354ab89690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember_a7151d6b-19c4-415e-848e-312f8a8c5050" xlink:href="arwr-20230331.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b64fad99-9823-469e-9173-9a354ab89690" xlink:to="loc_arwr_CollaborationAndLicenseAgreementMember_a7151d6b-19c4-415e-848e-312f8a8c5050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_64f24a0b-a6ad-43ed-ad89-e1a0f9c6ddc8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fc80252f-098b-4fb5-891a-91eb625c4758" xlink:to="loc_srt_RangeAxis_64f24a0b-a6ad-43ed-ad89-e1a0f9c6ddc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d43e830a-9b97-40e0-90ef-e5596d3121bb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_64f24a0b-a6ad-43ed-ad89-e1a0f9c6ddc8" xlink:to="loc_srt_RangeMember_d43e830a-9b97-40e0-90ef-e5596d3121bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f4e85206-1e47-4be4-b7a7-6cbcef819cbe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d43e830a-9b97-40e0-90ef-e5596d3121bb" xlink:to="loc_srt_MaximumMember_f4e85206-1e47-4be4-b7a7-6cbcef819cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3de9cc84-dc6d-4bfd-9881-a159efe005f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fc80252f-098b-4fb5-891a-91eb625c4758" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3de9cc84-dc6d-4bfd-9881-a159efe005f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_64bd2d58-a703-41a7-888f-0498a1ae987e" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentEarned"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3de9cc84-dc6d-4bfd-9881-a159efe005f2" xlink:to="loc_arwr_MilestonePaymentEarned_64bd2d58-a703-41a7-888f-0498a1ae987e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_8efeb35a-a73d-4f0f-ad4f-4b8ec79b0b3d" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentReceivableAtStartOfPhaseTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3de9cc84-dc6d-4bfd-9881-a159efe005f2" xlink:to="loc_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_8efeb35a-a73d-4f0f-ad4f-4b8ec79b0b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_4763c562-fbbc-4696-8670-124b622364a2" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3de9cc84-dc6d-4bfd-9881-a159efe005f2" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_4763c562-fbbc-4696-8670-124b622364a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_3b2aa193-70bf-483a-9ceb-b5757d7b9543" xlink:href="arwr-20230331.xsd#arwr_CommercialMilestonePaymentsAtFirstCommercialSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3de9cc84-dc6d-4bfd-9881-a159efe005f2" xlink:to="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_3b2aa193-70bf-483a-9ceb-b5757d7b9543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments_15a9fc00-c49a-49dd-b3e5-bd3e02442c44" xlink:href="arwr-20230331.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3de9cc84-dc6d-4bfd-9881-a159efe005f2" xlink:to="loc_arwr_SalesRelatedMilestonePayments_15a9fc00-c49a-49dd-b3e5-bd3e02442c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_0b965cb5-635b-45e4-ac1f-19bcacef3690" xlink:href="arwr-20230331.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3de9cc84-dc6d-4bfd-9881-a159efe005f2" xlink:to="loc_arwr_InitialTransactionPrice_0b965cb5-635b-45e4-ac1f-19bcacef3690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable_21650332-1936-472c-9562-837e2209bcb7" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3de9cc84-dc6d-4bfd-9881-a159efe005f2" xlink:to="loc_arwr_MilestonePaymentReceivable_21650332-1936-472c-9562-837e2209bcb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_7e148b97-43ff-4311-a4c1-8538c78b7a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3de9cc84-dc6d-4bfd-9881-a159efe005f2" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_7e148b97-43ff-4311-a4c1-8538c78b7a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cd8d130a-441f-4f0d-9bb7-44fe4d41b137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3de9cc84-dc6d-4bfd-9881-a159efe005f2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cd8d130a-441f-4f0d-9bb7-44fe4d41b137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_16b4adaf-4b9d-4b68-ac16-5422e4ce1fac" xlink:href="arwr-20230331.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc5014ee-de42-4b44-af9c-d033c4338e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_16b4adaf-4b9d-4b68-ac16-5422e4ce1fac" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc5014ee-de42-4b44-af9c-d033c4338e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_bedf5f95-2f1d-4add-a919-e886f60d3deb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc5014ee-de42-4b44-af9c-d033c4338e45" xlink:to="loc_dei_LegalEntityAxis_bedf5f95-2f1d-4add-a919-e886f60d3deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2d15fa1b-2a24-40b7-aba7-d1c7d80b4b7a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_bedf5f95-2f1d-4add-a919-e886f60d3deb" xlink:to="loc_dei_EntityDomain_2d15fa1b-2a24-40b7-aba7-d1c7d80b4b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember_5f9cfcf1-839d-42ba-ac53-ca2c09d5bc4e" xlink:href="arwr-20230331.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2d15fa1b-2a24-40b7-aba7-d1c7d80b4b7a" xlink:to="loc_arwr_HorizonTherapeuticsIrelandDACMember_5f9cfcf1-839d-42ba-ac53-ca2c09d5bc4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d3c43916-48ae-4480-b995-db41f78da932" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc5014ee-de42-4b44-af9c-d033c4338e45" xlink:to="loc_srt_RangeAxis_d3c43916-48ae-4480-b995-db41f78da932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8246b7ec-4cff-47af-ab33-6cbae9356bfb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d3c43916-48ae-4480-b995-db41f78da932" xlink:to="loc_srt_RangeMember_8246b7ec-4cff-47af-ab33-6cbae9356bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5b27cb67-3a0e-4cd2-9719-0f045edd15fc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8246b7ec-4cff-47af-ab33-6cbae9356bfb" xlink:to="loc_srt_MaximumMember_5b27cb67-3a0e-4cd2-9719-0f045edd15fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_348db157-83cf-466b-b7b3-630ee59612f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc5014ee-de42-4b44-af9c-d033c4338e45" xlink:to="loc_us-gaap_TypeOfArrangementAxis_348db157-83cf-466b-b7b3-630ee59612f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a72b424b-76af-41e4-824b-a545e5119c94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_348db157-83cf-466b-b7b3-630ee59612f8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a72b424b-76af-41e4-824b-a545e5119c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROXDHAgreementMember_cab3a597-e6bc-4a90-9ff4-e7e79da481dc" xlink:href="arwr-20230331.xsd#arwr_AROXDHAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a72b424b-76af-41e4-824b-a545e5119c94" xlink:to="loc_arwr_AROXDHAgreementMember_cab3a597-e6bc-4a90-9ff4-e7e79da481dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAgreementMember_06992aed-0c4a-4cf0-a40e-36cbacd4736f" xlink:href="arwr-20230331.xsd#arwr_LicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a72b424b-76af-41e4-824b-a545e5119c94" xlink:to="loc_arwr_LicenseAgreementMember_06992aed-0c4a-4cf0-a40e-36cbacd4736f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54267d7-65c0-4def-aa3c-213c4f1ce84b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc5014ee-de42-4b44-af9c-d033c4338e45" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54267d7-65c0-4def-aa3c-213c4f1ce84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_e98c2acc-fa33-4cc8-acbe-0267853a1bc3" xlink:href="arwr-20230331.xsd#arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54267d7-65c0-4def-aa3c-213c4f1ce84b" xlink:to="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_e98c2acc-fa33-4cc8-acbe-0267853a1bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_a1c3cda5-3318-48c1-b75c-c9fac36b07ae" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentEarned"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54267d7-65c0-4def-aa3c-213c4f1ce84b" xlink:to="loc_arwr_MilestonePaymentEarned_a1c3cda5-3318-48c1-b75c-c9fac36b07ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_c03dd5cc-ed29-489f-85bb-7c81d85a0b58" xlink:href="arwr-20230331.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54267d7-65c0-4def-aa3c-213c4f1ce84b" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_c03dd5cc-ed29-489f-85bb-7c81d85a0b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_80fdb939-8708-4cfc-aa0b-0c1c74663f74" xlink:href="arwr-20230331.xsd#arwr_NumberOfDistinctBundle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54267d7-65c0-4def-aa3c-213c4f1ce84b" xlink:to="loc_arwr_NumberOfDistinctBundle_80fdb939-8708-4cfc-aa0b-0c1c74663f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_68d1d117-422d-441d-a0fa-f1274e4d4664" xlink:href="arwr-20230331.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54267d7-65c0-4def-aa3c-213c4f1ce84b" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_68d1d117-422d-441d-a0fa-f1274e4d4664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_89044abd-638e-46d6-b8f2-f0b2e8d59ae7" xlink:href="arwr-20230331.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54267d7-65c0-4def-aa3c-213c4f1ce84b" xlink:to="loc_arwr_InitialTransactionPrice_89044abd-638e-46d6-b8f2-f0b2e8d59ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontMilestonePaymentReceived_adf4871e-c896-411b-aefc-1437343fe739" xlink:href="arwr-20230331.xsd#arwr_UpfrontMilestonePaymentReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54267d7-65c0-4def-aa3c-213c4f1ce84b" xlink:to="loc_arwr_UpfrontMilestonePaymentReceived_adf4871e-c896-411b-aefc-1437343fe739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_e3a41fcb-572c-40fc-98e8-dfbcf159ebec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54267d7-65c0-4def-aa3c-213c4f1ce84b" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_e3a41fcb-572c-40fc-98e8-dfbcf159ebec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_49b86a6e-d655-40dc-b2df-a2691d68f879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d54267d7-65c0-4def-aa3c-213c4f1ce84b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_49b86a6e-d655-40dc-b2df-a2691d68f879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_69dd9636-c651-4eaf-bbaf-f0b623ad6284" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_994d33bf-7c9e-449e-ae50-5b3ac670259a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_69dd9636-c651-4eaf-bbaf-f0b623ad6284" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_994d33bf-7c9e-449e-ae50-5b3ac670259a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_22f2152f-a4d1-40ba-baba-59570e71ea8a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_994d33bf-7c9e-449e-ae50-5b3ac670259a" xlink:to="loc_dei_LegalEntityAxis_22f2152f-a4d1-40ba-baba-59570e71ea8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_35a503de-e43b-486c-9843-25706c3a77f7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_22f2152f-a4d1-40ba-baba-59570e71ea8a" xlink:to="loc_dei_EntityDomain_35a503de-e43b-486c-9843-25706c3a77f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_55dcbbc8-e8ad-4bcb-8c4b-46698dce89d5" xlink:href="arwr-20230331.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_35a503de-e43b-486c-9843-25706c3a77f7" xlink:to="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_55dcbbc8-e8ad-4bcb-8c4b-46698dce89d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_896b8e26-5ed8-4d63-9360-abf2cad75798" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_994d33bf-7c9e-449e-ae50-5b3ac670259a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_896b8e26-5ed8-4d63-9360-abf2cad75798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_834364a9-4e29-462a-bf5f-f3e0f4b7b55b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_896b8e26-5ed8-4d63-9360-abf2cad75798" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_834364a9-4e29-462a-bf5f-f3e0f4b7b55b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAndCoFundingAgreementMember_1822aa9c-a425-40db-8644-0cf99dff5d4e" xlink:href="arwr-20230331.xsd#arwr_LicenseAndCoFundingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_834364a9-4e29-462a-bf5f-f3e0f4b7b55b" xlink:to="loc_arwr_LicenseAndCoFundingAgreementMember_1822aa9c-a425-40db-8644-0cf99dff5d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3754df41-9631-47ba-85aa-42f5969fa8c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_994d33bf-7c9e-449e-ae50-5b3ac670259a" xlink:to="loc_srt_RangeAxis_3754df41-9631-47ba-85aa-42f5969fa8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d6f5922c-442b-4a4d-8f23-0aeee773450c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3754df41-9631-47ba-85aa-42f5969fa8c6" xlink:to="loc_srt_RangeMember_d6f5922c-442b-4a4d-8f23-0aeee773450c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1065b2aa-b11f-4899-ba71-173ded9e7113" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d6f5922c-442b-4a4d-8f23-0aeee773450c" xlink:to="loc_srt_MinimumMember_1065b2aa-b11f-4899-ba71-173ded9e7113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_09d82a66-a81c-4527-a578-b278c91e38eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d6f5922c-442b-4a4d-8f23-0aeee773450c" xlink:to="loc_srt_MaximumMember_09d82a66-a81c-4527-a578-b278c91e38eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7a68f36c-23b0-4c95-8cc3-e94943d3f533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_994d33bf-7c9e-449e-ae50-5b3ac670259a" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7a68f36c-23b0-4c95-8cc3-e94943d3f533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cc0b09de-104b-432f-a27d-a3fedad0167a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7a68f36c-23b0-4c95-8cc3-e94943d3f533" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cc0b09de-104b-432f-a27d-a3fedad0167a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredRevenueMember_37eb2ec4-a7f2-4b53-97f4-1c55e93c8a09" xlink:href="arwr-20230331.xsd#arwr_DeferredRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cc0b09de-104b-432f-a27d-a3fedad0167a" xlink:to="loc_arwr_DeferredRevenueMember_37eb2ec4-a7f2-4b53-97f4-1c55e93c8a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_026a697e-b327-4e40-8c7d-cfb1d2d9b156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cc0b09de-104b-432f-a27d-a3fedad0167a" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_026a697e-b327-4e40-8c7d-cfb1d2d9b156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d832ae-d794-46d1-acdb-155e2cc81c12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_994d33bf-7c9e-449e-ae50-5b3ac670259a" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d832ae-d794-46d1-acdb-155e2cc81c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_575bee5d-4eeb-4750-ad8d-ad6d0ac6e3cb" xlink:href="arwr-20230331.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d832ae-d794-46d1-acdb-155e2cc81c12" xlink:to="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_575bee5d-4eeb-4750-ad8d-ad6d0ac6e3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_af7b7390-9d65-480e-8033-8d6139f5039f" xlink:href="arwr-20230331.xsd#arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d832ae-d794-46d1-acdb-155e2cc81c12" xlink:to="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_af7b7390-9d65-480e-8033-8d6139f5039f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_45ef0f8c-8b09-498b-a75c-2cd0bb80858e" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentEarned"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d832ae-d794-46d1-acdb-155e2cc81c12" xlink:to="loc_arwr_MilestonePaymentEarned_45ef0f8c-8b09-498b-a75c-2cd0bb80858e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_d4e99471-944d-46da-978d-17341261d557" xlink:href="arwr-20230331.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d832ae-d794-46d1-acdb-155e2cc81c12" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_d4e99471-944d-46da-978d-17341261d557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_dfa0045e-163e-4588-835c-10acae270536" xlink:href="arwr-20230331.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d832ae-d794-46d1-acdb-155e2cc81c12" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_dfa0045e-163e-4588-835c-10acae270536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_8225199b-1d7a-43b1-ad68-08d21df45801" xlink:href="arwr-20230331.xsd#arwr_NumberOfDistinctBundle"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d832ae-d794-46d1-acdb-155e2cc81c12" xlink:to="loc_arwr_NumberOfDistinctBundle_8225199b-1d7a-43b1-ad68-08d21df45801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_222844bc-2258-448d-91fd-2c758321424d" xlink:href="arwr-20230331.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d832ae-d794-46d1-acdb-155e2cc81c12" xlink:to="loc_arwr_InitialTransactionPrice_222844bc-2258-448d-91fd-2c758321424d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_05ec0ecf-b735-4a19-91ed-40e2af07e592" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d832ae-d794-46d1-acdb-155e2cc81c12" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_05ec0ecf-b735-4a19-91ed-40e2af07e592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1ddc454b-e8fb-4992-8f5c-77f517f34d38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d832ae-d794-46d1-acdb-155e2cc81c12" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1ddc454b-e8fb-4992-8f5c-77f517f34d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b44fbe98-3073-4fb8-9de8-594930dbac09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d832ae-d794-46d1-acdb-155e2cc81c12" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b44fbe98-3073-4fb8-9de8-594930dbac09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_fb4e945b-797e-4e97-b60f-3dbc465bf349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d832ae-d794-46d1-acdb-155e2cc81c12" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_fb4e945b-797e-4e97-b60f-3dbc465bf349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable_846482a8-c040-42a8-b174-1dfedf70308b" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentReceivable"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d832ae-d794-46d1-acdb-155e2cc81c12" xlink:to="loc_arwr_MilestonePaymentReceivable_846482a8-c040-42a8-b174-1dfedf70308b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d23290d6-83fe-4f22-ac21-ab836f54cb05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4cf35c5-18a3-463b-82ef-a6413f54df0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d23290d6-83fe-4f22-ac21-ab836f54cb05" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4cf35c5-18a3-463b-82ef-a6413f54df0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_37693928-1272-464b-89d2-ce350a9a4985" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4cf35c5-18a3-463b-82ef-a6413f54df0b" xlink:to="loc_dei_LegalEntityAxis_37693928-1272-464b-89d2-ce350a9a4985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a9a2ba16-9064-456c-81d5-8944313e498d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_37693928-1272-464b-89d2-ce350a9a4985" xlink:to="loc_dei_EntityDomain_a9a2ba16-9064-456c-81d5-8944313e498d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_1a3cf8f6-b6d0-4eab-b2b2-69ed32a8a5cb" xlink:href="arwr-20230331.xsd#arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a9a2ba16-9064-456c-81d5-8944313e498d" xlink:to="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_1a3cf8f6-b6d0-4eab-b2b2-69ed32a8a5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember_a4311f7c-7179-4216-ba28-0aaa3163303f" xlink:href="arwr-20230331.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a9a2ba16-9064-456c-81d5-8944313e498d" xlink:to="loc_arwr_JanssenPharmaceuticalsIncorporationMember_a4311f7c-7179-4216-ba28-0aaa3163303f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_fcbfe791-5412-4418-ac9f-946ff442b1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4cf35c5-18a3-463b-82ef-a6413f54df0b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_fcbfe791-5412-4418-ac9f-946ff442b1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dbf1e470-95d7-42ff-9ad1-2a91ffe1bb18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fcbfe791-5412-4418-ac9f-946ff442b1e1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dbf1e470-95d7-42ff-9ad1-2a91ffe1bb18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockPurchaseAgreementMember_8698a7a1-5058-41be-a174-8b6c384b6893" xlink:href="arwr-20230331.xsd#arwr_CommonStockPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dbf1e470-95d7-42ff-9ad1-2a91ffe1bb18" xlink:to="loc_arwr_CommonStockPurchaseAgreementMember_8698a7a1-5058-41be-a174-8b6c384b6893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c8925961-9271-46b4-ba4d-9f254e509b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4cf35c5-18a3-463b-82ef-a6413f54df0b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c8925961-9271-46b4-ba4d-9f254e509b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b53f7084-a821-4e49-9c19-fde331a4be92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c8925961-9271-46b4-ba4d-9f254e509b8d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b53f7084-a821-4e49-9c19-fde331a4be92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember_84c7baa9-4744-4ad5-add2-9b1e196f4e3b" xlink:href="arwr-20230331.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b53f7084-a821-4e49-9c19-fde331a4be92" xlink:to="loc_arwr_CollaborationAndLicenseAgreementMember_84c7baa9-4744-4ad5-add2-9b1e196f4e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAgreementMember_680a5db5-dec8-48cc-9968-2ede21c000a2" xlink:href="arwr-20230331.xsd#arwr_LicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b53f7084-a821-4e49-9c19-fde331a4be92" xlink:to="loc_arwr_LicenseAgreementMember_680a5db5-dec8-48cc-9968-2ede21c000a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JNJ75220795AROJNJ1Member_f21df10c-dc47-4bb0-95c0-b08db76f116d" xlink:href="arwr-20230331.xsd#arwr_JNJ75220795AROJNJ1Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b53f7084-a821-4e49-9c19-fde331a4be92" xlink:to="loc_arwr_JNJ75220795AROJNJ1Member_f21df10c-dc47-4bb0-95c0-b08db76f116d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JNJ3989AROHBVAgreementMember_2fd9e155-7c0a-49c8-8002-977c02f59292" xlink:href="arwr-20230331.xsd#arwr_JNJ3989AROHBVAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b53f7084-a821-4e49-9c19-fde331a4be92" xlink:to="loc_arwr_JNJ3989AROHBVAgreementMember_2fd9e155-7c0a-49c8-8002-977c02f59292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bed3ee1f-f836-49bc-8dcc-f529afe1746e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4cf35c5-18a3-463b-82ef-a6413f54df0b" xlink:to="loc_srt_RangeAxis_bed3ee1f-f836-49bc-8dcc-f529afe1746e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_41a01a85-66ae-4a3e-ac4c-0f597b9c9aac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bed3ee1f-f836-49bc-8dcc-f529afe1746e" xlink:to="loc_srt_RangeMember_41a01a85-66ae-4a3e-ac4c-0f597b9c9aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b9da71f8-59d9-4652-a8c5-ec168ca5a716" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_41a01a85-66ae-4a3e-ac4c-0f597b9c9aac" xlink:to="loc_srt_MaximumMember_b9da71f8-59d9-4652-a8c5-ec168ca5a716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39c0edf9-edc0-4f1c-b744-27edf3e0b352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d4cf35c5-18a3-463b-82ef-a6413f54df0b" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39c0edf9-edc0-4f1c-b744-27edf3e0b352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_77d3851f-c4b1-4a11-80fd-dc8494fbf474" xlink:href="arwr-20230331.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39c0edf9-edc0-4f1c-b744-27edf3e0b352" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_77d3851f-c4b1-4a11-80fd-dc8494fbf474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bca9e417-7435-4369-913f-99f696e088b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39c0edf9-edc0-4f1c-b744-27edf3e0b352" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bca9e417-7435-4369-913f-99f696e088b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_7347b66d-ebcd-4b73-ae0f-197d00bed05e" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentEarned"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39c0edf9-edc0-4f1c-b744-27edf3e0b352" xlink:to="loc_arwr_MilestonePaymentEarned_7347b66d-ebcd-4b73-ae0f-197d00bed05e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_da9322ae-87d6-4c5e-947c-2425108b2881" xlink:href="arwr-20230331.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39c0edf9-edc0-4f1c-b744-27edf3e0b352" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_da9322ae-87d6-4c5e-947c-2425108b2881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ab9df8b2-7922-42e0-aabf-2fda6de294e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39c0edf9-edc0-4f1c-b744-27edf3e0b352" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ab9df8b2-7922-42e0-aabf-2fda6de294e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_4f186cbf-4bd6-42ec-8381-83940c61be0e" xlink:href="arwr-20230331.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39c0edf9-edc0-4f1c-b744-27edf3e0b352" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_4f186cbf-4bd6-42ec-8381-83940c61be0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_5f71a64a-9b7e-4ca7-b85b-c848c00db303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39c0edf9-edc0-4f1c-b744-27edf3e0b352" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_5f71a64a-9b7e-4ca7-b85b-c848c00db303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_80b30edd-9a0f-4b4e-a1b8-595e6625278e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39c0edf9-edc0-4f1c-b744-27edf3e0b352" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_80b30edd-9a0f-4b4e-a1b8-595e6625278e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_fb2c516c-424e-4334-aa36-4fec10b8c2a8" xlink:href="arwr-20230331.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39c0edf9-edc0-4f1c-b744-27edf3e0b352" xlink:to="loc_arwr_InitialTransactionPrice_fb2c516c-424e-4334-aa36-4fec10b8c2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#CollaborationandLicenseAgreementsAmgenIncDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_34a4ae21-b94f-48c2-b7f6-a97dbce6e244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8f4c3a0-00f0-484a-99fc-9dea06c1a5b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_34a4ae21-b94f-48c2-b7f6-a97dbce6e244" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8f4c3a0-00f0-484a-99fc-9dea06c1a5b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_323b1a7f-e56b-4061-8636-0c69f9ca7805" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8f4c3a0-00f0-484a-99fc-9dea06c1a5b3" xlink:to="loc_dei_LegalEntityAxis_323b1a7f-e56b-4061-8636-0c69f9ca7805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_239caab0-639f-4d41-9bad-fbc1852e5aed" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_323b1a7f-e56b-4061-8636-0c69f9ca7805" xlink:to="loc_dei_EntityDomain_239caab0-639f-4d41-9bad-fbc1852e5aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_a2cd2c34-392b-43b3-8719-b1bf7cf35aad" xlink:href="arwr-20230331.xsd#arwr_AmgenIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_239caab0-639f-4d41-9bad-fbc1852e5aed" xlink:to="loc_arwr_AmgenIncorporatedMember_a2cd2c34-392b-43b3-8719-b1bf7cf35aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_81751317-3cc1-4b45-81b8-a2042f6f9799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8f4c3a0-00f0-484a-99fc-9dea06c1a5b3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_81751317-3cc1-4b45-81b8-a2042f6f9799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5aa1da77-ad4a-4e8d-a868-07191c81c4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_81751317-3cc1-4b45-81b8-a2042f6f9799" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5aa1da77-ad4a-4e8d-a868-07191c81c4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember_dd00da60-0e52-4270-a98c-160c636ec87b" xlink:href="arwr-20230331.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5aa1da77-ad4a-4e8d-a868-07191c81c4a6" xlink:to="loc_arwr_CollaborationAndLicenseAgreementMember_dd00da60-0e52-4270-a98c-160c636ec87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAndAROAMG1AgreementMember_0de395ba-2a2b-4cad-a72f-b8a8475aceea" xlink:href="arwr-20230331.xsd#arwr_OlpasiranAndAROAMG1AgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5aa1da77-ad4a-4e8d-a868-07191c81c4a6" xlink:to="loc_arwr_OlpasiranAndAROAMG1AgreementMember_0de395ba-2a2b-4cad-a72f-b8a8475aceea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAgreementMember_683b9b73-3d81-4b35-b0b8-64591f251e54" xlink:href="arwr-20230331.xsd#arwr_OlpasiranAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5aa1da77-ad4a-4e8d-a868-07191c81c4a6" xlink:to="loc_arwr_OlpasiranAgreementMember_683b9b73-3d81-4b35-b0b8-64591f251e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_39cd0d2b-b0cc-4bbc-8dd3-5f8040cce428" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8f4c3a0-00f0-484a-99fc-9dea06c1a5b3" xlink:to="loc_srt_RangeAxis_39cd0d2b-b0cc-4bbc-8dd3-5f8040cce428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_918a2d8b-633e-4e85-be6a-e89274e88a09" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_39cd0d2b-b0cc-4bbc-8dd3-5f8040cce428" xlink:to="loc_srt_RangeMember_918a2d8b-633e-4e85-be6a-e89274e88a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9a545397-45dd-4ffa-adb9-1987beb5f121" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_918a2d8b-633e-4e85-be6a-e89274e88a09" xlink:to="loc_srt_MaximumMember_9a545397-45dd-4ffa-adb9-1987beb5f121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5907ef1-9695-4088-9601-bddefd65070a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8f4c3a0-00f0-484a-99fc-9dea06c1a5b3" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5907ef1-9695-4088-9601-bddefd65070a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAgreements_4a23f5dc-8b8d-42fb-a30b-ac6b165ee625" xlink:href="arwr-20230331.xsd#arwr_NumberOfAgreements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5907ef1-9695-4088-9601-bddefd65070a" xlink:to="loc_arwr_NumberOfAgreements_4a23f5dc-8b8d-42fb-a30b-ac6b165ee625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_bf6446b9-3a6a-4f65-9f64-2762b3296137" xlink:href="arwr-20230331.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5907ef1-9695-4088-9601-bddefd65070a" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_bf6446b9-3a6a-4f65-9f64-2762b3296137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_47e30e30-f360-451f-bb6b-66f9005d6965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5907ef1-9695-4088-9601-bddefd65070a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_47e30e30-f360-451f-bb6b-66f9005d6965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceived_425ffa01-d8b5-43f6-95eb-9cce5bc602e5" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5907ef1-9695-4088-9601-bddefd65070a" xlink:to="loc_arwr_MilestonePaymentReceived_425ffa01-d8b5-43f6-95eb-9cce5bc602e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_09bcbecc-08f4-4ea7-8aa1-afb1865e1150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5907ef1-9695-4088-9601-bddefd65070a" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_09bcbecc-08f4-4ea7-8aa1-afb1865e1150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_126a293b-c74d-41a0-8d0b-98395ea4199f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5907ef1-9695-4088-9601-bddefd65070a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_126a293b-c74d-41a0-8d0b-98395ea4199f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_d42bab40-9edf-457b-aa85-10997e8a873e" xlink:href="arwr-20230331.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f5907ef1-9695-4088-9601-bddefd65070a" xlink:to="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_d42bab40-9edf-457b-aa85-10997e8a873e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d81f9533-9abf-4c57-a243-7e1fe089c17e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8c7f456b-53ea-438b-9b44-3f8b6118e27c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d81f9533-9abf-4c57-a243-7e1fe089c17e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8c7f456b-53ea-438b-9b44-3f8b6118e27c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a989467a-dbcf-40e8-8e7c-cffb46dc256d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8c7f456b-53ea-438b-9b44-3f8b6118e27c" xlink:to="loc_dei_LegalEntityAxis_a989467a-dbcf-40e8-8e7c-cffb46dc256d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a93962e2-cb29-41c4-98f3-aae4485ebf27" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_a989467a-dbcf-40e8-8e7c-cffb46dc256d" xlink:to="loc_dei_EntityDomain_a93962e2-cb29-41c4-98f3-aae4485ebf27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaTherapeuticsIncMember_2c5a98b2-b298-4f95-8946-1b805aa9f247" xlink:href="arwr-20230331.xsd#arwr_VisirnaTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a93962e2-cb29-41c4-98f3-aae4485ebf27" xlink:to="loc_arwr_VisirnaTherapeuticsIncMember_2c5a98b2-b298-4f95-8946-1b805aa9f247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_33144336-5d3e-4454-bf70-1d520a3ae878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8c7f456b-53ea-438b-9b44-3f8b6118e27c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_33144336-5d3e-4454-bf70-1d520a3ae878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a47802c9-c70c-4293-b6f7-f9180d8d36ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_33144336-5d3e-4454-bf70-1d520a3ae878" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a47802c9-c70c-4293-b6f7-f9180d8d36ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaLicenseAgreementMember_48c7a10c-46e5-4f6f-8331-a04bb9b43108" xlink:href="arwr-20230331.xsd#arwr_VisirnaLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a47802c9-c70c-4293-b6f7-f9180d8d36ce" xlink:to="loc_arwr_VisirnaLicenseAgreementMember_48c7a10c-46e5-4f6f-8331-a04bb9b43108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_a8465d68-254e-4867-a9bc-3d78512a0df9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8c7f456b-53ea-438b-9b44-3f8b6118e27c" xlink:to="loc_srt_ConsolidatedEntitiesAxis_a8465d68-254e-4867-a9bc-3d78512a0df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_6023dddf-f646-4ce6-b878-c05b8985d4aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_a8465d68-254e-4867-a9bc-3d78512a0df9" xlink:to="loc_srt_ConsolidatedEntitiesDomain_6023dddf-f646-4ce6-b878-c05b8985d4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_4b6d0043-31ce-41b9-89ea-c35a93a51153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_6023dddf-f646-4ce6-b878-c05b8985d4aa" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_4b6d0043-31ce-41b9-89ea-c35a93a51153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09a58e36-bff3-43aa-a03f-57be99794da4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8c7f456b-53ea-438b-9b44-3f8b6118e27c" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09a58e36-bff3-43aa-a03f-57be99794da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributedCapital_cee3453c-68b7-4fc1-957b-4e5bbdccee6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09a58e36-bff3-43aa-a03f-57be99794da4" xlink:to="loc_us-gaap_ProceedsFromContributedCapital_cee3453c-68b7-4fc1-957b-4e5bbdccee6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1fd8da40-b567-4459-92fc-6ec8696ea3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09a58e36-bff3-43aa-a03f-57be99794da4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1fd8da40-b567-4459-92fc-6ec8696ea3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_0b47d524-b13f-43d4-a917-5064b7c467a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09a58e36-bff3-43aa-a03f-57be99794da4" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_0b47d524-b13f-43d4-a917-5064b7c467a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b71b9622-3a32-4ef4-8e12-851ce2e53f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09a58e36-bff3-43aa-a03f-57be99794da4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b71b9622-3a32-4ef4-8e12-851ce2e53f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail" xlink:type="simple" xlink:href="arwr-20230331.xsd#PropertyandEquipmentSummaryofPropertyandEquipmentDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e02eab74-80bc-46e8-babb-e1378a59065c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross_f795b60c-96c6-4dc6-8b40-ccf95bf4686c" xlink:href="arwr-20230331.xsd#arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e02eab74-80bc-46e8-babb-e1378a59065c" xlink:to="loc_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross_f795b60c-96c6-4dc6-8b40-ccf95bf4686c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_8fc33cf4-666a-43c4-bc64-55502bbc2c97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e02eab74-80bc-46e8-babb-e1378a59065c" xlink:to="loc_us-gaap_Land_8fc33cf4-666a-43c4-bc64-55502bbc2c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentGross_98470d97-db6e-4ec4-a642-2f0c331be452" xlink:href="arwr-20230331.xsd#arwr_ResearchEquipmentGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e02eab74-80bc-46e8-babb-e1378a59065c" xlink:to="loc_arwr_ResearchEquipmentGross_98470d97-db6e-4ec4-a642-2f0c331be452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_bdc454fe-c7ac-43f9-aa77-fc616eb3fb05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e02eab74-80bc-46e8-babb-e1378a59065c" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_bdc454fe-c7ac-43f9-aa77-fc616eb3fb05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_9e2790b7-8d6b-4cc8-93e1-9ce4c7e7f1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e02eab74-80bc-46e8-babb-e1378a59065c" xlink:to="loc_us-gaap_ConstructionInProgressGross_9e2790b7-8d6b-4cc8-93e1-9ce4c7e7f1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_68efc6a7-1d83-4719-ab2a-2e5ed3a97403" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e02eab74-80bc-46e8-babb-e1378a59065c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_68efc6a7-1d83-4719-ab2a-2e5ed3a97403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2cccdaaf-8940-4a7f-ac7b-aeac5727be38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e02eab74-80bc-46e8-babb-e1378a59065c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2cccdaaf-8940-4a7f-ac7b-aeac5727be38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f998a29d-1f6e-4d1d-9d98-fdccd45ebe7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e02eab74-80bc-46e8-babb-e1378a59065c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f998a29d-1f6e-4d1d-9d98-fdccd45ebe7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20230331.xsd#PropertyandEquipmentAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e522a518-0903-4bb2-af78-1e3f4cbeb844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_d581fac1-e56e-41c5-8aaa-ed73cdbed27d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e522a518-0903-4bb2-af78-1e3f4cbeb844" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_d581fac1-e56e-41c5-8aaa-ed73cdbed27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6c1ea449-1c0a-43e3-8e94-2c798766395c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_e1f3e396-d7d6-44f8-80fe-b0fc4345974b" xlink:href="arwr-20230331.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6c1ea449-1c0a-43e3-8e94-2c798766395c" xlink:to="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_e1f3e396-d7d6-44f8-80fe-b0fc4345974b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_11637df3-9940-4a45-ac76-ff0038e76929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_e1f3e396-d7d6-44f8-80fe-b0fc4345974b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_11637df3-9940-4a45-ac76-ff0038e76929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_11978b5b-86c1-4c1b-a659-34c5d4c5573f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_11637df3-9940-4a45-ac76-ff0038e76929" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_11978b5b-86c1-4c1b-a659-34c5d4c5573f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_c91ee773-2ea5-49ef-a8b9-c0d84e0bef62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_11978b5b-86c1-4c1b-a659-34c5d4c5573f" xlink:to="loc_us-gaap_DebtSecuritiesMember_c91ee773-2ea5-49ef-a8b9-c0d84e0bef62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_46258328-58b5-4ddf-973a-2ddae5fa0899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_11978b5b-86c1-4c1b-a659-34c5d4c5573f" xlink:to="loc_us-gaap_CertificatesOfDepositMember_46258328-58b5-4ddf-973a-2ddae5fa0899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_d5b61299-5582-4e5b-9361-461353f7d2bd" xlink:href="arwr-20230331.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_e1f3e396-d7d6-44f8-80fe-b0fc4345974b" xlink:to="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_d5b61299-5582-4e5b-9361-461353f7d2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_9ae1ddae-3b00-4c43-83ff-ee1bac78d77a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_d5b61299-5582-4e5b-9361-461353f7d2bd" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_9ae1ddae-3b00-4c43-83ff-ee1bac78d77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_de361f3e-7941-495b-a655-769c43eda552" xlink:href="arwr-20230331.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_d5b61299-5582-4e5b-9361-461353f7d2bd" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_de361f3e-7941-495b-a655-769c43eda552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_790252ec-a739-40b3-b36a-87a423259e15" xlink:href="arwr-20230331.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_d5b61299-5582-4e5b-9361-461353f7d2bd" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_790252ec-a739-40b3-b36a-87a423259e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_9a48a9de-143c-42ca-964e-a5b42a235b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_d5b61299-5582-4e5b-9361-461353f7d2bd" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_9a48a9de-143c-42ca-964e-a5b42a235b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_33383518-211f-4078-b048-0771b9e943a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_d5b61299-5582-4e5b-9361-461353f7d2bd" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_33383518-211f-4078-b048-0771b9e943a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_cb8d8b13-477c-4718-b8b0-ac607f16172f" xlink:href="arwr-20230331.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_d5b61299-5582-4e5b-9361-461353f7d2bd" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_cb8d8b13-477c-4718-b8b0-ac607f16172f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_15c6e0d6-c386-41b0-8ff4-50aa2b3c761d" xlink:href="arwr-20230331.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_d5b61299-5582-4e5b-9361-461353f7d2bd" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_15c6e0d6-c386-41b0-8ff4-50aa2b3c761d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_18d98caa-a629-4c9f-957a-ab50c2c6889f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_d5b61299-5582-4e5b-9361-461353f7d2bd" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_18d98caa-a629-4c9f-957a-ab50c2c6889f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_361d44bd-067e-486c-b03d-7d9d1fdb3041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e9c80601-9008-44c2-b6c5-98821d383f99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_361d44bd-067e-486c-b03d-7d9d1fdb3041" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e9c80601-9008-44c2-b6c5-98821d383f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_3759b6c7-af4b-4001-95db-926a00ce460b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e9c80601-9008-44c2-b6c5-98821d383f99" xlink:to="loc_us-gaap_AssetAcquisitionAxis_3759b6c7-af4b-4001-95db-926a00ce460b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_d7342b84-9f61-4a00-96b6-95af2b600c49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_3759b6c7-af4b-4001-95db-926a00ce460b" xlink:to="loc_us-gaap_AssetAcquisitionDomain_d7342b84-9f61-4a00-96b6-95af2b600c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisMember_4b6ce4ae-ecfb-460e-aa20-ba3845da3f15" xlink:href="arwr-20230331.xsd#arwr_NovartisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_d7342b84-9f61-4a00-96b6-95af2b600c49" xlink:to="loc_arwr_NovartisMember_4b6ce4ae-ecfb-460e-aa20-ba3845da3f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_711bf9c9-e7be-4096-8094-0a7900254afe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e9c80601-9008-44c2-b6c5-98821d383f99" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_711bf9c9-e7be-4096-8094-0a7900254afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4523b65c-695c-4b9d-b798-ab5f56cb720b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_711bf9c9-e7be-4096-8094-0a7900254afe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4523b65c-695c-4b9d-b798-ab5f56cb720b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_920592e1-2ae7-44e5-9dbb-fcc0792125be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4523b65c-695c-4b9d-b798-ab5f56cb720b" xlink:to="loc_us-gaap_PatentsMember_920592e1-2ae7-44e5-9dbb-fcc0792125be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_f270a197-ebf7-4cab-a9d9-e1f931f273a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4523b65c-695c-4b9d-b798-ab5f56cb720b" xlink:to="loc_us-gaap_LicensingAgreementsMember_f270a197-ebf7-4cab-a9d9-e1f931f273a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8a4d3e3-28d0-4476-9a5d-c0c4eda0220c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e9c80601-9008-44c2-b6c5-98821d383f99" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8a4d3e3-28d0-4476-9a5d-c0c4eda0220c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2c7fef13-9109-49e0-a218-28c0bf377f50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8a4d3e3-28d0-4476-9a5d-c0c4eda0220c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2c7fef13-9109-49e0-a218-28c0bf377f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bb9d6944-106b-427e-9d15-db4a4989f9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8a4d3e3-28d0-4476-9a5d-c0c4eda0220c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bb9d6944-106b-427e-9d15-db4a4989f9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsImpairment_5a089c20-532c-4081-b11e-4a0bfc25f0b4" xlink:href="arwr-20230331.xsd#arwr_FiniteLivedIntangibleAssetsImpairment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8a4d3e3-28d0-4476-9a5d-c0c4eda0220c" xlink:to="loc_arwr_FiniteLivedIntangibleAssetsImpairment_5a089c20-532c-4081-b11e-4a0bfc25f0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bda60689-5d4a-4eb1-918a-d28b56ff8d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8a4d3e3-28d0-4476-9a5d-c0c4eda0220c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bda60689-5d4a-4eb1-918a-d28b56ff8d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8061383e-8b33-41de-adec-cc6419171cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e8a4d3e3-28d0-4476-9a5d-c0c4eda0220c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8061383e-8b33-41de-adec-cc6419171cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_c131252a-c45b-459c-8047-23deca880079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_361d44bd-067e-486c-b03d-7d9d1fdb3041" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_c131252a-c45b-459c-8047-23deca880079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#IntangibleAssetsExpectedFutureAmortizationDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_434b74a9-e9ed-4557-8392-82654e7a28be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_8312f58a-e722-499c-a822-97d2b3a60789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_434b74a9-e9ed-4557-8392-82654e7a28be" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_8312f58a-e722-499c-a822-97d2b3a60789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5d91d5c7-4fe7-4407-ba77-c7973104d847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_434b74a9-e9ed-4557-8392-82654e7a28be" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5d91d5c7-4fe7-4407-ba77-c7973104d847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_f10d8cfd-3edd-4baf-b71a-22235002f6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_434b74a9-e9ed-4557-8392-82654e7a28be" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_f10d8cfd-3edd-4baf-b71a-22235002f6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7ba9efee-ab1c-48c7-8c19-243232d82391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_434b74a9-e9ed-4557-8392-82654e7a28be" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7ba9efee-ab1c-48c7-8c19-243232d82391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_63700709-58e8-43ae-aa16-a04633d217e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_434b74a9-e9ed-4557-8392-82654e7a28be" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_63700709-58e8-43ae-aa16-a04633d217e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_c3ef219c-eb26-4cbc-b35f-a5fb7110d912" xlink:href="arwr-20230331.xsd#arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_434b74a9-e9ed-4557-8392-82654e7a28be" xlink:to="loc_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_c3ef219c-eb26-4cbc-b35f-a5fb7110d912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_921df573-8d60-466f-9a3d-55efb8de7959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_434b74a9-e9ed-4557-8392-82654e7a28be" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_921df573-8d60-466f-9a3d-55efb8de7959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f1d54c6f-d1ca-4550-b4b5-ca3cfb11266f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_690984f0-b602-49ec-94c2-5ee35dc99bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f1d54c6f-d1ca-4550-b4b5-ca3cfb11266f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_690984f0-b602-49ec-94c2-5ee35dc99bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d1598229-06a9-4b56-81cf-07db499992af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_690984f0-b602-49ec-94c2-5ee35dc99bcc" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d1598229-06a9-4b56-81cf-07db499992af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_04735908-8b31-4b80-9172-29a695ab2204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d1598229-06a9-4b56-81cf-07db499992af" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_04735908-8b31-4b80-9172-29a695ab2204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_37f8650b-a6a9-41eb-bd19-2b25dd8bdfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_04735908-8b31-4b80-9172-29a695ab2204" xlink:to="loc_us-gaap_SubsequentEventMember_37f8650b-a6a9-41eb-bd19-2b25dd8bdfa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0242b8cf-64a2-413c-821e-a559736550e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_690984f0-b602-49ec-94c2-5ee35dc99bcc" xlink:to="loc_us-gaap_PlanNameAxis_0242b8cf-64a2-413c-821e-a559736550e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e3d31ae8-c9b8-4250-a87b-99d3a39dfd27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_0242b8cf-64a2-413c-821e-a559736550e5" xlink:to="loc_us-gaap_PlanNameDomain_e3d31ae8-c9b8-4250-a87b-99d3a39dfd27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_5de05e7e-0e6d-44a6-979d-55ca14c85777" xlink:href="arwr-20230331.xsd#arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e3d31ae8-c9b8-4250-a87b-99d3a39dfd27" xlink:to="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_5de05e7e-0e6d-44a6-979d-55ca14c85777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b63bf135-489a-4b56-b1d3-49c71a070314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_690984f0-b602-49ec-94c2-5ee35dc99bcc" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b63bf135-489a-4b56-b1d3-49c71a070314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_762c9a98-5bf2-4535-b175-6f4e51f34663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b63bf135-489a-4b56-b1d3-49c71a070314" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_762c9a98-5bf2-4535-b175-6f4e51f34663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AtTheMarketAgreementMember_4d09330b-b04a-4490-a60d-343a5eaf5281" xlink:href="arwr-20230331.xsd#arwr_AtTheMarketAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_762c9a98-5bf2-4535-b175-6f4e51f34663" xlink:to="loc_arwr_AtTheMarketAgreementMember_4d09330b-b04a-4490-a60d-343a5eaf5281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0a3be423-b854-48ed-8a65-d1eb362dd6b0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_690984f0-b602-49ec-94c2-5ee35dc99bcc" xlink:to="loc_srt_RangeAxis_0a3be423-b854-48ed-8a65-d1eb362dd6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3ee23d51-1897-41f0-97d8-d23757e24350" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0a3be423-b854-48ed-8a65-d1eb362dd6b0" xlink:to="loc_srt_RangeMember_3ee23d51-1897-41f0-97d8-d23757e24350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_157ca472-a054-4a76-a53d-ff3fd6cf58c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3ee23d51-1897-41f0-97d8-d23757e24350" xlink:to="loc_srt_MaximumMember_157ca472-a054-4a76-a53d-ff3fd6cf58c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_73d9f5b9-a78c-4e29-90bf-3882a1d3a61e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_690984f0-b602-49ec-94c2-5ee35dc99bcc" xlink:to="loc_us-gaap_ClassOfStockLineItems_73d9f5b9-a78c-4e29-90bf-3882a1d3a61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9437bbfe-0ebe-44b5-b032-7013fb2432c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_73d9f5b9-a78c-4e29-90bf-3882a1d3a61e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9437bbfe-0ebe-44b5-b032-7013fb2432c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_705b713c-33f5-40d4-9ad1-de3dea77742c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_73d9f5b9-a78c-4e29-90bf-3882a1d3a61e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_705b713c-33f5-40d4-9ad1-de3dea77742c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_0cbe9db7-74b4-4062-8109-a742b5825120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_73d9f5b9-a78c-4e29-90bf-3882a1d3a61e" xlink:to="loc_us-gaap_CommonStockSharesIssued_0cbe9db7-74b4-4062-8109-a742b5825120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3910a217-c4cb-43cd-aa3d-7610a4889706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_73d9f5b9-a78c-4e29-90bf-3882a1d3a61e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3910a217-c4cb-43cd-aa3d-7610a4889706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f1113f9f-828d-4368-803b-ad1fa769a6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_73d9f5b9-a78c-4e29-90bf-3882a1d3a61e" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f1113f9f-828d-4368-803b-ad1fa769a6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_34113ac6-c8a9-469a-8ca0-066dea645359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_73d9f5b9-a78c-4e29-90bf-3882a1d3a61e" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_34113ac6-c8a9-469a-8ca0-066dea645359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_99af0d8b-cd64-4713-a7f6-5ffb360a7d54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_73d9f5b9-a78c-4e29-90bf-3882a1d3a61e" xlink:to="loc_us-gaap_PreferredStockSharesIssued_99af0d8b-cd64-4713-a7f6-5ffb360a7d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_887b8371-6db7-410d-950c-c79a67561f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_73d9f5b9-a78c-4e29-90bf-3882a1d3a61e" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_887b8371-6db7-410d-950c-c79a67561f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_72fb06da-ae13-4388-a534-3de3fd1b450e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_73d9f5b9-a78c-4e29-90bf-3882a1d3a61e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_72fb06da-ae13-4388-a534-3de3fd1b450e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_2af8db68-a007-4476-9def-f76926ba94ca" xlink:href="arwr-20230331.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_73d9f5b9-a78c-4e29-90bf-3882a1d3a61e" xlink:to="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_2af8db68-a007-4476-9def-f76926ba94ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_fd49844f-0d0a-4120-81c7-1cf65b148acf" xlink:href="arwr-20230331.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_73d9f5b9-a78c-4e29-90bf-3882a1d3a61e" xlink:to="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_fd49844f-0d0a-4120-81c7-1cf65b148acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_353f1a67-a3a0-4e40-bcab-79c9a197a35b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_73d9f5b9-a78c-4e29-90bf-3882a1d3a61e" xlink:to="loc_us-gaap_SharesIssued_353f1a67-a3a0-4e40-bcab-79c9a197a35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20230331.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_84e3d40d-925d-4ebe-96bc-e76f1d4c3d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_99434624-1fca-4840-8a2c-c79799318949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_84e3d40d-925d-4ebe-96bc-e76f1d4c3d48" xlink:to="loc_us-gaap_OtherCommitmentsTable_99434624-1fca-4840-8a2c-c79799318949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4ada3866-b37f-4fb0-b469-27e887e5e240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_99434624-1fca-4840-8a2c-c79799318949" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4ada3866-b37f-4fb0-b469-27e887e5e240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aa24faf8-e3a0-4e53-8a5c-aa3891ba7fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4ada3866-b37f-4fb0-b469-27e887e5e240" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aa24faf8-e3a0-4e53-8a5c-aa3891ba7fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VeronaTechnologyParkMember_283b39e6-0afb-49c9-8392-48fb4064df0e" xlink:href="arwr-20230331.xsd#arwr_VeronaTechnologyParkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aa24faf8-e3a0-4e53-8a5c-aa3891ba7fb9" xlink:to="loc_arwr_VeronaTechnologyParkMember_283b39e6-0afb-49c9-8392-48fb4064df0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DrugManufacturingFacilityMember_02c75a18-5b95-4b0c-b8d4-d176c29b6e00" xlink:href="arwr-20230331.xsd#arwr_DrugManufacturingFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aa24faf8-e3a0-4e53-8a5c-aa3891ba7fb9" xlink:to="loc_arwr_DrugManufacturingFacilityMember_02c75a18-5b95-4b0c-b8d4-d176c29b6e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LaboratoryAndOfficeFacilityMember_209d7bf6-2108-45bd-85e0-02d030ac05e8" xlink:href="arwr-20230331.xsd#arwr_LaboratoryAndOfficeFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aa24faf8-e3a0-4e53-8a5c-aa3891ba7fb9" xlink:to="loc_arwr_LaboratoryAndOfficeFacilityMember_209d7bf6-2108-45bd-85e0-02d030ac05e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FacilitiesMember_764bd8b4-a396-4f17-a45c-97974b98845e" xlink:href="arwr-20230331.xsd#arwr_FacilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aa24faf8-e3a0-4e53-8a5c-aa3891ba7fb9" xlink:to="loc_arwr_FacilitiesMember_764bd8b4-a396-4f17-a45c-97974b98845e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f938fc56-f519-4f1d-bdd3-7b55e0bc214d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_99434624-1fca-4840-8a2c-c79799318949" xlink:to="loc_srt_StatementGeographicalAxis_f938fc56-f519-4f1d-bdd3-7b55e0bc214d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2c2b3b09-7b90-41d1-b70f-c887779bb0c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_f938fc56-f519-4f1d-bdd3-7b55e0bc214d" xlink:to="loc_srt_SegmentGeographicalDomain_2c2b3b09-7b90-41d1-b70f-c887779bb0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_fd5a8012-d543-46dd-9003-d5f665497ad7" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WI"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2c2b3b09-7b90-41d1-b70f-c887779bb0c5" xlink:to="loc_stpr_WI_fd5a8012-d543-46dd-9003-d5f665497ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_29b80bb8-2708-41c0-84b6-be75899c8174" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_99434624-1fca-4840-8a2c-c79799318949" xlink:to="loc_srt_RangeAxis_29b80bb8-2708-41c0-84b6-be75899c8174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_965d99f4-324c-4f24-996b-435ac8ac83bd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_29b80bb8-2708-41c0-84b6-be75899c8174" xlink:to="loc_srt_RangeMember_965d99f4-324c-4f24-996b-435ac8ac83bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f7d0f563-af46-4e95-aada-93d67a0feaac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_965d99f4-324c-4f24-996b-435ac8ac83bd" xlink:to="loc_srt_MinimumMember_f7d0f563-af46-4e95-aada-93d67a0feaac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a7427cb0-fd68-437d-9997-47f7752ae8fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_965d99f4-324c-4f24-996b-435ac8ac83bd" xlink:to="loc_srt_MaximumMember_a7427cb0-fd68-437d-9997-47f7752ae8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_2031de9a-f3b3-48e4-9468-b29378f76d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_99434624-1fca-4840-8a2c-c79799318949" xlink:to="loc_us-gaap_OtherCommitmentsAxis_2031de9a-f3b3-48e4-9468-b29378f76d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_89858e84-3b0c-45f8-8ce9-95c1ab0bfa51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_2031de9a-f3b3-48e4-9468-b29378f76d92" xlink:to="loc_us-gaap_OtherCommitmentsDomain_89858e84-3b0c-45f8-8ce9-95c1ab0bfa51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TechnologyLicenseCommitmentsMember_832a2799-439e-4a02-b1b5-bef39b6c4cdd" xlink:href="arwr-20230331.xsd#arwr_TechnologyLicenseCommitmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_89858e84-3b0c-45f8-8ce9-95c1ab0bfa51" xlink:to="loc_arwr_TechnologyLicenseCommitmentsMember_832a2799-439e-4a02-b1b5-bef39b6c4cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_89b7037f-f6fd-44ec-af6b-8870a91d913f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_99434624-1fca-4840-8a2c-c79799318949" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_89b7037f-f6fd-44ec-af6b-8870a91d913f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_e074fd38-aea4-4504-89ac-44fb5b7da8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_89b7037f-f6fd-44ec-af6b-8870a91d913f" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_e074fd38-aea4-4504-89ac-44fb5b7da8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAcresOfLandPurchased_c06a4c13-1a96-4096-8a01-b3f1a6d6e73e" xlink:href="arwr-20230331.xsd#arwr_NumberOfAcresOfLandPurchased"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_89b7037f-f6fd-44ec-af6b-8870a91d913f" xlink:to="loc_arwr_NumberOfAcresOfLandPurchased_c06a4c13-1a96-4096-8a01-b3f1a6d6e73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_12cf6cff-7702-46a8-9175-c4ae5427ba66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_89b7037f-f6fd-44ec-af6b-8870a91d913f" xlink:to="loc_us-gaap_AreaOfLand_12cf6cff-7702-46a8-9175-c4ae5427ba66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities_aa306bea-e24e-48ac-98fb-26525e348f34" xlink:href="arwr-20230331.xsd#arwr_AmountIntendsToInvestForBuildoutOfFacilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_89b7037f-f6fd-44ec-af6b-8870a91d913f" xlink:to="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities_aa306bea-e24e-48ac-98fb-26525e348f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TaxIncrementFinancingAward_fc080bae-f192-47b3-8ac1-68f4ad5277d7" xlink:href="arwr-20230331.xsd#arwr_TaxIncrementFinancingAward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_89b7037f-f6fd-44ec-af6b-8870a91d913f" xlink:to="loc_arwr_TaxIncrementFinancingAward_fc080bae-f192-47b3-8ac1-68f4ad5277d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_29302104-f4ba-4f8d-b44c-4da9b1eb8a47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_89b7037f-f6fd-44ec-af6b-8870a91d913f" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_29302104-f4ba-4f8d-b44c-4da9b1eb8a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePayments_bdfa1375-f60e-438c-93a4-1d7d6eef9987" xlink:href="arwr-20230331.xsd#arwr_MilestonePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_89b7037f-f6fd-44ec-af6b-8870a91d913f" xlink:to="loc_arwr_MilestonePayments_bdfa1375-f60e-438c-93a4-1d7d6eef9987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6d2bd236-7f83-46e2-8887-275057e2bb58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_3a956c6c-fb80-45b6-9659-6851cdc44274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6d2bd236-7f83-46e2-8887-275057e2bb58" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_3a956c6c-fb80-45b6-9659-6851cdc44274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_244196e8-d63c-45e0-959d-74f3dc484feb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3a956c6c-fb80-45b6-9659-6851cdc44274" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_244196e8-d63c-45e0-959d-74f3dc484feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_11376fdb-ebe8-4386-bbb9-2732258c9b50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_244196e8-d63c-45e0-959d-74f3dc484feb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_11376fdb-ebe8-4386-bbb9-2732258c9b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInSanDiegoMember_13b1456f-8281-4f90-824e-1109665011bc" xlink:href="arwr-20230331.xsd#arwr_ResearchFacilityInSanDiegoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_11376fdb-ebe8-4386-bbb9-2732258c9b50" xlink:to="loc_arwr_ResearchFacilityInSanDiegoMember_13b1456f-8281-4f90-824e-1109665011bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CorporateHeadquartersInPasadenaMember_718d287e-68ad-423b-9f01-e3513068f45d" xlink:href="arwr-20230331.xsd#arwr_CorporateHeadquartersInPasadenaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_11376fdb-ebe8-4386-bbb9-2732258c9b50" xlink:to="loc_arwr_CorporateHeadquartersInPasadenaMember_718d287e-68ad-423b-9f01-e3513068f45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInMadisonMember_8a23909d-e058-4276-a624-001c11901ccd" xlink:href="arwr-20230331.xsd#arwr_ResearchFacilityInMadisonMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_11376fdb-ebe8-4386-bbb9-2732258c9b50" xlink:to="loc_arwr_ResearchFacilityInMadisonMember_8a23909d-e058-4276-a624-001c11901ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_08b5643f-fa91-4b3c-a23c-8f62dd661c0d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3a956c6c-fb80-45b6-9659-6851cdc44274" xlink:to="loc_srt_StatementGeographicalAxis_08b5643f-fa91-4b3c-a23c-8f62dd661c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e4bc02c7-1863-4f63-9a47-9f93703bc5bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_08b5643f-fa91-4b3c-a23c-8f62dd661c0d" xlink:to="loc_srt_SegmentGeographicalDomain_e4bc02c7-1863-4f63-9a47-9f93703bc5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_a1414d36-c9a8-4407-a472-6d57bc2b32b9" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e4bc02c7-1863-4f63-9a47-9f93703bc5bf" xlink:to="loc_stpr_CA_a1414d36-c9a8-4407-a472-6d57bc2b32b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_81c16974-e9a2-468c-b47d-b362090142db" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WI"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e4bc02c7-1863-4f63-9a47-9f93703bc5bf" xlink:to="loc_stpr_WI_81c16974-e9a2-468c-b47d-b362090142db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a16954b3-7866-4a64-b033-ac0a7a983d66" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3a956c6c-fb80-45b6-9659-6851cdc44274" xlink:to="loc_srt_RangeAxis_a16954b3-7866-4a64-b033-ac0a7a983d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fcb1d849-b75d-4b70-9031-694523a8024f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a16954b3-7866-4a64-b033-ac0a7a983d66" xlink:to="loc_srt_RangeMember_fcb1d849-b75d-4b70-9031-694523a8024f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b33e711c-7c7b-4969-9f94-aa7583040883" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fcb1d849-b75d-4b70-9031-694523a8024f" xlink:to="loc_srt_MaximumMember_b33e711c-7c7b-4969-9f94-aa7583040883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1c8aed6a-2c7f-48a5-93fe-ee15f0e5f124" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3a956c6c-fb80-45b6-9659-6851cdc44274" xlink:to="loc_srt_CounterpartyNameAxis_1c8aed6a-2c7f-48a5-93fe-ee15f0e5f124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f9ba3788-d2b0-414c-b74e-42d3f2370f9d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1c8aed6a-2c7f-48a5-93fe-ee15f0e5f124" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f9ba3788-d2b0-414c-b74e-42d3f2370f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ColoradoOwnerLLCMember_ddcc47d5-bb3f-4d87-8924-de47e631ba73" xlink:href="arwr-20230331.xsd#arwr_ColoradoOwnerLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f9ba3788-d2b0-414c-b74e-42d3f2370f9d" xlink:to="loc_arwr_ColoradoOwnerLLCMember_ddcc47d5-bb3f-4d87-8924-de47e631ba73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SorrentoValleyOwnerDELLCMember_417bb895-1c9b-4555-a85e-5b6baa6dc7b6" xlink:href="arwr-20230331.xsd#arwr_SorrentoValleyOwnerDELLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f9ba3788-d2b0-414c-b74e-42d3f2370f9d" xlink:to="loc_arwr_SorrentoValleyOwnerDELLCMember_417bb895-1c9b-4555-a85e-5b6baa6dc7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_1da1686d-feb9-4a96-aecc-f33b21279363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3a956c6c-fb80-45b6-9659-6851cdc44274" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_1da1686d-feb9-4a96-aecc-f33b21279363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ef5a4b64-9329-4dd2-94a7-9d67581c076e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1da1686d-feb9-4a96-aecc-f33b21279363" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ef5a4b64-9329-4dd2-94a7-9d67581c076e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_9c5ce116-0b0e-43b3-ba6e-27d3d6572dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1da1686d-feb9-4a96-aecc-f33b21279363" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_9c5ce116-0b0e-43b3-ba6e-27d3d6572dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_df2b1187-d965-4caa-9603-ed8cb20bb99c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1da1686d-feb9-4a96-aecc-f33b21279363" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_df2b1187-d965-4caa-9603-ed8cb20bb99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EstimatedPaymentsForOperatingExpensesYearOne_a5e98774-6fbd-41d9-aea2-cf7dc0416a97" xlink:href="arwr-20230331.xsd#arwr_EstimatedPaymentsForOperatingExpensesYearOne"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1da1686d-feb9-4a96-aecc-f33b21279363" xlink:to="loc_arwr_EstimatedPaymentsForOperatingExpensesYearOne_a5e98774-6fbd-41d9-aea2-cf7dc0416a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_aa7bfafa-2221-4ceb-9fb7-dc9744fac37d" xlink:href="arwr-20230331.xsd#arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1da1686d-feb9-4a96-aecc-f33b21279363" xlink:to="loc_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_aa7bfafa-2221-4ceb-9fb7-dc9744fac37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfOptionsToRenew_89315e68-df80-48d9-adc8-236d16b7e24a" xlink:href="arwr-20230331.xsd#arwr_NumberOfOptionsToRenew"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1da1686d-feb9-4a96-aecc-f33b21279363" xlink:to="loc_arwr_NumberOfOptionsToRenew_89315e68-df80-48d9-adc8-236d16b7e24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_80d107a7-c5c1-4ebf-a3ca-725605ff04cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1da1686d-feb9-4a96-aecc-f33b21279363" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_80d107a7-c5c1-4ebf-a3ca-725605ff04cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_3ea3318e-e52f-427f-b126-d2838974d619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1da1686d-feb9-4a96-aecc-f33b21279363" xlink:to="loc_us-gaap_ShortTermLeaseCost_3ea3318e-e52f-427f-b126-d2838974d619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#LeasesComponentsofLeaseAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bcc8d7c3-2e36-499b-87b4-58074dfe4a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_a76bb339-9fa4-4ac3-9b21-24462cf6b181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bcc8d7c3-2e36-499b-87b4-58074dfe4a5a" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_a76bb339-9fa4-4ac3-9b21-24462cf6b181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d6abb543-c00a-4c23-896b-27ae67710ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_a76bb339-9fa4-4ac3-9b21-24462cf6b181" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d6abb543-c00a-4c23-896b-27ae67710ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6b070898-d62b-4ff7-aa63-bc58fe052c43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d6abb543-c00a-4c23-896b-27ae67710ae6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6b070898-d62b-4ff7-aa63-bc58fe052c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d0255213-ef46-4548-81bc-752ba1a7811e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6b070898-d62b-4ff7-aa63-bc58fe052c43" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d0255213-ef46-4548-81bc-752ba1a7811e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_0dd624c6-7fac-4084-807b-528548767e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6b070898-d62b-4ff7-aa63-bc58fe052c43" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_0dd624c6-7fac-4084-807b-528548767e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_c1a9bff3-c054-4dc8-bab1-88340dd07e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_a76bb339-9fa4-4ac3-9b21-24462cf6b181" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_c1a9bff3-c054-4dc8-bab1-88340dd07e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_284d5c82-074f-499e-9397-a152778cd295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_c1a9bff3-c054-4dc8-bab1-88340dd07e0e" xlink:to="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_284d5c82-074f-499e-9397-a152778cd295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4de706b6-37ac-411f-8186-13dfec45218f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_284d5c82-074f-499e-9397-a152778cd295" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4de706b6-37ac-411f-8186-13dfec45218f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_dd69a605-759a-48e3-81e8-d5211fd47f53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_284d5c82-074f-499e-9397-a152778cd295" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_dd69a605-759a-48e3-81e8-d5211fd47f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f580a3ce-d80f-48ed-91d5-7c329048ace1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_284d5c82-074f-499e-9397-a152778cd295" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f580a3ce-d80f-48ed-91d5-7c329048ace1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_55f7781e-815b-46ae-9ac4-cb3eb0e84200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_c1a9bff3-c054-4dc8-bab1-88340dd07e0e" xlink:to="loc_us-gaap_LeaseCostAbstract_55f7781e-815b-46ae-9ac4-cb3eb0e84200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_af3f9d73-8af1-44a4-a09c-196b2815d74d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_55f7781e-815b-46ae-9ac4-cb3eb0e84200" xlink:to="loc_us-gaap_OperatingLeaseCost_af3f9d73-8af1-44a4-a09c-196b2815d74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_468be18f-12bf-446f-9459-279ee922fc64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_55f7781e-815b-46ae-9ac4-cb3eb0e84200" xlink:to="loc_us-gaap_VariableLeaseCost_468be18f-12bf-446f-9459-279ee922fc64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_580cb3c8-621c-45b0-a1bc-e21a350b7cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_55f7781e-815b-46ae-9ac4-cb3eb0e84200" xlink:to="loc_us-gaap_LeaseCost_580cb3c8-621c-45b0-a1bc-e21a350b7cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bab33de4-04b5-427f-ac8e-096b529d6786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_5fccab1b-f590-47a0-ba42-86a8d9d113c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bab33de4-04b5-427f-ac8e-096b529d6786" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_5fccab1b-f590-47a0-ba42-86a8d9d113c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_abaf4c4a-cea0-4658-b8b4-42b313340a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bab33de4-04b5-427f-ac8e-096b529d6786" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_abaf4c4a-cea0-4658-b8b4-42b313340a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_da691524-5ce6-4e6e-87d3-25fe8bba422d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bab33de4-04b5-427f-ac8e-096b529d6786" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_da691524-5ce6-4e6e-87d3-25fe8bba422d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9a2aed17-1472-4d45-8fc9-9f3105e55d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bab33de4-04b5-427f-ac8e-096b529d6786" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9a2aed17-1472-4d45-8fc9-9f3105e55d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_008988cd-b3a8-44ae-ac52-49945f2ca9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bab33de4-04b5-427f-ac8e-096b529d6786" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_008988cd-b3a8-44ae-ac52-49945f2ca9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_be995272-da66-4424-9891-a58c2645406c" xlink:href="arwr-20230331.xsd#arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bab33de4-04b5-427f-ac8e-096b529d6786" xlink:to="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_be995272-da66-4424-9891-a58c2645406c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8a600218-c081-45a9-a6cc-2db87f6db4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bab33de4-04b5-427f-ac8e-096b529d6786" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8a600218-c081-45a9-a6cc-2db87f6db4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_fa68b603-6e74-4cac-b6d1-2d040bb8f413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bab33de4-04b5-427f-ac8e-096b529d6786" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_fa68b603-6e74-4cac-b6d1-2d040bb8f413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ae518120-3202-4bac-884c-8305d06e1ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bab33de4-04b5-427f-ac8e-096b529d6786" xlink:to="loc_us-gaap_OperatingLeaseLiability_ae518120-3202-4bac-884c-8305d06e1ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" xlink:type="simple" xlink:href="arwr-20230331.xsd#LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9124fca4-a034-414b-bdf4-b079296149d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_ccbc045d-650f-48c0-aafe-0da70dc1c052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9124fca4-a034-414b-bdf4-b079296149d3" xlink:to="loc_us-gaap_OperatingLeasePayments_ccbc045d-650f-48c0-aafe-0da70dc1c052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_bed20a09-3e97-4f78-8183-22531a1bb99b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9124fca4-a034-414b-bdf4-b079296149d3" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_bed20a09-3e97-4f78-8183-22531a1bb99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ce858a6d-5bde-402c-8449-9f5173780565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9124fca4-a034-414b-bdf4-b079296149d3" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ce858a6d-5bde-402c-8449-9f5173780565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c319fd7f-e4e7-4306-9979-56298acd9c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d83449a-9cbe-478d-8405-86273b4528f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c319fd7f-e4e7-4306-9979-56298acd9c66" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d83449a-9cbe-478d-8405-86273b4528f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_df9d34a6-556c-4ed7-b3fb-0d0d7a82b104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d83449a-9cbe-478d-8405-86273b4528f2" xlink:to="loc_us-gaap_PlanNameAxis_df9d34a6-556c-4ed7-b3fb-0d0d7a82b104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_131d5dae-9bbd-4a57-a585-d5818417bdee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_df9d34a6-556c-4ed7-b3fb-0d0d7a82b104" xlink:to="loc_us-gaap_PlanNameDomain_131d5dae-9bbd-4a57-a585-d5818417bdee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_39cd5866-1f0e-403d-b1b3-10c5464a8047" xlink:href="arwr-20230331.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_131d5dae-9bbd-4a57-a585-d5818417bdee" xlink:to="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_39cd5866-1f0e-403d-b1b3-10c5464a8047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_2aff7c66-5f52-45db-abcf-8054ddc94de8" xlink:href="arwr-20230331.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_131d5dae-9bbd-4a57-a585-d5818417bdee" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_2aff7c66-5f52-45db-abcf-8054ddc94de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_371ce57a-5bd9-4fe4-9b89-1406c894871e" xlink:href="arwr-20230331.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_131d5dae-9bbd-4a57-a585-d5818417bdee" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_371ce57a-5bd9-4fe4-9b89-1406c894871e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementAwardsMember_ec092998-6723-40dc-8e61-9bdb28636738" xlink:href="arwr-20230331.xsd#arwr_InducementAwardsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_131d5dae-9bbd-4a57-a585-d5818417bdee" xlink:to="loc_arwr_InducementAwardsMember_ec092998-6723-40dc-8e61-9bdb28636738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_01716a3d-9879-42f7-b3cb-9596fa7380a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d83449a-9cbe-478d-8405-86273b4528f2" xlink:to="loc_us-gaap_AwardTypeAxis_01716a3d-9879-42f7-b3cb-9596fa7380a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5403ee58-cf70-4e78-b54b-377b202f47e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_01716a3d-9879-42f7-b3cb-9596fa7380a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5403ee58-cf70-4e78-b54b-377b202f47e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0209609c-25bc-4cd7-afc9-4c03abe580ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5403ee58-cf70-4e78-b54b-377b202f47e4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0209609c-25bc-4cd7-afc9-4c03abe580ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e4421ed0-f380-47c8-ac0a-5bf8c7b5b501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5403ee58-cf70-4e78-b54b-377b202f47e4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e4421ed0-f380-47c8-ac0a-5bf8c7b5b501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1419e6a-a3e3-4d58-b222-6cf6c4aadb31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d83449a-9cbe-478d-8405-86273b4528f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1419e6a-a3e3-4d58-b222-6cf6c4aadb31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7b8b76a5-a5e6-4b86-8ac8-9521791927ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1419e6a-a3e3-4d58-b222-6cf6c4aadb31" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7b8b76a5-a5e6-4b86-8ac8-9521791927ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2735e73d-22c0-4704-985f-ba8b31c5d537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1419e6a-a3e3-4d58-b222-6cf6c4aadb31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2735e73d-22c0-4704-985f-ba8b31c5d537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_437d7af2-4a44-4ab3-9d95-cae76688230f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1419e6a-a3e3-4d58-b222-6cf6c4aadb31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_437d7af2-4a44-4ab3-9d95-cae76688230f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_05f46952-aa04-488a-adaa-3dbcc7cfeb3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1419e6a-a3e3-4d58-b222-6cf6c4aadb31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_05f46952-aa04-488a-adaa-3dbcc7cfeb3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0ee0f74b-420b-40b4-b5ef-1978ff887ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1419e6a-a3e3-4d58-b222-6cf6c4aadb31" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0ee0f74b-420b-40b4-b5ef-1978ff887ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0f6f19ea-bfc3-48ee-83ef-0d76aa7e9800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1419e6a-a3e3-4d58-b222-6cf6c4aadb31" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0f6f19ea-bfc3-48ee-83ef-0d76aa7e9800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3aa4d51c-faea-43b0-ab76-2817c28023c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1419e6a-a3e3-4d58-b222-6cf6c4aadb31" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3aa4d51c-faea-43b0-ab76-2817c28023c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1b037966-522e-4ad0-ab83-15458d2082c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1419e6a-a3e3-4d58-b222-6cf6c4aadb31" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1b037966-522e-4ad0-ab83-15458d2082c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bdd52438-e9c4-4a69-8b7e-ffad10b10781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cee5cb3b-223b-49e0-95c8-c9cb7bb5e1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bdd52438-e9c4-4a69-8b7e-ffad10b10781" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cee5cb3b-223b-49e0-95c8-c9cb7bb5e1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_724d456d-c6ff-4fcb-bab7-0659f6fa4d63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cee5cb3b-223b-49e0-95c8-c9cb7bb5e1bd" xlink:to="loc_us-gaap_AwardTypeAxis_724d456d-c6ff-4fcb-bab7-0659f6fa4d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31fa804a-625b-4d68-898d-2c0614e684a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_724d456d-c6ff-4fcb-bab7-0659f6fa4d63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31fa804a-625b-4d68-898d-2c0614e684a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_edc4b2cf-8113-4156-b94a-6ffa5ee9d18f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31fa804a-625b-4d68-898d-2c0614e684a0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_edc4b2cf-8113-4156-b94a-6ffa5ee9d18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1e799c9b-454e-4fb7-ae72-989f82f48d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cee5cb3b-223b-49e0-95c8-c9cb7bb5e1bd" xlink:to="loc_us-gaap_PlanNameAxis_1e799c9b-454e-4fb7-ae72-989f82f48d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5101f235-2471-405d-b6c8-9c92814b7297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1e799c9b-454e-4fb7-ae72-989f82f48d64" xlink:to="loc_us-gaap_PlanNameDomain_5101f235-2471-405d-b6c8-9c92814b7297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_49b55c55-a934-4bcb-96b7-f6fee0d8c830" xlink:href="arwr-20230331.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5101f235-2471-405d-b6c8-9c92814b7297" xlink:to="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_49b55c55-a934-4bcb-96b7-f6fee0d8c830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_b534b39b-e85d-466a-937c-7aa4910ce3a5" xlink:href="arwr-20230331.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5101f235-2471-405d-b6c8-9c92814b7297" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_b534b39b-e85d-466a-937c-7aa4910ce3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_d9891e27-f8b1-47fa-87d1-e04d71e80ece" xlink:href="arwr-20230331.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5101f235-2471-405d-b6c8-9c92814b7297" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_d9891e27-f8b1-47fa-87d1-e04d71e80ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementAwardsMember_d1e4a9ee-b40b-433d-a616-843c72815e92" xlink:href="arwr-20230331.xsd#arwr_InducementAwardsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5101f235-2471-405d-b6c8-9c92814b7297" xlink:to="loc_arwr_InducementAwardsMember_d1e4a9ee-b40b-433d-a616-843c72815e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba4eebc0-7f64-41f0-96d1-050f9d6383ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cee5cb3b-223b-49e0-95c8-c9cb7bb5e1bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba4eebc0-7f64-41f0-96d1-050f9d6383ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5e0b33b8-8cbf-454f-a63e-7fa6b937e2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba4eebc0-7f64-41f0-96d1-050f9d6383ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5e0b33b8-8cbf-454f-a63e-7fa6b937e2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_709de95d-7c27-4c85-8b74-fc3182b29391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba4eebc0-7f64-41f0-96d1-050f9d6383ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_709de95d-7c27-4c85-8b74-fc3182b29391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_91e70d90-15b1-4081-9042-e0d3a18567fe" xlink:href="arwr-20230331.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba4eebc0-7f64-41f0-96d1-050f9d6383ce" xlink:to="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_91e70d90-15b1-4081-9042-e0d3a18567fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_23925da1-abb3-41ef-96ca-6c3d5e3f6890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_38f701b4-f4d0-4687-bcb9-21cd02c0351d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_23925da1-abb3-41ef-96ca-6c3d5e3f6890" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_38f701b4-f4d0-4687-bcb9-21cd02c0351d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c689e6fc-f3b9-4271-8d28-3813a9497448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_38f701b4-f4d0-4687-bcb9-21cd02c0351d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c689e6fc-f3b9-4271-8d28-3813a9497448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a9461a6f-5ab6-4d20-a1c4-cf868a9789f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_38f701b4-f4d0-4687-bcb9-21cd02c0351d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a9461a6f-5ab6-4d20-a1c4-cf868a9789f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1d14a850-5249-4653-b9af-e8a0fa86be05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_38f701b4-f4d0-4687-bcb9-21cd02c0351d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1d14a850-5249-4653-b9af-e8a0fa86be05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f6da8c8d-2b2b-4ed9-9586-3c98bbc0eff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_38f701b4-f4d0-4687-bcb9-21cd02c0351d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f6da8c8d-2b2b-4ed9-9586-3c98bbc0eff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d0392add-bf0a-4c2f-9eed-7a55dcc7d6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_38f701b4-f4d0-4687-bcb9-21cd02c0351d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d0392add-bf0a-4c2f-9eed-7a55dcc7d6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_425e4be0-0ec7-4664-8cd7-9de8d11c583f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_23925da1-abb3-41ef-96ca-6c3d5e3f6890" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_425e4be0-0ec7-4664-8cd7-9de8d11c583f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5ba37ee3-0143-448b-8253-0976b2057817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_23925da1-abb3-41ef-96ca-6c3d5e3f6890" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5ba37ee3-0143-448b-8253-0976b2057817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2709eda1-81b5-4b74-b696-f821147e8f51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5ba37ee3-0143-448b-8253-0976b2057817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2709eda1-81b5-4b74-b696-f821147e8f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_47213531-4bbc-403c-97f4-13cdeb9253fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5ba37ee3-0143-448b-8253-0976b2057817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_47213531-4bbc-403c-97f4-13cdeb9253fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c594607e-2b9c-46f2-b02b-e999a65eedd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5ba37ee3-0143-448b-8253-0976b2057817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c594607e-2b9c-46f2-b02b-e999a65eedd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ecbc913f-8fd6-40b8-a404-fcdc48485d98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5ba37ee3-0143-448b-8253-0976b2057817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ecbc913f-8fd6-40b8-a404-fcdc48485d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bf5ee629-3743-46a7-a568-545f01aa2610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5ba37ee3-0143-448b-8253-0976b2057817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bf5ee629-3743-46a7-a568-545f01aa2610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0d68153c-cfc5-43bd-8f96-c3186a60629d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_23925da1-abb3-41ef-96ca-6c3d5e3f6890" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0d68153c-cfc5-43bd-8f96-c3186a60629d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ebc37c22-46b7-4f09-aca4-84a6de6e3436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_23925da1-abb3-41ef-96ca-6c3d5e3f6890" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ebc37c22-46b7-4f09-aca4-84a6de6e3436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_395af10c-ab03-4873-9af2-ce3fff4bd1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_23925da1-abb3-41ef-96ca-6c3d5e3f6890" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_395af10c-ab03-4873-9af2-ce3fff4bd1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e600afa9-4d75-4e79-a1a4-9a46c852461a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_23925da1-abb3-41ef-96ca-6c3d5e3f6890" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e600afa9-4d75-4e79-a1a4-9a46c852461a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4926aa0d-25fc-4546-8c84-cf1c02c4e732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_23925da1-abb3-41ef-96ca-6c3d5e3f6890" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4926aa0d-25fc-4546-8c84-cf1c02c4e732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_acfb9a73-8acc-4322-849c-1223f016f59e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_33000ae9-4563-449d-a2a1-30d46d5f7d56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_acfb9a73-8acc-4322-849c-1223f016f59e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_33000ae9-4563-449d-a2a1-30d46d5f7d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_444a6aab-27ff-4e55-94d2-e0c3e1eeeed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_acfb9a73-8acc-4322-849c-1223f016f59e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_444a6aab-27ff-4e55-94d2-e0c3e1eeeed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_adefeeaf-048a-4eff-8ea3-831c60419da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_acfb9a73-8acc-4322-849c-1223f016f59e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_adefeeaf-048a-4eff-8ea3-831c60419da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a472e74c-f8cf-46f2-b1dc-65b9a08146bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_acfb9a73-8acc-4322-849c-1223f016f59e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a472e74c-f8cf-46f2-b1dc-65b9a08146bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b1afff98-b8d5-4c26-87af-02285ba79b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_acfb9a73-8acc-4322-849c-1223f016f59e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b1afff98-b8d5-4c26-87af-02285ba79b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#StockBasedCompensationSummaryofRSUsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_745dbf45-c266-4447-afa6-3e432e843d01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da1490d6-cc94-4183-8fed-cf859a9d947f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_745dbf45-c266-4447-afa6-3e432e843d01" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da1490d6-cc94-4183-8fed-cf859a9d947f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8a98fb46-7f41-4dd3-a2bd-67e353765f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da1490d6-cc94-4183-8fed-cf859a9d947f" xlink:to="loc_us-gaap_AwardTypeAxis_8a98fb46-7f41-4dd3-a2bd-67e353765f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f8a641b7-d982-4df1-bee0-d2ffc92ae558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8a98fb46-7f41-4dd3-a2bd-67e353765f5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f8a641b7-d982-4df1-bee0-d2ffc92ae558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2fc1b3c5-51a4-43cd-b0ba-e6ef443428aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f8a641b7-d982-4df1-bee0-d2ffc92ae558" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2fc1b3c5-51a4-43cd-b0ba-e6ef443428aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_488bbafc-910e-498e-932a-542a6ca46c56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da1490d6-cc94-4183-8fed-cf859a9d947f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_488bbafc-910e-498e-932a-542a6ca46c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b3db0f8c-92a2-4b18-ba96-3991a488c534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_488bbafc-910e-498e-932a-542a6ca46c56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b3db0f8c-92a2-4b18-ba96-3991a488c534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1cbf6769-038e-416c-9cd7-dad978f6b511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b3db0f8c-92a2-4b18-ba96-3991a488c534" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1cbf6769-038e-416c-9cd7-dad978f6b511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_52087326-a1d4-4782-b083-a066df20dc27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b3db0f8c-92a2-4b18-ba96-3991a488c534" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_52087326-a1d4-4782-b083-a066df20dc27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2e78c8e2-3438-449a-a298-74e5f6c53f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b3db0f8c-92a2-4b18-ba96-3991a488c534" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2e78c8e2-3438-449a-a298-74e5f6c53f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1197b29d-312d-4f2c-a03e-ab05bba630c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b3db0f8c-92a2-4b18-ba96-3991a488c534" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1197b29d-312d-4f2c-a03e-ab05bba630c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6233a2a1-81b0-44ab-8672-1778d34049b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b3db0f8c-92a2-4b18-ba96-3991a488c534" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6233a2a1-81b0-44ab-8672-1778d34049b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7ec7d5d9-2662-4913-b4f1-e4150e64a759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_488bbafc-910e-498e-932a-542a6ca46c56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7ec7d5d9-2662-4913-b4f1-e4150e64a759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7c815f97-1586-4b8b-b606-ef18ab3adaed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7ec7d5d9-2662-4913-b4f1-e4150e64a759" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7c815f97-1586-4b8b-b606-ef18ab3adaed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_39f33ca9-007b-44db-b0d2-056e21a9368a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7ec7d5d9-2662-4913-b4f1-e4150e64a759" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_39f33ca9-007b-44db-b0d2-056e21a9368a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d4a50ae9-8d0a-4a9b-a783-b97e75002925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7ec7d5d9-2662-4913-b4f1-e4150e64a759" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d4a50ae9-8d0a-4a9b-a783-b97e75002925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0bb39e3c-6699-4e09-be3f-99a65feda730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7ec7d5d9-2662-4913-b4f1-e4150e64a759" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0bb39e3c-6699-4e09-be3f-99a65feda730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e6685d24-3344-47a5-a543-52001fb5afee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7ec7d5d9-2662-4913-b4f1-e4150e64a759" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e6685d24-3344-47a5-a543-52001fb5afee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1480f651-97fe-4395-b519-c164f54678b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c182cff6-d826-45cb-9dcc-335749d75bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1480f651-97fe-4395-b519-c164f54678b1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c182cff6-d826-45cb-9dcc-335749d75bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8fa48f32-2e1b-4d61-9c05-5bf525d4ce04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c182cff6-d826-45cb-9dcc-335749d75bba" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8fa48f32-2e1b-4d61-9c05-5bf525d4ce04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_128ff8db-f779-48b3-8d01-e140cd995796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8fa48f32-2e1b-4d61-9c05-5bf525d4ce04" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_128ff8db-f779-48b3-8d01-e140cd995796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a2c3bc42-7640-4c51-895e-6334869d3197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_128ff8db-f779-48b3-8d01-e140cd995796" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a2c3bc42-7640-4c51-895e-6334869d3197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_182de0e8-4420-495b-908c-085f58baf77e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c182cff6-d826-45cb-9dcc-335749d75bba" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_182de0e8-4420-495b-908c-085f58baf77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c49b66b2-ca13-48d5-841f-48f540037024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_182de0e8-4420-495b-908c-085f58baf77e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c49b66b2-ca13-48d5-841f-48f540037024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8d7f18f9-ae93-4c77-9f8f-2b31b0f0c097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c49b66b2-ca13-48d5-841f-48f540037024" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8d7f18f9-ae93-4c77-9f8f-2b31b0f0c097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_46dc3457-fc62-4dce-a916-1c7e2be6235b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c49b66b2-ca13-48d5-841f-48f540037024" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_46dc3457-fc62-4dce-a916-1c7e2be6235b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0890d862-e65a-4345-a4ba-029b23ef2f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c49b66b2-ca13-48d5-841f-48f540037024" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0890d862-e65a-4345-a4ba-029b23ef2f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ea13b4f0-c951-46ae-a9f7-a8f193b3dd13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c182cff6-d826-45cb-9dcc-335749d75bba" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ea13b4f0-c951-46ae-a9f7-a8f193b3dd13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e7a6e392-1711-4355-8d21-104377fe48d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ea13b4f0-c951-46ae-a9f7-a8f193b3dd13" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e7a6e392-1711-4355-8d21-104377fe48d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_ce2aeb1f-d689-4e73-86e3-4d552e4f048a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e7a6e392-1711-4355-8d21-104377fe48d5" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_ce2aeb1f-d689-4e73-86e3-4d552e4f048a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_e0b7f91c-d849-4585-8dac-3c8070359a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e7a6e392-1711-4355-8d21-104377fe48d5" xlink:to="loc_us-gaap_MunicipalBondsMember_e0b7f91c-d849-4585-8dac-3c8070359a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotesMember_6ee253f4-caea-4ee3-ad9a-b3bfe2c10072" xlink:href="arwr-20230331.xsd#arwr_CommercialNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e7a6e392-1711-4355-8d21-104377fe48d5" xlink:to="loc_arwr_CommercialNotesMember_6ee253f4-caea-4ee3-ad9a-b3bfe2c10072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d5a370cb-2119-40ed-bb84-e4f0dd39a3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e7a6e392-1711-4355-8d21-104377fe48d5" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d5a370cb-2119-40ed-bb84-e4f0dd39a3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_d7c26fd5-7e70-44cb-84d9-af1560587638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e7a6e392-1711-4355-8d21-104377fe48d5" xlink:to="loc_us-gaap_CertificatesOfDepositMember_d7c26fd5-7e70-44cb-84d9-af1560587638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_771d90df-19fd-4f1f-848d-645d3220c75a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c182cff6-d826-45cb-9dcc-335749d75bba" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_771d90df-19fd-4f1f-848d-645d3220c75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b96e3731-5668-4694-a01a-02dd45c4386d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_771d90df-19fd-4f1f-848d-645d3220c75a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b96e3731-5668-4694-a01a-02dd45c4386d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_07dc6247-ef7b-4c48-bf70-a92123cd9501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b96e3731-5668-4694-a01a-02dd45c4386d" xlink:to="loc_us-gaap_MoneyMarketFundsMember_07dc6247-ef7b-4c48-bf70-a92123cd9501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5fb293f1-dcd7-44c6-bf1b-de89f9f55f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c182cff6-d826-45cb-9dcc-335749d75bba" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5fb293f1-dcd7-44c6-bf1b-de89f9f55f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_e2fa51f3-2988-44fd-a11d-65eb847dedde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5fb293f1-dcd7-44c6-bf1b-de89f9f55f0c" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_e2fa51f3-2988-44fd-a11d-65eb847dedde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1a904a3e-7810-4496-9dd1-179f2caaa894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5fb293f1-dcd7-44c6-bf1b-de89f9f55f0c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1a904a3e-7810-4496-9dd1-179f2caaa894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_84de6fea-7b6c-45a4-9e29-e6e4d5799808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5fb293f1-dcd7-44c6-bf1b-de89f9f55f0c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_84de6fea-7b6c-45a4-9e29-e6e4d5799808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_82d90712-014f-49ec-8d7e-68242ca089ed" xlink:href="arwr-20230331.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8544012-638e-4030-aab6-7d359d4adbac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_82d90712-014f-49ec-8d7e-68242ca089ed" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8544012-638e-4030-aab6-7d359d4adbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_93c92b41-b325-4b6c-904d-76ac9d2764d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8544012-638e-4030-aab6-7d359d4adbac" xlink:to="loc_us-gaap_TypeOfArrangementAxis_93c92b41-b325-4b6c-904d-76ac9d2764d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5284deda-6f72-4cc4-92b0-a2138fa40927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_93c92b41-b325-4b6c-904d-76ac9d2764d8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5284deda-6f72-4cc4-92b0-a2138fa40927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaAgreementMember_79b60433-6ab8-43f3-95b2-9deebf619223" xlink:href="arwr-20230331.xsd#arwr_RoyaltyPharmaAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5284deda-6f72-4cc4-92b0-a2138fa40927" xlink:to="loc_arwr_RoyaltyPharmaAgreementMember_79b60433-6ab8-43f3-95b2-9deebf619223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_45f9d37b-b24c-4754-b52e-6a4eb7be2489" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8544012-638e-4030-aab6-7d359d4adbac" xlink:to="loc_srt_RangeAxis_45f9d37b-b24c-4754-b52e-6a4eb7be2489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ff01ff7d-099c-4a0f-929d-407c36d3c642" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_45f9d37b-b24c-4754-b52e-6a4eb7be2489" xlink:to="loc_srt_RangeMember_ff01ff7d-099c-4a0f-929d-407c36d3c642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ac46d90e-9382-414c-9cdf-b675d46c1aa1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ff01ff7d-099c-4a0f-929d-407c36d3c642" xlink:to="loc_srt_MaximumMember_ac46d90e-9382-414c-9cdf-b675d46c1aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41083d56-4b99-413e-95f4-b4c7ce22b262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8544012-638e-4030-aab6-7d359d4adbac" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41083d56-4b99-413e-95f4-b4c7ce22b262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_5365f937-0786-41dc-b51d-be82c2fb0fdf" xlink:href="arwr-20230331.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41083d56-4b99-413e-95f4-b4c7ce22b262" xlink:to="loc_arwr_InitialTransactionPrice_5365f937-0786-41dc-b51d-be82c2fb0fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_8609744c-3dc9-4913-b03d-a977a55fdbba" xlink:href="arwr-20230331.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41083d56-4b99-413e-95f4-b4c7ce22b262" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_8609744c-3dc9-4913-b03d-a977a55fdbba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable_fe3e8fef-b98e-4708-bcb6-62b213b35212" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41083d56-4b99-413e-95f4-b4c7ce22b262" xlink:to="loc_arwr_MilestonePaymentReceivable_fe3e8fef-b98e-4708-bcb6-62b213b35212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_cc995809-7166-4528-b3b2-95ac59e4c263" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41083d56-4b99-413e-95f4-b4c7ce22b262" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_cc995809-7166-4528-b3b2-95ac59e4c263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponFDAApproval_bef4a019-bd72-469b-8642-154dadd31550" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentReceivableUponFDAApproval"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41083d56-4b99-413e-95f4-b4c7ce22b262" xlink:to="loc_arwr_MilestonePaymentReceivableUponFDAApproval_bef4a019-bd72-469b-8642-154dadd31550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_05f94da4-f7d2-4930-b10d-08554154a1bd" xlink:href="arwr-20230331.xsd#arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41083d56-4b99-413e-95f4-b4c7ce22b262" xlink:to="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_05f94da4-f7d2-4930-b10d-08554154a1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPaymentThreshold_5b0e2cf5-19d9-42c6-8f8e-cf9f8f7339d6" xlink:href="arwr-20230331.xsd#arwr_RoyaltyPaymentThreshold"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41083d56-4b99-413e-95f4-b4c7ce22b262" xlink:to="loc_arwr_RoyaltyPaymentThreshold_5b0e2cf5-19d9-42c6-8f8e-cf9f8f7339d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilitySaleOfFutureRoyalties_629b9527-7ea9-4f80-b140-84be9d45cdf8" xlink:href="arwr-20230331.xsd#arwr_LiabilitySaleOfFutureRoyalties"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41083d56-4b99-413e-95f4-b4c7ce22b262" xlink:to="loc_arwr_LiabilitySaleOfFutureRoyalties_629b9527-7ea9-4f80-b140-84be9d45cdf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_0da93f98-397b-460a-a47d-8cad8a7781c0" xlink:href="arwr-20230331.xsd#arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41083d56-4b99-413e-95f4-b4c7ce22b262" xlink:to="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_0da93f98-397b-460a-a47d-8cad8a7781c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="arwr-20230331.xsd#EarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_373d55c1-4d8e-4e54-9e4c-d7d01df4611d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_17963cd7-150c-4b5c-ae3a-de40315c1347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_373d55c1-4d8e-4e54-9e4c-d7d01df4611d" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_17963cd7-150c-4b5c-ae3a-de40315c1347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_956fcd6c-8578-407b-96e4-a1a2ab741be4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_17963cd7-150c-4b5c-ae3a-de40315c1347" xlink:to="loc_us-gaap_NetIncomeLoss_956fcd6c-8578-407b-96e4-a1a2ab741be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_04a53eee-8570-4d49-ac65-3d7546d0469d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_373d55c1-4d8e-4e54-9e4c-d7d01df4611d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_04a53eee-8570-4d49-ac65-3d7546d0469d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_14a018c1-287c-418d-9e01-fed1f619958c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_04a53eee-8570-4d49-ac65-3d7546d0469d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_14a018c1-287c-418d-9e01-fed1f619958c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_bcea3221-8071-4273-befe-ff17794ecb1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_04a53eee-8570-4d49-ac65-3d7546d0469d" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_bcea3221-8071-4273-befe-ff17794ecb1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4e632444-5f07-4d6e-bf2a-f558f1fd915f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_04a53eee-8570-4d49-ac65-3d7546d0469d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4e632444-5f07-4d6e-bf2a-f558f1fd915f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_bcbf8675-5fad-4695-a136-58151a0b6002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_373d55c1-4d8e-4e54-9e4c-d7d01df4611d" xlink:to="loc_us-gaap_EarningsPerShareBasic_bcbf8675-5fad-4695-a136-58151a0b6002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_54180bdf-fce5-43da-b9e2-d662c4cecfad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_373d55c1-4d8e-4e54-9e4c-d7d01df4611d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_54180bdf-fce5-43da-b9e2-d662c4cecfad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_972848f5-7df1-4063-ba81-38ed605e155d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_373d55c1-4d8e-4e54-9e4c-d7d01df4611d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_972848f5-7df1-4063-ba81-38ed605e155d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>arrowheadpharmaceuticals001.jpg
<TEXT>
begin 644 arrowheadpharmaceuticals001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55 \4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ***P/$'C;PUX6P-:UBVM7/2(DO)]=B@MCWQ0!OT4BL'4,
MIR",@TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[SMWE^1#Y.?[FP=/^!;J /3/"G@?5_B+:V_B7X@:C<7%I/B6TTF)C'$$/1F
MZ9'3'.,9/:KGQLTG3]&^$CVFF65O9VZW<.(X(P@ZGGCJ?>NV^'_B'3_$?@K3
M+JPE1O+MXXIHE/,4BJ 5([=./48->;?'GQEHMWX8D\.V5S]KOUGCDF\@;T@
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M<GGCT]Z^3?AQ=1V_Q4T.>9A$AO@"7.,%L@9_$T ?9]?+?[1/_)1[;_L&Q?\
MH<E?2-KK^FWVMW>D6MP)KNSC5[@1\K%N)PI/3<<$XZXKYM_:((/Q(MP#TTZ(
M'_ON2@#Z!^'W_).?#?\ V#+?_P!%K725S/PZE27X;^&V1@0-.A7(]0@!_4&N
MFH ^0O%>H'0?CO>:E,#BTUA+AAZH&#?RKZ[CD2:))8W#QNH964Y!!Z$5\T_M
M">$I['Q-%XE@B)L[]%CF<#A)E&!GZJ!C_=-7?A3\:K;1]-A\/^*'=;: ;+6]
M"EMB]D<#G [$9XX[9H ^BZAN+NVM#"+B>.(S2"*/S&"[W.<*,]2<'BN;F^)?
M@F"T-R_B?3#&!G"3AG_[X&6_2N-\/Z]+\4_B);ZE:0RQ>&/#Y9XFD&#<W++M
M#$>P)('4<9^]B@#URBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** *=_JVG:4B/J.H6MFCG"-<3+&&/H-Q&:L03PW,"302I+$XRCQL&5AZ@CK
M7%^-FG7Q9X1-M8)?R^;=8MWD"!OW)[D$<=:HP65WX<TJVTI[B]M]0U.^N;N.
MPT41-L4G<8U>8!55<@D_+DGB@#T:BO*;?Q;JUWH_AR*[OM0A>Z:_%U)8VT<E
MRWD2^6GRA64#D;BHQG&.,U.-2\5QKX=T2[DU62^NK&:\NWM?LJW!960*@,FU
M  'R0,MT'3)H ]/J&*\M9YYH(;F&2: @31HX+1D\C<!R,^]9WAE]7D\/V_\
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ML9-1N$Y$E^XD /\ N !?S!KGO^&D/#'_ $"-7_[YB_\ BZ/^&D/#'_0(U?\
M[YB_^+H ]D50JA5 "@8 '04M>-?\-(>&/^@1J_\ WS%_\71_PTAX8_Z!&K_]
M\Q?_ != 'L%U:P7MK+:W4*36\RE)(Y%RK*>H(KPGQ3^SDL]W)<>&-3C@C<Y%
MI>[BJ>RN 3CV()]S6M_PTAX8_P"@1J__ 'S%_P#%T?\ #2'AC_H$:O\ ]\Q?
M_%T <?I?[-^O2W2_VKK&GV]OGYC;;Y7(]@54?K7O7A7PGI/@W14TO28"D0.Z
M21SEY6[LQ[G]!VKS7_AI#PQ_T"-7_P"^8O\ XNC_ (:0\,?] C5_^^8O_BZ
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ML5B )**,[0 >@ KIZ* *]E8VNG6<=I9P)!;Q@A(T& ,G)_4DUF:?X0\/Z3J
MO[#2H(+H9'FIG=TQZ^A-;=% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% #)8HYX7AFC62)U*NCC(8'@@@]167_P (IX=_Z &E_P#@''_A6O10!D?\
M(IX=_P"@!I?_ (!Q_P"%'_"*>'?^@!I?_@''_A6O10!D?\(IX=_Z &E_^ <?
M^%'_  BGAW_H :7_ . <?^%:]% &1_PBGAW_ * &E_\ @''_ (4?\(IX=_Z
M&E_^ <?^%:]% &1_PBGAW_H :7_X!Q_X4?\ "*>'?^@!I?\ X!Q_X5KT4 9'
M_"*>'?\ H :7_P" <?\ A1_PBGAW_H :7_X!Q_X5S.I^-?$FF^&K[Q#)X9L1
MI]MO=0^J,)I(PV P40D#(P<;N]6;/Q5XEN-.T?5)/#EA_9^HM;Y>'4V>2%)B
MH5F0PJ#C<,@'_&@#=_X13P[_ - #2_\ P#C_ ,*/^$4\._\ 0 TO_P  X_\
M"LGPIXIU#7/$?B72[^SMK;^R)HHD\B1I-^]6.2Q ]!V'?K76T 9'_"*>'?\
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M . <?^%:]5[:^MKN>ZA@E#R6LHAF _@<JKX_[Y93^- %#_A%/#O_ $ -+_\
M ./_  H_X13P[_T -+_\ X_\*GUS6;3P_H=YJ]\S"VM(C(^T9)QV'N3@#ZUS
MTOB'Q7;:&=;D\/64UMY/GFS@O6-PJ8SW3:S8Z@$>Q/< VO\ A%/#O_0 TO\
M\ X_\*/^$4\._P#0 TO_ , X_P#"I8M9MTT&TU6\98(YXXF/.0&DV@*/7E@*
MTJ ,C_A%/#O_ $ -+_\  ./_  H_X13P[_T -+_\ X_\*UZKV5];:C;FXM)1
M+$))(MPZ;D<HP_!E(H H?\(IX=_Z &E_^ <?^%'_  BGAW_H :7_ . <?^%:
M]% &1_PBGAW_ * &E_\ @''_ (4?\(IX=_Z &E_^ <?^%:]% &1_PBGAW_H
M:7_X!Q_X4?\ "*>'?^@!I?\ X!Q_X5KT4 9'_"*>'?\ H :7_P" <?\ A1_P
MBGAW_H :7_X!Q_X5KT4 9'_"*>'?^@!I?_@''_A1_P (IX=_Z &E_P#@''_A
M6O10!'!!#;0)!;Q)%"@VI'&H55'H .E2444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$=@0 NT]N<^HQR /U.T\86UWI=[H%MKDES'<*+^+4;VW,%Q"?O$()2$;.,;
M!R:]*KSW0-/^(_DPZ-KESI(L(<))J-N[FXGC'8#@!B."W49R.>:]"H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-)!9NMHL\EV4)5I&W\*FX$ #DX.:]#KS;3O!GC30[.?P]H^NZ;!H#2R-!</
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRQW83=G(S^M;GB+Q7XDTSQ=9:)-XHT/2%;2DNYY;R 8$N=K*"7&26#$ = *
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M:RR1AL''4<_GVP-'\?>*FB\.74NN:'JDVJSQ))I%O#BXCC?JV58XVCDY  H
M]IHKR75_%OB*/QGXBTY/%N@:59:8(G3[;;C+;U+;!E\D@8R1Z]*;JWCWQ*O@
M?PCJ_P!KT[1KK5;K[/<FZA)14);$PW,-J[5W8/7>.: /7**\IT?QEXBLK.Z\
M1ZOJ%OJ?A>+3GN([FWL_(,L_F^6L8!)/.#SC'S"K>HCXJC2/[8M+O2_M;[<:
M*MKN$88@<RE@2R@Y/0<&@#TNBO)=>\2>/8M=,=E<6EE:W&LQZ59Q7%B2T@V
MO,"2,H"&/]:['P)=^(KS2[Y_$FTW$=_+# RVYAWQ(0H?:>>2&(]L4 =31110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!PWCK0_%6L:SH=QHB:2UKID_
MVLI?2R*7F 95X53P <]<YK,U3PAXRU."^U6YN]'DUZXM'T^WB0R);6<#@[V4
MX+-(3MY( XKTRB@#R30O OB_3+O3%BMO#VF11-:QWEUI\\PGN((3G805V_-W
M/&>]76T7XCKXUG\1QV_AAI6LQ8Q1O<3X2(.7SPG4G&?I7IU% 'C<7PW\8:M-
MI5CXGN=-NM'M[F6ZN5AO9Q+)+(Q;<#M'*YPHR!UI]A\-/$NFKXPL[,Z7#IVM
MVA@A1KN:5U8 JI9F7/*L<]>V*]AHH \9A^"UQ97GA6>WFM9#IR/+J1E=A]IG
MR)$'"G*;PHY_A X)J63X7ZYK0U_5?$::=<Z[>,OV,P7]Q'"B=#&P4#Y5'3@Y
M.<U[#10!XVG@'QQ/I'AC1M2B\-7FG:-(':*:65Q. &4!E*8.%;BM:3P/XE\/
M7'B"U\&G28M&U:/>EO=22(;69@5<QA5(P1@X]@.@Y].HH \?T3P#XQTM]-B@
MM_#NFB);:WN[ZPGF%Q-;QN&88*[<MSD\9Z$XKO-5U359?%>G:+I"QK&J_:M2
MN)$+".')"(O/WW(;Z!2:Z2B@ JAK:ZF^BW::/]G_ +1:,K ;EBL88\9) )X&
M3TZU?HH \JTGP-XRD\)VGA#5;K1K+0HT$=P]B9'N)TSEERP"KN.<GWJ_;>&O
M&/A;5=7A\+_V-+I6IW37:?;6=7M)& #<*/F7@8&1TKT:B@##\*^'$\-:2UL;
ME[N[N)GN;RZ<8:>9SEFQV'0 =@!5CQ%'JTV@7<.A_9?[1D39$UT[*BYX))4$
MY R1[XK4HH \>7X:^(8=&\*V,&G>&(Y=+N(KB[N 7$DS1L<#=LR01@GWXZ4_
M4O _C'4_$NK:I>Z5X4ODO&@$27,\_P"Y6$DKM(4$9/+=CTZ5Z]10!Y/JW@WQ
MYJ^C:+87TNAZ@+>]-_>B\FE9)7WOMB V<Q!67@]QCH.;_P#PA?B'PQK6K3>"
M!I$&FZG"K/:73NBP7 R"T813@$'./7V KTFB@#Q?1_AWXSTJTL[:UM_#EA/'
M#':RZG:3S"Y,(D#OCY=I9L=<9[9K2NO"7C:X\7:KK4VE^$;X7BQPQ1WS2R"&
M--V,?)U.<FO5J* ."T?PMXB\)>"Y;#0SI,NJ7-Y)<RK*7BMH ^<K$ "<+A0
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M ' ["O0Z* "O*[SX?:]XF\5ZCJ_BA-/EB2V,6EQ6E]/'Y+ \!BH'#9RQY/3
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8SP3TQBGW&E^,_&=G#I/B2PL-*TM61K[[/<^:][M((10!B-"0,Y)..*Q-/\
MA]J.N>.+[5O&/A739H+R0/Y@U%V^SHD854"* 'Y49SCK0!>N_'WBF;X4IXLT
MRPT[[5;RN+M'5Y(WC1RADBPP)'&[D] :U="\5Z[XH\5,-&.F3>&+5$6XOFBD
M#33%<LL)W8(&1R1Q[UJ^+K764\+OI7AC2K*43P/;%))1"D"%"H*K@@XSTXZ4
M[P#IVHZ/X.L=+U.PMK*:S00JEO-Y@=0!\Y.!AF.XD<_6@#IJXB\\0>(]>UJ_
MTSPBFGPP:;)Y-UJ-^K.K38R8HT7&2N1DD]^E=O7F]GI?C?PMJ6M6>B:=INH6
M&I7TM]!=W-T8S;-)RPD0 EP#TQ^?8 %2]^(GB"W^'.KZJ;;38=;T74/L%VD@
M=H9&#*,QX(/.]>IXYJ31O$_CC4=8L4BG\.:IIQOS:7TVG6\Y$&U [?.S;>A
M!&1DU4U_P+XAB\/Z?HNG65GJZ/J U35KBZG$7VN;=N9"F"-IX_  8KO/"&@P
M>'O#\=K#IT&GO*[7$]M!*9$21SDA20.!P!QP!B@#>KRWQ?XV\8Z;K.I1Z-:Z
M6+"UNK2RA-[!*7N)I@#A"K $+GFO4J\[\;V'C+5]?TL:=HMA/INF7T=[&TM]
ML:=U0@9&WY0&8^O2@#)OO'7C72O#>K75]%HB7MMJ\6FV[F"5(9=V-S?,^2 6
M'/ PK=:U+'Q7XEU#QS;:%9WOAR\MUTS[9=3VRR.%?.S:"'(&7.0#D[0:G\=:
M%KWB75?#]JFD:?=Z/:W*75XMQ<X#MAE*;2IRH#9]^F!6'IOA7Q3HFJ^*;[2?
M#.C67]H6Z6]E%!=A%B"Y!; 3!)SN/3D 4 9FG?$?QUJ^F-<:=-X8N[TI++%I
MT%M<//(D<FPM@/A<D@@$@D<U[3:^>;2'[5L^T>6OF[!A=V.<>V:\9\/>"/%N
MB-IZZ?X>TO2;H106EWJEO>AI'A60-(VS;@LV.3UQ@5[70!SOBSQ)-H4%E;:?
M:"]U?4IOL]E;LVU2V,L[GLB@9-8EO=?$BS\2:=9W\>BWEA=B1IKFV@E46I5"
M0"2W0L5 /7@U;\::)KD^M:#XBT"*VNKO26F#65S)Y:S)*H4[6_A88[^OX&%[
MOXAW>GW\YT;2K.1H/*M;+[87D\PGF1I0-H &<*!R>XH XK3_ (C^.M5L))=/
MG\,75[MG>'3X+:X>>5(GV%@ ^%R2,;B"170ZOXH\9P>,(M"M+GPU;8TM+Z:6
M^24!&R$89#]VW$#T')KGO#_@;Q=HBV*:=X>TO2[U88;2YU6"]#2-$)%>1MFW
M!9L8SR<8%:DGP]O_ !;XOUV\\7:'8K9WENL-I/%>%Y;78" 4&T<DG<<XZ8YH
M LV?CSQ1JOA6SET^QTY]7N-9;3%G19)+-T4$M.N"&V<8SGL:K>&?&OCO5]3T
M4W-OHLFFW][<6[26MM-N$<.=S[B^ "1@9_*MO28/'.B?#^#3$TW3;K5;9C:Q
MN+KRU,(4A93\OWN@V_CGM5KP%INO^'? ,>EWNF6B7MC&RV\<=UN6<X+99MOR
MY8GUQ0!E7^N?$'_A/7\.6$GAO:UJ]]&\L,Y,<(DV*'(;[Q]AC@TOCKQCXA\.
M:_I.GVE[X?MX;JSEFGGOTEQ&T0RQ^5NAR H&3G-)H-CXX3X@76NZIH>FQP7L
M,-LQ2_W&WB3<3M&WYB2<XXJAXC\'Z]XH\>2W>J^&],O-&-N+"+S+[#Q1^9N,
MR_+D.1V'3IF@#9\/:KX^U0:FLZZ(4%I#-IUXEM.D$S2#=SN;<0%ZC .2*@\%
M^)/%^L17&L:U/H,6A6LUQ%*]O#*)'$61O4EB N1GGG -=1K\FNZ=ID$/AC2[
M2ZD \O;/<^4(E PI'!S]*Y?PGX7U]/AK?>$-9M;:P!LY+:&Y@N/-:1I-Y=V&
M!CEL]3G)H 8=?^(.M:+)XDT.STJWTXQF>SL+J.22YNHP,@DJ0%+#E5'J,FH?
M%WC#QIHFC^'6L;72GUB_M]UQ82Q2,X=4WR%<. $49!R2<D5;TA_B1::79:&-
M$T:V-K&D']IM=F2-D4 96$ -D@="0,^E8L_@CQ1XDU[5]=\0026UTMMY6FPZ
M?JYB 4?\LRP3H3R6/?MZ '177C#6;OP#X<U70[6VEU369+:'$L;M#$S@F1F"
MG(5=K<YK T+QIX_U+4]-$L&ARV%SJLM@[VUM-G9%G?("7P%.T@9[]JT_"&F^
M-?"?PZBTF/2;"XU"VG=($>^P/)8LVXMMZ@G&.X]*L>#=.\6>&OATVF-I-BVI
MVN1;+]LRLY9RS.[;?EY8G'.<=J .5M/B)XXU 7B6EUX6EO8I;J.WL8K>X>:X
M$'4J QP#VW8S7KVDR7LNCV4FI)''?O C7"1@A5D*C< "3P#GO7C&C> _&6C6
M=NMAX?TNQU=83;OK,=\#+M>0,[E-N&;&0"<D"O<Z ,'Q7XD_X1S3X#!:F\U&
M]G6ULK16V^;*WJ>R@ DGL!7.1Z_XQT#Q-H]IXF72+FQUB4VZ-IZ.K6TVTL =
MQ^93@C/_ .HZ7CC0M7OY]%UG01!+J.CW+3);7#;4G1U*NN[L<=#5&/2?%.LZ
MK#XBUNQLH)M,BD;3-'BN=X,S+C?++MQG' P.,YH Y\>.O%]WXIU'1[;4O"D#
M0ZB;&VCGAG:29MN[HK=AP6( R*] \'7NMZCX6L[SQ%:1VFIRAFE@CC9 @W$*
M,,20=N#U[UQ/@/P+J-GX@;5?$F@:?%?QSW%W'J$%UOD>29N590HRH4G&3QV'
M/'J= &=KUW/8:!?7EM/:02P0M(LMV&,28&26V\XQZ5P_PV\<^(/$LVIVOB&T
ML[2YBMH;NU\J-D#Q2!L,P+$]E/XU:^(^B>)O%'V31+"T@;0I9$>_D^U^5)(H
M8YC'RG ^ZV><].._*S^ _%^A^)]5N?#MN;JTNM-?3TFU'53)(0V"'&5XVG.%
MZ=>>: '>'_C7<S^#=;U'6+:U_M2TE1+*WMD91<>8I,?#$G'RL2?[HJ-_B/XU
MAM]!EN[KPM9+JEA+?L]Q#,!#&HR,X?)+ C &23FDO/A?JP\-VEQ9Z-:?\)"V
MF'2I=U\/*AC"E/-7Y.9&4D'G !INI>!_%.JZBLFH^$-'O+.'3(M-MX&U+'E*
MASO5MF0QZ9 ''% &I>^-/'NF>$M9UBYM]%?[-+:BQD2VF6.[24#)4,^XG+H!
MTZ-4D7Q!\2:TGA!]$72$;6=\-U%=12,\,T0)FP PPH X!YY%1ZGH7Q U'1M/
MM[BPL)VCU@7[VYO J0PQD>5;@A>5XR3UXJWIO@'5-%^)6I^(K9(9=/-O/<V5
MH9MH6\E""09QP#L/S8Z$<<4 +'XC^(6J7WB)]'3PX]EI-]);(D\<P>;8 Q4,
M&QNP0,\#/M6;:_&&\NO&'AJV-M:0Z+JMK$\[,&,D$K^8H4OD+C<G''(J?0M!
M^(=MH5YH9L])L/[0N)Y[K4C<F5U,K$L5C &6 .!DXXK/LOA7?WAUK3]8TJ%-
M+>*W^PF"_'F9ME*1J3L. ^YBS8XW<"@!;CXL>(=2/BK4="@TJ+1=%A1XI+V&
M0O<;CA2,,!AL$CCH5K4T/Q;XXU35M/BBF\.ZC:FZCBU Z?;SDVJE/,.7+;<X
MXR,\G'M6%<>"O'$VCZM8#P]I*0ZI?0SRQK?\)!"$"0@;?NX3&<_A6YX?T+QC
MH=]+)IOA[2])L?\ 2+E[*WOMR75PZJJ G;\BKC( XH I:/\ %+Q!?)XJL;I=
M(AU+3(I;BRG\J46\\4+LLIQNR<;>,$>_2DN_'WCVVT.*^-MHD?EZ,-7N9)+:
M;RP';$<*_/\ ?(ZY.*H7?PK\2ZC\/])L3':V>MV$\T3R1W&[S[:?)E+' YRQ
MXYX'O78_$31_$NK:)'X=T'2K.;3&2'S99;ORVPC@^6%V]"%7G/<\4 3^"]<\
M8:CK][8^(K;3DMX+.&<26<$J?O).0F78@X .<=R*[EF"J68@ #))[57TY[R7
M3K=]0@BM[MD!EBBDWJC=P&P,_E3[RV6\LI[5V*K-&T9*]0",<?G0!P \1^-?
M$UE/K/A6#2K?28R_V07ZNTM\%)!8;2 BD@@9Y[\51U?XCZQ-X<\):MHITBS&
MMR&*8:GO*PL <MN#*-H*MR>3E:=I6C_$*R\-1^#DM],MK6&,VRZVLY9O)Z96
M'&?,VGN<9JGXB\#:U/JFCZ?8^&]-U#P[HUH]M;Q7=YM,I=%!D8;3AA@XQGGF
M@#=\&^(/%^LZU;M?G2+K09[%KF._L+::-6??M"9D/7ACTZ8]:] JII6FVVCZ
M3::;91>5;6L2Q1IDG"@8ZGK]:MT <5XCO/%]MJ&M0Z2JO'_9@N].<V^X"9&P
M\1/<L,8^OM3?'7B?7=&\/:9>Z%%9?;[V:.%+.]C=I)7<#"*%(P1R3GH!7;UY
M=J_@_P 1^+?'+WVMPM::58PR)IIL-3,<@?/WB0N<N, ], =^X!H6/C;5K[X/
MW7B@)8PZO:Q3--'(C>2KQ.P9< YY"\<]2*S-*\<>+(]6\-P:LWAV[CUEE!M=
M.,@N;<,F[>P+$;5[U@0>"O']MX%UCPO%I5D;?4;TSB234]TD:$J60G;\V=OW
MN#\QXKHK?P/JGA7Q#8Z_X3T738GN;(P:GIIN2L2OP0T;E2>N0>,''OF@"K>>
M./&::AXE,-[X3M['1KAH@;P2JTN%W;0=_P!X @'CKTK;3QQK.LVVC:?H>F01
MZYJ%@E_<_;&;R;*(\!FQ\S%CG:O'J:Y2'X4ZGJNAZS=ZKIEC:>*&O6U"RO8K
MCS"\A8OL<$8"=%[]<]N>C?3?&NE^)1XFLM*T^]N-0L8[?4+#[9Y?DR(3M9'*
MX*X/(Q^?6@#-UCQ_XL\,V/B"PU.'2IM7TZW@N[:XC1_)GADE$9!3=D,"<=?Y
M<LO_ (C^(5LELM+N]!O-=M=1CT^]C%O,(FEE8B-8OFR<!7W$G^'BI?$?P_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BN1\>^(]9\.6FEMHUK8W,U]?1
MV02Z=Q\S_=QM^A)/8#O570O%?B!O$][X<U_3]-BO8;#[?'-97#-#MW;=K[AE
M3GGZ T =Q17D<7Q*\52^![+7EL-"-Q?WD=O;6PGDW%78H"5]2V#U^[[\5?\
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M;J1Q(S,ZJ@15&#RW<T =G17G/BCQ;XS\)>##JU_IVB2W_P!K2%8+>65@R-P
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M%UZ]UR:/0(-$NM)&EOJD=S-),C"(97YQMX)<-QCH#S5&P^(GCC4;2QN+;3=
MN&N1;NUK;R323Q1S-A7=0,*."3D\"@#U^BO,[#XCZK<_$#6_"4UEIR7$*2C3
M9O,?RYI%4/L=L==K G XP?:LVR^)7B_4-(TJX@TO11/J*W5PI>241QV\& 78
MXR"3G'7C'3- 'KU%>6>&O'7C77+VTMY-(T=#>Z2^I6^V248&=L8<GIEB.F>*
MAT[XG^(-9TK3+73=-TV7Q-=7DL-Q8%Y MI%&2&>3^[SCOSGC)XH ]9HID/F^
M1'YX03;1Y@0G;NQSC/;-/H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+)59&>),XW%]@RWM4USX+\6>(YO$>OZS9ZK8ZI-&+:SL;'58%26V/'E,Q4@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*1?7+0JTTD(95P%(&&! '3MG% #XOBMJ;Z/=!]!M_P#A((]4_LV'24NR9)&
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M.OK;3(+-[&)GEAVQ%I,M*0&Z;0!@<UZ:B+&BHBA548"@8 % $5Y)<164\EK
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MX5FO%KGCS4]+_M#0Y]%T33[E+R1+N13-=3)]Q0JD[4!Y)/7B@#LIQJJZS:O
M;9]-9&6XC?*R(W574]&'8J<=<Y[5D>)/%,^EZA:Z-I&G'4];NT:6.W\P1I%$
M#@R2/SM7/ XR3Q735Y[K*ZYX=^(L_B*VT*XUK3[RPCM2+1U\VW9&+8VL1E3G
M/U_4 GTSQ3XQGU74](O_  O:QWMI9_:8I8KP^1.S, J[BGR]'SG^[TYJUX!\
M5:WXNT\ZG?:-:V.GR!A;RQW1D:0JY4_+M&!\IYS5;4/$'BZ7PQ?3Q^$+A+JX
MWPV=O'<QM+&I0XDEYP/FQP"3ZUA>&G\7P:9X5\-VWAV_T>ULWC%_>R21,LD:
MHQ8  DC<^/>@#<N?&?B#5+B\_P"$0\/PZC964C127=U<^2L\B_>2$8.[!XW'
M S3(?B6-5T?1VT'29;W6-5C>2.Q>0((%1BDC2OCA0P('&6[5C>&9?&GAGPRG
MA"U\+/)?VIDB@U1IT%H59BPE;G=D;L[<9.*98^'-7^&^OV=Y8:/<Z_IYTI;*
M5[9E$T<HD:1VVL1E69B>O'X<@&J/&_BVRFUFUU7PO:1S:=IK7XGBO6\B4!@
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MT:LRE&(!*DYP?2G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !47V:#[6;KR8_M!3R_-VC=LSG;
MGKC/.*EHH **** "BBB@ HHHH **** "BBB@ HHHH **** (H+:"U5UMX8XE
M=VD8(H&YF.68X[DDDFI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ***C=P@W%E"CJQ(Q0!)16>^M:7&^V34K13
MW!G4?UI8]:TN8XBU*S<^BS*?ZT 7Z*B$L<@!1U8'N#FGKGOF@!U%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%<UXM\96OA 6,E[!(\%S.(6D09$?!.3[<5OVUU#>6Z3V\B2Q. RNA
MR"/K0!-12 YI: "BF[C^/I36E"(6<A5'4DX H DHJ&.YBF&Z.1''JK C]*<9
M" 3M) ]* )**X^^\<.]U-:^'])GUEX/];+ ?W2'^[NZ%O;.:T?#/BFV\2VDC
MQ1/;W<#F.YM9>)(7!P01_6@#>S2 ^^?>N=U/Q,4U8:1I-N;R_ S+M^Y #T+G
MU]JA_P"$?U74!NU37;@ G_4VA\H#VW+AC^= '127MM%_K+B),==S@57?6]-C
M&6O[8#U\P5FKX+T%%(EL_M&?O-<R-*?S8FK$?A;P]&@1=%T\KZM;(?UQ0!=C
MU6QEV^7>V[;NF)!_C5A7) .00>]</XC\/^ -/0S:G#86#]4\J402$]MH4@D^
MF*Y?0M;U?P]I&M:JQU!M$4*FFPZCDRR2$GE=WS8QCK0!VOB'QC-::B-%T*T_
MM#67'W"V(X ?XG(!^N*R)]3\<>&$CU369[#4;#>$N8;:$Q-"">'#%CG!XQCO
M6[X,T#^R-(%W=KNU>_\ ])O9F7YC(W)7V"YP!V JE\1]573_  TNG0H9]0U)
M_L]I!]YF;J3CT '6@#L+:X2Y@CFC;,4BAU;U!YI99D@C:65PB("6+' %><>!
M[/7O#GB*+1]7U.2^2XL$EV,>(&!8;5'IA171WTB^(/$HT82'[-9*)KL(>'8_
M=0_CDD>U #YM1U?6=O\ 8YCM;/)#74Z[F;W5?3WS^%+%X1M993)J-U>7\A[R
MR;5_)<5T4<$<2*D:A5484*, 4[MTH PSX-\//@MID9(]68_UI5\&^'TSMTR,
M9'9F']:V@X/ YQZ4V6>.%#)-(D:+R6<[0/Q- '-R^ ]&W%X!=6SD<-%<-Q^9
M(_2N<UZ\UWX>PIJG]JOJFD!PDMK=(!,,]T9>OTQ6]J/CJT63[-HUK<:S<EMN
MVS4NB^[. 5'YU3M?"^I^(-6@U7Q2\:Q6[![;3(6S'&WJY_B/US0!VR/O12,_
M,,\U)2;>,4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'MO"5I?W4AGO]1B2YN)6ZDL-V/H,T =#I^F6NF6$=I9QK%$H^50._J?>O/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.U<^_P 2_!D0!.O6@P.V[I[<5D7OQK\%V89TO)KEE) 6),_CR1Q0!Z*2!DY
MQZFH+JZAL[:2XN)8XX8URSR'"@>YKS%OC##J0VZ;'96BMG$]_<D8_P" *AS^
M=4UU+P[J]PD_BWQO9WR(VZ*SMHVBB4^^<EOTH Z;P2LFL>(=?\3A66SO95AL
MR1@2QQA4\P>Q*D@UW852,YS[UQ]O\0O!=K D,.NV21( %5=P"@= .*L#XD^#
ME'&O6N/Q_P * -+5_#MGJ4\=X-T%_$,1W4+%7 ],CJ.O!XYJ]9P311!;B02L
M/X@ ,_@*Y]OB5X. _P"0_:_F?\*0?$GP@3G^WK3'KD]/RH ZO QBC:,YQ7*_
M\+*\'?\ 0>M/S;_"@?$KP?\ ]!ZT_-O\* .CNK*VOK=K>[MXYH6X*2*&!_ U
MS,G@QM/)D\.:A-IC]?)#%X3_ , .0!]!3_\ A9/@_P#Z#]I^9_PI!\2?!Q_Y
MC]ISVRW^% $4/B37M*;R]?T:1HE_Y>[%3(F/5@.1^5;NF>(-+UF,MIM_;W)'
MWD1QN7V*]1^-8Q^(_@YEQ_;MHP].?\*Y?6+WX;ZO/]LAU^&QOE.4N;1RC9[$
M@J0: /4MS9]N^13Z\9B^*8\+W*0:CJMEKFG,P1+FUW)-&/5U.0?P(KN(OB=X
M.EB20:[; ,,X;((^O% '745RO_"RO!W?7[0?BW^%'_"RO!O_ $,%I^;?X4 =
M517*_P#"RO!W_0P6GYM_A6YI6KV.MV?VO3[A)[?.T.G3/>@"]1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5GZWK-EX?TBXU/4)1';PKDGN3V ]23Q6A7ENKZD_BG
MQ%)=*OG:)H]P(+6U)PNHW_('/]U#^'% #K0ZAXFU:TU>]M<W[+OT[3Y ?+L$
M/_+:4=W/85T,<UIHDMS;V+"2X \W4]2EY*GW]6]%' %3,&T6S:))XUU>]7S;
MF[<;EB X+')^Z.BCUQ[US=WJB6:W=A<1I!HUPH:"53E9(SAC)N'S-,S'A?;/
M.: 'ZUJ5_!#97.DQ74%OJ!$!G,2K<-<%AY9=F!"QG)[?EFDTRQUZSU2?4K_R
M[<EU\Y99=D)G50K2J%&7# # )X.:U+&SU#?:W5S<?VG>BV$<$,T'D>5&64EY
MOF8%AM!X Z<#J:V+&2QDN4DNY&N+ES^ZN)8\(_\ US'0#]3[T 8\DNGS+)-:
M:5)<P7&IQRR23.8T2=2H5@.N-RJ?<FM]-.OS<-<>;96\K=6BMMS'ZDD$UE:O
M<1+?W<)D58YY8(F!/7;EI/\ QP@<<U=OM<L;IX+6.^6..1\3,&*,!C@>HSZT
M -NY;^*3[/;:I!->GA8Q:@[?]XAN!4(L9[?Q )1:Z;=7S1EVN#%L=0.!SSR<
MGGVIL6N6W^HT:W6&W)P;UX6\OZK@?-]20/>I(;UQ-LL[RS61VPTUWDO.P_NJ
M",#T_E0!!XI9M3\/W6GWZ2:?O /V@C?%D$$ D=CTK$U:S\2ZE>0RV<,"326@
MB:6UDPGDA\LJOCAVZ#LHR:ZG4KPRVB+<Q>7);S(]Q%G(9,]5/\2TR"RD&JZ@
M]G<""X5U(BZQ2(0",KV/4;AS]>E '-Z;JICU%K-/M<UW;E?.N3M\R$-]V-U'
M$FWHS#IQWKH+RS;49Y&55M-5\DQD2#?#=1YR58?Q#MZC)K*\1PSC2773[&*Q
M>!99;H)_KRIR6$+ ?QDG+=1D\9J.R2ZMM.M/MVK64FDM#D2Q[8AI\J[?+"MG
M+YR00WIZ$B@#(L-4D\"W7F103#P_)-Y=Y9GDZ9*Q^\I[Q$Y->IQ2QSPI+$X>
M-P&5E.00:Y>^CCOK2:]CM8Y[V.(1W<*\K<PD<@<\Y'*_E61X'U$:)J7_  B\
MMT]Q8W$9N]%N7 PT/&Z$GNR']#0!Z%1110 4444 %%%% !1110 4444 %%%%
M !1110 A&1BLF_\ #6BZK.)M1T?3[R0#;YEQ;)(V/J16O10!S_\ P@WA/_H6
M='_\ 8O_ (FC_A!O"?\ T+.C_P#@#%_\37044 <__P (-X3_ .A9T?\ \ 8O
M_B:/^$&\)_\ 0LZ/_P" ,7_Q-=!10!PGC#P1X;C\(ZG):>']*AF2!G61+.-2
MN.2<@>E:%EX-\*3V,$J^&](;?&I+-9H<\?2M[5[3[?HM]9YQ]HMY(L_[RD?U
MK%\"7XU'P?82<[HU,3Y]1_D4 <WXZ\#:-;Z,FKZ9H6FK/ICBY:!+5 D\:X+H
MRXYRH('UK=M?#?@B]TN+48M T4VLD8E$GV*,#:>_2NID1)%9'7<&&&!'#"O/
MO <(TZYUKP==*)$L7WP*W.Z!\@?E@#\: ,.\U#PG8WM[ /"FCW86Z\N#R+*+
M#1B*-CR!R<N:S_,MFUE@?"6@K8K<7 8#3X=^R%'8C[O4[*]7B\,Z-':):IIL
M'D*Y=4*<!CU/UX'Y5:.DV.<M:Q\EC]WH6!#?GDT >8QZAX7:\M(#X$TY9KB(
M2[$M(3\K$A3T_P!D\5I6EGX9UC1=6NM,\(:2)K.!BOF6,;?O0F2F,=CQ^%=O
M)H]@[Q2FSC$L V1.%Y3Z4FB:';:)I[VL*EO,E>21F_C9F))_$F@#R?3+_1M1
MU6TMQX6T)8;V91;EK"/F-0?,/3L2OYUM>---T;1[G2X=+\-:(3=^821I\;GY
M0""!MZ<UZ FB:8OEXL8 (E98\)RH;&['UP/RI;O1-.U"&&*[LXIHX?\ 5JZ\
M*,?_ %J /+[#4/"<ND(T_A/1FO2L?,=G&%+.I.0".@Q3+2_T)9!'=>%=$E>5
M$$2K9Q)\Q=UY)&,845Z>_AS1W:%SIT&^( (=GW1Z"I)-"TR2%X7LH3$PP1M^
MI_J?SH \U2[\+7\4K6?@[1U$=JTKM-:PJ5?86  QEN>.,UJ^#+7PEXGTPSR>
M%M'BD5_+(^Q1C<?9<5VK:#IC212&P@,D2&.-@OW5(P1^6:;_ &%8)<P3QVR1
MO"<@1\ GWH \QO5T?2_&$]M>^']%73(Y"L2QZ?&V_"9QN"Y#Y[$_A4EKJ/A2
M\@@9?!&DI/-+L4/:PJA7!).XC';]:]*?0-+?5/[1:QA^UL>9"N2>,?RIH\.:
M0+80?V;;^3Y@D";> W/- 'F]UJ'A:VBEE'@72S&)_L\3"UA^=\ GM_M=:AEU
M3PO:QZC<W7@W1$AA>-($^R1!GR&)!&.N%)_"O5)-$TV2!X6LH6A=_,="G#-Q
MR??@5'+X>TF<OY^G6\A;&2RYSCIF@#SJ&^\(R1S7?_"#Z8NGP%!-<&UB^0L,
M],9P 1FM&^@\*6>B:???\(;I(FOP&CB>UB7 V[CEB,=,UUNH>'+&\TN73A&8
M+>8CS%B&-XZ8_("KMSI=G=VZVUS;)+",'8PX% 'G/AZST37]5U)U\+Z%#86U
MNC1*UE#EF;?U.,_PU@VUW80%UO/#.@R7+SQJ(CI\2J$:3;N1@N",>YKV>*PM
MH#)Y-ND9=0K[1C<!T_F:I1>&=&M_.5-.MU$YS)A/O8YYH \SGU7PL]W=6EGX
M.T226WF2,N;6(J5+88@XQGI6[X=M_"'B#5KNQ3P=I<:P$@2&RB()!((^[ZBN
MR7P[I$;3.NG0#S<%\)][G//XBIK73;.SNGFM[58Y)#\S*,;N* ,__A!_"_!_
MX1O2!["RC'\A7G/C#P?H_AKQ9I.HZ;I.FR#49OL\VGS6ZNC#^^JD?*1GG&*]
MGK$?0+.76SJTJ--=(NV+?TB]=OH30!"O@?PF1G_A&M'/O]AB_P#B:7_A!O"?
M_0LZ/_X Q?\ Q-;R?=^O-.H Y\^!O"?_ $+.C_\ @#'_ (5JZ?IUEI=M]GL+
M."TAW$B.% BY]<"K=% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S'CS5YM+\-O
M#9,5U"_D6SM<#)WN<9_ 9/X51\)Z);:="B+\UCHZ-!$6'^LGZRRD8ZY) (]3
M69XBU0W'Q"/EJ9$T&Q:94(R#<2X2/^>/QKLX8(-+\-"&XE6*-(#YLI 'S$99
MC[DDGZF@#/.C#Q%I,TMU-/!)=NDB,G#1JIR@P>W&<'UK-LO#CZ/J$LTVRZ>4
M%(%D=I'FESGS7W?*I Z #CFM3PMKL=];)9/(C31)^[DC^Y,@XW#T(X!'8U6B
MO;?56U'4I+H6S6<GE6[MGY%'\?/4.3]" * *OBF:]TNTMX;9KE'E)>:X@C+M
M+)M;:F<' +;?KTJY8VMO>:8CQ7'E7*0J9[=W.Q. =N#]W!].E5/$%]>:SH=D
M;&._6,SG[3]C+)*&3A4R,$ OC)]!7&^+->UZPLM$M?LL%I=WDH2\EEA 6Y(3
M.3@$@\9[T =I-I&MV]_:7-F(7E5I'?S#O1MX7J>H(V#YAZ].:+[PMKFKV<@O
M]:1964_NXX%*9Q[_ ,ZY.U^(E]IUS$9M*NFB6#RQ#;3J\8. !]XKZ$YQGG%1
MMX_U2^TI(S972WT4H<&6X6-6'IE 21^'?O0!<BLIK*=84$L5XK;62,$CU* #
MC.W''3!!K133)IM/ATR33C%=Q!T."SER00&W$# &<Y!..PKFQXK\5?:;B[EE
MT%VFB*&.&&6.4>F)<'I[\58D\=ZC;0:6J6=^S02L\X@G1E=>RDOR1UXS^/%
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M^@FNVC<3*KQON0\@@\$'^=<-\26,%WX4O HWQZLJ9/7#1R"@#OQTI:1>E+0
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MI[FQM+L?O[:.4@$*9(PV/IFN:BL);&P2YOI9(9(&C4?-M5@&QG R22N![\4
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M8S,C$;O/501G@@Y[T <&NFWHC&;"YX SF!O^>3#T]2*K/:6;7<ICA7RS(2,
M@??7_P"O^M>B#PSXA#&*2RE2X_@C\W(<8Z[@,#\<=*:_A'Q0B,YT<D*"2%NE
M)/TH \W%G!Y:_NN=JYZ]</\ _6_2O5/@<EROA[#7R>0;B?%L3\WW\=/S.??%
M<U%(DT2R*S@'LP((]B#T-=9\(8<69D-@^3/<$7))QC?0!J:S(_A+Q-]JTVVM
M4BNHP3$T))G?<=RAQRK<C P0:MWWB"U\23V-C82R0S-(9(I)H_W,CJIW1GD-
MG!/0=CZ5VDD,4Q4R1JY4Y4L,X^E8MAX1TC3KJ.>"*0F)BT2O(66,G^Z#TH Y
MK58;[2X3;W4^'O[AYYVM]_ 5<+SVR0O'T'/4]=X<N+BZ\/V4UWGSVC&XL,$^
M^*Y+QAK$LNI-9179MGM,21A@0KOP02>A'4;<]Z[9;DII0NI=JL(?,;)P,XS0
M!Y]K -QXB\*+%\Q;6)YQ[HJ;2?SKTRO-]+1KWQ[HD,@7;9Z9)>,F[.UYG!'3
MVS7I% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MIWPVTR]LM!LY)+L-!)#O:#=G8['=C'08SU]_:O-M/TF37+P644+SVMJPFO\
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M8:EI7VQKA89C=;-C8M)"X7W&W(%4;SQ#!I%J7M],>.(R!2TN(AN;I\HRY)]
MM $FB^';;0'$UK+]GL_+#/"W&6P 6<]">,D]<]\5G^+=9?\ LLK')]FAN=T5
MO<2)F/S<'8TA[1[L#GK]*SH?$(U/Q/:6E[=":V$;,Z) Z1-*K;67!Y&P@$[S
M_$,+WKLM2FT]['[+<1Q7"7*%$ML ^<".@'I[]!0!Y7IFCW^J3S7%_9?9]26^
M1_.EA)DF8,00IR O"J69<@@BN]A\/ZOI\MK+9ZA;S/&)?,^T1D%O,P3ROHRJ
M?IFM72=*6QMX=X'F1QB-$#%A$@& JD\GW)Y/Z55UK7_L8FMK$127B1^9))*^
MV&V3^_*WIU.T<G';J #,U.YCTZRN;)+Y%N"/M&IWFW BC_B/L2.%%9_@?2CJ
MFK2^*[B!H+41_9='M6&!%;\9DQV9R/RK$T33;GQW?&3,R>%HYO.DGD&V35I@
M?O,.T8QP/2O68XTBC6.-0J*,*H& !0 ZBBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** ,+QCK,F@^%+^^@&Z[">5:IW:9
MR$C'_?3"N#T^UU;P=KOA.XOM*MK.R$(T2YGAO3.92_S1NP*+C]X#SD_ZPUZP
MR*X 90P!!&1GD=Z1D5QAU##(.",\T >+ZEK.G6OP_P#$.B37<:ZJ=>FQ9Y_>
MX-X) VWKMVG.[I[UTMCI_AZS^,NL-=6NGPW\UK:SV1D1%D>0F82-'GDL>,D<
MUZ ;>!I&D,,9=@ S%1DCT)IS0Q/*DK1H9$SM8J,KGK@]J /%]&T33K'P/X1U
MRWME357UJ!6N\GS"CW#(R;NNPJ2-O3VJ/4;6/4=5\51ZMJGA_3M374'%O=:C
MN6[MX@ 87A;<,+C!&WJ<YS7MGE1A%3RTVJ<@8X!IKVT$LJ2R0QO(GW7902OT
M/:@#SF3PYIFO>./%JZS:QWI@L+,()1E59DDRX7H&X&#U'8UA1V^B7<7PUU7Q
M+%8R1SZ9)'<75^J[780J8P[-P3G<1GOFO9@BAF8*-S<$XY--:W@>-8WAC:-<
M%5*@@8Z8% 'DNNN47Q=YS.NFGQ)9+J3(2,6IB@\S)'.W&,^V:T=9O/!-CH:P
M:+8Z)=V=UJ4,$P$@6QAD*,0\FW*8P.F.25SZUZ7Y:?/\B_/][C[W;FHQ:VXM
MS;BWB$!ZQ[!M_+I0!X=-:V-Y\/O',0ATZ>SLM1BGMELX\V\/R1;VB!S@8+YQ
MQRV.#78W T^/Q5X:'A867V4:7J?V06>TP[]T/3;Q][.??->AK#&JE5C0*1@@
M*,$8Q_*D2"&(((XD0("%"J!M!ZX]* /%M/'A]O#WA2;1W@;QF][;?:F1LWAD
MW#[4)OX]N/,SNXZ>U3:KH>G7'A?XAZU-;*^I6>HW+6MRQ)>W*)&ZF,_P'/)(
MQGO7L:V\*3-,L,:RN,,X4!C]32F*,JZF-=K_ 'ACAOK0!C0'27\51R-.?[<;
M303%YC?\>^_[VW[OW^,]:R/'7C*#0A;Z-!?V=GJNHJ1%/=RK'%;1]&E8DC./
MX5ZD^P-=CL7?OVC=C&['./2FR6\,Q!EAC<CH64&@#S)3H/AW4O ES9:C;2>'
MK2"[L1?^<K1"5E0@LX.T%BC_ (\59TO5-/?4?%^MMK2Z=I>HWMO:VNI(R!6>
M.$*S(S@H1D%<D$'%>AFW@,!@,,9B/6,J-I_"G&&(P^28D\K&W9M&W'IB@#S/
MPCK5AH5YXQNYM474M*M6BN9=;/SO,Y0@QEE^5RH"@!  -P&,U;\':UI&LZW?
M^*+S6=-.HW%KLAL8;N.1[.S0EOGVD_,2=S=AP.U>@+;PI#Y*PQK%C&P* OY4
MB6MO&24@B4D8)5 .* /.O#WB/1?&7C2WUN36-/1;99+?1]/^TIY[EN))F3.0
M6"X5>H7)/)K6N#_PD?Q*AM1\UAX=C%Q+Z-=R@B,?\ CW-[%Q77):6T;ATMXE
M8="J $5(J*I8JH!8Y8@=3[T <;XJ/]O^*M&\*I\UNI&IZD.WE1M^[0_[TF./
M1#5'Q'+8:!X@U75+;Q?:Z7=74,1O+&2))Y92BD(8T+!@Q' &&!XXKT (H<N%
M&XC!;')%-:W@>99GAC:5/NN5!8?0T >>02ZCX0^#NCZ:BE-=N88K&UC;JEQ+
MTS_N DG_ '#7;Z'I%OH.A66E6H_<VD*Q*3U; Y8^Y.2?<U>9%8J64$J<J2.A
M]J=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!SWC;7;GPYX6N=3M(XVE1XTWRJ62%6<*9& Y*J"2<>E9.J:WK>A>
M -7UO^UM,U9HH1+9W,%N40\X.X!V##T((KJ-8N;RUT]I++3#J3[@'MEE5&9#
MUQN^4GV)&?6O-+CP?JUUH'C(:;H1TJVU6WB2TTDS1\RJ3ODPK%(]P(& >=N3
M0!TNE^(=7MO%QT/4KRPU6)K![SS["W:-X2K ;73>^=V>,$'(/%9.F?$B[U#4
MM*MA8W@2]U:Y@W'3Y0/LT?F*N#C&X,$W'^'G(&*UH?"CZ%XM\S0+1;+2-3LW
MAOEL]D8MYEYCF53QD@LO /.TD5B>%/ ^MV&I>&;B_O=05+.TN)KB-I866.XD
M="8QA<D$&0DY/3@CN =_K$6KSVT<>CW=I:2L_P"\FN(3+M3!^ZH9<G..IQUK
MB[;QOK*>';Y)H[.?6(=;&B6TZ(RP3.64"0KDD !CD ]5(S70^-;CQ%%HRP^&
M[&2XNIY!'++&\:O;Q_Q.H=E!;L.>ISVQ7/2Z%?S^#K*TTOP[<:=/HU_!>VUM
M=W,3-=E&W/ET9AN;+<MCDT :=EJOB*T\1WGAR]N;"\NWTXWUC=BW:%,AMC)(
MH9N 2IR#T)I-)U;Q!:>.F\.:O=V6H++IQODGM[8P&(B0)L92S9!SP<YX-0Q1
MZ]=^(;[Q4=!EMY+72VL['3YYXO-GD+AV)*L50950.?4U'X,BUNTN;JYU;PY>
MKJ]^/,N[^:>#R\J#LB0([,J#H.#U)/6@!]MKNOV?C32=)O-2TO4TOUF-Q!9V
MY1K+8N0V=[94GY?F Y/'I5R37-=A^(>GZ3<P6<.EWD-R\05B\K>5LPS'@*#O
M^Z,^Y[#'31[_ %'Q9H^H67A,^'9;:X:;4+SS(1]H0JP,6(F)DW,0<L!C&>M6
MM8?79/B!I.I6_A>^FL]/BN8&E6XMQYGF&/#*#(#CY#U /3B@!=2\57-SXEO]
M+M=>TC1+>P9(3+?*)'N)F4.512ZX50RYZDD]L5+K_BBYMM>BT.+6-*THQVBW
M-WJ%ZH*Y9BJ)&A=1DE6/). !US67JF@:A9ZKXJCA\+QZO%KH#V]SOA B8Q"-
MDEWD,%!7<-H;J>]+%X:U#PUK%E>'1/\ A(4.BV^G2M&T7F)+%D;OWI7Y&#<X
M.>.10!?\0^(-3TQ_#MFOB'1[7[<DS3:E<6^87V*I7:IE &=W]XUN;-?N/#]J
MMEK&F2WLC9DO_LK&(QG)RD8D.3]T<MCJ?:L#1M/U'POX2TO3+KPRVKLHF=TM
M9(2+8O(7$8$K+E0&VY']WI5.VTSQ7X;\"W%OHVE*-0O]1EF6V@EC(TV"1B<)
MN*JQ4= #C<WH.0#9\,>)[J33_$!\03VI_L2[D@EO8$*1R(J*Y;:2<$9P1D\B
ML_0_&&NWMOXKFU"V@MVT^V2[LX-AW1H\;NJR<\M@+G&,$D4^S\,2:KX1&@#3
M]1\/PV\\<_F3R07#W3!B[%]K,&RP!;=U^G%&B^'_ !%I'B?Q+J=U=2ZI%/!"
M(8W2&/[8RH1@X'R;?N\X!SSF@"[X*U74M9CBN[GQ-H^I1O;J[VMC;!'A=@#\
MS>:W3D8P*["N#L=*O=4\<Z7K2^'&T*VT^":.9I6A\RZ+@!4Q$S#:I&[)/7&!
M7>4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!%<VT%Y;26US$D
ML,JE7C<9# ]B*\OU+PSJ'@V$+:6\^K^'(V,J0(W^E6#>L1[J!VKU6B@#B_#_
M (O6ZTQ;M9QJ6GJ/GN85_?1'.-LD77([D?E6\8],\0VHNK6>.3(PLT6"1[$>
MGL:RM9\ Z7J-[_:5A)/H^JC.+RP(1FR/XUQAQ]:YJ>Q\5Z+<F6_TB+5T&/\
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MERL;_P!D6]L"XE83MOV.%VED0<#/?).>*W5ATOP]#]INYU\XKM\Z7F1\<[5
MY/\ NJ*XNX\="^Q!%JUS<2L,>5H5D9">G25QCKGL*5-+\7:QC[!I]OH,;9'V
M_4)?M-[@C&5!R%/X\4 :WB3Q>EE8B>XG_L^RE&$SS=7 /3RH^HSGOZ]JQ]/\
M)7WBQ$.LV[:9H 82)IJ/F6Z/9YV_]EKI]!\":3HMPU],9M3U5^7O[]_-E/L,
M\*/85T] $<,,5M D$,:QQ1J%1%& H'0 5)110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!Y]8:OXTU2SU;5-/N=)E2SO[JWCT^6T=6E2*1E \T2<,0.N
MW&:VK?QSIUQH6FZI'::C,M_;BX6*UM))V1>^XJ"!@\>^.,U@Z2OBW1K+6-,L
MO#;M/<ZE=SV][-=PK JRRLRN0&+\ @XVY[4R3PYK6@V^AZ/9QZG?:-9Z=Y++
MIMVEL[76X?/(Q96V$9^Z3CN#Q0!JZG\0[*TNO#QLK6[O[/5]SK/;6LLA""-F
M&T*O+97E>H&2>E:6I>--(TJYE@G^V2-;QK+=&"TDE6U1AD&0J#MXR<=<<XQ7
M)V'A[7=%\-^"9?[*DNKK1KB9KJTAGCW[725,JS,%.-ZGK1?^&KV#Q)KEQ/H^
MM:A9ZLR2H--U7[.$/E*C1RIYJ _=^\-W!QVH [Y-;TZ35+?34NE:[N+8W<2*
M"0\0(&X-C&,L._>L76]5U6?Q1:>'-%GM[29K1[VXNIX3+LC#!%54W+DEB>2>
M M:6GBXT^73])M]):+38K$ 3FX#>2R[56+!^9N,_-[>]8^MVFJ:;XUM/$FGZ
M9+J<#6#V%S;P2(DJ?.'1UWLH(SN!&>X/- $6G^,[B+PMJ=UJD,<FIZ;?2:<8
MK8%1=3@@1A 22-^].,G&3V%7? NL:KK.C7;ZS]F^W6M_<6DAME*H?+?;P"36
M'I_@75+J--3NM2DTK47U.YU,V\21SK&TBA$!W @LJ+C([LV.QJ;PKX.U*#3=
M8M=<U*_VW&JSW,7V>86[D%V/F;H2#\X()4G QT% &_XBC\1%&ETC4].L((86
MD=KJV:4NPR<'YE"KCJ>36=I6H>(O%?A'1-8T^]L])FNK<2W$<]DUP&)QC;^\
M7:."><\$>G-#Q?8ZY(EAH%AI.H7^@>5F_ECO8S/. >(2TKAMIZLW)(.!CFM3
M6/[:O? CVND:3)IVH7*BU2"22/\ T1"VPOE6*X5,L I)Z#% !X#U;5M;TB[O
M=3N+:YB^V216<\$!B$T2';OVEFZL&QSTQ3O%LOB2SL[S4=+U+3+2TLK5IRES
M;-*TK*"Q#-O4(N .0">M7F\+V!T*QT>*6]MK6R14B^R7<D#85=HRR$$_CWYK
MF/%MGKEW?6.BQZ%?:AX:@B1K@Q7<7F7CK]V.0R.&V# +'DL?;.0#5DU75]3\
M,Z1JMOJ6G:&EU:+<7#7D)E*LR!@HRZ@ 9;)// J]X+UF\\0>$=/U34($AN9U
M8L(P0K ,5#J#R P 8>QJCK,LM[I]FM]X%DU.!T+-;.UL[6[] "KMMY'=6-3^
M ])U'1?"\=IJ?R2F>62.W\WS?LT3.2D6_P#BVC H Z6BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BH+F]MK(P"YG2
M+SY1#%O.-SG.%'N<&B&]MKBYN+>&9'FMF59D4Y,9(# 'WP0?Q% $]%%% !11
M10 4444 %%%17-S#9VDUU<.(X(4:21S_  J!DG\A0!+16<-=L&U>+2TDDDNI
M(1/B.%V5$.[:7<#:F=K8W$9QQ6C0 453N=6L;2&.6:X79)<):JR_-^]9]@7C
M.#N./;O4MS>6]GY/VB41^=*(8\C[SGH/T- $]%%% !113&EC21(WD17DSL4L
M 6QR<#O0 ^BLFZ\2Z59P),\\D@DN6M$2"!Y7>5=VY0B@L<;6)XQ@&K]I>6]]
M"9K:421AWC+ '[RL58?@010!/113(Y8Y2XCD1S&VQPK [6QG!]#@C\Z 'T44
M4 %%%9VGZYINJK;FSN1)]H@^TQ#:06CSC=@CCF@#1HHHH ***9%+'/$LL,B2
M1MT9&!!_$4 /HHHH **** "BJRZA:OJDFFK+F[CA2=X]IX1F95.>G5&_*DOM
M0M=.CA>ZD\M9IHX$.TG+NP51QZDB@"U1110!'-;P7"[9X8Y5]'4,/UKG[WP!
MX4U!MUSH=HS;MV57:<_A7244 <A_PJ[P9_T X/\ OIO\:NP> O"MO&J1Z':8
M7IN3<?UKHJ* (X8(;= D,21J!@!% 'Z5)110 453L-3M]2-W]F+%;:X:V=B,
M NN-V/4 G'U!JY0 45$]S!&TBM*@>-/,9<_,%YYQUQP?RIMC>V^HZ?;7UJ_F
M6US$LT3X(W(P!!P>1P: )Z*** "BBJK:A:KJD>FF3_2Y(6G6/:>45E4G/3JR
M_G0!:HIGG1B80F1/-*EPFX;BHX)QZ<C\Z?0 455?4+6/4X-.>3%W/#)/''M/
M*(5#'/3@NOYU:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>arrowheadpharmaceuticals002.jpg
<TEXT>
begin 644 arrowheadpharmaceuticals002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU1CH3NKUK(HR* % P**3(HR* %HI,BC(H 6BDW"C(H 6BDW"C<* %HHHSF@
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MD#E2 >O?IG%2^%+33_%7A[3]-M-;U4^(YM->[EN4U:9A#(K*%5T#%<-GIP<
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M5(;AX"=WS*5R "P!"\=.V?2@#G[2ZLH/C#XCTS7]<OX-$M$D>)&U2:%4(V$
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M>"<9'KTQ47Q%35/B%I=CX;T32[Z)99UFO+J\@D@2W"J2%.X 2$D_PDC*CV(
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M** "BBB@ HHHH **** "BBB@ I,"EHH 3 ]*,#TI:* # I,#TI:* "C HHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;_#[7-8\4_":ZO=;EN5NX3,L-TCM"\JJ@*OE0,\DCH<[>]>>>&?AC=:]X/\
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M]O<BP*^?-(I#<RQD+M48[9+D5P_A'2-9\!_%K4X8;+5+KP[J&?,NULG*J_+
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M$TDMRY*J ,!>?EZGD<U?T71=0UGPO:)_;^I1.NIS-<W"74GF20I)*JQ@GI_
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MY'##^IKDM4AU#0_A#H7C32-6U"+58(H9K@RW4DR7 ?A@R.Q7JP/ Z<?0 ]W
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M10!XIXC\/7^C_%NZUNY\/W^MZ)JL*HZV>YFB=5 R5!'0*>IQACWKT2'0?/\
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M.1$I &$'8>O)R>: -*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ IKD*I+$ #DD]J=7+>/-1GM]!73K**6:^U
M63['#'"0'VE29&&2.1&KD<]<=.H +?A;Q;IGBVRNKG39=ZVUU);./=3PWT9<
M,/KCJ#6[FO(/#LS>$/BDEB-)NM)TCQ! %BBNGC(^TQ+_  !&( *E>O4GZ5<O
MM-OM=^*FL:*/$>K6=F--AN0MM/M*N9#PO& N.N>?UH ]3W"C=]:\CT:TU*]U
M?Q;>/XBUETT35'D@MA< "7;'DH_RXV'@8'0"JTNJ:G)\'H?'L6JW0UI/](=A
M*WE.OG%3%Y6=H7!QG&>,]: /9<BD)R#7G?B349]%\6>&]:N[R]MM&U!7M;NV
M,\FR.9HRT9V<$'A@>.W0'FL/PWJ][>QZEX:N=0U--3GU2)K:2:ZD\X63CS0R
M]<8C5@?<@-0!WNF^*O[0\9:IX>-@\#:?"DK3/*I\S?TPHYQCO^%=)N%>3RZ;
M_:7Q3\4V@U*^M8X-+MSBWN&1F(4X+-G<<9]\YY.:@LO%FM7/P[\'9N\W6J7J
MVL]W+,8BVUFPN\ D%]H7.,\GOS0!Z_FC<*\\L[+7/#R>(WU+6[&RTZ6R,EHI
MO);A[)PNTOF0 E-QS]<"LG0-0U*T^('AJS235#9WVE.;AKVX+_:&1<B;86)C
MR3[?>QCB@#T/Q+K1\/\ AZ]U5;1[O[+&9&B1PI('7DU:TB^_M/1[._\ +\K[
M3 DWE[MVW<H.,]^M>374\OC#X?>,-=N[ZX66*:Y@M(4F=8[>./'RE5P&+#J2
M#U[=O2_!VW_A"M#V_=^P08_[]B@"#QAXNM_!FCG5;RQNKBU5E5S;[,J2<#AF
M%4U\>11:[;:+J>C:CIE_>1L]FEP8G6X*]5#1NP!_WB/U%8_QQ8I\++\+CYIH
M0>?^F@_PK3O/!]YKGB_2M;UBXM1#I)9[6WMD;+NP'S.Q/8@8 % &EX.\4+XL
MT634DLVM%6XDA$;RJ[?(<9..A]JZ#<*^?K07FE?"RY\16VKZA%<6FLR&V03%
M4"M.H8,IP'SSZCD^]=_XJG>[\0FWAO+ZX9=)=_[,LI_(\MRW$SR;@ ,< '/0
MX!YH ]"W"C<*\2EUG6M1\"^ KM];OK>ZO]1CM)Y8I4_>H789;/!;@?X$UL7N
MD:AIOC[POH$7B76YK6XANY9WEN"SM@$C!"\'YB,GH.A!Q0!ZKN%&:\3C_M6;
MP_X\B_X234V70+F46!2Y8,@4%@';&Y\=.21Q72SZG-JMAX,>74+J::ZLOM$^
MFV4FR2]+0@ABX*[45LG.0,D#T% 'H^ZC=7C.G>,-;L/A5>W$UPZ7L.LOIK7,
MS>8;6,R ;B3][8&P"WMFNLU:WG\&MJ>N6FK2RVXTR5DTR\N6<27"?/Y@9V)'
MRC! XH [K<*-PKR_0=/\42'PUKL>J6B6\JQM?-/J4TOVQ748 0J$5QDX"\9P
M*K0ZEJ#:-\2T_M2[ TV:7[%(UTY:#;$6X;K@'MSZ<T >I7%];6DEM'/*(WN9
M?)A!_C?:6Q^2G\JJV]Y?R:U>6LVEM#91*IAO3.K"<D<@(/F7'3)ZUY==12ZG
MK?PTFO+R^,]W:,99%NI$)/D9R,8P3GDX&<#GUL:CKNK:'XD^(DL%U<W'V'3+
M>:TCG8D1$JV2B]"H)R3CJ,>N0#UK<*-PKC+#2O)N=!URW\37)@FB N%N)C(F
MH&11L(!(53U(V #VQ7%Z_JU]I\#Z]8:I?W@77U7[7]H*6Y@:3;]F2/.'"XP2
M!USSP0 #T2[\5?9/'6G>&C8.WVV"2=;GS0 H0<C;U/.!VKH]PKSS7Y"OQI\)
M@L>;&[ &X8!VYSCKVZ^WM6/X;UJ6V\4:=9>([C4+/59+N9HKH7#R66JQL'"!
M.=HQN0@8'W5[G% 'KE17$KQ0NT<+3.!Q&I )_$D"I:0B@#FO"GBY?%0O9(=,
MN;6*UN'MG::2,GS$P&&%8^O6NESDXKP[3KBZMOA/XZNK>\GM+F#5KN0/;2@$
M-N'&<9QS]?I6[:R7VD>,_!+-JU_<-JUE(MY%/+E&(B5@0AP5P1_=SZG/4 ]4
MR!2UYKIZ7OCFU\27$NKW>F7MIJ$EK:>3,RK:+%C#%00&W?>.[L>.*]!L)A<6
M%O,MQ'<K)$K">/A9 0#N')X/7J>M %FF2S1P1/+*X2-%+,S'  '4FGUY]\:9
M[F'X;7B6^U5GFAAF<G&V-I!G\^ >O!- '3VOB*VDTB/5[I&LK&=HQ TQ^9Q(
MP5"5'W=Q9< G(SSCG%6U\5?:/'=YX8DL'A>WM!=K.90WF(6"\*!QSGJ<^U<O
M\5]/C-IX7\M[B%(]8MH5$$IC5%)/ISV&".1[55;1A=?&34K'[;?P0?\ "/P[
MVAG8.^)< LY.[/'4=>>>N0#U7<*-PKQS2_%>KCX3^'=MT9+F\U(:=)?33%"L
M8=L,77=@D*$W<_>SDGFNP\-Z5KFE>*+HWM];KIUU!F&P^V2W+I(K?,ZM( 0"
M&&1SR10!M3>([./7;C2NLMK:?:ISN *K_" I.6S@G(X&!DY(J!?%VE)X3_X2
M6ZG6#32GF!]V\[<X7A<_,?[O4'CM5VY\.:/=ZU%K$]A$^H11-"L_(.Q@05/8
MC!/7/6O,_B9H6F^&M&\,)8V4=KH4&O0SWD2 E,,>20>W4>W H [*7Q9JD&B2
M:S-X6O4LU@:;RQ/&UQ@<C,8/&1S][([BNBTN^CU+2K._C&V.Z@291D' 901R
M.#UJPQC:$ERA0KR3TQ_A7G6D21^,/%'B739[B:*PTR.WM[*&SN9(E",C$394
M@-G( ZC"CZD ](W"C<*\.O?$>NZA\'EOY]1NXKZSU467VF%BGVA1*J[GVC..
M2..XK7\1Z-J.@Z_X9T^T\4ZZR:IJ$ZRO+.'*!HSPO0#!)(X/)SV H ]:W"C-
M>2VVL:SX/\0^,M*CN;O5+.PTP:C9"\D,C1MC[F[[Q!_]E]ZBU34-4T3P%X9\
M5VVHWDVI3SVINU>1G2Z67[R>7DJO;&T9&.* /7]PHS7EVI6%]K?Q4N]'&O:Q
M96K:4EUBUG*F-_,X"\;0.!UYX],UB>)M2U.PTW5M2TS5]3U&[M-5CC^V0R,D
M,"!T7[/LSASSR<8.3D]B >RO?6T=_#8O*!<S1O+'&>K*A4,?P+K^=0:;=WMS
M]J^V:<UEY<[1Q;IED\Z,'Y9!M^[GT/(KS\6*W'QWE+7%Y'G1EFVI=.!N\T<8
MZ;?]GIR>#6*?$FLZ3H/B I?74KR^)_[.6[N&W&UA+;=P'0   #H.1]* /:-P
MHW"O/=1GN_"WQ%\-:?I\]S-8ZVMQ'=6\\SR[6C4,)59B2#\W('! _+DY%U6Z
MT?X@7S>(M8632;Z9+(_:654VX;G:/F'H.@]!DY /3==\22Z+K.D69TFYN+74
M)A ]Y&5V0.2 H8=>2?R]>E4].\9SW]OJTK>']0@?3+@QR0RX#O'MW!US@$X_
MAST(YYK6T0QZOHNBZI=1))<FUCG5V491GC&XCT)!(^AJ_;6%K9I*MO"J"5S)
M(>I=B "6)Y)P ,GTH 6RO;;4;*"\M)5EMYXQ)'(O1E(R#5BO/?A)/(NB:SIQ
M\H6^GZO<V]L$/W8]VX#';!8X&!Q7H5 "$XHSFN1\:2[K_1[1K^X5)GEW:;:%
MEFOL1GY0X8;5&<G) Z<U3^%FHZA>Z/JL&HW$LTMEJ<T"F:0R,JC!"ECRV,XS
M_2@#NZ"<45YY"]UXR\1>+--GU"YL3I;1V]DEM*\9B9D+"=@"-Y)Z \83CJ30
M!Z%N%&:\V%_>W?CO1?"5YJ4EQ9Q:.;J:X@=HFO90VS)*G( VEN#@EOI6>NIZ
MK;Z1\0-';4KXIHI:2RO Y$J*T6]8]Y!SM]2=WZ4 >L[A1N%>'ZM;:MI?PYTO
MQ!:^*=7-YJ#62.KW/R*&SD*%S_>]3G'>NCB@U3PM\4]%L(M9U'4K+5[:;[3'
M>2B0J\8SO7CY<D]  /T% 'IN:-U>.V^J:EKOPOUSQ<VHWEKK%K+<30^7*RI;
MB,Y$7EYVL,9!+#/-6M8O]1US6? >-6U#31K%N[7$5K*$7/E!N <'.>AY(SQS
MS0!ZQN%0W-Y;V<2R3R;%:1(U."<LS!5''J2*\IUZ&XTF'6K&UUS5]5FTK2 4
M'VHQFQ?;(XFF=2H9L $+@G '!SD4_$,C^(?#GPROKZXN#/<W]H)629DW-C);
M"\;LCJ!D9ZB@#UH7=Z=;:U.G,+$0AQ>^<N"^2"FS[W3!STYJ]N%>9:GJ=_H?
MQ'OHX+F]O(;7PY)=0V<DI9'D4M^))V@9P3[FLK4-4U&S^$^G>.[?4KIM74PS
MS;I7,4RO*%:(QYVA?FQP,_+GK0![%NI0<C->8ZBE[J7Q<M=+;5]2M[&YT5YY
M;6.8H 2VW"X&5/OP>.O:M7X6:C=7WA:XCNKN6Z:SU"XM4EE<,S(K?+DY.>#C
MJ: .X)Q1FN<\?:U=^'O NK:K8)ONK>',?&=I)"[OPSG\*Y36KB^\,0^$]:TV
M]NKN34+N"SO(9)WD2Z$J$[P"2%(*Y&T#KZ<4 >G;A1N]J\L33KW7/BCXCTJ3
MQ#K,%I:0VT\203*H1SM;@XZ<?=Q@Y)/(%9NK7VL7VF>(XIK[4+;Q1:ZB8],A
MM97&8R4V ("5*D-RQ'?K0![+N HW"O&?%4]_86/BJ2UUK5[^XTZ"#RG2X\I-
M/95#'<VX+*S<$C#'H#R:U/$UWJ-YK/P^4:K?V8U,,+F.VG$8;]TI)^OS$ ^_
M'.* /4&8["5&XXX'K5/2+N\O-,BGU#3GTZZ;.^U:992G/'S+P>.:XGP=+>+J
MWC/0Y=2O)X;&X0VTLLI>2,.A)&YN3R/I7.>']66#X5V/B+6];U:251/"EO'=
MNDEW.TI* ;6R6X(QSP3Z4 >S[A1NKR>>Y\0>%/AX\^H:D[ZSJ5U#'(LUXV+!
M)6V@(7R05&>>>03SMK7M[;Q!X;UN]U6YN;)=+:QDD?3SJ,UQ(\L8+;XS(HQQ
M@&@#?\9>*&\)Z(-2_L][Q/-2-E654V[F"@DGW/I71*<J#ZBO"_$\4FL_!:V\
M2WU]<37]W+#-(1,XC"M*/W8C^Z O R1U&<GO[G&1Y:X]!0 ZDS65XFN#;>&=
M4F&HIIQ6UD(O'7<(#M/SX'4CJ!Z^M>>:!?7]MX\TC3A/JBV&IZ1(S&\N"[S2
M*%/GA6)V$CMQUY44 >L;A4-U,T-K)-'$TK(I(C4@%O;)XKPIYM5A^&6L>(SX
M@UAKS3]7D6T,ES\NT3HN". X/H<C.<#J*[73;Q_&OB;Q)'=75U!:Z4D=O!;0
M7#Q .REFE8K@D]@,D  \<Y(!U/@[Q&/%GANUUD6AM1/NQ$9 Y7:Q7D@#TK>K
M@/@PNWX9::#DD/-EB,9/F-R/:N_H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI"<=: %HI-PHR*
M %HK,AU@2:_/I/V"_0PPB;[6\&+=\D?*KYY89Z5I9% "T5EZIK<6GZ4;^&VN
M]10.(_+T^/SG)+;3@ ] <Y],&M(,-H)X^M #JQY_#T-QXAM]::]O!/;HT<40
M=?*56V[AMV]]HR<YXK8SFDR!WH Y_P 2>#['Q1)9/>W5["UE+YT!M91&5?\
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M^8S/;W,K.J$\_(>HYYSG/O4N@>!=-T&&6/[5?Z@'A-N/M\YEV1'DHHZ 'O\
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M*VJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSCOMMGJEK-)<6KQH<LL:D$-@$<GU_"LA]<\7^)(=7O/#R3++;7SV]G$)K<0
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M(!\R-NJG/(ZGD8/- 'EMM-KNE^$_&^N:=K,MHUAK<\J0);J5E.Y =Y*DD8[
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MBYTZ(C:SL<N0_5=QQTP>HSZ ';Q,[0HTB;)"H+(#G:>XSWI]-CC6*-(T&U$
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M#/ 8X(YSD>N0 >F49 KG/#%S+J=UJNK?:II+*:Y,5G&Q^14C 1F _P!IP_X
M5SL;:GXVN?%,=OK=QI<^FWC65E';2;1&R*I$LF.7#$_=/ "G&: /1,CUHR/6
MO/=7U75;CQ+I/AR*X^TXTXW<\UK="U:Z?=LPO4@##,0I/;TYQ/$,_C7P_P#"
MO4;C4=3:WO[2Y06TL,RR,T!90!(VS+,,G)&": /69[F&V5&FD5 [K&N>[$X
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M0% &2QR3]*C;PA;_ /"7W'B:/4;^*^FM?LA56C,:Q\'"JR'!R >O7VXKHJ*
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M43(MO*R/OB(#H58,"I((!XQTZ$UGP^!X(?$-OKHUC5GOX+4VH>26-@Z%BQW
MIURW; &    !7544 <4?AIIA\,WNAM?Z@T5S=_;1.TB>;#/D'>K*H[COGVQ5
MS3O ]MI_B1M=.IZC<7KPB&5II%_>A3E=VU1TZ8& <#()KJ:* .3TWP%8Z/I>
MK:?I^H:C!;ZCYIVK*JBW9\Y,051@],9SC KHM.LSI^GVUH;B:Y\B-8_.G8-(
M^!C+' R:M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4449Q0 44F12T %%%% !1110 444F10 M%)D4M !1110 4444 %%%
M% !1110 4444 %%)D49% "T4 @]** "BBDR* %HI,C.,TM !1110 4444 %%
M%'2@ HI,BES0 4444 %%%% !111F@ HHHH **** "BBDR* %HHHH **** "B
MDR*,CUH 6BC(HH **** "BBB@ HHHH **** "BCI29'K0 M%%% !11G%% !1
M129'K0 M%%% !1110 449Q29'K0 M%)D4M !1110 4449% !111D9H ****
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M)A:,C+B0MR6Y*X'4^G) .VN_B!HUG/=+(+EH+2[6RN;I8OW<,QQA3SD\L!D
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MZ0-(B=GD6SSR@9B1N X#$8)'."<9.*VJ "BBB@ HHHH **** "BBB@ HHHH
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MD,0".I4\CGTH Z6@C/6N1_X6'I*QV-Y+#<Q:1?R^3;:DZ@0L^<#/.Y02" 6
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M1K^YU5#+96\3JK2H%#,V6(  ![GKQ6AI&K#5],^V+:3V^7D3R9L!P4<KR <
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M.%4 <?Q'T.-W0I['1;35];_MJ2]T*XD2:TD:Y>YV#:%9$R68DOG"C)R< =J
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MP(,\D,PR2!N &>#0!VN **I:3JMIK>EVNI6$HEM;F,21N.X/KZ$=".QXJ[0
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M\TDALD'CGUSV&#D]'\0=!FU[PG.EG'OU*S9;RQX!(FC.5 R1UY7\:ZD "EH
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MD>F>N:]+<90C)&>,BN?\->$+3PZ\LXOM2U&\E&QKK4;EII @8D*"> !GL.:
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MA<'/.<?G7H%QHC7?@BZT3R;>T:YL9;?RK9 D<6]",*!QQGKWQGCI6]@4$9H
M\A?3M2UCX9V/@.?2[R'5T\B&=G0B&*-) WF>:,JPPG0'=DC@5T&OVER/B'X-
MNH+.[FLM)CO$N9DA=@GF0JJ?[V2.V<=Z[[:*,"@#,\0RO'X?OA%;RW$LD#I'
M%$A8NQ4X' XSZ]!7#^![_5?#7PZT[2Y?#.KR:G;1N@@$2JC,68C+DX"\C)[>
ME>EX H(!- 'C5S\/-:T[P@FH2VT>K:VVL+J]]8Y&R8<@Q9/WL!B?KG\>P\+S
MVUTMUJ-GX/.B0"$KF2S2.>9CC( 3G:-H'(Y(&.E=L1FDP* /&='MO$>D?#[P
M]ILNCZFL9OI1J:V@VW,*,6*>6Q.<$L,LIR!D9&:W_A]IUYI^O>*K2\T*\L[6
M\N_/C:=TD1D** I()RQR2>6[@G/7T?:*-HH \5D\#:^OAK5-/=I&B\-R/-H#
M!CYDSAA,#P>PPB]\LW(Z#=U&VU^QL?#BO87$D5[<RW.L_P!GH//BDD^955LY
M !;86# X4=J]-VBC:,4 >"6NB:U:ZDELOAG4EAA\5+J+.R*RQP?*>-N[<0#U
M!.<>M='>6+>'_&>L37O@I]?T_5Y$N+>YCMHI7CD*X,;!N0..I/'X\>L;11M%
M %#1+9K32+>%K"UL"JG_ $6U \N($DA1@ 9YYP,9S6A110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7/^,]?;PYX=ENX(A/>RNEM9PGI)-(0J ].,G)Y' -=!7GOQ9MR-.T#4W,:
MVVG:S:S7#R 81"X7<3C@ D=Q0!:U?Q3%X/O=#T>YENKN\U&4>=<O%)(-H7YF
M4*,9)4 (O3.<>N-9>+(]#\?^*8]7U._FLX8K=[> K)*8U9-S$1JORCU8X[ ]
MJTOB$\UKKG@W4/*F>TMM4Q.T,3.4W(57A><$DCH>H_''LIH6\9>.[N2VDCAN
M[*)8FDMG E(BP1D+DD$X(!S[4 >A2>(]+32+;4UN?-MKH+]F,2EVG+#*JBCD
MD@'CV/I2Z3X@T[6WNXK*5S/:/Y=Q#+$T;Q,1D95@#R.0:\@-M<V_PP\#ZA<Z
M??36FE3L-1M84>.9$*NA?LPVY[==WI7H'@R/0KS4-0U?1M*NX/M"HDU[=F4/
M.PS\N),DA0!S[X[4 17^I>*8?$'B"&VTJ>:*&P,NF3AP(6DV#"%>-SE]W.<
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M"6YQGKC(R0.C;K3[K0=,^&NF7?VBYFL+M)+EA$[^2A5@,D8PJEMO/0+T.,$
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M)Y@E5@5*XSD'TQSFN<C\>Z-(^GNWVN&TU*0165W+ 5BG8] #U&><;@,X)Z4
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M:[N91%!"ADD<]%4#)/Y5A6GC/3;C4[.QE2YLY+^/S+)KJ,1K<@=0O.0<$'#
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M@UX7"1$*3A$;E1@'H.<CK0!V6VC;7/6OC'3)]5M-/E%Q:SWL1EL_M,?EBX7
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M#F(07<O@OX@VO]C:NLM_>SO:0O83;I0P4 J,="03V]\U[ ]W;QSK"\\:RO\
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MG:KK=SI,T5E<V$5NC)-&P9TR23E\CT' SG) Y-2_#[3=5T#PU=V>H:7/%/\
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M&#CH <URMIX*\1>%=#\+WEOI\.L7>F"=+NR>4,1#*0VV,MP2N!^/2@#K=/\
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M%8?A3Q18>+]"CU;3F8PL[1LK=593@C^1'L1TK;R* %HI,BC(]: %HI,BC(H
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M@L[RWO[*"\M95EMYXUEBD7HRL,@CZ@BI\B@ HJ*YN8;2UEN9WV0PH9';!.%
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MO;NUTZ<7-I;W#J5BD (# A0QQEL DCGIP* ,CXTQ74WPKU86N[*^6\FT_P
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M<.% 'W?ER,''OS0!AZXVJ77BKP58S>(;E#?03+=-I\PCB=EC&63H<DY]2,G
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MZWC>YN5,*$DA7D4YRP8@]CG''3/HMAX0M[%[60ZA?7$UG ;>SDG=";=" #M
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M ;2X4D  ') X-;7P^URWUPZA)9>(KC5;)/*$<-Y$J7%J_P V]7PJE@>,$^A
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M6;XIZUH+ZQ,;%-,2XA010AH9&;!*G;DX'3=GKSF@#N)IXK>%YII4CB0%G=V
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M1=-:SUJ\E\G[)&PE8!3\Y8G"X# ?*,D[B3C V-5\6:U)X,\,^-+?49;33W:
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M7S!0US;1S$*<C+*#Q[<U>H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=.GIT-]>P:=8S7EU((X(4+R,>P%<[H7CBUUCP;+XEEM)K2WB:56A;YY#L8J
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M4VBH+=2@C+;NA[Y YKK:YW2?$\NI>+=9T&33FMSIJQ-YQE#"4.,@@8X_,]*
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MY0)=/93F/[0  !O]P!@,,$9/- 'F=[KNLZI\)=&U"YU"[M]035H[5IX9B@N
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M\/W/AA_#TNGJVG.V]D+L6+DY+[L[MV><YIWAWPCIWAH.;5KJXG<;6N+R=II
MO&%!/11@<#T&<T <YXNE?P_XTT35;F^OET;4&>QNXQ?2)%%*5S&X4=.%8<8Y
MP>._.>&=8O+V+4_#,][JBZC=ZA%)9SRW<K2)9R+YJN&W=D5@<<9(!SS7J>N:
M)8^(--^P:A%YMN9$E*YQRC!A^&1^5-.@:<WB&/73;+_:$=N;9)?1"<X_SZF@
M#D-3-S'\8=)TU;R]^PW&D3[XA<M@$';N'.0W3YNOO7GUO80Q? SQ--"\DF[4
M)8_WDK,A43##;<D;O4X!.!QW/M4_AJQN?$MOX@E-P;^WC,41\XA%0]1MZ<UD
MS?#7P[/87E@\5Y]DNYC.\ NY BL7WG:N<+\V#QCH* ,:SCN-"^)NA6<6HWL]
MOJ6F2F=+B5W5WC"E64'Y5.,\ #J>.:]':L'_ (1'3FUVQUF1[M[ZQC,4,C7#
M8"$8((Z'/O6^U 'D5YX;UWPN]QXE^']_'<Z7<E[JYTFZ!VR>I0GGU.,CG'7I
M3-*U^;Q]JL=E96X@TM-(AFAL9+E[0;BS*S#RP2X4HH'88Z9-=N/ EA'9RV5M
M?:I;64Q8RVT5V=CAL[ASDJ#NYVD4W5OAWX>U>2PE:">TFL(1;V\ME,T+)$ <
M)D?PC/% ',F;7-$LO"?AS7=<\]KO4)+>\U"UF978*I>.(R'D,S;0>A(&.YJY
MK?A]-(\,>+[1-7N9K2:Q>>WT\S/NM5"$':Q8G:S9.#QV]:Z+4/ ^@ZGX>AT.
MYL<V4,@ECVR,'60?Q[\[MQR<G.3DU+IOA+3M-TJ[T_==78O$,=S/=SM++*,$
M<L?8G@8 R: /-[E)]/\ A?X*NK34=1A\Z]L1-BY=@58 $>RY4' XS]:Z73I)
MO%_BKQ=8WMU>V::=)':VD<$SQ&+*$^=P0&)/(SG 'OSK?\*]T+^RK'3 MY]E
ML9EG@1KIVV.OW3R3T!X'3VJW=^$;*XUF35X+B^L;Z9$CN);2;9YZKT#@@@\<
M;@ P'0B@#S"Z\0:WK7PBT?4KG4KJWOAJ\=H9[9VC,ZB7;E@!R>.V>1Z\5U>B
MBXTCXMWVC1ZC>7%E/I:71ANKB28K*'V[@6X'&!QZ#VKH=1\$:)J>BVNCRV\D
M6GVKB2.""0QC<#D$XZG///<YJQ#X7LH?$2Z[YEV]^L'V?<\[%3'Z%>G7G..M
M &W_  UQ_BBS3Q7L\,QJ#IZ2QRZG+P%1$(=8A_ML0O3HH.>H![ C*D>HKA_^
M%4^'"TS;M5S.SM*?[2F_>%\[BWS<DY.<]: *GC'7I8_$5M976@:O?:-;K'.Y
ML[;S$GF+93//W4VAL<Y.,CCFC\%-22Y\(SV3Z?<6[074LK/)'B,[I&( ;H6&
M.< 8P*]-B@CM[>.")-L<:A%4=@!@"L6U\(:59>&IO#]K'-#83%RXCE97.XY;
MYASS_+B@#/-I'XD\666KN"NGZ-YBVSL0!/.X52X_V5&5]V/H.>HNI7ALII43
M>Z1LRI_>('2N4TWX8^&])N;::VCO6%NP:.&6]DDB&.GR$[3CJ..H%=CVH \8
M-_J=W\(/^$ZAU6Y77HF:Y+K(PCVK*5,!C)V[ ,CIDD9ZFM3QI;C5=6\ 7EP;
MJWFO+V/S(H[EU$9\IF(7! !R<%A@D"NJB\ Z-"LD$8N5TV2;SFTT3'[,7SG.
MST)Y*YVY[5?U;PO8:S>V5W=-<B6RD$MOY<I41O@C< .^#0!KQ1"&!(E+D(H4
M%V+,<>I/)/N:\VTNP0_&WQ+)YMXH2QMY=HN)-K,<]1T*CG"DX]!Z>F 84#.<
M#K6#=^$M,O->?6F6XCOG@6!GAN'0,BG(RH.#@^HH \;TT3Z1\+=+\0V>IWD%
MU%JX0(LSK$R-,008QP203DD9QWZ5W6M2ZCK_ ,0-0\/Q^6;:TL(9HX);Z2 .
MS.Q,G[L98C" 9X!&>];0^'&@CP]%H"B]73(I!*D NG&&!R#G.>#SUZU8U_P)
MHWB.^M;^\%U%?6T?E)=6MPT4A3GY2PZC))^M $_@VSU33O#T5CK&J)J=[;,T
M;W*DDL,Y&[/.X @5SOQLR?A7JV!GF+\/WBUV^FZ?;Z58165I&4@B&%!8L>N2
M23R22223U)JCXD\,Z=XKTTZ;JJ2R6A8,T:2%-Q!R,D<\&@"KXIN+&V\!:G+J
M0!LQ8.)5)^\"F,#D<G.*\<\+0W>D:Q\,+C7C*MH;6XB@:4?ZN61GV D],JT8
M SVKU^;P)HUUY"WXO=0B@96CBO;R26,$=,J3@]NN>E:FMZ#IGB'338:G:K/!
MD,HZ%&'1E(Y4C)Y% '-_$WQ#JWA?PNNJ:6]H2)TAE2YA,BL'( /# C'T.<_C
M7/327-K\=]";6BDT=SI,D-E.(PJ>?U?;DDJ=O'7/S =ZZV\\!V&I6\5MJ=_J
MM]:1R+*EO<7190RDD$L '/7NQZ5IZ_X8TKQ);0PZC;EV@;?!,CE)86QC*N#D
M&@"]=?9C"!=^5Y6],"7&-^X;>O?=C'OBN$\' +\6O'^ .?L/3U\MZZBS\,PV
MLMO+/?ZC?/; ^2;NX+;">,X  8XXRV3QGKDU1C\ :3%JMUJ<5SJL-Y=LK7$L
M5_(GFE1A=P! ./I0!TRW$3W#0*X,JJ&90>0#G&?R-9/BZ<6_A35)3JO]E;;=
MO]-V%S!GC< .2?3'.:FT70++0A<_93<227,@DFFN9VFD<A0HRS$G  X':I=;
MT:R\0:1<Z5J,1EM+A=LBABI/.1@CD<@4 ><^&I+[3OB):Z6T5_9VE[HS2/%=
MSM))+*C!?./+!'('0'@8SCH.;E%\?!/C?5QKFKI>Z7JTOV8M>R83:4 R%X;C
M@9R![<UZ;:?#[1K34[+4DDU%[ZUA,"SRWLCLZ\8W9/..H'0>G3#A\/\ 11I6
MI:9F]-IJ4IFND^U/^\8]3G.1GN!Z4 8U]K,^K^-/#OAZ:X>&QNM+>_N/*D:,
MW+8P(\CD#JQ&1G]"SX<6@L?&/CFU1G:.*\@"&5V9POE\ EN2 , <G^5=%JO@
MC2]6M-.BD:[AN--&+.]@F*SQ<8.'.<Y'!SG-3:%X1TWP_J-]?6;7C7%\5:=I
M[IY Q QG!.,^_7\.* */CVX$=AI]NNHW-M+/?1A;>U!\V] R3 K C:&[L2 !
MU-<)!J&I1Z!\1[-KJ]L?[,(FM(Q<LTEONC+;0_)P2,\'&2>>]>G^(?#.G^)8
M;:.^$RM:SK<02P2F.2-QW5AR.M9(^'&@+_:NU+Q1J@ NQ]KD/F8!!.2<Y.>3
MGF@#B7M;RSG^'MY!KFHBYU>);:\WW1^>-H58[1RJX(X(.<D8)/-7['5=0\,W
MOC^SM+BYO(M*@6[M(;N9YF#M&6;DC)!;G&[UX'6NQ;P7ICKI:M)>G^RL?8S]
MH;,>%VCGJ?E..<U8M_"FFV^K:EJ2K.\VI#;=))*6CD&, ;#P,#CZ4 <?I>C^
M();S0=>MM7LX;9RC7K?;YI1>J_;:P"A@2=N.A.*PIK6ZN+3XC3_V]J^=+G9[
M0B]E58W6(,"=HYP0..<8''0GO-#^'.@>'[Q9[)+IDC):WMY[AI(;=CU9$/ /
MOS[8J1/ 6CQC5@K7H_M<?Z:?M+9EX(Z]N"1QB@#F)_$-WJC^ ='N)W6'6;<S
MWLJ,4:;9$#LR"" 2<G'/'UIN@V(TKXA>/(+.Z> K96[0R7,C,L?[G@EG/*J1
MZ\ 8[5UE]X$T:_T&PTB1+E8M/(-I/'.RS0XX^63KTX^E,M? 6DVUUJ5UYVH2
MW.I6_P!GNI9;MV,B[-F2,XSCVX[8H Y?P/J$EOXEM=(U:WU33-76TD5XYKAY
MK74&!7,T9)(+  '@#A_:ND^)UM'<_#G6_,DF016LD@\IV7)"G ;;U7GD'C\J
MT+#PK96-[;7CS7=Y/:(\=J]W,9#"KXW!2>>0H&3DX'6M/4]/MM6TRYTZ\C\R
MVN8FBE7.,JPP>>WUH \@O=/1$^%-I%<W<*SH2S1W+;U!MTR%)<[1C@8/R@\>
M^EINL:CX>MOB'!#<WEV-)836:W!>9TWH2>6.6&1GKZUUD/P_T>(:6?-U%Y-,
M8M;2/>.S*Q4*2<GGY5 QT Z5=T_PCI6G7VJ7D4<SR:K_ ,?JS2EUEX(^Z>!P
M2..U '):3HVN_;O#^O6VJVT5LZH;PS:C-/\ ;5D  &"H4-D_+CC.!TXKTL?=
MKD]!^'.@>';Q;BRCNF6(DP03W+R10$]2B$X!]^M=9T% 'C%II%]K9\>&7Q+K
M%K_9M])]F*7; (50,&?'4#:,#L,]^D<&HZIXCF^'376K:C:R:G;SBZ6VN/+\
MS8A D&, $CG/4;OQK7\*>''U/Q#XT^VC5[.UOKUF5 CVZW$3+C/(Z]1D88Y.
M?;M+CP?I5QJ.FWP6:&734*6BP2F-(E(P0%''( '- '):5:?;O&VJ>%+R^U*3
M3](T^%+8/>,KR[P"TC%<%B,[03D#!]:J:2WB+Q-\.-?L#J=Y'JVE7<]K9W\<
M[(\_EX*[MA&21\ISGUZUW6I>$[#4-9CUF-[BRU18_)-W:N%=H^NQL@@C//(S
MP*T-)TBRT33TL=/MUA@0EL#DLQ.2Q)Y))Y)- ''^$M=B\8R:-?6=Q<+%96 :
M]C%Q)CSVPJHW.'V[)"=W/*'O6##+KL\OQ'M=.U68WD5Q##9-<3E0A(SY:,>%
M8DX&,<D5Z3H^AV6@P7,.GQ>5'<7,ERZYX#N<G [#VK+_ .$%TGS]2G#WPEU)
MXY+EQ=."S(048'/RD8&,8H Y/1=8&H6'B6V_XG.CZPFG^:^FW,\DC0LOF$RP
MLQ)(8D X[BJ>B:O?WT/P^T"[N;C[#J.G//=3"5@]PRQDB+?D$#N0.2 !TS7>
MKX.TXK=M<27=S<W=L+26ZFES*802=@8 8!).?7/TJ)O 6AMHVG:8(9ECTQ]]
MC,)F\VW;.<J_7\#D4 <Q97M]9^*_%WA87=T-*MK!;RWF\X^9:EE&45R2V.I'
MI@US.G&]L_"/@#Q&-6U.6^N-1AAG,UQ(\;1N7!4J>!]<?B>*]9@\,6,%K>Q!
MKEYKX8N;J27,T@Z ;NP X & ,G&*SF^'F@G1],TH)=+9Z9-Y]HBW+ QR9)#9
MSDX)/7UH Y'QQ>WEAKFI3ZG#>W6AR0B"*]TN=P^E';\YDC4\YW*V3V XKTXW
M2_V)]KM2+A?L_FQ%?^6@VY&/K65J'@ZPU*>]>:XOEBOEV7=NDY$4PVA>5[<#
M&1@_I6]##';V\<$$:QQ1J$1%& J@8 'X4 >-_;=0O/@ZWCI=4NDUY \YF25P
MF%F9?)\O.W8!QT[9Z\UK>-+8:GK7@&YN#<P37=ZGF1Q7,BB,^46PO(VG)QG
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M/0%B<#VZ5I4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112$X&
M: %HID<J2KN1E93T*G(I] !1110 4444 %%%,,@7[Q XSR>WK0 ^BDSQFFQR
M)*NY&5AG&5.>: 'T444 %%%% !1110 4444 %%-DD2)"\CJBCJS' %*K!E!!
M!!Z$4 +1110 4444 %%%% !1110 45&TJ(ZHS*&;[H)Y/TJ0<B@ HHH/2@ H
MI%8$D9&1U'I2T %%%% !1110 44UW6-"S,%4<DDX I58,H8$$$9!% "T44SS
MHQ*(BZB0C(7/)'TH ?1110 444A.* %HID<J2H'C960]&4Y!I] !1110 444
M4 %%%% !113'E2,J&=5+' R<9/H* 'T45&T\:R",N@<]%+<G\/P/Y4 244BL
M&&001[4M !113%E1W9 REEQN4'D9Z9H ?141N81-Y/FQ^9_<W#=Z]*?'(LJ!
MT964]"IR#0 ZBBB@ HHHH **** "BHC<PB?R?-C\W^YN&[UZ5+0 4444 %%%
M% !1110 4444 %%%% !13%E1I&C#J77JH/(I] !110>E !14:3QR,RHZLR'#
M ')'UJ2@ HIDDBQ*6=E51U9C@"G*VX9'0]* %HHHH **** "BH5N87E,22QM
M(.JA@2/J*5+B&25HEEC:1>JA@2/PH EHHHH **** "BF+(KLRJRDKP0#T^M/
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ K-UO3;;5=.:VO6D^R9WS(C%?,4 G:2O.,X.!UQCH:TJ
MR?$&IWVDV"W-CH\^J-Y@$D-NZJX4]6&[KCTH XCX7)H\&O\ BFWT&\E33H[B
M-4TV8.&@<*0[ -@A2< #_8^E>FUQ^B:(]SXUO?%T^G2Z=+-9K8QV\A3>ZARQ
ME?:2 3\@ SD!>>HQNZ)?ZAJ$-TVHZ4VG-%=/#$IF$GG1K@"08 P"<X!YXSWH
M TZ*** "BBB@ KB_%_@W2-1@U;6;VW>YNQ8,D(,C 1[%8C ! Y)&<^@KM*R_
M$:W+^&]2CL[62ZN9+9XXH8W569F! Y8@#KG/IZ]* ///A[X)T75O .@:M<6Y
M:^*B:25I&;S,,W#*3M((&.E9_@'Q>/"W@73UNM&NQIIOWMFO=\:JK/(0."0S
M@<9;'KSQ7:_#ZSU/1?A]8Z9J&F7$%Y90,K1EXV\PY8X4JY'MR17"?\(QXI_X
M5'%X?'ANY&I+?B=HS<0%&42A^6\P9R/7)R/H: /1]9\7P:;JQTFVCAN+];?[
M2\<ETD*JNX  L?XB,D#';DCK5OPIXEL_%WANVUJQ61(9]WR28W(02"#CZ5R&
MO6&OZ1X[?Q#I_AQ=;L-1M(H+BU\Q$E@D0DAOFRIX)'UXR.,]QH:WPTQ6O[>&
MUF<EA;0D,L /1-P W'N3CJ: .;UCX@II4FLNND75Q::,T:WDP=5/S@'**?O
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M#LMM,5T#1@X&6;*C<?O$9XZ<\UG0Z5KX\6^"K\Z#>+;:;IKVUVYGAW([*%Y
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M+5[I8K.^NFLXUEO!!&,VZLN[YMQ&3MYPN3[5KZ7J=GK.EV^I:?.)[2X3?%*
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M$ &2RX&22<?=QGG&;<B5/BIJNHO8ZB;3^QQ:I,EE.RM(')*C"\]L%>*])HH
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M!\N1TZ=^VEXCL[R"\\#,FBS01V-^\TL&FVLDB6T)R%!\OC(!4-@GG=@$<'U
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ML%V[PR%20P(Z'CD&O.=+T'Q3HW@[PQJ,.D3S:IH5]/-/8/\ ?DBFW!MK?Q,
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M._-5+_1KO5/%6J^*([2^CB70SIUM 4\N6:1F9BP'50-RC) YSQ@<@'*O%O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ62:.W@AW;?-ED8*BY[#)Y/8 FF:)JNJ:A+?0ZGHLFG/;2!4<3"6.=2,[E;
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MN-H''/J10!TU%)D4N: "BBL3Q'XFLO#5M"]SOEN+J406EK$,R7$IZ*HZ#ZG
M'KR* -NBN0U'Q?J>B6T%SJOAV6*"6X2$R0722B(,X4,_ V]<]QT&>:Z[(]:
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M!C% ',^);5];\<^"$DNKFT,]E<.\UHZA^40E0^,C/JOX>M94?B#5_!VF^/\
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M-USD#&,8P,8Q2Z7X1M--N[:ZDNKN^N+2#[/:R7;JQ@3 !"X4<G'+')Z\XXH
MX3P_IKZCXE\3RWGBC6T@T35/-0?:P%VB,$B0<Y7@C&%X'!/.*%A>:C9:UX(N
M+6^U2[BO[IX;C4+J9ECU%&4L&$.X[0!]W.T\=".:]+TOPC8:5/JDL<MS,-38
MO=I<2!UD8C!.,8''''&*Q(OA-X=B@L(C+JDBV$A>V+W\G[I3U1<$;5^F#QUH
M R?#^EV\_P 6O&7EW%\C1QVW[Q;ILJ6C;(ZD$<Y ;H>@QBN>T'Q!JO\ P@7A
M6UEU&\<ZOKSVUQ?-,RN8Q*WRJYY!8@#L>HKU!O!VG'Q+-K\<EW#?2PK"WE3E
M4.WA6*]&89.-V1[52C^'&@+X>?0I8[F>Q,_VE!+.2\4O)WHPP0<DGK0!D0O?
M:)\41X=MKFZDT?5=->X59)R[6DB?*3&S$G!X)!SRV>U<4@U&'X9WWB)/$&MR
M7FG:LZP/)=.5*"X"'<HX;*E@<Y')Z<BO7[#PU;V-U<7K75U=:C/$(3>7#JTB
M(.BI@!5&>< <GDYK*'PWT7_A&[C0#+?'3[BX^TRH9\L[Y#9W8SU4'K0!UD$G
MFV\<G]]0WYBN%^(%YJ]AJ6FW=M:SW^D6\4DE_9V5TT5P02H64*I!8)@\>_/8
MCNK>$6]M% &9Q&@0,YRQP,9)]:R]6\/1ZGJ%OJ"7][97=O&\4<MK(H^5L;@5
M92K=!U!QC(YH \N0V'B/Q/X$&GZWJ%W;26]\/MA=EN NUL OU5QPI;CH<=<5
MI:'J;V?A7QQI]UX@N+:#3+^:VM]0F+S26R$*%Y^\Q!/'N>*ZNW^'NC6FHZ=?
M6QNH9M.W_9]DHV@N#YC$8P2V3DGUXQ3AX!T@V.M6DS7<\6LMOO!--NR_]Y>/
ME/3IZ#TH YGPU=ZA9_$V#2W6_M[2?1O.:&]N#))+(LF/.8;F",W(P"?<#MF6
MS8T?XL_,V\74_/FJ./*X^;H/QZ=*[;3_ (>:3I^K6&J+<ZG->V<1B$EQ>O)Y
MHXQO!..,# &![<"I$\!Z6EEK5IY]Z8=9=I+T&8?.S<,1Q\N1P<>@H M>!\?\
M(+H6TY'V"'G&/X!57XD;?^%;>(MQ('V"7I_NUNZ7IT6DZ9;Z? SM#;H(X]Y!
M(4=!P!T'%1:[HUOX@TB?2[N29;:X79*(7VEU[KGT/M0!YAIJ77A[Q'\.Q#JE
M\T>K63I=VTLKF([8$*[(S@(%+'  &,].M5?&FJ7=OIOB35]*U74;N:TU&-$N
MUE:."P(=%:!4W?O&/0_+M^;D]:]$7P/IPGT.7[1>G^Q%VV2F8 (,!<' ^;Y0
M!SV^IK/O_A=H&H_VLLKWZ1:G*9YH8[DK&LIZR*GW=WN0?7K0!0\1W<WAOQQX
M>UVZU*\BT:^#VEY!+</Y$,I0M&^PG R<J<\# [U0N[S5RF@V\%P_E>(KNXGV
MW-Y-$!!Y9,,.\[RA*E20,9((&.W;ZEX3TK5O#G]@WD4DMB"C8>5F?*L&SN.3
MU'ZFE\2>$]*\5:6FGZG QBCD66)HG*/$Z]"I'3C(_&@#+\&:5XCTF_U./6;V
MTDLI=CV=M%<R3M;]=XW.H.TGIUQTKL*Q/#?A>Q\,VSQVSW%Q/+@S7=W*99I<
M=-S'L.< 8 R>.36W0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%>>^+Q;ZKXH72T>:]G33)7ET]I6AMT4GB9Y #\V5"J
M"><\8H ]"HKQ*RU#4;KP7\/+Y[VX-P^J)!+*+ECOC#L-KD</T%=9IG[WXK>*
M-.>:X>U-A;R>2TK;$9BV[:-_&>.0/Q'\0!>\4>/8]'\,2ZYI5O'J,,5V+5RT
MA1<[PAP0I+88]AV//3/9 Y%?.T5E%;?L]2211R(\^H+&_P S8VBYX^7YN?H"
M>!UQ7H>GV1T#XQII]E<W)LKS16GFBGN)I=TRR@>9ER1G&T<'@ \#(R >CT9K
MQBRGFU[X5ZQXJO)9X/$EF]S.)%E8-:21$E8U4GY5P,%2.03GK5C5&N]>UKX=
M'49KNVGU&WE:\@@N9(B2(ADA5(V]3R!GYL4 >H2W&I+K44$=E"VFF$M)=&;#
MK)GA0F.1COD4[3M4M-46X:SF$R03M [+TWKC< >^"<?4&O.CHT&C?%;0=&M[
MB_>QDT:>-HY;N5^AQD$GY3CC*G/3@=3D>"O#(UGX8ZQ#I]Q<VFH+>7,=M)'=
M2*$97+*N W ).#P"<]^#0![3FJ>HZE:Z7#'+=2B-99D@3N6=V"J /J?YUPOA
M+6F\9WFBSJMQ;II-F3>Q!F4?:B?+\MLGY@NQSSGJI..,M^*MA;W-QX2:6$R-
M_;4"9#$8!//0B@#TCM17FNG06_B/QSXET75DG$&F0P0V,#3,-L;*<RKW+$X^
M8Y(['DYTOA5J.H7_ (1F349Y;F2SOI[6.YE;<TR(W#$]^I'X4 =3J<^I0"U_
MLVRANB]PJ3^;-Y?EQ'.7'!W$<<>]7@>*\^^*8E1/"\D4\\9;7;9'".P1ER3A
MP#C&0""0>0/6L+Q+//HGB35-1U:"XNM(N+B(1:O8SL7TP+M!CE1<?)N&<=#N
M.<DXH ]?S17CWB>]?3-;U*_U@7-UH<US%Y&K6$[%],(";HI$!!"D@$XZAN<D
M@5L6,CR^/_&=D);I[,6$$T40F?:I9"25YX)/H* /2:*\6L]>U(_#+P5&U[D:
ME>BVNKFYN'5L9<A6<$-R0 <=<8SS7:^$?#E]X=U_4/-U&#[)=Q*\6FVXD,=N
M4PI92Q.T$D\?X4 =+-<:DNM6T$5E"^G/&QFN6FP\;#[H"8^;/KD8J_FO/-<\
MV/XT^&@MQ.L4ME=,T;.QC+!< @$XSSS@#]:PO#L\NF>*=(@\16,INY[B1K77
M;:9Y+;4"\;; PS@-M8XR#C;@<'- 'K[' S7GNI_$N\TM(=5F\-7/_"-2RB(:
MAYH#@%MOF&/&0AZ@YY_&O0CTKD?$5N/%DJ^'[=P;&.=6U20KN4JA5O(!Z;V)
M4GT YZC(!:N_$MW+XAGT71;."[N;2%9[IIYS$J;L[4&%;+'&>< #OVJ71?%^
MG:QX5;Q '-O;1*YN4E(#0,F=ZMZ$8_+!KG+_ $R_\+^)=9\9Z?=Z?-I5];I)
M>Q7,K1E!&N T; %6)'KCTSWJO\/_  Q_:GP[NH/$MB1'K-Y+?26GF.A"NP90
M<$$=,XSTQF@#H/#OBC6]:OECN_"5YI=HT9D%S<3H0>F!M'.3GOC&#6]J^J6V
MBZ1=ZG>/LMK6)I9".N ,X'N>@KA/#6BGP9\03H&EWCMH5YI\EXME(Y<VLBNJ
M_*3T5MQ/N0?2KGQ>AFO?ACJJVK;O+*/(%8C**X+@X]@<T 7[3QE,NHZ-:ZOI
MZV UJ(O9?O2S!@H8QR@JNQ\$< GG(HO_ !C<)?:O!I>FK>Q:-'OOI&GV?,4+
M;(P =S  9S@<XSFL'QO_ *;J_P /8K.13(^I+.@1\YB6/<S#'4 =_>F> EBT
MO5OB&MTZPE-6EN9&D(7;$X+ACSTQGG_( .IOO&=A;^'=,U>V!N%U1XH[*/<$
M,C2<@'/3 R3U(P>,U)I'B1[O6[O0M1MH[75;:,7'EQR%TEA8X#HQ521G*D8X
M(KR3P[8WUKH7PKN;MY(K1+Z8L)NG[Q<Q'@$8(!P3S\W49R.Y$;S_ !^>6%\Q
M6WAY4GVDX#-,Q53Z''.#V% '7>(M=M_#FC2ZC<*TFUECCB0@-+(QPJ+GC))K
M)'C+^S;V:S\1VT.G3I9M>QLD_F)+&N=X!*K\R@ D>_'%8?Q;43Z+X?NE(>TM
M];MI9F'("989R.@R1SD5R?QUL+K5M6T^WL/GEMM+N[F=5R2L0*<D#U(P,\9H
M ]"LO&\K7&D'4].%C9ZT<6$OG;VR5#*LHP C,.@!;TJU?>*;H:U>Z9I.FI>R
M:= L]Z\EP(U3<"4C7 8ER!G!P,=^:XWQ:3>^"O %MI[O]HFO[%X$@8!]JQ$L
M5R?X01D]JTO Z-I_CSQ^EX(X96NXK@'@9B*,5;CVZGU/)H [70=;L_$6B6NK
M6$F^WN$W+ZJ>A4^X((/N*TJ\]^#*20?#FR\YO]?/<2PJ3_ 9#@C/8]>..:N?
M%+6KG1?"4;6SR1"[O8+2:>-MIAB=OG8''&0"N>,;L@Y H [4GBN0O/%NJ3:A
MJUMH&D0ZC_9+QQW"/<F*1W8!B(QM(.%/4D<\>]8VI1R>&?B-X7@T)9!9:R+A
M+^W5RR.$52)><_,-W+=P ":;\/\ 2;2'QMXSDC67=;:A&D9,[D8\K'()PQY/
M)R: /2E)902"I(R0>U+FN'^)UG>KX9&LZ=),+K2IH[MHXYFC\Z)&RZ':>1C)
M_"N3'BF+2?&]Y?P-<3Z)K-J\%@'GD=6N8PN0@)PH8MCJ.4)X'4 [W5O%-QIG
MC'0]"&GAXM3\W_23+C9L7=PH!SV')'?\>CE:18':)0\@4E5)P">PS7DVMZ";
M?Q;\.])NIY7E1+@7$RRN6<^6-V'^\,GOP<=Q5_P='+'!XZT<W-R;6ROI$M0)
MY3)$IC#!0S'=QQWY.>2#0!Z'IDU]/IT$NI6L5K>,N988I?,5#Z!L#/Y51\5Z
MS<>'O#-]J]M:Q7+6D1E:*24Q@J!DX(4\_P"<UY=X<U=YM%^'VB:C<EM/U2.X
M:YD+NK32+G9&S9!();D="1W'7H/$FD6NB>!/&EE!J%Q<Q-:M.EG*Q<6BLA 5
M2?X<J3C/&.GJ =[H]\VIZ)87[QB-[FWCF9 20I90<<@'OW JOKNLMH]O (+2
M2]O+F416]M&0"[=R2>B@9)/8"O,M-M6T3Q%\-I[.[O%;5+)HKR*:9@DBK K*
M/*W$+M+' 48''X^L:A?6NFV4M[>S)#;PJ7DD<X"B@#F_#'C.YUC6[_0=6TA]
M*U>SC69H3*)4EC)(WHP R,XZ^H]ZAN/'<KVFJZKI>G)?:/I3O%<S"?;)(R %
M_*7:0P4'J67)!QV)MZ#IDLVNWOB748UBN[Z-+>TA==LD-LN6"M_M$DLP[<#M
M7&ZOIVL> /#7B.VMY+"\TW5)YFLXF:1;@33_ "B%(U!5AG&,$?Q'% ';7GBZ
M$MH\.D0KJ%SJZ&6V'FA$$0 +2,W) &0. 3DU:\/>(HM=6\A*"&_L)S;WEOO#
M>6X[@]U/4' R.PZ5YUX=T.Y\/?$3PA;:AM#+X;-JN"2/.5MSC)QGAA@<].@K
M<\')(?B/X]O_ #!]A-S;PA\_*9$B&X9Z9&0#Z9H Z;7_ !(-)U#3=+MH%N=3
MU)V6WB:0(H"C+.QY( 'H"34.D>+[:^LM7DO52TN='=TOXO,W",*-V\'C*E1D
M$@=#Z5SNL0O'\=/#ER^T02:7<11DX'S@DD#(Y.". <]>W7F?$5C=ZG<_%>>P
MD#P_9[:+"@L&>.)2X&,C< "/4$]J .[M?&\V=(N=3TO[#IVLNL5E*9M[AVY1
M95"X7>.1ACZ'FGWOC&[&H:M;Z3IB7T6C*#?2-/L))7<4B4*VY@.H./3.:Y/Q
M:1?>!_A]!8R*)9M2T\PA"<@!#DC!S\O?GBK'@TQV!^)"73+'*FHW$\K-\H$;
M*65CGMM[X'XT >BZ3JEKK6D6FIV,GF6UU$LL;>Q'?T/8BN8OO'CQ)K-Y8Z;]
MKT[193#?2^;M<R#&X1+M(;:#SEEYXJ'X2PS6GPNT&.Z\Q9)(F9!*1DJS,RX]
MMO(]JYGP<4T_X:^.X;MTBF@O]068M\HW%  >?7C' H [[5?%<-K;Z5_9L2ZA
M=:PP6PC60(LB[-YD+=D"#)(!/08YJFGCJVL]/UN36HEM+W10#=V\<F\.K*"C
M1DA=RL3@9 Y!%<'HNF7.G>(OA7<WX<?\2R6W!?HCF%F522<@[3C&/8>V'\2K
M.YO?%?C"ZMT>6RM(;#[7MP54 @D'ONQSP1QG- 'KUEXKN$UJPTG6["/3KK48
M7FM0MQY@8KC,;?*,. <\9'!YKIP>*\Y\<%KKQ]X 2S;S'%W-.?+;)\H(-S=?
MNX[_ ,^E;OCM-4DT"-=&>,WHNHG6W>7R_M2J=QBW9&,@>O0&@!_C7Q3<>%;.
MQN8;!+I;F\BM6+RE-F\X!  )-=/7@VMZE::EX,FM[6WU#3KJ'7K)+O3;DL[6
MK' VQDGE25R,8'L.*[#1HET#XLZMI\%S.NF/I*7;QSSRS8D#[2^7)[#'!Z 4
M >DTFT5X=;SW-I?>#=2L9KJ>"[U4Q-JMS*1)?1R;B0R G:@Y"@G^%>*WI- @
MUWXLZ_I]Y>Z@+9+&WN(HXKZ53&Y?)(^;CE!P!CIT.* /5**\8T_2M5\;:5J5
M]_:D-A?VNHW"?:WEE-Q9!).$VA]J#8H4CN.3D\UH>+I-4L]8?5+JWFUK1#8Q
MQW$>GS-'<Z>^UB9E0$?>#'G(( [ <@'J]4]2N9[33KFXMXHY98HV=4D<HIP,
M\D X_(UE-<QWO@0W&GZH$273\P7\A*@93B1L\CU/I7!^'+A-/U"?1M9TBXTW
M6(]*FA!$C207X !>2,DX!^4$Y&3N&3QB@#T'PAKS^)_"EAK,ENMNUVA<Q*Y8
M+AB.I ST]*W*\&TFQ_LCX?\ @77K2:\CU"34H8&+7$AC\EW<,A0$*%.U3P,Y
MQR>M=#XY\K4-2\2I;FZOKG3]-61D:9K>'3G5&D619,X,I!! "]N2!F@#LO&7
MB>Y\+0:7/#8I=17E_%9R$RE3%O. V-IR/Q';UX+?Q1<R^/[KPS+8(D<5D+N.
MY$Q)<%MN-NT8_,UP_BV\DOOAKX'O+UDFFDU/3W=_O;C@Y."?F/7(/')K>MD*
M_'.];RSM;1$RZAL B7N3Q],>^: -BZ\57%K\0M/\,-91>5>6LEPMR)CN&WL5
MV^ON:ZBO,O%NF0ZQ\6_#]A=_:6M)],NEF6%FC#+D9#.K X/ (^GKQSXU/5O"
MWA?Q_9:??7%Q;Z3=11V,CRL[VZ2%0R[F&<(ISG)_#K0![;17GVC^'K^P\4Z=
MJL&L6,&F7$3))9V\LCB]<HS"0%V.6QSGDD Y)[;/Q U2^T7P)JVHZ<2+N"$%
M'"[M@+ ,V/8$G\* .HHKB].T'2+36='U?2]7N8DGMC&L/GM(+]2NY6;<225&
M3GKSR>U<7:7$VN?"S7/%%S<W$7B*SEN)EE64AK62,Y6-5S\JXXVD="<]: /:
M**\FU%[W5]=^'D]_/=6<U_$[7<,5P\>6\G. ,@+G)!( ;!(JC9Z.'N/B#I,M
MS?C3]&"3Z="U[(#!(T32%LAMY&0I&XD=2.<T >ST5XAX063Q+XITJ+5+V_F2
MZ\,B2X07C*)6,B@_=?(Z#.W'3GTK/:VE?X6:YJT^H7C7^@ZG+;Z=,;M\V\:2
MIA3M.&/)Y.>,8(&* /?Z*\I\,'_A.3XK;699S=VET;>VVS%#;QJN8Y$ Q@DD
MMN(R>!R!6!X;N=0\4:EX$FU>\NP]U:WD=QY5W(OGB-64-\O )'5A@D\YSB@#
MW6BN"^&ADMY/$^E"61K/3]7DAM4F=F>./"D+EB3M';GN:[V@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P=4\'Z+K.K1ZI
M>VC/=1Q&#<DKH)(SU5PI 9?8Y%;U% '*K\/?#D>A?V.EDZV@G%Q'B=]\3ALC
M8^<H!T 4CJ>Y)-G2_!NC:1JK:I:VS_;F@2!YY)F=G501EB3R3GDGK@5LS7MM
M;W5O;33(DURQ6%">7(4L<#V )JQ0!R3_  T\)O82V+:4WV6643-$+J8+N!)&
M/G^49).!@9[5IQ^%]+CUR+6A#.VHQ0^0D[W4KD1_W<%B,=^G6MJL?Q/KZ>&?
M#UYK$MK+<Q6J;WCC90<9Y/S$#^M %*7P)H,ES=2_994BO"7NK:*=TAN')'S.
MBD G@@]B"<@\8MWWA?2M2U.RU&Z@F:ZLL_9G2YE019&#A58#D<=*T=/O$U#3
MK:\C&$N(4E49S@, >OXU9- &1+X<TR?Q##KTD$IU*&,Q1R_:) %0]5V;MN#]
M/?K6/=:7:^"H+C4O#WARYOKJ\N,S007+=7)+. [%5&0,X [=AQ+JWC1;'65T
MJRTRYO[A9DBG,95$C+QLZJ&8C+$*..F#USP=O2-5M]<TJWU&U$@AG7<HD7:P
MYP01V(((H S?"6COI>G7%Q<V4%K?ZC=27EW'"=P5W8D*6_B(& 2."<GO5W7?
M#^G>([)+74H6DCCD65"DC1LC*<@AE((/TJ'4_$*6&I0Z7;6=Q?ZA)$TP@AVC
M9&."S,Q 7)X'J?SID7B[29/"\GB%IFCL858S;U^>)E.&1E&?F!XQZT 17/@K
M1KBXANHX9[6ZB@%L+BUN'BD:+&-C,#EAP.N3QUK9L+"VTRRCL[.!8;>(81%_
MG[GU)Y)K%TWQ=%=ZO%I5]IUWIE[<0FXM8[D+^^C'7[I.UAW4\BIK[Q5:V'BC
M3-!DM;LW&H[_ "IA%B(;$+D%CWP.@SUH GUGPYIGB#[+_:<$DPM91-"%GDC"
MR#HV%89([9JC+X)T>>:5I4NGBGD$EQ;/=R-#.PZ%T9B#R ??'.:Z2B@#G9O!
M6BSW%Q*T,X2ZF$]S +A_*F<8P63..-J\=.!1J7@G0]6U5]3N;207<L!MY7BG
M>,2IC&'"D!L=L@_H*Z*B@#F?^$"\.?\ "+_\(X=.W:8#N6)Y78HWJK$D@\GH
M:N>'?"VD^%[>2'2[=H_-(,CR2-([8^Z"S$G ' ':MJB@#&N_#&E7NO6^M7$$
MS:A;@K#*+J50@(P0%#!<'N,<]ZKV'@W2-/EMWBCN)$M7\RUAGN9)8[=MI7**
MQ(!P3],\8KH:Y[Q?XLA\(:;!?7%G-<12SI!F-E 0L< G)SCZ ]* .@(R,5QK
M?"OP>[R2/IMPSR9WL=0N26R<G/[SG)YKLZ* ,27POIUQ)"+A)9K:WV>19O(?
M(C*C"D(.#C QG(&,]:FUW0+'Q%I;Z?J"2& L&'E2M&RL.A!4@\5JUFWNL1VN
MIVVFQQM/>W"-(L:\!47 +L3T&2!ZDGIUP )I&A6.BQL+5)6DD $DT\S2R/@8
M&68DX]N@R>.:QO#?A1-,GUV2: I;:K,S/9/,9DY+[G.>A<,,KT  'K5Q/%UE
M-I<=_#%+)%/.(+91M!F)R0>ORK@$Y;' SZ5/K/B6TT:[LK)XY[F_OF*VUK;K
MN=\?>;D@*HSDDD4 -TOPII.CRPR6D$F;>/R;?S9WE$$>!E$W$[0<#I[=@ %U
M'PMI&I7<EU/:L)9T$=R8I&C%P@! 60*1O ST/TZ$@TSXLFM]4TW3]1T.]M)=
M0E\J)]\<B [&8@E6.,!?3Z9KIJ ,^^T33=1TI=-NK..2T7;LCQC85^Z5(Y!&
M.".E0Z=HEMH\=R]NLT\\YW2RS2;Y9<= 6/H.!6M10!R/A?P9;:3X6N=$O;:.
M6RN96D-G)*9TB4A1L#, 2,J6Z=6-:NG>&M/TUYY$2:XEGC$3RW<S3.8QT3+$
M_+UX]S6S10!AV'A32=-N;>>WMGS:J5MD>9W6W!&"(U)(4'VI^H>&=,U*^:]G
MAD2Y>+R))(9GB,D><[&VD;ASWK9HH Y#7/!T6H:MX>EM(?LZ:4X>.5)BJQ(K
M(?+6/H=P!&3T ]<5TFJ:;::QIMQIU_ L]I<(4EC8D!@?<<CZBK=8>L>)8],U
M"UTRWLYK_4[M'DBM8" =BXW.S,0%7D $GD\"@ TSPKINE7$=Q$MS+/#&889;
MFY>4PQD_<3<3M&,#CDA1DG&:DTSPSIFCWUU>V,4\=Q=MON&:ZE?S6QC+!F()
MQWJ+1_$T6K:AJ5BUC=6=SIVSSX[D+_$"05*D@C ZUL6US%>6L5S;R+)#*@DC
M=>C*1D$?A0 7$$=U;26\R!XI5*.IZ,I&"*QT\)Z0FG:18"U!M])D22T5CN*,
MBD Y/7KGZUNTUV*HS!2Q R%&,GVYH R+_P ,:5J6KVFJW5O*]]9DFWE%Q(OE
MY&#@!@.>_'-1VGA+1[%=2%M;S(=2;?=G[5*6E/KDMD?ABD\+^*8?%$>HO#9S
MVIL;Q[1TG*[BRXR<*3CKWIVI>(SIOB/3=)?2[Z2.^W 7L: PQ, 2%8YX)P:
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ME/N\Z.3+^;N^\6)R6)[DG.:I:_XKAT#4]&LI;.:7^U+H6T<J$;48^O.?TKH
M<T <WX<\"Z#X6G>73+:56.1'YT[RB%3CY4#$[1^ISUK?N[2WOK2:TNH4FMYD
M*21N,JRD8((J:B@#F?#O@+P_X7N6N--M)!)@K&9IGE\E3U5-Q.T<#IR>YI9?
M F@2W-U(+62."[8O=6D4[I!.Y(^9T! )XQZ$'D'C'2T4 8U]X8TK4=6M-4N8
M)C>68(MY$NI4\L$8. K <_3FJZ>"="CFU*9+6<2:FH2];[9-^_ & &^?T)'T
M)]:Z&N9U+Q>+6^U&ST_2[G5+C38HY;R*V9=Z"3)4*I.6; )P.V/6@!;'P)X?
MTV[ANK2UN8IX;?[+&XOIR4B_N#+\#@?D*#X#\/'2KG2_L<YL;F4RS0&]GVLY
M.2?O\9//'>NBAD\Z&.4*R;U#;7&&&>Q'8T^@#F9? FB/<//%'=6TDR".Y,%U
M(IND ("RG.7Z]3S[U/)X-T.35+'4?L3)=6$?EVK17$D:PKC&U55@H&..G-;]
M% &/HWAG2M!N;VXTZWDBEOI/-N6>>23S'Y^8[F//)Z5L5S]CXKM[[QCJ'AM;
M6:*YL8$G>20KM<,>-H!)QC!YQUZ5T% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5YMX_U6\TS6[::\CU5] %LVZ72)&$MK
M-GB20*1E<<#/'!X->DU@:CX<>]U-K^#5KVS>6(031Q!&22,;N,,IP<L>: /.
M9[&#4/'OP_EBUJ_NX;FQG*W"7;#.V%02O0@M@[NY).>E7K"YU'QCX<\2:_!K
M-Y97UE>W$5B(92L<*1;2%:/=M8L!R3_>XQ74O\/=&$>C+:27MD=(B>"W>UGV
M.R/C<K-C)S@]",$DC!Z*_@.S2\U&2QOKRQMM48O?VMN5V3,>I!*DIG)S@\Y[
M4 <]I_BZ^\2R^#;">6:Q75[%[NYDB/EO*T8'R*2,@$@ME>2.AQS1XITV_P!)
M^&7C"RO=7.I1"-I+02,3-#"0,*[$\X(.#[=>PZC7O ^E:WIVFVJF>P;3&5K&
M6S?RVMR!@!>V, <>U1/X%LIO"]UH5Q?:A-'>OYEY<22*\MPV ,DLIQPJ@8 Q
MM'X@&#\/]2?Q3-)<2W]U -*2*T73EF93E5!\V7!^?=V[8'.3T]'SD8[URT?@
M6RAURSUF'4-1CO[>V%JTJNG^D1CH)?DPYZ#)YX'<9IWA[2-0LO$^OW\EQ>_V
M?>2J8H+J0/AQD,R 'Y4Q@ =3CT H Y/QKX=O]+\46?BGPO*LUW<7B)<Z6[ 1
M7,JQN%;.?E8+N_$YXYSV_A#7K3Q+X;M=5LK9K:&<OF%@ 48.0P../O \UG:K
MX+FN]4%Y8ZW>V:R7BW<T(".H8)L)C+*2A*^G%7Y/"-C%X=MM%TV>\TRWMY%=
M'LIVC<D'+;F'WMV3G/7.: .7T977X\>)VE+'=IEL8<G("< X]/F!_6O/M9AG
M7P!XV;E=.'C!RP0X!3S%!X Y&=G<\CMCGV_4?#T-]JD&J0SSV>H11- +B *2
M8V()4A@0>1P<9%-C\*:0GAB3PZ;;=ITB,LB,3E]Q+,2>N223GUH Y7QN9C\3
MOAY]G8JZSWA;"[L)Y2AN/0C(SVZU?\4@GXB>!".BSWA.3_T[D5KZ;X6MK'4X
MM2GN+B^O((#:V\LX4&*+(. %4#)QRV,T_4O#<.IZYIVJRWEVD^G.[VZ1[-BE
MUVMD%"3D$CD_3% &W("T94,5)& PZCWYKQ%8/$FH>$_$NM?\)9JT5UHNH73V
MJ?*B,L>?E<8&X$?@/2O;9&"1LQS@#)P,UY-X(T&76+;Q%8W5YJ%K8W.J7+RV
M1A"K/"[8&"ZEE!(8'!YYZ4 276J7WB%=)N9=0NRT^A_:AI5A(T+B4C)F=U8
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MC=6)R #EL@'<QSQVZ#IENI/%?CCQ%I4U_=6UIH\<*0PVL[1,9&7>9&*\D=
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MM$+,1!6" $[3G^(D<AB.,"@#UDG KF_&WBW_ (0W03JK6#7<:R+&P$H0+D@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ I"N32T4 (!BEHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K$U#PS!?ZF;];^_M)FB
M$$@MI%"R)SPRE2#]X\]1V(R<[=% '+W/P_T"X@TF%(KBV32HVBMA:W#1'8P
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MS9('*DDC!YP>N>:["B@  P,4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)G
MFEH **** "BBB@ HHIN[VH =13=WMS3A0 44@.3BEH ***0GVH 6BD!S2T %
M%%-W4 .HINZE!S0 M%%% !1110 4444 %%)GG%+0 44@.32T %%%% !1110
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MFF7[-=;DBCW2*"J\[1ECZ8 [Y[51N/!E]XDT[QUJ,=M+:R:ZL0LH+@&.0^2
M07!X7<P_+TH [)/&MJM]IUO>6-Y91ZF#]AFG";9FQG;@,2K$$8# 9Z=>*H6'
MQ*L-2NIHK;2=8:*VNGM;F<VOR0,JEB7YX'';/;.,C.+>QWGC72O#.G2:/J-C
M+IUW#>7YN+8QH@B5E9$)SN8DC:!GCJ:D\%6^NV&C>,0NFW$%_<7MU=V NXV"
M2;E'EY]/F'(ZT =!IGCNSU*]TVW:PO;8:K \]@\^P>>$ +# 8E3\PQGK7(7O
MCNVU72?$A\2:#J@TFTOD@C2)E&UE9,*S(P(8N03@D=L]CGV5EJT_B/P?K/\
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M'N.1Z]LT =U16/::X;SQ%?Z5%:.8[)8_-N=XV[G&0F.NX#D_4>M;% !1110
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M+L6&.1@#.1GM772Z=J\OQ>L]9&E2C2X]*:T:Y>6+"2%R_"AMWH,X[_C7=44
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M0  %3OC;WZG<TB[O+[2;:YO[ V%U(FZ2U:02&,^FX<&KHZ44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !132W/%)N/K0.P
M^BF;CZT;CZT!8?13-Q]:-Q]: L/HIFX^M&X^M 6'T4S<?6C<?6@5A]%,W'UH
MW'UH'8?13-Q]:-Q]: L/HIFX^M&X^M K#Z*9N/K1N- #Z*9N/K1N/K0.P^BF
M;CZT;CZT!8?13-Q]:-Q]: L/HIFX^M&X^M 6'T4S<?6C<?6@+#Z*9N/K1N-
M6'T4T-FG4""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\L-Q#-'([%941 68E0?O+G/O6G%X-U'2]&\06VD7D<<^H70FMRY*K&I*EQD
MD$_/R.F0:0&E<>/-#MK&RO))9_*O'ECCVPLQ#Q@EE('0_*>/:KFD^*](UNZ:
MVL;@O($+C<A4,!C=C/7:64'T)KD]-\#ZO81^'XC]A9-.U:YO),2MS')OVA?D
M^\-_0^G7FM/PKX1N-#UK4KFY2UECDNIY[6X5W,JI*P8QE2-J@$=03GCIBF!V
M=%%%(84444 %%%% !1110 HZT^F#J*?3$PHHHH$%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(>AI
M:0]#0 RBBBD4%%%% !1110 4444 -=Q&A=B JC))["LO3/$%KJLD:P17"+-"
M9X9'0;)8\@;@03ZC@X/M6A=,JVLS.A=0A)7^\,=*\:MM*O\ P_9ZZGA;4;JZ
MTF?2Y+B.U<'S+&4D?(O0@D;N.#Q]"5<#VK-&:\@MY(&U/1(KR_N9=$OEF>RE
MMK=XA%/OC94498C&U@#[L!5%XO)TW4-7CN)C%#XBF@NE^:2-+4S \Q@C*Y Z
M=L]JH70]G6\@>\DM%E4W$:+(\8/*JQ(!/U*G\JFS7B]VL6B2:XUP+J\G.DV'
ME7,<+1O,/,*EB<,0#\NX$DD9%,TQ6U'1O"EE?W%Q'NUF\MG.6C<1[)0%&>0.
M5 ';@4D%SVO/-+7 ^%M$_LCQAJND?9 =/MVCO[.=SN8&1/+*Y/H4<_C7?=J
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MUV'@87DWBW69+J\E2>WN;B*2S:W8!HBZF%]Y.,!1A0!W:@+GI%%%% PHHHH
M**** "BBB@!1U%/I@ZBGTQ,****!!1110 4444 %%%% !1110 4444 %%%%
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MTER1I^H:D([L=I%52PC/LQ R.^*IJSL).ZN=JC)(NY'##U!R*=7*ZP8O#EQ
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M3 ]-HH%%(84444 %%%% "CJ*?3!U%/IB84444""BBB@ HHHH **** "BBB@
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M%%% "CJ*?3!U%/IB84444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4$Y/X4)J5C+?26,=Y;M>1*'DMUE4R(IZ$KG(%,+%JBJ-AK6EZH\R:?J5G=M
M=LJV\ZR&,^C8/'0]?2B76=+AAAFEU&TCBF?9$[3* [9Q@'/)SVI#+U%,,T2R
MK$9$$C LJ%N2!U('XBB.:*8N(I$<QML?:P.UL9P?0X(_.@1(.HI],'44^F#"
MBBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %<_P",O#<WBOPW=Z*EZEI%= +)(8#(P ((Q\RXZ=\UT%%
M$-K%)#:Q12NKR*H#,J[02.X&3C\S4U%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>arrowheadpharmaceuticals003.jpg
<TEXT>
begin 644 arrowheadpharmaceuticals003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDPG/[QMH.%X^OM7":%KT?A:[U_POXATB_N9KO4II[-1:F:.]27D+D9'&,'/
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M4G* @Y.=K$'&#CKTJO'XS=_B)=^'3878@MK-96D$!;+%C\PP#\F!U/)/ !H
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MZII'AN32[:X1!]IN(_*EN2,X^7D[0,8)/.>G%=?10!QGQ!M;+4(M+LKZVO\
M8T[2I?6 <RV+JORR (">K8Y!'/TKBM8L_$EY\*+^PN8KK4KEM17[%<+92>==
M0(Z$2R*%.&P#@G&0!7M%% 'CNN:I_8OCC7YTBU*TM[^QMXKFY_LUKF)F,9 ;
M"LK(RKQ@]<'(&.9=--A-??#U/#MOJ=WINF/<0RW#VD@\G*;1YAP ,GGGMSTK
ML?\ A"7M-9O]2T?Q!J6F&_D\ZX@C$4L;2< L!(C8)P.E=!IFF0:59BV@,CY8
MN\DKEWD<\EF8]2?_ *PX% 'E\6AZEJ[?$^UALKZV?5 ILI9;9H5GQ&PV@G Y
M/!SV;/-7/!QTS4[O2U/@6\LM6M/FN;J\M]J0,%P61R<L25 &!]>E>H44 >(!
M=1T7P-XR\)W^EZC+J$UQ<W%M/%9F6.YCD^8-N&1GY6)W<CCN,#U?PIO'A+2$
MEMI[:2.SBC:*=-KJ0@!!!Z5L44 >>ZNTVD_&&SUFZMKTZ9+I!LQ/# 9$$OF%
M]K;06Z#TQT]ZL^#O#0>'Q/>:A9R16GB"\>46-PI5EB(VY9<_*6Y)'!&0.U=S
M69K^E3ZSI,EE;:I=Z9*S*1<VI =<'..>QH XCX<Z/J$6J746IEI(/#IDTO3I
M"!B1&(8L<=P@C7/^][UZ55#1M(MM#TU+*U,CJ&9WEF;=)*['+,S=R2>M7Z /
M!FL-3A^$FM^&1H>IOJ2W\DGEK8NR,&E# *P!!RO/3 []L]M=I<3?%KPU>)IN
MH-:0Z9+%)<?97$<3N 5#':,' P?0G& <UZ'10!XSI-K:Z9->>&==\%7VI7YO
M+DV=R;</!=QO(7#EB=J ;QGKCZ\5[%!'Y-O%%A%V(%P@PHP.WM4E% 'FMW+<
MZ%\7M2O9]/O9K74]*CBMGM;<RAG1N0V!\N,]6.,'KV')QV&KO\ ].THZ)J)O
MEO$+P+9N6"^:7+!0!QC\.17NU% 'F^KVEQJGQ2@GM;2_BBFT*:T%\;.5$AE8
MDKECC& ?3@GKGIQEW-JLGP?7P>V@ZI_;6G7$4+I%:DQL!,,,'V[3G/KSUSUK
MWNB@#RGQ-%_9GC^#7M4\/:AJ>D7NG) 3;P[WM)5+$[E!S@JQR?<]:C\7:8S>
M =+M]'\+W5D'U>*[_L^"U+.L:MDM(%#*K$8.#].<$5ZU10!Y]X\L+/5;_39I
M9-7TR:*W>6UU>QMY";=C@;' 4D CJ#@\8^F)J$.O7&E> FU33;BXOK;4UN+M
MH;)SMC#,!(^T95R,,0.Y.1BO7** /%];U--&\4^,;1(M4@MM51$F=-.-RK'R
MV#O&490O#*#NR>E:-G<6=YXR\$W6B6FH2:-IMI<6;3K:S'RB$\M4D^7 P5[Y
MP>H'6NHB\$7%AJ5_<Z/XEU+3X+^X:YGMECBE3S&R6*[T)7)/\AV%='IFFPZ5
M8):0-*ZJ2S23.7>1B<EF8]22?\B@#RR/0;[5M!^(ME!I=W'+>ZA]KM1<6SPK
M=*"K #<1U*$'D?>SQT&MX7GTO7=4M)[?P/=Z?J=JI%S<WL/EBT8H<JC-RQ.1
MP .&R<=*])HH \'<7^G_  C\0>"+W2-2EU:V>0"5+:25+@&19!+O' SGU)X[
M]*]BT])+OPK!$J36DKV@C"RJ5>([<<CJ"*UJ* / IFOXO@^W@V;0=4_MC3KB
M-98XK1I4<&?<&#XQ\V>,'-=KXCN)M-^(?A77Y-/U![$VD]I)Y-L9'21@"JE5
MRW.#V[5Z110!X/<V>J7GP_\ '-E_8>I&YO\ 79+BUC%B[;U\Y#G"C'&T\Y(X
M[]^H\5Z;JT6M:+J_AX21W&L0C2KY"K1D+M++-L./FC DZCIZ5ZA7-Z=X2%IX
MBFUF\U?4=0E\R1[6&YDS%:A^H11[9 /8''KD WK2UBLK."T@4+#!&L<:CLJC
M 'Y"IJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *S-=UVVT"RBN;F.:7SKB.VBCA4%GD=MJCD@#
MZDUIUR7CZ76H=-L&TJWN9[<WB+?QV8_T@P'(/EG^$YQR"".Q% "IX^L!I^MW
M$UE>12Z(^V^M\QET!7<&!W[2,>^?:K4GC+3X[C0(S;WA37 #:3!%* E=^&^;
M(./8CWZUY_IF@ZT\_CO3X-"U"P75K99+.2ZE#;CM(^:16Y=B<G+$]<GU;'/K
M5V_P_,7A'6D&CMLN=R(@!\E4. 7'&6&&.T=>N"  =!)XJN-:\6>)?#%WI5X+
M*UM44;"J\LI8NS!L@'@#;GOD5C?#CQU9:1X)\)Z;>V6H@7K&V2]\K,'G-(V%
M+\9)YZ XP022#6D;;5=(^(OBN[72=0FM-4M81%<VT8*JRQD$GGELX ^4G\!6
M!%I&MVWPK\%:8-'U%;ZRU2.:Z@BC(,<:2.Q8X&&ZJ<>ISR0: /3M1\2I9ZF^
MF6EA=:A>QP?:)8K?8/+3.!N+,.6YP!G.#6;=_$;1+;P;_P )1&MS<6(.QUCC
M^>)\X*R GY2"<'],UEI;7WAGXH:MK+Z==7>E:U;PC[1;QF5X)HQM"%%!8*PP
M<XP#U[XYO4O"6K6OPL\06\>G7$VI:UJCWT5K$N7C5I%90Q'"L%&3SP> : .A
MUWQEHFI:=9G5O#VNBW;5(8;4O T):7AD<'<#M.X_7!!%;NK>.+31DU2:?2]3
M>TTW N+J../R\D X4LX)QN':L3XC6]]JWA+1H;#3[VZE^WVT\L2QMD1QG+;P
M1].#UZCI4'B"*\\3^,X;?5=-U!/#.E.LR1+:,_\ :$^<9( /[M.O/7WH Z3_
M (32VEM+%[;3[R2ZO+8W:6DFR)TBR!N<LP"YSQR3^M-@\?:'/X6;Q LLHMUF
M^S- 5!F68L%$14$_-DCC/0YZ5R/B:&[_ .$FT[Q-?>#9=;TN:S>SFLFMUEDM
M0LK%)!$V>64C./\ ]<FOZ!J=QX.TW4-&\-V^F7%EJT>IC2;:-$>1 -I#;2%\
MS!S] !U% !9W,L_Q^C,MC=V$S:$QDBGF5P_[T@%=I( P!WZCIW/>:UX@M-$>
MS@E5YKR^E\FUM8L;Y7P2>I   ')/ _$5P]I=:GK'Q<TW7(_#FK1:<-'-N\ET
MBQ>4[2DGY6(Z=#CDXR 1@G3\;Z=J,/BKPUXHLK:>ZM],>:.]AMQND\F10-RK
MU;! X&3Z T ;>E^+K35)]5M([2\CU'3/^/BQD11*<YVE.=K XX(..E<-X,M8
M/&5[JFIZKI^HKJ%IK,SPWJ2B/8L1 6$$/TP2",8//-=!HFFRR^/]<\7O9SVU
MI):):0K)"PEFVG+/LY8#@ < GTZ4OPVM;K3=-UJ&]L[FWDEU:ZNHQ+"R[HG;
M*D<=_3K[4 <G;_9/&NH>+9/$&DZM_H=X$@N+8A9+2.-%(0;7)#9R3@$?-^76
M>%_$6@V/@;1I-$M+PVUX[Q6%D3OGD;<Q.22<#@DL3@#J:J^$XKK3[CQG+<6-
M]$+[4);JU)MI,R(4501@9SGMP:Y72]&\2:'X7\$ZQ;Z+<S7>ASW4=[I^S$K1
MS'EUR>2 !Z]?8T =]%\0M-D,]L]G>Q:I#=?9#I[JOF-)M+?*0=I3 )+YP ,G
M%-3XC:4=-UNZ>TOUET5PM[:K&KR+D9##:Q!4X/S9QQ7)>)QK?B*;0_%C>#)+
MFPTV1]VDW:J;B:.6/:[F,Y'!"8!YXS@"M*XMC=^ ?$3Z7X*.B/?6IMX((;9$
MN;AL, 75!\J\\;CGENG&0#I_#'C"'Q0<P:3JEI";:*XCGNK?9'*KC.$;)!(X
MI-1\96UG/J,5I87FHMIBA[TV@0^2",XY8%FQSM&35OPA&\'@_1[:6"2"6"SB
MADBDC*%&5 ",8'<=N/2N2T5+_P %>)O%-O<Z7>W.GZI=OJ-E<6T32[Y' #1,
M%!V'.,%L# Y- &QJ'Q&T:R3198(;W4(-88+:S6<.]">>"<CYL@\=1SZ5?\-^
M+K3Q)=:C9QV=Y97NGNJ7%M=H%==PRIX)'(YKSFT\(:KX=TOP'I0L+BXEL=5-
M[>_9U+QP*Q8<L1@E<]AV/3(-=5X8M+Z+XH>+[V6QNH;*\6W^SSR1[4E*)M;'
M YR>_4=#B@"36/&-[;?$?3/#,6EW3VL\$LDLB[ 9>  4)895<G=T/&>@.>.\
M(>*[/P5;^+6N+'4KJS@UN;S9X(_,6!/E W,S>_;\:ZOQ-;ZI:?$W0-;M=,O+
MZSBLI[>1;49VNQ&-V6  Z<\_=Z=#7*G1]4;P/X^T_P#L>\6YU/499K-%M"WG
M(Q4J>0,=#]XY'Y9 .U\7:IX?&I>&(]4LKNZDN+Z-K"2$LL:2'HS$$ X'.#GZ
M5=D\91?;9X;;3;RZ@M[U+&6YA,96.5BH.X%MP4;N3CM7->([34+RU\!&'3M0
MD>QO+>>[58#NB4)M8LW8@]0,Y_(UGZII-_+XANM5\/VNKZ5XA&H*LD8C?[%J
M,(EVB20Y*<1DMS@^@SB@#T[5[6[O=+FMK&\-G/+A1<!=S1J2-Q4?WMN<'L<5
MYY:>'?\ A$_BOHMKH-]>O9WUM<S:G:3W+S!0  LQW$\L^T9]C7H6LW\VEZ3<
M7EO87%_-&!LMK< O(20.,D#OD^P-</X6UO6Y=6S>>#=4CU"^?%Q?W;*D448)
M8(,;B$4$A1CECDX+$T 5/&_A&+3]%U;7[CQ%XADOI&)AAM[]HH_-=@L<:H <
M+N91].I[U?UO7+[P);^$M#M[>]OOM-PEO/<EA*\F 2R@L<[F..N!C."#TV_$
M-E<:MXF\/V)MI6L+:9M0N)<?(6C7$:9SUWN&Q_L>F:ROB/8ZC+J'A34K&PN;
MZ+3M4$]Q!;#+[-I^8 G!Q[^O!% '/66N1^&?B7XSN!I>IW>8+:9XH,2M&-A9
MF;<< =N&^@[CT_1M7M=>T6SU6Q9C;7<0ECW#!P>Q'K7G]A:ZFWB[QMJ-SI5Y
M%!J&GPK;EH#(2PCVM&!CG#'UP>N<<CHOAI:7>G_#W2+&_MI[:ZMXVCDBG3:R
MD,<?A@C&* ,[QOXDM+SPYXGTZUL+Z^^PVDJW4ULP6.%_++ %MP)(RI( .!G/
M0BE\+>(8],\'^$=/6RNKJ^U"QW0Q1;>D:J79F8@#[P^I-<[!;ZUX;L_&GAR?
M0]1OUU-[NZL;JUB#QR"5/N,2<*PYX(YQP#D EE+XEM=/\(Z?>>']9.EQV1AN
M4MB@F>?A5#,'#)'CJ<KUYX% '8GXA:4?!/\ PE<=K?3:>K%95C1#)$0^P[@6
M' /<$\<]*U7\16R76BVX@G>35E9X0FQMBJ@<ER&Z $#(R,D#N,\C\,]'N8_!
M>H^'-:T>[M8_/N$?SPBI*DCOD(%)  &.F1SP33OAMH][";E]2N%NX]&DETC3
M)-O2&-R&;V)PD9_ZX]?4 ZS5?$=MINIVFE)#+=ZG=H\D5K"5#;%QN9BQ 4<\
M9/)X%5]*\6VFMZ1=WEC:W3W-G(T-Q8E56>*0'!!!8#WSGD?E6#KUCJ&D_%+3
MO%45E/=Z9)I[:?>FW4R/!\Y='$:_,P).#@''7ZS>&-(F@U_Q3XIGMIK>/5)%
M$$+*QE:.-=H<IU&[&0N,XQGTH POAC8V_BC1=*\27]I?Q:Q')+<R7XDV)=%G
M==O#$LH"J-I Q@8ZG/8^-[JY30&TW3Y$34=5<6-L6&0I?.Y\>BIN;\*S_A39
MW>E_#O2]+U"TGM;RU5Q+'-&5P3([#!/!X(Z9I9=/_P"$F\:3O?VFI6MKID(2
MQF226#S7?_6N&4CL%7!Z\D<4 -^&/B"?6O!,27_F'4],=K*]5E^;S(^!]25V
M_CFJ,WQ>TF.TN+Q-&UN:SM;E[>ZGCM<B KP2_/'?Z8YQD56TW3+OPA\5+UM.
ML=2N-!U6W5KN7RWE$5T.C;F)9@1U(SRWL:Q/#E^9O#OC[2;>SO+J\O=1OHH'
MCMWEC=G4J SXP,=]V..F: .[UKX@:9HMQI41M-0NQJB%[5[6#<L@V[@!DC+'
M(P!Z\XK-L_$.A:[XST4W.CZM9ZW-8RM +N-HA&G\:E<X)Z\X_&LRYT"_T6^^
M'VGVUO>7,.C[Q>SV\4C(NY ,]>03N]<#J.U:^L6]Y+\7- ODL+N6QM+.XCEN
M!&QCC=P,8XZD#!(]<'I0!5^%<2V]SXS@4R$1>(+A5\PDD+Q@<\GZ]^M7?%7@
MZ/6(]1U/5]>OK7R49K0VMPT,=HJ@$,0#\[9#$D]FP,8!J+X<VMW97WBL75A>
M6J7FLSWEN9T8+)&Y&&&1P3C.#STXXJ#Q9K>J7.L-I3^$-8O]%A.93 B;;P@9
M"DEA\F<9'?'/&00#(N->UV7P9X#TK5)I(=0U^XCBO9$?RY3 .3\W\+,I3.,'
M)('-:VF3S>'OB=>^$M.95T^YTA;^TA<.RV\H8QXSD_*=N3^ 'NNO6NL>(]/\
M.^(H='NK"]TG4EG-A(Z^:]N3LD^[T)7G;SD#&#D59L--EU#XC7WC&>SN(K.V
MTU+*R$D+"27YF=V\L_.,$[0"!F@#!\1^$YO#M[H.KZ;K>H3>(KC4H8;@R3,5
MOP22X,>=JJJ[C@<  _6NJ\>Z9H=SI$U[XBU2[L[*&(JGDW30A7.?F&TC>QX
M#9''3K7.6OB37[C7FU&^\!ZS+<!C'8B0(L=JAX)SD_,?XFQG' &.O8ZCXB>Q
MU.'3KK0-3N(YH0YN+6#SX0W.4..?3D@9S0!6^',UW<?#_2)K[4X]2G>')N4<
M-D9.U21U91A3[@YKJ:X#PW9WG@#P9$JZ->7<MYJ+R&RM=K-:K*QV@\XPH"@D
M$\GTKOZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***@O;N&PL;B\N&VPP1M+(WHJC)_
ME0!/16+X3\26OB[PU9ZU:+LCN%.8RV3&P)!4^X(KG=5^([Z9XXMO"7]ARS:A
M=*'@<7"K&R_,>I'!PIXQUXSWH [RBN,T;XB6NI>+;KPK>:;=:=K,*EUAG*LD
MJ@ Y5U)['/TJC:_$R:]\::AX4MO#TLNHV2EW*7<>PJ O.3CG+ 8_ES@ ]!HK
MD/!_Q"TWQ?=ZC8);7-CJ6G.5NK6Y RN&*G!!(.",&HM.\?-XCUK4+#PSI?\
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MVBG4(P)8#);&#\IXH [NBN,TOXB6MWXSD\):AIMUINKA2\22E7290N[*LI]
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M$F^WV^XO(\ZK'M !R#C/<=J .]HKFM3\5S:;K5SIS:6T@@L)-0\U9AAHD."
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MBL'PSXE_X2/^T =-N;![&X^SR1W.-^[:&Z D8P1WK>H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *XWQU<F[-AX>2VN[J*\?S;^*U4,WV5/O \@@,Q5>.2-P'I79
M5E1>'K"'7IM:0W/VZ9%C=C<N5* DA=I.T %F. .IH \<^"NHS>%_%VK^!]1A
MN;<3,;FS6ZCVN<#H0,C)3!ZX^4TOCE+T_M$Z!_9GDQWQL_W+SKF,MMEQG!SC
MM7IM]\._#>I>)%\0W-K<-JJ,K)<+=RJ5(Z8 ; Q4EWX!\/WWB2/Q#/;W!U6,
M8CN!=2J4&", !L#@GMWH \N^%<XUGXKZYJ'B<R1^+859!;^6$B2,!4)7N2!Q
M]#G)S5$RZ]%\>_&$WAX02:G%I[M''=#<) !%\HP1STQGZ'UKV#4/ 7AW4O$<
M?B":TECU:,*!=6]Q)$YP,#.UAGCCGJ..E)9> M T_P 1R^(+>&Y75)AB6X-W
M*Q<<<$%L$?*./:@#RSX4B/6?#OC74H[BZD\87<,RW2N@4QNPDV>6/<XX.,$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ I"0.I S2UY%XW6WU"[\9S6227MW8V"),]RP":>0A=3 ",F0@DY&T XYH
M ]9G,JP.8$1Y@IV+(Y12>P) .![X-<)HGCGQ)X@EU1+'PI:'^S;M[24R:MMW
M2+C./W/3!S73>$;N6^\':-=32F::6RA9Y"22S%!DG/.?K7(_"?'G>,\$D?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBCOO,,H8,VU7/5@N=H/)[5L:YH.F>)-+DTW5K1+JTD()1LC!'0@CD'Z5HT4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJECXL\87E]IEU;P:A=I/:N[(0ZJNWH#D'IU_3%8-AH-^N@:Y8ZSX8N+ZTO\
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M=&R-OC 5% P#CN2,>[<F@"UX(\26>B_#;PC9H@N=0O[?R[2TA8!I6 )8DL>
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\P^*7
MA#0H?!OB;7GLHWU.2,2BYDD*LC?(@"GMP!QW)]Z /3F944LQ"J!DDG  IL,T
M5Q$LL,B21MT=&!!_$5Y[HW@[P_IGAG3?$-OHYDNHM*W30P'FY\R(;LY."<9_
M,]\5G'QE<6GA_P $#P[H<5EI^JW21B(7*IY8W']T 5_BQR?P')R #U+[1 ;@
MV_G1^>%W>7N&['KCKBI*\TM6M]-^-FKWEPJVD7]@)<7#'"QKA\LQ/\6,<D^E
M7K;XHZ?+J&BPRP1+#K$ABMC#=I++&W&WS8Q]T'/4$XXSUH [VBLRSU.ZN->U
M+3Y=+N(+:U6(PWK$>7<%AE@O?Y>AZ_A6G0 44$9&#7B/]D>$O^%G>-8]:L[9
M;6WM;=X8B2I#%#N\M5(.3QPO>@#VZBO%/ 'C?Q)H^CV/AS5- U/4-5FAFNK,
MS.L<CPAC@/O.X<YY/8@#/6NOU+XH6.G6UY*]HJR:>%^VVLMW$DZDHK%8TR2Y
M4-ST'! )(Q0!WE1RW$$#1K--'&9&VH'8#<?09ZFN9/C>VNKK1K;3+<7$NK6;
M7MOY\OD@HNWY0<'+_-]T=@3FJ&L^(+.:?PC+J7AR9IKZ\18'E<#['*0<Y(.2
MV >,8/K0!V[ND<;22,JHH)9F.  .YI(I8YXEEBD62-AE60Y!^AK@?%^OMK7A
M_P 6:?I^CI?VNG6LL5S//)M4R>4S8B !WE.,\J0>F347AWQ3:^'/AIX0BEDM
MWO;ZTCBMHYIQ"APF2S,<[548!(!Y(XYH Z[Q-X;L_%>BR:3J$DZV<I4R)"P4
MOM8,.2"1R >,=*TK6#[+:10>:\OEJ%#OC<0.F< "N&M?BE:7&A^(;U=/:>YT
M%@+J&TN$E1@0?G23C*\-VSQT]+&F?$"XN]6\/VM[H$]C;:[;M):W+SJWSB,2
M%67&1P2 3R3V] #MZ*XC0/$NL:G\1=>TJYLXX;2P2)%03@E00S>9ZG=P,8&
M!SG(K0UWQ7<:9J-Q8V.D2WLEK9-?3N[-%&$!P%5MI#.<' XZ'F@#IZ*XC4_B
M1;6/A31?$$&EW-U;:J\:(JR(#&S]%/.2<\8 ^N*TM&\6G4?$>I:'?::^G7EG
M$EPJR3H_F1-D!OE/!!'(YQD<T =#/<0VT1EGFCBC'5Y&"@?B:D!R,CI7C?Q+
M\0_\)-\.9=0MM*4:9]MCCMKR=\2;A*!O5,?<)! .[)':O4]5U$:/X<O=3=2Z
MV=I)<$ 9SL0M_2@"[-<0VZ[II8XU]78 >G?ZBFR7=M$P62XB1F<( S@$L>0/
MKR./>N"^'&C6VM^&X?%.N0PZAJ^K!I999DWK'&6(6-%;(50!C ]ZYSQMX5L?
M"M]H][86QE2?Q%;7$5O'&))$^50R(7/0E<]0!D  ;: /9J9%-%.F^&5)$R1N
M1@1D=1Q7.Z'XKFU36=7TB\TF2QO]/6.40F=)#-&X.UE((&?EP1T!(YKG] \;
M^'],\)RWT.E+I44FK264=IYB*TDY/)8D@+SDDDG 'X4 >BU ;VU6Z%J;F$7!
MZ1&0;SWZ=:YC0O'46N:IJ>D16T+ZE8Q"8"VNEF@F4CC;* .<\$$#'\N>\"Z9
M#XGMI[S7-(AGF@U>YN(KX2X=94E*A> #@  >A '':@#T^BO*/B7%I\?Q&\%2
MWUJLT$KW"3QI 9'E&SY1A02W)X%;GAZW\/2:Y>7_ (=T.:UOK&V\EDEC:V$H
MD<D@JPSD&(\X[XH [NBN*T3X@-KLT=I;Z-+%J N98+BTFF"O;! ,NXQT^9<8
MSG(JSKWCFTTB]OK&$6TEW8VRW,RW5XENFUL[54G)+':>,8&1DC(H ZRBN4L_
M'NG:GHVBWNGPRRW&M,RV=H[*CDIG>6Y.%7')&>W!S5*^^(4NDZ%K&H:CH4\,
MND7*PW$/F8617("R1.R@.#N''!_3(!W%(S*B%W8*JC)). !7/R^*DA\7:=H#
MV4N=0M7N(+C=\HVC)5AC@_3-<WH_BG5M3G\9+JNB--9V#M#]GBN%8[1&,QA<
M#).6);/?'.!D ]#CD26-9(W5T895E.01[&G5Y]IWC:STSPMX5N;30UM=*U62
M.UA5)P%M68D -QTXZ^O'UW=7\966BSZB;M/]%L8XC)*D@W&21L+&%./F[]>
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M1L@QEE<G)5B/F]ADBO9** .9\.7WB&_62]U30(]'C2-E6R2=)I9GR"&W *%
MP0 3SN). !FK\/-/U/2=(O+/4]-FM)&OKBY1GDB=6621F ^1R<@$9R/SKL**
M . \9:;KMUXZ\+ZIIVCSWEII3S23[9X4#;TVC:&<'(]P*U3JGB*74?,B\*SV
M\,<9:1GN+<R7&!\D0PYV_,Q.2>@..3BNJHH \NBT'Q+IGB73O%UII4\NIZ@S
MQZY9^?"%$60$VG>!N10,8^]CYBO>UJUAXC\.^/KW7=%\/QZW9ZU%!'<PFX6*
M2WDB!4-EAC:5)_$<D<9]'HH \Z\5:+XGD/AOQ-IUK!<:OHTDTDFFK*H5XY@
MT:N5 )51C.!GDXS@5+XATWQ+XS^'^N6UWIL6GW-RB&SL6F61@4(?+.. S$8'
M/&!TYKT"B@#S.WL_%&H_$#PWKL^@/:6UM8S6TZRW:$H2<9.T]^V,Y]NH=9:/
MK^GZQXYA_L62>VU9FFM[D7$3;]R; H5R,D$DD,0 !QVSZ510!YSIG@NZU+X,
MIX1U6R:RO([;RU+NC 2@[E=64MQNQZ'KQ2W_ (-UK5?A<]E//$_B2X,=[-)*
M/D:=2K!,'.T *%XP.,\9->BT4 <GX7O_ !-J<X.L>'(=#2 $2%;E93<-R,*
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M/B5XFU:ZTF6WL-16%8)3)"V?+4@E@'+#/88/OBNZHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *P/$OC30_":Q_P!K73(\BEUBBC:1]@(!<A0<*,]3Q6_6
M=>_V?I(O-9GC D,:K+( 69U&=J >Y;  ZDT 2:3J]AKNEP:EIETES9S@F.5,
MX.#@]>0001@^E7:Y3X=^'I/#GA18)X?L\UU<2WCV^<B#S&R(Q_NC ^H-=70
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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@H **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>arwr-20230331xexx311001.jpg
<TEXT>
begin 644 arwr-20230331xexx311001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 0(W^DE?]
M@?SJ>JPXO#_N#^=6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH KC_ (_#_N#^9JQ5;_E]/^X/YU9H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@"M_R^G_<'\ZLU6_Y?3_N#^=6: "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH JKS?L/\ IF/YFK554_X_W_ZYC^9J
MU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,GT%3U G_'S)]!4] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.Q;RVN[B<QI-)C)5 %/3^\?7I44/Q#M;GP=JFMPV3BZTLE+NPDDVM&X."NX
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M3.L:;DR6(!QT/6O1#P*** /%]=T"PNWCUSPXFHZ)XL8JW]G1V[IYCD@$E2
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M;RXOH+2>4PY4[P0S*N>.1D#)K4M)KZUO+AKW6+2\M8("TR1P[9(6SP2%)R"
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M-1E@^Q[2,R;4521SQ@J>N*74=&O%\3ZU:WN@WNKV.K2)-;O'=LD"$(JE9EW
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MRF-!E%DAXD&<_0CV(J=?&VGS:?;7-M:WUS)<SRV\-K%$/-9X\[^K!1C:>IH
MZ6BN8_X3S2&TW3[^..]FBO\ S1"L-LSN6CSN0J,G=P<?2H--\=PWNI:K%/I]
MY9VEA'&[S7$00IN0O\XSD9&W QG- '745S%QX[TJSM+Z>[AO8&LXDGDA>'YS
M&S;0X /(SP>>.]07&O/J=YHEQ9#4+2 ZJUI)'/"8A<+Y$C[@",E<@8/'?B@#
MKJ*PK/Q9I][I=W?I'<HEK=&SDBDCQ)YNY5V@9Y)+ "H_'.HWFD>#-3U"PG,%
MU;QAT<*K8.1V8$4 =#17$:1K%V_B^WT[3-8;7=)-L[7=PWEO]FDS\G[R-0"6
MZ;3D@#-;)\7::-1CM<3[)+G[(ESL_<M+S\H;.>H*YQC/&: -ZBN5C^(.BO,$
M=+Z&(7+6DEQ+;%8HI0Q78[= 21^HSBK-_P",M-TZXF66*Z:UMY!#<7L<8:&"
M0X^5SG(^\,G! [D4 =#17,WOCC3;35+O38[74;NZM"@F6UM3($WIO!+= ,=R
M15OPKK[>)-"M]2:SFMO-4, X&&!Z%>3D4 ;=%<_<^,M*M))#-YXLXY_LTE\(
M\P))G&TMGL>"<8!XS4-[XYTK3[FZAN(;]1:7"6]Q*+8^7$6V[69N@4[UQ_*@
M#IJ*SO$%S-9^'-4NK:0QSP6DLL;@ [65"0<'(ZBN7\):@^K6^EW"^+)+G4)K
M9+FZL2870+A=XPB!DY88Y_/F@#N:*Y^'QCIDUY;PA+I(;J5H;:[>$B"9Q_"K
M>^#C.-V.,UGO\2M$2RFO3;ZH;2$/YDXLG**5;:5+= <]CZ]J .PHKE[GQ[I5
MK+=PO;:F9[5!*\0LGW&+G]X 1]P8/)Q71VUS%>6D-U ^^&9%DC;^\I&0?R-
M$M%<]I>IW,OBSQ#8W%XDMM9I;/&@C"^3O5RP)[\!3GWK!M/$^IMINB^(Y;O=
M8ZG?BW-EY2XCBD9EC*L!NW A<Y)!R<8XH [^BLKQ+KD/AOPY?:Q.I=+:/<%'
M\3$@*/Q8@5C:BOB33O#+ZQ_; DOK:(W4]H8(Q;N -S1J=N\<<!BQ/'- '745
MGZ5J]OJF@VNKJ?*M[BW6?]X<;%(R<GVJC8>+M-O[Q;54NH9)4:2V\^ H+I%Y
M)B)^]P0?7!S0!O45Q'AC5[[Q+J5S="^OK=;6_GB>V:TVPM$A*JF6&0_1CSD'
M(QBIO'?B:^T&*V&EJLDL3"\O4X)6T1@'QGN2P ]@WI0!V-%9FHZ_INEV%M?7
M,Y^RW,B1QS1H74E_NDE0< \<].162_Q T2%MEPFHP3%/,6&6PE61UW;<JNW)
MY]* .IHK D\9:/%>"%Y)A#YOD&\,+?9Q+G&PR=,YX],\9S1+XRT>"POKV62=
M(;&Z%I<%K=P8Y"0!D8S@[EYZ<B@#?HKDO&NOO8Z%J#Z?>207=A-:F5EC!&V2
M15VDD$?=)/'(X]>=2U\4Z5<I?-YTL'V$*UPMS"\3(&&5.& )SVH V:*YY/&>
MD_9+Z>X^U6AL@K2PW,#)*58X1E3J0QX'OQ4MKXLTRXL+R[E^T6@LG$=Q%<PL
MDB,P!4;>Y.X8QG.: -RBN,T7Q#<ZI\0K^S!O(K*/3HY1:W4'E,DA<@D C)!
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK*ULTVT,XC.&+)G<H/49'(K.T_Q/8:-I=FL5CK,S7^HSVR13,LDJ3!FRIRV
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M<4^8![DXY/T &_-?^3J=K9?9+IQ<*[>>D>8H]N.';L3GCZ5;)P"<$X["@"M
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MW%D;?5[-()$G#!D*HZC!'&#O!S[8QSFNPIJR([.JNK%#M8 YVG .#Z<$'\:
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MD4L:JN'!Y((7'Z^U=]10!PFJ>#;SQ%'J-WJCPVNI7-O#;P?9F,D< C?S 26
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M&=_-N8Y%=03\GR[590$R1QU%=U?7\.GI"\PE(EF2%?+C+_,QP,XZ#U/05:H
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M#KSG&>]6'T#1I+".QDTBP:SB8M';M;(8T)[A<8!Y-7XXHXHEBC14C4;511@
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M7&GV=UI[:?/;1/9L@C,!4;-H[8]*BCT?38KP7B64*W @%MY@7GRAT3Z>U '
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M&R-'&P8^0\D$CD@]<\U;LM6O+CPWHMG)J5Y+>2ZC<VZ0QN5EO$B=QAIL@H
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M/.AWK( '9"&4Y!!4@@CV-4G\):))::C:/9L8-1=9+I?/D_>,,8YW97&!P,#
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M+H6ZVV\S.<QJ<@$$X..>2,\GF@#E_"EW>:[8:?XBFUZ6(SSR)/8D*8ADE5B
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MXU71=/UNWC@U"W\Y(I!+'AV0JPR,@J01P2.O>J2>#]!C:,Q6 B\JZ%X@CE=
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M9W\TR'[S&3.XENAYY_"A_!7AV32I-,?3E-D]Q]J\KS7PLN<[E.[*?1<#D^M
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M,&'NSZS&M"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8BQN-,NY8RR<@B17.4R,'CTZ=> #H_\ A.M&=[-8!>7!O+3[7!Y%J[[TR 0
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MP%VC.W<N!N /<XSCE3X=U$R6>J-ILH,WB,:D]LI0O!$8_+R_.,Y 8@9QGV-
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MAB#--E0K98X 8=<]* .M-[:C4!8>?']K,1F$.[YM@(&['ID@5/7!Z=;W]O\
M%M1J%^MY*V@N0R0B(*//7@ $\9]3FMO5=1OKCQ#'H&FW26<YLVO'N'B$GRAP
M@4*2!R223Z#WR #H:*X#Q'XCU_2+>.-[NRBOHM,>[>""!IFEE3);.2 D6!U)
MSDX'2DO?&&IQSZ5/<21:787MK;R17$L!EADEDY='8',>!C;V.3DT =O::C9W
M[3BSNHIS;RF&7RW#;' !*G'<9'%6>@R:\PDUC4_#Z^+M6LWMC!!K<8DADB+-
M)O$"$!@PVX#>AYKMO%WF_P#"&ZT8)!'(+*8AL9QA"3W';//:@!;?Q5H%W?1V
M,&KVDEU(<1PK(-S\$Y [C /(XK8KR^WMBC?#2:8Q23,H59%B"L$^RDA<\DXK
M2D\6:M'X=7Q8'A;33=>4;'R?G6+SO*W;]W+YYZ8YQ[T =]17G6N>+]=T:W\0
M6YDLY-2LY8WL8Q;G]] REB2-_8+)DY_@Z<UIW_B/59M+O-1TB(3V0N8HHGAA
M\V18=H,DH7=\^"< ?[)ZT =E165X=U--7T2&\2]AO [./.BC,8(#$ %6Y4@8
M!'KFN;?Q7JI\,KXI@-I)8&YVFSV$/Y/F^5GS,_>Z-C;[>] '57FMZ7IUS%;7
ME_!!-*5"H[@'YCA?ID@@9ZX..E79)$AB>65U2-%+,[' 4#J2>PKC-%M[FZ\=
M^*H[N>&XMHY+7,+P9!'E;EQDG&"<].3SQ4M]+J3>.-0MA?@62:0LPMS%D#+N
MIYSU.WK^% '4V=Y;ZA9Q7=I,DUO*NZ.1#D,/45/7F/@C6-4TW3?!=C.]K)8Z
MG;2HL:1,'B\N,N&+[L-G&,;1C/4XK8\/^(_$&OSZ?J=O8_\ $FO'<.'1!Y48
MW;6#"3<S$@ @KWXZ9(!VU%<UXDUC4[+7-!TO3#:HVI2S(\EPC.$"1EL@ C_Z
M_M62_B/Q/=?;DTBQCO9].F2UE58U6.:4*C2X9Y%9!\Q ^4],Y.> #NZK+J%F
MVHOIZW,1O$C$K0!AO"$X#$>F:XG4O&6IQ7^IVD#V5M>6NH0VL%G<(SO<1OCY
MQA@3G)(QP I!]:MW>M:M!XAUVTL["SN[ZSTJ*: K&4>5V+94DD_+D9"_AGO0
M!VE%>9W?BG4=4T&WEL=7@69M4L[>1?LC12P;W7<DB%O4=CAAD>];T.I>([GQ
M9?Z3#/IWD6*6LLDCP.&=7W[E #8!.W@]O0]@#KJ*X'1_%NKWFNZ?832V4HO8
MKK,D%N_E121D8".6'F@ X. .>A]':%XD\07B>&KB]EL#%K0D0QPP,#$5B9PV
MXMS]SD8[]: .\HKEO LVHW&EWLFH7Z7;"_N8U(CVD;9G7GD^@P.PQUK+UKQG
MJ>DZO,FRVDABOH;?R(XV<^7(0-SRYPC9/"X)X]#F@#O:*X^S\2WTGC)](O98
M;,F>006TMLRFX@"':\<N=K-N&2,#C/ISIZ[JUW:ZII&DV)ACN=1>3]],I98T
MC4,V%!&6.0!R/6@#;DD2&)Y975(T!9F8X"@=23Z5D6S:%KVJ1:G:SPW5YIX:
M-7BE.8@XY!4'&",'D=@17'Z_K>I7WAKQ-IMW-!#<:9<Q0/,D)*SI(4*87=\I
M^89Y(KT"SM!;(SR")KF3'G31Q!/,(& 2.>@P.M %FBN2\6>(K_1[V.WMI;6)
M7M)9HPT3332R(,[0@(PN,DL3CMQ6;#XKU[4[ZSM[,Z?;BX\/QZLS2PN^QV/*
M@!AD?R]Z .]D"&)Q*%,>T[MW3'?/M5?3KFPNK)&TR:VEM%^1#;,K(,<8&WCC
MTKE]+\3ZGX@M]$BLEM[6>]T\WUQ-*AD6, JNU5!&26)Y)X ]35GX?9'A8K*8
MS<I?7BW!C7:ID^T29P/3IZ\4 =31110 4444 %%%% !1110 4444 %%%% &=
MI/W+G_KX>M&L[2?N7/\ U\/6C0 4444 %%%% !1110 4444 %%%% !6?=:)8
M7FK6FJ3Q2&\M 5@D69UV ]1M! .>^1S@5H5ROB7Q*;+6=/T*TNX[6[O%D<W,
MD/FK$J@'&W(R6)'T&: )(_ /AZ.ZCN$M9@\5R;J("ZDVQR$DG:-V%!)R0.O&
M:MS^$M'N4NHYH9WCN;A;J5/M4H!E'1N&X[<#CY1QP*EM-9@A%O8ZGJ%C_:AV
MQRK"VU3*1G:N>YZ@'FG?\))HG]H"P&K61O#+Y(@$ZE]^,[<9SF@!]_I5O=7-
MI?\ E-)>6 =K7]\R#++@AL<$' '(-4M"L+YKVZUG5[6VMM1N$2 102>8(XDR
M0"V!DEF8GVVCM6W--';P232N$CC4LS'L!UKBC\1+"XU#P]):7=JFF7_V@7,D
MYVM$4C#*,YPIY'7/6@"]X\T6[UW2].M;2"28)J4$TWERB-EB4DL0Q(P<=,<Y
MJ]+X2TF?2[RPFCGE2\9&N)7G<RR%""N9,[N,#'/'/J:NIKFE2:8-2CU"V>R8
M[1,L@*ELXQGUSQCKFI[&_M-2M5NK*XCN(&) DC;(R#@C\Z ,[6O"VE>(+>VB
MU&&21K4YAF65DE0XP<."#R.O/-17?@[1KNW2W:*>.%;?[*8X;F1%>+.=C -\
MPY/7GD^M66\2Z&ES%;-JUF)I93"B><N6D!P5^N>,>M33ZUIEK?1V4]_;QW4A
M"K$S@,2>@]B<''KB@#.O/!/A^_U>+4YK ?:401GRW9%D4= Z@@,!QP>PQTIU
MUX/TB\CU2.9;@IJCJ]THN' 8KC&.>. !QV%63XDT4W+VB:Q8?:077R_/4D,B
M[FR,_P (Y/I4%IKUM:>'K2^UG5M.)F'_ !\0-MBE.3C9DDGCZ]Z +*Z!8KK:
M:P//^VK"("XG<*ZC.-R@X8C<>H[T^]T6SU#4M/U"=9/M-@SM;LLA4*7&UL@<
M'CCFEFUK2[?35U&74;5;)\;+CS5*-GI@YP?PK \.>,H=1M=;O;^\LEL;+4&M
MX;A,JK)M4KG).3\V* -&#PCI5M9V5K"+A(K*Z:[BQ<-GS2222<Y/WFX/')JU
MK.@6&O);B]68-;2>;#)#,T3HV".&4@]":NV]W;7=JMU;7$4UNXRLL;AE(]B.
M*JVVO:/>3I!:ZM8SS2)O2.*X1F9?4 ')'!YH S8O!&B06R6\45PL4=ZM]&OV
MF0A)AD@KD\#))QWSS6G9Z/9V.I:AJ$"O]IOV1KAF<G=L&%P.V!Z4D6O:/.VV
M'5K&1MC/A+A"=JG#'@] >I[4Z+6]*GM9KJ+4[*2WA($LJ7"E(R?[QS@=1UH
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M*WN#;,JHI3G<GRY!W9ZD]>E='10!S=SX,L[R*Y,]]>O=SS03F['EK(K0G,>
M$"<'/53G/TQ8L?#$%EJ-]>M>WMR]];QV\RSNI!5 0""%!S\S9.>_TQN44 <;
M;?#C3K7^S_+U75\:>DD=L//4!$?JN N"/KR>A)  J_8>#;73XM#BCU"^:/1B
MYMU<Q_/N4K\^$YPK$#&/Q-='10!E:'H46@Q7$-O=W4L$LSS+%.RL(BS%F"D
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M0X&W&<Y(K:HH X!4MKCQ.T\]G))&OAQ5WO:N0#N)9>5^]@CY>OM6_P"!M_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)IX>-O+-'J*RK%+Y)$,;R,SX#855!+<$'(!% &]165)XCTE+&VO%N_-BN@3
M((VE>7'7:B@L<=^..^*I7OB/3[O3[*YTW7[**.:\CB$N!*)#D;HAZ,0<>V:
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M0<9S0!J45'+<0P6[W$LJ1P(I=I&8!54<Y)Z8JC!KVEW,5Q)#=JXMU#2C:=R
M]"5QG!P><=J -*BO+9?'.JBRT[4XM3L_)U.:.#[-)9O_ *-O;AE<??PO7/4]
M/2NJT.^OX]6NK75/$&G7B16PF$<</E2HA.0\G.!\I [=,T =1167:^(]&O!.
MT&I6SK!&)9#OP%C.</D_P\'GI3&\4Z$EK<W,FJ6\<5L0)C(VW9GID'GGMZT
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MF:E/-!8ZC:7,L/$J0S*[)]0#Q3+?7M(NI)([?5+*5XD,DBI.I*J.K'!X ]:
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MKN:".W1PC2!'*@JA8GG'O36\27_]H^++)Y]-MAI<<+6US<92-3*C$>:2QX!
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MK>E7=P]O;ZE9S3("6CCG5F4#J2 >U9VE:_ NG12:MK.CM--)+Y3VTX$;JI/
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MTR-;2>"W9\,(F4Q.,?)R2W/J>]>BT4 9'A@NGA/2UFAFADBM(XY(Y8RKJRJ
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M_'RY('7KQ5G14O;*]FMK2&]GT<V$Y"WMHR36#9_U*MM_> D< 9^[UZ9](HH
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MMU)-8SS",,S@'"*3N^]E6VYXYZUW_AA;&/PQIL6FS&:SAMUBCD9"A8*-IRI
M(.0<@]ZKWGA:*XU674;;5-3L)9]IG2UF4)*5  )#*V#@ ?+BM>RLXK"TCMH-
M_EIGEW+,23DDD\DDDDD^M $]%!('4T4 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 9VC_ /'F_P#UW?\ ]"K1K.T?_CS?_KLY_P#'JT:
M"BBB@ HHHH **** "BBB@ HHHH *Y35]2U/4;_6=)TJ:U@%A9J\KW$+2&1Y
MQ50 1A=J\GDY/3BNKK U'PG;WVK2ZE#J%_87$\ @N/LCH%F0=-P96Y&2,C!P
M: .5\(W\MOI7@&S$-K)%=6LOS/%F2,I&6RK9XSP#QVZU9L?'L\=MJ4^K-!%=
M6-I+<7&F&!HYHF5AL"DDB12#]X=\=,X&W9>"[.P71%BO[\KHZNEN&,?S!QM(
M;Y.>..,41^#;=VQJ.HWFI1K9O91K=>7D1N%#[F506)VCD_SYH +.3Q#+ 9-1
M.GSV-Q8F1C"K(T4A&=@!)#+@]<@\=*Y[PEK5T^D>&?#FGR0P7,FC"]>>6/S
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MU?7+76I-&UQ=(%5B(SE% P0%&/J>>>:FOO"J:A+K33W\YCU6S6TD144>6%#
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M8;"*VCL=/@:&X-U&QDDDVAF"@$!=H(Y.<GT R>M5S'X+5Q#%,5T\'RI?N/\
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MV2)"9(7;=QNSL;I\PZXZ"K^C>#AI-WI-RVI37,FG636*[XU4-&<8Z=,;5]:
M*=IXSN]2T_PS]GMH+>ZUOS,R2@O%#Y8)(P""Q..!D=_2HK;QOJ%UI%O(=/B@
MO;F\FM8MHEN$Q%G?(51=Q&5( 'KR>M9FL:"VDV.B: ;F[^PVWFR)=_V8MW%G
MLDD>#\V&8AN![$\C0L=&OO$>E1^;>S6;Z=<*^EWT5E]E<83#9A;^#DC'&1[4
M =/X>U*\U33#-?V3VEPDKQE61D$@!X=0P#!2,'!&:\V\1>,+6+Q_;:JNK0QP
MZ3?#39+-I<,\;K^^EV]P&*CT_=FO3;;3[NVTN6#^TI)KV0,3=S1@X<C (08
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MG#9W-VTEOM<M,JM"Y4-P!RN"0.AXYQFN@3P>OVS2YYKP2+9Z:^G21^5@2HP
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MH S](&VT(_Z:.?\ QZM"L_2#FS8G_GJ__H5:%( HHHI@%%%% !1110 4444
M%%%% !6!K'B&2SU>WT>PA@FU">WDN%6>;RT"J0 "0"<DL,<=C^._7!:G#I<G
MQCTN.YBM&F?3)6"R*I9G#KM//<!6Q]#0!U.C7VH7=G)+JUC#I\XF*+"ER)OE
MP,$L !G)/%:(EC9"ZR*5'5@>!7C6H+I#Z/>+&UN(!XRC4%&"JH.S.T@\# /(
MQT/I5N\&E:)/X]L19Q"P2:P(LXW,4:AT3<S!>B9.6QU&10!ZT)HC&9!*A0<%
M@PQ2JZ.3M=6VG!P<X->&:D-.3PSXUMTN;.8?:;"9#;Q"&,;B@)C'88R,@\\F
MM[585TR^\;V?AV)4E_LZTE^SVIPS'<_F' YW%3R>O([T >GW%PPL[B2T$<\\
M:,4C,@4,P' )[9/>DMKES9V\EXL5O<2("\8D#!6QR W&<'O7 -/X.U'PYKUY
MH%M#SI+K,/*,<"[02BN#A0X)^O'7I7/^*;W3[[3/LP%LMS'X<5HKB9?.,PP?
MDA7HK9'S.,D<>F0 >HOK3KXNAT(6RD2637AG,F,!7";=N.>6'.?7\=5I$3&]
MU7()Y..G6N#T;4[.X\:>'L7$;W$WAU_G,F3(2\1 ]S\KG\_2CQC8Z;J'Q"\)
M6VH10R1S17J2(YQO&Q=JGU&2<"@#N_-CWJGF+N89 SR1098PP4R*"3@#/?TK
MR.6PTU_$>HZ?K%_=6>HQ7ZMIT,%JK2O H4PB%RI;  ((# #YLXR:CU*U\.7%
MMXQCC6"/6X=1<Z?$LNV9)?+CVM$H/!9P>0.<<]!@ ]A:1%959U#-T!/)I'EC
MCSOD5<<G)Q7EM\UK--XOM_$#HNKB)#IQFQYH7R@4\CU/F9X3G=UJ72=$T[6_
M&4UKKUM!<7BZ18S7,+.>9P6W%ESR?NYSV/H: .X?7!=Z5/=Z)'%?R13F$QM,
M(P2K[7^8^F#CUQ6NS*N-S 9.!D]37B446DP?"R]C@CM8[U-91950 ."+HA >
M^0F[ ],]JU/$&F:7+_PGUZYMP]O- UNXDQY$WE(Q<#. Q<]>I.1ZT >L,Z(5
M#.JEC@ G&:5F5%+,P50,DDX %>2^-);&7Q!JUE>WNFSF]L(8K>2]G6+[ WS?
MO$W?>!SNRF3E0#CBNQU6T6U^%M[:Z1,DJII3K#+$<B0>6?F7&>O)'UH V=*U
M5-5LFODC\NS9CY$KL/WJ?W\=@><>HP>,U?,B! Y=0IZ,3P:X+6=1TZ#PIX4B
M>.);:Y\D1/=G_1HP(3CSA_$,'A<\L!R,9KF-+^QW7A*U@BUC2P;'4[S9::DH
M6"X7<V$(SB,[6R.N,\4 >S5BZGXA33M>T?3!"LIU&62(N)0#$50MRN.<X]JJ
MZ9?S7?PYAOM,M&AG.FEK:WW;RK!/D7)Z\@<UY[9/H/\ :/@.XTUK3^USYBW;
M;AYIE,)R)>^XR9^]SZ4 >R!U+E P+#J,\BN6F\6ZC.+B71?#[ZG!!=26;%;I
M8G\Q.&.UAC9GC.<^U<9X,L;'4M6TVZN]74Z[&TZ:A9):!99"0V]9R>608P"1
MCD <U!!9:1'\-/&ES!#:(Z7UW&DL84$*) 44$=NF!]* /8ED&Q3)M1L LI;H
M3_\ 7IS,J %F !..3WKS77+#1M2\2>*VN?(E"Z)#, 9/E#8FP^,XR!MP>V1C
MK65K4MIJ.HV%OKVJVMKI<VBQ&RGN8!+&TA!\PJQ.!(/EYZ],>X!Z[,[1Q,R*
M&?!V*6V[CV&:H>']6_MW0++5?L[6XNHA*(F;<5!Z<_3FO/X/[*GUO^S_ !5=
M"YLETB Z;+J*[&D!SYCKG_EH<)_M#CWKJ_AW/%<?#[1#'<).$M$C8ICY2!@J
M?<=/PH V]+NKR[L_-OK V,V]U\DRB3@,0&R..0,_C5RO)M&L]*N-/\*022HR
MRZO?H5$Y&5Q/A.#G:<)QWR!WKK/ *Q0V>LVEM(AM+?5IX[=$?<(T^4[?;YBW
M% %M?$MU/XBU+1K723+)8+$[R-<*JL) 2N.">Q_*M?3;N6^L4GFM);24EE:&
M7[RE6*]NH.,@]P0:X-;FR3XE^*!<:^-+_P!'LU!$T2;SM?/WP>F1T]:G\1K;
MZGI>D2:!>)=:_:LQTZ<_-YWE<2[CT*'!&>FXC% '?DA022 !R2:R=0UO[!K>
MCZ?]F\Q-2>1%F$F A6-GZ8YSM_6N"NM5T?\ L+PW-)&!X?N+I_[9WG+"X*_*
M)\=?WF=V1C@=J=<0>'KC4O"MEI\[OI+:G=!,S$(V86.V,@C]WN.S X/(Y!Y
M/468*I9B !R2>U*"" 0<@UX^;O3[/1%TRX2-[$>([JU@6XF(M8D!8@2_WU&<
MA21DXYXJEIDECJ=SX=TZ6[BN/(UN]M]D3F/$.'*J%#95#@87/3B@#VVD!#*&
M4@@\@CO7DD=Y!IWA;4X&G@6QM/%#PI:S2[(Y(0P8Q;B< ?>;YCCC'M43.+'P
M=J5[97ENMI<ZLCSQVD_GBSL6894JAV@'!) P,,1F@#V&L?7?$MAX>ETZ.]8A
MK^Z6VBQC@G^(Y/W0< GW%8_@6VL(&U-M+U5;^TE>.0"WB"6\3X((CP2,G +
M=,CUK-UJPO?&3:[]B%E/:K";"UD-V5,<BD.S@*A!/F!1U'^K]Z /0JAN+N"U
M,*SRA#-((HP>K,<G _ $_A7FUYXH35?!/AR\O9Q_9[W,<&MD-]S ((?'(4N!
MGU!]#3M0L_![P:+<026MQI?]MLIEG8-#'N@D)1&/ CW!>!QNH [S7=7BT#1+
MK59X99H;9-[I%C=M[XR0/UJC;^*H7UNSTF\L+RQN;V%I;8S^65EV\LH*L?F
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M+>TO NL$!);QD4)Y2\A@KD\C&/KSQ0!V.N:];:!!;2W,4\BW%S';+Y2@X9V
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ME6UG$K1+<=1LP6/FA>@.3T^M=;0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 4-+_P"/7C^^W\ZOUGZ1Q8C/
M]\UH4@"BBBF 4444 %%%% !1110 4444 %-,:%PY12PZ$CD4ZB@!GDQ8QY28
MSG&T=?6@Q1DL2BDMPQQU^M/HH 888B"#&A!QD;1SCI2B-%8L$4,>I Y-.HH
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M5W;<S*@!)]3[U+10!&EO#',\R0QK+)C>ZJ S8Z9/>E$,04J(DVGJ-HP:?10
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MQ@58HH K/I]E)))(]G;M))C>S1*2V,8R<<XP/RJ5;>%9FF6*,2L K.%&X@=
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ME_:OE;!=F ;LX]?O;?;-7J* .>3PP8M#NM.COY!+?RM)?7>T"27?][;CA>,
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M@NH"03%/&'4D=.#Q5BB@"I_9>GXM1]@M<6G-M^Y7]SV^3CY?PJW110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 9^E'=8H?5V/ZUH5G:+SIL9]S6C0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!4U34K?1]
M+N=0NV(@MT+OM&2?8#N2>!]:ACU-;73XKC6I;6PDE)PCS !>X7<<9;'7'?-8
M7Q'1O^$8BF*EK>"^MIKE1WB652WT'?/M5/QI<%==M83#+$C6$X-Y':M.SAL
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M<VINH+N"6W&<RQR!D&.O(XKS'4+=X+KQO#96D_V-;RPE:WLT WPJJ>?L7H>
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M:C%FWN%+?-&<\JYP,8YH ]<GO[.V,0GNX(O..(_,D"[S[9Z_A68FN2MXWET
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MAF\L+S0K9(;>X'C*W@NUE^1DE68H=SS?WE+;,9SR5P.. #U198W=D5U9DX8
MY*_6LF[UU;;Q%INDI''+]L$NYQ-\T110V"N.<_48KRWPW #I?V_2]4U&;7X-
M+N8I+1+-8WBE\MF_?' +_O?NDY)8Y_O8U=*O/"\_B/P7_9IM?/-M<1W'3?EH
MQE9<\EBQ;[W4EO6@#U6FB1"VT.I;G@'GC@UY5X>U#0@G@/3XY[?[7;S3%XOX
MHF,<H(.?NDR$<=SC%5XM%ME^'.JZEH\*_;UN[F)Y8AOD2W^T'<B+V'E\[>AS
M[T >N+-$\9D21&C&<L&!''7FE1UD0.C!E/(*G(->5V^E:,^C:S=6WBH/'>/:
MLT\EHD=HLBM\H= H4YP PXX(S70>#?$5C#I45G=I964LE_+;0&U8M!=OD,7B
M]%)?ITSQ0!VU,6:)XO-21&CP3O# C\ZY;X@3&#1[%YHFETS^T(1J*A<C[/SD
ML/[N[9GVKAO%D%L=.\53:5)$=#F^Q.K0,/*^U&9?,,9'&=F-Q7UY]@#V-71\
M[&5L$J<'.".U()8S*8A(AD R4W<@>N*IZ7I>GZ39/'I5O'##*QF/E\AV('S$
M]R<#FO/?"-_HS65A)J-K<OXLM9;B2ZCBB87'F8;>7Q@%2H4#)Q]T#G% 'IR2
MQR.Z)(C,G#*&R5^OI3Z\7T&:QF\1>'VMY[5(Y]/O%:U1"9,,%(CFD/\ K9,E
MF(.,$'CG)N>'=2TQG\ ?Z5 +BQM)UN#@[D_<E=A./O9_AZ^U 'K22)(6".K%
M3AL'.#Z&DCECEW>7(C[3M;:V<'T->1:?--9V&I6&B3VVJR'29I+/4; ;;I1N
M4^7.H_C.[(/WB<\=:<DFGIX?U74O#5Y<W5Z^G1I+':6HA6&(.H(8* ?-"E\'
M.<*?;(!Z%_PD:'QC%H$<4<@DLWN?M"39VE6"E2N/?.<_A6TTD:.B,ZAWSM4G
M!;'I7F^D7'AZ3XHZ:=!-H(?[&D1OLR@#.]2H./XL9Z\TGQ#BLX]8>_>;3;N6
M.Q$<VDWN%>:,N2&@<\B3*GIG[H]J /2Z:\D<94.ZJ6.%#'&3Z"O*/$^J6UA!
M\0H+N2.*YO8X/L\$I^:3-NBY4=\'/(Z$5>U&\T27Q+J]OXGC,MI<V5N=,=E+
M"2/;EUA*]'W[3P<D[?04 =M::T+G7=4TV2$0BQ,(64R ^;YBD],<8(QU.:U:
M\C\3VEA?IX[>6U\RYL[&U,(N/G>)O*SD9)^;D L.>O-=YKESJ(\!7=SI1:34
M#8[X2G+%MO4>I[CWH FN/$44/BNPT)(EE:ZAFE:591^Z,>W@KCON]1TJ_:74
M[622ZC!'93,Y4Q^<' Y(7YL#.1@X]\5YOI<OAF3QYX9.B?8PATRX6<1XW9(4
M@2'J6^_G//6L_38K5? 6B,VH:7#)#+?,EIJ&#;7,9D8%">BMM9=IZ@,>",T
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MZ?+G)WX4C<,YQU&,DU-)XM1]*T^[L=.N;B:^#&.%R(P@3[_F.<JN.G7D].Y
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M(*'"?+C(Q@'.*[;4=4M]-TZYO9!+-';_ 'TMT,CYXX"CG/(JXK!T##.",\T
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M**'2[*..*3SHT2W0!'_O  <-[]:1M"TEH)(#IEH8I)?/=/)7!D_OXQ][WZT
M<-J+:E?:OK%A;WUT=3:_B6RF@NBL4$.$+JRA@ 0 ^>"22O7''8>*'DM?!NL2
M032QRPV$SQRJY#JRQD@[ASG(K N_!$EY>WD]S8Z#>33R%DO)[5A*BD]&"G#$
M#@'*]!FNOCL8AIB6$X%Q"(1"XF 82#&#N!ZY[T >=Z/&MQXZT:\N;F?S6\*I
M<22M<./F#Q\MS@CN0>">2,UI>#+J_@UMM*U<7;7PL1,+D7K3VUV@8#S5#'Y&
M)/(''Z5U<F@Z1++;ROIEHSVR&.$F%?W:'JHXX'M3K#1M-TMG-A8V]L7X;RD"
M\9)QQT&2>/>@#E-6N8-1\8ZCH^IZK/I\46GQRV1CN# -S%M\N01N92%P#D#G
MWJI;32Z[XCUC3[S5+M;:QTVVFL)TN&@,F^,EKA@F,G=CJ,#TYKM=0T/2=6EA
MEU'3;2ZDA.8VFA5ROT)'Z47VB:7J<J2WNGVUQ)&"JO)&"P!ZC/I[=* .!TA]
M3U_5] 6]U._1;G1&FNA;W3PAW#J%<*",$C)R *BBN]>N?"GA_43/-?B.RE>[
MM(K\V]Q*N0%F#*1N*@<@GG=ZUZ2=.LFO8KTVD/VJ)/+2;8-ZI_=!ZX]JIR>&
MM$EMXX'TJT\J/<$41 ! W+ 8Z ]QTH Y"SU=O$>LZA:RWEY:V<6DV]S8;+AH
M9)!(A+2G:06(.T<Y (Z<TS0]2U#5=0\!W6IEA<W%A>O*/N[CB,!L#H2.?QKM
MKO0-(OWA>ZTVUE:%/+C+1#*I_='^S[=*FGTRQN;NUNI[6)[BTW?9Y&7F+=@'
M:>V<"@#SRTUJ[4V>G76HW$=I=^(+VUDN7G.\)&S&.(.3E=Q 7CG&>133(FDC
MQ-%#?WK;]=MX8_+N"99F:.+]T96.5'\);.0!^%=Z?#NC-93V;:;;-;7$AFEB
M:,%7<G)8@]\]ZC_X17P_]CDM!HFGB"4J9$6W4!RO0G Y(]: /-B]WJ%@8;ZZ
MN'6S\7Q0+LO9'"1$I\OF$AF +<'J#TQ6M=7E[?:SK=D-?CTJ?3IHUMA/<R I
M$$0A]NX+(&.[.[=Z5V1\*^'_ ++-;#1; 03LK2QK H#%?NDX';%2S^'=%N;Z
MWO9M*LY+JV $,K0KN0#H <=NWI0!YYXBOFU7P_XLN9[ZX%Q8ZDEI';I<.B)$
M)(P,H" V[+'+ _I7H'B=+J3PW>QV5]%8W4B!(KB63RU5B0!\W4$YP".<D8HO
M?#&@ZE=/=7NCV-Q/(H5Y)8%9F Z9..:NSZ?975B;&XM();0J%\AXP4P,8&T\
M<8&/I0!P5OJTT-O;0SG4K"[CUV"&X@N+QI@NZ,?*LA)W1L.0&[GZ5F^(;F:[
MTOQ% UY,XA\1VL<6Z0OY0)B.%SG #$\=*]%;PYHS6$MBVF6K6LKB22,Q@AV&
M,,?4\#GVIH\,Z$MK-;+HU@(9E"RH+= ' Z9XYQV]* ./O;;5=/UG6=+TK7II
M1-90S*M]=,WD2F4*$#YRGF+N QR#@CM3)-6NSH5EL.IV%W!XAMK6YMY[EI&3
M<Z%H]^<R1E6!!/4&NU'A[1Q93V8TZW^SSLKRILXD(Q@GUQ@8^E*WA[2'M4M6
MT^ PI,)U7;TD'1_]X>M 'F_BBZ;7/"7CF>\O[B.;3[MK:&W2X*(D:E=N4! ;
M>2W+ ^W2M;5=8ETSQ-?B75;BSLD\-"?<,R+#*9-@=4Z%NG^376:AX4\/ZK=/
M<W^CV=Q.X >22($MCIGUJ:3P_I$LK2OIUNSO;_96)0<P_P#//']WVZ4 >97&
MLZQ;0:_&EU>6T:^'TOH5>]:>1'W, ^XD[20 2JG'2NFU&VU#3(/#\T.M7\L]
MYJELMP9I<JR%274*!@ A>G^)K<A\%^&;<R&'0[%#)&8G(A'*'@CZ5?ET?3I[
M>VMY;2)XK5UD@5AD1LO0CT(H X32[S5]:UV\O%UJ"T%IJS6[027#[E17V"(P
M_<RZ\AN3D\'C MZ#=W]GXICMM7N;J0W1GEMKR*Y,EI<IU"E3Q&RKG@  X/)K
MK'\/:-)JPU5],M&OP0?M!B&_(Z'/K[U$GAC1H6FDATZW622-XSN4E<-]X8SP
M#WQC- &JCK(BNC!D89#*<@BO,M/N-?U+PK8W%O<S7TD5_=^?:?;6@FN8E=E
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MP/I\\E_<"[37A9R2-C>\8N"FUN/08/>NSLO"6A:=<6L]I8+%+:[O(99'^3<
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MX?U66"6_TN&XD@01H\F2=HZ G/S#ZY[^M &&-2U:U\8PIJ?G_8KF98[6YLY
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MT=((CYD>7E#,VS&[@_-C)P,@\U@2^&=7DT'1[<:5>P:GI^E1Q6UY:7<:M%.
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M=/GN+34+)KP3Y12$RF#AF' W'.1GIC/-4/\ A'M737;F[-O"T4F@+IX*3?\
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MN6::1 I.<?*N!QGGYNG'+?#^A:QIB>%8I[./;IMI+!<NLX."VT @=Q\N?QH
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MR.9!D@]068'Z>G- %1O$6GZ+-K5Y>ZC?S0QWL=NT3P$BW=E7 3 R5.X'/O\
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M(9C&1')(F=RJWJ-K?7!Q7.P:-K+6'AU)-+DCDLM9ENYU,T1VQ,92#PW/^M'
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M!N<&, CCY>6SQ]!C-)INMW]_)X3TB\U*:+[;9S33W"$(]R\> $!['JQQR<4
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M^&: .JGM++4X(_M5K!<Q_?031AP,CK@U+!!#;0K#;Q)%$O"I&H51] *\ZO\
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MCT<21M8/I+7@ 7G>)57.[TP35W5O$^BZ$^S4]1AMG\HS!'R69 <$@ 9/T'-
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MO;W$D4/^K5?+G4.H4 KU()Q^5>CO=VT5S%;27$27$P)CB9P&<#K@=3COBIJ
M.0^).(_A[?;HRX5[;**,DXGCX [U@>)K*XUL:_JFGZ7?QQMHIL%CDM'22XE9
MPPVIC<0HXR1W..!7?:SH]MKNF/I]X9! [*S>6VTDJP8<_4 _A5]%V(J[BV!C
M)ZF@#SWQ!8SB/PKJL>DZC<V=I \=U;61>&Y3S$0*0JLK<%"",]Z@\NST:]\+
M2IH-[;V[7-W*MJ5>XFCW)]]ERQR>I SC=ZYKTJLK4;&QDU?3;^ZO'@N(':.V
M3S@JR,PY7:?O$@=.O% '!26FH6*P7%GHEW!87NM2W3""R5[JWC,:J"JG_5[B
MK9/4 CH:KZ5IEQ;S>%;5]"U*..RU>\:?SH3(%#E]C%N01\R?-G&03DX)KUJB
M@#R3QG8:G<2>(+*VT2_6,RVLEL+"W'E7"J4W-(1RS +@*.F <=ZW9[C45F\9
M1/H]]OO(/-M76W+HX\A45>^6W<%1G\J[F*YMYI98HIXI)(2%E1'!*$C(##L<
M<\T^21(8VDD=411EF8X 'N: //-+CO=(UW2M8N-/O);&71(K%A':R/+;RH<D
M% -P4\\XZ@56\-Z)>:7K'A:"]L;E3;P7TI*P-)';^<X,<9?H"%#?3@=Z]-5E
M=%=&#*PR&!R"*6@#EOA[%-!X0AAN+6XM9$N+@^5/$T;*K2NR\$=-K"N4GTG4
MW\&7?A-M-N#JAU'?%=+"WE.IF$OG&7&,[21R=W&,5ZI10!S&G3S#X@:TC6-V
MD$EM;K'<O PC=DW[@&QC^,=^QIVOS21^*/#96SO)HTFE,LL,#.D0:,H"Q'3E
MA72T4 >5Z_8WL[>.U33;Z07EQ8FWVVKL)@@0/MXY VG_ ":N:_;W9U;Q5-8Z
M))=";2;>.&.6T;RYG5F)7H Q 9>/;':O2** /'[ZVU.>U\6[-*UR=M0TRW2"
M2YM?FD=2X887A?O#"X'':MG5](O-3O-4ALK.>![SPVD$<GD-'&9-S'RR< *<
M$#!QUKT>B@#A!J,NN^&]5?\ X134+"]&E26[/<6P$C$J=L4>/F=<DGH ...:
MYW4[?5SHMG8QZ1J*K)X86V9[:RS)).$9?)D8\H@/S8&,YZGH?7:* //-#CNI
M?$GA*X;3[Z**+1'@E:6W=1&_R@!CC )V$\^WJ*M>/HG%U97=JVHV^H10RK;W
M%O:-<PON*YAE15/#8'/;;7<T4 >8LFJV6K:TTV@RW,]_H,"I"D9,#.D;AXRP
M/'+8QG)SQZUCVD.HW:>(=NFZS(+OP]]FADN+#R5,BJYV*H "CD!1R?KUKV:B
M@#RJ2:9)M%U.[TO7#IDFD+8.MK$PEBD4\ET'S;6' /M6CI>BBV\7:7(-'N8;
M"#0)(8Q-&TOE,9 0A8C[VS/'U'->B44 >4>&],N;73O 48T^XMY[9[M;EC:L
M/)9HY%&\XXRQ7KUJ7PG8$/I6F:CHVL'5M+EDWS2LPMDX8&16Z,&!^Z.I/H,U
MZE10!Y'H.G2V.F_#V.33IX9[>ZG%R/LS!HR5<9?CC)*\FK>F0XT*]L+R#5[*
MXM]<EGCNH;-F$3,[%'Y4AUP<' /WATZUZC10!SW@J;4)O#H.I6L<$XGF ,<1
MB$R[R?-V'E=V2V/?/>N2EL[^]\.>+[6SMIVG_MIKGR6B9?M$(,9*J2,-N",,
M=_QKTZB@#S3Q"AUM=7U/3;.[2 ^'9K9U>V=&DE?F--I&2RX;H#C<!79^%K6W
MMO#6F^1:K;EK2$./*V-D(!\P(!R.G-;%% 'E>D6!&H'1M9TG6+C4(=5:\BE!
M9;5\REUFW#Y1@$\=\8[U*5DT[QL/$\6GW']CW-T;:2V6"3>DP4K]J\L#C(W*
M3C.#GJ<#T^B@#S;6H[VYL_&>F6EA?&[DNXKZ)EA8)-&JV^55\8+'RW&*S-<@
MM=5\&>([[3M(UU;N[@MXW-\DA>9A(#M5#DDJ!U QSUZUZY10!QEY:V*>._#Q
M@T[; MG=.62T(1&;R]N3MPK$(XYY[=ZYG3;F6ST?PY FF:A!;QSWH:Z@L7>:
MVW.Q1%5E.W>K#YB#QQQR1ZS10!Y#I$%TOA7P;9MIVHQ36FOAYEFMV!1<RDG.
M/NC>HSTZ^E=+\4#;+IFA-=PF:W&MVQEC$9D++\V1M'+<=N]=S67K>A6^NQV:
MSSW$/V.Z2[B:$J#YB9VYR#QS0!Y]XBTIM0T_Q1J.CZ;=);SBR'EB!D-Q)%-O
M=U3&3A<#..2#46OS-JH\:S1Z;J7DWNG6B6Q>QD'FE2P.!MX.7'!P>IZ"O6J*
M .#U]-%TO6O"#O8 VWFR"-8[;<0WE85B@&> /3C&>,<946GW-E=V.NV^GW1T
M@:[/=M:B%MZ1R0B,2^61D /N;&,@-FN]O]#AU#6-,U.2YN(Y=.9WA2,KL)92
MK;LJ2?E)'4=:U* /,+K2?.O=5U'=J=C:W6JQ3Z?<6UN6,$JPE6F>,@G8S97D
M<\=CFJIDU6TN-#U;5=)O?LJQ75O*^E(X97:4,)O+^\H?&<>_T%>LT4 >3:AI
M:65E"VB6NI:=>1Z8Z16ES;/<0W4#RR-Y+\$JY.">01O YQQWOBA9I_ VL(86
M-Q)ITR^5&"Q+F,C  Z\G%;E% 'FFEVL,GB#2VN[.8(OA=83*UHQ\N0'YAG;P
MVT'CK73^ %9/ FD1/#-"\4'EE)D*,-I(Y!Y&<9_&NDHH \7L$U"[>Q@AT[4[
M2X_L_4+2.'[&\<-I(^/+17QD],ER<=.G2M9%?Q#X,N;:P\.WUGK-OH[6337$
M)A(QC]TA_BW$$\?CC->I44 >;:A.?%?AC59-(\/7]IJ3:;Y#27$)A8@,&\E?
M[V?GZ>P[TW5 FN7EMJ.E6,UO%::/=0WL9MRA7?&/+@VX&6#9.!G'XBO2Z* /
M,(M-33O"?@W4/[*D:"W,!U.W@LR97(A95=U W-LD.<$'DYK/N;V5VUR]L=)O
M#%-K=I,DDNGS9A01@&81X!;#*>/?D5Z_10!XUY3W.GO;R6.HR@^+(;I_M5BZ
MEX&(^=AL QA3GCCN!FK^J65[Y_C1[*PGD1;^QN!!'&5^T1QA/,5.,-]U@17J
MU% 'F6NS)K.AW&JZ1H6K6H2]M9KT+;^5<7*ID$(IZE,J<XQQ[&NC\&1V3+?W
MEE::I$+AT,LVI*R23N!C(4XP ,#.!G\*ZJB@#SSQ%X9U*]\5W]C:(RZ5K]HA
MO9\\0O$<<<8!92J_F?X:K0V&K7GPOUV\U2"9]7N[$V_E%27*Q(47C&<LV]_^
M!UZ910!P%G<Q6?BFSGGL+H1SZ%#$EPMK(P\Q68E6PORD#UQUK'\.Z>]JOPX8
M6$L+PBY%T?L[*48Q%?GXXR2!SUKU>B@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH I:7SIEH?^F2_P#H-7:I:9QIMIC_ )YK_P"@
MU=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\_M?&&M
M:AJ6F0V@L ;V[N8)K5XF,EHL)(RY#=2 .JC&\?CWTK.L3M&F]PI*KG&X]AGM
M7E^DZ7KEJ(_L$_B*'57D#SPWL436BDME\OC)7)/W6+'C\ #7L?&&O:EJ,,EI
MHTDEA)?/:M^Y("1*Y0R^;NY(*Y*[?;/>H+?Q7XG^S6%]<0Z:\$NL-IDL,*/N
M*^8T?F*Q;C!7I@Y'.1TK:M_ UE:ZN][;ZCJ<5L]R;HZ>D^+?S<YW;<9^\ V,
MXSVQQ3H_!<$>DVVGC4[[$%^;]9CY9<R;R^#\F,;B3TS[T 9(\8:[>:T_]FZ4
M]QIT.H&TD"VYR44[7?S-V 0<G;MZ#K19^)/%-[!K=U;V^CM!IMY<VH65GC+^
M6/E;).U1GDY/3TK2'@:VBUV?4+;5-2M[>YG%Q<6$4H$,L@(.2,9P<<@'G]*E
M_P"$+L3HNMZ4]U=/;ZO/)<3$E0R.YR=I"CC('!STH Y^/Q)>:WHGBJPO'M[B
M.WTKSXYX;9X5<2))T#L=P&WAN_6KEC#NO/!;QK&+@:--Y;NN<'RX0,]\<GOW
M-7+7P*D%Q>S3ZUJ-R;ZP%E<"3RP& #*&X7@@,<#\\U?.AQZ:FGWJ37MRVD64
MD,,"!"TRE1P>!ECL7&"!F@#/T+Q5?:K9V,$UO#%JYO9;:^@4'; L>2QZY^Z8
M\'GEQ5_Q3K%WH]O9M:M:QK-.(I)I\N4&"0$C!#2,2,!0<U4\,::+C6=3\43Z
M7+I]SJ"QQ)!.H$JH@P6;!."Q[>B+5_Q%X<37S8R"^N;*XL9_.AFM]I()!4C#
M CH30!S>E>-]2U>VTRRC@M[?5+VYNK<RRQML00?>?R\@Y.1\I;@YYK0;7=>^
MV:=H4D5C:ZQ<K/(\[ R1+%&<!P@8$ELCY=W'.3Q54?#.T2S\N/6=26[BO'O+
M6\#()(&?[X&!R&[YZX'2KNH>!8;RVL6BU;4+?4[.1I$U%7!F<L 'W9&"" !C
M@  #H,4 5+KQ+KT,UEH\EO;P:U);RW,S16[W,81'"+A58'YLYY/R^^:;#XF\
M475[I%@-+LK2\O;.6::.Z+CR&C<*3P>0P(('!YZ\5H77@B&:&Q>VU?4K;4+/
M>!?K(&ED#MN</D88$C.,8'85G7F@7]OXO\/BPNKN.*WLKE)+QH1-O=F5B)#C
M +'<V>.1^% %"+Q;KFKZOX=M8WM["X-_>6E]%Y;21F6&)NF&!*'(('8XY.*T
M[3QCJFHW,<]AIAN-/^W-:N%@?<(U8H9?,SMZC.W'3OFKDW@>W9-,:VU&[MKN
MQGFN/M2!"\KR@B1FRN,G)YQQ26O@:&RU:6XM]5U!-/EN/M3Z<''E&7.<YQD+
MGG:#C/MQ0!SFM:C?>)=+\.:T$M5TYO$%L8(Q&6E"";8'+[L<^@7C(YKN/$FI
MSZ1H[WD'V92LB!Y+E]J1(6 9B,@L0.B@@D\5@_\ "NK=(H[6#6M1@T^"\%[;
M6J>61!*&W#!92=H.3M]ZW/$6@+X@LK6$W<MM+:W4=U#-&JDB1,XR",$<GB@#
MG-/\=7=Y8.OV:'[:VLG2879'B1OEW^8R,=R_+GY<Y) &1GB]-KVNV$EII=Y;
MV9U*]O&M[2=<B*2-4WM*R9)7 !&W=R<<XJNWPYMI+*_MY-7U!GN;U=0CGRBR
M07 &-ZD*.3Z=,=,5:N_ \=]I4<-QJ]^^I13BXCU,LHFC<#;\H  "XXVXY[\\
MT *^NZY;2V6F7MI:1:E?7DL%O,I+0F)%+^:5SD$J,;=W7O5,^-+R'4#I=S#;
M"^@U:WL9B P22*969709R&P.A)Q@U=D\%B6RM?,U>]?4[:Z^UIJ+;?,+[=I!
M&,;2H V^@HN/!<=S93*VI7*ZA+?)?M>JJ[A(F @"XQM"@#% %#4/%NM6DGB*
M.&SLYWTN[MHHMVY!*LP4X)R<,-X&>G?%1ZSK_B&'1?%<$OV2TO-.LTN8)X S
M@HZOQR1A@4(W?CBKK^!G9-3QKU\TFHSPSS-*D; -'MQ@!1C[J_@ />KE]X4.
MHR:T;C47,>JV:VDB+$!Y84, 5/U=CSZ^U &<D^HQZYX6@O+;3[FZFLYV^UR0
MLLL+*BY R3C.Y0>>>>E,T+Q7KM__ &#<7UC8Q6FJ336Y$3L71D61@W/&#Y9X
M_7M6M_PC=S]MTF\;5Y9)M.@DA#20J?-W@ EL8_NK^55]/\'-I]EHEJFJS.NE
MW4ERK/$I,N_>"I]!B1QQZCTH S3XWOYI+1[6VM=MQJ[:6UK+N$T.,_.V#Z*6
M(QP&'/KO>*]8U#1-+@N=.LXKN:2\AMS'*Y0$2.$Z]CD@9[9[UP>F0ZO#>W<]
MK-JL>O22R'['<Z8LB)EL@&X( *8P,ALXZ#H*ZKXC^<= LD@>YC8ZE;%I+>)I
M&15<,6V@'.W;G\!0!2U+Q=XATB#6XKO3[ WEA!'=PO&[^5-$S%2.>0P(/L?:
MK5]>ZI'?:!'KFFZ3(]SJ16/R]TAM\1LRL"P'SC!&1^%7-0\('5++4X[K4I&N
MM0CCA><1*/+C0DA57MDDDY)Z^PJ]J>AOJ=SI$\EYLDTZ<7'$8Q*VTJ<\\##-
M0!RL'CC7&BANYK'3UM#K?]E.$=R[?/LWCL,'USGVK<AUO5]1O;Q]+M;66SL[
MX6<D<A(E?!'F.&R%4+G@8.<'IQ58>!5&F)9?VD_RZK_:N_R1_K-V_;C/W<_C
M4J>"O(\07.HVFM:A;6MW.MQ<6$3+Y<CCKSC(#8YQUH P[_Q//H:^+KVRTC35
MGL;ZWBD=05:X$FT N1U8;_YU/J^N:E)!XB\/:Y9V:S'1I[VVDM69D:, J5;<
M!\P.TY]^U5_'/AZ2R\,>);FWEFN)]6NK6011P%BA21.@&2<*N3GTKI)?# OX
MKZ>[OWGO+VQ-D+@1!?+A;).%]23DGV'I0!@KXKO+#3M,TK2[*2XNHM)@N&(M
M99E8LN$3Y/N9VGYCP/0\XMR^-+V/5K"RNK2#2Y+F*%TBOBP,[,<21HXPH9..
M#G=N'2I9O ;&6PN[/7;VQU"UM%LFN+=4Q-$OW0RD$9'K5K4?!XU.R&GSZE-)
MI^V)3%,@D<%,?,LAY#-CD_B,9H VK1]1:^OENXK=;177[(T;$NR[?FW@\ YZ
M8J[6586VI1:YJ4MQ=2RV$HC^SQ2!!Y;#.[;MYV]/O<YSVK5H **** "BBB@
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MBBFR2)%&TDCJB("S,QP !U)- #J*C@N(;J%9K>:.:)_NO&P93]"*DH ****
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M#"_X2S6TT>.R0?:M4?5KC3%N(TC5F$89@X1F5-Q"XP3COST/4>%;C79]*?\
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MMI:Z@TDZN7$4F[<F!D$_+UX^A[5=/\,7UYXC\4?:+W4;*RO+L%H41?+NHO+
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MQAMVX!'''US4UYX(MYKV"\L]4U"PN%M5LYI(G5S<1 8 ?>K M_M=>: (OA@
M/AMH@"A?W)X#9_C;G_ZW;I775E>'=!M_#6B0:3:3SS6\&?+,Y4L 3G&54=R>
MU:M !1110 4444 %%%% !1110 4444 %%%% %/3/^0;:_P#7)/\ T&KE4],_
MY!MK_P!<D_\ 0:N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %<[I_B6RCM))=4US26#W<L4#PR;5V@\*23RP'WB.!^&:Z*O*;*QO?LN
MF1R:7?87Q7+>/NM7^6$^9AR".!\Z\_7TH ]+TW5+'6+07>GW4=S!N*;XSG#
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M\B0LOR@+O?&/N[LG/N:77I;#7-+\020PNUO+K]JQ8Q,A,82)&<'&<95^?QH
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M&SCG&,9[U/8^,+VX74[*>VM8]8M-12QC@61BL@8 K)TSC;O;Z(: .RHKB?\
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M%5V9B<*N<*/0<D_4FK-%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'F"5F=6*D KC)!( / 7%:C>"(8VLKRSO#!JMK=37?VHQ!EE>8_O0R9'RL.
M<C YXKJZ* .1F\$LXBFCU(+>_P!JKJDTS6^Y9) I0(%W#:H!]2?>M*3P_)_P
MERZ]!?&'?;+;3P>4&\Q58L,,3\O)YX_*MRB@#%U;0Y[[6=-U6TO$M[FQ69%$
ML/FHZR!<Y 93D;1CFLA_ CK=Z=?6NK-'>VLUQ/++);K()GF^\VW("D8P#S@
M#FNQHH XNR\$7MEHB:1_;,%U9!)4>*\L!(K[WWAB X^8$GGWZ<4^+P/<:=>6
M]QH^O7%D4LHK*=6A619EC7:KX.,.!WY^E=C10!R-YX,N3<ZE)INM/:QZC:I;
M7$<\/GYVIL#J2PPVW@YSFM>ST)8_"D>@WL_VJ(6GV220)LWIMV],G!VUKT4
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M!)R!O!VG9RN?Q[&W_P )GK-[J<Z:3I9N[>TOC:3K]F<;PI"R.LN[:"">$(/
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M::>MC ;NYN+'3Y6FLK6;:1"YS@Y RVW<VW/3/? KI#(@<(74.1D+GDTT3Q%
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MR>.1TKI_/O?[8-O]B7[!Y ?[5YHSYFXC9LQGI@YSWQ5I9$<D*ZL0 >#G@]*
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M!^7(;.<X!H Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"IIO_(-M?\
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M74GGVD=LB.I).YI7VY:(C'5O0#M7L5% '!>/;73[WQ3X/MM26)K>6ZG1ED;
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M*'\J1@V ?50<=.>E 'JU%>/^*-4EFL0XO+AKR#P_'=[Y+PPI"Y!(=%7F21B
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M^Q('N695A,Q0I@GD%>.<GTI?%"6_B/0_&$VH7LT=[I]T;6WA\]HTB0%0AV#
M;>2<DY]L4 >LQ2":%)5!"NH89]Z?45M&8K6&,D$HBKD=#@5+0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4BHJEBJ@%CEL#J>F3^5+10
M 4444 %%%% #7C23;O16VD,NX9P1W'O3J** "BBB@ HHHH **** "BBB@ HH
MHH :L:(6*HJECEB!C)]33J** "BBB@ HHHH **** "BBB@ HHHH 9+#%.FR:
M))%SG:Z@C]:6...&,1Q(J(.BJ, ?A3J* "BBB@ HHHH **** "BBB@ HHHH
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M(( I!ZC'3G)J6B@#-7P]HJ:>]@NCZ>MD[;WMQ;((V;U*XP3P*T0 JA5   P
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M!F V\J-V?7 /%=42 "2< =2:X#X:7-N?^$N(GCP-?NI2=X^X=N&^AP>>G!H
MZ7PSKW]OZ%:W\T,=M-.TJ^0)=^-DC(<' S]W/3O6OYL?F^5YB>9C.S<,X^E>
M.Z)#I-OI/@[4X/(74)==F22<-\YC)F!4GL,&/C_:'KR[P[#:76N>1K5]J$7B
M*'5VG%K;VRJV2_#&0IN,6P\C=C:.!T% 'L3.J8W,%R<#)QDTS[1#M1O.CQ(<
M(=P^8^WK7%?$NUM+R/PU!=A3')K<*/\ -M.PJX89&"!TSCVKEM=LM)L/$]WX
M?U&\N-+TG["B:>HMUF0KR75&96(?=@\<D@>@H ]?>6.-E5W52QPH)QD^U5+B
MYOH]6LK>&R22SE#^?<&8*8B!E0$QELGCCI7E?B*6PAUS4M.NKZUF%QHT%M&V
MJS>0UJQ#8897))X9L<@_IKK#IVE^+/"<$%S$\46B3I]HA(S(H5<,".N?G(_'
MWH ]"N]1L[*RN+RXN(TM[92TSEN$ ZY]_:I1-$45MZ@,N\9/4>OZBO$?)@.A
MZYIJG3]5C_L-IH=1M(_WH"D%5N$!($F3][KP2>^.BETGPMX@\9Z-:+#9RV$F
MD3,([9O+5V$B8^X1GHYQ[$]J /3?.B\WRO,3S,9V;AG'TI6=%959E#-]T$\G
MZ5XM<W^GVOB>SDADM;/R?$I1XRY>Y*J'5W=SR(S\H5.F#U/0.DLK&VT/5]3M
MXXDO(_%>VUE4_.BB5!M7TXW<=Q^% 'K,FK1,NHQV2_:[NQ7Y[=&"DL5W*NX\
M G].]&DZK%JFE6=]M\@W2!UB=P2#W&1P?J*YCPY#I4?CCQ98FULDN&FC=$\E
M0[1-!'O[<J6Z]LD^M9/CMK>TUYKV*XTZZEM[2%)-(NUP\B>8S*;=@<B0D8P!
MV7/:@#TVH)KVUM[2:ZFN(DMX06DD+#:@'7)KG/B!<7T?@*_GL5E678AD5!EQ
M$6'F=/\ 9W?K7%^(;>PO/[8/AFW@ETJ70)?M*V:*T/G!MT60O'F#D^HP* ._
M?Q*/^$DTK3([=7M]0LY+I+DR8*A=IQMQW##G-;ID18_,+J$QG<3QCZUY7!:^
M'M5\2^$+>.*REL?[,GD>./ C9QLY8#@\J>O4J?2L?3]02#PUX335+I$T'S+R
M%Y)(O.1)1*PB$@;(V[,A<_7MD 'MI8*I8D!0,DGI2UY0- T:ZU?PCICW-Q>:
M:\.H*K2LT7G+E"$XP2@R<#I@>E=-\0!-IGP_FCT^*3[-!Y*31PDEQ;!@' YS
M]W@\],T =>DB2KNC=7&<94YH1TD0.C*RGH5.17E>LW>A0^'+_4?"2R?8GGM&
MU(V<9\KR03N"KP-V,;QZ$9JGJ-IX?.F6QT[4?M%E?:Y9AY( ((H"<[S&5 VD
MJ!NQTXZ&@#UDZA:+J:::9E^V/"TZQ=_+4JI;VY8#W_ UDW7B"[TWP\^HZGIG
MV:Y\\016PF#[BTFR,E@, '()ZX![US=MHGAG0/B-;6<=G96Z-IG^CK+AF:0S
M'[I;)+?J![5E10:&/!%B9FL)86\1%8?,V,$3[;\R@GML4$^WM0!Z3I5SJ-Q#
M+_:=@EG-'*441SB5)%XPZG ('L0#Q3Y;B]35K:WCL0]D\;M+=>:!Y;#&U=O4
MYYY'3%<3K5C/X6\2P7?ANPB1=;B^PLL2 )#. 3'+@<!<;LX[+GKU+_3].T_Q
M]X?L,1"&/1KF%Q(1\T:A0-WX;OUH ]"I ZEBH8%A@D9Y%>/>#8;.TM_A[<Q%
M$N[EKI)WWY9U\M\*<GIN"X'0'ZT[0&L-5O\ 1XI=8TU[JRU"66:Z>Z"3WJEF
MV*8\[LD[.#T"CZ4 >P55O-0MK'3)]1GE M8(FE=UY^51DGCKTKF/B'<26UCI
M)FVC2&U&(:D6&0(<Y^;_ &-P7/X#H37-:Q:V<6G^.?L @.@'35:-4"^0EUM;
M/E]MWW#\N.2.] '3CQ;JGVBSMFT.-9=37?IS&['ENNTNPD.W<C!1GA6!)P#6
MOH6HZS?FX_M;0SI>P)Y>;I)O,)SN^[T P.O7-<,]AX=&I^ 1]DTO9<Q2&3]W
M'B7_ $?C/K\WZ^]4=?O6LM5\;O;%FLUN].-\D!.[R"N)L8Z$C@_C0!Z\KJZA
MD8,IZ$'(H5E=0RL&4]"#D5Y1KNH:%#H<USX:9QI<M_9MJ3VT.ZW2+D, N,=%
M7<.^0#U(J#5K+0(]!@>RU4W-O<:Y:E'A_<Q1%B XB*8 ^7)..A]#0!Z;J&LP
MV6H6>G(AFOKLDQPJ<81?O.Q[*/U) %:$I=8G:- [A254G&X]AGM7!:%I,&A_
M%*XL;.$0V*:*IMHPQ8 &8E\$DG[QR?J/:JGAIHK3QR(Q/8:FETUTT-[$V+J(
M[LM',.I48VJ>V .* .\TG58-8L1=0+(F':.2*1</$ZG#*P]015ZN4\*&5O$O
MB]AG[*=0C$?IO$*!\>_ S7 ZMJ.G_P#"5/=0SP6TEOXD@29KOFZ894.0QQY<
M !( .<\\CI0![361XHUP>&O#=[JYMS<"V0-Y8;;NR0.OXUY1):Z?#I.K:O"R
MB[MO%?EVTXF)\M/-3A><8(S]0/:CQ;=V%[HOC@ZX]N-;@O/)L8YV D6W!3R_
M+!QP<N20.<\YH ]FO;H65A<791G$,32%%QD@#.!GBJ^BZJFMZ)::I%!)%'=1
M"6-)"-VT\C."1R*9K4\)\,:A/YJ>2;.1A)N&T@H<'/3%9_@.1#\/]!8.I46$
M0)!X&%&: -+0]5_MK2DOOLSV^Z21/+=@Q^1RF<CUVUHUY'HT6E00>'=7CG:2
M^FU^> 2B4D[&>8; ,XV_=/''.>]4TU.P_P"$ITO4K._AMF;7989(YY@UVZ-N
M#&0Y&R,$ *A!Z@YH ]HHKS)[*[_X2Z_\&;9'TZ\NX=7$K$G9 "&>,'M^]C0#
MT#&LN&&#5O'%[-?>(H[+5+'5]L=NUL?/DB#_ +M$8.,H5X("\9)/7) /8:Y^
M/Q-)<SZ];6NESS7.DNB>2)%!GW*&&T]!P>]9WCZ_2T&B6][(8M(N[X0W\F[:
M-FTE59NRE@,^PQT-</<C3;'0?B/'HTL45M$\!A^S2\*=BYP0?[V10![/&S-&
MK,A1B 2I.<'TXIU>5^(A#;>)H]9DE@U&W4VD+VPG*75JV5*M#SAE;<I([Y-2
MZ1/H6J:[=MK%Y+;>)K75RJ8EVRL@?]VB+SF,KC<![DD9H [G1]=36+S5;=+=
MXFTZZ^S,7(.\[0V1CMS6M7D=Y?26I\3,KL+)O$L":@T9(*6Q5 Y)'(' !/UJ
MWJ%A;07&NZ=H6IKI^C7%C #+&^^"*Z>;:%R/N[EVA@#T;- 'J-%>+W.H_9_#
MT=A)!;:98IK M]1DA=KJTP81M( 92(R=A*D\'KW%7?)L=,L=&TVXUR.^\.7.
MK2K<211F*W7]T2L0.X@IYG)YQG([&@#T32->75=4U>P^RR0/ILZPL78'S-R[
M@PQT&"*=XDUQ/#?A^[U>2WDN$ME#&.,@$Y8#O]:Y3P9=>%]#F\1&TOK*WMGU
M988_WX"G]TFU5Y_O>8!ZX/I6O\2"P^'>M[7V'[/C.,\9&1^/3\: .H4ED4E2
MI(R5/4>U+7EFK#2=$UB_N=)O[][.32IY=4-E<^:V_<@C?<Q(5SE_P%8VDWD#
M:GJUA;:Y8:9!>Z)$ZO9R;DMY=^P;F_B?:1N8 'GMC- 'ME%>*W.IRZ=X?N--
M6VM;*&WU2VCU*>T9Y[1H70G<J@@JORIN7/?WJ\S6>CVEG:G6DO/#MWJRK=/:
MQF.V@4H<1JQ9OD+A2WS8'([F@#TG3M8&H:IJEC]G>)]/E2-F9@1)N0,",=!@
MUIUPG@$:5%X@\6P:081:I>QE4A<,HS&,D8[;MWY5G:I#9ZEJ?B]==D\N\L45
MM/<R%#%$8R4>/!^]OW<CG.![4 >F45Y&;%-6CUXZW)*;F'P]:W%Q"\S*$N3'
M(6<KG 88'L,UV\6I7T_PSCU2R0F_?25GB4G<?,,6X?4Y_.@#I:*\GT9[:.Z\
M&W>A2F2]OXV.K;)BS2CR\NTH.>0_0G'/'>H] U2.9OAO$;\//LN5N$\[+<Q,
M '&>N1QGN* /7**\]^&6CV3Z<=:\R>6\6XNK=6:Y=E5/.)QMSCL#D\UG^);>
M.\U_QN9Y[C_0M'CN+=$N'0+((Y"&PI&2"!^= 'J5%>;:(7MO$&B36\\LMS?^
M'I)Y3+,S^?-^Z()R<9Y/3M5#3WBN-%\-ZY;3./$ESJ4<5XP?]Y+\Y$R,G]U5
M+'&/E !&* /5G=8T9W8*J@EB>@%-MYX[JVBN(6W12H'1L8RI&0:\AE2*QEUJ
M*[$&K#4=/OIX+^"5MSJN'*3IG@J0JJ1C'2O1?"L-DO@[3DM63[.]JA8QR<9*
MC=R#QWH W:*\5LD>Q^$MCKD5[=>?=2I;WMQ++)*L5O\ :#N^4,,#& <8.">>
M:MW]Q'HVDW$]CKT-_I5SJ%G_ &A_9X=([6 DAR#YCD;@ " 01^- 'K]%>6Z[
M?:58::D>BZN#I5QJT2WDLA:>V@5HR=H*E3MW*A(W=3SP<5&-.@6?0+./7WU"
MWGUF8;[21XHUC: L8D(=LJ#WR<;B,C% 'I]U>6UE&CW,R1+)(D2%CC<[$*JC
MW)(J>O&K^WM)-&@MYF\RTL/&"VT)EE+>7"64LNXG..3R37>^.+J73/ %_/IS
ME/*BC"L@+;8RZAB,'.-A/(.?>@#J**\QMO#D&NZ/K-OI?B2WNENK:-X8[%'2
M.WF&=C9,CE6;&",CCM56'6#JG@K4_$]^U_9006$6G*+<[)"X8>:P+9&"Y"[N
MH"MWH ]+UC4DT?1KW4Y8WDCM(7F=$QN(49.,^PJQ:SBZM(;@*5$L:N >V1FO
M(;:]"67Q"TXW=F8UTI9(;:VN#(B9ADW[2QRQ^[N( YQP*U);RWL_$5VMS<K#
M!-X41@))-JLX+ D9[XV].>E 'I]0O=V\=W#:/*HGF5GCC[L%QN/X;A^=>1/>
MVU[X9\.VT^H;)_[":9I+JY*P)T4OM'S22@Y &1CFG^&/LNJZ_P"#KG49%GFD
MT1\R22'+2(Z!><\M_.@#U33[R>\6X,]C-:>5.\2"4J?-4='&#T/OS5RO);6]
M=-+6TNKF<:;/XIN+2ZD,K%A'EMB%\Y"E@H//3C/-0>(A-:OKVGV%Y=Q:7%?Z
M?Y#13MB&5VQ*JMGTP2IR 3G% 'L-%<5X2@6P\;^*].AEG:UA6S=$EF:0AG1R
MQRQ)R2!FH]4^R:KX^N])UJ:2.TBTQ9[0"8PJ"682/D$9(PN#VYZ4 =-JNL+I
MTEK;10&YO;MG6WMU<+OVJ68DG@  ?F15K3[MKZPAN7M9[5Y%RT$ZX=#W!KR?
M38CK^H?#V;7HF:[N;2\64O(0TBJH\MCC')'/XU[#0 4444 %%%% !1110 44
M44 %%%% !1110 4444 0P?\ 'O%_NBIJCA&(DS_=%24 %%%% !1110 4444
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M^4XR/PI_V.U-X+S[-#]J">6)]@W[?3=UQ[5BIXQTXV=]-+%<V\UG<+:R6TR
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MZ*&&1N&[+'ID)NZTV\\<Z59W+9$DEE%(L5Q>HR>7"[;=H()W'[ZY(! SSWP
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M2*",R+;KL<NV. HZ>Y]\<;\GB_3&5#8"?4F:U^V%+-0S+">C$$CKV'4\\<4
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MC.EV$4</B$:IMMKC"+&4*E5!48QD8]>>G>Y=>%M<EM_$/E6T&^XUB#4+4/.
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M<6H7$MQI&K3NZL?]=;QRX9& P/NC/X>]7+S7;J\T>768-2NX+34-3AM[&"%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC/,D;)$5!12>7.2. .>.:MT %%%4Y;RXCU6VM%L)9+>5'9[I679$1T4C.>:
M+E%<K)XQN)7N#I?A^^U*""X>V:6%XU_>(<,,,P./?VKJ5)*@D$$CH>U "T44
M4 %%1+<PO=R6JR*9XD61T[JK%@I_$JWY5*> 3C/M0 45E^'M<A\1Z-'J4$$L
M".[IY<N-RE&*G."1U![TNM:U#HT-ONC::XNIUM[:%" 9)#DXR> , G)]/7B@
M#3HK+TG5;K49)4N=&O=/,:J<W!0AR<Y"E6.<8'/'6KM[</:64T\=M+<O&NX0
MQ8WO[#) S]30!/13(G,D*.T;1LR@E&QE?8XXS3Z "BBJ;WTB:O#8BRN6CDA:
M4W0 \I2"!M)SD,<Y''//H: +E%%% !1110 456O[O[!I]Q=F&280QF0QQ8W,
M ,G&2!^M-TK4(]6TBSU&)'2.Z@2=4?[RAE! /OS0!;HHHH **CDGBA>)))%5
MI7V1@G[S8)P/P!/X5)0 45#=SM;6<]PL,D[11LXBB&7<@9VJ/4]!265R;RQM
M[EH)K<RQJYAF7#QY&=K#L10!/166^NPQ^)X=":";SY;5KE9?EV;58*1USG)]
M*U* "BBB@ HJ"^NUL;"XNW1W2"-I&5,;B ,G&2!GCUJ+2M1BU?2+/4H%=8;J
M%)D5_O , 1G'?F@"Y1110 4444 %%%% !15.ROS>37<9M+F#[/,8@TT>T2\
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M*** &1G**?44^D P !T%+0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R?B:-9?&7A!9O]0+B
MX?DX'F"([/QZX%<;X\U"$:OKC6UV(KRP:SW/<W)#(258+;H",#!)8G/.>*].
MUG2(-9LEAE9HY8I%FMYD^]#*OW7'TST[@D4?V/9W"B2_L[*ZNWA$4\S6Z_O!
MW'.3MSS@DT <WXEE=_'7@F2T=&,DMSE@00T7E GGTZ?CBNTK)@T.-=;.J7#I
M+)%&8;-%CVK;1GJ ,GYC@9/'  P.^M0!R_C.XN+BWM- L3 UUJDAC=)9=@-N
MH+2\@$C*C9G!^]6-X5GGT+Q_K7A^^%O;IJ"C5+.&*;>JEB5D4$JO)*YQC@ U
MW,EA9RWL=[):0/=Q#;'.T8+H.> V,CJ?S-,DTO3YKY+Z6PM7O$QLN&A4R+CT
M;&10!YI<2)_P@.N#>N1XG8$9[_;5/\J[CQFID\+W4*WUO922M&B37#,L>2Z_
M*Q7D!ON_C5\Z'I!@E@.E6)AF?S)(S;IM=O[Q&,$^]6Y[>&Z@>"XACFA<8:.1
M0RL/0@]: /*KJ<KX3$:V\^GW%MXB@BFA2Z9XPQ9-VQN,QD'(!Z$FI=>1]0\1
M:Q8KJ,27IOK;R)_[06$VT 1#(FW>&&06^Z"#NZ\<>BMHFDO91V3Z99-:QMN2
M VZE$//(7& >3^=<O<>";N>\OC(VB7*7<K2?:;O3!)<1@_P@Y ; P 3^1[@'
M.:[IL$FI^.PT]YMT[2X)[5?M<F$D$4A#?>Y.0.OJ?6M^"X$WB?PE]HFE=[[1
M9EE7S#ASMB;)&< \OSU_*NFMO#FD6UHMN;"VF_<);R22PJSS(@  <X^;[HZ^
ME61I&FA[=QI]H&MEV0$0KF)?1>/E'TH \DEM+6T^%GBNZLE,$L6J3QI+#*X)
M43@#)SSP<?2N@U2^TB]\7:_I_B'5'L3:I!)ISB8Q,B; S-'V9M^1T).,=*[9
M= T9+62U72+!;>1@SQ"V0(Q'0D8P34LND:;<2P2S:=:226^!"[PJ3%CIM)'&
M/:@#RCQ%J2CQ-/=VUVZ26^M6D$DUS>;9%7"[DCB& (\$DD]<GTINNJ8[+QUJ
MT-Y=BYT^^AELW6Z<K$Q$9R%S@]3UR,<"O5Y]%TJZEFEN--LYI)E"RO) K&0#
M& Q(Y P.OH*:V@Z.ZSJVE6)6X8-,#;IB0@Y!;CDY)ZT <II&GZ:GQ7\03OA;
MH0VKP S,"Q99=Y"YP> .W'M4FO7%M=^/[?1]8G$>E?V8UQ&C2F)9)C)M.6!&
M2%Y [9SZ5URZ=8I=1W265NMQ''Y22B)0ZI_=!QD#VIFH:1IVJB,:A86UT(FW
M1^=$'VGU&>E 'C&FS,WA7PWI*ZE9VNF3W%\'ENV?RW=9?W:ED=#DAB1S@]>>
M*V=2T>TN--\$V][J!U:0:H;5KP2.HFC_ 'AX^;D#"C=DGCK7I,N@://8-8RZ
M79-:,_F& P+L+?WL8QGWJ:;2M.N(H(IK"UDCM\>2CPJ1%CIM!''X4 >::WJ%
M]HTOQ ;3[FY3[*FGB/YVD,*-_K"N<X^4L>.G6K>L#1;7P3XEF\.ZO/(CV23[
M(KMG6)N<,&SD%L<C/\/2O0_L%F+F:X%I!Y\Z[)9?+&Z1>F&/4CV-5[?0=(M=
M/DL(-+LX[.5MTENL"A'/J5Q@]!^0H \R\027&J^(I--N]>LM)@@T^"6SENW=
M#N8'<\961 6! Z[NW'6K.IZ;%J-YXHDN-2OY'L]'@N(0MW(BB4QR$R;,X!^1
M3CH,].:]%N-$TJ[6V6XTVTE6UQ]G#PJ1%CIMXXZ#IZ4^72=-GFFFFT^TDEG3
MRY7>%2TB\?*Q(Y' X/I0!YRFH6.NZE:6?B749K6V?1+>YL9GN?L_F2,I,DN0
M0"XXP.@YXJW>7-Q:>)M)DTV[N;UCX?N)(C-(W[]E"[&*]-Q]<<YKMYM!TBXB
MMHIM+LGCM3F!&@4B(_[(QQ^%3MIUD]['>O9V[7<:[4G,2EU'/ ;&0.3^= 'E
MGA?<(5U-?%]BC7FG2^=''YF\.$R9)=\C;2AZD!1SCN*Z7P)OL[_4--NX'AOH
MH('D$=R9K>53O ECR<J6P=P/H*ZB'0])MY;J6'3;2.2[S]H985!ESUW<<Y]Z
M=IND:;H\3Q:;8V]I&[;F6",(&/J<4 >8>-]06+6-;N;:]>*[T^>R DGN2OEL
MVT[((Q@$%2S,6)[C!QD,UFW6]A\?7QU&]S8/'-9&.[<)&WE!P5P><D].G/&*
M]-N_#^C7]Q+/=Z593S2H(Y))(%9G48(!)'(X'Y4]=$TE4N$73+(+<_Z\"!<2
M]_FX^;\: .'UN33]4U3Q)!K.HR0-864;6:"Y: *K1$M(,, Q+';SG& .]=%&
MV[X9(\<C C2 5>-RI!$/4$<BM.X\/Z-=M UQI-C*T"[(B]NIV+R-HXX')XJU
M!8VEM9_8X+6"*UP5\B.,*F#U&T<<Y/YT >8Z)IHEF\&127^H,NJ:.[WG^EN#
M+L6)E7@_*!N/W<'&<DY-,@OXYO"?AS3+RXN9I+B^NH(HFNC%'(D4CJ!+(,L%
M5=N,<D@5Z4NB:2DEM(FF6:/:\0,L"@Q#GA2!QU/3UJ.7PYHD\!@ETBQ>$S?:
M#&T"E?,QC?C&,X'6@#R/1=FJW?A%=3OFN7@U"_M6F2[<?(J,5PP8'Z'.2,#)
M%:FFSW6IZS-J<VOV]A?VVL&W:V9I&E\L/L6#9OVD,,<[>N3G.37I'_".:(8'
M@.DV7DO-]H=/(7:TG]\C'7WJ4Z-IAU8:J=/M3J 7:+GRAYF,8^]UZ<4 ><:7
M8ROX.\4ZL^JZJ]Q;'4((5:]?;&J%BN!G.1@<YS5/7-5FDT0".^N_MEMX=ANF
M>2^:!(F*<,H7F21B.C<=/7!]2L]$TNPM9[6TT^VAM[@DS1)$ LA(P=PZ'(XJ
M"3POH,OD^9H]B_DQ&&+= IV(<@J..!R>/>@#EM-NC>^//#ERTHE>7P^[,X(.
MYM\>>GOFKGC6=]$U31?$3W%R+""5K6]@C9MK)(I"MM!QD-@=,_,/2NDM]#TJ
MUN+>>WT^VBEMHO(A=(P#''_='H.>E6KBWANHO*N(DECW*VUQD94@@_@0#^%
M'FWA235VOY-!OFNOM.E3R7S[II'RCH##&7)^89=Q@_\ /.J?AG4;N>RT_7KO
MQ7!'*\<YO;;+O+(0K,PV%RJ% A(VJ.G?//JRP1).\RQJ)9  [@<L!G )]LG\
MZI0^']'MKVXO(=+LX[FY!6:585#2 ]03CG/?UH \KL-2O5GMH_MDK6NHZ'<S
M.)[LRR387*RNA)6)B2?E4D=L\<:_@*Y74/[)L-5DNK6XMM*A;3X([AEBGA*+
MNE^7&YP>"I^Z,8SR:[*/P;X9B"B/0=.0*& VVZC 88;MW'%3CPUHBFS*Z5:
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M:<S3+XE&HLJS1_ZGS-^<ENO;'K[<U/J?A;6;^_\ %SPP+";N>SNK"61U*R/
MJ_*P!R,E>X[T 2>+_%AF\(ZK-ITM]IVH:=-;&:*2/9(JR2*!GKD%2>ASQ^%=
M7I>OV6KW=W:P">.XM-GG13Q-&RAQE3@]B :Y?7++Q5XF\'WUM=:3;V=S*;?R
M[9+E7)*2AW8OP "%  _,\\;FG:;>0^--:U.6():W-O;1PMN!+%/,W<#I]X4
M&K^,-,T6ZGMYTN96MHEGNF@BW+;QG.&<Y'7!X&3QTI;CQAIEOK)TH1WLUV&B
M#+#:NX59,X<D# 7CDUR_CCP_XDUS4-2@@T^&]T^:P\NT+W8C6"7DLQ0@[G/
M!/ ]1DUMZ3INJ-KVJ3ZA8"W@U"P@A+Q7"OY;H'!7H"<^9P<?PGVR 7;3QAI=
MYJ%M:H+A%NRRVEQ)$1%<E>3L;Z GG&<<9J76_%.F^'[JUM;S[2UQ=I(T$4%N
MTC2; "0 HZ\BN7\(>&]5T::RT^[\/:,D=@2/[73:99TP0NU0-RL<C))Z9ZUO
M:UI-[=>,_#>JV\*26U@+E9\N R^8J!2 >O0T +<^-M*M(_-G2\2!!%]HF-NP
M2V,@!59.ZG#+D=LC.*?+XQTN'4OL;"XVB[6R-R(LQ"<XQ&3USR.<8]ZYNY\+
M:E9^(]4^S^'=)U:SU.?[2EY>E-UJQ #!E*DLN1D >M4]=\->);[5Y;H::MY)
M!K$%W:S27JJBVZ8.Q%_A.<[CCG_:Q0!V\/B:RGU1K%8KD 2O"+@Q8A9T!+KN
M[8VGJ!TXS4$'C+29[VUM_P#2(X[QBEI<O$1#<L.R-_+.,]LUSS>%M3N]?EN(
MK1]*%W]HCU%H;D/;W,;*RHP3.?,R5).!T;DYJ33M"UR73_#>BW]FD46C7"2R
M7JRJ5E6($1A%'S98$9W 8P>M &O;>/-$NI;=$:[19[DVBRRVKHBS D;&8@ -
MQTJ<>,=(.HK9>9/N:\:Q67R6\LS@9*;L=>OMQ7+R:%KDWAVUM/[(E2>/Q!]O
M=3-%Q"9VESD/UP0,>M5[OPWXGG\06FH7&GI=S6NL"X^T?;  ;;!"K&A^[@,=
MW0DCOG( +^@^-;;3GO[+6KN^E=-6GM8[J2V8QJH?:BM(JA0:F3Q4=$\0>+I-
M6N;J;3;"2U$86/?Y"R1ECPHZ9.,\]JA;PWJMSIVLZ!/I^+;4=5DNC>^<NQ86
MD$G !W[\# XP#SGBK]OI+)XD\72ZQ;)'I.JK B2RRH%D"Q;&!&<CVH Z./5;
M:6_@LT\QI9K?[2I"':$R!R>QYZ?7TK%U+4+VV^(FB6<=U(+*ZL[AI;?:I4LF
MTANF<_-Z]A5?X>Z7<66C/<W5W]K:4B"VF.<FUB++%GZ@EO\ @56M4TV^F\?:
M'J45JSV=K;7$<LH=1M9PNT8)R?N]O6@# 369FG\)W%EKUY=65UJ%Q#,9HQ'Y
M@7S#\P(!&TC ]@.*ZN#Q1I]QI=OJ"+<"*Y?R[96B(><]1L7J1@$YZ8!/3FN%
MC\%ZI>>'-$TF_P!,F18[R[:Y=+B,-"DN_:X(;DC>..>A]LV=3T#Q+J^B:0VH
MZ3:WVH:/=$/!+*@BOXBI3<#D[6Q@X;'/Y4 ;^HZZFHVFF7FE7T\2KJT5I<P[
M0ISO"O&X(R"/;'XBKT?C#29+#5;P-.L>ERM%=!H2&5AU '?KVK$&C:D-#L/*
MT"TL)(]5ANC8V$B#9$F,EV.%=N.W^SZ9J*^TE+[XDQBPNXVLKB%;C5;=#D%X
M7'E$XZ$L<$=PAH Z7Q-X@C\.>'+C5Y()91&%"QJO)9B%4'T&2,TRX\6:;:QQ
M&5+SS7C,S0+:2-+%&#@NZ 95<COU[9IOC329M;\(:A86R&2=U5XD#!=SHZN!
MD\#)4"L9;76+#Q7<:^FCSW,6J64<4ELD\?F6TJ9P#N8+M(/)!.#GB@#K;74;
M.]TZ/4+:YCDLY$\Q9@WRE?7-9NF^+=)U6ZBM[>297G@-S 98&19H@<%U)'3D
M=<<$&J_A30;WPYX#M-'\Z.2^@@<!V)*"1BS ?[H)Q]!7$Z=X7\1SW]F]WI]S
M;2RZ9<65U>/=1R;)'QAU4'"Q\?*H'X=R =#>^+S<^+O#4.F37)T^\DG60O!M
MBG58R048KD\CC!YXQD&M^+Q7H\^E_P!HPW+O;_:1:?ZAPWG%@NS:0&SD@=*Y
MK3;;Q"[>%;>]\.^2FD.4N)%N(BIQ"T:L@W9*_,">A&, &K5KX3NK?Q[=71"-
MH4C#4(XSCY;S;L) ]-N6SCKCTH VIO%>DP:C'922S!I9OLR3"!S$9O\ GGY@
M&W=P>,]1CKQ50>/O#Q+_ .E3 1^:)"UM( C1G#*<KPV>B]>1QR*YS2O"]YIW
MB2>*;PM87(.HF[AUAY%^6-I"YROWMZYP,<9YZ#G7L='NE\,ZY9WVBFX^UZC<
M3BU:2-?.BDEW##*W4*?XB#D8SC% &V?$NG+92W,GVF/RY_LQA:W<2F7 8(J8
MRQ(((QD>_6L#Q'XI,_A^&]T:[GMY8M4@M;B.2'8ZY=0R,KC(X8'CVYK$D\->
M(I-(8QVD]S;6.H)<V6G:I.C2RQ>44=&=20,;CMR>W/:KM[X=O+CPJL>G^&H-
M-E?4K>Y^QPO&'$:,I+.V0I;@X /3'O0!V-OXATNZ.I".Y(.FDB[$D3IY7&[G
M<!D8&<C(JQ<ZG9V>E2:G<3B.SCB\YI6!X3&<XZ].W6N/UK15OO'=J=/OHD2]
MBV:O;J03)%"RLI([$DA#GJK&NG\1PW]QX;U&'2U1[YX&6!7Q@OCCKQ^?% %:
M+Q9IUQ%=F)+OS[:!9V@:UD#LCYV,!C)!(/3I@YQ7G<OBC75TW0M2.I:RG]IS
M0PW-N=-&%#G?N@?9@\#:!\Q()/O6YH&E:S8:Q>7CZ#=I'<Z6D1,MW')*TJER
M=Q+=26'? 'ITI?["UI?"7@W3_P"RY3<:7>V\UT/.B^58P0<'?SG/&/3G% &S
M:>([31('M=3U2[OVBE"RW;V946_F8*)*5&T$ C)XQD9QD5>NO%^CV>HM9RSR
M;HY5AFE6%C%#(V-JN^-H)R.,]QG%<G=>%;N'Q3J9D\,6.L0:A.+BWOYW7-LQ
M"@K(#R5&"1M^G?C0TVT\3:'KVK6<&FP76GZA>M>07C3 "#>1O#I]XX[8ZXZC
MJ #:\/>*(]?OM6MDMIX?L-TUNIDA<;@%4DDD8!RQXSG&#BLC6O%\S3^)M*M(
M;RUGTW3_ #XKL0Y&_:[=P0%^0 $]><=!5[PMIVH:7K'B*.ZM"MO=Z@UY!<!U
M*NK*HVXSD$;3G(K-UG2M7;6_%'V;3)+B'5M+2"&9944*ZI*N"&(/5U_#/TH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BLOQ+<SV7A;5KNUE,5Q;V<LL;@
MX94)'!!':N.LM1\0VMUX8EN=:DO(M;M'\Z/[/&H@<0^8KH0/P.[()R>,X !Z
M+17EEIKGB6W\'Z+J]UKJRRZS+;V@#6R*MMYC',@Q]YMHQ@\9.<<8-K6?%NJ>
M']2US2OM9F2&*V>"]N57-N9G$9+;5 8#.X#&>".>P!Z317$:]=ZOX7T>_N!K
MHO#,;:.V^TK&KP%G$;N2  1\P(R, ^U0>9XYM-*U21HS<#S(7M$$T3W'E_\
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MQ0!UZ(L:*B*%51@ = *6O-IM?\16]UXHU-M51]/T*>3;8_9%W3@Q!E5I 00
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M<N+G3M2-F[I&J>>$FC +#!Q]X=,=* /2],UFPUA)FL9_,\E_+E5D9&1NO*L
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MPOJUG:Q&6XN+.6*- 0-S,A Y) ')K-\-^%[:QT?3#=07 OH+-8&$UT\ODDJ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[AS_ 'MQX/Y '\:X]M=\0S6-E<S2W<4<EC</J"26^U4< ;,,5QR20,'D5?\
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MQ:_:DF2%RA4E0N"!@@[LYZ#'/6@"U#X=TJW?3WBM K:<C):'>W[E6X('/0C
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MV/*F#9#D] ,<D\'CKP:J2:_;W=[H@TS5M.:"^>0[&RSSHJDGR\'@@CG/\^*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKJ\ ]12X [5<9N.G0B4%+4Y%O&T=@676+"ZL2.K%"Z?F*NP^-/#]Q$)%U2
M_P!\E?YUO21I(NUT5E]",UF7GA[1[]P;G3+64CIOA%:<U%[Q:]&1RU%L[^I
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]OVRST:VW_=\Z&-<_GUI5:OM)>2T00ARK7=C5\?>$,?\C1HO_@?%_P#%4O\
MPGOA#_H:=$_\&$7_ ,52/IOA46ZSMI^C>46VB0PP[23Z$\5=7PSH!4'^P],/
M_;I'_A6191_X3[PE_P!#3H?_ ('Q?_%5%<?$'PFEO(Z^)-(D*J6"I>QDG'8
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M)_X,(?\ XJC_ (3WPA_T-.B?^#"+_P"*J[_PC&@?] /3/_ 2/_"C_A&- _Z
M>F?^ D?^% %+_A/?"/\ T-.A_P#@PB_^*H_X3WPC_P!#3HG_ (,(O_BJN_\
M",>'_P#H!Z9_X"1_X5"VA>%TNEM6TK1Q<.NY8C;Q;R/4#&<<&@"#_A/?"/\
MT-.B?^#"+_XJC_A/?"/_ $-.B?\ @PB_^*J[_P (QX?_ .@'IG_@)'_A1_PC
M'A__ * >F?\ @)'_ (4 4O\ A/?"/_0TZ)_X,(O_ (JC_A/?"/\ T-.B?^#"
M+_XJKO\ PB_A_P#Z >F?^ D?^%'_  C'A_\ Z >F?^ D?^% %+_A/?"/_0TZ
M)_X,(O\ XJC_ (3WPC_T-.B?^#"+_P"*J[_PC'A__H!Z9_X"1_X4?\(QX?\
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MX"1_X4G_  B?AS_H :7_ . D?^% $!\;>%QU\1Z/_P"!L?\ \51_PF_A8_\
M,QZ/_P"!T9_K4P\)>&Q_S -,_P# 1/\ "E_X1/PX?^8!IG_@)'_A0!!_PFOA
M@]/$6D?^!L?^-3VGBG0KZ[2UM=;TVXN)/N10W2,Q_ $YI#X1\-G_ )@&F?\
M@(G^%2VOAO0[*X2XM=(L8)D^[)%;JK#\0* -2BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3(94T\7+[4,GG3[@#&J!]RH 22YR..M4]3UF.Y^(G@;798S''+I$]VZCDJ#
M[D>]=!J/PQT_4[N:YFU;5!)/9FSF/F(3(A??SE>/FYXP./K5U/ =DFJ:#?"\
MN2=&LQ9PQD(5D384);C.2#VH P++Q_JQM?#VL7D5G_9VN7IM4MHXV\R ;BJ-
MOW88Y'/ ]JSM6^)GB+3I->F2VTM[72=22TVF.0/(C%L<[\ X7KCOTKKK+X>Z
M79G3HC<74UEID[7%G:2,I2)R<YR!E@"3C)_.J%[\+=/OX=6BEU2^VZI>+>3$
M"/(9=V /EZ?-^E $&M>/=6A\3:MI.C:;]J?3(XF:+[++*\[,02 R'$8"DX+
MY->@12>;"DFQDWJ&VL,$9[$>M<K>> ;2X\3'7[?4]0LKZ2(0W+6SJOGJ, [O
MEX) '3'08Q76 8  Z"@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD4,5'&X>9UZ\5E7*:K<ZAXWUN1%%]H[,UM+'>.OE@18VC"\J%)?'&6 !ZDT
M>S45X5IEE9Z7I'@W7+VREGO-3OH$9DOW5=V3MD9<88G.2/4=>37H%OXWO[_5
M'33M#>ZTV+5?[,EN$E.]" -TA0+]P$]<T =K17 Z9\3(-3UJ*UBLE-I+?O8K
M(DI:0$#Y9"FWA">.O'>GZ)XXUS7=9N+.U\-*UM9:B]G>7(O%PBJ<;@I )/?&
M.GUX .[HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !0:** "DQS2T4 036L=PI26-'4]5<;A^1K-7PMHB3><
MNC::LF<[UMD#?GBMFBJ4I+9B<8O=$:Q! %50%'0#M3\&EHJ7J,!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>arwr-20230331xexx312001.jpg
<TEXT>
begin 644 arwr-20230331xexx312001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M/4'%2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !03CK144CE9(
MU'1LYH 9;='_ .NAJQ5>V^Z__70U8H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "H)O^/B'_@7\JGJ";_CXA_X%_*@ M_NM_OFIZ@M_NM_OFIZ
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J";_CXA_X%_*IZ@F_X
M^(?^!?RH +?[K?[YJ>H+?[K?[YJ>@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *@E_U\/\ P+^53U!+_KX?^!?RH ;:$E6S_?;^=6:K6W^K./[[
M?SJS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDUKT4 %%%% !1110 4444 %%%% !1110 5!-_P ?$/\ P+^53U!-_P ?$/\
MP+^5 #++_5#_ 'F_]":K55++_5+_ +S?^A-5N@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *@F_X^(?^!?RJ>H91^_B_'^5 $5E_J5_WF_]":K=
M5++_ %*_[S?^A-5N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ***HZQK%CH.E3ZEJ,ZPVT*Y9CU/H .Y/0"@"]17)V7BG6M0T'
M^V[?PUFT=#+%$UYBXDCQD$($(R>PW=ZAU?QO=V/B[3/#MIHZ7-SJ%M]HC>6[
M\H+@,2I^1NR&@#LJ*Y;5/%5_HOA'4=:O]%$4]E)M-L+G*R+N4;E?9T^;T[52
M7XA"V30)=5TM[6WUL)]GFBF$JQLP4A7R%(^\/7O0!VU%<=K?CBXT,P-/H4QC
MN;\V%N3.JM(VX@-@CA3C@U+K?C&Z\/Z#J6J7^AS(MC)&FU9@5E#X 96QT!8
M\4 =917(ZMXUFTBWT S:29+G676)(8[@8C=L8!8@9'S=:NW7B.[TZWU.:_TA
MXH[*S:[#QS!UDV@DH#@8;COZT =#17)1?$#3$\$6_BB^1[6WN"1# #OD=LD!
M0.Y.TU8M_$&MFUCO;KPS)#:R%?E6Z5YT4G[S)@  =2 Q(':@#I:*QO$OB73_
M  KI8U#47VQ&5(@ >268 D#O@98^P-2:CJEU;SVD5AIK7PN(WD,BRA$15"XR
M3Z[N* -6BN1\+>-9_%-K:7UOHDT=C<3/"9C,K&,JI.64#H2,9]33M&\=6FJ7
M_B"WGMS91:&Y2YGED!4\L,CCI\A_2@#K**XZ#QO<WGA^X\16NB.^C0AW$CW
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M0+M"J%/;'%)Y4>,;%QUQB@#D](\:Z'):Z+IMCJ-K>7TZQPB&*7)7"98G&<8
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MU[Q%<V^MSPBWU\W7V>&0&.=!(6!9>I!QP<X^M>Q*H484 #T I%1$^ZJC/H*
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M]];K)9H)+E3(,PJ1D,WH,<\TJZKI[P13K>VYBEA:>-_,&UHUQEP?[HR.?<4
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MQ9XHRRHX4#.6)S]%6O4** /-+[1KZYUJ6UTZUFMEG\)M:QR")HXUF+C:I8#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI'"A<D,1T''05S4WB77[#0=;UN74K65-*U&6V^S26X031HP& P.0YSP>1[4
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M:REID1T97&1\KY_(T =516:VO6":I_9Y>7SMXC+B)C&'(R$+@;0V.<9Z5I4
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M&DDD(P,*6^0;3D]]W'K3EL-4UJ^T&YGTR]T\Z+!+YRNR'SG:-5"(0WS#J<G
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MB90BJ2.>#\I/..U5O&FC^)-9;6+:'2[J:WN(+=K,1311HK*5+^:-P+/P0,Y
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M@%L#H,D#/U->=#QG>:E#X.U1[:^MQ>7,V^WMCN6=1$^!M4DGG;][ &"3@<@
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MM+9I7;9C<I4<A@3CVP<XJ;P]XGGUW4M2MVTFZM8K258P\VP$916PX#$@_-T
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MJ[NM/>TU.YFL;9;B9XX P\O:3O+9 Z ^F3TS0!U%%55U&U;2AJ8DS:&#[0)
M"?DV[LX')XK%B\:Z?(95DM+Z&1+'^T%B>(%I(,XW *QQVX.#STZT =)17,6O
MCC3[R=X(;+4_-^QF^B1[;:9XAC)0$\GD<'&>V:T;#Q%9:G8Z7=VJRO'J7,(P
M-R@*6)89X Q@]>2!WH UJ*S[[6;73]2TVPF$GG:@[QP[5R,JI8Y].!65<>-K
M"V2S)L[]WN[J:TCCBB#-YL3%64X;U4X/3C/% '2T5R$WC@RVEM-8:1>2R-J?
M]GW$3F-7@=3\P.7P21TP<=R?6R?&UH-:ETD:9JK7-NZK<%+;?' &3>&=U)4
M@CO0!TU%8%IXOTV]_L+RDN,:TLC6I9 ,;%W'=SQP#ZT0>,-+GU&UM!YRK=R/
M%;3L%\N5USD#!W#H<;@ <<9XH WZ*S-6UN+2I;6#[-/=75VS+#!!M#-M&6.6
M*KP/?)[9K,3Q7++X@MK!-(NQ;36 O3,VP,@)4<KNSQD@C!.>@- '345S%EXV
MM[Z18UTO4(I)K5[JU258U-PBXS@;_EZC[^W-0:;XW%QX=TN_NM.G6\U$$V]M
M&8P9<+N)4L^ H'=BOTY H ZZBN63Q[IDO]F+!:WTTNHO+'#%%$I99(_OHWS8
M4C\L<YQS26OC_2KL6SBUU&*&>Z^Q&66WVK%/DCRVR<YR,9&1D@9SQ0!U5%<W
MJ/C73=-O3!+'.\"7*VLUU'L,<,K;<!ANW?Q#) (!XSFHI/'>GQR3 V.H^5;W
MXL+F<P@1PN2H!9BW*DL.1G&1D#(R =317.Z1XDN-2\5:UI#Z;+#%IQB43%D.
M2R[LG#=",8P/K@\5:U+Q EA?BQM["[U"[$/GR16H3,<><!B791R<X R3@\<4
M ;%%<3K/B*354\.KI$-Y<:?JDS&62VE6%V14=B@;>K*P*Y/3H1GM6V]Q'X5T
M6VBFFO\ 47,RP0F0^9-*[L=H+' XZ9..!R: -NBLK0]?M==2[\B.6*:SN&MK
MB*4#*..V02#U'(-9.H>/]-TZ745ELM1>/39EBO)DA!2+=C#9W<CYAP,GVH Z
MNBN=7QC9#^T!<6E[;264"W)AEC'F2Q,2%9%!)Z@C!P1QD"L_5_'R:?I&JSQZ
M;/\ ;]/>&.6UE>/*>:0$8E6(QD] <_3K0!V5%<UJ7C.UTMI%EL+UY+>)9[M$
M\LM;1G."WS_-]TG";C@4C^.+ :G%86]AJEU),D,T;V]J71HI?NR;@?E48.=V
M.E '345R.D^(;2"TNC;C5[^:75YK403X9UE W,BDD!8U .,FJFL^)O[3TSPS
M?Z5/<017.NPVTRYVL0"X=&P<$97L2#B@#N:*P?&6IWNC^$M1O=/B=[J.%O+9
M=N(SCACN(R!^/T-8T>K+X36=IX/$%UOMA=3P7$R3"T1,JSAV?G<>=JLQXX H
M [>BN>O_ !?9V:*T-G?7V+9;N46L08PQ-T9LD<GGY1DX!..*-/\ $DU_XLU#
M25T^86]K!!(+@E0/W@<Y(+9 (4 #&<YSCB@#H:*R=3U^+3[V*PAM+F^OY(S,
M+:V"[A&" 7)9E &3CKDGI6;+X]TD6VFS6\5Y=?VDDAM4@AW,[Q_>C(SPPYZ\
M<'F@#J**HW6JVUCHYU.\WV\"QB1ED7YUSC"[1_%D@8'?BLL>,+5&O8;RPOK2
M\M;8W9M940O)".K)M8J?<9R* .BHKED\=V$EU;6R:=JS37<'GVJ_9<>>G&2N
M3QC.3NQQ]1EM]K]AJ6E^']2CN-4MK>\U")8OLZA69R6'ER@_P$@@_2@#JZ*Y
MWPYXDN=<U/6;:;3I;6.PNO(1F*'.%4D-ACSDD\<8QSFA/%##Q5J6EW%D\%I8
MVR7$EX[H% .\EC\V0N%],YSG YH Z*BL"P\66E[?VEK):W5H;Z,RV+SJNVY0
M $E=K$@X(.&P<=JWZ "BBB@ HHHH **** "BBB@ HHHH **** "HW_UL?XU)
M3'^^GXT 5-*XTJV!Y^05>JEI/_(+M?\ KD*NT %%%% !1110 4444 %%%% !
M1110 4444 %%(K*XRK!AZ@YI&D1"H=U4L=JY.,GK@?D: '4444 %%%% !112
M,P52S$  9)/:@!:*** *FI-?KITYTR.W>]VXA%PY6/=ZL0"<#KC'/3CK7/\
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MBMXXX8U2.-1M1%    Z ?2@#F/%_A3_A*+W2!,D;V5N\WVA6<J^'C*ADX/S
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MSUKM:* /-= \(^(;'5=,OKNTT_SHX)X+VX^V.\L[.5_>DE.?N\+G@=QTI_\
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M>6%O;V\_FL'1XW=FSA> 1(1D'(QTKFY_ 6LS6WB"&&STRSCOX+/R(HKEW"O
M^[!)0$[N<L><GH>M>C'4K4:NNEEV^UM ;@+L.-@8*3NQC.2.,YI-4U2TT;3I
MM0OY#%;0C=(X1FVCUPH)H X^YT#Q GB*?6(=.T>Z&HP(MQ:W4A(MI57 97V9
M9<=1@9]NM;VEZ5?VGB&XO+C[.T#Z?;6JO&=I+QF0L=F,*#YG !/2MT$$ CH:
M6@#SJ3PIX@BM[J)(;*ZMKC7)[Z>S:X9%N(7 VJS[>-K<E<$''?NMGX/UJ/0]
M,LG@TV!K#7O[0"0RL(S#O=L*-GRXWX ]!U%>B44 8_BK3KO5_"^HZ=8F);JX
MA,<;2L54$]R0#_*N>\3>&]?UJ9W":==1/IYAB@NIF5+:X;AI  AW\'@G!&.,
M9-=9:ZM97NHWUA!*6N;$H+A"A&PN,KR1@Y'/%7: //\ 2_#WBO0+V&[LETRX
M>ZL8+:_CFG<!98DV+*K;>01C*X']:W-/TC5;'QA>ZB_V6>TO;6WCEE,A617B
M#Y(3;@@EO[PQ7244 <UJ>E:C;^+8?$6FPQ7;&R-C-;22^40N_>'5L'OD$&L_
M0?!][HDNADM;3_96NY;IM[#:\Q!^08.0.1V_6NUHH Q/%FC3Z]X<N+&TF2&[
MW)+!(XRHD1PZY]LKBLBZT+5]9OI]3N[>WMKE=*EL88!.6#228+,6 X48P."3
M[5V5% ',VNB7\6N:+?.EL8[/3'M)0)"2)&,9ROR\C]V1GCKTK-C\+:POAGP]
MIVZU2XT_4X[N=EF;:8UD9B%.W))#8P<?6NXHH YWP_H]_I.M:[+.+=K6_NS=
M1.DAWC*JNTKMQ_"><^E4=5\,7FI:[K@81C3]6TQ+4S"3#Q.N_P#AQS]\=QT-
M=A10!QVF:%JTDOAM-2A@@70XR#)#+O$[^7Y2[1@$#!).><X SUKL:** "BBB
M@ HHHH **** "BBB@ HHHH **** "F-_K$_&GTQ_OI^- %32/^07:_\ 7(5>
MJCI/_(+M?^N0J]0 4444 %%%% !1110 4444 %%%% !7"03ZI_PF;V&KW.IV
MHNI;A;)X'5K::+:2H&!F.15&><Y()],=W65;^&]+M=1^W10R^?YLDR[[B1T1
MWSO949BJD[FY '4^M '":&UQ;>"_"]M#J>HO/?[F^SQ./,F(0G D;B- <$GD
MFJ=A=ZAKMGX!N-0U"Z\^6^NHY6CD"Y,?FJIX R<#&<>OK7=KX&\-K906@TT>
M1!.;B)?.D^1R,'!W9"D#E?N^U.'@GPZMK;VR::J0V]PUS"L<CKLD;J00<XY/
M'3VH YK3-0\1ZWJ$VJ6U[:06]MJ;V\L,MX0JQ*^S88A%]\CD'?U([<5TGBR[
M>WM;&&*YN8IKF[6)8K4+YL_RL=BLQ 0<9+=@I]:F;PEH+:^-<.FQ?VD#GS@2
M,GIN*YVD^^,U:U?1-.UVVCM]1M_.CCD$J8=D96 (R&4@CJ>] &-X!U"]U'0+
MA[Z6226*^N( 9'#LJJY !8 ;L>N*P[M]86VU34(]?OE:TUE+>&';&8]C21*0
MPVY88<XY%=MI6BZ=HD<T>FVJ6Z32F9U4G!8]2 3P/8<55/A71FLI[1K5V@N+
MK[9*IN)"6ER#NSNSU4<9QQTH YF6^O=&B\7VUUXBN1#9P0317MQ"LKP&16W8
M50H/*C X )K U:;4[G1/&NG7MQJ$<%O:VTT$<]PKR@/O#!BHZ':,KDCWKT>Y
M\,:/>3:C+<V?FMJ,2PW8:1]LBJ,+\N< CL0 :KIX)\.QQW*+IB8NH!;SYD<F
M1/<YR3S][K[T <]J']LOK\OAS2-09#9V"2Q//>F-RSLXWMB)]X7:HQP/KGB2
M*/7-4\7"T/B&6&!-+M+N7[($*/*78-LROW&"$^O([<5N7?@?PU?0V<5SI,,B
MV8Q"2S!@,Y(+ Y8$DD[B<DDGK6C%HUA!J[ZK% 4O'@%NSAVQY8.0NW.WCZ=S
MZT </_;&H'3;Z"35[L3'Q%)90^4BF:9  1$A.%3_ 'CT />J U'4=0\(.FIR
M,\UGXHBM5WL'956=,*6 &XC)&<<UW,W@W0;B"XAELF9)[K[8^;B3(F/5U.[*
MGG^'%-7P5X>2UFMH[ QPS7"W3K'/(N95Z-D-D$'GCOS0 _QE UQX-UA%GE@(
MLY6W1$9("$XY!X/0]_I7)N]W%INC:?8:UJ<LDFFM>"%&19N5&UWD(VK$I.,8
M))QUQ7?ZAI]MJFGS6-XC26TR[)$#LI8>F5(/ZUCWG@G0+Z.UCGM)"MK ;:,K
M<R*QB/\  S!MS+[$F@#EM%U_5/%KZ+IDNI3:?)-HPU"2XM=H>:7S#'C!! 48
M+$#KGMBM.RM-3;Q[8?:=;GG$6D9G\D(L<D@D53A2IP#@DX.<@<@<5I7'@'PW
M<:;96#:>4@LF)M]DSJZ9.6&_=NP?3-:+>'=,-[97:6YBDLH_*A$,C(H3((4J
MI 8 @$ YYH S/$<NI'Q'H-C9:G+9PWAN$G"1HQ(6/<"-P."/R]C7-0>(=;ET
M32]+>YD-]<ZC=6+7'F+%*5A+@#<590YP.<<X..3FO0+K2K.\U"ROIXF:YLBY
M@<2,NS<,-P#@Y [YK-N?!N@W>DS:9-9%K66X:Z(,SEEE)R75B<J<YZ8ZGU-
M',I?^((6TGP]JVIK;SWE]/$;NWE1YEB2,.B$E0HD.X G'0 ]ZLZG>:M9R:7X
M=CU7[7<W$EQON%F6"8JFUDCW8(W[9%).,D#WK<G\%Z#<:&FCRV6ZU23S5)D;
MS!)_?WYW;O?/MTI]WX/T&]T>'2IK!3:POYD6UV#H^<[@^=V3W.<GO0!RVH77
MBFTTC2WNIKJ2&V,XU";2GCDF3:0(F8,/GP,[P .>>V*-2UV^CO\ 2]0;4[Z/
M1+B&V\B_MHD:%W9OG$Z$%EW# !&-N?K73S^#M%GMK>!8;B".W0Q+]FNI8BR$
MY96*L"P)Y.<\Y]:?)X3TB26-O(D6-%C3[.DSB%UC^X&3.TXP.U '*3:[JH\3
M6EQ:ZC/=64FL?89-J(ELJ88>6 ?G:0$<N,#(Q[58LT\3Z_#KLMKXCDM7M;^[
MM[6)+:+!VG"!V8'('L >>IK9E\!>'IKMKEK257-R+L!+B1527C+*H.%)QS@<
MU9326\/:?J,FA6S7-W<S&X,%S=,%>1B-QW'.WC)X':@#+\(Z_<>(5T_%S)OL
MK/9J:,B@FZ)VE6&.""DAP,?>7L:77H+B7X@^'$CO[V"-[>Z9DA9-H*>7R0RG
MKN(/?IC')K:T#3I-/T]VN8H8[VZF>YNA#]WS&/3.!G PN>^W-2ZCH>G:K=6=
MS>6YDFLV+0.)&0J3C/W2,@[1P<CB@#@H_$.K2>%X/&$6HRL[ZEY+Z=A3'Y)G
M\H1@8SO PV<@YSVXKI_'%]=V.EV!LKV6TFFU.V@WHJMN#N 0<CI@D\8Z#WJW
M%X3T>#5#J$5NZ.TAF,(F?R?-/_+3RL[-_OC/?K5[4])LM9MXX+^$RQQRK,F)
M&0JZG*L"I!R#0!YQJ>HZ_81^,%C\07;KH1AFMR\<>Z4NBN5D(7!7.1@ =>M7
M?&.M:K#!?W6FZA=">QTV.Y,%LJ+'"S$DO*SYW9 X0#/!Z9!KL+CPQH]T^J/-
M:%SJBJEX/-<"4*-J\9P, 8R,51U#P%X=U.<S75D[.UN+9\3N-Z 87=@_,P'0
MG)_*@#E]4UB?3_'NJ0QRO:"_M["!M1"!DM2?-P2#W8_*,C&3R>QTM=NM>N]>
MFT'2;J1)+.PCN%F$Z1O)(Q=0S@H0R@J,@!>OTKH&\(Z');W$$ED9([FVCM9@
M\SGS(T^Z#SU&3SUYZU7OO V@:BEFMQ;3,;12D3_:I=^PG)1FW;F7V)^E !K,
MES=_#N]FDN5CN6TUI6FLGRNX)N.QB/NDC\C7*/IUQ-K_ (,M$U6[BDDTJX/V
ME0GF*"L9PORX'IG&<>_->CRV5M-8/8O"OV5XC"T2_*-A&,#'3CCBLVR\+:3I
M\]C<0P2F>QA:&WDDN)'*HW4<M@_CZ#T% ''MX@UK4+7PUI4,\GVJ^MIY)IXI
M$A>0Q$* K,K $\L0!V&,5V?AN35'T6-=9DMY+^-W21X&!4X8XS@ ;L8S[YJK
M=^"M O=(M=,ELV%O:.7MV69Q)$Q.25DSNY)YY_D*UK'3K33=/CL+2!8[:-2J
MQ]>O)SGJ2222>22<T >:WFKZF= UZTUC4M4M-5BTJ6=[0I$48 X$D,BJ,H<A
M2#E@#UR,UH:Y?:EIMJEG8ZWJ,UQ%I<EUY4,,)<$#(>1V4*(QC  &X^]=/'X0
MT>.&>%HIYHIK9K3;<7,DNR%NJ+N)V@X'3^Z/056?P!X>D6$/;3L8X&MRQNI-
MTL9YVN=V7 /0'IVH YK3]1O;[Q'9:O+?7N!X9BU VL.PJS,060#;T;:.G.>A
M'2K&FW_BNYL[?5Y;N..RO+"25E::-MDACWH8E" \8((8MQ]*Z.T\%Z)8S:=+
M;031OI\7DPXN'Y3.X*_/S 'D \"FZ=X'\/Z5<W$]G9&-IU="OFL5C#_>"*3A
M,^U '+:;>^);J7PF)?$4F-;T]Y)PMK&/**QHP9./O'=R3D=< < )9^*M;N=!
MT&T69I;^^O[FUDN04C++%YF,$J55CM7^$]#796OA;3;.729(A/G2HGAM TS$
M(C#!!&>>,#GT%5W\#Z#)H)T66U>2S\XW"[Y6+I(3DLK9R#DGH>Y]: .;GU#Q
M3!=Z'IMSJD<$\^HS6TKQ".9FB\K>N_Y0 X![ #H<'.*HS:AJ]_I45M<:Q=;[
M7Q6NG>?&L:O)&'4J6&W&0>>!CCD&NV3P?H\2:8L<4R?V;,9X")WR7/WF8YRQ
M/OZFD?P;H\EA>6;1S^5=WGVZ0B=PPFR#N5@<J<@=* ,34-4U32_%-O;ZC?WU
MKIS3V\-K=+#%+!<9 #)-A0R2,V<,,+TXXYT_&^HZAIMCI;Z==?9Y9]3M[9V,
M8<%';:<@_GQCI5P^%-*-TLQ2X*AXY# US(T3.@ 1BA."0%7GU4'K5O5M&L];
MAMXKU9"MO<)<Q[)"A$B?=/'7'I0!Y]?ZQXCTV#Q5_P 3V2;_ (1^2*6-GMXP
M;A717V28&-HY'R@'GK5SQ?XEU*U34+C3+^<26%C%<-;V\49CB9LM^_9QR& &
M%4[NOM747/A'2;L:P)HYF&K[/MG[YAOV# QSQQQQ4%]X$T'49IY+F"<FX@6W
MG5;F15E51A2Z@X9@.A/2@#.U>?4-:E\16L&JR6*:=:*JQP*C&1WB+EGW*3MY
M  &.C<UF1ZCKUZ;'1=%F\EK?1+>X!61$+.X(!.]&RHVC@8//6NEN_ V@WLR2
MS07'F+;BV=DNY4,T8Z+(0P+_ (YI+OP'X>O([)9+6939)Y4+I<R!Q'G.PMNR
M5]B>.U &SI<EW+I5K)?B 7;1*9OL[%H]V.=I/:L/5M2OHO'6CZ9!<M%;75G=
M/(H53EEV;6Y';)]JO0:!%;>)5U2#,,:V?V40I(VPC((^3[J[<<8Z[NV*M7&C
MV=UK%GJLJ/\ :[1'CB8.0 KXW CH>@H X+PYKNO23>"[J\U>2ZBUF*9+B!H8
MU4%4+*P( .>.><?2MWXB_P#($T[_ +"UG_Z-%:]IX7TFRCTN."W8+I3.;/,C
M'R]X((Y/(P2.<U=U#3+/58(X;V$2QQRI,@W$8=3E3P>QH XS4?$&M6UUXZ2U
MF,ITV*V:T1D7]UOCW.1P,]R <].]4KVXU&Y\.^-!]MN[G18M-<6<ES%AI&:)
MC)\Q4$A2!CZD=N.D\0^&DN;74YM/M$DNM2,*WB/.R>='&?X3T1]O .*S],\'
M9>>VGCU"#29K=HIK6XU.2;SB64\88[!@$$@Y.XB@"!KC5+*?4+*[U>Y>S.A?
M;1+'&BO"ZDAA'@9 VXZ[C[YK?\&PO;>"]*,EU-<EK.&0&7;E 8U^4;0.![Y/
MN:MCP_IXOX;T+/YL5J;09N'*F+T()P3[GGWJ71]'L]"T]+&Q$H@3H)96D(X
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MQ]N#STKAM6T2?Q&8FT.TN-/$.BS6GF3PO;Y+A=D0# $@;6)(R!FJ4FEW&O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK:B6::/[-<)<H8B!EEZ Y!XYJ_110 4444 0P6L-NTK1)M:5R\C9)+-[D^V
M/0  <"IJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ IC_ 'T'UI]1O_K8_P : *FC?\@:R_ZXI_Z#
M5^L_1?\ D#67_7%/_0:T* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTF*VANO,4*94D+[2 =VT\ \=,T =-;>*])N%O2TLUL;./SIEN[=X6$?.'"N
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MPZ T,YP"J3%D.SKU^0_F* .@E\6Z+%:V-Q]JDE2^B,ULL%O+*\B  EMB*6
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M5+"PACETJXDD7Q-)=XC*-B)F8B3.[IAOKUKH_&\%U<^&6BL[2:ZF^U6TGEQ
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ME-\B)M7S8!*K;URW)(7..I)KKO&]E>ZCX,U*UT^)Y+MXP8D1@&)# \$D<\4
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M#T%$6-%1%"JHP% P /2EK@K7Q=JLN@033/91W U26PGF$3-N",P!CB!+,S8
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MF&YE\F"03KMEDR1M4Y^9L@C YX-3W5U;V-L]S=W$5O!&,O+*X15'N3P*\_\
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M'^^OXT 5-*_Y!5A_U[I_Z"*O51TK_D%6'_7NG_H(J]0 4444 %%%% !1110
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MI7;D84;F"\ MGC/')J6Q\*6E@FAI'=73)HZ/' K;/G#(4^?"CD ]L>^:WJ*
M,#3?#'V/58=0NM3N]0FMH&M[=K@)E$8J3DJH+'Y1R??U--UGPC;:SJ,M\VH7
M]I+-9FQF%K(JB2(DM@[E)!R3R,5T-% '-V/@ZVL+Z"\74;^26'3O[.4R&/\
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M+X<:V7C+C[$R[7/()& ?J"<_A745F>(=&3Q!H%YI,DS0I=)L:1 "0,@\9^E
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M=(2RAN(;AY-I9I'=<;BVTC]V>@[BMN\U73M/BCEO+^VMXY?]6\LJJ&^A)YH
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M;9=2M#<1 F2+SUW)CDY&>,=_2@"]15"VUO2KRZ6UM=3LY[AD\Q8HYU9BO]X
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M1$UQIZ:>EJTLJO(1.K;@ V,XV8SR>]36^KZ9>71M;;4;2>X""0Q13*S;3T;
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M%O!'++-)$ B11L[,=P( "@GM6G?.P\)7#I9O=M]A8BUY5I?D^YZ@GIZUK44
M>*_O)K*^6.UOKF:Z\,F"*/\ LYUAC8$D0H-O\'3+$Y/0YXK?U/38- L_#6I6
M>FS6VG1(QO\ ^SK91*DC1J%D9-I)Q\X)QD;J]+HZT 87A.RL[+1-EA%>1VTD
MTDJ?; 5=MQR6VG!4$Y(! Z]!FN'T_17C^&VH20Z7+_:L=](9 D&VX:+[2LC*
M,C)#1J..AXZUZK10!YD;;1M6L;^_MI-=A^TRVKG49;8C9-'DHWE[1D)@!C@C
MD<\9&;)*AU+PK)KMK:K"-5O<S) RQW7[O*S;",C+'/IQD<5Z_63JFA1ZGJVD
M:B;B2&7397D0* 0^Y=K Y]L]* //!IC6%U'J=O:3CP[_ ,)$;DVXMR0J&(+Y
MP7^X),D<<  BH-=TLW.IWEVL/FZ)?:_I[0Q["4<A<3OCT/()Q@X->P44 >82
MV%N=3\:0E[BP@%[930SVMOO$3JBG?M P0&7YOQIZR7NH:%H$US:*9+?Q%'NN
M(;9HUF3+?OMI'RABW/;/UKTRB@#Q^_TN"YTWQ9H\VER/K=_J\LM@#;'<5.S9
M('Q@*,,<Y[&MCQ-INIWLWBRVLXYGGDTJS57\HXGV/(TB*2,$E3C'^U7I%% '
M%>#SIE]K-SJEA%JYEDM4BGEOHC$JD'Y8PNT L.<D9 SUYJ?5HG/Q-\/S>3(8
M5M+E&E$9**QV[06Q@$[3^5==10!Y/]GN)?!O]@BRN(O$\6JB5&\HAB_G[_/#
M]"NPD;L^U;O@K2+#^W_$]Y/IT']H1ZS,T4\D \Q8V5<;6(S@G?T]Z[NB@#@O
M%\GV/Q;9W.H+J/\ 9,]B]KYUG#YOER%LD,NUCA@ .!VK$U6V_LO3K%]*@O[:
M>&P6%=,OK4S+>PEV(B+*"4D'/TW#W->L44 >9ZY.T+^-H)-&FO;BZA@GAMC;
MRM'*HB13\ZC'# \9!.TUDS1SW4?C&&-=0OI+W2[9H96T]XA-MW[MJA1@#( !
MY.."V,U[%1G- 'G\5G87_BR/4?#]FT-K;Z7-!<RI;&))"Q'EQ@$ EAAB>.!@
M=ZIZ+;WEOHWP[_T"X\ZVE=9U:!@8089$.[(^7DCKUKTRB@#RBW,UO_:=E"LM
MYICZ;=DQ7-F5N+%G^8PD@8D#,1@#/W>..NOHUG#::SX-:WT]XD&D313.EN5"
M.1$0'..#E7Z]\^M>@44 >3Z5ILOV3PS;W6G3GRM>NI94DMF(129=K-QP,LI!
M/K3+X&QTJZG9+JV6#Q6;JV'V5S&5QG+*!GRS\_*@\X->MUEZUH<6M);EKN\L
MYK:3S(I[20(ZD@@]00002.10!@^!;C29[C6)[.Y$E]>7/VJYC\B2(1@C:H7S
M$4L..N.I/2N4\;&::_\ $<!LKZ$F2TD5+2S>3[6J%?WDDFT@*N" JE3D'K7I
M6E:*FEM)*U[>7UQ( K3W<@9MHSA0  H'/8#/?-:= 'E-S8--8>,+@:;<&6?5
M;6:!C:/O>/=$<J"N<##9].<U-XBE\NV\;:9>:9=W%]J"[[%X[:203IY2A K*
MI *,"2./UKU"@D#J: ,+Q"PO/ VIF**60S:?*(X_*;>Q*' V$9SG'&,UR=AI
M,$?B/P<_]DM'!#HKK+OMB1&Q5<*QV_>SOX/.2?6O2:* /)-/>6PT?PA%<6%W
M 4-Y&UVME)+-;*7^6-4VG:74@ D' ''M9\&&0:%X*26UO%DM+JZ2;S+:0&,%
M)0,DCI\R#/3/'8X]2HH \CTG3YX/#/A'&G7,=Q'XA>6X_P!%=75"TOS-QD##
M)R>V/2K$\[V>CZ[:G39Y)O\ A(FE9FMI&%O&T@*3X ^<#;D*#Z9XKU2B@#QY
M1/=^'?&]FD.JR^9?0R0M-9LLLG^K!< (!GY,@ <  X%:WBO2Q>Q>-Y(--DFN
MI;*!(7%LQ9\ Y"''/.,X]J]+HH X*]AFD\86EP+:X:W'AZ9)'\EMNXLI"GC[
MW!^7K[54\-Z:ML/ K-IL]K-#I\Z3!(77:YC7/F$# +$,<-W]\5Z13)8DFA>)
MP2CJ58 XX/'6@#R7PY/H]S/H-M>WQ2/2KB9X/M-K*LDC2L0JR,R; 1NY(8Y(
M%>NUSMGX2BM(;>U;5]4N+"WQY=G-)'Y8"XV@E4#L!@8!8].<UT5 !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !2$9Q2T4 5;'BRM@.1Y:
M_P#H-6JJ:<=VGVS#H8D_]!%6Z "BBB@ HHHH **** "BBB@ HHHH *\T\2:I
M=:[%X<O6L;=-+EU^V2W9V)F8!\!R,8 ;#<=<8/L/2ZX;_A ]06"TL8]>7^SK
M"_2^LXY;7?(C*Q8(S;QE1GTS^E #KO78M!/B?4O[*MH;F"YMXI9HV9A*K*NV
M23"@@*KY( /0\FK2>*[MX-+@CCL;B]U.YDCMG@G+0F%!N,N>O"X^7U.,]ZOG
M0K^&YU>YL]42.6_FBF7S+;>(]BJI4_,-RL%QV(R>:R%^'_\ H5O(E^EGJT%Z
M]]'<6EN%BC=P%=5C)/R$ <$YSSGM0!#XC>\NK;P]+JNGQVUY#XA@C4JX<,NX
MX=2.0&&.#@^M6+[QK<P6&I:Q:V$<^E:9=M;7*ERLQV'$CJ,8P">AZ@$Y%7[O
MPQ=7EG8I/J[RW%OJ"7[S2PY#LO154, B^PS^9)JE+X'=EU33XM2*:+JEPUS=
M6YC)E#L065),X56QR""?3K0!8MO%;WOBV31X!;*L3C<DK%99(C'O$J \,NXA
M<#)ZFJ5OXXN9='TF]:RA#7FL_P!F2*'.%&]UWC_OG.*O:AX3GU36K2XN[Z%[
M.TNUN[=5M]L\3+C$8DS_ *LG)(QGMFJ*_#^6-;6"/6W%G::F-2AA-LI._<S%
M6;/(RWM^- $8\;ZJKZS=2Z1 -+TBXN(;F5+C+D1QAEVJ0,DD@'TS[5I>'O$V
MH:KJLEG>:5+#&(1(+A(9E1).,Q-YB+E@""".#STI]MX0B6S\0V5W=&>UUJXD
MG=438T>]0I .3G  P<=<^N!8T'0]1TME.H:]<:D(HO)A5XEC"KD$EL??;Y0
M3TY]30!#J>OWXUJ?1]&M(;B\MK3[7()W*!@20B+CN2#R< >]1R^(M3N=0NK#
M3-/@-U96D=Q=)<S8VR."5A!7(S@'+9QTZYIVK>%KJZ\0#6]*UF73+QK<6TV(
M5F61 VX<-T()/-,E\*7%MJYU32-2$%S/:I:71NHC,)53A9.&4^8!D9)(.>E
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MH]&?2YTC0AG#8!93GCH/7O0!FF[U;4/'OA*\U#3[2U@F2Z> 1S&24*8LXDX
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M0J"R;L[3CD9[UST6@:F-;T;4;G4X[AK.*=+C=%@R&7:3LP?E *@ '/'YUTE
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M@U)=EU%D[ $5\\G: I48VMZ\]-XS9O[7\)Q2,1:2:LOF#/#.$9HP?^!#/U%
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M*Y&>X_&LO2KEK7P'XN.9K?Q3"DTFI,'_ 'AEVG9(F,84@97'3GZT >H$X4D
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MW;FVG:/FR!^-<]HUQJWB9O",&JZCJ-O]OTRZ-RMO<-$9=C 1OQT)!!SW^G%
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MSCTH ]3HK/M;>TCUK4)XKV26YE$8FMVGW+" #MPG\&1S[UH4 %%%% !1110
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MY!9:0US=Z9.D*PBX5?/W*K9W, %X;WZ5T->)ZB-&/A3X@Q:-):+:"\@, @D
MC!*Q@[><8W%AZ5T.M?8[;Q\E\6L-3,M]:0F$MMNK%R%V-&?XHR"&(&!R?0X
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M2RJ_DEPJAE^8@*6<'@].U;FH>*[?38-:EFLKIAI*H\H383(K#.5RW;GK@\4
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MK(6"C<0WS EEY3=P:LZGXTL=+NYXI;6[>*WFB@GN%10B/(?E W$%NV=H.,T
M;\5I;0$&*WBCP2WR(!R>IH^RV_F22?9XM\HVR-L&7'H3WKEQXFN+J^\3V5QI
M]W!:Z9'CSX7C#@&+>2/G^\0<KZ8YP>*FL?$5O;Z1I4&G0:EJ\\UBETB-(AG,
M) P\C.RC))]<DY]* .@%A9J(PMI !$VZ,",?(?4>AJ66&.>,QS1I)&W574$'
M\#7-CQSITJ:4;6TOKE]4$OV:..-0Q>+AT;<PVD'C)X]ZUM#UFWU[2TOK9)(U
M+,CQ2@!XW4E65L$C((H LKI]DL+0K:6XB<Y9!&-I/N,4JV5JDPF2VA64# <(
M P&,8S].*YR+Q[IKI>SO:WT-G8S30W5U)$!'$\>,C()SDG QGGTS5&_\8V^L
M^&_$<%J+FRO[339;E2L\9(&UMK*\3L 01TR#0!V@MX!<&<0QB8C!DVC<1Z9Z
MTU+.UC614MH5$O\ K J ;_KZ]37)P^,8M*\.6<EU;WMTUOI<%W=S#;A591SN
M=AN8X)P,FKD'B>[NO%*:=;:5-)8M8QW7V@/&"-Y.TX+@X^4CH3GT') .@6UM
MUMS;K!$(#QY80;?RZ4&SMF@6%K>$Q(<JA0;0?85R6E^([33-.TFSMK76;^34
M%GEM_.=))24;YE9BP P6&"3C&.:T;;QC8WNEZ7>6MO<2RZF[QV]L-H<LF[>"
M2=HV[&[]N,T ;C6=JZ(CVT+(AW*I0$*?4>AITEO!,\;RPQR-&<HS*"5/J/3I
M5#0];CUVSDN8K2ZMA',\#+<JJMO0[6Z$]""/PK$L?&,_G:_+J>FR6UCIUT;>
M*161R[ )A,!LEV+@@ 8YP3F@#KJCBMX(8C%%#''&<Y5% !S[5FV.OQ7>K2:5
M-:SV=\L N5AFVG?$3MW J2.#P03FLR^\178\:R>'DTZ>2W_LTW+S0NH898J"
M/F! ^4CCG)'  S0!T:6=K' T"6T*PM]Z-4 4_44+9VJ2)(EM"LB+M5@@!4>@
M/85QW@GQ3Y^C>'[&_2]-S>66]+NXY6=T4%^2=W .=Q&#V)J_:>/=(O-5L[*/
MS E\66UN"R%92OL&++G!P6 SB@#H!86:M&RVD ,?*$1CY><\>G-/>V@DF29X
M(VE3[KL@++]#VK+UGQ):Z+?6-E-;W4]Q?"3[.EO&&W,B[BO7@D=.WJ169>?$
M+1[%\7 E18S&MR69 UNSX^5D+;B1D9V@XS[' !T[VMO)(TCP1,[)L9F0$E?0
MGT]J6"W@MD*6\,<2$Y*QJ%&?7BN?U'QI8:;]LE>WNI;2RG6VNKB)5*QR-MPN
M"0Q^^O(!Z_6DN-8L-/US5;NYGU%&L].2>6%VS!Y9+$,B9^_E6!/'2@#?>TMI
M&=I+>)S( '+(#N Z ^M->PLY#(7M(&,A!?,8.[Z^M<]?^+;FWTZ*XBT.]\Q[
MNW@*.\6")'4 JP?:V0V!@XSUP.:FB\7QRZO/I8T?5/MEOY1EC$:,$63.&+*Y
M7 QZYYX!P< &W+86<RHLMI!(L8P@>,$*/0>E31QI%&L<:*B*,!5& !]*YRP\
M:V6H7T%K%97J-=0RSVID5%\Y(S@D ME<GIN S2:1XWL-::P^RV6H+'?QN]M+
M+"%1R@)*YW=>#[>] '345@>%-?N/$5A<W,^GR6GEW,L*AF0@A79<?*QY&WGH
M,GC(K?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@".,?(OT J2
MF1GY%^@-/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y
MOX@D#X?:\20/]#D'/TJHVD:QKDD6H7CV$;1:;-!;+;N[+(\P7+L2H*KA5P.3
MR>:ZB^EB@L+B::)IHXHV=HT3>S #. O<\<"FZ=-#<:;;3V\#00R1*Z1.FPH"
M,@%>Q]J .:O?"]_<:%H'DRVT>KZ*T;P\DPR;5V,IXR R]\9!K.OO M_J:W^K
MRSV]KX@GN;>Z@\IR\,+0*509*AB""V>.XXXY[^L^ZUBUL]8L-+E$OVB^\PPD
M)\OR+N.3]* .:U3P]XEUW1()+V]TZ#6K.YCNK06Z,8%=000V[YB&#'MQQ3[W
M0_$NH6-E>RSZ9%K-C="X@BA#BW(VE&5F(W'(9N0!CCBNRK/UG6;/0=-?4+]G
M6W1E5F1"V"S!1P/<B@#D[GPSXEO;+69)I=+6]N[JUN[=%:0QHT+(=K':"1\@
MY [FEOO#OBB_MO$@D_LE9-4MXDA5)9,1LHP=Q*\C!)Z=0.*["'4(IM3N;!8Y
MA+;HCN[1D(=V<!6Z$C'..F15N@#E-=T77+F]TO6M)>P35+6%X9X+HLT,B/M+
M ,!D$%00<?6JNO\ AO5=?TV*UOK+2+A_()$RR20O;7&<AHV"L=H&/0G'OBNU
MJI?:C#IYMA,LS?:9U@3RHF?#-G!; X''4\"@#/U+2+N_\$W.C-<))>S:>UL9
MWSM:0Q[=Q[X)YK$LO#FN6FI:1K(%D;ZVL#IUS;"X<1R1 Y1E?9G=G&05[]>.
M>U#*Q8*P)4X8 ]#UY_,4M &+X7T1]"TJ2&:59+BXN);J<I]T/(VXA>^!TYK
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MTU1)]HBB69LH=NUB0,-T)X/% %7Q!93ZCIRVL5C87L3R 7$%Z2$:/!S@@'#
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MY!KI]+U*VUC2[;4;-F:VN$$D;,I4D'V-6)I4MX))I"0D:EV(4DX R>!R?PH
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M[RUO,"@1QG;D= 0<5TNDI?1Z>BZ@EI'<9/[NT!\M!V4$\G [X'T%7:* //\
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M&T8&">3FM'5M$U/4O^$9D5+1)-.NTN+E?-;& A4A#MY^]WQTKJ*0L 0"0,G
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M\CN,!4^8Y0'))..V :W_ !/;7%[:>%7L]/N"EOJMO<2Q+'@PQJK Y';&1P*
M-FY\4Z+9W[6<]Z$E1UC=O+<QQNW17D VJ3Z$BL[QKXK@\/:'?F"YV:E';&6)
M1;O*%/\ #OV@A03P"Q'Z5@76CZJNA>(O##6$LLFI7LLMM>*N8=DKALN>H*<Y
MX[#%5M3L-;TS3_%ND_V->Z@VK)NM;NU"LO,0CVOD@KMV^_6@#T*VO&?0(;V:
M149K597<KD*=N2<#M[5E6OBK2K#3; :GKMO<7%S;_:(YA"8O/3J&5.2.",#J
M:T],\Z'PW9[[>19DM$S"V P8(/E^N>*Y/0+:Z@/@U+C3KM#8Z;)!.6A.(I"L
M:@$_\ ;D?UH [+3]2L]5TZ+4+&=;BUE4LDB9(8#@\=>H(Q5./Q1HLMM;W$=^
MC0W%Q]FC<*V#+G&SIP<\8-9OP_M+JQ\-/!>6TMO+]LN'$<J[3M:0LI_(BN=U
M?P=J\UYXAM;-S'82/_:UD5/)O"/N].@92V/]I?>@#H_$OB)[![/[%=P((]3@
MMK[S%X5'&X_,2 #MY[]14^H>);"?PQ?ZCINLV=N(28OM4ZEDBDXX9>#GD?GW
MK&GL+Z'0-!EFL))[Z;4XK^_2.,GRRV2Y(Y/R A0.OR@5F^(=,U.]TOQY;0:?
M=L;^:$VB>6<2[4C5B.W5#SZ 4 =KJ'B/2M%\F+4]0BCF=03A2<#IO(&=BY!Y
M/'O6(WC2#3O%NN6>KWT$%A:Q6S6WR'=EU8L3C)(X!ST JC<-J.D^*]5N9M O
M-5T[6K6!8EBC#B-D0@QRJQ 53N)R>.?K5>_TK4I+SQNS:=(TE]H\5O;M%$=D
MD@C=65#Z;F7\/I0!W]U?VUII\E_+)_HR)YA= 7ROJ ,D_A7'-X_@N-0\,W%O
M<1P:5J*W)N?/3#*4C#* 3[L.F<]*Z328)AX1LK=XGCG%BD;1N,%6" $'\:X+
M0;;4&F\!?:-%U&!=+CGM[DS6_",8E56XS\I8'DXZ9Z<T =AJOB"WFT2TO]+U
MJR@BFNTB$\JEU?YL-&!V8X(YZ5I?V]I?]J#31>(;POL$8!/S;=VW.,9V@G&:
M\];2=3/@NYL!IMW]I'B'S]GE'F/SQ)O![KM[COQUK2:VU"U\<)-I-MJ"I<7Y
M-];W,)>U*;<&XCD(PCXXP#DYQC Y .QU/7-+T;RO[2OH+42[MAE;&[ R?TJE
M+XS\/0VUM</JD0AN8UECDPQ&QL@,QQ\@)!&6QR,=:H>+;">[USPO.EF]Q;VU
M^7GVIO" H5#$>FXCGMUK US2&MO%6K&^T+5]7L-5CB$"V%Q(D2;4VF.15=0%
M)YR>/F/O0!UNH>-?#>ESS07NKV\4L+JDB$DE2PR,@#I[]!WJQJ7B?1M(FBBO
MK](GD7> %9L)_>8J#M7_ &C@=>:X=98;+Q/XJTUM(NKMYM/M($CMH&E0?NF7
M8S_P@Y'+8'!.>*DTK2]0\)7%_;7]E?:I;WNFV\$4ENK3?/%&4:(X&5!+$AC@
M8ZD4 =E?>*]!TV3R[O5;:-_*6;;OR2A( ;CL2147A[Q7I_B26^CLB_\ HL[0
M_.C#>%QEN0,<DC'7C-<YX6\/7^C:YHD=];O(L&@_99)L;T27S0VS/L 0/H*T
MO!,-W97OB2SNK"YA#:M/=1SN@$<J2'*[3G)X'/&!0!J?VHL6NZCY^JV8LK2U
MC>2 KAX6);+L^<8('3V_.YI>L6&LPR2V$YE6-]C@HR%6P#@A@"."#^-<SKEL
MT^NZXESI%[>65UI=O!B!<>9MEDWA6[,!*IP<9P?2KG@P:BD=^EW)=3VJRJ+2
MXO;?R;B1-HR) 0"V#P&(!- $-KXN@LM<UFSUS5;&".*]6"S5OD;!C1SN[8RX
M&3WS6[=Z_I5A>+:75]%%.Q4;6/3<<+D]!D],]:XW5;2Z,WB[2FT>\N)-:D7[
M)((0T!!A1-S./N[64D[CV&T9)K,D\/S6NI:GI.IZ%J>JQ7QB-M-;W,J6K$1(
MF)@K@* R9R03CUXH [5O$%K8:IK3ZCK5@ME:+!^Z VO;E@V=Y[EL< >G2KVG
M>(M'U:6XBL-2M[A[<!I1&^=H/?Z<=:X/Q79WT\OCN.#3KZ8W=C:1VYCMG82L
MN[<%(&#C>,X]_0U;U*V9O$M_-<65V-.?PN8'<*T2L^\G8'(P&P>_3- '7VOB
M31KR[2TAU& W#J'CB9MC2*<X90<;AP>1D5+J>N:7HS1+J-[%;&57:,2'&X(
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH HZOI%GKNES:;J$;26LP D17*;@#GJ"#U%7$0
M1QJ@)(4  L<G\33J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** *<&EVEMJEWJ,4;+<W:HLS;R0P087CH, GI5RBB@ HHHH **** "BBB
M@ JMJ&GVNJV$UC>PB:VF7;(A)&1]1S5FB@#)LO#EC97,=QYEY<RQ9\HW=W)-
MY>>,J&) ."1GK@XS4E[HEK?:QI^J2M*+FPW^1L;"_. &R.^0!6E10 4444 9
MUGHMM8ZOJ&IPO-Y]^4,ZL^4)50JD#MP *T:** "BBB@ J*"VAM@XAC5/,<R.
M1U9CU)]34M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!@:OJ<TFOV/
MA^RE\F>XC>ZN)@,F.!"!\N>-S,P /.!GVKG-.\9Q:/J_B2#6KR]F@M;]424P
M%U@C*KC<57"C)-:6I01Z7\3=-UNX?;!?6#Z8&/19?,$B GMN&X#W'O5&?0=9
MSXNT^.Q#QZY(?)N_-7RXU:,(Q89W9&#C .>* -J?6)-+\5:?:S77VBPUD/\
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M5M(3+/&@\O*$JI) !;V&:S]/T;4K7QS9:@VFP0V:Z.;1S:LJQPR&7?M"Y!(
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M&\J"AW'GKQTYJ[X?\-ZCHM_X:22U$D5G8W,5Q*CKMCDE=7  )!(&TC('<>^
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M:Z+/$\OG31QK:&^5I(&'F0#K(HQDC\,\CBKB^)-):XM8!=$/=VIO(=T;@-"
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BC-% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% ",RHA=V"JHR23@ 5B0>,= N
M-0M["/4!]JN,>1$T3J9002&7(^9<*?F''OS2>-8WD\$:X(YWA(L9F+( 20$)
M(Y!X/3UYXKF=,N]2TN/P':+J#30:A$5E62&/(46X95!"@@ CZGN: /0Z*\QL
M/$OB(66EZA<:FDR3Z]_9C0&V10T9D9-Q(&=PP,8P..0:FN_$VK0>*;5H-0DN
M;276%TZ5$A06J*0?E#$;VE&,D@E1T]J /2**\TDU[Q+#;ZAJ)U:-H++718+;
M_94_>1F5%^9OHW&,&M4:KK.LWVNO8:I;V":3>+ (9D4QNBA6=Y&(W $%@,8Q
MB@#K(=2L[C4;JPBG5[JU"-/& <H'!*Y^H!I;_4+72[&6]O9EAMHAN>1LX4?A
M7'7_ (@U*VN?%L8U*UMTL?LWV:>:'(C$BY/"\NW91W.*R+[6]4O?!WCFTOGN
M1]C@"Q&YCCCF"21!B&$?R]_K@X/I0!Z@K!U#*<@C(-+65JMS/9^%+RZMI!'/
M!9/+&Q7< RH2.._2N.AUKQ,FC:#)-J"75UKJQ-&(+>.(VX$)D8*7)5F; Z\#
MG Z"@#T:BO-Y-7\90WFBZ9/>6EO=7=]<6[N\*2DQK'O1G"' ?!Z#'0=CS*GB
M37;.Z?P_>7<,EZ=4CLDU%8U7]V\9E#;/N[\#:.V2#@]P#OKFV@O+=[>YA2:%
MQADD4$'\#4M>9Z_XJ\0:.NL:9%=1R7=C-:/!=RQ+^]BF;:5=0  0<\@<CMWJ
M]+I&NCQKH2ZAXFEN,)=7"K#:1Q(NT1KMQ\V>)&&3SZ8/- '6:5=Z5=S:@=,:
M)I([IHKLHN#YR@ AO4@8%:5><7&N^(;?2[Z6'4[=IXO$*6"LUJNWRV9%P0#Z
ML<GK].S[KQ+XAT?3_%D,DBZC=Z6\#0S+"%(CE4$DH, [!D^_K0!Z)17*>&[W
M5[GQ'JL$U^;[2;:.+[/<- JF1V&6&Y0 =O'0?Q>HK,U6[U"V^)D\@U&<65EH
MAO3;+$C;AYA#("1D9\M3GK^% '?54NM3LK*YMK:YN8XIKI]D",>9&]!7%0>)
MM7MK7PQK-Q=I<VNNW,<$EHL( M_-!9"C !CMQ@[LYY/%:/CQ9WD\,K;2)%,=
M:C".Z;@I\J7G&1GZ9H UM0\)Z!JM^+Z^TJVGN<!3(Z\L!T#?WOQS6PB*B*B*
M%51@*!@ 5YQ/XJU[3KBX\/S2B\U$:A#:PWT<21EDDC:3[I.T. I7GCD'!Z'K
M?#4VLO;7,.M*OG13$1.60NT9&1O"?*".1QU SB@#1O\ 4;/2[4W-]<1V\ 8+
MO<X&2< ?G5JO+O%E]J.O>#]:U!-0,-E;WXMA9B%#N6.=4)9CELEN1@C P.:O
MMXB\4:IK6I/H]L3::=??9BCM"L,BICS-Y8^8&Y)! Q@#KS0!Z%533]3LM5MF
MN+&X2>%9&B+ITW*<$?F*Y&SU[5/^$V_LS4[N2Q>2>86UI+;*8;J$*=C1R 9W
M# +!CWXJA%XNU0Z#9RW=W%:1R:O-97.HI$H$"(6"G:V5&XJ!N/ S]* /2**\
MW.M>*AHUI<KJ,;-/K:V,,LEFH66 N561AD8!QGC\,9S3V\5ZUIUCKUK-,M]>
MVVIQ6-K,(TC/[U5(X)"Y&3C)&3C- 'HM5H+^TN;NYM8+B.2>VV^=&IR8]W(S
M]<&N)CUWQ/86@M=5C6WGO]0BM+"XN#$9$5PQ)=8R5++L..@.1[U;\*6]S;>-
M_%D5U>O>2 69\UXU0D;'P"% ''TH [2BN+U'Q%J5MJOBVWBE3R]-TQ+RVS&#
MM<HY(/J,H/S-45UOQ#J-[:6]OJ<%JMQH":BS?90Y63*@XR?4GKZGV( /0B0!
MD]*K6&HV>JVBW=A<QW%NQ*B2,Y!(.#S]0:XS1/$FJ>([?0[&.\CL[JXTQ;^[
MN%C5G;YM@"*1M&6!)R#@<#UKFO#VNZM8>'='T/2XYI[V[N+Z22: 1!\1S'.T
M2$+R3D^@''J #V&BO.QJ_C*XGT'39KBUTV_O8[J.XS"DVQH@"KX5B 2&4[<X
M'OTKI/$>L76@Z%:NI26[GG@LQ*5^57D8*7V]\<G% '045YWJWB;6_#ESKVFS
M7:7TMMI']I6ER\*J5^8H4<+@'D9&,<5H7/B#5AK[V$$D>UO#[:@@\K<1,&"C
M'J.>E ':45SOA&76;[2+/5-4U"&9+RR@E6"*WV>6Q4$L6SR3GI@ =JR%U_5H
MO';Z=J%W]@MY+D):036P,5U%L_@F'_+3=_">W% '<T5Y[IWB_5[K1?"=]))#
MOU+4I+2Y41\% T@!'H0(Q^=4I/$_BFWTK5M=:^M9K71M3EM9;-;7:US&KA2=
M^X[2 <@ =10!Z?17FR>*/%VJZW<7.C:<TVEVFH-:.A:%8V1.'9F9@X;.3P,=
M.M:^ES^)]6N=5QJEM;QV-[/;1H;,%I?D!0L=QP 6!XY(ZXSP =E4%G>VVH6P
MN+29)H2S*'0Y&5)4C\""/PKD/#/B74/$4&FVYG6"_A25M458A^[=&V*A!^[N
M.6^B'UK*'B778_"6F7X9H[=KN[6_O+2S60P*DKJC&+^[D98CGCKDT >A2:C9
MQ:A#I\EQ&MW,C/'"3\SJO4@>U6:X@^*;E-;THK=6]W8S:++>R-"F/,=-O*D\
M@')X_.JUOX@URWM?#VLW5_#<VFN310&U2%5%L9E)0JW5MI&#GKSTH ] HKS+
M2O%'B*2S\/:G=ZA!+#?ZL^G2VRVP7*[I0'W9)R-@X'_UZ]-H **\T75=3T&Z
M\47[ZB+IFU6*RACN%"QQLZ1;6)!X50YR!UQUYS70Z5J.J67C!_#NI7BZ@)+'
M[;#=>4L3+APC(57@]00?K0!U5%<5J-[XCOO&FHZ'I>J6UE%%817,;O:B0JQ<
M@CD]]O7MGIWK)TGQ/XE\32:1'97EG8/>Z7+<2%K;S LD<PC)'(Z^G;/>@#TN
MBO/;WQ)KZZ+JGB.WN8?LVF7DD+V'D#$T<3A';>3D$X8C'3@<U:O?%6H:3KFK
M6%RR2M/:Q7&C1B+8SLS%#&<]2'9/P_&@#K_[1L_[3_LW[1']M\GS_(S\WEYV
M[L>F>*J>5I%OXD,@:)-7NH.5\P[Y(D/7;G& 3UQWKF]2\0W>B>*-16Y6"YCL
MO#_V[<L061F5R"N[T)7./>JMS/JVCZ[INJZSJ$-]''IE[<E(H1&(RJQLRJ1G
M<N.A//US0!Z%17$^&=8\3:A?V-U=V<ATN_@,K-+Y"" E0R"/8[,X/(.X ]#Q
MR*EU_4/$$GC*WT+2-0M;-+C3WN!)+;>84=7 ]><@X]N: .QHK@;3Q#XGU'5A
M=V5C))IR7[V<L3>0L0C20HTF\OYF_(SC;CMSUJ.T\3:POBO3XI;U+W3[V^GM
M7%M:YAAVJ[(%EX+M\HW'D##>E '6ZKX:T;6Y8YM1T^*>6-=JR'*L%],@@X]J
MN6>GV=A;Q6]I;10Q1 A%10-N>OY]_6N!L?&6J6)U677)_*O+2TN+EM)>VV8"
MM\ABEZ2+@')R3DU;AUG7[*YT(7.I6]Y'KL;A2+<*+63RO,4K@_.O48)STYH
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M?S-+MX+BUN+NT5)&5P20R# 'W>,@$9Y% 'I]9:^(]&:VBN5U.V,$MS]D202
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MEKYYC7"[\<X'IFK5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!7O[&WU/3Y[&[1GM[A
M#'*JN5+*>",@@BJ/_"-:5_Q*_P!S+_Q*O^/,^?)^[XV_WOFXXYSQ6G++'!"\
MTTB1Q(I9W=@%4#J23T%9T7B/1KC3[B^@U.TEMK?_ %LBRC"<X&?3/;U[4 5D
M\':''90VBVTH@AN_MT:_:925FSG?G=GKDXZ<U1G^'>@7%T]P5O48W?VQ5CO9
M51)<Y+*H; )YR<9Y."*E\*ZQJ.OV]MJ?VK39M/N(-[PPAA+;2'!$9.2&PIP<
MX.1D#!K,N/%E_J.IZM;Z'J6A0_V;(J;;Z0D3+L#.^Y6^4 D#H>0<X[ &Y+X1
MTB73KVR\J=8KRX^U2D7#EO.R&#@DG!R ?3CI4=SX+T>ZUG^U'2=9G %Q''*5
MCN<=#*@X?'O^-36GB"P@TRU;5=:TD736ZRR/%<JL;#C+IDYV9/!]Q5V76M*@
MLX;R;4[..VG_ -5,\ZA).,_*Q.#QZ4 9=]X+TO4GU5KF2Z8:GY1G42X"F/&P
MK@9!&/6HF\!Z2UOJ<)FU C4XECNBUTS%\8^;YL_,0,9].!BM>;7M&MT1Y]6L
M(EDC\U"]RBAD_O#)Y'OTJ1M6TU-/34'U"U6R?&VY,RB-LG PV<')H ;-I<5Q
MHCZ5)-.87@^SM(6'F,I&#SCJ1WQ6;<^#=*O/#MGHL_VAH+(+]FF$N)HMOW2K
MCD$#CZ5->ZL96TE]*U/23#=7 #&:;/GQ@'<(=I^9^GM5U-8TR6_:PCU&S>\4
MD&W6=3(".ORYS0!QNN^$WBU'PQ%IL>H-!:W4DMU=Q39G!:/:'9V.6.0 >O Q
MC'%=!/X.TFZTR2RN%GD,DXNFN6F;SO.  $@?J"  !C@ 8QCBCPMK=UK2:N+N
M.%'L=2FLE,0(#*FW!.2>>:TAK&EM=_91J5F;GS/*\D3KOWXSMQG.< \4 9%Y
MX*TR^TZ>TGFNV>YFCFGN?,'G2LGW 6QT7 P!CI[G.AJ&@VNI7NGWDTMTD]B6
M\MH9C'N#;=RMCJ#M7CVJ6+7-(G>9(=5L9'@7=,J7"$QC.,M@\#ZTZ#6-+NKP
MV=OJ5G-=! YACG5GV\'.T'..1S[T 83> M.:&:+[=J(2:^_M!P)E_P!?G=N^
M[ZX..G JIXG\*.]AJMQ8)>7EQJ,L#74(N1$Q2-@1Y;8&U@!QDX^M=2FK:;)?
M-8QZA:-=IG=;K,ID&.N5SFLW5/&GAS2+.:XN=8LB8T+^5'.C2/CLJ@Y)H SO
M#>GZE'K!N6?7(K$0E6BU6[24R.2,%54MMQCKNYSC'>MB\\.6%]KD&KR&=;J*
M+R6\N4JLL>=P5P/O ')Q[\Y%0Q>((KV]T^2RU'27TZ>%Y7W7(,S8!^X <$ @
M[CGC!]*O6^MZ3=W2VUMJEE-<.F]8H[A&=E]0 <X]Z ,ZQ\':783VS1M<O!:2
M-+:VLDNZ*W<YY1>V 2!DD#/%7]8T6UUJ&W2Y:9'MIUN()87*M'( 0".QX8C!
M!'-.DUS28KMK235+)+E3AH6N$#CIU7.>X_.K5S=6]G;O<74\4$*#+22N%5?J
M3P* ,6X\&Z/=Z3<:?<QRS">47$EP\I,QE  $@?J"  !C@#C&.*OZ/H]OHME]
MFMY+B8LVYYKF4RR.>F68\G@ ?04JZWI+VHNDU2R:W9B@E%PA0L.HSG&?:GV^
MJZ==V<EY;:A:S6L1(DFCF5D3 R<L#@8[T 8&H?#W1]0FO',^H6\-[*)KBVM[
MHI%(X(.XKZD@'ZU8E\$:++K)U/9<)))@SPI<,(K@@8!D3.'/UZ]\TFA>)UUO
MQ/K6GV\UI<6=BD#13V[[MQD#%@2"0<;>V*GO?$^GQZC=:/;WUJ-7CMS+'#*X
MP6P2%QD$GY22!R!S0 ZW\,6<&HK>-/=S^7-)<0PS3;TBD?.XJ,9'WF&,X&:Y
MO7?"7V.RLK2PL]3N[/[7-=7#VEZ(KF-W'522H*DELBNA\+^);;7M(L))+FT&
MI3VJ7$MI%*-R!@#G;G<!SWK4AU.PN;R2T@OK:6YB&9(4E5G3G'*@Y% ')Z7X
M6N[\%]4N]62UANH;JQ@N[E))HW0-EF8 C!)'RY.-N<\X&I-X*TBZBUB*[6:X
MBU:02W"2/P''W2N "N,#\A6O=:KIUC)Y=W?VMN^PR;99E0[!U;!/3WIIU?3%
M@BG;4;012H9(Y#.NUT R6!SR,<YH R!X'TDZ1+ITSWMP)'23[1-<LTRLGW"K
M]1M[8]3ZFK&B^%K30]0N[Z*\U"XN+M569KJX,F[;POY#BKS:UI2/;(VIV2M=
M -;J9U!F!Z%.?FS[4V?7='M7*7&JV,+"3RBLEPBD/_=Y/7VH SM7\':;K-_/
M>3RWD,ES;?99UMYS&LR#. P'7&X_RZ4EKX-L+.:*6&[O@T5@=/3=*&Q%Z<CK
MGG/MZ<5K7&K:=:74=K<ZA:PW$N/+ADF57?/3 )R:&U?34N/L[ZA:+-YBQ>69
ME#;SG"XSG)P<#KQ0!B#P)I266G6\,U]!)IR-%;7,-P4E6-NJ%AU'U':HT^'N
MB1Z1!IZO>C[-.T\%R+@B>)V.6VOU /<=ZVQKND$7!&JV3?9E+SXN%/E =2W/
M'3O6<OB6+4['2[O1KS3BEW.@9;J7:QC(Y"@'/F<K@'UYH DB\*6,%]IMW'-=
M"33Q((LR[MY?[[.2"6+=SG\JT-6TJTUO39M/OHR\$H&<'#*0<AE/8@X(-*^K
M:;%J"Z?)J%HEZP!6W:91(0>F%SFFOK6E1NJ/J=DKM-Y 4SJ"9>/DZ_>Y''7D
M4 9R>$;!K6_BO9KK4)+Z$V\T]TX,GE<X12H 4 DG@=3DYJ*S\%:?97ZWJWFI
M2W*VALP\MT6/E'M^&!^//6ND) !). .]4;;6=+O8II;34K.>.#_6O%.K"/\
MWB#Q^- #M)TV'1]*MM.MWE>&VC$<9E;<VT=!GV''T%9DGA*TGU:*^N+R^G2&
MY^UPVLDH,4<O/S 8W?Q'C./:JOA[Q'>^(KE;NSDTQ]+,DT;Q+(3<1!251C@D
M'<5)Q@8!')J&^\575QXCO-&T:?2EFLH4DD:]D.V4L3E5*G*[0I).#UZ#K0!-
M'X TB*6V:.:_6*UNS=V\"W)$<3DDD*.P.X\?EC)SD^&?"$TMUK,VKO?QVT^K
MSW2:?(Z>1,A;<CL ">N#C=C@9%=-I^M1)I=M)J^HZ2EU*K,3;7(\I@">4+8)
M  Y]#FKLFK:;%IRZC)J%HEBP!6Y:91&0>A#9Q0!C2>!M(?79=45KR/SW$EQ:
M1W#+;SR Y#N@ZG@>Q[@UJ:9HT.E7%_-#/</]MG-Q(DK[E5SP=O&0, #'L*F.
MJ:>(HI3?VOERJ6C?SEPX')(.>0*(]4T^73_[0COK5[+!;[2LRF/ X)W9Q0!!
MI^@V&EW>I7=G%Y5QJ,OG7$@ZEL8&/;J?J369!X,M;2R@M;34]3MQ TK(\<R[
MOWC!G!RI!!89Y'&35Z[U836%K=:1>Z9,DUPB>9+.#&Z%L,$*GE\9P*MMJVFK
MJ T]M0M!>GI;&9?,/?[N<T 9MOX1TRSO=.N;8S1#3[8VD$08%/+/4-D$G.!D
MY[5%IW@S3],N87@N;UK:V+-:V<L@:&V9LY9 1G/)QDG&>*DT/6[O4=?\0:=<
MQ0JFFSQQQ-'G+*Z!_FSWY[5J3:II]O>)9SW]K%=2+N2!YE5V&<9"DY(S0!B0
M^!M-@L-/LDN+WR;"\-[!F121*23D_+R,LW'^T?;%[0]-N]/EU-[BYGECN;MI
M88YIC*8E( P">@)!(4<#.*+#Q5H>I6UW<VVIVI@M9&2:1I555QU.2?N^_0TE
M]XKT2PM+.ZDU&V>&\G2"!XY58.S$#(.<8&<D]A0!7N_!>E7TVJO<&Z>/4P/M
M$'GGR]P"@.J] XV+@^U6M)\/0:5=2W;7=Y?7<B"+[1>2!G6,'(08  &>>F3W
M)JX^JZ='=P6CW]JMS<#=#"TRAY1ZJN<D?2FG5],$RPG4;3S6E,*IYZY,@ )0
M#/WL$''7F@#E+[PS?ZC\1KJ^%WJ5A9OIL<(N+.1%\Q@[$H<@GH0<@#ZUT%MX
M9TZRO["[M%D@:QM6M(HT;Y#&2"0<C)Y .<YR*T8+VTNHWDM[J&9$.':.0,%/
MN1TJ&#6-,NK8W-OJ-G+ K[#+'.K*&Z8R#C/M0!D2^"=-DU&>X$]XEM<SBYN;
M!)!]GFE'\3+C/4 D @$@9!K3OM#L-1U/3M1N80]UI[NUN_\ =W+@\?D?J!3;
MOQ!I-GIU]?R7]NT%B&^T&.16,; 9VD _>]!UY%*FOZ0UM;3MJ5I&ES_JM\Z#
M<<9('/)'<"@"*\\-Z??:M-J-RKO)/9&PEC)^1X22Q!&,YR3R#698> K"QN;6
M=]1U6[-LCQ1K=7.]1$P ,9& "O'U]20!C?U/48-)TRYO[E@L-O&TC9(&<#H,
M]ST%86B^([BYLEU35+O1X=+F@CD26.?:8I&&3&Y8X) (YX^E $N@^"M-\/77
MFVD]])$F[[-;W%P9(K4-U$8/3/3))/7GDUH2Z';2^(K?7#),+J"!K=5##848
MY.1CUQW["K3ZC8QQQR/>VZI*,QL95 <=<@YYJ:*:*:)98I$DC895T8$$>H-
M'.KX'TF/7)-3CDO(UEE%Q+9).1;23 Y$A3^]G!ZXR <5!;?#[2;2XM)8+O4T
M%G=/=6\8NB$BWYW(!_=.3GOR>>3G>BUG2[BVDN8=2LY((FV22I.I5&]"0< T
M7>LZ;8P2S7-_;1I%%YSEI1PG][KTH R;3P7802AKJZOM0C6W>VBAO)0ZQQN
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MS5I+HG]R1@+@  8P,8 Y )R:DD\$Z9)X?L-&::\\C3Y5EM95FVRQ,N=N& [
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MZUS.CV$4.F> 1#I\]O<17TCW!%HZLF5<$OQQDE!D]O85ZSN7<%R-QYQGFEH
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MF:&9(YKBW:-I(V4.!"%.,CG!!%9&NR/!XU$MAON9)+VV2YTVXM"1)MV$3PR
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MV%748#(5!<% ^X8'&2 >E>I44 >2:QI,*>%/%@M-+=+PZVC6XCMF5R%>+!3
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M-8[O11B.4VX9),Q["2A;@XY!SP: ,"ZUJ/Q/I?A#5VM5AG_MY83WQM\U3@D
MX.T'!J>XOIO#EUXSU/2K&"XE@O()+B$L4Q%]GC+. !U!+'WP:O6G@6>STW3[
M)=7$BV6J'459[7EB2QV'##N[<_3@=[-_+;^%+C4]3U&26ZMM6N8U6W@LV=U?
MRPFW@G((3T')]Z -6TUE+_6I+2U"RV\5K'.\X/\ %(3L4?\  03^(]:Q/%GC
M*X\-27)^QP&*"W$Z&:;:UT<G<D84$C:!R3P,CMS5OP)X?'AWPO!;-$T4\K&:
M5&;<4+=$S_LJ%7\*J^(/!$NM:AJ5S#JYMDU&R%G.C6XD(49QL;(VYSR.<_R
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ*XN8+2!I[F:.&%.6
MDD8*H^I-2T %%1P7$-S$)8)4EC)(W(P(R#@C(]""*DH **IW6K:;8RB*[U"T
MMY"-VR694./7!-36MW;7L/G6EQ#<19QOB<.,^F10!-114%W>6MA;-<7ES%;P
M+C=)*X11G@<F@">BBB@ HHHH **KM?6B7R6+74*W<B&1("XWLHZD+U(]ZL4
M%%0VMY;7T/G6EQ%<1;BN^)PRY!P1D>AJ:@ HHILDB0Q-)*ZI&@+,S'  '4DT
M .HK+;Q)H:VOVIM8L!;[S'YIN$V[@,E<YZ@=JTU970.C!E89!!R"* %HHJ&>
M\MK:2&.>XBB>=_+B5W"F1L9PN>IP.@H FHHHH **** "BBB@ HHJ&ZN[:RMV
MN+N>*"%<;I)7"J,\#DT 345!:7EK?VR7-G<17$#_ '987#JWT(XH6]M7O9+-
M+F%KJ-0[PAP753T)7J!0!/1110 4444 %%0W5Y;6-N;B[N(K>$$ R2N%4$G
MY/O4U !1110 4444 %%1PSPW,?F02QRIDC<C!AD'!&1[U)0 45!)>VL-U#:R
M7,*7$^?*B9P'DP,G:.IP!FEMKNVO(C+:W$4\88H6B<, P.",CN* )J**@-Y:
MB]%F;F(73(9!#O&\J#C=MZX]Z )Z*** "BBB@ HHHH **** "BBB@ HJ*XN;
M>S@:>YGB@B7&9)7"J/Q-2*RNH92&4C((.010 M%%% !114*7=M)=26R7$37$
M8!>(."Z@]"1U% $U%%% !1110 445!=7EK91K)=7$4",P16E<*"QX &>Y]*
M)Z*** "BBB@ HHHH **9--%;PO-/(D42 L[NP"J!W)/2D@GBN;>.X@E26&50
M\<B,&5E(R"".H(H DHHHH **** "BBB@ HHJ&YO+:S1'NKB*!7<(IE<*&8]
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M72)9$+,AD(88,A^8A ,DD$ #'%/TOQAK,5E;ZO/IN="ELGN6CBMO+%DB1[D
M?<?,! Q]T<]..*ZQO#5N_B-M;>ZNFG>T%G)"VPQ21@D\C;G.2>A%4-(\#6>D
M.\2ZAJ%QIH#K!I\TN880X(8#C+#!( ).,^O- %:WO?%UWI0U.&;3#;WM@US$
M/+/^B.5#1KG)\P'/)P,$9QC@UK*\U :9X(-\+.]^UO'F9[8[XC]F9P0Q8_/P
M<MQG)X%:FA^"K?1,QKJFIW5JBLEM;7$^4MU88(4 #/' SG Z5+9^$H[:RTJV
M?5=0F&ESB6W9S&. AC"$!,%0I(]>2<T 9L7BW4DN]0T>YAMCK,5_%;6RQ(P2
M2*0;EE(+9X19&(!_@Q4(\3Z_?:Q(VF6/FV=MJ36$T)@ZHK!7E\W=P0<G;MZ=
MZZ1_#MA)XIB\0LC?;HK8VRG/R[2<YQZCD9]":H)X-MX=?FU*UU+4+>"XE\^X
ML8I<0RR]=Q&,C) )P>>_'% &)'XMU]E@O)4T];5==.E/'&C[I5,OE[\D_*0>
M<<Y]JEG\6ZY=W]\^CZ<;B#3[YK.2W\DDS[2N]A)N 0C)P,'IUY&-<^#+(V4E
MJ+R]"-J?]IJP9,QR[]^!\GW=W8Y/O4,W@2R?6[G4(-0O[6"]<27ME!*%BN&'
M<\9&>^",T 5[#Q-?S^-9M*O9;>R F=(K&>!@\T*J<2QRYVL2<97' SW%+X.\
M3WVNW=Q#?RVT-S&A:;3FMWBGMFR !\Q(=,<[ACDCZ"_)X3$]]%/<:K>S107$
MMS#')L)B=PPPK[=VT;C@9XXY.!3]*\,MIVK+J-SJ][J$L=L;6'[2L0*1DJ3D
MH@+'*+R??UH @OM9O[[Q+/H&CW%O;7%I;+<3S7$)E!W'Y4 ##' .2?48KF+_
M %O4?$*>#+I#!:22ZG)'+"\32*LT8D7/WAD94X'7GKQ79:EX<2\U>+5K2]GL
M+]8C \L 4^;&>@8,"#@\@]O>JK^"[);71H;6[NK?^R93- 04;S'.=S/E3DG+
M=,?>/M@ H^.3<Z'X,_XD\D-@QNH5D\F':&\R4!L $8R6R>I//KFLF]FU?3_'
M^LW5I)8-=0Z''-,\D+A'VO(<!0V<G &2W:NT\1:%#XCT6739YY8%=D<2Q8W*
MRL&!&01U JC#X1A6]O;RYU*]NKB\LA92M)Y8^3GD84?-DL?3G&.* ,63QIJ&
MJBS@T:'R[E]-AU&3_1S/_K,[8\!EQTY;)ZBNF;4;\>$GU*6T6UU!;-IFMY?G
M6.0+G:<$9&:R6\!6RP:7]EU2_L[S3K<6B7ENRK)) .B.""IQ].O-;\FEPOHL
MFEK+,D3PM"9-VZ3!&"<L#EN<Y.>: .._X2SQ&EAI#75O81W.M;#:);1R2M"O
ME%Y&8$@,?NX (ZG)..97\4:Y9Z9:QZI!%83W&I&Q%]-'M3R]A99BF[Y2Q&W!
M;&?7I6K>^#+6_P##=CI$U[=B2P*M:7J,$FB900IR !P..G/UK&\1Z#>Q:=IU
MB+G6KV)9GGN+Z(I--OV[0IC8;=AR>@XP..<T 0WOB>_N/"EU>7EGI=[;QZK'
M9QEHB\5PGF*ID )QU/'4 J>M:4GB74QXRFTF62UL$,BQVL=U Q^U+MR9$D#
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MK62*>.XBFB"EDD1MRG# @\]C6 OP]$277E>(-3$ES?1WSR.(F/FI@Y V8&2
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MN[FNK;5KZQFNK5;6]\C9MN55=H+ J<-CC(QQ6BVCKIW@B71HFGNXX;![>,.
M7=0A 7Y0!G&!_P#7YH PK'Q/XE:3P[+>6FFBVUN,A/)W[K>3RC(NXD_," >
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M./[[LX 7ZGM7EKP&V^'O@WQ396RW%WH\<!94Y9X6'ER(/?G\"#4^OVTFB_\
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M=4:1%9NBE@":&FB601M(@<]%+#)_"O+=6:"XMO&=EJ@1M<DN&.E*X'FNFQ3
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M+21J8H;NV=LKD(HE7)]AC/X4 :=MXD:7Q??:/-';QV]O:QW$=P)L^9O)&#D
M#[IZ$_6MV26.( R2(@/0L<9KRO6K+1]2\2>))/L=O=6\7AU7MU6,,%.';*#L
MV&4\<C</6JDMQ;R76F)XDU.Y.FWFAP0VMU# LR22[2)5RT;8=L \8/ 'M0![
M%48GA8.1*A"?>PP^7Z^E<YJ%O>6_PUFM]%-XUTFF[;;SN+C.SC.,?/C]:\\G
MA\-7OA+5]0L[N\ENH=&>&>&:W2**)@1M5]L:YD#?=R2>M 'LZRQNQ575F')
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M **** *]G90V$'DP X+,[,QRS,QR23W)-6*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .2^)+JO@R0-/%
M7N[4+)+]U3YZ')]@ 2?84:CX.DU^&_?5-14W%S#%%#):1E%@\MRZL 2<DL<G
MGH />NMHH XO4?"&MZQX=NK#4O$"3W4WDJLBVVR)!'('SL#<LQ49.>G0"M;6
M]!N=6U+0[I;F&-=.N#/(AB)\TE=N <\#!/KVK>HH XNV\"S6NDMH":A&="-W
M]H$)A/FJF\2>4&W8V[AUV]">_-5M4\ ZG<VFNZ=8:U!!INL7!N98YK4R21NQ
M!?:P<#!('4<5WM% &/KN@1>(/#4VC7<S*)8U!FB&"KJ00P!SCD X_6L6\\&Z
MGK6BO::WKQGN4*-;2P6XC2)T.5<J2=S9X/(XX&.M=E10!@:;HEY_;O\ ;FKS
M6SWRVOV2-+5"L:IOW$Y;))/'L,=^M4]'\#6>EV.MV)F9[74C)&B*-OV>!]Q\
MI>O 9Y#^/2NKHH Y'3_#&O6NE/IUSX@BGMHK-K6U1;39U7:K2?-\V!V&*2\\
M(WTGAW0K>SU1(-7T54%O=F,E),)L(9<]&'6NOHH X^\\-:]='3M4_M:U&N6<
MKR?ZEA;LCJ%:+&=P7Y0<Y)SDX]+WACP_?Z+=ZO<W]_!=2:C<BX/DP&,(=NW'
M+'(P!_\ 7KHJ* .,O?">K2:EKHM+^T2PUS:+EGC;SH0$V$)SM.0.IQC/0U0U
M/3]#\0^(M(T&Q\XRZ&X6[V1NJI;A.(F; #!B$XR> U>A44 5[^U^W:==6F_9
MY\3Q;L9QN!&?UKE])\(ZCI]UX>DGU&UFCT:VDM55+=D,B,J+U+'D; ?Q-=A1
M0!QH\&7:>'[/2TOX,VVJ?V@)&A/S 3&4)C=ZG&?3M3Y_"E_>>+++5;B:Q5;.
M=YDN88F2Y=#N A?G!4!AS_L].2:Z^B@#'U;1YK_5]&OX)88VT^9Y")$+%U9"
MA48(QPV<\\@5G/X:U6WU[4;W2]8CMK74BC7$,MMYC(X4*6C;<,$J!U!&>U=3
M10!YK!;:CJWC3QOIUA=6D=K</;PW+.6,D:FW"LT>.-PY'/<?A6R?"%[I-_=S
M^'KFVBCU""*WNDO%9]GEIL5TVXR=IY4X!]:[&B@#F='\)_V'JMC+:7"?8K33
M18")H_G8AMV_<#CD]1CO4WAS0KS1+S6/,N8);2]OI+R(*A$BF3!(8YQ@8QP/
M?/:N@HH XV\\)ZJ^K:Z;6^M4L-<"BY9XV\Z$"/RR$YVG([G&,]#67K/PYU&\
MCU:SL-1LXK&^AAAC\^W9Y8$C  B1MV GRYZ=>W>O1J* ./O/"VIZCK]A?7DV
MFG[)<+.EU# T=P .L0YP4/.<D\'H>M)H?A/5]&)TH:M$_AZ-WDBB$1%P0Y8F
M-FSC;ELY R?:NQHH X&U\#:S!::3IC:M:/I^CWZ75HS0,99%4-A'^8 8W$9'
M7VQ71>)] DURULVMKG[/?6%TEW;.PRF]<C:X[J02#BMRB@#BM6\&7NNZ?J;7
M=W;P:CJ'V=&,:%XX8X9-ZJN<%B3DDG'7IQSN6>C36WBG4-8,Z-'>6\,1B"$%
M6CW<YST.\]NU;-% ')^+/#%[XBGC5#IXB4HT=Q(C"XM75LEHV7KGTX^IJOJ/
MA'6+A];MK'4K&VL-3N$NCOMF>19 $#+]X#:?+4YZ\GZUVE% '%S>%=>M=?OK
M[1]8MX(-55?MR2Q,QBD"[?,AP>"1V;I[TE[X(NKQ/%4!OHA%K:1!)"I9XBBA
M/F'\60 <Y')-=K10!EZIHL>L^&KC1KQAMN+?R7=%Z''W@#Z'D?2J7AW3O$=K
MC^W]4M;L11F&);>(KY@R/WDA)Y; Q@8 R>N:Z&B@#CM'\#'1M*UZSM=0>)[_
M ,Q+21<G[)$=Q15Y_A9V/'K5;0O!VL:=J4%Q<7>F+"NF?V?)';P."<$D,"3U
M+'))'MCO7=44 <3#X.U334\.2Z?>V;7>DVSV;F>-MDD; #< #G<-H.,\^HJO
M%X*UN&PTF+^T-.N)+&]N)VCGMV,,@E9FW%<\NI8E>@Y_$]]10!P&G^"-;L$T
M1O[2TYY=*O+B5#]F=0\<VX,6PWWOF) &!VSWJW=>"+FX&MR+J$:7%Y?1:A:.
M(SB&6+&T-S\P^49Z=37:44 <-J_@O4?$5CJ4VI7-G%JEU;Q6T)@5FBBC202G
MKAB68<^@ ZXYT9=&U*UUS4]?BN;59KC3%@"-&[B.5,D-QRRY8\8!X%=110!D
M:9_:>H>%XUU3;;:C- RR&$$!&.0& )R#C!QGK7':=X UNW2SCEOM*C2'39]/
MD\FV<LXDQ\Y.X9<D9)/ZYR/2** .+M?!]_%-X;,UQ;&/2+![&386S(K*$W#(
MX("*<>K'T&8-.\'Z_:G1+>;4]/>TT28M:L+=_,ECV%,/\P (#'D9SQ^/=T4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%WC( QE,<\_G6C;Z_K.IW'VK2[&VGTQ+YK.1&;;-M5BKR@DXP"#\N"2.XZ4
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M]BO9+,-%(6$K)]YL$# Y&.3WK?H **** "BBB@ HHHH **** "BBB@ HHHH
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M2\,SZ->WT\S3VYAEN@JJ[9&"V -H^F*YQ/AY,QN?M/B*[F6ZTT:=,HMXE!0
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MZN=,2TECAC&8I.6+JV3R&8\8(K0U/6HM/O;*P2,S7UZS""$''"C+,Q[ #^8
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MBA&[IEV_3TI;;P0;'6[FZL];OK?3KJX^U3Z<@78TF<G#$;E4GJ!C/3I7644
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3Y-+TW[9IVDQ1VWB2V%S<V;*]G*&B^9DSPJX5 R],CWKV:.*.)-D<:(G]U5
M%(((1$(A$@C'\&T8ZYZ4 <=\2X[=_A9J?V=$\E88VA$8PJ@.NW;CH,5A>(=-
MTC0M8T:(O';>'[P3RS7-POVF*2Y(7:TA<D9*@X)]3BO4J;)&DJ%)$5T/56&0
M: /)[>;2])O/#T6I7<UUX6$%S'!<7\8\DS;_ )2>VW;N"$\8Z>M-OY-)AO\
M2+"\NWM_#+6$B6,U_$)4,HD8$DMT.W&PGG'3&:]:>*.6,QR(KH>JL,C\J22*
M.9=LL:NN<X89% 'EECI&C7OB;3K.]EN;FS;P^=C7C-&\P6;Y69<C.%&1D= #
MCBFZ:=&:'P!<:A]DEA-M<0"6X"MG:HV*2>X.<#UKU4Q1F42F-3(HP&(Y ^M+
MY:<?(O!W#CH?6@#B_BREJWPZU)[A(BZ&/RFD )5C(H^7/0XST]ZIZDFG:?\
M$'3Q;M%9VIT.Z*FV 4 ;@V5"]3C<W'O7?R11S)LEC1UZX89%*(XU" (HV#"X
M'W?IZ4 >-QB72?#^LV=A':WES'I\#'4]*<YN+<2 .)$R=LNPN=V<GGTK6U.Y
M\(0^'=2OM#19;6Z-HDRPN4M4;?\ *9,#Y?5QU(QGK7IJ11QEBD:J7.6*C&3Z
MFD$$*P^2(D$738%&W\J /'+6\LT\$>.+:.^LY52Z1U%L@BB"LL>"B;CA"<@<
M\XS7HWC:YNH/ ^J7&G&4S"#*M;C<^TD;BOOM)Y_&MX11KNQ&@W_>PHY[<TX
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MTTVW:25@Y=%(!8;2 "6[$].E &K?^-K:STZ'4(M/N[BT>Q6_:8;418FZ#+$
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M<SJ0XC&W!3)Z9']*OV&G>*IM-O8-7_L@.;.2"+[)O'G.PP&<D?+TZ 'J?3%
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MJ$;R2%VX(^?'7MGVH K:7\0]%N+B*SDE:-6M7N(II)HY#(B#+%@A)5MOS88
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MVTQ;]^,[/O=NF._M5O2O#>O:+J\]K:3Z:VAS7C78DD1C<Q[FW-&/X2">,GD
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%V^<C*!@*!@')XJ'3O.E\2^ [^74KF\DU&WNKF;S)=R!S"IPB]% W$8'IZT
M>FT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (RAE*
ML 01@@]Z2...&,1Q(J(.BJ, ?A3J* "BBB@ HHHH B^S0?:3<^3'YY79YNT;
MMO7&>N/:I:** "BBB@ HHHH **** "BBB@ I&574JRAE(P01D$4M% #8XTB0
M)&BH@Z*HP!3J** "BBB@ HHHH **** "BBB@ HHHH K7&G65Y*DMS9V\\D?W
M'EB5BOT)'%6:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** *]]86FIV4EG?6\=Q;2C#Q2KN5N<]/K5*/PUHD
M6COI,>E6BZ>[;FMQ$-C'.<D>O Y]A6K10!ER>'-'EL)+&33H'MI)!*\;+D,X
MQACW)&!^0I\F@:5+/=SR6$+RWD0AN69<F5 ,!6]>*T:* ,NS\-Z+I\UM-9Z;
M;V\ELC)"T2;2BL22!CL22:)O#FCSZG_:4EA";LE6:3!&\K]TL!PQ&!@D'':M
M2B@"JNG6::E)J*VT8O9(Q$\X'S,@.0N?3-0ZEH>F:NT37]HDSQ9\N3E77/4!
MA@X/<9P:T** *DVEV,^F'39;6)K$H(_(*_)M'08].*BUC0]+U^S^R:K90W<&
M=P60?=/J#U!^E:%% &9'X=T>%=/$6G0(-.S]DVKCR<]=OUQSZU>N;:&\MI;:
MX020RJ4=#T8'J#[5+10!F3>'M*N+&ULI+0>1:,'MU5V4PL.A4@Y4CM@\5&OA
MC1EM/LHLE,/GBYPSL2)?^>@).0W?/7//6M>B@#GKKP+X7O9[F>YT6UEDN9/-
ME9E/S/G.[KP3WQU[YJTWA?1&L[NT.G1"WNW$DT0R%9P<AL9X/ Y'/ ]!6O10
M!C7?A/0;_5X-6N],@FOX-NR9\D_+TSS@D>IS4EWX:T>^:]:ZL(Y3?($N=Q/[
MT @KGGMC@]NV*U:* ,.#P;X=M7NWATBV5KN+R;@[<F5.X.>N< GU/)S6H+&V
M_L[[ 8@;7RO)\MB2"F,8R>>E6** ,RY\/:1>:*NCW.GPRZ>BA4@<95 .FWN,
M=L=*P=8\#6]R/#]IIMK:V^FZ==F>6(2/&Q&TCY2HR6R<Y)'3K78T4 9;>'-(
M?3&TY[&-[9I/-96)+&3.=^[.[?G^+.?>A?#FD+8M9_84:%YOM#AR69Y<YWLQ
M.XMD#DG/ K4HH S[W0],U&[M+N\LTFGM#F!WR2G0_CR >>X!JJGA/1([>.!;
M+$<=W]M3]Z^5G_O@YSGDUM44 <AXE\&1:C;%+"RL91/>"YO(+QW5+@@,,[@&
M*-EARHY "GCBJMCX$ TF_L);.QL[6YA$0LH;F:XAW!MP<[MAR#V '?)/;N:*
M *46EVPT6/2KA!=6RP+ RS -YBA<?-ZYQ60O@'PLH;;H\*EH/LS,&8$Q_P!T
MG.3QQGKCCI7244 9B>'M+2_@O1;$W$%M]E1VE=OW7]P@G!'USV]*J6?@KPWI
M]S%<6ND012PN9(F&?W;'KMR?E^@XK>HH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** *6JZE'I5@]U)')*052.&+!>5V("JN2!DDBF:1J4^IVKS7&EW>G
M,K[1'=;-S# Y&UCQS^E4_$MOX=U"W@T_Q$UH8YG)@CN)=A9@.JG(.0#V]:S_
M  G/#HVAR07.HE]/2^-MIL]RP!DB.T(H)^]\VY0>X''&* .LHHHH Q=<\02:
M-N9-)O;Y(H&N)GMS&%B1?4NRY/!X&3Q6-_PL ?\ "//K;:!J269M3=0N[0XE
M48R/E<E3@Y^8#@'&3Q6[XH(7PEK)) 'V&;D_[AKCII(!^S^&C^1/[%5?F/\
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M: "3CGUH ]!T758=<T6SU2W21(;J(2HLF-P!]<5?KE/ 4K#X9Z.\&))%L1M
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M)X8T?3T^(GBFYC1S-;RP!&,[M@O#\V03@\YZ].V*[N@ HHHH **** "BBB@
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MSPQ8)DYST[D]^M<PGB^ZC\;6[7$&IBVN-$,ZZ>L09C*)1E@ 3CY0>6(_,@$
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M&4T[^T(["YN95:5HML%T@B8C!/)Y (Z CGFDD\81:3;R36IU+4_M.N_82)T
M^SL64-&HX. ,A0>_?% '2P^'K&WUF'4(8+>$6]N8(8XH%38"23\P&<>B]!R>
M<\6M1TK3M7@$&HV-O=Q Y"SQ!P#ZC/2BZU.VL-*DU*[9H+>./S7+J=RC'0CK
MGMCUK)C\9Z;_ *<+N&]L9+.)9I([J JS(QPI4#.[)XQUSQB@#7GTK3KF"&"X
ML+66& @Q1R0JRQD# V@CC ]*@D\.Z)-$(I='T]XPYD"-:H0&/5L8ZG R:I?\
M)?I\9N8[J"[MKJWM_M1M98OWKQ?WU"DYQCD=1W JI%X^TJ>Z@MH;34WFNK87
M-JHM&'VA/]G/I[X'N>* -^YTO3[Q(4NK"UG2 YB66%6$9_V<CC\*2^TC3=4*
M'4-/M+LQYV?:(5DVYZXR#CH*Q'\>Z*NG:5>H+N6/5)3#;K';LS[P2"K#L001
M^%,A^(&D38_T?4$"W0LYR]J0+>4MM"N>G)QTSU&<9H Z2UM;>RMTM[2WB@@3
M[L<2!57OP!P*@BT;2X+J6ZATVSCN9@1+,D"AW!Y.X@9.>^:Y[5O$,6CZEKUZ
MLU]<OIVGI*]AM BP2V'4GOP<^PJ*'QU-+K.C:?\ V)?*U];M-(6C *XVC(^;
M[OS9)SP,?@ = /#FAK$D0T;3A'&YD11:IA6.,L!C@\#GV%7YX(;J!X+B*.:&
M0;7CD4,K#T(/6L"#QOHT]_!;!Y4BN6=+>Z=0(IF7J <Y'0XR #@XS3M.\9:5
MJ6I6UE%YZ-=QM):22( ERJ\DH<YZ<X(!QSB@#6BTK3H+%[&&PM8[-\[[=(5$
M;9ZY4#!S49T/26@:!M+LC$R+&T9MTVE5.54C'0'D#M3-2UNWTZ[M;,Q37%Y=
M;C#;P %F"C+-EB  ,CJ1UKF?$7BR2]\+0W&@)=/)<7L=G(4 22!O,570AB"K
M$9 /OG(X- ':0P16T"001)%%&H5(T4*J@=  .@JD- T86PMQI%@(!)YPB%LF
MW?C&[&,;L=^M9-S/<^$/"&I:CNO]2:%6N4ANY5,D*[1\A?/(7!).2>O6L5O%
M%Y;^.+62X@U)K>;0S/\ V?"@DQ)YH&_"D@?*#R3WQU.* .W33;&*:XFCLK9)
M;D8G=8E#2_[QQ\WXU'#HNE6UI+:0:9916TW^MA2!51_]Y0,'\:SI/&.E#3;"
M]M_/NA?QF2WBA3YW48W'#$  9 .3U(J_IFLV>L:+'JMBS36TB%U"K\V1D%<>
MH((QZT "Z#HZ6+V2Z38K:.V]H!;H(V;U*XP3P.:GN]/LK^V%M>6=O<0 @B*:
M(.H(Z<$8K L_'FDWU@M]%!J"V\@40O);,@F=F("(3P6X]<8YSP<3IXRTM[)9
MU\\S-=_81:[1YIG_ +G7;T^;.<8YS0!KW6FV%];+;7=E;7$"XVQ2Q*ZC'3 (
MQ276E:=?6\=O=V%K<018\N.6%75,# P",#BN9U+Q?IM]X:U:X275;)+&86]S
M+! !+#(""5!.5.. 3R/FZ\BM:?Q19Q:M+IR074\D$L,-Q)$@*PM*1L#9(/.0
M<@$#/- &C>:9I^H1QQWMC;7*1G*+-$KA3Z@$<4R;1],N)IIIM.M))9T\N5W@
M4M(O'RL2.1P.#Z"N7L_B%#]DU>]U+3KRUM+"_-IY@C# 8*K\V">=Q.<<8(ZU
M<'CW3FB=A8ZF'CMWNI8I+;RWCA5BI<AR.,@X R3Z4 ;JZ5IR?9MNGVJ_9<_9
M\0J/)SUV<?+^%2W=G:W]NUO>6T-Q"V"8YD#J?P/%8-[XXTJSN?LZPWUS*;,7
MJ"WM6</"?X@>GYX].O%59_'"MK7ARVL+*:ZLM8B>9;A ,[0 >!D$8W MGH.F
M3T .I^QVOV,6?V:'[*$""'8-@7TV],>U)=6-I?",7=K!<")Q)&)8P^QAT89Z
M'WK!@OKW1I;^35)[FZCN;_RM/B,<:NVX9V+@@;1@X+$'Y2>XSMV-XNIZ<ERD
M4\ E!&R5=DB$$@@CL<B@"(Z)I)$0.EV1$,AEC_T=/D<G)8<<$D#D>E*^BZ5+
M/)/)IEF\TC*[R- I9F7[I)QR1V/:N,\#^-$;P]I$&L27SW-U-+ M]/"?*DD\
MUPJ;_P"]M QVXQG((K?E\::3#*"WVC[&;C[*+Y8\P>;G&W=UZ\;L;<\9S0!I
MR:'I$LTDTFE6+RRN'D=K="SL.A)QR1ZT]](TV1KEGTZT9KH 7!:%3YP'3?Q\
MWXUEMXQTM-1%H5N2GVT6!N1'^Z%P<?N\YSGD#.,9[U!;>/-&NK^XM$%XOV:6
M:*YG>V988#&N6WN> .P]Q]* -6]\/:+J,=O'>Z397"6X A62!6$8'0+QP/;I
M4T^DZ;<W'VB?3[26?RS%YLD*LVPYRN2,XY/'O7))XCN;_P"(VCVL":A;6,UC
M-*8YT")-@C:XZG/7@X(XX&:Z?5-:@TMX83#/<W4V3';6R!I&48W-@D  9')/
M<4 6[.QM-/@$%E:P6T()/EPQA%R>^!Q4*Z/IB:HVIKI]J+]EVFY$2^81_O8S
M7,>(?&49\,6U]H_GRBZO([5W2,AH<R*KJP."K\D#WKHM%LYK.TD\V]N[E99#
M+$+O&^%"!^[)ZG!SUYY]J )[;2M.L[J6YM;"U@N)L^;+%"JN^3DY(&3SSS5N
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ANT>2SGCB_UC1LJ_-MY(XYP<?7%<CHOAC5=/U3P[=3_ &4I
MIVCG3YPDK$[QMPR_+R#L[XQGOBNTJDVKV*:S'I#3$7TD)G2(HV&0'!(;&.O;
M.: .-M?#GB73M)T(0)I\M[I]_/*Z-,P0Q2^9T;;G(W^G:I+#PQK6FZW=P16F
MCS:=<7K7BWTJ_P"D1!WWNFW:03R0IR .OM77:3JMIK6G1WUDSM Y8*7C9#E2
M0>" >HJ[0!P\7A75AX4\5Z8XM!<:M=7,UN1,Q55EQC<=O!'L#3G\-:Y_:]K>
MPO:PM#H+Z?O$S%DG."&'R\J"HYZ\].*[:D#*6*@C<.HSTH \WT#PMXCT_7X+
M^?3],B0:2]C,4NF9Y)-VX.Q*<EB!GT!//&*ZGPGHESI'@NQT74#'YT,)AD,+
MEE(R>02 >A]*Z"B@#AO#F@^)].LD\.WLE@=$M@\2W*%C//"0P5=N,*1D9/MQ
MZTW2_#6M_8]&T34X[46&C7"31WD4I+7 CSY:^7CY#RN3D_=]Z[NJMOJ%M=7=
MS;02>9);%1*5&55CSMSTW8Y(Z@$>HH X>'P=K4>AZ?:,++SK77O[3;$[;3'Y
MA? .S[WS8Z8XZT[4O"NOSZ;XITNV2P:WU6Z-S!-).RL"WEY4J$/ V'G//%>@
M44 <IK&DZO\ \)!IGB/3;:UFNX+9[:YM)9RH9&(;Y'V]0P/)'(]*S8_!>H0V
MD$D9M_MD^O+K%VK2'8G.2B';\V!W(&?:N]HH P?%^B7&NZ&(+.5([RWGBNK?
MS/N,\;!@K>QQBJVGZ->7?BF?7]4MH;8M8+8I;*_F$J6WN6/3KP!Z#GKBNGHH
M X31/ ,MGH>N:9>7>Y+R*2RM' #&"URY0>YS(Q/T [5GGPQXENO"M[I5QIFB
MV\JV3VL<MJ?GN6("AB2/D&,D]23Z=#Z710!3TJ.:+2+..YB$4Z0HLB!MP5@
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MYDNGO"6DB8.H5 5^15!'R@\G%>@:GJUEI%H+J^F,4)=8]P1G^8G &%!/6KM
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-)M (D (P<\#'N:T+[4+[3=?M=1U6>XDL9'MHDNK&<F*%F5=R2P\?*[<AN2
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME:&(?9I23(OWHR N0_;:>3VK"U;1=3N- \+WD.C"YN-*4"?3)I51G4Q>6P#
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M[U;;C=Z*?QQ61I^F>(M'L_#6J6^C27$ME#<6MW8-*BRA)'#!T.[:?NCOT_,
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M*[<AO8CGM5>^\=Z5!IUI>6HGNDN=02PVK;R*T;[P'#*5W!@,G:1DXP*Y/2]
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MRTMIKE;JS-U>/9P"2UE*NXD9%&_9M!.,XSQR#TKHXKV":\N+2-F,UN%,HV,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]1L18S[?* \L=Q\G#'+?]]'CICI:* .>M?"4%K>:1=+J-\SZ7:M:0JQCPR'
M.["=<*O(Q]T>^:,'P\L+6RTFWAU/4T?2Y9I+>=9$$F)3EU.$P023VS[UU]%
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M(VX(4(P)]E]<5)X@U>?Q%X,O]5MKC_B73WEBMBKH#MQ+$68XY/SD@C=_#VH
M],H) !). .]>=W_B?6/#R^)8)[T7\EB+(V\\L*($\\E3N"@# (SS]#ZU1\5O
MXCM/"^J)=ZA(+5C;&%FEB:=MTRHZG:@&S##'&>Q)'% 'H<>LV,NMSZ.DQ-_!
M"L\D9C880G .[&#SZ&K]>:ZG!J,/Q U$V>KS0SV_AY9#<-#&[N1+(0"-H4#.
M,X7H.W6GV_B?6O$ TNQM&EMKF;2([]Y(FC0R2-QQO5@5!'( S\PY]0#T>BN
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MD_BS2+?Q%::(UTAN[F(R+@\ 94*,^K;N,>AH EM?#>FV6J1ZA;1R1SQVXMD
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MVRK<PVWV2-A_#%D':!]169+X,TN>U>WEDO&1[T7Q)N&SYPY# ]N><#BNBHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*OY<_C7;#I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LKQ#=M9:!J5RGWX;:
M5Q]0F:U:BG@2XADAE57CD4JRL."#P?TH YKX=VRVG@72(E((\@-GU)))_G75
M5YMX5U3_ (0R^F\*ZY)Y,"R%]-N96PDL9_@R>,CW->C)*LBJR%65N0RG((H
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M"O+C=:MXK\=>';I_#]_IO]F^:UTUTH"<[>%;//2O45.5!SG- "T444 %%%%
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M#*NJ'0]*#-T4VL>3^E $/_";^%O^ACT?_P #HS_6E_X3;PN?^9CTC_P-C_\
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MPY_T =+_ / 2/_"@"O\ \)OX7_Z&+1__  .B_P :0^.O"H&3XFT8#U-]%_\
M%5:_X13P[_T =+_\!(_\*/\ A%?#PZ:#IG_@)'_A0!4_X3WPC_T-&B?^#"+_
M .*H_P"$]\(_]#1HG_@PB_\ BJN?\(OX?_Z >F?^ D?^%'_"+^'_ /H!Z9_X
M"1_X4 4_^$]\(_\ 0T:)_P"#"+_XJC_A/?"/_0T:)_X,(O\ XJKG_"+^'_\
MH!Z9_P" D?\ A1_PB_A__H!Z9_X"1_X4 4_^$]\(_P#0T:)_X,(O_BJ/^$]\
M(_\ 0T:)_P"#"+_XJKG_  B_A_\ Z >F?^ D?^%'_"+^'_\ H!Z9_P" D?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 !&1@U\Y>$/$DNB^'GL+B*:UT?4-7DAN]3A(WH-B
M?NQ_=]V[ G'/3Z,8$J0#@D<'TKBK'X9Z79^%-2\.F[N9[2_E\YFE"%HWX^9<
M#K\HH ->UJT\#V&A:5HMG"@OKA8(0D+2JB#&Y]J$,[<CODDYK,U#QSXDMK;0
M$73;:WO-0U%[&07EO+&K#< DBKN#*I!S@Y/;M6A)\,;*?P_9:3-J^I.-/G$U
ME<ED$L'^R#MZ=#STP*OWO@>"_;1Y+G5+^6?3+K[6)796::3*_>XP!\H&% %
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
F444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>arwr-20230331xexx321001.jpg
<TEXT>
begin 644 arwr-20230331xexx321001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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MO8#-/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"(?+/CU
M6I:@#$W9'HG]:GH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@"NO_'XW^X/YFK%5U_X_&_W!_,U8H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@"LO_'X?]P?S-6:KH,W;'_8'\ZL4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M61,E=RG(R"01^!!%>7W6LZG?^)?%%G-<7-M%'X>$X@24_NI2BL2/0\D<5O\
MPIMA#\/=,E\Z9S,C,5D<L$^9AA1V% &C>>.] L-6BTZYN9HY)9#"DIMW\HR
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% $"?\?4G^Z*GJO'_ ,?LO^Z*L4 %%%% !1110 4444 %%%%
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MD'Y6.>O3'I5_Q-J=[X,\5>'39W5S/IVIS?9;FVN9VFP<J%="Y+ _,<\XX'%
M'H=%>4ZSK&O^$O%4_B![RXO/#;7AMKJU)+"V&%PRY)[DGC'3'<5VOA.[BU&#
M4;Z"]DNX)KV0Q.92ZA.,!03@#D\"@#H:*\IU;6S'\6]1T[4M;O+/3$L%>)(K
MEX\2X3&T*?F8Y/&#GTK-U'Q)XM@\"^')=0N;JSOKO4C!*Y01220GID8X/OP>
MA]Z /:**R+]&?7=)A$\Z1!99"J2LH<KMQNP?F')X->4KXFD^W>./[1\3WEI/
MIUQ)'I4*W6"QW2 *$_CY"#D' H ]MHKR[5?$?B:Q^'.A:IJ5G=B0SK_::V^8
MY3",X)(Y0G"DXQZ9&:NVNNV6H^$O$>KZ!K]Y-%#I[/';3NS2VDJ([9W,2Q!X
MZY'RG!QP #T2BO.M O=2OO@O'?->W+W\D3N]P9CYG$I!(;/'RCM72>+=2N-#
M\*S?V:KRZ@Z?9[)"^YVD*GG+<L0H9N>3MH Z&BN5\(^(%\6^ X;YI6%P86AN
M#&Y5ED48)!'()X88]17%Z1XMUK0+E]$\67SRPZE:>?I^IYV8+)]W(Z')ZYX/
ML10!Z]17GWB'3;VW\(76M1:YJ<9M])5H8H[IQ^] 9FD8YRQ.0.>F/RM_#RUN
M[KP_I.MW&KZA<2SVS^?%/.TB.Q888 GY2-IZ>M ';45YW\2+74-*\.:[X@M]
M;U&&93!]FAAN&2.(;D1OE'4G+'\JIZUJVH^!_ $.MKJ%W<WU_;6\/EWDIF6*
M=E+,ZY/'&[CIPOX@'J%%>:>)(-5\,_#N/7H-=U"75K7RIII)9F>.?>R@H8S\
MH7YN, 'BNOT_6;G6O!,>L6$ %W<61EAA)R!+M.%YQD;N.U &Y17E/A#Q9::I
M<V6FZCJNJ:=XEAG"W,-S(QCNF!^9 I.U<^@"D'ID=:ESK4B?%G7]/U/6=5BT
MR"%&@AM[EUQ(WE  8Z ES[<T >PT5YWXPUG6/!WAK2])L;V2[U._NFMHKZX
M+(I?()SP6 95R>.,^U=$OAFY@@M3!KVJ&ZBE1Y9)K@NLX# LI0Y501G[H&*
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MX8BN,  ELG)R .!FO0J* //[G0/'USXGEU%-6TBVMG/E($1GD@ASR$+)C<<
MGU('8"O0*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@"M'_P ?DW_ :LU6C_X_)O\ @-6: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBN,U6VAD^*^@N\2,RV%PP)'<,N#^&XX^IH [.
MFO(D:[G=5'JQQ3JXCP[:VWBR]UK4]8MXKSR;^6QM[>;$D<$<>%X4C 9CDD]<
M$4 =JSJI 9@"QP 3UIU><>(]!MO#T_AU-+MT/F>(%EBB9MHC+1$%0W)"Y7/]
M#@5HR>-[Z'2;V5]+A>]L]6339(HYSM?<5PRD@<_..#CZT =FTL:R)&SJ'?.U
M2>6QUP*?7)O=W*^)_#\>K:+9-J$R76RY@G+_ &95 SC*#.X%1VZFLQ/&FIZE
MX;UB]L_[.CEM+"2<HLC&6VE4$F.1& .0!UQC(_, [^BN4LM?U.9M,TJ-+6;4
MYK 7L\LC,J)'PJG &2Q)]@,'Z53_ .$ZO;B?2+6QTB-KN^GN;:6.6Y*B"6#.
MX9V\KWSUQVS0!VQ95QN8#)P,GJ:6O,]4URYUB313/IT4>K:=XC6TDC$N4)\F
M0Y5\9"D;3TSQTK;F\:3Z;IU\^J6,:7EMJ*:>L<#M(DC.J.K<+NQM?) !/'2@
M#L:*X:?QSJ5OIHG.B,93J$-I&T@DA2=)#PZ;T!SV(/0\Y-=;I<M_+IT<FJ6\
M-M=Y;S(XI-Z !B 0V!G*X/3O0!<HKR^Q\39^(]I?_P!I6\UEJ[2V"P+,K&!8
M_P#5-@<C>V\\_P!X5T^K^)M1M?$%SH]AIUO+)#IWV_SY[DHNW<R[=H4G/R^O
M>@#J:*Y;4/%LMIX:M]?CM;0V,UK',HENG1V=QD1JHC;).0!TZ]!5+5_&FJ:/
M8BYO='MK4I9BZ>*2[W-(V3F*,!<DA1DL1@9].: .UW#=MR-Q&<4M<//J=M#X
M[BUJ562!?#,MR_&6""5&Q]<9JU!XPNH[G1AJ%A##;ZS&SVKQSEFC(7>$<$#D
MJ1R.^1Z$@'745QNC>,[[4[C06N-)BMK768Y#"1<^8ZLJ;\D;0-I (ZYZ<"G:
M1XVDU;4+(1Z<_P#9]]N$,JK(7CP"0TGR;0&QV8XX_  ["BBN'\*Z;:^*M)?6
M];BCOY[NXF,22_.MK&'*A$'\.-N<C!)- ';EE#!21D]!GK0S*N-S 9.!D]37
M!WFFW&C>*O#<-D/MMSY-\D<ES(1M0E&4.W)(7..Y-/F\3V^K^&O#FJ7FD)+]
MJU>& 1F<CR)A*R"12!\V&4D XXH [JFF1%959U#-T!/)KCQXXEFU-$M-.-S8
M&]-DTD7F,XPVTRX";=@8$?>SCFJ.AV3:]XQUZ76-/M)S8WT)AE\YB]N4C5E"
M?*.,G)Y')/!H ] HK@/%$%E-\2=%6^TXWT+6$^8A#YG(9<$KWQD_G6DEVOA_
MPG>ZMI'A^9%\YY9-.8^4RJI\MF50"!\J!\=\GGF@#K:*YF7QA"FA3ZW';B73
MVD2*R='):X9B%!*[<J-QQW. 3CH*H1^.ITBNX[G2W6Z2ZAM;1@)$ANWE)"X9
MT!&,'=P>G&<B@#M:*YBY\1:MI5HKZGI$*N;^"T5XKG*2+(P7S%^7(P3C:0,X
MZUG>)_%&J1Z?XCM-.AAM[K3GMXDG:4G<LV,,!MX89'K0!V^Y0X7<-Q&0,\TM
M<G/>%/'-C#+I%J=3?2YG2X6X8XPZ_N\[1\I)!SC(YX]9-*\8C5-.TZX6R\J>
MXDE6Z@>7FU6+/F,3CG!V#H,[Q0!U%%<7H7CN36]2L4BTV;[%>ABD@@F!A &5
M+L4"$$#^%C@D=>M3>*[B:X\2^'- \XQV6HM</=!6*M(L2*P0$<X);G'4"@#K
MJ:9$5PA=0YZ*3R:XGQ'#;>#[C1+_ $>U6V$^HQV=Q;P#8DR2!ADJ."P(!!QG
MMTK"U."[U%O&5_<Z=82W.FR[[>X:Y826QC@#)Y9$?."2V,@$D_6@#U(31,VU
M9$)SC 8=?2GUYGHVE:;9R^#;^?P[9_;+Q%1;R&Y8%&$!=79-H#,P#9ST]372
MZ=XDU'4I+:\@TJ)M&GEDC%P+C]Y&J%AYC*0 %)7& 2>1]* .GHKCM.\:W&I7
MEJ;?33)8WH8P2+Y@:/"EE,F4VA6QU!.,CK5OPCXEU'Q/90ZA-HHL;&:'?%*;
MI9"S;L8V@# XSD_E0!TU->1(UW.ZJOJQP*Y?4/%=W$-6N=.TZ.ZLM(8I=L\Q
M21V50SB-=ISM4@Y.,]!ZUE7Y7Q/XWL;6:RL[[1Y](:XC2>1A\KO&#(!L.'P<
M#GH>HH [^BL#Q!>P^&_#"Q6LD=N2$L[4RR85"WR@EF/\(RW)_AK(^'&JO<^'
M+O3/M,=Y<Z1<26BR^8")D!S&V1G@CC//W: .VHKSR'XBZO)X:BU]O"RK8S,B
M1'^T%+.S2;, ;/7UQ6W#XFU2:^ATLZ-!'JY@>YFMWO@4BC#!5.]4.2Q/3''/
M- '445R-EXX%[/H86P"0:C--:S.T_P UK/&&^0@##9*X!R/6GZ%XS7742-;6
M%;HWTMH\*7&\!(QDR@[1E2"N.!]X<\T =4K*PRI!'J#2UYEX"UZXTGPWX?LI
MM/06%[>W%K'<B?Y@_F2L/W>WID%<[NW3%;FF^._[3N[+[/IDLEC>3/"D\>]F
M3!(#.-@4*2.H<XR/? !V-(2!C) SP*Y"P\=>=JD-G?64-H7AFFD5;KS9+<1X
M)$BA<!B"#@$FJ4^I7>K^(?!U_+I"6]M-<SO;SF8M($-O(0&7: NX8;&X_=H
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M>9?:>]C<+(R-$SAP<'&Y2.JGJ,@'VK)\4W=PU]HNBVSE#J5RPG93@^1&NZ0
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M %%%% !1110 4444 %%%% !1110 4444 58.;J;ZC^56JJV__'S/]5_E5J@
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MN/3TKJZYBY\:0VVIZI9#1]3F&EJKW4T0B*(K+N! ,@8\ ]!GB@#2\.#5!H<
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M[T#^)1_=]"<9],8)RW\76\,NJB:RN4BTNX2&XD 5MJL@;S, YV@$9[@<XX-
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M!4CT"8^(K'6;J_$LUM9O;,JP[ Y9@2WWCCH./UI-.\+VNGZ]JVJ"1I/[1(S
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M;'.2!SCU%8$WV&SN[$:!<.UI?Z1=S:AMN#)D"-3'(YSPVXD;N,\UZB%"J%4
M #  [55M]+T^T$XMK"UA^T$M-Y<*KYI/=L#D_6@##\":=%;^&=/U 3W,]S?V
M-L\[SS-)R(QC&>G4]*X_6K76+KQ+XX_L>Z(V+9_:;5%7=<1>2=ZJQ&5;&<$>
MOTKU2**.&,1Q1K&@Z*HP!^%-6W@2=IUAC65AAI H#$>Y_"@#B&U/2?L7@BYT
MJ<6^F&[\E TFT*OD2 (V3U# #![BN>O[N.Y^&_BWR[P7,:Z]B)A(6 3[1$5
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M$YZ^]>GW-K;WMNUO=013PMC='*@93@Y&0>.HI/L=KES]FAS(-K_(/F'H?44
M>7Z_(VK^)[FQU'6[33(H[&";3YKE&/S$$O)$1(@W@XZ[N@P.N>[OOL+>#9/[
M;D-S9&S'VJ1D*%UVC<Q4<KZX'2M!]*TZ1+9'L+5DM2#;J85(A(Z;./E_"K=
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M'49A/]JO"/-M6VJI&"IWK\H( Q]1574?">L:AIWC.R2&*,ZI<QRVDCRC# ;
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M(K<HMW<01ADMR^-H89R3R#A0< C/6G^$+"YL?#=JU^Q?4;E1/=NW5I&4=?H
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M@ HHHH **** "BBB@ HHHH **** "@X[T5R/C2.>35/"Z17MQ;A]3V'RMO\
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MS3-3M-8TV#4+*0R6TXW1L5*DC..AY[5R6FWFOW^L>(F.ME+33;J2.. 6L9+
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MD2.^OX+=W&0LC@'&<9]AGO4-_P")]"TQI5O=8L8'B95D1YUW(6&0",Y&0":
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MMW%G;;-5DL;,KE/- "X!R3\V6([?2@#9U'1;+5);::X61;BV),,T,AC=,C!
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M:T,%L%,[F4#RPWW2<],]O7M0!'!X3TJW6VB1;HV]JRO#;O=2/$A7!7Y2Q'!
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M;R3!;102PE$(;#[P0Q)(/*<8 ZU+=Z_H]A<&WN]4LX9P5!B>90X+'"_+G/-
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M9-W;(\<3ACPKXW#'0]!7$V7BZ[UNQMM4L]3T&VMI9=C0W;9:/$FT8*L,D@'
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M+=1+#-)+.[2-&IR$WDY SGC/<UF:/X\LI['0$U.6*+4-4MO.*Q@A$X]R<9/
MK>LM?TG4;Z6RL]0MY[F(,SQ1OD@!MI/T!X^M $/_  C6F&^^V/'+),;+[ Q>
M5B&A_ND9Y^O6J8\#:$L%M"(;G9;PM;K_ *7+EHFQF-CN^9>!\IXX%:VH:OI^
MDHC7]Y#;A\[?,;&<=3]!W/:L3Q1XL@T@:9;V]S DNI2A$N'7S$CCVDF3 (W=
M !SWSVP0"[;^$]+M!IPMQ<I_9T3PVV+F0[%<88<GGH,>F!CI2V_A73;:+38H
MOM0339&EM@;ESM8@@YY^;@D<]B1WJS;7<ECH@NM:O+0&-2TMR@,<97)VMACQ
MD8R,]<XJ-/$NB2:=-J"ZK:?9(&VRRF4!8SV#9Z'D?G0!!:>$=%L=6?4K:T:*
M=Y#*465_*\P\%Q'G;N]\55?P%H#31N(;I(XKC[3'!'>2K$DN<[E0-A3GGBM>
MRUO2]2DN8[*_M[A[5MLXCD!\L^_IT/Y57@\4Z!<V]S/#K%D\5L TSB9<1@]"
M?8]CWH MZIIMMK&G36%V',$N XC<H>"#P1R.16=)X1TJ9=465;B3^U(TCNRT
M[9D"C:O?CCCBIG\4Z#''-(VKV@6&7R)#YH.V3&=OUX/Y'TJM>>--!LKO3()-
M2M<:B&:*7SE"! I.\L3C!(VCU)]J -R"%+:WB@CSLC0(N3DX P.:DK(L=65X
M=3NKK4=.DM+6=T$ENQQ"J@$K(22-PSSC%2)XCT22Q>^&K60M8WV/*\ZJJ-V#
M$G@^QH TZ*S;'Q#HVII<O8ZI:7*6PS,T4RL(QR<DCC'!Y]JFT[5=/U:%IM/O
M(;E%.UC$X.T^A'8_6@"Y1110 4444 %%%% !1110 4444 %%%% %*T_X_+S_
M *Z ?^.BKM4K/FYNCZRC_P!!%7: "BBB@ HHHH **** "BBB@ HHHH *YGQC
M:K/#92++J=K<0NSPWFGP&8PMMQAT )96Z8QV[5TU% 'GMM<:KI^J:7?W^A73
M33:)]F,=E!E8Y0^[8<'" C'4@?E5+38]3\/1^&-0O-%O[JWATIM/GMX(?,EM
MY=P.[9Z$+C([8S7IQ( ))  ZDU%;7=M>P^=:W$4\1)&^)PRY'7D4 <7!;,/'
MFAS+H\UI:1:5,-BVY\N LX*H2HVAL Y /\ZU/A]%-!X%TR"X@G@FC5U:.:-H
MV7YV[, >F*Z0R(KJA=0[9VJ3R<=<4Z@#SW0=3M/ASHB:!K0N(_(F=;.=(6=+
MM7<LH5@,!^<%6QTSTYJG-H.HZ5;:=JT]C/)(^OOJEY!;*9GA6164 !>6(^7.
M,]Z]'O+*UU&U>UO+>*X@<8:.50RG\#3+:&VTRUAM4E98P=D8FE+L?098DG\Z
M /-=NIP6.KS_ -AWH\[Q)]H#FT\R:"%D"^=$O.6&",@'&[-5[?3;R/3)+>XT
MO4W1O%L=R1/;M(S0':2[8!R, Y/3/%>N44 </JFF70\>R?9;26."[T&2SAGB
MC/EQR^86^8CA>#GGKVK(T2Q9[&.*Y\/ZW%J>FV,L,DUU<2R0J3$5/DC<0^[C
MA1Q^ SZ?10!YU)H]PGP8CLH=-E2_2VA66!82)"T<B[N ,MT8]\]1G-7O$VFW
MC>)K"32Y1"NM1FRU 9V/Y2@L)%[[@N]<_P"T*[>LNTT"PL]8N=5C25KNXX9I
M)6<*#U"@G"@X'3T% &@0EO;$(A"1I@*@SP!T KR7P]H&H:-X9T#Q%9:;=/?6
M"/%?:;/"P=XRY+-&K8PXZC'7I['UZB@#S#5(?M'BC4+N]T;7[_2M8M(4@2S\
MZ':5#*T<R97 .<Y;CD^IIT36&G>--=LKK3+FX4Z1:P+!!!)<G&UE*%P"1G@;
MFQG&:]-K.M]%MK;7;W6$>4W-W'''(I8;,)G;@8]SW[T <1H.GZEX3U&R?5[>
M[N[5]&BM UO T_DR(26C*H"<'/WL8XQZ52\+>';S3?$7AVWU:PFF$>FW/S-
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M* "BBB@ HHHH **** *=J +FYQ_SU_\ 915RJ5IS<W7_ %U_]E%7: "BBB@
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M34_,:\TY-/WBV52BJ' ( ./XSQQT'UH $\5RC7])@N(8(M+U2Q-Q;W.\Y\T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIK$ TF[ +D9KD]6
MUJXU'4&T70WQ<8_TFY7I;@_UJ+Q9XC6&9=&L[J."ZD&9IY&VK#'W.?7TJ#1O
M$'A71K+[-ITTUP%),DD<#NS-W+''-==.C**YW&[Z?YF$JB<N6YT6B:#::)!Y
M=NN9&^:69^7E;N6-:U86G>+]#U27R[>^029P$D^1B?H:W%;/:N>HJG->HG=F
MD7&WNAG.<5E>([C[/X?U*3;G;;N1_P!\UJUSGC:8IX<GC4$M-)%"/?<X!_2G
M22YUZA-^ZS5T>#[/I%G%C 6%1CTX%7\TP82-5'  P!5'4=;T[28P]]=Q0 ]
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M %%%% !1110!G:><SW?_ %W/_H(K1K,TT_O[ST^T''_?(K3H **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M10!GZ9C_ $G_ *[M6A6?IO6Z_P"NYK0H **** "BBB@ HHHH **** "BBB@
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M)!?^]MSC=QUQFM6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **0D#K1N&,T7 8["-&9B H!))/2N!42^.];8EB/#UF^!M
MZ74@///<"K?B6^N->U8>&--D,:LNZ]G4_P"K3T!]:Z)(;/0=$*1*([6UB)X'
M8#G\373!.C&_VGMY>?S,96J/7X486N :OJ5KX:M%"VRJ);UD_@C'W5'U/Z9K
MK+:%8($B1=L:*%5?[H Z5SG@RU9K6?6IU(NM4?SWW?PIT1?P'\ZZ<-6=62T@
MME^95/;F?4=BJ.HZC:Z5837MW((X(5+,Q/:KI8 UXS\3M:O=5\26_ARQADE2
M B5D&?WDAZ#Z &JP]'VU11Z#J2Y5<Q]2\17?B+Q1"^I75S;Z:7$ALD&1Y8.5
M#+UW,0./>O1K/2=2\3R)<ZLKV6EHV8M/7CS5[%^_3M57P3\/(=%ACO=45+C4
MF^<CJJ$_UQQ7H ''3\*Z<3B8)J-'IU_R,:=)OWID,%O!:6ZQ01)%$HX55P *
MQ/#@6YFU'4PK#[3<,HX[)\G]#5[Q#J"Z;HMS<$,65"% [L> /UIVAV/]G:)9
M6G>.(!CZMW/YYKD5U3<GU-'\:78TP.*6BBLC4*@N(Q(I!/8C'X5/FJE]>P65
MO)<7$BI%&NYF--*[T$VK:G(>!KVWTWPI.MU<*L=G<21EF8< $8_.M6SM[C6K
MR+4;^"2*VC<FVMF!'T=P>_H.U<;X'L6\0ZE?WLKN-*BNRT4!X+2<'+#TP17J
MN,# '%=>*]RHTOB>_D<]&\XIO8 !3J0#%+7&=(51U2*XN-,O(;1_*N'A=8Y-
MN=K%>#[U>I">#0#.8\$O.= BBNL?:879)<*%&X'.,#CO73BL+PT@%M=2#[LM
MW,1_WUC^E;HK2K\;,Z?PH6BBBLS0**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,_3.?M1
M_P"F[5H5GZ7TN?\ KX:M"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!F:,2T=R2<G[0]:=9&A,SQ3E@1^_?\ I6O0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !12'I33P#0!@>
M--5ETOP_.UJN^]G'DVR \L[<<?GFK7AO1XM"T*UL4R61/WC'JSGJ3^-86JD:
MK\0-*L0I:'3XVNY,?WR,+79 Y /K6U3W*<8]]7^AE'63E\A?X>*Y'P)(LUA?
MW6[<T]_*Y/X*/Z5UYZ&N.\%+]D?6-,<\VU^Y7_=8!@?U-$%>G+Y!+XXG7NX1
M2S': ,DFN*M _BSQ,-0<$Z3IKD0#J)I.06QZ"KGCG49H-,@TVT8K=ZC*($9>
MJ@_>;\OYUOZ381:9I=O91 !84"YQU..33A^[I\_5A+WYVZ(M#&*?133Z5SFH
MK' SG%<IK<DNN:U#H4/-K'B2^<'H.H3\:N>)-<72;%4A7S+ZY;R[6'^\Y[GV
M'7\*D\.:0=(T[$[>9>3MYMS+W9S_ (=*WA[D?:/Y?YF4O>?+]YLQ *F%&%'0
M>E/IA('6L#4]>E:[.FZ/&+J^_C.<)"/[S'O]*SA%S=D6Y**U+>K:W#IP6)1Y
M]Y*/W-NA^9S_ $'O532]%F>[_M+6)%GO&YCCQ\L ]%]3[U-H^BK8R/=7#-<W
M\O\ K+B0<D>B_P!U?:MOO5N:BN6'WD).3O+80*%Z"N9\>7YL?"]PB?ZVY(MX
MQ[N<5TS' KB=49/$'CFTTT#=:::!<3XZ>9SM']:,/'W^9K1:A5=HV1U.DV2:
M?I-K:*H BB5:OTP$8Q1N Y)%9-MNYHE8?144D\40S)*B#W.*P[GQCH-NQ!U.
M)F!(*Q@N1]0M5&$I?"KB<XK=FQ>74=G;R7$S!8XQDDUCZ!:3.\^K7BE+J\()
MC/\ RR0?=7\JY^;79?$=T+BRL+F\TVW<%(E4K]H;U.[C:/2M1-0\6SH!#H-O
M:CUN+E6_] KH=&4(V=DWOJON,/:QE*ZV.MHKD_L?C"Y4+)?V5J#U\F,L1^=(
M?#.L3?\ 'QXGO_<0JB_TK/V45O-?B:>T?2)UN1ZT9'K7*_\ "%1.%\[6-9D/
M?=>-C\J4>!-(('F_:9\=/-G8XHY*?67X?\$.:I_+^)TDD\<0)=T0>K-51]7T
MY/OZE:K]95']:RQX)T(@;K+=]7;G]:G3PCH"=-*MC]4!HM1[O[O^"'-4[(L_
MV[I).!JUGG_KNO\ C0==TD==6LOQG7_&H/\ A%M!_P"@/9?]^5I?^$6T'_H#
M67_?E:7[KS&G4\B=-;TN5ML>J63-Z"=3_6KT<JR*"C!AZ@UAR^#=!FS_ ,2R
M%,_\\LI_(U2?X?Z7YGF03WUNXZ>3*%_I34:+ZM?+_@BO4[+[SKJ*Y ^&=8M%
MSI_B*\)'1+G]X*A_M7Q7I(W:CI,5Y$.LMH^3CUQUH5)2^&28>UM\29VM%<QI
MOC71M1E$+2FVG_YYW"E3^M=&LB.H*,&!Z$&LYPE!VDK%QG&6Q)13<]*=4E!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!F:-CRKC'
M>X>M.LO165H)RIR/M#5J4 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 45GZO<ZA:V32:;8I>W.X!86G\H$=SNVGI]*YS^V?''_ $*%
MA_X-A_\ &Z .SS29]JXW^V?'/;PA8#_N+#_XW0-9\=_]"EI__@U'_P ;H [+
M/L:,^QKC?[:\=_\ 0HV'_@V'_P ;H_MKQU_T*5A_X-A_\;H [+/L:8QPO(-<
MA_;7CK_H4;#_ ,&P_P#C=']L^.3P?"5CU'35AZ_]<Z3#J,T!O.^(7B&4X.Q(
MHU]AC'\U-=DI^48Z8XKRJSU/Q9IOCV^/_"-V?GZA"K"W.I@ ;>X;9SW[=ZZ8
M:SXYP,>$;''OJP_^-UT8AJ4E;LOR,Z6D;>9V/:N-U.,Z!XRAU?)%I?(+>Y_N
MHP^ZQ_E1_;/CK_H5M.'_ '%1_P#&ZK:C=>,=3L)K.Y\)Z>T4JE3C51D>_P#J
MZBE-1E[VST8YQYD3^,]UGJ6C:\8FFMK*5A.%YVJP #8KK+2\@NK9)X)%>)QE
M64YR*\YT_6?%]E%'X?O/#=C=R>60C/J842)Z?<.<52L-.\=^'[^2XTO0K6.Q
M)WM8'4@^?7!V<?E6LN5Q47NMO-$1YE)M+??R/7-W'2L[5]7MM(LI+F<G"\(H
MQEV[*/>O/;WXG:YIS,M]X6MK5PNX)+J/)]A^[Y-0PZGXDUZ^M]8N/#NG31Q#
M-O;/JZIL/]YALY-3&A)6E43L-U$TU%ZG7:%I-W=W8UW5_FNW!\B'M I]O7%=
M'++'#&TLC*BIRS,>!ZUP6H>-_%&E0K-=>&M.52<+&NK!F8^V$K*O=3\3:S+'
M+J>D:2MJ!YBVCZN(_H7^7GZ4VIU'S25D)3C!63NSK&O]0\42&+2VDM-,!(DN
MV&&E'^QGI]:W]-TNUTJV$%K#M3J23EF)Y))K@F\?ZS9*$;1]%"@?P:N"H]O]
M6:K#XHZX[!;?PY:W9[FWOV8#_P AT2A4FN6,;(2<(ZR=V>J9/I02,5P&G>+_
M !KJ0WQ>"X$C[/+J04'V'[NI[_5O'DUG)'#X:L;5R.)CJ@;;^'EBL'&SML;-
MZ7.EUW6+?1-(N+^X<*D29&>YZ ?G7%^&=>TO1;&1[N62XU>^D,\T<$9=QGHN
M<8XKDK33?$OB75#<2:3]OM[5S',KZJH21_\ 9;9T_"N\MKWQ=9QA(/!.G1A1
M@;=5'_QNNN3I4X\F[>_0P]^4N;9%PZSXCU J-/T-;=?^>EXV/T'-/&B>(+T$
MZGKGEH>L5E&%X_WCR*K?VUXW&2?"-B/^XL/_ (W6?J/CKQ)ITB02^%[-[F0[
M4@BU4,Y]]OE\#ZXK*,V]*<4OZ[EN"WDS9/A#1+13<WOG7(3EI+N<L![\G%5+
M6RC\1$1VEHMGH8^\0@1KGZ>B_P ZR[\>,=9GADO/"MJT$:AEM&U8!2WJW[OG
MZ5KC5_&R@!?!]B . /[6'3_OW1[9K=W9/LT^FAUEO;QVT*Q0QJD:C 51@ 5+
MBN._MGQQ_P!"A8?^#8?_ !NE_MKQO_T)UA_X-Q_\;K#7J;)6T1V&1ZT _C7(
M?VWXX_Z$^R_\&X_^-T'6O')''A"Q'UU<?_&Z!G8?A0:XTZSXZ_Z%33E^NJC_
M .-TG]L^.^WA/3C[_P!JC_XW0!V>*;N'O^1KCO[9\=?]"MIH_P"XJ/\ XW0-
M8\=$_P#(L:9_X-/_ +"@#LMP]_R-&X>_Y5QPU;QV>OAG2Q]=3/\ \12_VKXY
M[^&M*/\ W%#_ /$4 =?N'H?R-+N]C^5<?_:OCGMX:TK_ ,&A_P#B*/[3\=_]
M"YI/_@S/_P 10!UX('K^5!(/4'\JY#^TO'7_ $+FD_\ @R;_ .(H.I>.^WAW
M2O\ P8M_\10]0-Z_T73-47;>V<4PQP6C&1]#BN=?PIJ&DN9O#VJRQ^MM<Y>,
M^PXXJ3^T_'G_ $+FE?\ @P;_ .(H_M3QUW\-Z5_X,R/_ &2M859QT3T(E3C(
M6R\7FUNEL?$%L;"YR )#_JI?<&NN65' *'<#R".AK@M1E\6:I:/;7WA'29XF
M!!5]2X_#Y,BL>R_X3WPV99+30[6;3P=PM#J'F.OLK;>GX4Y>SFKQT?8E<\-]
M4>KALF@L!Z_E7 6/BSQ5J:/)8>'=+EVG#J-6&4/H1Y?!JW_;/CKOX7TP?75/
M_L*RE%IV9HFGL=GO'O\ D:=7%C5_'9'_ "*^F?\ @S/_ ,11_;'CK_H5M-_\
M&@_^-TAG:45Q?]L>.O\ H5M-_P#!H/\ XW1_;'CK_H5M-_\ !H/_ (W0!VF:
M*XS^V?'/?PKIO_@U'_QNI[/5O%TMY%'>>&K&W@9P))5U(.4'J%V#/YT =911
M10 4444 %%%% !1110 4444 %%%% &9HP'V><X _TB3I]<5IUGZ2 +>7'_/=
M_P#T*M"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $
M*@]12>6O]T?E3J* &[%_NC\J-B_W1^5.HH ;L7^Z/RHV+_='Y4ZB@!OEK_='
MY4>6N"-HY]J=10!RGC'1;FZCM=4TP#^T=.;S(EP/WB]U_&KN@>(;/7K0/$RK
M<)\LT+</&W<$5N,,D5S&M>#+/4+D7ME-)IU^#GS[;C=_O#O6\9QE#DGI;9F3
M4DVX]3IP!2$<=ZXAX?B!IPQ;W6GZFG0>='L('X$<T@N/B-,P3[)I$"GJ^6)7
MWY:DJ"Z27WA[7^ZSHM?T6+6+(*)&@N8CNAG4?-&?\*YD^/DTN233-3BW:@@"
MQM RE)STXYX]_2K \-^(]18#5?$LWDG[T5G$L88>F[K^57V\/>&]$TZ=I[2W
M2WV_OII_F8^Y9N<UK!TH^[/WO0B7,VY1T(+3PZFKRC4O$'D74I_U< PT40[8
M]3[UCZMHV@W][)8:3IOVF_<?O91,XBB]V(.,^PJE;Z'K-X\S:'=W-EH\@^6&
MY<DS<]5QRJGUK;L-6;PY;"VNO#5Q:0)DF2U!F0^Y(Y_.MWS1=XRN^W8R23T:
MWZCM)^&VB64)-Y;K>SNN&:3D#_=':L>^LO"D/B=?#VE^'TO]4V>9,&N&6*!?
M5V^;'T -=5:^-?#]X,IJ<"$#)68E"/KFN!T>YMO#'Q;UB^U"ZC^P:R@-I>F4
M,A((^4G)QZ#-<TYXGF;DV;0ITDM$C=O+BR\,:;J5[/X/M8I+&!;@/$RR+*I;
M;A7*@Y[X(%=;I&I6FI:5;7:+'&9[>.9X0P8Q[U# 'TZUS7CK5K+4OAUKYL9E
MN%6 #S(FRI;(X!]?I7*^##;6/Q"TJ(-'##)X5A>4!_E=_D&3ZGK6+<Y/4U2B
MCUM[R!8B4FC=@I(4.O..W7%<))XDO?%<<>G6UO\ V9'DK?S/*I$8!^ZK@X)(
M]/6N!\(+:7NG7(EFAMWM[BX::[GG(*HV0$0;NA7/-4=.FF@\#>&+FRN ;R'[
M5*UM<*/)N4W8=6)XW@=!UYXK6,?9^\]7T(E)2]WH>Y6VHZ+HUQIOA^*:))I8
MCY$08'Y5'4_7]:MWVLZ=I[%)YT$O41#YG;KT49)Z&O*VBCF\?>%+S5(H]/BN
MM'_<JH(:.0A<)D]2,FLT17T7AV6RA>4^+%\0_)O;,Y4<@YZ[-F3^=9?WF[W*
ML^AZ7+J&J:NI\JXBT:U) #2;?M#D]!C.%^AY]JKV]WI_AOQ?8Z"ED[2W]O)<
M2:A)-N;:@YWD\]:X75AI3>*/B&NIR1+(+>(V63\V_P MB2@]<A>?>B\MI9-=
M\'VVN!GN1X>N/M"3GGS!&3\WJ<C--U';E6B!15[L]J:YA6W,S2)Y6-P<L-N/
MKTI!=6Y17WQ;7QL;<,-GIC\J\(LM2O8/AUX)NIIY1ID5W/'>R,AE1!O8)O7^
M(#/0UI^*K:VM/!.B"RU2:\MI]?C=+@ Q?(V\[5_V1G K,L]IB>&=2T;1NH.,
MJ0:R)/$NFQ>+X?#;,HO);9K@=,#!&%^I&X_1?>IK*TTKPOHUPT(2UL8RT\C%
MR1SR6R:\B\56.IP:?IGQ"A-F;A;M;IWA9B[(Y4(A[84*$('J?>@#W$HB@DA0
M!U)%1F:U%O\ :#+$(,9\S<-N/7/2O+_$=[I7B'X@>"+B0PS:=<V\TK)-C;@J
M=H8'_:&,'N,5R^GZIIUC\*C<7,<5W?PWMS;:;#-ATC+A26VM\N%!W<C&2/6@
M#WAKBUCC>1IXE1,;V+@!<],GMU'YUA^+/%$/AC2;74?LHO(KBX2 ;) /O D,
M#@Y'%>:PGP]H&D>'=-L[X75V+QA/<K^\M#,T8#LX _>;0P" 8^O45F7%P!\&
M=,AEF)>'7-A#C:5 +GH>@ (/MF@#WIY[>.9(7FC25_N(7 +?0=Z=-)%#$TDT
MBQQKU9FV@?C7C&N?(?',>HJAUR>ZA.EKC,SINQ%Y/<GUV]"#4?B:*";Q'=+J
ML=L]\GA!C+YIY%V%;D#^)\8QGG'3H* /:99;>"+S9IECC_OO)@?F34@48X)_
M.O"I+YHK/P)/JUPRZ(;"2)YFB\Y4FP5.Y2",@;0.XY]*]>\*6T5GX8L+>"YN
MKF"-"(YKM2LCID[200#C&,>V* -C:/?\Z-H]_P S2T4 )M'O^=+BBB@ I"H)
MSS^=+10 FT4A0$8Y'T-.HHL!R.O^';BVN3K?A]EBU!3NE@/"7(]/9O>M70-=
MM]<L?.B#1S(=LT$@P\3#J"*UV /45QGB*WE\/:O'XDL(\Q$!-1B'&Z+_ )Z8
M]5_E6\7[5<DM^G^1E+W'=;'9[0><G\S2[1[_ )U';3QW-M%/"P:.10R,.X/2
MI:PV-1-H]_SHVCW_ #I:* $VCW_.C:/?\Z6B@ HHHH **** "BBB@ HHHH *
M*** "BBB@#/TK_CWE_Z[O_Z%6A6?I?\ Q[R'_IN__H5:% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$>-DLD2LRX.1@D9%.2PLX[Q[Q+2!;J0;7G6,!V''!;J>@_*@"Q1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 9^E?\>K'_IJ__H5:%9VDC%B,_P!]OYUHT %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%<EX[U?5+'35M-!^;571[D +NQ#%@O\
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M#&=I/4C</;N,C!H Z&BLS5M;BTJ2WA-M<W5Q<;C'#;A2Q5<%F^8@<9'&<G/
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M_C33[>R^TR6M^H2#[1/&T&U[>/)&74D$9VL<#)P,XH Z2BN6\1>*+>'2KY+
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MI7H%[I]EJ<'D7]G;W4.<^7/$LBY]<$8I;*PL]-MQ;V-I!:P Y$<$81<_0#%
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MVMIUDFM'$<Z@'Y&(S@_A0!B6&FZE>>*HM<U*V2T^SV/V5(EE#EW9@SMD<;>
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M %%%% !1110 4444 9^C_P#(.B^IK0K/TC_CP3ZFM"@ HHHH **** "BBB@
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M\2;4CE\O*-@#Y1O//7'>NB'@O1QI+:=BZ*-,DYF:Y=IMZ8VD.3D8Q@8XJ$^
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M0E#J8RNX.#QCKG/I6'J'C/0-/TEM2;4K>6 2+$#%(&R[8P.OH<_3FFW"?:?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% &=HI)T>V)/)7-:-9NA<Z+:G_ &:TJ "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH S=!_P"0):_[M:59>@2>;HEF_JE:E !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9VB1B/1[11T"5HU
M1TC_ )!5M_N"KU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 4=(_Y!=M_NU>K/T7G2;;_=K0H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@"AHPQI-MG^Y5^J.D_\@JU_ZYBKU !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 4M(_P"05:YZ^6*NU2TH[M,M2.GE"KM
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%-(;>#N^7'3%.H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"CI
M/_(*M?\ KF*O52TG_D%VO_7(5=H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ Q
MFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** *.D?\@NU_P"N0J]5+2QMTRT'_3-?Y9J[0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% %+3.=,M/^N:_^@U=JEI7_(+M
M/^N2?^@U=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"EI
M1SI=H?\ IDG_ *#5VJ.DC_B56@](D_\ 0:O4 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!1TG_ )!-F?6%/_0:O51TG_D$67_7%/\ T&KU
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4=)_Y!%E_P!<
M4_\ 015ZJ6E?\@JQ]H$'_CHJ[0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% %+2QC2[0?\ 3)/_ $&KM4],_P"0;:_]<D_]!JY0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% %+2_^099>\"'_ ,=%7:H:
M2-NDV(_Z=T_]!%7Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH I:7QIEG[0(/_ !T5=JEI>?[,M,C!\I./^ U=H **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@"IIQ)TZV)[Q)_P"@U;JIIO\ R#;7_KDG
M_H-6Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J:><V-L
M1T\I/_0:MU3TS_D&VO\ UR3_ -!JY0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% %/3/^0;:YZ^4G_H-7*JV/\ QXVW&,1KQ_P&K5 !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 5K1M]I;OC&Y%./3Y:L
MU!;J8X(D(QM51^E3T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!7M"QM(2>I09S5BH;8[H(V'0H*FH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@""S&+6+_<%3U!:'_1(C_L"IZ "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH BA0+#&@Z #%2U'$<Q(>G XJ2@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (XQE5/J*DID:E8T5C
MD@<T^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &1_,BD]
M<4^F1\H*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "#C
MI2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44U1@4Z
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
&*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>arwr-20230331xexx322001.jpg
<TEXT>
begin 644 arwr-20230331xexx322001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M]0<5)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(6 ('K0!#
M;'*M[.14]5K3E),_\]#5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *8_WEI],?JM $5MPK8_OFK%5[;[K_P#70U8H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "FMVIU(2!0!7M>5;_?;^=6:JV?^J)_VV_G5J@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:PR1[4ZB@"K9_ZD_[[
M?SJU52SXA^CL/UJW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** (S( X5B%)/ )ZU)33&A<.5!9>AQTIU
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZGIQ>>R-S+,MBWR-\WR@>9R/EZU9E\3ZW<>*;/PA:M:QZDEKY^HWPB+I'Q_
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MSW3$10@8Z@<DGH,?4^_&VOQ&U%/!$E_?64":LNIG2D121&9>/F(ZX'/'MV[
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M"/:F^&]'\4Z+X;UJ!K.Y@34KCR]/LDD$C6,3LVY\YPN%;..N5KU:B@#RJ_\
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M:(LRV-W*?^?B52R#/8* N?\ ?K;UWQ38^'[BVMKF&\FN+I)'@BMH#(TFP L
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M+NW-U'%:H&<1  EB"0 !D#KG/ !- &_16;%JBZKX=.I:,R7'G6[26Q/ 9L'
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M*KVE[%>K*T0?$4KPDLN,LIP<>HSD?A5B@ HHHH **** "BBB@ HHHH ****
M"BBB@"EI/_(-A^E7:HZ0<Z9 ?5<U>H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *X_2;/7O#'A&ULUBT^:[CO&+*LDC!XGD9R%^4$/\
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M9:3IL]]J,RPVD*YE=@2 .G0=>M1M+IVC6<*)'';PR2+'%%#%C<S= JJ/QZ=
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M?V&HW'VE[=YO*D@E(^<@D$,IP#C@@UU=4K_5[#2WM4O;I(7NIE@@5NLCL0
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MY@6.78KERVX<GH!U/2NZK(3Q+I4FKC3$GD-P96A!\A_+,BJ69 ^-NX 9(S0
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ME%YT&E/()I'EP^UHBF<'J2QR?I75U6O]0M=,M&NKR3RX%*J7VEL$D = >Y%
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M],BC$4*1AF8(H4%V+$X]2>2?>GT %%%% !1110 4444 %%%% !1110 4444
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MU?JUAX:\,C5+2=3'XFD>6)K9F8AGG8$(!E@0P/ -7;O3[E9]4U?3-+G2UO\
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MYS;)IDT33"-BBN74@%L8!PI_R10!J6FNV)N8M,N=1LSJP11+#&_!DQ\P7/\
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M%/[/L);>W&DS12E;9T"Y\LJKDC@Y5C\W.?K7>T %%%% !1110 4444 %%%%
M!1110 4444 4M*.=,M3_ -,Q5VJ>F#;IEH!_SS7^57* "BBB@ HHHH ****
M"BBB@ HHHH *I7::;;7":E=FWAEC'EK<2,$(!_AW'J,]O6KM>/Z_>:U?>&O&
M37U]#/;VVJPV\4(B*[")8,8.XX7!Z8ZDG/.* /67LK:2]CO'A5KB-2D<C<E
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MU[4_$]H-$MWEL;:>YU<6S21QL5ECP61L;\J#M(*Y.?44 =JMQ"\\D"31M-&
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M6XRF<9)X)-7)_$-UI<MF=:TZ.TMKJ185GAN?-$<C?=63*KMR>,C(S^==!D4
M<UJ'@G3]2375GNKP?VUY0N"C(-@CX4)\O''7.:L:SX5M=9FLKEKV^M+ZS4K%
M>6D@23:1A@?E*D'KT^F*V7N((YXX'FC663.R,L S8ZX'?%.9T12SL%51DDG
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ML:C;TP.E*Z)(,.JL/0C- '&^+;75M(\#:L^G:C?7EQ(ZRM+*5,D<7RA]FQ0
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M,!I!N&>P(!KJUM;=+AKA8(EG<8:4( S#W/6BXM+:\0)<V\4Z [@LJ!@#Z\T
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MMR@''7O_ (FO4IK&TN7WSVL$K[=FYXPQV^G/:FKIUBHD"V5N!*H60")?G Z
M\<B@#S_6+RPO?$OB*RUZ:-8[?3(WT^.:38C!D8R.O."V[ SUXKH_! 2;X<:,
MN<JU@BG:V/X<'D=*W)M-L;A8UGLK:58QM0/$K!1Z#(XJ>&&*WB6*&)(XUX"(
MH 'X"@#R*UMX[+X=:)KK:C=QR71@AO[J6>655A+DG*AQ@9VJ<$'!/J<Z5M;H
M^B-::5XETO4@=162*V=72U?$9+0!M[GG[_4@$=*]&2PLX[5[5+2!;=\[HEC
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% %+22#I5H?6%"/^^15VJ.
MDC&DV/\ U[I_Z"*O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% #)H8KB%HIXDEB889'4,#]0:6.*.&)8HD5(U&%51@ >@%.HH *
M;)&DL;1R(KHP(96&01Z$4ZB@!L<4<,2Q1(J1J,*JC  ] *=110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRR22X.[>??.-O;IU!KJJX#X:PRWW]K^)KB/$FK7;-"?^F"?*OYD-^&#WKOZ
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MBB@ HHHH **** "BBB@ HHHH J:>-MA;+Z1J/_':MU6LO^/*W_W%_P#0:LT
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M!L$TT=[JUY<W]ZIY=VVQX] G3'Z^],U?P]IFDZ)>7.GVJ6TL :Y5H^H8<]Z
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M%?\ 0R6'_?9_PH ZVBN2_P"%G>"O^ADT_P#[^'_"E_X6=X*_Z&33_P#OY_\
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M_&KZO=R:IJV/]=-]R(_],UZ"NN P,"N3'Q-\$C_F9;#_ +^?_6I?^%G>"?\
MH9;#_OY_]:@#K"<#-<SXF\3I8*FFZ:R3ZW=@?9;<J2.?XV]%'6H#\3?!)!'_
M  DMA_W\_P#K5SVC^)_!.G^)-6URY\4Z=-=WQ158.<1QJ,!0#F@#<T_P%8P:
M#);W9,NH7!,UQ?9_>&8]6#=1@]/:K?AK7)3++HFK'9JMIWQ@3QC&'7U]_>H!
M\3/!6<GQ+IY_X'6=J?C'P%JDD-P?$EA'=P$F&=9<,GJ/H: .VN6)M)RHYV-M
M_*N2^%0 \"6NWIY\Y_\ (C5D#XM:0;Z]L+F>S$"Q9@O8KD,LI(/!7 V]/4U#
M\//&?AO2/!EK;ZAK5E!,))B4:7D9D8C]* /4Z*Y0_$OP6!D^)-/_ ._M)_PL
M[P3_ -#+8?\ ?S_ZU '645R7_"SO!/\ T,MA_P!_/_K4O_"SO!/_ $,MA_W\
M_P#K4 =/<01W-O)!*BO'(I5E;H0>M>>IX,\6Z.T^G^'==MK;1Y7+1K<1M)+;
M@_PJ?2MO_A9O@K_H9+#_ +^4?\+,\%_]#'I__?V@"]X;\+6WAZW?$LUU=S'?
M/=W#;I)#Z9[#T%:]Q;1W";9(HY!Z2 ,!^!KFQ\2_!9_YF/3_ /OZ*/\ A9?@
MS_H8]/\ ^_HH Z.VLX;6/9##'$O]V-0H/X#BISR"*Y3_ (6;X*'_ #,EA_W\
M_P#K4?\ "SO!1_YF2P_[^?\ UJ *-WX+U32-1EU'P=J$-BUPV^XLKA2UO(W]
MX <J?I4&?BB9"GV?PXH_YZ R$?@,UJ_\+,\%_P#0QZ?_ -_:7_A9G@P_\S'8
M?]_10!E_\([X^U)F&H^*K6RA(QLT^UY_-OF'_?5/M/A3HOG+/J]S?ZQ<#G=>
MSEE_!?3ZYK1_X67X,_Z&.P_[^BD_X69X+_Z&.P_[^T ;MEH]AIJ".RLK>W0=
M%BC"C^5754K]/KFN6_X67X,_Z&*P_P"_HH_X67X,'_,QV'_?T4 =717*?\+,
M\%_]#'8?]_,T?\+,\%_]#'8_]]T =717*?\ "R_!G_0QV'_?T4O_  LKP9V\
M1Z?_ -_10!U5%<L/B1X./3Q#8?\ ?T4'XD>#AU\0V'_?T4 =317*_P#"R?!W
M_0PV'_?T4_\ X6)X1_Z&'3_^_P!0!T]%<S_PL/P@>GB'3_\ O\*/^%A>$?\
MH8=/_P"_XH Z:BN9_P"%A>$?^AAT_P#[_BM32]>TS6XGETR]@NXD;:SPN& /
MO0!I4444 %%%% !1110 4444 %%%% !1110!%;C$*#T45+34 "X IU !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,:&-B2R*2>N1UH
M\F/_ )YK^0I]% #/)B_YYI_WR*/)B[QI_P!\BGT4 1^1%_SR3_OD4>1%_P \
MD_[Y%244 1^1%_SR3_OD4ODQ?\\T_P"^13Z* (_(A_YY)_WR*/(B_P">2?\
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M? \VO>&X])O]=N9I1<BXDNGB7+$ @*%&%4=.G]:ZFX@>XL);<RA9)(BGF!>
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M;33JDUVS+ G=RJEC^04\U8WKOV;ANQG&>: '44A8 @$C)Z#UH#JR[E8$>H-
M"T4T.K*&# J>X/%5[[4;33;":^NYTBMH02[D\#_Z_;% %JBD+*&"EAD]!GK0
M2%&20![T +12%U"[BP Z9)H9E099@!ZDT +10"#T.:IZA<W=LMN;2R%UYEPD
M<N91'Y49.&?GKC^[U- %RBDW#.,C/I0&5B0&!QP<'I0 M%95QK!@\2V.D?9P
MRW<$TOGB3[IC*97;C_;'.:;=ZX+7Q/INBFV+&]AEE$V_ 3R\<8QSG<* ->BB
MB@ HK)O]=CL/$&DZ0]M,SZEYHCF!78OEH6(/.<X'I5/5O%L6F7>H0)937/\
M9ULMU=LKJNQ&SC;N(W'"L<<=N>: .BHJHU\K:2=0MXVF0P>?&@^4N-NX#GIG
MWJAI?B%=4\)IK\=G(B20-.D!9=Q SCGISB@#:HJI9WPN=*AOYD%NDD(F97<'
M8I&>3TX%9=EXE>]@L;Q-*N!87I40W ="0&^ZS+G(!_$C(R!0!OT50UC6+/0M
M,EU"^D9((\#Y5+,S$X"@#J22!5+^WKR$VC7FAW<$5S*L0821N8BQP#( W ^F
M: -RBBN=E\5@OJALM,NKV'2W,=RT10-O"AF5%8@L0"/3/;- '145%!<)/;0S
MC*K*H90W!Y&<?6I"RJ0"P!/3)ZT +15)M3A>:^M;0K<7UI$LCVX;:<L&* D\
M#.T_2I+&>XGTZWGO;;[)<.@:2 R!_+8]5W#@X]: +-%%% !16:=70>(UT8VT
MZNUJURLYQY;!652!SG/SCM5#4?%)TW488I-)O6LGN$M6O0%"+(QVCY2=Q&2!
MD#'UH Z&BL?5]<DT^X2TL],N=2O&3S## \:[%S@%B[#KSC&>AJ+4/$HL[Z/3
MX=/N+N^-J;N6",J#%$#C))."2> !UP: -VBJEGJ$.I:5#J-B?/AGA$L/;<",
M@<]/QZ56\.ZW%XBT&UU:&%X8[@,1'(02,,5YQ]* -2BBB@ HK'?72GC"+0#:
MG]Y9-=BX\S^ZZKMVX]^N>U:Y(49) 'J: %HI"0HR2 /4TM !1110 444@(/0
M@]J %HHJGIMU=W<,KWFGM9.LSHB-*K[T!^5\KTR.<=J +E%96DZS_:E]JUM]
MG,7]GW7V?<7SYGR*V[IQ][ISTK5H **Q](UW^U=4UBR^RF$Z;<+!N+[O,RH;
M.,<=?>M"*^MI[NXM(IE>>WV^<@_@W D9_ 4 6**0$'H0>W%9OB#7+7PYHESJ
MMV':*  E$^\Q)P /?F@#3HJ&UN8KVS@NK=M\,\:R1MZJPR#^1J:@ HHHH **
MIZM?'3-(O+\0F;[-"TOEA@I8*,D9/TJ2QN?MNGVUULV>?$LFW.=NX XS^- %
MBBBB@ HK,?6 GB6'1C;2[I;5[D3Y&S"LJD>N<N*TZ "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#,\0ZLNAZ!>ZD5WM!$S(F,[WQ\J_B<5P&MZ7J?A1M \17-[:W)T^?
MR;@6]JZ22QS$F0G]XP8Y); 4=SVQ7J5% '-^,!:7WA@>9J)LHI98I(;Q0&1&
M#!T9@>"F0,YXKC)IA>>&-/>:WT^&2+Q' 3<6F?(G *L9DST!'!QQD&O5Z* /
M(=6N-,_MS6],U74=.@@GU2&X,]VI2=0FPL@4IAEP H.[&&)Y[KK5CI=U=?$*
M=;:VDQ86S6CJ@/S>4W*$=\[>GM7<-X5NA-/'%X@O8]/GDDDDM?+B8_.26 D*
ME@,D_0<"NAM[>*TMHK:%=L42"-%SG"@8 _*@#R76!:3:LJ>)+^^M;.^TF".T
MEBMHYEF&TF1-SHY$A;D8QGCOBKEW<V-GJ&LVNMQ2AY=&C33&O4+,Z>5\\8[&
M3?R0.3^%>I44 <IX9>X?X7:>+ _Z8FEJD8QR)5CP!SW##%<GI:V=W!X*73(_
M+UF&<+J:!<2J@C83^?W^9L?>Z[J]7HP,]* /(].T/1HOA-K6H?9(?[06UO8)
M'<Y:/YW95P>%_@(  Z@]Z9J^H64%_I/VJXT^2WN?#:VZQWTQ2)68_?5@&&>,
M'H0 .:]?P/2L&^T'4)-6DOM.UN2S$RJLT,ENLR$+P"N<%3S[CVH Y(V6DVR^
M +2TU"RNHX;F11<AU(FQ&P?!'7+8X]<9YK M8M&@TS2=0M/LB2_\)=Y<<T;
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MU'K7H MH VX0Q@[]^0H^]TS]?>ECMX87=XH8T:0Y<JH!8^_K0!PGB*QTZ_\
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M?&#M_"K6H>'=&AU_P;#'YHAU%IVN'^V2$SDV_&6W9Y..AYS[UZ4UA9NSLUI
M6D^^3&/FYSSQSS3C:VY\K-O$?)_U>4'R?3TZ"@#SN[M]--UXHT_4SY)L+2,:
M69"0T,"Q<-$3R2'#9(Y) !JO?P:E:OI=[=6K2WWB'2_[-N8MF56ZV@I(X[8
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M86=O)YD-I!&_3<D8!_,58H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=TRVSP1N@,?& =W4CD$CC- &(]W=+\4[F%7GFAAT47$=JDYVM(9"N=I(4,0
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M(D00(K%R^2%!+< X/KBGIXCT_5[KPM?0)J.V_,S6WER!$)$;%DE7=\W .."
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MVMW(RH)&QMEP%.XKSP?PQUH <?'-E*]FEA87]\UY9&]@$$:_,@(!!W$8//?
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MPDY4H'58B"H &W[Y^O>M3Q'?SMXGT/0A<SVEK?K.TDT!VNY1050-_#U))'/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !112$X&<9H 6BD!R,XQ2
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M,W_O=FT],YI_:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HJ&2YCBGCA8G?)G;P>W\JE!R,T +1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 (5!Z_SI0,#%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
(4 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779212757232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 24, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARROWHEAD PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-0408024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">177 E. Colorado Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pasadena<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">304-3400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARWR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,900,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000879407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779215237152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 134,959<span></span>
</td>
<td class="nump">$ 108,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">69,434<span></span>
</td>
<td class="nump">1,410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short term investments</a></td>
<td class="nump">346,046<span></span>
</td>
<td class="nump">268,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">9,935<span></span>
</td>
<td class="nump">7,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">14,436<span></span>
</td>
<td class="nump">20,204<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">574,810<span></span>
</td>
<td class="nump">405,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">185,228<span></span>
</td>
<td class="nump">110,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">11,112<span></span>
</td>
<td class="nump">11,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">78,834<span></span>
</td>
<td class="nump">105,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">41,114<span></span>
</td>
<td class="nump">58,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">891,308<span></span>
</td>
<td class="nump">691,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,556<span></span>
</td>
<td class="nump">2,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">39,551<span></span>
</td>
<td class="nump">46,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and benefits</a></td>
<td class="nump">5,494<span></span>
</td>
<td class="nump">12,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">2,711<span></span>
</td>
<td class="nump">2,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">29,839<span></span>
</td>
<td class="nump">74,099<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">87,151<span></span>
</td>
<td class="nump">138,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">80,070<span></span>
</td>
<td class="nump">78,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">1,075<span></span>
</td>
<td class="nump">55,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_RoyaltiesLiabilityNoncurrent', window );">Liability related to the sale of future royalties</a></td>
<td class="nump">257,906<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">339,051<span></span>
</td>
<td class="nump">134,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Noncontrolling interest and stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value: Authorized 290,000 and 145,000 shares; issued and outstanding 106,869 and 105,960 shares</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,260,310<span></span>
</td>
<td class="nump">1,219,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(332)<span></span>
</td>
<td class="num">(136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(813,405)<span></span>
</td>
<td class="num">(820,755)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Arrowhead Pharmaceuticals, Inc. stockholders&#8217; equity</a></td>
<td class="nump">446,772<span></span>
</td>
<td class="nump">398,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">18,334<span></span>
</td>
<td class="nump">19,819<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total noncontrolling interest and stockholders&#8217; equity</a></td>
<td class="nump">465,106<span></span>
</td>
<td class="nump">418,339<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities, Noncontrolling Interest and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 891,308<span></span>
</td>
<td class="nump">$ 691,939<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_RoyaltiesLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_RoyaltiesLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779212728864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">290,000,000<span></span>
</td>
<td class="nump">145,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">106,869,000<span></span>
</td>
<td class="nump">105,960,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">106,869,000<span></span>
</td>
<td class="nump">105,960,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779213185696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 146,267<span></span>
</td>
<td class="nump">$ 151,805<span></span>
</td>
<td class="nump">$ 208,813<span></span>
</td>
<td class="nump">$ 179,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">74,881<span></span>
</td>
<td class="nump">75,985<span></span>
</td>
<td class="nump">158,576<span></span>
</td>
<td class="nump">141,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">23,221<span></span>
</td>
<td class="nump">34,267<span></span>
</td>
<td class="nump">44,206<span></span>
</td>
<td class="nump">59,262<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">98,102<span></span>
</td>
<td class="nump">110,252<span></span>
</td>
<td class="nump">202,782<span></span>
</td>
<td class="nump">201,012<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">48,165<span></span>
</td>
<td class="nump">41,553<span></span>
</td>
<td class="nump">6,031<span></span>
</td>
<td class="num">(21,768)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Interest income</a></td>
<td class="nump">4,560<span></span>
</td>
<td class="nump">1,054<span></span>
</td>
<td class="nump">7,242<span></span>
</td>
<td class="nump">2,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(5,057)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,906)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">1,759<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="nump">1,052<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (loss) income</a></td>
<td class="num">(489)<span></span>
</td>
<td class="nump">2,813<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="nump">3,262<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income tax expense and noncontrolling interest</a></td>
<td class="nump">47,676<span></span>
</td>
<td class="nump">44,366<span></span>
</td>
<td class="nump">5,882<span></span>
</td>
<td class="num">(18,506)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss) including noncontrolling interest</a></td>
<td class="nump">47,676<span></span>
</td>
<td class="nump">44,366<span></span>
</td>
<td class="nump">5,865<span></span>
</td>
<td class="num">(18,506)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest, net of tax</a></td>
<td class="num">(999)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,485)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Arrowhead Pharmaceuticals, Inc.</a></td>
<td class="nump">$ 48,675<span></span>
</td>
<td class="nump">$ 44,366<span></span>
</td>
<td class="nump">$ 7,350<span></span>
</td>
<td class="num">$ (18,506)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Net income (loss) per share attributable to Arrowhead Pharmaceuticals, Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.46<span></span>
</td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="nump">$ 0.41<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average shares used in calculating</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">106,757<span></span>
</td>
<td class="nump">105,545<span></span>
</td>
<td class="nump">106,394<span></span>
</td>
<td class="nump">105,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">108,143<span></span>
</td>
<td class="nump">107,929<span></span>
</td>
<td class="nump">107,893<span></span>
</td>
<td class="nump">105,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">$ (74)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">$ (196)<span></span>
</td>
<td class="num">$ (38)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss)</a></td>
<td class="nump">$ 47,602<span></span>
</td>
<td class="nump">$ 44,367<span></span>
</td>
<td class="nump">$ 5,669<span></span>
</td>
<td class="num">$ (18,544)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779207433472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Non- controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Sep. 30, 2021</a></td>
<td class="nump">$ 408,822<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">$ 1,053,386<span></span>
</td>
<td class="num">$ (69)<span></span>
</td>
<td class="num">$ (644,692)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">24,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">2,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(62,872)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62,872)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">372,560<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">1,080,035<span></span>
</td>
<td class="num">(108)<span></span>
</td>
<td class="num">(707,564)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,798,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Sep. 30, 2021</a></td>
<td class="nump">408,822<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">1,053,386<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="num">(644,692)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(18,506)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">452,266<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">1,115,373<span></span>
</td>
<td class="num">(107)<span></span>
</td>
<td class="num">(663,198)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,702,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">372,560<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">1,080,035<span></span>
</td>
<td class="num">(108)<span></span>
</td>
<td class="num">(707,564)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,798,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">33,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">1,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">667,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">44,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">452,266<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">1,115,373<span></span>
</td>
<td class="num">(107)<span></span>
</td>
<td class="num">(663,198)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,702,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Sep. 30, 2022</a></td>
<td class="nump">418,339<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">1,219,213<span></span>
</td>
<td class="num">(136)<span></span>
</td>
<td class="num">(820,755)<span></span>
</td>
<td class="nump">19,819<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">19,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Interest in joint venture</a></td>
<td class="num">(486)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(486)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(41,325)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,325)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">396,372<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">1,239,178<span></span>
</td>
<td class="num">(258)<span></span>
</td>
<td class="num">(862,080)<span></span>
</td>
<td class="nump">19,333<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Sep. 30, 2022</a></td>
<td class="nump">$ 418,339<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">1,219,213<span></span>
</td>
<td class="num">(136)<span></span>
</td>
<td class="num">(820,755)<span></span>
</td>
<td class="nump">19,819<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">145,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">$ (196)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">7,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">465,106<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">1,260,310<span></span>
</td>
<td class="num">(332)<span></span>
</td>
<td class="num">(813,405)<span></span>
</td>
<td class="nump">18,334<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,869,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">396,372<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">1,239,178<span></span>
</td>
<td class="num">(258)<span></span>
</td>
<td class="num">(862,080)<span></span>
</td>
<td class="nump">19,333<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">20,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">665,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(74)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Interest in joint venture</a></td>
<td class="num">(999)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(999)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">48,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 465,106<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">$ 1,260,310<span></span>
</td>
<td class="num">$ (332)<span></span>
</td>
<td class="num">$ (813,405)<span></span>
</td>
<td class="nump">$ 18,334<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,869,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779215276816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 5,865<span></span>
</td>
<td class="num">$ (18,506)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash flow from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">40,002<span></span>
</td>
<td class="nump">58,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,358<span></span>
</td>
<td class="nump">5,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">(Accretion) amortization of note premiums/discounts</a></td>
<td class="num">(82)<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties', window );">Non-cash interest expense on liability related to the sale of future royalties</a></td>
<td class="nump">7,906<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(68,024)<span></span>
</td>
<td class="nump">8,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">20,309<span></span>
</td>
<td class="num">(3,313)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">6,688<span></span>
</td>
<td class="nump">1,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(27,279)<span></span>
</td>
<td class="nump">3,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(99,135)<span></span>
</td>
<td class="num">(54,926)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">1,205<span></span>
</td>
<td class="nump">580<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(107,187)<span></span>
</td>
<td class="nump">1,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(66,225)<span></span>
</td>
<td class="num">(10,530)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(192,528)<span></span>
</td>
<td class="num">(148,391)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from maturities of investments</a></td>
<td class="nump">141,994<span></span>
</td>
<td class="nump">55,781<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(116,759)<span></span>
</td>
<td class="num">(103,140)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercises of stock options</a></td>
<td class="nump">1,096<span></span>
</td>
<td class="nump">3,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Proceeds from the sale of future royalties</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">251,096<span></span>
</td>
<td class="nump">3,731<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">27,150<span></span>
</td>
<td class="num">(97,988)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate on cash, cash equivalents and restricted cash</a></td>
<td class="num">(196)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract', window );"><strong>CASH, CASH EQUIVALENTS AND RESTRICTED CASH:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">BEGINNING OF PERIOD</a></td>
<td class="nump">108,005<span></span>
</td>
<td class="nump">184,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">END OF PERIOD</a></td>
<td class="nump">134,959<span></span>
</td>
<td class="nump">86,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes (paid) refunded</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Expense, Liability Related to Sale of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received by a corporation from a shareholder during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779218636496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Significant Accounting Policies</a></td>
<td class="text">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Recent Developments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead Pharmaceuticals, Inc. and its subsidiaries (referred to herein collectively as the &#8220;Company&#8221;) are primarily engaged in developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company&#8217;s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#8220;RNAi&#8221;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. The Company&#8217;s RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s current pipeline:</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"/><td style="width:16.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Therapeutic Area</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Stage</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Product Rights</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cardiometabolic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-APOC3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2b and Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-ANG3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2b</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Olpasiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amgen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pulmonary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-ENAC2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-Clinical</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-RAGE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-MUC5AC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-MMP7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liver</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK-4532990 (formerly ARO-HSD)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fazirsiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Takeda and Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">JNJ-3989</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Janssen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">HZN-457 (formerly ARO-XDH)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Horizon</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-C3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-PNPLA3 (formerly JNJ-75220795)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Muscle</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-DUX4</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-Clinical</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CNS</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-SOD1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-Clinical</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates lab facilities in San Diego, California and Madison, Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company&#8217;s principal executive offices are located in Pasadena, California.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first half of fiscal 2023, the Company continued to develop and advance its pipeline and partnered candidates. Several key recent developments include: </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">announced interim results from ARO-RAGE administration in Part 1 of the ongoing Phase 1/2 study in normal healthy volunteers which included:</span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">reductions in soluble RAGE (sRAGE) as measured in serum after two doses on Day 1 and Day 29;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">duration of pharmacologic effect persisted for at least 6 weeks after the second administration of the 92 mg does with further follow up ongoing;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">reduction in sRAGE as measured in bronchoalveolar lavage fluid (BALF) at Day 31 after a single dose;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">reduction in in serum sRAGE were observed after a single dose;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">the pooled placebo groups experienced a mean sRAGE increase of 8% in BALF and a mean decrease of 1% serum</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">safety and tolerability;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expanded TRiM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform to include an optimized intrathecal administration for central nervous system (CNS) delivery with distribution throughout the brain and in all relevant brain cell types. The first development candidate to utilize this new delivery platform, ARO-SOD1, is anticipated to have a clinical trial </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">application (CTA) filing in the third quarter of 2023 to begin clinical studies. In preclinical studies, ARO-SOD1 achieved 95% spinal cord tissue mRNA knockdown after a single intrathecal dose in human SOD1 transgenic rats and maintained greater than 80% spinal cord tissue mRNA knockdown three months after a single intrathecal dose in non-human primates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">dosed the first patient in Takeda&#8217;s Phase 3 REDWOOD clinical study of Fazirsiran for the treatment of alpha-1 antitrypsin deficiency associated liver diseases, triggering a $40.0&#160;million milestone payment to the Company which is expected to be paid in the third quarter of fiscal 2023;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">dosed the first patient in GSK&#8217;s Phase 2b trial of GSK4532990, formerly called ARO-HSD, an investigational RNAi therapeutic for the treatment of patients with non-alcoholic steatohepatitis (NASH), triggering a $30.0&#160;million milestone payment to the Company which is expected to be paid in the third quarter of fiscal 2023;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARO-APOC3 for reducing triglycerides in adult patients with familial chylomicronemia syndrome (FCS). ARO-APOC3 was previously granted Orphan Drug designation by the FDA and the European Union;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">announced interim results from Part 1 of AROC3-1001, an ongoing Phase 1/2 clinical study of ARO-C3,  which included;</span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">a dose-dependent reduction in serum C3, with 88% mean reduction at highest dose tested;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">a dose-dependent reduction in AH50, a marker of alternative complement pathway hemolytic activity, with 91% mean reduction at highest dose tested;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">duration of pharmacologic effect supportive of quarterly or less frequent subcutaneous dose administration;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">safety and tolerability;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">received notice from Janssen of its decision to voluntarily terminate the Research Collaboration and Option Agreement (the &#8220;Janssen Collaboration Agreement&#8221;) between the Company and Janssen. The Company regained full rights to ARO-PNPLA3, formerly called JNJ-75220795, upon termination of the Janssen Collaboration Agreement, which took effect on April 7, 2023. ARO-PNPLA3 is in Phase 1 clinical trials that are now being developed by the Company;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">initiated dosing in ARO-MMP7-1001 (NCT05537025), a Phase 1/2a single ascending dose and multiple ascending dose clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-MMP7, an investigational RNAi therapeutic designed to reduce expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF), in up to 56 healthy volunteers and in up to 21 patients with IPF;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">enrolled the first subject in a Phase 1 randomized, placebo-controlled trial to assess the safety tolerability, pharmacokinetics and pharmacodynamics of a development-stage medicine, HZN-457 (formerly ARO-XDH), which is out-licensed to Horizon, triggering a $15.0&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2023;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">enrolled the first subject in Amgen&#8217;s Phase 3 trial of Olpasiran, triggering a $25.0&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2023;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">entered into a Royalty Purchase Agreement (the &#8220;Royalty Pharma Agreement&#8221;) with Royalty Pharma Investments 2019 ICAV (&#8220;Royalty Pharma&#8221;) on November 9, 2022, pursuant to which Royalty Pharma paid $250.0&#160;million upfront (See Note 11 &#8212; Liability Related to the Sale of Future Royalties of Notes to Consolidated Financial Statements of Part I, &#8220;Item 1. Financial Statements.&#8221;);</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">announced Topline Results from SEQUOIA Phase 2 Study of Fazirsiran (formerly ARO-AAT) in patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease in which;</span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">fibrosis regression was observed in 50% of patients receiving Fazirsiran;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">median reductions of 94% of Z-AAT accumulation in the liver and mean reductions of 68% in histologic globule burden were observed;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">treatment emergent adverse events were generally well balanced between Fazirsiran and placebo groups;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">results were consistent with AROAAT-2002 open-label study previously published in The New England Journal of Medicine.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Consolidated Financial Statements include the accounts of Arrowhead Pharmaceuticals, Inc. and its subsidiaries (wholly-owned subsidiaries and a variable interest entity for which the Company is the primary beneficiary). Subsidiaries refer to Arrowhead Madison, Inc., Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;), and Arrowhead Australia Pty Ltd. For subsidiaries in which the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interests retained in such entity by the respective noncontrolling party.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The financial data of the Company included herein are unaudited. In the opinion of management, all material adjustments of a normal recurring nature have been made to present fairly the Company&#8217;s financial position at March&#160;31, 2023 and the results of operations and cash flows for the periods presented. All intercompany transactions and balances have been eliminated. Certain prior period amounts have been reclassified to conform with the current period presentation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain financial information that is normally included in annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, has been omitted from the accompanying interim consolidated financial statements and related notes. Readers are urged to review the Company&#8217;s Annual Report on Form 10-K for the year ended September&#160;30, 2022 for more complete descriptions and discussions. Operating results and cash flows for the six months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the fiscal year ending September&#160;30, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s primary sources of financing have been through the sale of its securities, revenue from its licensing and collaboration agreements and the sale of certain future royalties. Research and development activities have required significant capital investment since the Company&#8217;s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company&#8217;s pipeline of drug candidates and its headcount have both expanded significantly. Additionally, significant capital investment will be required as the Company&#8217;s pipeline matures into later stage clinical trials and as the Company plans to increase its internal manufacturing capabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, the Company had $135.0 million in cash and cash equivalents (including $7.3 million in restricted cash), $346.0 million in short-term investments and $78.8&#160;million in long-term investments to fund operations. During the six months ended March&#160;31, 2023, the Company&#8217;s cash and cash equivalents and investments balance increased by $77.6 million which was primarily due to the $250.0&#160;million upfront payment received from Royalty Pharma (Note 11) and $40.0 million in milestone payments from Horizon and Amgen, partially offset by cash used to fund its operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company is eligible to receive up to $3.6 billion in developmental, regulatory and sales milestones, and may receive various royalties on net sales from its licensing and collaboration agreements, subject to the terms and conditions of those agreements. The revenue recognition for these collaboration agreements is discussed further in Note 2.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Significant Accounting Policies </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to the significant accounting policies disclosed in the Company&#8217;s most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no recent accounting pronouncements that have significantly impacted this Quarterly Report on Form 10-Q, beyond those disclosed in the Company&#8217;s most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779213342512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text">COLLABORATION AND LICENSE AGREEMENTS<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of revenue recognized:</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.818%"><tr><td style="width:1.0%"/><td style="width:33.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.555%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">29,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">120,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Horizon</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,918&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">21,667&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,585&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Takeda</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">116,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">132,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Janssen</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">111&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,066&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">355&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,066&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amgen</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">146,267&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">151,805&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">208,813&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">179,244&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance of receivables and contract liabilities related to the Company&#8217;s collaboration and license agreements:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.696%"><tr><td style="width:1.0%"/><td style="width:57.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Receivables included in accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">70,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">6,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contract liabilities included in deferred revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">30,914&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">130,049&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Glaxosmithkline Intellectual Property (No. 3) Limited (&#8220;GSK&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 22, 2021, GSK and the Company entered into an Exclusive License Agreement (the &#8220;GSK License Agreement&#8221;). Under the GSK License Agreement, GSK has received an exclusive license for GSK-4532990 (formerly ARO-HSD). The exclusive license is worldwide with the exception of greater China, for which the Company retained rights to develop and commercialize GSK-4532990. The Company completed its Phase 1/2 study of GSK-4532990, and GSK is wholly responsible for all clinical development and commercialization of GSK-4532990 in its territory. Under the terms of the agreement, the Company has received an upfront payment of $120.0&#160;million and recognized an additional $30.0&#160;million at the start of a Phase 2 trial. The Company is also eligible for an additional payment of $100.0&#160;million upon achieving a successful Phase 2 trial readout and the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to the Company of up to $190.0&#160;million at first commercial sale, and up to $590.0&#160;million in sales-related milestone payments. The Company is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the GSK License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibility to complete the Phase 1/2 study (the &#8220;GSK R&amp;D Services&#8221;). Due to the specialized and unique nature of the GSK R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. Beyond the GSK R&amp;D Services, which are the responsibility of the Company, GSK will be responsible for managing future clinical development and commercialization in its territory. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price totaled $120.0&#160;million, including the upfront payment, which was collected in January 2022. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company has allocated the total $120.0&#160;million initial transaction price to its one distinct performance obligation for the GSK-4532990 license and the associated GSK R&amp;D Services. As the Company has completed its performance obligation related to this agreement, the upfront payment of $120.0&#160;million was fully recognized during the six months ended March 31, 2022. Further, GSK dosed the first patient in a Phase 2 trial in March 2023, triggering a $30.0&#160;million milestone payment to the Company which is expected to be paid in the third quarter of fiscal 2023. There were no contract assets and liabilities recorded as of March&#160;31, 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Horizon Therapeutics Ireland DAC (&#8220;Horizon&#8221;) </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021, Horizon and the Company entered into a collaboration and license agreement (the &#8220;Horizon License Agreement&#8221;). Under the terms of the Horizon License Agreement, Horizon received a worldwide exclusive license for HZN-457, a clinical-stage medicine being developed by Horizon as a potential treatment for people with uncontrolled gout. The Company conducted all activities through the preclinical stages of development of, and Horizon is now wholly </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">responsible for clinical development and commercialization of, HZN-457. The Company received $40.0&#160;million as an upfront payment in July 2021 and an additional $15.0&#160;million upon Horizon&#8217;s initiation of a Phase 1 clinical trial in January 2023, and is eligible to receive up to $645.0&#160;million in additional potential development, regulatory and sales milestones. The Company is also eligible to receive royalties in the low- to mid-teens range on net product sales. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Horizon License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibilities to conduct all activities through the preclinical stages of development of HZN-457 (the &#8220;Horizon R&amp;D Services&#8221;). Due to the specialized and unique nature of these Horizon R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. Beyond the Horizon R&amp;D Services, which are the responsibility of the Company, Horizon is responsible for managing future clinical development and commercialization of HZN-457. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price totaled $40.0&#160;million, including the upfront payment. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company allocated the total $40.0&#160;million initial transaction price to its one distinct performance obligation for the HZN-457 license and the associated Horizon R&amp;D Services. Revenue was recognized on a straight-line basis over the timeframe for completing the Horizon R&amp;D Services. The Company determined that the straight-line basis was appropriate as its efforts were expended evenly over the course of completing its performance obligation. Further, Horizon enrolled the first subject in December 2022 in a Phase 1 randomized, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HZN-457, triggering a $15.0&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2023. There were no contract assets and liabilities recorded as of March&#160;31, 2023.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 7, 2020, Takeda and the Company entered into an Exclusive License and Co-Funding Agreement (the &#8220;Takeda License Agreement&#8221;). Under the Takeda License Agreement, Takeda and the Company will co-develop its Fazirsiran program, the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, Fazirsiran, if approved, will be co-commercialized under a 50/50 profit sharing structure. Outside the United States, Takeda will lead the global commercialization strategy and will receive an exclusive license to commercialize Fazirsiran, while the Company will be eligible to receive tiered royalties of 20% to 25% on net sales. The Company received $300.0&#160;million as an upfront payment in January 2021, recognized an additional $40.0&#160;million upon Takeda&#8217;s initiation of a Phase 3 clinical study in March 2023, and is eligible to receive potential development, regulatory and commercial milestones of up to $527.5&#160;million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Takeda License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of Fazirsiran drug product is completed and delivered to Takeda (the &#8220;Takeda R&amp;D Services&#8221;). Due to the specialized and unique nature of these Takeda R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. Beyond the Takeda R&amp;D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States. Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the 50/50 profit sharing structure within the United States. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts are recorded as research and development expenses or general and administrative expenses, as appropriate.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has allocated the total $300.0&#160;million initial transaction price to its one distinct performance obligation for the Fazirsiran license and the associated Takeda R&amp;D Services. Revenue is recognized using a proportional performance method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). The Company previously expected these clinical trials to extend to September 2025 in order to demonstrate long term safety and efficacy in the open label extension part of the studies; however, Takeda now intends to initiate a new open label extension (OLE) study available to patients participating in these Phase 2 studies that will initiate as early as July 2023. Based on this new information, patients enrolled in the SEQUOIA and AROAAT2002 studies are expected to complete their Phase 2 study visits between June 2023 and June 2024, shortening the Company&#8217;s performance obligation. As a result, effective the second quarter of fiscal 2023, the Company changed its estimates of the revenue recognition to better reflect these newly estimated proportional performance periods. The effect of these changes in estimates resulted in accelerated revenue by $61.4&#160;million, or $0.57 per share (diluted) for </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each of the three and six months ended March&#160;31, 2023. There were $30.9 million of contract liabilities recorded as deferred revenue, of which $29.8 million  was classified as current as of March&#160;31, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, Takeda dosed the first patient in the Phase 3 REDWOOD clinical study of Fazirsiran, triggering a $40.0&#160;million milestone payment to the Company which is expected to be paid in the third quarter of fiscal 2023. The Company also recorded $9.4&#160;million as accrued expenses as of March&#160;31, 2023 that was primarily driven by co-development and co-commercialization activities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 3, 2018, Janssen, part of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, and the Company entered into a License Agreement (the &#8220;Janssen License Agreement&#8221;) and the Janssen Collaboration Agreement. The Company also entered into a stock purchase agreement with JJDC, Inc. (&#8220;JJDC&#8221;), Johnson &amp; Johnson&#8217;s venture capital arm (the &#8220;JJDC Stock Purchase Agreement&#8221;). Under the Janssen License Agreement, Janssen received a worldwide, exclusive license to the Company&#8217;s JNJ-3989 (ARO-HBV) program, the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. Beyond the Company&#8217;s Phase 1/2 study of JNJ-3989 (ARO-HBV), which the Company was responsible for completing, Janssen is wholly responsible for clinical development and commercialization of JNJ-3989 (ARO-HBV). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Janssen License Agreement, the Company has received $175.0&#160;million as an upfront payment, $75.0&#160;million in the form of an equity investment by JJDC in the Company&#8217;s common stock under the JJDC Stock Purchase Agreement, and milestone and option payments totaling $73.0&#160;million, and the Company may receive up to $0.8 billion in development and sales milestone payments for the Janssen License Agreement. The Company is further eligible to receive tiered royalties on product sales up to mid-teens under the Janssen License Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 7, 2023, Janssen voluntarily terminated the Janssen Collaboration Agreement. Upon termination, the Company regained full rights to ARO-PNPLA3, formerly called JNJ-75220795, the only candidate for which Janssen had exercised its option.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, Janssen exercised its option right for JNJ-75220795 (ARO-JNJ1), which resulted in a $10.0&#160;million milestone payment to the Company. This $10.0&#160;million milestone payment was recognized entirely as of September 30, 2021. The Company conducted its discovery, optimization and preclinical research and development of JNJ-75220795 (ARO-JNJ1), ARO-JNJ2, and ARO-JNJ3 under the Janssen Collaboration Agreement. All costs and labor hours spent by the Company have been entirely funded by Janssen. There was no revenue recorded associated with the Company&#8217;s agreement with Janssen for the six months ended March 31, 2023 and 2022. There were no contract assets and liabilities recorded as of March 31, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Janssen License Agreement, the Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibility to complete the Phase 1/2 study of JNJ-3989 (ARO-HBV) and the Company&#8217;s responsibility to ensure certain manufacturing of JNJ-3989 (ARO-HBV) drug product is completed and delivered to Janssen (the &#8220;Janssen R&amp;D Services&#8221;). Due to the specialized and unique nature of these Janssen R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the transaction price totaled approximately $252.7&#160;million, which includes the upfront payment, the premium paid by JJDC for its equity investment in the Company, two $25.0&#160;million milestone payments related to JNJ-3989 (ARO-HBV), and estimated payments for reimbursable Janssen R&amp;D Services to be performed. The Company has allocated the total $252.7&#160;million initial transaction price to its one distinct performance obligation for the JNJ-3989 (ARO-HBV) license and the associated Janssen R&amp;D Services. The Company recognized this transaction price in its entirety as of September 30, 2021, as its performance obligations were substantially completed. Future milestones and royalties achieved will be recognized in their entirety when earned. There were no contract assets and liabilities recorded as of March 31, 2023. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Amgen Inc. (&#8220;Amgen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2016, Amgen and the Company entered into two collaboration and license agreements and a common stock purchase agreement. Under the Second Collaboration and License Agreement (the &#8220;Olpasiran Agreement&#8221;), Amgen received a worldwide, exclusive license to the Company&#8217;s novel RNAi Olpasiran program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the first collaboration and license agreement (the &#8220;First Collaboration and License Agreement&#8221; or the &#8220;ARO-AMG1 Agreement&#8221;), Amgen received an option to a worldwide, exclusive license to ARO-AMG1, an RNAi therapy for an undisclosed genetically validated cardiovascular target. Under both agreements, Amgen is wholly responsible for clinical development and commercialization. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Olpasiran Agreement and the ARO-AMG1 Agreement, the Company has received $35.0&#160;million in upfront payments and $21.5&#160;million in the form of an equity investment by Amgen in the Company&#8217;s common stock. Further, the Company received additional an $55.0&#160;million in milestone payments; $10.0&#160;million upon Amgen&#8217;s initiation of Phase 1 study in September 2018,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$20.0&#160;million upon its initiation of a Phase 2 clinical study in July 2020, and $25.0 million upon its first subject enrollment in a Phase 3 trial in December 2022. The Company has substantially completed its performance obligations under the Olpasiran Agreement and the ARO-AMG1 Agreement. There were no contract assets and liabilities recorded as of March&#160;31, 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, Royalty Pharma and the Company entered into the Royalty Pharma Agreement. In consideration for the payments under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive up to an additional $535.0&#160;million in remaining development, regulatory and sales milestone payments payable from Amgen and Royalty Pharma. See Note 11.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Joint Venture and License Agreement with Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2022, Visirna and the Company entered into a License Agreement (the &#8220;Visirna License Agreement&#8221;), pursuant to which Visirna received an exclusive license to develop, manufacture and commercialize four of the Company&#8217;s RNAi-based investigational cardiometabolic medicines in Greater China (including the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan). Pursuant to a Share Purchase Agreement (the &#8220;Visirna SPA&#8221;) entered into simultaneously with the Visirna License Agreement, the Company acquired a majority stake in Visirna as partial consideration for the Visirna License Agreement. Under the Visirna SPA, entities affiliated with Vivo Capital also acquired a minority stake in Visirna in exchange for $60.0&#160;million in upfront capital to support the operations of Visirna. As further consideration under the Visirna License Agreement, the Company is also eligible to receive potential royalties on commercial sales.</span></div>During the six months ended March&#160;31, 2023, the Company performed manufacturing and development work pursuant to a Clinical Supply Agreement between the parties contemplated by the Visirna License Agreement. The Company received $0.9&#160;million as consideration for this manufacturing and development work, and there were no contract assets and liabilities recorded as of March&#160;31, 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779215546464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">PROPERTY AND EQUIPMENT<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s major classes of property and equipment:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Computers, software, office equipment and furniture</span></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,198&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,182&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Research equipment</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">46,873&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">38,283&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">42,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">42,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">127,216&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">56,373&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">221,300&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">141,851&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(36,072)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(31,554)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">185,228&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">110,297&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for property and equipment for each of the three months ended March&#160;31, 2023 and 2022 was $2.2 million. Depreciation and amortization expense for property and equipment for the six months ended March&#160;31, 2023 and 2022 was $4.5 million and $4.3 million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in the construction in progress during the six months ended March&#160;31, 2023 was mainly due to the continuing developments of manufacturing, laboratory and office facilities in Verona, Wisconsin as well as a new laboratory and office facility in San Diego, California. See Note 7.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779218525104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">INVESTMENTS<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.002%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.265%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.265%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.265%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.269%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Short-term investments (due within one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">346,046&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,755)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">342,291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity certificate of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total short-term investments</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">346,046&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,755)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">342,291&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Long-term investments (due within one through three years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">78,834&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,709)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">77,125&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total long-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">78,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,709)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">77,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.596%"><tr><td style="width:1.0%"/><td style="width:45.323%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.185%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Short-term investments (due within one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">218,391&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,661)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">214,730&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity certificate of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total short-term investments</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">268,391&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,661)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">264,730&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Long-term investments (due within one through three years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,569)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100,303&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total long-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,569)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779218579232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text">INTANGIBLE ASSETS<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. The following table presents the components of intangible assets: </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.361%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Impairment</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Useful Lives</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(amounts in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,545&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,183&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,857&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,745&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,112&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,958&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,857&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,895&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,962&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed annually for impairment and more frequently if potential impairment indicators exist. No impairment indicators were identified during the six months ended March&#160;31, 2023 and 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with definite useful lives are amortized on a straight-line basis over their useful lives. Intangible assets amortization expense was $0.4 million for each of the three months ended March&#160;31, 2023 and 2022, and $0.9 million and for each of the six months ended March&#160;31, 2023 and 2022. None of the intangible assets with definite useful lives are anticipated to have a residual value.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated future amortization expense related to intangible assets as of March&#160;31, 2023:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"><tr><td style="width:1.0%"/><td style="width:71.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.099%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortization Expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ending September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2023 (remainder)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779218541040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s shares of common stock and preferred stock:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"><tr><td style="width:1.0%"/><td style="width:27.208%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.826%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Par Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Authorized</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">290,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">145,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;16, 2023, the Company&#8217;s stockholders approved an increase in authorized common shares, par value $0.001 per share, from 145,000,000 to 290,000,000. The amendment to the Amended and Restated Certificate of Incorporation was filed on April 27, 2023. The Company does not have any current intention to issue shares in connection with acquisitions or pursuant to any equity financing outside of its existing equity compensation plans.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and September&#160;30, 2022, respectively, 13,075,198 and 14,000,392 shares of common stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under the Company&#8217;s 2004 Equity Incentive Plan, 2013 Incentive Plan, and 2021 Incentive Plan, as well as for inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 2, 2022, the Company entered into an open market sale agreement (the &#8220;Open Market Sale Agreement&#8221;), pursuant to which the Company may, from time to time, sell up to $250,000,000 in shares of the Company&#8217;s common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering (&#8220;ATM Offering&#8221;). The Company is not required to sell shares under the Open Market Sale Agreement. The Company will pay Jefferies LLC a commission of up to 3.0% of the aggregate gross proceeds received from all sales of the common stock under the Open Market Sale Agreement. Unless otherwise terminated, the ATM Offering shall terminate upon the earlier of (i) the sale of all shares of common stock subject to the Sales Agreement and (ii) the termination of the Sales Agreement as permitted therein. The Company and Jefferies may each terminate the Open Market Sale Agreement at any time upon prior notice. As of March&#160;31, 2023, no shares have been issued under the Open Market Sale Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779218525104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were no contingent liabilities recorded as of March&#160;31, 2023. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;20, 2021, the Company completed a purchase of 13 acres of land in the Verona Technology Park in Verona, Wisconsin, which is being developed into an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility which will support the Company&#8217;s process development and analytical activities. The Company intends to invest between $200.0 million and $260.0 million into the build-out of the facilities. As part of this acquisition, the Company entered into a development agreement with the City of Verona to construct certain infrastructure improvements within the tax incremental district and will be reimbursed up to $16.0&#160;million by the City of Verona by future tax increment revenue generated from the developed property. The total amount of funding that the City of Verona will pay under the Tax Incremental Financing program is not guaranteed and will depend on future tax revenues generated from the developed property. The Company will also receive up to $2.5 million of refundable Wisconsin state income tax credits from the Wisconsin Economic Development Corporation (WEDC) as incentives to invest in the local community and create new jobs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Technology License Commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has licensed from third parties the rights to use certain technologies for its research and development activities, as well as in any products it may develop using these licensed technologies. These agreements and other similar </span></div>agreements often require milestone and royalty payments. Milestone payments, for example, may be required as the research and development process progresses through various stages of development, such as when clinical candidates enter or progress through clinical trials, upon NDA and/or certain sales level milestones. During the three and six months ended March&#160;31, 2023 and 2022, the Company did not reach any milestones.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779215574976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LEASES<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;19, 2021, the Company entered into a 15-year lease for approximately 144,000 square feet of office and research and development laboratory space in San Diego, California. This facility replaces the Company&#8217;s current office and research facility located in San Diego, California. The increased capacity of this new facility compared to the Company&#8217;s current research facility in San Diego will accommodate increased personnel for its expanding pipeline of current and future drug candidates. The lease payments which began on April 19, 2023, the rent commencement date, will be approximately $119.0 million over the initial 15-year term. The Company also estimates payments for operating expenses to be approximately $3.0 million for the first year of the lease, and these payments will continue throughout the initial 15-year term. The Company expects to pay approximately $32.0&#160;million for leasehold improvements, net of tenant improvement allowances. Pursuant to the lease, within twelve months of the expiration of the initial 15-year term, the Company has the option to extend the lease for up to one additional ten-year term, with certain annual increases in base rent. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Significant Leases</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pasadena, California</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases 49,000 square feet of office space located at 177 Colorado Blvd. for its corporate headquarters from 177 Colorado Owner, LLC, which lease expires on April&#160;30, 2027. The lease contains an option to renew for one term of five years. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">San Diego, California</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company subleased space from Halozyme, Inc. for additional research and development facility in San Diego, California. The term of this sublease commenced on April&#160;1, 2020 and ended on January&#160;14, 2023. On December 23, 2022, the Company entered into a new six-month lease agreement with 11404 &amp; 11408 Sorrento Valley Owner (DE) LLC, effective January 15, 2023. The lease will end on July 15, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Madison, Wisconsin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases space for office and laboratory facilities, which expires on September 30, 2031. The lease contains options to renew for two terms of five years. After accounting for additional rental square feet added pursuant to amendments to the lease agreement in 2019 and 2020, the Company currently leases a total of 111,000 square feet.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease assets and liabilities along with their classification on the Company&#8217;s consolidated balance sheets were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"><tr><td style="width:1.0%"/><td style="width:28.807%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.807%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.378%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,711&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,776&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">80,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">78,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.839%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lease Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,033&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">840&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,003&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,507&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,815&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,963&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost primarily related to operating expenses associated with the Company&#8217;s operating leases. There was $0.4&#160;million and $0.3&#160;million short-term lease cost during the three months ended March&#160;31, 2023, and 2022, respectively. There was $0.7&#160;million and $0.5&#160;million short-term lease cost during the six months ended March&#160;31, 2023, and 2022, respectively.   </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents payments of operating lease liabilities on an undiscounted basis as of March&#160;31, 2023:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.545%"><tr><td style="width:1.0%"/><td style="width:79.997%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.803%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amounts</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2023 (remainder of fiscal year)</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">3,070&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">8,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">11,800&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">12,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">11,297&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">102,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">149,212&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(66,431)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total operating lease liabilities (includes current portion)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">82,781&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.969%"><tr><td style="width:1.0%"/><td style="width:60.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.519%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating cash flows from operating leases (in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779213351472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three plans that provide for equity-based compensation. Under the 2004 Equity Incentive Plan (the &#8220;2004 Plan&#8221;) and 2013 Incentive Plan (the &#8220;2013 Plan&#8221;), 173,983 and 3,518,957 shares, respectively, of the Company&#8217;s common stock are reserved for the grant of stock options, stock appreciation rights, restricted stock awards and performance unit/share awards to employees, consultants and others as of March&#160;31, 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 18, 2021, the Company&#8217;s Board of Directors approved the Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan (the &#8220;2021 Plan&#8221;), which authorizes 8,000,000 shares (subject to certain adjustments) to be awarded for grants of stock options, stock appreciation rights, restricted and unrestricted stock and stock units, performance awards, cash awards and other awards convertible into or otherwise based on shares of the Company&#8217;s common stock. The maximum number of shares authorized under the 2021 Plan will be (i) reduced by any shares subject to awards made under the 2013 Plan after January 1, 2021, and (ii) increased by any shares subject to outstanding awards under the 2013 Plan as of January 1, 2021 that, after January 1, 2021, are canceled, expired, forfeited or otherwise not issued under such awards (other than as a result of being tendered or withheld to pay the exercise price or withholding taxes in connection with any such awards) or settled in cash. As of March&#160;31, 2023, the total number of shares reserved for issuance under the 2021 Incentive Plan was 6,126,788 shares, which includes 139,053 shares that were forfeited under the 2013 Plan. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there were 743,726 shares reserved for options and 738,875 shares reserved for restricted stock units issued as inducement grants to new employees granted outside of the Company&#8217;s equity-based compensation plans under Rule 5635(c)(4) of the Nasdaq Listing Rules.   </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of awards outstanding:</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.711%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2004 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2013 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Inducement Awards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Granted and outstanding awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">173,983&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,629,457&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35,151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">743,726&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,582,317&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,889,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,701,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">738,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,330,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">173,983&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,518,957&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,737,119&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,482,601&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,912,660&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Awards</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the stock option activity for the six months ended March&#160;31, 2023:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,721,384</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">20.73&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">32,151</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">33.03&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cancelled or expired</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(25,581)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">58.07&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(145,637)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">7.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,582,317</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">21.26&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">4.5 years</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">30,107,439&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercisable at March&#160;31, 2023</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,348,193</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">18.75&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">4.2 years</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">30,100,306&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values represents the amount by which the market price of the underlying stock exceeds the exercise price of the option. The total intrinsic value of the options exercised during the three months ended March&#160;31, 2023 and 2022 was $1.4 million and $10.8 million, respectively. The total intrinsic value of the options exercised during the six months ended March&#160;31, 2023 and 2022 was $3.6 million and $23.3 million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to stock options outstanding for the three months ended March&#160;31, 2023 and 2022, was $2.2 million and $2.7 million, respectively. Stock-based compensation expense related to stock options for the six months ended March&#160;31, 2023 and 2022 was $4.6 million and $5.7 million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the pre-tax compensation expense for all outstanding unvested stock options in the amount of $7.6 million will be recognized in the Company&#8217;s results of operations over a weighted average period of 1.0 year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#8217;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the assumptions used in the calculation of grant-date fair values of these stock options based on the Back-Scholes option pricing model:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Expected dividend yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:114%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:114%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:114%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">86.4&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Expected term (in years)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:114%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.25</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Weighted average grant date fair value per share of options granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:114%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">24.80&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">N/A</span></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) The dividend yield is zero as the Company currently does not pay a dividend. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(2) The risk-free interest rate is based on that of the U.S. Treasury yields with equivalent terms in effect at the time of the grant. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(3) Volatility is estimated based on volatility average of the Company&#8217;s common stock price. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(4) The expected term represents the period of time that stock options granted are expected to be outstanding, by using historical exercise patterns and post-vesting termination behavior. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(5) No options were granted during the six months ended March 31, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units (&#8220;RSUs&#8221;), including market-based, time-based and performance-based awards, have been granted under the Company&#8217;s 2013 and 2021 Plans and as inducements grants granted outside of the Company&#8217;s equity-based compensation plans. At vesting, each outstanding RSU will be exchanged for one share of the Company&#8217;s common stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of the Company&#8217;s RSUs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Grant<br/>Date<br/>Fair Value<br/>Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">4,069,431</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">62.96&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,098,544</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">34.67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(763,132)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">54.20&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(74,500)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">57.28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">4,330,343</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">57.62&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs was determined based on the closing price of the Company&#8217;s common stock on the grant date, with consideration given to the probability of achieving service and/or performance conditions for awards.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023 and 2022, the Company recorded $18.4 million and $28.2 million of expense related to RSUs, respectively. For the six months ended March&#160;31, 2023 and 2022, the Company recorded $35.4 million and $49.7 million of expense related RSUs, respectively. As of March&#160;31, 2023, there was $153.6 million of total unrecognized compensation cost related to RSUs that is expected to be recognized over a weighted-average period of 2.5 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779218579232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company employs a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value of a financial instrument is the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date using the exit price. Accordingly, when market observable data are not readily available, the Company&#8217;s own assumptions are used to reflect those that market participants would be presumed to use in pricing the asset or liability at the measurement date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on the consolidated balance sheets are categorized based on the level of judgment associated with inputs used to measure their fair values and the level of market price observability, as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#160;&#160;&#160;&#160;Unadjusted quoted prices are available in active markets for identical assets or liabilities as of the  reporting date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#160;&#160;&#160;&#160;Pricing inputs are other than quoted prices in active markets, which are based on the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     Quoted prices for similar assets or liabilities in active markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     Quoted prices for identical or similar assets or liabilities in non-active markets; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     Either directly or indirectly observable inputs as of the reporting date.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#160;&#160;&#160;&#160;Pricing inputs are unobservable and significant to the overall fair value measurement, and the determination of fair value requires significant management judgment or estimation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. Thus, a Level 3 fair value measurement may include inputs that are observable (Level 1 or Level 2) and unobservable (Level 3). The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and consideration of factors specific to the asset or liability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses prices and inputs that are current as of the measurement date, including during periods of market disruption. In periods of market disruption, the ability to observe prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level 1 to Level 2, or from Level 2 to Level 3. The Company recognizes transfers between levels at either the actual date of the event or a change in circumstances that caused the transfer. At March&#160;31, 2023 and September&#160;30, 2022, the Company did not have any financial assets or financial liabilities based on Level 3 measurements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques utilized by the Company:  </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:33.194%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.077%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Municipal securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,034&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,034&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">95,786&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">95,786&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">306,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">306,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certificate of deposits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:33.194%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.077%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,727&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,727&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">271,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">271,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certificate of deposits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779218513088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Sale of Future Royalties<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract', window );"><strong>Liability Related To The Sale Of Future Royalties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock', window );">Liability Related to the Sale of Future Royalties</a></td>
<td class="text">LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2022, the Company and Royalty Pharma entered into the Royalty Pharma Agreement, pursuant to which Royalty Pharma agreed to pay up to $410.0&#160;million in cash to the Company in consideration for the Company&#8217;s future royalty interest in Olpasiran, a small interfering RNA (siRNA) originally developed by the Company and licensed to Amgen in 2016 under the Olpasiran Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Royalty Pharma Agreement, Royalty Pharma paid $250.0 million upfront and agreed to pay up to an additional $160.0&#160;million in aggregate one-time milestone payments due if and when the following milestone events occur: (i) $50.0&#160;million on completion of enrollment in the planned OCEAN Phase 3 clinical trial for Olpasiran, (ii) $50.0&#160;million upon receipt of FDA approval of Olpasiran for an approved indication (reduction in the risk of myocardial infarction, urgent coronary revascularization, or coronary heart disease death in adults with established cardiovascular disease and elevated Lp(a)), and (iii) $60.0&#160;million upon Royalty Pharma&#8217;s receipt of at least $70.0&#160;million of royalty payments under the Royalty Pharma Agreement in any single calendar year. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the payment of the foregoing amounts under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the terms of the Royalty Pharma Agreement and concluded in accordance with the relevant accounting guidance that the Company accounted for the transaction as debt and the funding of $250.0&#160;million from Royalty Pharma was recorded as a liability related to the sale of future royalties on its consolidated balance sheets. The Company is not obligated to repay this upfront funding received under the  Royalty Pharma Agreement. This liability is amortized over the expected repayment term using an effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. The interest rate may vary during the term of the agreement depending on a number of factors, including the amount and timing of forecasted net revenues which affects the repayment timing and ultimate amount of repayment. The Company will evaluate the effective interest rate quarterly based on its current revenue forecasts utilizing the prospective method. For the three and six months ended March&#160;31, 2023, the Company recognized non-cash interest expense of $5.1&#160;million and $7.9&#160;million, respectively, on the consolidated statements of operations and comprehensive income (loss).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Related To The Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Related To The Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779218525104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">EARNINGS PER SHAREThe following table presents the computation of basic and diluted earnings per share for the six months ended <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023 and 2022. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48,675&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,366&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,350&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18,506)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average basic shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105,034&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of dilutive securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,386&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,384&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,499&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average diluted shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">108,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">107,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">107,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105,034&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.07&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities representing approximately 4,350,000 and 4,069,000 shares of common stock were excluded from the computation of diluted earnings per share for the three and six months ended March&#160;31, 2023, respectively, because their effect would have been anti-dilutive. There were no potentially dilutive securities with anti-dilutive effect for the six months ended March&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779218368752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no recent accounting pronouncements that have significantly impacted this Quarterly Report on Form 10-Q, beyond those disclosed in the Company&#8217;s most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779218600528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ScheduleOfCurrentProductsTableTextBlock', window );">Schedule of Company's Current Pipeline</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s current pipeline:</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"/><td style="width:16.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Therapeutic Area</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Stage</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Product Rights</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cardiometabolic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-APOC3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2b and Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-ANG3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2b</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Olpasiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amgen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pulmonary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-ENAC2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-Clinical</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-RAGE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-MUC5AC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-MMP7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liver</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK-4532990 (formerly ARO-HSD)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fazirsiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Takeda and Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">JNJ-3989</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Janssen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">HZN-457 (formerly ARO-XDH)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Horizon</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-C3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-PNPLA3 (formerly JNJ-75220795)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Muscle</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-DUX4</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-Clinical</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CNS</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-SOD1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-Clinical</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ScheduleOfCurrentProductsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Current Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ScheduleOfCurrentProductsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779218438112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Revenue</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of revenue recognized:</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.818%"><tr><td style="width:1.0%"/><td style="width:33.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.555%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">29,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">120,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Horizon</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,918&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">21,667&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,585&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Takeda</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">116,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">132,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Janssen</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">111&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,066&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">355&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,066&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amgen</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">146,267&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">151,805&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">208,813&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">179,244&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Receivables and Contract Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance of receivables and contract liabilities related to the Company&#8217;s collaboration and license agreements:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.696%"><tr><td style="width:1.0%"/><td style="width:57.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Receivables included in accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">70,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">6,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contract liabilities included in deferred revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">30,914&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">130,049&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779218606128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s major classes of property and equipment:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Computers, software, office equipment and furniture</span></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,198&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,182&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Research equipment</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">46,873&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">38,283&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">42,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">42,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">127,216&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">56,373&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">221,300&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">141,851&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(36,072)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(31,554)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">185,228&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">110,297&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779218606128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock', window );">Summary of Short-term and Long-term Investments and Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.002%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.265%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.265%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.265%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.269%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Short-term investments (due within one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">346,046&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,755)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">342,291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity certificate of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total short-term investments</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">346,046&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,755)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">342,291&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Long-term investments (due within one through three years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">78,834&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,709)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">77,125&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total long-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">78,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,709)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">77,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.596%"><tr><td style="width:1.0%"/><td style="width:45.323%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.185%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Short-term investments (due within one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">218,391&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,661)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">214,730&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity certificate of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total short-term investments</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">268,391&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,661)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">264,730&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Long-term investments (due within one through three years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,569)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100,303&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total long-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,569)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Held to maturity securities and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779218509984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text">The following table presents the components of intangible assets: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.361%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Impairment</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Useful Lives</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(amounts in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,545&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,183&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,857&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,745&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,112&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,958&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,857&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,895&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,962&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Intangible Assets Future Amortization Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated future amortization expense related to intangible assets as of March&#160;31, 2023:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"><tr><td style="width:1.0%"/><td style="width:71.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.099%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortization Expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ending September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2023 (remainder)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779218579232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Shares of Common Stock and Preferred Stock</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s shares of common stock and preferred stock:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"><tr><td style="width:1.0%"/><td style="width:27.208%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.826%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Par Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Authorized</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">290,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">145,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779218597120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Assets and Liabilities and Lease Cost</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease assets and liabilities along with their classification on the Company&#8217;s consolidated balance sheets were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"><tr><td style="width:1.0%"/><td style="width:28.807%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.807%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.378%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,711&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,776&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">80,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">78,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.839%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lease Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,033&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">840&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,003&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,507&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,815&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,963&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents payments of operating lease liabilities on an undiscounted basis as of March&#160;31, 2023:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.545%"><tr><td style="width:1.0%"/><td style="width:79.997%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.803%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amounts</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2023 (remainder of fiscal year)</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">3,070&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">8,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">11,800&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">12,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">11,297&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">102,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">149,212&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(66,431)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total operating lease liabilities (includes current portion)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">82,781&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.969%"><tr><td style="width:1.0%"/><td style="width:60.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.519%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating cash flows from operating leases (in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779212702720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of Awards Outstanding</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of awards outstanding:</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.711%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2004 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2013 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Inducement Awards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Granted and outstanding awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">173,983&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,629,457&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35,151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">743,726&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,582,317&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,889,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,701,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">738,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,330,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">173,983&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,518,957&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,737,119&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,482,601&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,912,660&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summarized Information about Stock Options</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the stock option activity for the six months ended March&#160;31, 2023:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,721,384</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">20.73&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">32,151</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">33.03&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cancelled or expired</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(25,581)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">58.07&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(145,637)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">7.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,582,317</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">21.26&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">4.5 years</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">30,107,439&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercisable at March&#160;31, 2023</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,348,193</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">18.75&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">4.2 years</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">30,100,306&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used to Value Stock Options</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the assumptions used in the calculation of grant-date fair values of these stock options based on the Back-Scholes option pricing model:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Expected dividend yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:114%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:114%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:114%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">86.4&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Expected term (in years)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:114%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.25</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Weighted average grant date fair value per share of options granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:114%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">24.80&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">N/A</span></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) The dividend yield is zero as the Company currently does not pay a dividend. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(2) The risk-free interest rate is based on that of the U.S. Treasury yields with equivalent terms in effect at the time of the grant. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(3) Volatility is estimated based on volatility average of the Company&#8217;s common stock price. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(4) The expected term represents the period of time that stock options granted are expected to be outstanding, by using historical exercise patterns and post-vesting termination behavior. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(5) No options were granted during the six months ended March 31, 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Share Activity Related to RSUs</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of the Company&#8217;s RSUs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Grant<br/>Date<br/>Fair Value<br/>Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">4,069,431</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">62.96&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,098,544</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">34.67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(763,132)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">54.20&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(74,500)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">57.28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">4,330,343</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">57.62&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779218525104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques utilized by the Company:  </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:33.194%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.077%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Municipal securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,034&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,034&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">95,786&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">95,786&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">306,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">306,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certificate of deposits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:33.194%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.077%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,727&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,727&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">271,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">271,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certificate of deposits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779215514656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text">The following table presents the computation of basic and diluted earnings per share for the six months ended <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023 and 2022. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48,675&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,366&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,350&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18,506)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average basic shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105,034&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of dilutive securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,386&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,384&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,499&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average diluted shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">108,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">107,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">107,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105,034&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.07&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779213969312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 09, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000<span></span>
</td>
<td class="nump">$ 135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,300<span></span>
</td>
<td class="nump">7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,046<span></span>
</td>
<td class="nump">346,046<span></span>
</td>
<td class="nump">$ 268,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,834<span></span>
</td>
<td class="nump">78,834<span></span>
</td>
<td class="nump">$ 105,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_IncreaseDecreaseInCashAndInvestments', window );">Increase in cash and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_HorizonTherapeuticsIrelandDACAndAmgenIncorporatedMember', window );">Horizon and Amgen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_UpfrontMilestonePaymentReceived', window );">Upfront milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda | License and Co-Funding Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK | Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember', window );">Horizon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_UpfrontMilestonePaymentReceived', window );">Upfront milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_AmgenIncorporatedMember', window );">Amgen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_UpfrontMilestonePaymentReceived', window );">Upfront milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_RoyaltyPharmaMember', window );">Royalty Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_UpfrontMilestonePaymentReceived', window );">Upfront milestone payment received</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_IncreaseDecreaseInCashAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in cash and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_IncreaseDecreaseInCashAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_OrganizationAndSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_UpfrontMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_UpfrontMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_HorizonTherapeuticsIrelandDACAndAmgenIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_HorizonTherapeuticsIrelandDACAndAmgenIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseAndCoFundingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_LicenseAndCoFundingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_AmgenIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_AmgenIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_RoyaltyPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_RoyaltyPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779207256208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 146,267<span></span>
</td>
<td class="nump">$ 151,805<span></span>
</td>
<td class="nump">$ 208,813<span></span>
</td>
<td class="nump">$ 179,244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">29,323<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arwr_HorizonTherapeuticsIrelandDACMember', window );">Horizon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,918<span></span>
</td>
<td class="nump">21,667<span></span>
</td>
<td class="nump">14,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">116,156<span></span>
</td>
<td class="nump">20,821<span></span>
</td>
<td class="nump">132,468<span></span>
</td>
<td class="nump">41,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">3,066<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="nump">3,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arwr_AmgenIncorporatedMember', window );">Amgen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arwr_HorizonTherapeuticsIrelandDACMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arwr_HorizonTherapeuticsIrelandDACMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arwr_JanssenPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arwr_JanssenPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arwr_AmgenIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arwr_AmgenIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779213386992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration and License Agreements - Receivables and Contract Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Receivables included in accounts receivable</a></td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="nump">$ 6,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities included in deferred revenue</a></td>
<td class="nump">$ 30,914<span></span>
</td>
<td class="nump">$ 130,049<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126942793&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779213340640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Nov. 22, 2021</div></th>
<th class="th"><div>Oct. 03, 2018</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,839,000<span></span>
</td>
<td class="nump">$ 74,099,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember', window );">Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 252,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK | Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo', window );">Milestone payment receivable at start of phase two</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree', window );">Milestone payment receivable upon achievement of phase two and first patient dosed in phase three</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK | Collaboration and License agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CommercialMilestonePaymentsAtFirstCommercialSale', window );">Commercial milestone payments at first commercial sale</a></td>
<td class="nump">190,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_SalesRelatedMilestonePayments', window );">Sales-related milestone payments</a></td>
<td class="nump">$ 590,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CommercialMilestonePaymentsAtFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial milestone payments at first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CommercialMilestonePaymentsAtFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment receivable at start of phase two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableAtStartOfPhaseTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment receivable upon achievement of phase two and first patient dosed in phase three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_SalesRelatedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales-related milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_SalesRelatedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779212779824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 18, 2021 </div>
<div>USD ($) </div>
<div>bundle </div>
<div>obligation</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,839,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,099,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember', window );">Horizon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_UpfrontMilestonePaymentReceived', window );">Upfront milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember', window );">Horizon | ARO-XDH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement', window );">Cash received as due under collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember', window );">Horizon | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctBundle', window );">Number of distinct bundle | bundle</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember', window );">Horizon | Maximum | ARO-XDH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="nump">$ 645,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash receivable as upfront payment due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctBundle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of distinct bundle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctBundle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of distinct performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_UpfrontMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_UpfrontMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_AROXDHAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_AROXDHAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779207005712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 07, 2020 </div>
<div>USD ($) </div>
<div>obligation </div>
<div>bundle</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,267<span></span>
</td>
<td class="nump">$ 151,805<span></span>
</td>
<td class="nump">$ 208,813<span></span>
</td>
<td class="nump">$ 179,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="nump">$ 0.41<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda | License and Co-Funding Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement', window );">Cash received as due under collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctBundle', window );">Number of distinct bundle | bundle</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda | License and Co-Funding Agreement | Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda | License and Co-Funding Agreement | Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda | License and Co-Funding Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales', window );">Percentage of eligible to receive tiered royalties on net sales</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda | License and Co-Funding Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales', window );">Percentage of eligible to receive tiered royalties on net sales</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 527,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 527,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash receivable as upfront payment due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctBundle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of distinct bundle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctBundle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of distinct performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of eligible to receive tiered royalties on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseAndCoFundingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_LicenseAndCoFundingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=arwr_DeferredRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=arwr_DeferredRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779210411120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Janssen Pharmaceuticals, Inc. (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2018</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development, regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,267,000<span></span>
</td>
<td class="nump">$ 151,805,000<span></span>
</td>
<td class="nump">208,813,000<span></span>
</td>
<td class="nump">$ 179,244,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,839,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,839,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,099,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember', window );">Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 252,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember', window );">JJDC | Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderCollaborationAgreement', window );">Upfront payment</a></td>
<td class="nump">175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember', window );">JJDC | Common Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="nump">73,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development, regulatory and sales milestones payments</a></td>
<td class="nump">800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | JNJ-75220795 (ARO-JNJ1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | JNJ-3989 (ARO-HBV) Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivedAsDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received as due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivedAsDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_CommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arwr_CommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_JNJ75220795AROJNJ1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_JNJ75220795AROJNJ1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_JNJ3989AROHBVAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_JNJ3989AROHBVAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779206816560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration and License Agreements - Amgen, Inc (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 28, 2016 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_AmgenIncorporatedMember', window );">Amgen | Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfAgreements', window );">Number of agreements | agreement</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_AmgenIncorporatedMember', window );">Amgen | Olpasiran and ARO-AMG1 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderCollaborationAgreement', window );">Upfront payment</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">$ 21,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceived', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_AmgenIncorporatedMember', window );">Amgen | Olpasiran Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments', window );">Additional remaining development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 535,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional remaining development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivedAsDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received as due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivedAsDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_AmgenIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_AmgenIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAndAROAMG1AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAndAROAMG1AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779207409760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Proceeds from the sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,267<span></span>
</td>
<td class="nump">$ 151,805<span></span>
</td>
<td class="nump">208,813<span></span>
</td>
<td class="nump">$ 179,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_VisirnaTherapeuticsIncMember', window );">Visirna Therapeutics, Inc. | Visirna License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_VisirnaTherapeuticsIncMember', window );">Visirna Therapeutics, Inc. | Visirna License Agreement | Variable Interest Entity, Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Proceeds from the sale of future royalties</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received by a corporation from a shareholder during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_VisirnaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_VisirnaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_VisirnaLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_VisirnaLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779208569888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Summary of Property and Equipment (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross', window );">Computers, software, office equipment and furniture</a></td>
<td class="nump">$ 2,198<span></span>
</td>
<td class="nump">$ 2,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">2,996<span></span>
</td>
<td class="nump">2,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ResearchEquipmentGross', window );">Research equipment</a></td>
<td class="nump">46,873<span></span>
</td>
<td class="nump">38,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">42,017<span></span>
</td>
<td class="nump">42,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">127,216<span></span>
</td>
<td class="nump">56,373<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">221,300<span></span>
</td>
<td class="nump">141,851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(36,072)<span></span>
</td>
<td class="num">(31,554)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 185,228<span></span>
</td>
<td class="nump">$ 110,297<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Computers, software, office equipment and furniture gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ResearchEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research equipment gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ResearchEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779213130880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense for property and equipment</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779207198640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short-term investments, Held to maturity, Adjusted Bases</a></td>
<td class="nump">$ 346,046<span></span>
</td>
<td class="nump">$ 268,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent', window );">Short-term investments, Held to maturity, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent', window );">Short-term investments, Held to maturity, Gross Unrealized Losses</a></td>
<td class="num">(3,755)<span></span>
</td>
<td class="num">(3,661)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent', window );">Short-term investments, Held to maturity, Fair Value</a></td>
<td class="nump">342,291<span></span>
</td>
<td class="nump">264,730<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Long-term investments, Held to maturity, Adjusted Basis</a></td>
<td class="nump">78,834<span></span>
</td>
<td class="nump">105,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent', window );">Long-term investments, Held to maturity, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent', window );">Long-term investments, Held to maturity, Gross Unrealized Losses</a></td>
<td class="num">(1,709)<span></span>
</td>
<td class="num">(5,569)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent', window );">Long-term investments, Held to maturity, Fair Value</a></td>
<td class="nump">77,125<span></span>
</td>
<td class="nump">100,303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember', window );">Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short-term investments, Held to maturity, Adjusted Bases</a></td>
<td class="nump">346,046<span></span>
</td>
<td class="nump">218,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent', window );">Short-term investments, Held to maturity, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent', window );">Short-term investments, Held to maturity, Gross Unrealized Losses</a></td>
<td class="num">(3,755)<span></span>
</td>
<td class="num">(3,661)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent', window );">Short-term investments, Held to maturity, Fair Value</a></td>
<td class="nump">342,291<span></span>
</td>
<td class="nump">214,730<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Long-term investments, Held to maturity, Adjusted Basis</a></td>
<td class="nump">78,834<span></span>
</td>
<td class="nump">105,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent', window );">Long-term investments, Held to maturity, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent', window );">Long-term investments, Held to maturity, Gross Unrealized Losses</a></td>
<td class="num">(1,709)<span></span>
</td>
<td class="num">(5,569)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent', window );">Long-term investments, Held to maturity, Fair Value</a></td>
<td class="nump">77,125<span></span>
</td>
<td class="nump">100,303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificate of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short-term investments, Held to maturity, Adjusted Bases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent', window );">Short-term investments, Held to maturity, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent', window );">Short-term investments, Held to maturity, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent', window );">Short-term investments, Held to maturity, Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of held to maturity securities and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779206507520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 11,112,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,112,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,962,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember', window );">Novartis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">24,857,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,857,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,857,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">13,745,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,745,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,895,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">11,112,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,112,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,962,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember', window );">Novartis | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">21,728,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,728,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,728,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">12,545,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,545,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,770,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">9,183,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,183,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,958,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember', window );">Novartis | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">3,129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,129,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,125,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 1,929,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,929,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,004,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_FiniteLivedIntangibleAssetsImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_FiniteLivedIntangibleAssetsImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=arwr_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779207146320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Expected Future Amortization (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2023 (remainder)</a></td>
<td class="nump">$ 850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">3,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 11,112<span></span>
</td>
<td class="nump">$ 11,962<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779206511376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 02, 2022</div></th>
<th class="th"><div>Apr. 27, 2023</div></th>
<th class="th"><div>Apr. 26, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,000,000<span></span>
</td>
<td class="nump">145,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,869,000<span></span>
</td>
<td class="nump">105,960,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,869,000<span></span>
</td>
<td class="nump">105,960,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember', window );">At The Market Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember', window );">At The Market Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance', window );">Common stock shares value reserved for future issuance</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock', window );">Percentage of commission to sales agent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember', window );">2004 Equity Incentive Plan, 2013 Equity Incentive Plan, 2021 Equity Incentive Plan and Inducement Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, share reserve for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,075,198<span></span>
</td>
<td class="nump">14,000,392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,000,000<span></span>
</td>
<td class="nump">145,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock, capital shares value reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CommonStockCapitalSharesValueReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission on aggregate gross proceeds from sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779212915648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br> ft&#178; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 20, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>a</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_TaxIncrementFinancingAward', window );">Tax increment financing award</a></td>
<td class="nump">$ 16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">State income tax credits</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=arwr_TechnologyLicenseCommitmentsMember', window );">Technology License Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_VeronaTechnologyParkMember', window );">Verona Technology Park | Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfAcresOfLandPurchased', window );">Land purchased, number of acres | a</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_DrugManufacturingFacilityMember', window );">Drug Manufacturing Facility | Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Planned area of the site (in sq ft) | ft&#178;</a></td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_LaboratoryAndOfficeFacilityMember', window );">Laboratory and Office Facility | Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Planned area of the site (in sq ft) | ft&#178;</a></td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember', window );">Facilities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AmountIntendsToInvestForBuildoutOfFacilities', window );">Amount intends to invest for buildout of the facilities</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember', window );">Facilities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AmountIntendsToInvestForBuildoutOfFacilities', window );">Amount intends to invest for buildout of the facilities</a></td>
<td class="nump">$ 260,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AmountIntendsToInvestForBuildoutOfFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount intends to invest for buildout of facilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AmountIntendsToInvestForBuildoutOfFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfAcresOfLandPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of acres of land purchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfAcresOfLandPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_TaxIncrementFinancingAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Increment Financing Award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_TaxIncrementFinancingAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=arwr_TechnologyLicenseCommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=arwr_TechnologyLicenseCommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_VeronaTechnologyParkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_VeronaTechnologyParkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_DrugManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_DrugManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_LaboratoryAndOfficeFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_LaboratoryAndOfficeFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779206364368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 19, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>option</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>option</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>option</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 23, 2022</div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>option</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Estimated lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember', window );">Research Facility in San Diego | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases (in sq ft) | ft&#178;</a></td>
<td class="nump">144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Estimated lease payments</a></td>
<td class="nump">$ 119,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_EstimatedPaymentsForOperatingExpensesYearOne', window );">Estimated payments for operating expenses</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances', window );">Payments for leasehold improvements, net of tenant improvement allowances</a></td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember', window );">Research Facility in San Diego | California | Sorrento Valley Owner (DE) LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember', window );">Research Facility in San Diego | California | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | option</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember', window );">Corporate Headquarters In Pasadena | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases (in sq ft) | ft&#178;</a></td>
<td class="nump">49,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember', window );">Corporate Headquarters In Pasadena | California | Colorado Owner, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember', window );">Research Facility in Madison | Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases (in sq ft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EstimatedPaymentsForOperatingExpensesYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated payments for operating expenses year one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_EstimatedPaymentsForOperatingExpensesYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfOptionsToRenew">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options to renew.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfOptionsToRenew</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of leasehold improvements net of tenant improvement allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_SorrentoValleyOwnerDELLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_SorrentoValleyOwnerDELLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_ColoradoOwnerLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_ColoradoOwnerLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779212766816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract', window );"><strong>Lease Assets and Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 41,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">2,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">80,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total</a></td>
<td class="nump">3,003<span></span>
</td>
<td class="nump">$ 1,507<span></span>
</td>
<td class="nump">5,815<span></span>
</td>
<td class="nump">$ 2,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">2,343<span></span>
</td>
<td class="nump">905<span></span>
</td>
<td class="nump">4,412<span></span>
</td>
<td class="nump">1,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">420<span></span>
</td>
<td class="nump">1,033<span></span>
</td>
<td class="nump">840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAndLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779206862240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2023 (remainder of fiscal year)</a></td>
<td class="nump">$ 3,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">8,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">11,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">12,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">11,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive', window );">2028 and thereafter</a></td>
<td class="nump">102,813<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">149,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(66,431)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities (includes current portion)</a></td>
<td class="nump">$ 82,781<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due year five and after year five.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779215234272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash Flow and Other Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 2,503<span></span>
</td>
<td class="nump">$ 2,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779207012736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 18, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 10.8<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="nump">$ 23.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized pre-tax compensation expense</a></td>
<td class="nump">$ 7.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period to recognize pre-tax compensation expense</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 18.4<span></span>
</td>
<td class="nump">$ 28.2<span></span>
</td>
<td class="nump">35.4<span></span>
</td>
<td class="nump">$ 49.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized pre-tax compensation expense</a></td>
<td class="nump">$ 153.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period to recognize pre-tax compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember', window );">2004 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance (in shares)</a></td>
<td class="nump">173,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance (in shares)</a></td>
<td class="nump">3,518,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,518,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember', window );">2021 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="nump">6,126,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,126,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_InducementAwardsMember', window );">Inducement Awards | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance (in shares)</a></td>
<td class="nump">743,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">743,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_InducementAwardsMember', window );">Inducement Awards | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance (in shares)</a></td>
<td class="nump">738,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">738,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_InducementAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_InducementAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779206951296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">2,582,317<span></span>
</td>
<td class="nump">2,721,384<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">6,912,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember', window );">2004 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">173,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">173,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">1,629,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">3,518,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember', window );">2021 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">35,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">1,737,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_InducementAwardsMember', window );">Inducement Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">743,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">1,482,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">4,330,343<span></span>
</td>
<td class="nump">4,069,431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | 2004 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | 2013 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">1,889,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | 2021 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">1,701,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Inducement Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">738,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_InducementAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_InducementAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779208562624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summarize Information about Stock Options (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">2,721,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">32,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Cancelled (in shares)</a></td>
<td class="num">(25,581)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(145,637)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">2,582,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options Outstanding, Exercisable (in shares)</a></td>
<td class="nump">2,348,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 20.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">33.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled (in dollars per share)</a></td>
<td class="nump">58.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">7.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">21.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share)</a></td>
<td class="nump">$ 18.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Term (Years)</a></td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 30,107,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 30,100,306<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779219472688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Assumptions Used to Value Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.69%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">86.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share of options granted</a></td>
<td class="nump">$ 24.80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779219262960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of RSUs Activity (Details) - Restricted Stock Units (RSUs)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning of period (in shares) | shares</a></td>
<td class="nump">4,069,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,098,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(763,132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(74,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">End of period (in shares) | shares</a></td>
<td class="nump">4,330,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 62.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">34.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">54.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">57.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 57.62<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779206550592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market instruments</a></td>
<td class="nump">$ 53,743<span></span>
</td>
<td class="nump">$ 39,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">23,074<span></span>
</td>
<td class="nump">1,973<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">7,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">95,786<span></span>
</td>
<td class="nump">41,727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">306,950<span></span>
</td>
<td class="nump">271,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Certificate of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Certificate of deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market instruments</a></td>
<td class="nump">53,743<span></span>
</td>
<td class="nump">39,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">23,074<span></span>
</td>
<td class="nump">1,973<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Certificate of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Certificate of deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">7,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">95,786<span></span>
</td>
<td class="nump">41,727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">306,950<span></span>
</td>
<td class="nump">271,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Certificate of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Certificate of deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Certificate of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Certificate of deposits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arwr_CommercialNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arwr_CommercialNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779212784704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Sale of Future Royalties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 09, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties', window );">Non-cash interest expense on liability related to the sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,906<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember', window );">Royalty Pharma Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderCollaborationAgreement', window );">Upfront payment</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial', window );">Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponFDAApproval', window );">Milestone payment receivable upon FDA approval</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments', window );">Milestone payment receivable upon receipt of royalty payments</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_RoyaltyPaymentThreshold', window );">Royalty payment threshold</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LiabilitySaleOfFutureRoyalties', window );">Liability related to the sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties', window );">Non-cash interest expense on liability related to the sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="nump">$ 7,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember', window );">Royalty Pharma Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivedAsDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received as due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivedAsDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LiabilitySaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability, Sale of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LiabilitySaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable Upon Achievement of Enrollment in Phase 3 Clinical Trial</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponFDAApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable Upon FDA Approval</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponFDAApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable, Upon Receipt Of Royalty Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Expense, Liability Related to Sale of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_RoyaltyPaymentThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Payment Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_RoyaltyPaymentThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139779208585744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 48,675<span></span>
</td>
<td class="num">$ (41,325)<span></span>
</td>
<td class="nump">$ 44,366<span></span>
</td>
<td class="num">$ (62,872)<span></span>
</td>
<td class="nump">$ 7,350<span></span>
</td>
<td class="num">$ (18,506)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average basic shares outstanding (in shares)</a></td>
<td class="nump">106,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,394<span></span>
</td>
<td class="nump">105,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">1,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,499<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average diluted shares outstanding (in shares)</a></td>
<td class="nump">108,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,893<span></span>
</td>
<td class="nump">105,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">4,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,069<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>arwr-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:arwr="http://www.arrowheadresearch.com/20230331"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="arwr-20230331.xsd" xlink:type="simple"/>
    <context id="i2413801f016643d1afe7ea8782b19367_D20221001-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i32b8a1c0e5854d3ba284b51410976f38_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="i8658828dac144310891d79034519aac1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0f0b57d9696a4178850cfeeb887a0527_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3ef217d1ae014653950af714ba114e79_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i50a4e54f5bfb4716b45f934eaa14113d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib3d20c6e34ff445d941da59d04a42801_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia0d8fd51248444d7b2cc18251bffd261_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8fab671f9d1f4bcc811ab238a0e9d2aa_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iae8bf4236a96463d85eb67cec5f9436c_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if22a765bc5e6493cb9f1b2ed13cb4e3a_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iea981497ed1441a1adcdec1001a8e970_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0d6492fefa7340f3887bfa04169628a6_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie91d240ca96944a3b6fa19d2e3be66f2_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id07ee53b35c546489aa1141fb795a81e_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9f0f0f39856c41238ff79dc13354c8e0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if30cb9af4bf44698ad1355d4cb3e5076_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8c12fc21190440f4b646777c6721e378_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i07b211def5654e32b5476f84e9f9dd7a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i40ebfdae8cd740beb807ce422f45197d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie756775941ef43fd80b1a267081ca9a1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib195d18380a947c684949421e1dcd365_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4fa04963a7944b6d8829bc8de0678c19_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i01a9fa326aef4dc0830ea895f2568994_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i808343e416724a7ab9e17a71f299ad91_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i98f503ba5e1a4de99077aecc556aa3ce_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie34dd58815de44edb4894780fe72ea8f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8a699bc0f28f4ae7aeca3fe229161d36_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8b4b2f94dd8f410e88a3c296a630fd9a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifeb60a45426b407eb7975d28f670c511_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic3613bbfc4a8440c99ce1bf55975a119_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i84b78e6fbe2a41cdbc5069a20bac2479_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iac8802180c9145218b8bd2c6aa534a09_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id534cbaab59b43ad982991d831ecc480_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i154ad50f88ea4503a5defebce13af0ba_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3144d66a7c174bff86ddf2ab9afe90cd_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iadfd6b159c9446f4ad12848ede62bfea_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6f3fdde941ae47dfb11186c305ab632c_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i26989504186e41ed84cd5f5d555e3de0_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idc7933727b4b46368d3b521b47747ef5_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5b43fbce18ea4f85835fbd0288c1735d_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0d11611625c842c192a76949637ab1ad_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i18800dd8b03b46b48aaf88b9fb7044b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1161b10586074a64b54fd01340222fd9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i82df41dcbf8c408098779e2309253d00_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia3c56824a9954cc8afb80ad2017d4a48_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ice8878b3a2d14233b9b372038ed81850_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib7611db3737a4c7a959ce6e212f2636a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i00be0b1806084dec8196472cc1ddf3df_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia5de09ecb41b49789bdf45c6d67a4d62_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iab63cc1254d34693ab73656849db98e4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3d29a460a2c54ed2abee1109c64c2f63_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0151ff9c71de4a0499c8804305f5adc0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9b0b1cc7a9a8460aa79e6b253f97b6ea_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic6ff5ed1bf3742a98dc9cde7d7ace25c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i68254b76d5ec47889b72791c3fea708a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib25506c96c484cef99aa0e6030c5ad3c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2b1b88ad17754cd781fd0282509470f4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i43a3ecb8edc343d68a3d398bc46eaa91_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ieab41d2e8cba4cf79954078e0cabd689_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib5defaeb7ae444faaeff3aef533d099f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i98ffa0a0b1d34836b2777d4632a82434_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id543e56d77b6424381c9e219cda252c8_D20221109-20221109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:RoyaltyPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-09</startDate>
            <endDate>2022-11-09</endDate>
        </period>
    </context>
    <context id="i9f80c327fd0f46fcb58660b1d4a93b3f_D20221001-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:RoyaltyPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i77ee61f67e7d4807a1b41dc07bbe6011_D20221001-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:HorizonTherapeuticsIrelandDACAndAmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i15c28c33dc6b4b10bbc915f499ad8066_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia1384505727044d59609bba3ee71e812_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iccbf1d7ac531418d9578213f88b95f24_D20221001-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i269e350e160c4ea6ad74071baf18573a_D20211001-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i60b798e3a061472cbe491224489dd4fd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i825f9542073f4d75985f228f8558ca2e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6cd6b96847294914b272df50802b449e_D20221001-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i243b609737ea4d7eb695ad185cb74491_D20211001-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i082bc8d425934d3a809c260cf43f2098_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4920d739b45b45edbeea74ee7c5f1a5e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i233b4f8cd26e4e908334e04db7e1672d_D20221001-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i36bee665f89b4b8bb8cf30907efbb23d_D20211001-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i41d99afba4a04457ae92c14f6d2288e4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic2d18d01d1ba459c819e19a2f426f844_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i64ad46fbf63445bbab41c28a191959cc_D20221001-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8cddef21baaf4bf9bfe75fd694a89239_D20211001-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4a36c9033466491aa13ecfd0d8b71fd8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i66bbdb26e9194e4fbb451ef54849270f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iee762a06741d4eb7a18728ac4c642e6b_D20221001-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iaeb9254172ee4a51a8dd7073ba5f92c6_D20211001-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i691de1d520624cd1b1ffd39dc3bdc01d_I20211122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-22</instant>
        </period>
    </context>
    <context id="i3271e7a0f6144468b240efa725ae2d39_I20211122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-22</instant>
        </period>
    </context>
    <context id="i237d8e5c7b234033bc777c8a0a3b0d52_D20211122-20211122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-22</startDate>
            <endDate>2021-11-22</endDate>
        </period>
    </context>
    <context id="i3d90a2de7f4e49f596cb460bdc10f3ca_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="i882e29fc588d4797a46ee5a39680339a_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="i59d79924ebeb447c886bc284402909d2_I20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="i82576571409c4b7f9b8bb80fb3c9a00e_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="i8b82750996f043c38f0f0871c175613b_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="i711eaa11f2714195b20f945bbd192ec3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idadf7ab9198248d8be15ad2d0459d433_D20201007-20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-07</startDate>
            <endDate>2020-10-07</endDate>
        </period>
    </context>
    <context id="ia6534598f573472fa49c88f3543fef50_D20201007-20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-07</startDate>
            <endDate>2020-10-07</endDate>
        </period>
    </context>
    <context id="i3776d7ed0187438ba605de53d95d0524_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i5df73d39e5de43059a0154473c1fc57f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2220001e31ea4ab6af2ee0d3e5c38388_D20201007-20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-07</startDate>
            <endDate>2020-10-07</endDate>
        </period>
    </context>
    <context id="iee5b7af13da443ca9a9e86096b5e0768_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i587c88b790cf4957a1f2e9ff83d976c3_D20221001-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5a2e6ffc46c94788ab81d4390fdee866_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">arwr:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iecaadb3d3d994f3383d71ba13d40433e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i66aef91f08484848847318e56657242a_D20181003-20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JohnsonAndJohnsonInnovationJJDCIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="id0ed9d7c6a704f9c9edc96118a125065_D20181003-20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JohnsonAndJohnsonInnovationJJDCIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="i82a308c1dd274f2e8e0a6f7e4ad9c114_I20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-03</instant>
        </period>
    </context>
    <context id="i076faa12769447e9be5b69d21b9bf0ed_I20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-03</instant>
        </period>
    </context>
    <context id="i2c30ebd6d9024acdba5d304d894ee2a4_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="ia34c6824ddbd426ea939bb344ff03287_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0cf61607a2de42a1b21f3f65fa7d4921_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i69f05a11406a48f2a92c762736aedab3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6a26ad8e16504e72b2689ba702142228_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib6ca215027754381a471291a60f53443_D20181003-20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="i497a7ae1faa04b0b9671b12bf3055d80_I20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-03</instant>
        </period>
    </context>
    <context id="ibd242108c98b440c9d40f8441267573b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i57ec6b70a6104026b8b41cb652df4ebb_I20160928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-28</instant>
        </period>
    </context>
    <context id="i5f5f8caf41684c1ab6c099861fb8c323_D20160928-20160928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-28</startDate>
            <endDate>2016-09-28</endDate>
        </period>
    </context>
    <context id="i9405e8a861cd439b9331928b2bbd63e1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i75cdb28a2e3a4ffd972787e5034b8cb6_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="ibd5f89a84f804aad9a58e70315cd9ffe_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i18dfb4f2db2a4e89865ff817bb733953_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1d8b33b9a77247749e39326804eed524_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1923b3729416425e9e9c1f77d0a63e84_D20220425-20220425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:VisirnaLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-25</startDate>
            <endDate>2022-04-25</endDate>
        </period>
    </context>
    <context id="i6bca132899c842c2905496adc8f95181_D20221001-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:VisirnaLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6de19fc5f51b4e9888754036904b53f2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:VisirnaLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2763c2350df84087ae24e66c081a59da_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i770057db11544c24ad5a17c97ffb3a9f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4963dadcf66e4834a7a45b5f75765cb7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie3f0180b2cd14a14919b19c765f13d23_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5b40500b5f154e638fec3502314b61ad_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i43111cfc508d42d1a23d0e3818674d52_D20221001-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iaefcccfc8a3c49a885837a695c3852d6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5d9b66e3437446e6a4e87dc026f2f51d_D20221001-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iae265843759f4671ae3ffdba000744f2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1e874cdd6f5c448fb4d8544628558c18_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i633b04e751e24ba3905af5e05905fd6e_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia0176372a9404016aaf7cbb1312079fa_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i99c440889d934b9a991b649900bea075_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia6d2dec926374fd7a06a9cc5ff555ad3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5e6eba04dc734b4d8c9dac99153326ea_I20230426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-26</instant>
        </period>
    </context>
    <context id="i5a2307967ccd4758a76576f944c97966_I20230427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-27</instant>
        </period>
    </context>
    <context id="i946d734bd0924e3c88051efb2fda8a0b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i68db699bce364d8482aa0ec6406b9e97_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i93974846852e4d2e86d9713058a0d972_I20221202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-02</instant>
        </period>
    </context>
    <context id="idb7a13077dbb473bbf383cb6cf031d5f_D20221202-20221202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-02</startDate>
            <endDate>2022-12-02</endDate>
        </period>
    </context>
    <context id="ibec649ac666a4282b702eb4164c1aa47_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iabd7d953444246219ae89c140ed43582_D20211220-20211220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:VeronaTechnologyParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-20</startDate>
            <endDate>2021-12-20</endDate>
        </period>
    </context>
    <context id="i6f6537bef0da416db817189fd3163b28_I20211220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:DrugManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="icaf4446772ec44ed9ba6f8dddc59fe68_I20211220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:LaboratoryAndOfficeFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="i0f101a6f09c746a696cf6e40e90e0784_I20211220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="i608519b3c5264256971820f095be404f_I20211220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="i174690ddc75d4855ac133c1051fa0058_I20211220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="i87a265da333847a7a7a27032890bbae3_D20211220-20211220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2021-12-20</startDate>
            <endDate>2021-12-20</endDate>
        </period>
    </context>
    <context id="i21fbfd552ab74a5b8d34cf53f412fb99_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id49087344a124915998dbc4016b35524_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if91aa501385d4acda003508cc04433bd_D20221001-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7c55337dc9d5489f93889b362e414346_D20211001-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idd3e5aec48f6451c954c613028ae62ea_I20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="ic5ae44bfc90d442180f61be9e9844f29_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="idc3f86aeb9e54ad2a0c1aea7e97e6026_I20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="i68677c28e8fe477fa44323fceff8350f_I20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="ifbd2b67bde2642ceb93902cc376061d6_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:ColoradoOwnerLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i15669b32d03d4c7994f8ce62df1576ee_I20221223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SorrentoValleyOwnerDELLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-23</instant>
        </period>
    </context>
    <context id="ia816458e6d964f63bac38dc0e0214686_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i159523f6f89347ed97ef204e3f438e67_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia5215e7abf324f20be6a6162e55086ae_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ica3faf3d13c049288fea256fa28a33f5_D20221001-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3a9802653ed047b494adfc65fd05c202_D20211001-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2202af7f697f4a768cccd43c0a966d51_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7a904235b2704d1281b976507352cfcc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0104fc96cb744d06baa957d09374a4b9_D20221001-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie31baa0092254ca4a31017b25a53ca08_D20211001-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0eb27783d00443259f37672e22a51d89_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6f8f5aa4479d4452a8f944d74f31a91a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i474bf33fa2dd4412b27d2d7dadd0143f_I20210318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="i85d0e738f7ad46a78439146ca6b1ce57_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia821a22f759c491095cdffcc22a16326_D20221001-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i82aee549d7ee4c17a0af2cb7b4160c1d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i415e58bd2ac14492bc9b71cfcaa0eb68_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3814d26ffec743bdbd368c8d17e1c599_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i513ac43a6b4641d5aa151e55bdb1adb8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ife4b80c909b0481bb55da5cc80d82206_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6930053b987b4dcb9ec1e29905995970_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib6cd39bcc4aa4f2bb3274f9594d5294a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie621a6d7b2894935b2a8275238e99a30_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id48977f119694d19b519cfbd1b536975_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9390b1d02afc409d88c4726d14169331_D20221001-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3a8a84b6b8274985b99c61c1887f17e4_D20211001-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icd78c85c0ede4725b46aebc7e69ca686_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id9777e3d0f0044f9a5ae125314a8b62e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ied3ebc51b45741a1b31064cbf68604f1_D20221001-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib2c010a50c4c41249cf51a81f611ddb4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i805db888d835420986d4e8a91b283687_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i17e779fd14684b3e966d950f0421cb5d_D20211001-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia24340fff8444dbb848ee908a5350d12_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2860ca5f992241c38da43e79e2b1c5f5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8730e93a554e482bbc30293e7122903d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9e07cc9368c3473882925939ec3292a4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if5e50e79a52647fd8ae13612e15c69cf_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9a17cbdd764b419ab72a0c4122118bba_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5266edfdef7545fb95e73d3313d505d6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8049c9628c0e483abd37d06554b9e7d1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib089174a5cf348c1802beeaa2b977442_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib16740a1de40482aba6561a9747b4a94_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i75aef6171137470d8e8e9cb8a2a83af6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2164b78caabc43fda358fdbd89914f21_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5e3601b78983427db6b155d1b0307701_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib1b3c3e0baf84de3bd52125e28ec4b76_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9f174aafdabf4608bf7c653ec8825fdd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if15ee248bfc441c796bf3f458c740ed7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia24fba933c2d4cd0b16bded19b1bb09c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5fbaa59436d843fe988d685090ab4af0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if043a0f1a28f41ad9782a0f46b2240b1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3a07989748524f1f9e510ca832e4367d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4ca3440b89af4805ae8534cd78394ea4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idbc036b73a0349f8aeef68b475d74e60_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0f8f0fdb41494916a8ccd82071a0dfa2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i04d5b678d5744ea1bb9862b56fd512dd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1024c68fa8084ef7ba0a4aa7d7e3620a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i37966ce3d820452881dc0a4feb57c9d8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8e92174f5fd64f259dd75f387bad521c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1df1d8731bf74f8f93e44854a34edda1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i22bc3c1a36b14889bca7b7d519b1e3a1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3fbe7cc097934385a0f7656c8c178477_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i14946c523e3c4c16a7a727f5f8768473_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic88cc70b817c4141873c6deeb572df1c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id6a9654ad2f04e9eb78471c7b782bdc0_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i783e40d9f7b349e687c2fafc7b31322b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if2cf83fb724d4e508f15e0cdb9fed5a5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2b8bc25ae7384b7b86bdeee4af8033ca_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5fe25e9421f84420b7997e575e069958_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibf039f9333f3461faaee52cf3325669f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2bbf95567b5f4f188e2a8249da064586_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2193adeae864400ea2611b5ffcc9bdf0_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i64d56047f58a464c9b4c5f44f3ce0413_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i213da95ed9fc43649772cb98aa5ba619_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3d13c9a5b243437ea4291fc58b35695b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie16b8c3eba024536a3a52b37dbdf8bd8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3ba6acf54b0d4e5e9290dc7371ab7074_D20221109-20221109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-09</startDate>
            <endDate>2022-11-09</endDate>
        </period>
    </context>
    <context id="ie3454e80f761434b82e05233642d0a59_D20221109-20221109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-09</startDate>
            <endDate>2022-11-09</endDate>
        </period>
    </context>
    <context id="ie1daa5e406944e308bb4bedb06fb3198_I20221109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-09</instant>
        </period>
    </context>
    <context id="i72781a23d66b49918170b8f70f504ec4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2c76d9b4843b4551a837b21eebd9dfdb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i55d4c31deffd475f8b184224f06e6834_D20221001-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="bundle">
        <measure>arwr:bundle</measure>
    </unit>
    <unit id="obligation">
        <measure>arwr:obligation</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="agreement">
        <measure>arwr:agreement</measure>
    </unit>
    <unit id="acre">
        <measure>utr:acre</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="option">
        <measure>arwr:option</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80L2ZyYWc6YWY1NjFlOTE0MGViNDA0MWI3OWU3YzQzMmI1OTFkZGUvdGFibGU6OGY5MDMxN2JiYTczNDFmYjg2Y2I2OGFmYTQ0NDUwN2IvdGFibGVyYW5nZTo4ZjkwMzE3YmJhNzM0MWZiODZjYjY4YWZhNDQ0NTA3Yl8yLTEtMS0xLTQ2NjQy_09fbb423-84cf-46fb-9034-9160d4922f25">0000879407</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80L2ZyYWc6YWY1NjFlOTE0MGViNDA0MWI3OWU3YzQzMmI1OTFkZGUvdGFibGU6OGY5MDMxN2JiYTczNDFmYjg2Y2I2OGFmYTQ0NDUwN2IvdGFibGVyYW5nZTo4ZjkwMzE3YmJhNzM0MWZiODZjYjY4YWZhNDQ0NTA3Yl8zLTEtMS0xLTQ2NjQy_af8b0345-0f6e-4133-a095-7f814a4ddaa4">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80L2ZyYWc6YWY1NjFlOTE0MGViNDA0MWI3OWU3YzQzMmI1OTFkZGUvdGFibGU6OGY5MDMxN2JiYTczNDFmYjg2Y2I2OGFmYTQ0NDUwN2IvdGFibGVyYW5nZTo4ZjkwMzE3YmJhNzM0MWZiODZjYjY4YWZhNDQ0NTA3Yl80LTEtMS0xLTQ2NjQy_339a3e59-d71d-4780-9038-2d7f94693707">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80L2ZyYWc6YWY1NjFlOTE0MGViNDA0MWI3OWU3YzQzMmI1OTFkZGUvdGFibGU6OGY5MDMxN2JiYTczNDFmYjg2Y2I2OGFmYTQ0NDUwN2IvdGFibGVyYW5nZTo4ZjkwMzE3YmJhNzM0MWZiODZjYjY4YWZhNDQ0NTA3Yl81LTEtMS0xLTQ2NjQy_5c63a36e-5c39-401a-b9ab-c8870fb8629b">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80L2ZyYWc6YWY1NjFlOTE0MGViNDA0MWI3OWU3YzQzMmI1OTFkZGUvdGFibGU6OGY5MDMxN2JiYTczNDFmYjg2Y2I2OGFmYTQ0NDUwN2IvdGFibGVyYW5nZTo4ZjkwMzE3YmJhNzM0MWZiODZjYjY4YWZhNDQ0NTA3Yl82LTEtMS0xLTQ2NjQy_7ecfb885-17b7-44cd-ba33-4e1df9e556f6">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF8yMjU0_527670ea-74f3-49db-b4c9-59fc07e3b6d7">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGFibGU6ODVlYTU3YWUwZTA3NGMzNTgwMWJmZjcwNDBiM2NlYTEvdGFibGVyYW5nZTo4NWVhNTdhZTBlMDc0YzM1ODAxYmZmNzA0MGIzY2VhMV8wLTAtMS0xLTQ2NjQy_cbd918ba-79f7-4585-a882-d4de0794231d">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF8zMjk4NTM0ODg1NjE5_371af999-af95-43c0-a999-e5304c40167f">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGFibGU6Y2FiMDlhYTJkNWQ1NDU2ZGE3ZjEzMTA0YmFmNDBjNmIvdGFibGVyYW5nZTpjYWIwOWFhMmQ1ZDU0NTZkYTdmMTMxMDRiYWY0MGM2Yl8wLTAtMS0xLTQ2NjQy_1e630b41-2822-4392-a302-77e43c8b30cf">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF8yMjYw_c51b8b14-ee90-46e3-b873-499b25db20f5">001-38042</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF8yMjU1_f5f4468b-1b13-44aa-9455-f71aba600330">ARROWHEAD PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGFibGU6MjQ0MTVlOGExM2RmNGZjNzk3ZTkxNWZlNzQyOWE5YjYvdGFibGVyYW5nZToyNDQxNWU4YTEzZGY0ZmM3OTdlOTE1ZmU3NDI5YTliNl8wLTAtMS0xLTQ2NjQy_1492cf38-eb1d-4898-b688-30996c6a2e40">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGFibGU6MjQ0MTVlOGExM2RmNGZjNzk3ZTkxNWZlNzQyOWE5YjYvdGFibGVyYW5nZToyNDQxNWU4YTEzZGY0ZmM3OTdlOTE1ZmU3NDI5YTliNl8wLTItMS0xLTQ2NjQy_91c0316b-fb7c-4df5-8465-c8a39a1cc639">46-0408024</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF80ODA_869656dc-d81c-4ea9-925d-cfbdff10a841">177 E. Colorado Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF80ODQ_694aa62e-72f5-487e-97ef-04e5ef0fc9c7">Suite 700</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF80ODc_1ce9f0c8-e932-4d92-ab5e-b03233ea1c23">Pasadena</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF80OTE_05a3000f-a323-4ab6-bc18-aa3fcfc4a8b8">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF80OTQ_fa264b43-b2c9-41f2-8ec7-18b4633f182d">91105</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF80OTg_ae52be97-4647-453f-99a7-d6a1f4707cf4">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF81MDI_94553d35-c1d0-49c7-9e29-4281664f219a">304-3400</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGFibGU6YTg0OTE3MWFmNjkxNDMzMThhMTYwZTY0ZmRhYjA5ZjgvdGFibGVyYW5nZTphODQ5MTcxYWY2OTE0MzMxOGExNjBlNjRmZGFiMDlmOF8xLTAtMS0xLTQ2NjQy_d37cd16c-999c-4266-9c85-d1baa3b74287">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGFibGU6YTg0OTE3MWFmNjkxNDMzMThhMTYwZTY0ZmRhYjA5ZjgvdGFibGVyYW5nZTphODQ5MTcxYWY2OTE0MzMxOGExNjBlNjRmZGFiMDlmOF8xLTItMS0xLTQ2NjQyL3RleHRyZWdpb246MzIxZGYwNzAwNTRiNGI3NWEwN2ZlMmQzZGIxYzA2YjFfNA_cabd31d0-456b-47e9-8fe0-6cd554605559">ARWR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGFibGU6YTg0OTE3MWFmNjkxNDMzMThhMTYwZTY0ZmRhYjA5ZjgvdGFibGVyYW5nZTphODQ5MTcxYWY2OTE0MzMxOGExNjBlNjRmZGFiMDlmOF8xLTQtMS0xLTQ2NjQy_18f70943-3e00-4d6e-b6de-66a1d486f052">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF8yMjU2_287ef12f-63ed-42c8-b2eb-1458774e0ef2">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF8yMjU3_76f1340b-46ea-437b-9f9c-28d730541ac9">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGFibGU6MGMxZTYwNTQ2MGVjNDZmZGIzOGNiNDRhOTRlYjJjZjUvdGFibGVyYW5nZTowYzFlNjA1NDYwZWM0NmZkYjM4Y2I0NGE5NGViMmNmNV8wLTAtMS0xLTQ2NjQyL3RleHRyZWdpb246ZDdmZGIyMDc2MWY1NDZiMjkzNzg1NmVjNDQzMDcyMjlfNA_3b4f3a65-45dc-42c7-ae2f-4a5bc583dc1b">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGFibGU6MGMxZTYwNTQ2MGVjNDZmZGIzOGNiNDRhOTRlYjJjZjUvdGFibGVyYW5nZTowYzFlNjA1NDYwZWM0NmZkYjM4Y2I0NGE5NGViMmNmNV8yLTMtMS0xLTQ2NjQy_88e9f6c5-93a4-4f3d-a53e-7373cd5c6279">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGFibGU6MGMxZTYwNTQ2MGVjNDZmZGIzOGNiNDRhOTRlYjJjZjUvdGFibGVyYW5nZTowYzFlNjA1NDYwZWM0NmZkYjM4Y2I0NGE5NGViMmNmNV80LTEtMS0xLTQ2NjQy_30afddd0-d7c0-4235-a6e0-2ef44929f864">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF8yMjUz_471ddcd0-e154-4718-b6f6-5bf7cd5cf93a">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i32b8a1c0e5854d3ba284b51410976f38_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xL2ZyYWc6YWYwYTM1MzRhYjZkNDJhN2I0ZThlNDlmNzQxOTkxZWQvdGV4dHJlZ2lvbjphZjBhMzUzNGFiNmQ0MmE3YjRlOGU0OWY3NDE5OTFlZF8yMjQ4_5903f111-5bfb-4786-8e08-f3a3dae60d36"
      unitRef="shares">106900421</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfNC0xLTEtMS00NjY0Mg_48dd0e40-06e8-4ef3-8564-e88dc0b6f827"
      unitRef="usd">134959000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfNC0zLTEtMS00NjY0Mg_ab37ed06-7070-4513-9bb5-c1d5858da46b"
      unitRef="usd">108005000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfNS0xLTEtMS00NjY0Mg_d073cacc-54c4-4a5a-95c3-474840bf30db"
      unitRef="usd">69434000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfNS0zLTEtMS00NjY0Mg_54874135-6f7f-4653-9434-4e2c66c16cd3"
      unitRef="usd">1410000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfNi0xLTEtMS00NjY0Mg_21e68537-d7ed-43f8-aa52-4d4a5f79348b"
      unitRef="usd">346046000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfNi0zLTEtMS00NjY0Mg_b5ce376a-c166-43ec-a026-729377eb4355"
      unitRef="usd">268391000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfNy0xLTEtMS00NjY0Mg_bba2a328-0e0c-40c9-8f05-fbeb71b3a6b1"
      unitRef="usd">9935000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfNy0zLTEtMS00NjY0Mg_56337aea-619d-413c-86bc-3d0b1edc4018"
      unitRef="usd">7289000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfOC0xLTEtMS00NjY0Mg_30554da7-68a3-4336-9b99-7a10f3e575e4"
      unitRef="usd">14436000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfOC0zLTEtMS00NjY0Mg_9e1b0a6f-538a-4038-a2ef-e871678cd535"
      unitRef="usd">20204000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfOS0xLTEtMS00NjY0Mg_0918c131-3508-4602-93ae-14da6edd43ac"
      unitRef="usd">574810000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfOS0zLTEtMS00NjY0Mg_541f3512-154c-4e58-b29b-829677bae0b0"
      unitRef="usd">405299000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMTAtMS0xLTEtNDY2NDI_66ab3394-4800-46d9-b122-74558e6718ac"
      unitRef="usd">185228000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMTAtMy0xLTEtNDY2NDI_880cae80-4516-4119-b7c8-77e125408c8d"
      unitRef="usd">110297000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMTEtMS0xLTEtNDY2NDI_693ae0b4-aef2-4b40-bae0-b5912f30e214"
      unitRef="usd">11112000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMTEtMy0xLTEtNDY2NDI_e0429a22-1ae5-4b87-ae54-a512451bea47"
      unitRef="usd">11962000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMTItMS0xLTEtNDY2NDI_64a5fb5b-36df-47f0-bd11-1b70a8d81aaa"
      unitRef="usd">78834000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMTItMy0xLTEtNDY2NDI_b74b7d03-2942-498b-9329-97c96124a98a"
      unitRef="usd">105872000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMTMtMS0xLTEtNDY2NDI_cda583ff-49bd-4357-a1ce-6e04586c7c95"
      unitRef="usd">41114000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMTMtMy0xLTEtNDY2NDI_2acf0cf4-36a8-401a-8f50-65754b1677fc"
      unitRef="usd">58291000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMTQtMS0xLTEtNDY2NDI_2dfc06e6-4ade-40c1-8242-a32f22c930ce"
      unitRef="usd">210000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMTQtMy0xLTEtNDY2NDI_b0a0dd34-1751-47a8-b477-186c8395735d"
      unitRef="usd">218000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMTUtMS0xLTEtNDY2NDI_510cb478-aa43-4404-804c-1f51d3c3cb60"
      unitRef="usd">891308000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMTUtMy0xLTEtNDY2NDI_d47a32d0-25dd-417f-914f-65ec56d4981b"
      unitRef="usd">691939000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMTktMS0xLTEtNDY2NDI_ca7534ca-3ab2-4aa1-8366-c78dfee903d3"
      unitRef="usd">9556000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMTktMy0xLTEtNDY2NDI_64e537a5-4f75-4054-b3de-7fde55f433e5"
      unitRef="usd">2868000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjAtMS0xLTEtNDY2NDI_b60dcfb4-1d26-4f28-8d22-cd81a5c64a75"
      unitRef="usd">39551000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjAtMy0xLTEtNDY2NDI_bf6968be-d481-48b0-9702-3e6d3028b7a7"
      unitRef="usd">46856000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjEtMS0xLTEtNDY2NDI_92c8758d-bc08-49a0-a5a2-584db4d0afc8"
      unitRef="usd">5494000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjEtMy0xLTEtNDY2NDI_3f946a5d-9e82-4597-836e-154f1eb9f5a4"
      unitRef="usd">12251000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjItMS0xLTEtNDY2NDI_8f0d48a8-c208-4601-9051-ae9c40de2e18"
      unitRef="usd">2711000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjItMy0xLTEtNDY2NDI_b51715cd-62e8-4631-8ec5-e43c36803cae"
      unitRef="usd">2776000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjMtMS0xLTEtNDY2NDI_d670f986-4694-445c-9c29-cbd6c60b8d37"
      unitRef="usd">29839000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjMtMy0xLTEtNDY2NDI_704be648-df52-4c6a-a94e-1d1c3f925468"
      unitRef="usd">74099000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjQtMS0xLTEtNDY2NDI_a27bd374-4b7b-4cd2-8d8c-858c8012358e"
      unitRef="usd">87151000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjQtMy0xLTEtNDY2NDI_50758edf-362d-4d57-9ac5-89b32004bda4"
      unitRef="usd">138850000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjYtMS0xLTEtNDY2NDI_50798f35-772b-4bc3-a20f-08f72212b20d"
      unitRef="usd">80070000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjYtMy0xLTEtNDY2NDI_923582ed-e4b5-4250-9615-ff3660a6c0b8"
      unitRef="usd">78800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjctMS0xLTEtNDY2NDI_cf021839-4df5-4bf1-a613-d73b9d2ea1e9"
      unitRef="usd">1075000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjctMy0xLTEtNDY2NDI_2809e855-a1fc-4c1f-b34d-db7bd0dd139b"
      unitRef="usd">55950000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <arwr:RoyaltiesLiabilityNoncurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjgtMS0xLTEtNDY2NDI_421c249c-b704-4702-b0b4-c58323d84123"
      unitRef="usd">257906000</arwr:RoyaltiesLiabilityNoncurrent>
    <arwr:RoyaltiesLiabilityNoncurrent
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjgtMy0xLTEtNDY2NDI_69fa4a71-f8cd-49d6-963b-afe708f83e94"
      unitRef="usd">0</arwr:RoyaltiesLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjktMS0xLTEtNDY2NDI_0a423d3a-60af-4090-b562-4c3055d2ba87"
      unitRef="usd">339051000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMjktMy0xLTEtNDY2NDI_701d2929-695b-4e44-a2dd-2b34cb6ac0ca"
      unitRef="usd">134750000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzAtMS0xLTEtNDY2NDI_6199af1b-64db-49d2-ad17-3c869c887125"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzAtMy0xLTEtNDY2NDI_7dfddae8-46e3-4c7a-be71-4b92886eb0af"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzItMC0xLTEtNDY2NDIvdGV4dHJlZ2lvbjpkYzBmY2JiODBlYmU0MWJhYjM2MzM3ZGRmY2JlMDNhZV8xOA_0d697c91-02e7-40cf-b909-ee902a657e1d"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzItMC0xLTEtNDY2NDIvdGV4dHJlZ2lvbjpkYzBmY2JiODBlYmU0MWJhYjM2MzM3ZGRmY2JlMDNhZV8xOA_21f6e68d-cc62-4cfb-ac91-3702e0a72a50"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzItMC0xLTEtNDY2NDIvdGV4dHJlZ2lvbjpkYzBmY2JiODBlYmU0MWJhYjM2MzM3ZGRmY2JlMDNhZV81NDk3NTU4MTQwODE_68878432-9267-4d27-92ff-52e38f88eaca"
      unitRef="shares">290000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzItMC0xLTEtNDY2NDIvdGV4dHJlZ2lvbjpkYzBmY2JiODBlYmU0MWJhYjM2MzM3ZGRmY2JlMDNhZV81NDk3NTU4MTM5ODU_37ea2947-f45c-43a0-ad66-de455a3e23e3"
      unitRef="shares">145000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzItMC0xLTEtNDY2NDIvdGV4dHJlZ2lvbjpkYzBmY2JiODBlYmU0MWJhYjM2MzM3ZGRmY2JlMDNhZV83Nw_620f3319-af46-4c81-ad88-e71499d6965c"
      unitRef="shares">106869000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzItMC0xLTEtNDY2NDIvdGV4dHJlZ2lvbjpkYzBmY2JiODBlYmU0MWJhYjM2MzM3ZGRmY2JlMDNhZV83Nw_eccbf077-9547-422f-bade-26f51551839f"
      unitRef="shares">106869000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzItMC0xLTEtNDY2NDIvdGV4dHJlZ2lvbjpkYzBmY2JiODBlYmU0MWJhYjM2MzM3ZGRmY2JlMDNhZV84NA_5221e5fb-5384-4204-9e88-6e9426f68a58"
      unitRef="shares">105960000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzItMC0xLTEtNDY2NDIvdGV4dHJlZ2lvbjpkYzBmY2JiODBlYmU0MWJhYjM2MzM3ZGRmY2JlMDNhZV84NA_56203224-4966-4b5a-a24e-e7919cdcb5e9"
      unitRef="shares">105960000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzItMS0xLTEtNDY2NDI_71c0b202-b66f-41c6-a935-00e246814f00"
      unitRef="usd">199000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzItMy0xLTEtNDY2NDI_214f83d4-48fd-44aa-9cb6-d210524d0692"
      unitRef="usd">198000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzMtMS0xLTEtNDY2NDI_4db92913-7625-4818-91c9-6ec5084f2c99"
      unitRef="usd">1260310000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzMtMy0xLTEtNDY2NDI_7e4aede2-6ca9-42f8-8fa8-4c103e45bfef"
      unitRef="usd">1219213000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzQtMS0xLTEtNDY2NDI_6815d31a-4818-48b9-9d93-3a778fedc2f2"
      unitRef="usd">-332000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzQtMy0xLTEtNDY2NDI_995e1fee-4eff-47eb-93d6-bbe4f4ff6914"
      unitRef="usd">-136000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzUtMS0xLTEtNDY2NDI_cd664a42-4499-4aa1-99fb-710d03ac6679"
      unitRef="usd">-813405000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzUtMy0xLTEtNDY2NDI_f3d9e68d-7802-45e9-9d7b-51f22bbad10a"
      unitRef="usd">-820755000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzYtMS0xLTEtNDY2NDI_2213b9e7-2892-4987-be9c-6c263f83f77d"
      unitRef="usd">446772000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzYtMy0xLTEtNDY2NDI_267553da-970f-46de-8fd6-43266a5dbc7c"
      unitRef="usd">398520000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzctMS0xLTEtNDY2NDI_0e9b81a9-2b02-4b10-a772-3735184f403d"
      unitRef="usd">18334000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzctMy0xLTEtNDY2NDI_2f4629b9-312c-4480-87d8-ac9ff97261c7"
      unitRef="usd">19819000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzgtMS0xLTEtNDY2NDI_0fa8a271-3a6a-4b2b-b17c-68a37f9eb2ca"
      unitRef="usd">465106000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzgtMy0xLTEtNDY2NDI_9a6b4f8f-0f3b-4a09-a214-96ac8dee5dd5"
      unitRef="usd">418339000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzktMS0xLTEtNDY2NDI_56d5b9cd-9c27-440e-8629-3c40db9fe2f0"
      unitRef="usd">891308000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xNi9mcmFnOmQ3ZTNiM2ZhMTg0NDRlY2Y5NjA5NzY4NGNmOGNlMWEzL3RhYmxlOjViNmEyNTM4ODdjOTQ3ZGZiNjk1OWFiMTc1Nzg5MzM3L3RhYmxlcmFuZ2U6NWI2YTI1Mzg4N2M5NDdkZmI2OTU5YWIxNzU3ODkzMzdfMzktMy0xLTEtNDY2NDI_9811d40b-d36d-4dfe-b2fb-cafc936575fe"
      unitRef="usd">691939000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMi0xLTEtMS00NjY0Mg_a9ac8f37-dc6b-4f4a-8bec-65d278821aec"
      unitRef="usd">146267000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMi0zLTEtMS00NjY0Mg_1b1cc81a-e90c-4025-8d3d-589fad468b7d"
      unitRef="usd">151805000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMi01LTEtMS00Nzk1MA_88b851c5-c3f5-4594-8065-e989d2a6aa5e"
      unitRef="usd">208813000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMi03LTEtMS00Nzg3NA_20978eef-b079-4d4f-ae40-0e88e003dad0"
      unitRef="usd">179244000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNC0xLTEtMS00NjY0Mg_1cfffc65-a00c-4e55-bb53-296451b43706"
      unitRef="usd">74881000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNC0zLTEtMS00NjY0Mg_41fba41f-10bf-4b1c-9163-9774d3331a61"
      unitRef="usd">75985000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNC01LTEtMS00Nzk1MA_74a5ea54-629f-4bf5-992f-fcad19a2e2ec"
      unitRef="usd">158576000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNC03LTEtMS00Nzg4Mg_de026be0-cf6f-4595-b773-dd808947acb9"
      unitRef="usd">141750000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNS0xLTEtMS00NjY0Mg_581e594a-5160-40ee-862a-73645c4c3a1a"
      unitRef="usd">23221000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNS0zLTEtMS00NjY0Mg_c62880ef-9003-4e4a-a759-4a414fe7b19f"
      unitRef="usd">34267000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNS01LTEtMS00Nzk1MA_60c08bfc-d4bb-445e-8daf-c5d3add4050e"
      unitRef="usd">44206000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNS03LTEtMS00Nzg4Mg_ca3119e4-e5fc-466d-9916-a019f3dac4aa"
      unitRef="usd">59262000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNi0xLTEtMS00NjY0Mg_e1727091-7135-4786-b2ae-e6a9ac4fb8d8"
      unitRef="usd">98102000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNi0zLTEtMS00NjY0Mg_71b68290-84f8-43f7-b969-123733e41d01"
      unitRef="usd">110252000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNi01LTEtMS00Nzk1MA_90a19d3b-198d-491b-adf9-46a5c5b5cb1c"
      unitRef="usd">202782000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNi03LTEtMS00Nzg4Mg_ac0a0d0e-e7d5-42a7-b879-da4e8f2ac737"
      unitRef="usd">201012000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNy0xLTEtMS00NjY0Mg_7f929f9c-7910-48ec-9e3a-d8341d93fcf2"
      unitRef="usd">48165000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNy0zLTEtMS00NjY0Mg_4b68f936-4d9a-402d-b23f-05187c0e87e6"
      unitRef="usd">41553000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNy01LTEtMS00Nzk2Nw_e100ff59-ac0d-43c5-aa7e-83fd34c0857b"
      unitRef="usd">6031000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfNy03LTEtMS01MDIwMQ_4ffd8411-e758-461e-b1af-7d4db6f6105b"
      unitRef="usd">-21768000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTAtMS0xLTEtNDY2NDI_1f298cff-8df0-4aa9-8864-ae0e25595abd"
      unitRef="usd">4560000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTAtMy0xLTEtNDY2NDI_a0a09d10-0b88-4130-9d31-6f11a235fbe8"
      unitRef="usd">1054000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTAtNS0xLTEtNDc5NTA_34adf2c4-d153-4337-aa82-442dcba56d80"
      unitRef="usd">7242000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTAtNy0xLTEtNDc4OTA_4bb0b89d-370b-417c-ad01-1fb221c11ed7"
      unitRef="usd">2210000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InterestExpense
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTEtMS0xLTEtNTU0NDY_164558e2-b695-4c65-8fd3-ef613dfc6ec2"
      unitRef="usd">5057000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTEtMy0xLTEtNTU0Njg_dbc1007e-01f6-46b9-844e-09b468d7dc79"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTEtNS0xLTEtNTU0MjU_bcfb836a-ca9a-4e01-9914-9b6830e4ff0b"
      unitRef="usd">7906000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTEtNy0xLTEtNTU0NTk_9b7a88b8-9887-42cf-8718-8eb78faf0216"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTEtMS0xLTEtNDY2NDI_86415db8-7ccb-4d12-bff5-9d4c2c05f140"
      unitRef="usd">8000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTEtMy0xLTEtNDY2NDI_b457a947-6a19-4ab7-a749-f4467670bc48"
      unitRef="usd">1759000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTEtNS0xLTEtNDc5NTA_c95d839f-221a-43ff-b0f9-0c69e2367c64"
      unitRef="usd">515000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTEtNy0xLTEtNDc4OTA_17138869-98f6-4ff1-acd1-bb553f2c0138"
      unitRef="usd">1052000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTItMS0xLTEtNDY2NDI_38d179d9-0fd1-4655-b7fb-0ceb6d7e101d"
      unitRef="usd">-489000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTItMy0xLTEtNDY2NDI_0b20b606-9d40-4110-8de2-5fac86064fde"
      unitRef="usd">2813000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTItNS0xLTEtNDc5NTA_aa6cb6b9-9a10-4b74-937c-45ab8b49bd5e"
      unitRef="usd">-149000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTItNy0xLTEtNDc4OTA_305a824e-ec09-4bda-8dae-ed5afba9307f"
      unitRef="usd">3262000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTQtMS0xLTEtNDY2NDI_fd342931-bd33-48f7-9786-1b9a7cfea3f1"
      unitRef="usd">47676000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTQtMy0xLTEtNDY2NDI_30a6bd66-d127-41fa-a837-5801d4194b1e"
      unitRef="usd">44366000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTQtNS0xLTEtNDc5NTA_c9f91157-1a55-429d-a091-a2dd4dfc9be0"
      unitRef="usd">5882000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTQtNy0xLTEtNDc5MDE_f9200491-4c5c-4387-8e36-bacb7b832728"
      unitRef="usd">-18506000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTUtMS0xLTEtNDY2NDI_058f9c9f-3af9-42d2-b388-9ad108c79ee1"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTUtMy0xLTEtNDY2NDI_26f1f4e5-b2d4-4fed-a698-dd0c4bd8c916"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTUtNS0xLTEtNDc5NTA_540ed32c-25ce-4b89-8e76-7ef6fc997eab"
      unitRef="usd">17000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTUtNy0xLTEtNDc5MDE_3407fcd9-0389-430a-a4b3-99e35bec17a5"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTYtMS0xLTEtNDY2NDI_21a628e5-fa85-495b-8d31-85227ffc8ed7"
      unitRef="usd">47676000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTYtMy0xLTEtNDY2NDI_1cca6dd3-5395-42bf-b585-9866de8b5476"
      unitRef="usd">44366000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTYtNS0xLTEtNDc5NTA_f963e2c9-6127-4d21-9b7b-3010cd3f1621"
      unitRef="usd">5865000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTYtNy0xLTEtNDc5MDE_0d7cbbe4-177f-4bb1-8f03-857557c1525a"
      unitRef="usd">-18506000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTctMS0xLTEtNDY2NDI_cf7ea14a-46e2-49eb-9c72-c36c68c96bed"
      unitRef="usd">-999000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTctMy0xLTEtNDY2NDI_5607e2c6-592a-4579-963f-fd3fd8075e43"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTctNS0xLTEtNDc5NTk_6bb92f85-c01f-46da-a2c9-4357619ed565"
      unitRef="usd">-1485000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTctNy0xLTEtNDc5MDk_d2e29d31-78f6-47f8-930c-cf23c29feb78"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTgtMS0xLTEtNDY2NDI_c89a5c05-418e-4378-a6e5-abe5e17b078e"
      unitRef="usd">48675000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTgtMy0xLTEtNDY2NDI_b9a34c73-bc39-46ed-aadd-5a77770950e8"
      unitRef="usd">44366000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTgtNS0xLTEtNDc5NTA_d8fa2d1d-bfc2-4d43-8efa-2139635b977a"
      unitRef="usd">7350000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMTgtNy0xLTEtNDc5MDk_ccf0f792-f284-44ca-aa98-dae2218a8c25"
      unitRef="usd">-18506000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjEtMS0xLTEtNDY2NDI_390be610-b125-4f84-8fa1-352a648eb9d9"
      unitRef="usdPerShare">0.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjEtMy0xLTEtNDY2NDI_c94657e0-3e29-4765-8bd1-8196414c2000"
      unitRef="usdPerShare">0.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjEtNS0xLTEtNDc5NTA_92b2b925-9f44-422e-978e-c4788c4eeff2"
      unitRef="usdPerShare">0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjEtNy0xLTEtNDc5MTc_0ed0174a-bbfd-415b-bdd2-dfcb9f261641"
      unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjItMS0xLTEtNDY2NDI_fe654c12-b00b-4b4f-b3b9-d8eedaa52213"
      unitRef="usdPerShare">0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjItMy0xLTEtNDY2NDI_dab3270d-f2a3-4184-9036-d3f3f89a3148"
      unitRef="usdPerShare">0.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjItNS0xLTEtNDc5NTA_3e688076-7139-4e85-af8e-04a684a26b18"
      unitRef="usdPerShare">0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjItNy0xLTEtNDc5MTc_7a5a69fa-2b76-4445-b2f2-531ad103289c"
      unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjQtMS0xLTEtNDY2NDI_43b2b571-4f98-4b2e-9b7c-00ab552530e4"
      unitRef="shares">106757000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjQtMy0xLTEtNDY2NDI_e0bea119-f5a0-4d4a-ab14-e2aabdccf4d1"
      unitRef="shares">105545000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjQtNS0xLTEtNDc5NTA_b5d1eeb6-d1e1-4c26-9e5c-9cec6028d380"
      unitRef="shares">106394000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjQtNy0xLTEtNDc5MTc_65cc41a3-26ed-4d2a-81d8-17e06f9820d0"
      unitRef="shares">105034000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjUtMS0xLTEtNDY2NDI_6f168b64-c634-4cb2-b4c5-f99231bd993e"
      unitRef="shares">108143000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjUtMy0xLTEtNDY2NDI_90f17e91-616e-4d8a-be64-0f031a60b81e"
      unitRef="shares">107929000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjUtNS0xLTEtNDc5NTA_e941440e-0067-4dc9-9b7b-cee73b5b6747"
      unitRef="shares">107893000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjUtNy0xLTEtNDc5MTc_f1c2852d-377a-4e9a-8dbb-9691e5ca8999"
      unitRef="shares">105034000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjgtMS0xLTEtNDY2NDI_f3847e8b-35fb-441e-9f94-7151da646701"
      unitRef="usd">-74000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjgtMy0xLTEtNDY2NDI_4b92ee2d-3ab5-4104-86ac-3d6adb6d3905"
      unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjgtNS0xLTEtNDc5NTA_68a3ee7d-4616-4df4-ab6e-13353b495091"
      unitRef="usd">-196000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjgtNy0xLTEtNDc5Mjk_87141f03-d745-4ee4-ac5a-6684461a1b82"
      unitRef="usd">-38000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjktMS0xLTEtNDY2NDI_f409f75e-0104-4c8e-9087-842b9780cf33"
      unitRef="usd">47602000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjktMy0xLTEtNDY2NDI_02d47a6f-903e-4488-a60e-92b9b623b9af"
      unitRef="usd">44367000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjktNS0xLTEtNDc5NTA_50106183-6236-4df8-8d5f-89d00144fe50"
      unitRef="usd">5669000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8xOS9mcmFnOjBkNzZhMzZjOTcwYTQzMDRiNjI5YmFjM2U2OTJiZWIzL3RhYmxlOjBlNWVlZGI0NTY2NzQzY2Y5ODY0ZjAyM2FhNjRkOTdkL3RhYmxlcmFuZ2U6MGU1ZWVkYjQ1NjY3NDNjZjk4NjRmMDIzYWE2NGQ5N2RfMjktNy0xLTEtNDc5Mjk_96680a7a-31e0-400c-9e96-f0631ecfaa2c"
      unitRef="usd">-18544000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i3ef217d1ae014653950af714ba114e79_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xLTEtMS0xLTQ4MzM4_6acb5e9e-60ea-4728-86dd-3308c8ceb0be"
      unitRef="shares">105960000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3ef217d1ae014653950af714ba114e79_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xLTMtMS0xLTQ4MzM4_7de1d55c-affb-46b3-a218-3123b4975f7d"
      unitRef="usd">198000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i50a4e54f5bfb4716b45f934eaa14113d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xLTUtMS0xLTQ4MzM4_3a9fc751-4b95-49af-a2a7-cf194e434412"
      unitRef="usd">1219213000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib3d20c6e34ff445d941da59d04a42801_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xLTctMS0xLTQ4MzM4_92289d4f-f262-4776-96fb-b9c1e0ed3235"
      unitRef="usd">-136000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia0d8fd51248444d7b2cc18251bffd261_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xLTktMS0xLTQ4MzM4_640f2e66-b6d7-4550-b2cc-dea259315179"
      unitRef="usd">-820755000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8fab671f9d1f4bcc811ab238a0e9d2aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xLTExLTEtMS00ODMzOA_14763fc7-9c8f-41c0-8d05-a403a67fcbfd"
      unitRef="usd">19819000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xLTEzLTEtMS00ODMzOA_e0ec15f1-fe8c-4d9a-98a9-56fa7c66d404"
      unitRef="usd">418339000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iae8bf4236a96463d85eb67cec5f9436c_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8yLTUtMS0xLTQ4MzM4_3b375606-331b-4329-9372-e9ac40567b84"
      unitRef="usd">19390000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if22a765bc5e6493cb9f1b2ed13cb4e3a_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8yLTEzLTEtMS00ODMzOA_e6bba5b6-dc5d-441e-ad6a-f50941960d46"
      unitRef="usd">19390000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iea981497ed1441a1adcdec1001a8e970_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8zLTEtMS0xLTQ4MzM4_c9f01236-7c17-4f2f-8673-f3510b2c55ae"
      unitRef="shares">82000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iae8bf4236a96463d85eb67cec5f9436c_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8zLTUtMS0xLTQ4MzM4_f790dff7-100e-4ebf-9c2f-66fe0c985972"
      unitRef="usd">576000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if22a765bc5e6493cb9f1b2ed13cb4e3a_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8zLTEzLTEtMS00ODMzOA_82123c31-80b6-4745-98db-1cac8e414bbe"
      unitRef="usd">576000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="iea981497ed1441a1adcdec1001a8e970_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV80LTEtMS0xLTQ4MzM4_8e9c0728-0f24-4f0e-a4e9-cf4ad175a87b"
      unitRef="shares">98000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="iea981497ed1441a1adcdec1001a8e970_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV80LTMtMS0xLTQ4MzM4_d41a828b-9446-4145-93a3-22ddb0bf3778"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="iae8bf4236a96463d85eb67cec5f9436c_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV80LTUtMS0xLTQ4MzM4_14530284-2691-45f9-b879-19c5f3aa01bc"
      unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="if22a765bc5e6493cb9f1b2ed13cb4e3a_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV80LTEzLTEtMS00ODMzOA_74d7ac8c-9747-42c3-8493-965679f9fba4"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i0d6492fefa7340f3887bfa04169628a6_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV81LTctMS0xLTQ4MzM4_68f76e48-ff03-423a-baef-bf3fa1f974a3"
      unitRef="usd">-122000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="if22a765bc5e6493cb9f1b2ed13cb4e3a_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV81LTEzLTEtMS00ODMzOA_5a684adb-f74b-42ed-afed-ae648114d737"
      unitRef="usd">-122000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ie91d240ca96944a3b6fa19d2e3be66f2_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV82LTExLTEtMS00ODQwNw_83b8cf00-e378-4537-bd3b-b79006801fef"
      unitRef="usd">486000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="if22a765bc5e6493cb9f1b2ed13cb4e3a_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV82LTEzLTEtMS00ODQxNw_d1b70449-9a94-4cf5-877f-6d272c7d0fbb"
      unitRef="usd">486000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:NetIncomeLoss
      contextRef="id07ee53b35c546489aa1141fb795a81e_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV82LTktMS0xLTQ4MzM4_a5ab09fd-7843-43aa-bc29-7fca10612a20"
      unitRef="usd">-41325000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if22a765bc5e6493cb9f1b2ed13cb4e3a_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV82LTEzLTEtMS00ODMzOA_5aab13a8-74cd-4f6b-9c42-5ccdc6119872"
      unitRef="usd">-41325000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i9f0f0f39856c41238ff79dc13354c8e0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV83LTEtMS0xLTQ4MzM4_25b6df04-d141-423b-af1e-df85bbaeea3f"
      unitRef="shares">106140000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9f0f0f39856c41238ff79dc13354c8e0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV83LTMtMS0xLTQ4MzM4_17a23ea2-0c6a-431d-bc04-bb4927d253a4"
      unitRef="usd">199000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if30cb9af4bf44698ad1355d4cb3e5076_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV83LTUtMS0xLTQ4MzM4_3869c83c-0e62-4173-82a7-3ae2e084b951"
      unitRef="usd">1239178000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8c12fc21190440f4b646777c6721e378_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV83LTctMS0xLTQ4MzM4_a48099c4-987b-4d84-863c-b179cd0375cc"
      unitRef="usd">-258000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i07b211def5654e32b5476f84e9f9dd7a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV83LTktMS0xLTQ4MzM4_4e0869d4-8982-4cf9-8aee-097044f21706"
      unitRef="usd">-862080000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i40ebfdae8cd740beb807ce422f45197d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV83LTExLTEtMS00ODMzOA_ac1fabec-1dbb-423c-a1dd-74bf22ac12d3"
      unitRef="usd">19333000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie756775941ef43fd80b1a267081ca9a1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV83LTEzLTEtMS00ODMzOA_268e80aa-58dc-4af5-b64d-0ae0ed3b9cfe"
      unitRef="usd">396372000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib195d18380a947c684949421e1dcd365_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV85LTUtMS0xLTQ4Mzk0_d6bc99cf-e665-4a6c-940d-d60df8a1b288"
      unitRef="usd">20612000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV85LTEzLTEtMS00ODM5NA_1e57434f-d109-481f-a703-85449134b5f1"
      unitRef="usd">20612000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4fa04963a7944b6d8829bc8de0678c19_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xMC0xLTEtMS00ODM5NA_f78dae9f-dd5c-4575-91e0-0082feaf9080"
      unitRef="shares">64000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib195d18380a947c684949421e1dcd365_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xMC01LTEtMS00ODM5NA_5e625ea3-e3d4-4993-bea9-4f1e4892f704"
      unitRef="usd">520000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xMC0xMy0xLTEtNDgzOTQ_da53ef73-cb0a-4fb5-808b-894213cf71f2"
      unitRef="usd">520000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i4fa04963a7944b6d8829bc8de0678c19_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xMS0xLTEtMS00ODM5NA_8e762351-846a-444e-8835-f5bd7855ced6"
      unitRef="shares">665000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i01a9fa326aef4dc0830ea895f2568994_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xMi03LTEtMS00ODM5NA_38a47f5f-2bb5-41d9-a7ef-0a161f898551"
      unitRef="usd">-74000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xMi0xMy0xLTEtNDgzOTQ_3441c682-5991-4c97-9e35-54879e1755c4"
      unitRef="usd">-74000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i808343e416724a7ab9e17a71f299ad91_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xMy0xMS0xLTEtNDgzOTQ_f946224b-6252-4f8b-bb9e-b3d6868cff4e"
      unitRef="usd">999000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xMy0xMy0xLTEtNDgzOTQ_a84d54ce-b970-49c8-9abd-c5377070365f"
      unitRef="usd">999000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:NetIncomeLoss
      contextRef="i98f503ba5e1a4de99077aecc556aa3ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xNC05LTEtMS00ODM5NA_47bcf542-4341-41b0-a1fc-c1c2633594fb"
      unitRef="usd">48675000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xNC0xMy0xLTEtNDgzOTQ_cf5e2968-b022-410e-8c2c-900dd3e9dc88"
      unitRef="usd">48675000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ie34dd58815de44edb4894780fe72ea8f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xNS0xLTEtMS00ODM5NA_b05fed92-01d1-4578-b0b7-f54e500f6fe5"
      unitRef="shares">106869000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie34dd58815de44edb4894780fe72ea8f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xNS0zLTEtMS00ODM5NA_5b039c4d-0dc9-45fa-b37b-89189b25d974"
      unitRef="usd">199000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8a699bc0f28f4ae7aeca3fe229161d36_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xNS01LTEtMS00ODM5NA_15132e4b-a67d-4aaa-bbc2-5532c036b5b4"
      unitRef="usd">1260310000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8b4b2f94dd8f410e88a3c296a630fd9a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xNS03LTEtMS00ODM5NA_ca0ef1a9-cdb8-4ec1-9112-4581b0a28c6e"
      unitRef="usd">-332000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifeb60a45426b407eb7975d28f670c511_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xNS05LTEtMS00ODM5NA_149fc9f9-aef6-4010-840d-afedd45040d2"
      unitRef="usd">-813405000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic3613bbfc4a8440c99ce1bf55975a119_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xNS0xMS0xLTEtNDgzOTQ_c4268cc8-7e5d-47b7-ab62-2e7b1166852b"
      unitRef="usd">18334000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6YmE4NWMxYzRjZTQ5NGViNjg4NzE2ZWRhYmY4Yzk0NzEvdGFibGVyYW5nZTpiYTg1YzFjNGNlNDk0ZWI2ODg3MTZlZGFiZjhjOTQ3MV8xNS0xMy0xLTEtNDgzOTQ_c68842c0-c76a-4444-98d4-efe2e382b31b"
      unitRef="usd">465106000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i84b78e6fbe2a41cdbc5069a20bac2479_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xLTEtMS0xLTQ4MzM4_23d3e5c2-1543-4f11-a5d6-f7ef4cec6b86"
      unitRef="shares">104327000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i84b78e6fbe2a41cdbc5069a20bac2479_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xLTMtMS0xLTQ4MzM4_45388b9c-43eb-45d2-b3b0-065d1731ae8e"
      unitRef="usd">197000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iac8802180c9145218b8bd2c6aa534a09_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xLTUtMS0xLTQ4MzM4_e5c30be8-216c-4c1c-9a47-e1efa0174405"
      unitRef="usd">1053386000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id534cbaab59b43ad982991d831ecc480_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xLTctMS0xLTQ4MzM4_38159181-5302-4585-b32d-b62c5e5ce08f"
      unitRef="usd">-69000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i154ad50f88ea4503a5defebce13af0ba_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xLTktMS0xLTQ4MzM4_a60ed6a1-a18e-4225-adc6-87df3084efbc"
      unitRef="usd">-644692000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3144d66a7c174bff86ddf2ab9afe90cd_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xLTExLTEtMS00ODMzOA_2ef3ca59-f59a-454f-b236-4be7da17f218"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iadfd6b159c9446f4ad12848ede62bfea_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xLTEzLTEtMS00ODMzOA_f2e8969a-9649-482c-8fed-b08f07e489e2"
      unitRef="usd">408822000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6f3fdde941ae47dfb11186c305ab632c_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8yLTUtMS0xLTQ4MzM4_de12aa51-9907-4962-baae-a97efe3e858f"
      unitRef="usd">24504000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i26989504186e41ed84cd5f5d555e3de0_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8yLTEzLTEtMS00ODMzOA_33d5e8ed-e79f-477c-9d6f-b2bfd6e3fc10"
      unitRef="usd">24504000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="idc7933727b4b46368d3b521b47747ef5_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8zLTEtMS0xLTQ4MzM4_84a8ff61-b63c-45b6-a0ae-301cd904e5c0"
      unitRef="shares">208000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6f3fdde941ae47dfb11186c305ab632c_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8zLTUtMS0xLTQ4MzM4_eff0339a-53f5-4d7c-9136-5d75af2597f7"
      unitRef="usd">2145000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i26989504186e41ed84cd5f5d555e3de0_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8zLTEzLTEtMS00ODMzOA_6d67e06b-a0f4-4df9-af83-7894343e950e"
      unitRef="usd">2145000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="idc7933727b4b46368d3b521b47747ef5_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF80LTEtMS0xLTQ4MzM4_d38a0269-4d50-4b3b-a84c-3448ea3f561f"
      unitRef="shares">263000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i5b43fbce18ea4f85835fbd0288c1735d_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF81LTctMS0xLTQ4MzM4_38b495b3-40a9-4093-9f10-364915eeb9c6"
      unitRef="usd">-39000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i26989504186e41ed84cd5f5d555e3de0_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF81LTEzLTEtMS00ODMzOA_53be6843-f3bc-4172-885d-25724e9d2480"
      unitRef="usd">-39000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i0d11611625c842c192a76949637ab1ad_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF83LTktMS0xLTQ4MzM4_a6c09778-9b0d-4ea3-ad13-6e6362ad36fa"
      unitRef="usd">-62872000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i26989504186e41ed84cd5f5d555e3de0_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF83LTEzLTEtMS00ODMzOA_6549d9eb-77a5-4885-bdd4-6c5f4e766f7c"
      unitRef="usd">-62872000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i18800dd8b03b46b48aaf88b9fb7044b1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF84LTEtMS0xLTQ4MzM4_b8922727-49c7-4ce1-9c02-1e69fdd8209f"
      unitRef="shares">104798000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i18800dd8b03b46b48aaf88b9fb7044b1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF84LTMtMS0xLTQ4MzM4_60efdc9d-a3a3-4064-9d43-16c2e29fba39"
      unitRef="usd">197000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1161b10586074a64b54fd01340222fd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF84LTUtMS0xLTQ4MzM4_02c1a4d9-22db-4379-92d9-f47f29f6f306"
      unitRef="usd">1080035000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i82df41dcbf8c408098779e2309253d00_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF84LTctMS0xLTQ4MzM4_f2a4c080-8781-4983-8057-4f7263dbcd1c"
      unitRef="usd">-108000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia3c56824a9954cc8afb80ad2017d4a48_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF84LTktMS0xLTQ4MzM4_07b452c0-fe4a-4507-a9d7-caedb558a9df"
      unitRef="usd">-707564000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ice8878b3a2d14233b9b372038ed81850_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF84LTExLTEtMS00ODMzOA_2fc36793-2ecf-4347-a903-2c08d8b695a7"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib7611db3737a4c7a959ce6e212f2636a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF84LTEzLTEtMS00ODMzOA_dd43b2f1-0189-48c0-af54-8c7c50b1001d"
      unitRef="usd">372560000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i00be0b1806084dec8196472cc1ddf3df_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF85LTUtMS0xLTQ4NDk4_23593cd4-a4db-494d-a91f-002d2ef837d3"
      unitRef="usd">33802000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF85LTEzLTEtMS00ODQ5OA_f2efbeeb-a656-4ef2-9adc-263d47b63c4f"
      unitRef="usd">33802000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia5de09ecb41b49789bdf45c6d67a4d62_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xMC0xLTEtMS00ODQ5OA_cd733635-8d78-4052-9551-934b1020c3fe"
      unitRef="shares">237000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i00be0b1806084dec8196472cc1ddf3df_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xMC01LTEtMS00ODQ5OA_53f5d129-e49b-4c9c-8db8-10912723bd19"
      unitRef="usd">1537000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xMC0xMy0xLTEtNDg0OTg_88ff1145-10cb-413b-921a-dbd27def2de5"
      unitRef="usd">1537000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ia5de09ecb41b49789bdf45c6d67a4d62_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xMS0xLTEtMS00ODQ5OA_1205424c-45ff-49f3-a79d-9b3713f7948f"
      unitRef="shares">667000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ia5de09ecb41b49789bdf45c6d67a4d62_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xMS0zLTEtMS00ODQ5OA_8b6e30ea-9f87-403d-a0a6-1d6d83c66647"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i00be0b1806084dec8196472cc1ddf3df_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xMS01LTEtMS00ODQ5OA_112186ad-a1c7-4ce9-b23e-61150564c696"
      unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xMS0xMy0xLTEtNDg0OTg_9ff084f4-cb4e-4187-b7d0-13f7317d1d32"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="iab63cc1254d34693ab73656849db98e4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xMi03LTEtMS00ODQ5OA_65a8c747-54da-4224-a4fb-e5000e42ab2b"
      unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xMi0xMy0xLTEtNDg0OTg_44a95ff4-9f99-451c-92ce-bfec2b4c502b"
      unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i3d29a460a2c54ed2abee1109c64c2f63_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xNC05LTEtMS00ODQ5OA_d2cfa232-eea4-45a6-8b9e-879269ce91a8"
      unitRef="usd">44366000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xNC0xMy0xLTEtNDg0OTg_408031aa-9c5d-43cd-81d5-bb3b7c0b37d5"
      unitRef="usd">44366000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i0151ff9c71de4a0499c8804305f5adc0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xNS0xLTEtMS00ODQ5OA_c5fbf1e5-1558-4c31-88aa-8a550915f8b4"
      unitRef="shares">105702000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0151ff9c71de4a0499c8804305f5adc0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xNS0zLTEtMS00ODQ5OA_dd3130c7-9042-487b-bd20-4f54b6970f03"
      unitRef="usd">198000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9b0b1cc7a9a8460aa79e6b253f97b6ea_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xNS01LTEtMS00ODQ5OA_e39f94c2-bc9b-4f57-bb95-ba30d58da6a1"
      unitRef="usd">1115373000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic6ff5ed1bf3742a98dc9cde7d7ace25c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xNS03LTEtMS00ODQ5OA_78ac4192-32ce-41dc-ab33-2279798e057b"
      unitRef="usd">-107000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i68254b76d5ec47889b72791c3fea708a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xNS05LTEtMS00ODQ5OA_1b5bb2cf-06e8-420a-a977-09c92ff8410d"
      unitRef="usd">-663198000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib25506c96c484cef99aa0e6030c5ad3c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xNS0xMS0xLTEtNDg0OTg_024108b2-1275-4be1-b093-de86a94c5d4d"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2b1b88ad17754cd781fd0282509470f4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNzQ4Nzc5MDY5ODM1L2ZyYWc6MDU0MjA0MDdhNGJlNDJmOWJmMDYwYTE3ZjQ1MzM5ZmIvdGFibGU6MDI0NWQ0MjdmMWJmNDdhOGE1MjQzZGYxNWEwZGYzOTAvdGFibGVyYW5nZTowMjQ1ZDQyN2YxYmY0N2E4YTUyNDNkZjE1YTBkZjM5MF8xNS0xMy0xLTEtNDg0OTg_b080f251-fba2-4ffd-8116-e348cfe18702"
      unitRef="usd">452266000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMy0xLTEtMS00NjY0Mg_9066091b-205b-4984-9f2f-bb68a3ba9232"
      unitRef="usd">5865000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMy0zLTEtMS00NjY0Mg_d75bfb83-5f27-4267-9877-7ab627d39041"
      unitRef="usd">-18506000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfNS0xLTEtMS00NjY0Mg_d3931ddc-b812-48f1-9b0a-942f1ca61f22"
      unitRef="usd">40002000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfNS0zLTEtMS00NjY0Mg_35ad094c-7b31-4bd5-a876-49e6ecad3e55"
      unitRef="usd">58307000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfNi0xLTEtMS00NjY0Mg_1b4429d4-92f6-4cbc-ac37-872cdd2a05a9"
      unitRef="usd">5358000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfNi0zLTEtMS00NjY0Mg_496e02b4-be55-4b2a-8bd7-36b79fe830d2"
      unitRef="usd">5167000</us-gaap:DepreciationAndAmortization>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfNy0xLTEtMS00NjY0Mg_d38f3ac1-deb0-4e55-a36a-30fc0c1207fd"
      unitRef="usd">82000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfNy0zLTEtMS00NjY0Mg_f0a67c51-6e30-48b9-9e7c-01d922c47dc0"
      unitRef="usd">-329000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfOC0xLTEtMS00NjY0Mg_8bfb6280-2de8-408b-b67c-7ddc701325cf"
      unitRef="usd">7906000</arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties>
    <arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfOC0zLTEtMS00NjY0Mg_1a7e3423-5fe2-4e2c-9d51-4f6cf0073c10"
      unitRef="usd">0</arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTAtMS0xLTEtNDY2NDI_858e685d-b2ff-468d-8cdb-6a2e2cf93f16"
      unitRef="usd">68024000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTAtMy0xLTEtNDY2NDI_aa10348d-1d08-4a0f-9a39-199934702884"
      unitRef="usd">-8938000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTEtMS0xLTEtNDY2NDI_3d627fdb-02d9-4230-ac6d-b1201a4f4ae6"
      unitRef="usd">-20309000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTEtMy0xLTEtNDY2NDI_188739e1-d0ad-4cd2-add9-81f07d905511"
      unitRef="usd">3313000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTItMS0xLTEtNDY2NDI_fcfa6ef3-8186-4ff7-a76b-ff4770a2701c"
      unitRef="usd">6688000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTItMy0xLTEtNDY2NDI_477a14d4-367c-4ea5-8f58-4346736a4b70"
      unitRef="usd">1146000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTMtMS0xLTEtNDY2NDI_62a40a61-f337-41f4-bd23-4f0e5c0af805"
      unitRef="usd">-27279000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTMtMy0xLTEtNDY2NDI_4bfb8945-be01-4de6-995e-12b64d5192ec"
      unitRef="usd">3699000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTQtMS0xLTEtNDY2NDI_1efa19c0-da98-437b-8a67-a67605528620"
      unitRef="usd">-99135000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTQtMy0xLTEtNDY2NDI_9b51faa0-519f-4f37-b8ab-3bccbae5d384"
      unitRef="usd">-54926000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTUtMS0xLTEtNDY2NDI_5cb03aa3-2f7f-4222-92b5-75a4fd357452"
      unitRef="usd">1205000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTUtMy0xLTEtNDY2NDI_2702e40c-71e7-419b-a912-7eda377e97cc"
      unitRef="usd">580000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTYtMS0xLTEtNDY2NDI_8088e1f3-785e-46c3-9afe-71bf9da63aec"
      unitRef="usd">-107187000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTYtMy0xLTEtNDY2NDI_8dd92aca-03d9-4926-8063-21005b632c06"
      unitRef="usd">1421000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTktMS0xLTEtNDY2NDI_a5cdd201-01fb-4cc1-bb4a-084eaba569ec"
      unitRef="usd">66225000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMTktMy0xLTEtNDY2NDI_bf868e38-9573-4df3-a28a-d5c1ecf83ed2"
      unitRef="usd">10530000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMjAtMS0xLTEtNDY2NDI_92aed93c-14ab-41b2-9d40-b0015249c056"
      unitRef="usd">192528000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMjAtMy0xLTEtNDY2NDI_952faa29-8008-40d6-aa82-c794562fe071"
      unitRef="usd">148391000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMjEtMS0xLTEtNDY2NDI_feb979af-4a9b-4580-89eb-f927c0dad596"
      unitRef="usd">141994000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMjEtMy0xLTEtNDY2NDI_802a7469-616a-4df1-b012-2a05601be849"
      unitRef="usd">55781000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMjItMS0xLTEtNDY2NDI_276f8c1f-d926-4e7a-9ba1-b88a256dbec1"
      unitRef="usd">-116759000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMjItMy0xLTEtNDY2NDI_b921d1a2-a11a-439d-866f-6350b91065de"
      unitRef="usd">-103140000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMjUtMS0xLTEtNDY2NDI_f55c30d4-0060-4546-9641-19de32939a91"
      unitRef="usd">1096000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMjUtMy0xLTEtNDY2NDI_dade8206-17a6-4cd5-bb79-ab3a4411fcd3"
      unitRef="usd">3731000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMjYtMS0xLTEtNDY2NDI_15a6cedd-4c64-4e53-babc-af57b2541fa3"
      unitRef="usd">250000000</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMjYtMy0xLTEtNDY2NDI_4ec58a45-88c8-4dba-b4ea-2c18819c50c5"
      unitRef="usd">0</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMjctMS0xLTEtNDY2NDI_2bfc7bd3-bcd1-4523-bfa5-62c04501399d"
      unitRef="usd">251096000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMjctMy0xLTEtNDY2NDI_f9e7c8aa-69d7-4d11-a431-ca859b24a3df"
      unitRef="usd">3731000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMjktMS0xLTEtNDY2NDI_28c0530e-e438-407e-a4e4-feac24ebe3d8"
      unitRef="usd">27150000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMjktMy0xLTEtNDY2NDI_615903fe-1b1f-4956-9b71-baed07dccb3e"
      unitRef="usd">-97988000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMzEtMS0xLTEtNDY2NDI_97fdd19a-7438-4129-872a-534fdb232964"
      unitRef="usd">-196000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMzEtMy0xLTEtNDY2NDI_8c27354a-8adf-4389-b811-a507a67a90dd"
      unitRef="usd">-38000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMzMtMS0xLTEtNDY2NDI_2658a225-2e7b-44ad-9e30-3d4847cfc220"
      unitRef="usd">108005000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="iadfd6b159c9446f4ad12848ede62bfea_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMzMtMy0xLTEtNDY2NDI_aa78d23d-c08e-42c6-8f25-aafcadf83ab6"
      unitRef="usd">184434000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMzQtMS0xLTEtNDY2NDI_6e8865c3-b4c4-427f-8b35-721dd15f5a2c"
      unitRef="usd">134959000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i2b1b88ad17754cd781fd0282509470f4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMzQtMy0xLTEtNDY2NDI_04f2bf41-bf1c-4475-9bb4-16428df86636"
      unitRef="usd">86408000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMzctMS0xLTEtNDY2NDI_f6fabe42-551c-445f-83fa-e5048cc9848b"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMzctMy0xLTEtNDY2NDI_6d5fef60-d576-4a91-a0fb-f936061c2669"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMzgtMS0xLTEtNDY2NDI_26e3ff19-aa5d-48b4-92d5-1874dda11684"
      unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8yNS9mcmFnOmY3ZGU2NDlhNjYyMDRlZmViNDQwNjEwM2Q5YzE5NmFmL3RhYmxlOjM0MDM5Yzk1M2U5YTRiNTg5OWIxZDFkMDQxYzllMDBjL3RhYmxlcmFuZ2U6MzQwMzljOTUzZTlhNGI1ODk5YjFkMWQwNDFjOWUwMGNfMzgtMy0xLTEtNDY2NDI_fae8541f-04c2-4b21-a30e-a4630031197b"
      unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfNjY0Mg_75f75db6-d7e5-405a-a73d-5dc3e86ecfc8">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General and Recent Developments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrowhead Pharmaceuticals, Inc. and its subsidiaries (referred to herein collectively as the &#x201c;Company&#x201d;) are primarily engaged in developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company&#x2019;s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#x201c;RNAi&#x201d;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. The Company&#x2019;s RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s current pipeline:&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Therapeutic Area&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Stage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Product Rights&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cardiometabolic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-APOC3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 2b and Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-ANG3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 2b&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Olpasiran&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amgen&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Pulmonary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-ENAC2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Pre-Clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-RAGE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-MUC5AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-MMP7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Liver&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;GSK-4532990 (formerly ARO-HSD)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;GSK&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fazirsiran&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Takeda and Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;JNJ-3989&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;HZN-457 (formerly ARO-XDH)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Horizon&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-C3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-PNPLA3 (formerly JNJ-75220795)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Muscle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-DUX4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Pre-Clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;CNS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-SOD1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Pre-Clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates lab facilities in San Diego, California and Madison, Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company&#x2019;s principal executive offices are located in Pasadena, California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first half of fiscal 2023, the Company continued to develop and advance its pipeline and partnered candidates. Several key recent developments include: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;announced interim results from ARO-RAGE administration in Part 1 of the ongoing Phase 1/2 study in normal healthy volunteers which included:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;reductions in soluble RAGE (sRAGE) as measured in serum after two doses on Day 1 and Day 29;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;duration of pharmacologic effect persisted for at least 6 weeks after the second administration of the 92 mg does with further follow up ongoing;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;reduction in sRAGE as measured in bronchoalveolar lavage fluid (BALF) at Day 31 after a single dose;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;reduction in in serum sRAGE were observed after a single dose;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;the pooled placebo groups experienced a mean sRAGE increase of 8% in BALF and a mean decrease of 1% serum&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;safety and tolerability;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;expanded TRiM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; platform to include an optimized intrathecal administration for central nervous system (CNS) delivery with distribution throughout the brain and in all relevant brain cell types. The first development candidate to utilize this new delivery platform, ARO-SOD1, is anticipated to have a clinical trial &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;application (CTA) filing in the third quarter of 2023 to begin clinical studies. In preclinical studies, ARO-SOD1 achieved 95% spinal cord tissue mRNA knockdown after a single intrathecal dose in human SOD1 transgenic rats and maintained greater than 80% spinal cord tissue mRNA knockdown three months after a single intrathecal dose in non-human primates;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;dosed the first patient in Takeda&#x2019;s Phase 3 REDWOOD clinical study of Fazirsiran for the treatment of alpha-1 antitrypsin deficiency associated liver diseases, triggering a $40.0&#160;million milestone payment to the Company which is expected to be paid in the third quarter of fiscal 2023;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;dosed the first patient in GSK&#x2019;s Phase 2b trial of GSK4532990, formerly called ARO-HSD, an investigational RNAi therapeutic for the treatment of patients with non-alcoholic steatohepatitis (NASH), triggering a $30.0&#160;million milestone payment to the Company which is expected to be paid in the third quarter of fiscal 2023;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARO-APOC3 for reducing triglycerides in adult patients with familial chylomicronemia syndrome (FCS). ARO-APOC3 was previously granted Orphan Drug designation by the FDA and the European Union;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;announced interim results from Part 1 of AROC3-1001, an ongoing Phase 1/2 clinical study of ARO-C3,  which included;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;a dose-dependent reduction in serum C3, with 88% mean reduction at highest dose tested;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;a dose-dependent reduction in AH50, a marker of alternative complement pathway hemolytic activity, with 91% mean reduction at highest dose tested;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;duration of pharmacologic effect supportive of quarterly or less frequent subcutaneous dose administration;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;safety and tolerability;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;received notice from Janssen of its decision to voluntarily terminate the Research Collaboration and Option Agreement (the &#x201c;Janssen Collaboration Agreement&#x201d;) between the Company and Janssen. The Company regained full rights to ARO-PNPLA3, formerly called JNJ-75220795, upon termination of the Janssen Collaboration Agreement, which took effect on April 7, 2023. ARO-PNPLA3 is in Phase 1 clinical trials that are now being developed by the Company;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;initiated dosing in ARO-MMP7-1001 (NCT05537025), a Phase 1/2a single ascending dose and multiple ascending dose clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-MMP7, an investigational RNAi therapeutic designed to reduce expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF), in up to 56 healthy volunteers and in up to 21 patients with IPF;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;enrolled the first subject in a Phase 1 randomized, placebo-controlled trial to assess the safety tolerability, pharmacokinetics and pharmacodynamics of a development-stage medicine, HZN-457 (formerly ARO-XDH), which is out-licensed to Horizon, triggering a $15.0&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2023;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;enrolled the first subject in Amgen&#x2019;s Phase 3 trial of Olpasiran, triggering a $25.0&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2023;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;entered into a Royalty Purchase Agreement (the &#x201c;Royalty Pharma Agreement&#x201d;) with Royalty Pharma Investments 2019 ICAV (&#x201c;Royalty Pharma&#x201d;) on November 9, 2022, pursuant to which Royalty Pharma paid $250.0&#160;million upfront (See Note 11 &#x2014; Liability Related to the Sale of Future Royalties of Notes to Consolidated Financial Statements of Part I, &#x201c;Item 1. Financial Statements.&#x201d;);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;announced Topline Results from SEQUOIA Phase 2 Study of Fazirsiran (formerly ARO-AAT) in patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease in which;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;fibrosis regression was observed in 50% of patients receiving Fazirsiran;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;median reductions of 94% of Z-AAT accumulation in the liver and mean reductions of 68% in histologic globule burden were observed;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;treatment emergent adverse events were generally well balanced between Fazirsiran and placebo groups;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;results were consistent with AROAAT-2002 open-label study previously published in The New England Journal of Medicine.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation and Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim Consolidated Financial Statements include the accounts of Arrowhead Pharmaceuticals, Inc. and its subsidiaries (wholly-owned subsidiaries and a variable interest entity for which the Company is the primary beneficiary). Subsidiaries refer to Arrowhead Madison, Inc., Visirna Therapeutics, Inc. (&#x201c;Visirna&#x201d;), and Arrowhead Australia Pty Ltd. For subsidiaries in which the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interests retained in such entity by the respective noncontrolling party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). The financial data of the Company included herein are unaudited. In the opinion of management, all material adjustments of a normal recurring nature have been made to present fairly the Company&#x2019;s financial position at March&#160;31, 2023 and the results of operations and cash flows for the periods presented. All intercompany transactions and balances have been eliminated. Certain prior period amounts have been reclassified to conform with the current period presentation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain financial information that is normally included in annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, has been omitted from the accompanying interim consolidated financial statements and related notes. Readers are urged to review the Company&#x2019;s Annual Report on Form 10-K for the year ended September&#160;30, 2022 for more complete descriptions and discussions. Operating results and cash flows for the six months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the fiscal year ending September&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company&#x2019;s primary sources of financing have been through the sale of its securities, revenue from its licensing and collaboration agreements and the sale of certain future royalties. Research and development activities have required significant capital investment since the Company&#x2019;s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company&#x2019;s pipeline of drug candidates and its headcount have both expanded significantly. Additionally, significant capital investment will be required as the Company&#x2019;s pipeline matures into later stage clinical trials and as the Company plans to increase its internal manufacturing capabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2023, the Company had $135.0 million in cash and cash equivalents (including $7.3 million in restricted cash), $346.0 million in short-term investments and $78.8&#160;million in long-term investments to fund operations. During the six months ended March&#160;31, 2023, the Company&#x2019;s cash and cash equivalents and investments balance increased by $77.6 million which was primarily due to the $250.0&#160;million upfront payment received from Royalty Pharma (Note 11) and $40.0 million in milestone payments from Horizon and Amgen, partially offset by cash used to fund its operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In total, the Company is eligible to receive up to $3.6 billion in developmental, regulatory and sales milestones, and may receive various royalties on net sales from its licensing and collaboration agreements, subject to the terms and conditions of those agreements. The revenue recognition for these collaboration agreements is discussed further in Note 2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no changes to the significant accounting policies disclosed in the Company&#x2019;s most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no recent accounting pronouncements that have significantly impacted this Quarterly Report on Form 10-Q, beyond those disclosed in the Company&#x2019;s most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <arwr:ScheduleOfCurrentProductsTableTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfNjY0NA_115db421-049b-4d33-a7d6-ba445937362e">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s current pipeline:&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Therapeutic Area&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Stage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Product Rights&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cardiometabolic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-APOC3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 2b and Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-ANG3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 2b&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Olpasiran&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amgen&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Pulmonary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-ENAC2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Pre-Clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-RAGE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-MUC5AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-MMP7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Liver&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;GSK-4532990 (formerly ARO-HSD)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;GSK&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fazirsiran&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Takeda and Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;JNJ-3989&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;HZN-457 (formerly ARO-XDH)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Horizon&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-C3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-PNPLA3 (formerly JNJ-75220795)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Muscle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-DUX4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Pre-Clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;CNS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-SOD1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Pre-Clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</arwr:ScheduleOfCurrentProductsTableTextBlock>
    <arwr:MilestonePaymentReceivable
      contextRef="i43a3ecb8edc343d68a3d398bc46eaa91_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfMzI5ODUzNDkwNTg0Ng_960b4608-1095-4796-8a05-e7185838b7dd"
      unitRef="usd">40000000</arwr:MilestonePaymentReceivable>
    <arwr:MilestonePaymentReceivable
      contextRef="ieab41d2e8cba4cf79954078e0cabd689_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfMzI5ODUzNDkwNTg2MQ_fca2bdba-c460-4b2c-a5a6-79c94156e60b"
      unitRef="usd">30000000</arwr:MilestonePaymentReceivable>
    <arwr:UpfrontMilestonePaymentReceived
      contextRef="ib5defaeb7ae444faaeff3aef533d099f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfMzI5ODUzNDg5NTY4MA_5a2ef277-0cea-40f7-8a56-47a903bae2e4"
      unitRef="usd">15000000</arwr:UpfrontMilestonePaymentReceived>
    <arwr:UpfrontMilestonePaymentReceived
      contextRef="i98ffa0a0b1d34836b2777d4632a82434_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfMzI5ODUzNDg5NTY5NQ_3e38f089-c47c-4d62-844f-7d8da903471f"
      unitRef="usd">25000000</arwr:UpfrontMilestonePaymentReceived>
    <arwr:UpfrontMilestonePaymentReceived
      contextRef="id543e56d77b6424381c9e219cda252c8_D20221109-20221109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfMzI5ODUzNDg5NTcxMA_42ee71e6-a65f-47d1-8b1e-bec5a8f0d273"
      unitRef="usd">250000000</arwr:UpfrontMilestonePaymentReceived>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfNTQ0MQ_e30b5eb8-0e31-495c-b0bd-83dccac0dc89"
      unitRef="usd">135000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfNTQ4NA_9626c1c8-e4dc-4c23-a78b-5318396b5de5"
      unitRef="usd">7300000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfNTUwOA_085ea4f5-4c58-4c59-88ed-1df0e31ca2a0"
      unitRef="usd">346000000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfNTU0MQ_c72e9663-7d48-427c-ad24-a7e262fe1ec5"
      unitRef="usd">78800000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <arwr:IncreaseDecreaseInCashAndInvestments
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfNTY5Nw_289cf1eb-13ea-4afd-8d20-d437b133796e"
      unitRef="usd">77600000</arwr:IncreaseDecreaseInCashAndInvestments>
    <arwr:UpfrontMilestonePaymentReceived
      contextRef="i9f80c327fd0f46fcb58660b1d4a93b3f_D20221001-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfNTQ5NzU1ODQwOTY1_da7e4f4a-043a-4acb-a10b-d8e12b501709"
      unitRef="usd">250000000</arwr:UpfrontMilestonePaymentReceived>
    <arwr:UpfrontMilestonePaymentReceived
      contextRef="i77ee61f67e7d4807a1b41dc07bbe6011_D20221001-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfNTQ5NzU1ODMzNzc0_5070b3ad-0e21-4bc6-9a1c-0123201cd92b"
      unitRef="usd">40000000</arwr:UpfrontMilestonePaymentReceived>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfMjc0ODc3OTA5MjAyMg_a1f0274a-2632-4e2d-aac5-32b7dd652899"
      unitRef="usd">3600000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zMS9mcmFnOmJmNzFhYTZkNmQ4NDQ1YzNhYzcyMzRhYmJjMjAxMGZhL3RleHRyZWdpb246YmY3MWFhNmQ2ZDg0NDVjM2FjNzIzNGFiYmMyMDEwZmFfNjY0Mw_6fdad132-25d7-4127-853b-b8655ab2992d">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no recent accounting pronouncements that have significantly impacted this Quarterly Report on Form 10-Q, beyond those disclosed in the Company&#x2019;s most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMTgyMjc_0badf8f2-737b-4cb5-bbaa-42af9ead7590">COLLABORATION AND LICENSE AGREEMENTS&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of revenue recognized:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.818%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.798%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;GSK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;120,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;29,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;120,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Horizon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;21,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Takeda&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;116,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;132,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;41,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amgen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;146,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;151,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;208,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;179,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balance of receivables and contract liabilities related to the Company&#x2019;s collaboration and license agreements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Receivables included in accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;70,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;6,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contract liabilities included in deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;30,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;130,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Glaxosmithkline Intellectual Property (No. 3) Limited (&#x201c;GSK&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 22, 2021, GSK and the Company entered into an Exclusive License Agreement (the &#x201c;GSK License Agreement&#x201d;). Under the GSK License Agreement, GSK has received an exclusive license for GSK-4532990 (formerly ARO-HSD). The exclusive license is worldwide with the exception of greater China, for which the Company retained rights to develop and commercialize GSK-4532990. The Company completed its Phase 1/2 study of GSK-4532990, and GSK is wholly responsible for all clinical development and commercialization of GSK-4532990 in its territory. Under the terms of the agreement, the Company has received an upfront payment of $120.0&#160;million and recognized an additional $30.0&#160;million at the start of a Phase 2 trial. The Company is also eligible for an additional payment of $100.0&#160;million upon achieving a successful Phase 2 trial readout and the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to the Company of up to $190.0&#160;million at first commercial sale, and up to $590.0&#160;million in sales-related milestone payments. The Company is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of the GSK License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;amp;D services, including the Company&#x2019;s responsibility to complete the Phase 1/2 study (the &#x201c;GSK R&amp;amp;D Services&#x201d;). Due to the specialized and unique nature of the GSK R&amp;amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. Beyond the GSK R&amp;amp;D Services, which are the responsibility of the Company, GSK will be responsible for managing future clinical development and commercialization in its territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the initial transaction price totaled $120.0&#160;million, including the upfront payment, which was collected in January 2022. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company has allocated the total $120.0&#160;million initial transaction price to its one distinct performance obligation for the GSK-4532990 license and the associated GSK R&amp;amp;D Services. As the Company has completed its performance obligation related to this agreement, the upfront payment of $120.0&#160;million was fully recognized during the six months ended March 31, 2022. Further, GSK dosed the first patient in a Phase 2 trial in March 2023, triggering a $30.0&#160;million milestone payment to the Company which is expected to be paid in the third quarter of fiscal 2023. There were no contract assets and liabilities recorded as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Horizon Therapeutics Ireland DAC (&#x201c;Horizon&#x201d;) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 18, 2021, Horizon and the Company entered into a collaboration and license agreement (the &#x201c;Horizon License Agreement&#x201d;). Under the terms of the Horizon License Agreement, Horizon received a worldwide exclusive license for HZN-457, a clinical-stage medicine being developed by Horizon as a potential treatment for people with uncontrolled gout. The Company conducted all activities through the preclinical stages of development of, and Horizon is now wholly &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;responsible for clinical development and commercialization of, HZN-457. The Company received $40.0&#160;million as an upfront payment in July 2021 and an additional $15.0&#160;million upon Horizon&#x2019;s initiation of a Phase 1 clinical trial in January 2023, and is eligible to receive up to $645.0&#160;million in additional potential development, regulatory and sales milestones. The Company is also eligible to receive royalties in the low- to mid-teens range on net product sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of the Horizon License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;amp;D services, including the Company&#x2019;s responsibilities to conduct all activities through the preclinical stages of development of HZN-457 (the &#x201c;Horizon R&amp;amp;D Services&#x201d;). Due to the specialized and unique nature of these Horizon R&amp;amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. Beyond the Horizon R&amp;amp;D Services, which are the responsibility of the Company, Horizon is responsible for managing future clinical development and commercialization of HZN-457. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the initial transaction price totaled $40.0&#160;million, including the upfront payment. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company allocated the total $40.0&#160;million initial transaction price to its one distinct performance obligation for the HZN-457 license and the associated Horizon R&amp;amp;D Services. Revenue was recognized on a straight-line basis over the timeframe for completing the Horizon R&amp;amp;D Services. The Company determined that the straight-line basis was appropriate as its efforts were expended evenly over the course of completing its performance obligation. Further, Horizon enrolled the first subject in December 2022 in a Phase 1 randomized, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HZN-457, triggering a $15.0&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2023. There were no contract assets and liabilities recorded as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Pharmaceutical Company Limited (&#x201c;Takeda&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 7, 2020, Takeda and the Company entered into an Exclusive License and Co-Funding Agreement (the &#x201c;Takeda License Agreement&#x201d;). Under the Takeda License Agreement, Takeda and the Company will co-develop its Fazirsiran program, the Company&#x2019;s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, Fazirsiran, if approved, will be co-commercialized under a 50/50 profit sharing structure. Outside the United States, Takeda will lead the global commercialization strategy and will receive an exclusive license to commercialize Fazirsiran, while the Company will be eligible to receive tiered royalties of 20% to 25% on net sales. The Company received $300.0&#160;million as an upfront payment in January 2021, recognized an additional $40.0&#160;million upon Takeda&#x2019;s initiation of a Phase 3 clinical study in March 2023, and is eligible to receive potential development, regulatory and commercial milestones of up to $527.5&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of the Takeda License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;amp;D services including the Company&#x2019;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of Fazirsiran drug product is completed and delivered to Takeda (the &#x201c;Takeda R&amp;amp;D Services&#x201d;). Due to the specialized and unique nature of these Takeda R&amp;amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. Beyond the Takeda R&amp;amp;D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States. Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the 50/50 profit sharing structure within the United States. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts are recorded as research and development expenses or general and administrative expenses, as appropriate.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has allocated the total $300.0&#160;million initial transaction price to its one distinct performance obligation for the Fazirsiran license and the associated Takeda R&amp;amp;D Services. Revenue is recognized using a proportional performance method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). The Company previously expected these clinical trials to extend to September 2025 in order to demonstrate long term safety and efficacy in the open label extension part of the studies; however, Takeda now intends to initiate a new open label extension (OLE) study available to patients participating in these Phase 2 studies that will initiate as early as July 2023. Based on this new information, patients enrolled in the SEQUOIA and AROAAT2002 studies are expected to complete their Phase 2 study visits between June 2023 and June 2024, shortening the Company&#x2019;s performance obligation. As a result, effective the second quarter of fiscal 2023, the Company changed its estimates of the revenue recognition to better reflect these newly estimated proportional performance periods. The effect of these changes in estimates resulted in accelerated revenue by $61.4&#160;million, or $0.57 per share (diluted) for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;each of the three and six months ended March&#160;31, 2023. There were $30.9 million of contract liabilities recorded as deferred revenue, of which $29.8 million  was classified as current as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, Takeda dosed the first patient in the Phase 3 REDWOOD clinical study of Fazirsiran, triggering a $40.0&#160;million milestone payment to the Company which is expected to be paid in the third quarter of fiscal 2023. The Company also recorded $9.4&#160;million as accrued expenses as of March&#160;31, 2023 that was primarily driven by co-development and co-commercialization activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Janssen Pharmaceuticals, Inc. (&#x201c;Janssen&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 3, 2018, Janssen, part of the Janssen Pharmaceutical Companies of Johnson &amp;amp; Johnson, and the Company entered into a License Agreement (the &#x201c;Janssen License Agreement&#x201d;) and the Janssen Collaboration Agreement. The Company also entered into a stock purchase agreement with JJDC, Inc. (&#x201c;JJDC&#x201d;), Johnson &amp;amp; Johnson&#x2019;s venture capital arm (the &#x201c;JJDC Stock Purchase Agreement&#x201d;). Under the Janssen License Agreement, Janssen received a worldwide, exclusive license to the Company&#x2019;s JNJ-3989 (ARO-HBV) program, the Company&#x2019;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. Beyond the Company&#x2019;s Phase 1/2 study of JNJ-3989 (ARO-HBV), which the Company was responsible for completing, Janssen is wholly responsible for clinical development and commercialization of JNJ-3989 (ARO-HBV). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Janssen License Agreement, the Company has received $175.0&#160;million as an upfront payment, $75.0&#160;million in the form of an equity investment by JJDC in the Company&#x2019;s common stock under the JJDC Stock Purchase Agreement, and milestone and option payments totaling $73.0&#160;million, and the Company may receive up to $0.8 billion in development and sales milestone payments for the Janssen License Agreement. The Company is further eligible to receive tiered royalties on product sales up to mid-teens under the Janssen License Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 7, 2023, Janssen voluntarily terminated the Janssen Collaboration Agreement. Upon termination, the Company regained full rights to ARO-PNPLA3, formerly called JNJ-75220795, the only candidate for which Janssen had exercised its option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, Janssen exercised its option right for JNJ-75220795 (ARO-JNJ1), which resulted in a $10.0&#160;million milestone payment to the Company. This $10.0&#160;million milestone payment was recognized entirely as of September 30, 2021. The Company conducted its discovery, optimization and preclinical research and development of JNJ-75220795 (ARO-JNJ1), ARO-JNJ2, and ARO-JNJ3 under the Janssen Collaboration Agreement. All costs and labor hours spent by the Company have been entirely funded by Janssen. There was no revenue recorded associated with the Company&#x2019;s agreement with Janssen for the six months ended March 31, 2023 and 2022. There were no contract assets and liabilities recorded as of March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of the Janssen License Agreement, the Company determined that the key deliverables included the license and certain R&amp;amp;D services including the Company&#x2019;s responsibility to complete the Phase 1/2 study of JNJ-3989 (ARO-HBV) and the Company&#x2019;s responsibility to ensure certain manufacturing of JNJ-3989 (ARO-HBV) drug product is completed and delivered to Janssen (the &#x201c;Janssen R&amp;amp;D Services&#x201d;). Due to the specialized and unique nature of these Janssen R&amp;amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the transaction price totaled approximately $252.7&#160;million, which includes the upfront payment, the premium paid by JJDC for its equity investment in the Company, two $25.0&#160;million milestone payments related to JNJ-3989 (ARO-HBV), and estimated payments for reimbursable Janssen R&amp;amp;D Services to be performed. The Company has allocated the total $252.7&#160;million initial transaction price to its one distinct performance obligation for the JNJ-3989 (ARO-HBV) license and the associated Janssen R&amp;amp;D Services. The Company recognized this transaction price in its entirety as of September 30, 2021, as its performance obligations were substantially completed. Future milestones and royalties achieved will be recognized in their entirety when earned. There were no contract assets and liabilities recorded as of March 31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%"&gt;Amgen Inc. (&#x201c;Amgen&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 28, 2016, Amgen and the Company entered into two collaboration and license agreements and a common stock purchase agreement. Under the Second Collaboration and License Agreement (the &#x201c;Olpasiran Agreement&#x201d;), Amgen received a worldwide, exclusive license to the Company&#x2019;s novel RNAi Olpasiran program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the first collaboration and license agreement (the &#x201c;First Collaboration and License Agreement&#x201d; or the &#x201c;ARO-AMG1 Agreement&#x201d;), Amgen received an option to a worldwide, exclusive license to ARO-AMG1, an RNAi therapy for an undisclosed genetically validated cardiovascular target. Under both agreements, Amgen is wholly responsible for clinical development and commercialization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Olpasiran Agreement and the ARO-AMG1 Agreement, the Company has received $35.0&#160;million in upfront payments and $21.5&#160;million in the form of an equity investment by Amgen in the Company&#x2019;s common stock. Further, the Company received additional an $55.0&#160;million in milestone payments; $10.0&#160;million upon Amgen&#x2019;s initiation of Phase 1 study in September 2018,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$20.0&#160;million upon its initiation of a Phase 2 clinical study in July 2020, and $25.0 million upon its first subject enrollment in a Phase 3 trial in December 2022. The Company has substantially completed its performance obligations under the Olpasiran Agreement and the ARO-AMG1 Agreement. There were no contract assets and liabilities recorded as of March&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, Royalty Pharma and the Company entered into the Royalty Pharma Agreement. In consideration for the payments under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive up to an additional $535.0&#160;million in remaining development, regulatory and sales milestone payments payable from Amgen and Royalty Pharma. See Note 11.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Joint Venture and License Agreement with Visirna Therapeutics, Inc. (&#x201c;Visirna&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 25, 2022, Visirna and the Company entered into a License Agreement (the &#x201c;Visirna License Agreement&#x201d;), pursuant to which Visirna received an exclusive license to develop, manufacture and commercialize four of the Company&#x2019;s RNAi-based investigational cardiometabolic medicines in Greater China (including the People&#x2019;s Republic of China, Hong Kong, Macau and Taiwan). Pursuant to a Share Purchase Agreement (the &#x201c;Visirna SPA&#x201d;) entered into simultaneously with the Visirna License Agreement, the Company acquired a majority stake in Visirna as partial consideration for the Visirna License Agreement. Under the Visirna SPA, entities affiliated with Vivo Capital also acquired a minority stake in Visirna in exchange for $60.0&#160;million in upfront capital to support the operations of Visirna. As further consideration under the Visirna License Agreement, the Company is also eligible to receive potential royalties on commercial sales.&lt;/span&gt;&lt;/div&gt;During the six months ended March&#160;31, 2023, the Company performed manufacturing and development work pursuant to a Clinical Supply Agreement between the parties contemplated by the Visirna License Agreement. The Company received $0.9&#160;million as consideration for this manufacturing and development work, and there were no contract assets and liabilities recorded as of March&#160;31, 2023.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk2NzQxMg_c6f94478-7418-430c-982d-e3566dab8e5a">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of revenue recognized:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.818%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.798%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;GSK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;120,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;29,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;120,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Horizon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;21,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Takeda&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;116,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;132,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;41,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amgen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;146,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;151,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;208,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;179,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15c28c33dc6b4b10bbc915f499ad8066_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfMy0yLTEtMS01MzYwMA_d40a8f07-e479-48de-b4a4-ab36a7bbde45"
      unitRef="usd">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1384505727044d59609bba3ee71e812_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfMy00LTEtMS01MzYyMw_fee2bb3d-97cc-4519-a7e4-2601f9f89834"
      unitRef="usd">120000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iccbf1d7ac531418d9578213f88b95f24_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfMy02LTEtMS01MzYzMw_6c596975-5df1-4676-89d3-07b5bc70af56"
      unitRef="usd">29323000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i269e350e160c4ea6ad74071baf18573a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfMy04LTEtMS01MzY0Mg_61df706c-3315-4237-8e8f-2f2578496180"
      unitRef="usd">120000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60b798e3a061472cbe491224489dd4fd_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNC0yLTEtMS01MzYwMA_9fcdff37-45e8-4dc8-843e-7173f749199e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i825f9542073f4d75985f228f8558ca2e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNC00LTEtMS01MzYyMw_09be4e36-a304-48b3-befd-5cfc8966851e"
      unitRef="usd">7918000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6cd6b96847294914b272df50802b449e_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNC02LTEtMS01MzYzMw_e747a5d7-6735-4200-bd74-0eb7e306e577"
      unitRef="usd">21667000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i243b609737ea4d7eb695ad185cb74491_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNC04LTEtMS01MzY0Mg_3dfa2ce3-bc67-4d1f-8153-a0ccd15d864f"
      unitRef="usd">14585000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i082bc8d425934d3a809c260cf43f2098_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNS0yLTEtMS01MzYwMA_64aac0cc-ee4a-47a4-834c-34e8ce6c9ba2"
      unitRef="usd">116156000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4920d739b45b45edbeea74ee7c5f1a5e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNS00LTEtMS01MzYyMw_f0f49a0c-6478-4409-8f9a-77294a1e27cc"
      unitRef="usd">20821000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i233b4f8cd26e4e908334e04db7e1672d_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNS02LTEtMS01MzYzMw_946aa4cd-8606-4d1f-a3d8-0d42ab8b5b0b"
      unitRef="usd">132468000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36bee665f89b4b8bb8cf30907efbb23d_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNS04LTEtMS01MzY0Mg_90897013-f67a-42ec-9498-d681c6660592"
      unitRef="usd">41593000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41d99afba4a04457ae92c14f6d2288e4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNi0yLTEtMS01MzYwMA_3d8366d2-804f-4aa0-83d1-aaec033543c9"
      unitRef="usd">111000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2d18d01d1ba459c819e19a2f426f844_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNi00LTEtMS01MzYyMw_5c7a4b01-6e74-4f39-b7b3-ea3a5c5969e4"
      unitRef="usd">3066000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64ad46fbf63445bbab41c28a191959cc_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNi02LTEtMS01MzYzMw_0529aa6a-069c-461e-9053-06d1a69fec73"
      unitRef="usd">355000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8cddef21baaf4bf9bfe75fd694a89239_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNi04LTEtMS01MzY0Mg_631d2033-2a68-496f-bf64-d3a8765a5045"
      unitRef="usd">3066000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a36c9033466491aa13ecfd0d8b71fd8_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNy0yLTEtMS01MzYwMA_52ce82ea-77ee-4d10-bb9f-e769ec457eee"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66bbdb26e9194e4fbb451ef54849270f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNy00LTEtMS01MzYyMw_f72673db-3b1d-43e6-ac41-30a147ebc202"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee762a06741d4eb7a18728ac4c642e6b_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNy02LTEtMS01MzYzMw_7599cc38-1d97-44cb-9432-2543838cf356"
      unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaeb9254172ee4a51a8dd7073ba5f92c6_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfNy04LTEtMS01MzY0Mg_7fa28eec-b3a9-4207-bbd7-4c13cf770579"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfOC0yLTEtMS01MzYwMA_5ee0a318-ee98-4e75-b3d7-f6c959e96727"
      unitRef="usd">146267000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfOC00LTEtMS01MzYyMw_c9dc324d-45be-4b3a-8884-a8274edf28de"
      unitRef="usd">151805000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfOC02LTEtMS01MzYzMw_23e5ea76-0b60-48b0-b975-c74dce1a0269"
      unitRef="usd">208813000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOjdmMWZlYmYxNDgyZjQyYmZhODEyMTMxOWZhMzAwOTY3L3RhYmxlcmFuZ2U6N2YxZmViZjE0ODJmNDJiZmE4MTIxMzE5ZmEzMDA5NjdfOC04LTEtMS01MzY0Mg_5f3d553d-46a5-4488-a41b-73a022af09c4"
      unitRef="usd">179244000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk2NzQxMw_df43b9c8-62c8-4a42-a526-8706d50ce387">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balance of receivables and contract liabilities related to the Company&#x2019;s collaboration and license agreements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Receivables included in accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;70,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;6,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contract liabilities included in deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;30,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;130,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsReceivableNet
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOmEzZjg0NzllNzQ1MjQ4ZTQ4MzQ2MTBhZWVlY2NhNzM5L3RhYmxlcmFuZ2U6YTNmODQ3OWU3NDUyNDhlNDgzNDYxMGFlZWVjY2E3MzlfMi0yLTEtMS01Mzc0Nw_37f0768e-2b28-41d1-bcf8-58e587885d75"
      unitRef="usd">70000000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOmEzZjg0NzllNzQ1MjQ4ZTQ4MzQ2MTBhZWVlY2NhNzM5L3RhYmxlcmFuZ2U6YTNmODQ3OWU3NDUyNDhlNDgzNDYxMGFlZWVjY2E3MzlfMi00LTEtMS02MDQwNQ_ec3b5236-5217-4fbf-86d9-f61c86a05503"
      unitRef="usd">6174000</us-gaap:AccountsReceivableNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOmEzZjg0NzllNzQ1MjQ4ZTQ4MzQ2MTBhZWVlY2NhNzM5L3RhYmxlcmFuZ2U6YTNmODQ3OWU3NDUyNDhlNDgzNDYxMGFlZWVjY2E3MzlfMy0yLTEtMS01Mzc0Nw_6ee33f7c-1bda-4921-8b31-58c9018a03cb"
      unitRef="usd">30914000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RhYmxlOmEzZjg0NzllNzQ1MjQ4ZTQ4MzQ2MTBhZWVlY2NhNzM5L3RhYmxlcmFuZ2U6YTNmODQ3OWU3NDUyNDhlNDgzNDYxMGFlZWVjY2E3MzlfMy00LTEtMS02MDQwMg_35960ab8-731e-4a98-97eb-dc63d8ab055e"
      unitRef="usd">130049000</us-gaap:ContractWithCustomerLiability>
    <arwr:MilestonePaymentEarned
      contextRef="i691de1d520624cd1b1ffd39dc3bdc01d_I20211122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzUzMQ_1b37ff2d-319b-45f4-88f5-8025a7a2c102"
      unitRef="usd">120000000</arwr:MilestonePaymentEarned>
    <arwr:MilestonePaymentReceivableAtStartOfPhaseTwo
      contextRef="i691de1d520624cd1b1ffd39dc3bdc01d_I20211122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzU0Nw_cc8abd13-6d66-4bf2-8de8-0430fbde80b5"
      unitRef="usd">30000000</arwr:MilestonePaymentReceivableAtStartOfPhaseTwo>
    <arwr:MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree
      contextRef="i691de1d520624cd1b1ffd39dc3bdc01d_I20211122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzU2Mg_506db687-80c4-43f3-af21-10ba7cf8de96"
      unitRef="usd">100000000</arwr:MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree>
    <arwr:CommercialMilestonePaymentsAtFirstCommercialSale
      contextRef="i3271e7a0f6144468b240efa725ae2d39_I20211122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzU3OA_4076c555-df74-477c-91f1-5418eda36931"
      unitRef="usd">190000000</arwr:CommercialMilestonePaymentsAtFirstCommercialSale>
    <arwr:SalesRelatedMilestonePayments
      contextRef="i3271e7a0f6144468b240efa725ae2d39_I20211122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzU5NA_ec349108-315c-486c-bf17-3e26808e19da"
      unitRef="usd">590000000</arwr:SalesRelatedMilestonePayments>
    <arwr:InitialTransactionPrice
      contextRef="i237d8e5c7b234033bc777c8a0a3b0d52_D20211122-20211122"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzYxMA_d21931d5-4366-4c63-9e61-f94c5b7437f3"
      unitRef="usd">120000000</arwr:InitialTransactionPrice>
    <arwr:InitialTransactionPrice
      contextRef="i237d8e5c7b234033bc777c8a0a3b0d52_D20211122-20211122"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzY0MA_d21931d5-4366-4c63-9e61-f94c5b7437f3"
      unitRef="usd">120000000</arwr:InitialTransactionPrice>
    <arwr:InitialTransactionPrice
      contextRef="i237d8e5c7b234033bc777c8a0a3b0d52_D20211122-20211122"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzY1Nw_d21931d5-4366-4c63-9e61-f94c5b7437f3"
      unitRef="usd">120000000</arwr:InitialTransactionPrice>
    <arwr:MilestonePaymentReceivable
      contextRef="ieab41d2e8cba4cf79954078e0cabd689_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzY2MA_b3be8a7b-b6ee-4d41-a876-03b7e836d553"
      unitRef="usd">30000000</arwr:MilestonePaymentReceivable>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ieab41d2e8cba4cf79954078e0cabd689_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfNDk0NzgwMjQxMDY5OQ_1e0c2d53-220a-490a-a215-7e2895704dc7"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="ieab41d2e8cba4cf79954078e0cabd689_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfNDk0NzgwMjQxMDY5OQ_35b5ac89-f84d-43e9-ae74-31ec9532adce"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement
      contextRef="i3d90a2de7f4e49f596cb460bdc10f3ca_I20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzY3NQ_f75f8f1c-b4d3-40c2-9381-96346d7f3c71"
      unitRef="usd">40000000</arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement>
    <arwr:MilestonePaymentEarned
      contextRef="i882e29fc588d4797a46ee5a39680339a_I20230131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzY5MA_bf2e911f-a671-40ba-98ab-4d986e364a3d"
      unitRef="usd">15000000</arwr:MilestonePaymentEarned>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="i59d79924ebeb447c886bc284402909d2_I20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzcwNQ_57d86c61-1d3b-4aa7-9f9e-82a2e28b4e37"
      unitRef="usd">645000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:NumberOfDistinctBundle
      contextRef="i82576571409c4b7f9b8bb80fb3c9a00e_D20210618-20210618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzcyMA_eabe34fe-629c-4147-a901-26cdca7c3301"
      unitRef="bundle">1</arwr:NumberOfDistinctBundle>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="i82576571409c4b7f9b8bb80fb3c9a00e_D20210618-20210618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzcyMQ_7b57bb33-2a0f-402e-b932-0ef90f58c94d"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:InitialTransactionPrice
      contextRef="i8b82750996f043c38f0f0871c175613b_D20210618-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzczNw_a7ecebe4-ad54-4f66-9f67-dca7faaaf0af"
      unitRef="usd">40000000</arwr:InitialTransactionPrice>
    <arwr:InitialTransactionPrice
      contextRef="i8b82750996f043c38f0f0871c175613b_D20210618-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1Mzc2NQ_a7ecebe4-ad54-4f66-9f67-dca7faaaf0af"
      unitRef="usd">40000000</arwr:InitialTransactionPrice>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="i8b82750996f043c38f0f0871c175613b_D20210618-20210618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1Mzc2Nw_b3921d03-af37-4afa-9433-a9ef949642a1"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:UpfrontMilestonePaymentReceived
      contextRef="ib5defaeb7ae444faaeff3aef533d099f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1Mzc3OA_daad74ad-617a-4587-834a-e425fa28c88d"
      unitRef="usd">15000000</arwr:UpfrontMilestonePaymentReceived>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i711eaa11f2714195b20f945bbd192ec3_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfNTQ5NzU1ODM0NjI0_b863dd36-9d2a-4f76-bef0-65b1dd06c7af"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i711eaa11f2714195b20f945bbd192ec3_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfNTQ5NzU1ODM0NjI0_f0a41a0b-aa83-4e91-94da-7f3aa5151eaf"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales
      contextRef="idadf7ab9198248d8be15ad2d0459d433_D20201007-20201007"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1Mzc5Mw_245a6bcc-e221-4146-b635-3e360e68fcdb"
      unitRef="number">0.20</arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales>
    <arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales
      contextRef="ia6534598f573472fa49c88f3543fef50_D20201007-20201007"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1Mzc5OA_6ed996d2-5e84-4c42-ab9c-efa29d5634f9"
      unitRef="number">0.25</arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales>
    <arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement
      contextRef="i3776d7ed0187438ba605de53d95d0524_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzgwMw_070555fc-5dee-43d9-8b0f-9017b5174fcf"
      unitRef="usd">300000000</arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement>
    <arwr:MilestonePaymentEarned
      contextRef="i43a3ecb8edc343d68a3d398bc46eaa91_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzgzNQ_7f25f1cc-281e-42a1-952a-b54ed397a2c6"
      unitRef="usd">40000000</arwr:MilestonePaymentEarned>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="i5df73d39e5de43059a0154473c1fc57f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzgxOQ_44360422-fee6-46be-bfb8-c173e43ff308"
      unitRef="usd">527500000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="i2220001e31ea4ab6af2ee0d3e5c38388_D20201007-20201007"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk2NzQxNA_65e58ef6-48f0-4504-8471-a8c4a1dc1f25"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:NumberOfDistinctBundle
      contextRef="i2220001e31ea4ab6af2ee0d3e5c38388_D20201007-20201007"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk2NzQyMg_8f1b863a-48bb-483b-bf8c-819ece79fbee"
      unitRef="bundle">1</arwr:NumberOfDistinctBundle>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="i2220001e31ea4ab6af2ee0d3e5c38388_D20201007-20201007"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk2NzQyMw_24eda9ef-fe4b-4bd6-8dab-4c40db2f555d"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:InitialTransactionPrice
      contextRef="i2220001e31ea4ab6af2ee0d3e5c38388_D20201007-20201007"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1Mzg1MA_323a9fe4-56d9-4e3f-8ac5-567082a5d871"
      unitRef="usd">300000000</arwr:InitialTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee5b7af13da443ca9a9e86096b5e0768_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfNDk0NzgwMjQxMjE1MQ_0ce95761-1b96-422f-9681-7c4a2fd8d373"
      unitRef="usd">61400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i587c88b790cf4957a1f2e9ff83d976c3_D20221001-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfNDk0NzgwMjQxMjE1MQ_303125b1-c891-4b5f-8b7b-3a95092e193f"
      unitRef="usd">61400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iee5b7af13da443ca9a9e86096b5e0768_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfNDk0NzgwMjQxMjE2Ng_10376751-a99e-4182-a060-fcb63a811d71"
      unitRef="usdPerShare">0.57</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i587c88b790cf4957a1f2e9ff83d976c3_D20221001-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfNDk0NzgwMjQxMjE2Ng_3e9170b6-e3c1-4b43-9671-595c85f394d4"
      unitRef="usdPerShare">0.57</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i5a2e6ffc46c94788ab81d4390fdee866_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfNTQ5NzU1ODUxNjY0_ce4e5666-31dc-4808-81f6-68eacab06842"
      unitRef="usd">30900000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5a2e6ffc46c94788ab81d4390fdee866_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMjc0ODc3OTE0MTU5OA_49a0d6a3-f222-4cb1-a8fd-82b2e570c8a0"
      unitRef="usd">29800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <arwr:MilestonePaymentReceivable
      contextRef="i43a3ecb8edc343d68a3d398bc46eaa91_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1Mzg4MA_42b095e5-5de3-4f78-b8b8-0d77155f202d"
      unitRef="usd">40000000</arwr:MilestonePaymentReceivable>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="iecaadb3d3d994f3383d71ba13d40433e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1Mzg2Ng_4537c17f-15f8-4437-94d8-3d0e2a7702ba"
      unitRef="usd">9400000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <arwr:CashReceivedAsDueUnderCollaborationAgreement
      contextRef="i66aef91f08484848847318e56657242a_D20181003-20181003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1Mzg5NQ_b523835b-6ed1-439b-b61a-e4dc529c1ca3"
      unitRef="usd">175000000</arwr:CashReceivedAsDueUnderCollaborationAgreement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="id0ed9d7c6a704f9c9edc96118a125065_D20181003-20181003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzkxMQ_8f98d0f3-f7cc-46e0-982c-c452a553bb91"
      unitRef="usd">75000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <arwr:MilestonePaymentEarned
      contextRef="i82a308c1dd274f2e8e0a6f7e4ad9c114_I20181003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1MzkyNg_627c6dd6-96bf-4190-ade3-906caabafec0"
      unitRef="usd">73000000</arwr:MilestonePaymentEarned>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="i076faa12769447e9be5b69d21b9bf0ed_I20181003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1Mzk0MQ_208c9d33-9530-4823-8e57-03fe142c446e"
      unitRef="usd">800000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:MilestonePaymentEarned
      contextRef="i2c30ebd6d9024acdba5d304d894ee2a4_I20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1NDEwNA_9d3fdaeb-0e07-48f8-8f75-334efcad6f95"
      unitRef="usd">10000000</arwr:MilestonePaymentEarned>
    <arwr:MilestonePaymentEarned
      contextRef="ia34c6824ddbd426ea939bb344ff03287_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1NDExOQ_178ec5cf-0d55-43e7-9f85-a506dd4c8b17"
      unitRef="usd">10000000</arwr:MilestonePaymentEarned>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0cf61607a2de42a1b21f3f65fa7d4921_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1NDEzMw_1e0d5c21-56e5-4134-b1d1-3af4350954e1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69f05a11406a48f2a92c762736aedab3_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1NDEzMw_a009d228-0725-45e1-b211-4abc7811344e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i6a26ad8e16504e72b2689ba702142228_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1NDEzNA_31863aef-3bc8-46b9-a9a8-ed809068ceeb"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i6a26ad8e16504e72b2689ba702142228_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1NDEzNA_e88a1895-ce2b-429c-b8fe-53d51fe8476e"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <arwr:InitialTransactionPrice
      contextRef="ib6ca215027754381a471291a60f53443_D20181003-20181003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1Mzk3OA_409dac45-11fb-4cfe-adaa-9fe820e4c1ea"
      unitRef="usd">252700000</arwr:InitialTransactionPrice>
    <arwr:MilestonePaymentEarned
      contextRef="i497a7ae1faa04b0b9671b12bf3055d80_I20181003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1Mzk5NA_575e847d-e0af-4889-9077-eab108f38ac3"
      unitRef="usd">25000000</arwr:MilestonePaymentEarned>
    <arwr:InitialTransactionPrice
      contextRef="ib6ca215027754381a471291a60f53443_D20181003-20181003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1NDAwOQ_1bc3381f-1955-4b82-96be-a3637e89ce8c"
      unitRef="usd">252700000</arwr:InitialTransactionPrice>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="ibd242108c98b440c9d40f8441267573b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1NDAyNA_48d66b0e-84c7-4a88-a12a-a1e23011fa02"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ibd242108c98b440c9d40f8441267573b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1NDAyNA_4b2c4e45-5020-416e-aa55-bbdba42390cb"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <arwr:NumberOfAgreements
      contextRef="i57ec6b70a6104026b8b41cb652df4ebb_I20160928"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMTQzODg_25f17bc8-245e-4260-9cc0-04146c1d8eae"
      unitRef="agreement">2</arwr:NumberOfAgreements>
    <arwr:CashReceivedAsDueUnderCollaborationAgreement
      contextRef="i5f5f8caf41684c1ab6c099861fb8c323_D20160928-20160928"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk2NzMxMw_2c7b54a0-390b-4bf2-8a91-60d11c1f349f"
      unitRef="usd">35000000</arwr:CashReceivedAsDueUnderCollaborationAgreement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i5f5f8caf41684c1ab6c099861fb8c323_D20160928-20160928"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk2NzMyOA_decd54f7-cb02-44ac-9762-88728e0fcfef"
      unitRef="usd">21500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <arwr:MilestonePaymentReceived
      contextRef="i9405e8a861cd439b9331928b2bbd63e1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk2NzM0Mw_f0fc60aa-269c-40b9-830b-890ceb0b0c41"
      unitRef="usd">55000000</arwr:MilestonePaymentReceived>
    <arwr:MilestonePaymentReceived
      contextRef="i75cdb28a2e3a4ffd972787e5034b8cb6_I20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk2NzM1OA_1959b620-4852-4121-a252-6f14ae1f2db1"
      unitRef="usd">10000000</arwr:MilestonePaymentReceived>
    <arwr:MilestonePaymentReceived
      contextRef="ibd5f89a84f804aad9a58e70315cd9ffe_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk2NzM3Mw_d989e5d0-60fe-4e0f-b27b-8e97eeb80acc"
      unitRef="usd">20000000</arwr:MilestonePaymentReceived>
    <arwr:MilestonePaymentReceived
      contextRef="i18dfb4f2db2a4e89865ff817bb733953_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk2NzM4OQ_0f1874d8-b14e-43d8-889c-3a7394c24fc3"
      unitRef="usd">25000000</arwr:MilestonePaymentReceived>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i9405e8a861cd439b9331928b2bbd63e1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk2NzQwNA_46d06d2f-e0d2-40da-9455-cd6e47ff55c7"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i9405e8a861cd439b9331928b2bbd63e1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk2NzQwNA_8c2b686f-b18f-48f7-86d0-d4d144b16ae8"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="i1d8b33b9a77247749e39326804eed524_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1NDE1MQ_15c47ca9-e7a1-47c9-a5e7-2d150c95df74"
      unitRef="usd">535000000</arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="i1923b3729416425e9e9c1f77d0a63e84_D20220425-20220425"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMTc2NzU_c32bac54-961f-4ffd-8e48-7e9f338975ee"
      unitRef="usd">60000000</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6bca132899c842c2905496adc8f95181_D20221001-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1NDE2Nw_0733466d-5d62-41e7-8c5f-b56023c943ad"
      unitRef="usd">900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i6de19fc5f51b4e9888754036904b53f2_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1NDE4MA_c0b6ba94-02e5-46b3-8e8f-8be42dabe5a7"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i6de19fc5f51b4e9888754036904b53f2_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNC9mcmFnOmU0NzBkMWFkYmNlNzRhMzM5OWUzMDg1MzBkNGY3ZDBkL3RleHRyZWdpb246ZTQ3MGQxYWRiY2U3NGEzMzk5ZTMwODUzMGQ0ZjdkMGRfMzI5ODUzNDk1NDE4MA_e9c6e24d-3e00-4ea1-8c4e-00bf50ad10a2"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RleHRyZWdpb246N2E5NDNlYWZmYjJhNDhjOTkyZDg4YjFlMjQ1OWE0NjRfNTM4_dd23f202-b2ee-4df8-bb4e-9d84328bedae">PROPERTY AND EQUIPMENT&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s major classes of property and equipment:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Computers, software, office equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;46,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;38,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;42,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;42,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;127,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;56,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;221,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;141,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(36,072)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(31,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;185,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;110,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense for property and equipment for each of the three months ended March&#160;31, 2023 and 2022 was $2.2 million. Depreciation and amortization expense for property and equipment for the six months ended March&#160;31, 2023 and 2022 was $4.5 million and $4.3 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The increase in the construction in progress during the six months ended March&#160;31, 2023 was mainly due to the continuing developments of manufacturing, laboratory and office facilities in Verona, Wisconsin as well as a new laboratory and office facility in San Diego, California. See Note 7.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RleHRyZWdpb246N2E5NDNlYWZmYjJhNDhjOTkyZDg4YjFlMjQ1OWE0NjRfNTM5_a8aa93cd-80db-469d-bb59-4c991ef27906">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s major classes of property and equipment:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Computers, software, office equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;46,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;38,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;42,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;42,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;127,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;56,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;221,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;141,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(36,072)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(31,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;185,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;110,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfMi0xLTEtMS00NjY0Mg_a1306196-ff6d-41a4-81db-eb75e254350c"
      unitRef="usd">2198000</arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross>
    <arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfMi0zLTEtMS00NjY0Mg_438aafb5-2b20-44dc-965b-b77d519848b7"
      unitRef="usd">2182000</arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross>
    <us-gaap:Land
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfMy0xLTEtMS00NjY0Mg_a4930c6b-7aef-43e1-ac9d-9aa918cc488b"
      unitRef="usd">2996000</us-gaap:Land>
    <us-gaap:Land
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfMy0zLTEtMS00NjY0Mg_584b2883-4c8a-4a3a-9bd4-c98341bfd622"
      unitRef="usd">2996000</us-gaap:Land>
    <arwr:ResearchEquipmentGross
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfNC0xLTEtMS00NjY0Mg_72591d8e-15b9-49b6-afc2-546d1d06bc38"
      unitRef="usd">46873000</arwr:ResearchEquipmentGross>
    <arwr:ResearchEquipmentGross
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfNC0zLTEtMS00NjY0Mg_5e84da18-6e9b-42d0-a661-1ba1fe14a559"
      unitRef="usd">38283000</arwr:ResearchEquipmentGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfNS0xLTEtMS00NjY0Mg_57b2425b-bc67-4acf-880d-dd40202e2514"
      unitRef="usd">42017000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfNS0zLTEtMS00NjY0Mg_250834b0-e4ee-4541-8252-9859894b3999"
      unitRef="usd">42017000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfNi0xLTEtMS00NjY0Mg_e0c21d09-9d3d-42e2-8676-287db8a9e5c8"
      unitRef="usd">127216000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfNi0zLTEtMS00NjY0Mg_0217f7a6-26c1-4821-9f83-c5cd3a88547f"
      unitRef="usd">56373000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfNy0xLTEtMS00NjY0Mg_196dafe5-db84-48b7-a12d-448e9c4433ee"
      unitRef="usd">221300000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfNy0zLTEtMS00NjY0Mg_09d0f609-d33f-47db-8b4c-80ae8b6143b6"
      unitRef="usd">141851000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfOC0xLTEtMS00NjY0Mg_b8a3bc0e-5402-47f0-8e0e-13699e190938"
      unitRef="usd">36072000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfOC0zLTEtMS00NjY0Mg_4cd41ec0-445c-496d-8900-20159280d0d4"
      unitRef="usd">31554000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfOS0xLTEtMS00NjY0Mg_e0b10a66-ca48-435c-a688-42caddc895bd"
      unitRef="usd">185228000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RhYmxlOjIyZTViNzU5ZjQ2MDQ3NjliNjU4YTBmZGVlMGViODlhL3RhYmxlcmFuZ2U6MjJlNWI3NTlmNDYwNDc2OWI2NThhMGZkZWUwZWI4OWFfOS0zLTEtMS00NjY0Mg_9ca47d73-2c9e-487e-ac41-cc82afa166f3"
      unitRef="usd">110297000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RleHRyZWdpb246N2E5NDNlYWZmYjJhNDhjOTkyZDg4YjFlMjQ1OWE0NjRfMjMx_6fc7ec88-31d9-4f6a-98a5-5bea2aa7b33e"
      unitRef="usd">2200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RleHRyZWdpb246N2E5NDNlYWZmYjJhNDhjOTkyZDg4YjFlMjQ1OWE0NjRfMjMx_6ffd94ed-4daa-43ea-ae97-790260701f64"
      unitRef="usd">2200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RleHRyZWdpb246N2E5NDNlYWZmYjJhNDhjOTkyZDg4YjFlMjQ1OWE0NjRfNTQ5NzU1ODE0NjMy_2ce4aecb-09d8-425f-afb3-e0b43c2aa7e4"
      unitRef="usd">4500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl8zNy9mcmFnOjdhOTQzZWFmZmIyYTQ4Yzk5MmQ4OGIxZTI0NTlhNDY0L3RleHRyZWdpb246N2E5NDNlYWZmYjJhNDhjOTkyZDg4YjFlMjQ1OWE0NjRfNTQ5NzU1ODE0NjE2_8cda687a-c29c-4c39-a42a-bb9b30b40a28"
      unitRef="usd">4300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RleHRyZWdpb246MWRkZTQ0ZGYwM2Y5NDA2MmJjMDk5MTM5Yzk5MzA3YmNfODE_c33eb79a-77f1-4cb9-ac68-b1683b4c7be3">INVESTMENTS&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Short-term investments (due within one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Held to maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;346,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;342,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Held to maturity certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;346,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;342,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Long-term investments (due within one through three years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Held to maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;78,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,709)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;77,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;78,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;77,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.596%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.323%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Short-term investments (due within one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Held to maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;218,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;214,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Held to maturity certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;268,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;264,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Long-term investments (due within one through three years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Held to maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;100,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;100,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RleHRyZWdpb246MWRkZTQ0ZGYwM2Y5NDA2MmJjMDk5MTM5Yzk5MzA3YmNfODI_568f401c-8ceb-4b33-be08-da87c437ef86">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Short-term investments (due within one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Held to maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;346,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;342,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Held to maturity certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;346,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;342,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Long-term investments (due within one through three years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Held to maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;78,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,709)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;77,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;78,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;77,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.596%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.323%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Short-term investments (due within one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Held to maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;218,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;214,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Held to maturity certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;268,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;264,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Long-term investments (due within one through three years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Held to maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;100,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;100,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i2763c2350df84087ae24e66c081a59da_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfNS0xLTEtMS00NjY0Mg_6bf88455-b8da-4ec8-84ca-2ee04afd42c2"
      unitRef="usd">346046000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent
      contextRef="i2763c2350df84087ae24e66c081a59da_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfNS0zLTEtMS00NjY0Mg_7acded8f-11e5-46b4-bd5e-6f6cba55c3bf"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent
      contextRef="i2763c2350df84087ae24e66c081a59da_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfNS01LTEtMS00NjY0Mg_e6dcb382-b28a-4079-8d2d-8a982095a198"
      unitRef="usd">3755000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent
      contextRef="i2763c2350df84087ae24e66c081a59da_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfNS03LTEtMS00NjY0Mg_0a4be636-57ef-44c1-b064-7e62e6af7329"
      unitRef="usd">342291000</us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i770057db11544c24ad5a17c97ffb3a9f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfNi0xLTEtMS00NjY0Mg_bef67d42-6c94-413c-a9cb-99dac965a583"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent
      contextRef="i770057db11544c24ad5a17c97ffb3a9f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfNi0zLTEtMS00NjY0Mg_de049feb-cd0b-43bd-9e99-94b35d9e826b"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent
      contextRef="i770057db11544c24ad5a17c97ffb3a9f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfNi01LTEtMS00NjY0Mg_ada71fa6-1523-4264-b45b-832ca17be177"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent
      contextRef="i770057db11544c24ad5a17c97ffb3a9f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfNi03LTEtMS00NjY0Mg_09c99b05-f9cd-4018-bf53-e0ce6aa07a34"
      unitRef="usd">0</us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfNy0xLTEtMS00NjY0Mg_bbbb5ce7-ba2a-431f-b7ca-2f2936975273"
      unitRef="usd">346046000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfNy0zLTEtMS00NjY0Mg_d280d863-9c7c-417b-9d59-1c9df820e2f9"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfNy01LTEtMS00NjY0Mg_918eb891-05f4-4542-b7fe-49b91da94782"
      unitRef="usd">3755000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfNy03LTEtMS00NjY0Mg_48f100a8-2139-44b8-bb8b-4ede925cb565"
      unitRef="usd">342291000</us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="i2763c2350df84087ae24e66c081a59da_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfMTAtMS0xLTEtNDY2NDI_59ee8223-4118-4326-a027-1f419974031a"
      unitRef="usd">78834000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent
      contextRef="i2763c2350df84087ae24e66c081a59da_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfMTAtMy0xLTEtNDY2NDI_d336351c-6eba-49ce-8d8a-0f396bd9ec22"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent
      contextRef="i2763c2350df84087ae24e66c081a59da_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfMTAtNS0xLTEtNDY2NDI_1cae1181-9f21-473b-8286-6c8f2f519666"
      unitRef="usd">1709000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent
      contextRef="i2763c2350df84087ae24e66c081a59da_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfMTAtNy0xLTEtNDY2NDI_bbd61950-a6a9-4f07-a327-5602705ab718"
      unitRef="usd">77125000</us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfMTEtMS0xLTEtNDY2NDI_ee4bbf33-61b0-4cd7-939f-cf638fb6eccb"
      unitRef="usd">78834000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfMTEtMy0xLTEtNDY2NDI_f3fd44d0-6336-4572-bd07-9d641e577487"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfMTEtNS0xLTEtNDY2NDI_e1061ee6-3753-4719-8773-997875bf5795"
      unitRef="usd">1709000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUyMmY2ZDNhMjk1ODRmZGViNmY4NmU0OTJjNWY2Y2UwL3RhYmxlcmFuZ2U6NTIyZjZkM2EyOTU4NGZkZWI2Zjg2ZTQ5MmM1ZjZjZTBfMTEtNy0xLTEtNDY2NDI_ea47fb6e-9811-4666-9328-5a50c426a435"
      unitRef="usd">77125000</us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i4963dadcf66e4834a7a45b5f75765cb7_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfNS0xLTEtMS00NjY0Mg_c9e29cff-4fad-4d08-99d4-8c947ad9c692"
      unitRef="usd">218391000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent
      contextRef="i4963dadcf66e4834a7a45b5f75765cb7_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfNS0zLTEtMS00NjY0Mg_38c4326c-89c7-4ce2-a8d8-c1a3fcc819fc"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent
      contextRef="i4963dadcf66e4834a7a45b5f75765cb7_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfNS01LTEtMS00NjY0Mg_ed2aefcd-e369-47d9-b47d-57e032a40b46"
      unitRef="usd">3661000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent
      contextRef="i4963dadcf66e4834a7a45b5f75765cb7_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfNS03LTEtMS00NjY0Mg_06c7ea18-e9a4-4d03-af19-61eea2311a41"
      unitRef="usd">214730000</us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="ie3f0180b2cd14a14919b19c765f13d23_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfNi0xLTEtMS00NjY0Mg_e721c65c-2fdf-426d-a907-5a024697d2a7"
      unitRef="usd">50000000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent
      contextRef="ie3f0180b2cd14a14919b19c765f13d23_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfNi0zLTEtMS00NjY0Mg_cf0e7e02-ad0d-4864-ab68-e72dcd5a3cce"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent
      contextRef="ie3f0180b2cd14a14919b19c765f13d23_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfNi01LTEtMS00NjY0Mg_5a794ddd-26c8-419b-8ee2-6fbf7627101d"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent
      contextRef="ie3f0180b2cd14a14919b19c765f13d23_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfNi03LTEtMS00NjY0Mg_b94b9746-8f23-49dd-b662-28c87a060779"
      unitRef="usd">50000000</us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfNy0xLTEtMS00NjY0Mg_ca159b22-a136-4e5a-9480-e27ec269f46e"
      unitRef="usd">268391000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfNy0zLTEtMS00NjY0Mg_5cb3c7f2-3fe8-422e-848c-1c68eca6c4e0"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfNy01LTEtMS00NjY0Mg_cbf25486-84cd-4c64-b5cd-ca62437bfab7"
      unitRef="usd">3661000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfNy03LTEtMS00NjY0Mg_251ae7e6-0d85-41c8-82fb-4bbcf32d8884"
      unitRef="usd">264730000</us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="i4963dadcf66e4834a7a45b5f75765cb7_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfMTAtMS0xLTEtNDY2NDI_e936db46-c540-4b20-99ce-b13b9823f9fb"
      unitRef="usd">105872000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent
      contextRef="i4963dadcf66e4834a7a45b5f75765cb7_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfMTAtMy0xLTEtNDY2NDI_79d0e3e4-03a5-441c-bb18-027552fef4e3"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent
      contextRef="i4963dadcf66e4834a7a45b5f75765cb7_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfMTAtNS0xLTEtNDY2NDI_0ef9c284-15c0-4883-a9d7-7a9e430ef104"
      unitRef="usd">5569000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent
      contextRef="i4963dadcf66e4834a7a45b5f75765cb7_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfMTAtNy0xLTEtNDY2NDI_513d50c7-43ca-4b7a-880f-532c7f28f0aa"
      unitRef="usd">100303000</us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfMTEtMS0xLTEtNDY2NDI_2e075cb7-1158-4035-aa10-abc203e36597"
      unitRef="usd">105872000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfMTEtMy0xLTEtNDY2NDI_ee61a79e-a727-4451-a619-59d8a4a09232"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfMTEtNS0xLTEtNDY2NDI_08dccc90-671c-401d-975d-af7bdee2ecb4"
      unitRef="usd">5569000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MC9mcmFnOjFkZGU0NGRmMDNmOTQwNjJiYzA5OTEzOWM5OTMwN2JjL3RhYmxlOjUwNDk5MmY3NjkwYTRjMGM4N2RlYzk5YzM0YWJkMmZkL3RhYmxlcmFuZ2U6NTA0OTkyZjc2OTBhNGMwYzg3ZGVjOTljMzRhYmQyZmRfMTEtNy0xLTEtNDY2NDI_5c10c98e-2e21-4940-95ad-575e3478946a"
      unitRef="usd">100303000</us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RleHRyZWdpb246YTQxM2FkNzlhMTNmNGQ5MTlhNTBmMDQ4MjQzMGYyNzhfODY2_d8505421-3346-44f9-949d-fdf18e90f666">INTANGIBLE ASSETS&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. The following table presents the components of intangible assets: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reviewed annually for impairment and more frequently if potential impairment indicators exist. No impairment indicators were identified during the six months ended March&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with definite useful lives are amortized on a straight-line basis over their useful lives. Intangible assets amortization expense was $0.4 million for each of the three months ended March&#160;31, 2023 and 2022, and $0.9 million and for each of the six months ended March&#160;31, 2023 and 2022. None of the intangible assets with definite useful lives are anticipated to have a residual value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the estimated future amortization expense related to intangible assets as of March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ending September 30, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2023 (remainder)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RleHRyZWdpb246YTQxM2FkNzlhMTNmNGQ5MTlhNTBmMDQ4MjQzMGYyNzhfODY3_766fa0bb-49b1-4977-81c4-935bffa27384">The following table presents the components of intangible assets: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5b40500b5f154e638fec3502314b61ad_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfMy0xLTEtMS01MjY2OA_91650265-54d2-493d-bb95-f850f8228312"
      unitRef="usd">21728000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5b40500b5f154e638fec3502314b61ad_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfMy0zLTEtMS01MjY2OA_6ca6039a-9aec-48c4-bb8f-bd21f3cee6eb"
      unitRef="usd">12545000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment
      contextRef="i5b40500b5f154e638fec3502314b61ad_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfMy01LTEtMS01MjY2OA_cdfeda7e-15af-4021-8d2e-c133a1bc9a89"
      unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5b40500b5f154e638fec3502314b61ad_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfMy03LTEtMS01MjY2OA_6fa3f9e3-a1d4-48cf-bfda-e14d5e43b2fe"
      unitRef="usd">9183000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i43111cfc508d42d1a23d0e3818674d52_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfMy05LTEtMS01MjY2OA_75084d2d-8fb9-4a0c-8343-0736d3e51840">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iaefcccfc8a3c49a885837a695c3852d6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNC0xLTEtMS01MjY2OA_46f37db0-8228-48cf-afe7-275741d4b89a"
      unitRef="usd">3129000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iaefcccfc8a3c49a885837a695c3852d6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNC0zLTEtMS01MjY2OA_a482742d-d672-4c1c-9a16-e132919e31f3"
      unitRef="usd">1200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment
      contextRef="iaefcccfc8a3c49a885837a695c3852d6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNC01LTEtMS01MjY2OA_80df4e69-76b9-4a9e-9151-08c870b91464"
      unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iaefcccfc8a3c49a885837a695c3852d6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNC03LTEtMS01MjY2OA_d980d9c1-aff6-4035-8115-fcea2fc13211"
      unitRef="usd">1929000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i5d9b66e3437446e6a4e87dc026f2f51d_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNC05LTEtMS01MjY2OA_a5511b72-8042-421f-899c-c7bbe70f7f4c">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iae265843759f4671ae3ffdba000744f2_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNS0xLTEtMS01MjY2OA_ab05dfd6-e385-4b50-af92-49eb821c42cf"
      unitRef="usd">24857000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iae265843759f4671ae3ffdba000744f2_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNS0zLTEtMS01MjY2OA_520b2dbd-3f17-4060-bbf8-b5776db90538"
      unitRef="usd">13745000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment
      contextRef="iae265843759f4671ae3ffdba000744f2_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNS01LTEtMS01MjY2OA_da79601d-cbcf-4b44-9e8f-9d1a2e4cb676"
      unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iae265843759f4671ae3ffdba000744f2_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNS03LTEtMS01MjY2OA_7a38a631-c8ac-49f2-b1b6-ffc630f2b3c8"
      unitRef="usd">11112000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1e874cdd6f5c448fb4d8544628558c18_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfMy0xLTEtMS00NjY0Mg_cb7380d4-018b-4eec-81a1-9bdc4162a92a"
      unitRef="usd">21728000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1e874cdd6f5c448fb4d8544628558c18_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfMy0zLTEtMS00NjY0Mg_e1bfe6a7-999c-44af-a449-94debac647f2"
      unitRef="usd">11770000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment
      contextRef="i1e874cdd6f5c448fb4d8544628558c18_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfMy01LTEtMS00NjY0Mg_f0e6a1eb-0417-4d9e-b436-0f4fcfe19fd4"
      unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1e874cdd6f5c448fb4d8544628558c18_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfMy03LTEtMS00NjY0Mg_8522afdf-63af-44a4-978c-5cfe08b31994"
      unitRef="usd">9958000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i633b04e751e24ba3905af5e05905fd6e_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfMy05LTEtMS00NjY0Mg_c0583a76-ef5f-45b3-bdcd-977a6b03276c">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia0176372a9404016aaf7cbb1312079fa_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNC0xLTEtMS00NjY0Mg_10087a1a-5e1b-4e88-bc1c-692c175ea9eb"
      unitRef="usd">3129000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia0176372a9404016aaf7cbb1312079fa_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNC0zLTEtMS00NjY0Mg_6ecb9f29-b133-407c-b376-1182293d7d96"
      unitRef="usd">1125000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment
      contextRef="ia0176372a9404016aaf7cbb1312079fa_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNC01LTEtMS00NjY0Mg_f6ea478c-0001-4a6b-9d1d-543667287a74"
      unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia0176372a9404016aaf7cbb1312079fa_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNC03LTEtMS00NjY0Mg_ac4c5287-14a7-4ea0-906d-fb329a945e2b"
      unitRef="usd">2004000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i99c440889d934b9a991b649900bea075_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNC05LTEtMS00NjY0Mg_958fc78f-03ef-4c35-ada2-f4b04da71c4b">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia6d2dec926374fd7a06a9cc5ff555ad3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNS0xLTEtMS00NjY0Mg_07d17bdf-178d-4cf4-a54b-01ee8494017a"
      unitRef="usd">24857000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia6d2dec926374fd7a06a9cc5ff555ad3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNS0zLTEtMS00NjY0Mg_d69e8cfd-07e0-489b-b6f2-eba338dd4366"
      unitRef="usd">12895000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment
      contextRef="ia6d2dec926374fd7a06a9cc5ff555ad3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNS01LTEtMS00NjY0Mg_82990ea0-2722-4031-88f1-c5d2cbb27db0"
      unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia6d2dec926374fd7a06a9cc5ff555ad3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOmU2NjdiYjIyNzg0OTRlZDM5MDAwYmIzNWVlNDc2NzdlL3RhYmxlcmFuZ2U6ZTY2N2JiMjI3ODQ5NGVkMzkwMDBiYjM1ZWU0NzY3N2VfNS03LTEtMS00NjY0Mg_326b44f1-b53b-4869-aca2-acf58910c0ee"
      unitRef="usd">11962000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RleHRyZWdpb246YTQxM2FkNzlhMTNmNGQ5MTlhNTBmMDQ4MjQzMGYyNzhfNTQ5NzU1ODE0ODYz_40875f54-1d68-44f0-811e-fc6bdfccd17c"
      unitRef="usd">400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RleHRyZWdpb246YTQxM2FkNzlhMTNmNGQ5MTlhNTBmMDQ4MjQzMGYyNzhfNTQ5NzU1ODE0ODYz_e91bf4b4-01a2-4906-ac7f-71d366adc71a"
      unitRef="usd">400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RleHRyZWdpb246YTQxM2FkNzlhMTNmNGQ5MTlhNTBmMDQ4MjQzMGYyNzhfNTQ5NzU1ODE1MTMw_da8bb87c-d08d-4497-8ee2-e13ab39e95b2"
      unitRef="usd">900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RleHRyZWdpb246YTQxM2FkNzlhMTNmNGQ5MTlhNTBmMDQ4MjQzMGYyNzhfNTQ5NzU1ODE1MTMw_dd1ab035-a1a6-4087-bfe3-b5baf5c711eb"
      unitRef="usd">900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RleHRyZWdpb246YTQxM2FkNzlhMTNmNGQ5MTlhNTBmMDQ4MjQzMGYyNzhfODY4_6f00f351-d4d2-4802-87f7-a76db8817630">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the estimated future amortization expense related to intangible assets as of March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ending September 30, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2023 (remainder)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOjkxMTI4Y2NkZjFmNzQxM2U4YmM0OWM1ODRmNzYwM2JmL3RhYmxlcmFuZ2U6OTExMjhjY2RmMWY3NDEzZThiYzQ5YzU4NGY3NjAzYmZfMi0yLTEtMS00NjY0Mg_d79ef93a-38ca-4699-9452-382516a3b4dc"
      unitRef="usd">850000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOjkxMTI4Y2NkZjFmNzQxM2U4YmM0OWM1ODRmNzYwM2JmL3RhYmxlcmFuZ2U6OTExMjhjY2RmMWY3NDEzZThiYzQ5YzU4NGY3NjAzYmZfMy0yLTEtMS00NjY0Mg_7f3f325f-11a3-4317-8f9c-ee920ed623d5"
      unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOjkxMTI4Y2NkZjFmNzQxM2U4YmM0OWM1ODRmNzYwM2JmL3RhYmxlcmFuZ2U6OTExMjhjY2RmMWY3NDEzZThiYzQ5YzU4NGY3NjAzYmZfNC0yLTEtMS00NjY0Mg_4017e555-67b9-4cb8-b243-829b644a574a"
      unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOjkxMTI4Y2NkZjFmNzQxM2U4YmM0OWM1ODRmNzYwM2JmL3RhYmxlcmFuZ2U6OTExMjhjY2RmMWY3NDEzZThiYzQ5YzU4NGY3NjAzYmZfNS0yLTEtMS00NjY0Mg_4818532e-b714-4353-a5cd-a4f932710f89"
      unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOjkxMTI4Y2NkZjFmNzQxM2U4YmM0OWM1ODRmNzYwM2JmL3RhYmxlcmFuZ2U6OTExMjhjY2RmMWY3NDEzZThiYzQ5YzU4NGY3NjAzYmZfNi0yLTEtMS00NjY0Mg_1782be16-a056-4f46-a296-b081794c3287"
      unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <arwr:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOjkxMTI4Y2NkZjFmNzQxM2U4YmM0OWM1ODRmNzYwM2JmL3RhYmxlcmFuZ2U6OTExMjhjY2RmMWY3NDEzZThiYzQ5YzU4NGY3NjAzYmZfNy0yLTEtMS00NjY0Mg_4ded4757-60fa-4760-9190-6d4d57d5fe0a"
      unitRef="usd">3462000</arwr:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80My9mcmFnOmE0MTNhZDc5YTEzZjRkOTE5YTUwZjA0ODI0MzBmMjc4L3RhYmxlOjkxMTI4Y2NkZjFmNzQxM2U4YmM0OWM1ODRmNzYwM2JmL3RhYmxlcmFuZ2U6OTExMjhjY2RmMWY3NDEzZThiYzQ5YzU4NGY3NjAzYmZfOC0yLTEtMS00NjY0Mg_2c837120-e3b1-4ece-b2a0-9d851ef7c393"
      unitRef="usd">11112000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RleHRyZWdpb246MzU3YjIwNjYxMWJlNDBmNTg1YjMxYmIyODUyZWY3NjZfMTUyMw_3e4fa470-ec0d-42ea-a9af-484500dd5dd2">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s shares of common stock and preferred stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Par Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;106,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;106,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;145,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;16, 2023, the Company&#x2019;s stockholders approved an increase in authorized common shares, par value $0.001 per share, from 145,000,000 to 290,000,000. The amendment to the Amended and Restated Certificate of Incorporation was filed on April 27, 2023. The Company does not have any current intention to issue shares in connection with acquisitions or pursuant to any equity financing outside of its existing equity compensation plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023 and September&#160;30, 2022, respectively, 13,075,198 and 14,000,392 shares of common stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under the Company&#x2019;s 2004 Equity Incentive Plan, 2013 Incentive Plan, and 2021 Incentive Plan, as well as for inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 2, 2022, the Company entered into an open market sale agreement (the &#x201c;Open Market Sale Agreement&#x201d;), pursuant to which the Company may, from time to time, sell up to $250,000,000 in shares of the Company&#x2019;s common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering (&#x201c;ATM Offering&#x201d;). The Company is not required to sell shares under the Open Market Sale Agreement. The Company will pay Jefferies LLC a commission of up to 3.0% of the aggregate gross proceeds received from all sales of the common stock under the Open Market Sale Agreement. Unless otherwise terminated, the ATM Offering shall terminate upon the earlier of (i) the sale of all shares of common stock subject to the Sales Agreement and (ii) the termination of the Sales Agreement as permitted therein. The Company and Jefferies may each terminate the Open Market Sale Agreement at any time upon prior notice. As of March&#160;31, 2023, no shares have been issued under the Open Market Sale Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RleHRyZWdpb246MzU3YjIwNjYxMWJlNDBmNTg1YjMxYmIyODUyZWY3NjZfMTUyNA_ec26ffc8-539a-457c-a02d-119c332dc648">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s shares of common stock and preferred stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Par Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;106,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;106,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;145,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfNC0xLTEtMS00NjY0Mg_a763e7d5-9c28-4da5-a90b-39c9406eeb0e"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfNC0yLTEtMS00NjY0Mg_68878432-9267-4d27-92ff-52e38f88eaca"
      unitRef="shares">290000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfNC0zLTEtMS00NjY0Mg_93cbed37-c7d5-4bf7-b9d1-b17aae226da4"
      unitRef="shares">106869000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfNC00LTEtMS00NjY0Mg_7815066b-78bf-40d4-9046-5a669c0f3334"
      unitRef="shares">106869000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfNS0xLTEtMS00NjY0Mg_123ceabf-d1c9-4700-ade0-f5acf2bc67bc"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfNS0yLTEtMS00NjY0Mg_84cdf664-8042-4c87-957c-ba52c76c3805"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfNS0zLTEtMS00NjY0Mg_e4d301ab-3b61-4d73-ac4e-57dcef3f6f73"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfNS00LTEtMS00NjY0Mg_1e5774bd-2a52-4524-abf4-5fc3fc7b68fe"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfOC0xLTEtMS00NjY0Mg_1a305e1e-07db-427b-b467-775c2173e2eb"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfOC0yLTEtMS00NjY0Mg_b3d513f4-39ad-4182-aa3c-1892c12dac6d"
      unitRef="shares">145000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfOC0zLTEtMS00NjY0Mg_ab1d569e-f02b-4d15-ac30-8f824e744579"
      unitRef="shares">105960000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfOC00LTEtMS00NjY0Mg_df868778-c401-4c01-9a6a-191a164a85a4"
      unitRef="shares">105960000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfOS0xLTEtMS00NjY0Mg_bfeb5512-80ce-4491-91e9-17f0d5420a9f"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfOS0yLTEtMS00NjY0Mg_2619fe6e-bb40-43c1-a8fd-14f12b16b7bf"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfOS0zLTEtMS00NjY0Mg_75084334-78c3-4d4b-bf55-6d63d432d6d2"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RhYmxlOjJiYjhjMmZiMTc3MzQ3NTY4YWFiNDUwYjE1YTNiYjYxL3RhYmxlcmFuZ2U6MmJiOGMyZmIxNzczNDc1NjhhYWI0NTBiMTVhM2JiNjFfOS00LTEtMS00NjY0Mg_b42f5ebc-1f39-4490-9547-4194309f55c7"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RleHRyZWdpb246MzU3YjIwNjYxMWJlNDBmNTg1YjMxYmIyODUyZWY3NjZfNTQ5NzU1ODE2MDk0_a763e7d5-9c28-4da5-a90b-39c9406eeb0e"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5e6eba04dc734b4d8c9dac99153326ea_I20230426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RleHRyZWdpb246MzU3YjIwNjYxMWJlNDBmNTg1YjMxYmIyODUyZWY3NjZfMzg0ODI5MDcwMDA5NA_52dacc92-9a69-4040-8123-484f1159a8ff"
      unitRef="shares">145000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5a2307967ccd4758a76576f944c97966_I20230427"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RleHRyZWdpb246MzU3YjIwNjYxMWJlNDBmNTg1YjMxYmIyODUyZWY3NjZfMjc0ODc3OTA3MjEwMg_e35da04a-de1e-4bd2-bf3f-b7be7cb8c875"
      unitRef="shares">290000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i946d734bd0924e3c88051efb2fda8a0b_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RleHRyZWdpb246MzU3YjIwNjYxMWJlNDBmNTg1YjMxYmIyODUyZWY3NjZfMjc0ODc3OTA3MTc3MA_0004f534-5d04-4072-95e4-fa8cedca8615"
      unitRef="shares">13075198</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i68db699bce364d8482aa0ec6406b9e97_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RleHRyZWdpb246MzU3YjIwNjYxMWJlNDBmNTg1YjMxYmIyODUyZWY3NjZfMjc0ODc3OTA3MTc3NQ_469e4e91-82bf-46d7-9f47-9d5f33fda0b5"
      unitRef="shares">14000392</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <arwr:CommonStockCapitalSharesValueReservedForFutureIssuance
      contextRef="i93974846852e4d2e86d9713058a0d972_I20221202"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RleHRyZWdpb246MzU3YjIwNjYxMWJlNDBmNTg1YjMxYmIyODUyZWY3NjZfNTQ5NzU1ODE2MTMy_2f584913-f037-4345-90bb-3023d97944b2"
      unitRef="usd">250000000</arwr:CommonStockCapitalSharesValueReservedForFutureIssuance>
    <arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock
      contextRef="idb7a13077dbb473bbf383cb6cf031d5f_D20221202-20221202"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RleHRyZWdpb246MzU3YjIwNjYxMWJlNDBmNTg1YjMxYmIyODUyZWY3NjZfNTQ5NzU1ODE2MTM2_1c8b1d08-927b-4b6d-aace-6aa9e7a22dad"
      unitRef="number">0.030</arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock>
    <us-gaap:SharesIssued
      contextRef="ibec649ac666a4282b702eb4164c1aa47_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80Ni9mcmFnOjM1N2IyMDY2MTFiZTQwZjU4NWIzMWJiMjg1MmVmNzY2L3RleHRyZWdpb246MzU3YjIwNjYxMWJlNDBmNTg1YjMxYmIyODUyZWY3NjZfNTQ5NzU1ODE2MTg2_28d00d1d-ede2-4a2b-9d8e-0aac9af4857c"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80OS9mcmFnOjA5YzM1M2Y1OTYyOTQzY2JiZWRjYjAyMWZmZTBkZWYwL3RleHRyZWdpb246MDljMzUzZjU5NjI5NDNjYmJlZGNiMDIxZmZlMGRlZjBfMjI4Mw_13d4a746-6529-4180-a3f6-626d33703c56">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were no contingent liabilities recorded as of March&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;20, 2021, the Company completed a purchase of 13 acres of land in the Verona Technology Park in Verona, Wisconsin, which is being developed into an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility which will support the Company&#x2019;s process development and analytical activities. The Company intends to invest between $200.0 million and $260.0 million into the build-out of the facilities. As part of this acquisition, the Company entered into a development agreement with the City of Verona to construct certain infrastructure improvements within the tax incremental district and will be reimbursed up to $16.0&#160;million by the City of Verona by future tax increment revenue generated from the developed property. The total amount of funding that the City of Verona will pay under the Tax Incremental Financing program is not guaranteed and will depend on future tax revenues generated from the developed property. The Company will also receive up to $2.5 million of refundable Wisconsin state income tax credits from the Wisconsin Economic Development Corporation (WEDC) as incentives to invest in the local community and create new jobs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Technology License Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has licensed from third parties the rights to use certain technologies for its research and development activities, as well as in any products it may develop using these licensed technologies. These agreements and other similar &lt;/span&gt;&lt;/div&gt;agreements often require milestone and royalty payments. Milestone payments, for example, may be required as the research and development process progresses through various stages of development, such as when clinical candidates enter or progress through clinical trials, upon NDA and/or certain sales level milestones. During the three and six months ended March&#160;31, 2023 and 2022, the Company did not reach any milestones.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80OS9mcmFnOjA5YzM1M2Y1OTYyOTQzY2JiZWRjYjAyMWZmZTBkZWYwL3RleHRyZWdpb246MDljMzUzZjU5NjI5NDNjYmJlZGNiMDIxZmZlMGRlZjBfMzky_2b4fe717-2518-43e5-b21b-a53a07ed7fd2"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <arwr:NumberOfAcresOfLandPurchased
      contextRef="iabd7d953444246219ae89c140ed43582_D20211220-20211220"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80OS9mcmFnOjA5YzM1M2Y1OTYyOTQzY2JiZWRjYjAyMWZmZTBkZWYwL3RleHRyZWdpb246MDljMzUzZjU5NjI5NDNjYmJlZGNiMDIxZmZlMGRlZjBfNDkz_ca0a8561-cf3b-42e8-82cb-0fbe708954f3"
      unitRef="acre">13</arwr:NumberOfAcresOfLandPurchased>
    <us-gaap:AreaOfLand
      contextRef="i6f6537bef0da416db817189fd3163b28_I20211220"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80OS9mcmFnOjA5YzM1M2Y1OTYyOTQzY2JiZWRjYjAyMWZmZTBkZWYwL3RleHRyZWdpb246MDljMzUzZjU5NjI5NDNjYmJlZGNiMDIxZmZlMGRlZjBfNjA5_d8e1c1b7-88f6-4953-b296-9df5e8dd4758"
      unitRef="sqft">160000</us-gaap:AreaOfLand>
    <us-gaap:AreaOfLand
      contextRef="icaf4446772ec44ed9ba6f8dddc59fe68_I20211220"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80OS9mcmFnOjA5YzM1M2Y1OTYyOTQzY2JiZWRjYjAyMWZmZTBkZWYwL3RleHRyZWdpb246MDljMzUzZjU5NjI5NDNjYmJlZGNiMDIxZmZlMGRlZjBfNjcz_22318aab-ca8e-4b60-a84c-b834f6037197"
      unitRef="sqft">140000</us-gaap:AreaOfLand>
    <arwr:AmountIntendsToInvestForBuildoutOfFacilities
      contextRef="i0f101a6f09c746a696cf6e40e90e0784_I20211220"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80OS9mcmFnOjA5YzM1M2Y1OTYyOTQzY2JiZWRjYjAyMWZmZTBkZWYwL3RleHRyZWdpb246MDljMzUzZjU5NjI5NDNjYmJlZGNiMDIxZmZlMGRlZjBfODM3_17bd2d99-0312-45f7-b46b-167ce3934c3a"
      unitRef="usd">200000000</arwr:AmountIntendsToInvestForBuildoutOfFacilities>
    <arwr:AmountIntendsToInvestForBuildoutOfFacilities
      contextRef="i608519b3c5264256971820f095be404f_I20211220"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80OS9mcmFnOjA5YzM1M2Y1OTYyOTQzY2JiZWRjYjAyMWZmZTBkZWYwL3RleHRyZWdpb246MDljMzUzZjU5NjI5NDNjYmJlZGNiMDIxZmZlMGRlZjBfODQ0_0e779cc4-ae5c-4d11-bc24-7b6c10b11920"
      unitRef="usd">260000000</arwr:AmountIntendsToInvestForBuildoutOfFacilities>
    <arwr:TaxIncrementFinancingAward
      contextRef="i174690ddc75d4855ac133c1051fa0058_I20211220"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80OS9mcmFnOjA5YzM1M2Y1OTYyOTQzY2JiZWRjYjAyMWZmZTBkZWYwL3RleHRyZWdpb246MDljMzUzZjU5NjI5NDNjYmJlZGNiMDIxZmZlMGRlZjBfMTEwMQ_eb2f0c54-9044-45a0-93b2-ae920d64a697"
      unitRef="usd">16000000</arwr:TaxIncrementFinancingAward>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="i87a265da333847a7a7a27032890bbae3_D20211220-20211220"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80OS9mcmFnOjA5YzM1M2Y1OTYyOTQzY2JiZWRjYjAyMWZmZTBkZWYwL3RleHRyZWdpb246MDljMzUzZjU5NjI5NDNjYmJlZGNiMDIxZmZlMGRlZjBfMTQzNA_141afa3f-71b3-4102-8a08-31d8ea062932"
      unitRef="usd">2500000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <arwr:MilestonePayments
      contextRef="i21fbfd552ab74a5b8d34cf53f412fb99_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80OS9mcmFnOjA5YzM1M2Y1OTYyOTQzY2JiZWRjYjAyMWZmZTBkZWYwL3RleHRyZWdpb246MDljMzUzZjU5NjI5NDNjYmJlZGNiMDIxZmZlMGRlZjBfMjI1OA_401e8f48-0cde-456d-a956-a7bec159a4b9"
      unitRef="usd">0</arwr:MilestonePayments>
    <arwr:MilestonePayments
      contextRef="id49087344a124915998dbc4016b35524_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80OS9mcmFnOjA5YzM1M2Y1OTYyOTQzY2JiZWRjYjAyMWZmZTBkZWYwL3RleHRyZWdpb246MDljMzUzZjU5NjI5NDNjYmJlZGNiMDIxZmZlMGRlZjBfMjI1OA_50aa96ee-d578-42a2-a292-919864e14cb1"
      unitRef="usd">0</arwr:MilestonePayments>
    <arwr:MilestonePayments
      contextRef="if91aa501385d4acda003508cc04433bd_D20221001-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80OS9mcmFnOjA5YzM1M2Y1OTYyOTQzY2JiZWRjYjAyMWZmZTBkZWYwL3RleHRyZWdpb246MDljMzUzZjU5NjI5NDNjYmJlZGNiMDIxZmZlMGRlZjBfMjI1OA_7c3b52b7-c433-43a3-96c6-10a8f9f2b498"
      unitRef="usd">0</arwr:MilestonePayments>
    <arwr:MilestonePayments
      contextRef="i7c55337dc9d5489f93889b362e414346_D20211001-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80OS9mcmFnOjA5YzM1M2Y1OTYyOTQzY2JiZWRjYjAyMWZmZTBkZWYwL3RleHRyZWdpb246MDljMzUzZjU5NjI5NDNjYmJlZGNiMDIxZmZlMGRlZjBfMjI1OA_ce89f8d4-2e08-41cd-babe-69bf73e9dcf2"
      unitRef="usd">0</arwr:MilestonePayments>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfMzAxMw_9327b49b-7495-4d94-b178-c7913c6adaf2">LEASES&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;19, 2021, the Company entered into a 15-year lease for approximately 144,000 square feet of office and research and development laboratory space in San Diego, California. This facility replaces the Company&#x2019;s current office and research facility located in San Diego, California. The increased capacity of this new facility compared to the Company&#x2019;s current research facility in San Diego will accommodate increased personnel for its expanding pipeline of current and future drug candidates. The lease payments which began on April 19, 2023, the rent commencement date, will be approximately $119.0 million over the initial 15-year term. The Company also estimates payments for operating expenses to be approximately $3.0 million for the first year of the lease, and these payments will continue throughout the initial 15-year term. The Company expects to pay approximately $32.0&#160;million for leasehold improvements, net of tenant improvement allowances. Pursuant to the lease, within twelve months of the expiration of the initial 15-year term, the Company has the option to extend the lease for up to one additional ten-year term, with certain annual increases in base rent. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Significant Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Pasadena, California&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company leases 49,000 square feet of office space located at 177 Colorado Blvd. for its corporate headquarters from 177 Colorado Owner, LLC, which lease expires on April&#160;30, 2027. The lease contains an option to renew for one term of five years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;San Diego, California&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company subleased space from Halozyme, Inc. for additional research and development facility in San Diego, California. The term of this sublease commenced on April&#160;1, 2020 and ended on January&#160;14, 2023. On December 23, 2022, the Company entered into a new six-month lease agreement with 11404 &amp;amp; 11408 Sorrento Valley Owner (DE) LLC, effective January 15, 2023. The lease will end on July 15, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Madison, Wisconsin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company leases space for office and laboratory facilities, which expires on September 30, 2031. The lease contains options to renew for two terms of five years. After accounting for additional rental square feet added pursuant to amendments to the lease agreement in 2019 and 2020, the Company currently leases a total of 111,000 square feet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease assets and liabilities along with their classification on the Company&#x2019;s consolidated balance sheets were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Lease Assets and Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;41,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;58,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;80,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;78,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease cost primarily related to operating expenses associated with the Company&#x2019;s operating leases. There was $0.4&#160;million and $0.3&#160;million short-term lease cost during the three months ended March&#160;31, 2023, and 2022, respectively. There was $0.7&#160;million and $0.5&#160;million short-term lease cost during the six months ended March&#160;31, 2023, and 2022, respectively.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents payments of operating lease liabilities on an undiscounted basis as of March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2023 (remainder of fiscal year)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;3,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;8,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;11,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;12,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;11,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;102,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;149,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(66,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total operating lease liabilities (includes current portion)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;82,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.969%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating cash flows from operating leases (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="idd3e5aec48f6451c954c613028ae62ea_I20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfNTg_26e45a35-9ee9-4634-844e-8130d3457033">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="idd3e5aec48f6451c954c613028ae62ea_I20211119"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfOTA_cf7fdef8-1d3b-496a-a597-8e591b632288"
      unitRef="sqft">144000</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="idd3e5aec48f6451c954c613028ae62ea_I20211119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfNzU1_5e5fb5c8-a75c-4b9a-b73d-94a7c69d30a7"
      unitRef="usd">119000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="idd3e5aec48f6451c954c613028ae62ea_I20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfNzc1_26e45a35-9ee9-4634-844e-8130d3457033">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <arwr:EstimatedPaymentsForOperatingExpensesYearOne
      contextRef="idd3e5aec48f6451c954c613028ae62ea_I20211119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfODY4_9e77c97d-88f2-4dc2-8d98-884222bdd2f6"
      unitRef="usd">3000000</arwr:EstimatedPaymentsForOperatingExpensesYearOne>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="idd3e5aec48f6451c954c613028ae62ea_I20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfOTYw_26e45a35-9ee9-4634-844e-8130d3457033">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances
      contextRef="ic5ae44bfc90d442180f61be9e9844f29_D20211119-20211119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfMzI5ODUzNDg4NjgzMA_32b3a1a5-d405-48f7-83f3-06a04dd76564"
      unitRef="usd">32000000</arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="idd3e5aec48f6451c954c613028ae62ea_I20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfMTE2MQ_26e45a35-9ee9-4634-844e-8130d3457033">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <arwr:NumberOfOptionsToRenew
      contextRef="idc3f86aeb9e54ad2a0c1aea7e97e6026_I20211119"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfMTIzMg_be158c19-5f39-4be7-befa-20fcaf7dd187"
      unitRef="option">1</arwr:NumberOfOptionsToRenew>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="idd3e5aec48f6451c954c613028ae62ea_I20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfMzAwOQ_2c503502-1772-4d1c-ace8-3d3116ecd7e4">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="i68677c28e8fe477fa44323fceff8350f_I20211119"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfMzI5ODUzNDg4Njg0NQ_a9f914f5-9cdc-431e-a3ad-f8f8b73e129c"
      unitRef="sqft">49000</us-gaap:LandSubjectToGroundLeases>
    <arwr:NumberOfOptionsToRenew
      contextRef="ifbd2b67bde2642ceb93902cc376061d6_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfMTU1Nw_707adc11-0986-4fdf-af4a-7196e3346e28"
      unitRef="option">1</arwr:NumberOfOptionsToRenew>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ifbd2b67bde2642ceb93902cc376061d6_I20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfMTU2OA_285ddf5d-d8fb-4d6b-9252-ec53d5726c66">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i15669b32d03d4c7994f8ce62df1576ee_I20221223"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfMzAxMA_2067725b-615b-4a34-ae5e-033f28b77720">P6M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <arwr:NumberOfOptionsToRenew
      contextRef="ia816458e6d964f63bac38dc0e0214686_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfMjI3OA_316228af-532d-43b2-a8be-b0f77e3d1e33"
      unitRef="option">2</arwr:NumberOfOptionsToRenew>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ia816458e6d964f63bac38dc0e0214686_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfMjI5MA_0477252e-6949-4a76-9873-d218d5463143">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="ia816458e6d964f63bac38dc0e0214686_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfMjQ1NQ_8fe05848-393d-4fd4-b8df-db4ac194ca68"
      unitRef="sqft">111000</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfMzAxMQ_5f9327ff-1f95-491c-8c69-373b2b6ad32c">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease assets and liabilities along with their classification on the Company&#x2019;s consolidated balance sheets were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Lease Assets and Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;41,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;58,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;80,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;78,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOjc5YTgzMzZkZjZkNjQ4N2M4MjA4ZWEyZGZmM2NjYzAzL3RhYmxlcmFuZ2U6NzlhODMzNmRmNmQ2NDg3YzgyMDhlYTJkZmYzY2NjMDNfMy0zLTEtMS00NjY0Mg_7a036cae-7eba-4c29-b59d-68069236ec1d"
      unitRef="usd">41114000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOjc5YTgzMzZkZjZkNjQ4N2M4MjA4ZWEyZGZmM2NjYzAzL3RhYmxlcmFuZ2U6NzlhODMzNmRmNmQ2NDg3YzgyMDhlYTJkZmYzY2NjMDNfMy01LTEtMS00NjY0Mg_535d6a1a-a577-46d4-a0d6-4f8262400764"
      unitRef="usd">58291000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOjc5YTgzMzZkZjZkNjQ4N2M4MjA4ZWEyZGZmM2NjYzAzL3RhYmxlcmFuZ2U6NzlhODMzNmRmNmQ2NDg3YzgyMDhlYTJkZmYzY2NjMDNfNS0zLTEtMS00NjY0Mg_a1f1b8c7-2e75-4ede-b673-313ef4068342"
      unitRef="usd">2711000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOjc5YTgzMzZkZjZkNjQ4N2M4MjA4ZWEyZGZmM2NjYzAzL3RhYmxlcmFuZ2U6NzlhODMzNmRmNmQ2NDg3YzgyMDhlYTJkZmYzY2NjMDNfNS01LTEtMS00NjY0Mg_cebaceaf-d4e2-4650-8ce6-74e322e6b40b"
      unitRef="usd">2776000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOjc5YTgzMzZkZjZkNjQ4N2M4MjA4ZWEyZGZmM2NjYzAzL3RhYmxlcmFuZ2U6NzlhODMzNmRmNmQ2NDg3YzgyMDhlYTJkZmYzY2NjMDNfNi0zLTEtMS00NjY0Mg_6f951844-0134-42e3-9c40-f406a8105452"
      unitRef="usd">80070000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOjc5YTgzMzZkZjZkNjQ4N2M4MjA4ZWEyZGZmM2NjYzAzL3RhYmxlcmFuZ2U6NzlhODMzNmRmNmQ2NDg3YzgyMDhlYTJkZmYzY2NjMDNfNi01LTEtMS00NjY0Mg_6509b918-b00c-4e64-81b7-fdce3e37dcee"
      unitRef="usd">78800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseCost
      contextRef="i159523f6f89347ed97ef204e3f438e67_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfNC0zLTEtMS00NjY0Mg_543b98e5-36e4-40de-a7f7-038cba7488c5"
      unitRef="usd">2343000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ia5215e7abf324f20be6a6162e55086ae_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfNC01LTEtMS00NjY0Mg_703a141c-a733-464f-8aaf-133760238d29"
      unitRef="usd">905000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ica3faf3d13c049288fea256fa28a33f5_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfNC03LTEtMS01MzI5Mg_eefe7f88-0e32-44da-81f2-77cd8f6b45c5"
      unitRef="usd">4412000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i3a9802653ed047b494adfc65fd05c202_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfNC05LTEtMS01MzMwMA_7d0b22d7-a91a-4e85-94a0-1097435ac574"
      unitRef="usd">1783000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i2202af7f697f4a768cccd43c0a966d51_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfNS0zLTEtMS00NjY0Mg_4c9457e2-cc76-4b72-8a08-eb304de41cd9"
      unitRef="usd">500000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i7a904235b2704d1281b976507352cfcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfNS01LTEtMS00NjY0Mg_473dabdd-e4f9-4e35-8218-8bff399a69ce"
      unitRef="usd">420000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i0104fc96cb744d06baa957d09374a4b9_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfNS03LTEtMS01MzI5Mg_3c679d63-4745-4d43-af66-333d52e92533"
      unitRef="usd">1033000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ie31baa0092254ca4a31017b25a53ca08_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfNS05LTEtMS01MzMwMA_dbcd16a9-2e43-4654-819e-8551abdf459f"
      unitRef="usd">840000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i159523f6f89347ed97ef204e3f438e67_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfNy0zLTEtMS00NjY0Mg_80eddad3-80c8-435c-87df-b6b45fc8a0fd"
      unitRef="usd">160000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ia5215e7abf324f20be6a6162e55086ae_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfNy01LTEtMS00NjY0Mg_737b9b70-fdd7-4351-b031-9b5d8a52e4e5"
      unitRef="usd">182000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ica3faf3d13c049288fea256fa28a33f5_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfNy03LTEtMS01MzI5Mg_c9d90d57-86e4-41cf-a882-a7b11594d873"
      unitRef="usd">370000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i3a9802653ed047b494adfc65fd05c202_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfNy05LTEtMS01MzMwMA_b839a690-2992-492d-8416-4b5c251f032c"
      unitRef="usd">340000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i2202af7f697f4a768cccd43c0a966d51_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfOC0zLTEtMS00NjY0Mg_dbf4f371-d0b9-41dd-a924-54bf09699862"
      unitRef="usd">0</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i7a904235b2704d1281b976507352cfcc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfOC01LTEtMS00NjY0Mg_a26e83fd-e6db-4eaa-9fb4-5b8f166f491b"
      unitRef="usd">0</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i0104fc96cb744d06baa957d09374a4b9_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfOC03LTEtMS01MzI5Mg_8825e082-8ff4-4c91-b785-e00329f9a701"
      unitRef="usd">0</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ie31baa0092254ca4a31017b25a53ca08_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfOC05LTEtMS01MzMwMA_65069419-c06c-4ef3-9333-4547f2526d76"
      unitRef="usd">0</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfMTAtMy0xLTEtNDY2NDI_5a4f7b62-513e-4489-bea5-1348d1553b57"
      unitRef="usd">3003000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfMTAtNS0xLTEtNDY2NDI_85c9279a-9450-4d25-96d7-11d097afb5ec"
      unitRef="usd">1507000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfMTAtNy0xLTEtNTMzMTY_896d5631-7baf-4e7e-8602-4d1ca0ce24fe"
      unitRef="usd">5815000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmM4MGIzMGU2ZWQ1OTQzYjk5ZWE2NGY3MTJhMzU4ODUzL3RhYmxlcmFuZ2U6YzgwYjMwZTZlZDU5NDNiOTllYTY0ZjcxMmEzNTg4NTNfMTAtOS0xLTEtNTMzNTY_eecb3c5f-bfb9-47f1-ac20-2818f7c71065"
      unitRef="usd">2963000</us-gaap:LeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfNTQ5NzU1ODE3MDMw_43f993c7-a601-4b42-92e6-61caf8a96f75"
      unitRef="usd">400000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfNTQ5NzU1ODE3MDM4_e84537b8-5f28-4a22-b0af-8807c730d498"
      unitRef="usd">300000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfNTQ5NzU1ODE3MDQ1_17ffc282-d77e-4a2f-b33c-d6e960dc296c"
      unitRef="usd">700000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfNTQ5NzU1ODE3MDUy_902410d5-cf5f-427d-9799-4c7b2c5200c1"
      unitRef="usd">500000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RleHRyZWdpb246NGE4OTdiYWE3ZjU4NDUxM2EwODMyZWU2Y2UyZWUxODdfMzAxMg_4b891fd9-3962-4396-ae13-74c826e2bdb8">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents payments of operating lease liabilities on an undiscounted basis as of March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2023 (remainder of fiscal year)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;3,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;8,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;11,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;12,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;11,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;102,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;149,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(66,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total operating lease liabilities (includes current portion)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;82,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.969%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating cash flows from operating leases (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmRjZmUzOGM4OWM1ZjQyMTY5OTg0MDVjMTA5NTM3ZjVkL3RhYmxlcmFuZ2U6ZGNmZTM4Yzg5YzVmNDIxNjk5ODQwNWMxMDk1MzdmNWRfMi0xLTEtMS00NjY0Mg_5e5c8648-73b3-4839-9c9f-fcd7710f4d7c"
      unitRef="usd">3070000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmRjZmUzOGM4OWM1ZjQyMTY5OTg0MDVjMTA5NTM3ZjVkL3RhYmxlcmFuZ2U6ZGNmZTM4Yzg5YzVmNDIxNjk5ODQwNWMxMDk1MzdmNWRfMy0xLTEtMS00NjY0Mg_0a7b5950-9075-4d51-8f58-c1caf33ac293"
      unitRef="usd">8094000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmRjZmUzOGM4OWM1ZjQyMTY5OTg0MDVjMTA5NTM3ZjVkL3RhYmxlcmFuZ2U6ZGNmZTM4Yzg5YzVmNDIxNjk5ODQwNWMxMDk1MzdmNWRfNC0xLTEtMS00NjY0Mg_7625f58b-8ef3-4a66-920f-0bb6fd9e91ca"
      unitRef="usd">11800000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmRjZmUzOGM4OWM1ZjQyMTY5OTg0MDVjMTA5NTM3ZjVkL3RhYmxlcmFuZ2U6ZGNmZTM4Yzg5YzVmNDIxNjk5ODQwNWMxMDk1MzdmNWRfNS0xLTEtMS00NjY0Mg_5de8ca92-c498-47ea-9a17-15f33692f942"
      unitRef="usd">12138000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmRjZmUzOGM4OWM1ZjQyMTY5OTg0MDVjMTA5NTM3ZjVkL3RhYmxlcmFuZ2U6ZGNmZTM4Yzg5YzVmNDIxNjk5ODQwNWMxMDk1MzdmNWRfNi0xLTEtMS00NjY0Mg_c75eda20-e66a-45d3-8385-2a0193cbbb7a"
      unitRef="usd">11297000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <arwr:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmRjZmUzOGM4OWM1ZjQyMTY5OTg0MDVjMTA5NTM3ZjVkL3RhYmxlcmFuZ2U6ZGNmZTM4Yzg5YzVmNDIxNjk5ODQwNWMxMDk1MzdmNWRfNy0xLTEtMS00NjY0Mg_436b9cf9-6937-490d-aeb0-3bc2d3c6ad95"
      unitRef="usd">102813000</arwr:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmRjZmUzOGM4OWM1ZjQyMTY5OTg0MDVjMTA5NTM3ZjVkL3RhYmxlcmFuZ2U6ZGNmZTM4Yzg5YzVmNDIxNjk5ODQwNWMxMDk1MzdmNWRfOC0xLTEtMS00NjY0Mg_9a97bd54-67e2-473e-bc80-23ed992a3471"
      unitRef="usd">149212000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmRjZmUzOGM4OWM1ZjQyMTY5OTg0MDVjMTA5NTM3ZjVkL3RhYmxlcmFuZ2U6ZGNmZTM4Yzg5YzVmNDIxNjk5ODQwNWMxMDk1MzdmNWRfOS0xLTEtMS00NjY0Mg_91ed4656-b61b-4209-9461-9f2a36235c6b"
      unitRef="usd">66431000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOmRjZmUzOGM4OWM1ZjQyMTY5OTg0MDVjMTA5NTM3ZjVkL3RhYmxlcmFuZ2U6ZGNmZTM4Yzg5YzVmNDIxNjk5ODQwNWMxMDk1MzdmNWRfMTAtMS0xLTEtNDY2NDI_081b82cb-aae3-4330-802b-ef87b1e8631e"
      unitRef="usd">82781000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOjZkMDFjMzVmYzMxYjQ2ZTViZTFiNjhhOGEzNTIzZWJiL3RhYmxlcmFuZ2U6NmQwMWMzNWZjMzFiNDZlNWJlMWI2OGE4YTM1MjNlYmJfMy0yLTEtMS00NjY0Mg_395e9ecc-c26d-4e13-aa23-97f99abd5fe1"
      unitRef="usd">2503000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOjZkMDFjMzVmYzMxYjQ2ZTViZTFiNjhhOGEzNTIzZWJiL3RhYmxlcmFuZ2U6NmQwMWMzNWZjMzFiNDZlNWJlMWI2OGE4YTM1MjNlYmJfMy00LTEtMS00NjY0Mg_01eeae30-d2fa-4b15-9797-49211ad24a64"
      unitRef="usd">2171000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOjZkMDFjMzVmYzMxYjQ2ZTViZTFiNjhhOGEzNTIzZWJiL3RhYmxlcmFuZ2U6NmQwMWMzNWZjMzFiNDZlNWJlMWI2OGE4YTM1MjNlYmJfNS0yLTEtMS00NjY0Mg_f92ca510-0b52-4ac1-8859-74464a27b595">P6Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i2b1b88ad17754cd781fd0282509470f4_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOjZkMDFjMzVmYzMxYjQ2ZTViZTFiNjhhOGEzNTIzZWJiL3RhYmxlcmFuZ2U6NmQwMWMzNWZjMzFiNDZlNWJlMWI2OGE4YTM1MjNlYmJfNS00LTEtMS00NjY0Mg_5cc043fc-1a59-44f0-ac86-4d51e52a3a2b">P7Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOjZkMDFjMzVmYzMxYjQ2ZTViZTFiNjhhOGEzNTIzZWJiL3RhYmxlcmFuZ2U6NmQwMWMzNWZjMzFiNDZlNWJlMWI2OGE4YTM1MjNlYmJfNi0yLTEtMS00NjY0Mg_7ba26c9c-9072-498b-88ed-d85d40465ffc"
      unitRef="number">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i2b1b88ad17754cd781fd0282509470f4_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81Mi9mcmFnOjRhODk3YmFhN2Y1ODQ1MTNhMDgzMmVlNmNlMmVlMTg3L3RhYmxlOjZkMDFjMzVmYzMxYjQ2ZTViZTFiNjhhOGEzNTIzZWJiL3RhYmxlcmFuZ2U6NmQwMWMzNWZjMzFiNDZlNWJlMWI2OGE4YTM1MjNlYmJfNi00LTEtMS00NjY0Mg_f00445ed-9d55-4059-9b8f-481f2b6c450c"
      unitRef="number">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfNDg0NQ_624efc4b-b585-4d4a-8d97-68e0842011b9">STOCK-BASED COMPENSATION&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has three plans that provide for equity-based compensation. Under the 2004 Equity Incentive Plan (the &#x201c;2004 Plan&#x201d;) and 2013 Incentive Plan (the &#x201c;2013 Plan&#x201d;), 173,983 and 3,518,957 shares, respectively, of the Company&#x2019;s common stock are reserved for the grant of stock options, stock appreciation rights, restricted stock awards and performance unit/share awards to employees, consultants and others as of March&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 18, 2021, the Company&#x2019;s Board of Directors approved the Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan (the &#x201c;2021 Plan&#x201d;), which authorizes 8,000,000 shares (subject to certain adjustments) to be awarded for grants of stock options, stock appreciation rights, restricted and unrestricted stock and stock units, performance awards, cash awards and other awards convertible into or otherwise based on shares of the Company&#x2019;s common stock. The maximum number of shares authorized under the 2021 Plan will be (i) reduced by any shares subject to awards made under the 2013 Plan after January 1, 2021, and (ii) increased by any shares subject to outstanding awards under the 2013 Plan as of January 1, 2021 that, after January 1, 2021, are canceled, expired, forfeited or otherwise not issued under such awards (other than as a result of being tendered or withheld to pay the exercise price or withholding taxes in connection with any such awards) or settled in cash. As of March&#160;31, 2023, the total number of shares reserved for issuance under the 2021 Incentive Plan was 6,126,788 shares, which includes 139,053 shares that were forfeited under the 2013 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, there were 743,726 shares reserved for options and 738,875 shares reserved for restricted stock units issued as inducement grants to new employees granted outside of the Company&#x2019;s equity-based compensation plans under Rule 5635(c)(4) of the Nasdaq Listing Rules.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of awards outstanding:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.711%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2004 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2013 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Inducement Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Granted and outstanding awards:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;173,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,629,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;35,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;743,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,582,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,889,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,701,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;738,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,330,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;173,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,518,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,737,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,482,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,912,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the stock option activity for the six months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,721,384&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;20.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;32,151&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;33.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Cancelled or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(25,581)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;58.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(145,637)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;7.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,582,317&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;21.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;30,107,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Exercisable at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,348,193&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;18.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;30,100,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic values represents the amount by which the market price of the underlying stock exceeds the exercise price of the option. The total intrinsic value of the options exercised during the three months ended March&#160;31, 2023 and 2022 was $1.4 million and $10.8 million, respectively. The total intrinsic value of the options exercised during the six months ended March&#160;31, 2023 and 2022 was $3.6 million and $23.3 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense related to stock options outstanding for the three months ended March&#160;31, 2023 and 2022, was $2.2 million and $2.7 million, respectively. Stock-based compensation expense related to stock options for the six months ended March&#160;31, 2023 and 2022 was $4.6 million and $5.7 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the pre-tax compensation expense for all outstanding unvested stock options in the amount of $7.6 million will be recognized in the Company&#x2019;s results of operations over a weighted average period of 1.0 year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#x2019;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company&#x2019;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the assumptions used in the calculation of grant-date fair values of these stock options based on the Back-Scholes option pricing model:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Six Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Expected dividend yield&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:114%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:114%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:114%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;86.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Expected term (in years)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:114%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Weighted average grant date fair value per share of options granted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:114%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;24.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) The dividend yield is zero as the Company currently does not pay a dividend. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(2) The risk-free interest rate is based on that of the U.S. Treasury yields with equivalent terms in effect at the time of the grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(3) Volatility is estimated based on volatility average of the Company&#x2019;s common stock price. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(4) The expected term represents the period of time that stock options granted are expected to be outstanding, by using historical exercise patterns and post-vesting termination behavior. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(5) No options were granted during the six months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units (&#x201c;RSUs&#x201d;), including market-based, time-based and performance-based awards, have been granted under the Company&#x2019;s 2013 and 2021 Plans and as inducements grants granted outside of the Company&#x2019;s equity-based compensation plans. At vesting, each outstanding RSU will be exchanged for one share of the Company&#x2019;s common stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity of the Company&#x2019;s RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date&lt;br/&gt;Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4,069,431&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;62.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;1,098,544&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;34.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(763,132)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;54.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(74,500)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;57.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4,330,343&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;57.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of RSUs was determined based on the closing price of the Company&#x2019;s common stock on the grant date, with consideration given to the probability of achieving service and/or performance conditions for awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2023 and 2022, the Company recorded $18.4 million and $28.2 million of expense related to RSUs, respectively. For the six months ended March&#160;31, 2023 and 2022, the Company recorded $35.4 million and $49.7 million of expense related RSUs, respectively. As of March&#160;31, 2023, there was $153.6 million of total unrecognized compensation cost related to RSUs that is expected to be recognized over a weighted-average period of 2.5 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i0eb27783d00443259f37672e22a51d89_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMjA4_31a28fd5-3b17-4944-956a-c119de600ff5"
      unitRef="shares">173983</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="i6f8f5aa4479d4452a8f944d74f31a91a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMjc0ODc3OTA3NDI5Ng_499c2b9e-4eb4-4252-b3f7-1d70d24f168b"
      unitRef="shares">3518957</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i6f8f5aa4479d4452a8f944d74f31a91a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMjc0ODc3OTA3NDI5Ng_9f0f12f7-fc94-4b59-b541-0607970f970b"
      unitRef="shares">3518957</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i474bf33fa2dd4412b27d2d7dadd0143f_I20210318"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfNjAx_ab34b581-d780-463f-ae69-3e96a755d022"
      unitRef="shares">8000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i85d0e738f7ad46a78439146ca6b1ce57_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMTUxMA_c2b80836-5913-4aa4-b847-ea9307977e79"
      unitRef="shares">6126788</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ia821a22f759c491095cdffcc22a16326_D20221001-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMTUzNg_cd996014-9ed1-459b-a157-8307a679ebc3"
      unitRef="shares">139053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i82aee549d7ee4c17a0af2cb7b4160c1d_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMTYxMg_de5665e2-128e-4fb6-a62d-88b67208aa2d"
      unitRef="shares">743726</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i415e58bd2ac14492bc9b71cfcaa0eb68_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMTY0Nw_f867709e-32fb-4aac-b0a7-4ac6711847c8"
      unitRef="shares">738875</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfNDg0Mg_8465ea04-7fb0-4288-9166-0dfec185a652">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of awards outstanding:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.711%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2004 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2013 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Inducement Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Granted and outstanding awards:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;173,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,629,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;35,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;743,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,582,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,889,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,701,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;738,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,330,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;173,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,518,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,737,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,482,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,912,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0eb27783d00443259f37672e22a51d89_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfMy0xLTEtMS00NjY0Mg_2b068925-6b09-45dc-8702-8e5045d8a713"
      unitRef="shares">173983</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6f8f5aa4479d4452a8f944d74f31a91a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfMy0zLTEtMS00NjY0Mg_ec4ee187-0bd5-43fe-a32c-2a405490df00"
      unitRef="shares">1629457</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i85d0e738f7ad46a78439146ca6b1ce57_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfMy01LTEtMS00NjY0Mg_7b1f9c62-9031-45f8-bd2e-ec4993790b5a"
      unitRef="shares">35151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i3814d26ffec743bdbd368c8d17e1c599_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfMy03LTEtMS00NjY0Mg_3901a358-e391-4a1a-aba4-41c83c28dd3b"
      unitRef="shares">743726</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfMy05LTEtMS00NjY0Mg_1f121558-d145-4e22-8533-df72dc700de9"
      unitRef="shares">2582317</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i513ac43a6b4641d5aa151e55bdb1adb8_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfNC0xLTEtMS00NjY0Mg_2a6b15df-6c0a-4790-9f99-afc1f6c50fec"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ife4b80c909b0481bb55da5cc80d82206_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfNC0zLTEtMS00NjY0Mg_81b7161b-a715-4c0a-b5e4-ef2e48dbf714"
      unitRef="shares">1889500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i6930053b987b4dcb9ec1e29905995970_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfNC01LTEtMS00NjY0Mg_65cc24db-59fb-4dad-a2d5-28717b7172b0"
      unitRef="shares">1701968</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i415e58bd2ac14492bc9b71cfcaa0eb68_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfNC03LTEtMS00NjY0Mg_9b7c9724-dbda-4f03-a561-c111ab5e993d"
      unitRef="shares">738875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib6cd39bcc4aa4f2bb3274f9594d5294a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfNC05LTEtMS00NjY0Mg_ad4f0a0f-c5e0-496c-b289-f32b9bba3ae2"
      unitRef="shares">4330343</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="i0eb27783d00443259f37672e22a51d89_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfNS0xLTEtMS00NjY0Mg_a03f9258-0216-4356-ab0b-34fe6f878835"
      unitRef="shares">173983</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="i6f8f5aa4479d4452a8f944d74f31a91a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfNS0zLTEtMS00NjY0Mg_499c2b9e-4eb4-4252-b3f7-1d70d24f168b"
      unitRef="shares">3518957</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i6f8f5aa4479d4452a8f944d74f31a91a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfNS0zLTEtMS00NjY0Mg_9f0f12f7-fc94-4b59-b541-0607970f970b"
      unitRef="shares">3518957</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="i85d0e738f7ad46a78439146ca6b1ce57_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfNS01LTEtMS00NjY0Mg_5ed782b2-db91-4176-bd26-92878cd7ec35"
      unitRef="shares">1737119</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="i3814d26ffec743bdbd368c8d17e1c599_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfNS03LTEtMS00NjY0Mg_a59f2f60-1d1f-43aa-b72d-0a60a0a30c3e"
      unitRef="shares">1482601</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjY1YWFjM2Y5N2FjZDQ0YWM5OWU3NTY5ZDkxMmUwZWY0L3RhYmxlcmFuZ2U6NjVhYWMzZjk3YWNkNDRhYzk5ZTc1NjlkOTEyZTBlZjRfNS05LTEtMS00NjY0Mg_95893998-9e39-4c04-8cf6-2ba25100cbc8"
      unitRef="shares">6912660</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfNDg0Mw_a2b9f15c-b5da-4f6c-8fe5-801659264b94">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the stock option activity for the six months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,721,384&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;20.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;32,151&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;33.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Cancelled or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(25,581)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;58.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(145,637)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;7.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,582,317&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;21.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;30,107,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Exercisable at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,348,193&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;18.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;30,100,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfMS0xLTEtMS00NjY0Mg_c746cdf6-6543-4f34-a2fc-c3e24f5940bc"
      unitRef="shares">2721384</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i0f0b57d9696a4178850cfeeb887a0527_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfMS0zLTEtMS00NjY0Mg_89d4a25e-5765-430e-8f17-60b2f17ee0d6"
      unitRef="usdPerShare">20.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfMi0xLTEtMS00NjY0Mg_0147ce4c-2172-43b5-bfd2-ef870fdfe3f9"
      unitRef="shares">32151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfMi0zLTEtMS00NjY0Mg_64da63e5-04fb-4914-a763-565656a491c7"
      unitRef="usdPerShare">33.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfMy0xLTEtMS00NjY0Mg_e2236dd1-b738-4fb8-9ef2-84ec64b34a71"
      unitRef="shares">25581</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfMy0zLTEtMS00NjY0Mg_f020b441-5d8b-4cfe-8c0c-1cd03a547b79"
      unitRef="usdPerShare">58.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfNC0xLTEtMS00NjY0Mg_ed323ba3-a284-4008-9424-a48fc77cd7c4"
      unitRef="shares">145637</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfNC0zLTEtMS00NjY0Mg_a9926038-4ba8-4f7e-94bf-09ea700097af"
      unitRef="usdPerShare">7.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfNS0xLTEtMS00NjY0Mg_4187b4b1-89b1-4e4a-8162-aac30ddf2580"
      unitRef="shares">2582317</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfNS0zLTEtMS00NjY0Mg_7e5eb66c-1a89-444e-8ac2-bc06f9dd1054"
      unitRef="usdPerShare">21.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfNS01LTEtMS00NjY0Mg_e285a4ab-63e5-40a1-a5f9-cda23f21d74f">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfNS03LTEtMS00NjY0Mg_ae0d43f6-1f0d-4b9e-8e2f-cc0a7b7bcbb0"
      unitRef="usd">30107439</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfNi0xLTEtMS00NjY0Mg_d4a13504-1368-4214-84a4-afcee7507d8e"
      unitRef="shares">2348193</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfNi0zLTEtMS00NjY0Mg_62dc77da-3444-471d-a34d-70e15818dfcb"
      unitRef="usdPerShare">18.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfNi01LTEtMS00NjY0Mg_16757f4d-1af3-4283-b192-93d5cc940b0d">P4Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i8658828dac144310891d79034519aac1_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOmUzMzAyN2RmMmQ1NDQ3ZDFhOWJjYzFiNzZiODY2N2ZlL3RhYmxlcmFuZ2U6ZTMzMDI3ZGYyZDU0NDdkMWE5YmNjMWI3NmI4NjY3ZmVfNi03LTEtMS00NjY0Mg_9023b2d6-f3f5-45a8-a278-832a30a0c557"
      unitRef="usd">30100306</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ie621a6d7b2894935b2a8275238e99a30_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMjQyNQ_93b094f9-6b16-4f5f-9486-0b8da6c27e95"
      unitRef="usd">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="id48977f119694d19b519cfbd1b536975_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMjQzMg_12480c50-816a-46ad-824f-c4c16c8aabcd"
      unitRef="usd">10800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i9390b1d02afc409d88c4726d14169331_D20221001-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfNTQ5NzU1ODE5NjEz_3fbad3b1-c646-413d-8a90-def2d5e34fc0"
      unitRef="usd">3600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i3a8a84b6b8274985b99c61c1887f17e4_D20211001-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfNTQ5NzU1ODE5NjQ1_bc190aa8-bac9-435a-a70d-3f9f85197448"
      unitRef="usd">23300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie621a6d7b2894935b2a8275238e99a30_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMjU2Mg_19e5df5e-be75-4a22-ac0f-7da9ba2f8e0c"
      unitRef="usd">2200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id48977f119694d19b519cfbd1b536975_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMjU2OQ_8af653ed-e833-44e4-8a00-4dbffba646bb"
      unitRef="usd">2700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9390b1d02afc409d88c4726d14169331_D20221001-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfOTM0NTg0ODg0MTM0NQ_abb5a5f4-1c39-4ddf-9bda-3c0245ad8599"
      unitRef="usd">4600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3a8a84b6b8274985b99c61c1887f17e4_D20211001-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfNTQ5NzU1ODE5NjMy_f6dc5959-29ef-4e9a-958c-bc39d5b7ad73"
      unitRef="usd">5700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="icd78c85c0ede4725b46aebc7e69ca686_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMjY5MQ_a6363d02-1a13-4686-8ba2-e58119289ffd"
      unitRef="usd">7600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ie621a6d7b2894935b2a8275238e99a30_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMzI5ODUzNDg4OTA5NQ_f73a3266-7d22-45be-9027-b20670e3a88f">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMzI5ODUzNDg5MjI2Mg_46495058-2938-4d44-9e03-f331d0db9e3a">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the assumptions used in the calculation of grant-date fair values of these stock options based on the Back-Scholes option pricing model:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Six Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Expected dividend yield&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:114%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:114%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:114%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;86.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Expected term (in years)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:114%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Weighted average grant date fair value per share of options granted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:114%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;24.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) The dividend yield is zero as the Company currently does not pay a dividend. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(2) The risk-free interest rate is based on that of the U.S. Treasury yields with equivalent terms in effect at the time of the grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(3) Volatility is estimated based on volatility average of the Company&#x2019;s common stock price. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(4) The expected term represents the period of time that stock options granted are expected to be outstanding, by using historical exercise patterns and post-vesting termination behavior. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(5) No options were granted during the six months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjA5NWY3YjA1NGE2ZDRmZDM5YTI3NDM2ZDdkYzY4YzdkL3RhYmxlcmFuZ2U6MDk1ZjdiMDU0YTZkNGZkMzlhMjc0MzZkN2RjNjhjN2RfMi0xLTEtMS01OTY5Mg_51363651-f444-4269-846e-800dfeb0df5a"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjA5NWY3YjA1NGE2ZDRmZDM5YTI3NDM2ZDdkYzY4YzdkL3RhYmxlcmFuZ2U6MDk1ZjdiMDU0YTZkNGZkMzlhMjc0MzZkN2RjNjhjN2RfMy0xLTEtMS01OTY5Mg_399739a7-144d-4eac-95ca-e7635a24e5b8"
      unitRef="number">0.0369</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjA5NWY3YjA1NGE2ZDRmZDM5YTI3NDM2ZDdkYzY4YzdkL3RhYmxlcmFuZ2U6MDk1ZjdiMDU0YTZkNGZkMzlhMjc0MzZkN2RjNjhjN2RfNC0xLTEtMS01OTY5Mg_6f89d120-44c6-4062-bfac-3a4ad2b1b694"
      unitRef="number">0.864</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjA5NWY3YjA1NGE2ZDRmZDM5YTI3NDM2ZDdkYzY4YzdkL3RhYmxlcmFuZ2U6MDk1ZjdiMDU0YTZkNGZkMzlhMjc0MzZkN2RjNjhjN2RfNS0xLTEtMS01OTY5Mg_e10af671-7f45-46c4-8cad-938e48793730">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjA5NWY3YjA1NGE2ZDRmZDM5YTI3NDM2ZDdkYzY4YzdkL3RhYmxlcmFuZ2U6MDk1ZjdiMDU0YTZkNGZkMzlhMjc0MzZkN2RjNjhjN2RfNi0xLTEtMS01OTY5Mg_b0377c51-8b6b-44cd-833e-badfe4632142"
      unitRef="usdPerShare">24.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfMzI5ODUzNDg5MjI2Mw_68ef4ffd-260d-494d-ac41-3bee99cbb459"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfNDg0MQ_52ab47d6-59f0-410c-9a52-27815bb94471">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity of the Company&#x2019;s RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date&lt;br/&gt;Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4,069,431&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;62.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;1,098,544&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;34.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(763,132)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;54.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(74,500)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;57.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4,330,343&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;57.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id9777e3d0f0044f9a5ae125314a8b62e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjU4YzM0Y2E2MGQyZTQyYjJhNzc4OTVmYzQxMTRiZWE1L3RhYmxlcmFuZ2U6NThjMzRjYTYwZDJlNDJiMmE3Nzg5NWZjNDExNGJlYTVfMS0xLTEtMS00NjY0Mg_626da335-cf21-454b-b80e-407381dcfe5b"
      unitRef="shares">4069431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id9777e3d0f0044f9a5ae125314a8b62e_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjU4YzM0Y2E2MGQyZTQyYjJhNzc4OTVmYzQxMTRiZWE1L3RhYmxlcmFuZ2U6NThjMzRjYTYwZDJlNDJiMmE3Nzg5NWZjNDExNGJlYTVfMS0zLTEtMS00NjY0Mg_4dea1ccb-d0b0-4ce3-a95a-ecb222522e3a"
      unitRef="usdPerShare">62.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ied3ebc51b45741a1b31064cbf68604f1_D20221001-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjU4YzM0Y2E2MGQyZTQyYjJhNzc4OTVmYzQxMTRiZWE1L3RhYmxlcmFuZ2U6NThjMzRjYTYwZDJlNDJiMmE3Nzg5NWZjNDExNGJlYTVfMi0xLTEtMS00NjY0Mg_28ba23eb-99b8-4cf3-bb57-b3d1e58af1c7"
      unitRef="shares">1098544</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ied3ebc51b45741a1b31064cbf68604f1_D20221001-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjU4YzM0Y2E2MGQyZTQyYjJhNzc4OTVmYzQxMTRiZWE1L3RhYmxlcmFuZ2U6NThjMzRjYTYwZDJlNDJiMmE3Nzg5NWZjNDExNGJlYTVfMi0zLTEtMS00NjY0Mg_15a3c528-2c93-40d0-86ab-3d4b5a04e92e"
      unitRef="usdPerShare">34.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ied3ebc51b45741a1b31064cbf68604f1_D20221001-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjU4YzM0Y2E2MGQyZTQyYjJhNzc4OTVmYzQxMTRiZWE1L3RhYmxlcmFuZ2U6NThjMzRjYTYwZDJlNDJiMmE3Nzg5NWZjNDExNGJlYTVfMy0xLTEtMS00NjY0Mg_f10c8120-67a3-4157-a14b-516be876f8ac"
      unitRef="shares">763132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ied3ebc51b45741a1b31064cbf68604f1_D20221001-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjU4YzM0Y2E2MGQyZTQyYjJhNzc4OTVmYzQxMTRiZWE1L3RhYmxlcmFuZ2U6NThjMzRjYTYwZDJlNDJiMmE3Nzg5NWZjNDExNGJlYTVfMy0zLTEtMS00NjY0Mg_806275c4-e084-4a73-9bff-26d818dfad93"
      unitRef="usdPerShare">54.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ied3ebc51b45741a1b31064cbf68604f1_D20221001-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjU4YzM0Y2E2MGQyZTQyYjJhNzc4OTVmYzQxMTRiZWE1L3RhYmxlcmFuZ2U6NThjMzRjYTYwZDJlNDJiMmE3Nzg5NWZjNDExNGJlYTVfNC0xLTEtMS00NjY0Mg_a75b6b9b-bdb3-4b55-bab8-bc97c08a298a"
      unitRef="shares">74500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ied3ebc51b45741a1b31064cbf68604f1_D20221001-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjU4YzM0Y2E2MGQyZTQyYjJhNzc4OTVmYzQxMTRiZWE1L3RhYmxlcmFuZ2U6NThjMzRjYTYwZDJlNDJiMmE3Nzg5NWZjNDExNGJlYTVfNC0zLTEtMS00NjY0Mg_14edda48-3b6f-4e20-afd1-c93ff29e2a11"
      unitRef="usdPerShare">57.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib6cd39bcc4aa4f2bb3274f9594d5294a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjU4YzM0Y2E2MGQyZTQyYjJhNzc4OTVmYzQxMTRiZWE1L3RhYmxlcmFuZ2U6NThjMzRjYTYwZDJlNDJiMmE3Nzg5NWZjNDExNGJlYTVfNS0xLTEtMS00NjY0Mg_12b3ee7c-f2dc-4800-8e3d-97275bdc9ece"
      unitRef="shares">4330343</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ib6cd39bcc4aa4f2bb3274f9594d5294a_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RhYmxlOjU4YzM0Y2E2MGQyZTQyYjJhNzc4OTVmYzQxMTRiZWE1L3RhYmxlcmFuZ2U6NThjMzRjYTYwZDJlNDJiMmE3Nzg5NWZjNDExNGJlYTVfNS0zLTEtMS00NjY0Mg_256fb540-72cd-41e7-b6df-7dca48efbbef"
      unitRef="usdPerShare">57.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib2c010a50c4c41249cf51a81f611ddb4_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfOTM0NTg0ODg0MTUyOA_36c9f74e-fd94-41d5-b67a-caaced790fea"
      unitRef="usd">18400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i805db888d835420986d4e8a91b283687_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfOTM0NTg0ODg0MTYwMg_80f3b67d-4f11-41cd-b373-885e4c2c6685"
      unitRef="usd">28200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ied3ebc51b45741a1b31064cbf68604f1_D20221001-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfOTM0NTg0ODg0MTQwMw_5c52b424-02ed-4fa7-9151-9536a80b6e94"
      unitRef="usd">35400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i17e779fd14684b3e966d950f0421cb5d_D20211001-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfOTM0NTg0ODg0MTQyNw_ce02b5d9-fcad-4256-8bcc-4151d3d0e84e"
      unitRef="usd">49700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="ib6cd39bcc4aa4f2bb3274f9594d5294a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfOTM0NTg0ODg0MTY1Mg_7938242f-a2cb-4e39-a29a-890c813c523c"
      unitRef="usd">153600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ied3ebc51b45741a1b31064cbf68604f1_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81NS9mcmFnOjdhYmFlYWYzNmJlZjQ3YzFiZjdmYmY4MjY2OGIzMmZmL3RleHRyZWdpb246N2FiYWVhZjM2YmVmNDdjMWJmN2ZiZjgyNjY4YjMyZmZfOTM0NTg0ODg0MTY3MQ_8a8e1150-ca2f-4e33-9b51-bad8c5f1aa4c">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RleHRyZWdpb246OGJiOWUwNTJiZTJkNDE1MGI3YWQ5ZWU2NWI4NDhhMGNfMzAzMw_32dc6ef2-6182-4979-8248-26ccddf3081d">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company employs a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value of a financial instrument is the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date using the exit price. Accordingly, when market observable data are not readily available, the Company&#x2019;s own assumptions are used to reflect those that market participants would be presumed to use in pricing the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities recorded at fair value on the consolidated balance sheets are categorized based on the level of judgment associated with inputs used to measure their fair values and the level of market price observability, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1&#160;&#160;&#160;&#160;Unadjusted quoted prices are available in active markets for identical assets or liabilities as of the  reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2&#160;&#160;&#160;&#160;Pricing inputs are other than quoted prices in active markets, which are based on the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;     Quoted prices for similar assets or liabilities in active markets;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;     Quoted prices for identical or similar assets or liabilities in non-active markets; or&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;     Either directly or indirectly observable inputs as of the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3&#160;&#160;&#160;&#160;Pricing inputs are unobservable and significant to the overall fair value measurement, and the determination of fair value requires significant management judgment or estimation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. Thus, a Level 3 fair value measurement may include inputs that are observable (Level 1 or Level 2) and unobservable (Level 3). The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and consideration of factors specific to the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses prices and inputs that are current as of the measurement date, including during periods of market disruption. In periods of market disruption, the ability to observe prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level 1 to Level 2, or from Level 2 to Level 3. The Company recognizes transfers between levels at either the actual date of the event or a change in circumstances that caused the transfer. At March&#160;31, 2023 and September&#160;30, 2022, the Company did not have any financial assets or financial liabilities based on Level 3 measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information about the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques utilized by the Company:  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.194%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.077%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. government bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;23,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;23,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;95,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;95,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;306,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;306,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;53,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;53,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.194%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.077%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. government bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;41,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;41,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;271,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;271,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;39,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;39,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RleHRyZWdpb246OGJiOWUwNTJiZTJkNDE1MGI3YWQ5ZWU2NWI4NDhhMGNfMzAzNA_4277abce-40f5-4078-9b28-5e52817d995a">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information about the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques utilized by the Company:  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.194%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.077%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. government bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;23,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;23,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;95,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;95,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;306,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;306,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;53,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;53,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.194%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.077%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. government bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;41,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;41,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;271,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;271,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;39,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;39,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ia24340fff8444dbb848ee908a5350d12_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNC0xLTEtMS00NjY0Mg_724dc5eb-6c5a-4c9a-b36d-ee494173e599"
      unitRef="usd">23074000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i2860ca5f992241c38da43e79e2b1c5f5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNC0zLTEtMS00NjY0Mg_5276bb09-5f92-4e47-ba03-c95aad6035b6"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i8730e93a554e482bbc30293e7122903d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNC01LTEtMS00NjY0Mg_dc43237d-d17c-451b-a82a-f96e7c0ff272"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i9e07cc9368c3473882925939ec3292a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNC03LTEtMS00NjY0Mg_6f888bb7-cc59-4f05-9078-525fa0646c62"
      unitRef="usd">23074000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="if5e50e79a52647fd8ae13612e15c69cf_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNS0xLTEtMS01MzQzMw_9ac07017-1fba-4818-bead-ff4be70a8619"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i9a17cbdd764b419ab72a0c4122118bba_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNS0zLTEtMS01MzQzMw_0c351a5d-0908-4982-86f5-ab4a612a459e"
      unitRef="usd">7034000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i5266edfdef7545fb95e73d3313d505d6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNS01LTEtMS01MzQzMw_a5a330a4-e7de-4c12-90a8-4dc8730cee19"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i8049c9628c0e483abd37d06554b9e7d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNS03LTEtMS01MzQzMw_ccc27183-8359-41a8-aad5-a163d6769bce"
      unitRef="usd">7034000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ib089174a5cf348c1802beeaa2b977442_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNS0xLTEtMS00NjY0Mg_5561dc4d-0720-43ac-b9d2-23da17f4be42"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ib16740a1de40482aba6561a9747b4a94_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNS0zLTEtMS00NjY0Mg_45b0e64c-4d1e-4853-b1c7-4c2a1aeaadd3"
      unitRef="usd">95786000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i75aef6171137470d8e8e9cb8a2a83af6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNS01LTEtMS00NjY0Mg_0db0083c-e63b-45a0-a291-abc7e35212b7"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i2164b78caabc43fda358fdbd89914f21_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNS03LTEtMS00NjY0Mg_1139c951-d309-463c-b329-cc07e5616684"
      unitRef="usd">95786000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i5e3601b78983427db6b155d1b0307701_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNi0xLTEtMS00NjY0Mg_bfc9c6f7-7fe1-4fb2-8164-1da99843291f"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ib1b3c3e0baf84de3bd52125e28ec4b76_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNi0zLTEtMS00NjY0Mg_5dccd698-3069-4e92-af3d-9518be8da98f"
      unitRef="usd">306950000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i9f174aafdabf4608bf7c653ec8825fdd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNi01LTEtMS00NjY0Mg_6b720efd-3e86-43dd-85e0-4ead1d863e0a"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="if15ee248bfc441c796bf3f458c740ed7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNi03LTEtMS00NjY0Mg_cd04e9c3-5780-4a0d-972b-af57a1ef2e20"
      unitRef="usd">306950000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia24fba933c2d4cd0b16bded19b1bb09c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNy0xLTEtMS00NjY0Mg_a9670593-5f03-4714-ba63-cf1b8b4760c1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5fbaa59436d843fe988d685090ab4af0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNy0zLTEtMS00NjY0Mg_dbe58e0a-c99e-4e8e-8a83-17f5aadcd185"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if043a0f1a28f41ad9782a0f46b2240b1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNy01LTEtMS00NjY0Mg_8d4d7a56-2d87-47a9-876b-77b530d92b09"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3a07989748524f1f9e510ca832e4367d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfNy03LTEtMS00NjY0Mg_311118ee-f607-4804-91ab-0d8985b55b62"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4ca3440b89af4805ae8534cd78394ea4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfOC0xLTEtMS00NjY0Mg_ca2afffd-85b2-40c4-8fb4-b9d490e95bfa"
      unitRef="usd">53743000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="idbc036b73a0349f8aeef68b475d74e60_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfOC0zLTEtMS00NjY0Mg_c945b078-adc4-4905-8348-cdf7ffa33b86"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0f8f0fdb41494916a8ccd82071a0dfa2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfOC01LTEtMS00NjY0Mg_fc981fdc-5d49-44a5-bfc0-f7c149cc4d5c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i04d5b678d5744ea1bb9862b56fd512dd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOjJlNmZmNGQwZjVjMDRhYzZiYzI2NDIxN2ZjODI4MGY3L3RhYmxlcmFuZ2U6MmU2ZmY0ZDBmNWMwNGFjNmJjMjY0MjE3ZmM4MjgwZjdfOC03LTEtMS00NjY0Mg_38664d95-991b-414f-ad07-6355167290ad"
      unitRef="usd">53743000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i1024c68fa8084ef7ba0a4aa7d7e3620a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNC0xLTEtMS00NjY0Mg_1cf29f2f-0de5-497a-a96d-a0f3f974769e"
      unitRef="usd">1973000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i37966ce3d820452881dc0a4feb57c9d8_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNC0zLTEtMS00NjY0Mg_2b181344-edd6-48b8-b7a6-f8b9a9d9bcc8"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i8e92174f5fd64f259dd75f387bad521c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNC01LTEtMS00NjY0Mg_dd25f7cd-2580-407b-9707-5824b19de236"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i1df1d8731bf74f8f93e44854a34edda1_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNC03LTEtMS00NjY0Mg_7e46a4d2-71b2-4b64-b013-4dcc1789f92e"
      unitRef="usd">1973000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i22bc3c1a36b14889bca7b7d519b1e3a1_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNS0xLTEtMS00NjY0Mg_89d351b5-c5d9-4a28-b778-ec770acfcc30"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i3fbe7cc097934385a0f7656c8c178477_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNS0zLTEtMS00NjY0Mg_04e7592d-b0fe-4d05-8339-4a11fa6cccbd"
      unitRef="usd">41727000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i14946c523e3c4c16a7a727f5f8768473_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNS01LTEtMS00NjY0Mg_1a0af1a4-89f0-4326-b737-26c627bbbb28"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ic88cc70b817c4141873c6deeb572df1c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNS03LTEtMS00NjY0Mg_1da03057-6eb4-4951-9100-68fb78a47c1b"
      unitRef="usd">41727000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="id6a9654ad2f04e9eb78471c7b782bdc0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNi0xLTEtMS00NjY0Mg_04b1625b-6cb9-4cb2-b3e8-5d84cdfc2b13"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i783e40d9f7b349e687c2fafc7b31322b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNi0zLTEtMS00NjY0Mg_ee6967bc-d48e-4a34-8e81-fcae7c6cab21"
      unitRef="usd">271333000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="if2cf83fb724d4e508f15e0cdb9fed5a5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNi01LTEtMS00NjY0Mg_e2eeaa68-e964-45cc-b7c1-1f6e84c13c67"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i2b8bc25ae7384b7b86bdeee4af8033ca_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNi03LTEtMS00NjY0Mg_0ed0587b-e1e6-4f93-b5a6-047e5dca80a5"
      unitRef="usd">271333000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5fe25e9421f84420b7997e575e069958_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNy0xLTEtMS00NjY0Mg_7eaa5aae-026b-441b-803f-7f5d9606f370"
      unitRef="usd">50000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibf039f9333f3461faaee52cf3325669f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNy0zLTEtMS00NjY0Mg_881f64f7-0a93-4b88-a51e-7f77ca7b82d9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2bbf95567b5f4f188e2a8249da064586_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNy01LTEtMS00NjY0Mg_5ca32dcf-0dc4-4b4d-891e-64d300c796ff"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2193adeae864400ea2611b5ffcc9bdf0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfNy03LTEtMS00NjY0Mg_adc7617b-8b95-4b6c-88e6-054e4a8e03fc"
      unitRef="usd">50000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i64d56047f58a464c9b4c5f44f3ce0413_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfOC0xLTEtMS00NjY0Mg_5e5ad9a0-d5bd-4534-8afe-774ce1212693"
      unitRef="usd">39262000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i213da95ed9fc43649772cb98aa5ba619_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfOC0zLTEtMS00NjY0Mg_bfb4719e-583e-4f63-93e2-8f7e13daf866"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3d13c9a5b243437ea4291fc58b35695b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfOC01LTEtMS00NjY0Mg_3cd79976-145a-4672-81a0-41b747b1b8e0"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie16b8c3eba024536a3a52b37dbdf8bd8_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl81OC9mcmFnOjhiYjllMDUyYmUyZDQxNTBiN2FkOWVlNjViODQ4YTBjL3RhYmxlOmM0MDcxZWNiOGNjYTQxZWNiYTEwMmFlY2U2ZDExN2EzL3RhYmxlcmFuZ2U6YzQwNzFlY2I4Y2NhNDFlY2JhMTAyYWVjZTZkMTE3YTNfOC03LTEtMS00NjY0Mg_cd7dc528-0d7d-468d-820d-9695866c0b0c"
      unitRef="usd">39262000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl82MS9mcmFnOmQzZDQ2Njc4Y2ZlNDQzZjJhN2M3OTVmNDk5NGQ4ZWNmL3RleHRyZWdpb246ZDNkNDY2NzhjZmU0NDNmMmE3Yzc5NWY0OTk0ZDhlY2ZfMjcwNA_a8715b44-eb5b-49d5-97b4-6a37344aaaff">LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 9, 2022, the Company and Royalty Pharma entered into the Royalty Pharma Agreement, pursuant to which Royalty Pharma agreed to pay up to $410.0&#160;million in cash to the Company in consideration for the Company&#x2019;s future royalty interest in Olpasiran, a small interfering RNA (siRNA) originally developed by the Company and licensed to Amgen in 2016 under the Olpasiran Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Royalty Pharma Agreement, Royalty Pharma paid $250.0 million upfront and agreed to pay up to an additional $160.0&#160;million in aggregate one-time milestone payments due if and when the following milestone events occur: (i) $50.0&#160;million on completion of enrollment in the planned OCEAN Phase 3 clinical trial for Olpasiran, (ii) $50.0&#160;million upon receipt of FDA approval of Olpasiran for an approved indication (reduction in the risk of myocardial infarction, urgent coronary revascularization, or coronary heart disease death in adults with established cardiovascular disease and elevated Lp(a)), and (iii) $60.0&#160;million upon Royalty Pharma&#x2019;s receipt of at least $70.0&#160;million of royalty payments under the Royalty Pharma Agreement in any single calendar year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In consideration for the payment of the foregoing amounts under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated the terms of the Royalty Pharma Agreement and concluded in accordance with the relevant accounting guidance that the Company accounted for the transaction as debt and the funding of $250.0&#160;million from Royalty Pharma was recorded as a liability related to the sale of future royalties on its consolidated balance sheets. The Company is not obligated to repay this upfront funding received under the  Royalty Pharma Agreement. This liability is amortized over the expected repayment term using an effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. The interest rate may vary during the term of the agreement depending on a number of factors, including the amount and timing of forecasted net revenues which affects the repayment timing and ultimate amount of repayment. The Company will evaluate the effective interest rate quarterly based on its current revenue forecasts utilizing the prospective method. For the three and six months ended March&#160;31, 2023, the Company recognized non-cash interest expense of $5.1&#160;million and $7.9&#160;million, respectively, on the consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;</arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock>
    <arwr:InitialTransactionPrice
      contextRef="i3ba6acf54b0d4e5e9290dc7371ab7074_D20221109-20221109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl82MS9mcmFnOmQzZDQ2Njc4Y2ZlNDQzZjJhN2M3OTVmNDk5NGQ4ZWNmL3RleHRyZWdpb246ZDNkNDY2NzhjZmU0NDNmMmE3Yzc5NWY0OTk0ZDhlY2ZfNTQ5NzU1ODE2ODI3_63bad34a-3227-4301-b599-037882760f0a"
      unitRef="usd">410000000</arwr:InitialTransactionPrice>
    <arwr:CashReceivedAsDueUnderCollaborationAgreement
      contextRef="ie3454e80f761434b82e05233642d0a59_D20221109-20221109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl82MS9mcmFnOmQzZDQ2Njc4Y2ZlNDQzZjJhN2M3OTVmNDk5NGQ4ZWNmL3RleHRyZWdpb246ZDNkNDY2NzhjZmU0NDNmMmE3Yzc5NWY0OTk0ZDhlY2ZfMjc0ODc3OTA3MjQyMw_5bdce068-5b4e-4004-bc89-c3ef4445c3e2"
      unitRef="usd">250000000</arwr:CashReceivedAsDueUnderCollaborationAgreement>
    <arwr:MilestonePaymentReceivable
      contextRef="ie1daa5e406944e308bb4bedb06fb3198_I20221109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl82MS9mcmFnOmQzZDQ2Njc4Y2ZlNDQzZjJhN2M3OTVmNDk5NGQ4ZWNmL3RleHRyZWdpb246ZDNkNDY2NzhjZmU0NDNmMmE3Yzc5NWY0OTk0ZDhlY2ZfNTQ5NzU1ODE2ODMz_d51da58a-7fb5-4380-84d2-b5c8d97b9895"
      unitRef="usd">160000000</arwr:MilestonePaymentReceivable>
    <arwr:MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial
      contextRef="ie1daa5e406944e308bb4bedb06fb3198_I20221109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl82MS9mcmFnOmQzZDQ2Njc4Y2ZlNDQzZjJhN2M3OTVmNDk5NGQ4ZWNmL3RleHRyZWdpb246ZDNkNDY2NzhjZmU0NDNmMmE3Yzc5NWY0OTk0ZDhlY2ZfNTQ5NzU1ODE2ODQw_636b8278-8941-4bd6-b44a-17ce18fb1980"
      unitRef="usd">50000000</arwr:MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial>
    <arwr:MilestonePaymentReceivableUponFDAApproval
      contextRef="ie1daa5e406944e308bb4bedb06fb3198_I20221109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl82MS9mcmFnOmQzZDQ2Njc4Y2ZlNDQzZjJhN2M3OTVmNDk5NGQ4ZWNmL3RleHRyZWdpb246ZDNkNDY2NzhjZmU0NDNmMmE3Yzc5NWY0OTk0ZDhlY2ZfNTQ5NzU1ODE2ODQ3_fb6c0e5c-c59d-4d74-8a88-192735c18955"
      unitRef="usd">50000000</arwr:MilestonePaymentReceivableUponFDAApproval>
    <arwr:MilestonePaymentReceivableUponReceiptOfRoyaltyPayments
      contextRef="ie1daa5e406944e308bb4bedb06fb3198_I20221109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl82MS9mcmFnOmQzZDQ2Njc4Y2ZlNDQzZjJhN2M3OTVmNDk5NGQ4ZWNmL3RleHRyZWdpb246ZDNkNDY2NzhjZmU0NDNmMmE3Yzc5NWY0OTk0ZDhlY2ZfNTQ5NzU1ODE2ODU0_39ef0bfc-01f2-4eaf-a24d-b6177b02303b"
      unitRef="usd">60000000</arwr:MilestonePaymentReceivableUponReceiptOfRoyaltyPayments>
    <arwr:RoyaltyPaymentThreshold
      contextRef="ie1daa5e406944e308bb4bedb06fb3198_I20221109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl82MS9mcmFnOmQzZDQ2Njc4Y2ZlNDQzZjJhN2M3OTVmNDk5NGQ4ZWNmL3RleHRyZWdpb246ZDNkNDY2NzhjZmU0NDNmMmE3Yzc5NWY0OTk0ZDhlY2ZfNTQ5NzU1ODE2ODYx_e0085bf7-3798-47f5-9802-ec978c338da4"
      unitRef="usd">70000000</arwr:RoyaltyPaymentThreshold>
    <arwr:LiabilitySaleOfFutureRoyalties
      contextRef="i72781a23d66b49918170b8f70f504ec4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl82MS9mcmFnOmQzZDQ2Njc4Y2ZlNDQzZjJhN2M3OTVmNDk5NGQ4ZWNmL3RleHRyZWdpb246ZDNkNDY2NzhjZmU0NDNmMmE3Yzc5NWY0OTk0ZDhlY2ZfNTQ5NzU1ODE2ODY3_6cd4646b-edf9-409b-a9d5-ec67681e0361"
      unitRef="usd">250000000</arwr:LiabilitySaleOfFutureRoyalties>
    <arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties
      contextRef="i2c76d9b4843b4551a837b21eebd9dfdb_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl82MS9mcmFnOmQzZDQ2Njc4Y2ZlNDQzZjJhN2M3OTVmNDk5NGQ4ZWNmL3RleHRyZWdpb246ZDNkNDY2NzhjZmU0NDNmMmE3Yzc5NWY0OTk0ZDhlY2ZfNTQ5NzU1ODE2NzA2_b54dd923-63be-4636-b9b4-df9a56f50362"
      unitRef="usd">5100000</arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties>
    <arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties
      contextRef="i55d4c31deffd475f8b184224f06e6834_D20221001-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl82MS9mcmFnOmQzZDQ2Njc4Y2ZlNDQzZjJhN2M3OTVmNDk5NGQ4ZWNmL3RleHRyZWdpb246ZDNkNDY2NzhjZmU0NDNmMmE3Yzc5NWY0OTk0ZDhlY2ZfNTQ5NzU1ODE2NzI0_d76b0191-2209-4220-8f25-f876a258949f"
      unitRef="usd">7900000</arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90ZXh0cmVnaW9uOmFhMDUyZTRlNDEzMDRkODY4YzUyMDliMTVmYTA4MDI4XzMyOTg1MzQ4ODc5NDY_a63a7d27-49e7-4c5e-a65c-6e71bba8da81">EARNINGS PER SHAREThe following table presents the computation of basic and diluted earnings per share for the six months ended &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.901%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;48,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(18,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average basic shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;106,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;106,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average diluted shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;108,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;107,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;107,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities representing approximately 4,350,000 and 4,069,000 shares of common stock were excluded from the computation of diluted earnings per share for the three and six months ended March&#160;31, 2023, respectively, because their effect would have been anti-dilutive. There were no potentially dilutive securities with anti-dilutive effect for the six months ended March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90ZXh0cmVnaW9uOmFhMDUyZTRlNDEzMDRkODY4YzUyMDliMTVmYTA4MDI4XzQ5NDc4MDIzMjk2MTk_93b48d78-6c5a-4648-9e27-e9de900fecbb">The following table presents the computation of basic and diluted earnings per share for the six months ended &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.901%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;48,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(18,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average basic shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;106,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;106,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average diluted shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;108,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;107,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;107,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzQtMi0xLTEtNjE2ODQ_c89a5c05-418e-4378-a6e5-abe5e17b078e"
      unitRef="usd">48675000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzQtNC0xLTEtNjE2ODQ_b9a34c73-bc39-46ed-aadd-5a77770950e8"
      unitRef="usd">44366000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzQtMS0xLTEtNjAwMTM_6653344e-7290-4f1b-a216-a2448ea31f0b"
      unitRef="usd">7350000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzQtMy0xLTEtNjAwMjQ_fa99b872-13e5-4bb4-b9ee-bc24019a365a"
      unitRef="usd">-18506000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzctMi0xLTEtNjE2ODQ_43b2b571-4f98-4b2e-9b7c-00ab552530e4"
      unitRef="shares">106757000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzctNC0xLTEtNjE2ODQ_e0bea119-f5a0-4d4a-ab14-e2aabdccf4d1"
      unitRef="shares">105545000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzctMS0xLTEtNjAwMTM_219673e7-6e68-420a-a455-3d04c2ce69d8"
      unitRef="shares">106394000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzctMy0xLTEtNjAwMzA_e54cbc2c-d03f-4152-8bf3-855265075ef5"
      unitRef="shares">105034000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzgtMi0xLTEtNjE2ODQ_20b21b2e-2579-4b87-9519-d8456bd743d3"
      unitRef="shares">1386000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzgtNC0xLTEtNjE2ODQ_bd35fc42-7010-4255-984b-fc33f8f1724e"
      unitRef="shares">2384000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzgtMS0xLTEtNjAwMTM_56576fe9-9ad4-4278-9e16-a1e230b36176"
      unitRef="shares">1499000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzgtMy0xLTEtNjAwMzA_a8837bed-b629-4b7e-adcb-f43260f9dc72"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzktMi0xLTEtNjE2ODQ_6f168b64-c634-4cb2-b4c5-f99231bd993e"
      unitRef="shares">108143000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzktNC0xLTEtNjE2ODQ_90f17e91-616e-4d8a-be64-0f031a60b81e"
      unitRef="shares">107929000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzktMS0xLTEtNjAwMTM_509e6301-5bc6-43d6-ab2c-8b355d7a53ef"
      unitRef="shares">107893000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzktMy0xLTEtNjAwMzA_095af4df-1a2e-4ee2-a47b-38eeea36d7df"
      unitRef="shares">105034000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzExLTItMS0xLTYxNjg0_d5e36991-9958-4131-88e8-9875c7757531"
      unitRef="usdPerShare">0.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzExLTQtMS0xLTYxNjg0_0c1808ae-e617-4f9d-a6d1-9ef64a98cdf9"
      unitRef="usdPerShare">0.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzExLTEtMS0xLTYwMDEz_1d07f3ac-a21c-4689-8121-db19601964da"
      unitRef="usdPerShare">0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzExLTMtMS0xLTYwMDQw_e16b6a67-1aba-40eb-b842-5f324f6772c9"
      unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzEyLTItMS0xLTYxNjg0_5d55b7a7-0bfd-4d3e-918c-b3bc3f76970e"
      unitRef="usdPerShare">0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1857f5a716e04c5b8d57e2b5d5d98d3a_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzEyLTQtMS0xLTYxNjg0_8fc86bcd-968f-48c4-9dbd-5f5563306efa"
      unitRef="usdPerShare">0.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzEyLTEtMS0xLTYwMDEz_475d4bd4-ff91-466f-83c9-8a1f4ccadd60"
      unitRef="usdPerShare">0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90YWJsZTpjNWZjMDkwMTk3YTc0MGMyOTNjZDU3NDQ2ODI2YWFlNC90YWJsZXJhbmdlOmM1ZmMwOTAxOTdhNzQwYzI5M2NkNTc0NDY4MjZhYWU0XzEyLTMtMS0xLTYwMDQw_332aafea-9780-4b41-b3aa-8703c90ec6ad"
      unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90ZXh0cmVnaW9uOmFhMDUyZTRlNDEzMDRkODY4YzUyMDliMTVmYTA4MDI4XzU0OTc1NTgxODU3Mw_b882762a-1cec-419a-b57e-1efdf2659c59"
      unitRef="shares">4350000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2413801f016643d1afe7ea8782b19367_D20221001-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90ZXh0cmVnaW9uOmFhMDUyZTRlNDEzMDRkODY4YzUyMDliMTVmYTA4MDI4XzU0OTc1NTgxODEyMQ_c92c2d30-5fd5-47b3-b55e-bff4cf9f078e"
      unitRef="shares">4069000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i81d49ec2e39a4e61bcf1ece6f92acd0a_D20211001-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NmQ1NjQ2MmEwZDQwYzk5ZDgwMjYyNTRlYTJkNGQ2L3NlYzpjODZkNTY0NjJhMGQ0MGM5OWQ4MDI2MjU0ZWEyZDRkNl80MjEvZnJhZzphYTA1MmU0ZTQxMzA0ZDg2OGM1MjA5YjE1ZmEwODAyOC90ZXh0cmVnaW9uOmFhMDUyZTRlNDEzMDRkODY4YzUyMDliMTVmYTA4MDI4XzMyOTg1MzQ4ODc5NDc_dc02d67b-6ae7-478a-9d0d-321b40545a9f"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>77
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MD, X8*T\W*GL=[4=#]4WY.R7G/T#6Z;B,(44,T!]/>)>4QYGUHI$90T!STO
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M1CRUWC)>GVBY*'9=GZ76,BD.YX*'0ID;X/NIE'I[8GZ@W+@?_ =02P,$%
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M+^/Z"\4WW?NL.ZX4K[N/IFN8, ;Z]Q7GZNG"O"+;OQ)=_ -02P,$%     @
M^("B5H&0_2"C @  ; <  !@   !X;"]W;W)K<VAE971S+W-H965T,RYX;6RM
M55MOFS 4_BL6FZ96ZL(E@5Y&D-I,5?<P*6JT[6':@P,GP:JQF6V2;K]^QX:B
MI"6]2.,!?#G?Y^^S#\?I5JH[70(8<E]QH:=>:4Q]X?LZ+Z&B>B1K$#BSDJJB
M!KMJ[>M: 2T<J.)^% 2)7U$FO"QU8W.5I;(QG F8*Z*;JJ+JSQ5PN9UZH?<P
M<,O6I;$#?I;6= T+,-_JN<*>W[,4K *AF11$P6KJ7887L\3&NX#O#+9ZITVL
MDZ64=[;SI9AZ@14$'')C&2A^-C #SBT1ROC=<7K]DA:XVWY@OW;>T<N2:IA)
M_H,5IIQZ9QXI8$4;;F[E]@8Z/['ERR77[DVV;6Q\ZI&\T496'1@55$RT7WK?
M[<,.()P< $0=('HM8-P!QLYHJ\S9^DP-S5(EMT39:&2S#;<W#HUNF+"GN# *
M9QGB3#:30DO."FJ@(%>44Y$#65@Z38[F5($P)1B64WY,/I+WQ">ZQ%&=^@97
MMQQ^WJUTU:X4'5CI*U4C,@Y/2!1$XP'X['GX FJ$!PX>[<-]]-P;CWKCD>,;
M'^(S:!G3T1"Y(M=,H'%&.9E+S5Q^_;Q<:J,PRWX-66VY)\/<]L^[T#7-8>KA
MKZ5!;<#+/KP+D^#3D/'_1+:W#>-^&\;/L>/Y5Q6ZQ3S+[TY(31794-X .6*"
M%))SJC2I0;6G?CRT%2W_J>.W-6.3!:,@"%-_L^OQI:@]\9->_.0-XMO$)+0Q
MI53L+^:S-=&.#BIOR>,=3=%YT#Z/U#^-#"?QH\@]!W'O('Z[ Z9U\[+Z^*FF
M(#E+SI^J'XJ,SY/#ZI->??)V]7A5:$-%P<3Z)0O)JRT,10Y;\'=JH;V'L.RL
MF="$PPJQP>@4251;V]N.D;4KCTMIL-BZ9HG7(2@;@/,K*<U#QU;<_H+-_@%0
M2P,$%     @ ^("B5BN%D3[N!@  _R(  !@   !X;"]W;W)K<VAE971S+W-H
M965T-"YX;6RM6EMOVS84_BN$5PPMD,0B=<\2 XGE;@'6+6C:]6'8@V(QME99
M]$@Z2?_]J(LEBSQFDTUYB"WY.Y]T+CS\2.GBB?&O8DVI1,^;HA27D[64V_/I
M5"S7=).*,[:EI?KE@?%-*M4A7TW%EM,TJXTVQ90X3C#=I'DYF5W4YV[Y[(+M
M9)&7])8CL=ML4O[MFA;LZ7*")_L3'_/56E8GIK.+;;JB=U1^WMYR=33M6+)\
M0TN1LQ)Q^G YN<+G"Q)5!C7BCYP^B8/OJ'+EGK&OU<%-=CEQJCNB!5W*BB)5
M'X]T3HNB8E+W\4]+.NFN61D>?M^SOZ^=5\[<IX+.6?$ES^3Z<A)-4$8?TETA
M/[*G7VCKD%_Q+5DAZO_HJ<4Z$[3<"<DVK;&Z@TU>-I_I<QN( P/% QN0UH#H
M!MX1 [<U<%]Z!:\U\%YZ!;\UJ%V?-K[7@4M2F<XN.'M"O$(KMNI+'?W:6L4K
M+ZM"N9-<_9HK.SF;LU*P(L]223-T)]6'J@(I$'M OV\I3ZML"I26&9JSC2K%
M=54CCQ3=E$NVH>CMKTR(=^@4?;Y+T-LW[Y!8IYP*E)?HTYKMA#(4)^C-X/AB
M*M6-5Y>?+MN;O&YNDARY21=]8*5<"[0H,YH!]HG=/K#83U7 NJB1?=2NB97P
M0\K/D(M/$'&("]S/_.7F!'+G_UU]\9^O/@B&VY606_.Y1_C:4NB*!_UY=2\D
M5RW@+RC5#9D'DU5]\5QLTR6]G*AJ$Y0_TLGLQQ]PX/P$Q7E,LF1,LL5(9(.,
M>%U&/!O[["-]I.6.0M%O#(/:L)I$'F?8"T@07DP?#^,*P'P<.?X0EI@PXD01
M=H>P!< 6QL3S.MC 2[_STK?67=N?RA6BSVK>%%2<0Q[[8];;F&3)F&2+D<@&
MF0BZ3 3?J3=!4[Y<U_-$IHJO8-NJ$T#I:)C\@UH(/54R6OT!*#^.]/(S4=B/
M_##0R@^ >3CT';C\PL[IT.KTS[14]5?4/J>9FIKSJNE5L@=R.S3N@;B$Z&Z;
M*-<S!F=BHCR/.+K7)LJ/24!@IZ/.Z<CJ]"<FE<O,&'F0RY%Q W&$':*Y;**P
M OD:+#%A:O8*(PVV@&#8P4>\CCNO8ZO7?:?)6]E35+('<CHV<Q/A0"O<.8#"
MOJ^US<1$!8ZKE<S"!)T2' 81[#%V>EWHV+NK7%/>^=OF^1W885NFD5KLJ&S)
MJ&R+L=B&.3G0ZMA:AS>EI(I7MFD!<X'-TO(#1ZL_ (4=W]/J#T"%Q-.''(!2
MC>U(<\6D]Y6\S->V]$!GB5G\ON/K8@: .;JK %,8&SW5RC1TM%?/V"H%FX%V
M@DH*3I>M\>$5(]T]$Z)FMUCWT$3YV-?] Z@<_TCWQ+T<Q78]VLX:=4=I6J>M
M@CTS%5X4ZTZ;*&((SP3BPEZL>VVBW*,S)>[E*;9JKOVZJ'7XGCXP3O<-5:;/
M^\*N!43)U/E2<E84S333%#\8']\<X6&@BYXY!//<(- C9,+\R)A6 =0ICOR#
M\3&,42\<L5TYWACA %TV%9S1T;X+20 (#G5';31#'WN=B.U"\3<JA[JA.BIV
M697HU^0=D'U0WB%U".0=D(>1KE,6 ,J:]UY&8KN.K&)2Q0*E4O+\?B?3^T*5
M 3L6D+H_5IM2JE+ X)C"[S2.C:9AHHPB 8BPIZ\\%E:F84QZD8GM*M.L$STX
M5UR1KFF:H=MURC=*:.QDODP+<5+MQYV!@8F-M;<7!:$N2"$85#4F+'1]1P^.
MB;)5#>DU*;%K4C-"2I@W6XZOC14H9,FH0G94MF14ML58;,-$]D*6V(7L=2KR
M)7J;ERA3 SWEHD\DN*IJZ:+#X7;FZ:T/1NDK21#EA,[@3U]E 4:GSAD^LLHB
MO<HE=I6;Y,6NVGE_12@(Y*0^GF$4UD,!H;X;"M/(%HI>!Q/[-O*7^ID.S4[3
M1[7:7M']HX2=4/%1X5%C=[DKZF4X&)=1]Y5'94M&95N,Q3;,4R_FB5W,]V.W
M21!<I::DQHZ:=O2E&8CS?;V>$YC/C3V].$$^QSVRU4QZ,4_L8OYPH-K\-H4R
M=B+LN;K?$"Z,B;YJ@W%1K.^P@SB+W[U )\$+MH&6@V=_@RGX4)G!DZIU!?#J
M@3DF6S(JVV(LMF&J^G4&L:\SWJOU9;Y2C7+'.2V7WY#D:2F*M'D@G_V]$[)^
MM@LF*30E6^CI16N"C!D%X,&QOHT"H=QC$TB_IB#V-<7\>)&"+D>FY T#8W\:
M@BEEK._) S _"/2=!@!5*6/C2=CTX('^AO)5_2:%4,-P5\KFP6QWMGM;XZI^
M1T$[?XW/YQ@XG^#S1?,N1D_?O!KR(>6KO!2HH _J4LY9J'H*;]ZV: XDV]:O
M$]PS*=FF_EK);,HK@/K]@3&Y/Z@NT+WS,OL74$L#!!0    ( /B HE:4 2A@
M%@P  %M]   8    >&PO=V]R:W-H965T<R]S:&5E=#4N>&ULO9UA<]LV$H;_
M"L?M])J94TP2)"BECF<:BT S<]?+).W=AYO[P$BTS58B79*VDW]_H*0( K&"
M2/M-OB22O'B7PBY(X.&"NGBLZC^;VSQOO4_K5=F\/KMMV[M7Y^?-XC9?9\W+
MZBXOU5^NJWJ=M>IM?7/>W-5YMMPT6J_.0]_GY^NL*,\N+S:?O:LO+ZK[=E64
M^;O::^[7ZZS^_"9?58^OSX*S+Q^\+VYNV^Z#\\N+N^PF_Y"WO]^]J]6[\[W*
MLECG95-4I5?GUZ_/?@Y>21YU#386_R[RQ^;@M==]E8]5]6?WYNWR]9G?'5&^
MRA=M)Y&I_Q[RJWRUZI34<?RU$SW;^^P:'K[^HBXV7UY]F8]9DU]5J_\4R_;V
M]=GTS%OFU]G]JGU?/?Z2[[Y0W.DMJE6S^==[W-HF[,Q;W#=MM=XU5D>P+LKM
M_]FG74<<- B.-0AW#<*A#=BN >LU"),C#:)=@ZC7@!UK$.\:Q'T/_I$&?->
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M](?2-^5J90TM=!@7DJM?J5HG1Q-6");1%$N2@H54_U2,I !L"298K,"-BK,
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M6O5%LG5Y0?7(I&1Y^7%%<$JX%E"_+QF3;U_T"^H[SM%_4$L#!!0    ( /B
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M_9B>LS<Q_ZYT(HOU-[0"]BXM('! )"E!'I<YQ,2\V+('GQ1XI8=@7# 2%GR
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M"M"'(_21<_2[N^^(>6E864L:EK5,8" &\JQJRV-RO+!'"JD%'#8JP2?39D9
M.4]7%(@2&1T5 EP%G7,#>VX9^%=P'L6 S8T.@O^NO<4>7^:S"9@+XEI*H ?/
M$TE=P#(%KDW)#,7!!1R"++-YS$B@]9&W*=;6#KX)_#R&8^:MT(3?5H$/S1ZB
M [@J=O4+3[+'+QG"._@:I&^F4'CN"*>5;\&PM45V.&_EZ6KMK-I!P&UW;;>K
M8\#+4C@ETIFP/C(R:I'*W^#;E!=E+GSNME=S=B!S8"7(NS#@ %BGUS*K';ME
M1%,6'?S4HLG-7&0&=+?EM2C3*";&XIHE<)'4LT>*S\5668/M.D5@ PO/#4];
M++?GMV2;V+@!6V$+L>/Y86^^0E$N2^+=#T2!7;??JWRH^Y*\#J":5'.3S&8Y
M' 9$"O 01C5=?%O+6C'!<6###7X#21J?"6BU1&B.B*Q)$$89BNL1*<W6G1@\
MA4R:;@,L/O?,'W9.@ CP&EW4,\BXQ.Y6$%)5:&#GVAZR'<7V\818>P>+)R%:
M/:D"LF_&%'>U5B Y)*9+G<!!Z9V W(08/9LWD#4&SZ83NSV0H_P@/A(DJ<)Y
M5.9.[!JRI<1D2V(W6QI7(=$HN8F<NQ'5BZ4N!,-'9BE$\P%^N%J)W,3M)H#8
M"2;M2&8T4:)V948/8< "ATM229+_6N81^PU4$Q$B\&$I-5H9[DZZ XJXP3^I
MJG,8$!M$6YN1^.E,J')28@)6S<1D4"5^N"C/1%G(4+-W*"E8Y^7\107P[4 ?
MY+\OX9BC,P?PW5+[0?Y=$JB&FW?+W@GO-P!D[\R:UAI(>H"].Q-X^X]/8#*G
M 1[!NKTCP(D0T"M<M!"H$M87PJ*+;<T4K 34<*I ]$]'Q:4SH<!Z3#PI4Y(H
M>JF(K0"8M;%\BJ@"*087304^(^=BG:MR9>(11)7*,Q.)Q!+?1ZNE04B./-#'
M5&WZ /\/@?W <:I)>,7IPVD#P.DN#(^NN8S)+X]HHQ9F'\W:2-I33\(5QELZ
M^.3L>50?I3)L+P9,#%/0.#N GD63)]-9$TWZ<+\2L,>IH &387V#".OX<4M6
MX9%01QGK*6*U.<(!-:"T&+,#@_8CRSV&\O\(79*5*&=!/VL_3LL[?=6]P5)=
M"^>_'YSVG>0' :KGL^X1G]82_5ED.KT[,/V/8<Y.O#G]M\%-9RM[H&:?<@S8
ME:U9;DSAQ^$^#!X,+R.P-'9$)<L%U\ "=>/ @$S$,N>)</4&A*A.$OW[W>:V
MNO9$VJ@" BR"XV!80QZ))>P,_PFL(> C5(KG@>!6T1FJ,M=D\1Z-_3C:@['N
M$"*U@*%&L[I<_!.= GC-EQ ]3#$6"\\>O!UAM(A4@OP,6!;S4"S4D8<_3)!$
MV ;@4AO8K_E2%&"&A8K159"-PN0U!T)#]0UX0A@21>P^C+8I3_##VLC:(+H1
MT>\(HI'I/FS6 GW[GX.;[67(I3DAX6;8R-'7KHZ;T3YVO@@+A2(YI06'@5OP
MQROD...%.GH-7AEYV5TPMZO?"4/WC>VED:H%H3IRI6E4W=?\=U!#"?J%(&0%
M5AAT1F@CLZ.52(7-"$!QP[+@J5"E!BOA$9@?N!GBPM6GN<1E7*K"0J %+S%W
ML3<![B;,IN"&/DN@\GN^AV(ECT%=CQ!N%K+(MYDV]R: [$4:;@?L5QAD%>U+
M2M*E>U&(7O59P=TO;244+<J544(T*J]4C[$>N<W9;'@\&R*'EA),%I0)#P$.
M!@ *>/X!NR@+C2E)QZY6&+1'C$5<'+.*U8+''>$-G58A5@: TAR'*3NO/DP=
MSKM<\,\(UA>+70V @]ZM/KH$E?\K#AG/_NJ0JD6HW1G#9'BWE*%&\J-@3\5_
MNE.'K^US3_(P81XHQ&)DJRJP)W6X6U[051'77NE[-CX=S!SA_6B^WW[_;X/Y
M/X3EO5JQ0RP9A%R/'=>O_O[EXMW<R"S8F:72E<(M7<%G?G4QGW\>#X>NY$S>
M#M*Q5!.BM,0#@\HE1RO%R=@N43N\*"]75>HE_>(8KF699 H_5E8=KOH^4XB>
M)?^T#.*>\H>>8_Q@^N#[S?LM<:L^9[TO>.RX44K^,X P$'DRC&PPKPZNWO9'
MNQ0XO%DY>1BU+ W[0#H5'$7)NF"N:3/'IOT!B69VG6.G2(6,R+6%MU7!#\--
ME7*W<Z,['C*P!5, _P(H1PZ!VIO;6M,LX:C\K#* "&?#,^.;X:2Z#->!989E
M#>'/Q/18H ;YN ^UEQR\L=N:-H+RVF1A!KK$9@L+5NQ9W;" -=.#.];_FV'O
M7A,RSUOMR<EZ#*Y.R60C(P,(06 >SVE\,'ICCY!$%&L%J!A["DT"9[I+7.7]
M1FH\2.TOP97H4EM^U&GPSCAW+.?,G<_',WD.O1&_00,?-@4!WNI&&M19%^>-
MKC2JAA1ZQ'<(Z>3#Z^8>P $S-%=4H-PT:R1@"@2]6*Q0S\%GV@R*B .+A'7#
MK4MAL/.4@;6(V&Q C:"^?5K*'[.UVH 0\LJ?8?D6D@2@B<BS$ ;-!*_N.]=]
M</'AU4,7Y6ZXC+F%+58>VG-#E)*FEATN5EIB3  @?U-O"T"(8ZL,O'"E7$B;
MGCO)4[$"*9.I:;,ERZXVKA):RY<>@3H"N$VOW7V*'^$ANOGT;IWV+$2Q$<+>
M8E"7%B[NWDVI90+RR+0/C_0%K#DF'N YRA@0%\A74!/N[0EJ,Q2$:ZSCFNLT
MI_C5Q4:KC9 LFYQB@<OF8HDWG%96P&/4Y\IV>HT37DL564]NZ*X1A"&'RLXU
M->:059^:P'I X369+;;L\&0TF-;%,##3P^%@=HJ;4701[$$DXQ)F/20C%AR\
MK3UE08V15##?>Z_73.WQ.NZ\<II44^EL\JN]?+LY+L!9!E(<CL\'9XWKQS &
M_VA@,[XK82+&JLX:P;MF?F -=<^U8^%UYUR]>OGKQ<7+=L[10)KM(LKTS[^)
M]"J*6M5L/3ROQ4[!+PSS$DM?+G!V<<SZ$40DN<063E#<* ?C25&5[HJ!:H Q
MJ+I1FV4:B,?OTG!056?LJ*[RS 0IPRM..R9H../NY2U+;*K[7JU3C9VU&$/=
MN^"6.L\M[8]NW]YR3K6\&]GLCJ[&=XBP10AH4/B-927(B3>N: E#OG__\D6;
MF?"1(R/H/GWE0D&R!F/S3&*$!RXVSPEK <!$"BX=!7M+5[V,J038>>,;=%=
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MI[,#4[)U;PJ5T0]C ; K5$(OUX(#(W  ?+]4<!#[!C>H?BGMV;\ 4$L#!!0
M   ( /B HE8/A]JY\0,  -\(   8    >&PO=V]R:W-H965T<R]S:&5E=#DN
M>&ULK59M;]LV$/XK!S4H6D"P),IO26T#>1M6H,F\)&TQ#/M 2V>+*T6J)!7'
M_?4[4K:3#HF[ OLBOMT]]]P=CZ?)6ILOMD)T\%!+9:=1Y5QSDB2VJ+#FMJ<;
M5'2RU*;FCI9FE=C&("^#4BT3EJ;#I.9"1;-)V)N;V42W3@J%<P.VK6MN-F<H
M]7H:9=%NXT:L*N<WDMFDX2N\1?>QF1M:)7N44M2HK- *#"ZGT6EV<M;W\D'@
MD\"U?3('[\E"ZR]^\;Z<1JDGA!(+YQ$X#?=XCE)Z(*+Q=8L9[4UZQ:?S'?HO
MP7?R9<$MGFOY692NFD;C"$I<\E:Z&[W^%;?^##Q>H:4-7UAWLGVR6+36Z7JK
M3.M:J&[D#]LX/%$8IR\HL*T""[P[0X'E!7=\-C%Z#<9+$YJ?!%>#-I$3RB?E
MUADZ%:3G9G-#^35N UR5</FU%0U%W$T21]A>(BFV.&<=#GL!9PA76KG*PJ4J
ML?Q>/R%.>V)L1^R,'02\XJ8'>18#2UE^ "_?.YH'O/P'CL8PEURY[_V%/T\7
MUAFZ(G\]YWJ'W'\>V9?-B6UX@=.(ZL*BN<=H]OI5-DS?'>#=W_/N'T+_B03]
M .?FM_GES=T?<'I] 9>_?WP_O[J\OH.["F&I)=6F4"MP?"%Q6Z#B&UIP='RN
MZX:KS>M78Y:-WEFZ?7]K X7DUI*$7D+SE"+N*)X I;"H]CF$6VP<U@LTD*=A
MB\$;H<B$;BUIVK?!4NO0V!BL7KHU-QB3@:4H\!$W6%FV1@G7&H0C8'%V/.[&
M,8,/_IC%Q\?#[?>&4A*(/"+TA_%XE$,^CMDXAP](55UI68*HR95[]#(6^BQ.
ML]%N.->*+DC;/27$F@17E&P+&1O%+!O"8!CGA,E8%N=I"ED_B\>#C,"M/8'3
MHFCK5G*')3T9=$L*P;M'B<CR6ALGOG4;;_)AG([86YID\6#0?POS9Z,;@Z(7
M^PBR\2!FS+N?96G,CD=P<1 ?'^@YMS[GYH6\A2/D%#!*K<^_JPPBU%UYHR_O
M?V<VA-SG<\TM'+$>HY=*2C+7^W_8>!96//P$AWYOL.,03F@CWVW$U$QL@Z$=
MR$TOE(!0A?'7 ,*%1"A>2G?9FE H_X&1)^+;HMR0%H51[Y"=4*T'*9$(Z*:[
M;A3LFJMV26]0,!&#Y MMN-.F"\FV#DA 2.$$E1[Q^H1&*Q[#9V$]9=HAHVOJ
M<7[D=$?6AV$V'N26*[@0N-(QG',I*.)*\![5*\*U=@BCWG/O6/*DZ=1H5J&U
M6O*O5:[K/_O=??<^[9K6HWC7^BEP*Z$L2%R2:MH;#2(P73OM%DXWH84MM*.&
M&*85_8&@\0)TOM3$<[OP!O;_-+-_ %!+ P04    " #X@*)6K/H_04P#   ;
M"0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6S-5MMNVS@0_15"+8H$
M4"-*LF0WL0W8:=H&:(J@SF8?%GV@I;'%5B)5<A37?U^2LI5DZ]A^66!?Q-O,
MF3,7<C1<2?5#%P!(?E6ET".O0*S/@T!G!51,G\D:A#E92%4Q-$NU#'2M@.5.
MJ2J#B-(TJ!@7WGCH]F[5>"@;++F 6T5T4U5,K:=0RM7("[WMQE>^+-!N!.-A
MS98P _RKOE5F%70H.:] :"X%4; 8>9/P?-JS\D[@GL-*/YD3Z\E<RA]V<9V/
M/&H)00D96@1FA@>XA+*T0(;&SPVFUYFTBD_G6_0/SG?CRYQIN)3EWSS'8N0-
M/)+#@C4E?I6K3[#Q)[%XF2RU^Y)5*YL8BUFC458;9;.NN&A']FL3AR<* _J"
M0K11B!SOUI!C^9XA&P^57!%EI0V:G3A7G;8AQX5-R@R5.>5&#\?7X@$TFBBC
M'@9H .UVD&V4IZUR]()R2FZDP$*3*Y%#_EP_,$0Z-M&6S33:"WC#U!F)0Y]$
M-(KWX,6==['#BP][YY/W,$?"1$ZN?C8<UV0&6:,X<M#DG\E<HS(5\FU7$%H;
MO=TV[*TYUS7+8.29:Z%!/8 W?O,J3.G%'@]ZG0>]?>B'\K-7>3>UZR_W5[.[
MFZLO=S-R5P"YE%7-Q/K-JT$4]B\TX8\622;-[=,(.9$+@D9X(4MSC;E8GI.)
MMILF8UG1I8R<7 LC)QMMXJQ/R23_WCCU*3,XY*.2>OO]P+@B]ZQL@,P*J? M
M@JJ>&3_)S=F*8\$%D0+(&I@Z)9^@S E*<P?09F]MKJ!)JW[,Y6L2]U*?]E(S
M<TY%%V9V$OO])#EUIY$?O0O_!,I (5_PC"%8SW*HI>;88;PTWDED)=&[?3B6
MS&<IEH<C@(62S;*P([3QT$<%I#_P!W'O.870[]-WED*_[X=1LG&CW,GC.(2V
M(&90(U1S4"2FKBBB_T=11.' CTVD_Y6'- U/W6G/[\?TZ*)(J$\I_:,6-ML'
M2B)*]U))6RK_;4F$-/$'_>@YA\1/4I?1D%(_IO&!HC@.8]<C&#QI6!6HI6O+
M]KEI!+:]J]OM.O^D;7B/XNUO@WF EEQH4L+"J-*S?N(1U;;B=H&R=NUO+M$T
M4S<MS-\+*"M@SA=2XG9A#73_0^/?4$L#!!0    ( /B HE9BCM;[F00   $+
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;)5646_;-A#^*P>U*%)
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M9SCP0-4#5[TPLG1#SDH:&IF<F-&,BLH>H.^II)IN%M9 ._7._@502P,$%
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M ,8.K"I1"IY!)\*X^%7I89/E!7@8N(W:5HO$MK5924(ZUT@+Y44SON B=U.
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MIK$E7]()03E:@/<+:YO-#2GH/YU>_Q]02P,$%     @ ^("B5KV@7_#0"P
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MV(75F"8<O0<!Q(NWVRQKW'NQJ_;$SA9:RZFL:DTQCZ@$,@YJV B#8;6UEL;
MBYL/%]-/[+DG<2@R%(#*X$%P"G^9 1LIW55/+#5U'%@9J3K$DOLX%;*NG5U"
M'.\/F6%='*6X&,F>PU($N OR-VERM>B<\E]8O%K;3+J<L2A32!<W#47C%NQ*
M9I$3C%< 6$J?-5HZ]5VF+;#6+Y<D71"Y\L1>YB1#&7.28YQY#"&\(K!RKA6&
M2RZB1=MI[.4X*YBPR]AIKNM=N;<WC!\1%H[+\9.X;/.JKY^-<,D@-)0'L?-V
M*W]%7UT]-Q[8_A*1HT^H&@^RH $BC61R.+ F'B)7+Y5W:X&-)KZ!J);Y)BO;
M_)CE)R6D/#<U%72JD^CQ$B%$/W#]9+%0Z5:(+D- ](G+/Y7XH];T-Y4^V]CJ
MB(]G,*_17ECGIGFL/U-UM0T,-K:B)TC^@6G4$"I3ZB;-(JR@\U6^"^R+:6,.
M(369;O)8%SB^@;JY-!DE<L:*B-3CW5A$6CA!BT:E7:$$D;8:9]H$=5V6,<*-
ME^WQ$)V&YLEP3#F<9'T ^JCMH>E5CX&O9*0P$$(]GB5:=#>(W?8@]NT@WIH8
M,?6H=$2>"6DUG&"9N=31F7C \]NA!9^,!451HHO.@"-NOZ'$6M>=.T?:A.<_
M0%VV PT/+N %Q'=!?8<\.E42IV\USM;X$JW&M'%R1>-CI1A!14'QU/TP#QVW
M^XI":?/DS4M[8!+%RMTFQ8&GG6T;(:_']*YLH]& 3*0G+\44(@YSBJ!4I$[1
MH,1ZU."+RE0=U6I54$=%Z<"&Q0:%'V%&7)?<./,FCNV.RKUX3]V<<&-*W &M
MA&GBN8<S#JI9YX?0S+SNM*26DHBGJI9SW'%P(&&0!E<SQ].M 4G2^4;&H/FV
M"/K@)VE6A":N*H;=*N?FV>W;9M$*K.XK-*7UA8Q\;3 QR*$A]-F(?&V<8^LM
MQ!XY&!C GN^=FQAQOFX5=P2X[ JQ1/ B<*^^B2I=%XBO"P*'?3C<G?:WCXU<
M<0L326FL^24>X'K,S$Z<D6(!O]D_Z,N7K>R\W?^U^S"$F@Z87@\[DFV5(09A
MH-08H0ZGLC0N?-NF*ASD2[ZHQICAG<2NMM[O[3]WHA]MW-8JPM3F.RG7/1*5
M+F[]U_[:.TVWO8?MZ<Z,X"RXL6LJ(#K>?_MF@&-"O(>FEV#K>/>;VX";9'S$
MX$?]\P:L%Q9]OGUA _T_ \[^ E!+ P04    " #X@*)6#*BVN+H#  "Z"
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6R-5EN/VCH0_BNCM*JV4DJN
M!-@"$K3;TSYTA:"G?:C.@TDFQ-HDSK&=A?WW9^Q #JNREY>,;_/YFYLGT[V0
M=ZI U'"HREK-G$+KYMKS5%I@Q=1 -%C33BYDQ31-Y<Y3C4266:6J]$+?3[R*
M\=J93^W:2LZGHM4EKW$E0;55Q>3#$DNQGSF!<UI8\UVAS8(WGS9LAQO4?S<K
M23.O1\EXA;7BH@:)^<Q9!-?+V)RW!WYRW*NS,1A+MD+<F<FW;.;XAA"6F&J#
MP$C<XR<L2P-$-/X]8CK]E4;Q?'Q"_V)M)UNV3.$G4?[BF2YFSMB!#'/6EGHM
M]E_Q:,_0X*6B5/8+^^YLY#N0MDJ+ZJA,#"I>=Y(=CGXX4Q@_I1 >%4++N[O(
MLOS,-)M/I=B#-*<)S0RLJ5:;R/':!&6C)>URTM/S&R9K7N\4K%#"IF 2IYXF
M7+/KI4>,98<1/H&1P'=1ZT+!39UA]EC?(SX]J?!$:AD^"_B=R0%$@0NA'T;/
MX$6]D9'%BUYM)/Q>;)66E!/_7+*W@XLOPYDZN58-2W'F4"$HE/?HS-^]"1+_
MXS-DXYYL_!SZ*R/R L9B??OM]J\-K&[6L/FZ6-_\*!!R45(-$C9HMBT1+/E:
M*]"TF8JJ:36SI2)RD^D\!59GD/&RU9@!GG@UQ$M9)]*;8'45/T#5I0":%  *
M8%KT$;0P- @'\*.0B(_2Y>SLAF">V+(P!N)L=,5KNEVTBN"5"WA(L=%G[%@E
M6K+N/=RV%4JFA;R&6WKF>$VV(ER50M'F6XC';C(:FD'L1DE"@Y$;#7V25\'8
M'?K)>_B,M:#BZS!^V4K'[ .[)]@='GUE+U5 #Y_2Q,BX.? 3=S0<D1RZPWAH
MY]$DMG,_BN$FS^EQ,NZV3J;G"12FK>2:$U+@1N,$0OJ2AAM/)O#NS3@,PH]_
M,CC%Z"*'L1O$$<F1.PDG5HXG4<]A:<E?".Y;\ =QTHG0"G]D?.(/@C%YY.FL
ML!K#3@1_**Z$IISCK"P?+EHM\9B6ACQK&BD.G!Y?I..Q"8OK^[Y-J-CUDXF=
MG:S.31)3'@*]FND=[)'(4%:4K<FE7(KJ4J*_(KVU35ISYPN)[A)[U:!M-.6#
M"UM,6:L, '()V$5[+]HR@X)"1_M(?8E,_7#RA*D00]MRKP4T+WAKSW7Q&.%T
MS>MJ,QQ<>K&\LWY"I;.S75.1YZB>NM;2K_:->='UH_^/=UV=;MOQ6D&).:GZ
M@]'0 =EURFZB16.[TU9HZG5V6-#/!4IS@/9S02XX3LP%_>_*_#]02P,$%
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M"9;N5=:;$-FP2CD.G]IQ=G_@M[?->4DU4U3L<<4:<%?Q0@J</0Y]-XOB /7
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M%5$<T?/4'[&3O3@(Z1EX21K!+U@36.FD1$X=3W+9<NL&?*)/$<&/R,XX]$G
MCR)(8Q^^""VY@7V7?BI;"-(0(O):1,+?H='E<?CIW>>#L@1P )'G^Y$S9>0G
MG#9>&HR<P:?C"'IZQ6C3*T;]O:+[=G(>W K;ZBY9:+<-01?)W9+ACU\-G^M<
MFDRU-9?@E3#2[.L@_>JY671ERIJL<[EK)=PZ&O%<K7M(7VIW=-I=.C.FPSW
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M7GW<<(EW3:%I GZ?*V6[!]J@O[V>_@M02P,$%     @ ^("B5H9M6^M_ P
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MK2S60Q8[2FSS!7]W0BF1Y)L;2B(JLP;Z]Y40ZG$GZZ!:E3K[#U!+ P04
M" #X@*)61"XB<5P$  #Q&P  &0   'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6RUF=MNXS80AE^%4!?%+M!&(G6PG=H&DDCM;KL!@F2WO2AZP5BT+40279*V
MMWWZ4H=(ED0S<4KG(I'H^3]Q9LB)QISN*7OB:T($^):E.9]9:R$VE[;-%VN2
M87Y!-R27GRPIR["0MVQE\PTC."Y%66HCQPGL#">Y-9^68W=L/J5;D28YN6.
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M9*UBU?E2=2/HICQ >:1"T*R\7!,<$U88R,^7E(KGF^(!S2G?_#]02P,$%
M  @ ^("B5AB_/_29 @  008  !D   !X;"]W;W)K<VAE971S+W-H965T,S(N
M>&ULK55=;],P%/TK5IC0)HWE<QT;::2MTP02B&IE\(!X<)+;QIIC!]MI![^>
M:R<+V=96/)"'Q!_W')][;-^D&ZGN=05@R$/-A9YZE3'-A>_KHH*:ZA/9@,"9
MI50U-=A5*U\W"FCI0#7WHR"8^#5EPLM2-S9762I;PYF N2*ZK6NJ?ET!EYNI
M%WJ/ [=L51D[X&=I0U>P '/7S!7V_(&E9#4(S:0@"I93[S*\F"4VW@5\9;#1
MHS:QF>12WMO.AW+J!580<"B,9:#X6<,,.+=$*.-GS^D-2UK@N/W(?N-RQUQR
MJF$F^3=6FFKJO?5("4O:<G,K-^^AS^?4\A62:_<FFSXV\$C1:B/K'HP*:B:Z
M+WWH?1@!PF0'(.H!T;\"XAX0NT0[92ZM:VIHEBJY(<I&(YMM.&\<&K-APN[B
MPBB<98@S&:;/:2X5[4P5)?G("MPD()<K!8#[931Y0VZA +:F.0?M@F92&(5;
M@-$T9YP9AA.'UV HX_H( 7>+:W)X<$0."!/D2R5;C3"=^@8UVY7]HM=WU>F+
M=NC[1-4)B<-C$@51O 4^VP]?0(/PP,&CIW ?G1KLB@:[(L<7[^#[K%94L-_.
MK6/K@I:<E7_-FRO0:%DW()?DA@DJ"D8Y6>!@;^?WRUP[]WYL\Z,3D&P78"_U
MA6YH 5.OL6NI-7C9ZU?A)'BWS9W_1/;$JWCP*M['GHW/#!,%;TLH[6F@12%;
MZX,: K;YT)%/'+FM1>OL+, G]=?C!%]&3<*S9 AZ(CP9A"=[A0^'FX\.]S@#
M+!.@%+85K$&T6^4G+X3%P7F8/)/_,BJ,@R Y?Y: /[K@MKCBK5@QH0F')0*#
MD[-3CZBN8'4=(QMWYW-IL(*X9H4U'I0-P/FEE.:Q8\O(\-?(_@!02P,$%
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MDWQQ3<F""CT MB\Y5R\K^KUR]9\*T_\ 4$L#!!0    ( /B HE85?.NHG04
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MJ[*>+E71?&%)\-H9Z*O:%+@8>P3ZY[,BHQM)8O%O0_>N=FGTF]/(1^8+D>*
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M ]/%-C\L8[&NQFB$!0HS@K(D)!P%NB&S-V$:Q3<VTEI\2)H+2O- :7Y).WR
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MH''&6\=!FO\F3V5;;4#6AY3'81DL>A#Z4?&7?BT_B). T;D HPPP:@&F>2;
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M\'B?/[AK%7,>A_GFCM$-2[(&XOV'..8O+[($QP?>+?X%4$L#!!0    ( /B
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M=<!P3X!5!5C'9AA4 8-C,PRK@.&Q&495P.C8@'$5,#XV8%(%3%X'6'L"IE7
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MX!LBLM::EAWD_N9J[0A+LU)\4$+?95JG)MK"F#YQ08O"2*?D(XMTI0&YG L
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MX)XEB_025.4X"<&?F#\1B:<1 1,R6W,J*1'@_:UZCT;B@TKY.+D%[]]] .\
M3<#7)5L+%2>&ME3%ZQ+L65[H=58H:BE4C70!7'@&D(-<0_A-=_B$K%2XDX:C
M>KBM6E;T#15]0VD^MRV?VD_A6MG^:PX^DR@$7YEJAM0=^%5MQ55KDW[<JY3@
M3I)8_&UJ1S9^SSR^WMV78H5G9&2I[2L(WQ!K_/MOT'?^,#7G2,EJK7*+5KE=
MV<?E2E)+H%@^9UG;)%.K.6O;&;@*_U$KGH3@6FU,XQK)1O+3D?03:C-V>[[3
M\X?VIFJW*4-^WQW 0E8STBN,](YDY!-G0H#'1#U8(_J?,O1)/5"-AK(1O4JE
MSHZ7+D7-AE?8\%[+QKVZ-T^,UZCRW T\;\>+2>7[+=/B%W[\(_GYB"D'WW"T
M)B8+?J,XMX=09=%D'IHRY/<"MV52@L)$T&FB?,2^8(]0XU0$C0*#?M_M[=AH
MJJ#C]0-DMM$O;/2/8^/P'=+?NT.Z%#47@\+%X)5<M&^007/IP\ 9[%@QJ#S/
M'YCM0*?\DG>.8ZA[A^2CU)96 -'N+C?(H..XCMMBH\(JL-/&+9E*((JO4&.)
MG1E>^K5YK&QUOR5CP+>&#'A4RCA6MGJ[2LZ IP.-?"AO'VD8= BVHP8L60.>
M'C;@?MKHE-2ME+P!WP XX&'$892U(@<LF0.>!CK@@=1AT"'8CAVPY YX,O"
MAY&'0=:%'K!D#WAR^(#[Z:-34G=2\@<\/8# PPC$)&M'$%0B"#H)@J##$,0@
MZT(05"((ZD:0&\(EG=,9ED2?DH1DQ025QH9W9WKQ7_"O@2*H<MSQUBB"CGO@
M\1HH@DH40:=#$=1$C-UGD$'B.>JG9;67$().#R%H/X1T2NI62@A!;P AJ$D7
M#2]=DKJ7$C[0:> C'\;O*K\I,:TLNW("K8__U2-@H>8?1&2NXIR+0/GGV8EZ
M=B/9*CV4GC(I69Q>+@D."=<"]?F<,?E\H\^YB_]KC/\'4$L#!!0    ( /B
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M*ZCGJSB6KS<I07F4=/8_4$L#!!0    ( /B HE;S2 1AT0(  )H)   9
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M<D'033'U\9D*09/BXYK@D+"\@=R^I%3L%_+9E/6$WOF_4$L#!!0    ( /B
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M#Y1<9'M'W4JE9)A]G0L^%7%:0/\^DU(]':0.UGNNC?X#4$L#!!0    ( /B
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M<'?\G/VC,X]F%E3#!\F_L\JLYT$>D J6M.7FJ]Q^@M[0V.8K)=?NDVS[LU%
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M2T5I#M#^0@B]G9@+VB8=_P502P,$%     @ ^("B5DM5RJ&,!@  KC8  !D
M  !X;"]W;W)K<VAE971S+W-H965T-3 N>&ULQ9MM;]LV$,>_"N$50PNLMD39
MEITE!A*+P@(L79 @ZXMA+QB9CH5*HD?2>1CVX4<]1#)EA;';"](7C23S?B?=
MG8[4W];Q Q??Y(HQA1[3)),GO952ZZ/!0$8KEE+9YVN6Z4^67*14Z5UQ-Y!K
MP>BB,$J3 7:<\2"E<=:;'1?'+L7LF&]4$F?L4B"Y25,JGLY8PA].>F[O^<!5
M?+=2^8'!['A-[]@U4S?K2Z'W!C5E$:<LDS'/D&#+D]ZI>Q3B:6Y0C/@S9@]R
M:QOEEW++^;=\YWQQTG/R,V()BU2.H/K//9NS),E)^CS^J:"]VF=NN+W]3 ^+
MB]<7<TLEF_/D:[Q0JY/>I(<6;$DWB;KB#[^QZH)&.2_BB2S^1P_E6'_:0]%&
M*IY6QOH,TC@K_]+'*A!;!IK3;8 K ]PV&+Y@X%4&7MO ?\%@6!D,]_4PJ@Q&
M^QJ,*X-Q$?LR6$6D ZKH[%CP!R3RT9J6;Q3I*JQU@.,LKZQK)?2GL;93LVO%
MHV^?SW1N%FC.4UVPDA8I_XR^4"%HGG?T,6"*QHG\I(_>7 ?HXX=/Z .*,W01
M)XD>+(\'2I]+3AQ$E=^STB]^P:^'+GBF5A*1;,$6'?:!W7YLL1_H&-2!P,^!
M.,-6X 45?>2YOR#L8*_C?.;[F^.NR_DQ[^3'O(=[F+N3PMRUQ-*KB\HK>,,7
M>"1=)_R),514%_ICG5=45XU8,7E3/9)K&K&3GNZ:DHE[UIO]_),[=G[M2A D
M+("$$4A8" 0S$CNL$SLLZ-Y+W6)%!4,=W>)4MXKLCNDI1Z&S)[0][I(^%8=/
M'ZA8H+]^UTATKE@J_^ZJB"%D14#" D@8@82%0#"C(D9U18RLM_IYID2LUQD1
MNJ?)AB&^1+RXW25BCTQ$L>SL[F<EU74*;+[\N9^Y_>'QX'X[?UV#G/[$'!5T
MC/+Z8W,0Z1B$O;YGC@JMU_J=D1S7D1Q;(UG.Q+?%/1-MWUOL,=]F75$LB2[>
MOJH^;D6Q<Y#?"F+'H.%.$#L&C=JDT'J5WQE#OXZA;XWA3298Q.^R^%\=1,W_
MK.CCWL'T=TO$;X=@;O5_:$OQ=^.YXY% >@R!8$9R)G5R)M;D?"U6^3HQ])X)
M_=2"UDS$?($41W76#DZ:W:6+GA@575.#U>[0/$+"""0L!((9^9[6^9Y:@W_%
MI)X;HCSCY3KP)HN51!^OKF_DIZY<6G&'SOV0L  21B!A(1#,2+#K- ^/SCNO
M!ZL3 "H*4%H 2B.@M!"*9A;&EJK@@B]F*J2YW)OL+ J[AN%)>]43/ _;GER]
M49M&NFC#Z<ZBQGZYWQM.W(03O]VZIF*;<1WM+)'G]G,X^.;8SRL!]1I"T<P\
M-;J':Q<^WF2)8_=Y< L$E4E>B0<NUE\2C5%:J'6=?0]4'8&BF070Z".N]6%[
MAAUGB,@_FU@]H?,LTO-<KI]>)K13_K+##LXLJ-P!2B.@M!"*9B:YD3S<T7NO
M>H"$B*HP(&D!*(V TD(HFED8C8+COB+AY F7J$*C)1<HEG)#=2- '^,,R>+S
MSF>?BCS:GBU];SKQVI,TD+Q2Y7(_KP34:PA%,[/4:$2N723"CNOMTYPAA9<Y
M*"T I1%06@A%,[/;B$SNY+V;,Z1",P>E!: T DH+H6AF831JE&N7HWZD.4]W
MVJ0W<B?3D=_NSJ"JT[YN":C;$(IF?@W?:$K8*DW,OFS26R;R+Y+*C.296K(X
M?ZIZ)4UV\*$W)B@MJ&C&3.M-G5%[I@7U&D+1S%0V*A"VJT#YSPGVF&GME(/S
M!DD+0&D$E!9"T<SL-J(4QN\\TV)(;6@.2@M :024%D+1S,)H5#!L5WUV.CC=
MJ!47A7CY6@OW=MKDV,5C?]+ZTG]N/X6#D[FG6P+J-NQP.W&*?[5;,P6-#H7M
M.M1YMMA$K+G5)/H/[?VK+#O[X-L.5)8"I1%06@A%,W/>R%+XO64I#"I+@=("
M4!H!I850-+,P&ED*OYDLA7<%(G_H^;C]W9']# [.Y7Y>":C7$(IF9JF1I;!=
MENIJV0?_A,+NX^ [%%2T J414%H(13-SWXA6^+U%*PPJ6H'2 E : :6%4#2S
M,!K1"K^9:(5WU2/?FTS\4;MU@VI6>WHEH%Y#*%J9I<'6ZS0I$W?%BT\217R3
MJ?(EB/IH_7+5:?%*4>OXF7LT=SN.!^X1*5^=:O#EFUP75-S%F40)6VI73M_7
M@13ERU'ECN+KXF6>6ZX43XO-%:,+)O(!^O,EY^IY)W=0OZ(V^Q]02P,$%
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M+\\KY4"RK3DC+)E4)PYSN5%G/.#Z!?5\Q9@\#72 ZM0X^0%02P,$%     @
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MVTZ09@-^GPFAMQ-CH&YDDS]02P,$%     @ ^("B5H,TXP: !P  K4D  !D
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M8Q1AGG=0WR\8D[M&/D!U$CGY#U!+ P04    " #X@*)6;%^6='P$  #U%0
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MKZ%]%\HKKJH'R[J/]09J479;'?-6J<M0=J_O#*\W?U[:_/'JTT]02P,$%
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MZY.UZ[_^I:"_YZVIN_=\-ORW<?4*4$L! A0#%     @ ^("B5@=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " #X@*)6$T['9.X    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " #X@*)6F5R<(Q &  "<)P  $P
M        @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( /B
MHE;+'<WZ\P4  ,0?   8              " @0T(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " #X@*)6]2,,0<\&   >'0  &
M        @($V#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%
M  @ ^("B5H&0_2"C @  ; <  !@              ("!.Q4  'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( /B HE8KA9$^[@8  /\B   8
M              " @108  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"
M% ,4    " #X@*)6E $H8!8,  !;?0  &               @($X'P  >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ ^("B5N$X5&T'!P
M[QP  !@              ("!A"L  'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;%!+ 0(4 Q0    ( /B HE;TPT&R]!(  /<Q   8              " @<$R
M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #X@*)6,ADP
M\!05   U30  &               @('K10  >&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL4$L! A0#%     @ ^("B5@^'VKGQ P  WP@  !@
M ("!-5L  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( /B
MHE:L^C]!3 ,  !L)   9              " @5Q?  !X;"]W;W)K<VAE971S
M+W-H965T,3 N>&UL4$L! A0#%     @ ^("B5F*.UON9!    0L  !D
M         ("!WV(  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M    " #X@*)6F !*?]8%  "N#0  &0              @(&O9P  >&PO=V]R
M:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( /B HE9)BD0.AP4  '8,
M   9              " @;QM  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
M4$L! A0#%     @ ^("B5FS4B;=3"   1A4  !D              ("!>G,
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " #X@*)6O:!?
M\- +  "P(   &0              @($$?   >&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;%!+ 0(4 Q0    ( /B HE8Q^D:+,0<  'P3   9
M  " @0N(  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @
M^("B5AMOER*T!@  &!   !D              ("!<X\  'AL+W=O<FMS:&5E
M=',O<VAE970Q-RYX;6Q02P$"% ,4    " #X@*)6#*BVN+H#  "Z"   &0
M            @(%>E@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4
M Q0    ( /B HE9=Q#&MGP(  .,%   9              " @4^:  !X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ ^("B5B3^G_]8 P
M8P<  !D              ("!)9T  'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"% ,4    " #X@*)6F#_EV:4#  !Q"   &0              @(&T
MH   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( /B HE9"
M.B$?'@,  )T&   9              " @9"D  !X;"]W;W)K<VAE971S+W-H
M965T,C(N>&UL4$L! A0#%     @ ^("B5KVN*)EA P  5@D  !D
M     ("!Y:<  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
M" #X@*)6CASPL)$#  #2"   &0              @(%]JP  >&PO=V]R:W-H
M965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( /B HE9SAW$#P@(  $@&   9
M              " @46O  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L!
M A0#%     @ ^("B5MSHJ5?2!   X0L  !D              ("!/K(  'AL
M+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #X@*)6 ;SJW!<&
M  #)#@  &0              @(%'MP  >&PO=V]R:W-H965T<R]S:&5E=#(W
M+GAM;%!+ 0(4 Q0    ( /B HE:&;5OK?P,  +0(   9              "
M@96]  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ ^("B
M5K@G?CT\ P  /P<  !D              ("!2\$  'AL+W=O<FMS:&5E=',O
M<VAE970R.2YX;6Q02P$"% ,4    " #X@*)6Z&%E4; %  "A*@  &0
M        @(&^Q   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0
M   ( /B HE9$+B)Q7 0  /$;   9              " @:7*  !X;"]W;W)K
M<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ ^("B5AB_/_29 @  008
M !D              ("!.,\  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q0
M2P$"% ,4    " #X@*)6Q%L8O-0$  "U(   &0              @($(T@
M>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( /B HE85?.NH
MG04  +LL   9              " @1/7  !X;"]W;W)K<VAE971S+W-H965T
M,S0N>&UL4$L! A0#%     @ ^("B5E>*:.T["   _$X  !D
M ("!Y]P  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #X
M@*)6$G4A&. '  #G6   &0              @(%9Y0  >&PO=V]R:W-H965T
M<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( /B HE9 U%@X]00  ((E   9
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M970T,2YX;6Q02P$"% ,4    " #X@*)6A<.5580%  !6*@  &0
M    @(&' @$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (
M /B HE;S2 1AT0(  )H)   9              " @4(( 0!X;"]W;W)K<VAE
M971S+W-H965T-#,N>&UL4$L! A0#%     @ ^("B5@#J;0]P!0  W"L  !D
M             ("!2@L! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"
M% ,4    " #X@*)6:\=!Q+@%   ++@  &0              @('Q$ $ >&PO
M=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( /B HE9LT^QYD <
M ']-   9              " @> 6 0!X;"]W;W)K<VAE971S+W-H965T-#8N
M>&UL4$L! A0#%     @ ^("B5F8V;O^5!   -QL  !D              ("!
MIQX! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " #X@*)6
MA@*UIO$"   F"   &0              @(%S(P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0X+GAM;%!+ 0(4 Q0    ( /B HE8>Y@X#V (  + '   9
M      " @9LF 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%
M  @ ^("B5DM5RJ&,!@  KC8  !D              ("!JBD! 'AL+W=O<FMS
M:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " #X@*)6$]C+6A0%  #L)
M&0              @(%M, $ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+
M 0(4 Q0    ( /B HE:YA]? ^0,  $$.   9              " @;@U 0!X
M;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ ^("B5ED[9\#:
M @  % <  !D              ("!Z#D! 'AL+W=O<FMS:&5E=',O<VAE970U
M,RYX;6Q02P$"% ,4    " #X@*)6YVO6GU0#  #4"@  &0
M@('Y/ $ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( /B
MHE:#-.,&@ <  *U)   9              " @81  0!X;"]W;W)K<VAE971S
M+W-H965T-34N>&UL4$L! A0#%     @ ^("B5OU_D)R\!   E1P  !D
M         ("!.T@! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4
M    " #X@*)6;%^6='P$  #U%0  &0              @($N30$ >&PO=V]R
M:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( /B HE94%E6O1P,  ,H4
M   -              "  >%1 0!X;"]S='EL97,N>&UL4$L! A0#%     @
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H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !! $$ OA$  !Y? 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>247</ContextCount>
  <ElementCount>275</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>72</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Organization and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Liability Related to the Sale of Future Royalties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties</Role>
      <ShortName>Liability Related to the Sale of Future Royalties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Organization and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Organization and Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Collaboration and License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables</Role>
      <ShortName>Collaboration and License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/PropertyandEquipment</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/Investments</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/IntangibleAssets</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/StockholdersEquity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/Leases</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/StockBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/FairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/EarningsPerShare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Organization and Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Collaboration and License Agreements - Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails</Role>
      <ShortName>Collaboration and License Agreements - Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Collaboration and License Agreements - Receivables and Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails</Role>
      <ShortName>Collaboration and License Agreements - Receivables and Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails</Role>
      <ShortName>Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails</Role>
      <ShortName>Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails</Role>
      <ShortName>Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Collaboration and License Agreements - Janssen Pharmaceuticals, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails</Role>
      <ShortName>Collaboration and License Agreements - Janssen Pharmaceuticals, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Collaboration and License Agreements - Amgen, Inc (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails</Role>
      <ShortName>Collaboration and License Agreements - Amgen, Inc (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails</Role>
      <ShortName>Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Property and Equipment - Summary of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail</Role>
      <ShortName>Property and Equipment - Summary of Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Property and Equipment - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails</Role>
      <ShortName>Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Intangible Assets - Expected Future Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails</Role>
      <ShortName>Intangible Assets - Expected Future Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/StockholdersEquityTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Leases - Components of Lease Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails</Role>
      <ShortName>Leases - Components of Lease Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails</Role>
      <ShortName>Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Stock-Based Compensation - Summarize Information about Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Summarize Information about Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Stock-Based Compensation - Assumptions Used to Value Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Assumptions Used to Value Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of RSUs Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Liability Related to the Sale of Future Royalties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails</Role>
      <ShortName>Liability Related to the Sale of Future Royalties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="arwr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/EarningsPerShareTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="arwr-20230331.htm">arwr-20230331.htm</File>
    <File>arrowheadpharmaceuticals.htm</File>
    <File>arwr-20230331.xsd</File>
    <File>arwr-20230331_cal.xml</File>
    <File>arwr-20230331_def.xml</File>
    <File>arwr-20230331_lab.xml</File>
    <File>arwr-20230331_pre.xml</File>
    <File>arwr-20230331xexx311.htm</File>
    <File>arwr-20230331xexx312.htm</File>
    <File>arwr-20230331xexx321.htm</File>
    <File>arwr-20230331xexx322.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="658">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>82
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "arwr-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 22,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 658,
    "http://xbrl.sec.gov/dei/2022": 30
   },
   "contextCount": 247,
   "dts": {
    "calculationLink": {
     "local": [
      "arwr-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "arwr-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "arwr-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "arwr-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "arwr-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "arwr-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 454,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 47,
   "keyStandard": 228,
   "memberCustom": 39,
   "memberStandard": 28,
   "nsprefix": "arwr",
   "nsuri": "http://www.arrowheadresearch.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.arrowheadresearch.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Investments",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.arrowheadresearch.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Intangible Assets",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.arrowheadresearch.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.arrowheadresearch.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.arrowheadresearch.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.arrowheadresearch.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Liability Related to the Sale of Future Royalties",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties",
     "shortName": "Liability Related to the Sale of Future Royalties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Earnings Per Share",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.arrowheadresearch.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Organization and Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "19",
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i8658828dac144310891d79034519aac1_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i8658828dac144310891d79034519aac1_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "arwr:ScheduleOfCurrentProductsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Organization and Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables",
     "shortName": "Organization and Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "arwr:ScheduleOfCurrentProductsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Collaboration and License Agreements (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables",
     "shortName": "Collaboration and License Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.arrowheadresearch.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Investments (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.arrowheadresearch.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.arrowheadresearch.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.arrowheadresearch.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.arrowheadresearch.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Earnings Per Share (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.arrowheadresearch.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i8658828dac144310891d79034519aac1_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i8658828dac144310891d79034519aac1_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Organization and Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "arwr:IncreaseDecreaseInCashAndInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Collaboration and License Agreements - Revenue (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails",
     "shortName": "Collaboration and License Agreements - Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i15c28c33dc6b4b10bbc915f499ad8066_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i8658828dac144310891d79034519aac1_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Collaboration and License Agreements - Receivables and Contract Liabilities (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails",
     "shortName": "Collaboration and License Agreements - Receivables and Contract Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i8658828dac144310891d79034519aac1_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i8658828dac144310891d79034519aac1_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
     "shortName": "Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i691de1d520624cd1b1ffd39dc3bdc01d_I20211122",
      "decimals": "-5",
      "lang": "en-US",
      "name": "arwr:MilestonePaymentEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i8658828dac144310891d79034519aac1_I20230331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "arwr:DevelopmentRegulatoryAndSalesMilestonesPayments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
     "shortName": "Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i3d90a2de7f4e49f596cb460bdc10f3ca_I20210731",
      "decimals": "-5",
      "lang": "en-US",
      "name": "arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i8658828dac144310891d79034519aac1_I20230331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "arwr:DevelopmentRegulatoryAndSalesMilestonesPayments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
     "shortName": "Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i3776d7ed0187438ba605de53d95d0524_I20210131",
      "decimals": "-5",
      "lang": "en-US",
      "name": "arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i8658828dac144310891d79034519aac1_I20230331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "arwr:DevelopmentRegulatoryAndSalesMilestonesPayments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Collaboration and License Agreements - Janssen Pharmaceuticals, Inc. (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
     "shortName": "Collaboration and License Agreements - Janssen Pharmaceuticals, Inc. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i66aef91f08484848847318e56657242a_D20181003-20181003",
      "decimals": "-5",
      "lang": "en-US",
      "name": "arwr:CashReceivedAsDueUnderCollaborationAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i8658828dac144310891d79034519aac1_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Collaboration and License Agreements - Amgen, Inc (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
     "shortName": "Collaboration and License Agreements - Amgen, Inc (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i57ec6b70a6104026b8b41cb652df4ebb_I20160928",
      "decimals": "INF",
      "lang": "en-US",
      "name": "arwr:NumberOfAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "agreement",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromContributedCapital",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
     "shortName": "Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i6bca132899c842c2905496adc8f95181_D20221001-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i8658828dac144310891d79034519aac1_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Property and Equipment - Summary of Property and Equipment (Detail)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail",
     "shortName": "Property and Equipment - Summary of Property and Equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i8658828dac144310891d79034519aac1_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Property and Equipment - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetail",
     "shortName": "Property and Equipment - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i8658828dac144310891d79034519aac1_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HeldToMaturitySecuritiesCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails",
     "shortName": "Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i8658828dac144310891d79034519aac1_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i8658828dac144310891d79034519aac1_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
     "shortName": "Intangible Assets - Schedule of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AmortizationOfIntangibleAssets",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i8658828dac144310891d79034519aac1_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Intangible Assets - Expected Future Amortization (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails",
     "shortName": "Intangible Assets - Expected Future Amortization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i8658828dac144310891d79034519aac1_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i8658828dac144310891d79034519aac1_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Stockholders' Equity (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.arrowheadresearch.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i8658828dac144310891d79034519aac1_I20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i8658828dac144310891d79034519aac1_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i174690ddc75d4855ac133c1051fa0058_I20211220",
      "decimals": "-5",
      "lang": "en-US",
      "name": "arwr:TaxIncrementFinancingAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i8658828dac144310891d79034519aac1_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShortTermLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i8658828dac144310891d79034519aac1_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Leases - Components of Lease Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails",
     "shortName": "Leases - Components of Lease Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i8658828dac144310891d79034519aac1_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails",
     "shortName": "Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i8658828dac144310891d79034519aac1_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails",
     "shortName": "Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "iadfd6b159c9446f4ad12848ede62bfea_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements of Stockholders\u2019 Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i26989504186e41ed84cd5f5d555e3de0_D20211001-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "ie621a6d7b2894935b2a8275238e99a30_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "ie621a6d7b2894935b2a8275238e99a30_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i8658828dac144310891d79034519aac1_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
     "shortName": "Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i8658828dac144310891d79034519aac1_I20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i0f0b57d9696a4178850cfeeb887a0527_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Stock-Based Compensation - Summarize Information about Stock Options (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails",
     "shortName": "Stock-Based Compensation - Summarize Information about Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Stock-Based Compensation - Assumptions Used to Value Stock Options (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails",
     "shortName": "Stock-Based Compensation - Assumptions Used to Value Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "id9777e3d0f0044f9a5ae125314a8b62e_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of RSUs Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "ied3ebc51b45741a1b31064cbf68604f1_D20221001-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i04d5b678d5744ea1bb9862b56fd512dd_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i04d5b678d5744ea1bb9862b56fd512dd_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Liability Related to the Sale of Future Royalties (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails",
     "shortName": "Liability Related to the Sale of Future Royalties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "ie3454e80f761434b82e05233642d0a59_D20221109-20221109",
      "decimals": "-5",
      "lang": "en-US",
      "name": "arwr:CashReceivedAsDueUnderCollaborationAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Earnings Per Share (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.arrowheadresearch.com/role/EarningsPerShareDetails",
     "shortName": "Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i6aac1ab0581f48c6b564d72f2534d29d_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Organization and Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies",
     "shortName": "Organization and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Collaboration and License Agreements",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Property and Equipment",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.arrowheadresearch.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20230331.htm",
      "contextRef": "i2413801f016643d1afe7ea8782b19367_D20221001-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 72,
   "tag": {
    "arwr_AROXDHAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ARO-XDH Agreement.",
        "label": "A R O X D H Agreement [Member]",
        "terseLabel": "ARO-XDH"
       }
      }
     },
     "localname": "AROXDHAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional remaining development regulatory and sales milestones payments.",
        "label": "Additional Remaining Development Regulatory And Sales Milestones Payments",
        "terseLabel": "Additional remaining development regulatory and sales milestones payments"
       }
      }
     },
     "localname": "AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_AmgenIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amgen Incorporated.",
        "label": "Amgen Incorporated [Member]",
        "terseLabel": "Amgen"
       }
      }
     },
     "localname": "AmgenIncorporatedMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_AmountIntendsToInvestForBuildoutOfFacilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount intends to invest for buildout of facilities.",
        "label": "Amount Intends To Invest For Buildout Of Facilities",
        "terseLabel": "Amount intends to invest for buildout of the facilities"
       }
      }
     },
     "localname": "AmountIntendsToInvestForBuildoutOfFacilities",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_AtTheMarketAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-market agreement.",
        "label": "At The Market Agreement [Member]",
        "terseLabel": "At The Market Agreement"
       }
      }
     },
     "localname": "AtTheMarketAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash receivable as upfront payment due under collaboration agreement.",
        "label": "Cash Receivable As Upfront Payment Due Under Collaboration Agreement",
        "terseLabel": "Cash received as due under collaboration agreement"
       }
      }
     },
     "localname": "CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CashReceivedAsDueUnderCollaborationAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received as due under collaboration agreement.",
        "label": "Cash Received As Due Under Collaboration Agreement",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "CashReceivedAsDueUnderCollaborationAgreement",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreements.",
        "label": "Collaboration And License Agreement [Member]",
        "terseLabel": "Collaboration and License agreements"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreements.",
        "label": "Collaboration And License Agreements [Abstract]",
        "terseLabel": "Collaboration And License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "xbrltype": "stringItemType"
    },
    "arwr_ColoradoOwnerLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Colorado Owner, LLC.",
        "label": "Colorado Owner L L C [Member]",
        "terseLabel": "Colorado Owner, LLC"
       }
      }
     },
     "localname": "ColoradoOwnerLLCMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CommercialMilestonePaymentsAtFirstCommercialSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial milestone payments at first commercial sale.",
        "label": "Commercial Milestone Payments At First Commercial Sale",
        "terseLabel": "Commercial milestone payments at first commercial sale"
       }
      }
     },
     "localname": "CommercialMilestonePaymentsAtFirstCommercialSale",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CommercialNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Notes",
        "label": "Commercial Notes [Member]",
        "terseLabel": "Commercial notes"
       }
      }
     },
     "localname": "CommercialNotesMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CommonStockCapitalSharesValueReservedForFutureIssuance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock, capital shares value reserved for future issuance.",
        "label": "Common Stock Capital Shares Value Reserved For Future Issuance",
        "terseLabel": "Common stock shares value reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesValueReservedForFutureIssuance",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CommonStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock purchase agreement.",
        "label": "Common Stock Purchase Agreement [Member]",
        "terseLabel": "Common Stock Purchase Agreement"
       }
      }
     },
     "localname": "CommonStockPurchaseAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computers, software, office equipment and furniture gross.",
        "label": "Computers Software Office Equipment And Furniture Gross",
        "terseLabel": "Computers, software, office equipment and furniture"
       }
      }
     },
     "localname": "ComputersSoftwareOfficeEquipmentAndFurnitureGross",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CorporateHeadquartersInPasadenaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Headquarters in Pasadena",
        "label": "Corporate Headquarters In Pasadena [Member]",
        "terseLabel": "Corporate Headquarters In Pasadena"
       }
      }
     },
     "localname": "CorporateHeadquartersInPasadenaMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Current",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Current",
        "terseLabel": "Short-term investments, Held to maturity, Gross Unrealized Gains"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Noncurrent",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Noncurrent",
        "terseLabel": "Long-term investments, Held to maturity, Gross Unrealized Gains"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Current",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Current",
        "negatedTerseLabel": "Short-term investments, Held to maturity, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Noncurrent",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Noncurrent",
        "negatedTerseLabel": "Long-term investments, Held to maturity, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_DeferredRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred revenue.",
        "label": "Deferred Revenue [Member]",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "DeferredRevenueMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_DevelopmentRegulatoryAndSalesMilestonesPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development regulatory and sales milestones payments.",
        "label": "Development Regulatory And Sales Milestones Payments",
        "terseLabel": "Development regulatory and sales milestones payments",
        "verboseLabel": "Development, regulatory and sales milestones payments"
       }
      }
     },
     "localname": "DevelopmentRegulatoryAndSalesMilestonesPayments",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_DrugManufacturingFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Drug manufacturing facility.",
        "label": "Drug Manufacturing Facility [Member]",
        "terseLabel": "Drug Manufacturing Facility"
       }
      }
     },
     "localname": "DrugManufacturingFacilityMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_EstimatedPaymentsForOperatingExpensesYearOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated payments for operating expenses year one.",
        "label": "Estimated Payments For Operating Expenses Year One",
        "terseLabel": "Estimated payments for operating expenses"
       }
      }
     },
     "localname": "EstimatedPaymentsForOperatingExpensesYearOne",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_FacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facilities.",
        "label": "Facilities [Member]",
        "terseLabel": "Facilities"
       }
      }
     },
     "localname": "FacilitiesMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_FiniteLivedIntangibleAssetsImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Impairment",
        "label": "Finite-Lived Intangible Assets, Impairment",
        "terseLabel": "Impairment"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsImpairment",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_GlaxosmithklineIntellectualPropertyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glaxosmithkline Intellectual Property Limited.",
        "label": "Glaxosmithkline Intellectual Property Limited [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "localname": "GlaxosmithklineIntellectualPropertyLimitedMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Held to maturity securities and marketable securities.",
        "label": "Held To Maturity Securities And Marketable Securities Table [Table Text Block]",
        "terseLabel": "Summary of Short-term and Long-term Investments and Marketable Securities"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "arwr_HorizonTherapeuticsIrelandDACAndAmgenIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Horizon Therapeutics Ireland DAC and Amgen Incorporated",
        "label": "Horizon Therapeutics Ireland DAC and Amgen Incorporated [Member]",
        "terseLabel": "Horizon and Amgen"
       }
      }
     },
     "localname": "HorizonTherapeuticsIrelandDACAndAmgenIncorporatedMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_HorizonTherapeuticsIrelandDACMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Horizon Therapeutics Ireland DAC.",
        "label": "Horizon Therapeutics Ireland DAC [Member]",
        "terseLabel": "Horizon"
       }
      }
     },
     "localname": "HorizonTherapeuticsIrelandDACMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_IncreaseDecreaseInCashAndInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in cash and investments.",
        "label": "Increase (Decrease) In Cash And Investments",
        "terseLabel": "Increase in cash and investments"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndInvestments",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_InducementAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inducement Awards",
        "label": "Inducement Awards [Member]",
        "terseLabel": "Inducement Awards"
       }
      }
     },
     "localname": "InducementAwardsMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_InitialTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial transaction price.",
        "label": "Initial Transaction Price",
        "terseLabel": "Initial transaction price"
       }
      }
     },
     "localname": "InitialTransactionPrice",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_JNJ3989AROHBVAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "JNJ-3989 (ARO-HBV) Agreement.",
        "label": "J N J3989 A R O H B V Agreement [Member]",
        "terseLabel": "JNJ-3989 (ARO-HBV) Agreement"
       }
      }
     },
     "localname": "JNJ3989AROHBVAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_JNJ75220795AROJNJ1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "JNJ 75220795 ARO JNJ1.",
        "label": "J N J75220795 A R O J N J1 [Member]",
        "terseLabel": "JNJ-75220795 (ARO-JNJ1)"
       }
      }
     },
     "localname": "JNJ75220795AROJNJ1Member",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_JanssenPharmaceuticalsIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Pharmaceuticals, Incorporation.",
        "label": "Janssen Pharmaceuticals Incorporation [Member]",
        "terseLabel": "Janssen"
       }
      }
     },
     "localname": "JanssenPharmaceuticalsIncorporationMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Johnson and Johnson Innovation-JJDC, Incorporation.",
        "label": "Johnson And Johnson Innovation J J D C Incorporation [Member]",
        "terseLabel": "JJDC"
       }
      }
     },
     "localname": "JohnsonAndJohnsonInnovationJJDCIncorporationMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_LaboratoryAndOfficeFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory and office facility.",
        "label": "Laboratory And Office Facility [Member]",
        "terseLabel": "Laboratory and Office Facility"
       }
      }
     },
     "localname": "LaboratoryAndOfficeFacilityMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due year five and after year five.",
        "label": "Lessee Operating Lease Liability Payments Due Year Five And After Year Five",
        "terseLabel": "2028 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability Related To The Sale Of Future Royalties",
        "label": "Liability Related To The Sale Of Future Royalties [Abstract]"
       }
      }
     },
     "localname": "LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "xbrltype": "stringItemType"
    },
    "arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability Related To The Sale Of Future Royalties",
        "label": "Liability Related To The Sale Of Future Royalties [Text Block]",
        "terseLabel": "Liability Related to the Sale of Future Royalties"
       }
      }
     },
     "localname": "LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "arwr_LiabilitySaleOfFutureRoyalties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability, Sale of Future Royalties",
        "label": "Liability, Sale of Future Royalties",
        "terseLabel": "Liability related to the sale of future royalties"
       }
      }
     },
     "localname": "LiabilitySaleOfFutureRoyalties",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_LicenseAndCoFundingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and co-funding agreement.",
        "label": "License And Co Funding Agreement [Member]",
        "terseLabel": "License and Co-Funding Agreement"
       }
      }
     },
     "localname": "LicenseAndCoFundingAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_MilestonePaymentEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment earned.",
        "label": "Milestone Payment Earned",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePaymentEarned",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Receivable",
        "label": "Milestone Payment Receivable",
        "terseLabel": "Milestone payment receivable"
       }
      }
     },
     "localname": "MilestonePaymentReceivable",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePaymentReceivableAtStartOfPhaseTwo": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment receivable at start of phase two.",
        "label": "Milestone Payment Receivable At Start Of Phase Two",
        "terseLabel": "Milestone payment receivable at start of phase two"
       }
      }
     },
     "localname": "MilestonePaymentReceivableAtStartOfPhaseTwo",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Receivable Upon Achievement of Enrollment in Phase 3 Clinical Trial",
        "label": "Milestone Payment Receivable Upon Achievement of Enrollment in Phase 3 Clinical Trial",
        "terseLabel": "Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial"
       }
      }
     },
     "localname": "MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment receivable upon achievement of phase two and first patient dosed in phase three.",
        "label": "Milestone Payment Receivable Upon Achievement Of Phase Two And First Patient Dosed In Phase Three",
        "terseLabel": "Milestone payment receivable upon achievement of phase two and first patient dosed in phase three"
       }
      }
     },
     "localname": "MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePaymentReceivableUponFDAApproval": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Receivable Upon FDA Approval",
        "label": "Milestone Payment Receivable Upon FDA Approval",
        "terseLabel": "Milestone payment receivable upon FDA approval"
       }
      }
     },
     "localname": "MilestonePaymentReceivableUponFDAApproval",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Receivable, Upon Receipt Of Royalty Payments",
        "label": "Milestone Payment Receivable, Upon Receipt Of Royalty Payments",
        "terseLabel": "Milestone payment receivable upon receipt of royalty payments"
       }
      }
     },
     "localname": "MilestonePaymentReceivableUponReceiptOfRoyaltyPayments",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment received.",
        "label": "Milestone Payment Received",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePaymentReceived",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "Milestone Payments",
        "verboseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Interest Expense, Liability Related to Sale of Future Royalties",
        "label": "Non-Cash Interest Expense, Liability Related to Sale of Future Royalties",
        "terseLabel": "Non-cash interest expense on liability related to the sale of future royalties"
       }
      }
     },
     "localname": "NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_NovartisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis.",
        "label": "Novartis [Member]",
        "terseLabel": "Novartis"
       }
      }
     },
     "localname": "NovartisMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_NumberOfAcresOfLandPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of acres of land purchased.",
        "label": "Number Of Acres Of Land Purchased",
        "terseLabel": "Land purchased, number of acres"
       }
      }
     },
     "localname": "NumberOfAcresOfLandPurchased",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_NumberOfAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of agreements.",
        "label": "Number Of Agreements",
        "terseLabel": "Number of agreements"
       }
      }
     },
     "localname": "NumberOfAgreements",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_NumberOfDistinctBundle": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of distinct bundle.",
        "label": "Number Of Distinct Bundle",
        "terseLabel": "Number of distinct bundle"
       }
      }
     },
     "localname": "NumberOfDistinctBundle",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_NumberOfDistinctPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of distinct performance obligations.",
        "label": "Number Of Distinct Performance Obligations",
        "terseLabel": "Number of distinct performance obligations"
       }
      }
     },
     "localname": "NumberOfDistinctPerformanceObligations",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_NumberOfOptionsToRenew": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options to renew.",
        "label": "Number Of Options To Renew",
        "terseLabel": "Number of options to renew"
       }
      }
     },
     "localname": "NumberOfOptionsToRenew",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_OlpasiranAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Olpasiran agreement.",
        "label": "Olpasiran Agreement [Member]",
        "terseLabel": "Olpasiran Agreement"
       }
      }
     },
     "localname": "OlpasiranAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_OlpasiranAndAROAMG1AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Olpasiran and ARO-AMG1 agreement.",
        "label": "Olpasiran And A R O A M G1 Agreement [Member]",
        "terseLabel": "Olpasiran and ARO-AMG1 Agreement"
       }
      }
     },
     "localname": "OlpasiranAndAROAMG1AgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_OrganizationAndSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and significant accounting policies.",
        "label": "Organization And Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization And Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "arwr_OrganizationAndSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and significant accounting policies.",
        "label": "Organization And Significant Accounting Policies [Table]",
        "terseLabel": "Organization And Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSignificantAccountingPoliciesTable",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of leasehold improvements net of tenant improvement allowances.",
        "label": "Payments Of Leasehold Improvements Net Of Tenant Improvement Allowances",
        "terseLabel": "Payments for leasehold improvements, net of tenant improvement allowances"
       }
      }
     },
     "localname": "PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of commission on aggregate gross proceeds from sale of common stock.",
        "label": "Percentage Of Commission On Aggregate Gross Proceeds From Sale Of Common Stock",
        "terseLabel": "Percentage of commission to sales agent"
       }
      }
     },
     "localname": "PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of eligible to receive tiered royalties on net sales.",
        "label": "Percentage Of Eligible To Receive Tiered Royalties On Net Sales",
        "terseLabel": "Percentage of eligible to receive tiered royalties on net sales"
       }
      }
     },
     "localname": "PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arwr_ResearchEquipmentGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research equipment gross.",
        "label": "Research Equipment Gross",
        "terseLabel": "Research equipment"
       }
      }
     },
     "localname": "ResearchEquipmentGross",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_ResearchFacilityInMadisonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research facility in Madison.",
        "label": "Research Facility In Madison [Member]",
        "terseLabel": "Research Facility in Madison"
       }
      }
     },
     "localname": "ResearchFacilityInMadisonMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_ResearchFacilityInSanDiegoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Facility in San Diego.",
        "label": "Research Facility In San Diego [Member]",
        "terseLabel": "Research Facility in San Diego"
       }
      }
     },
     "localname": "ResearchFacilityInSanDiegoMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_RoyaltiesLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties, Liability, Noncurrent",
        "label": "Royalties, Liability, Noncurrent",
        "terseLabel": "Liability related to the sale of future royalties"
       }
      }
     },
     "localname": "RoyaltiesLiabilityNoncurrent",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_RoyaltyPaymentThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Payment Threshold",
        "label": "Royalty Payment Threshold",
        "terseLabel": "Royalty payment threshold"
       }
      }
     },
     "localname": "RoyaltyPaymentThreshold",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_RoyaltyPharmaAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Pharma Agreement",
        "label": "Royalty Pharma Agreement [Member]",
        "terseLabel": "Royalty Pharma Agreement"
       }
      }
     },
     "localname": "RoyaltyPharmaAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_RoyaltyPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Pharma",
        "label": "Royalty Pharma [Member]",
        "terseLabel": "Royalty Pharma"
       }
      }
     },
     "localname": "RoyaltyPharmaMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_SalesRelatedMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-related milestone payments.",
        "label": "Sales Related Milestone Payments",
        "terseLabel": "Sales-related milestone payments"
       }
      }
     },
     "localname": "SalesRelatedMilestonePayments",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_ScheduleOfCurrentProductsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Current Products",
        "label": "Schedule of Current Products [Table Text Block]",
        "terseLabel": "Schedule of Company's Current Pipeline"
       }
      }
     },
     "localname": "ScheduleOfCurrentProductsTableTextBlock",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of held to maturity securities and marketable securities.",
        "label": "Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]",
        "terseLabel": "Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of held to maturity securities and marketable securities.",
        "label": "Schedule Of Held To Maturity Securities And Marketable Securities [Table]",
        "terseLabel": "Schedule Of Held To Maturity Securities And Marketable Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding",
        "totalLabel": "Total (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "arwr_SorrentoValleyOwnerDELLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sorrento Valley Owner (DE) LLC",
        "label": "Sorrento Valley Owner (DE) LLC [Member]",
        "terseLabel": "Sorrento Valley Owner (DE) LLC"
       }
      }
     },
     "localname": "SorrentoValleyOwnerDELLCMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda Pharmaceuticals United States of America Incorporated.",
        "label": "Takeda Pharmaceuticals United States Of America Incorporated [Member]",
        "terseLabel": "Takeda"
       }
      }
     },
     "localname": "TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TaxIncrementFinancingAward": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Increment Financing Award",
        "label": "Tax Increment Financing Award",
        "terseLabel": "Tax increment financing award"
       }
      }
     },
     "localname": "TaxIncrementFinancingAward",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_TechnologyLicenseCommitmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology license commitments.",
        "label": "Technology License Commitments [Member]",
        "terseLabel": "Technology License Commitments"
       }
      }
     },
     "localname": "TechnologyLicenseCommitmentsMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand four equity incentive plan two thousand thirteen equity incentive plan Two thousand twenty one equity incentive plan and inducement grants.",
        "label": "Two Thousand Four Equity Incentive Plan Two Thousand Thirteen Equity Incentive Plan Two Thousand Twenty One Equity Incentive Plan And Inducement Grants [Member]",
        "terseLabel": "2004 Equity Incentive Plan, 2013 Equity Incentive Plan, 2021 Equity Incentive Plan and Inducement Grants"
       }
      }
     },
     "localname": "TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TwoThousandTwentyOneIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one incentive plan.",
        "label": "Two Thousand Twenty One Incentive Plan [Member]",
        "terseLabel": "2021 Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyOneIncentivePlanMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TwoThousandsFourEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousands four equity incentive plan.",
        "label": "Two Thousands Four Equity Incentive Plan [Member]",
        "terseLabel": "2004 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandsFourEquityIncentivePlanMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TwoThousandsThirteenIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousands thirteen incentive plan.",
        "label": "Two Thousands Thirteen Incentive Plan [Member]",
        "terseLabel": "2013 Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandsThirteenIncentivePlanMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_UpfrontMilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront milestone payment received.",
        "label": "Upfront Milestone Payment Received",
        "terseLabel": "Upfront milestone payment received"
       }
      }
     },
     "localname": "UpfrontMilestonePaymentReceived",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_VeronaTechnologyParkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Verona technology park.",
        "label": "Verona Technology Park [Member]",
        "terseLabel": "Verona Technology Park"
       }
      }
     },
     "localname": "VeronaTechnologyParkMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_VisirnaLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Visirna License Agreement",
        "label": "Visirna License Agreement [Member]",
        "terseLabel": "Visirna License Agreement"
       }
      }
     },
     "localname": "VisirnaLicenseAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_VisirnaTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Visirna Therapeutics, Inc.",
        "label": "Visirna Therapeutics, Inc. [Member]",
        "terseLabel": "Visirna Therapeutics, Inc."
       }
      }
     },
     "localname": "VisirnaTherapeuticsIncMember",
     "nsuri": "http://www.arrowheadresearch.com/20230331",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "verboseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r165",
      "r335",
      "r336",
      "r339",
      "r340",
      "r377",
      "r446",
      "r507",
      "r510",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r165",
      "r335",
      "r336",
      "r339",
      "r340",
      "r377",
      "r446",
      "r507",
      "r510",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r163",
      "r164",
      "r253",
      "r258",
      "r452",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r210",
      "r463",
      "r514",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r286",
      "r409",
      "r424",
      "r447",
      "r448",
      "r460",
      "r471",
      "r479",
      "r512",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r286",
      "r409",
      "r424",
      "r447",
      "r448",
      "r460",
      "r471",
      "r479",
      "r512",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r210",
      "r463",
      "r514",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r279",
      "r286",
      "r313",
      "r314",
      "r315",
      "r385",
      "r409",
      "r424",
      "r447",
      "r448",
      "r460",
      "r471",
      "r479",
      "r505",
      "r512",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r279",
      "r286",
      "r313",
      "r314",
      "r315",
      "r385",
      "r409",
      "r424",
      "r447",
      "r448",
      "r460",
      "r471",
      "r479",
      "r505",
      "r512",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r163",
      "r164",
      "r253",
      "r258",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r208",
      "r209",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r462",
      "r478",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r208",
      "r209",
      "r431",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r462",
      "r478",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_WI": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WISCONSIN",
        "terseLabel": "Wisconsin"
       }
      }
     },
     "localname": "WI",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14",
      "r477"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r419",
      "r432"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Receivables included in accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r211",
      "r212"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r61",
      "r134"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r141",
      "r420",
      "r429",
      "r430"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r22",
      "r25",
      "r97",
      "r376",
      "r425",
      "r426",
      "r489",
      "r490",
      "r491",
      "r495",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r322",
      "r323",
      "r324",
      "r495",
      "r496",
      "r497",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r86",
      "r87",
      "r288"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash flow from operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r41",
      "r53",
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities excluded from computation of diluted earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of Land",
        "terseLabel": "Planned area of the site (in sq ft)"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r109",
      "r118",
      "r137",
      "r161",
      "r198",
      "r201",
      "r205",
      "r217",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r335",
      "r339",
      "r353",
      "r477",
      "r508",
      "r509",
      "r552"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets and Liabilities, Lessee [Abstract]",
        "terseLabel": "Lease Assets and Liabilities"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r130",
      "r144",
      "r161",
      "r217",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r335",
      "r339",
      "r353",
      "r477",
      "r508",
      "r509",
      "r552"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r50",
      "r213",
      "r224",
      "r414"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Certificate of deposits"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r103",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r43",
      "r132",
      "r450"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market instruments"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r38",
      "r43",
      "r45"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "terseLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r38",
      "r43",
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "END OF PERIOD",
        "periodStartLabel": "BEGINNING OF PERIOD"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations [Abstract]",
        "terseLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r38",
      "r105"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificate of deposits"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r331",
      "r332",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r17",
      "r112",
      "r123"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r64",
      "r237",
      "r238",
      "r433",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserve for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r495",
      "r496",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r8",
      "r477"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value: Authorized 290,000 and 145,000 shares; issued and outstanding 106,869 and 105,960 shares"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r93",
      "r101",
      "r146",
      "r148",
      "r153",
      "r415",
      "r421"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Receivables and Contract Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r273",
      "r275",
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r273",
      "r274",
      "r278"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Contract liabilities included in deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r273",
      "r274",
      "r278"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r273",
      "r274",
      "r278"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r468",
      "r470",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent": {
     "auth_ref": [
      "r215"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), classified as current.",
        "label": "Debt Securities, Held-to-Maturity, Fair Value, Current",
        "terseLabel": "Short-term investments, Held to maturity, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityFairValueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent": {
     "auth_ref": [
      "r215"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.",
        "label": "Debt Securities, Held-to-Maturity, Fair Value, Noncurrent",
        "terseLabel": "Long-term investments, Held to maturity, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityFairValueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "terseLabel": "Debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r41",
      "r59"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r41",
      "r196"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense for property and equipment"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r277",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Summary of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r290",
      "r318",
      "r319",
      "r321",
      "r325",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r154",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r179",
      "r181",
      "r183",
      "r184",
      "r185",
      "r189",
      "r344",
      "r345",
      "r416",
      "r422",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://www.arrowheadresearch.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r154",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r181",
      "r183",
      "r184",
      "r185",
      "r189",
      "r344",
      "r345",
      "r416",
      "r422",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://www.arrowheadresearch.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Net income (loss) per share attributable to Arrowhead Pharmaceuticals, Inc.:"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued payroll and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period to recognize pre-tax compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r542"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized pre-tax compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r542"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized pre-tax compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r69",
      "r127",
      "r149",
      "r150",
      "r151",
      "r166",
      "r167",
      "r168",
      "r170",
      "r176",
      "r178",
      "r191",
      "r218",
      "r272",
      "r322",
      "r323",
      "r324",
      "r327",
      "r328",
      "r343",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r376",
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r346",
      "r347",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r254",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r347",
      "r382",
      "r383",
      "r384",
      "r458",
      "r459",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r346",
      "r347",
      "r348",
      "r349",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r254",
      "r280",
      "r285",
      "r347",
      "r382",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r254",
      "r280",
      "r285",
      "r347",
      "r383",
      "r458",
      "r459",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r254",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r347",
      "r384",
      "r458",
      "r459",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r254",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r382",
      "r383",
      "r384",
      "r458",
      "r459",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r350",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r214",
      "r216",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r225",
      "r226",
      "r227",
      "r255",
      "r269",
      "r341",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r457",
      "r500",
      "r501",
      "r502",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful Lives"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r135",
      "r232"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2023 (remainder)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r56",
      "r413"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r54",
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r56",
      "r412"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails",
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesCurrent": {
     "auth_ref": [
      "r49",
      "r499",
      "r504"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current",
        "terseLabel": "Short term investments",
        "totalLabel": "Short-term investments, Held to maturity, Adjusted Bases"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "auth_ref": [
      "r51",
      "r215",
      "r414"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Fair Value",
        "terseLabel": "Held to maturity securities"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesNoncurrent": {
     "auth_ref": [
      "r49",
      "r499",
      "r504"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Long-term investments",
        "totalLabel": "Long-term investments, Held to maturity, Adjusted Basis"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r26",
      "r107",
      "r113",
      "r125",
      "r198",
      "r200",
      "r204",
      "r206",
      "r417",
      "r456"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income tax expense and noncontrolling interest"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r162",
      "r177",
      "r178",
      "r197",
      "r326",
      "r329",
      "r330",
      "r423"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "auth_ref": [
      "r543"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "terseLabel": "State income tax credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes (paid) refunded"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r410",
      "r492"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r492",
      "r549"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r106",
      "r115",
      "r152",
      "r195",
      "r362"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r155",
      "r158",
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Interest and Dividend",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterestAndDividend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedLabel": "(Accretion) amortization of note premiums/discounts"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r52",
      "r108",
      "r116",
      "r126",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Land": {
     "auth_ref": [
      "r488"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.",
        "label": "Land",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "Land",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land subject to a ground lease.",
        "label": "Land Subject to Ground Leases",
        "terseLabel": "Office space leases (in sq ft)"
       }
      }
     },
     "localname": "LandSubjectToGroundLeases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r373",
      "r476"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease Cost"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Assets and Liabilities and Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements, Gross",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Estimated lease payments",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r551"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2023 (remainder of fiscal year)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r13",
      "r111",
      "r121",
      "r477",
      "r494",
      "r503",
      "r547"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities, Noncontrolling Interest and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r16",
      "r131",
      "r161",
      "r217",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r336",
      "r339",
      "r340",
      "r353",
      "r477",
      "r508",
      "r552",
      "r553"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r161",
      "r217",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r336",
      "r339",
      "r340",
      "r353",
      "r508",
      "r552",
      "r553"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r239",
      "r487"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Contingent liabilities"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r20",
      "r110",
      "r120",
      "r161",
      "r217",
      "r244",
      "r246",
      "r247",
      "r248",
      "r251",
      "r252",
      "r353"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r76",
      "r94",
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedTerseLabel": "Interest in joint venture"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market instruments"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Municipal securities"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r157"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r157"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r38",
      "r39",
      "r42"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash (used in) provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r27",
      "r42",
      "r114",
      "r124",
      "r129",
      "r145",
      "r147",
      "r151",
      "r161",
      "r169",
      "r171",
      "r172",
      "r173",
      "r174",
      "r177",
      "r178",
      "r182",
      "r198",
      "r200",
      "r204",
      "r206",
      "r217",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r345",
      "r353",
      "r456",
      "r508"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss) attributable to Arrowhead Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.arrowheadresearch.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r96",
      "r100",
      "r145",
      "r147",
      "r177",
      "r178",
      "r491"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss attributable to noncontrolling interest, net of tax"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r91",
      "r272",
      "r495",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other (loss) income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r198",
      "r200",
      "r204",
      "r206",
      "r456"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r367",
      "r476"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Total operating lease liabilities (includes current portion)"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r365",
      "r370"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r363"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r372",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r371",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r0",
      "r46",
      "r47",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r143",
      "r477"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments",
        "verboseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r7",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r142",
      "r228",
      "r229",
      "r451"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromContributedCapital": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received by a corporation from a shareholder during the period.",
        "label": "Proceeds from Contributed Capital",
        "terseLabel": "Proceeds from the sale of future royalties"
       }
      }
     },
     "localname": "ProceedsFromContributedCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from the issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r37",
      "r85"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercises of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r129",
      "r145",
      "r147",
      "r156",
      "r161",
      "r169",
      "r177",
      "r178",
      "r198",
      "r200",
      "r204",
      "r206",
      "r217",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r334",
      "r337",
      "r338",
      "r345",
      "r353",
      "r417",
      "r456",
      "r474",
      "r475",
      "r491",
      "r508"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss) including noncontrolling interest"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r63",
      "r434",
      "r435",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r60",
      "r133"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r62",
      "r122",
      "r418",
      "r477"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r43",
      "r45",
      "r132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r10",
      "r76",
      "r119",
      "r428",
      "r430",
      "r477"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r127",
      "r166",
      "r167",
      "r168",
      "r170",
      "r176",
      "r178",
      "r218",
      "r322",
      "r323",
      "r324",
      "r327",
      "r328",
      "r343",
      "r425",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r193",
      "r194",
      "r199",
      "r202",
      "r203",
      "r207",
      "r208",
      "r210",
      "r276",
      "r277",
      "r411"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r54",
      "r55",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r54",
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r79",
      "r80",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Summary of Awards Outstanding"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r287",
      "r289",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Share Activity Related to RSUs"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r78",
      "r80",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summarized Information about Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Assumptions Used to Value Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r65",
      "r67",
      "r68",
      "r70",
      "r71",
      "r72",
      "r73",
      "r74",
      "r75",
      "r76",
      "r138",
      "r139",
      "r140",
      "r192",
      "r256",
      "r257",
      "r258",
      "r260",
      "r264",
      "r269",
      "r271",
      "r460",
      "r486",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r66",
      "r67",
      "r68",
      "r70",
      "r71",
      "r72",
      "r73",
      "r74",
      "r75",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of Shares of Common Stock and Preferred Stock"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails": {
       "order": 2.0,
       "parentTag": "arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "End of period (in shares)",
        "periodStartLabel": "Beginning of period (in shares)",
        "terseLabel": "Share-based payment award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of RSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted- Average Grant Date Fair Value Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Common stock, share reserve for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Options Outstanding, Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "terseLabel": "Number of shares forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value per share of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r294",
      "r295"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails": {
       "order": 1.0,
       "parentTag": "arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Number of options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "verboseLabel": "Shares issued"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r368",
      "r476"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r19",
      "r69",
      "r127",
      "r149",
      "r150",
      "r151",
      "r166",
      "r167",
      "r168",
      "r170",
      "r176",
      "r178",
      "r191",
      "r218",
      "r272",
      "r322",
      "r323",
      "r324",
      "r327",
      "r328",
      "r343",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r376",
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r191",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r69",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Common stock - restricted stock units vesting (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r7",
      "r8",
      "r69",
      "r76",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r7",
      "r8",
      "r69",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Common stock - restricted stock units vesting"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r19",
      "r69",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r8",
      "r11",
      "r12",
      "r48",
      "r477",
      "r494",
      "r503",
      "r547"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Arrowhead Pharmaceuticals, Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r91",
      "r92",
      "r99",
      "r127",
      "r128",
      "r150",
      "r166",
      "r167",
      "r168",
      "r170",
      "r176",
      "r218",
      "r272",
      "r322",
      "r323",
      "r324",
      "r327",
      "r328",
      "r343",
      "r355",
      "r356",
      "r360",
      "r376",
      "r426",
      "r427",
      "r494",
      "r503",
      "r547"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total noncontrolling interest and stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Noncontrolling interest and stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r77",
      "r160",
      "r257",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r272",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r361",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r361",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r361",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r214",
      "r216",
      "r255",
      "r269",
      "r341",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r500",
      "r501",
      "r502",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by the United States government.",
        "label": "US Government Debt Securities [Member]",
        "terseLabel": "U.S. government bonds"
       }
      }
     },
     "localname": "USGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r98",
      "r335",
      "r336",
      "r339",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r369",
      "r476"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r498"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "terseLabel": "Effect of dilutive securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r180",
      "r185"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/EarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average diluted shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://www.arrowheadresearch.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r179",
      "r185"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/EarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average basic shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://www.arrowheadresearch.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted-average shares used in calculating",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://www.arrowheadresearch.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942793&loc=d3e3073-115593",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r481": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r482": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r483": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r484": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r485": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4616395-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>83
<FILENAME>0001628280-23-014856-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-014856-xbrl.zip
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M\,:'J(*R/C+AET=,"]],/2N128UT!0.M(*('I9&$*J8,]3Q%JXA>'LUZZ$:
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M/5=;J@OINIP,M580RC5:>>L#FG8NB/:> '#NZE3;6U6I+J"^5GDA.%?!FR!
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M?10UV!E:.>',<&>H9M0REI0P'@PE1OB0,"Q KT,E9[)&W+$:]FWQ7%$S&Z,
M$U2,X*FRQ":&L4'>C$T\K4'O]8WW=A"^;)RS=7;>[5_%6&[,WCN?Y3GBMV#G
M4Z^.<CAUZ=0"5$2A76#64P##G#=.Y=;KN6&+F^R&K*/T]R,& 1T_BJ&4_ZM>
M9S3</WBU0L!-!'!-(3"94O0*N LN<*F]#E1%ZH6I9R!14UD(RJT'CE0')-"
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M 69^3=HW0YV*@RP#CUHUW$N;\;P_G-ZO\O 5"%XK#' 9-(;7T6@=I!;$$.O
MIAJT8*@B8FJ1REP&^"8"W))$+=,)J U&:8:_@W2, =KB%7RK@I@5X;P%OHA=
M9;11H 72")I,%)1XJSF+:)%5'2*F7P2^54$,>,L!+9LV-H$FPD8M..2MY]Q
MK%GI[HINWC*D9W:8CV+)_\HMYM[9;OQXMOK'\I-^+UXU[>!M'#V_^'X!2E7
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M0)&HM/:TF9>$&YP^:F0!W)E!?<$]ZA+MLW5C[A;L_Z"KU_2'<@@K5__-6&>
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MK>U_.LVSUEGKEGYC-Q.+1YLA/_>JN>E9\_4AWO.HTSQ]^Z'UX9BVSO*X7G[
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MH5!,QNM]C!B/_,!T??4>WV\,>^<9GL.Y57>;WM\N>O8B=-#[7.]R7,GI_)&
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M)2%P**@2M "%!,"!4@5%!J^Y$8J+D#6T2D5,L]STP54E&,#M!R&,-WULW,H
MYECRO;CFQ;=/P]V;%__8NU?$PM[^T@O;U+**M69G;U]]P8@$)1X-;&[7!;P
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M3E2#H=[D+9D71&-BWC2YV4R2;C9SS<^NTN%G[2(KHN\6T=,!8A%M#)&!]-8
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M#9C>V#2Z2\DL(=5PME6?#SQ0TEFXEZ"2SC))9]HOH*B3FAD"&I,&Y$F!,](
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ML6/G1AEC%SS\>A#0/ <42]@H3X:^YJDNG&V>G6Z*]_XB68N_HQ*%T)&!DT8
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M*ZTMEE;I7:LRITTRY^OVM\D>=.?I>[*[]_Z=UBGE22*RL/%9YU#NP#!J(;C
M5(B)A2C:IW/N98#0HOO:WJ.R?FWVD]6&MTOAJM<SOC+*B$"&'E"D!&@2!ZM,
M@)+Y0'E2!G7:V)3RUD2U]'*0/_W(AU6T<YZ\P#N"=B-/*K*7A.SI0SOM9.0D
M6C!)*T#" UAB)= @@^9>2HDJBY"*Z_7"]5SULF_O7KTJ\[<B_&X1/NU.I911
M+6W&-9U48#3@&(\@*15$2/32R(L0?OT\W@KN=?#\5"M5*U4K52NMHY7:ZD6]
M0L34K/RE.":FG:@FI:Q:$T+>ET9 FC<Q3@4"Q2O!J0HT<'9Y6O[J8/^P8@Z/
M6RQV_'&/Q<[XM*UBQYX& 3^L$,0'=<Y:K52M5*WTP*TTC[NY) QXR@0&CM)P
MZQ270FHTP1D=<6X=5UL MT_0]0B?\E9)8;57J"#;W0(R5G)HDX,H\L2,R*QC
M;@'^Z K\2L\UI*R&E*TCEE;I#*F+:!L7T1FO"*(U(B4$DXP!%-2#83Z"2]$S
MEV<":=LJ.E]8V3Q] :<N >7W'V/C,ED-?O.L[_0:U!0G82<C*O\9QM@YS&_=
M'W5B/\30V;9#OW^NER"[12_!M?7\5O]\M5*U4K52M5*U4INL-(<(YX$9BY)8
MY@7&P*R+D5)BO$3/DN1SB_#:;_M.A/7.$R*FO%.!^6099Q"CQ:RKK03M3 2M
M#)/&1T.MWMA$['(I6W386!%]C6+3/\Z()_99"?/7"=**"=(^OTNE_+NB_%E?
M"M&$4VO!>!$ N0^@:1#@''?*$\=5$"WD_+D#3"YVX\[C:5D);?]N#VS?QXX=
M+]AE<K[<^F1P9\J/W:+#1.L6P/DR_0@5-"7C%0T1+4%CO-8$.1&9^(*?=,&Y
M3GA=<_'=H_%H;/MEQ"J[+8W=9A/[O$@NT2B "J$!/:>@=>8Z;84@AHJD'99&
MB**K+BC:MSY::8%@7H^>-XOGJ_O2$>=V([.>#'Y!TM>BZ+MVMVT!K4]G=8;
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M2EO.%>&Q<$1*&XB)@A(1I):%+SW'29V,ZA9MIF(]8LX ZDO('5/&&RGS$O"
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M7I3<TBEY /A)Y\+#-D*5 V+#N#-:8DWI#) E^M.+3N^L[0> =F=M4+@ONF&
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M]BZ>6Y+)*5M^IF$!D<8^/K*FUG1\5<? #I)@C<N_[^Z^GB#RI&1]L@18DIV
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M30V6#=>E5DI[RV/CFGE@U+GLFJ$&>&T4.;&"2B*U$\3%,A#E2Z]-GFO%L"=
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MC57T")DW6<?%EZ-'AV,L.SHJ]VM\^ZU^YQRW!H+PR+'!;@ZPY)_6J;;$K"]
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M'7L]\G+<36;\^FY;]=,WRF.[[-I+UYCJ,WV/3/I:H8+XTGX%9:\-6AR&U4Y
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M=K6>"UF,-^SF6B83$D_]7N=2L,!5OMD  S<"JP_!Z"6+%C)=A=@/0G/5TA[
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MA+%+ ML 0I,^G%-S5O^XWLWY\J)CR?71L7FX!2E[+8.07%*+0\[",D%C*JF
MG:6!!WG ,KL^3DCM?%62Z ?0$^<WI&GL-M_4LBN]).7&"# D!]1?J0'*"=.8
M)$RDY"P0FZ**5BM-'3%,JKG:SXRY!LKA\/2?-FA\6]WP!NS-0EINEU'JHWYL
MPOO^:A>1@X^+2*=C1#H*A[O-#V?[7]YV]CL[IWO-#SR_I][YP'??[?S8;^[@
M1K-]V-C>P].(U*!O1&,;WOUEO[,'[VQL'Q[M-K_!.[[RO:.W[?K1![+[Y0V,
M)[=UK/.#$"C+S<"0HS$B'I)&#F0# MKEH'>Z&&R<CJS6L-+PLI#SASBGSNE
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MR"3-D!<^, O;R55:VQ1RG:V49_%7HX;IDE'#SXYO[TK^7IO35+'NW;+N;/
M,3+8% 4"@<M1#D/*C0!!&',=C8==9;D>"J5DG>'K2J)<Q[N+AM+?H0RN>/:A
M9&W%LP_&LS/BU@2<)*C-@;&$..C*2#OND<8V:B<)9TZ"VLS)NA9DE7CVN1OP
M[T';?%7;\G[4&97U>4(\[D??NNB>9CL]&&O9#>QEV?6_/8)B<6DKMB_M!/S>
MCD5GIV[8NK0AUV):!6=W!6>[LW$)8.DSYW%$@N<F0"IAI"/\29@T)A(#LDBO
M;3*YCM5L</3OE?W_#/C]KI22BM]7D-]G<B%\X"3ZG 8A/.)@@.2V2S@W7Q.&
M:AQPX,#O9%T(OAK\OJ"CX/(KB%EA/>6?N04@UFO=.!/U.#>3G,$D0V^4RS 4
MNN$OF%)/)@/M+A9@I?%ZE?P^C5A!\-U!\&P81\2.8"LE\I9KQ!G@L)4:?J,>
MZ-5K(UP "U*+=4J7S9N] T9Y&)]0!6T5M#V\>ZR"MKN%MFGMT@"DJ: 8HMY$
MQ+6*R'I.D/>:VF2)E(GE8HIXG9IE@UL>$=H*%?2/HHK5Y6+=EXO7S1;-&H\T
M5S1[,@7.MF_RF-7BC^.BP'4N1SR_C%GQ5;3^<-*Z87C8C_&GQ;R+AV36KIW8
MP7+UL;/&8QT6FB2NO71"\J!HHH+Q0$TH:OHQ3!:NC[V(Y?I$"F(_<"G ^E']
MQX%,7D4/R@PCP2">I$5&6X&$BY9:JQQC<2F1 &J02L(J(B/F7C@=A(K4B2""
MT8'9<?^&\0;3:H/O?8-3,#P&Q(.U.=_9(AN-0F"!4(D5)DGRM4VZ,>LLO+:/
MY$;M3F!GT<X!MP>;6Q40K6CQ?NJ.?A"@WY#=[?QW_?2 ^LAM] YA$[(I)1*R
MR3$$QA9G/D-/S+'Q<WK9G[<S7;:1K2:!F^AI9,;R*(GSB40?93+4^H!+:"(3
M<JB@Z<'(X0T]T#Z 3:TL\C2WF/?,(,NI1<X9QX DL*4YW7)C-B)J0@ZY#]O@
M./I<T;Q]^M/.:4]1V\OE;%M=W\]Y +56V>C$7Q,&70O+]6<IP#6WMVN?PJUQ
MTGYQ7--YJN==41CW2F^+]5K;@DY_T05O7$(0+IB4M,\-HF*_ESMS?6D-BH89
M1>N,D]ANYW]MK0O+=.-CR@;PL/#;K?BUMUY[#=L$[-5M76Z;IQZD3<^\RNTO
MNN ^G5KU6Q7<Y[@JN'^EX#Z_]X+[.T5'OH*K=T"*N>Q_ 7SX%@OS.7MBAJ>?
MH@<NSUP,7[X&?0YPHMFWD[Y#P\'*%>?']4F[D*.WW_;??<:-=Q\[]>U&!Z3;
M"=S?VCO;$K# 9[M?X!G-^DF#_GTT+='J7SY^VV]^P/OO]D[J= ^DVQ:,]>^C
M^C9(Q&9=%)+Q;(OM=1H))-F!!V/)*6.14HF $',@Q+S,+=NE9HY[Y2*;KLU/
M=-+ $E1&SSE5P7$1C:%>"^<""7ZZ#OM.X]\WGYJY'O^G6Q3D_^G;[JL@?Y$'
M_Y_8#LU>W6:1,454%Q1W\7$S_UG^>+%$M7,@I$X<$X^TCPYQ,,B1BUBC  OO
M.5,QZ>=3K'^Z&G_K IS*%EN#'"<V]E6=5_9_]3-E[]'JX0,O;.!2!"U;$)\+
MN)/>?8UYLD&EN/."^/!4I:O!/JW!F@=I-4#),RRQOW71EFM^.X*[7[4G7V5_
MYW*5_3M=K*?7S:*0>%LABV 0:']9D&QWV\WB22U$D0516&:?NV#GY8;BH?8.
MC(QJ4:86Y7TO]R5ZP:ORUK;ZM7]M>Q3G(<B4^Z4TWN^J,\P- +S$*E?O6_9]
M2R?">!_C\D6Q'B;F9CY5?SKL]8<(6*USQ>3Y+7MB3UK#PU:WUNO&VFFT_9F8
MWMLLR2*;5#WCD9]QFT!JMBIT/M_&SQZ@?+30&?N :B$Z (!SE\\UL41/*7JP
MF.=UT8-/(@JPF,$RQ^Q*,D^9P"%ICK6RD?(HI<>:6&&"733 ^3KWX-P.U2L:
M"'A;%^$X$/#S:;VS1_>W&X?UHV]D=_MC#OYK-3I[,.;/>+?Y]U'CRQ[=HY]/
MI@,!&\V=T_VC_6]U^N9TM_F9-XK@OQVZ?_25[C<_B'JG3N#[H_WF7_-*U4F7
MM.9"(*>#13QZC33W%M$8,;<I<.KIVB;C<AWS)8O+/%JL<H4:SQDUBA.%?%YU
M 117 >12>ELVH'SO:S>;4-FL7+3G?04F"X')=%2QLC[$H!,B) K$I>/(!1&1
M3-([*X1G+JUM%DY^^F<%)A68S)_!,CFQCX4FV1]3Z2=W#RED.@=+!N^8SFWO
M<Q\0K S2@0:DK=$4&V&)R6GOZTK,!@Q>EP5;8<G+P9)',&=N0I/LQ2R<F!5V
MW#UVL.D*0):[*)E$0N667]P3Y+#D2$5)H[1),9I[ 7"Z3LV2%8 >I<[/?/?F
MT_3_^#RV!*,;QGR@&F(1^7BK6C]SEF7E:W\LBTU*82Q4<(0(H&/*;0#)I[Q1
M*3EF3;H75TME&-T.B69+^+J8I J<(ND-1YPPCZSQ#AD0*]Y(885FMS2,EH*)
M^RKALZA'O&+C7V/CRO>Q,BP^[?L($7.3HD,^8(<X<P&9: S*C0)$,%%3Z2H6
MKUC\P1T2%8O?EL6G?1$V6$62E8@(RA"G8$HX+AS2C'K88Q>)4A6+5RQ^_XZ"
MBJ=OR],S/@+CC7%8H&1\0!P3C5P2.1W91VDM5I;Q5>3I>RJV]YBQ4,W>T+9K
M@[D14;]4B/E)NUJ?>&6I9;'UKHKF53$E#X6IL]T2'/Q'^*B0LS27'B$).95C
M2A(U3!HEJ&*WC"E9W<IX%095&%1Y:58-FF:\-+ERLI8,&:\\XF"T(1.$0<2;
MD#3%D29S6W6O@J8*FNX]WN6QL*F*=[D?@)KV,1FBHX--15@DGIO.4M"=4D3<
M.-AI:[C2=-EXEPJ9*F1:>:6IBIYY9"2:]HQQG0C&5B-*F$&<.XV<TP[Q&**A
MPCLAQ2VC9QZD?]:]IX1.ES:^]YS)ZH4O)2WT?:_[]>=9H<-#F.;7PW'MYIPC
M.JB21%_*,ZHDT2JJ^BGHA?>=)-KH=7VE#=ZM-EAO;F5-L/#K-[;W:".7HS,Q
M:IKC'@C)S7"H1!93A4CBQ!C%,2-V;5/I=<UF^Y%5J5T5<#RE/-'K0*5RQ-\>
M3TZOXDE@3#)!/)+16<2-CT@';1%.S$@7<KUV6N6*5H#R3')%*S7E?F"E,:6F
M$&\C*"@$F40)XHHYI*F62'J=:!+$2)F[OJ\K;*I\T0I/5L&R6<CC7>''/>''
ME%KB7)#$"(RLM+DO%E;(,C!SA 1C!POK%-%@YJAU0F</X)Y6RNB3" =MS_.$
M+AMP^Q).&W]Q[L\%E.\[?K3"X?O X3<S[J88N7.),22)PXC[H)!A)B&?)-/)
MR>B]NYV[Z1<YY9&3<"JHJZ!N!<)4*P?9W2/@E"::6 J<!XPD8Q)QH2AR =11
M$R0G42C%]9UG&U806$'@HT_ZJ83#5JK@_0#AM$LO$BQ)C!(Q)1CBBABDE6+(
M&*65<$DH(Y9UZ54(6"'@ZB+@JH;=5HAW3X@WI?I%RU6V<9'1A" NI03CEVHD
MK,">4VDY$[=S0CX2[E4AN<_[A<7^_E%T2]Q<O6:,QFP((V_9BY%1=A]-^(B^
M_NM?Z!BH>378IS78Q1I'5KT8K^W%^"D>#V/'Q7Z-X:(?([TB^ZI^C#/V==6/
ML>K'6/5CK/HQ5OT8J_=5_1BK?HS5,ZI4NRK5[NG[@KF1+-C@DY21:\:MLEPX
MD9104GBG"E\PQ8;AJG;>SWR_)XWM;Z+>V6.-HV\G>\V/1_ NWJ P)ACCWED=
M[WWY^UN]L_]MUO>[A7>;WT[WCSS=;?YUV'A7AWE]9?OO_CW:;;:/ZF?Y^@^G
M^YV/\_HQ>A.I\2DAGFQ /&"=FP1PI+WAR@;CI:%KFY3H=?88/4NJ,/8*-:IJ
M=ZL*)M/5[ICV.5'7(VV\0MQ'BJP.&GEB6?)>$Y-\E6-7@<D=!N0\%IJ\M/IT
M#P4I,_T8 [4Q^8 BDP9Q%0QR\#.W6,.,6HX=E[D^G92SVDF57U=AR2.8,U5%
MN4?"CIE>"]*K:(E&T5B>;1N&;"(&Y>@^2QDAEI-LV_!UQ? 33ZY[:OZ?JA_C
M4M@46<)$8T=](-P2;HAQ!)1L*1)A@;+*U;)J<#3;E#$J2CQ($D132+F=4T#6
M8(6$Q91+HT#346N; J\#T:U0YY>[]HI7K/QKK%SY/U:&PZ?]'S[A"'8)13;@
M@+B6'%DG0?]0-/@@+ /Z7L7F3A6+/P\6?T$]&1^*Q:?]$<(JPT,(B$JO$8>-
M13I&BF1R24FJ"":A8O&*Q2MGP8HS]K2SP!GNC.(2Z92+CAI@<2<E151[K2R6
M6"FS@MIYU9=Q\4CI)^UR?6%YACAA)U0PTDC+B=):8)]B=#HSHZ!5;,G*0>IL
M7T9OB3".@CE$<D6)*"PR7&,4J8J>2I.X!'.(REO$EE0MABH,6GD,JCPU*P--
MTYX:X1WS*E'$4@0SCM*(--<>$2]U]%9Z'G'5E[&"II6->WDL;*KB7NX'H*;]
M3-XE*K@&<Y3[@+B7'#D!OP$V4<Z42]:I9>->*F2JD&GEE:;*,?;(2#3M&*."
MV*BB1#AH@3CQ&FF:'.+.^<1HT%KS;,7=(HJF*@)3O;#JRWB#*[3JRU@]HTH6
MK9)%GX%>>-_)HB^L5N"#:(/S^C)&PV1P7"(O. 8ED&)D<C,U1Y@SFK)DDEO;
M)%BL:T6K'*\*.1X=.1ZH[CRN &4Q0)DJ/JI,P)%%CC"S8%^"@8F<(QIAJH2@
M*28>694T6@'*,TD:K?24^X&5Z2KN.";CJ>:(" ]ZBM8,61,44M9$SN!;@OG:
MIE@7LFK,6.')2I@V54WTQ\2/*;5$$!8$SF4LF+=@YRB+M,8)"49SX(!.V-IL
MY^!UAMD33QY]$@&A56?&JE/%*D605D!\'T \VYF11JRR%$6$"(TX9@)92S"R
MSE/,(I/"J%LZG*JN/!7655A7N<A6#@*G^_-$2:PR$5E%02'E@B KB4'"!&VY
MQ88R6K5FK"#PV4'@4XF(K73!^P'"&:>>#MY[@Y%4Q(,N2 (R2@1DDW(A1AJ]
M6]JI5R%@A8"KBX"K&GE;(=X](=ZT&](3[(V.B$9*$#<<(R-LKG\I(N-*&RYO
MZX:L>C-6+WR8WHQCLFR,.H"!OOP[0U>K.[(%G5[NWC@F")Y;+19% >&"5_T(
M>E?K>QQW6 1ZS]AXZ:YQ>SE\<8MU0+BCX?6WS+0[NFN$)W@AB"?LG$'+U;KT
M,P^WP$VO91"22VIQX( (8/EA*JG@T=+ @SS@;&URTV'_8IN_1N3ZT7X#%0EF
M^,JV3^SI8.V/J_TR6UUT>=6G%ZQ<ELVB)=6\H5[3>K-DZ?M=T?D'!@U \IK8
MJ/WO%;J[*BTI)TQCDC"1DK- ;(HJ6JTT=<0PJ0ZVL[2$12#HHJ/Q54&YTQW:
M[M<6$/K68!"'@^W6P+=[@U$_-N$U?[5[_MMC2[W3L=3KO,'U9N-P?]N+/9!R
M^T<?O\$:P>^?3_:/0$)M[^#ZV5^=^I'G(,':\3\?3_>_A&-'N=QK?OA1IV^_
M-<[:A_",#HQ%U)OMPT83KM^&]QY].*N_@[&>':9=D%H' 10/P4%:,<8EXCP9
M9+@)*(5$=#0X22E+U07X/X:MK#E8:3U\800!:DZ&NR Q50FS@)T2 I8^@B)Q
MG+FV/XIKFSL@5QOO=OYZ_Z:V]>G3F^:G68RY3*=3>%-NRD_?>1UERZMZ<N[E
MUTJGY4>M;@ L>475 Q#_?#BYH,J:+<BR-ABYH^B'.:3:=GH@FL_&J]#U[5&(
MM6,P:7->@>V&FJVU6X"& [CY:S_&?,A6@X5O#6W9A\X.X/+^,-=L'1[&6J/W
M'?YJ#6H?&UNM\GTUZ_\[:I4@#*^HU6W?']8H)O?/D)_\80RC=MQ-;UN@)\?W
M(#'"-)<VLV1ZP0S*#I24R6+G0)UT6:=4"FGB.3),N)0L54SS:0;%DE(/Q@5/
M0?$HDA442\=X$E9[G!GZ*H,V@3A2K]WNG8""4"O[+Q_WXZ @M$PYOM<Y[G6+
M/X&66M-$^ZIV,T<OPYEKUP# 3^>T^<"-HX&X-W I=I?M'$W%!B>+]?9=YK&$
M;AAS'_V-N9358*O!WL=@S0:3BXWGA;8?+AK,UE[;?O\T@_-6IS?J7E]Z?<82
MO+F3]^(6Y=/N"%XV<KXX$LC+>*Y:58MYB\7<Z1S;5C]KG-7RW6+Y&J!Z+\_3
MSQ7C/@]B&K5KV0*X&B3XJYA/R1+MC)_$4OUF"V(99&-M>-@;P:/"8@GD=]$^
M^KDL(BS>G,S[%U"C8*LPX$HKGY'U6C;.J^H#U3.J*@B_=O+[3^F5JXH=K,H,
MECB*%XYC@;$3B0@>)=,I>B8 & EWDMA0',6/79@71_$[C;?3'LT;_)B%%?=$
M#M]OY^4L#]\[GVGC*+3VCG9.&V=?\2Z,97^[+NK;6R=[G9VSQI=_VXUM3QMG
MH3U]^+[?W*,-^G>K?K3#=K<_B,:[?[_5S[Z=U+?_@N?5R?Z7S[AQML<:]-]4
MOZA?3&#.='?KP! )>R8%$CQ0Q T+R#DC4-(")TVI9J3HC;VNJ*X2DRO8>!*P
M<<EE<=EC40')'0+)V1202&\E9L8B8Z-'7'L.0*(3<H&2Q$"MD3'73*'K@HL*
M2"H@>7P@*8*A;T"1"U_=ZE<H?QJ80:8PPX<4@U41$6$3XI@2I .-R!/&+''>
M6&VJLB@5:*P0:"R@?33B4XD7?AJHP:8UC619,I$A2P+/F@8H&2E8% D/(G+F
M:(IKFV:=Z$>H6?!<3B"6XKRYL4Z<$4)\\@+KP&D@EK)<!$L3+15L%%T@UNEZ
M)BN//MZW8*<OLQI,P[\*HW[V4E?,M0ASB2GF4K!=/-" ='(&<8L]THPSA!63
M@45!-,>@QO-K(Y?NO'#'BKLPWY>AA%57]VLDKHW)>X !;9GGH-!IH9FRT@C/
MM*!!5F["E8.%QNL9-R&7B:G@,,HNP5+FYMA51)50',2PT\;F5AV$SB8E5@UA
M*UZN?'>KQ-W3OCO+-56@HZ$@%47<$X^,)1(T:D8- 56;) 9"?YVN5%O8BKM7
MC+LKA]I#,_*T0TWCD'B4!BE9:.\F(D,$03@W>,;.$"YYU;F]8N7*S;5ZO#SM
MY@H&N-EX HIVDF5-.$V(0,E'2Y,'T4Q(%LKF6:O<OQ9'^+0\9B(8)V5DG"G.
M99261ZV"QU0FF@0)E<=L%?ATVF-FA2#$@=ZL,0?EF9*$M#$>>>5<5#BIQ'V.
MH/D5C]G3K6@[D_2X7NO&F:#]I>*DG_2IV@NKUV,CE4(#H F3N%3$1I92<!;&
M!QB7:.7]6SV(^S3C_;,.BY""1)'E]IA.8%!*3 X7C Y,"<^I3P!Q?%T+M4K=
M,6]U@%^!4 5"E=MR%6%IVFTI*'8TN(!8(@HL)(F1<TDC)Y22P1DLF,ZEA];5
MLB&'%2Q5L+3ZL%3Y6Q\:@:;]K<$J(W.%5N]\ L6(<V2B3LCD<)?(O9-*WM;?
M6D%0!4$K#T&5G_C!,6C:3ZPLTU8R@KRV'DRR1)$C3J*4O&0X4<=\UH+(.B'+
MM@Y9(0A:]-+YE5>)J$JO5B_\.=D\_QH&G^+Q,'9<[-<8+NH8T*J.0?6,JHY!
M5<?@I:8$D:@5]R'()#SG.CD>M.!<4BV$]D3/;RE0'5&L1AT#F-,>KG\]\$XQ
MC0-'F&B'>(P>:6(),BYX3B2UAMJJCD$%&T\*-JI#A8>K8S !DDA<BM(J9'(0
M!^<V(<MY+N\>(N@YDJM$"W-:J26#H2L@J8#D/H"D.@9XK#H&$\Q(&!"#1(<P
MSP>1P43D.),()YY\BL2D<-NPZPHT*M!X).VC<MS?3QV#"6IH0:E-(2')<O43
M;CDR2GLD #*P=HP8PW,= R-6WF)YSG4,)&,.\Z@$B90[RPP6-HF(!?R2@HQ%
M5#:91&6/>:Z*RGZD.@;G_@ L-+-*HI@$,)=P#+G@<RM59:7#C"KIJSH&51V#
MQ8_*,5&2*6H-QQP3:6U2WCG"X$G*)%NY"5<.%B[5,9C  L"T5I98),#.1SQJ
MC5Q.=Y:&>J)$M"97*:SJ&%2\7/GN5I^[IWUW,GIG$C4(MI(ACI5'CH$.0(BF
MU+"0&T?GE$E"EXT'KKC[!7%WY5![K#H&YPXU&2W/MC#.9A4'C3V'U 8D.)-2
M41#AJJIC4+'RG0CJRLUU/W4,)KQL/?<"6!81;A6HW!8C@V5 R3%J8&-%I*!R
MTW6,^3/FY)=4Q\ 8SSG6V@3#N(,]-L1);@S&#G9?B<ICM@I\.NTQ,T(GKW1"
MF,6$N&<"V6 I2MQA'JPBGKNJCD%5Q^!E)LK(0$$?,!2TD=Q*VV)IC?<B)2&$
M#:SR_JT>Q'V:\?YA%8AR(2&B= "(2QQ9P1W")$;-0<<DRE9U#"H0>L$@5+DM
M'ZZ.P026@C11^Q005A$CKHU#3B:*HK.,Z1"RTZ-HG:1-5<=@A5BW@J6[@:7*
MW_I8=0S.0Y$H6.?9,T,5I;G6)$%:)X*\"-0[1W/I]ZJ.005!SQ:"*C_QH]4Q
MF& 0H])Q#J#C!'.@!4F#K+<4?B2A#<$>QU@D7ACY8NL85&4,JA?^E&K^&%IX
M]V;!(QDE6]U18</!)Z'U??-_X<?D(1W;_]KJ%J.65P7=T6@P;*73\J-6-X#R
M]8JJXDUW*@H(7D@6[$R[7VNV'VO]^+T53V*HV2[,L=T^S?A<:YVKB_!YJ($5
M&VNI'_\[@D_@DE:J'?=RNG8KNW4OKH5) H\/>_U!+?YH#88;M4;OFN]/(CRR
ME=>DE5KP^C#JPU;4AH>Q-FC]@#=VAX?P%%BU4*O;OC\LX8F1HN("*X:5!=+&
M.6 ]HXTY:0T/0<BF0I+61L5Q3:T-$K7<,UMZ%6!E0*1;&&[?YL>A_.B:LX/6
MH-8#O,V+V>I?N7VC-H<*+ODH8-N.<PAK[<0.:O^S3#*%%BH)JXB,F'OA=! J
M4B>""$8'9LNZVYA,SJNFRB$A,:U%7/:<[*9I16(Q+4(^32VB'?_S\73_2SAV
ME,N]YH<?=?KV6^.L?0C/Z,!81+W9/FPTX?IM>._1A[/Z.QCKV6%J-$%C./M,
M=K??P#/WS@XXUDHDP1$)4B/0#'"N?Q]1\M*%Y'T@RB^E)$IK/<FE;#5)7,-3
MA.1!T40%XX&:LKPZFVSS3-6K:IOO99NC(2YQEQ/W;:XHC"5H?"HA10*3T@:O
MB%W;Q!NSP0$S']0 W]J9"+(4B-8?YH(W&92'A_T8%X?E]>*W91!$D\!-]#0R
M8WF4Q/E$HH\R&6I]P';ZQ+LBK?LE+5)OUD\.@M7.:>51P/FXAQN%=(PTM[6R
MCIEHA*-+(0CEA&E,$B92<A9(;H$7K5::.F*85',;-%3;?-_;'#*JYW %8G.C
M%*V02Y&!'>EL$H ?),?TXXW9B/[K$20#P#2*+*?:@?8("LWXUIGH@9]J2:!:
M^M9Q/H:I#7NU0_L=/@-]=] *H.C6OMOV*$YICS<$Y-R*;J]2ZB=_&,.H'7OI
M!A?)V]%PU(^7B?I-J9(ULT72A/'\U>[Y;R^,8$',\0.9,$Y,$!1 UT!<8XJT
M2@K97*E:ZQSFB-=J$7CZ&%9]V!_%M:=I$#2!W%.OW>Z=%"91WOC:,1!NKH]5
M\$*$X78*PDX%N<S7X?NQ/2'^6>:Q12F[.>SW:A&#BM!YP779KU(,]JI!#\O6
MML>#^&KRRY^A-3ANV]-7K6XQ^>*F/\>/+SU#V4TS[3,JWE=^_>=)*PP/7QFQ
M(;',?LYQO-3XQ>6W9*-P@4YYLLKO%-DP0E_[-=X@M_J.; C.;GGG]8.E? ,;
ML]!C%PP>NQ\_RB-'7>K%:CA>9I4QMOY"_-WCG&PL-M6]:/NU-]T\W*FBE0L4
MK+R=X^YFY_!J4\9OK2Z@:V\$CPB#W^\CBWF5C\$*U>NW?NS8+ #[O]]'3=-?
M3L18M46[]NQPH1D^EZ-#+8765 ?K">>,8&U(4 8S+HC)#J/Y)= 16R:F:E8A
M_C@AU5W0I[,AMU?$K3^'$\2C;S_JS1V^1QO?]H_>=AIG65/^S/<Z=;S[I0YF
MVT?X;.^D3O_N3)\@PK-_U(\.C_;HQT[]RQYK;,,[FX>MO;,/8N_L,V^\@\^.
MML[V.ONIWL*GTW%4RL1DF$5,>XNX-+EJFZ#P)Q5$6N9X\&N;6JQ2$^NG(+ 7
MQF!^%Z*9SIW\LTMM>QS<:<#[FR>Q_3W6"T_&"XAH>"@\.IW!(Y588E0D1(AE
M"#99(9V,1S$:BF.0E 61T]%!HWOX D\O0RL4]UK=_J6GYSX.AF55J7G2JZ#K
MKJ"K\7H&NG(J3!1"(*F<0=P[C1SE#&EJG.3<"L7MK:"K4J86A2Y9*5-/ 8CR
MT7(%17<&19]FH4@3+1B-R"G"08L2#%GA [(<;#VJ"$[:5%K4O4*1JK2H9PE>
M;WNC?H5==X9=LQXIDH_8(Y'(8B$13QQ^HT8BAS51AGM&M:K4J/OCPN9A[$>;
MAK%?*5,/AD<_2>?+^..GTHNW\A95B'3GB#3KD^(A!JZ$0A(GB[B2&!EB,)*!
M!Z&"2!';7 "5+YMDLT+:U(K56[ZAK,QCG%.^A.S'7YQ[A>155N1CX/7NK"..
M>LT4;#R*S!'$HP<[F.82>D$+$I/RS+!;=G?^-2;Y18R?2FR\JP;-]YBQ=S6W
MKH@OG*F$-I-Q=WT$XA@\-O_7]?_8O#9L<;P\/$<4'O<&K?S45T5L)##C.)"0
MX (6+MTU#D/$%[=8!]LX&EY_R[QXR,<('R7\ZEI<_IF'6V"(US(("2J*Q8%C
M;X 9,)54\&@IZ#'R@,NUR4V'_0O:^ K, _; -U28!*]L^\2>#M;^N+I-L$>7
M5WUZP:[?MAMC3O4#!.3.5S0:@$ UN5&[[P#Q8<]_.^RU@:<&;_X[:@U/&[UA
MW&X-?+LW&/57)OJ[T1K+@:,Z:="=T_KV'JTWW[;VFQ\ _P&/O^R<U;_D+/:O
MI-[Y-^,ZG8[^KI]]9GM'.R> T3_@VG9C^Z].H_F5[!W5?^QU=DYWMS_#M1G7
M]U.]^?FT?G+ (D^6*\!QCP/B-%ID36[[H[G . 01 BVE-X '&$=9FAI)>$C8
M>8LCI]0:+RUCS(2B*I"=B1?_U-Q]_?_^L_M^^\W'3T6M#O5G[<V'SSO-O6MK
M-DXR!RZC5KD_/WWY0V4<[*:"M/XZ?=VV@\%+)J/&UD'T5*;D-1+,@/DFE$<6
MTX (,9XQ&KSD^N[2")A<J32"P:@#XX>'E(D$KWL=&-CIF-('M<&A[<<B,\#W
M.IU>'C+029&1<]R/*?;[,92?+90FL/CZ/'#> -[@@M\F;X"J#8IOES=PTV.)
MW-"45H_55*Y:FH-YFFD.GPI.ODUBPW-+^/C']FO_YF2_13Q%SR.386LT/.QE
ME ^+SWF,GU/3?B8+LC,8C*K%&"_&[F@X&-HB+>B>\.'G"[4 W#Z3U;Y]5M%*
M'A)> S@7V:2U22+IW>:8/70%J&=WA#+?1GA]2<W_I5RF9WG6\3Q.-/Z)_4(;
MO).3C3D%'TL:*CP,H&OM]C\-<]IYH7)=O'I\A(&?IL]A?(3Q=VOOZ/"HWMEO
MU9N>U<\^,'@OW_ORMM78_GRR=_2&[#4;<,W>C^DCC'KG[];NN_KI?F?G1^/,
MGS6V/<SQ\'#ORPYN-/^"Y_U[6*=_MQI';^?UW+1*LJB"0,93C7BP EF#'6+&
M&XYEC ['7)\#8[)"03 O-T*M]*,\ ,.59MZ%OO\T#A*?"!=.'R1*K97FC")#
MI0(NI I^2PD)&IE.6D?K<^\+@]?Q2@6C57QX+T?Z,VQ86ID5"]XA"T[W>3#,
MNQB80CY+0^Z20LX$@AQ1UD9*9;!\;9-@N:[EJK:?KECP_ECPDF^CXL,[Y$,\
MG9>KB<!2.J2T2XCCP)'!7")AI30>)\;82O+A;9KKK;@)_\_5@[D%8DN?M+%>
MV>2+F CG1%&9Y7>&@K/-\ AE/EH P$"\05QAC&R(&"5A?:+.2^7\K<SR^U,Y
M*LWB5AQ4V=GWR%;3=K;F/B0I.=*84\2]!CL[A^DX*ZA7TC.-Q=JF6-[*KMCJ
ML17V>5PUSVQ>P;YD3X29IBWFR /#Q#K$G"2(!\60]3PBH8*/B269%+ME7[**
MG5:1G:XU@2N>NBU/35N_) JEN N(@D1"7%".0 OD2"3/DE=.ZA0?D:?FYX?(
M!T\/69TS^R<72G&U7&\.]*["*9Z +Z8*IWBQX10X80<ZE9%&6DZ4U@+[%*/3
M6EDLJ%JX?V853G&W\GMW-IR"6(9%)!%A%1SB5#GDN%1(*>$I42S2LMU)%4ZQ
M&EPW5X>^#X:KW#SWR(73;A['@B ,U&9F;$"<:(JL91X1;:@G%(PC&7(VZRT<
M/14?KCH?5N$4C\&"T\XAZT@0TD24, 5!&(A UC.,=-*41\6Y4+DP(!;K1E8L
M^/)8L JGN!\^G'8HA:2E5DHCSS%!W,,/8Z5%Q!!+)+=:E&%-J\:'53C%4S?6
M*YM\$1.A"J>X>Q2<#:=P*3HA"$4:^YB;S0(*DF@040D'P2FV)E7A%$] LZC"
M*1Z3K6;JGTEB4I01.<<QXLP39'4*B/!$J"/2*9>J<(HGP%95.,7#,].TQ:P$
MUIPQCI3V#"QF[I!+N<E'D"QP1H,,M JG>$;L5(53W#E/35N_CM,DHO.()&:R
MWH>1$5PA3@QGV ![>?78X10W5ZU\BEW&=[N7VW\3659M6)]?%^Q29<*:/3[N
M][Z#@0QC;G5]/]I!A%]J]ER=.Z\>5G#0>NW8]FO?LZ54^Y\J47TUB^,UFA]$
MX^PSV=U^0^O;W_ OI9S7CF._W/SU6NKW.K7EX%R LNHLYL$KQAT/VAO8?&.(
M8(S*:,<;SJF\[Y.]ET8%];.ON7JSJ&_[D_KVEFAL'8A\$.<-S0Y) &<,)H0F
ME.6JFXD08<"42.>G='-MB-JPMRP!6-A>9:3R/E?:UT"+0LED./<&/I;G!* J
M KAC CCR0 ">[3:W6/WHS4D.(&8B #-:6!L2$7>!@L;+$@*S,2KOM-=*G&>]
MSR6 C5HN10D;TPWP_V&FARQDMO('A1@)M8]Q4(!Q[766Q ED\3#F.+B=KN_U
MCWO]LJKJB1W44JL-E\$?6\?]5KM&52FWRG>,Y58M]$!.=GO#VJ']#F^&3_P(
M]#IX=PO(K%L\#$;1RJ;2I.@E2# @PFXL"?2D-3RL6?_?4:LL_SRH]?JUXU%_
M,++E#/)#8U&D%X;4M5V?BVSV0%ELA6+DK>&@%G^T0.3#Y^,+02SFQD'E9([;
M(+PW[JB,YB/J$9=J/Y6JQ*0 5+&QYX&,X^_&T8SK-5CRW,2D]3VV3]>7Q ?#
M9<BB(6!#>61>:YPKN3N:@M46NX4U@@(4_@+]);R^M#5;_;[M?HV95O\ZO;CD
M'WN:/]HZL?T FI_+G<?'J/+=MMI9/WS;Z[^#>Q>LY_^BP26;&%L'0)H\"3"G
M1< <I(L".2,B!TK5/@9OM22YOR];QTJL$Z-GA4LFLN6H1^K@I#'.1R9!N>":
M6HNCEZ#5.!/-XC[-BGH>DWH:'PZX-)%'0Y"F.0L=0 &9!(:C"2(Q!F" 7:8>
M7D@F9F:[.UQ7\/@D]F-&J-C/=@[L1B$J .1C;70,5\4?L>];@P+H>\>E?,B$
M^#V6> \?P]U#L V'DX/$@B@'M:]Y@[, Z]?L9-^+%Q1?P$5@8LTUP2AP2JVL
M"I^E8A9B(-K^ 2&2$96PF0_S>("0R>P7 YA?NYW_+6;6#2-?D&LYAD&M8T&$
M@8CK@H"(G>-V[S3"&I5#^SB"\0K)Q&_^]]_X[WFF>;0-.PCVO[7W8WF7KQIL
MU&I/7[J!E;P=?1F*3R>RZ]+^U(J"D["AH%ADI0#((79A!?O?XK V $:MV:_]
M6"[O;_F^O*$4_[F;+ZN7EWW*EVU-+BLN('_^OGY%W3@Y;/G#*R_NV-.Q=36$
M"1=*%?R[7AODO1T=YP]NM+:G92HS"G1ZJ06-/-"H93"*, S:-X;?:(F*L"CT
M&E0L>I9=4KA?V^/6T+9+C"N,[(]CA@*<>SL:COIQ9\Q4%>#]U"1OUD\/:!*:
M&\)0PDPASC@8Y]B!20[*#FP1F$>.@B8NKM?$LY)[ 7GS8.8*# X/^[W1U\/:
MWS$E8!^XZ_W[UP @OF!R6]:0ST0.Z/<U4SA@SA]93^ZW0!\^MNWUPB\$_QLB
MN!2-V:)7/ V>\-N8&;::]=KN^,,)^5]5Z%NE.M_/BG3F-B#N@L['D[F S>OY
MZNH#3UIP][$]O3JWFBT6 , ^<PLL4<E'U[)1MQ#D4YP4G++ .$H%Y[AB#JPE
MS;R3'K:-@&0:-VZ 'V@>2UUM O@/"!H8/"SO;GI]/K3=[M97F-=7L)+>]7N#
MP3_]GH\Q#-X"'.19E]>.&?&<@1!]V1Q$#XC7C@2LD<DQ_]S)@*SU$4EK3526
MTF##VB;;F.6<_V_",':R\" M8>6!ULNE!]KTL56H"QF3;2;.@C/&]UUAK,7H
M]7,7[H<'P'7]DZQM@*3I@*T)^D,I@R[S368%>.?Y):6BDJ^*MM]NP>M@(+^U
M?C_GV?RWO6"A:15H,')'8)]-C/5/Q5S.!U=H%[^UQH^;O'3,-'.O'V2G8*<U
MS,I/GE!L=:]R9'[B!3."=(.!9Y%W/J&;EPLPIK#)"V%8S!U0"+ (8*/EXT;M
M6C-U6>/395/!6"^EM)R"YJDPC8X3R3VQEJOEC,]%CVM?MO#[2@^H#A@'$E ,
MD2)NJ<L-W"+"P,#&)JZ%\FN;W=ZU.G[A"G(1Z*=P^X3%F'"J/]7<[F0+-M0R
M:S<KPH_=X$K=>X.K0H -\[H.MKI@-.>%!+W! \.O7I>KW4\3BM\2>V=U4J=[
M9+>Y=[K;_ "T_7=K_\O'H[VCK=/ZE_W.?O.O;T"Y)S,4O]T^ JH_ PX1C:,=
MT=@&VN_\W=Y_UVC!.W_ G>WZNX_M_:._P+[=X?63 \("MXI+) 4U.2L&(\L2
M_$EE8$QAYH6<[G(EA%0>6T"BI#CQU'(23,(T$1%BKD$TU<[H]6Z]OM.LOVDT
M/]6V&MNUU[N-YD[CW9O&ZYTWGV[1Z.KG[[\Z7D\3J*H2:,<P#K:KA:6B41CA
MI.;<\YL:+MT?AQ1/?)5MEI9?@&?>MX:MK\4B/'TK]^VL&3EE:@)R7E8)OEL0
MKB,P%]JVU2E]'VW0BMH3=0CXNO"HYZ?T^O"G[6?W-QBTA=[A1@,8PV"P4=LI
MU87C7N&6AP>TLU)5JE#9;9^?GUT6,+&QVV34G?RUGO^<?FTV%8#:LAL^&PKP
MA2M\+'F(A?[6Z8WR.4!6V.R@UX4O0=. W>CDRZ[.NS 2K/? -& 9M%O6M=J%
MP[]7RHWRMCRN/.I"G>G'TGET[RUFYR@4[V$0%Z!ZNI4';MM;P]>VWS^%#PLC
M?.4UC0?'W;-O8%H[#N*,*$0%T6!:1X$<)0Y9P2Q6,:B4P[KF:1=^LN##<P+)
M^BM8 [E_2<B*[WR]<V,A[YA9(<2[)+Z?/N1=<NR5^T++HRER%0+RD5T[9A:W
MV1_G#VV)8-?RM_4S 2S6!16,8)SS+.B JZ,VP.PX!LZ$IH7F1 BE&$U^N<G'
M-CD]V/(Y/"V]!V3[9SRR\&*YN+'][>S 6VRUD 3YQ')>?]1(4^\03BXJP%7!
M4^[TS.:<(OFQ#=S.<F(LN/X%6.S:6C/ZPRY0Y=?3VC]@(^1ORV_6:U] :\VR
MIKL^=M""6'$Q2Z$0O\=V[_B28[@(F_I1R N0.-?;G/]-P^D#JR0%4RXF'$"S
MDL%IHH@V*3 BF:.Z$! S9#,;WK@%$J^DEZ?A<'UP&H+W'(!-23QQ"FD-6C<'
MM@5)8"08FTE$'8IX%* A>8V#=?#?$5B;L+R]82WT1U]!=^J.$GP[*IPT\%NI
M0F0R^R6B\&#S<BZ5HM%S'H-Q5B887_ B1_M71'%G1.'/#BAE1%OKD+<ZQ\!(
M,,HT]\AIQI/$3!&C\D'C D31MBZ'L_3Z)0WT4FKY>$$7)8P4BN=@='S<ZP_G
MNND+?1<4Y3',G+OD;->V3XM0UL)+_[U01J9<Z3D")@R*^)=N/K $Q!J>9+_(
M,L=%.!%,@.*P\6"L6FFD3S*"2#,X8J7Y->0GKDBRK4(7WRD'U.SM%,-YV^O_
M-6JU0V\TW$UORW5I92_<(M0I7QAU[F[7V0%1+M!@#,*,Y')TN2D"EPX1L,HC
M Q/;L]R7!.,Y?NT:J%;MO->9>I8A (DUV">.>4$EIT(:$$D4 ST(!V3 4T4
M#T0 '_ !CDH9[SFR4?A<QH$@YRE'RDE/L"/$P"YL4GDC 11Z2L8:EQ<?P>I/
M?/GI? \*-_JQ[8^_ FWG4HC<3>?B5X'JW&=?1-D5=V7L@V>.52ZX)>M5P_[(
M#VL>C'W;R@-,?5M^-@(T;76*,/3"'"D>--;:AO9'&9:>OP$<#*TR$*.@\ )8
M78[M:'5<]D:$6QR5$T \@T'2*A&X%@)L=,9@H05)%F-QG>B]2OI-^V-G,LJW
MDP#"(CJH(O2Y9GKSS4G]PT%T-&$OBG83'+#.8F1 !P;*!QH/DH,DRI)8SJ'T
MTLR;D+L[G4=X\&DJ0A.NDA'0R_?8'<4:V/FQ7WA\RL@+>,*%I@_T> RT>EK*
MVV$O4]_8W01O2*,BB0CNL<-YKSX_D;XXEP :J>U<(N5S.LFO^MJWG<FY^%?0
M+W)<T3B:MGA4B,>Q6T3*7IK1>!Z#929RU1O6'O0F1YVW8!VM+)4B6,:8YLKF
M_U*%&=4YD,%&]A-3^(*')NIK#A#N1%BHCQ%>E'&J<,G"!Z\!?5K#2FQ<PTT?
MSAI;!X03FRQ+2!''$">8(FVQ1HR &62QI(;EB)(-<;W8*$+=,FT77M9S@[A6
MQ'-G#NIU2M+SY7Y<T-O%M6_@WUZGY6O;EZ3$ZTN!W[]]>;/]^O?L2VM-@MDN
M*[!CY&_WLMZ;3[$S!9;Z=4Y/@G'D4+:CGELLWGJ5?&Z7G _OP5#H#@I^?#YN
MN,L <PC[VRXG>0Y+K7XH%([L4\U[7.3K%7L_@J68J ;#R2KERXJ@QN&@B-\L
M.A)G.KBB?YQ;1E>"(8M0I=,,?@%4#/A[6!Q\C.^LY2.+C-[PU(M17GYQ@9:#
M2P%_Y;E($;Y1&[1@\6R_MLAY\M6ZS5S 0A[W2AWK53^V;2;_/T]:87@(JUQD
MRUZZ:]RZ'%_<8MV@UQX-K[]EIG_V(]$"$5.K<^GG8?\BI?-K1 [8^ANR"0;[
MRK9/[.E@[8^K# #4?WD!I^=>SG#S?UW_C\UY;UV&EQYIN>:?Q?[\;/42??9@
M ;N3J+H,Z8"FO6YY6-;OG=HVH.AQ&;@.Y%T__W[RV7K!;/&'S4[R]<DYX7F4
MWCA"\%I&G'@Q"FT&?BEXO PYG!PP#G+H6^&9O73C>FTPRH\#WCV$\7M8F\+E
MX7.>=@"\'Y3F1Y&S,W[V^9//KP:K )2*]3)8J+&]-8E>G(!*&;[5SJ^]6!I8
MANW2E5?8&H>PE,6T!JT?M0YLQF%^=3[WN2XA9C:"&(:\S'$A)<FE( 2U3G$K
MG Y@X"?!$B<T.6,*%8IA<B4.X_K3A/--'2<H#*H#PMG #+*[=0#,%'7B&F$?
M(E@>.7;0"(FL<M'G1$CNS,U5JJ;C1+G!6C'.+:'<P!.,#BX7@)..P?;R,J!F
MLI&TVL@[VDB!K34R1A2$THA3"]8CS0FNQ&C)(^'>D:4V,AEBK0"LU2)PZX/%
MF FLO0<3E3$7YD9&51OYRQNI/'.".H4\+#/BS#)DI)>(8*N32=1QHY?:2.6%
M8$P%;X+@VB3#M#:.@?SDA#,NQ]8IKCCR;C?21UAL'3BB$8Q/3GQ SKJ(I'%)
ML6B"3T7TQ7#&#+W%!SGNI]!%3B]+]5E5?$YXQF*!GH*N>*"GOO= S_=9F8N[
MQ]G%!+K2^UPB9+ B@9VD?A[*_/%P=_L;V^N\/6QD0M_^0.K-QF%]^^M9O?-O
MN]%IM/._]>97-DWDC7=O^&XSM/:^O&%%^//VYQ]U^N9D=[L.UWRF>S2',G_^
ML;L=4OULZT?]Y, PJ@"1'%+<",2#X;EKM49>&<*\M,$"D4\%2CICHP_:$1L\
M)RJYX)PD3 2MN3>830=VOG^S]>E6$9P_?]'5@6DN3))&!!=@-4C07DJJ3=3P
MH("+4.>GZ(W8!4,@GRF<!P41,R\H:.ILXR9F"H%% 6O+=9)<$&\$]["PF&H;
M0:[8\5D!(681'FK&?B?G]G2'&<VNB!.8LG\51OU3,+5>&(,UFKG(8>3",H%,
MC 9QR3@"<S<B#6L-!I)0 %.EA^$J;Z"\7F#DY;"N;,O>/B!CF9V^T!GPS+:#
MD?BI#+1M]MX5A9M+^'P2X1D/OO>[35 ?DDHA)HU(R&%?1EIDA5%(1V&(DXQ2
MG4-V.+\Y.B,6J8F3B(S"!7*=X^)2$ ? E"_*7WT"N-INQ:^]]=IK #?8K&[+
M9I]@:W 1WM&/QVVX?C _]W)<HV3>",Z?D)W<PP)[KG]C/*_+%6H@'N#6\J2I
M.+'-KO#SI^7P1CM.J+QI2+/CN/S^\T#IG$ 6QG[_\?L!OP:YK$K[W"\;?QR7
M]?1JQZWCF$&X2#X;ORG/>GQ@5<1/7?ATRIF5K#IQ0(WC95S\FE.O)T5AQJ@]
M+F96/#8/+7;'>>[Y<>OG9\%767Z9TZS;L?SL(=8\J'\_B3:?& _;T[';*WJ6
M]?#P?_:9'(@HDA->(ZMR" 2H(<@I%I#A5GEI L,VGPL3<U,(!(C^\N"U!7N>
MDQ$JR?[86^O)+XKVG#\ZE6B:C[ GJ1N#"RC)^-2;;$I&J7S$4QPU/2I(%*Z$
M-Y-,DPD:O.WUSPGHS7BH>S#?W6Z%$O,5A>T]?F"B4MZHD(-[*=A@GB(=C(8_
M.:74A4"3G)__?8X1D]R?U.H/AK6"Q,9A4H5D6I\D&ET14EG23 RHR4%$#K"J
ML&:%"*2Y=W+G6)-1Q)?GU3FTY_8HXF'[.7<)C/' .24:)TE<--' ^!(U8]<D
M4 !: $XF*+*;"H+(E5UW+H73->)P-S5CUW:'ES[>:K=[)[E<R].(J7D$/\^.
MV-W^?-;8_LH;1_#LK0-&';/$"A0X%@BX%XP2EAC",I<W#4H*R0%OZ$^CU5)O
M;*3FK;H2^K@."GT9CEGLU^7O<GF'\8YMU/ZY5$SH$EI- B=/8OM[G)Q@C@$-
MB+?5OU+5H<*J%2&UYAM:_W ':'75KW4X/K O2YIE2H%=C>/$V0L?R4^*XI1W
M3VM!GB4M;70F"FX#M=@3&ZV*1D6)J9RO!5V7^K9;UEQK]CY&,&=GJ0(@Z:37
M#X/8?;&.D7ISYRS75H]$: ]2012UU5U4R,5D04@D;Y,*@6BPBWK=."<G+H0B
M@.A!^;W84-O.;#^7V<^W]65MYMG6R2[PNQ?Y9)DBHE167XE'UD>-6&"$R.B#
MBB!.@&,+!I_F^C'#%S'WDQ@7V^V.8'\G[IHB",YE/N\7%8AN'U^X,@&4NT7X
MW2<86E%6& 1@Z4Y=Q:G=<#91CB/DK/)"(K\JHL3S56N;_]B!#3'GHUZX 2?3
M>XQ3E%=75.!V25A+);QJ"78:U5&GR)5*EG-&6?(Q)0WTGRI7^@/HK[CQX<":
M9 A/N0E \(@S$I%E-J"DDW:*14*-7]OD9AG'>NDPG[BQ[; &8 ;$ J1I0Z_V
M5_M[V#AW%4^*?\?:8;0A/VZ8.U 4L<%7;ML]Z<;^>EF>L'0)E^I*H<+F^,&Q
M:_A*%6IUV:.<"1 0<5#6\)SH/_U8N,MA.,NI.\D%ZJ1R(>;L. ]J#S.8>L^4
MQ)*$0MTAYH8:PY6ZLZRZ\YDT3@X45C9X0A V6B*>0D(V<8L4,3(RQF6D^AIU
M)TO'2Y4=YNHZRVQKI>O<>B?I[M8!U2*$) (*.N76U-(A0P5%T0L6A*+22[FV
MF7(:4E9V!M/:SFHJ+[>4\'-/^E9'Q ]&KEV>]I7@7N#S?VR[=W::2TGM='T)
MZ9<LBFN/5N<>,,X><$ZXM3C2G+S__)0O3 %^&8"-BY>5X=GP_=\6=-_^Z?@*
M/JG*<Z7B,_MYR>?B0/4FT"!"2N,8#9@%[I4Q/&D/IE%(1"@9XZ2R,IVIS7!+
MA\@+Q8T<9@6X@7--#.&0)/"#6U9D14>$&4L4E!;X$J]M#EH_4.'LFC&22D*:
M2E$FA&->^S^V<_QG\;NN?>H5Q]6]VK^VW8ZGI0)2^VW[S>^E$I(+F1;=+29D
M5B/B<J>2\C7%P< X2_/O4?O21<\(O.HVM 8Y/?P\X6]UD&MLG(QA*Q\ 7L1>
M7 KRN,B GZB7EQ3+\Q8GM5*O9&2N7CGI$_ +6J751'*AHPQ&\B29LY[IX'$$
M:XB#T?332G&55KDDIASM,-!%&)&4:IN0 !0',RCGFVL7D<-)J<@"B=G/.CR9
M4QXNRZG!S]3*9?:U4BMOO94B-YSA63K0'%O.#8@')9'1BJ% B0Z"2T8XNUFM
MW,I)AT6PTZBH_#>KV12Y^I>-7_@V1T)=[AXU:88UN'(><TGN@/J3;8E)SAB>
M*DM71DNUSQ',CNL-W%2:;HZGY7:(,EM%JG*U+$F,,)</!SI%+#37B!D6LK7*
MD=-@L@;'K2>&>RMSX"(A/_6O;,S$>-]K=#_L[.O>8-C,.?\O.JS_PX%(.; _
M)412#NLWQ"/MI4%,@9APT@9&9^HO/\G8^&;9Q."XUQVG#D\@"R30.-7]<@%4
ML/X &R<%?EK]7,IW,"A;^Q4GRMUK^H]T![UV$? 9:LZVBYY+@\.87U$4UBVZ
M%N5S[<&K7]*1BWZ^%TGS?5!7$2QEVQX/XJO)+W^"YGK<MJ>O6MUB08J;_AP_
M?IQIG[/+I_H'%R\LOQXGGAN]H;3*2=NYF?!%?^)Q6OI&D<\]U;NX_([J#8W5
MM5_C#7+M=_?TV)N_ WBY\\$2O<&4?D*#U72AQQ:=I<<$<=ZVG<UMVS[5L+VL
MT_ X'=NO*8=>@,'6!1B\OP"#Z>;<3WVNKZ] V1*SPWEN:\]G(8HB![5)?8.[
M78@Q)H]1-C=O+P1#+4_JSR>U2M,. DJOK-1/4&"\#D7BZ/Q%6'PQ?^TA/[W4
M+/&^)[%SOQ65I7HC>$08_#YOUZ:*]8AB8>X,!)[LI3^C:>N_?2VL1#3>2>]C
M3.DFZFC'-*-H/0QM7),K>IXJ<%D/7@ #G\/D/^;?42^AT9W.?)K<EEDQ7'L"
MZ_8_TZNTU POSZPHA+9*4[OWCB>S7J<IOV<>S&[Z/(B%%KJ8YXD]3:_%X5[G
M1WOWR(N])GQ_MO]M_PC>>?2!-VB=UX^V>/&.=_N=.FT<[9UMG4WN@7>-]NEG
MV3AKP_OJ9XW.QP[,CS:VO[*]LZ^G]>W#8C[[G;VS/;BWOMU(]5-\]K[Y9EC_
MA&%.>[C^]4!9S*2W$:GH+.*>&N2$"4AJ+ UE,GH2UC8Y62>$7Q/:_BN<D'6*
M)3FB@J4*EGY:TQX[H8*11EI.E-8"^Q2CTQK(7=!K&L-7L/1XL$2F8$DP$:0E
M.?]?J=P0GB.+0PX$TU12(!"5\VV$7J>&K! L5;;$+]@23TAK?CTI\#!E.K3O
MRE6V:A-^_PO3NY9<Z-R5F"MGG[(TNA\E^;RLQ)@6*W%T5^*H\6E&2[8D$:>]
M0C0J@7@,$3FI&&*$Q<2QU(SG\NKKBBPIC>Y/%ZZX[SYUP8K[[I'[II5!#Z:I
MCS:AP'/'<"DPRG&W2/'(*(W2<>P*[E/RX;GO!3A(&[TN\G>B\3R'U9A1A<X3
M]R=KE)N]+7:<N+3#8@YZW]YY\91A_9Z5*B!Y7R'['2-[:T:ODLD(HCE'F#">
M^[PR9#S'*.M45A,L>*[!J_$Z5M<5UGC"WL>*F1]&1ZN8^5Z8>5I- [W,.$,T
M<AA[,)(D1SKWWTW!1Q9S-?88US:57M=S8F ?V6?W1Q$0^"0B$$EN_UFVOUDV
M!#$7312W"[&[,011;6AF[B.J#\N[C^J#+^EM!U0-]ED-=K&8T07=U@_L:S>+
MN)$?,A!++Q2(U2P:+=7+\F1O+AHLY=C#N_ I/]%E^=3ZL<BB/+\XXYQ]4D45
MWV7\YY.@]P6CC.\R9'9^_/'S64_Z@%';SV?5*BJ\3RI\/A'QE#PW"*Y"XE_
MI2_@=&HZ?-\OIE$^AZE_O*;V4A7!7X7*+NAZ)\((RI),N<NTBL&HF"CFD27.
M=!Q7$;B^"?'/?/#9O'L!3G<86_W=SEG]W6>Z_^4#*;IL'L'8OKRAC7<PBR:\
M_^PSST4YIYWN>V=?3_:.ZB?[S?WV_O;GW&6SM=MLPUSV\/Z1_P%S/6LTO_)&
MLY$:KV=.T 1GSN@H$).1(XY#1%8EA3#3WEG%M?8BQT8PSE;(YUYA4H5)UV.2
M%92(J*Q+C') (Q>EE432* 3.I>=_TD][,4RJ8&<9V)D^ZU.86<)SV7*5.S9+
MGI"V-B'"<@55RG2@9FW38%&!3@4Z3P)TO&7))A8(\Y@;JG6*E@J9+-66L21^
MTON]4H0>&)'8&)%(KG8.B 24&572&N'(*.(\6*1)HD@I'W22CHNL"/%U3FB%
M214F/0E,8M;DEO2"Q8!Y[CG.;4A>BA2P\(!"XUYA^)<4H0J3[@R3Q 4FU4_J
M6P<J8$=I4,@:8A&/6N0VIA@1;!1GPGJA^-HF65=ZE8RSNX]W> * \RYV@37:
MA2?-ADZKVQH,,ZM\CY,&HE7&V\*X!5!$;5))&I5R95;MO0\<%"MKI R"W(E3
MJ8*FQ:%I-J.->\.%BA1YKR3B3E$PX+!&T3',0P33+H !)Y:-U*SRV>Z;MY0U
MF%,F'%6P481JXHR2 BLFJ$_>5\Z1!^>M:><(5RQ8%P**/!D0^TP@38E&VJ7$
MC+'2^ BF"*UX:\5X"[B&)V^D=PH,2"R=M4: $F>8XI8[4_D 5HOQIGT S$ME
M@F2(*RX0!Y4#V20E8HP%0:.AHFBCN@X;5['>:K%>9 2X#6-#J>#><LM @BE'
MA17,@V)R)Z9NQ5W+<->T-1N<#T1:@VCDV><O<GZ/B4@+04#<)2Y,6MO4_!'$
M6A6P]%PN?0$!2__:?JO(&*OBE>XQ7JE*KKVO")\)_5:"]5:"=;8&I\8Q!!L8
MTMAKQ)GP2*N0D,NG5LEKBU, M56N4M9LQ:4K'O-2<>DO<NE,R M3SCB%40I!
M92XER&%&D'$B:-B^R*, +M7/\'BYXM+["A*IN/07N73:!>1-,#@(A701#TM\
M0E9KBJQR!#0A'K1B:YNL*B?SC+GTSL,F*B[]12Z==B4YS?(Q"$;4&(H 20/2
MG.1S2-@@01+.O?8VV;*NI"HLH@J+6&%<NO.PB#FX=/ET*;5^Q(#.8K]7X=42
M>+4[FV437.*)*8("=@:TBA"0-90CP5W"1AJC)5W;+'I?TC^KHZ758KL[CYBH
MV.Z>V&[:Y+941LU20%'^_^R]>5,;R98'^E4J>#,OW!$D-_?%/4$$W> >][L2
M;1NW!_YQY&J$A<35TA@^_3M9)8&0A)&P (&K9RX6J)9<SOF=)<\2'.+16F22
M [9S.A$I$S?$U6RWIFRW\F"*FNT>B.VF;6BPET7$8#3KE,"&]H8@I[1 $8->
M;I*Q"I.:[=:4[58>2%&SW0.QW;11#"J)-)P8Y+',]5,30X;E[$K!5:*"RJ#D
M$[)='6/Q4B[]"6(L#KH#VRX>-*[@ =/U;M8*8\"PH3O,$2-+% M[F6E^*UF9
MER+J96YT8!T6FB2NO71"\J HR K& S5A:7]2':6\<CG?.-@9-"[PMRSKF[N'
MM+G[]K.P/"DG*1*$1<2Y-LA%*Q!A7 <B!'-";6RS35"W5^3_7@7;K'F*<XV9
M-68N$@VGA4K"*B(CYEXX'7(6G!-!!*,#LTL[ VO,?!#,;'ZXB9E:>$.5L<AP
M@1&(-X$,&$2(D("-LLF)Z'-JA\"JQLP:,VO,7.6Y)2=,8Y(PD9*S0&R**EJM
M-'7$L%$$\3*>W!HS'P8SQWKF0>.R<7#X60-""LD(4LXFQ&'3D):8 GH2;[&/
ME*>XL2TV-5E5F:X:,VO,K#&S[$]( C?1T\B,Y5$2YQ.)/LIDJ/4!VZ7=\#5F
M/@AF[G^XQDR8V^<8O6->).12CO10B2#K*494$YV45P3+LIZJD2_!-I_3^VPT
MJ>;P%%C$+]<+K?I3JQ-B9_":JA)75\JF!-\WPZXXZP%_].!=12^V[2"&8M"=
MZ&8[BF;K%[;?[_I6><%Y:W!<#(YSDYI3F,5%>?2B?NU/-\'M;Q4'Q[$7BW/;
M+_[K$1UX8AHD/AQW>X.#V#M=$BWD\T2+=OS?]Q='G\*9HUPV_]CC^P>A=?AI
MCQV=?.3-W8_?&G3O?'^W ==\I(?T8_[WV_YN2,V#=Z)Y^1&>O\<:NXWSSYPE
M8YA7R$I8;.XX189&B21H2DE;(Y,"ML=;_!:F!R)NY\W.<9++4,"/NB-J"E@-
M!?#/47/!E--()*H1MY0BAT%MUAH#[#,,XEQG"K@-]L<4T,\;@ :P Y/H$X:]
M#!<93 9E![33;MGL*UXW^ZH>P\AFD7E]LR2EO.>; %C]L^AST&W[XKY0\Z,V
M7$UH*R&T=^0S42EYJBD*"@PR(#30-1CS*,AH) Z>&NDSH=WFQ[HOU/RH1EI3
MP$HHX./%9X.!&W$0R"=0-#E5 1EE0-OTRE$O*,:>9 JXS2I?&&KZK6\_ #3%
M]?GYE6:8*:K5&9:-[6[HAB/]B^<6MF?=?BM?\+K4M.!IUYUKLQ$U<==(Z<77
MMU@'*NYP</LM,SV5GDC')')J=29^'E]%R9S9+Q&Y7K1?D4TPV->V?6XO^AO_
MNJE8@U8]N8#3<Z]FN/T_K@?WS7GKU,94[*5S/19I1' !")8$T"\EU29J9VS
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M,R.6ZA0$8H[D(V7.D1'2(D^("5%BG%(N.*'8IM&S82\EX2Q'!3+I)*SE7)D
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M_DE_7:.*^*L^T:A!H94B=QI[@XW#7!/GA A6>*]QR G <MU!H=9P?@@9IOV
M0 &*Y,;G5A'0<#(\.!$YBHE&KH-+BO#L!]3:;(HYB;XU-KP@;)"&82R8,UHY
M'KPST9-(C<'"&&$4KK'A16/#M*M1@EB@/#@D3,YA"38@2X- 5"NB #84=>49
M@<)DT\C9[-$:&UX0-JPLSZS&AN>(#=,.3=A\;Q3E*+@ %D7"#%DA22Z"1BQH
M$,:P<'M^6XT,+P@9G/2!&>=]KB^0J'.,*IY 8>!!4,,?(8*@1H8G1(9IGZD-
M@ 86)^1%Q(@;Z9&CVJ#$J#/.668CW=CFFXSA3<;7J2_H/:(3UZ>1\Z)QU[>
M5Q7'.<HJA$D5H3O,.8IE+.=B0>@O$=M^.*BQ+KWYK.'MPXPKU6*6#!4:84HD
MXDQ(9!UVB/$49=)*:_:=ZJ_?![<5,.&3G0#7"%(7[ZT19!Z"3+M<ZX*_-:DL
M2"HK+Q)<RY^?3?[\<)AP+7^>.:A,N_5%#+F4$D7!Y5A$HF2.();(4-!>?5#1
MEQKLIF)JDQ!38\A/CR$_'+1<8\@SQY!I][\5)M$D,2BM)($5;"URB@:$K<06
M6X8]BQE#N*:;$B^9B%!CR O$D!^.H*XQY)ECR/1!@1':,&,T,I&9''K$D?9)
M(NHL%01C[W*)3+EI"&"(7#;TZ DQ9('6D_/K!YJ'+(U8/O%UMNA;?H&3@](%
M4%0L,5WS9@T*>);#&S-U7<QS5,SS_+.ESB0B/'*B/)>7'ND4!8+MD,)0R9WA
M/UDQSUR3=K*52&%']'+5ZJC?^E:<PAN/^T7N_Q#F-6%8J  HH<^KO">76U3>
MKP#C=TLEDBU)S(-4S.3U8)_58.EBQ6-76!AR)D(@E?\]KWIIE=-]%0WL7]K*
MC#O*H[(/]*BO?/EY;]2;I_SEK]R?I_H4>T6YG/5J+K.:[^.I;75@(N5OO\.3
MLMX]M.WR]X/8.RU>'4;;Z_]2K^N<2KA?OO3B%SNHUO(M+%ZKTV_Y\K>_;7L8
M?[ 68DHX^65K(8*&LC'12?WQW 4DRY;]R0J(@^)#/!O$'(PW4K-PJ6;1J<;N
MR]#)[V_>X#>_+V[;K:MSI5RM)<.4$G9"!2.-M)PHK07V*4:GM;)8T.J0AV+#
M<)V>OG(/RNG'R\;ESD63OC]MY#'NOF-'NV^.]S_]>9+O;5X>M?9W#RD8;>UI
M#\K10>,2QL.._CB$L7S$8.!];7S:$X>G33#TWK+FZ5L.1AX[.OT[-69CD;SB
MTH<DD12<@;''.+(T>>19I#P)P['S.3U=4;()"MZ<X^%[5" =L=EMD+X:]ISK
M 5VCC/221_]KX2#5Y>;^/(%IV ^@:I7HL!)TH@^(36.U9Z3PC#7'4FFL06DY
M4)K)*#6!6RHB$DKFRG(X(IV(0A(["O_&B(/,A<BWU _'?B\K\1\T8^0.7%RM
M"O,C3W^"$3Y09'VET#X!"(XJ>R]A^;P\G?->3OX'53[+7;EJZ/E'K]OOU^KG
MRI"^-:-^8L*5C]PC2A0%I'<"N10HBDDKG$**+)F-;4;GEB)<A=?@F=8?NZ\>
M]8,<M[Q"U5^*X6JE:G6L-JU421ZL9%$@S',JOB%@Z2G)D)#Y_RS\P2M@-;:%
MGT^-[2>Y=&E7VY32]&Q4E-]S<'Z[7;6RC]_.6KV%])5%%V"ML?75<]=D]O)^
ME??\'/W)'Q=>9YL81$J9#($@IYC.'9US4%*B2//H)7>,6T7 9A6;0L]J,HL<
M@-S?&/M>@8$YK%DK/X^E_,SAT5H#6AV+3FM "5/L."=(! T:D$\1:8\](CY@
M9@573H&Q(?067K(,ZU(B_QDXC];Z&2_-$31F\9?F"GIZ#2H'[+TM6]OO#GNP
M;!7"5G$QD\&?5SM0*TBK0M\Y!61C8)0YRY"EFB.@&5"0. 4CE.ODE?)!^5PF
MDHM-R6;Q=R4A(K6SYZGUG8K1:FWG ?AM6MNQQE")LRWB;#9(5 1^<PEA$ZT"
M4C7*IHUMM2663(NHW3TO/[)J3O!Z'55UGQ.NNNG'3X"]LU%5G.3RQXX@;> '
MC]PB321%L.4,AY"HT/A[33\>-:IJA%<_9535<G-_GL!TNX)X/W2JHZJ>!RA-
M*X0JBNBD](A8;1#G/")M/47.8YE," 0+,, HV5JV?=@/LM5S<(S=K=.M*QX\
M6'9MYFAW-].[I9G^*FUD(F,D)XO0&RH+K(I_'8:]BVA[-1XL@@?317PBU<)R
MZU 9%<"Q)<B*9) /EK)$22[]MK'-M\1TZGF1UWR1S+*51WZ_8$UDW@R? [[,
MU3=6HF?@!]0SKM*IRDRJVA9:(<S,U/F).'"6) )Q$Q#/52MUI EYCZURRGF7
M6X PO$FPVN1LV6)A#WGTMK3KY^X\P_5S_8QT[++>P(^Z?E93,>5YPMYZ^W\F
M=KGV_ZP8\V;#F@.WA G,$6%2(TX)1YI;GILEQJ@$5D''[/]A7&^"PKW*R.:'
MKB'V;#2L52S \T2BM7?X3(!1[?!9'0K-1'SG!M,J6,0XYX@K$I!E/""%(Q&:
MZ)"\V]@F>FOI]DK/K[KBCVEMZ\K[Z^K<N9W!;W/ND-JY\T.\/^W<(5()E8#9
M8?L9:"":(=A]B@P+PON<UH]#=N[0>SMW[E! 7HPB\3(4@@?TR*P&)VYZ9$AM
MGJP0'&8Z+\+>.AHD2BP)Q(75R%*ED6;4,FRQ%T*-7#)XD^$ECX.>M/YI+I^X
MYB4G[;BP4]$:TWSQ3R;Z?M&+5_4G<U%)>PIJRJ!P%\7Y<<L?EW^#N7Z-@^(L
M*\CCTI2@R\1>^R('[U15*N,WL#-#]9 X4JEOWE+5L=PJ\H &N</;]&!N7MB_
M>DPH0AE,6WXY..[%>&?=R\)V0EF9J3BW_>*_EH"I*"FQ,JC<_8\;)ARUFBI!
MF8[& *F6J@S#Y)8(1B0>R'*YCF LN^/=QYLLGR=TW;NX;./DW47SW6?#'#8\
M&21=[GV61$*&:XFP V$D/571Y,X16[.5A@I@QW99>Q6H:1DB"EP;I1(A1AH>
MB'$@XWQR@3C!I%&BTH?'1$1K(EIK(KK,RBWE&H04SD%5%G%I ]*4)^2Y)])K
M:YT'Y9;@K=F&XF,JV@2L[9_%7,8WMB]^% <7J?Y[?Q0TS&!' J8V>8Y-T-IS
M164@G$@#U'I'''=-P.M#P,V#=Z)Y^9'L[^Z)YLG>Y6>6G W,$>0E!SPD#$C9
M&@P+E6@0D?'D\^G8UJP.=F\\9%9;S9UT($JYT<(9XR7Q1&N5BROQDIS(F)QJ
M/'PVY/2.?':>&&Q!GW?6F]Q:U"*K<$ LF:1![BG.]<8V95NS9PZW(>,B1<O7
MN\Y[F>N%2AL4..&:0G-- _@<8<)M4,<#"(!BLLI[O^A.A,6/*[TOJ?-N/KW2
MN]-N=WV>X'Q&W:M6H>:P^1K'1YHU#A-%2"(B%Q58S)929#U.2 5KG*5)1YS+
M9%Z[T]90;:W)X,?(8/_=9VV3%"P&%#5CB//(05ICC'AP"00YB'#G,AG,1O3?
MAJ[WQZ9E.D^LD>ZY*!7^I(2V?]# S8,O>#_W8LF?WWVVS@DK$D?$YR9'(8#)
M[/*IGL>4"QNT,":[\M=91:QW?0D]KG'Q.<G@A1$&41,3XM%89(3VR $)!.&4
M#8IM;(O%@>;Y:W$[_6R*SP&WS1(&SWJY_\VW^2":L=*VVS?TN6'GG]C/R'H3
M5EN=2=<KO'$9OO%!::^%QS%$@$GAN+31>16E\59J.?]8999=]D[/VMV+&#_$
MWC\M'^<S3;,[FD'56JLTFB:__[W;'S2[@\,(@_/=+QU8ZS!9]J"6]/,E_:%H
M .A*)AF(/40L 4D/>X<T*'HH"@T:&6CF*86</?T=T#V'?PN7)?AX]<?$E7?)
M=B[^W_]'4Z)^S6[__K ]*.F[>Q9'%8&*[C\1J+8X'QV@%[8Z02_.2ALY7_R]
M*(![61&/1(65E?^FVQO]*5_WT@( [D^ EV_%_N['R^;N%[Y_L"-  TB*64:E
M!',## \N7$0&4X4<Q5+A"-):I^PTQW,/\U\ ]I>=VFRK=^V2C=8?%S=;LF7Z
M*UJ@!</03TN=N5NQ6\AG;7#/EUQKM!CVQU[;W]H6=.\/_KC;AJ&.'I-/R?(%
MI]T0V]/>C[R\F<M:G:&M C4G5G,T8IX[KIUU^R55OR[5=Q#!UXW6_OMFM[Q1
M$!6^OL6Z?K<]'-Q^RTS;FB?:%:*G5F?BYW'O^CCX"YC-O6B_(IM@L*]M^]Q>
M]#?^=9,4@0XG%W!Z[M4,M\ON-_/>.K4Q%630Z!W6@H+V:KFCRA$9DB:.>A>"
MRSRS%#<\(?'/)=7,#-5L2V(M;;L00=T#(1)*G6?8SX?,8XX8T_U-3AKT;+8:
M1_K/YNBH.72+3G=0'(/0*3*^YWM!3 V .RKIE$T*D =%&K;;%_DAG7X"^>3:
ML3I,"1'V&G:U&N#H$.4N'@;NM;E%>&9>=S%75E;7C\ZRY_#W9@&K<!Y!],*_
MMM\?GHX4NWSFWJL*7!2=,@0^WW,,"PWCSUIC.WXK9]4?NI-*;X:A]EIY2OVM
MXK?H;5[.>6.*(T$YI4J6B^=!:H)F %L/B^AA_$!0K=3R,%1X;VC!='O Q$7J
M=4_AX=W^W$W)XW*C$< 3.U_BE:8Z,=Q6YVPXN#%I>$V1L1"FD;>I6MSIK1@#
MYN8H7J!5;7=)5/TQ)72BC_T^K <\YJS7_:<50$G.WHE6U:D2[H!_3J/M#WMQ
M_GZW!K<MU33./GYCV,ECB4DE^>\QC^U<K^I/W21V0CT1C9.WV3G*)3<""PW&
M:BXW%#A')F*&$JQ]P,$9T%!><,/8DA=& 3L3K#?L7RO\8$KY8?L*"DN@0B5L
M77-(?\0T_6D8J9R#(ZS[[2Z59:$FL[?*MV?3=E;1+:UDW1R5+C:@'VV.:A8I
M0;E6/13+B-@/K6]%H_*-[UW[Q@M&-I=IGKA,<L%]<AS7;]UN9'W^R&Q_JB6C
MRQ#5RZ@;EQWWI;8. P I"%KJ12NVKTK9KG1$8DN+!08UQ_;.M(78%IDCE+)P
MS4_8V'Y%?KDCT7F!.NH_D%CY?-().J,$XE46&V4K"RIZ QI5&3(TH;&/R71W
M1*7O0?6ZZ?Y.K6\QH,O8Z[Z,Y(*3'='\=,@.3W9(\X\]"L\\/=IMB,.#MZRY
MVX#?P]?#2]#J+\/7Z>2"QNY7 L]N-78_XL,#&.\?1U\;E^WCQHG'C4OXG;X_
M:9X<G\"_DRV=R/[!H0!K0! FF10$I3+KD$J#-)<1:8Q#B@Y^"+NQ7=K.]->Z
M?=\*:V4^IE!<#$*:_]JYCZ*U;+;84TF_]ZW^5Y1R.%@KKWSL#XI>;MC]'*4?
M75SZ/2M15AKNCRK*^(.*LDQS;X#DWHXHKA)E(Y&%:"VS[I99%S,RBQFCF+$*
M$<X#XM%Z9(2W*"K)A*4\"J?+*.PEJQ/]H/1Y D[Y[U74V5\(T==*6I5S7U):
MO3 +[I]NEA?MUN#B6<HOM@+K[5D)MI=JH_U]18>U:%M6M$VT71F+-IFT"8!O
MB',O$<>2(I= OC'+;8!]=]+PC6TMYV1</DGAO2=@HD5DWJ/TN5IW*?D(-MUI
M*X1V7 =YF,,7BE>M3E40Y9=G*13Y74+QV;46FS3GUJ[ZT??$VLLM<O18LNW#
MC&R+!-LD%4$J<8&X]!QI;P,R3$>NE6&*X8UMN45G2EC75L[/9>6,JY!=!5%7
ML:!3(1@YM+HHZ[A6H=A5_$5Y*=SZ+"6 N$4"U)767T9=KW5I_7='BO\?F8=N
M:_M7?KD+K'@E/^LSN&4$X^P9G,-,*2\(TDZZ;/D%I!F+R-F0(I>,$DXWMBG?
MTDLV_WNIG8[777+?;GG=+)(V/]POMS\>S11EW"[?=T>8)3*K#[.\FF;YP->M
M ;S>+Z"RO"*_5#'E-X),<K3XH_J_5H>*/WN,PNJBC\\_2QT33RD@*G-_"<,#
MLIX3Q%R,QGCGN# ;VWG59E/U;'\RGK_PPUZ.Q<]Q^5T@YQSV?F8O"GM%>-^I
MAO*L^8M6_-6;?YZ=&6TB"-D.QN']'[<^;!4'O3+F_Z)BRGYQWAH<%_$_PQ:H
MU#FQ(?M1RF2%6"4?V"K_8  S&C^GU+!?ZMJR7XIKE_;-_+2K1;T^>[DR4$9+
M,YUJXKNGI]W.9!;,2UTW7M%DO.&/FRJ0>9T*6Y)329LW@^?'QENVZ:X?U<UY
MN1/)X)LYVZA*##QNP0-Z6>)/5,ZT WC[*.D)++$!&J=$3>8XN7AL_VEU>R]U
M0\0O1;-[M;#G@ ]7JWMG*;QBE*Q/IY)1%ROJ^@"K<)WQ<>LRS,3YELOP?I0$
M!S,K\X2*CZ!R].^?=+$NN2T3\ZHX**M2_>)51AZ*?WW_X6.__$A^_643T-RW
MAV4N756.MBI@LUERX:B83<DJL5?J+QU_]=<R27RS2HT# =VY(J&RANU<R*.8
M7!6P(<5?;3O./LQ2)0Q]U7J^>M UPV?NSCEJM^!H%E"#BWF%=\[R"[:*G<$X
M[W&S2E2<K!T!JW&5WA^_50EY5<9EMQ.O/4AW ?A6^:!J38HOL0/(G[/T\GO'
M:7T9JTJV@L'UTTC+A4?WJYQ\ $282&^T!..*0%/7@LUR//^&<AG]<2O^4_XA
M7^S!WK$@K2?VKA@ $<=!?XIW'S]);U++OJ;7D@U++BQUZYV<"PE[^U-GZ35S
M^:!WGP6UCJL@D3 )(TZP1\8*BJC21#AG.%=DV<R\IX>J>6EX8$;!8.$AHT2\
M$1'<QH49SA;*E,OUQ!\]+\[(+6[(O=+BR)9AMW]][TPSNH7U?5/?OO<=QP^0
MPY<'RQXE+>['NLJL51)3=38TSHLOZRQD)EGM0=G+6*6Q^QJ5JS1R8I>?2T]V
M^2F[L\L/V=53E+Z>\M>_8'E+@?;SG<%-M%_-3H /\6P0,[F-JGGARD!8O-GD
M2G,GGL^AS]P^D\$HI2(+.&',>0(A;R.A@A%NM9,TEH7'* ;9\%!])O=*A?IM
M![2R8:E<[H/<[1V :CPZ KHJ%/73])\\^<@/+QOXD.Y1>,_%T<&[BT-X9_/2
M\_V#OT\/+]]]:QR\;\'[R/3Y3_/@^*1Q^?[D\. 0YO1GN[G[9POFQYJ77T3S
MT]%)<W?O6_.//V%N?Z?&AYG^DY+*8!D3R"=*$!?<(:=Q1!PKIDGP*0JWL<TW
ML32;G)'[])]<>6_OGZ$GY0_._7D"UNVGU/=#K=4=PRR.63_+B?6C(=9TKTH>
MHB7>.Q2P TO51X:L$19%[RBE@M)<0V9;TBVS9#>J)\H972XJM@(UMJ@&]P3<
M_4?E5EO"''AY2E8,+#HOB.-"<6*)8P1+[EV26F*>[JJ%_:C:ULV FUK96AET
MS3;[IKDP+% &,L9I@*[$D'-"(<<"B4+;1+S:V":;V.A-P6?3+%9A8C_3Y-S[
M*@X_R(F/J$'\G(%OC\:+TVH$$99Y036BWC P=P)&6EJ'6.!.6,RCH7%CF_$M
M.5LY_7&:6B[CY?E.;-U:*PM_ESKS*HS(YX!?KUZN%E%M9*U%K!RY+F:TB$2P
MUSE/4RH+R$5 @;"$.R2(=%$KF;3U&]M*LDW"9KL,_?*@*8P_5^KT2U [;C)N
MK7:LF'FGU0Z-)57"<Q2QYHA;Q9!Q*2$J@R8Z)!M,;M?"M^@ZQ=N_-!_%FVXO
MQ=;+\U*\8 7C:LMJ'6/5,#51"V(,4U8))YUQR 4'.H83 CGK-'+>*(^UI49;
MT#'XIL"S.+6(BE'[*9ZKPC!BQ"' 2:TMK)@-9YP4/(9@N4;,R=S<#91^FP)!
MWK"4J(G4$@+:@MJBL_W+U\])\0)"4>8TE5M9&,HH[@_TIB)TASF*L#QC^AF#
M5)ST@1GG/;>6)^H<HXHG(PP/@AINYW?'JX-47@0,S@:I$.I8C,JC1(-'7&.,
M=&0!&06VE O>1!]SD IC>)/QV8;ECQJD,D*Y53#U"PMA6>7*/$^PNUW_NQ_B
MU0$N+P#MII4^*F1R@F.DJ ^(DZB0DR%WD/>@"L;D7$RETB=GO;M+NHA6R)$_
MI$7>+$VP6*K?>B?)S?:AS#'RH\9[52[H9%IOV?JIW2WS2D<=ZQ;(ZAW=>%VA
M:+/*J09DR1EM57O8XDOKG]@99X>=];I@R%<)Q/"**J4KOW6<]06Z[K^ZO1M)
M7?"XT+IN)5]EH;V 7J%O1EEP@^.<R'Y[*NI53B'=O%$$(+?K[>6KEVG\[*C'
M!%N!/?><4&Y\$L1JDB0A(3@^M]MNW3#]WOEM^P<-W#SX@O=SGMO!QXO]G<],
M>I,4CR@%PP%@@P" 519Y:WT,RN 4;>Y9.J?0Z57+YDP1RVR[QB(XK7703'"*
MC9:!1VT-<50SJ4=YCN-MI_6VKW3;#\_+HY?$8)]!I"9"8-M!N#JF&-):1.ZI
MEU*+C6VJMV;%ZM6VYUZDHT[Q97FUJD1 AO;-W/3TK&JOV;[8*L;@,C_+_:8+
M897X\H..Q)K0?HC0WITWSC\++ZCCE"-,8Z8VJY A@B CF+0:.QES(64F5HDO
M1$6E3 J$2\W!6C92!B-PPIP2[T0HMYV,M[W&EQ5O^T7S_+./F,)*&Y1R95$.
M:CS28-#E" T26,!1\^RE,%NS 67?PY=YX+)3M@"=@R0E@/1BJ6<NI97<R_R<
MI9J]4=/>#Y4V.9]VKDS)TO+L'W0'MCWY_>_=_J#9'1Q&&)SO?NF 2C=!A=5-
MT^9I38B5H",@Z)1AFG*:D*7>(1Z9@4_&(FURX%".>F0>]!O!MF8S)"8I<9 W
M!JBF=[4+-^M?^&XN^W13#%:5=7+MHILE=":>T05[L+#%^3@W=ES'Z+I$S_<*
M1MQ+OCT2D58'TR#Y1W_*U[VT2LZK(E36>/=96QT)$1@T;YJ/MU@.A@%!Z6S0
M7B0"6 2$2K=FBC)7E=;G5 C*I-+J5'VX[RC44-V:,ZT7K>YPPVYE\LGLUMNK
M1HTNX[EVQ&P=X*M6RO]]LW;'R.^#KV^QKM]M#P>WWS*3=?]$2T',% U,_,S#
M+3G,@[$E))?4XL"Q-R9H3"45/%H:>)"?A=X8WW3<NSXB_1*1ZT7[%=D$,WQM
MV^?VHK_QKYLD O0QN>K3"W8[G7V7VO0C$-<MA1WV#_8*@K>^"\(KJ-ISY2[>
M;?6SYRO'$ZQ+#9[]W\?0>-PZ/&FW&[L?+PY//\+W[[XU#WYK >Q]W?_T=[MY
M\G=K?_<=/SSX[60:&O?_^+.U_^GC>?/@S]91'LON'FG\\98=?GHGCCY]I,U/
M;WES]QC&TDR-RYU+L!L8#5[&1)$DFB)NE$$@QS6BTOL0$L.:C/0V@#@03%FD
M4&\M9=(YR4#U3S8K<H'Z1*UQ4>DX7;/GS<[;]\7?.__^N%<T]G8^?'R_U]AK
M'GRXM>K]N'[3)+!6FW/WFV^.-'K*A -S-GK!P4:Q >,4J2 *>WB*OKN>T%HZ
M$0\F#/98*A9]4&XF7+_'+5!O0%&_J%2C,U 1>H"RX_I#K<[9,-<H[):75^L[
MB/ZXT_K/$"X9]BL5ZK0LG3GI4]XJ9GW,\.)6QW9\"_2VUM593E;'RE)'I]UA
M+K.9AW'>';;#2#&+(!S*E_1CNPV69V'[_3C(-<+.;*O\8M"#%4JEVM9NC=W'
MK6RE%N7A0/NBNF1D:+@X.,\5VZJ2;_"4[/]OG955UT9%/4?S*8=7UM:O:BH.
MRCJ.K<&X8.6.SRX0^*9]L5F<'U\_L^NRP[JLM02WV[)J8Z[""G@=8),+^X]M
MM?/7FW/=Z-WS<I;CBKKE[>.E[L74+NNI'7?[HTJ1\R9RM8*YSB2L<WDO/".O
M2Q[]>#I7BWF]<K>LP0MPJ>_DR5;5XL;3;<'3KSQ9,/-)BAT=?, .Y$.E4:73
M=GGHT#^.Y9-@8[(;XDNW5QH/-TY,VA',X4SW)\/PI5Q&6.PN4']^4'D2,N*N
M:2Z"FV$0UR.I1GSCD>,MKPYC1M16;M]FKB=8517[3F6PV3U:3.>\4?A3T;MW
M&SVA)OKO<K5(Y8.8_?FQ8T,>,BS^?X;=_$^YG-6N7G%H"22E:V.TZ-4Q4RZC
M7!X;5AS4GV2A3%.V/SXCR[5>N[VRRNHJV>C)UY7>MJY_C>!E1-UE#<GL#\E@
MU9E:ZIG%S3C:\L?E73>XZ:I0WNO;#8RI%;Q!K&R]U[2L22I_+?)_[VXL4::V
M?@M>:7NWT-K,(OZZ&/\^ZR6Y9L!%U@>41S2U1G#5BUNFO5;):*$%(BV7?\_K
MU+G^[5HK&?/F%4K=$Z2>H3Q@2^#6L#.Q9ED(]V%>K01DU[FJ:)L=AA8TTPG-
M84)UVKR2W>/ "CLN9SMQPZB8;?_&\V&^M@J+NM8@8$-'9=?A(2] (WO;N2K4
MZP'M^YNWZ423JVLOX-=VMB'@@M!*H/KGM2F5HRN"GF?C;!7POOX0Q,OH9=<Z
M5:MSZUVEK@;?5X)IZJI)+1FNR:6F,R[UXJ :9+\X!B8K*T3?%ED#8BT72AZ/
M Z9_Y::>0VZ+O3N;7T.8H"U&1'_;?7DQJRK8U\9>?GDIM:]I_]5(E\H$.!+_
MOY24?8-#1E>Q7RKK;]JLR>C<[X\+-%?'S^/Y^9&%6!DQPPSFHZ589MK7C'2M
M<W?"5,11R7I^T.W!^IY%G]\_?LNL-?0">&S2!P!LU;]2<V%EIK=\U#ED0C!,
MFX&31=-'Y?*KHY'^A%T26OW>L#1>2Y;[W@45$XYM3]B'BI[BG%%F6BU] KE8
M>E6F_#1/ZMJ7T,^$U^I?QX3!IVP'>YM-7UCZ";?#U<E/&W8=B" _L=<]+<:4
M#M^/*'TS4\3$=_3Z.W:#TJ_/D?I73HG^E;]AA$^PTK$UTH?+ L]#T&%*)\-H
MQ>&R"NEM455DSU3N6ST_/,W)'CZ.]JN<5"5;QB\KR[W?%L)Q2Z'2FU$=H15*
M3T59V#[_X=IE<ZU<7?]M4LVZ K4QY$R0SE/57)]L4 2#W^F$?U^/N%&-+^QW
MWL=,^$#+O]E^J[]6%=>?PMO;W/G,J5+6^5QJ,XE<;U,CXZA&(@JJB0K&"#OM
M0U4D:F,#-Q03SJTV) B:+(O,66626[9"^]JBZ731]JM>+JU.=9I:QLBX[G P
MU[UGY[NA1NPRQPUE,[!4!)JYK-7?',%B:&7O4_]VU64$*?.=M[E33^FUNI@<
MYNMB(0/[:0K*FRW-]7T*RC.V10Q??8UVOH75_1[[_5=R:>K!/J_!JD<IU4_)
MNK5K7JS8_,V8]66JQB]3E_\^V:CKMU8C%721Q, ;N3%3<[Y[-19?TON^X1FM
M-ZW7^U'7F]7K_4CK788'KA1R)Z30"UFC5Z4'L#N$1X3^+_,6:RJ,353Z[X^*
MK/K2N9<N7[[#Q_C]!CQKE)I>4ES9=?9+/C[HE XIUP7*6SPY=G:^ZYZ07\YZ
MB83\.3-<U\3Z<FI+9#18RAG'*27-.0_.@54;H\':"B9P(/26C 8V[>GZW]@.
M!]V&'0Q[K<'%A^PE*)T)$^GNBU3^8,_3R37*A?^SW3P].H5WGQ^=_'W2V(6_
M7QZU#B_?TN;NVV]->@1C><L;?QRRZ5SXQNE'>G1ZB(]V?SMM?FJ<-_]X<](\
M_?.DD7/=3_;8$<R[<?(%GAOFU2%3E <OHD/2"XNX-Q8Y)@.*D1M.%(O"F(UM
MRC;!DOWA9/BY^':OI/9[0NKB-49J:'K&T$2UQ-Z*9 REG'BF@^4L*A.I(UXD
M\4#0E%K?8D"YO7V-2LNATG2%#D&5= X;!'M($8]<(6<Q0]X(:X/$3#A9A8T0
M^FL-2S4L/0M8THKA:)@5 BA:4^<\P]0 ,!%*#6:AAJ4U@R4R!4O!<T:9"B@0
MY1$7Q"&KJ47)R*@\Z,)4T1J6:EA:@ZDM 4LF8N6]85)[QA73FAHJ##/1,_AD
M>6W(K2,VL>D^HTEK[9Q"W@N#>,("F1SR(*A(%DLNO:1K:,@M5_A^G<&D 2R6
M4Y?:1?^*]&\]'GBFQ;>7A98DHL!@>%E!)5<I:!L)DX1&(KPT/M4:SUJARG5A
M6-*X?)<S9HWU6&&B$$G.(JZ)1B[:@%+B+BILM23FGAK/PRDV+[7T_=*"W8*:
MZD)0DCM.C'6*6IQKXE%"0%3<5G.F%NQ/RH*74RR(/1/$BH"PP1IQHRG2,@ED
M';< I98+$S>VU29F2\KUF@$?F@%!ZLD84HA)"2Z2,R(J%H#?6!!8!%F+OS7C
M/3+%>U98QK#E**H0$?>$@E)M@0N#S\X<4(-K\;>VW*<Q-]Y(JCV.7#/K E,!
M2R&X,["?I!9_Z\B";(H%O?=4$<V09MFN)<!]U@80?T2R()4TSC^=^'LYUNOO
MW=/3V"L38CK=06VY.JP-4=P*GQC7GFA,78S64F>4XORAHAMJT?VCENO5$:*0
M)'@.:K.B&'%F/7(F4$19 +,HFZ_\OK[Z6G0_./<1J3BV)$2.N:;660G;:8WB
M"JP>4[NDUY(%IT_QN7 X2NY!72:@/6O!D"->@1Y-+;$ IB&PC6TC-I6>K9-:
M<^"3<J 2-B9)%"$,F X''74TWFE++:C2J39=UXWYIL^J<7 8:^91E,PA+BS.
M-8H)LLZKR 1(/:=J^;>FW$>)Y$YI;V&W.$O!,J%3<$$;0WBBM>FZEBPX?20+
MV&F\$00%AL%TE<",CE&#O,<J@CXCI>9/)_]^@O2$W[N]LVXOUZ4(T0V6.Y>]
M?Y3+<P8>$9G$!*#':,:I"DXZ(D0@#C.L%'XHX*G%_OTPIS5C]KKDC9=)(94B
M03PYBC0($T2"-49S@!^27G"(6LW(5Q:T8YY%[&S2/$3F0E;Y1*0Z>E M'DI_
MKS6('^+FF3CXX'V01B.&)6@0T5!D4^[+*XAV40-/:^!F^'+3"%QS\XOE9I.R
M+]J"(> 2EUB[I+P4+'JMJ4BACAQ?-T:>ML:E4Q3'%!"+6B+.0D!:1 PL;0,)
M6@)2VUHLOWQ&3D3$2#DPL.><>&6D2RQQH;WB. 95B^5UY.9IP]X'#++8,R24
M!AZV&"2RH@YDLU"6Q$0CQ>LHEE_0<74>2BI+Q^4"<2&6G95^^E-K2\'BLX8Q
M3P,'*G5$YH8PQ( YX+#QB\++SKAUP)MN[P,@Q37 [$8WN/ZM5A=6 3 7,U:\
M-5)A80!@$F:(*\*1LY(AGXC3CBN)/:F=]VO*A )8T K#F0R:LQ2-UD%J@0W.
M(;L)UTRXGDPX;7P'%X4&O1QY8R)HZCHB;35#1*6<A>X#R>VL:R9<2R9,F#.+
M$[%4)TYL,$I3^)U+1RD'N5@SX7HRX;3AK ,/R@J):- *)*$U2"OID%).,!P,
M!;6F9L(U94+@0&6T45P+4$Q),E$0[ %#:03IJ!9V6]5,^+A,.&WO,@+_Z1A1
MDAB84&..#+$.X:"-%DX()Y\REO(G.,EN=#OQ8MQY8J)91'V0?0OT<&\9!T&O
MC4U L,)&+1B8Q$HSP^/B10U^M_WCG4[(_^S]9]CZ!V $EGU.;]W:X;8J -J?
MK5+G+;4II>PT=Q1Q[#G2R?$<T<T-CD:X9#>V!=M4G*V1OZWVGJ^6J8/SF$FG
M0*]@W"1M8<HR^T-$4#S*A2WK>S)UK5#<EY^G36MO<FRXT@C,:(Z A072C&OD
M0U(I6<:<?LGUW6J&'C$T3CKA%!PGW'!#I-7>!TVQ(A:'9!?.LJH9^I$9>MI,
M3]YHDH)' @0RXMP*Y)+'*"D/6^L]#\+7#/T3,#1LM)-*!Z$XJ-G$.:,E=4*F
M( A=/%"E5KN?@JMG['XM)0]&(&.(0P#2"00V5D@R(8A4U& ;UE#M+OT!_RH[
M=&V/&H#]ZT:WONKW4>>WLJG8C19A(^+GN9]7>:X,%[SNQ;;-S9=';;P(+CEC
MXJY1^PU\?8MU_6Y[.+C]EIEN$JOF[P4;PE%\LUW:Y,_CWK6KYDM$KA?M5V03
M#/:U;9_;B_[&OV[V5VMUT.0"3L^]FN'V_[@>W#?GK=]MU3:U:Q531T^9R,?<
MT0NNN0,2Q2E2013VTCE]VWUW]OK;KEO#/;<&9O5@Z]9P3]%ZYZHQ;3'N25NW
MAZO;PZW;>M?MX>KV<"]SO>OV<'5[N&=VZ4]P:EVWA_MYNPH03+F7.EF--8])
M.8LMMU8%%9FDN"H^3+%AN,YTN<L#>-K C5W_[>A3L[7_1_/D\.!=^?GP8.^\
M<?JF?4@_TJ/=O6]-NG<Y[0$\O'QWWKS,U[SEA[1YW-S-GV&\!SL7AY_^/CDZ
M./K:.-ACAP?->>WAB$_4))H0#E$@;I1%ULB +$XLY7)<,A<?)IM&K9,#L.YW
M4B/3=Z(2E9'21Y8/&KF@6I/@ 9M2=$)Y$_0#(=-+.VQ\/%":CAZ@CFC".$<Q
M!(FX=AHY925*VAEK@G'>ZQ=\V%C#THN$)1T-)8HGD8+DB0H3@A*):="<<NT.
M7\/2FL'23'>X0$52/B J<E8P5@X9A142FG)'3(B4O>2@IAJ67B0LD9!(T(H1
MEP"<=#(L<JX%MXR#^+6DMN/6$9NF(SE4Y-+R0)$B.8#:28X<)BPWLO!$:9,,
M74,[[@75*ZC+Z]\L<$J=9YY8)AWA6H/*;I530>1*!9$]&*K4RL[] &6VO+XV
M@0GB!/(B&,0MS3:8TBAZI;#UR7O8NCHO<SVYCR47E??8*,,XT\+BI*207F=9
MP)6J9?HZLN"T&P3SJ(2A 21YBB#)RR0*EIF1D&2E]]Z%C6U.-A55-0>N%P?F
M? ?I!661>>Z)M,K"+H'MKY4$#F2U_%LSYILV]HG%-A'+$>C.N;T,E2#_F$(T
M]UE6#OZC]_5!UMSWT-SGM?9>8:>)\IQP N:MER'F P *YNY#N=IJ^?=#+#A3
M7C]8S+!02$:7DP@%089@C*1.3FG+E2?NZ>3?3Q#>49?77SJ!65HC!;>!IEQ!
M,KJL;A,/IJ^F+GA<B_VUPIS9\OJ8.R*I<$AZ!YJV=Q0Y%C4207,?DJ>.L!?L
MXZ\9>=P>2[/(<3!).<9-E%IYFFP"3F:$4>IJ#6(=N7G:@HY1&JF<1X%KL* M
M W4^:H*2MU%YZ:VC9&.;*K+)V#KYQ6MN7G&Q0.J39J U4AYX%%CG,MW8!V=2
M#,**6BRO&2-/6^.1YMZ\4J-H))@"PGNPQCU!),D(@IF >7??9G<U(S\C1J9.
M.T\%H#?3W"FG<_GK&+E-&C/FZZ#CM>3F:<,>QX"%5@Y%$B7BR3#DA)4(<Q5%
M\%9C*]91++^@X^JZO/[\RMZ1BF@X)4ES3K%3Q@!)*E 6I#%BX<CA^]4SK5'F
M!U!FML:^ HU!6!L1IM(ASHE#("024DD$([%,3.&-;8$W@?IJ!_YZ,:)+F!F0
M"XPEQB5)L(U1@!+/&!52FO2PC%CK[??EP6D#7&O0T'E2"%L0\MQIC:P@$7A0
MJ1P1I&FHJWNO*Q-2YY(10BHG$D]$ZTBMIMP$BR476M9,N)Y,.&T\"V\9#3[G
M^.5BG(X'I TPH>2!89Q[E*7[MHRMF?#A.\4;9D.T44L.#XN62D* (9/WQH6T
M\(E2K9(^ 2=.&[XV>"4)&+[:&9&CM#T"5 7#5_#(K8Z@GOJG4TE_@A/MNLS^
MDO #,D)(S,%FTI9+#IC#/6@#/#$?,2<+Q['5]3X?'7_FE-D74=A@+$9!N("X
MR.=A-H$ZKKB/!,2_-&QCFYE-*ND:^=UJ+_JJ=0H6K!$QF.0YD]PH1;TSVEKA
MK"3F@9FZUNSOR\_3YK5+CBMB(A*:1<239,BP2)%.*N8]3EJ^Y(S4FJ''^1Z!
M,&^ >REGG*EH.34D>:$=$]*(A:-5:H9^9(:>-M69#_G(02+"A45<*N!E O*:
M$Z>X<L2!C5 S],MGZ$BDTYY%9S$%-4U:9@5U3 4P^;5;O(1-K78_!5?/MI-7
MP0NJ$88/P-4Z($US3WG 9I#0'COLUU#MOEEF?Z:@_IR_7!5X+ZG$:PG&(Y?4
MXL"Q-R9H##,4/%H:>)"?)=FXHRJ\+N%AI;PZ4S)_?C'-YO[!7D'(5O$_-SH+
M3"G28 %K3!(F4G(0PF!+@?#5.=B;&";5Y]W,I@1C@J[;8E0<:GOGO=?_;EG7
M:K<&%^]S\X$8#KH'QS%[Y_;3F^$ V/)]]\*VLUON -[Y6[OKOSXM!]+&AQ$'
MGKZ[A&?3YHD'CCAJ-W?A=[B_21ML_^#OT^;N5P'OX,!AI\!-[?B_[R^./H4S
MT%#DT6[S:W,7^.CR^.3H]"-N[C9/8:SL\-*+YJ=#O'_P%1_M'@.'':7&B3]O
M[GR&-27"Y8I03CC$31#(*,<1 *-BG%MK4ZH@%*@QAIV,8X8+DT2@UI"L%EDG
M2#(A9+6($19A)R+ VAGLQ: WC!O;_WZ[\]O;?[\]."S>[_U[YV!OMSC8+P[^
M=Z_XL//OO6+_3?'FX\'']WO%^_W#G7\?O-W[,-MT8K+;P=R6!'>.Z39.D#=E
MV\FP/VBEB^I/K4X 5']-U2,PRWS)MM\IFMU_JOKHIBJ/OED,CF/Q>_<4AG-1
MV$XH*EJ^*/XZMB!IBK)\;@Q%JS/HEM=.?;_SI1=C=LYM%F?#7G]H.X,"KCP_
M;OGCZ6MMOC;DK\_L13$\RY_^:QG]&<Q>ZY/@#N?XT&BHP<$KIHAU"BL^XF."
M#1I_N"%WQ0VN?@LO:MGV00]6M'KW7T >"XI8^9,Q>//@G6A>?B3[NWMT?_<M
M^RQA,P*P!F*4*L098*<3QB#,E-9429RPS5E?>.LV%SD0>+ODN$[A0?$I1O0U
MIL7\YVZGWPJQ5W$F;,OD!:5VK7[M%ZF$X*(WHK562;#][#<N]MMGMM^"#=XL
M;-&'_6M77R?@G\Z7XGUSIWC5;\$_OQ1=D+2M#EQQ 13S3VQWSX!2W<4,>[2!
M1#K]BHIW3K_$<OP4) L0+@RUO/[JM=?< 0+J!NP\1_CX:X*_OX\$4]^<V598
MBM$CXZ!^Z%P.@0#^.DTC%I0QR6G 5ICE&#VKU>^CCZU_0.3T=X?Q8]ZIWW/;
M&->MB.MJ[#7WWR+>\?ZNAV?NL,;)NXO&^6?A@H]8:@3R/B(@&(Z<UP:!-90X
MYP+^I1O;5,SC_V+,^L.SU(-]+QEKGG  &L\*<K[)MI>C(!*L%9%C:3B/#&OG
MN(O!89D<(V9DF=U!.(U6&X"DVXE_V8M,'!41946[)I.[A43C\G,0L U"6Z22
M$R D-$8Z5[]RPNL FJ'11FQL@S!81$C8+T A7\I0V-S="9 MTU&U09EFRA/"
M(@QCT4HE19T?QTX)5 E8O7N>$?_Z!L#X?'G7^V'O=?&J]<LZD=?',X D?]R"
M0>8O]M->IP=SR)_?=@!4^Y']#OB<3<*#7BM37$V.=Y'CNW/0622($J61-IP@
M[H)$8*Q81)2/1"<P!G49:GHG-7:S;G)ZUHXEG703:,GC_2E:%<V=M6VG WBV
M__O>3K,H]ZQ@A1_M6C'(VU:J-!,ZRJO6^I'AF]V=G;.S7O>?FLH6HC+V.3GI
M<10>>6$"XD'ETUNM$3%4,>$)8)Y8B,J&L/Q%+^_&V2 3&6Q%84=[D7^_5C,S
M'65967Y9&FLA)PWDA[P"XVU8$=*(,GNM_M=\^^E%U]M>R'38ZB3;*R_:+(:]
M+YF,?1<DL^U=P #^L7T_;-M>Z])6E\#;KKX^CK8W*$*K'S.%AV@'QR58AV$;
MX/6\!;\"=0$UM?K',++RC=WQ$Z_NRW =V_"F 5SS[[-7]I=?-LL_ DNL'T^\
MK_9D/XWTW-%%"P9E_=P,\A%_9B8F[))'F"2*>+0)6<H#<I(HY4H'G-O87D I
M*!GDIJUQ915.\(T=%&V@LL'CD]%-^C@X!KOTN-L.-9W<32>'WSY'C+5P22&F
MC$8YN F!@*8H>J.T9TP'RS>VU0+B.EUY!Z[TQ&MK_38SMH0QL/K[H#BV8Y$W
MI1, LRX \5Z".?_V-@?+:(WRLE7:,ZC=W:P]V]/N<+&UFW$!M/K9D]@:M"L3
MKU>9XT7VR/3&SO.B"X_LG8-(R$,H6[ZZBY&39<HY=(>OY6#BTEX\M:T.O![V
MH)6?.?EZ^'Z.#7'6'>3!ELZ@F9&\>#?/Y.*!V@J6DFT/2\&<)SV(O=/^F#1N
M99TLNH&X?'L82G6DL!XTAF [/E8Z0:F(E!(_7PU?#K,/_DOQ9=BJKAH< VS?
M<+Y5%\'CQG0ZN/;<%C#.LOA1?G%)M+!-^7DPT&507X%U0"QE04K'C2&:Y/)D
M2>$D,(^>W](W7<P_+II[1%2#_P+@SSY+'[CDTJ$8DD$<&X=L/D^*7BJI2<0L
M'TO.]R_=1/_4ZYY.4^JY+36$W% P9-JQ17N\:46O.N0;0TX?]B.3T0TW<XE6
MH%$#6&0,S9T(RWN<;9?4"[IN'/1O A% 8*<+J JJ\)?Q"WHQ.[L&Q_#=V!<V
MIMP11H4)P+F5W_*+X!'7<X!? *Q[ V#[4.3&;^7]\=M9]/G-Y6M+1LWL7 S[
M);IWBI@27)"1\<J+7M85.XV#XVZHIG/;-?!*(-VLUE<+D7WDW9'%D;\O&?J\
M.VR#IM\I(35_53(M+(2+Y:!:)5BD(8B%JU$#0K1\ZZQ\;+N5XAA\; _X_\L$
MXD^-&1;VGVRAA&'I[!^#U]7M5V 5XED<H04 20$LF0_(\I8#/75[_4UX<D:R
M\5,J,5A!3>MTA#)92GI0,F&0G3C(5E/L#(%*JH,P6RY:?P1[5XM?W9T?!-82
M\/_@ZN%991E?=Y.,SH&LKS"YVM9;=N0_0S#-8@^$V-5NE 0[[/7RVT=#O!HY
MD.  J.=R/$VP)?MGHP>/">#-&'I!E:VLMG[K6W$*='N<!7SFI@98DL<5!S)2
M'C*RFX>,F>^^=$K*!*9%Y=G/U< SB7;Z<5G<IE[)8!S7G#DN!+&:*4=)C"Z8
MD((K#PP8)C=.^&\%\&:WD\\,WHX&M5>-:38*H,;W>^%[\W*'?G:"AV H0Y*Y
MB+AD$CG80 1H;X4$<<LDW=@66^0.=,\TN RE"!&X9R0 TP2N1-*.:$XI3UA&
MJ1F?&PM24\I34<I;_#DHZ3 QL!\4@R8 /Y%.5*!<H]E2H0TW"<S +?-]2MD$
MX!GC6?MB<RR;;HCO_@#^J6P  *#NV<@RZH_TV=.S7CR&#:Z@%GZ/Q:MVM]__
M9>NFUC\;<K5XL!6G:Q]M11\LVFH<#[EG>QT00_V_8N\#J#IQ3<*J<"._I_/G
M\='EV?'AP0YI "T?';S[UKC< ?K]0O?_:)#&R8XX/-DC1_#^_=V=B_W?#3[Z
MOV/L3__NV$]FN'_ZYC@'1![!6)J[>Y<->#9HO/SP\N-%8[?=:@ OP;/S^_G_
M738N]@^^D,;E.[Z_"[RR>_C92F95R#$7)L(/+R*R4G@DHR+.61VL)C,Q5DP[
M)QA7D@5.@G><NX Q%Y;A7,UG.L9J;^=]\VWSCP_%7WOOBP__N_-^[_M!5,_1
MS+TE\NO.E;JYLBE&>!QVB@K"F;9&BQ"<XF"=4!R4N@HG?BA6^>"/8QAFZ3+-
M-+_9?LOO=,)NJSW,0BCKW#\O(X%0V?7Y\V7CY"MM''S];$!5U$%I)'T9Q,\U
M,A'X*IH0#<:@4SLWPTA:60H:IJ?.\J"H,Q:H*S$EC,46JVE&.KAQ^ES&Z()>
M'?NEB*G$S^G9<&#'YX@N[UDI;4*U:T4<[6H!P@C,2MC7*__'C.H]RZ2SL;^W
ML.V(-;@ WBF+3,'5KTM+&(3=K^>M,#@&QBKY9N*N*A#Y-;Z^Q3J0IC#P6V^9
M  1?QA8^$?M3,B6S)WX>]Z[SM;]$Y'K1?D4VP6!?V_:YO>AO_.LFY@'@32[@
M]-RK&6[_C^O]:WO>6^<BT6+(,@?![B+1Y>#ZB;9GCA59LD7&PX6=K##VBN6N
MR+478B^'X+?M63^^'G_X-;3Z9VU[\;K5*4=2WO3KZ%DC&L_[.A6&7RY6]?7U
MEF_A:MM'"?JC-X^^WBJ_FDH.J+YC<@O,D5N_QEODGM]Q+.]UY_<&2]B6P;=_
M70_V)QKL8@-:L";CK9EF2UQJ%JGT6,F>QTD[TPO95@>E2ZU1R?.]:U=: ?AW
M:]V+E[\L'T#)66!1'I&^)A(G*WE2&N5G@Z+T(Q1Y1;Y7:V7]EC@+UP4H[.[9
M+KYD(Z$Z]9R7LYYT%1S[TZU:384/286/")&4_!A&?K<>U4+6RV@_'MK7M-A6
MO"HC+[M#>$3H;Q;QFX^P%-<&_2BNYI<IV_#%%?NZQ:F<O15V *]:A/WO7:N@
M?L;+>L;+J?+>+(O<31PG_8#RL&BMS75;@_]:H&#B$H41UKMLB+36$^NPT"1Q
M[:43,GOJ$A6,!VK"7=$*,_5#@(+>E@3T;R"?9U$CY-XG (>?_NP?'9R=-#\=
MG31VOYXW#KZRPP.?WW6Q?] \.=K]R)J[[W*2,CW\]*;='-_S?W_^_^U]^7/;
M1M+HOX+R<[Z27X$T -[V]US%2'*BC24YHKS9W5]20V H(@8!+@[)S%__NGL&
M%P^)I Z"U&QM$IL$!S-]=T\?X^'$P?XBL-[YW>5U_\?EM3.^^!O/==8ZMRY@
M[[9Q<?+OYOE?_QG_^X]OQK_^_CT^E\/G+OZB\HX_[6Z/M6RC56N:.*NJT>G6
M6)NW:FS(6]SL#(U.E[_YU.SJ[4ZKZDUZE;#8 V%A=EN=48MUS#8WFG9KV'5:
M'6X-6T[+Z76=!A-WA*FPL)2PV*&PN#@N"XMACS6:=J=1&]HX$+[-G1H#&JT!
M.N%_1J]E\"X(BZ;>:+>5L%#"XO$M0[=)*%#"8C>6Q2 5%GUXU_F?[7:KT6@V
M>:UC]8Q:<V0.:\PRVU@;U^QRU@"L#M]\ZNB-5N7GX"A9L:L3'&T@++JFT^QQ
MV^*-'FORMCFT1R:W>7O4LYCM&,*R,%-AL=2RB."\\"<E-5Y.:LP*4N.OW_\<
ML5YOV.U8-;/!<5;!L%D;]C@'B\-J&B;8'^T6>_/)[.HM8]'$6(@T/*'$D/&9
MN00CLR72,BH21%)K'.X:^Q@@7!XA/^%^,'']=6/DSW/9_9H>/:A;E^6&PA_T
M%W1(85/LALO44[J0BK0@B:.845'<LU[*O*X&T@*XSQT,3C';%XB]H'+&RQ'E
MA$>7.6(I/UP99T]GG-D+P>)F8V@-6QT3AR=WP3BS>*TW[-@UPV##5@LP;/ F
M&&=&6^^T.A5J*:W8_,G9_,G#N(K-=\;F\V%>;@PY,\U>#1!LU)I.D]78T&S6
MN,78T+'M4=,QD<U;>JNYX:608O/]8O,G#\ J-M^=-I\+T%IFK]UI\$X-*\5K
M3<L -F^V6K6& Q+=LGF[YW2%-F_TFHK-#YG-GR!TJMB\*FQ>C*C^W?^3MYKV
M$/BYYAB-4:UIMJQ:=SAJU+I@L;=;1J?%1RVAS8U&E=A\'^-=RWGQE!K:8#TL
M5<%BNX4HFWS\% &P@QQ*O</H@BPQ7Y!6?0>K2-?OJZ]$UCHBZV8ASF 90\O$
MZ(+5ZO1JS6&W4^NUP!]QNLU6>^ATP!)M@,C2&]W*IYF\0AY]F=" XM&7Y=&%
M7#"GT1K93:O6 4R"]]#";K;-86UD-QJC[LCL6$W^YI,%/+JA4:%X]&#\>L6C
M+ZQ'YSS\5KO5:8]XK]9C3A-XM(,M83 %R^2 TV&C;7;:J$>;O57-QA2/'KI3
MOBF/5F_J\OZPYYQGSKK8UI/CI  +S=P.KS''!A7:;%AM8]1S[(ZUY=CE%W#
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MCH,0/7'XK3 P$!H3-L-M.AS>X. NA_R>$]6U/P M01)KGCMQR7G%4]UPGX=
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MP? 9$6XE50Z(<<'0(5R3O2Y^S\F6>M 4 K\@XCF4$8"3  F* [+0Z4CMW3,
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M')0AE!%M*M*%8$99[ "E@6[YL E-B'UEEB)%G0!"'IM&_$/ZAX\@F*<>FWT
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M_'9U?#K8?R%[7>!$4*_ Z6 EA*A?0:R,7!^--(=4=@ "B30.LF\8)#?CDOC
M1S"N$_C"SM"E"+[E: *,PF!"CWB@=_T(^1R_AE.2ZI7>,6A\Z;L69 8XNYR$
MA!][L](K;1[&(,X7)%==NP(SA4;4XTL<V(,73'%A-//<6Q$S&+-;G@<&(\"-
M.X)SPT,VF[H8*\B%''R-QNHR;QJ_F.;.?2AL(%L*V*(-)-\U]ZK4'P6YB(=@
MT=*W9/92NB"91?!#>BG\,V'X<]Q.9BY%,7#QO+E4U_I9- A53U$2B^4DNO/
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M"4[F*B33,__@HQ&GJZXO7XYU$N+(SE&F#8 Z;TB\^\Y[$#I@&/OHLGK".42
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MQEX4*-< Y:,5R[T*T991B.PJ75P\,3L.<(!7[L,IRG\A=&UM!W0J;@=8*\V
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M1#,\QEB,=)T%EXILOX-">"^9@Z766552Q,W+E-\EOA3J4U=]VGD6;F>WNM1
M="<8SVM)3M.$TJ-OZM0@I:N]HZ.CW6>E?/DUR%4B7;ZK_NSV]KO]7@VQ1=I8
M739\ZL9TFZA#,O#JU2&F6[,.N2.L2!=,E/JSJ%B-_!%;L1-B M7Z@SH"!7%V
M)NQQUR5>%<5?+:[^J*/J2TR$G/,Z0A?E]5\Y8C&E3&H.ZIOHN_G<HV,6?@%?
M*3TYCI7EEHQC\YF9#W)&I/X'I@*',]\P?'?GG,T)EQX1Z;E$,YAR,C[IJ!FE
M&QO'WWP\VH&:Q$4R I8U7OV\"R3$OTQ:$M,JI3OI",# )V'?V-SP.2=U&SY7
M\PL-@?Z?;[^#_;KM!Q(G\/\_FN^2<=WF XE'O0:M5]3W\#ORW)/.*0-'N(/4
M=P^W%Q7\&"T[I(K9QHR3&GW<T__U4#=QGKM(4_V\NUIVA4L@B#ND'_7?JRH>
M$4=%2@A7=*,RW7*GYI)%7\:]6-JW5##?<U7,\ G[RC6XFQ(B18/^+N)DQ& ?
M.OX.>I L0$A8H8@7"IF]02/%#>;0JBF1'M1S<S@MLS6"UJ\.&GJWQ/L?+05Q
MT5N"C8=@>775!*;N*9M!*Z>$"N^17$"8/R.73*PW!&L+,P+^O@SP1!QB8Y0(
M1" 1+8E$H4ST3DE]4P4VOI/,^3YEODNX^/Q[X,F7C0&?P]H(\T%UF-/L__;7
MP_W>AW^B4,P;K.-3+*;G/GO:W#!..!I!_*DZB(HKTFQ;!-J03S#U_M"U  MU
MYTVH-X:YB<J!X[" 2H].;J##''".:^-7B[D1R@_*0?6$XS,1< (?TNRU>4T)
M0(D$%(MH$:RGS(=0F_&XZR\]!R8=,IAP$BI\@[%HXF@$\' 5P"6>&L&(*TK8
MM@BTFS ,?8&.4)/'7+6_-DZY3(S0'*U"$[/1J"P8M0B,"_I(A&PV5M*TIJ[O
M[:UV?8JZ5?TM,9UX(Y\,A&@2=F<8&'N^E^WYF 4*>;2H_S?@?#=PLGO[JQBD
MF?R]C4[T;.:%@U^'J-J#(;21^U7&RPA,/SM9+[A%L6R*7XL0NB18-  C(C/V
M^_O5?@\)6]3!V@)\@D;K# VX@[H^S:Q1EHT1@(-<B]35G%":58L@.<<>_P7[
M ;D"981>:>86Y7,Q O+3*B"*#]*,4)I3B_"X]/#(\V%FO"6^RF1()J?D#ON$
MC<\#"1URRUZP+YM,&C58&Y'+1.P+YBCBCB1#P!\I 2H'$XI "QDMPO0SYA3F
M4W%#^-T4<U(;N0P#(SZ9@#QF@8 'TDQ:!$"=;-6?DA*KG!KK9<+WNJDQ]"[^
MJTT+$77 N,<0%FX7[TB$">W]3,:@/MJAJ#9A;<Q?-@2X*E\CJIEL1)7L:!N1
MS,MP-@2OA)41KTSF(C]EVD:$4AG,AL!D.1CQR"0L4CS:"<)R/K0Q$KELC'!D
M\AB9Y&H;0<FF2!O"4LC("$Q^?F,EX]I&;,)$6T,\EHB-&&12&B%Y&WL]/TVW
MSJ@H8F9$)9.N*,K\M1&GW.1=0YC*>!E1RB0M"M*!;01I-074$)\"-D9H,FF(
M;#ZIC:C4R0$,7%>+Q?X%'3,^TT1G1&*O_@;G3<DUX=Y?/R'114D%4*H&Z%U8
MAS:IBS&C<$L>"0U(V#-;R%BL\#?"WRQST461G!CC5MF$"B XQ'O4MC):O.?8
MD?$""HR9+<)?4;)1,3(IDLJ*L:C!8JN!J@-*5>)-:_*P^^+C9R9FGIQ^!VH"
M,3?Q?>+( /MQ>NJ:]2\]*$'<K6E0HUH8M2EG1THE;5JI#4I7)TG:O;MF.ZC_
M#Q35ZDV]\H#]RKCW!P144\+QG 32<\0%)SX4/1N<;DV=*DDUJD\F(551?2+I
M*"T>1?(15.!-4_)7/;X3%]^ RS_#CNXT[*L0&M.7;5N?ZJ*-.I/)E574F; *
M:+D.**K$FXDI0^\;I@+:M]QUXH(Z6],7HT2CFF32>175))*\HB?B1W4R<.=-
M/?+ &LPFA&Y3&U8%&,'/9 TK@J\%::C?D,X=ELRC\A?X"WHUYW=UK=<OGO X
MQ4N.P38-Q;HU,NI2HQ-2RI"HFJ&H:OG%PGO0HOHM.3,M-C=YZ_]WP6R&^0L;
MY_W8,!/75(Y182J>VU)K&:$XM<FR:*-"^U)M>5V_R0QL7?XFO-]G,JV%>+_E
M4W-VHRS&W-V4<2D)GUTR.E'_I@I!3UYA_AWZ:>23.^($?*U\VX;%&U4DYU1;
ML@]FR0[H6G25^!^1JHC^<ZFX4JJD,BBI32MGB]6M,.IR3C=0.^-7?VFN*W4E
M&-4ADX/-[L,!I8CD**W(V:?SAK7X_#PG#@3MX0&%P0Q&3K2^M2FLS1*,6.=L
M@<MB'<N)SUJD);42ZNQ6JJ:0%G,R0I?)3N;ORFHA/"6G6#?IJC448P0V)X58
M<H[VS7'+;,B[!M"@(H^-U[L+V!B1*]JDUT4+7JT<D&$WJ&0VH^%]3/J;<(+1
M>9&UUZ@;B##"F3V,&,.9R%'^C_XZGB[#5$J[%YW#?EK$+E=81D' XCX].M%E
M4AVE$F@/U(7N5EM]U/V*PEM3&S98 :.N9/)P"UU)A4])/5(W_=%)I$!IK=&I
M.Y2N#M+U>5.G#:#Y6^_5%>JWWIM*V:!2\WGX$ 3VXQL"P7X/Y93PE">U.-<>
M4JUKE-:1:52:3'HWI32)X.3F0CU?:>%+OF/JL'U\T*"%6I)_.&!M][(B6Q/6
M!YG4;N'I@[8[H/D]OC#G7SA6]E -PT"J1S[46T%Z\WGCP;Z^1"/\F;1M"?RI
M&2,2'0[\1'BXV?YMG*^"Y?U!4H81CU@@=?'A7'W>BGY4%&E4D/R;TLH4!"0O
M30-:=DB&(NEO"K+H-HCX@EG8*P]"S=7Z2-'VM*.Z/*-J9/*^):J1$HN47.44
MA(>GWA3#8.9O[Q[$P(%I=]T4<3T11OCS<\?&J4/)0K&P5N*=>PXQ]TLPHGG)
MIZB(B^6"2CG[3L Y3,)K)3W^S+H9-2R3Q"XZ<UG\"]2R**D6UQ1AF2;7@4M4
MW38'MY4O9&L<RM:68%28;.Z\[LUOK<1Z]>!M4T2+^!AQRR3)\T[P_G\#\_/N
M\@M\X>>E5_K4&WW1FZ,:-O4\V&_7P6Q$^' \<*"EP_$E6+F; %!1LW '?&^A
MC["==,;85\^+J7<&3SKE1-13NS_5ZV*2!^I),O4RZ_&<<(^Y]_K1,#<(MX9V
MD A @B<#]>D+9\'\I!,6]R29=5#XQECT#42,$\(OX ?%)7F+,-.F*\\G0C)*
M;O"+^B4YF/<P9_3\;#"8SSE[5(\O%32P!@=S:\,W.V7\TRA\6PEZ@8P\6:L+
M9E C"7Y0A3ZXQ\\7U FGL7./@D08#X,GS(M1+2.QM)6Q(L+@EQYUY*> NCXQ
MZNUJ\5?76+6Z3KCC87]5\\0 L.!")B74U%/8POJ,+$7V0AE![-]S#%& HWC?
M<,\I;GAA^3K8KC00QH*[O1:N;L2_(DHYTPT,*QRVKZCTQE5W\2[VL<MFV*,5
M6G+'N'H>3J4"?/(R?**$GWV^O#PM;Y&)RH:673.J5BG4V5N8Z:3:A$:3];78
M\[QG:B@-LY<8%YFA];BNH=%_BC%./]=C<B!216L8HJW8X&S_WX?Q1 :">_(L
M/_G,^5[8OD:\MJCP,I92Q7-X@LJR0,7EXG[J<4GTR3(HXSV2&U"D\F%=F=R&
M\:W23 &,0G''QA(\'<!G#(8V.?5 W?, 0@D%&<@5Q1K=@).E,^\9&<EDR_Q7
MXH/V1BO\+P/'"6:!5ND'RHG#)M3[@[CJ*4@P:BKK051U"_IH YPM[;-P.+]$
MKM;]%,RZV@1;V!.%Y9NW;[O.RN!V^.O9UXJ^2D%A&P9\_DG'\N:4T]C0JH?Y
MF#/HZ-RHM22.-])9ZSPO&X_$J SRCR'IV]O"_QGG[DVPMF0J7[@A]?Q3$YFM
M1BJ.D=1&^/- [RBH&5V54=HPT!O,H%^ \W;FYE7.MJK%8*:V&JIH2[FD+#PI
M>,[XI\#S719(T'#L1*LZA?U3CXFE;DKAG2&,SZ/3^N7CI 8#&X;+#>$J\, 3
ML&+Z (L0(&%(!Q,8W!/09^V)WW#F$.**<\YFH<5391G5Z]&%"K$1WEOLI'E8
MORI!$!;3>,H?B+. /%"7\*4['!;&L#C^J<7$UA3&;;0F%8WEEPMZA5U/F(:%
MD<R&P1#G7**M,O?LEE#R9$S1K!9_[31-W->+R+H\+B\J;JF%;A@BGVXG\CZU
M/.Q6%E5$*;;,>D=A9QBH+&UKLFYSS:3:)U-FD H*VV"&/@/7F>KZN,?!B5H<
M&8E2X>(_,&:'M'BUIQX36QW3TALBRP&N1&H#W-?L$7/I&?1UM90--5_V7?+N
M7(N:4CP(*S/8T@(TL(?Q4"4M1CBC^)XX4\I\-GFYP?R[(2E60F$#>NEEB',6
M\/ J@H;K& 8&-K1WZ,^Q\#A6BC:X'0ZNOO0JYCZJ4-K0POBV%PBA0K<$8BLW
M<*(G.,QYO<KTEB3O4H'B*9Y[$OOAZ1B]S52YM1Q"+9CWPO3<A1"!FK-*=X8T
M86?KY/GM^EO_Z/ (-/;KIU\JJGHYC5U*WB0-7;C58DVN&^@95QY/7U1.(AB1
MB^83E=;9[*$4#N9KHHM^>DF*1,ZAWL(6A;&#\$H[9<A!9J"G87WR]'Z*:50F
M=2"MV)C\V?783M@MM FH9XSBG9X5QUP52AM&GLE;,[6R&K4-+:WPSD%TUW=Y
MF^OSL:'UU?,$C7(#K[0>FO)6"YS55(EX6XZAU!-\_0(!=$XQT/ +"LX3"3-J
M8'8, 9X]];-1!Y/MY0-Y!XC+X?A&&4IH;8,MZCD\+,UI+=:4%RO.%58JRXEL
M=5?S%+=9-%I.;H-ZI]]1&QA><+M4,P>P%(7A:3-FKYU122\/?O8]?9NE6D/1
M*V3W'@%E6RCRD%X3J;/2E58;Z["S8H$Q[VD3\4"59P"62JHC1(,95,G!R4JR
MR?E8CZ<-H^2,C E7N(7OR94WMZ"P#>V H/K#P?[^WH>C PBLX5//&(07E+>A
M-=FEW#M,SSPR8767@%?I;&C=91BC,/X"IC3<H1Q7V+!!RDQH0_M6G2)U#K1D
M_V-1<6N=B$6Z/8HO4[>R&LQE!4H; #R-3?57@MW? W!C"1<7] 8+[!**34%X
M)6(;VAGM*:Z79# 0V="N<W5XF5RJ74"K-X5?S.;8XZ6;B"I2VSH\DY!3I_H,
M0[*HM TPGO%@<H5I,(9:!\KCK39+&,EL:%OITKE: XN>TJKHB#9F9T-?G($[
MZ;-YF#^8J$U X0ROHX?%["B,J;+:?&P=PJLGQ"'NTC>1@>CA".(NC8?Y7*.)
M_-4/G%\2L*HD_]K8^%B2VL6I]M"<@SU6BCR&Z33^7'QV8&W&MJI&^9T0^M-<
M#L?+1[NJ9Y>KLK,TE9?L(JB[Z\!*-V:QE[^\%=ER-M2^^NECTQ:F)IQ>._-6
M[$3&;\BDWXY)C \+> /'M )/2T=LXTT!QI3M)CB_MA;%=E<G&"O:M'(:&RQ#
M3=_6:M\U.7&B%[U$=)@UFBG7/L;2A*FE([W<U1@X4P_<=_5#LF2HKBM0MP7=
M0!-5PYE0EB_\=0KM;>C6-)3U/]>O#;K'VE:"LH.FNTS?T&.\U:>HM T68R#!
M>PGGG:HW&910V-"BI1FGQN1D4QMJ6(S/E(/E57]']J%_ZH-GYJA[O[S&U_G5
M$V'I*&UX?GL+!\>6V-H:S']C4RKTAH+HKPM*V:/6]&_?SD[K'(ENP,F&81=G
M%(;A(V7J^IF+F;K4,CR;<DU@,-P3"M"DOA[X^J48IVRGPKI\;3T;7/MVE76N
M57FM!0S@#Z"=D?#?"WU/G=Y,MWA=N>0&QBK$UNZ@K+//J'2S?0-&]NRO3Y[Q
MO"7*D #5IM8(-L'ZU0>.OE99.%-HP<<?_@M02P,$%     @ ^("B5F&Q==-*
M'   ,A,! !4   !A<G=R+3(P,C,P,S,Q7V-A;"YX;6SE75ES&T>2?O>OT&I?
M-ZVZ#\?8$SJ]BI MA22/9Y\0=62)&(, IP'HF%^_62!XB"<(5(,M>\)#B60+
M_57E5WE55M;?_O[Y</+@(W;S\6SZXT/^/7OX *=IEL?3#S\^_.W]"W /__[3
M=]_][;\ _OGD[:L'SV9I>8C3Q8.G'88%Y@>?QHN#![]GG/_QH'2SPP>_S[H_
MQA\#P$^K?_1T=O2E&W\X6#P03,B+O^U^<-(%Y")"0J= "9D@RI@A:Z:DX;P@
M-__SX0?F@\7B(\BL Z@@'7AO-4B+O&A?>+1N]:&3\?2/'^J7&.;X@ 8WG:^^
M_?'AP6)Q],.C1Y\^??K^<^PFW\^Z#X\$8_+1R=,/UX]_OO3\)[EZFGOO'ZU^
M>_KH?'S5@_2Q_-$_?WGU+AW@88#Q=+X(TU1?,!__,%_]\-4LA<5JSF_%]>#:
M)^IW</(8U!\!%R#Y]Y_G^>%/WSUX<#P=W6R";[$\J'_^]O;E5Z\,73?[=( A
M=SC'T*6#[]/L\%%]\M'3V70^FXQS%?.3,*DC>'> N)C3.%:?N_ARA#\^G(\/
MCR9X\K.##LN/#T/WJ8,J<":/T?SW]1_VZ QH"I.TG*SFY15]O_[("J8Q9OR\
MP&G&XTDZ>?MDEKYZ:%)%-.M._N4D1)RL?CI:SN%#"$>C=XM9^N-@-LFT?I[_
M>SE>?'DY39-E73QO9ET=QN/%HAO'Y2+$";Z?_3JCI35=$%+ZQ \OIPND$2Q&
M7J)1FB>:L4+DUL3PR+2!%-$&-"(*4[Z>WSH9<YJ-%1U*F,<5)]:PB!M"/,+)
M8G[RDRH*L1)#6^3'LFLY?Z/$I ^N9& Z6%"^> A263!:J\R21AY3[W/Q];C.
ML?)QEQ[,.GJ05.7#!Y^P*K:UUCR&1&R\1->OU^SZB4?SY>'AZC-AO,##DW]?
M5>B]<VPQ:RJF8S;0N'>ERR_CZ:Q;3<!Z4$(6+JQ!R,EG,AZ>@V-%@'$N!QFB
M"(HU)LM%#)M01?QUJ+*3B)H1Y?%\3BI_Q(K+V04:@\12G08#7I%OH9RTWJ-G
M+NC&]#A^<QO\3Y==1Y[6R(O 2 H67,P$7@H)H8XJ*9.]#=RQ;'L9QAK D+3A
M%I*]2-'M)[<9/U\?84>CG7YXA>2XO:WS]KK\-L<5M%$)J6@I'#BI$)0E!1N=
M8N M)^4JN2EH&LO[1D!#4G$-Y-]N\IOQX4TW(U"++V_(85T\GN:JO(]JE/4K
M(;)&QV*\@UP#'A4B:5#-(UAM;!!.LV1:+_^;\&S"!OGML*'9U#<CPXOQE$;]
M:OP1,UG1,/TP)F-]/-**R<CBM3(2;-$,%'<4"?/@(0G%HY1.9I<;T^%F1)L0
M0GT[A&@X_>WLQ>( NS4&\MG6ILNR8(W+"J)4CEPK1 A<<_#&)R9<])*W=F^N
M!+() ?2W0X#=)[N9W/\7)_G][)>P6%:?^AVF^N<8S^,R5B6'Y*<'FQ(YZQ'!
MAZ3!QLQU"$*4W#IW<#NJ31AAOAU&-!9#,WJ\&H<XGJR@G+BS4DNO;;$0Z"NI
M)U,@8@Z0'4^%Z\BXD(WI<!G%SN%/2K/E=#%_$[[40/5D;+H$)-4K0!I#@HN1
M9CLF"0G)%"N&6GC5.@ZZ$LF0 J(=.7 I.-I]ZMM%\2EU2\Q7C% )P;(4FDPO
M,Z2,,_GG1@A0)5LM>!$J-@_LKP,SI.BH/1D:"* 9'YX?'DUF7Q#?XJ2F]Z^
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M)9 AN6'MB+#[G/=QXN84AV>>RX@02Q!51S%POE8U)D2ADQ"6-S^6>0G%D K
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M#K$+KP+RL'5R6,YN*YD:2,DNEO^[$8=D2I*\ &(B:R!&1:*Q9 UDF85-.IO
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M(2H=P?-2HF*ZH&_M2-R-Y!"4H8&,!PB8N?O\Y1(;!NN4*A)0"_*8>*[G1RC
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M9MS<6Q/U,2C% T<PV]:)523>OI%:P4G-&[Z(;/[J-V 4F!0$6VIA*RW!VZ*
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M^18D+O(?&:U#QH.P2,)"379)ZYCF'K!V=>_3@/M;]07:<C!$<.0RB#?"O/M
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MC=HWUS5ZG^"[)2P<W\-N48ZU QB/_'H5DOBXJN[WX:F8&Z-6)%4JHI?"C4P
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MU>WM?(;1T2A EA@$.1*2X24F*E?C24Z8*K6MDF!*T0K:VVGRI[1J<E(QW=H
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MZ#>4C&T""%DSQWFS//R/6AD^/.B5GT.IAL[&K;CVNY@O1Y]*9U<RERJ[)##
M"%Q&(HU"IU!Q0$P2@@G I75-Q@3\UIWQ %\]C07?-7CACLKKC5]QM6X+XK%J
M1P,8;1R.)EHXA0/1P?C[]'6P7,4!?!].SI3E;!*ASB$<3S..4RZA-DT4.HFH
M9:,=3:<F\,B$79^_-@:KS-NU_VO\[>[;8U7**'5RM%PG6FZ(8M@C%U,F87V]
M3F3>-]K ^@)SWS4ZW+S;R>RS&C9KN]-T\W;Y)_@%_/M?_P=02P,$%     @
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M9HNB) NF.RBR/Q?5#S\L&2DKS,_*!4X^H?\%V\>@_A'T QCZ?_I>\!_^XW\
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M@*%'A4=I*%)/(!/Z.-?1U*BCEA4TPEZ!2EP%*6@%-F..L_AVLX9+U 9FC/Z
M&1.&*1I'R*(0[$\/RZ\_JR9JGE!_V=##V89'H093]5I:,'Z^GU7QGF1Y%<!Q
MLWA>E<4'\57,_2:)+>:"BB@,(0]8"I&'U*9"Q@1&'HH9E0BGH56&F(Z^ID8,
ME6S MS,<NK TLQL<(30P"6@IZY@Z?0U:"ZKO&E6 #9 CV  31W9#5T^CF@T&
M*N];#2:O](@-_K*LMBY+U?1<O-Q^6XC\[;L/']XT7S5%*%*V@P>QIT]?N!=
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M]'E,1>)'4"*,%-V+ *94!A!+QD4<!VI3;U5>]*"':5J66D+;I!W[T)EQZT6
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M ?1(0B%*.($I#5*(91KY#"=1$%J=T.RT/C7V;X2SH_U=O,PHNC<* ]-I(]<
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M-EC_QDR5P)I1=&0H# $;2SR8I\OX.%!ZSZCW3/&'@-\O+"V5@-\= @[^LF:
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M4!=A8^.\2EWP5.N[J3ZUK#3V.-8Z![3# 6) ^'HFL1JYC:H;*OL:'CF/P[^
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MGK$CY:UZ:!PSM:65QM'+NS+#O'!L_F.Z?KQY,5_$DUK6[L]KW1 K4WDL29Q
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M%4&I/6:B?C436N6-C4*J6@ [.E^5/0@-S*#2'%C5?<LHM./>SB<]H-DSIX0
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M!;AR'OFW/ <X/BKC.PK8T_-G/0TX#G>/!P(G! 8^$[@WSZO2#B(9D8A0LZ3
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M$4#3[!1N=Z'%)-%I&F/!((OM/H>0!!*>$)@RC!(6L2257NV[O:2/C8X*I8K
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M6U!7K$)2XHBK]SR%/H"4^X E:N+#D$4<24(Y,3J.:>QE;!-?609J0[WOE*E
MVVHH#M2,IT& S05*/<_WG[Q[;V.D-_$>O0>O^%O0)9)V%BR+V)D+T :*EBGC
MO"UVCPHY9:VK\%@;#HT!L;-?'BX$UF;_7M"K]<-=PUSSXA3JUVSU<KW.5XM7
MN=SLMJ:!\/T4Q1@@+BB DB% _0B!6!*?!B&4E%H=4#?V-C9FK(W=3:;19]6S
MM2@4;#U1BY@LY9N<KRU+D3<C;QK^<H1G[^&O"LK?E:%>;>G.28[+Z)<!),ZB
M7TU]#1S],G#[./IE\J4+2X/>9#F?+?*U>IXV 1DA,$L0(@"%C $(4PXP"S&
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M"-4.'MX6D%Y>-1\YHF,03^_JPE]'0OW"07(JI'ZI+2X%7*8^HW'JARE(<$P
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MRR><+?%R$L'KP!$IM& L5>(1"=[4]S4Q<U?H)RRU]DCW"C(.L\MPX#E<VQU
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MY\M:[_&FO ]?)MD)IAG-)S)?BSXX[2P9)7"G4S#:%>4'>)RSBXCC!I@]@75
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MR)/SK%LW^!QP.N,^=QTB'>C%]MTL YKBQ3+^"6=8IJL)&M3<.U_)R&DU!V7
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M0[W-:Z2 'V_2REZ[M<^<871& D/G0<5$205Z#9DP:HTL.0;9?'X/232N-SG
M^K?=14/%=^\>U@'@W5Z8^V9<&[IJMLVZ'A&WD3NYVAG>E.N#733G>CY?KI;K
M-IJQBG-)]O<-@#8SSPIE^H4B<@)@J:P9R4#T0B<AL"1L_5[Y,(D/;L:Y[>@_
M71_]:EEQJW3M_@C96U%K(FA929TA95DJK8,W>32%W2_RN [OB/B\T^#SB*;N
MWH/^'*:+_P@G9_@+[1.DDKVO).__H+;^<PMA&[G/;R-=@>5:ZVK.C1 %026A
M*P#R1>OJ$ETTG$E56F=&#\ESJ.N[[[.O72/9@B$P#L5C#44T([0G7AERI,L\
M:,I@CC#93MQ6,US<=DKMC-"]R[G=*'0U7WW$RN8ZO]-2=9^\;_M/;YP;[CFM
M SW6NB/KW=ZK[\_'OM-^]0JL27!>ZZI5#H7 FBH97XZ0C..H=2A2EL=TO>?8
M![4*WGZX:Z>_EH>Z_*!P67N*,0<A2%J=PFJOK"Q!FL9S'=E?'0,5-WH"#VV6
M[KW:R["84;I=V:S6P>,^ONO.9[3U4 ^+V.K*[]8@WZ E+%)T7!@('LC:VB3:
M'9,#*8)R02I30NL,:9,L!Q-ZW?K<*TBCL<9YJ<$['D!)+\&I>E<N@N:TG+A+
MK1^3;A1FY&N^%CBX0ZS51/'=^Y)=JAJ/5;C900'G6(6<,A>4J9;#Q5I([APE
M_+0=0BZ)F1PX"M/Z2>5PA9R_XN_7/GPQG]&7Z3R37@_U]?S/:\]S+!?::0LQ
M%5WC @Z^\$()",^.A6AL;D\SNYN,W192[H*<NZ2R QKJNW*![^M+V<$=X,4H
MX[F_^Z8YO//+/ 1=,P+C:WEM,!2?8TE@47*N319)M:[#;N_\UBG*;^DCYK.:
MD3P_6]2%38LJGZ75N6*OG>\:;7/T'$K1-./$,T3#(D2;4LD:BU;Z,6#M,F"W
MWFL7T]](!H?0=/<>Z]&JY_W=U+8??>0R[@$=4ILRVJ!S-+$8\#PJVA%C)5,K
M'M!(%QAW,38_N^ZBF/O%=!D^D)D^7 SU#C_C[ QOK;Z8*4ZPI!BK:F,LE3)4
MIGO04ABNE<HRM7[OMI5@WT,!]R[(N^=^LK'U.F"WNJ_3^;HDX%EU+!=GA[>W
M!Z^*,0FA,GZ",MF"*]E "%D47PK-N7DW@-W%')<?:WRX#FW9[C?^^XKY]]_K
M'_BTX3D(!MS1'Z\DIYC2"H\!BM$(2F"B<-,0/*SGF)@HXO:-U!-F(KAVM^O1
MRE0BB.!<3=L%.!$\A&*0*UH,7K9^Z?FX5+VS#NR"E:U9!_:S2??^Z5J%\?YN
MZ>Z'#,8[,* 3VJ&F6W%G><H9,L_NG(W9><O )5Z,3\F[U/J1S_#L ^OL_-_Q
M)+^?7[;.O5%;?E5X?O7M\ZW[YOZM*I^F=1&<48D2=\4A"ID@,EU<KH]5O'P,
M48UD>3(D ;L ZL9IRI'M]03\V<V:XD.<VKV?-"POP(#N;;>Z;F>,%:ZV0DRE
M$B>: CXI!U)F%X6RRMO6)1A'90>X.H6DU&>ZPM?3SWAGV%L+)?/B#2('DPHE
M0H'^B%(5D"E*'] ZPUOK9 \QGQ)[P"XHNU/?.[ %.S@7N9SB_*$IGK^@>G8Z
M7ZPN4OV77^JS]=MN'@OGGF8)3OM"43&E\<&A 1LE;0!)21];G^BUE'_<DY3C
MP_KH-N]^:[];T+__YK[QLX9FTAAP@[_%G:"PHM!SL"9[4#(8"-(JX-H'+1TO
M6%KO5HWY-+XY^//2N*_/3\+RV@O1%)P0GA7@)5/<JBS2*M,2LE.Y.*YS**W)
M>QX1J2ONC%WLOWEO/5SUW?N5BR+8O7W)C7\_1$GY@#[C5FDQ9XY'+3-@K&Q+
M2GAPJCZ_=$7Y&(HSHO5[CM:%Y?1IM4CO=HY;E(S*!!"R6%#14>"7E01A8RJH
M(N7:;(B)W16EJU+R7>Q]MY3\<%5W$&/?5Q'_[6;J\ESEUA1MYIKKQ,#6CFS*
M86U Z!Q8M $E=\+GUNWU]A!SW(BY*=*&-5'W.]3]U  '1K^;/N\8K 8#[F@'
MUH[7_B7.)@_1UX-8;3P$+SD@#YK+C%PV/]D?E]O@6JCWK:S]NA3/TFKZ^>[Z
M2EJYG)F%5)_H*2D%N*(%A,*3*\Q$GIM3V.TEZ9-F,M@%C0_$\$,9MH/M^[%9
MKOW/FT_UR^6&&:.VB5,^!"PA \68 Z^L!L>ER88,P'SKW?QPJ<?=W#N&=6.#
M=PKQ"Y4^^STL\O495Y: <Q0LEV>GY]^[-7N)G&'@$H*KG829X62&( "ETI+Y
ME$B"(\!]_QEL!7WY#P+](P&ATV5PTP"7':S7>OC;;$IJKVK9X 4H 4C.< />
MR?79>*BDU06*UJ@H4?7H!CP^;#&%K1:"^@=9",>"0O?)XKT\2/OGB@]]W!$(
MG ;,%!^DZXF")2UYA,2UK^5-!J*.$BR/)429LFS>ZWU(&J=KE^67HYS?)%Y[
MASW%Y87F\QM:0NELL9C./M#BFM[>.3#[G 3CM&)]JH2U$F)RE#+H$(M2//#F
M?'9-)] Q3=0NN'O@1<21C=R]4[S##;&W/]SP2<.2L0QY:[R)BL,'IF5@MA[1
MUA9!B!!5,H!HM)#!*V%;GX0-1<ERM3!NCU"!GVAYO)B>G%5BHIM+P%FC,VH-
MI5;.JR0\>,$TR)*B#BH+KENK8$]1.Z5SV05#F[W9<$;KWF_M0@'P+.?I^O=.
M7LW*?'&Z_D<O<!6F)_LXNE9#C\>)L+5"AB=*L($I*V4 $W,$A2& $Y3M".Y5
M2,:'I%O?/P]$E'#= (_V8:\K<R)52BAH_4M&X8.R3( OS( .27#!@R^W6S5N
MJ ?8>>ANR1-V@<.-Y_[#:G_$4YZ,T\EK_!!.7M(<5E^??9DN)\S+*% AL""K
MZ-:"RT:"\YJA9<E;]U")[Q+3GS_,/_]('WV^7NB+JV5RSX CLC$.;-=Y&R6/
MC(]SJ5_,3\-T-D'-*4.BS1T9RZ"R\^ B3Z 3NJ"<5(+%@\!Q?;1QD'&PN>8-
M=#>BS=<KXWWX.^;PEN*^TY#P;$6+XF193_3JX5Y8X?)->7:*"_KVJUF:+SY5
M2A+,O^!IQ,4$8]6'1R@\"5 1*9L-)0"6;$6B*6N5MMIZ#I%B//#L;_3Y&!88
M&VI_.0E?YLO3Z>KCW^GG^&JVPI,33*NS<')9%OQZ>CJ]FEP(*I%J*)])NIX;
M>P/.&%W/25PI7"2G'@VS]QIYG-O?=I :5--CP^C?YXOI_\QG[S_B(GQ:KY?E
MJP6>4+;RXMGSB_E8R8N+DB8@HZX]?!C$R!D886,HRFJ*";="SA:#C7-?V@XL
MK?4Y-CZ>G7[ V3VN,HGBF2L"T->V)5H6\%%;"#QZ822W[#;7PP9,;!A@G.O"
M=CAHH;>Q;7].=/[U?#.]D-_E++U2%I@JY-L,1X@H&$C"K+ ^2)795G:_Y\.W
MLKGNU^:'ZJN#=POOZ?<H0EHLPNS#^DYS'<=GZU1PH4#(M6E'U DHKB_UF9U*
MAC'OL35]U;V"C!-)'#'G;6>&#K!T3?QZJ??K?!:NOO.>OEJ&M'[J<[%42#N<
M<UIM2/LBU(?VM%1JL98,3'"3M7/-^5EW$W'<([H&H)@?ST)C;UZ7')^US^S/
M9[-,Z_,;W^?%=*2.*(7Q%'CQ=9R.0#FC@&2XM#H';HO8:B][?*R1#W>'M/-\
M.*6/C:$;O+'/[O+&7DR)62VL$13/B\A H300>?:07&"1!XHBRG9->;8;;]S7
MU$?#T@#*'Q%/R\6*9D1Q BY(SZNOOX937/MO+M +9Q,$Q2A,X(I<MQ>AOF'A
M2F0F3=RJ-H4&N+;CT=^N=KM-8X^3:Q\QG&JB])%!\PX_G2W2QW -^;>G=)FW
M8+86A8)D'44"GI),%W@ *^G/DF3:\MKV$21M+= X>UX;F\^'-L#86]N#YU2T
M(C>=7SC!G#".UPII#\I%"<[17YDD1ZM8YEFKK?:Z/048#U0#X6#KP\-&1AD;
M>+MX_M?UN'V%I\M)2A0W%D,;?*[]%2+E.]&@!J^$RMX;S=1VQXU[#3_.8>01
M-\HC669L[/TR/<'E:C[#BP*/=YAP^GFM-6NB9HP6J?>5!0LI(PDL9Q!*1^VD
M3)IO%\-O'N.)O-C8T[3S]GH>&RY_^T1JI$3CWME@GECZ_>2\!<,MK31-L87+
MI8 5R)BVS&BS'7?L(P,]D6//!L!IJ?$.3D"?A^7'>A9"_ZE\5Y_#R3IK7CVG
ME/DK:6Y=]3#QDAO.G :=8B&'G0P$FA505(JT0 )'?.AQT%[-(;81[(FDAX?!
M;CA3=8"_J]+"[::'R(JWI#&MN*U<]*4^7/!0,";EG')%M$;BCB(^D4BL#2:'
M-%\'Z-S$!G[1:6W"M \)F80H&%*H8&SEYJ)0H02KI$TIN=;-2A\1:9P+ZI'0
MU](\':/MU_DL7<S(<F^X4[7'J4ZD,AO!)T_>G1MDM+8<-J?,?ERJK3!GOG/,
M[6FDL1.(5[.TJ/QO+_#\OZ]F%X[\6K.%"46R3B2TP%UM^R(H+7*<]&6M](I+
M;:+?[FACF]&V0I-]XF@:1O=C@^D%?L:3^:?S?.C#V4G]W:]5D10,++]E3,M+
M[HJ)<JIHIP.04_:4*_FJN:!!6A:1D>YBW Y7.PZ\%<3<]P"Q(2W2?;'GHSU5
M+YH]GI<P#M,L]M801VX:^] $NVH>:S!JDVP&*40]-0D(/O("EO("6;00Q;8.
MI)L(/F3SV$D,(D<=$P4.M7&C4XI2>8MU,9:4;=%9MBYR?4B>[Z%5["XXVZ55
M[$ZV&OFZ_I?PO^>+R^:AR_7%LXJ1%1DM8,#*[NL]>"]999#2&IU,AFW%W?7(
MO?S=D4=G$VUDT7DS]8X,CGI'_*;<F,/%E;%6V11K*31 'VIH0,FTK*>+49&8
MWEJV'4GW(QC9*,!XU^J'6G3>6KUCQ_D[EYMYBAP%,@]!5A:FXB/$9!T()YE)
MS+.8MBO)&*2P;Q#0-++T055^NZA];$QM4Y46K#-1D=(XJQR'A1+BR%4$IYFC
M-$4J7?SA+WO&?,(Z$'):*W=LL!Q40LV5Y<EZ7KL,4PSH@P2GN*A]Q91/1MGB
MMG-&@Q>Q-[^Y' A>1S/'V+C[:Y@MR5"W9GHU*3+?90%MH4Q"N @H=7W Z4IU
MP@Z292[)G)EBVSV\V'K(<>X=!T+4,(H>&SZ;'D=*GAP:6TE(:'=6T9/K-92?
M%EZB42'2=KW=B]5#7J0VOQ0<"!HME-C!9=^&W//JS%<7QJ.FN(UQPPG8B8"=
M:L-)X3B+Q3+3O!W?8S*-WB2A;;8^B"DZ@-:%_#^3!I_/9^N#K_^DI.%R ;[\
MDD[.UG5OY&+I?_E]^$*KQUF&BG(#7BO*2Q+@O)20@\G>:>]SL(W1MH>871X7
M[8F3.R]IAC7:]W!;<_E$=QEJ]>:YDJX1,0][C[/EX$>_X=E'*5W=_82L#3HK
MP'O-0!F%M'&K B)GF75VFO[X'N]^+BY\KYGP5UQ-BF;%6"? 6%.I/;P#QX0'
M(<B[A*@-*ZT=\;V"? ^W/;L@ZP[QP,'6Z2 2N&\G^=;I<1*=DC&&!,$HRK=K
M$N4*9Y0Z(:54$3/3S5]U/R30N.'E^)!K9ZVGO]EO<=;]ZUQ>''</N?'O)<B1
M@X##E75@0+ 5&\*U11)3EI5FP4N-H +YTRA#A&B1F1!RT;<=SYYL% /T>[DV
MY&>\RS21-OSX.NW$><9:$NT<6A1@GI:R*E%3\%ZKSCA&(W125@_7]*75+$8L
M&!P&;IN[)HQB^,X8Q!/GHAADX((0M8J;<END?4YDEV,H/DC_4*C^1!C$>[']
M RSCNQBB)Y9Q'ZQ5R2&XE&DI%@J=0](2;*88)D=)0<Q#]0M/E65\)W-M8AG?
M17=CWW3L_%2!R6(RH\E)5TDH*Q>%+]("MRD$4RAP-ML1G3V-%R*'&?>@1R&[
M:+J#%/9^2D&5@\\6(V3'%"A/?P3/,Q3A=."4=HG\'=-]=K9!M3-5!WC;E3RN
M9O<AU_=_3DA*^#V2KJP$\NFZWCIZXYMW(GKZE* [@>) 2M!=+#3VOKDEHV"P
M7/-L(G"?2'V<TAJGJDNG,,,%ES2[S:,V/)UC-]2@.]E[#SK'790_-C-?5=-Z
MP9%.A HL0C A@Y*8(53:<.2!%9],SFFKTX;'F/<N!QRWJ7PG&^/^)N@!-Q=P
MSR2IDXQF&KT%Q2B+\0P+H-;>9 (]CUO=$FR#G+$?;>]IK-OFWD-SH]<$?9F>
MGIU>"%X4.BV8 8[*UB9#"J(-%DR*"8LCOQ=;E'K<&'1DH^]CLGD+_740\C;P
MD:^_O8&1&7U*3D%.]88TEDS[L.,0N/8T/<;T;<;R!I>*[>0?YQ5M9_O6Z, 8
M.PR_S>Y6.R9CIDTA9I&U@V 919:<EK1SCE2K?&5/1>_L=OW)[O_\<</L\8S]
M$"_C'IKO#3Q7+TB>K7Y;A<7J37E;.7K?_SZ?.)(OUH?KP<KZ@H_5)AFJD,8<
M)NLCBS+OA:@'!AWWS*I/F+6R4;_8^]LGLB_9!C^O]7DU/]+[S]/%<O665$X_
M>#%?8GXU._\I00XGRAJ9M!%08DPUGZZ] BT#+A3M($(:%;8[FA] N''3S-ZQ
M?!R;CXWYY_/34US4]UBW-;%\MEI/\^HW*N_-1$81 O<2+*L4F4Y2-)0P0M16
MVVRCUVJ[VJQ=1QXWN.P#K8-::VPHKFF5WN')NBSI]O0F7 =?$F.0:IFM\CE#
ME*@A9HE,*"62VJ[,Z\%AQBGVZ@MD[>PP-J)>S:8K6@G7]/-V,4TX8=$;G2B9
M,U)36J=104B\ /<QA81%WKEVVDC)=^\ XW Z]H6B%KH?&S\/\-P+;C1A09#<
MTH"R(H&O6[Z3%H5@-)EH#XSKQN%R[ M%C2S0Q3GAW??IM1QM]2NN+BEW+7+E
MUF>GLKXND9PTI!('IZ5+UM5CT&/4%-P2:QS"QVYP.)0!.\7DMYJ)RSFE[#*O
MI_I*U8:.A9'.8J0IJH(J*QZY;%U3M8U<6Z'2_T.B\B 3[@W+S[B(\S[J7QYD
M[!FRWF6K@8]<W[*[,HY;S\)-5"&'>B3H*_J-JP&A :V$0)60EY"^^WJ6VC*.
M*T3(6.O38F5@*#Y!IBDF):5#U9K"]1^TGF47N!VAGF47PW=6SQ(Q%UV\!E$X
M:3+D7)\A>D#G3#$LT[;V4+3Z1SW+3K9_H)YE%T/T5,\B,M<E\ @B" 6*4402
M8K"0>;+9L:@H7OX.ZUEV,M>F>I9==#?V,<HV!(JDD%12[<\@JUL6,9R7<*0@
M$O-9QZ2V>QW0BIUR^*J5G4RX*R'E+OKLX;WD>F7DZO8\;<;*!:3LQ#&(GA9*
MCI2W6)>#EUL]?VKZSO8I%:#LLZ/L;X(></.M0[(RT6("E>K!BZ7X+D0IZZ/!
M@+XV>BG?X3O;G8RUX9WM+IKKZIVMCL*F:"S(4/N3I2S 6]I&66%*8Z[.-34P
M>8?O;'<RV<9WMKOHKX.SROM+H:1R.7)M:9M+I IC*C%!)%5(AJB]J54EC?/F
M_4L9GU+%QCX[23M3=8"W70NG@A51"17!FGJXP%&!JW\-FE:3YMPGKQHC\3LH
M9=P)% >6,NYBH;%3IF?OWOS7BW^_73R7R,V'2O:+ICXL"YZ!+T4!6K0^!^5X
MWNZH]-Z/?UJ%BCM9<]Y4M6.#8T-I)3/>BX 96%*AQ@8,@J*M7=:X(&5EI2E;
MH>. .M;!DJ6CP:.!<CO8O9K>3V:MA+'9@M&I=E%$BC>#3" XA0*%)W2J_;.$
M/ZJ2!HG-1@/&V$ZS=H>]5JBP_-LGLM5L=?&NZ,49_FU&0+AYCW3I R;H71(A
M)2B!\BR5DCOGIF8T?:=EX#%M^>CY "F^HPJGG8 S'\.*8\-U0RE7X$FF7'O*
M2NY N<0I7M8)DB\A21.9#8,7T3V-ZJ:](=9 \V.#9]?&Q8G)G#4M#,S"UX9\
M!9R.%#LE"GN=#BS>9M,\8BOIIU& M#?<AK35V#C\]:S&SF_*B^ER-9VEU4]G
MLTSQBV,E1R\].,M<C:43Z8I%"JUYLLH86>QVI1SW?_YW5"BT-ZH::+XW\+S%
M19DO3L,LX9MX,CWO([*<&)=YYMR"$B+7!XX9 BL!"A=6U=>-QNP'IOO'^XX*
MA)J!JX%EQ@;;IFH5YYE2(68PE%6!,ME =$5 85&@R]H'W*[,X_NO%-H;3BUT
M/S9^+O*0^\M5:O28BW*6(R3G#2C.(P0D[\N5M%+)@E9NUWSUD8&^HYJAO?'4
MTA9='.4]7G>",BA>4@1=RZ 4H]EXAPYRB:G4*H*(6]V%_U$XU!",0QFP4TS>
MJ3I1/CH3#$(V6M.<<H(H,BE.&,^S<<59?P10?L>%0ZU1>9 )OX?"H?MZ,3^?
MGWX*LZ]'Z):S_>A'+B':4RU=-<HS/F=OI(%D- >%H4",] =%DT;(D(UPK=]G
M=-$H;X#[)^]5EC(6L,G79X?^HB&#CC(D8YF@T+RQ*K^78J7Q,'V$6J9=<-%9
M+9,01?!*]!A4KLUG8X 8Z _MM65(R4)PAY6B?.^U3#O9_H%:IET,T5,MD]1!
M,YD14,D(RID:P"L)@L0V209K'^P\^E1KF78RUZ9:IEUT-_9!SWVAT/)OLQH#
MK1WT\DUY1I$T??L5K9[%I[IVOG6/T3JG&),#=)47.U*^YY**]=VC=YG"=9_U
M8U'DP5)T4OVTD]'G8UB@@SS[_D>SSIOH4!C0F!VE?4:"EX9!B$6DD*VVOI]'
M[T^I?&J?3:R=J3K VZZO+)U4E<W24^Q9+Z.-(/=?- 6@$EE1T<8[O4C_>/2^
M(R@.?/2^BX7&WELOSQUF^?G\Y[-9GLX^W'Z&RYT0(?A$\898'TB1_S9* 4O%
M^UR*SEN6"3\^UM-Z#K^3G>][[]Q(Z3W4A)Y7EEBM<E$<*$&FR-124.IT"*!$
MT=[X$ES:JLG=/VS/GGTVP_U-T -N+MN8&!)/U&L8)2@RI,P&7!$26$!$:Z72
MK$5AZ;4A>Z@EWLE8FWKV[*"YL6N)I[-KM;"<&5V9DB'R2I#FO*<TUG+@EC*4
M["F1Y0]UUMVZEOCZH'W4$N]DLGD+_8UM^!M%T,QG)X(Q$!PG'6AA(6CK( KK
MDN<HW8,<1L,5D3=/FYH9?F_]=9#?_!1.ZBNUWSXBKE[7WZY*K][/!N.*- F$
MC Q4\AI<2A+0*Z]DED7+K1S #HG,)EF^NW*E0[+J)@;K%'@7!V$IL4C+"(&S
M>A EZV&JL!F"+)A#9MP\R(+5"GICGBRWM?86$-I#]6,GQR\NQGR'GW%V=NG%
MI<4H,"D(MM120"W!VZ* )ZW1R^0"V^Y=X;T?WQ\:]C'<O*D6.W FSU):G-&H
M%Z]UIGAY","$"<9;A"AI(U:H&"T34DLJD6>1?>2Z=6/W3;*,>S;<&#I-%=\!
M@)H^0F,L.RD"0K9>U6?:'$+*$3BM'9$2Q87\R?>L'*R@H[-P:S1@C+V[OL5%
MJG;_0)9X>3+],"5-OI]?/!E_/\6Z9<R_AI.ZYM_,?L75NCQOHJV.B#K3DD=R
M)I;4'+*KW8Y-9J1ME"ENM?WN-_YW5!&^$UCFQ[7<V. \J.@]%!NMK'0VV6A0
MCB$XPAZX;+CT13/Z8RN(#DY=\#3JRO<&ZM&L.#9<-Q30*XV%%9? 4?P%JC94
M#K6 7J3,8G3,:3<X=<'3J"7?&V(--#\V>'8MA\\**>"Q'+Q2N>HJ4.I&?IQ;
MJ;@P/&N]78'F$-0%3Z/(?&^X#6FKL7&X98US+H%5NE3@1E*PK9T#)VEI<8HA
M @K+M#1;P>\?KOI\;]0-8)G>P';)UB"$YMZ33K(-H&3D-3QUP%P6/!>:$^-[
M@6L'GHRG47O>#$Q[:'YL\&PJGQ=".*4B;?-"NTH.GL'SDFG7MYJ4Q950>2OT
M'$)=\#1*S?>&3PO==W >>'$:_C-I^;ZRT)=?TLG9^F'8<HGTO_P^?)DPC8EA
M*D!Y"64D@7N:(M*VSE"$PBQJW_K8;P\QOZ,2]'U >BP#-ZS]W1_%-=NA.2PI
M(/CM(]GGQ?3D;$7I#\\Y*:TBH"N1TA\OP!6*!*PMFMLB59:MG\MO$.4[*CT_
M!(TM#-6!UWRP@KXJ]**(/BI5(GH'DED)]+4#G]&!]LI+EF-(M^]HA^5!N!)M
MN_-C]MT#<@A+]@[02XJ'$BDK5SJ"K?>7]+6%:%@!F6-21D=:=MVR=/#O]VYC
M,!N.G:X\T-'=*:.<" X24PQ4_2IRJR@)*YB+99*Y[6[3-H^Q':R^\YN(1B9H
MAJ31Z%[^2FJE(6_5DKZ:I2%97AX=],CD+KLIH2M.ERRD\"P;<+*0WRM"T H0
MM RBDZ9HE2)KW37Y>^5TR2H5J9,&[@*%-D9&<*+R21G%9:FE(:QU)><?G"Z'
M8OH(G"Z[X*(S3A=IC9=>..#""A*=$DOGLX"$4K/@@_+N(>_P!Z?+3K9_@--E
M%T/TQ.E"HHD8N '/# 58VB1P/&L27BG))9+<^2  O>R2TV4G<VWB=-E%=V.G
M)'^=?R1O7=WTQ5>O9K/YY[7N__K7%\^O:$3H&Y<%;T&FXHJA/"NSRKP5(8HH
MP'C,%).[H+=\^+?[V)WPM^QDX/GQM#TZF#:%TW=F%4A/O-@$EEM/N1;I,@9:
M=BR$(+F1A)3M7N9M/>0XS_ :0F<0W79P4O?;65Q.\S0LOM:W,V_*;ZMY^OO:
M&9<4"UK/02LN*HE^[5GD"WAE2JFEFQQYZ[A\DS#?'=_//@%.6Y/U@+TK\7\-
MI_3E-3U=+-@<"T=E&7B=:SN'0I,)F8,(GI>"/$;>^@;M<:E&#K?;F/\VJ-K:
M8NR]\/G\]'0^6T_G[=DB?0QW^VHZXUVP@;3%ZDL)'A%"/7!TT23I5#3.;]E9
M[]&Q1@9,8]/.A]-S!T[I?N*LY+RH3:'!"\O)7T=%N[K*X(O0"C7S\<&$[(]N
M[T-LA(>;J@.\[4JW%;4LECD%P8G*O*P\^,0]E(SDE8**V/SUTW= ?+<3* XD
MOMO%0N/OD]>+?N[>T5SZ<)5L#)7CS2K*FP*E3"%G ;Z&%-X4A7*[0X?MQGM:
M!'@[V7L^K/+'QM.&*1C'@LY10\:T;F&:P'OC0&!&P1-C+(BM\/,]-(C?&R\-
ME#LV/O[ZZU^M%H)9KY^]>T-_XQ>3*/5U.V<)<E(4@<988]'$(#*7HS6%<[/=
MF_%-(XP;.1T-(TT4W %*I'>>)O#O/_W';;B+DCURK<$F%D!YPKQCC-RAI6]4
MRD!Q.P#:C)2-HXQ;9'=,M+11= \DFNM +V*6B+Q <=*0T#&!R[7QNA8^4"9K
ME<%MPN.FY*M/B3-MGX1L?Q/T@)L+N"L>& ].@S$!*<R2""&I!(R0;J-//H3O
MD'QU)V-M(%_=17-=<7!&GX/EI3ZCSI6Z6@ORH 1]3-RX%#3]L 53\^X<G(.3
MK^YDLHT<G+OHKX.CEJ9O8*5/#'/Q@+EV0"P\0:SYF;#T78DL2OT'^53G^];H
MP!@[T+YBAL'\;/D($XRU63I-6T52D=>R/$[Q8,F44#CE58E%V>WZW>\RZG=$
M-+43,.[G[VELI0Y\\MO%/"'F92T0?;5<GJW)%,JU:Z5)3,&CXA:LJM6@TM1J
M4%G ^V*\0>9<9(T=[:-"?4>L4ON@<ACCC>T,-W 86:EL-"8#QE0;=UD) 5D!
M[FUFC.)GIO]@CSK,P370_-C@V9F1*'@I:@F5LYGRKJ01O+()A!*:,Q>%<]LQ
MK/SCLD?M#;<A;=4%'\$^I N!DKE"<P'KA0 ED$$(L8 H.9B,PBMLO<T.Q:KQ
M-&BH#MEXAS;PJ"C>A6N+U.9,HEFH6)>FP 1..@IYI5<L&1Z1;;<Y-V1!>QK$
M57M[SP$LTT$><M\RJJMG]2NN+HO==;$\&!7 QUKLGH*%Z'0$RJQ<8BQ'PE3S
M(Y]'Q?J.V+ .<8FM#=@I)N\P,#C2"BDM@P^L+C95GU?&>B2KT1BAA;U-;ML/
MB\;3H+]JC<J#3#AVGK.)=ZY$D30WB3P]B:^D5!1=U!NE@HFSZ)((;JN-^!#.
MOZ=!8+7WSMM"]T^?.N/9Z0><#<R4<7N,(Q-C/#C%KG@PI HJH. 0O:KM%Y,@
M+!<#P=L<$QH42C7>?;Y7'HSHBDHR,&"LD%MP-4SQ)56>K\!,XD''UM'E'SP8
MAV+Z"#P8N^"B-QX,(2,/M@!J$T$Q0^F?H8V)\C]?/(7?[D&6G#]X,':R_4,\
M&#L8HB<>#$&Q4@B1@9&>EF*N3:)CR%!BXDX+U &_2QZ,7<RUB0=C%]V-G55<
M!CP7U?28+XOI1<HB43PK?6T5+*,$9[F'R&.Q];U'"-N]"M\P0">,%CN9:MY8
M;QT<=-Q?L^6XU5QR"S(E7M-B#:ZFQ4$P)8HIWOK6_*#[UUP^)?*!?7:5=J;J
M &^[OJ^GY<)SL!9")ETIK-W:7&W*0&N*5[I+%9IW-WWZ-9<[@>+ FLM=+#3V
M9K=EV5_.C.5@:)6BKO=UEE$&XA)P0V& -)B<_<>MN=S)WGO47.ZB_+'Q].;D
M4UA.24<TG6?OWCS[Y2_\]G181NEU#"!"C0<2Q1;!B@+1!:>L#@DQ;(6EQ\=Z
M6K68>^.HL=+[P="=XE(9?7UY);.K3EQJB(R<N%':\R(T1[W=H]]-(SRMNLP&
M>#E P3U42YTGJ#YEE@G5D:54BTEKU5"6H(MCBKZ%2FQ%R]2TRNXIT9[L$X+O
M;X(><',!=\]=$-E%2G5K<SQT!'<T =!Y8>FO+FS7DN1I5=GM9*P-57:[:*ZK
M*CL?M-+26U Z9U"E!/*>T0/W%$1AU(6+K8@$GUZ5W4XFVUAEMXO^.DBNF]Z5
M%^V9Q<+!&Z]!,>?H*\8AYHPE&\TL"]M@I^<JNZ=4'7[(T=%HP!@[N+Y\,7EU
MP3]10<BB<VV,32&D$B5"D(S^2"9RHQ&-T%N%U7<_^SNJF-O)R/>]4=U3XV,#
M9J>"OUB,4H;V QEH:U'%:/#T+1#6B"B%-UQNUX>\>5GFTRB VQMD@UFI@TW\
M\<H^95$R^A\4:6@GJ!6G,1H*=4SQC.ELO&G= :=-6>;3J*7;!Y7#&&]L9WA_
MSS#,$R4TQ<*D$XJP:VUI,> U1O"43^F8#!.XW1ZZ:83OJ%9N;R?71/L=.+1M
MR@.8CRDB)>B,HMS:[,&""X%#*)$["A$XUZU+X%K5=SR-DK=#G%IK W:*R3O%
M 5R8(+R,D*RBN)53[N4RQ:W>25IO07'*OWJM[W@:E7"M47F0"<>OO'R6\W3]
M,/WD'=;72=/9AYT+II6((2H&'G.A\,)2FE7)ICCSWJ(+SLKMJC(/E^4[JH[;
M>P\_LD6??HG)7^?3V>H_Z*NS!=[S\]]IL?_'=#E=S,+[C[@(G];]@ ;OWGJH
M4,?N[MI4B5U5O63'B]=2@J\%]"II"T$H"19Y0>9\XK9US>7W6O7BDBVJOG+6
M$@.E$8ZVQ:@4R.*BX=RAL%NQ;OY1]7)$3!^AZF477'16]1*\\\K8 #DFTB1#
M!PYM@E1*5"8GH6]3F?]1];*_[1^H>MG%$#U5O00OO1$H($7A*5](BE*%(BGB
M0J6<QEB$/0A +[NL>MG)7)N[OVZON[%/-N\/?R[9UY,FA40!- \'BGQS[5)I
M@$?'= B^"+7=M<Y#HW12_[*3T>9#:+"#TZ#[']&3*962TH#.]0F)T@IBL0QX
MUH(%&=#9U@T0_S&*8/;99-J9J@.\[?KT-2CKF$@>DF65:L)+B*98*)X[EMW_
MW]Z7-;>5(^F^W_^2=[ O+S="99=K'&&7';:K)N:)@=7FM,3CYN(JS:^_"9*2
M*%F4N.#P@.KNF%'9DDSD\B&1">02N0JU@YX74 2S%RB.+(+91T.-G'U;RB\$
M[DY7AM4(E61Y+<]@4)+@B/ >MRFG9+=N,D\N<UXE+WMI]Y%#LH*H!TXKO0MN
M4USZ#^,T6WF.1B@9R\@K61K@&(6Q:YEDP:,VDC)'8JZ15+QM_1>7G7[(V5A-
M00V";.VF*C0O,<8,68G2!S8I\&B^(1#IC34R"K=3,NH!,!LR5JNGV6>@<H"8
M&_"C_G33<=DU;R?XF6DV7T4V'Z?C*S>]_B5-4AZ',JW[QMYZ%0D1'#@-J8Q#
MMAB5X"X+'*,5[B2ELG:;G_TH; MDAV"B.YF"&H!?U2=&8ITT";U5GS'\%MPY
M] -X!JE]LE9;$5WM=E[_3K?O*4@=#!@-;(K-#,AEBL;8+]"HO'+?QW-W.<*?
M<2%Y &6\1I\W4+#E25LDZ7T,^&/E*\/\:8I>4,[^7DAY(G'U2+4U ,)#FK33
MC)&<$P2\1$]*"&G!LHP<IV#*P!3'4^WKOKZZ\)]']O\Q<.U;P0U@>*>L2R]T
ME$R +Y-]!(\"0P"J01(EO [E2:>^TU G;?8\:@&.P6AM!3:*R9]R+KU&QUTQ
M!MQQAB=$%F 298!!:4@L2?2@FDV;/8^2@MJH/$J%S><<HFOS/4WGUVX2?_WG
M8KS,O/R\N"HA:)<?^^$J"^Z03,)#EZJ;'UB%X4I9?S?+?;QTD_G%QIJWV4^)
ML.2\1H01O[P*-^"=]Y HU\9)2Y2LG8;V+%%'-AF[^KXHX/[<Y?E?:!T^Y#P.
MZ6Z127RSF$[&)3OSMVDWFXVRMM(K$L"JH$!$_&)*QF\(&7^0A3(J/ >]PY8>
M-OJI"XX'S<;Z5$(#1_$[W, CDP/G :VS4J6TE0=T)((2(*4DS/O @GTJ7>F0
MO5/6'38(Z0<U!\MUZ.?<3VO[?RN&%9RM$9I$JR%Z51J@( M."08L$^2-^B0>
M#LG>8E,>__QA??P>#4<%<;9@'9*;I6_=97Q[]7W:_5BYFBM.? Q"BIP@:!=*
M]:@%5]JJY:"H2IYG_V1G^(-LQE9JAG7*>[8D=730 )K*Z]!\NEB&(6\G*+6O
MJ*@U*S8Q;8G78&)IF!Z" <L3!1N2"#KI3$/]-D%;R1FV8K=?/-720@. VBJH
M%3?*)-P)3@.-!N/;TC[=>>8 (\\4N;-:5)_V]S1%PY;<]@NKBKHX'%G=W%W6
M2:T,87%5BBI3?)V0B#!>J@G_?)G6A3D75]UTOB[:V<K\B(40HG.Y)"X3$&4D
MA NE]C*Y(#73/O':SP&U:!^V\+9?M ZBW_UQ;5>XGJ2OA=)^;>;O:3[*UAK'
M; 2:BWL::00;K8$<D4LAD\<CX%06$^D9=@3E0/9R7SU4LY:GO#B]*VA_.UG.
M'E[MOIH7ID\MT?]%Z<X,GNZ"5#+F)#5 +.&E@RT#E[4!FG@6P2=OJ@_ZZ^V"
M]&:!76SW*$I#LPNTS&(JZ6!!EIXR#E+4/$2?(M-/57,>PO@N=#5_9[H'7AX:
MM^IZ:?YUZ.WD1YK-E['Y[1O)YV_(+1)P]:Z;?"W_W?@EM!7OW?0?:!#\9?J<
MPF*Z2I8\O/U$90KJFL@^Q5/)@FZL_CKYFSTQO[Y;_79KJ$"3$\("#:3<ZR8.
M)ED!+&AKM%+<5G]KVIVZHVZ![S(@_S-=QB_=>S<O'[^YS..:664[)II1&%9!
MU%&!$-F@:Y03>)*#X$)BF+?;Q)OCZ!C6M/8$I'O7RR?44P/W/+==+]XNKZYN
M2_,H55S'S,&N@B\A2_"E(&<DPB2M+*L]7VX+*<,@[N10Z.KKI0%X+;-C<.4B
MJ,]I^F,<QI.O&[U6[KB;E1+1V>,_6M<Y4&JU\=*#465F6J >G)(6N @RXO]+
MS6N'T#7I']9T5@'4PU+OH;3; +++^7.WX=?E,<'2E+3FP)*3(&S*X(RW$$@T
M(A&?LF+5XZ&?Z1BXUGLP5/P4*AVIH@9@]@HCR7$>XZ\506' U\W&M]7)BDG#
MF0&Y[#)<*L"LY@Y8C"[)[(BI/@/V"7*&33EI!G2U%#9TTLK!OL^[VR38*+VB
MS%J0TK!E(0I8KE"@BG+)LX[,[S:@^GA:A@'G4$[D$ ILP%9NX_,F9]JZ1,M.
M ^X)NCHH/C \9TB)>O1Y3-2Z=B+$,R2=8VQS(#RZ_G0UX*/V4I3W_8S[G&V\
MAOXQF:;0?9V,_S?%W_"8N6$U)A0:;G+05J#PK%R>-A+0]4:V4W1RQSS X^@X
M1Q-Y'!9/K;RAC_0#6'W7S6ZWI+:$298".,TM".(Y>*X<&.T$XTS:1'<;*7(<
M'</DM9XC3@]5WK')%%]Z"K+O,_W&C:=_NLM%NCLRA'$V)J""EQY0P8%5(H&3
M7C#'N/2\=N'Z/O0-DTC;PEG?FQ8;]CE+Q>":(\ZYX>6UEU%:6K=J@\Z[*&.Q
M2PU?LH*[G4:\5G [[Z@:)@VW!316UMB9.I\;W 9OHO&TI([J4/)'D5OC21G^
M2'2FBFJ6^_0_]P1E]23><SS:CU#AF7JA&]Q2&50B44'@1I4F5 1,S@(D<8YY
M'K2BN]TK'4W*,'F\YPC8(U1X9N[H)I<F6A-*[;\JK;N#S:4G#_[52Q)84,94
M'T^V)XG#I &WX ;TJ<LS2*F;N\G7,8IUV>YD=J.++C_\R5%9<_LN4CLQ[B@F
M*^6^_=9U\:_QY26"^:=EQ[-PV<T6TW2;M83HC4+X"$3I9<?0@)XGCZ"CC31'
MSXFH'2OL16"](4EOQI/Q/+TKXU(?+KM^^+#!D#+"S1)B0(C P*L@P1K#:$0'
M/5=_W=R=NF%?V/O#U/;A157UU4#@OB3](OQS,9XMJPE6#>FUM$BT!I>%Q\"O
M<",CGBI,.4)"$HK4OD)ZC(Y6AA;5U?G#.K%C%= @B-;Y U%SP;P198H]>B-(
M.5CERPQHEYE7R(BH;;H>IV3@)OY':_@9R!P@[J&CW]^['VXZ'\_N^BDCRRY!
M"AFEH4@"#( (>,>-D-'QO..;ROW/;4OOAZBIJR.S!FS$$T;TE^OW[G^ZZ:M+
M-ULUC->4^FR#A:0]'M7$*C#$"B!.HX5E4KA<>XS,'N2U,N:HUV.I+W6UC<0[
MQGYW5VF]885DW"L90%G\(KR-X+4U)>3-4@6O675O:$\2!T^I[@<JNT/R:+TU
M ,N/;EYR+]?6W3(B+4L4F$NE!W#";1N]AQP"T991)GUM$WB/@&8A=;RJ'Y;)
M'RSW!D"S&MA4^D??SM1>,Y*9)HY:#<EG9"0X#\Y&W'@T6T[QI]S5=KZW$C/L
MB7E*,-711P/ >D)H=Q?/R3@12TDA,Y'@9M'HQ3H9(: /FZ)#?)#:5:J[T-7*
MK*VA'+3#%-0VZ%8]GEC0.67*P5)B2]4* <=*@H()Q&>N=9;D=(!KH#%M?13L
M#K/]5=(VQ#:>;.]UD?!X B@K!%!26M8QG= EH!*B%TY88XL_>SK0;:&RV2.V
M=QC64-O0UV%/L/?VZKL;3Y>=P&2IC J,@.0,'1-B*'A*4[E#\CDPF8E_T%]G
MRRW93LL->XKVAJB>Y-VV:2L=OWQTBBACH0S" Y$\NAW4.(C,>*ER-E'5+OMY
MFJ)A6^H.:;+V54<#[2JW<_/'+.7%Y;MQ3B-T9BEZK0F,YQP$C0E<3 %"4():
MJFD(M;N\[T+7L+UV!P3:@:IIP)9MGN0??DI4&07**9/,01 2SW9I Q@B-#".
M/#EC"-'57Q:?I&A8]^MTB1 5]7)VV6&__OT]!?0RWRS*+(Y-253,#GM^D7ZS
MP_9D<I#L,,&%U\)92#9%1)G48+AE8)B2(FF')VCMN_&39H<]%>QL**2H:C)#
M9)=;2S0PY<)I%MSE?Z.*1P8W8I;H3R3-&(;EN!.=P3_9D@W*T?70YI1!ZXYD
MGU,^V3XHW"><[4/##9SH^['\.QJ6+W^ERQ_I?3>9?YN-9+0TRE!&NB[?98@&
M7P91!&TUIT1$(T[G6NY"\3EY!*>#\E%Z/3L4EWWZY:]NE"F))N0(/$64KW<9
MO*8.&&-<$L*RJCZQ]R!"A[WR:16SAVCQ/*&*V$LC[9U%BC$^]#1@>(![TP1J
M@0G..(N&<5L[]_Y 4H>]0&H:KGMK\BP!^Z9;3$>*:PPKB05IDBDS9DL>)%7@
MB%"<1T9U&AZOA=)AKZ%:ANO>>FSWO>8F?M[D]"+CLK=\!IXRH^BM)\\4B. #
M>"XS.)GQ.,$SQM+=^AP=0<2P8Z+ZA^))E=2VZ2QO#9;1F*7F9>@: :%4!NMX
M!"E3]B8F;>4)+P-V??KI;?!3$Z9P7[TT/X3G\[P+_RA3)!'5JW;T1UR+;O^P
MNM>?.Q)=Z9ISM<(MLC)&OB*@TB,-KB"+@!=>0G \9$\I0T!4WI;W*:A7QKJ4
MXR_7RU3*56Z;LL0:D9$E1<KU5 I@2X*;3(G+&*SUH79NX!/D#'NQ>(3>MU>B
M'B?R!@ZMSPL_2_]<H/Q^_8%?2C_B98U I-(:QBP0A587!:/ T)"!Z.B%Q?\Q
M5WM;;"&EE0+4(U7]$$(5Y-XF?-8)W$1H+BTQY:V;(B.&@*6: ;-.6>D\8Z3V
M'+*MQ P,H1JJ?AX^!\B]/0"M\_2YSD9)4OJ7%M'0Y,''<FGBF8S1^)A=[13C
M1PEI#CB'*/EIZ!P@\09@4^;9E6J1Y48BK-3RXLY1PJ$=ICQ@7$!+FT9I-5=X
MM*?:,^HWUV^E%+7N 76PA!M"QWJW)!XY=<E L-Z 8.CJ.:,]6!NYXS;FR&H_
M6]ZG8. 9D =K<@LD#A#KT'>%7_[JOGSK%F7@8+E:6L4";R<!Q3?^D0IC&[_Q
MY=MX.D]I\LQO_87?OOXP28_\VO)2(RY"6DU&=W<5:#(F(I-.0)**((138+4M
MMPW!41&,U/H!%K=</+;"41O8/@22W;GCHP%+6YR)<1R[Z?5G=WL&+0V-5]QG
MRB4(8]W*N_4T<CR%@J:.:,)I'_[_H\2T4HM8/X0\7O8M@.B._+*7/^3E "47
M-OJU:,6"==: ]!GE))$W3[4$E462-'.A%*^-IF>I&CXZJ*#^AZ"JJXNAS_V+
M^9=O:=6X\[88_*9U3R26<XQX/"FU'\+B6:%(!"ZXD\EER0S=Z23>OL;  *FL
MRJZ^7 >$QVPZ'WURDZ]KM]AQGP3CX(T4N&]2!..4A(B!,%<L1N5WNG# 3]VP
M+?BW.[MR;\%ALV9JGTB'R[(% -S<@*3$>)04J+$:(R,4@=710&1<2YV8X+N5
MM>\"@2'-PQ'*>JCN R0WL,+?N[_'5XNK->%4ZN"$9N!(8=YIA7$PCY SSU&%
M+$U0%51^;]&!E7Z(RKH:\FO SUQ:N;7->W=;]:=YM%EZ"TZ; "(Q"Y;X#-P8
MYM!M<HK6+F1YE)!A,]/Z"E*.EWD+P.FNKKK)DH>/;OIA^GE>&ATLN[)_3-//
MWU#"(RNX]CZ7P+TT52M/R9YP!II0GGW)]JQ>=KL#6<-ZH!64_Q!.E371%KB6
M],\N%O-OW;0,JAAI(KTN=[2<9PSG2!1@7:00$X_)::T%JYV_\00YPSYT] JF
MHR3?(HC>SF8+9(,$GVST&K3P>$(3Q<"4%D$.Z??2,$E9[8?4+:0,>P=W O <
M(/$6@?-A,9_-W22.)U]'W%+B&-401/ @>(C@2FJD5OA]8=!U)#OYQ\>@9X.>
M88/F$T#H4-DW@*./-^L^?39G2O$0MAD,,Q&Y4F6"./> IC5C^&"=RM6?8G>B
M;%CONSZV>M!'<RC[Z=#F KEQ04$P)8D%R0<3' &B%![:JMQOUDZQ?YJB84L\
M^D;54?)O%$WK4]Q:ETDT'D)4H@PQY"BNK$#F[+DB3D=9^_5R.S7#%FJ<!D4'
MR+U1!&T>XL9H;[BFH(I'*"B)8"4)I;#>*2T5S:IZ _&G21IFR-YIL72H!AH
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MIM_"VS(DO)N4P[E;G=D7*-'E5,R;Z*.,%SRV*'>O5?HHV#V<S7Z*>7T()NK
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MM?D)&1AQ3O!\3'@\2E4N2VT$Q] R<1*%BC+K*$_^5'PL4V==E+X/QJMY4;W
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M;'0MRZ&/SS27'QO&E(T-_@=02P,$%     @ ^("B5D2)TQX\ 0  _P$  !@
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M4L*F4Q"Q=F2'P6QT+<NAC\\TEQ\;QI2-#?X'4$L#!!0    ( /B HE;W]0I
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MI*;\LT@#I%3 MJ2$C500L6YDA\%L="W*H8_/-)<?&\:4C0W^!U!+ 0(4 Q0
M   ( /B HE;>52R L0(  &(&   <              "  0    !A<G)O=VAE
M861P:&%R;6%C975T:6-A;',N:'1M4$L! A0#%     @ ^("B5LOL[70'W0$
M%?$5 !$              ( !ZP(  &%R=W(M,C R,S S,S$N:'1M4$L! A0#
M%     @ ^("B5HP8B\O5$@  YL\  !$              ( !(> ! &%R=W(M
M,C R,S S,S$N>'-D4$L! A0#%     @ ^("B5F&Q==-*'   ,A,! !4
M         ( !)?,! &%R=W(M,C R,S S,S%?8V%L+GAM;%!+ 0(4 Q0    (
M /B HE:D&I]L:U@  $3K P 5              "  :(/ @!A<G=R+3(P,C,P
M,S,Q7V1E9BYX;6Q02P$"% ,4    " #X@*)6]SK7CFO7  ": @D %0
M        @ % : ( 87)W<BTR,#(S,#,S,5]L86(N>&UL4$L! A0#%     @
M^("B5C2IW %FC0  -(0& !4              ( !WC\# &%R=W(M,C R,S S
M,S%?<')E+GAM;%!+ 0(4 Q0    ( /B HE8.LN5,/ $  /\!   8
M      "  7?- P!A<G=R+3(P,C,P,S,Q>&5X>#,Q,2YH=&U02P$"% ,4
M" #X@*)6O<X\$CP!  #_ 0  &               @ 'IS@, 87)W<BTR,#(S
M,#,S,7AE>'@S,3(N:'1M4$L! A0#%     @ ^("B5D2)TQX\ 0  _P$  !@
M             ( !6] # &%R=W(M,C R,S S,S%X97AX,S(Q+FAT;5!+ 0(4
M Q0    ( /B HE;W]0I / $  /\!   8              "  <W1 P!A<G=R
J+3(P,C,P,S,Q>&5X>#,R,BYH=&U02P4&      L "P#L @  /],#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
